[
{"Name" : "ORZID CDSS PLACEHOLDER" , "Term1" : "Placeholder " , "Term2" : "Under Construction", "DisplayText" : "CDSS PLACEHOLDER" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "This menu or quick order is currently under construction..."}
]},
{"Name" : "ORZID GMENU ABX GENRL ALT AM LIST", "Term" : "This is the list that the CDSS user will see if the user indicates a need for an alternative drug. It will have all formulary drugs. Greg Filice Created 24-Jan-03", "DisplayText" : "List of antimicrobials" , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Item" : "PSJIZID ALT ACYCLOVIR 500MG IV BID", "DisplayText" : "Acyclovir 500mg iv bid", "Text" : "Acyclovir IV", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "PSJZID ALT ACYCLOVIR 800MG PO TID", "DisplayText" : "Acyclovir 800mg po tid", "Text" : "Acyclovir PO", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID ALT AMIKACIN 250MG IV QDAY", "DisplayText" : "Amikacin 250mg iv qday", "Text" : "Amikacin IV", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "PSJZID ALT AMOXICILLIN 500MG PO TID", "DisplayText" : "Amoxicillin 500mg po tid", "Text" : "Amoxicillin PO", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "PSJZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid", "Text" : "Amoxicillin-clavulanate PO", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX ALT AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydration BEFORE&AFTER", "Text" : "Amphotericin B Liposomal (Ambisome)", "Mnemonic" : "14"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN 2GM IV Q6H", "DisplayText" : "Ampicillin 2gm iv q6h (alt 2)", "Text" : "Ampicillin IV", "Mnemonic" : "16"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3gm iv q6h", "Text" : "Ampicillin-sulbactam IV", "Mnemonic" : "18"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID ALT ATOVAQUONE SUSP 750MG PO BID", "DisplayText" : "Atovaquone susp 750mg po bid", "Text" : "Atovaquone PO", "Mnemonic" : "20"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID ALT AZITHROMYCIN 500MG ONCE THEN 250MG QD 4DS", "DisplayText" : "Azithromycin 500mg once then 250mg q24h for 4 days", "Text" : "Azithromycin IV", "Mnemonic" : "22"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID ALT AZITHROMYCIN 500MG PO ONCE THEN 250 QD 4DS", "DisplayText" : "Azithromycin 500mg po once then 250mg qday for 4 days", "Text" : "Azithromycin PO", "Mnemonic" : "24"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID ALT AZTREONAM 2GM IV Q8H", "DisplayText" : "Aztreonam 2gm iv q8h", "Text" : "Aztreonam IV", "Mnemonic" : "26"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID ALT BENZATHINE PENICILLIN 1.2MU IM ONCE", "DisplayText" : "Benzathine Penicillin 1.2mu IM once (alt)", "Text" : "Benzathine Penicillin IM", "Mnemonic" : "28"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID ALT CEFADROXIL 500MG PO Q12H", "DisplayText" : "Cefadroxil 500 mg PO Q12H ($) [R]", "Text" : "Cefadroxil PO", "Mnemonic" : "30"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID ALT CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin IV", "Text" : "", "Mnemonic" : "32"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir PO", "Mnemonic" : "34"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID ALT CEFEPIME 2GM IV Q8H", "DisplayText" : "Cefepime 2gm iv q8h", "Text" : "Cefepime IV", "Mnemonic" : "38"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID ALT CEFOTETAN IV 2GM Q12H", "Text" : "Cefotetan IV", "Mnemonic" : "40"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID ALT CEFOXITIN 2GM IV Q6H", "Text" : "Cefoxitin IV", "Mnemonic" : "42"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ALT CEFPODOXIME 200MG PO Q12H", "DisplayText" : "Cefpodoxime 200mg po q12h", "Text" : "Cefpodoxime PO", "Mnemonic" : "44"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID ALT CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2gm iv q8h", "Text" : "Ceftazidime IV", "Mnemonic" : "46"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 500MG IM ONCE", "DisplayText" : "Ceftriaxone 500mg im once (ALT)", "Text" : "Ceftriaxone IM", "Mnemonic" : "48"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 2GM IV QDAY", "DisplayText" : "Ceftriaxone 2gm iv qday", "Text" : "Ceftriaxone IV", "Mnemonic" : "50"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID ALT CEFUROXIME 500MG PO BID", "DisplayText" : "Cefuroxime 500mg po bid", "Text" : "Cefuroxime PO", "Mnemonic" : "52"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID ALT CEPHALEXIN 500MG PO Q6H", "DisplayText" : "Cephalexin 500mg po q6h", "Text" : "Cephalexin PO", "Mnemonic" : "54"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID ALT CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400mg iv q12h (ALT)", "Text" : "Ciprofloxacin IV", "Mnemonic" : "56"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ALT CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500mg po q12h", "Text" : "Ciprofloxacin PO", "Mnemonic" : "58"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID ALT CLARITHROMYCIN 500MG PO BID", "DisplayText" : "Clarithromycin 500mg po bid", "Text" : "Clarithromycin PO", "Mnemonic" : "60"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID ALT CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600mg iv q8h (ALT)", "Text" : "Clindamycin IV", "Mnemonic" : "62"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID ALT CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300mg po q6h", "Text" : "Clindamycin PO", "Mnemonic" : "64"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID ALT CLINDAMYCIN 2% CRM VAG APPLFUL QHS", "DisplayText" : "Clindamycin 2% cream vaginal applicator full qhs", "Text" : "Clindamycin Vaginal", "Mnemonic" : "66"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID ALT CLOTRIM 1% CRM TOP TO AFFECT AREA QID", "DisplayText" : "Clotrimazole 1% cream topical to affected area qid", "Text" : "Clotrimazole Topical", "Mnemonic" : "68"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ALT CLOTRIMAZOLE 1% CRM VAG APPLFUL QHS", "DisplayText" : "Clotrimazole 1% cream vaginal applicator ful qhs", "Text" : "Clotrimazole Vaginal", "Mnemonic" : "70"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID ALT DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100mg iv q12h (ALT)", "Text" : "Doxycycline IV", "Mnemonic" : "74"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID ALT DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100mg po bid", "Text" : "Doxycycline PO", "Mnemonic" : "76"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID ALT ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1gm iv q24h (ALT)", "Text" : "Ertapenem IV", "Mnemonic" : "78"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID ALT ERYTHROMYCIN 500MG IV Q6H", "DisplayText" : "Erythromycin 500mg iv q6h (ALT)", "Text" : "Erythromycin IV", "Mnemonic" : "80"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "DisplayText" : "erythromycin 0.5% ointment oph to affected eye qid", "Text" : "Erythromycin OPTH", "Mnemonic" : "82"},
{"Row" : 42, "Column" : 1, "Item" : "PSJZID ALT ERYTHROMYCIN 500MG PO FQID", "DisplayText" : "Erythromycin 500mg po fqid", "Text" : "Erythromycin PO", "Mnemonic" : "84"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID ALT FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h (ALT)", "Text" : "Fluconazole IV", "Mnemonic" : "86"},
{"Row" : 44, "Column" : 1, "Item" : "PSJZID ALT FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday", "Text" : "Fluconazole PO", "Mnemonic" : "88"},
{"Row" :1, "Column" : 1, "Text" : "ALTERNATIVE ANTIMICROBIALS", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Item" : "PSJIZID ALT GANCICLOVIR 500MG IV Q12H", "DisplayText" : "Ganciclovir 500mg iv q12h", "Text" : "Ganciclovir IV", "Mnemonic" : "90"},
{"Row" :5, "Column" : 2, "Item" : "PSJIZID ALT GENTAMICIN 5MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg iv q24h", "Text" : "Gentamicin IV", "Mnemonic" : "92"},
{"Row" :6, "Column" : 2, "Item" : "PSJZID ALT ITRACONAZOLE 200MG PO QDAY", "DisplayText" : "Itraconazole 200mg po qday", "Text" : "Itraconazole PO", "Mnemonic" : "94"},
{"Row" :7, "Column" : 2, "Item" : "PSJIZID ALT LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin IV", "Text" : "Levofloxacin IV", "Mnemonic" : "96"},
{"Row" :8, "Column" : 2, "Item" : "PSJZID ALT LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin PO", "Text" : "Levofloxacin PO", "Mnemonic" : "98"},
{"Row" :9, "Column" : 2, "Item" : "PSJIZID ALT MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem IV", "Mnemonic" : "100"},
{"Row" : 10, "Column" : 2, "Item" : "PSJIZID ALT METRONIDAZOLE 500MG IV Q6H", "DisplayText" : "Metronidazole 500mg iv q6h (ALT)", "Text" : "Metronidazole IV", "Mnemonic" : "102"},
{"Row" : 11, "Column" : 2, "Item" : "PSJZID ALT METRONIDAZOLE 500MG PO TID", "DisplayText" : "Metronidazole 500mg po tid", "Text" : "Metronidazole PO", "Mnemonic" : "104"},
{"Row" : 12, "Column" : 2, "Item" : "PSJZID ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "DisplayText" : "Metronidazole 0.75% gel vaginal 1 applicatorful qhs", "Text" : "Metronidazole Vaginal", "Mnemonic" : "106"},
{"Row" : 13, "Column" : 2, "Item" : "PSJZID ALT MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid (ALT)", "Text" : "Minocycline PO", "Mnemonic" : "108"},
{"Row" : 14, "Column" : 2, "Item" : "PSJZID ALT MOXIFLOXACIN OPH 1 DROP TID", "DisplayText" : "Moxifloxacin oph 1 drop tid", "Text" : "Moxifloxacin Ophthalmic", "Mnemonic" : "110"},
{"Row" : 15, "Column" : 2, "Item" : "PSJIZID ALT NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2gm iv q4h", "Text" : "Nafcillin IV", "Mnemonic" : "112"},
{"Row" : 16, "Column" : 2, "Item" : "PSJZID ALT NEOMYCIN 1000MG PO TID", "DisplayText" : "Neomycin 1000mg po tid (ALT)", "Text" : "Neomycin PO", "Mnemonic" : "114"},
{"Row" : 17, "Column" : 2, "Item" : "PSJZID ALT NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100mg po Q12H", "Text" : "Nitrofurantoin PO", "Mnemonic" : "116"},
{"Row" : 19, "Column" : 2, "Item" : "PSJZID ALT PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin 500mg po qid (ALT)", "Text" : "Penicillin PO", "Mnemonic" : "118"},
{"Row" : 20, "Column" : 2, "Item" : "PSJIZID ALT PENICILLIN 4MU IV Q4H", "DisplayText" : "Penicillin 4MU iv q4h", "Text" : "Penicillin IV", "Mnemonic" : "120"},
{"Row" : 21, "Column" : 2, "Item" : "PSJIZID ALT PIP/TAZO 3.375 GM IV Q6H", "DisplayText" : "Piperacillin/tazobactam 3.375 GM IV Q6H (ALT)", "Text" : "Piperacillin/Tazobactam IV", "Mnemonic" : "122"},
{"Row" : 22, "Column" : 2, "Item" : "PSJZID ALT PYRIMETHAMINE 75MG PO QDAY", "DisplayText" : "Pyrimethamine 75 mg po qday", "Text" : "Pyrimethamine PO", "Mnemonic" : "124"},
{"Row" : 23, "Column" : 2, "Item" : "PSJIZID ALT RIFAMPIN 300MG IV Q12H", "DisplayText" : "Rifampin 300mg iv q12h (ALT)", "Text" : "Rifampin IV", "Mnemonic" : "126"},
{"Row" : 24, "Column" : 2, "Item" : "PSJZID ALT RIFAMPIN 300MG PO BID", "DisplayText" : "Rifampin 300mg po bid (ALT)", "Text" : "Rifampin PO", "Mnemonic" : "128"},
{"Row" : 25, "Column" : 2, "Item" : "PSJZID ALT SULFACETAMIDE SOLN OPH 1 DRP QID", "DisplayText" : "Sulfacetamide soln oph 1 drop qid", "Text" : "Sulfacetamide OPTH", "Mnemonic" : "130"},
{"Row" : 26, "Column" : 2, "Item" : "PSJZID ALT SULFADIAZINE 1000MG PO QID", "DisplayText" : "Sulfadiazine 1000mg po qid (ALT)", "Text" : "Sulfadiazine PO", "Mnemonic" : "132"},
{"Row" : 27, "Column" : 2, "Item" : "PSJZID ALT TERBINAFINE 250MG PO QDAY", "Text" : "Terbinafine PO", "Mnemonic" : "134"},
{"Row" : 28, "Column" : 2, "Item" : "PSJZID ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS", "DisplayText" : "Terconazole 0.4% vaginal 1 applicatorful qhs", "Text" : "Terconazole 0.4% Vaginal", "Mnemonic" : "136"},
{"Row" : 29, "Column" : 2, "Item" : "PSJIZID ALT TOBRAMYCIN 5 MG/KG IV Q24H", "DisplayText" : "Tobramycin 5 mg/kg iv q24h (ALT)", "Text" : "Tobramycin IV", "Mnemonic" : "140"},
{"Row" : 30, "Column" : 2, "Item" : "PSJZID ALT TRIMETHOPRIM 100MG Q12H", "Text" : "Trimethoprim PO", "Mnemonic" : "142"},
{"Row" : 31, "Column" : 2, "Item" : "PSJZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1ds tablet bid", "Text" : "Trimethoprim-sulfamethoxazole PO", "Mnemonic" : "144"},
{"Row" : 32, "Column" : 2, "Item" : "PSJIZID ALT TRIMETH/SULFA 5MG/KG IV Q12H", "DisplayText" : "Trimethoprim/sulfamethoxazole 5 mg/kg iv q12h", "Text" : "Trimethoprim-sulfamethoxazole IV", "Mnemonic" : "146"},
{"Row" : 33, "Column" : 2, "Item" : "PSJZID ALT VALACYCLOVIR 1000MG PO BID", "DisplayText" : "Valacyclovir 1000mg po bid (ALT)", "Text" : "Valacyclovir PO", "Mnemonic" : "148"},
{"Row" : 34, "Column" : 2, "Item" : "PSJZID ALT VANCOMYCIN SOLN 125MG PO Q6H", "DisplayText" : "Vancomycin soln 125mg po q6h", "Text" : "Vancomycin PO", "Mnemonic" : "150"},
{"Row" : 35, "Column" : 2, "Item" : "PSJIZID ALT VANCOMYCIN 1000MG IV Q12H", "DisplayText" : "Vancomycin 1000mg iv q12h", "Text" : "Vancomycin IV", "Mnemonic" : "152"},
{"Row" : 18, "Column" : 2, "Text" : "Oseltamivir (see Influenza Menu)"}
]},
{"Name" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "Term" : "This page gives the user the opportunity to select an alternative drug. Created by Greg Filice 31-Dec-02", "DisplayText" : "Need an alternative antimicrobial? (inpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX ALLERGIC TO RECOMMENDED DRUGS", "DisplayText" : "Patient allergic to recommended drugs", "Text" : "Allergic to recommended drug(s)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX DECREASED RENAL CLR", "DisplayText" : "Decreased renal clearance", "Text" : "Decreased renal clearance", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX LIVER SECRETORY", "DisplayText" : "Liver secretory", "Text" : "Liver secretory or metabolic impairment", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX DRUG INTERACTION", "DisplayText" : "Drug interaction", "Text" : "Drug interaction", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX MULTIPLE INFECTIONS", "DisplayText" : "Multiple infections requiring antimicrobials", "Text" : "Patient has multiple infections requiring antimicrobials", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX ISOLATE NOT SUSC TO RECOMD DRUG", "DisplayText" : "Isolate not susceptible to recommended drug", "Text" : "Adjust therapy based on antimicrobial susceptibility", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OTHER ADVERSE DRUG AFFECT", "DisplayText" : "Other adverse drug affect order set", "Text" : "Other adverse drug effect", "Mnemonic" : "14"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX ALTERNATIVE OTHER REASON", "DisplayText" : "Other reason", "Text" : "Other reason", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Please Click Here to contact the CDSS team", "Mnemonic" : "18"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Information about drug allergies", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "NEED AN ALERNATIVE ANTIMICROBIAL?", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If you cannot use the recommended antimicrobials or you believe another one"}, 
{"Row" :6, "Column" : 1, "Text" : "would be better for your patient, you can order another drug. Please indicate"}, 
{"Row" :7, "Column" : 1, "Text" : "the reason you need an alternative drug below."}, 
{"Row" : 18, "Column" : 1, "Text" : "Note: Alternative antimicrobial selections will be reviewed and we may contact"}, 
{"Row" : 19, "Column" : 1, "Text" : "prescribers to learn more about situations that need alternatives, improve the"}, 
{"Row" : 20, "Column" : 1, "Text" : "CDSS, and in some cases offer suggestions."}, 
{"Row" : 22, "Column" : 1, "Text" : "Clarification/Comments: ", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help and Additional Information Menu", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN IP", "DisplayText" : "INPT CONSULTS MENU", "Text" : "Inpatient Consult Menu - place consults to specialty service", "Mnemonic" : "4"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN OP", "DisplayText" : "OUTPT CONSULT MENU", "Text" : "Outpatient Consult Menu - place consults to specialty service", "Mnemonic" : "6"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "DisplayText" : "Need an alternative antimicrobial? (inpatient)", "Text" : "Inpatient Alternative Antimicrobials to CDSS Recommendations - select here", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "DisplayText" : "Need an alternative antimicrobial? (outpatient)", "Text" : "Outpatient Alternative Antimicrobials to CDSS Recommendations - select here", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact Information", "Mnemonic" : "14"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Antimicrobial Information", "Mnemonic" : "16"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important Drug Properties", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)", "Text" : "Antimicrobial Cost Information", "Mnemonic" : "20"},
{"Row" :1, "Column" : 1, "Text" : "GENERAL INFORMATION", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "LEGEND ________________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "[DI] = Important interactions between antimicrobial and other drugs"}, 
{"Row" : 16, "Column" : 1, "Text" : "[H] = Hepatic excretion of antimicrobial"}, 
{"Row" : 17, "Column" : 1, "Text" : "[M] = Minimal risk posed by antimicrobial"}, 
{"Row" : 18, "Column" : 1, "Text" : "[O] = Other important antimicrobial property"}, 
{"Row" : 19, "Column" : 1, "Text" : "[R] = Renal excretion of antimicrobial"}, 
{"Row" : 22, "Column" : 1, "Text" : "($) = <10 dollars per day"}, 
{"Row" : 23, "Column" : 1, "Text" : "($$) = 10-50 dollars per day"}, 
{"Row" : 24, "Column" : 1, "Text" : "($$$) = 51-100 dollars per day"}, 
{"Row" : 25, "Column" : 1, "Text" : "($$$$) = 101-400 dollars per day"}, 
{"Row" : 26, "Column" : 1, "Text" : "($$$$$) = >400 dollars per day"}, 
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "9"}
]},
{"Name" : "ORZID GMENU ER/UC ABX LYME DISEASE", "DisplayText" : "Lyme Disease ER/UC" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis ER/UC", "Text" : "Lyme Disease Prophylaxis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease (Outpatient)", "Text" : "Erythema migrans associated with Lyme disease", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME ACUTE NEURO DISEASE", "DisplayText" : "Lyme Acute Neurological Disease ER/UC", "Text" : "Acute neurological disease associated with Lyme disease", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "DisplayText" : "Arthritis associated with Lyme disease (Outpatient)", "Text" : "Arthritis associated with Lyme disease", "Mnemonic" : "10"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME CARDIAC DISEASE", "DisplayText" : "Lyme Caridac Disease ER/UC", "Text" : "Cardiac disease associated with Lyme disease", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an"}, 
{"Row" :6, "Column" : 1, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30"}, 
{"Row" :7, "Column" : 1, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness."}, 
{"Row" :8, "Column" : 1, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and"}, 
{"Row" :9, "Column" : 1, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick"}, 
{"Row" : 10, "Column" : 1, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not"}, 
{"Row" : 11, "Column" : 1, "Text" : "be treated with antimicrobials."}, 
{"Row" : 13, "Column" : 1, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who"}, 
{"Row" : 14, "Column" : 1, "Text" : "have been bitten while in endemic areas."}, 
{"Row" : 17, "Column" : 1, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged."}, 
{"Row" : 26, "Column" : 1, "Text" : "References"}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 29, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 30, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}
]},
{"Name" : "ORZID GMENU ER/UC ACUTE SINUSITIS", "DisplayText" : "ED Acute Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "DisplayText" : "Acute sinusitis--mild to moderate disease (Outpatient)", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis - Opt CDSS", "Mnemonic" : "4"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEVERE SINUSITIS", "DisplayText" : "ED Severe Sinusitis", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be"}, 
{"Row" :7, "Column" : 1, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute"}, 
{"Row" :8, "Column" : 1, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2"}, 
{"Row" :9, "Column" : 1, "Text" : "minor symptoms."}, 
{"Row" : 10, "Column" : 1, "Text" : "Major Symptoms", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "1. Purulent anterior nasal discharge"}, 
{"Row" : 12, "Column" : 1, "Text" : "2. Purulent or discolored posterior nasal discharge"}, 
{"Row" : 13, "Column" : 1, "Text" : "3. Nasal congestion or fullness"}, 
{"Row" : 14, "Column" : 1, "Text" : "4. Facial pain or pressure"}, 
{"Row" : 15, "Column" : 1, "Text" : "5. Hyposmia or anosmia"}, 
{"Row" : 16, "Column" : 1, "Text" : "6. Fever"}, 
{"Row" : 17, "Column" : 1, "Text" : "Minor Symptoms", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "1. Headache"}, 
{"Row" : 19, "Column" : 1, "Text" : "2. Ear pain, pressure or fullness"}, 
{"Row" : 20, "Column" : 1, "Text" : "3. Halitosis"}, 
{"Row" : 21, "Column" : 1, "Text" : "4. Dental pain"}, 
{"Row" : 22, "Column" : 1, "Text" : "5. Cough"}, 
{"Row" : 23, "Column" : 1, "Text" : "6. Fatigue"}, 
{"Row" : 25, "Column" : 1, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials"}, 
{"Row" : 26, "Column" : 1, "Text" : "according to the following criteria for mild to moderate or severe bacterial"}, 
{"Row" : 27, "Column" : 1, "Text" : "sinusitis."}, 
{"Row" : 29, "Column" : 1, "Text" : "Mild to moderate bacterial sinusitis", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Symptoms persisting beyond 10 days"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection"}, 
{"Row" : 33, "Column" : 1, "Text" : "initially improving for 5-6 days then worsening with new development of fever,"}, 
{"Row" : 34, "Column" : 1, "Text" : "headache or increased nasal discharge."}, 
{"Row" : 37, "Column" : 1, "Text" : "Severe bacterial sinusitis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39"}, 
{"Row" : 39, "Column" : 1, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial"}, 
{"Row" : 40, "Column" : 1, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness."}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 49, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 52, "Column" : 1, "Text" : "manifestations and diagnosis"}
]},
{"Name" : "ORZID GMENU ER/UC APPENDICITIS W/O PERFORATION", "DisplayText" : "ED Appendicitis Without Perforation " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "DisplayText" : "ED Appendicitis with Perforation", "Text" : "Link to appendicitis with perforation menu", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFAZ 2GM METRO 500MG IV ONCE SURGERY ER/UC", "DisplayText" : "CEFAZ 2GM METRO 500MG IV ONCE SURGERY ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R] <AND> metronidazole 500 mg IV once STAT", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG METRO 500MG IV ONCE SURGERY ER/UC", "DisplayText" : "GENT 5MG/KG METRO 500MG IV ONCE SURGERY ER/UC", "Text" : "Gentamicin 5 mg/kg IV once STAT ($) [R,O] <AND> metronidazole 500 mg IV once", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM ONCE ER/UC", "DisplayText" : "Ertapenem 1 gm IV once STAT ($$) [R,DI]", "Text" : "Ertapenem 1 gm IV once STAT ($$) [R,DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITHOUT PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with an acutely inflamed appendix and no gangrene or perforation are"}, 
{"Row" :6, "Column" : 1, "Text" : "considered to have uncomplicated appendicitis. Patients with gangrene,"}, 
{"Row" :7, "Column" : 1, "Text" : "perforation, peritonitis, or abscess have complicated appendicitis. Treatment"}, 
{"Row" :8, "Column" : 1, "Text" : "with antibiotics is an option for patients who are unfit for surgery or refuse"}, 
{"Row" :9, "Column" : 1, "Text" : "surgery. Treatment with antibiotics should not be used routinely as an"}, 
{"Row" : 10, "Column" : 1, "Text" : "alternative to surgery."}, 
{"Row" : 12, "Column" : 1, "Text" : "Select for treatment of complicated appendicitis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Surgical prophylaxis for uncomplicated appendicitis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "($) [DI] infusion beginning 60 minutes before incision < OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "STAT ($) [DI] infusion beginning 60 minutes before incision"}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment of patients who are unfit for surgery or refuse surgery", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Initial treatment"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Step down treatment after completion of initial intravenous treatment"}, 
{"Row" : 31, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Appendicitis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Salminen et al, JAMA, 2015, 313(23):2340-2348"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Appendicitis"}, 
{"Row" : 39, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date article: Management of acute appendicitis in adults"}
]},
{"Name" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "DisplayText" : "ED Appendicitis with Perforation" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "DisplayText" : "CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "DisplayText" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 500MG IV ONCE STAT", "DisplayText" : "CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITH PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treat until normalization of temperature, WBC and GI tract functioning"}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "STAT ($) [DI]"}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "once STAT ($) [DI]"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 25, "Column" : 1, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results.", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Appendicitis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Solomkin JS Clin Infect Dis 2003, 37: 997"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-date"}
]},
{"Name" : "ORZID GMENU ER/UC ASPIRATION PNEUMONIA", "DisplayText" : "ED Aspiration Pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community acquired pneumonia (CAP) < OR >", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "DisplayText" : "ED Nosocomial Pneumonia", "Text" : "Nosocomial pneumonia", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ASPIRATION PNEUMONIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is"}, 
{"Row" :6, "Column" : 1, "Text" : "often accompanied by fever and/or an infiltrate. Bacterial pneumonia occurs in"}, 
{"Row" :7, "Column" : 1, "Text" : "a minority of patients who aspirate, typically about 3 days later. The patient"}, 
{"Row" :8, "Column" : 1, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia"}, 
{"Row" :9, "Column" : 1, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and"}, 
{"Row" : 10, "Column" : 1, "Text" : "newly purulent sputum."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails"}, 
{"Row" : 13, "Column" : 1, "Text" : "risk of side effects and selection of resistant organisms."}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases"}, 
{"Row" : 16, "Column" : 1, "Text" : "that develop after an episode of aspiration. For more information, consult"}, 
{"Row" : 17, "Column" : 1, "Text" : "Pulmonary or Infectious Diseases."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for patients with pneumonitis but without lung abscess or putrid", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "sputum", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary. If"}, 
{"Row" : 22, "Column" : 1, "Text" : "pneumonia is confirmed, treat as"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treament for patients with LUNG ABSCESS", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Refer to Lung and Mediastinum section of the inpatient or outpatient"}, 
{"Row" : 29, "Column" : 1, "Text" : "Antimicrobial CDSS"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 35, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 36, "Column" : 1, "Text" : "Luna CM Crit Care Med 2003, 31: 676"}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Lung Abscess"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405"}, 
{"Row" : 39, "Column" : 1, "Text" : "Roig J J Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 40, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}
]},
{"Name" : "ORZID GMENU ER/UC BACT MENING W/O GRM STAIN RES", "DisplayText" : "ED Bacterial Meningitis Without Gram Stain Results" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSCZID DEXAMETHASONE 10MG IV ONCE ER/UC", "DisplayText" : "Dexamethasone 10 mg IV once STAT ($)", "Text" : "Dexamethasone 10 mg IV once STAT ($)", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> vancomycin 15mg/kg IV once STAT", "Mnemonic" : "6"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H STAT", "DisplayText" : "MEROPENEM 2GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "Text" : "Meropenem 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg once STAT ($) [R]", "Mnemonic" : "10"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R] <AND> ceftriaxone 2 gm IV once STAT", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "14"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX MOXI 400MG VANCO 15MG/KG TMP/SMX 5-25MG/KG IV STAT", "DisplayText" : "MOXI 400MG VANCO 15MG/KG TMP/SMX IV STAT", "Text" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI] <AND> vancomycin 15mg/kg once", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all"}, 
{"Row" : 14, "Column" : 1, "Text" : "community acquired cases that might be associated with S. pneumoniae."}, 
{"Row" : 15, "Column" : 1, "Text" : "Dexamethasone must be given before (1 to 20 minutes) with antimicrobials."}, 
{"Row" : 17, "Column" : 1, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be"}, 
{"Row" : 18, "Column" : 1, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for"}, 
{"Row" : 19, "Column" : 1, "Text" : "advice and assistance."}, 
{"Row" : 21, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Step 1 of Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "(Discontinue if isolated pathogen is not S. pneumoniae)"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Step 2 of Treatment, Select One of the Following: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Any Other Condition Associated with Impaired Cellular Immunity.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 33, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 43, "Column" : 1, "Text" : "($) [M] vancomycin 15mg/kg once STAT ($) [R]"}, 
{"Row" : 45, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 48, "Column" : 1, "Text" : "STAT ($) [R] <AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV once"}, 
{"Row" : 49, "Column" : 1, "Text" : "STAT ($$$) [R,DI]"}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Age > 50 years"}, 
{"Row" : 56, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Age 1 mo to 50 years"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 58, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 60, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 62, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 63, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID GMENU ER/UC BEBTELOVIMAB EUA", "DisplayText" : "Bebtelovimab (EUA) Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "DisplayText" : "Bebtelovimab EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "Bebtelovimab (EUA)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)"}, 
{"Row" :5, "Column" : 1, "Text" : "for treating patients that meet specific criteria. bebtelovimab is"}, 
{"Row" :6, "Column" : 1, "Text" : "not FDA approved drug."}, 
{"Row" :7, "Column" : 1, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis."}, 
{"Row" :9, "Column" : 1, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 20, "Column" : 1, "Text" : "Inclusion Criteria", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "ALL of the following criteria must be met for a patient to receive: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19 and is diagnosed with mild to"}, 
{"Row" : 24, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "Note: patient may be hospitalized for some other reason."}, 
{"Row" : 26, "Column" : 1, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19."}, 
{"Row" : 27, "Column" : 1, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an"}, 
{"Row" : 28, "Column" : 1, "Text" : "increase in baseline oxygen flow rate due to COVID-19."}, 
{"Row" : 29, "Column" : 1, "Text" : "4) Administration will begin within 7 days of symptom onset."}, 
{"Row" : 30, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components."}, 
{"Row" : 31, "Column" : 1, "Text" : "6) Patient has at least one risk factor for progression to severe disease"}, 
{"Row" : 32, "Column" : 1, "Text" : "including hospitalization or death."}, 
{"Row" : 33, "Column" : 1, "Text" : "See link below for complete list: "}, 
{"Row" : 35, "Column" : 1, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA"}, 
{"Row" : 36, "Column" : 1, "Text" : "The provider has communicated with the patient/caregiver regarding"}, 
{"Row" : 37, "Column" : 1, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/"}, 
{"Row" : 38, "Column" : 1, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an"}, 
{"Row" : 39, "Column" : 1, "Text" : "unapproved drug that is authorized for use under an EUA, given information"}, 
{"Row" : 40, "Column" : 1, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver"}, 
{"Row" : 41, "Column" : 1, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)"}, 
{"Row" : 43, "Column" : 1, "Text" : "Exclusion Criteria", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID."}, 
{"Row" : 46, "Column" : 1, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available. Click", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 53, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid"}, 
{"Row" : 54, "Column" : 1, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and"}, 
{"Row" : 55, "Column" : 1, "Text" : "frequent handwashing) according to CDC guidelines."}, 
{"Row" : 48, "Column" : 1, "Text" : "order set below to complete order form and place IV order for administration.", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Note: order does not contain medication order. ED provider will order.", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX BEBTELIVOMAB ED INFO", "DisplayText" : "Bebtelivomab ED Info", "Text" : "INV-Bebtelovimab 175 mg IV Push ONCE", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Text" : "moderate illness."}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite Wounds Eikenella Corrodens ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "DisplayText" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Mnemonic" : "14"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "16a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "DisplayText" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Mnemonic" : "18"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "20"},
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 28, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 42, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite Wound Methicillin-Resistant Staphylococcus Aureus ER/UC" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 10DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 10 days", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 10DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Mnemonic" : "10a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 14DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 14 days", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 14DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "14"},
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 15, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 18, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 25, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 28, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS METH SUSC S. AUREUS", "DisplayText" : "Bite Wounds Methicillin-Susceptible Staphylococcus Aureus ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "DisplayText" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE ER/UC", "DisplayText" : "Cefazolin 2 gm IV once STAT ($) [R]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "14a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "DisplayText" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Mnemonic" : "20"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE ER/UC", "DisplayText" : "Cefazolin 2 gm IV once STAT ($) [R]", "Text" : "", "Mnemonic" : "22"},
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 15, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 17, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 20, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treat for 14-21 days."}, 
{"Row" : 27, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 30, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 32, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "", "Mnemonic" : "16a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "16b"}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite Wounds Pasteurella Multocida ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "DisplayText" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Mnemonic" : "14"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "16a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "DisplayText" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Mnemonic" : "18"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA"}, 
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 28, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 42, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite Wound Streptococci ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE ER/UC", "DisplayText" : "Cefazolin 2 gm IV once STAT ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 10DS 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID for 10 days ($) [H,O]", "Text" : "Clindamycin 300 mg PO QID for 10 days ($) [H,O]", "Mnemonic" : "10a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 10DS 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID for 10 days ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE ER/UC", "DisplayText" : "Cefazolin 2 gm IV once STAT ($) [R]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 14DS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 14 days", "Text" : "Clindamycin 300 mg PO QID for 14 days ($) [H,O]", "Mnemonic" : "18a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 14DS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :5, "Column" : 1, "Text" : "Infection but no arthritis - 10 days joint involved - 14-21 days"}, 
{"Row" :6, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 13, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: "}, 
{"Row" : 20, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 27, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: "}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH STREPTOCOCCI", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "", "Mnemonic" : "14a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "14b"}
]},
{"Name" : "ORZID GMENU ER/UC BITE WOUNDS", "DisplayText" : "Bite Wounds ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Mnemonic" : "4"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 58, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Mnemonic" : "10"},
{"Row" : 60, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 61, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 64, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "DisplayText" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Text" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Mnemonic" : "14"},
{"Row" : 66, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Text" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Mnemonic" : "16a"},
{"Row" : 67, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite Wounds Pasteurella Multocida ER/UC", "Text" : "Pasteurella multocida", "Mnemonic" : "18"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite Wounds Eikenella Corrodens ER/UC", "Text" : "Eikenella corrodens", "Mnemonic" : "20"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS METH SUSC S. AUREUS", "DisplayText" : "Bite Wounds Methicillin-Susceptible Staphylococcus Aureus ER/UC", "Text" : "Methicillin-susceptible Staphylococcus aureus", "Mnemonic" : "22"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite Wound Methicillin-Resistant Staphylococcus Aureus ER/UC", "Text" : "Methicillin-resistant Staphylococcus aureus", "Mnemonic" : "24"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite Wound Streptococci ER/UC", "Text" : "Streptococci", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS"}, 
{"Row" :5, "Column" : 1, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried"}, 
{"Row" :6, "Column" : 1, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually"}, 
{"Row" :7, "Column" : 1, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites,"}, 
{"Row" :8, "Column" : 1, "Text" : "streptococci and staphylococci."}, 
{"Row" : 10, "Column" : 1, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic"}, 
{"Row" : 11, "Column" : 1, "Text" : "and debride non-viable tissue."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult orthopedic surgery for all bite wounds involving the hand."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antibiotic Prophylaxis Indications: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,"}, 
{"Row" : 16, "Column" : 1, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,"}, 
{"Row" : 17, "Column" : 1, "Text" : "Advanced liver disease"}, 
{"Row" : 19, "Column" : 1, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients"}, 
{"Row" : 20, "Column" : 1, "Text" : "with superficial wounds with no puncture that do not involve the face/"}, 
{"Row" : 21, "Column" : 1, "Text" : "genitals/hands is not recommended."}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrobial Treatment: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empiric treatment for suspected or established infection following bite wound."}, 
{"Row" : 25, "Column" : 1, "Text" : "In these cases, therapy should be directed against pathogen identified"}, 
{"Row" : 26, "Column" : 1, "Text" : "by Gram stain and culture whenever possible."}, 
{"Row" : 28, "Column" : 1, "Text" : "Rabies Prophylaxis: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases."}, 
{"Row" : 30, "Column" : 1, "Text" : "Contact infectious diseases for assistance."}, 
{"Row" : 32, "Column" : 1, "Text" : "Consider tetanus immunization status: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus."}, 
{"Row" : 34, "Column" : 1, "Text" : "If immunization is lacking, and: "}, 
{"Row" : 35, "Column" : 1, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td"}, 
{"Row" : 36, "Column" : 1, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)"}, 
{"Row" : 38, "Column" : 1, "Text" : "Select below for Tetanus vaccination information page: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection."}, 
{"Row" : 43, "Column" : 1, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat"}, 
{"Row" : 44, "Column" : 1, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,"}, 
{"Row" : 45, "Column" : 1, "Text" : "treat 14 to 21 days."}, 
{"Row" : 47, "Column" : 1, "Text" : "Prophylaxis: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Duration 3 to 5 days: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Empiric treatment for suspected or estabished infection: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Duration 7 to 14 days: "}, 
{"Row" : 59, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 63, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy: ", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 69, "Column" : 1, "Text" : "Pathogen directed bite wound therapy: ", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 78, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 79, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 80, "Column" : 1, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85"}
]},
{"Name" : "ORZID GMENU ER/UC BRONCHITIS", "DisplayText" : "ED Bronchitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Mnemonic" : "4"},
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Doxcycline 100 mg PO BID for 5 days ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "DisplayText" : "Doxycycline 100 mg BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]", "Mnemonic" : "10a"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 51, "Column" : 1, "Item" : "PSJIZID AZITHROMYCIN 500 MG IV ONCE ER/UC", "DisplayText" : "AZITHROMYCIN 500 MG IV ONCE", "Text" : "Azithromycin 500 mg IV once STAT ($) [M< OR >", "Mnemonic" : "14"},
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($) [R]", "Mnemonic" : "16"},
{"Row" : 56, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "BRONCHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific"}, 
{"Row" :6, "Column" : 1, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray. If an"}, 
{"Row" :7, "Column" : 1, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and"}, 
{"Row" :8, "Column" : 1, "Text" : "need not be treated for it."}, 
{"Row" : 10, "Column" : 1, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobials provide no benefit. If bronchitis persists beyond 2 weeks,"}, 
{"Row" : 12, "Column" : 1, "Text" : "additional diagnostic workup is needed to find a cause. If a patient has"}, 
{"Row" : 13, "Column" : 1, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis."}, 
{"Row" : 15, "Column" : 1, "Text" : "For symptomatic treatment dextromethorphan and benzonatate combined with"}, 
{"Row" : 16, "Column" : 1, "Text" : "guaifenesin has shown some benefit. Benzonatate and guaifenesin"}, 
{"Row" : 17, "Column" : 1, "Text" : "alone did not show benefit. Also, allergy medicines and codeine"}, 
{"Row" : 18, "Column" : 1, "Text" : "do not appear to help the symptoms."}, 
{"Row" : 20, "Column" : 1, "Text" : "Refer to the outpatient or inpatient Antimicrobial CDSS for treatment of"}, 
{"Row" : 21, "Column" : 1, "Text" : "Pertussis recommendations"}, 
{"Row" : 24, "Column" : 1, "Text" : "Acute bronchitis in patients with COPD", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence"}, 
{"Row" : 26, "Column" : 1, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are"}, 
{"Row" : 27, "Column" : 1, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically"}, 
{"Row" : 28, "Column" : 1, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,"}, 
{"Row" : 29, "Column" : 1, "Text" : "pulmonary embolism and pneumonia."}, 
{"Row" : 31, "Column" : 1, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases"}, 
{"Row" : 32, "Column" : 1, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patient"}, 
{"Row" : 33, "Column" : 1, "Text" : "with COPD exacerbation who have increased sputum purulence and volume."}, 
{"Row" : 35, "Column" : 1, "Text" : "Treatment for MILD DISEASE: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "No antibiotics recommended"}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment for MODERATE DISEASE", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Treat for 5 to 7 days."}, 
{"Row" : 45, "Column" : 1, "Text" : "Treatment for SEVERE DISEASE", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "side effects outweigh the benefits.", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017."}, 
{"Row" : 61, "Column" : 1, "Text" : "Access: http://www.goldcopd.org"}, 
{"Row" : 62, "Column" : 1, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125"}, 
{"Row" : 63, "Column" : 1, "Text" : "Mandell chapter: Bronchitis"}, 
{"Row" : 64, "Column" : 1, "Text" : "Sanford keyword: Bronchitis"}, 
{"Row" : 65, "Column" : 1, "Text" : "Murphy TF Chest 2000, 118: 204"}, 
{"Row" : 66, "Column" : 1, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503"}
]},
{"Name" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "DisplayText" : "CAP treated in an INPATIENT setting " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN INPATIENT SETTING", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Inpatient, non-severe CAP (NOTE: DURATION of therapy)", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM IV AZITHROMYCIN 500MG PO STAT", "DisplayText" : "Ceftriaxone 2GM IV STAT ($) [M] <AND> Azithromycin 500mg PO STAT ($) [M]", "Text" : "Ceftriaxone 2GM IV STAT ($) [M] <AND> Azithromycin 500mg PO STAT ($) [M]", "Mnemonic" : "14"},
{"Row" : 67, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" :5, "Column" : 1, "Text" : "Be sure of the diagnosis.Careful reviews have shown that over half of"}, 
{"Row" :6, "Column" : 1, "Text" : "people treated for community-acquired pneumonia do not in fact have"}, 
{"Row" :7, "Column" : 1, "Text" : "pneumonia.Pneumonia is likely in persons with 3 or more signs or symptoms"}, 
{"Row" :8, "Column" : 1, "Text" : "including a) new infiltrate (or, no prior film for comparison) b) new"}, 
{"Row" :9, "Column" : 1, "Text" : "crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills"}, 
{"Row" : 10, "Column" : 1, "Text" : "e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea"}, 
{"Row" : 11, "Column" : 1, "Text" : "or tachypnea, and no likely alternative explanation for the presentation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Common alternative explanations include heart failure, thromboembolic"}, 
{"Row" : 13, "Column" : 1, "Text" : "disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or"}, 
{"Row" : 14, "Column" : 1, "Text" : "tumor. Most of the latter conditions do NOT benefit from antimicrobials."}, 
{"Row" : 16, "Column" : 1, "Text" : "Recommendation for duration of antibiotic therapy for CAP: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be"}, 
{"Row" : 18, "Column" : 1, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-"}, 
{"Row" : 19, "Column" : 1, "Text" : "associated sign of clinical instability before discontinuation"}, 
{"Row" : 20, "Column" : 1, "Text" : "of therapy."}, 
{"Row" : 21, "Column" : 1, "Text" : "Criteria for clinical stability: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Temperature less than/equal to 100 degrees F"}, 
{"Row" : 23, "Column" : 1, "Text" : "Heart rate less than/equal to 100 beats/minute"}, 
{"Row" : 24, "Column" : 1, "Text" : "Respiratory rate less than/equal to 24 breaths/minute"}, 
{"Row" : 25, "Column" : 1, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg"}, 
{"Row" : 28, "Column" : 1, "Text" : "Ability to maintain oral intake"}, 
{"Row" : 29, "Column" : 1, "Text" : "Normal mental status"}, 
{"Row" : 26, "Column" : 1, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--"}, 
{"Row" : 27, "Column" : 1, "Text" : "PO2 greater than/equal to 60 mm Hg on room air"}, 
{"Row" : 43, "Column" : 1, "Text" : "Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Text" : "References: "}, 
{"Row" : 68, "Column" : 1, "Text" : "Sanford website"}, 
{"Row" : 66, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45"}, 
{"Row" : 53, "Column" : 1, "Item" : "PSCZID PNA VANCOMYCIN 15MG/KG IV STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : ""},
{"Row" : 48, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage"}, 
{"Row" : 36, "Column" : 1, "Text" : "positive for MRSA. (See below for prior respiratory isolation of MRSA)"}, 
{"Row" : 38, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures"}, 
{"Row" : 40, "Column" : 1, "Text" : "are positive for P. aeruginosa. (See below for prior respiratory isolation"}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPER-TAZO 4.5 GM + AZITHROMYCIN 500MG PO STAT", "DisplayText" : "Piperacillin 4.5GM IV STAT ($$) [R] <AND> Azithromycin 500mg PO STAT", "Text" : "", "Mnemonic" : "20"},
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME 2GM IV STAT+AZITHROMYCIN 500MG PO STAT", "DisplayText" : "Cefepime 2GM IV STAT ($$) [R] <AND> Azithromycin 500mg PO STAT ($) [M]", "Text" : "", "Mnemonic" : "22"},
{"Row" : 58, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Select regimen below for P.aeruginosa, obtain cultures to allow deescalation"}, 
{"Row" : 41, "Column" : 1, "Text" : "of P. aeruginosa)"}, 
{"Row" : 62, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Mnemonic" : "24"},
{"Row" : 61, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : ""},
{"Row" : 60, "Column" : 1, "Text" : "Alternative for P. aeruginosa: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "ADD MRSA coverage to above regimen, otain cultures/nasal PCR to allow"}, 
{"Row" : 52, "Column" : 1, "Text" : "for deescalation"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"}
]},
{"Name" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING SEVERE CAP", "DisplayText" : "CAP treated in an INPATIENT setting -SEVERE CAP " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 37, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment on INTENSIVE CARE UNIT (ICU)", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Alternative Standard Regimen: ", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 97, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 64, "Column" : 1, "Text" : "Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)", "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Recommendation for duration of antibiotic therapy for CAP: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be"}, 
{"Row" : 24, "Column" : 1, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-"}, 
{"Row" : 25, "Column" : 1, "Text" : "associated sign of clinical instability before discontinuation"}, 
{"Row" : 26, "Column" : 1, "Text" : "of therapy."}, 
{"Row" : 27, "Column" : 1, "Text" : "Criteria for clinical stability: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Temperature less than/equal to 100 degrees F"}, 
{"Row" : 29, "Column" : 1, "Text" : "Heart rate less than/equal to 100 beats/minute"}, 
{"Row" : 30, "Column" : 1, "Text" : "Respiratory rate less than/equal to 24 breaths/minute"}, 
{"Row" : 31, "Column" : 1, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg"}, 
{"Row" : 34, "Column" : 1, "Text" : "Ability to maintain oral intake"}, 
{"Row" : 35, "Column" : 1, "Text" : "Normal mental status"}, 
{"Row" : 32, "Column" : 1, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--"}, 
{"Row" : 33, "Column" : 1, "Text" : "PO2 greater than/equal to 60 mm Hg on room air"}, 
{"Row" : 95, "Column" : 1, "Text" : "Liu C Clin Inf Dis. 2011, 52:285"}, 
{"Row" : 96, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2007, 44:S27"}, 
{"Row" : 93, "Column" : 1, "Text" : "References: "}, 
{"Row" : 98, "Column" : 1, "Text" : "Sanford website"}, 
{"Row" : 94, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45"}, 
{"Row" :3, "Column" : 1, "Text" : "SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Criteria for Defining SEVERE Community-acquired Pneumonia", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Validated definition includes either one major or three or more minor criteria"}, 
{"Row" :7, "Column" : 1, "Text" : "MAJOR CRITERIA: "}, 
{"Row" :8, "Column" : 1, "Text" : "Septic shock with need for vasopressors"}, 
{"Row" :9, "Column" : 1, "Text" : "Respiratory failure requiring mechanical ventilation"}, 
{"Row" : 10, "Column" : 1, "Text" : "MINOR CRITERIA: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Respiratory rate greater than or equal to 30 breaths/minute"}, 
{"Row" : 12, "Column" : 1, "Text" : "PaO2/FiO2 ratio less than or equal to 250"}, 
{"Row" : 13, "Column" : 1, "Text" : "Multilobar infiltrates"}, 
{"Row" : 14, "Column" : 1, "Text" : "Confusion/disorientation"}, 
{"Row" : 15, "Column" : 1, "Text" : "Uremia (blood urea nitrogen level greater than 20 mg/dl)"}, 
{"Row" : 16, "Column" : 1, "Text" : "Leukopenia* (WBC less than 4,000 cells/microliter)"}, 
{"Row" : 17, "Column" : 1, "Text" : "*Due to infection alone (i.e., not chemotherapy induced)"}, 
{"Row" : 18, "Column" : 1, "Text" : "Thrombocytopenia (platelet count less than 100,000 microliters)"}, 
{"Row" : 19, "Column" : 1, "Text" : "Hypothermia (core temperature less than 36 degrees C)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Hypotension requiring aggressive fluid resuscitation"}, 
{"Row" : 71, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "34"},
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "32"},
{"Row" : 70, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 89, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "50"},
{"Row" : 91, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "54"},
{"Row" : 90, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPER-TAZO 4.5GM IV AZITH 500MG IV STAT ER/UC", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV STAT ($$) [R] <AND> Azithromycin", "Text" : "", "Mnemonic" : "38"},
{"Row" : 74, "Column" : 1, "Text" : "Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : "PSCZID PNA VANCOMYCIN 15MG/KG IV STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Text" : "", "Mnemonic" : "36"},
{"Row" : 79, "Column" : 1, "Text" : "Prior respiratory isolation of P. aeurginosa in the last 12 months: ", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "SELECT REGIMEN BELOW: ", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : ""},
{"Row" : 88, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : ""},
{"Row" : 44, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or"}, 
{"Row" : 47, "Column" : 1, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below"}, 
{"Row" : 59, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "COVER for P. aeruginosa. Obtain cultures to allow deescalation or"}, 
{"Row" : 62, "Column" : 1, "Text" : "confirmation of need for continued therapy. SEE P. aeruginosa section below"}, 
{"Row" : 73, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Prior Respiratory Isolation of P. aeruginosa in the last 12 months: ", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months: ", "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV AZITHROMYCIN 500MG IV STAT", "DisplayText" : "Cefepime 2 GM IV STAT ($$) [R] <AND> Azithromycin 500 mg IV STAT ($) [M]", "Text" : "", "Mnemonic" : "40"},
{"Row" : 84, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM AZITH 500MG IV STAT ER/UC", "DisplayText" : "Ceftriaxone 2 GM IV STAT ($) [R] <AND> Azithromycin 500 mg IV STAT ($) [M]", "Text" : "", "Mnemonic" : "30"},
{"Row" : 83, "Column" : 1, "Text" : "500 mg IV STAT ($) [M]"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 40, "Column" : 1, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "(Specific therapy should be guided by culture results.)"}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "DisplayText" : "Stepdown empiric treatment for CAP with oral antibiotics", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Mnemonic" : "3"},
{"Row" : 49, "Column" : 1, "Text" : "Recommend blood and lower respiratory tract specimen cultures for all patients", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "with Severe CAP.", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET LAB SPUTUM CULT & GRAM STAIN", "DisplayText" : "Sputum Culture and Gram Stain", "Text" : "Lab Order: Sputum Culture & Gram Stain", "Mnemonic" : "4"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET LAB BLOOD CULTURE X2", "DisplayText" : "Blood Culture x2", "Text" : "Lab order: Blood culture x2", "Mnemonic" : "5"},
{"Row" : 54, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or"}, 
{"Row" : 57, "Column" : 1, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below"}
]},
{"Name" : "ORZID GMENU ER/UC CAP OUTPATIENT TREATED SETTING", "DisplayText" : "CAP treated in an outpatient setting (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Mnemonic" : "16a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Text" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Mnemonic" : "30a"},
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "30b"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING"}, 
{"Row" :5, "Column" : 1, "Text" : "Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,"}, 
{"Row" :7, "Column" : 1, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing"}, 
{"Row" :8, "Column" : 1, "Text" : "conditions, or use of immunosuppressing drugs)"}, 
{"Row" : 10, "Column" : 1, "Text" : "Outpatient and UNcomplicated: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure,"}, 
{"Row" : 20, "Column" : 1, "Text" : "conditions, or use of immunosuppressing drugs)"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford: Community Acquired Pneumonia"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 43, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Outpatient and comorbidity: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "DisplayText" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Mnemonic" : "17a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "17b"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "DisplayText" : "Non-VA for above order", "Text" : "Non-VA order for above", "Mnemonic" : "19b"},
{"Row" : 52, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45"}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "DisplayText" : "Cefdinir 300mg PO BID for 5 to 7 days ($) [R] <AND> Azithromycin", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin", "Mnemonic" : "20a"},
{"Row" : 32, "Column" : 1, "Text" : "500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "DisplayText" : "NON-VA order for above", "Text" : "", "Mnemonic" : "20b"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "DisplayText" : "Amox-clav 875/125mg po bid x5days <AND> Azithromycin 500 then 250", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Mnemonic" : "19a"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "DisplayText" : "Amox-clav 875/125 mg po bid <AND> Doxycycline 100mg po bid x5days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Mnemonic" : "22a"},
{"Row" : 36, "Column" : 1, "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]"}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "22b"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG BID DOXY 100MG BID", "DisplayText" : "Cefdinir 300mg po bid <AND> Doxycycline 100mg po bid x5 days", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline", "Mnemonic" : "24a"},
{"Row" : 40, "Column" : 1, "Text" : "100 mg PO BID for 5 days ($) [DI]"}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG BID DOXY 100MG BID", "DisplayText" : "Non-VA for above", "Text" : "Non-VA for above", "Mnemonic" : "24b"},
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing"}, 
{"Row" : 24, "Column" : 1, "Text" : "ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PNA CEFTRIAXONE 2GM STAT ER/UC", "DisplayText" : "Ceftriaxone 2 GM STAT ($) [M]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 26, "Column" : 1, "Text" : "ORDER OUTPATIENT PRESCRIPTIONS BELOW: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : ""},
{"Row" : 46, "Column" : 1, "Text" : "ORDER OUTPATIENT PRESCRIPTION BELOW: ", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [R,DI]", "Text" : "", "Mnemonic" : "28"},
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"}
]},
{"Name" : "ORZID GMENU ER/UC CELLULITIS", "DisplayText" : "ED Cellulitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID GMENU ER/UC MORE ABOUT CELLULITIS", "DisplayText" : "ED Approach to Cellulitis", "Text" : "More about cellulitis...", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "DisplayText" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE ER/UC", "DisplayText" : "Cefazolin 2 gm IV once STAT ($) [R]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "20"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin IV", "Mnemonic" : "22"},
{"Row" : 56, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG CIPRO 400MG METRO 500MG IV ONCE STAT", "DisplayText" : "VANCO 15MG/KG CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> Vancomycin 15 mg/kg IV", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL CELLULITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and"}, 
{"Row" :6, "Column" : 1, "Text" : "often associated with bacterial pathogens. The most common pathogens are group"}, 
{"Row" :7, "Column" : 1, "Text" : "A streptococci and Staphylococcus aureus. Group B streptococci are associated"}, 
{"Row" :8, "Column" : 1, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on"}, 
{"Row" :9, "Column" : 1, "Text" : "and legs of patients with athlete's foot (tinea pedis)."}, 
{"Row" : 11, "Column" : 1, "Text" : "Mild cases can be treated with oral antimicrobials. Moderate to severe cases"}, 
{"Row" : 12, "Column" : 1, "Text" : "should be treated initially with intravenous antimicrobials. Switch to oral"}, 
{"Row" : 13, "Column" : 1, "Text" : "drugs after clinical improvement."}, 
{"Row" : 15, "Column" : 1, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma, a"}, 
{"Row" : 16, "Column" : 1, "Text" : "history of MRSA infection, injection drug use, or infections not responding"}, 
{"Row" : 17, "Column" : 1, "Text" : "to first line beta-lactams."}, 
{"Row" : 21, "Column" : 1, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "if not improved in this time.", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Mild: Cellulitis without systemic signs of infection", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Empirical treatment for MILD cellulitis", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative for Penicillin Allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "MRSA Suspected Mild Cellulitis", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Moderate: Cellulitis with systemic signs of infection", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical treatment for MODERATE cellulitis", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Alternative for penicillin allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Severe: Cellulitis in patients with signs of deeper infections", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction)."}, 
{"Row" : 47, "Column" : 1, "Text" : "Patients may also qualify as severe if they are neutropenic, have a"}, 
{"Row" : 48, "Column" : 1, "Text" : "hematologic malignancy or congenital immunodeficiency, or are receiving"}, 
{"Row" : 49, "Column" : 1, "Text" : "immunosuppressant therapy. Consider whether surgical drainage is necessary."}, 
{"Row" : 51, "Column" : 1, "Text" : "Empirical treatment for SEVERE infection", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "15mg/kg once STAT ($) [R]"}, 
{"Row" : 55, "Column" : 1, "Text" : "Alternative for penicillin allergy or MRSA suspected: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "once STAT ($) [R] <AND> Metronidazole 500 mg IV once STAT ($) [DI,H]"}, 
{"Row" : 60, "Column" : 1, "Text" : "References: "}, 
{"Row" : 61, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 62, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg PO bid ($) [R]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"}
]},
{"Name" : "ORZID GMENU ER/UC CHOLANGITIS", "DisplayText" : "ED Cholangitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "DisplayText" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h once STAT [R,DI]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "DisplayText" : "LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [DI,O]", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CHOLANGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)"}, 
{"Row" :6, "Column" : 1, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure."}, 
{"Row" :7, "Column" : 1, "Text" : "The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and"}, 
{"Row" :8, "Column" : 1, "Text" : "Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as"}, 
{"Row" :9, "Column" : 1, "Text" : "part of a mixed infection."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "once STAT ($) [DI]"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 25, "Column" : 1, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,"}, 
{"Row" : 36, "Column" : 1, "Text" : "Cholangitis, Cholecystitis)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Gallbladder Infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date article: Acute cholangitis"}
]},
{"Name" : "ORZID GMENU ER/UC CHOLECYSTITIS", "DisplayText" : "ED Cholecystitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [DI]", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "DisplayText" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "DisplayText" : "LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "14"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "16"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Mnemonic" : "18"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin 15", "Mnemonic" : "20"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "Text" : "Meropenem 1 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once", "Mnemonic" : "22"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "CHOLECYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Adequate biliary drainage is the definitive treatment. Antimicrobials should be"}, 
{"Row" :6, "Column" : 1, "Text" : "prescribed only if signs of infection like leukocytosis or fever are present or"}, 
{"Row" :7, "Column" : 1, "Text" : "if the patient is elderly. Surgery and Gastroenterology involvement are"}, 
{"Row" :8, "Column" : 1, "Text" : "essential."}, 
{"Row" : 10, "Column" : 1, "Text" : "Most cases are associated with E. coli, Enterococcus, Klebsiella, and"}, 
{"Row" : 11, "Column" : 1, "Text" : "Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric"}, 
{"Row" : 12, "Column" : 1, "Text" : "anastomosis is present. For community-acquired acute cholecystitis, enterococcal"}, 
{"Row" : 13, "Column" : 1, "Text" : "coverage is not required because Enterococcus has not been shown to be"}, 
{"Row" : 14, "Column" : 1, "Text" : "pathogenic in these patients."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "If needed, antimicrobial therapy should be continued only until adequate"}, 
{"Row" : 18, "Column" : 1, "Text" : "drainage is established, then stopped."}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Community-acquired acute cholecystitis", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of mild to moderate infection and biliary-enteric anastomosis present", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "once STAT ($) [DI]"}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment of severe infection, advanced age or immunocompromised patient", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 43, "Column" : 1, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Health care-associated infection", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "mg/kg IV once STAT ($) [R]"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "STAT ($) [R]"}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 55, "Column" : 1, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 56, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "Refer to Inpatient Antimimicrobial CDSS"}, 
{"Row" : 64, "Column" : 1, "Text" : "References: "}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,"}, 
{"Row" : 67, "Column" : 1, "Text" : "Cholangitis, Cholecystitis)"}, 
{"Row" : 68, "Column" : 1, "Text" : "Sanford keyword: Gallbladder Infections, Acute Cholecystitis"}, 
{"Row" : 69, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 70, "Column" : 1, "Text" : "Up-to-Date article: Treatment of acute calculous cholecystitis"}
]},
{"Name" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,"}, 
{"Row" :6, "Column" : 1, "Text" : "including \"atypical\" pathogens.Specific therapy should be guided by culture"}, 
{"Row" :7, "Column" : 1, "Text" : "results."}, 
{"Row" :8, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how"}, 
{"Row" : 14, "Column" : 1, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be"}, 
{"Row" : 15, "Column" : 1, "Text" : "treated safely outside of the hospital."}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "DisplayText" : "CAP Pneumonia Severity Index (PSI) Calculator", "Text" : "", "Mnemonic" : "08"},
{"Row" : 23, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent"}, 
{"Row" : 28, "Column" : 1, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia."}, 
{"Row" : 30, "Column" : 1, "Text" : ">> Setting-specific treatment regimens <<"}, 
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)"}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP OUTPATIENT TREATED SETTING", "DisplayText" : "CAP treated in an outpatient setting (Outpatient)", "Text" : "", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk f"}, 
{"Row" : 16, "Column" : 1, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and"}, 
{"Row" : 17, "Column" : 1, "Text" : "should be used to augment clinical judgment. If social circumstances"}, 
{"Row" : 18, "Column" : 1, "Text" : "or cognitive dysfunction would interfere with success of outpatient"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment, the patient should be hospitalized."}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "DisplayText" : "CAP treated in an INPATIENT setting", "Text" : "CAP treated in an Inpatient setting - NON-SEVERE CAP", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING SEVERE CAP", "DisplayText" : "CAP treated in an INPATIENT setting -SEVERE CAP", "Text" : "CAP treated in an Inpatient setting - SEVERE CAP (ICU)", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Text" : "Note: Healthcare-associated pneumonia (HCAP) no longer used in 2019"}, 
{"Row" : 38, "Column" : 1, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA"}, 
{"Row" : 39, "Column" : 1, "Text" : "and/or P. aeruginosa are use to guide whether to start appropriate"}, 
{"Row" : 40, "Column" : 1, "Text" : "coverage empirically."}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Fine MJ, et al. N Engl J Med (1997) 336: 243-250"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"}
]},
{"Name" : "ORZID GMENU ER/UC COMP CYSTITIS", "DisplayText" : "ED Complicated Cystitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID GMENU ER/UC PYELONEPHRITIS", "DisplayText" : "ED Pyelonephritis", "Text" : "Pyelonephritis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture", "Text" : "Urine culture", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "DisplayText" : "Acute bacterial prostatitis (Outpatient)", "Text" : "Acute prostatitis", "Mnemonic" : "8"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "10a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12"},
{"Row" : 52, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days", "Mnemonic" : "14a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16"},
{"Row" : 57, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "18a"},
{"Row" : 58, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "20a"},
{"Row" : 61, "Column" : 1, "Item" : "PSHZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 63, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 7DAYS", "DisplayText" : "Cefdinir 300mg PO BID ($) [R] for 7 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "22a"},
{"Row" : 64, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 7DAYS", "DisplayText" : "Cefdinir 300 mg PO BID ($) [R] for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "24"},
{"Row" : 68, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "26a"},
{"Row" : 69, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "26b"},
{"Row" : 73, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "28"},
{"Row" : 80, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "", "Mnemonic" : "30"},
{"Row" : 82, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Mnemonic" : "32"},
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "30"},
{"Row" : 77, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM ONCE ER/UC", "DisplayText" : "Ertapenem 1 gm IV once STAT ($$) [R,DI]", "Text" : "Ertapenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "32"},
{"Row" : 89, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "38a"},
{"Row" : 90, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "38b"},
{"Row" : 92, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "40"},
{"Row" : 95, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "42"},
{"Row" : 96, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "44a"},
{"Row" : 98, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "46"},
{"Row" :107, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "48a"},
{"Row" :108, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "48b"},
{"Row" :110, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "", "Mnemonic" : "50"},
{"Row" :112, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Mnemonic" : "52"},
{"Row" :116, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG TID 7DAYS", "DisplayText" : "Amoxicillin 500 mg PO TID for 7 days ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R] for 7 days", "Mnemonic" : "54a"},
{"Row" :117, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 500MG TID 7DAYS", "DisplayText" : "Amoxicillin 500 mg PO TID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "54b"},
{"Row" :119, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV ONCE ER/UC", "DisplayText" : "Ampicillin 1-2 gm IV STAT ($$) [R]", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R]", "Mnemonic" : "56"},
{"Row" :122, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "58"},
{"Row" :123, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "60a"},
{"Row" :124, "Column" : 1, "Item" : "PSHZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "60b"},
{"Row" :126, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days", "Mnemonic" : "62a"},
{"Row" :128, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "64"},
{"Row" :130, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "66"},
{"Row" :3, "Column" : 1, "Text" : "COMPLICATED CYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Complicated cystitis is defined as symptomatic bladder inflammation and symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "due to a bacterial infection in people with certain conditions (see below)."}, 
{"Row" :7, "Column" : 1, "Text" : "Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated"}, 
{"Row" :8, "Column" : 1, "Text" : "cystitis is commonly associated with Enterobacteriaceae, but more resistant"}, 
{"Row" :9, "Column" : 1, "Text" : "pathogens occur, including the Gram-positive pathogens staphylococci and"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterococci."}, 
{"Row" : 12, "Column" : 1, "Text" : "Signs and symptoms that may indicate infection has extended beyond the bladder"}, 
{"Row" : 13, "Column" : 1, "Text" : "include fever/other signs of systemic infection, flank pain, costovertebral"}, 
{"Row" : 14, "Column" : 1, "Text" : "tenderness, and pelvic or perianal pain in men. Pyelonephritis should be"}, 
{"Row" : 15, "Column" : 1, "Text" : "considered in these patients: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Urine culture should be obtained before antimicrobials are given to guide"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment of complicated cystitis: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Prostatitis should be considered in men with recurrence of urinary tract"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection: "}, 
{"Row" : 26, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 27, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 28, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 30, "Column" : 1, "Text" : "Complicating conditions", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Cystitis is considered complicated when one or more of the following is present: "}, 
{"Row" : 32, "Column" : 1, "Text" : "o Pregnant women"}, 
{"Row" : 33, "Column" : 1, "Text" : "o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter"}, 
{"Row" : 34, "Column" : 1, "Text" : "or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)"}, 
{"Row" : 35, "Column" : 1, "Text" : "o Immunocompromise"}, 
{"Row" : 36, "Column" : 1, "Text" : "o Persistent infection, relapse, recurrence, or treatment failure"}, 
{"Row" : 37, "Column" : 1, "Text" : "o In some cases, men and patients admitted to health care settings may be"}, 
{"Row" : 38, "Column" : 1, "Text" : "considered complicated"}, 
{"Row" : 40, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Treat for 7 days. If patient is febrile, may extend duration up to 14 days total"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Mild to moderate disease", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 49, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 51, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 56, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 59, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 66, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 71, "Column" : 1, "Text" : "Severe disease or if patient cannot take oral therapy", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 79, "Column" : 1, "Text" : "High risk of Pseudomonas or Gram-negative MDR bacteria: "}, 
{"Row" : 81, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 75, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 83, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 88, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 91, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 94, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 97, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" :100, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" :101, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" :102, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" :103, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" :104, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" :106, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" :109, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :111, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :114, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" :115, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :118, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :121, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" :125, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :127, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" :129, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :131, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :134, "Column" : 1, "Text" : "References: "}, 
{"Row" :135, "Column" : 1, "Text" : "Drekonja et al., JAMA, 2021, 326(4)324-331"}, 
{"Row" :136, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :137, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :138, "Column" : 1, "Text" : "Sanford keyword: Cystitis"}, 
{"Row" :139, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" :140, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" :141, "Column" : 1, "Text" : "Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16"}, 
{"Row" :142, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated urinary tract infection (including"}, 
{"Row" :143, "Column" : 1, "Text" : "pyelonephritis) in adults"}, 
{"Row" :144, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :145, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :146, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}, 
{"Row" :147, "Column" : 1, "Text" : "Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5"}
]},
{"Name" : "ORZID GMENU ER/UC COVID-19 MPLS PHARMACOLOGIC GUIDELINES", "DisplayText" : "Outpatient COVID-19 Pharmacologic Treatment Guidelines" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "DisplayText" : "Minneapolis COVID-19 SharePoint Site", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Minneapolis On-Call Schedule - Infectious Disease", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 MONOCLONAL ANTIBODY SOP", "DisplayText" : "Monocolonal Antibody Allocation SOP", "Text" : "Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "DisplayText" : "Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19", "Text" : "Paxlovid (EUA)", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX MOLNUPIRAVIR EUA", "DisplayText" : "Molnupiravir for treatment of COVID-19", "Text" : "Molnupiravir (EUA)", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "OUTPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional Informati"}, 
{"Row" :8, "Column" : 1, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies an", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should b", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "discussed with the infectious diseases service. ***", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "OUTPATIENT TREATMENT OF COVID-19", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "If you have any questions on the selection of therapy, please contact Infectious"}, 
{"Row" : 20, "Column" : 1, "Text" : "Disease."}, 
{"Row" : 16, "Column" : 1, "Text" : "DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "ORAL COVID-19 ANTIVIRALS (Paxlovid or Molnupiravir): ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144"}, 
{"Row" : 33, "Column" : 1, "Text" : "Inpatient Pharmacy - Off-Tours: 31-3128"}, 
{"Row" : 35, "Column" : 1, "Text" : "*Please be ready to spend time on the phone with the pharmacist to complete EUA"}, 
{"Row" : 36, "Column" : 1, "Text" : "documentation, address medication questions and determine the best method of"}, 
{"Row" : 37, "Column" : 1, "Text" : "delivery."}, 
{"Row" : 25, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 30, "Column" : 1, "Text" : "Please contact Pharmacy to determine supply and availability."}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "DisplayText" : "COVID-19 Medication Interaction Check", "Text" : "Interaction checker for COVID-19 medications website link", "Mnemonic" : "14"}
]},
{"Name" : "ORZID GMENU ER/UC CUTANEOUS ABSCESS", "DisplayText" : "ED Cutaneous Abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] for 7 days", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO bid for 7 days ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CUTANEOUS ABSCESS"}, 
{"Row" :5, "Column" : 1, "Text" : "Incise and drain and cover the site with a dry dressing.For small abscesses,"}, 
{"Row" :6, "Column" : 1, "Text" : "systemic antimicrobial therapy is rarely necessary."}, 
{"Row" :8, "Column" : 1, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or"}, 
{"Row" :9, "Column" : 1, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases for assistance."}, 
{"Row" : 12, "Column" : 1, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration: Treat for 5 to 7 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mild to Moderate Cases: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Moderate or high suspicion of MRSA", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Low suspicion of MRSA", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "For SEVERE cases empiric coverage with MRSA agent", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "For Perirectal/Anorectal Abscess", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Refer to the inpatient or outpatient Soft Tissue Section of the Antimicrobial"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword:Skin infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 33, "Column" : 1, "Text" : "CDSS"}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"}
]},
{"Name" : "ORZID GMENU ER/UC DIVERTICULITIS", "DisplayText" : "ED Diverticulitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7 DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]<AND>", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX NV TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AN Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days", "Text" : "Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 7DS 500 BID METRO 7DS 1G BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Mnemonic" : "12a"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 7DS 500 BID METRO 7DS 1G BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-Tazobactam 3.375g IV once STAT ($$) [R]", "Mnemonic" : "14"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "DisplayText" : "CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once", "Mnemonic" : "16"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "DisplayText" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Mnemonic" : "18"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 500MG IV ONCE STAT", "DisplayText" : "CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Mnemonic" : "20"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]", "Mnemonic" : "22"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R]", "Mnemonic" : "24"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "DIVERTICULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in"}, 
{"Row" :6, "Column" : 1, "Text" : "the colon, causing pain and disturbed bowel function."}, 
{"Row" :8, "Column" : 1, "Text" : "Mild disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 14, "Column" : 1, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "BID ($) [DI] for 7 to 10 days"}, 
{"Row" : 24, "Column" : 1, "Text" : "Moderate disease", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "If symptoms fail to respond within 48 to 72 hours, consult General Surgery."}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "STAT ($) [DI]"}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative for beta lactam allergy"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "once STAT ($) [DI]"}, 
{"Row" : 37, "Column" : 1, "Text" : "Severe, life-threatening disease", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Consult General Surgery."}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 43, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 45, "Column" : 1, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 48, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Mandell chapter: Diverticulitis and Typhlitis"}, 
{"Row" : 51, "Column" : 1, "Text" : "Sanford keyword: Diverticulitis"}, 
{"Row" : 52, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management"}
]},
{"Name" : "ORZID GMENU ER/UC EMERGENCY DEPARTMENT MAIN MENU", "DisplayText" : "ED Emergency Department Main Menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "DisplayText" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Text" : "[click here]", "Mnemonic" : "20"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID GMENU ER/UC SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "ED Suspected Bacteremia, Blood Cultures Not Yet Positive", "Text" : "[click here]", "Mnemonic" : "22"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID GMENU ER/UC BRONCHITIS", "DisplayText" : "ED Bronchitis", "Text" : "[click here]", "Mnemonic" : "24"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "26"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "DisplayText" : "ED Appendicitis with Perforation", "Text" : "Appenditicitis with perforation", "Mnemonic" : "28"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS W/O PERFORATION", "DisplayText" : "ED Appendicitis Without Perforation", "Text" : "Appendicitis without perforation", "Mnemonic" : "30"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID GMENU ER/UC CHOLANGITIS", "DisplayText" : "ED Cholangitis", "Text" : "Cholangitis", "Mnemonic" : "32"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID GMENU ER/UC CHOLECYSTITIS", "DisplayText" : "ED Cholecystitis", "Text" : "Cholecystitis", "Mnemonic" : "34"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID GMENU ER/UC DIVERTICULITIS", "DisplayText" : "ED Diverticulitis", "Text" : "Diverticulitis", "Mnemonic" : "36"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID GMENU ER/UC SPON BACT PERITONITIS", "DisplayText" : "ED Spontaneous Bacterial Peritonitis", "Text" : "Spontaneous Bacterial Peritonitis", "Mnemonic" : "38"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "DisplayText" : "ANTIVIRAL TREATMENT OUTPATIENT", "Text" : "Antiviral treatment for influenza", "Mnemonic" : "40"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX LYME DISEASE", "DisplayText" : "Lyme Disease ER/UC", "Text" : "[click here]", "Mnemonic" : "42"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID GMENU ER/UC BACT MENING W/O GRM STAIN RES", "DisplayText" : "ED Bacterial Meningitis Without Gram Stain Results", "Text" : "[click here]", "Mnemonic" : "44"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID GMENU ER/UC IMMUNOCOM NEUT FEVER", "DisplayText" : "ED Neutropenic Fever", "Text" : "[click here]", "Mnemonic" : "46"},
{"Row" :3, "Column" : 1, "Text" : "EMERGENCY DEPARTMENT ANTIMICROBIAL CDSS MENU", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "This menu contains links to treatment recommendations"}, 
{"Row" :5, "Column" : 1, "Text" : "for the most common infections treated in the Emergency Dept."}, 
{"Row" :6, "Column" : 1, "Text" : "For infections not included in this menu, refer to full Outpatient or"}, 
{"Row" :7, "Column" : 1, "Text" : "Inpatient Antimicrobial CDSS for recommendations."}, 
{"Row" : 21, "Column" : 1, "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Bacteremia", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Bronchitis", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Conjunctivitis", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Gastrointestinal", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "For infections not listed, see GI"}, 
{"Row" : 35, "Column" : 1, "Text" : "section of the CDSS."}, 
{"Row" : 43, "Column" : 1, "Text" : "Influenza", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "For chemoprophylaxis see Lung and"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mediastiunum section of the CDSS, use"}, 
{"Row" : 46, "Column" : 1, "Text" : "ED order set for vaccination."}, 
{"Row" : 49, "Column" : 1, "Text" : "Lyme Disease", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Meningitis, Bacterial", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "For pathogen specific, nosocomial and"}, 
{"Row" : 54, "Column" : 1, "Text" : "trauma associated treatement see CNS"}, 
{"Row" : 55, "Column" : 1, "Text" : "section of the CDSS."}, 
{"Row" : 58, "Column" : 1, "Text" : "Neutropenic Fever", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "For infections in other"}, 
{"Row" : 60, "Column" : 1, "Text" : "immunocompromised conditions, see"}, 
{"Row" : 61, "Column" : 1, "Text" : "Immunocompromised Patients section of"}, 
{"Row" : 62, "Column" : 1, "Text" : "the CDSS."}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID GMENU ER/UC PHARYNGITIS", "DisplayText" : "ED Pharyngitis", "Text" : "[click here]", "Mnemonic" : "52"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID GMENU ER/UC ASPIRATION PNEUMONIA", "DisplayText" : "ED Aspiration Pneumonia", "Text" : "Aspiration", "Mnemonic" : "54"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community Acquired Pneumonia (CAP) (Updated Feb2020)", "Mnemonic" : "56"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "DisplayText" : "ED Nosocomial Pneumonia", "Text" : "Nosocomial", "Mnemonic" : "58"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Post-exposure Prophylaxis", "Text" : "[click here]", "Mnemonic" : "60"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID GMENU ER/UC SEPSIS AND SHOCK", "DisplayText" : "ED Sepis and Septic Shock", "Text" : "[click here]", "Mnemonic" : "62"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID GMENU ER/UC ACUTE SINUSITIS", "DisplayText" : "ED Acute Sinusitis", "Text" : "[click here]", "Mnemonic" : "66"},
{"Row" : 33, "Column" : 2, "Item" : "ORZID GMENU ER/UC BITE WOUNDS", "DisplayText" : "Bite Wounds ER/UC", "Text" : "Bite wounds", "Mnemonic" : "68"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID GMENU ER/UC CELLULITIS", "DisplayText" : "ED Cellulitis", "Text" : "Cellulitis", "Mnemonic" : "70"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID GMENU ER/UC CUTANEOUS ABSCESS", "DisplayText" : "ED Cutaneous Abscess", "Text" : "Cutaneous abcesses", "Mnemonic" : "72"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "DisplayText" : "ED Foot Ulcer With DM", "Text" : "Diabetic foot ulcer", "Mnemonic" : "74"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "DisplayText" : "ED Furuncles and Carbuncles", "Text" : "Furuncles and cabuncles", "Mnemonic" : "76"},
{"Row" : 44, "Column" : 2, "Item" : "ORZID GMENU ER/UC SUPP ODONTOGENIC INFECT", "DisplayText" : "ED Suppurative Odontogenic Infections", "Text" : "[click here]", "Mnemonic" : "78"},
{"Row" : 51, "Column" : 2, "Item" : "ORZID GMENU ER/UC COMP CYSTITIS", "DisplayText" : "ED Complicated Cystitis", "Text" : "Cystitis, complicated", "Mnemonic" : "80"},
{"Row" : 52, "Column" : 2, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient)", "Text" : "Cystitis, uncomplicated", "Mnemonic" : "82"},
{"Row" : 54, "Column" : 2, "Item" : "ORZID GMENU ER/UC PYELONEPHRITIS", "DisplayText" : "ED Pyelonephritis", "Text" : "Pyelonephritis", "Mnemonic" : "84"},
{"Row" :9, "Column" : 2, "Text" : "Pharyngitis", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Pneumonia", "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Text" : "Rabies Post-Exposure Prophylaxis", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Sepsis and Septic Shock", "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Text" : "Sinusitis, Acute", "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Text" : "For chronic, fungal and nosocomial"}, 
{"Row" : 25, "Column" : 2, "Text" : "sinusitis, see Head and Neck section"}, 
{"Row" : 26, "Column" : 2, "Text" : "of CDSS"}, 
{"Row" : 29, "Column" : 2, "Text" : "Skin and Soft Tissue Infections", "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Text" : "For infections not listed, see Skin"}, 
{"Row" : 31, "Column" : 2, "Text" : "and Soft Tissue Infection sections of"}, 
{"Row" : 32, "Column" : 2, "Text" : "CDSS. See above for rabies exposure."}, 
{"Row" : 40, "Column" : 2, "Text" : "Tooth Abcess and Other Suppurative", "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Text" : "Odontogenic Infections", "Header" : 1}, 
{"Row" : 42, "Column" : 2, "Text" : "For other oral infections see Head"}, 
{"Row" : 43, "Column" : 2, "Text" : "and Neck section of CDSS"}, 
{"Row" : 46, "Column" : 2, "Text" : "Urogenital", "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Text" : "For urogenital infections not"}, 
{"Row" : 48, "Column" : 2, "Text" : "listed, see Genitourinary section of"}, 
{"Row" : 49, "Column" : 2, "Text" : "CDSS"}, 
{"Row" : 13, "Column" : 1, "Text" : "CDSS-MicroGuide Web and Mobile App", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "DisplayText" : "MicroGuide Mobile App Instructions", "Text" : "[click here]", "Mnemonic" : "8"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "[CLICK HERE]", "Mnemonic" : "50"},
{"Row" :6, "Column" : 2, "Text" : "Help Page", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Text version", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Text" : "Beta-lactam Allergy Assessment *Updated", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "PDF version *Preferred", "Mnemonic" : "4"},
{"Row" : 55, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually transmitted infections", "Mnemonic" : "85"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 INFORMATION", "DisplayText" : "COVID-19 INFORMATION", "Text" : "Minneapolis VAHCS SharePoint Site", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Text" : "COVID-19", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC COVID-19 MPLS PHARMACOLOGIC GUIDELINES", "DisplayText" : "Outpatient COVID-19 Pharmacologic Treatment Guidelines", "Text" : "Outpatient COVID-19 Antimicrobial Treatment Guidelines", "Mnemonic" : "12"},
{"Row" : 70, "Column" : 1, "Item" : "PSCZID TEST2 CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Test CEFTRIAXONE 2GM IV ONCE ER/UC clinic infusion order", "Mnemonic" : "999"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINE", "DisplayText" : "Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines", "Text" : "Inpatient COVID-19 Antimicrobial Treatment Guidelines", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 2, "Item" : "ORZID3 GMENU ABX BALANITIS", "DisplayText" : "Balanitis and Balanoposthitis", "Text" : "Balanitis and balanoposthitis", "Mnemonic" : "79"},
{"Row" : 53, "Column" : 2, "Item" : "ORZID GMENU ER/UC EPIDIDYMITIS", "DisplayText" : "Epididymitis", "Text" : "Epididymitis", "Mnemonic" : "83"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID GMENU ER/UC NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing Infections", "Text" : "Necrotizing infections", "Mnemonic" : "77"}
]},
{"Name" : "ORZID GMENU ER/UC EMP INTRAV W/ VANCO", "DisplayText" : "ED Neutropenic Fever IV Treatment with Vancomycin " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Vancomycin 15 mg/kg IV once STAT($) [R] <AND> cefepime 2 gm IV once STAT", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM GENT 5MG/KG VANCO 15MG/KG ONCE STAT", "DisplayText" : "PIP/TAZ 4.5GM GENT 5MG/KG VANCO 15MG/KG ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($)", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "DisplayText" : "AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN"}, 
{"Row" :5, "Column" : 1, "Text" : "Discontinue vancomycin after 3 days unless culture results indicate that"}, 
{"Row" :6, "Column" : 1, "Text" : "continued therapy is needed.Gentamicin is optional.Contact Hematology-"}, 
{"Row" :7, "Column" : 1, "Text" : "Oncology or Infectious Diseases for advice."}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "($$) [R]"}, 
{"Row" : 16, "Column" : 1, "Text" : "mg/kg IV once STAT ($) [R] < OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "5 mg/kg IV once STAT ($) [R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "[R] < OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 31, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 32, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID GMENU ER/UC EMP INTRAV W/O VANCO", "DisplayText" : "ED Neutropenic Fever IV Therapy Without Vancomycin" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] < OR >", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] < OR >", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM IV GENT 5MG/KG IV STAT", "DisplayText" : "PIP/TAZO 4.5GM GENT 5MG/KG IV STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "DisplayText" : "AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN"}, 
{"Row" :5, "Column" : 1, "Text" : "Gentamicin is optional.Contact Hematology-Oncology or Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "advice."}, 
{"Row" : 13, "Column" : 1, "Text" : "mg/kg IV once STAT ($) [R]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Vancomycin must be added to aztreonam for coverage of Gram-positive organisms."}, 
{"Row" : 18, "Column" : 1, "Text" : "[R] < OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730"}, 
{"Row" : 27, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-Date"}
]},
{"Name" : "ORZID GMENU ER/UC EPIDIDYMITIS", "DisplayText" : "Epididymitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY 10DAYS", "DisplayText" : "CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Mnemonic" : "6a"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY 10DAYS", "DisplayText" : "CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "8a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 53, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) for 10 days", "Mnemonic" : "10"},
{"Row" : 56, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "12"},
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "14a"},
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 64, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 DOXYC 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "16a"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 DOXYC 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 69, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRI 1GM IM X1 + DOXY 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "18a"},
{"Row" : 71, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTRI 1GM IM X1 + DOXY 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "20"},
{"Row" : 75, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($)[R,DI]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "22a"},
{"Row" : 76, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" : 78, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV ONCE ER/UC", "DisplayText" : "Levofloxacin 500 mg IV once STAT ($)", "Text" : "Levofloxacin 500 mg IV once STAT ($)", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Epididymitis is inflammation of the epididymis and when testicles are involved"}, 
{"Row" :6, "Column" : 1, "Text" : "is referred to as epididymo-orchitis. Acute epididymitis is the most common"}, 
{"Row" :7, "Column" : 1, "Text" : "cause of scrotal pain in adults. Other features include scrotal erythema and"}, 
{"Row" :8, "Column" : 1, "Text" : "edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually"}, 
{"Row" :9, "Column" : 1, "Text" : "unilateral. It is primarily caused by infection but can also result from trauma"}, 
{"Row" : 10, "Column" : 1, "Text" : "and autoimmune diseases. Testicular torsion should be ruled out before"}, 
{"Row" : 11, "Column" : 1, "Text" : "treatment. Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 12, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 13, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 are associated"}, 
{"Row" : 14, "Column" : 1, "Text" : "with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if"}, 
{"Row" : 15, "Column" : 1, "Text" : "the patient has been in the hospital for more than 48 hours or received a course"}, 
{"Row" : 16, "Column" : 1, "Text" : "of antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 17, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 19, "Column" : 1, "Text" : "A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be performed in all cases of suspected epididymitis before starting"}, 
{"Row" : 21, "Column" : 1, "Text" : "treatment to guide therapy: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 25, "Column" : 1, "Text" : "treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve"}, 
{"Row" : 29, "Column" : 1, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal"}, 
{"Row" : 30, "Column" : 1, "Text" : "pain and referral to a urologist should be considered."}, 
{"Row" : 32, "Column" : 1, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older men"}, 
{"Row" : 33, "Column" : 1, "Text" : "should have their residual urinary volume checked. If the residual volume is"}, 
{"Row" : 34, "Column" : 1, "Text" : "elevated, the patient should be seen by a urologist as epididymitis is unlikely"}, 
{"Row" : 35, "Column" : 1, "Text" : "to respond if the prostate is blocking the vas deferens."}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical treatment in men who practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "for 10 days ($) [R, DI]"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Empirical treatment in men who do not practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Age >/= 35 years or", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "biopsy, vasectomy): ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 52, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 55, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 57, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 61, "Column" : 1, "Text" : "Age < 35 years", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 63, "Column" : 1, "Text" : "Patient weighing less than 300 lbs"}, 
{"Row" : 65, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 68, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater"}, 
{"Row" : 70, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 73, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 77, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 79, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Text" : "References: "}, 
{"Row" : 83, "Column" : 1, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 84, "Column" : 1, "Text" : "Sanford keyword: Epididymo-orchitis"}, 
{"Row" : 85, "Column" : 1, "Text" : "Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3"}, 
{"Row" : 86, "Column" : 1, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults"}, 
{"Row" : 87, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID GMENU ER/UC FOOT ULCER W/ INFECT SURR TISSUES", "DisplayText" : "ED Foot Ulcer With Infected Surrounding Tissues " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "DisplayText" : "Approach to foot ulcers with infection", "Text" : "Approach to foot ulcers with infection", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Mnemonic" : "14a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM IV VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFTR 2GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV STAT ($) [M] < AND > Vancomycin 15mg/kg IV STAT ($) [R]", "Mnemonic" : "22"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL/SULBACT 3GM VANCO 15MG/KG STAT", "DisplayText" : "AMPICIL/SULBACT 3GM VANCO 15MG/KG STAT", "Text" : "Ampicillin-sulbactam 3 gm IV STAT ($) [R] <AND> Vancomycin 15 mg/kg IV", "Mnemonic" : "24"},
{"Row" : 67, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> vancomycin 15mg/kg", "Mnemonic" : "28"},
{"Row" : 70, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV STAT", "DisplayText" : "CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV STAT", "Text" : "Ceftazidime 2 gm IV STAT ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)", "Mnemonic" : "30"},
{"Row" : 73, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV STAT ($$$$) [R] <AND> metronidazole 500 mg IV STAT ($) [DI]", "Mnemonic" : "32"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES"}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation."}, 
{"Row" :9, "Column" : 1, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved."}, 
{"Row" : 10, "Column" : 1, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe."}, 
{"Row" : 11, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Mild: ulcer with superficial inflammation", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks"}, 
{"Row" : 18, "Column" : 1, "Text" : "Oral therapy, no MRSA coverage: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Oral therapy, MRSA coverage: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Moderate: Ulcer with inflammation, extension into fascia", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks"}, 
{"Row" : 38, "Column" : 1, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen"}, 
{"Row" : 39, "Column" : 1, "Text" : "is reasonable following clinical improvement."}, 
{"Row" : 41, "Column" : 1, "Text" : "Oral therapy with MRSA coverage: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "STAT ($) [R,DI]"}, 
{"Row" : 57, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Severe: Extensive local inflammation plus systemic toxicity", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Intravenous regimens for SEVERE (limb-threatening) infections", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Duration: treat to resolution of symptoms usually 2-4 weeks"}, 
{"Row" : 64, "Column" : 1, "Text" : "A switch to an oral regimen is reasonable following clinical improvement."}, 
{"Row" : 68, "Column" : 1, "Text" : "IV STAT ($) [R]"}, 
{"Row" : 71, "Column" : 1, "Text" : "[R] <AND> metronidazole 500 mg IV STAT ($) [DI]"}, 
{"Row" : 74, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV STAT ($) [R]"}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 78, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 66, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 72, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial"}, 
{"Row" : 37, "Column" : 1, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data."}, 
{"Row" : 63, "Column" : 1, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data."}, 
{"Row" : 62, "Column" : 1, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial"}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 14DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>", "Mnemonic" : "18a"},
{"Row" : 44, "Column" : 1, "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]"}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID + TRIMETH SULF BID 14DAYS", "DisplayText" : "Amoxicillin-clav 875/125 bid x14days +Trimeth-sulfa bid 14days", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX CLAV 875 + DOXY 14DAYS", "DisplayText" : "Amoxicillin-clavulanate 875 mg po BID ($) [R] <AND> Doxycycline", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline", "Mnemonic" : "20a"},
{"Row" : 48, "Column" : 1, "Text" : "100 mg PO BID for 14 days ($) [DI]"}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID 14D+DOXY 100MG BID 14D", "DisplayText" : "Amoxicillin-clavulanate 875/125mg bid x14days + Doxycycline 100mg bid x14days", "Text" : "Non-VA order for above"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"}
]},
{"Name" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "DisplayText" : "ED Foot Ulcer With DM " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITHOUT infection of surrounding tissues", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC FOOT ULCER W/ INFECT SURR TISSUES", "DisplayText" : "ED Foot Ulcer With Infected Surrounding Tissues", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobials should not be used to treat colonization."}, 
{"Row" :8, "Column" : 1, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local"}, 
{"Row" :9, "Column" : 1, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain"}, 
{"Row" : 10, "Column" : 1, "Text" : "may not be present in patients with neuropathy. In patients with substantial"}, 
{"Row" : 11, "Column" : 1, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues"}, 
{"Row" : 12, "Column" : 1, "Text" : "will be dusky, mottled, or cool. Capillary refill may be impaired. Patiets"}, 
{"Row" : 13, "Column" : 1, "Text" : "with diabetes and ulcers are at risk for gangrenous infections. If there is any"}, 
{"Row" : 14, "Column" : 1, "Text" : "suggestion of gangrene, consult surgery immediately."}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 23, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}
]},
{"Name" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "DisplayText" : "ED Furuncles and Carbuncles " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Mnemonic" : "4"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Mnemonic" : "16a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "18a"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "FURUNCLES AND CARBUNCLES"}, 
{"Row" :5, "Column" : 1, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous"}, 
{"Row" :6, "Column" : 1, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a"}, 
{"Row" :7, "Column" : 1, "Text" : "inflamed nodule that usually develops as a complication of folliculitis. A"}, 
{"Row" :8, "Column" : 1, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous"}, 
{"Row" :9, "Column" : 1, "Text" : "tissue.Contact a wound care nurse for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous"}, 
{"Row" : 12, "Column" : 1, "Text" : "abscesses, and large furuncles."}, 
{"Row" : 14, "Column" : 1, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct"}, 
{"Row" : 15, "Column" : 1, "Text" : "to incision and drainage should be made based on the presence of systemic"}, 
{"Row" : 16, "Column" : 1, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired"}, 
{"Row" : 17, "Column" : 1, "Text" : "host defenses."}, 
{"Row" : 19, "Column" : 1, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "recommended consider a decolonization regimen.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Mild infection: Purulent infection without systemic signs of infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Recommend incision and drainage. No antibiotic indicated."}, 
{"Row" : 26, "Column" : 1, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Recommend incision and drainage. Culture material and use results to guide"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 29, "Column" : 1, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time."}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Alternatives", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Severe Infections: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Patients who have failed incision and drainage along with oral antibiotics"}, 
{"Row" : 51, "Column" : 1, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished"}, 
{"Row" : 52, "Column" : 1, "Text" : "neutrophil function."}, 
{"Row" : 53, "Column" : 1, "Text" : "Recommend incision and drainage. Culture material and use results to guide"}, 
{"Row" : 54, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 55, "Column" : 1, "Text" : "Treat for 5 days. Reevaluate patient and extend or modify treatment if not"}, 
{"Row" : 56, "Column" : 1, "Text" : "improved in this time."}, 
{"Row" : 60, "Column" : 1, "Text" : "References: "}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 62, "Column" : 1, "Text" : "Sanford keyword: Furuncle, carbuncle"}, 
{"Row" : 63, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 64, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg PO bid ($) [R]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"}
]},
{"Name" : "ORZID GMENU ER/UC IMMUNOCOM NEUT FEVER", "DisplayText" : "ED Neutropenic Fever" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "DisplayText" : "Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient)", "Text" : "If patient IS a candidate for oral therapy", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "ED Neutropenic Fever, Not a Candidate for Oral Therapy", "Text" : "If patient is NOT a candidate for oral therapy", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute"}, 
{"Row" :6, "Column" : 1, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500"}, 
{"Row" :7, "Column" : 1, "Text" : "cells/microliter. The risk increases dramatically when the ANC is <100"}, 
{"Row" :8, "Column" : 1, "Text" : "cells/microliter. Because of these risks, patients with fever and neutropenia"}, 
{"Row" :9, "Column" : 1, "Text" : "to this degree should receive empirical antimicrobial therapy immediately."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000"}, 
{"Row" : 11, "Column" : 1, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter"}, 
{"Row" : 12, "Column" : 1, "Text" : "within the next 48 hours. For this purpose, fever is defined as a single"}, 
{"Row" : 13, "Column" : 1, "Text" : "temperature greater than 38.3 degrees Celsius."}, 
{"Row" : 15, "Column" : 1, "Text" : "Initial therapy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined"}, 
{"Row" : 18, "Column" : 1, "Text" : "above. Vancomycin should only be given when there are clear indications for its"}, 
{"Row" : 19, "Column" : 1, "Text" : "use."}, 
{"Row" : 21, "Column" : 1, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who"}, 
{"Row" : 22, "Column" : 1, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of"}, 
{"Row" : 23, "Column" : 1, "Text" : "severe disease, like hypotension. Outpatient antimicrobials for neutropenic"}, 
{"Row" : 24, "Column" : 1, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Modification to therapy", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Refer to the Systemic Infections section of the Antimicrobial CDSS"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 39, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sipsas NV Cancer 2005, 103: 1103"}
]},
{"Name" : "ORZID GMENU ER/UC LYME ACUTE NEURO DISEASE", "DisplayText" : "Lyme Acute Neurological Disease ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more"}, 
{"Row" :6, "Column" : 1, "Text" : "extensive neurological disease with intravenous antimicrobials."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 13, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for 14 to 21 days"}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment of neurological disease other than Bell palsy", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 14 to 28 days."}, 
{"Row" : 23, "Column" : 1, "Text" : "References"}, 
{"Row" : 25, "Column" : 1, "Text" : "Halperin et. al., Neurology (2007) 69.91-102"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 28, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID GMENU ER/UC LYME CARDIAC DISEASE", "DisplayText" : "Lyme Caridac Disease ER/UC" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" :9, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment of first degree or second degree heart block", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment of third degree heart block or other manifestation", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References"}, 
{"Row" : 21, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 23, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID GMENU ER/UC LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis ER/UC" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "DisplayText" : "IXODES IDENTIFACTION LINK", "Text" : "Ixodes scapularis identification", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX TICKBORNE RISK MAP", "DisplayText" : "TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "PSCZID DOXYCYCLINE 200MG STAT", "DisplayText" : "Doxycycline PO 200 mg STAT ($) (DI)", "Text" : "Doxycycline PO 200mg once STAT ($) [DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-"}, 
{"Row" :6, "Column" : 1, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis"}, 
{"Row" :7, "Column" : 1, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%"}, 
{"Row" :8, "Column" : 1, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease."}, 
{"Row" :9, "Column" : 1, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease"}, 
{"Row" : 10, "Column" : 1, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes"}, 
{"Row" : 11, "Column" : 1, "Text" : "scapularis tick."}, 
{"Row" : 13, "Column" : 1, "Text" : "All following criteria must be met to be considered for prophylactic treatment: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)"}, 
{"Row" : 15, "Column" : 1, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes"}, 
{"Row" : 16, "Column" : 1, "Text" : "scalpularis. Follow link below for identification guide: "}, 
{"Row" : 18, "Column" : 1, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of"}, 
{"Row" : 19, "Column" : 1, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area."}, 
{"Row" : 20, "Column" : 1, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed."}, 
{"Row" : 21, "Column" : 1, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes"}, 
{"Row" : 22, "Column" : 1, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota"}, 
{"Row" : 23, "Column" : 1, "Text" : "counties where there is high risk of tickborne disease are shown in the"}, 
{"Row" : 24, "Column" : 1, "Text" : "following link: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the"}, 
{"Row" : 27, "Column" : 1, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B."}, 
{"Row" : 28, "Column" : 1, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed."}, 
{"Row" : 29, "Column" : 1, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick"}, 
{"Row" : 30, "Column" : 1, "Text" : "bite in New England or Mid-Atlantic States."}, 
{"Row" : 32, "Column" : 1, "Text" : "Prophylactic treatment if all above criteria are met", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}, 
{"Row" : 39, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 40, "Column" : 1, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)"}, 
{"Row" : 41, "Column" : 1, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html"}, 
{"Row" : 42, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)"}, 
{"Row" : 43, "Column" : 1, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf"}, 
{"Row" : 44, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)"}, 
{"Row" : 45, "Column" : 1, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf"}
]},
{"Name" : "ORZID GMENU ER/UC MORE ABOUT CELLULITIS", "DisplayText" : "ED Approach to Cellulitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "DisplayText" : "ED Foot Ulcer With DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "THE APPROACH TO CELLULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments"}, 
{"Row" :6, "Column" : 1, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the"}, 
{"Row" :7, "Column" : 1, "Text" : "affected limb reduces swelling. Heat reduces discomfort."}, 
{"Row" :9, "Column" : 1, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry. In patients with"}, 
{"Row" : 10, "Column" : 1, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence"}, 
{"Row" : 11, "Column" : 1, "Text" : "of recurrent infection."}, 
{"Row" : 13, "Column" : 1, "Text" : "In many cases of cellulitis, the affected area is usually not well-"}, 
{"Row" : 14, "Column" : 1, "Text" : "differentiated from unaffected areas of the skin. Erysipelas is a special case"}, 
{"Row" : 15, "Column" : 1, "Text" : "with typically a well-defined border and raised, orange-peel appearance."}, 
{"Row" : 17, "Column" : 1, "Text" : "For treatment of erysipelas refer to the Soft Tissue Section of the inpatient or"}, 
{"Row" : 18, "Column" : 1, "Text" : "outpatient Antimicrobial CDSS."}, 
{"Row" : 20, "Column" : 1, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with"}, 
{"Row" : 21, "Column" : 1, "Text" : "advanced diabetes."}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Cellulitis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID GMENU ER/UC NECROT INFECT DIRECT THERAPY", "DisplayText" : "Necrotizing Infections, Direct Therapy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV CLINDA 900MG IV ONCE STAT", "DisplayText" : "PENICI 4MU IV CLINDA 900MG IV ONCE STAT", "Text" : "Penicillin 4 million units IV STAT ($) [R] <AND> clindamycin 900 mg", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900 MG IV ONCE ER/UC", "DisplayText" : "Clindamycin 900 MG IV ONCE", "Text" : "Clindamycin 900 mg IV STAT ($$) [H,O]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin 4 million units IV STAT ($) [R] <AND> clindamycin 900 mg", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900 MG IV ONCE ER/UC", "DisplayText" : "Clindamycin 900 MG IV ONCE", "Text" : "Clindamycin 900 mg IV STAT ($$) [H,O]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV STAT", "DisplayText" : "PIP/TAZ 3.375GM CLINDA 900MG VANCO 15MG/KG ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> clindamycin 900 mg", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANC 15MG/KG ONCE STAT", "DisplayText" : "CEFTR 2GM IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV STAT ($) [M] <AND> clindamycin 900 mg IV STAT", "Mnemonic" : "16"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "Text" : "Meropenem 1 gm IV STAT ($$) [R] <AND> vancomycin 15 mg/kg IV STAT ($) [R]", "Mnemonic" : "18"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CIPROFLOXACIN 400MG CLINDA 900MG VANCOMYCIN 15MG/KG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV STAT ($) [R,DI] <AND> clindamycin 900 mg IV", "Mnemonic" : "20"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT", "Text" : "Gentamicin 5 mg/kg IV STAT ($) [R,O] <AND> clindamycin 900 mg IV STAT", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "NECROTIZING INFECTIONS--PATHOGEN-DIRECTED THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Clostridial infections", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "IV STAT ($$) [H,O]"}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "_______________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Group A Streptococcal infections (S. pyogenes)", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "_______________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "IV STAT ($$) [H,O]"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "______________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Polymicrobial infections", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "______________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "These are more common in injection drug users, or in patients who have had"}, 
{"Row" : 33, "Column" : 1, "Text" : "recent abdominal surgery or trauma, vulvo-vaginal infection, or genital or"}, 
{"Row" : 34, "Column" : 1, "Text" : "rectal abscess."}, 
{"Row" : 36, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "IV STAT ($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]"}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R] < OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 45, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "STAT ($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]"}, 
{"Row" : 48, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]"}, 
{"Row" : 51, "Column" : 1, "Text" : "_________________________________________________________________________", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 57, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 58, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 59, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID GMENU ER/UC NECROT INFECT EMP THERAPY", "DisplayText" : "Necrotizing Infections, Empiric Therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV STAT", "DisplayText" : "PIP/TAZ 3.375GM CLINDA 900MG VANCO 15MG/KG ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> clindamycin 900 mg", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANC 15MG/KG ONCE STAT", "DisplayText" : "CEFTR 2GM IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV STAT ($) [M] <AND> clindamycin 900 mg IV STAT ($$)", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "Text" : "Meropenem 1gm IV STAT ($$) <AND> vancomycin 15 mg/kg IV STAT ($) [R]", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CIPROFLOXACIN 400MG CLINDA 900MG VANCOMYCIN 15MG/KG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV STAT ($) [R,DI] <AND> clindamycin 900 mg IV", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT", "Text" : "Gentamicin 5 mg/kg IV STAT ($) [R,O] <AND> clindamycin 900 mg IV STAT", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL THERAPY FOR NECROTIZING INFECTIONS"}, 
{"Row" :5, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "IV STAT ($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]"}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 10, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]"}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "STAT ($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 26, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 27, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID GMENU ER/UC NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing Infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID GMENU ER/UC NECROT INFECT EMP THERAPY", "DisplayText" : "Necrotizing Infections, Empiric Therapy", "Text" : "Empirical therapy of necrotizing infections", "Mnemonic" : "4"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID GMENU ER/UC NECROT INFECT DIRECT THERAPY", "DisplayText" : "Necrotizing Infections, Direct Therapy", "Text" : "Pathogen-directed therapy of necrotizing infections", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "NECROTIZING INFECTIONS"}, 
{"Row" :5, "Column" : 1, "Text" : "Call Surgery immediately and consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Necrotizing infections involve tissues skin and/or deeper structures, including"}, 
{"Row" :8, "Column" : 1, "Text" : "fascia and muscle.These infections destroy tissue, often rapidly, and are"}, 
{"Row" :9, "Column" : 1, "Text" : "often fatal if not treated promptly and appropriately.Necrotizing infections"}, 
{"Row" : 10, "Column" : 1, "Text" : "usually result from trauma, surgery, and/or ischemia.These infections can be"}, 
{"Row" : 11, "Column" : 1, "Text" : "monomicrobial (e.g., with streptococci or clostridia) or polymicrobial (usually"}, 
{"Row" : 12, "Column" : 1, "Text" : "with a mixture of aerobes and anaerobes).Fournier gangrene is usually"}, 
{"Row" : 13, "Column" : 1, "Text" : "associated with mixed infection.Myonecrosis is most commonly associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Clostridium species."}, 
{"Row" : 16, "Column" : 1, "Text" : "Necrotizing infections differ from cellulitis in several ways.Necrotic"}, 
{"Row" : 17, "Column" : 1, "Text" : "infections typically have one or more of the following: (1) severe, constant"}, 
{"Row" : 18, "Column" : 1, "Text" : "pain, (2) bullae, (3) bruising or necrosis of overlying skin, (4) gas in tissues"}, 
{"Row" : 19, "Column" : 1, "Text" : "which can be felt or seen on images, (5) edema that extends beyond areas of"}, 
{"Row" : 20, "Column" : 1, "Text" : "erythema, (6) local anesthesia, and (7) signs of systemic toxicity, such as"}, 
{"Row" : 21, "Column" : 1, "Text" : "fever, leukocytosis, delirium, or renal failure."}, 
{"Row" : 23, "Column" : 1, "Text" : "Necrotizing infections must be treated with both antimicrobial therapy and"}, 
{"Row" : 24, "Column" : 1, "Text" : "surgical procedures (excision and/or drainage).Call surgery to see the patient"}, 
{"Row" : 25, "Column" : 1, "Text" : "immediately in all cases.Obtain tissue and blood cultures and begin empirical"}, 
{"Row" : 26, "Column" : 1, "Text" : "antimicrobials.For several necrotic diseases and/or pathogens, a combination"}, 
{"Row" : 27, "Column" : 1, "Text" : "of two antimicrobials is recommended including a bactericidal antimicrobial"}, 
{"Row" : 28, "Column" : 1, "Text" : "active at the cell wall or membrane (e.g., beta-lactam or glycopeptide) and an"}, 
{"Row" : 29, "Column" : 1, "Text" : "antimicrobial that rapidly inhibits protein synthesis and thus inhibits toxin"}, 
{"Row" : 30, "Column" : 1, "Text" : "production, typically clindamycin."}, 
{"Row" : 31, "Column" : 1, "Text" : "Repeat debridement should be performed daily until no further debridement is"}, 
{"Row" : 32, "Column" : 1, "Text" : "necessary. Antibiotic therapy should be tailored as soon as culture results"}, 
{"Row" : 33, "Column" : 1, "Text" : "become available."}, 
{"Row" : 35, "Column" : 1, "Text" : "Administer antibiotics until further debridement is no longer necessary, the"}, 
{"Row" : 36, "Column" : 1, "Text" : "patient has improved clinically, and fever has been absent for 48-72 hours."}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical antimicrobials", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Pathogen-directed treatment regimens", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "_________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 49, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 50, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "ED Neutropenic Fever, Not a Candidate for Oral Therapy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID GMENU ER/UC EMP INTRAV W/O VANCO", "DisplayText" : "ED Neutropenic Fever IV Therapy Without Vancomycin", "Text" : "Empirical intravenous regimens WITHOUT vancomycin", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID GMENU ER/UC EMP INTRAV W/ VANCO", "DisplayText" : "ED Neutropenic Fever IV Treatment with Vancomycin", "Text" : "Empirical intravenous regimens WITH vancomycin", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Vancomycin is not recommended as a standard part of the initial antibiotic"}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 21, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sipsas NV Cancer 2005, 103: 1103"}, 
{"Row" :6, "Column" : 1, "Text" : "regimen.Consider adding Vancomycin for specific clinical indications: "}, 
{"Row" : 11, "Column" : 1, "Text" : ">>Hemodynamic instability"}, 
{"Row" : 10, "Column" : 1, "Text" : ">>Pneumonia,"}, 
{"Row" :9, "Column" : 1, "Text" : ">>Skin or soft-tissue infection,"}, 
{"Row" :8, "Column" : 1, "Text" : ">>Suspected catheter-related infection,"}
]},
{"Name" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "DisplayText" : "ED Nosocomial Pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "DisplayText" : "More about Nosocomial pneumonia...", "Text" : "More about Nosocomial pneumonia...", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID GMENU ER/UC PNEUMONIA HAP NEW", "DisplayText" : "ED Hospital Acquired Pneumonia", "Text" : "HOSPITAL ACQUIRED PNEUMONIA (HAP)", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" : 11, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" : 14, "Column" : 1, "Text" : "VENTILATOR ASSOCIATED PNEUMONIA (VAP) - Refer to Lung and Mediastinum section of"}, 
{"Row" : 15, "Column" : 1, "Text" : "the inpatient or outpatient Antimicrobial CDSS for recommendations"}, 
{"Row" : 17, "Column" : 1, "Text" : "Empirical therapy must be re-evaluated at 72 hours.", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Duration of Therapy: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 22, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 23, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 24, "Column" : 1, "Text" : "culture and susceptibility tests."}, 
{"Row" : 26, "Column" : 1, "Text" : "Pathogen-specific treatment", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Certain respiratory pathogens that are usually treated in unique ways are listed"}, 
{"Row" : 29, "Column" : 1, "Text" : "here. Other respiratory pathogens are treated with drugs effective for"}, 
{"Row" : 30, "Column" : 1, "Text" : "pneumonia and active against identified organisms."}, 
{"Row" : 31, "Column" : 1, "Text" : "Recommended duration of therapy for more resistant pathogens"}, 
{"Row" : 32, "Column" : 1, "Text" : "(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment."}, 
{"Row" : 33, "Column" : 1, "Text" : "Refer to pathogen-specific treatment regimen below for recommendation."}, 
{"Row" : 35, "Column" : 1, "Text" : "Pathogen-specific nosocomial pneumonia treatment regimens", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Refer to Lung and Mediastinum section of the inpatient or outpatient"}, 
{"Row" : 37, "Column" : 1, "Text" : "Antimicrobial CDSS for recommendations."}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 43, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 44, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676"}, 
{"Row" : 45, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 47, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}
]},
{"Name" : "ORZID GMENU ER/UC OTITIS EXTERNA", "DisplayText" : "ED Otitis Externa " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "DisplayText" : "ED Furuncles and Carbuncles", "Text" : "Furuncles and carbuncles", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "DisplayText" : "Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s) QID ($)", "Text" : "Neomycin-polymixin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "DisplayText" : "Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "DisplayText" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]", "Mnemonic" : "8a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "DisplayText" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "OTITIS EXTERNA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Localized Disease", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus."}, 
{"Row" :7, "Column" : 1, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep"}, 
{"Row" :8, "Column" : 1, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed."}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to the Furuncules and Carbuncles page for antibiotic recommendations."}, 
{"Row" : 11, "Column" : 1, "Text" : "__________________________________________________________________"}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute diffuse and chronic otitis externa", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Most commonly associated with Pseudomonas aerogenosa and Staphylococcus"}, 
{"Row" : 15, "Column" : 1, "Text" : "aureus/epidermidis. Irrigate to remove cerumen, desquamated skin and purulent"}, 
{"Row" : 16, "Column" : 1, "Text" : "material which can improve effectiveness of topical antibiotics. Avoid products"}, 
{"Row" : 17, "Column" : 1, "Text" : "that contain neomycin if the tympanic membrane is perforated."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 7 to 10 days"}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred treatment if tympanic membrane is intact", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "($) [M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "__________________________________________________________________"}, 
{"Row" : 31, "Column" : 1, "Text" : "Complicated Cases", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "For cases resistant to topical therapy alone, diabetic patients,"}, 
{"Row" : 33, "Column" : 1, "Text" : "immunocompromised patients, cases where infection has spread beyond ear canal"}, 
{"Row" : 34, "Column" : 1, "Text" : "and in those where topical therapy cannot be delivered effectively. Culture"}, 
{"Row" : 35, "Column" : 1, "Text" : "secretions to guide therapy."}, 
{"Row" : 37, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "In addition to topical therapy above <ADD>"}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery (2014) 150.S1-S24"}, 
{"Row" : 47, "Column" : 1, "Text" : "Sanford keyword: Otitis Externa"}
]},
{"Name" : "ORZID GMENU ER/UC PHARYNGITIS", "DisplayText" : "ED Pharyngitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment of Gonorrheal Infections - Opt CDSS, change parental orders to STAT", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "DisplayText" : "HIV, Rapid", "Text" : "HIV Rapid Test", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "DisplayText" : "More About Pharyngitis", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score - Opt CDSS", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "DisplayText" : "Strep A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 500MG PO BID 10DS", "DisplayText" : "Penicillin V 500 mg PO BID ($) for 10 days [R]", "Text" : "Penicillin V 500 mg PO BID for 10 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 500MG PO BID 10DS", "DisplayText" : "Penicillin V 500 mg PO BID ($) for 10 days [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSCZID BENZATHINE PENCIILLIN 1.2MU IM ONCE ER/UC", "DisplayText" : "Benzathine penicillin 1.2 million units IM once STAT ($$$) [M]", "Text" : "Benzathine penicillin 1.2 million units IM once STAT ($$$) [M]", "Mnemonic" : "14"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)", "Mnemonic" : "20a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" :3, "Column" : 1, "Text" : "PHARYNGITIS AND TONSILLITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and"}, 
{"Row" :6, "Column" : 1, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal"}, 
{"Row" :7, "Column" : 1, "Text" : "pharyngitis, use link below for recommendations."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider HIV screening for patients with pharyngitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcal Pharyngitis and Tonsillitis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by"}, 
{"Row" : 15, "Column" : 1, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk"}, 
{"Row" : 16, "Column" : 1, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for"}, 
{"Row" : 17, "Column" : 1, "Text" : "Modified Centor score criteria and for more details."}, 
{"Row" : 21, "Column" : 1, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Antimicrobials are not indicated"}, 
{"Row" : 24, "Column" : 1, "Text" : "GAS Pharyngitis and Tonsillitis Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: "}, 
{"Row" : 38, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Streptococcal Pharyngitis"}, 
{"Row" : 47, "Column" : 1, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629"}, 
{"Row" : 48, "Column" : 1, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis"}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "18a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "18"}
]},
{"Name" : "ORZID GMENU ER/UC PNEUMONIA HAP NEW", "DisplayText" : "ED Hospital Acquired Pneumonia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "DisplayText" : "LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM GENT 5MG/KG VANCO 15MG/KG IV STAT", "DisplayText" : "PIP/TAZO 4.5GM GENT 5MG/KG VANCO 15MG/KG IV STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5", "Mnemonic" : "12"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "DisplayText" : "CEFEPIME 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> gentamicin 5 mg/kg IV once STAT ($)", "Mnemonic" : "14"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG GENT 5MG/KG VANCO 15MG/KG STAT", "DisplayText" : "LEVOFLOXACIN 750MG GENT 5MG/KG VANCO 15MG/KG", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> gentamicin 5 mg/kg IV once", "Mnemonic" : "16"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "DisplayText" : "AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT [R]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Development of pneumonia 48 hours or more after hospital admission."}, 
{"Row" :6, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" :7, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" :9, "Column" : 1, "Text" : "Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s): ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Prior intravenous antibiotic use within 90 days"}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 13, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 15, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 16, "Column" : 1, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no"}, 
{"Row" : 17, "Column" : 1, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal"}, 
{"Row" : 18, "Column" : 1, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for"}, 
{"Row" : 19, "Column" : 1, "Text" : "MRSA."}, 
{"Row" : 22, "Column" : 1, "Text" : "Empiric Treatment: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "No Risk of MDR Pathogen(s): ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "15 mg/kg IV once STAT ($) [R] < OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative for penicillin allergy: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "once STAT ($) [R]"}, 
{"Row" : 36, "Column" : 1, "Text" : "Risk of MDR Pathogen(s): ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "mg/kg IV once STAT ($) [R] <AND> vancomycin 15mg/kg once STAT ($) [R] <OR>"}, 
{"Row" : 42, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg once STAT ($) [R]"}, 
{"Row" : 44, "Column" : 1, "Text" : "Alternative for penicillin allergy: ", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "STAT ($) [R] <AND> vancomycin 15mg/kg IV once STAT ($) [R]"}, 
{"Row" : 50, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "<AND> vancomycin 15mg/kg IV once STAT ($) [R]"}, 
{"Row" : 55, "Column" : 1, "Text" : "References: "}, 
{"Row" : 57, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1."}, 
{"Row" : 58, "Column" : 1, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163"}, 
{"Row" : 59, "Column" : 1, "Text" : "Chastre J. JAMA 2003. 290:2588."}, 
{"Row" : 60, "Column" : 1, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371."}, 
{"Row" : 61, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676."}, 
{"Row" : 62, "Column" : 1, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119."}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID GMENU ER/UC PYELONEPHRITIS", "DisplayText" : "ED Pyelonephritis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "6a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once ($) [M] < THEN > one of the oral regimens below", "Mnemonic" : "8"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "10a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12"},
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] for 14 days", "Mnemonic" : "14a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 56, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 14DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 14 days ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 14 days", "Mnemonic" : "16a"},
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 14DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 62, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Mnemonic" : "20"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "22"},
{"Row" : 66, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "24"},
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "< ADD > Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "26"},
{"Row" : 76, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Mnemonic" : "28a"},
{"Row" : 77, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "28b"},
{"Row" : 79, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "30"},
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "32"},
{"Row" : 83, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "34a"},
{"Row" : 85, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "36"},
{"Row" : 95, "Column" : 1, "Item" : "PSOZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days", "Mnemonic" : "38a"},
{"Row" : 96, "Column" : 1, "Item" : "PSHZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "38b"},
{"Row" : 98, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400 MG IV ONCE ER/UC", "DisplayText" : "Ciprofloxacin 400 MG IV ONCE", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI]", "Mnemonic" : "40"},
{"Row" :101, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "", "Mnemonic" : "42"},
{"Row" :103, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Mnemonic" : "44"},
{"Row" :107, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV ONCE ER/UC", "DisplayText" : "Ampicillin 1-2 gm IV STAT ($$) [R]", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R]", "Mnemonic" : "46"},
{"Row" :109, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R] for 14 days", "Mnemonic" : "48a"},
{"Row" :110, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "48b"},
{"Row" :113, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "50"},
{"Row" :114, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "DisplayText" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Mnemonic" : "52"},
{"Row" :116, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Mnemonic" : "54a"},
{"Row" :117, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_", "Text" : "Non-VA order for above", "Mnemonic" : "54b"},
{"Row" :119, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV ONCE ER/UC", "DisplayText" : "Linezolid 600 mg IV once STAT ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV once STAT ($$$$) [DI,O]", "Mnemonic" : "56"},
{"Row" :3, "Column" : 1, "Text" : "PYELONEPHRITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Features of pyelonephritis include fever/other signs of systemic infection,"}, 
{"Row" :6, "Column" : 1, "Text" : "flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most"}, 
{"Row" :7, "Column" : 1, "Text" : "cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "and Pseudomonas, are more likely if the patient is elderly, has been in the"}, 
{"Row" :9, "Column" : 1, "Text" : "hospital for more than 48 hours, or received a course of antibiotics."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobial therapy: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Drugs active against enterococci (ampicillin, piperacillin) or staphylococci"}, 
{"Row" : 16, "Column" : 1, "Text" : "needn't be used if Gram-negative bacilli predominate on the smear. Broad"}, 
{"Row" : 17, "Column" : 1, "Text" : "spectrum antimicrobials are needed if patient is at risk of having a multi-drug"}, 
{"Row" : 18, "Column" : 1, "Text" : "resistant (MDR) organism."}, 
{"Row" : 20, "Column" : 1, "Text" : "Judge severity of infection based on clinical signs and symptoms, including"}, 
{"Row" : 21, "Column" : 1, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever."}, 
{"Row" : 22, "Column" : 1, "Text" : "Oral regimens are preferred over IV if severity is mild or moderate and patient"}, 
{"Row" : 23, "Column" : 1, "Text" : "can tolerate oral antibiotics. In patients with severe or persistent disease,"}, 
{"Row" : 24, "Column" : 1, "Text" : "new renal failure, or suspected urinary obstruction, obtain a renal ultrasound"}, 
{"Row" : 25, "Column" : 1, "Text" : "to rule out obstruction or other complicating condition. Consult urology if"}, 
{"Row" : 26, "Column" : 1, "Text" : "abnormalities are found."}, 
{"Row" : 28, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 29, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 30, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 32, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical"}, 
{"Row" : 34, "Column" : 1, "Text" : "response, 7 days of treatment may be adequate. A longer duration may be required"}, 
{"Row" : 35, "Column" : 1, "Text" : "in severe infection, resistant organisms, presence of obstruction, underlying"}, 
{"Row" : 36, "Column" : 1, "Text" : "renal disease, immunosuppression, neurologic or structural abnormality, and men"}, 
{"Row" : 37, "Column" : 1, "Text" : "in some cases. A 7-day course of ciprofloxacin has been shown to be as effective"}, 
{"Row" : 38, "Column" : 1, "Text" : "as a 14-day course."}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 48, "Column" : 1, "Text" : "Oral treatment after single dose of ceftriaxone IV above: "}, 
{"Row" : 50, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 52, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 59, "Column" : 1, "Text" : "History of Pseudomonas or ESBL isolate", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 64, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 68, "Column" : 1, "Text" : "History of MRSA, add to intravenous therapy above", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 78, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 81, "Column" : 1, "Text" : "Alternative or isolate resistant to preferred antimicrobials: "}, 
{"Row" : 84, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 87, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" : 88, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" : 89, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" : 90, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" : 91, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 93, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" : 94, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 97, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :100, "Column" : 1, "Text" : "Isolate resistant to preferred antimicrobials: "}, 
{"Row" :102, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :105, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" :106, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :108, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :112, "Column" : 1, "Text" : "Resistant isolate or alternative to preferred antimicrobials: "}, 
{"Row" :115, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :118, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :120, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :123, "Column" : 1, "Text" : "References: "}, 
{"Row" :124, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :125, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :126, "Column" : 1, "Text" : "Sanford keyword: Pyelonephritis, Acute"}, 
{"Row" :127, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis"}, 
{"Row" :128, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :129, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :130, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS AND SHOCK", "DisplayText" : "ED Sepis and Septic Shock " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX SOFA ONLINE CALCULATOR", "DisplayText" : "SOFA Online Calculator", "Text" : "SOFA Online Calculator", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GMENU UC/ED SEPSIS 2", "Text" : "ED sepsis order set", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS AND SEPTIC SHOCK", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Per the Sepsis-3 task force, sepsis is defined as life-threatening"}, 
{"Row" :6, "Column" : 1, "Text" : "organ dysfunction caused by dysregulated host response to infection."}, 
{"Row" :8, "Column" : 1, "Text" : "The Sequential Organ Failure Assessment (SOFA) score can be used to help"}, 
{"Row" :9, "Column" : 1, "Text" : "identify organ dysfunction. An acute increase of 2 or more points in a patient"}, 
{"Row" : 10, "Column" : 1, "Text" : "with sepsis is associated with in-hospital mortality greater than 10%. Neither"}, 
{"Row" : 11, "Column" : 1, "Text" : "the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the"}, 
{"Row" : 12, "Column" : 1, "Text" : "sole method of identifying sepsis related organ dysfunction."}, 
{"Row" : 16, "Column" : 1, "Text" : "Septic shock is a subset of sepsis in which profound circulatory, cellular and"}, 
{"Row" : 17, "Column" : 1, "Text" : "metabolic abnormalities occur. Septic shock is associated with in-hospital"}, 
{"Row" : 18, "Column" : 1, "Text" : "mortality greater than 40%."}, 
{"Row" : 20, "Column" : 1, "Text" : "Early intervention is crucial to prevention of death from sepsis. Antimicrobials"}, 
{"Row" : 21, "Column" : 1, "Text" : "active against likely pathogens and supportive treatment to maintain vascular"}, 
{"Row" : 22, "Column" : 1, "Text" : "perfusion should be initiated immediately."}, 
{"Row" : 24, "Column" : 1, "Text" : "Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture"}, 
{"Row" : 25, "Column" : 1, "Text" : "and susceptibility data are available."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of Sepsis or Septic Shock", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock"}, 
{"Row" : 33, "Column" : 1, "Text" : "Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377"}, 
{"Row" : 34, "Column" : 1, "Text" : "Singer et al., JAMA (2016), 315(8) 801-810"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS EMPIRIC THERAPY SITE UNK", "DisplayText" : "ER/UC Sepsis, Site Unknown or Suspected Intraabdominal Infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AZTR2GM METRO1GM VANCO15MG/KG IV STAT", "DisplayText" : "AZTR 2GM VANCO 15MG/KG METRO 1GM IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 1 gm IV once STAT", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "DisplayText" : "Gentamicin 5 mg/kg IV STAT ($) [R,O]", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "DisplayText" : "Abdominal CT", "Text" : "Please Click Here To Order an Abdominal CT", "Mnemonic" : "12"},
{"Row" :7, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "IV once STAT ($) [R]"}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 13, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 15, "Column" : 1, "Text" : "For Severe Penicillin Allergy: "}, 
{"Row" : 17, "Column" : 1, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]"}, 
{"Row" : 19, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT"}, 
{"Row" : 22, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 24, "Column" : 1, "Text" : "Consider abdominal CT", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH UNKNOWN INFECTIOUS SITE", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"},
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS PNEUMONIA", "DisplayText" : "ER/UC Sepsis, Suspected Pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM VANCO15MG/KG AZITHRO500MG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG AZITHRO 500MG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT( $$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV AZITH500MG ONCE STAT", "DisplayText" : "CEFEPIME 2GM VANCO 15MG/KG AZITH500MG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "DisplayText" : "LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> vancomycin 15 mg/kg IV once", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "DisplayText" : "Gentamicin 5 mg/kg IV STAT ($) [R,O]", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Mnemonic" : "14"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Nosocomial pneumonia preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "IV once STAT ($) [R]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Community acquired pneumonia preferred treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "IV q12H ($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 25, "Column" : 1, "Text" : "($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]"}, 
{"Row" : 27, "Column" : 1, "Text" : "For severe penicillin allergy in nosocomial and community acquired pneumonia", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "STAT ($) [R]"}, 
{"Row" : 31, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT"}, 
{"Row" : 34, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 36, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED PNEUMONIA", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS PROTOCOL ANTIMICROBIALS", "DisplayText" : "ER/UC Sepsis Protocol Antmicrobials " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS EMPIRIC THERAPY SITE UNK", "DisplayText" : "ER/UC Sepsis, Site Unknown or Suspected Intraabdominal Infection", "Text" : "Unknown Infectious Site (see below for Intraabdominal Infection)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS PNEUMONIA", "DisplayText" : "ER/UC Sepsis, Suspected Pneumonia", "Text" : "Suspected Pneumonia", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED MENINGITIS", "DisplayText" : "ER/UC Sepsis, Suspected Meningitis, CNS Infection", "Text" : "Suspected Meningitis, CNS Infection", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP NATIVE VALVE ENDOCARD", "DisplayText" : "ER/UC Sepsis, Suspected Native Valve Endocarditis", "Text" : "Suspected Native Valve Endocarditis", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP PROS VALVE ENDOCARD", "DisplayText" : "ER/UC Sepsis, Suspected Prosthetic Valve Endocarditis", "Text" : "Suspected Prosthetic Valve Endocarditis", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID GMENU ER/UC NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing Infections", "Text" : "Suspected Necrotizing Infection", "Mnemonic" : "12"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED SKIN SOFT TISSUE", "DisplayText" : "ER/UC Sepsis, Suspected Skin Soft Tissue Infection", "Text" : "Suspected Skin Soft Tissue Infection", "Mnemonic" : "14"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED URO SEPSIS", "DisplayText" : "ER/UC Sepsis, Suspected Urosepsis", "Text" : "Suspected Urinary Tract Infection (AKA Urosepsis)", "Mnemonic" : "16"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "DisplayText" : "Sepsis Suspected Intraabdominal Infection ER/UC", "Text" : "Suspected Intraabdominal Infection", "Mnemonic" : "18"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP C. DIFFICILE", "DisplayText" : "ER/UC Sepsis, Suspected Severe Clostridium Difficile Infection", "Text" : "Suspected Severe Clostridium Difficile Infection", "Mnemonic" : "20"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "ED Neutropenic Fever, Not a Candidate for Oral Therapy", "Text" : "Suspected Neutropenic Fever", "Mnemonic" : "22"},
{"Row" :2, "Column" : 1, "Text" : "INITIAL EMPIRIC ANTIBIOTIC GUIDELINES FOR SEPSIS"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP C. DIFFICILE", "DisplayText" : "ER/UC Sepsis, Suspected Severe Clostridium Difficile Infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSCZID VANCOMYCIN 125MG/2.5ML PO ONCE ER/UC", "DisplayText" : "Vancomycin 125MG PO once STAT", "Text" : "Vancomycin 125MG PO once STAT", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV VANCOMYCIN 500MG PR ENEMA ONCE STAT", "DisplayText" : "METRO 500MG IV VANCOMYCIN 500MG PR ENEMA ONCE STAT", "Text" : "Metronidazole 500MG IV once STAT AND Vancomycin Enema 500MG PR once STAT", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site: Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given: 1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "If No ileus: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "If ileus: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP NATIVE VALVE ENDOCARD", "DisplayText" : "ER/UC Sepsis, Suspected Native Valve Endocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM GENT 2MG/KG VANCO 15MG/KG ONCE STAT", "DisplayText" : "PIP/TAZ 4.5GM GENT 2MG/KG VANCO 15MG/KG ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "GENT 5MG/KG IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site: Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given: 1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Gentamicin 2 MG/KG once STAT AND"}, 
{"Row" : 14, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 18, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Gentamicin 2 MG/KG once STAT AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP PROS VALVE ENDOCARD", "DisplayText" : "ER/UC Sepsis, Suspected Prosthetic Valve Endocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "DisplayText" : "PIP/TAZ4.5 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTR2 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "DisplayText" : "AZTR2 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site: Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given: 1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Gentamicin 2 MG/KG once STAT AND"}, 
{"Row" : 14, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 15, "Column" : 1, "Text" : "Rifampin 300MG IV once STAT"}, 
{"Row" : 19, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Aztreonam 2GM IV once STAT AND"}, 
{"Row" : 21, "Column" : 1, "Text" : "Gentamicin 2 MG/KG once STAT AND"}, 
{"Row" : 22, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 23, "Column" : 1, "Text" : "Rifampin 300MG IV once STAT"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "DisplayText" : "Sepsis Suspected Intraabdominal Infection ER/UC " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM METRO 1GM IV ONCE STAT", "DisplayText" : "CEFEPIME 2GM METRO 1GM IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND>metronidazole 1 gm IV once STAT", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 1GM IV ONCE STAT", "DisplayText" : "CIPRO 400MG METRO 1GMMG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 1 gm IV once", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "DisplayText" : "Gentamicin 5 mg/kg IV STAT ($) [R,O]", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "DisplayText" : "Abdominal CT", "Text" : "Please Click Here To Order an Abdominal CT", "Mnemonic" : "12"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 18, "Column" : 1, "Text" : "For severe penicillin allergy"}, 
{"Row" : 20, "Column" : 1, "Text" : "STAT ($) [DI]"}, 
{"Row" : 22, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT"}, 
{"Row" : 25, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 27, "Column" : 1, "Text" : "Consider Abdominal CT", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R]", "Mnemonic" : "4"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED MENINGITIS", "DisplayText" : "ER/UC Sepsis, Suspected Meningitis, CNS Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX TRIM/SULFAM 5MG/KG VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "TRIM/SULFAM 5MG/KG VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "8"},
{"Row" :5, "Column" : 1, "Text" : "Site: Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given: 1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy and Listeria is NOT a concern: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Ceftriaxone 2GM IV once STAT AND Vancomycin 15 mg/kg IV once STAT"}, 
{"Row" : 13, "Column" : 1, "Text" : "(Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 17, "Column" : 1, "Text" : "No Penicillin Allergy and Listeria IS a concern (Patient with age > 50", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "yrs, alcoholism, or impaired cellular immunity: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Ceftriaxone 2GM IV once STAT AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 21, "Column" : 1, "Text" : "Ampicillin 2GM IV once STAT"}, 
{"Row" : 24, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern): ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV once STAT AND"}, 
{"Row" : 28, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED SKIN SOFT TISSUE", "DisplayText" : "ER/UC Sepsis, Suspected Skin Soft Tissue Infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID GMENU ER/UC NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing Infections", "Text" : "Necrotizing infections recommendations", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set.", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT", "DisplayText" : "CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Site: Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given: 1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Aggressive surgical debridement is recommended.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "For necrotizing infections refer to those recommendations for treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT <AND>"}, 
{"Row" : 18, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 22, "Column" : 1, "Text" : "Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "hypotension, etc.)", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Ciprofloxacin 400 MG IV once STAT <AND>"}, 
{"Row" : 25, "Column" : 1, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED URO SEPSIS", "DisplayText" : "ER/UC Sepsis, Suspected Urosepsis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO STAT", "DisplayText" : "PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO STAT", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT", "DisplayText" : "CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "DisplayText" : "Gentamicin 5 mg/kg IV STAT ($) [R,O]", "Text" : "<ADD> Gentamicin 5 mg/kg IV STAT", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED URINARY TRACT INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Pencillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV STAT AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 14, "Column" : 1, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)"}, 
{"Row" : 18, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Ciprofloxacin 400 mg IV STAT AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV STAT (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 21, "Column" : 1, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)"}, 
{"Row" : 25, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose"}, 
{"Row" : 28, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 30, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEVERE SINUSITIS", "DisplayText" : "ED Severe Sinusitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "8a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Mnemonic" : "10a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3gm IV once STAT ($) [R]", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "16"},
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Mnemonic" : "18"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "DisplayText" : "Cefepime 2 gm IV STAT ($$) [R]", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Mnemonic" : "20"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "22"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "SEVERE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A"}, 
{"Row" :7, "Column" : 1, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently."}, 
{"Row" :9, "Column" : 1, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees"}, 
{"Row" : 10, "Column" : 1, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4"}, 
{"Row" : 11, "Column" : 1, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the"}, 
{"Row" : 12, "Column" : 1, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses"}, 
{"Row" : 13, "Column" : 1, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT"}, 
{"Row" : 15, "Column" : 1, "Text" : "immediately. Closely monitor all patients who present with severe signs and"}, 
{"Row" : 16, "Column" : 1, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours."}, 
{"Row" : 18, "Column" : 1, "Text" : "Outpatient Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Treatment of hospitalized patient", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment failure", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,"}, 
{"Row" : 41, "Column" : 1, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If"}, 
{"Row" : 42, "Column" : 1, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of"}, 
{"Row" : 43, "Column" : 1, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT"}, 
{"Row" : 44, "Column" : 1, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be"}, 
{"Row" : 45, "Column" : 1, "Text" : "cultured."}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 56, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "References: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 60, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 61, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 62, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 63, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 64, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 65, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 66, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Chronic"}, 
{"Row" : 67, "Column" : 1, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic"}, 
{"Row" : 68, "Column" : 1, "Text" : "rhinosinusitis"}
]},
{"Name" : "ORZID GMENU ER/UC SPON BACT PERITONITIS", "DisplayText" : "ED Spontaneous Bacterial Peritonitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [DI]", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg po qday ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO QDAY ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg po qday ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 42, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "12"},
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "DisplayText" : "Levofloxacin 750 mg IV STAT ($) [DI]", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or"}, 
{"Row" :6, "Column" : 1, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease"}, 
{"Row" :7, "Column" : 1, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250"}, 
{"Row" :8, "Column" : 1, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens"}, 
{"Row" :9, "Column" : 1, "Text" : "are isolated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first"}, 
{"Row" : 12, "Column" : 1, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with"}, 
{"Row" : 13, "Column" : 1, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1"}, 
{"Row" : 14, "Column" : 1, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients"}, 
{"Row" : 15, "Column" : 1, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more"}, 
{"Row" : 16, "Column" : 1, "Text" : "information."}, 
{"Row" : 18, "Column" : 1, "Text" : "SBP", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Prophylaxis in a patient with a previous SBP episode", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Treat initially with an intravenous antimicrobial then step down to an oral"}, 
{"Row" : 36, "Column" : 1, "Text" : "antimicrobial when the patient can tolerate oral treatment."}, 
{"Row" : 38, "Column" : 1, "Text" : "Duration of antimicrobial therapy"}, 
{"Row" : 39, "Column" : 1, "Text" : "Treat for a total of 7 days (intravenous and oral)"}, 
{"Row" : 41, "Column" : 1, "Text" : "Preffered initial treatment"}, 
{"Row" : 44, "Column" : 1, "Text" : "Initial treatment, alternative for beta-lactam allergy"}, 
{"Row" : 47, "Column" : 1, "Text" : "Step down treatment"}, 
{"Row" : 48, "Column" : 1, "Text" : "Refer to Intpatient Antimicrobial CDSS"}, 
{"Row" : 49, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "(less than 1 gm/dL peritoneal fluid)", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Refer to Intpatient Antimicrobial CDSS"}, 
{"Row" : 56, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" : 59, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial"}, 
{"Row" : 60, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and"}, 
{"Row" : 62, "Column" : 1, "Text" : "prophylaxis"}
]},
{"Name" : "ORZID GMENU ER/UC SUPP ODONTOGENIC INFECT", "DisplayText" : "ED Suppurative Odontogenic Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 14 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 450MG PO TID 7D", "DisplayText" : "Clindamycin 450 mg PO TID for 7 days ($) [H,O]", "Text" : "Clindamycin 450 mg PO q8h for 7 to 14 days ($) [H,O]", "Mnemonic" : "8a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 450MG PO TID 7D", "DisplayText" : "Clindamycin 450 mg PO TID for 7 days ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "DisplayText" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Text" : "Ampicillin-sulbactam 3gm IV once STAT ($) [R]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "DisplayText" : "CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once STAT", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV ONCE ER/UC (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]", "Mnemonic" : "16"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "18"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "DisplayText" : "Meropenem 1GM IV once ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "TOOTH ABSCESS AND OTHER SUPPURATIVE ODONTOGENIC INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential and tooth"}, 
{"Row" :6, "Column" : 1, "Text" : "extraction is required in most cases. All patients should be referred to the"}, 
{"Row" :7, "Column" : 1, "Text" : "dental service for assessment and direction of treatment. Empirical coverage for"}, 
{"Row" :8, "Column" : 1, "Text" : "likely pathogens (streptococci, Peptostreptococcus, Finegoldia, Bacteriodes and"}, 
{"Row" :9, "Column" : 1, "Text" : "other oral anaerobes is required. Immunocompromised patients need additional"}, 
{"Row" : 10, "Column" : 1, "Text" : "coverage for Pseudomonas aeruginosa."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Dental Service", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment of mild to moderate disease in immunocompetent patients or step-down", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "therapy after initial intravenous therapy. Adjust duration for a total of 7-14", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "days of antimicrobial therapy.", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 26, "Column" : 1, "Text" : "Treatment of severe disease in immunocompetent patients", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 33, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 35, "Column" : 1, "Text" : "Treatment in immunocompromised patients", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head"}, 
{"Row" : 48, "Column" : 1, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252"}, 
{"Row" : 49, "Column" : 1, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic"}, 
{"Row" : 52, "Column" : 1, "Text" : "Infections"}
]},
{"Name" : "ORZID GMENU ER/UC SURG GENTAMICIN SPECIFIC DOSING", "DisplayText" : "ED Surgery Gentamicin Specific Dosing " , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 240 MG DOSE LESS 50KG ER/UC", "DisplayText" : "Gentamicin 240 mg IV beginning 60 minutes before incision", "Text" : "Gentamicin 240 mg IV beginning 60 minutes before incision", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 300 MG DOSE 50-75KG ER/UC", "DisplayText" : "Gentamicin 300 mg IV beginning 60 minutes before incision", "Text" : "Gentamicin 300 mg IV beginning 60 minutes before incision", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 400 MG DOSE 75-100KG ER/UC", "DisplayText" : "Gentamicin 400 mg beginning 60 minutes before incision", "Text" : "Gentamicin 400 mg beginning 60 minutes before incision", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 500 MG DOSE 100-125KG ER/UC", "DisplayText" : "Gentamicin 500 mg IV ONCEinning 60 minutes before incision", "Text" : "Gentamin 500 mg beginning 60 minutes before incision", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 600 MG 100-125 KG ER/UC", "DisplayText" : "Gentamicin 600 mg IV beginning 60 minutes before incision", "Text" : "Gentamicin 600 mg IV beginning 60 minutes before incision", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "Recommended Gentamicin Doses based on patient weight: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Weight equal/less 50kg: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Weight greater 50 kg and less 75 kg", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Weight equal 75 kg and less than 100kg: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Weight equal to 100 kg and less than 120kg: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Weight equal/greater 120 kg: ", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "ED Suspected Bacteremia, Blood Cultures Not Yet Positive" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "DisplayText" : "Bacteremia", "Text" : "Link to Bacteremia order menus in the Inpatient Antimicrobial CDSS", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "DisplayText" : "Ceftriaxone 2 gm IV once STAT ($$) [M]", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "DisplayText" : "CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] < AND > Vancomycin 15mg/kg IV once", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "DisplayText" : "PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) <AND> vancomycin 15 mg/kg", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT", "DisplayText" : "VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT", "Text" : "vancomycin 15 mg/kg IV once STAT ($) [R] <AND> gentamicin 5 mg/kg once STAT", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If blood cultures are positive, refer to the Bacteremia order menus in the", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "inpatient Antimicrobial CDSS (link below).", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "***ALERT*** Leaving ED Antimicrobial CDSS! When ordering antimicrobials from the"}, 
{"Row" :8, "Column" : 1, "Text" : "inpatient Antimicrobial CDSS, STAT priority must be manually selected."}, 
{"Row" : 11, "Column" : 1, "Text" : "Choice of antimicrobials", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Select antimicrobials active against any suspected site of infection that may be"}, 
{"Row" : 13, "Column" : 1, "Text" : "present. Return to main menu and refer to the source infection's page within"}, 
{"Row" : 14, "Column" : 1, "Text" : "the Antimicrobial CDSS."}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients with an intravascular catheter, refer to the intravascular-", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "associated infection page in the Systemic Infections section of the Inpatient", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Antimicrobial CDSS", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Empirical therapy for mild to moderate infection, focal infection not found", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical therapy for severe infection", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "STAT ($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Empirical therapy for immunosuppressed patients", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "IV once STAT ($) [R]"}, 
{"Row" : 31, "Column" : 1, "Text" : "For patients with penicillin allergy", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 36, "Column" : 1, "Text" : "References"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Treatment Guidelines 2010, 8: 94"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Enterococci"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Staphylococci"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Streptococci"}, 
{"Row" : 43, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID2 GMENU ABSCESSES" , "Term1" : "Abscess, skin and soft tissue", "DisplayText" : "Abscesses:Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess", "Text" : "Cutaneous abscess", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and carbuncles", "Text" : "Furuncles and carbuncles", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, CARBUNCLE, AND PYOMYOSITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "This section describes management of skin and soft tissue infections.For"}, 
{"Row" :6, "Column" : 1, "Text" : "information on abscesses in other areas, please return to the main CDSS menu and"}, 
{"Row" :7, "Column" : 1, "Text" : "choose the appropriate organ system."}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword:Skin infections"}
]},
{"Name" : "ORZID2 GMENU ABX ABOUT THE CDSS", "DisplayText" : "About the CDSS" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "More information on antimicrobial restriction policy", "Mnemonic" : "4"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO USE CDSS", "DisplayText" : "How to use the CDSS", "Text" : "How to use the CDSS", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ABOUT THE ANTIMICROBIAL COMPUTERIZED DECISION SUPPORT SYSTEM (CDSS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The Antimicrobial CDSS is a tool within the Computerized Patient Record System"}, 
{"Row" :6, "Column" : 1, "Text" : "that offers antimicrobial prescribing advice to clinicians at the point of order"}, 
{"Row" :7, "Column" : 1, "Text" : "entry. The system is structured as an order menu decision tree that contains"}, 
{"Row" :8, "Column" : 1, "Text" : "quick orders pre-programmed with appropriate antimicrobial regimens for specific"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious diseases."}, 
{"Row" : 11, "Column" : 1, "Text" : "Goals", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Improve patient outcomes, reduce rates of microbial resistance, prevent adverse"}, 
{"Row" : 13, "Column" : 1, "Text" : "patient outcomes, optimize costs and improve providers' lives. In addition to"}, 
{"Row" : 14, "Column" : 1, "Text" : "these goals, the program fulfills antimicrobial stewardship quality standards"}, 
{"Row" : 15, "Column" : 1, "Text" : "implemented by the Joint Commission."}, 
{"Row" : 17, "Column" : 1, "Text" : "Rationale", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "*Improved patient outcomes"}, 
{"Row" : 19, "Column" : 1, "Text" : "In a 2013 study, Minneapolis Veterans Affairs Medical Center (MVAMC)"}, 
{"Row" : 20, "Column" : 1, "Text" : "antimicrobial courses ordered through the Antimicrobial CDSS were significantly"}, 
{"Row" : 21, "Column" : 1, "Text" : "more likely to be appropriate from start to completion, (44%) compared to non-"}, 
{"Row" : 22, "Column" : 1, "Text" : "CDSS courses (33%, P = 0.013). This is consistent with other studies that have"}, 
{"Row" : 23, "Column" : 1, "Text" : "shown significant improvement in appropriate use of antimicrobials when CDSS"}, 
{"Row" : 24, "Column" : 1, "Text" : "programs are utilized."}, 
{"Row" : 26, "Column" : 1, "Text" : "*Restricted formulary"}, 
{"Row" : 27, "Column" : 1, "Text" : "The Minneapolis VAHCS has a restricted antimicrobial formulary. A restricted"}, 
{"Row" : 28, "Column" : 1, "Text" : "formulary reduces cost of health care and is an integral part of antimicrobial"}, 
{"Row" : 29, "Column" : 1, "Text" : "stewardship. The Antimicrobial CDSS provides a method of formulary restriction"}, 
{"Row" : 30, "Column" : 1, "Text" : "that doesn't require a call back from pharmacy or a prior authorization for the"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobial to be approved."}, 
{"Row" : 34, "Column" : 1, "Text" : "*Increased efficiency"}, 
{"Row" : 35, "Column" : 1, "Text" : "Along with being able to order restricted antimicrobials without a prior"}, 
{"Row" : 36, "Column" : 1, "Text" : "authorization or call back from pharmacy, the Antimicrobial CDSS provides quick"}, 
{"Row" : 37, "Column" : 1, "Text" : "orders pre-programmed with appropriate antimicrobial regimens for specific"}, 
{"Row" : 38, "Column" : 1, "Text" : "infectious diseases. Using the system saves time and increases the efficiency of"}, 
{"Row" : 39, "Column" : 1, "Text" : "the ordering provider."}, 
{"Row" : 41, "Column" : 1, "Text" : "Features", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "The CDSS has been developed locally with input from a broad, representative"}, 
{"Row" : 43, "Column" : 1, "Text" : "group of clinicians. Recommendations have been based on local susceptibility"}, 
{"Row" : 44, "Column" : 1, "Text" : "patterns, clinical evidence, local preferences, and national guidelines. The"}, 
{"Row" : 45, "Column" : 1, "Text" : "CDSS provides a way for clinicians to select alternative drugs when the"}, 
{"Row" : 46, "Column" : 1, "Text" : "recommended drugs are contraindicated."}, 
{"Row" : 48, "Column" : 1, "Text" : "Detailed instructions can be found in the link below."}, 
{"Row" : 52, "Column" : 1, "Text" : "References"}, 
{"Row" : 54, "Column" : 1, "Text" : "Dellit et al. Clinical Infectious Diseases 2007, 44:159-7"}, 
{"Row" : 55, "Column" : 1, "Text" : "Filice et al. Infection Control and Hospital Epidemiology. 2013, 34.6"}, 
{"Row" : 56, "Column" : 1, "Text" : "Rawson et al. Clinical Microbiology and Infection. 2017, 1e9"}
]},
{"Name" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY" , "Term1" : "Restrictions on antimicrobials", "DisplayText" : "Antimicrobial restriction policy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIAL RESTRICTION POLICY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Medication orders placed using the CDSS system will NOT require Infectious"}, 
{"Row" :6, "Column" : 1, "Text" : "Disease approval. Because prescribing advice within the system has been"}, 
{"Row" :7, "Column" : 1, "Text" : "developed with input from a broad, representative group of clinicians and the"}, 
{"Row" :8, "Column" : 1, "Text" : "recommendations that have emerged are based on site-specific susceptibility"}, 
{"Row" :9, "Column" : 1, "Text" : "patterns, clinical evidence, local preferences, and national guidelines,"}, 
{"Row" : 10, "Column" : 1, "Text" : "INFECTIOUS DISEASE APPROVAL FOR RESTRICTED ANTIMICROBIALS WILL NOT BE NEEDED at"}, 
{"Row" : 11, "Column" : 1, "Text" : "participating VA sites. Clinicians are still encouraged to seek advice from"}, 
{"Row" : 12, "Column" : 1, "Text" : "Infectious Diseases whenever it would be helpful."}, 
{"Row" : 14, "Column" : 1, "Text" : "Restricted antimicrobials ordered outside the CDSS system will continue to need"}, 
{"Row" : 15, "Column" : 1, "Text" : "ID approval."}
]},
{"Name" : "ORZID2 GMENU ABX ACKNOWLEDGEMENTS", "DisplayText" : "Acknowledgements" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "ACKNOWLEDGEMENT", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "This project was funded as a VISN 23 Strategic Planning Project for FY2005-2007."}, 
{"Row" :6, "Column" : 1, "Text" : "It addresses the VISN's efforts to build a culture of continuous quality"}, 
{"Row" :7, "Column" : 1, "Text" : "improvement, evidence-based practice and optimal resource utilization."}, 
{"Row" :9, "Column" : 1, "Text" : "This project has been guided by our project collaborators as well as the efforts"}, 
{"Row" : 10, "Column" : 1, "Text" : "of the guideline review committee members. We would like to thank these"}, 
{"Row" : 11, "Column" : 1, "Text" : "individuals for their time and thoughtful input."}
]},
{"Name" : "ORZID2 GMENU ABX ACNE", "DisplayText" : "Acne" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 1% LOTION TOPICALLY Q12H", "DisplayText" : "Clindamycin 1% lotion topically q12h ($) [M]", "Text" : "Clindamycin 1% lotion topically q12h ($) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 2% GEL TOPICALLY Q12H", "DisplayText" : "Erythromycin 2% gel topically q12h ($) [DI]", "Text" : "Erythromycin 2% gel topically q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 2% GEL TOPICALLY Q12H", "DisplayText" : "Erythromycin 2% gel topically q12h ($) [DI]", "Text" : "Erythromycin 2% gel topically q12h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID2 DOXYCYCLINE 12WKS 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID2 MINOCYLCINE 12WKS 50MG PO Q12H", "DisplayText" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "DisplayText" : "DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "Text" : "Doxycycline 100 mg PO q12h($) [DI] for 12 weeks <AND> erythromycin 2% gel", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "DisplayText" : "MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks <AND> erythromycin 2% gel", "Mnemonic" : "16"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Relcalcitrant Acne and Rosacea", "Text" : "Recalcitrant acne", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "ACNE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acne is an inflammatory skin condition caused by excess sebum production, gland"}, 
{"Row" :6, "Column" : 1, "Text" : "obstruction and infection with Cutibacterum acnes. Early disease manifests with"}, 
{"Row" :7, "Column" : 1, "Text" : "black heads and white heads and little inflammation. Small papules and pustules"}, 
{"Row" :8, "Column" : 1, "Text" : "are present in mild disease. Severe disease occurs when comedones, papules,"}, 
{"Row" :9, "Column" : 1, "Text" : "pustules and less often cysts are present."}, 
{"Row" : 11, "Column" : 1, "Text" : "The goal of treatment is prevention and reeducation of new comedones and"}, 
{"Row" : 12, "Column" : 1, "Text" : "creating an environment that is inhibitory for C. acnes. General skin care"}, 
{"Row" : 13, "Column" : 1, "Text" : "treatment measures include utilizing gentle skin cleansers, avoiding aggressive"}, 
{"Row" : 14, "Column" : 1, "Text" : "scrubbing, using non-comedogenic skin products, and avoiding picking of lesions."}, 
{"Row" : 15, "Column" : 1, "Text" : "Diet's role in therapy remains uncertain."}, 
{"Row" : 17, "Column" : 1, "Text" : "Non-Antimicrobial therapy includes benzoyl peroxide topical/wash, salicylic acid"}, 
{"Row" : 18, "Column" : 1, "Text" : "topical, and tretinoin topical. These agents can be used as monotherapy in early"}, 
{"Row" : 19, "Column" : 1, "Text" : "disease and in addition to antimicrobial treatment in mild to severe disease."}, 
{"Row" : 21, "Column" : 1, "Text" : "Early Disease: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mild Disease: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Severe Disease: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "topically q12h"}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "topically q12h"}, 
{"Row" : 39, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 43, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Sanford keyword: Acne Vulgaris"}, 
{"Row" : 48, "Column" : 1, "Text" : "Up-to-Date Article: Pathogenesis, clinical manifestations, and diagnosis of acne"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-to-Date Article: Acne vulgaris: Overview of management"}, 
{"Row" : 50, "Column" : 1, "Text" : "Zaenglein et al., N Engl J Med, 2018, 379(14)1343-1352"}, 
{"Row" : 51, "Column" : 1, "Text" : "Zaenglein et al., J Am Acad Dermatol, 2016, 74(5)945-73.e33"}, 
{"Row" : 41, "Column" : 1, "Text" : "**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS" , "Term1" : "Prostatitis, acute", "DisplayText" : "Acute Bacterial Prostatitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE DOXY 100MG PO Q12H", "DisplayText" : "Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "6"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 1GM IM ONCE DOXY PO 100MG Q12H GONOCOCC", "DisplayText" : "Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "8"},
{"Row" : 48, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days", "Mnemonic" : "10"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) for 14 days", "Mnemonic" : "12"},
{"Row" : 53, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE BACTERIAL PROSTATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute bacterial prostatitis typically presents with fever, dysuria, chills,"}, 
{"Row" :6, "Column" : 1, "Text" : "malaise, myalgia, pelvic or perianal pain. On exam, the prostate gland is tense,"}, 
{"Row" :7, "Column" : 1, "Text" : "boggy, and extremely tender. The urinalysis reveals pyuria, and the urine"}, 
{"Row" :8, "Column" : 1, "Text" : "culture is positive. Men with dysuria and fever but without pyuria and/or"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteriuria should be seen by a urologist. If there is any suspicion of abscess,"}, 
{"Row" : 10, "Column" : 1, "Text" : "especially in men older than 40 years, the patient should be seen by a urologist"}, 
{"Row" : 11, "Column" : 1, "Text" : "and transurethral prostate resection for drainage should be considered."}, 
{"Row" : 13, "Column" : 1, "Text" : "Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 14, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 15, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 and those who"}, 
{"Row" : 16, "Column" : 1, "Text" : "are at high risk of sexually transmitted infections are associated with N."}, 
{"Row" : 17, "Column" : 1, "Text" : "gonorrhoeae and C. trachomatis. Resistant organisms are more likely if the"}, 
{"Row" : 18, "Column" : 1, "Text" : "patient has been in the hospital for more than 48 hours or received a course of"}, 
{"Row" : 19, "Column" : 1, "Text" : "antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 20, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 22, "Column" : 1, "Text" : "A urine Gram stain and culture should be performed in all patients to guide"}, 
{"Row" : 23, "Column" : 1, "Text" : "antimicrobial therapy: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "There is limited data on duration of antimicrobial treatment for prostatitis. 14"}, 
{"Row" : 28, "Column" : 1, "Text" : "days minimum is required. 4 to 6 weeks may be necessary to completely eradicate"}, 
{"Row" : 29, "Column" : 1, "Text" : "bacteria in the prostate to ensure patient does not progress to chronic"}, 
{"Row" : 30, "Column" : 1, "Text" : "bacterial prostatitis."}, 
{"Row" : 31, "Column" : 1, "Text" : "_____________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Hydration, bed rest and analgesics are recommended along with antimicrobials"}, 
{"Row" : 35, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 37, "Column" : 1, "Text" : "Age < 35 years and those at high risk of sexually transmitted infections", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Patient weighing less than 300 lbs: "}, 
{"Row" : 40, "Column" : 1, "Text" : "14 days"}, 
{"Row" : 42, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater: "}, 
{"Row" : 44, "Column" : 1, "Text" : "14 days"}, 
{"Row" : 46, "Column" : 1, "Text" : "Age >/= 35 years", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652"}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Prostatitis"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-To-Date article: Acute Bacterial Prostatitis"}
]},
{"Name" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance..." , "Version" : "Minneapolis", "Contents" : [
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "[CLICK HERE] to open Infectious Diseases on call schedule", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "WHOM TO CONTACT FOR ADDITIONAL ASSISTANCE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "CDSS Team", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Contact for issues regarding"}, 
{"Row" :7, "Column" : 1, "Text" : "navigation or content of the CDSS"}, 
{"Row" : 11, "Column" : 1, "Text" : "Erik Stensgard, PharmD, BCPS"}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial CDSS Program Manager"}, 
{"Row" : 13, "Column" : 1, "Text" : "(612) 271-4121 -OR- Microsoft TEAMS"}, 
{"Row" : 14, "Column" : 1, "Text" : "Email: Erik Stensgard@va.gov"}, 
{"Row" : 16, "Column" : 1, "Text" : "Bobbie Masoud, PharmD, BCPS"}, 
{"Row" : 17, "Column" : 1, "Text" : "Clinical Pharmacist CDSS"}, 
{"Row" : 18, "Column" : 1, "Text" : "(612) 719-6778 -OR- Microsoft TEAMS"}, 
{"Row" : 19, "Column" : 1, "Text" : "Email: Bobbie.Masoud@va.gov"}, 
{"Row" : 20, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Infectious Diseases", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Contact for issues regarding"}, 
{"Row" : 24, "Column" : 1, "Text" : "antimicrobial treatment"}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZ GTX ABX PHARMACIST NUMBERS PHONE/PAGER", "DisplayText" : "PHARMACIST PHONE/PAGER NUMBERS", "Text" : "[CLICK HERE] to open list of", "Mnemonic" : "12"},
{"Row" :5, "Column" : 2, "Text" : "Antimicrobial Stewardship", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Text" : "Contact for issues regarding"}, 
{"Row" :7, "Column" : 2, "Text" : "antimicrobial stewardship"}, 
{"Row" :9, "Column" : 2, "Text" : "Muthu Narayan, DO"}, 
{"Row" : 10, "Column" : 2, "Text" : "Antimicrobial Stewardship Physician"}, 
{"Row" : 11, "Column" : 2, "Text" : "Pager: 612-818-3936"}, 
{"Row" : 13, "Column" : 2, "Text" : "Eric Geurkink, PharmD, MBA, BCPS"}, 
{"Row" : 14, "Column" : 2, "Text" : "Antimicrobial Stewardship Pharmacist"}, 
{"Row" : 15, "Column" : 2, "Text" : "Pager: 612-818-0841"}, 
{"Row" : 17, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "Pharmacy Staff", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Contact for pharmacy related"}, 
{"Row" : 21, "Column" : 2, "Text" : "antimicrobial issues"}, 
{"Row" : 24, "Column" : 2, "Text" : "pharmacists' phone/pager numbers"}, 
{"Row" : 25, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Text" : "Microbiology", "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Text" : "Contact for microbiology issues"}, 
{"Row" : 30, "Column" : 2, "Text" : "Phone extension: 31-2408"}, 
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "DisplayText" : "E-mail Antimicrobial CDSS Staff", "Text" : "CDSS Team Email: VISN23AntimicrobialCDSS@va.gov", "Mnemonic" : "2"}
]},
{"Name" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "DisplayText" : "Adjust existing antimicrobial therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "ADJUSTING EXISTING ANTIMICROBIAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "To change the DOSE of a CURRENTLY ACTIVE antimicrobial", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Right click on the active order and change the dose as needed."}, 
{"Row" :8, "Column" : 1, "Text" : "To change from the CURRENT ANTIMICROBIAL MEDICATION", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "We encourage clinicians to consult the CDSS when considering alternative"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobial therapy due to an adverse drug reaction, a culture result, or a"}, 
{"Row" : 11, "Column" : 1, "Text" : "need to switch from intravenous to oral therapy. Many of the CDSS advice menus"}, 
{"Row" : 12, "Column" : 1, "Text" : "contain more than one antimicrobial recommendation. If a suitable alternative"}, 
{"Row" : 13, "Column" : 1, "Text" : "is not listed on the advice menu, clinicians have the additional resource of an"}, 
{"Row" : 14, "Column" : 1, "Text" : "expanded menu of alternative medications that can be accessed by selecting the"}, 
{"Row" : 15, "Column" : 1, "Text" : "Need an alternative antimicrobial? link at the top of each advice menu. To"}, 
{"Row" : 16, "Column" : 1, "Text" : "order an alternative medication using this link prescribers will need to"}, 
{"Row" : 17, "Column" : 1, "Text" : "indicate the rationale behind the choice."}, 
{"Row" : 19, "Column" : 1, "Text" : "Note: Restricted antimicrobials ordered outside of the CDSS system will still"}, 
{"Row" : 20, "Column" : 1, "Text" : "require Infectious Diseases approval."}
]},
{"Name" : "ORZID2 GMENU ABX AEROMONAS" , "Term1" : "Aeromonas diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Aeromonas " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 3 days($) [R,DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH AEROMONAS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8(94)"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford keyword: Aeromonas sp."}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-to-Date article: Aeromonas infections"}
]},
{"Name" : "ORZID2 GMENU ABX AMOXICILLIN CHALLENGE ALLERGY", "DisplayText" : "Amoxicillin Challenge " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" :3, "Column" : 1, "Text" : "Amoxicillin Oral Challenge for Low Risk Patients", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Amoxicillin challenge protocol: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "To be given ONLY after patient has been evaluated with thorough beta lactam"}, 
{"Row" :7, "Column" : 1, "Text" : "history and found to be low risk, AND has given consent for amoxicillin"}, 
{"Row" : 10, "Column" : 1, "Text" : "Place order for medications: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX AMOXICILLIN CHALLENGE ALLERGY INPATIENT", "DisplayText" : "[Click here] Amoxicillin 500mg PO once + Epinephrine 0.5mg/0.5ml IM once prn", "Text" : "", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Text" : "challenge."}, 
{"Row" : 18, "Column" : 1, "Text" : "Khan DA, et al. J Allergy Clin Immunol.,2022,150(6):1333-1393"}, 
{"Row" : 19, "Column" : 1, "Text" : "Drug allergy: A 2022 practice parameter update"}, 
{"Row" : 11, "Column" : 1, "Text" : "Inpatient orders: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Clinic orders: "}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX AMOXICILLIN CHALLENGE ALLERGY CLINIC", "DisplayText" : "[Click here] Amoxicillin 500mg PO once + Epinephrine 0.5MG/0.5ML IM once prn", "Text" : "", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES" , "Term1" : "Antimicrobial shortages updates " , "Term2" : "Shortages of antimicrobials updates " , "Term3" : "Updates on antimicrobial shortages" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Select individual antimicrobial listed below for current status on shortages.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Currently NO antimicrobial shortages.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ANTIVIRAL TREATMENT", "DisplayText" : "ANTIVIRAL TREATMENT " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 50, "Column" : 1, "Item" : "PSJZID OSELTAMIVIR 75 MG PO BID 5DAYS", "DisplayText" : "Oseltamivir 75 MG PO q12h for 5 days", "Text" : "Oseltamivir 75 mg po bid for 5 days ($) [R]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "Antiviral Therapy Recommendations: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Who to Treat: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "The decision to treat should be based on clinical symptoms and/or presence of"}, 
{"Row" :7, "Column" : 1, "Text" : "a high risk condition, and should NOT be delayed until laboratory test"}, 
{"Row" :8, "Column" : 1, "Text" : "results are available."}, 
{"Row" : 10, "Column" : 1, "Text" : "It is important to use antiviral drugs early to treat influenza in people who"}, 
{"Row" : 11, "Column" : 1, "Text" : "are very sick with influenza (for example hospitalized people) and people who"}, 
{"Row" : 12, "Column" : 1, "Text" : "are sick with influenza and have a greater chance of getting severe"}, 
{"Row" : 13, "Column" : 1, "Text" : "complications. If a patient is not in a high-risk group or is not hospitalized,"}, 
{"Row" : 14, "Column" : 1, "Text" : "healthcare providers should use clinical judgment to guide treatment decisions."}, 
{"Row" : 16, "Column" : 1, "Text" : "People who have a greater chance of serious influenza complications include: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "*Persons who have chronic pulmonary (including asthma) or cardiovascular"}, 
{"Row" : 22, "Column" : 1, "Text" : "*Persons who are immunocompromised due to any cause (including immunosuppresion"}, 
{"Row" : 23, "Column" : 1, "Text" : "caused by medications or by HIV infection)"}, 
{"Row" : 25, "Column" : 1, "Text" : "*Persons younger than 19 years of age who are receiving long-term aspirin-"}, 
{"Row" : 26, "Column" : 1, "Text" : "or salicylate-containing medications and who might be at risk for experiencing"}, 
{"Row" : 27, "Column" : 1, "Text" : "Reye syndrome after influenza virus infection"}, 
{"Row" : 28, "Column" : 1, "Text" : "*Residents of nursing homes and other long-term care facilities"}, 
{"Row" : 31, "Column" : 1, "Text" : "*Persons who are extremely obese (BMI greater than or equal to 40)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Antiviral Treatment: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "If indicated, antivirals should be started as soon as possible.Maximal"}, 
{"Row" : 35, "Column" : 1, "Text" : "benefit occurs when started within 48 hours of symptom onset.However,"}, 
{"Row" : 36, "Column" : 1, "Text" : "antivirals should not be withheld if symptoms began more than 48 hours prior"}, 
{"Row" : 37, "Column" : 1, "Text" : "and the patient meets criteria for treatment and remains severely ill."}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment Dosing: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such"}, 
{"Row" : 41, "Column" : 1, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have"}, 
{"Row" : 42, "Column" : 1, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using"}, 
{"Row" : 43, "Column" : 1, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the"}, 
{"Row" : 44, "Column" : 1, "Text" : "bronchodilator."}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]"}, 
{"Row" : 59, "Column" : 1, "Text" : "Alternative for patients unable to tolerate or absorb oral oseltamivir: ", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Peramivir 600 mg IV q24h for 5 to 10 days ($$$$$) [R]"}, 
{"Row" : 66, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "*Adults aged 65 years or older"}, 
{"Row" : 19, "Column" : 1, "Text" : "(except isolated hypertension), renal, hepatic, hematologic, metabolic"}, 
{"Row" : 20, "Column" : 1, "Text" : "disorders (including diabetes mellitus), neurologic and"}, 
{"Row" : 21, "Column" : 1, "Text" : "neuro-developmental disorders"}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 56, "Column" : 1, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for"}, 
{"Row" : 57, "Column" : 1, "Text" : "patients wt <80kg ($$$) [DI]"}, 
{"Row" : 61, "Column" : 1, "Text" : "Hospitalized, high risk: ", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Acute, uncomplicated: ", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "Peramivir 600mg IV Once ($$$$$) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Extending the duration of treatment for oseltamivir or peramivir may be"}, 
{"Row" : 47, "Column" : 1, "Text" : "needed for those patients with prolonged illness or who are immunosuppressed."}, 
{"Row" : 24, "Column" : 1, "Text" : "*Pregnant women and women up to 2 weeks after the end of pregnancy"}, 
{"Row" : 29, "Column" : 1, "Text" : "*Non-Hispanic Black persons, Hispanic or Latino persons, and American Indian"}, 
{"Row" : 30, "Column" : 1, "Text" : "or Alaska Native persons"}, 
{"Row" : 67, "Column" : 1, "Text" : "Centers for Disease Control (CDC) (Accessed 9/20/22)"}, 
{"Row" : 68, "Column" : 1, "Text" : "https://www.cdc.gov/flu/professionals/antivirals/summary-clinician"}, 
{"Row" : 69, "Column" : 1, "Text" : "UpToDate Seasonal influenza in adults: Treatment"}
]},
{"Name" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "DisplayText" : "Approach to bacteremia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Sepsis, severe sepsis, and septic shock", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "Suspected bacteremia, blood cultures not yet positive", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Mnemonic" : "6"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Interim report of Gram-positive cocci in pairs", "Mnemonic" : "8"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and clusters", "Text" : "Interim report of Gram-positive cocci in pairs and clusters", "Mnemonic" : "10"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and chains", "Text" : "Interim report of Gram-positive cocci in pairs and chains", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "DisplayText" : "Interim report of Gram-negative bacilli", "Text" : "Interim report of Gram-negative bacilli", "Mnemonic" : "14"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "DisplayText" : "Interim report of Gram-negative cocci", "Text" : "Interim report of Gram-negative cocci", "Mnemonic" : "16"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Interim report of Gram-positive bacilli", "Mnemonic" : "18"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "DisplayText" : "Interim report of yeast", "Text" : "Interim report of yeast", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO BACTEREMIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Bacteremia usually results from a focal infection somewhere in the body. If a"}, 
{"Row" :6, "Column" : 1, "Text" : "focal infection is not obvious, a careful search should be made beginning with a"}, 
{"Row" :7, "Column" : 1, "Text" : "detailed history and physical examination."}, 
{"Row" :9, "Column" : 1, "Text" : "If a focal infection seems to be the source of the bacteremia, select"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials active against pathogens likely to be present in the focal"}, 
{"Row" : 11, "Column" : 1, "Text" : "infection. Return to the main menu and select the relevant diagnosis or"}, 
{"Row" : 12, "Column" : 1, "Text" : "syndrome."}, 
{"Row" : 14, "Column" : 1, "Text" : "For infections with signs and/or symptoms of severe sepsis, like hypotension or", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "end organ dysfunction", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Sequence of evaluation", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Obtain blood cultures before starting antibiotics when signs or symptoms suggest"}, 
{"Row" : 20, "Column" : 1, "Text" : "bacteremia. Obtain 2 or 3 blood culture sets from different venipuncture sites"}, 
{"Row" : 21, "Column" : 1, "Text" : "within a 24 hour period. When suspicion is strong and the patient's signs and"}, 
{"Row" : 22, "Column" : 1, "Text" : "symptoms have not responded, obtain 2 blood culture sets the next day. For more"}, 
{"Row" : 23, "Column" : 1, "Text" : "information about blood cultures, see recommendations on the Q-drive"}, 
{"Row" : 24, "Column" : 1, "Text" : "Q:\\MICROBIOL INFO FOR CLINICIANS\\BLOOD CULTURE Recommendations.doc"}, 
{"Row" : 26, "Column" : 1, "Text" : "Empirical treatment of suspected bacteremia if local infection is not apparent", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "and blood cultures are not yet positive", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Cultures usually become positive after 1 or more days. Usually interim results"}, 
{"Row" : 31, "Column" : 1, "Text" : "are reported first, followed by final identification and sensitivities after"}, 
{"Row" : 32, "Column" : 1, "Text" : "another day or two. Adjust antimicrobials as appropriate as this sequence"}, 
{"Row" : 33, "Column" : 1, "Text" : "unfolds."}, 
{"Row" : 35, "Column" : 1, "Text" : "Preliminary results of a positive culture are available", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "When a focal infection is not apparent, the type of bacteria growing in blood"}, 
{"Row" : 37, "Column" : 1, "Text" : "culture might suggest a focal infection and direct the search for a diagnosis."}, 
{"Row" : 38, "Column" : 1, "Text" : "When a focal infection is apparent, it may suggest the identity of the bacteria"}, 
{"Row" : 39, "Column" : 1, "Text" : "growing in blood cultures before the laboratory completes its identification."}, 
{"Row" : 40, "Column" : 1, "Text" : "Preliminary positive results should lead to changes in antimicrobial therapy to"}, 
{"Row" : 41, "Column" : 1, "Text" : "target suspected pathogens, narrow the spectrum, reduce toxicity, and reduce"}, 
{"Row" : 42, "Column" : 1, "Text" : "costs."}, 
{"Row" : 52, "Column" : 1, "Text" : "References"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell Chapter Sepsis, Severe Sepsis and Septic Shock"}
]},
{"Name" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS" , "Term1" : "Endocarditis, approach to", "DisplayText" : "Approach to Endocarditis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE CRITERIA", "DisplayText" : "Modified Duke Diagnostic Criteria", "Text" : "Diagnosis with Duke Criteria", "Mnemonic" : "4"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Penicillin Desensitization protocol", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO ENDOCARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious Diseases and Cardiology consults are essential for proved cases and"}, 
{"Row" :6, "Column" : 1, "Text" : "encouraged for suspected cases. See diagnosis page for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "Attempt to identify the pathogen before starting antimicrobials. At least three"}, 
{"Row" : 11, "Column" : 1, "Text" : "sets of blood cultures should be obtained from different venipuncture sites."}, 
{"Row" : 12, "Column" : 1, "Text" : "These cultures should be drawn at different times with the first and last"}, 
{"Row" : 13, "Column" : 1, "Text" : "culture separated by at least one hour."}, 
{"Row" : 15, "Column" : 1, "Text" : "For a patient who is not clinically stable, or if the progression of the illness"}, 
{"Row" : 16, "Column" : 1, "Text" : "is rapid, draw 3 sets of blood cultures and then initiate empirical"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobial therapy and/or surgical intervention."}, 
{"Row" : 19, "Column" : 1, "Text" : "Ascertain whether any antimicrobials were taken during the previous 2 weeks to"}, 
{"Row" : 20, "Column" : 1, "Text" : "help interpret culture results."}, 
{"Row" : 22, "Column" : 1, "Text" : "Penicillin susceptibility data are used to determine appropriate antimicrobial"}, 
{"Row" : 23, "Column" : 1, "Text" : "therapy for streptococcal endocarditis. Because bacteria in cardiac vegetations"}, 
{"Row" : 24, "Column" : 1, "Text" : "are not actively dividing, and are protected from host defense mechanisms,"}, 
{"Row" : 25, "Column" : 1, "Text" : "bactericidal antimicrobial regimens are necessary to treat bacterial"}, 
{"Row" : 26, "Column" : 1, "Text" : "endocarditis. The minimum inhibitory concentration (MIC) cut-off levels used to"}, 
{"Row" : 27, "Column" : 1, "Text" : "select therapy for endocarditis differ from those used to select therapy for"}, 
{"Row" : 28, "Column" : 1, "Text" : "other infectious diseases (see below)."}, 
{"Row" : 30, "Column" : 1, "Text" : "Penicillin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Beta-lactam antibiotics are more effective than vancomycin for treating"}, 
{"Row" : 32, "Column" : 1, "Text" : "susceptible gram-positive pathogens. For patients with penicillin allergy that"}, 
{"Row" : 33, "Column" : 1, "Text" : "is known or suspected to be class I (anaphylaxis, angioedema, or hives),"}, 
{"Row" : 34, "Column" : 1, "Text" : "penicillin desensitization or therapy with a cephalosporin is usually the best"}, 
{"Row" : 35, "Column" : 1, "Text" : "approach."}, 
{"Row" : 39, "Column" : 1, "Text" : "When gentamicin is used for synergy against gram positive bacteria, serum"}, 
{"Row" : 40, "Column" : 1, "Text" : "concentrations should be 3-4 mcg/ml peak and < 1 mcg/ml trough. Once daily"}, 
{"Row" : 41, "Column" : 1, "Text" : "gentamicin dosing can be used for streptococcal cases but not for staphylococcal"}, 
{"Row" : 42, "Column" : 1, "Text" : "or enterococcal cases."}, 
{"Row" : 44, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 51, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ABX APPROACH TO ACUTE MENINGITIS", "DisplayText" : "Approach to Acute Meningitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "DisplayText" : "Bacterial meningitis without Gram stain results", "Text" : "Community acquired meningitis", "Mnemonic" : "4"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "DisplayText" : "Bacterial meningitis associated with trauma or nosocomial infection", "Text" : "Meningitis associated with trauma or nosocomial infection", "Mnemonic" : "6"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "DisplayText" : "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia", "Text" : "Gram-positive diplococci suggesting Streptococcus pneumoniae", "Mnemonic" : "8"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "DisplayText" : "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis", "Text" : "Gram-negative diplococci suggesting Neisseria meningitidis", "Mnemonic" : "10"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes", "Text" : "Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes", "Mnemonic" : "12"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GNB", "DisplayText" : "Bacterial meningitis with Gram negative bacilli", "Text" : "Gram negative bacilli", "Mnemonic" : "14"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "DisplayText" : "Bacterial meningitis with S. pneumoniae", "Text" : "S. pneumoniae", "Mnemonic" : "16"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "DisplayText" : "Bacterial meningitis with N. meningitidis", "Text" : "N. meningitidis", "Mnemonic" : "18"},
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "DisplayText" : "Bacterial meningitis with L. monocytogenes", "Text" : "L. monocytogenes", "Mnemonic" : "20"},
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "E. Coli, Pseudomonas, or another organism", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO ACUTE MENINGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Meningitis is an inflammation of the meninges and tissues surrounding the brain"}, 
{"Row" :6, "Column" : 1, "Text" : "and spinal cord. It is characterized by an abnormal amount of white blood cells"}, 
{"Row" :7, "Column" : 1, "Text" : "in the cerebrospinal fluid (CSF) and symptoms include headache, fever, mental"}, 
{"Row" :8, "Column" : 1, "Text" : "status changes, nuchal rigidity, and nausea."}, 
{"Row" : 10, "Column" : 1, "Text" : "Acute Meningitis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "The sudden onset of meningeal symptoms within hours to days caused by several"}, 
{"Row" : 12, "Column" : 1, "Text" : "infectious etiologies, including bacterial, viral, fungal and protozoa, as well"}, 
{"Row" : 13, "Column" : 1, "Text" : "as non-infectious etiologies. Bacterial meningitis is the most common type of"}, 
{"Row" : 14, "Column" : 1, "Text" : "meningitis, accounting for up to 90% of cases where a CSF culture was obtained"}, 
{"Row" : 15, "Column" : 1, "Text" : "prior to starting antimicrobials. Non-bacterial meningitis is commonly referred"}, 
{"Row" : 16, "Column" : 1, "Text" : "to as aseptic meningitis (refer to \"Negative CSF culture\" below for"}, 
{"Row" : 17, "Column" : 1, "Text" : "recommendations)."}, 
{"Row" : 19, "Column" : 1, "Text" : "Patients with acute bacterial meningitis often have severe symptoms and present"}, 
{"Row" : 20, "Column" : 1, "Text" : "soon after onset of infection. The relationship between predisposing factors and"}, 
{"Row" : 21, "Column" : 1, "Text" : "common bacterial pathogen are listed below."}, 
{"Row" : 23, "Column" : 1, "Text" : "Predisposing Factors and Common Bacterial Pathogens", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "*Age 2-50 years - S. pneumoniae, N. meningitidis"}, 
{"Row" : 25, "Column" : 1, "Text" : "*Age > 50 years - S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic"}, 
{"Row" : 26, "Column" : 1, "Text" : "gram-negative bacilli"}, 
{"Row" : 27, "Column" : 1, "Text" : "*Immunocompromised state - S. pneumoniae, N. meningitidis, L. monocytogenes,"}, 
{"Row" : 28, "Column" : 1, "Text" : "aerobic gram-negative bacilli (including Pseudomonas aeruginosa)"}, 
{"Row" : 29, "Column" : 1, "Text" : "*Basilar skull fracture - S. pneumoniae: H. influenzae, group A and"}, 
{"Row" : 30, "Column" : 1, "Text" : "beta-hemolytic streptococci"}, 
{"Row" : 31, "Column" : 1, "Text" : "*Head trauma: after neurosurgery - Staphylococcus aureus, coagulase-negative"}, 
{"Row" : 32, "Column" : 1, "Text" : "staphylococci (especially Staphylococcus epidermidis), aerobic gram-negative"}, 
{"Row" : 33, "Column" : 1, "Text" : "bacilli (including P. aeruginosa)"}, 
{"Row" : 35, "Column" : 1, "Text" : "Initial Management of Suspected Acute Bacterial Meningitis", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" : 37, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" : 38, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" : 39, "Column" : 1, "Text" : "to obtain CSF for establishing diagnosis and determining infectious"}, 
{"Row" : 40, "Column" : 1, "Text" : "organism/susceptibility. Computed tomography (CT) should be performed prior to"}, 
{"Row" : 41, "Column" : 1, "Text" : "LP in some patients (see list below). If CT must be obtained prior to LP or"}, 
{"Row" : 42, "Column" : 1, "Text" : "there is another delay in performing LP, empiric antimicrobials should not be"}, 
{"Row" : 43, "Column" : 1, "Text" : "delayed and initiated immediately after obtaining blood cultures only."}, 
{"Row" : 45, "Column" : 1, "Text" : "Relative LP contraindications (no absolute contraindications exist): "}, 
{"Row" : 46, "Column" : 1, "Text" : "Anticoagulation therapy or bleeding disorder, spinal epidural abscess, raised"}, 
{"Row" : 47, "Column" : 1, "Text" : "intracranial pressure."}, 
{"Row" : 49, "Column" : 1, "Text" : "Computed tomography scan should be performed prior to lumbar puncture in cases"}, 
{"Row" : 50, "Column" : 1, "Text" : "with the following: Immunocompromise, history of CNS disease, new onset seizure,"}, 
{"Row" : 51, "Column" : 1, "Text" : "papilledema, abnormal level of consciousness, focal neurologic deficit."}, 
{"Row" : 53, "Column" : 1, "Text" : "LP and CSF Analysis", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "LP opening pressure is often elevated in bacterial meningitis. CSF findings"}, 
{"Row" : 55, "Column" : 1, "Text" : "characteristic of bacterial meningitis include CSF glucose <40mg/dL, CSF to"}, 
{"Row" : 56, "Column" : 1, "Text" : "serum glucose ratio </=0.4, CSF protein concentration >/=200 mg/dL and CSF WBC"}, 
{"Row" : 57, "Column" : 1, "Text" : ">1000 microL."}, 
{"Row" : 59, "Column" : 1, "Text" : "Empiric Treatment After Blood Cultures are Drawn, and CSF is Obtained, or if LP", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Must be Delayed", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "Empiric Treatment Based on CSF Gram-Stain Results", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Text" : "When gram stain results are available, adjust antimicrobials to optimize therapy"}, 
{"Row" : 71, "Column" : 1, "Text" : "Treatment Based on CSF Isolated Organism", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "When infectious organism is identified, adjust antimicrobials to optimize therap"}, 
{"Row" : 78, "Column" : 1, "Text" : "Negative CSF Culture", "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Text" : "Patients who have a negative CSF culture but have symptoms and CSF findings"}, 
{"Row" : 80, "Column" : 1, "Text" : "consistent with bacterial meningitis should be treated based on likely pathogen."}, 
{"Row" : 81, "Column" : 1, "Text" : "Patients with negative CSF culture, symptoms of acute meningitis but have labs"}, 
{"Row" : 82, "Column" : 1, "Text" : "inconsistent with bacterial meningitis should be considered to have aseptic"}, 
{"Row" : 83, "Column" : 1, "Text" : "meningitis. Aseptic meningitis is caused by a variety of non-bacterial"}, 
{"Row" : 84, "Column" : 1, "Text" : "infectious etiologies and non-infectious etiologies. Consult Infectious Disease"}, 
{"Row" : 85, "Column" : 1, "Text" : "for more information."}, 
{"Row" : 86, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 89, "Column" : 1, "Text" : "References: "}, 
{"Row" : 90, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 91, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 92, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 93, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 94, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 95, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 96, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 97, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU ABX APPROACH TO UTI", "DisplayText" : "Approach to Urinary Tract Infection (UTI) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic Bacteriuria", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Candida urinary tract infections", "Mnemonic" : "8"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "DisplayText" : "Uncomplicated Cystitis", "Text" : "Uncomplicated cystitis", "Mnemonic" : "10"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "DisplayText" : "Complicated Cystitis", "Text" : "Complicated cystitis", "Mnemonic" : "12"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Pyelonephritis", "Mnemonic" : "14"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU UROSEPSIS", "DisplayText" : "Urosepsis", "Text" : "Bacteremia or sepsis with urinary tract source (aka urosepsis)", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO URINARY TRACT INFECTION (UTI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Urinary tract infections (UTI) occur in patients with symptoms of infection in"}, 
{"Row" :6, "Column" : 1, "Text" : "the lower urinary tract (cystitis) and/or the upper urinary tract"}, 
{"Row" :7, "Column" : 1, "Text" : "(pyelonephritis). Cystitis refers to infection of the urinary bladder, but"}, 
{"Row" :8, "Column" : 1, "Text" : "inflammation often extends into the urethra. Typical signs and symptoms include"}, 
{"Row" :9, "Column" : 1, "Text" : "dysuria, increased urinary frequency, urgency, and/or suprapubic tenderness."}, 
{"Row" : 11, "Column" : 1, "Text" : "Uncomplicated cystitis occurs in people with structurally and neurogenically"}, 
{"Row" : 12, "Column" : 1, "Text" : "normal urinary tract. Most cases of uncomplicated cystitis occur in"}, 
{"Row" : 13, "Column" : 1, "Text" : "pre-menopausal, non-pregnant, sexually active young women and is associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S."}, 
{"Row" : 15, "Column" : 1, "Text" : "saprophyticus. Complicated cystitis occurs in the conditions listed below and is"}, 
{"Row" : 16, "Column" : 1, "Text" : "associated with Enterobacteriaceae, but more resistant pathogens occur,"}, 
{"Row" : 17, "Column" : 1, "Text" : "including the Gram-positive pathogens staphylococci and enterococci. Features of"}, 
{"Row" : 18, "Column" : 1, "Text" : "pyelonephritis include fever/other signs of systemic infection, flank pain,"}, 
{"Row" : 19, "Column" : 1, "Text" : "costovertebral tenderness, and pelvic or perianal pain in men. In rare and"}, 
{"Row" : 20, "Column" : 1, "Text" : "severe cases, urinary tract infections can also present with bacteremia, sepsis,"}, 
{"Row" : 21, "Column" : 1, "Text" : "multiple organ system dysfunction, shock and/or acute renal failure."}, 
{"Row" : 23, "Column" : 1, "Text" : "When a patient presents with symptoms of cystitis, like dysuria, increased"}, 
{"Row" : 24, "Column" : 1, "Text" : "frequency, and suprapubic pain, perform a urine culture. Antimicrobial therapy"}, 
{"Row" : 25, "Column" : 1, "Text" : "is not indicated for pyuria in the absence of symptoms. Patients with signs and"}, 
{"Row" : 26, "Column" : 1, "Text" : "symptoms of pyelonephritis should have a urinary culture and susceptibility"}, 
{"Row" : 27, "Column" : 1, "Text" : "obtained and a urine Gram-stain performed prior to starting empirical"}, 
{"Row" : 28, "Column" : 1, "Text" : "antimicrobials to guide therapy. Patients presenting with bacteremia, sepsis,"}, 
{"Row" : 29, "Column" : 1, "Text" : "multiorgan dysfunction, shock and/or acute renal failure should be treated"}, 
{"Row" : 30, "Column" : 1, "Text" : "accordingly with urinary tract as the foci of infection."}, 
{"Row" : 32, "Column" : 1, "Text" : "Asymptomatic bacteriuria occurs in patients who have bacteria in the urine but"}, 
{"Row" : 33, "Column" : 1, "Text" : "do not have symptoms of a urinary tract infection. Asymptomatic bacteriuria is"}, 
{"Row" : 34, "Column" : 1, "Text" : "further discussed elsewhere: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 38, "Column" : 1, "Text" : "treatment: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Candida urinary tract infections are discussed elsewhere: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Complicating conditions", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Cystitis is considered complicated when one or more of the following is present: "}, 
{"Row" : 46, "Column" : 1, "Text" : "o Pregnant women"}, 
{"Row" : 47, "Column" : 1, "Text" : "o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter"}, 
{"Row" : 48, "Column" : 1, "Text" : "or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)"}, 
{"Row" : 49, "Column" : 1, "Text" : "o Immunocompromise"}, 
{"Row" : 50, "Column" : 1, "Text" : "o Persistent infection, relapse, recurrence, or treatment failure"}, 
{"Row" : 51, "Column" : 1, "Text" : "o In some cases, men and patients admitted to health care settings may be"}, 
{"Row" : 52, "Column" : 1, "Text" : "considered complicated"}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "References: "}, 
{"Row" : 65, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infection"}
]},
{"Name" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA" , "Term1" : "Aspiration pneumonia " , "Term2" : "Pneumonia, aspiration", "DisplayText" : "Aspiration pneumonia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community acquired pneumonia (CAP)< OR >", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Nosocomial pneumonia", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "DisplayText" : "Lung abscess", "Text" : "Lung abscess", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "ASPIRATION PNEUMONIA"}, 
{"Row" :4, "Column" : 1, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is"}, 
{"Row" :5, "Column" : 1, "Text" : "often accompanied by fever and/or an infiltrate.Bacterial pneumonia occurs in"}, 
{"Row" :6, "Column" : 1, "Text" : "a minority of patients who aspirate, typically about 3 days later.The patient"}, 
{"Row" :7, "Column" : 1, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia"}, 
{"Row" :8, "Column" : 1, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and"}, 
{"Row" :9, "Column" : 1, "Text" : "newly purulent sputum."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails"}, 
{"Row" : 12, "Column" : 1, "Text" : "risk of side effects and selection of resistant organisms."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases"}, 
{"Row" : 15, "Column" : 1, "Text" : "that develop after an episode of aspiration.For more information, consult"}, 
{"Row" : 16, "Column" : 1, "Text" : "Pulmonary or Infectious Diseases."}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment for patients with pneumonitis but without lung abscess or putrid", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "sputum", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary.If"}, 
{"Row" : 21, "Column" : 1, "Text" : "pneumonia is confirmed, treat as"}, 
{"Row" : 26, "Column" : 1, "Text" : "Treament for patients with LUNG ABSCESS", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 33, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 34, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Lung Abscess"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405"}, 
{"Row" : 37, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 38, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}
]},
{"Name" : "ORZID2 GMENU ABX ASSOC COLITIS" , "Term1" : "Clostridium difficile, mild to moderate disease", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX INI EPI ABX ASSOC COLITIS", "DisplayText" : "Initial Episode of Antibiotic Associated Colitis...", "Text" : "Initial Episode", "Mnemonic" : "4"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX FIRST RECURRENCE ABX ASSOC", "Text" : "First Recurrence", "Mnemonic" : "6"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND RECUR ABX ASSOC COLITIS", "DisplayText" : "ORZID2 GMENU SECOND RECURRENCE ABX ASSOC COLITIS", "Text" : "Second Recurrence", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic"}, 
{"Row" : 18, "Column" : 1, "Text" : "therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C."}, 
{"Row" : 19, "Column" : 1, "Text" : "difficile PCR testing should be completed to confirm diagnosis of C. difficile"}, 
{"Row" : 20, "Column" : 1, "Text" : "infection."}, 
{"Row" : 22, "Column" : 1, "Text" : "Antibiotic risk (rank order): ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,"}, 
{"Row" : 24, "Column" : 1, "Text" : "Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,"}, 
{"Row" : 25, "Column" : 1, "Text" : "vancomycin, metronidazole"}, 
{"Row" : 26, "Column" : 1, "Text" : "Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampin"}, 
{"Row" : 27, "Column" : 1, "Text" : "Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine"}, 
{"Row" : 29, "Column" : 1, "Text" : "Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence"}, 
{"Row" : 30, "Column" : 1, "Text" : "suggests that antacid therapy, especially with PPIs and H2 blockers, increases"}, 
{"Row" : 31, "Column" : 1, "Text" : "the risk for C. difficile disease and recurrences. Avoid antacid therapy"}, 
{"Row" : 32, "Column" : 1, "Text" : "without clear indication, especially in patients at risk for primary recurrent C"}, 
{"Row" : 33, "Column" : 1, "Text" : "difficile disease."}, 
{"Row" : 35, "Column" : 1, "Text" : "The preferred route of antimicrobial therapy for C. difficile infection is by"}, 
{"Row" : 36, "Column" : 1, "Text" : "mouth. Intravenous metronidazole should be used only when oral therapy cannot"}, 
{"Row" : 37, "Column" : 1, "Text" : "be used to deliver drug to the colon. Intravenous vancomycin does not get into"}, 
{"Row" : 38, "Column" : 1, "Text" : "colonic contents and is not effective."}, 
{"Row" : 40, "Column" : 1, "Text" : "C. difficile infection usually responds to antimicrobial therapy, especially if"}, 
{"Row" : 41, "Column" : 1, "Text" : "other antimicrobial therapy has been stopped. Relapse is usually due to failure"}, 
{"Row" : 42, "Column" : 1, "Text" : "of normal colonic flora to re-establish itself, rather than antimicrobial"}, 
{"Row" : 43, "Column" : 1, "Text" : "treatment failure. If symptoms do not respond to appropriate antimicrobial"}, 
{"Row" : 44, "Column" : 1, "Text" : "therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after"}, 
{"Row" : 45, "Column" : 1, "Text" : "their first episode of C. difficile infection."}, 
{"Row" : 50, "Column" : 1, "Text" : "Third Recurrence: Consult Gastroenterology and/or Infectious Disease", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 57, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 58, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical"}, 
{"Row" : 60, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 55, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 56, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" :7, "Column" : 1, "Text" : "CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in"}, 
{"Row" :8, "Column" : 1, "Text" : "24 hours after discontinuation of laxatives) and laboratory confirmation of CDI."}, 
{"Row" : 14, "Column" : 1, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory"}, 
{"Row" : 15, "Column" : 1, "Text" : "case of CDI within 12 weeks after a prior episode."}, 
{"Row" :3, "Column" : 1, "Text" : "CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "If diarrhea has improved or resolved prior to starting C. difficile"}, 
{"Row" : 10, "Column" : 1, "Text" : "treatment, consider re-assessing the diagnosis before initiating therapy."}, 
{"Row" : 11, "Column" : 1, "Text" : "The Infectious Disease service is always available to discuss CDI testing"}, 
{"Row" : 12, "Column" : 1, "Text" : "and results."}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "<Click here> Information on C. difficile lab testing", "Mnemonic" : "2"}
]},
{"Name" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic Bacteriuria" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl >30 mL/min, for 5 days", "Mnemonic" : "4"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "6"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "DisplayText" : "Urological procedures", "Text" : "Antimicrobial prophylaxis for urological procedures", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ASYMPTOMATIC BACTERIURIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Asymptomatic bacteriuria is common in women and elderly people, especially in"}, 
{"Row" :6, "Column" : 1, "Text" : "those with chronic medical problems (e.g., diabetes, spinal cord injury,"}, 
{"Row" :7, "Column" : 1, "Text" : "institutionalized patients, catheterized patients). Most patients have no"}, 
{"Row" :8, "Column" : 1, "Text" : "adverse outcomes and receive no benefit from treatment of asymptomatic"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteriuria."}, 
{"Row" : 11, "Column" : 1, "Text" : "Patients who have no symptoms of cystitis (i.e., no dysuria, pain, urgency)"}, 
{"Row" : 12, "Column" : 1, "Text" : "should not be treated. The presence of pyuria (>7 wbc/hpf) or positive leukocyte"}, 
{"Row" : 13, "Column" : 1, "Text" : "esterase, urine nitrate, or urine bacteria is not a sufficient indication for"}, 
{"Row" : 14, "Column" : 1, "Text" : "antibiotic treatment. Screening and treatment of asymptomatic bacteriuria is"}, 
{"Row" : 15, "Column" : 1, "Text" : "indicated for pregnant women and patients who will have urological procedures"}, 
{"Row" : 16, "Column" : 1, "Text" : "and may be indicated in patients < 1-month post-renal transplant. If an"}, 
{"Row" : 17, "Column" : 1, "Text" : "indwelling catheter is in place and can be removed safely, it should be done as"}, 
{"Row" : 18, "Column" : 1, "Text" : "the bacteriuria may clear."}, 
{"Row" : 20, "Column" : 1, "Text" : "Bacteriuria in pregnant women is associated with pyelonephritis, premature"}, 
{"Row" : 21, "Column" : 1, "Text" : "delivery, and lower birth weight. Screening for bacteriuria is recommended at"}, 
{"Row" : 22, "Column" : 1, "Text" : "least once early in pregnancy. If bacteriuria is not found upon initial testing,"}, 
{"Row" : 23, "Column" : 1, "Text" : "further screening cultures are not needed. If bacteriuria (>10,000 CFU/mL) is"}, 
{"Row" : 24, "Column" : 1, "Text" : "present, the patient should be treated. Testing should be repeated throughout"}, 
{"Row" : 25, "Column" : 1, "Text" : "the pregnancy to detect recurrences."}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Pregnant women, empirical treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 31, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Patients having urological procedures", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Renal transplant recipients < 1 month after transplant", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Screening and treatment of asymptomatic bacteriuria may be indicated. Consult"}, 
{"Row" : 45, "Column" : 1, "Text" : "nephrology for recommendations."}, 
{"Row" : 46, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infections"}, 
{"Row" : 51, "Column" : 1, "Text" : "Nicolle et al., Clinical Infectious Diseases, 2019, 2.68(10)e83-e110"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Bacteriuria, Asymptomatic"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in"}, 
{"Row" : 54, "Column" : 1, "Text" : "pregnancy"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with asymptomatic bacteriuria"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-To-Date article: Kidney transplantation in adults: Urinary tract infection in"}, 
{"Row" : 57, "Column" : 1, "Text" : "kidney transplant recipients"}, 
{"Row" : 58, "Column" : 1, "Text" : "US Preventive Services Task Force, JAMA, 2019, 322(12)1188-1194"}
]},
{"Name" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "DisplayText" : "Azithromycin for Prevention of Exacerbations COPD " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "DisplayText" : "RESOURCE QTC PROLONGATION FOR DRUGS", "Text" : "Please Click Here for Resource for Drugs that Cause QTc Prolongation", "Mnemonic" : "4"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ GMENU COPD-EXACERBATION MAIN IP", "DisplayText" : "COPD Exacerbation Orders...", "Text" : "Inpatient COPD Exacerbation Orders", "Mnemonic" : "6"},
{"Row" : 51, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN LONGTERM COPD PULM", "DisplayText" : "Azithromycin 250 mg po daily", "Text" : "Azithromycin 250 mg po daily long-term for COPD ($) [DI]", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "Azithromycin for Prevention of Exacerbations in Advanced COPD", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)"}, 
{"Row" :4, "Column" : 1, "Text" : "exacerbations in people with advanced COPD (Albert et al, see below)."}, 
{"Row" :5, "Column" : 1, "Text" : "Of note, in the study there was no benefit in the most severely ill"}, 
{"Row" :6, "Column" : 1, "Text" : "subgroup that was on the most pulmonary medications.People"}, 
{"Row" :7, "Column" : 1, "Text" : "with frequent exacerbations have more doctor visits and hospitalizations than"}, 
{"Row" :8, "Column" : 1, "Text" : "people with fewer or no exacerbations.Frequent exacerbations are associated"}, 
{"Row" :9, "Column" : 1, "Text" : "with rapid decline in lung function and quality of life and increased risk of"}, 
{"Row" : 10, "Column" : 1, "Text" : "death."}, 
{"Row" : 12, "Column" : 1, "Text" : "To receive daily azithromycin, patients must meet the following criteria and"}, 
{"Row" : 13, "Column" : 1, "Text" : "receive approval from pulmonary service.The evidence that benefits of daily"}, 
{"Row" : 14, "Column" : 1, "Text" : "azithromycin outweigh risks is limited to people who meet the following"}, 
{"Row" : 15, "Column" : 1, "Text" : "criteria."}, 
{"Row" : 17, "Column" : 1, "Text" : "Eligibility Criteria: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "*Age >40 years"}, 
{"Row" : 19, "Column" : 1, "Text" : "*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of"}, 
{"Row" : 20, "Column" : 1, "Text" : "postbronchodilator forced expiratory volume in 1 second [FEV1] to forced"}, 
{"Row" : 21, "Column" : 1, "Text" : "vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the"}, 
{"Row" : 22, "Column" : 1, "Text" : "predicted value), *AND*"}, 
{"Row" : 23, "Column" : 1, "Text" : "*Were either using continuous supplemental oxygen or had received systemic"}, 
{"Row" : 24, "Column" : 1, "Text" : "glucocorticoids within the previous year, *OR*"}, 
{"Row" : 25, "Column" : 1, "Text" : "*Had gone to an emergency room or had been hospitalized for an acute"}, 
{"Row" : 26, "Column" : 1, "Text" : "exacerbation of COPD."}, 
{"Row" : 27, "Column" : 1, "Text" : "Exclusion criteria: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "*Asthma"}, 
{"Row" : 29, "Column" : 1, "Text" : "*People with hearing impairments"}, 
{"Row" : 30, "Column" : 1, "Text" : "*Congestive heart failure"}, 
{"Row" : 31, "Column" : 1, "Text" : "*Resting heart rate > 100 beats per minute"}, 
{"Row" : 32, "Column" : 1, "Text" : "*Use of medications that are associated with torsades de pointes (with the"}, 
{"Row" : 33, "Column" : 1, "Text" : "exception of amiodarone)"}, 
{"Row" : 34, "Column" : 1, "Text" : "*Prolonged QTc interval (>450 msec)"}, 
{"Row" : 35, "Column" : 1, "Text" : "*Use of medications that prolong the QTc interval"}, 
{"Row" : 38, "Column" : 1, "Text" : "If, after trying all of the standard treatments, patients are still having"}, 
{"Row" : 39, "Column" : 1, "Text" : "acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin"}, 
{"Row" : 40, "Column" : 1, "Text" : "may be considered."}, 
{"Row" : 41, "Column" : 1, "Text" : "Note: Guidelines for COPD can be found on the CPRS Tools Menu."}, 
{"Row" : 42, "Column" : 1, "Text" : "Select below for Inpatient COPD order sets for comprehensive management: ", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "If the patient meets the criteria and is willing to have audiometric testing"}, 
{"Row" : 46, "Column" : 1, "Text" : "and an electrocardiogram, please place a Pulmonary Consult for long-term"}, 
{"Row" : 47, "Column" : 1, "Text" : "Azithromycin therapy for the prevention of exacerbations of COPD."}, 
{"Row" : 49, "Column" : 1, "Text" : "Pulmonary is the only approved provider for ordering long-term", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Azithromycin therapy for COPD.", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD.New"}, 
{"Row" : 55, "Column" : 1, "Text" : "England Journal of Medicine 2011, 365:689-698"}, 
{"Row" : 56, "Column" : 1, "Text" : "Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.New"}, 
{"Row" : 57, "Column" : 1, "Text" : "England Journal of Medicine 2012, 366:1881-1890"}
]},
{"Name" : "ORZID2 GMENU ABX BACTEREMIA" , "Term1" : "Bacteremia", "DisplayText" : "Bacteremia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "DisplayText" : "Approach to bacteremia", "Text" : "Approach to bacteremia...", "Mnemonic" : "4"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "Suspected bacteremia, blood cultures not yet positive", "Text" : "Suspected bacteremia, blood cultures not yet positive...", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "DisplayText" : "Interim report of Gram-negative cocci", "Text" : "Interim report:Gram negative cocci", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "DisplayText" : "Interim report of Gram-negative bacilli", "Text" : "Interim report:Gram negative bacilli", "Mnemonic" : "10"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Interim report:Gram positive cocci in pairs", "Mnemonic" : "12"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and chains", "Text" : "Interim report:Gram positive cocci in pairs and chains", "Mnemonic" : "14"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and clusters", "Text" : "Interim report:Gram positve cocci in pair and clusters", "Mnemonic" : "16"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Interim report:Gram positive bacilli", "Mnemonic" : "18"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "DisplayText" : "Interim report of yeast", "Text" : "Interim report:Yeast", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "Bacteremia", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Bacteremia, PRELIMINARY results", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Last reviewed July 2017", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "DisplayText" : "Bacteremia associated with Staphylococcus aureus", "Text" : "with Staphylococcus aureus", "Mnemonic" : "24"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "DisplayText" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Text" : "with Coagulase-negative Staphylococci (CNS)", "Mnemonic" : "26"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "with Candida spp.", "Mnemonic" : "28"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "DisplayText" : "Bacteremia associated with Listeria monocytogenes", "Text" : "with Listeria monocytogenes", "Mnemonic" : "30"},
{"Row" :6, "Column" : 2, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 2, "Text" : "Bacteremia, FINAL results (specific pathogens)", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "_____________________________________", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX BALANITIS", "DisplayText" : "Balanitis and Balanoposthitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CREAM TOPICAL BID", "DisplayText" : "Clotrimazole 1% cream topical bid", "Text" : "Clotrimazole 1% cream topically q12h ($) [M] for 7 days", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID NYSTATIN CREAM BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M]", "Text" : "Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150 mg PO once ($) [R,DI]", "Text" : "Fluconazole 150 mg PO once ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 0.75% CREAM TOPICALLY Q12H", "DisplayText" : "Metronidazole 0.75% cream topically q12h ($)[DI]", "Text" : "Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days", "Mnemonic" : "12"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "DisplayText" : "Metronidazole 500MG PO q12h", "Text" : "Metronidazole 500 mg PO q12h ($) [DI] for 7 days", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "BALANITIS AND BALANOPOSTHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Balanitis is inflammation of the glans penis and is often associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "erythema and pruritis. When the foreskin is also involved, the condition is"}, 
{"Row" :7, "Column" : 1, "Text" : "known as balanoposthitis (also referred to as balanitis in this discussion)."}, 
{"Row" :8, "Column" : 1, "Text" : "There are a variety of causes of balanitis, but most are due to poor hygiene of"}, 
{"Row" :9, "Column" : 1, "Text" : "the foreskin in uncircumcised men resulting in candida infection. Other, less"}, 
{"Row" : 10, "Column" : 1, "Text" : "common causes, include bacterial infection (typically sexually transmitted or"}, 
{"Row" : 11, "Column" : 1, "Text" : "anaerobic bacteria), dermatologic conditions, malignancy as well as others. Men"}, 
{"Row" : 12, "Column" : 1, "Text" : "with Candidal balanitis often have a white curd-like exudate compared to a thick"}, 
{"Row" : 13, "Column" : 1, "Text" : "foul-smelling purulent exudate in menu with anaerobic bacterial balanitis."}, 
{"Row" : 15, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 16, "Column" : 1, "Text" : "treatment: "}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Candidal balanitis empirical treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Mild to moderate cases", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Severe cases", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Bacterial balanitis empirical treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Mild cases"}, 
{"Row" : 37, "Column" : 1, "Text" : "Moderate to severe cases"}, 
{"Row" : 39, "Column" : 1, "Text" : "___________________________________________________________________________", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "References: "}, 
{"Row" : 43, "Column" : 1, "Text" : "Edwards et al., International Journal of STD & AIDS, 2014, 25(9)615-526"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Balanitis"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-to-Date article: Balanitis in Adults"}, 
{"Row" : 46, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID2 GMENU ABX BARICITINIB EUA COVID-19", "DisplayText" : "Barcitinib Emergency Use Authorization for COVID-19 " , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "Patients with eGFR >/= 60 ml/min/1.73 m2: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 4MG PO QDAY X14DAYS", "DisplayText" : "Baricitinib EUA 4 mg po qday for 14 days or until discharge (COVID-19) ($$$) [R]", "Text" : "Baricitinib 4 mg PO qday for 14 days or until discharge (COVID-19) ($$$) [R]", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Text" : "Patients with eGFR 30-59 ml/min/1.73 m2: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Patients with eGFR 15-29 ml/min/1.73 m2: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Patients with an eGFR < 15ml/min/1.73 m2 or those on dialysis: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Baricitinib is NOT recommended"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "02"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 2MG PO QDAY X14DAYS", "DisplayText" : "Baricitinib EUA 2 mg po qday for 14 days or until discharge (COVID-19) ($$) [R]", "Text" : "Baricitinib 2 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]", "Mnemonic" : "16"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 1MG PO QDAY X14DAYS", "DisplayText" : "Baricitinib EUA 1 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]", "Text" : "Baricitinib 1 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "Barcitinib Oral", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 4MG + ADMINISTRATION INSTRUCTIONS", "DisplayText" : "Baricitinib 4 mg NG qday for 14 days + Administration Instructions", "Text" : "Baricitinib 4 mg NG qday for 14 days or until discharge (COVID-19) ($$$) [R]", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 2MG + ADMINISTRATION INSTRUCTIONS", "DisplayText" : "Baricitinib 2 mg q day for 14 days + Administration Instructions", "Text" : "Baricitinib 2 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]", "Mnemonic" : "18"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 1MG + ADMINISTRATION INSTRUCTIONS", "DisplayText" : "Baricitinib 1mg NG qday x 14 days + Administration Instructions", "Text" : "Baricitinib 1 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]", "Mnemonic" : "24"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 4MG + ADMIN INSTRUCTIONS", "DisplayText" : "Baricitinib 4mg G Tube qday x 14 days or until discharge ($$) [R]", "Text" : "Baricitinib 4 mg G Tube qday for 14 days or until discharge (COVID-19)", "Mnemonic" : "14"},
{"Row" :9, "Column" : 1, "Text" : "($$$) [R]"}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 2MG + ADMIN INSTRUCTIONS", "DisplayText" : "Baricitinib EUA 2mg G Tube qday x 14 days or until hospital discharge ($$) [R]", "Text" : "Baricitinib 2 mg G Tube qday for 14 days or until discharge (COVID-19)", "Mnemonic" : "20"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 1MG+ ADMIN INSTRUCTIONS", "DisplayText" : "Baricitinib 1mg G Tube qday x 14 days + Administration Instructions", "Text" : "Baricitinib 1 mg G Tube qday for 14 days or until discharge (COVID-19)", "Mnemonic" : "26"},
{"Row" : 15, "Column" : 1, "Text" : "($$) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "($$) [R]"}
]},
{"Name" : "ORZID2 GMENU ABX BEBTELOVIMAB EUA", "DisplayText" : "Bebtelovimab (EUA) Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "DisplayText" : "Bebtelovimab EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "PSJZID INV-BEBTELOVIMAB 175 MG IV ONCE", "DisplayText" : "Bebtelovimab 175 mg IV push once", "Text" : "INV-Bebtelovimab 175 mg IV Push ONCE", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "Bebtelovimab (EUA)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)"}, 
{"Row" :5, "Column" : 1, "Text" : "for treating patients that meet specific criteria. bebtelovimab is"}, 
{"Row" :6, "Column" : 1, "Text" : "not FDA approved drug."}, 
{"Row" :7, "Column" : 1, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis."}, 
{"Row" :9, "Column" : 1, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 20, "Column" : 1, "Text" : "Inclusion Criteria", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "ALL of the following criteria must be met for a patient to receive: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19 and is diagnosed with mild to"}, 
{"Row" : 24, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "Note: patient may be hospitalized for some other reason."}, 
{"Row" : 26, "Column" : 1, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19."}, 
{"Row" : 27, "Column" : 1, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an"}, 
{"Row" : 28, "Column" : 1, "Text" : "increase in baseline oxygen flow rate due to COVID-19."}, 
{"Row" : 29, "Column" : 1, "Text" : "4) Administration will begin within 7 days of symptom onset."}, 
{"Row" : 30, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components."}, 
{"Row" : 31, "Column" : 1, "Text" : "6) Patient has at least one risk factor for progression to severe disease"}, 
{"Row" : 32, "Column" : 1, "Text" : "including hospitalization or death."}, 
{"Row" : 33, "Column" : 1, "Text" : "See link below for complete list: "}, 
{"Row" : 35, "Column" : 1, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA"}, 
{"Row" : 36, "Column" : 1, "Text" : "The provider has communicated with the patient/caregiver regarding"}, 
{"Row" : 37, "Column" : 1, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/"}, 
{"Row" : 38, "Column" : 1, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an"}, 
{"Row" : 39, "Column" : 1, "Text" : "unapproved drug that is authorized for use under an EUA, given information"}, 
{"Row" : 40, "Column" : 1, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver"}, 
{"Row" : 41, "Column" : 1, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)"}, 
{"Row" : 43, "Column" : 1, "Text" : "Exclusion Criteria", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "If patient received tixagevimab plus cilgavimab previously, discuss with ID."}, 
{"Row" : 46, "Column" : 1, "Text" : "If above requirements are met, place medication order: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Monitor patient during infusion and 1 hour after infusion completed."}, 
{"Row" : 50, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 51, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid"}, 
{"Row" : 52, "Column" : 1, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and"}, 
{"Row" : 53, "Column" : 1, "Text" : "frequent handwashing) according to CDC guidelines."}, 
{"Row" : 23, "Column" : 1, "Text" : "moderate illness."}
]},
{"Name" : "ORZID2 GMENU ABX BELL'S PALSY" , "Term1" : "Bell's palsy", "DisplayText" : "Bell's Palsy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme Disease", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PREDNISONE 60MG Q24H 7D VALACYCLOVIR 1000MG PO Q8H", "DisplayText" : "PREDNISONE 60MG Q24H 7D VALACYCLOVIR 1000MG PO Q8H", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX PREDNISONE 60MG Q24H 7D ACYCLOVIR 400MG PO 5X/DAY", "DisplayText" : "PREDNISONE 60MG Q24H 7D ACYCLOVIR 400MG PO 5X/DAY", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO 5X/day ($) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BELL'S PALSY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others"}, 
{"Row" :6, "Column" : 1, "Text" : "include Borrelia burgdorferi or trauma. Some cases are idiopathic. Risk factors"}, 
{"Row" :7, "Column" : 1, "Text" : "Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper"}, 
{"Row" :8, "Column" : 1, "Text" : "respiratory infections. Neurology consult is encouraged."}, 
{"Row" : 10, "Column" : 1, "Text" : "If Lyme disease is suspected, refer to the Lyme disease treatment page: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment with prednisone and an antiviral within 72 hours of symptoms onset"}, 
{"Row" : 14, "Column" : 1, "Text" : "improves the chances of a complete recovery."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 19, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 23, "Column" : 1, "Text" : "for 10 days"}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27"}, 
{"Row" : 29, "Column" : 1, "Text" : "Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361"}, 
{"Row" : 30, "Column" : 1, "Text" : "Jalali et al., Laryngoscope, 2021, 131.1615-1625"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Antivirals against Herpes Viruses"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Herpes Simplex, Bell's Palsy"}, 
{"Row" : 33, "Column" : 1, "Text" : "Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Bell's palsy: Treatment and prognosis in adults"}
]},
{"Name" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of Beta-lactam Reaction [CLICK HERE]", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT BETA-LACTAM ALLERGY FACTS", "DisplayText" : "Important Beta-lactam Allergy Facts and Reaction History", "Text" : "Important Beta-Lactam Allergy Facts and Obtaining a Detailed Reaction History", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "ASSESSMENT OF BETA-LACTAM REACTION AND ALTERNATIVE TREATMENT", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "This guide is intended to aid clinicians in assessment of beta-lactam"}, 
{"Row" :8, "Column" : 1, "Text" : "reactions and selection of appropriate alternative therapy. It is not a"}, 
{"Row" :9, "Column" : 1, "Text" : "substitute for clinical judgment and should not be used as a sole resource when"}, 
{"Row" : 10, "Column" : 1, "Text" : "selecting antimicrobial therapy."}, 
{"Row" : 13, "Column" : 1, "Text" : "Reaction Assessment and Selection of an Alternative Beta-lactam", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "- If the same or a different beta-lactam was subsequently tolerated without"}, 
{"Row" : 15, "Column" : 1, "Text" : "reaction, that beta-lactam may be used."}, 
{"Row" : 16, "Column" : 1, "Text" : "- If reaction was intolerance (e.g. headache, GI symptoms), family history of"}, 
{"Row" : 17, "Column" : 1, "Text" : "reaction, or if the patient denies allergy, any beta-lactam may be used."}, 
{"Row" : 18, "Column" : 1, "Text" : "- See below for treatment based on type of reaction (severe vs non-severe)."}, 
{"Row" : 19, "Column" : 1, "Text" : "- If reaction is unknown and patient denies any severe reactions (see below for"}, 
{"Row" : 20, "Column" : 1, "Text" : "list of severe reactions), reaction is considered non-severe."}, 
{"Row" : 21, "Column" : 1, "Text" : "- If patient is in a suitable care setting, observation during the first 15"}, 
{"Row" : 22, "Column" : 1, "Text" : "minutes to 1 hour after first dose of therapy may be performed to monitor for"}, 
{"Row" : 23, "Column" : 1, "Text" : "signs/symptoms of an allergic reaction."}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "SEVERE REACTION TO BETA-LACTAM: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "If the patient experienced a known severe reaction (use link below for severe"}, 
{"Row" : 30, "Column" : 1, "Text" : "reaction list), AVOID ALL Beta-Lactam Antibiotics. If beta-lactam therapy is"}, 
{"Row" : 31, "Column" : 1, "Text" : "ideal, contact Infectious Diseases for desensitization or alternative."}, 
{"Row" : 32, "Column" : 1, "Text" : "Severe Reaction Examples: "}, 
{"Row" : 33, "Column" : 1, "Text" : "- Anaphylaxis"}, 
{"Row" : 34, "Column" : 1, "Text" : "- Reaction needed medical intervention"}, 
{"Row" : 35, "Column" : 1, "Text" : "- Mucosal, cardiovascular or respiratory system involvement"}, 
{"Row" : 36, "Column" : 1, "Text" : "- Hemolytic anemia"}, 
{"Row" : 37, "Column" : 1, "Text" : "- Immune hepatitis"}, 
{"Row" : 38, "Column" : 1, "Text" : "- Interstitial nephritis"}, 
{"Row" : 39, "Column" : 1, "Text" : "- Acute interstitial nephritis (AIN)"}, 
{"Row" : 40, "Column" : 1, "Text" : "- Skin desquamation"}, 
{"Row" : 41, "Column" : 1, "Text" : "- Drug reaction with eosinophilia and systemic symptoms (DRESS)"}, 
{"Row" : 42, "Column" : 1, "Text" : "- Stevens-Johnson syndrome (SJS)"}, 
{"Row" : 43, "Column" : 1, "Text" : "- Generalized exanthematous pustulosis"}, 
{"Row" : 44, "Column" : 1, "Text" : "- Toxic epidermal necrolysis (TEN)"}, 
{"Row" : 45, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "NON-SEVERE REACTION TO BETA-LACTAM: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Select an alternative non-cross-reactive beta-lactam for therapy based on"}, 
{"Row" : 51, "Column" : 1, "Text" : "beta-lactam class patient had a reaction to. Refer to PDF document above for"}, 
{"Row" : 52, "Column" : 1, "Text" : "detailed cross-reactivity chart."}, 
{"Row" : 54, "Column" : 1, "Text" : "PENICILLIN CLASS REACTION", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "(e.g. Amoxicillin, ampicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin,"}, 
{"Row" : 56, "Column" : 1, "Text" : "penicillin, piperacillin, ticarcillin)"}, 
{"Row" : 57, "Column" : 1, "Text" : "Use: Cefazolin, cefdinir, cefuroxime, ceftazidime, ceftriaxone, cefepime,", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "ertapenem, imipenem, or meropenem", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "1ST GENERATION CEPHALOSPORIN CLASS REACTION", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "(e.g. Cefadroxil, cefatrizine, cefazolin, ceftezole, cephalexin, cephalothin,"}, 
{"Row" : 62, "Column" : 1, "Text" : "cephapirin)"}, 
{"Row" : 63, "Column" : 1, "Text" : "Use: Dicloxacillin, nafcillin, cefazolin (unless reaction was to cefazolin)", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "cefdinir, ceftazidime, ceftriaxone, cefuroxime, cefepime, ertapenem, imipenem,", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Text" : "or meropenem", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "2ND GENERATION CEPHALOSPORIN CLASS REACTION", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "(e.g. Cefaclor, cefamandole, cefonicid, cefotetan, cefoxitin, cefprozil,"}, 
{"Row" : 69, "Column" : 1, "Text" : "cefuroxime)"}, 
{"Row" : 70, "Column" : 1, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, piperacillin,", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "cefadroxil cefazolin, cefdinir, ceftazidime, ceftriaxone, cephalexin, cefepime,", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "ertapenem imipenem, or meropenem", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "3RD-5TH GENERATION CEPHALOSPORIN CLASS REACTION", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "(e.g. Cefdinir, cefditoren, cefepime, cefiderocol ,cefixime, cefpirome,"}, 
{"Row" : 76, "Column" : 1, "Text" : "cefoperazone, cefotaxime, cefpodoxime, ceftaroline, ceftazidime, ceftibuten,"}, 
{"Row" : 77, "Column" : 1, "Text" : "ceftizoxime, ceftolozane, ceftriaxone)"}, 
{"Row" : 78, "Column" : 1, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,", "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Text" : "piperacillin, cefadroxil, cefazolin, cephalexin, ertapenem, imipenem, or", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "meropenem", "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Text" : "CARBAPENEM CLASS REACTION", "Header" : 1}, 
{"Row" : 83, "Column" : 1, "Text" : "(e.g. Ertapenem, imipenem and meropenem)"}, 
{"Row" : 84, "Column" : 1, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,", "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Text" : "piperacillin, cefadroxil, cefazolin, cephalexin, cefdinir, ceftazidime,", "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Text" : "ceftriaxone, or cefepime", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 89, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 90, "Column" : 1, "Text" : "Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital"}, 
{"Row" : 91, "Column" : 1, "Text" : "Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625"}, 
{"Row" : 92, "Column" : 1, "Text" : "Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,"}, 
{"Row" : 93, "Column" : 1, "Text" : "2017"}, 
{"Row" : 94, "Column" : 1, "Text" : "Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-"}, 
{"Row" : 95, "Column" : 1, "Text" : "Reactivity. Pharmacy, 2019, 7(3)103"}, 
{"Row" : 96, "Column" : 1, "Text" : "Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart"}, 
{"Row" : 97, "Column" : 1, "Text" : "Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis"}, 
{"Row" : 98, "Column" : 1, "Text" : "Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious"}, 
{"Row" : 99, "Column" : 1, "Text" : "Diseases, 2020"}, 
{"Row" :100, "Column" : 1, "Text" : "Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved"}, 
{"Row" :101, "Column" : 1, "Text" : "safely. BC Medical Journal, 2019, 61(9)350"}, 
{"Row" :102, "Column" : 1, "Text" : "Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo"}, 
{"Row" :103, "Column" : 1, "Text" : "the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?"}, 
{"Row" :104, "Column" : 1, "Text" : "Clinical Infectious Diseases, 2019, 68(1)157"}, 
{"Row" :105, "Column" : 1, "Text" : "Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,"}, 
{"Row" :106, "Column" : 1, "Text" : "321(2)188"}, 
{"Row" :108, "Column" : 1, "Text" : "Immunol. 2010, 105(4)259"}, 
{"Row" :109, "Column" : 1, "Text" : "Sanford keyword: Drug Allergy, Beta-lactams"}, 
{"Row" :110, "Column" : 1, "Text" : "Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-"}, 
{"Row" :111, "Column" : 1, "Text" : "Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-"}, 
{"Row" :112, "Column" : 1, "Text" : "1542"}, 
{"Row" :113, "Column" : 1, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of"}, 
{"Row" :114, "Column" : 1, "Text" : "cephalosporins and related antibiotics"}, 
{"Row" :115, "Column" : 1, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features"}, 
{"Row" :116, "Column" : 1, "Text" : "Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol"}, 
{"Row" :117, "Column" : 1, "Text" : "Pract. 2018, 6(1)72"}, 
{"Row" :107, "Column" : 1, "Text" : "Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma"}, 
{"Row" :4, "Column" : 1, "Text" : "Streamlined Version (PDF form)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX BLANK PAGE", "DisplayText" : "BLANK PAGE" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "RECOMMENDATIONS NOT AVAILABLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Recommendations for this condition are not available within CDSS. Please refer"}, 
{"Row" :6, "Column" : 1, "Text" : "to facility guidelines or other clinical resources for recommendations."}
]},
{"Name" : "ORZID2 GMENU ABX BRONCHITIS" , "Term1" : "Bronchitis " , "Term2" : "COPD exacerbation " , "Term3" : "Exacerbation of COPD", "DisplayText" : "Consider Antibiotic " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "DisplayText" : "Pertussis", "Text" : "Pertussis", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI] < OR >", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Mnemonic" : "12"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "DisplayText" : "Azithromycin 500mg IV once then 250 mg IV q24h x 4days", "Text" : "Azithromycin 500 mg IV once on day 1, then 250 mg IV q24 for 4 days ($) [M< OR >", "Mnemonic" : "16"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R]", "Mnemonic" : "18"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "20"},
{"Row" :2, "Column" : 1, "Text" : "BRONCHITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific"}, 
{"Row" :5, "Column" : 1, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray.If an"}, 
{"Row" :6, "Column" : 1, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and"}, 
{"Row" :7, "Column" : 1, "Text" : "need not be treated for it."}, 
{"Row" :9, "Column" : 1, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimicrobials provide no benefit.If bronchitis persists beyond 2 weeks,"}, 
{"Row" : 11, "Column" : 1, "Text" : "additional diagnostic workup is needed to find a cause.If a patient has"}, 
{"Row" : 12, "Column" : 1, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis."}, 
{"Row" : 17, "Column" : 1, "Text" : "Acute bronchitis in patients with COPD", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence"}, 
{"Row" : 19, "Column" : 1, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are"}, 
{"Row" : 20, "Column" : 1, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically"}, 
{"Row" : 21, "Column" : 1, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,"}, 
{"Row" : 22, "Column" : 1, "Text" : "pulmonary embolism and pneumonia."}, 
{"Row" : 24, "Column" : 1, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases"}, 
{"Row" : 25, "Column" : 1, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patients"}, 
{"Row" : 26, "Column" : 1, "Text" : "with COPD exacerbation who have increased sputum purulence and volume."}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for MILD DISEASE: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "No antibiotics recommended"}, 
{"Row" : 31, "Column" : 1, "Text" : "Treatment for MODERATE DISEASE", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Treat for 5 to 7 days."}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment for SEVERE DISEASE", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "side effects outweigh the benefits.", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017."}, 
{"Row" : 49, "Column" : 1, "Text" : "Access: http://www.goldcopd.org"}, 
{"Row" : 50, "Column" : 1, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125"}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Bronchitis"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Bronchitis"}, 
{"Row" : 53, "Column" : 1, "Text" : "Murphy TF Chest 2000, 118: 204"}, 
{"Row" : 54, "Column" : 1, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503"}
]},
{"Name" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT" , "Term1" : "Bronchitis in otherwise healthy patient", "DisplayText" : "Bronchitis not benefited" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :2, "Column" : 1, "Text" : "BRONCHITIS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Acute bronchitis is a clinical syndrome with a brief, self-limited"}, 
{"Row" :5, "Column" : 1, "Text" : "pneumonia on chest radiograph. It is accompanied by dry or productive cough"}, 
{"Row" :6, "Column" : 1, "Text" : "lasting up to 3 weeks, is most prevalent in winter, and is primarily caused"}, 
{"Row" :7, "Column" : 1, "Text" : "by viruses. More than 1 in 20 people have acute bronchitis per year, with"}, 
{"Row" :8, "Column" : 1, "Text" : "highest rates during the winter months.This discussion does not pertain to"}, 
{"Row" :9, "Column" : 1, "Text" : "acute exacerbations of chronic bronchitis, a clinical syndrome also"}, 
{"Row" : 10, "Column" : 1, "Text" : "frequently associated with viral infection, but in which bacteria play a more"}, 
{"Row" : 11, "Column" : 1, "Text" : "important role."}, 
{"Row" : 13, "Column" : 1, "Text" : "Narcotic cough suppressants, expectorants, antihistamines,"}, 
{"Row" : 14, "Column" : 1, "Text" : "decongestants, and beta 2-agonists have been used to treat patients with"}, 
{"Row" : 15, "Column" : 1, "Text" : "acute bronchitis, but controlled trials have not clearly concluded that they"}, 
{"Row" : 16, "Column" : 1, "Text" : "are beneficial."}, 
{"Row" : 18, "Column" : 1, "Text" : "Empirical antibacterial therapy has repeatedly been shown to provide no"}, 
{"Row" : 19, "Column" : 1, "Text" : "benefit for most patients.Acute bronchitis remains one of the five most"}, 
{"Row" : 20, "Column" : 1, "Text" : "frequently cited rationales for excessive antibiotic use in outpatients."}, 
{"Row" : 21, "Column" : 1, "Text" : "Acute bronchitis and other acute respiratory syndromes (otitis media,"}, 
{"Row" : 22, "Column" : 1, "Text" : "sinusitis, pharyngitis,upper respiratory infections) account for"}, 
{"Row" : 23, "Column" : 1, "Text" : "approximately 75% of ambulatory prescriptions in the United States.Current"}, 
{"Row" : 24, "Column" : 1, "Text" : "guidelines, endorsed by a number of national societies, including the"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infectious Diseases Society of America, do not recommend the routine use of"}, 
{"Row" : 26, "Column" : 1, "Text" : "antibiotics for uncomplicated acute bronchitis in otherwise normal persons."}, 
{"Row" : 28, "Column" : 1, "Text" : "If pertussis is suspected, early therapy with macrolides or"}, 
{"Row" : 29, "Column" : 1, "Text" : "tetracyclines is indicated to prevent transmission, although the clinical"}, 
{"Row" : 30, "Column" : 1, "Text" : "findings early in pertussis infection are indistinguishable from viral causes"}, 
{"Row" : 31, "Column" : 1, "Text" : "of bronchitis, and the incidence of disease is very low.Treat for pertussis"}, 
{"Row" : 32, "Column" : 1, "Text" : "only when a patient has likely been exposed to other cases."}, 
{"Row" : 34, "Column" : 1, "Text" : "Asthma attacks often have symptoms resembling bronchitis.Asthma"}, 
{"Row" : 35, "Column" : 1, "Text" : "attacks do not benefit from antimicrobial therapy."}
]},
{"Name" : "ORZID2 GMENU ABX C DIFF TESTING 2 STEP", "DisplayText" : "C Diff testing two-step " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "C diff 2-step testing helps differentiate between C diff infections vs."}, 
{"Row" :4, "Column" : 1, "Text" : "colonization allowing providers to avoid unnecessary antibiotic use for"}, 
{"Row" :5, "Column" : 1, "Text" : "Veterans. With improved C diff testing, Veterans benefit with reduced"}, 
{"Row" :6, "Column" : 1, "Text" : "incidence of health-care acquired C diff and appropriate antimicrobial use."}, 
{"Row" :8, "Column" : 1, "Text" : "New testing process will provide more accurate CDI test results. Our previous"}, 
{"Row" :9, "Column" : 1, "Text" : "method of testing for C diff infections was very sensitive, leading to an"}, 
{"Row" : 10, "Column" : 1, "Text" : "over-diagnosis of C diff infections (CDI)."}, 
{"Row" : 12, "Column" : 1, "Text" : "New 2-step C diff testing: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "1st step (PCR): high sensitivity for C diff"}, 
{"Row" : 15, "Column" : 1, "Text" : "2nd step (reflex test): automatically completed if the PCR is positive-"}, 
{"Row" : 16, "Column" : 1, "Text" : "detects toxin"}, 
{"Row" : 18, "Column" : 1, "Text" : "Ordering criteria for C diff lab panel: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "-Only acceptable specimen is unformed stool (i.e. stool that conforms to the"}, 
{"Row" : 22, "Column" : 1, "Text" : "the shape of the container)"}, 
{"Row" : 19, "Column" : 1, "Text" : "-Symptomatic (patient has had 3 or more watery stools in 24 hours or"}, 
{"Row" : 20, "Column" : 1, "Text" : "presents with ileus suspected to be due to C diff)"}, 
{"Row" : 23, "Column" : 1, "Text" : "-No other explanation for diarrhea such as laxative use or recent initiation"}, 
{"Row" : 24, "Column" : 1, "Text" : "of tube feedings"}, 
{"Row" : 37, "Column" : 1, "Text" : "ii) Evaluate for other causes of diarrhea"}, 
{"Row" : 36, "Column" : 1, "Text" : "i) No treatment or isolation needed for CDI"}, 
{"Row" : 34, "Column" : 1, "Text" : "PCR Negative (Toxin testing will not be performed): ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "i) Initiate severity-based CDI therapy"}, 
{"Row" : 43, "Column" : 1, "Text" : "ii) Stop acid suppressive medications and concomitant antimicrobials if"}, 
{"Row" : 44, "Column" : 1, "Text" : "possible"}, 
{"Row" : 45, "Column" : 1, "Text" : "iii) Place patient in enteric isolation"}, 
{"Row" : 35, "Column" : 1, "Text" : "Interpretation: CDI Not Present"}, 
{"Row" : 40, "Column" : 1, "Text" : "Interpretation: CDI Present"}, 
{"Row" : 47, "Column" : 1, "Text" : "PCR Positive -and- Toxin Negative: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Interpretation: CDI MAY be Present"}, 
{"Row" : 51, "Column" : 1, "Text" : "ii) Place patient in enteric isolation"}, 
{"Row" : 52, "Column" : 1, "Text" : "iii) Treatment decision should be individualized, consider treatment for"}, 
{"Row" : 53, "Column" : 1, "Text" : "severe, non-resolving, or otherwise unexplained diarrhea strongly"}, 
{"Row" : 54, "Column" : 1, "Text" : "suggestive of CDI"}, 
{"Row" : 25, "Column" : 1, "Text" : "-Testing should NOT be ordered for formed stool, asymptomatic patient, or"}, 
{"Row" : 26, "Column" : 1, "Text" : "to perform \"test of cure\""}, 
{"Row" : 39, "Column" : 1, "Text" : "PCR Positive -and- Toxin Positive: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Place laboratory order for C diff panel: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[Click here] C diff treatment recommendations"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[Click here] C diff treatment recommendations"},
{"Row" : 30, "Column" : 1, "Item" : "LRTZ MB C. DIFFICILE TOXIN PCR", "DisplayText" : "C. difficile toxin (PRC)", "Text" : "[Click here] C diff lab panel", "Mnemonic" : "04"},
{"Row" : 27, "Column" : 1, "Text" : "-Repeat orders within 7 days not accepted without Infectious Disease approval"}, 
{"Row" : 32, "Column" : 1, "Text" : "***Interpretation of C diff lab panel: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "All positive C diff PCR tests are now tested for C diff toxin for confirmation."}, 
{"Row" : 49, "Column" : 1, "Text" : "i) PCR positive, toxin negative may represent colonization or infection,"}, 
{"Row" : 50, "Column" : 1, "Text" : "clinical judgement is needed"}, 
{"Row" :2, "Column" : 1, "Text" : "Clostridioides difficile (C diff) 2-step lab testing", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "The Minneapolis VA Health Care System (MVAHCS) is using 2-step testing for"}, 
{"Row" :5, "Column" : 1, "Text" : "C. difficile infection (CDI), replacing our current testing method which is a"}, 
{"Row" :6, "Column" : 1, "Text" : "single Polymerase Chain Reaction (PCR) test."}, 
{"Row" :8, "Column" : 1, "Text" : "Benefits of 2-step testing are that it can be useful in differentiating patients"}, 
{"Row" :9, "Column" : 1, "Text" : "with true infection vs. those that may simply be colonized."}, 
{"Row" : 11, "Column" : 1, "Text" : "What will change: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "-All positive PCR tests for CDI (whether stand-alone CDI tests or the enteric"}, 
{"Row" : 13, "Column" : 1, "Text" : "pathogen panel testing for CDI and other pathogens) will reflex to a toxin test"}, 
{"Row" : 14, "Column" : 1, "Text" : "(a test that detects C. difficile toxin responsible for disease)."}, 
{"Row" : 16, "Column" : 1, "Text" : "-Patients with BOTH a positive PCR and toxin will be reported as"}, 
{"Row" : 17, "Column" : 1, "Text" : "\"Toxigenic C. difficile detected. Repeat testing should not be performed.\""}, 
{"Row" : 19, "Column" : 1, "Text" : "-Patients with a positive PCR but a NEGATIVE toxin test will be reported as"}, 
{"Row" : 20, "Column" : 1, "Text" : "\"C. difficile detected by PCR, toxin negative by EIA. Possible disease or"}, 
{"Row" : 21, "Column" : 1, "Text" : "colonization. Interpretation requires clinical judgement.\""}, 
{"Row" : 23, "Column" : 1, "Text" : "What will not change: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "-C. difficile testing should be performed on patients with high suspicion of"}, 
{"Row" : 25, "Column" : 1, "Text" : "of CDI, WITHOUT other potential causes of diarrhea (e.g., laxatives, tube"}, 
{"Row" : 26, "Column" : 1, "Text" : "feedings, other medications)"}, 
{"Row" : 28, "Column" : 1, "Text" : "-Negative PCR tests will be reported as negative"}, 
{"Row" : 30, "Column" : 1, "Text" : "-Repeat testing within 7 days is strongly discouraged, unless there is a"}, 
{"Row" : 31, "Column" : 1, "Text" : "significant change in stool pattern/disease severity"}, 
{"Row" : 36, "Column" : 1, "Text" : "-Formed stool will not be tested"}, 
{"Row" : 40, "Column" : 1, "Text" : "Test Interpretation: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Negative PCR: \"Negative\""}, 
{"Row" : 43, "Column" : 1, "Text" : "Positive PCR, Positive Toxin: \"Toxin producing C. difficile detected\""}, 
{"Row" : 45, "Column" : 1, "Text" : "Positive PCR, negative toxin: \"C. difficile present, no toxin detected."}, 
{"Row" : 46, "Column" : 1, "Text" : "This may represent colonization or disease. Interpretation requires clinical"}, 
{"Row" : 47, "Column" : 1, "Text" : "judgement. Consider treatment for severe illness otherwise consistent with"}, 
{"Row" : 48, "Column" : 1, "Text" : "CDI. Discussion with Infectious Disease may be helpful.\""}, 
{"Row" :3, "Column" : 1, "Text" : "Clostridioides difficile 2-step Testing", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Minneapolis Clinical On-Call Schedule (Infectious Disease)", "Mnemonic" : "02"},
{"Row" : 33, "Column" : 1, "Text" : "-Patients with ongoing diarrhea (regardless of cause) should be placed in"}, 
{"Row" : 34, "Column" : 1, "Text" : "contact plus precautions"}, 
{"Row" : 38, "Column" : 1, "Text" : "Infectious Disease Service is always available to discuss CDI testing/results.", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "**From 11pm to 7am, PCR test results will be reported WITHOUT the confirmatory"}, 
{"Row" : 51, "Column" : 1, "Text" : "toxin test, which will be run the next morning. Postive PCR results will be"}, 
{"Row" : 53, "Column" : 1, "Text" : "\"C. difficile detected by PCR, confirmatory toxin testing pending. Recommend"}, 
{"Row" : 52, "Column" : 1, "Text" : "reported as: "}, 
{"Row" : 54, "Column" : 1, "Text" : "deferring antibiotic treatment in clinically stable patients where the"}, 
{"Row" : 55, "Column" : 1, "Text" : "diagnosis of C. difficile is not certain.\""}, 
{"Row" : 57, "Column" : 1, "Text" : "Isolation for patients who are suspected of having CDI and who are receiving"}, 
{"Row" : 58, "Column" : 1, "Text" : "treatment."}
]},
{"Name" : "ORZID2 GMENU ABX C. AURIS CPO 4J/SCI SCREENING", "DisplayText" : "C. auris and CPO 4J and SCI admission screening " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX C. AURIS CPO HIGH RISK", "DisplayText" : "C. AURIS CPO HIGH RISK ORDER SET", "Text" : "[Click here] Place orders for laboratory and nursing for High Risk Category", "Mnemonic" : "04"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX C. AURIS CPO MEDIUM RISK", "DisplayText" : "C. AURIS CPO MEDIUM RISK ORDER SET", "Text" : "[Click here] Place orders for laboratory and nursing for Medium Risk Category", "Mnemonic" : "06"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX C. AURIS CPO LOW RISK NURSING TEXT ORDER", "DisplayText" : "C. auris and CPO Low Risk Nursing Text Order", "Text" : "[Click here] Place nursing text order Low Risk Category (no labs required)", "Mnemonic" : "08"},
{"Row" :6, "Column" : 1, "Text" : "All patients admitted or transferred to 4J or SCI will be assessed for risk"}, 
{"Row" :7, "Column" : 1, "Text" : "criteria below."}, 
{"Row" : 11, "Column" : 1, "Text" : "** High Risk **", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "** Medium Risk **", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "** Low Risk **", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Does not meet High or Medium risk criteria above"}, 
{"Row" :2, "Column" : 1, "Text" : "Candida auris and Carbapenamase-Producing Organisms (CPO) Screening", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients to assess for risk criteria: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Risk Categories: High, Medium or Low", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "1) Hospitalized overnight in an international hospital in the last 12 months"}, 
{"Row" : 14, "Column" : 1, "Text" : "2) Exposure in domestic healthcare facility with a known outbreak Candida"}, 
{"Row" : 15, "Column" : 1, "Text" : "auris or CPOs"}, 
{"Row" : 20, "Column" : 1, "Text" : "Does not meet High Risk criteria above"}, 
{"Row" : 21, "Column" : 1, "Text" : "< AND >", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Meets criteria for at least ONE of the following: "}, 
{"Row" : 23, "Column" : 1, "Text" : "1) Transferred from another healthcare facility,"}, 
{"Row" : 24, "Column" : 1, "Text" : "2) Resides in a State Veterans' Home,"}, 
{"Row" : 25, "Column" : 1, "Text" : "3) Overnight stay in a Military Healthcare facility,"}, 
{"Row" : 26, "Column" : 1, "Text" : "4) Resides in a nursing home/long term care facility"}, 
{"Row" : 36, "Column" : 1, "Text" : "Reference: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "MVAHCS CANDIDA AURIS AND CARBAPENAMASE-PRODUCING ORGANISMS SCREENING SOP"}, 
{"Row" : 38, "Column" : 1, "Text" : "Effective Date: December 7, 2022"}, 
{"Row" :3, "Column" : 1, "Item" : "ORZ GTX ABX URL SCREENING C AURIS & CPO", "DisplayText" : "Link to SOP", "Text" : "[Click here] Link to above SOP document", "Mnemonic" : "02"}
]},
{"Name" : "ORZID2 GMENU ABX CAMPYLOBACTER" , "Term1" : "Campylobacter diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Campylobacter " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 5 days ($)[R,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CAMPYLOBACTER", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is"}, 
{"Row" :6, "Column" : 1, "Text" : "rare."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 20, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Campylobacter"}, 
{"Row" : 23, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 25, "Column" : 1, "Text" : "Campylobacter infection"}
]},
{"Name" : "ORZID2 GMENU ABX CANDIDA UTI" , "Term1" : "Candida urinary tract infection " , "Term2" : "Urinary tract infection (UTI), candida", "DisplayText" : "Candida urinary tract infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "Fungemia Associated with Candida spp.", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 3 days before and 3 days", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h", "Text" : "Fluconazole 400 mg (6 mg/kg) IV q24h ($) [R,DI] for 3 days before and 3 days", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q24H", "DisplayText" : "Fluconazole 200 mg po q24h ($0.20) [R", "Text" : "Fluconazole 200 mg (3 mg/kg) PO q24h ($) [R,DI] for 14 days", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 200-400MG IV Q24H", "DisplayText" : "Fluconazole 200-400 mg IV q24h ($13/day) [R", "Text" : "Fluconazole 200 mg (3 mg/kg) IV q24h ($) [R,DI] for 14 days", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 14 days", "Mnemonic" : "14"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h", "Text" : "Fluconazole 400 mg (6 mg/kg) IV q24h ($) [R,DI] for 14 days", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA URINARY TRACT INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A positive urine culture for candida usually reflects colonization. Treat"}, 
{"Row" :6, "Column" : 1, "Text" : "cystitis only if the patient has symptoms of urinary tract infection (e.g."}, 
{"Row" :7, "Column" : 1, "Text" : "dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient"}, 
{"Row" :8, "Column" : 1, "Text" : "will undergo invasive urological manipulation"}, 
{"Row" : 10, "Column" : 1, "Text" : "Asymptomatic candiduria in a patient with a urinary catheter should not be"}, 
{"Row" : 11, "Column" : 1, "Text" : "treated without an additional indication. Removal of catheter is strongly"}, 
{"Row" : 12, "Column" : 1, "Text" : "recommended. Contact Infectious Diseases for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Neutropenic patients with asymptomatic candiduria should be assessed for"}, 
{"Row" : 15, "Column" : 1, "Text" : "candidemia because they are at risk of dissemination. Obtain blood cultures and"}, 
{"Row" : 16, "Column" : 1, "Text" : "assess potential sources of candidemia such as central venous catheters. Refer"}, 
{"Row" : 17, "Column" : 1, "Text" : "to fungemia page for treatment recommendations."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Patient undergoing invasive urological manipulation: "}, 
{"Row" : 23, "Column" : 1, "Text" : "after procedure"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "after procedure"}, 
{"Row" : 28, "Column" : 1, "Text" : "Symptomatic candida cystitis: "}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Pyelonephritis: "}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "Resistant candida: "}, 
{"Row" : 40, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Pappas et al., Clinical Infectious Diseases, 2016, 62(4)e1-e50"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infections"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Candida Infections of the Bladder and Kidneys"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-To Date article: Candidemia in adults: Epidemiology, microbiology, and"}, 
{"Row" : 48, "Column" : 1, "Text" : "pathogenesis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Urinary Tract Infections"}, 
{"Row" : 39, "Column" : 1, "Text" : "Consult Infectious Diseases for treatment options"}
]},
{"Name" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS" , "Term1" : "Candida vulvo-vaginitis " , "Term2" : "Vaginitis, Candida " , "Term3" : "Vulvo-vaginitis, candida", "DisplayText" : "Candida Vulvo-Vaginitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150 mg PO once ($) [R,DI]", "Text" : "Fluconazole 150 mg PO once ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE VAGINAL CRM 1% 1 APPLFUL QHS", "DisplayText" : "Clotrimazole vaginal cream 1% 1 applicatorful qhs", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 7 to 14 days", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID TERCONAZOLE 0.4% CRM VAG QHS", "DisplayText" : "Terconazole 0.4% cream vaginal QHS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 7 days", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO Q72H", "DisplayText" : "Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]", "Text" : "Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE VAGINAL CRM 1% 1 APPLFUL QHS", "DisplayText" : "Clotrimazole vaginal cream 1% 1 applicatorful qhs", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 10-14 days", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID TERCONAZOLE 0.4% CRM VAG QHS", "DisplayText" : "Terconazole 0.4% cream vaginal QHS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 10-14 days", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO QWEEK", "DisplayText" : "Fluconazole 150mg po qweek", "Text" : "Fluconazole 150 mg PO every 7 days ($) [R,DI] for 6 months", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA VULVOVAGINITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Candida vulvovaginitis typically presents with valvular irritation, burning or"}, 
{"Row" :6, "Column" : 1, "Text" : "pruritus. Vaginal pH should be measured, and the specimen should be examined"}, 
{"Row" :7, "Column" : 1, "Text" : "under the microscope for clue cells (epithelial cell coated with bacteria) to"}, 
{"Row" :8, "Column" : 1, "Text" : "exclude bacterial vaginosis. In candida vulvovaginitis, the vaginal pH is"}, 
{"Row" :9, "Column" : 1, "Text" : "typically normal (4-4.5) and vaginal discharge is typically thick and curdy with"}, 
{"Row" : 10, "Column" : 1, "Text" : "white plaques on vaginal mucosa. Diagnosis is confirmed by identifying fungus or"}, 
{"Row" : 11, "Column" : 1, "Text" : "yeast with KOH prep."}, 
{"Row" : 13, "Column" : 1, "Text" : "Most non-C. albicans species respond to fluconazole treatment except C. krusei"}, 
{"Row" : 14, "Column" : 1, "Text" : "and C. glabrata. C. krusei can be treated with topical agents as for complicated"}, 
{"Row" : 15, "Column" : 1, "Text" : "candida vulvovaginitis below. C. glabrata treatment is complicated and azole"}, 
{"Row" : 16, "Column" : 1, "Text" : "therapy is frequently unsuccessful. Consult Infectious Diseases in patients with"}, 
{"Row" : 17, "Column" : 1, "Text" : "C. glabrata vulvovaginitis."}, 
{"Row" : 19, "Column" : 1, "Text" : "Recurrent candida vulvovaginitis is treated as complicated candida"}, 
{"Row" : 20, "Column" : 1, "Text" : "vulvovaginitis for induction treatment, followed by maintenance regimen for 6"}, 
{"Row" : 21, "Column" : 1, "Text" : "months."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of uncomplicated candida vulvovaginitis", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment of complicated candida vulvovaginitis (e.g. immunocompromised, severe", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "disease, pregnancy) or recurrent infection induction treatment", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "Recurrent candida vulvovaginitis maintenance regimen following induction", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "treatment above", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Treatment of C. glabrate vulvovaginitis", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Failure of azole therapy is common, alternative topical treatments below require"}, 
{"Row" : 44, "Column" : 1, "Text" : "compounding by a pharmacist. Please call pharmacy to order."}, 
{"Row" : 45, "Column" : 1, "Text" : "Topical flucytosine cream (17%) qhs for 14 days"}, 
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "Topical boric acid capsule 600 mg intravaginal qhs for 14 days"}, 
{"Row" : 48, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 53, "Column" : 1, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Vulvovaginitis"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-to-Date article: Candida vulvovaginitis: Treatment"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date article: Candida vulvovaginitis: Clinical manifestations and"}, 
{"Row" : 57, "Column" : 1, "Text" : "diagnosis"}, 
{"Row" : 58, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID2 GMENU ABX CARDIOVASCULAR" , "Term1" : "Cardiovascular Section", "DisplayText" : "Cardiovascular" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS", "DisplayText" : "Approach to Endocarditis", "Text" : "Approach to Endocarditis", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS", "DisplayText" : "Diagnosis of Endocarditis", "Text" : "Diagnosis of Endocarditis", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EC NV EMP THERA", "DisplayText" : "Native Valve Endocarditis - Empirical Therapy", "Text" : "Empirical Therapy", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC NV SEL PATH", "DisplayText" : "Native Valve Endocarditis--Selected Pathogens", "Text" : "Selected Pathogens", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "DisplayText" : "Prosthetic Valve Endocarditis--Empicaral Therapy", "Text" : "Empirical Therapy", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "DisplayText" : "Prosthetic Valve Endocarditis--Selected Pathogens", "Text" : "Selected Pathogens", "Mnemonic" : "14"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease", "Text" : "Cardiac Lyme Disease", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "DisplayText" : "Infections involves cardiovascular devices (excluding valves)", "Text" : "Cardiovascular Device Infections (Excluding Valves)", "Mnemonic" : "18"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Catheter-Related Bloodstream Infections", "Mnemonic" : "20"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX MYOCARDITIS", "DisplayText" : "Myocarditis", "Text" : "Myocarditis", "Mnemonic" : "22"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERICARDITIS", "DisplayText" : "Pericarditis", "Text" : "Pericarditis", "Mnemonic" : "24"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "DisplayText" : "Suppurative Thrombophlebitis--Empirical Therapy", "Text" : "Suppurative Thrombophlebitis", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "++CARDIOVASCULAR++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Endocarditis", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Native Valve Endocarditis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Prosthetic Valve Endocarditis"}, 
{"Row" : 17, "Column" : 1, "Text" : "Other", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Section last reviewed9/2020", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX CDSS VERSION", "DisplayText" : "CDSS VERSION" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "VERSION 1.0"}, 
{"Row" :2, "Column" : 1, "Text" : "3-5-2020"}, 
{"Row" :5, "Column" : 1, "Text" : "NEW TEXT"}, 
{"Row" :7, "Column" : 1, "Text" : "AUTOMATION", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "AUTOMATION", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX CELLULITIS" , "Term1" : "Cellulitis", "DisplayText" : "Cellulitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU MORE ABOUT CELLULITIS", "DisplayText" : "The approach to cellulitis", "Text" : "More about cellulitis...", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]", "Mnemonic" : "16"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "22"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg IV", "Mnemonic" : "26"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG CIPRO 400MG METRO 500MG IV Q8H", "DisplayText" : "Vancomycin 15mg/kg iv q12h Cipro 400mg iv q8h Metro 500 mg iv q12h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Vancomycin 15 mg/kg IV", "Mnemonic" : "26"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "28"},
{"Row" :2, "Column" : 1, "Text" : "BACTERIAL CELLULITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and is"}, 
{"Row" :5, "Column" : 1, "Text" : "often associated with bacterial pathogens.The most common pathogens are group"}, 
{"Row" :6, "Column" : 1, "Text" : "A streptococci and Staphylococcus aureus.Group B streptococci are associated"}, 
{"Row" :7, "Column" : 1, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on feet"}, 
{"Row" :8, "Column" : 1, "Text" : "and legs of patients with athlete's foot (tinea pedis)."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild cases can be treated with oral antimicrobials.Moderate to severe cases"}, 
{"Row" : 11, "Column" : 1, "Text" : "should be treated initially with intravenous antimicrobials.Switch to oral"}, 
{"Row" : 12, "Column" : 1, "Text" : "drugs after clinical improvement."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma, a"}, 
{"Row" : 15, "Column" : 1, "Text" : "history of MRSA infection, injection drug use, or infections not responding"}, 
{"Row" : 16, "Column" : 1, "Text" : "to first line beta-lactams."}, 
{"Row" : 20, "Column" : 1, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "if not improved in this time.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Mild: Cellulitis without systemic signs of infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical treatment for MILD cellulitis", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative for Penicillin Allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "MRSA Suspected Mild Cellulitis", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Moderate: Cellulitis with systemic signs of infection", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Empirical treatment for MODERATE cellulitis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Alternative for penicillin allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Severe: Cellulitis in patients with signs of deeper infections", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction)."}, 
{"Row" : 44, "Column" : 1, "Text" : "Patients may also qualify as severe if they are neutropenic, have a"}, 
{"Row" : 45, "Column" : 1, "Text" : "hematologic malignancy or congenital immunodeficiency, or are receiving"}, 
{"Row" : 46, "Column" : 1, "Text" : "immunosuppressant therapy.Consider whether surgical drainage is necessary."}, 
{"Row" : 48, "Column" : 1, "Text" : "Empirical treatment for SEVERE infection", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative for penicillin allergy or MRSA suspected: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "q12h ($) [R] <AND> Metronidazole 500 mg IV q8h ($) [DI,H]"}, 
{"Row" : 57, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 58, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "", "Mnemonic" : "24"}
]},
{"Name" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "Chlamydia & GC PCR/LCR test", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis", "Text" : "Treatment of recurrent or persistent cervicitis", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia Urethritis", "Text" : "Treatment for chlamydial or non-gonococcal cervicitis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "The main diagnostic signs that characterize cervicitis are 1)women who present"}, 
{"Row" :8, "Column" : 1, "Text" : "with purulent or mucopurulent exudate in the endocervical canal or on an"}, 
{"Row" :9, "Column" : 1, "Text" : "endocervical swab specimen and 2)sustained endocervical bleeding induced by"}, 
{"Row" : 10, "Column" : 1, "Text" : "gentle passage of cotton swab through the cervical os. One or both signs may be"}, 
{"Row" : 11, "Column" : 1, "Text" : "present."}, 
{"Row" : 13, "Column" : 1, "Text" : "Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually"}, 
{"Row" : 14, "Column" : 1, "Text" : "transmitted cervicitis pathogens. Nucleic acid amplification tests for these"}, 
{"Row" : 15, "Column" : 1, "Text" : "pathogens are more sensitive than culture and should be used for patients at"}, 
{"Row" : 16, "Column" : 1, "Text" : "risk for sexually transmitted cervicitis."}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients who have recently been treated for cervicitis", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "When diagnosed with sexually transmitted cervicitis, the patient's sexual"}, 
{"Row" : 23, "Column" : 1, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually"}, 
{"Row" : 24, "Column" : 1, "Text" : "transmitted infection. If diagnostic tests for the cause of cervicitis are not"}, 
{"Row" : 25, "Column" : 1, "Text" : "feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to"}, 
{"Row" : 26, "Column" : 1, "Text" : "partners."}, 
{"Row" : 28, "Column" : 1, "Text" : "Initial treatment of patients and sex partners", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C."}, 
{"Row" : 30, "Column" : 1, "Text" : "trachomatis. Treat for both pathogens unless one is ruled out by lab test."}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment for gonorrhea cervicitis", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}
]},
{"Name" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia Urethritis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1 gm PO ONCE ($) [M]", "Mnemonic" : "8"},
{"Row" :4, "Column" : 1, "Text" : "CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS OR RECTAL", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for chlamydial or non-gonococcal urethritis or cervicitis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Sanford keyword: Urethritis, cervicitis: chlamydial"}, 
{"Row" : 17, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}, 
{"Row" : 13, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU ABX CHOLANGITIS" , "Term1" : "Cholangitis", "DisplayText" : "Cholangitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h for 7 to 10 days ($$) [R]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h for 7 to 10 days [R,DI]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "CHOLANGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)"}, 
{"Row" :6, "Column" : 1, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure."}, 
{"Row" :7, "Column" : 1, "Text" : "The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and"}, 
{"Row" :8, "Column" : 1, "Text" : "Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as"}, 
{"Row" :9, "Column" : 1, "Text" : "part of a mixed infection."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "[DI] for 7 to 10 days"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 25, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,"}, 
{"Row" : 41, "Column" : 1, "Text" : "Cholangitis, Cholecystitis)"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Gallbladder Infections"}, 
{"Row" : 43, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Acute cholangitis"}
]},
{"Name" : "ORZID2 GMENU ABX CHOLECYSTITIS" , "Term1" : "Cholecystitis", "DisplayText" : "Cholecystitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "16"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "18"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "20"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "22"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "24"},
{"Row" : 61, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "26"},
{"Row" : 63, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "28"},
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "CHOLECYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Adequate biliary drainage is the definitive treatment. Antimicrobials should be"}, 
{"Row" :6, "Column" : 1, "Text" : "prescribed only if signs of infection like leukocytosis or fever are present or"}, 
{"Row" :7, "Column" : 1, "Text" : "if the patient is elderly. Surgery and Gastroenterology involvement are"}, 
{"Row" :8, "Column" : 1, "Text" : "essential."}, 
{"Row" : 10, "Column" : 1, "Text" : "Most cases are associated with E. coli, Enterococcus, Klebsiella, and"}, 
{"Row" : 11, "Column" : 1, "Text" : "Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric"}, 
{"Row" : 12, "Column" : 1, "Text" : "anastomosis is present. For community-acquired acute cholecystitis, enterococcal"}, 
{"Row" : 13, "Column" : 1, "Text" : "coverage is not required because Enterococcus has not been shown to be"}, 
{"Row" : 14, "Column" : 1, "Text" : "pathogenic in these patients."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "If needed, antimicrobial therapy should be continued only until adequate"}, 
{"Row" : 18, "Column" : 1, "Text" : "drainage is established, then stopped."}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Community-acquired acute cholecystitis", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of mild to moderate infection without biliary-enteric anastomosis", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment of mild to moderate infection and biliary-enteric anastomosis present", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment of severe infection, advanced age or immunocompromised patient", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 43, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 45, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Health care-associated infection", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "IV q12h ($) [R]"}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 55, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 56, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 64, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 66, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 71, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,"}, 
{"Row" : 72, "Column" : 1, "Text" : "Cholangitis, Cholecystitis)"}, 
{"Row" : 73, "Column" : 1, "Text" : "Sanford keyword: Gallbladder Infections, Acute Cholecystitis"}, 
{"Row" : 74, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 75, "Column" : 1, "Text" : "Up-to-Date article: Treatment of acute calculous cholecystitis"}
]},
{"Name" : "ORZID2 GMENU ABX CHOLERA" , "Term1" : "Vibrio cholerae diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Cholera (Vibrio cholera)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 300MG PO ONCE", "DisplayText" : "Doxycycline 300mg po once (Var)", "Text" : "Doxycycline 300 mg PO one-time dose ($) [DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CIPROFLOX 1000MG PO ONCE", "DisplayText" : "Ciprofloxacin 1000 mg PO one-time dose ($) [R,DI]", "Text" : "Ciprofloxacin 1000 mg PO one-time dose ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary Treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Aggressive hydration and electrolyte replacement are essential"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Tetracycline intolerant patient"}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients who are hospitalized or unable to take oral medications"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Vibrio cholerae"}, 
{"Row" : 24, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and"}, 
{"Row" : 26, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 17, "Column" : 1, "Text" : "**Duration: 3 days**"}
]},
{"Name" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN" , "Term1" : "Pelvic pain syndrome/prostatitis, chronic " , "Term2" : "Prostatitis/pelvic pain syndrome, chronic", "DisplayText" : "Chronic protatitis/Chronic pelvic pain syndrome " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID IBUPROFEN 600MG PO Q8H", "DisplayText" : "Ibuprofen 600 mg PO Q8h", "Text" : "Ibuprofen 400 mg PO q8h for 2 to 3 weeks", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "This syndrome presents with intermittent perineal and/or low back pain,"}, 
{"Row" :6, "Column" : 1, "Text" : "obstructive voiding symptoms, relatively normal examination, and negative urine"}, 
{"Row" :7, "Column" : 1, "Text" : "cultures. Antimicrobial therapy is not indicated."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult urology for non-antimicrobial therapy recommendations (e.g."}, 
{"Row" :9, "Column" : 1, "Text" : "alpha-adrenergic antagonists, anti-inflammatory medications) to reduce symptoms."}, 
{"Row" : 11, "Column" : 1, "Text" : "Anti-inflammatory treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome"}
]},
{"Name" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS" , "Term1" : "Prostatitis, chronic", "DisplayText" : "Chronic bacterial prostatitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "DisplayText" : "Chronic protatitis/Chronic pelvic pain syndrome", "Text" : "Chronic prostate pain syndrome", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] for 4 weeks", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 4 weeks", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC BACTERIAL PROSTATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Chronic bacterial prostatitis usually presents as recurrent urinary tract"}, 
{"Row" :6, "Column" : 1, "Text" : "infections with the same bacterial etiology. Pain, tenderness, and fever may"}, 
{"Row" :7, "Column" : 1, "Text" : "accompany intermittent episodes of cystitis, but men are usually asymptomatic"}, 
{"Row" :8, "Column" : 1, "Text" : "between episodes and the prostate examination may be normal. Non-steroidal anti-"}, 
{"Row" :9, "Column" : 1, "Text" : "inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain or"}, 
{"Row" : 10, "Column" : 1, "Text" : "if the patient's symptoms do not respond to therapy, consult urology. The"}, 
{"Row" : 11, "Column" : 1, "Text" : "presence of hematuria may be a sign of carcinoma, especially in older men, and a"}, 
{"Row" : 12, "Column" : 1, "Text" : "urology consult should be requested."}, 
{"Row" : 14, "Column" : 1, "Text" : "A urine culture should be performed in all patients to guide antimicrobial"}, 
{"Row" : 15, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 17, "Column" : 1, "Text" : "Chronic prostate pain syndrome should be considered in patients who have"}, 
{"Row" : 18, "Column" : 1, "Text" : "symptoms of prostatitis but have negative urine cultures. Chronic prostate pain"}, 
{"Row" : 19, "Column" : 1, "Text" : "syndrome is discussed elsewhere: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "4 weeks minimum and up to 6 weeks of treatment is required. Durations longer"}, 
{"Row" : 24, "Column" : 1, "Text" : "than 6 weeks may be needed in treatment of resistant organisms. Treatment with"}, 
{"Row" : 25, "Column" : 1, "Text" : "trimethoprim/sulfamethoxazole requires a treatment duration of 1 to 3 months."}, 
{"Row" : 27, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 35, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Rees et al., BJU Int, 2015,116.509-525"}, 
{"Row" : 40, "Column" : 1, "Text" : "Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Prostatitis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Up-To-Date article: Chronic bacterial prostatitis"}
]},
{"Name" : "ORZID2 GMENU ABX CHRONIC MENINGITIS", "DisplayText" : "Chronic Meningitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC MENINGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Subacute meningeal symptoms, including headache, fever, and nausea for 4 weeks"}, 
{"Row" :6, "Column" : 1, "Text" : "or more. Chronic meningitis is caused by a long list of infectious and"}, 
{"Row" :7, "Column" : 1, "Text" : "non-infectious etiologies. Treatment is based on etiology and empirical"}, 
{"Row" :8, "Column" : 1, "Text" : "treatment is not urgent unless tuberculosis is suspected. Consult Infectious"}, 
{"Row" :9, "Column" : 1, "Text" : "Diseases for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Chronic meningitis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Chronic meningitis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 17, "Column" : 1, "Text" : "Up-to-Date Article: Approach to the patient with chronic meningitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS" , "Term1" : "Colitis, cytomegalovirus (CMV)", "DisplayText" : "CMV Colitis or Esophagistis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "DisplayText" : "Valgancicilovir 900MG PO q12h", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "DisplayText" : "Ganciclovir 5 mg/kg IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "DisplayText" : "Foscarnet 90 mg/kg IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CMV COLITIS OR ESOPHAGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 3-6 weeks. Patients may be converted to oral therapy after initial"}, 
{"Row" : 14, "Column" : 1, "Text" : "intravenous therapy and after clinical improvement of severe disease."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of mild to moderate disease or following clinical improvement of", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "severe disease", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 29, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 33, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CMV ENCEPHALITIS" , "Term1" : "Encephalitis, Cytomegalovirus (CMV)", "DisplayText" : "CMV Encephalitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5MG/KG IV Q12H FOSCAR 90MG/KG IV Q12H", "DisplayText" : "Ganciclovir 5 mg/kg IV Q12H Foscarnet 90 mg/kg IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "DisplayText" : "Valgancicilovir 900MG PO q12h", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "CMV ENCEPHALITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration is likely to be prolonged and is individualized based on response."}, 
{"Row" : 14, "Column" : 1, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and"}, 
{"Row" : 15, "Column" : 1, "Text" : "after clinical improvement of severe disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "($$$$) [R,O]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Oral treatment following clinical improvement", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 29, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 33, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CMV MAIN PAGE" , "Term1" : "Cytomegalovirus (CMV)", "DisplayText" : "Cytomegalovirus (CMV) Main Page " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "DisplayText" : "CMV Colitis or Esophagistis", "Text" : "Colitis or esophagitis", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV ENCEPHALITIS", "DisplayText" : "CMV Encephalitis", "Text" : "Encephalitis", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY", "DisplayText" : "CMV Polyradiculopathy", "Text" : "Polyradiculopathy", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "DisplayText" : "CMV Retinitis", "Text" : "Retinitis", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV PNEUMONIA", "DisplayText" : "CMV Pneumonia", "Text" : "Pneumonia", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CYTOMEGALOVIRUS (CMV)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antiviral toxicity information", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "The major toxicities of both ganciclovir and valganciclovir are neutropenia."}, 
{"Row" :7, "Column" : 1, "Text" : "Nephrotoxicity is the major toxicity associated with foscarnet, which may be"}, 
{"Row" :8, "Column" : 1, "Text" : "reduced by concomitant saline administration (generally 0.5-1L)."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Immunocompetent patient", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Infection is rare and usually associated with minimal or no symptoms."}, 
{"Row" : 13, "Column" : 1, "Text" : "Mononucleosis can be associated with CMV, but is more commonly associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Epstein Barr virus. Antiviral treatment is not usually necessary as most"}, 
{"Row" : 15, "Column" : 1, "Text" : "patients recover without intervention."}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Immunocompromised patient", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Patients in whom the risk for CMV disease is increased include solid organ and"}, 
{"Row" : 20, "Column" : 1, "Text" : "bone marrow transplant recipients, persons receiving prolonged immunosuppressive"}, 
{"Row" : 21, "Column" : 1, "Text" : "chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of"}, 
{"Row" : 22, "Column" : 1, "Text" : "less than 50 cells/microliter."}, 
{"Row" : 24, "Column" : 1, "Text" : "CMV treatment recommendations", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 35, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 39, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CMV PNEUMONIA" , "Term1" : "Pneumonia, Cytomegalovirus (CMV)", "DisplayText" : "CMV Pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5 MG/KG IV Q12H IMMUNE IG 0.5 GM/KG", "DisplayText" : "Ganciclovir 5 mg/kg and IV IG 0.5 gm/kg IV qother day", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> intravenous immune globulin", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900 MG PO Q24H", "DisplayText" : "Valganciclovir 900 mg po q24h", "Text" : "Valganciclovir 900 mg PO Q24h ($$$) [R,O]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "CMV PNEUMONIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "CMV pneumonia occurs almost exclusively in bone marrow transplant recipients,"}, 
{"Row" :6, "Column" : 1, "Text" : "usually within the first 120 days after transplantation. In these patients, CMV"}, 
{"Row" :7, "Column" : 1, "Text" : "pneumonia is severe and requires aggressive treatment. Treatment is complex and"}, 
{"Row" :8, "Column" : 1, "Text" : "requires Infectious Diseases consultation."}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Induction therapy is indicated for 3 to 6 weeks, followed by maintenance"}, 
{"Row" : 12, "Column" : 1, "Text" : "therapy. Duration of maintenance therapy is not well established."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "0.5 grams/kg IV every other day"}, 
{"Row" : 18, "Column" : 1, "Text" : "Maintenance therapy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 29, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY" , "Term1" : "Polyradiculopathy, Cytomegalovirus (CMV)", "DisplayText" : "CMV Polyradiculopathy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "DisplayText" : "Valgancicilovir 900MG PO q12h", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "DisplayText" : "Ganciclovir 5 mg/kg IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "DisplayText" : "Foscarnet 90 mg/kg IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CMV POLYRADICULOPATHY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration is likely to be prolonged and is individualized based on response."}, 
{"Row" : 14, "Column" : 1, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and"}, 
{"Row" : 15, "Column" : 1, "Text" : "after clinical improvement of severe disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of mild to moderate disease or following clinical improvement of", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "severe disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 30, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 34, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CMV RETINITIS", "DisplayText" : "CMV Retinitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "DisplayText" : "Ganciclovir 5 mg/kg IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "DisplayText" : "Foscarnet 90 mg/kg IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID GANCICLOVIR 4MG INTRAVITREOUS INJECT ONCE", "DisplayText" : "Ganciclovir 4mg intravitreous injection", "Text" : "Ganciclovir 4mg/0.1mL intravitreal injection STAT ($$$$) [R,O]", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID FOSCARNET 2.4MG INTRAVITREOUS INJECT ONCE", "DisplayText" : "Foscarnet 2.4 mg intravitreous injection", "Text" : "Foscarnet 2.4mg/0.1 mL intravitreal injection STAT ($$$$) [R,O]", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5MG/KG IV Q12H FOSCAR 90MG/KG IV Q12H", "DisplayText" : "Ganciclovir 5 mg/kg IV Q12H Foscarnet 90 mg/kg IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h", "Mnemonic" : "12"},
{"Row" : 47, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "DisplayText" : "Valgancicilovir 900MG PO q12h", "Text" : "Valganciclovir 900 mg PO q12h($$$) [R,O]", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900 MG PO Q24H", "DisplayText" : "Valganciclovir 900 mg po q24h", "Text" : "Valganciclovir 900 mg PO q24h ($$$) [R,O]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "CMV RETINITIS AND ACUTE RETINAL NECROSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "For sight threatening lesions (lesions within 1500 microns of the fovea)"}, 
{"Row" : 13, "Column" : 1, "Text" : "intravitreal infections of ganciclovir or foscarnet are recommended in addition"}, 
{"Row" : 14, "Column" : 1, "Text" : "to systemic treatment. Contact Infectious Diseases for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy"}, 
{"Row" : 18, "Column" : 1, "Text" : "after initial intravenous therapy and after clinical improvement of severe"}, 
{"Row" : 19, "Column" : 1, "Text" : "disease. Treat acute retinal necrosis with IV therapy for at least 7 days and"}, 
{"Row" : 20, "Column" : 1, "Text" : "until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance"}, 
{"Row" : 21, "Column" : 1, "Text" : "therapy after completion of treatment is indicated when CD4 count <100."}, 
{"Row" : 22, "Column" : 1, "Text" : "Discontinue maintenance therapy when CD4 count is >100 for 6 months."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment acute retinal necrosis or severe disease", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Intravitreal antiviral in addition to systemic antiviral may provide added"}, 
{"Row" : 26, "Column" : 1, "Text" : "therapeutic efficacy."}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Optional add-on therapy for acute retinal necrosis"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "For cases not responsive to Intravenous therapy with foscarnet and ganciclovir", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "used alone", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "($$$$) [R,O]"}, 
{"Row" : 41, "Column" : 1, "Text" : "In cases not responsive to first-line therapy, second-line therapies may be"}, 
{"Row" : 42, "Column" : 1, "Text" : "effective. Their use is highly specialized and must be done by someone"}, 
{"Row" : 43, "Column" : 1, "Text" : "experienced with HIV/AIDS medicine."}, 
{"Row" : 45, "Column" : 1, "Text" : "Treatment of mild to moderate retinitis or after clinical improvement of severe", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "retinitis/acute retinal necrosis", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Maintenance therapy", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 57, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 58, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 59, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 61, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID2 GMENU ABX CNS" , "Term1" : "Abscess, brain " , "Term2" : "Central Nervous System section", "DisplayText" : "Central Nervous System" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPROACH TO ACUTE MENINGITIS", "DisplayText" : "Approach to Acute Meningitis", "Text" : "Approach to acute meningitis", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "DisplayText" : "Bacterial meningitis without Gram stain results", "Text" : "Community acquired", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "DisplayText" : "Bacterial meningitis associated with trauma or nosocomial infection", "Text" : "Associated with trauma or nosocomial infection", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "DisplayText" : "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia", "Text" : "Gram-positive diplococci suggesting Streptococcus pneumoniae", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "DisplayText" : "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis", "Text" : "Gram-negative diplococci suggesting Neisseria meningitidis", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes", "Text" : "Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes", "Mnemonic" : "14"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GNB", "DisplayText" : "Bacterial meningitis with Gram negative bacilli", "Text" : "Gram negative bacilli", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "DisplayText" : "Bacterial meningitis with S. pneumoniae", "Text" : "S. pneumoniae", "Mnemonic" : "18"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "DisplayText" : "Bacterial meningitis with N. meningitidis", "Text" : "N. meningitidis", "Mnemonic" : "20"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "DisplayText" : "Bacterial meningitis with L. monocytogenes", "Text" : "L. monocytogenes", "Mnemonic" : "22"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "E. Coli, Pseudomonas, or another organism", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "++ CENTRAL NERVOUS SYSTEM ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Meningitis", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Empiric Treatment Prior to Gram Stain Results"}, 
{"Row" : 12, "Column" : 1, "Text" : "Empiric Treatment Based on Gram Stain Results"}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment Based on Isolated Pathogen"}, 
{"Row" : 28, "Column" : 1, "Text" : "Last reviewed 11/2021", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU APPROACH TO BRAIN ABSCESS", "DisplayText" : "Approach to Brain Abscess", "Text" : "Approach to brain abscess", "Mnemonic" : "26"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "DisplayText" : "Brain abscess resulting from contiguous or hematogenous spread of infection", "Text" : "Contiguous or hematogenous spread of infection", "Mnemonic" : "28"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "DisplayText" : "Post-surgical or post-traumatic brain abscess", "Text" : "Post-surgical or post-traumatic", "Mnemonic" : "30"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "DisplayText" : "Brain Abscess with Nocardia spp.", "Text" : "Nocardia spp.", "Mnemonic" : "32"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "DisplayText" : "Brain Abscess with Pseudomonas spp.", "Text" : "Pseudomonas spp.", "Mnemonic" : "34"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "DisplayText" : "Brain Abscess with Toxoplasma gondii", "Text" : "Toxoplasma gondii", "Mnemonic" : "36"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "DisplayText" : "Bell's Palsy", "Text" : "Bell's Palsy", "Mnemonic" : "38"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX CHRONIC MENINGITIS", "DisplayText" : "Chronic Meningitis", "Text" : "Chronic Meningitis", "Mnemonic" : "40"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "DisplayText" : "Cranial epidural abscess", "Text" : "Cranial epidural abscess", "Mnemonic" : "42"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "DisplayText" : "Neurosurgery", "Text" : "Neurosurgery prophylaxis", "Mnemonic" : "44"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "DisplayText" : "HSV Encephalitis", "Text" : "Herpes simplex encephalitis", "Mnemonic" : "46"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease", "Mnemonic" : "48"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "DisplayText" : "Spinal epidural abscess", "Text" : "Spinal epidural abscess", "Mnemonic" : "50"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "DisplayText" : "Subdural Empyema", "Text" : "Subdural empyema", "Mnemonic" : "52"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH", "DisplayText" : "Suppurative intracranial thrombophlebitis", "Text" : "Suppurative intracranial thrombophilia", "Mnemonic" : "54"},
{"Row" :5, "Column" : 2, "Text" : "Brain abscess", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Empiric Treatment"}, 
{"Row" : 12, "Column" : 2, "Text" : "Treatment based on Isolated Pathogen"}, 
{"Row" : 17, "Column" : 2, "Text" : "Other", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR" , "Term1" : "Colonized respiratory tract patient on a ventilator", "DisplayText" : "Colonized respiratory tract in patient with a ventilator" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Nosocomial Pneumonia", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The respiratory tracts of persons who are intubated, have a"}, 
{"Row" :6, "Column" : 1, "Text" : "tracheostomy, or have other abnormalities of the larynx or trachea are"}, 
{"Row" :7, "Column" : 1, "Text" : "usually colonized with bacteria and often fungi. The bacteria can be of"}, 
{"Row" :8, "Column" : 1, "Text" : "relatively low virulence (e.g. coagulase negative staphylococci, streptococci,"}, 
{"Row" :9, "Column" : 1, "Text" : "candida) or of potentially greater virulence (Staphylococcus aureus,"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterobacteriaceae, pseudomonas). Candida and enterococci are common"}, 
{"Row" : 11, "Column" : 1, "Text" : "respiratory tract colonizers and they almost never cause pneumonia. There is"}, 
{"Row" : 12, "Column" : 1, "Text" : "no benefit from treatment of patients with systemic antimicrobials simply"}, 
{"Row" : 13, "Column" : 1, "Text" : "because the respiratory tract is colonized with a potential pathogen and there"}, 
{"Row" : 14, "Column" : 1, "Text" : "is no evidence of an infiltrate. Systemic antimicrobial therapy will select for"}, 
{"Row" : 15, "Column" : 1, "Text" : "resistant organisms and may lead to other adverse effects."}, 
{"Row" : 17, "Column" : 1, "Text" : "See below for ventilator-associated pneumonia treatment recommendations in"}, 
{"Row" : 18, "Column" : 1, "Text" : "patients with a new or progressive infiltrate and at least one of the following: "}, 
{"Row" : 19, "Column" : 1, "Text" : "fever greater than 100.4F, leukocytosis, leukopenia or purulent bronchial"}, 
{"Row" : 20, "Column" : 1, "Text" : "secretions."}, 
{"Row" : 24, "Column" : 1, "Text" : "References"}, 
{"Row" : 26, "Column" : 1, "Text" : "Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111."}
]},
{"Name" : "ORZID2 GMENU ABX COLONIZED WOUNDS" , "Term1" : "Colonized wound " , "Term2" : "Wound, colonized", "DisplayText" : "Colonized wounds" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "DisplayText" : "Decubitus ulcers", "Text" : "Decubitus ulcers", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Diabetic foot ulcers", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "COLONIZED WOUNDS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Open wounds are usually colonized with bacteria and often fungi. This is true of"}, 
{"Row" :6, "Column" : 1, "Text" : "ulcers (see below), post-operative wounds, traumatic wounds, and others. Then"}, 
{"Row" :7, "Column" : 1, "Text" : "bacteria can be of relatively low virulence (eg, coagulase negative"}, 
{"Row" :8, "Column" : 1, "Text" : "staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus"}, 
{"Row" :9, "Column" : 1, "Text" : "aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds"}, 
{"Row" : 10, "Column" : 1, "Text" : "that are moist or covered. There is no need to treat patients with systemic"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials simply because a wound culture is positive for a potential"}, 
{"Row" : 12, "Column" : 1, "Text" : "pathogen. Topical antimicrobials are not effective in nearly all circumstances"}, 
{"Row" : 13, "Column" : 1, "Text" : "and can select for resistant organisms or lead to other adverse effects."}, 
{"Row" : 14, "Column" : 1, "Text" : "Systemic antimicrobial therapy may be indicated if there are signs of infection."}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 22, "Column" : 1, "Text" : "Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-Date article: Clinical assessment of chronic wounds"}
]},
{"Name" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA" , "Term1" : "Community-acquired pneumonia (CAP) " , "Term2" : "Pneumonia, community-acquired (CAP)", "DisplayText" : "Community-acquired pneumonia (CAP)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "DisplayText" : "CAP Pneumonia Severity Index (PSI) Calculator", "Text" : "CAP Pneumonia Severity Index (PSI) Calculator", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "DisplayText" : "CAP NON-SEVERE treated in an Inpatient Ward setting", "Text" : "CAP NON-SEVERE treated in an Inpatient Ward setting", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING", "DisplayText" : "CAP SEVERE treated in an ICU setting", "Text" : "CAP SEVERE treated in an ICU setting", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "DisplayText" : "Stepdown empiric treatment for CAP with oral antibiotics", "Text" : "Stepdown empiric treatment for CAP with oral antibiotics", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)"}, 
{"Row" :5, "Column" : 1, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,"}, 
{"Row" :6, "Column" : 1, "Text" : "including atypical pathogens.Specific therapy should be guided by culture"}, 
{"Row" :7, "Column" : 1, "Text" : "results."}, 
{"Row" :8, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk for"}, 
{"Row" : 13, "Column" : 1, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how"}, 
{"Row" : 14, "Column" : 1, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be"}, 
{"Row" : 15, "Column" : 1, "Text" : "treated safely outside of the hospital."}, 
{"Row" : 16, "Column" : 1, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and"}, 
{"Row" : 17, "Column" : 1, "Text" : "should be used to augment clinical judgment. If social circumstances"}, 
{"Row" : 18, "Column" : 1, "Text" : "or cognitive dysfunction would interfere with success of outpatient"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment, the patient should be hospitalized."}, 
{"Row" : 22, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent"}, 
{"Row" : 26, "Column" : 1, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia."}, 
{"Row" : 28, "Column" : 1, "Text" : "Empiric treatment for CAP treated in an Inpatient setting: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Note: These regimens may also be used to convert patients to oral medications"}, 
{"Row" : 35, "Column" : 1, "Text" : "prior to discharge."}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Fine MJ, et al. N Engl J Med (1997) 336:243-250"}
]},
{"Name" : "ORZID2 GMENU ABX COMP CYSTITIS" , "Term1" : "Complicated cystitis " , "Term2" : "Cystitis, complicated", "DisplayText" : "Complicated Cystitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Pyelonephritis", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "DisplayText" : "Acute Bacterial Prostatitis", "Text" : "Acute prostatitis", "Mnemonic" : "8"},
{"Row" : 48, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "10"},
{"Row" : 51, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days", "Mnemonic" : "12"},
{"Row" : 55, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "14"},
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3GM PO QOD 3 DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "16"},
{"Row" : 59, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "18"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "20"},
{"Row" : 63, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "22"},
{"Row" : 67, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 7 days", "Mnemonic" : "24"},
{"Row" : 74, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "30"},
{"Row" : 77, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R] for 7 days", "Mnemonic" : "32"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "26"},
{"Row" : 71, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,O]", "Mnemonic" : "28"},
{"Row" : 84, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "34"},
{"Row" : 86, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 7 days", "Mnemonic" : "36"},
{"Row" : 89, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "38"},
{"Row" : 90, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "40"},
{"Row" :100, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "42"},
{"Row" :102, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "44"},
{"Row" :105, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R] for 7 days", "Mnemonic" : "46"},
{"Row" :109, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R] for 7 days", "Mnemonic" : "48"},
{"Row" :111, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 1GM IV Q6H", "DisplayText" : "Ampicillin 1-2 gm IV q6h ($$) [R]", "Text" : "Ampicillin 1 gm IV q6h ($$) [R] for 7 days", "Mnemonic" : "50"},
{"Row" :114, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "52"},
{"Row" :115, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3GM PO QOD 3 DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "54"},
{"Row" :117, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days", "Mnemonic" : "56"},
{"Row" :120, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 7 days", "Mnemonic" : "58"},
{"Row" :3, "Column" : 1, "Text" : "COMPLICATED CYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Complicated cystitis is defined as symptomatic bladder inflammation and symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "due to a bacterial infection in people with certain conditions (see below)."}, 
{"Row" :7, "Column" : 1, "Text" : "Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated"}, 
{"Row" :8, "Column" : 1, "Text" : "cystitis is commonly associated with Enterobacteriaceae, but more resistant"}, 
{"Row" :9, "Column" : 1, "Text" : "pathogens occur, including the Gram-positive pathogens staphylococci and"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterococci."}, 
{"Row" : 12, "Column" : 1, "Text" : "Signs and symptoms that may indicate infection has extended beyond the bladder"}, 
{"Row" : 13, "Column" : 1, "Text" : "include fever/other signs of systemic infection, flank pain, costovertebral"}, 
{"Row" : 14, "Column" : 1, "Text" : "tenderness, and pelvic or perianal pain in men. Pyelonephritis should be"}, 
{"Row" : 15, "Column" : 1, "Text" : "considered in these patients: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Urine culture should be obtained before antimicrobials are given to guide"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment of complicated cystitis."}, 
{"Row" : 22, "Column" : 1, "Text" : "Prostatitis should be considered in men with recurrence of urinary tract"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection: "}, 
{"Row" : 26, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 27, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 28, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 30, "Column" : 1, "Text" : "Complicating conditions", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Cystitis is considered complicated when one or more of the following is present: "}, 
{"Row" : 32, "Column" : 1, "Text" : "o Pregnant women"}, 
{"Row" : 33, "Column" : 1, "Text" : "o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter"}, 
{"Row" : 34, "Column" : 1, "Text" : "or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)"}, 
{"Row" : 35, "Column" : 1, "Text" : "o Immunocompromise"}, 
{"Row" : 36, "Column" : 1, "Text" : "o Persistent infection, relapse, recurrence, or treatment failure"}, 
{"Row" : 37, "Column" : 1, "Text" : "o In some cases, men and patients admitted to health care settings may be"}, 
{"Row" : 38, "Column" : 1, "Text" : "considered complicated"}, 
{"Row" : 40, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Treat for 7 days. If patient is febrile, may extend duration up to 14 days total"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Mild to moderate disease", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 49, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 52, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 54, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 56, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 58, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 61, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 65, "Column" : 1, "Text" : "Severe disease or if patient cannot take oral therapy", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 73, "Column" : 1, "Text" : "High risk of Pseudomonas or Gram-negative MDR bacteria: "}, 
{"Row" : 75, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 76, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 69, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 78, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 83, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 85, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 88, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 91, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 93, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" : 94, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" : 95, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" : 96, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" : 97, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 99, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" :101, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :103, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" :104, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :107, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" :108, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :110, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :113, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" :116, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :118, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" :119, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :121, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :124, "Column" : 1, "Text" : "References: "}, 
{"Row" :125, "Column" : 1, "Text" : "Drekonja et al., JAMA, 2021, 326(4)324-331"}, 
{"Row" :126, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :127, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :128, "Column" : 1, "Text" : "Sanford keyword: Cystitis"}, 
{"Row" :129, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" :130, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" :131, "Column" : 1, "Text" : "Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16"}, 
{"Row" :132, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated urinary tract infection (including"}, 
{"Row" :133, "Column" : 1, "Text" : "pyelonephritis) in adults"}, 
{"Row" :134, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :135, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :136, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}, 
{"Row" :137, "Column" : 1, "Text" : "Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5"}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture", "Text" : "Urine culture", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIAL COST INFORMATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cost is represented as dollar ($) signs in parenthesis following the antibiotic."}, 
{"Row" :6, "Column" : 1, "Text" : "The number of $ signs represent the cost ranges below: "}, 
{"Row" :8, "Column" : 1, "Text" : "$ = Less than 10 dollars per day"}, 
{"Row" :9, "Column" : 1, "Text" : "$$ = 10-50 dollars per day"}, 
{"Row" : 10, "Column" : 1, "Text" : "$$$ = 51-100 dollars per day"}, 
{"Row" : 11, "Column" : 1, "Text" : "$$$$ = 101-400 dollars per day"}, 
{"Row" : 12, "Column" : 1, "Text" : "$$$$ = Greater than 400 dollars per day"}, 
{"Row" : 14, "Column" : 1, "Text" : "The displayed cost of an antibiotic is an estimate based on usual daily doses"}, 
{"Row" : 15, "Column" : 1, "Text" : "for an 80kg patient. Costs may change frequently due to VA contract negotiations"}, 
{"Row" : 16, "Column" : 1, "Text" : "as well as supply and demand effects. Antibiotic cost and formulary are reviewed"}, 
{"Row" : 17, "Column" : 1, "Text" : "by members of the Antimicrobial Subcommittee annually."}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 MAIN MENU", "DisplayText" : "COVID-19" , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINE", "DisplayText" : "Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines", "Text" : "Antimicrobial Inpatient Treatment", "Mnemonic" : "04"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting", "Text" : "Inpatient Vaccinations", "Mnemonic" : "06"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 INFORMATION", "DisplayText" : "COVID-19 INFORMATION", "Text" : "SharePoint Site and More Info", "Mnemonic" : "08"},
{"Row" :3, "Column" : 1, "Text" : "COVID-19: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINE", "DisplayText" : "Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Select here for help, legend, consults, alternative antimicrobials and more (Ip)", "Mnemonic" : "2"},
{"Row" :2, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "[Link] Minneapolis On-Call Schedule-Infectious Disease", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "DisplayText" : "Minneapolis COVID-19 SharePoint Site", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 PHARMACOLOGIC INPT TREATMENT GUIDELINES", "DisplayText" : "Minneapolis VAHCS COVID-19 Pharmacologic Inpatient Treatment Guidelines", "Text" : "Minneapolis VAHCS COVID Pharmacologic Inpatient Treatment Guidelines", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX REMDESIVIR 200MG LOAD THEN 100MG Q24H 5DAYS", "DisplayText" : "Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 4 days", "Text" : "Remdesivir 200mg IV once on day 1, then 100mg IV daily for 4 additional days", "Mnemonic" : "9"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID DEXAMETHASONE 6MG PO QDAY FOR 10DAYS COVID", "DisplayText" : "Dexamethasone 6 MG PO q24h for up to 10 days", "Text" : "Dexamethasone 6 MG PO q24h for up to 10 days", "Mnemonic" : "12"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX BARICITINIB EUA COVID-19", "DisplayText" : "Barcitinib Emergency Use Authorization for COVID-19", "Text" : "Baricitinib PO/NG/GT", "Mnemonic" : "14"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "DisplayText" : "Tocilizumab for treatment of COVID-19", "Text" : "Tocilizumab IV", "Mnemonic" : "16"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID INPT AND OPT ORDERS", "DisplayText" : "PAXLOVID INPT AND OPT ORDERS", "Text" : "Paxlovid (Nirmatrelvir 300 mg and ritonavir 100 mg) PO BID for 5 days", "Mnemonic" : "18"},
{"Row" :4, "Column" : 1, "Text" : "INPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info."}, 
{"Row" :9, "Column" : 1, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies and", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should be", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "discussed with the infectious diseases service. ***", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "HOSPITALIZED DUE TO COVID-19", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to COVID-19 Pharmacological Inpatient Treatment Guidelines to determine"}, 
{"Row" : 18, "Column" : 1, "Text" : "whether monotherapy or combination therapy with remdesivir and dexamethasone is"}, 
{"Row" : 19, "Column" : 1, "Text" : "appropriate. For patients on dexamethasone with rapidly increasing oxygen needs"}, 
{"Row" : 20, "Column" : 1, "Text" : "and systemic inflammation, add a second immunomodulatory drug (see"}, 
{"Row" : 21, "Column" : 1, "Text" : "Immunomodulatory Treatment below)"}, 
{"Row" : 35, "Column" : 1, "Text" : "Immunomodulatory Treatment", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "MVAHCS recommends baricitinib over tocilizumab in patients on high flow nasal"}, 
{"Row" : 37, "Column" : 1, "Text" : "cannula oxygen or non-invasive ventilated patients that can take PO or NG. For"}, 
{"Row" : 38, "Column" : 1, "Text" : "patients who cannot take PO or NG, or for those who are mechanically ventilated,"}, 
{"Row" : 39, "Column" : 1, "Text" : "we recommend tocilizumab.These treatments are to be added on to dexamethasone,"}, 
{"Row" : 40, "Column" : 1, "Text" : "with or without remdesivir.Consult Infectious Diseases for more details."}, 
{"Row" : 43, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 45, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "HOSPITALIZED FOR REASONS OTHER THAN COVID-19", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Treatment is recommended for patients with confirmed mild to moderate COVID-19"}, 
{"Row" : 50, "Column" : 1, "Text" : "and are at high risk of progressing to severe COVID-19."}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "DisplayText" : "COVID-19 Medication Interaction Check", "Text" : "Interaction checker for COVID-19 medications website link", "Mnemonic" : "17"},
{"Row" : 28, "Column" : 1, "Item" : "LRTZ SET REMDESIVIR X5 DAYS", "DisplayText" : "Remdesivir Labs", "Text" : "Lab orders for monitoring remdesivir treatment (CMP, CBC with diff, INR)", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 6MG IV QDAY FOR 10 DAYS COVID", "DisplayText" : "Dexamethasone 6 MG IV q24h for up to 10 days", "Text" : "Dexamethasone 6 MG IV q24h for up to 10 days", "Mnemonic" : "13"},
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Dexamethasone (PO/IV): ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Remdesivir (IV): ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "**Place medication orders for inpatient and outpatient (included in order set)"}, 
{"Row" : 54, "Column" : 1, "Text" : "Preferred treatment, within 5 days of symptom onset: ", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Alternative, within 7 days of symptom onset: ", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX REMDESIVIR 200MG IV LOAD THEN 100MG Q24HH 3DAYS", "DisplayText" : "Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 2 days", "Text" : "Remdesivir 200mg IV once on day 1, then 100mg IV daily for 2 additional days", "Mnemonic" : "21"},
{"Row" : 61, "Column" : 1, "Item" : "LRTZ SET REMDESIVIR X3 DAYS", "DisplayText" : "Remdesivir labs x3 days", "Text" : "Lab orders for monitoring remdesivir treatment (CMP, CBC with diff, INR)", "Mnemonic" : "22"},
{"Row" : 60, "Column" : 1, "Text" : "< AND >"}, 
{"Row" : 27, "Column" : 1, "Text" : "< AND >"}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE CLC", "DisplayText" : "CLC COVID VACCINE (PFIZER-BIONTECH) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACCINE CLC WITH 15 MINUTE MONITORING", "DisplayText" : "COVID-19 vaccine with 15 minute monitoring", "Text" : "First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC 3RD DOSE CLC 15 MINUTE MONITORING", "DisplayText" : "COVID-19 Vaccine 3rd Dose with 15 minute monitoring CLC", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE CLC 15 MINUTE MONITORING", "DisplayText" : "COVID-19 Vaccine Booster Dose with 15 minute monitoring CLC", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "GMRCTZ COVID-19 VACCINE VACCINATION APPROPR NURSING TEXT ORDER", "DisplayText" : "COVID-19 Vaccine appropriatenness nursing text order", "Text" : "<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACCINE CLC WITH 30 MINUTE MONITORING", "DisplayText" : "COVID-19 vaccine with 30 minute monitoring", "Text" : "First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)", "Mnemonic" : "12"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC 3RD DOSE CLC 30 MINUTE MONITORING", "DisplayText" : "COVID-19 Vaccine 3rd Dose with 30 minute monitoring CLC", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Mnemonic" : "14"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE CLC 30 MINUTE MONITORING", "DisplayText" : "COVID-19 Vaccine Booster Dose with 30 minute monitoring CLC", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "GMRCTZ COVID-19 VACCINE VACCINATION APPROPR NURSING TEXT ORDER", "DisplayText" : "COVID-19 Vaccine appropriatenness nursing text order", "Text" : "<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY LIVING CENTER AND SPINAL CORD INJURY COVID-19 VACCINE ORDERS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with NO history of anaphylaxis (to oral medication, food, insect,", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "etc.), and NO history of immediate allergic reaction to non-COVID vaccine or", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "injectable medication", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Patients with history of anaphylaxis (to oral medication, food, insect, etc.),", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "OR history of immediate allergic reaction to non-COVID vaccine or injectable", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "medication", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "_________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and"}, 
{"Row" : 25, "Column" : 1, "Text" : "Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service"}, 
{"Row" : 26, "Column" : 1, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html"}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE JANSSEN INPT", "DisplayText" : "COVID VACCINE (JANSSEN) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACCINE JANSSEN EUA", "DisplayText" : "COVID-19 Vaccine Janssen EUA", "Text" : "[CLICK HERE] for link to COVID-19 vaccine EUA", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACCINE BOOSTER DOSE ELIGIBILITY CRITERIA", "DisplayText" : "COVID-19 Vaccine Booster Dose Eligibility Criteria", "Text" : "[CLICK HERE] for a comprehensive list of eligibility criteria", "Mnemonic" : "6"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN WITH 15 MINUTE MONITORING", "DisplayText" : "COVID-19 Janssen Vaccine single dose with 15 minute monitoring", "Text" : "Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Mnemonic" : "8"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN BOOSTER WITH 15 MIN MONITOR", "DisplayText" : "COVID-19 Janssen Vaccine booster dose with 15 minute monitoring", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Mnemonic" : "10"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN WITH 30 MINUTE MONITORING", "DisplayText" : "COVID-19 Janssen Vaccine single dose with 30 minute monitoring", "Text" : "Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Mnemonic" : "12"},
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN BOOSTER WITH 30 MIN MONITOR", "DisplayText" : "COVID-19 Janssen Vaccine booster dose with 30 minute monitoring", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "JANSSEN (JOHNSON & JOHNSON) COVID-19 VACCINE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Generally, mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) are preferred"}, 
{"Row" :6, "Column" : 1, "Text" : "over Janssen (Johnson & Johnson) vaccine. Janssen may be preferred in those who"}, 
{"Row" :7, "Column" : 1, "Text" : "have a contraindication to mRNA vaccines or are at risk of not showing up for a"}, 
{"Row" :8, "Column" : 1, "Text" : "second dose. By placing this order, the patient will be administered the vaccine"}, 
{"Row" :9, "Column" : 1, "Text" : "dose the same day or the next business day when vaccine doses are available."}, 
{"Row" : 11, "Column" : 1, "Text" : "Prerequisites", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "All Orders: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Placing this order implies that you have already discussed the following with"}, 
{"Row" : 14, "Column" : 1, "Text" : "the patient: The patient meets the below criteria and understands that"}, 
{"Row" : 15, "Column" : 1, "Text" : "this vaccine is an unapproved vaccine under an Emergency Use Authorization"}, 
{"Row" : 16, "Column" : 1, "Text" : "(EUA). The patient has been offered a copy of the EUA Fact Sheet: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Booster Dose Additional Prerequisites: "}, 
{"Row" : 21, "Column" : 1, "Text" : "o If first dose was Janssen (Johnson & Johnson) - patients are eligibile 2 month"}, 
{"Row" : 22, "Column" : 1, "Text" : "after receiving the 1st dose"}, 
{"Row" : 23, "Column" : 1, "Text" : "o If first dose was Pfizer (BioNTech) or Moderna - patients are eligible"}, 
{"Row" : 24, "Column" : 1, "Text" : "5 months after the second dose."}, 
{"Row" : 26, "Column" : 1, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Absolute: "}, 
{"Row" : 28, "Column" : 1, "Text" : "1. Already received a 3rd dose of COVID-19 mRNA vaccine or Janssen booster dose"}, 
{"Row" : 29, "Column" : 1, "Text" : "2. Active infection with COVID-19"}, 
{"Row" : 30, "Column" : 1, "Text" : "3. Received monoclonal antibody or convalescent plasma for COVID-19 treatment in"}, 
{"Row" : 31, "Column" : 1, "Text" : "the last 90 days"}, 
{"Row" : 32, "Column" : 1, "Text" : "4. History of anaphylaxis requiring treatment with epinephrine to any Janssen"}, 
{"Row" : 33, "Column" : 1, "Text" : "COVID-19 vaccine ingredient"}, 
{"Row" : 34, "Column" : 1, "Text" : "5. History of any allergic reaction to previous COVID-19 vaccine or ingredient"}, 
{"Row" : 35, "Column" : 1, "Text" : "(including PEG) OR polysorbate"}, 
{"Row" : 37, "Column" : 1, "Text" : "Relative: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Active infection where vaccine side effects may confuse diagnostic or"}, 
{"Row" : 39, "Column" : 1, "Text" : "treatment course"}, 
{"Row" : 41, "Column" : 1, "Text" : "Please Note: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Booster doses may NOT be given at CBOCs, other satellite clinics or another"}, 
{"Row" : 43, "Column" : 1, "Text" : "VA/hospital."}, 
{"Row" : 45, "Column" : 1, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "If a booster dose is indicated, it should be administered 5 months after the"}, 
{"Row" : 47, "Column" : 1, "Text" : "2nd dose of an mRNA vaccine (Pfizer (BioNTech) or Moderna) or 2 months after the"}, 
{"Row" : 48, "Column" : 1, "Text" : "Janssen (Johnson & Johnson) vaccine."}, 
{"Row" : 50, "Column" : 1, "Text" : "Order COVID-19 Vaccine (Janssen) Dose: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Patients with NO history of anaphylaxis (to oral medication, food, insect,"}, 
{"Row" : 52, "Column" : 1, "Text" : "etc.), and NO history of immediate allergic reaction to non-COVID vaccine or"}, 
{"Row" : 53, "Column" : 1, "Text" : "injectable medication"}, 
{"Row" : 57, "Column" : 1, "Text" : "Patients with history of anaphylaxis (to oral medication, food, insect, etc.),"}, 
{"Row" : 58, "Column" : 1, "Text" : "OR history of immediate allergic reaction to non-COVID vaccine or injectable"}, 
{"Row" : 59, "Column" : 1, "Text" : "Medication"}, 
{"Row" : 63, "Column" : 1, "Text" : "Risks and Benefits: ", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "Benefits: "}, 
{"Row" : 65, "Column" : 1, "Text" : "May prevent contracting a symptomatic COVID-19 infection"}, 
{"Row" : 67, "Column" : 1, "Text" : "Risks: "}, 
{"Row" : 68, "Column" : 1, "Text" : "Common Side Effects: "}, 
{"Row" : 69, "Column" : 1, "Text" : "1. Injection site reactions: pain, redness of the skin and swelling"}, 
{"Row" : 70, "Column" : 1, "Text" : "2. General side effects: headache, feeling very tired, muscle aches, nausea, and"}, 
{"Row" : 71, "Column" : 1, "Text" : "fever"}, 
{"Row" : 72, "Column" : 1, "Text" : "Uncommon Anaphylactoid Reactions: "}, 
{"Row" : 73, "Column" : 1, "Text" : "1. Dyspnea"}, 
{"Row" : 74, "Column" : 1, "Text" : "2. Tachycardia"}, 
{"Row" : 75, "Column" : 1, "Text" : "3. Severe rash"}, 
{"Row" : 76, "Column" : 1, "Text" : "4. Angioedema"}, 
{"Row" : 77, "Column" : 1, "Text" : "5. Syncope or pre-syncope"}, 
{"Row" : 78, "Column" : 1, "Text" : "Rare but Serious Adverse Events"}, 
{"Row" : 79, "Column" : 1, "Text" : "1. Thrombosis with Thrombocytopenia"}, 
{"Row" : 80, "Column" : 1, "Text" : "2. Guillian-Barre' Syndrome"}, 
{"Row" : 82, "Column" : 1, "Text" : "_________________________________________________________________________", "Header" : 1}, 
{"Row" : 84, "Column" : 1, "Text" : "References: "}, 
{"Row" : 85, "Column" : 1, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and"}, 
{"Row" : 86, "Column" : 1, "Text" : "Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service"}, 
{"Row" : 87, "Column" : 1, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html"}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACCINE CLC INTERIM GUIDANCE", "DisplayText" : "COVID-19 INFORMATION", "Text" : "CDC COVID-19 Vaccine Interim Clinical Considerations", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID COVID-19 VACCINE ONCE", "DisplayText" : "COVID-19 Vaccine Once Dose", "Text" : "Monovalent COVID-19 vaccine once dose", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID2 COVID-19 BIVALENT VACCINE ONCE", "DisplayText" : "COVID-19 bivalent vaccine (Pfizer-BioNTech) booster dose", "Text" : "Bivalent COVID-19 vaccine booster dose", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "INPATIENT COVID-19 VACCINE RECOMMENDATIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For up to date COVID-19 vaccine recommendations, refer to the CDC: "}, 
{"Row" :8, "Column" : 1, "Text" : "Monovalent Primary Vaccine Series", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Give 2 doses of monovalent COVID-19 vaccine separated by at least 3 weeks to"}, 
{"Row" : 10, "Column" : 1, "Text" : "those who have not received a previous COVID-19 vaccine dose. 3 doses are"}, 
{"Row" : 11, "Column" : 1, "Text" : "required for immunocompromised individuals, use link above to refer to CDC"}, 
{"Row" : 12, "Column" : 1, "Text" : "for list of immunocompromising conditions and specific recommendations."}, 
{"Row" : 15, "Column" : 1, "Text" : "Bivalent Booster", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Give 1 bivalent COVID-19 vaccine dose after completing any monovalent COVID-19"}, 
{"Row" : 17, "Column" : 1, "Text" : "primary series and at least 2 months after last non-bivalent COVID-19 vaccine"}, 
{"Row" : 18, "Column" : 1, "Text" : "dose, regardless of the number of COVID-19 booster vaccines received."}, 
{"Row" : 20, "Column" : 1, "Text" : "_________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and"}, 
{"Row" : 24, "Column" : 1, "Text" : "Professional Resources. Atlanta, GA, US Department of Health and Human Services"}, 
{"Row" : 25, "Column" : 1, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html"}
]},
{"Name" : "ORZID2 GMENU ABX CRYPTOSPORIDIA" , "Term1" : "Cryptosporidium parvum diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Cryptosporidium parvum" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID NITAZOXANIDE 500MG PO Q12H", "DisplayText" : "Nitazoxanide 500mg po q12h", "Text" : "Nitazoxanide 500 mg PO q12h for 3 days ($$$) [M]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CRYPTOSPORIDIUM PARVUM", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antibiotic therapy is usually used only for persons with severe disease or"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompromised persons."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial treatment for patients without HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobial treatment for patients with HIV/AIDS", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS."}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 21, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Cryptosporidiosis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of cryptosporidiosis"}
]},
{"Name" : "ORZID2 GMENU ABX CYCLOSPORA" , "Term1" : "Cyclospora cayetanensis diarrhea/gastroenteritis", "DisplayText" : "Cyclospora cayetanensis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 7 to 10 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CYCLOSPORA CAYETANENSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with allergy to sulfonamides."}, 
{"Row" :7, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimicrobial treatment for patients without HIV/AIDS", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Antimicrobial treatment for patients with HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS."}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Cyclosporiasis"}, 
{"Row" : 20, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-Date article: Cyclospora infection"}
]},
{"Name" : "ORZID2 GMENU ABX DELAYED STANDARD ABX CV SURG", "DisplayText" : "Standard (Non PCN allergic) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE", "DisplayText" : "VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE OPEN HEART", "Text" : "Vancomycin 1500mg PRE-OPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET ABX CEFUROXIME 1500MG PRE-OP & INTRA-OP DOSES", "DisplayText" : "CEFUROXIME 1500MG PRE-OPERATIVE & INTRA-OPERATIVE OPEN HEART", "Text" : "Cefuroxime 1.5gm PRE-OPERATIVE dose **AND** 1.5gm INTRAOPERATIVE dose", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX DERM HIGH RISK SITE PROPHYLAXIS", "Term" : "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS", "DisplayText" : "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 2GM PO ONCE 'C'", "DisplayText" : "Cephalexin 2gm po once (Var)", "Text" : "Cephalexin 2 GM PO ONCE - 1 hour prior to procedure ($) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1 DS TAB PO ONCE PENVK 500MG PO ONCE", "DisplayText" : "TMP/SMX 1 DS TAB PO ONCE PENVK 500MG PO ONCE", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS tablet PO 60 minutes before incision ($)", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "DisplayText" : "Cefazolin 1gm iv once", "Text" : "Cefazolin 1 gm IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 mg/kg IV 120 minutes before incision ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antibiotic prophylaxis is recommended for prevention of infection for the listed"}, 
{"Row" :6, "Column" : 1, "Text" : "high risk conditions: "}, 
{"Row" :8, "Column" : 1, "Text" : "2. Groin or Lower Extremities"}, 
{"Row" :9, "Column" : 1, "Text" : "3. Skin flaps and grafts"}, 
{"Row" : 10, "Column" : 1, "Text" : "4. Wedge excision of lip or ear"}, 
{"Row" : 12, "Column" : 1, "Text" : "Contaminated, dirty or infected wound may warrant antibiotic prophylaxis if"}, 
{"Row" : 13, "Column" : 1, "Text" : "patient is not currently on an antimicrobial for treatment of infection at the"}, 
{"Row" : 14, "Column" : 1, "Text" : "surgical site. Surgical prophylaxis is covered by antimicrobials for treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "of infection at time of surgery. No additional antimicrobials are necessary."}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "MRSA risk factor", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "[R,DI] < AND > penicillin VK 500 mg PO 60 minutes before incision ($) [R]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Unable to take oral medications", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 30, "Column" : 1, "Text" : "MRSA risk factors and unable to take oral medications", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283"}, 
{"Row" : 39, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 40, "Column" : 1, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site"}, 
{"Row" : 42, "Column" : 1, "Text" : "infection in adults"}, 
{"Row" : 43, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 44, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}, 
{"Row" :7, "Column" : 1, "Text" : "1. Extensive inflammatory skin disease (e.g. high tension)"}
]},
{"Name" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "Term" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS", "DisplayText" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE INFECTED SKIN, SKIN STRUCTURES", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "OR MUSKULOSKELETAL TISSUE PROCEDURES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "There is a lack of evidence supporting antimicrobial prophylaxis to prevent"}, 
{"Row" :6, "Column" : 1, "Text" : "prosthetic joint infections in patients undergoing procedures on infected skin,"}, 
{"Row" :7, "Column" : 1, "Text" : "skin structures or musculoskeletal tissue procedures."}, 
{"Row" :9, "Column" : 1, "Text" : "For more information contact Infectious Diseases."}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________"}, 
{"Row" : 14, "Column" : 1, "Text" : "References: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic"}, 
{"Row" : 16, "Column" : 1, "Text" : "hardware infection"}
]},
{"Name" : "ORZID2 GMENU ABX DERM POST-OP INFECTIONS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 500MG PO QID 'THREE DOSES'", "DisplayText" : "Cephalexin 500 mg PO QID, three doses post-operatively ($) [R]", "Text" : "Cephalexin 500 mg PO QID, three doses post-operatively ($) [R]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 1DS PO BID 'ONE DOSE'", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV Q8H '2 DOSES'", "DisplayText" : "Cefazolin 1 gm IV q8h, two doses post-operatively ($) [R]", "Text" : "Cefazolin 1 gm IV q8h, two doses post-operatively ($) [R]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "DisplayText" : "VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP CEPHALEX 500MG Q6H X3 METRON 500MG Q8H X2", "DisplayText" : "CEPHALEX 500MG Q6H X3 METRON 500MG Q8H X2", "Text" : "Cephalexin 500 mg PO QID, three doses post-operatively ($) [R] <AND>", "Mnemonic" : "16"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500MG BID PO X1 METRON 500MG TID PO X2", "DisplayText" : "CIPRO 500MG BID PO X1 METRON 500MG TID PO X2", "Text" : "Ciprofloxacin 500 mg PO BID, one dose post-operatively ($) [R,DI] <AND>", "Mnemonic" : "18"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS BID PO X1 METRON 500MG PO TID X2", "DisplayText" : "TMP/SMX 1DS BID PO X1 METRON 500MG PO TID X2", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Mnemonic" : "20"},
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 500MG IV Q8H X 2", "DisplayText" : "Metronidazole 500 mg IV q8h x 2 doses post-op", "Text" : "Metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]", "Mnemonic" : "22"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG Q12H IV X1 METRON 500MG Q8H IV X2", "DisplayText" : "CIPRO 400MG Q12H IV X1 METRON 500MG Q8H IV X2", "Text" : "Ciprofloxacin 400 mg IV q12h, one dose post-operatively ($) [R,DI] <AND>", "Mnemonic" : "24"},
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "DisplayText" : "VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]", "Mnemonic" : "26"},
{"Row" : 62, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG BID PO 'ONE DOSE'", "DisplayText" : "Amoxicillin 500 mg PO BID, one dose post-operatively ($) [R]", "Text" : "Amoxicillin 500 mg PO BID, one dose post-operatively ($) [R]", "Mnemonic" : "28"},
{"Row" : 64, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS TAB PO BID X1 PENVK 500MG PO TID X2", "DisplayText" : "TMP/SMX 1DS TAB PO BID X1 PENVK 500MG PO TID X2", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Mnemonic" : "30"},
{"Row" : 67, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV Q6H 'THREE DOSES'", "DisplayText" : "Ampicillin 2 gm IV q6h, 3 doses post-operatively ($$) [R]", "Text" : "Ampicillin 2 gm IV q6h, 3 doses post-operatively ($$) [R]", "Mnemonic" : "32"},
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H 'TWO DOSES'", "DisplayText" : "Clindamycin 600 mg IV q8h, 2 doses post-operatively ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h, 2 doses post-operatively ($$) [H,O]", "Mnemonic" : "34"},
{"Row" :3, "Column" : 1, "Text" : "DERMATOLOGIC SURGERY POST-OPERATIVE ANTIBIOTIC PROPHYLAXIS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "RECOMMENDATIONS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Conditions that may warrant dermatologic surgery post-operative antibiotic"}, 
{"Row" :7, "Column" : 1, "Text" : "prophylaxis: "}, 
{"Row" :8, "Column" : 1, "Text" : "1. Large wound (>5cm)"}, 
{"Row" :9, "Column" : 1, "Text" : "2. Long procedure where wound is open for a long time"}, 
{"Row" : 10, "Column" : 1, "Text" : "3. Wound near cartilage or bone (e.g. some nose, scalp or ear sites)"}, 
{"Row" : 12, "Column" : 1, "Text" : "If patient received pre-operative antibiotics, select the same antibiotic for"}, 
{"Row" : 13, "Column" : 1, "Text" : "post-operative prophylaxis. Duration of antimicrobial prophylaxis should not"}, 
{"Row" : 14, "Column" : 1, "Text" : "exceed 24 hours. Durations longer than 24 hours have not been shown effective in"}, 
{"Row" : 15, "Column" : 1, "Text" : "preventing surgical site infections."}, 
{"Row" : 17, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 20, "Column" : 1, "Text" : "Operations involving trunk or extremity away from axilla or perineum", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Penicillin allergy or MRSA risk factors"}, 
{"Row" : 25, "Column" : 1, "Text" : "[R,DI]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Severe infections or patients unable to take oral medications"}, 
{"Row" : 30, "Column" : 1, "Text" : "Penicillin allergy or MRSA risk factors and severe infection or patient unable"}, 
{"Row" : 31, "Column" : 1, "Text" : "to take oral medications"}, 
{"Row" : 34, "Column" : 1, "Text" : "Operations involving the axilla or perineum", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]"}, 
{"Row" : 38, "Column" : 1, "Text" : "Penicillin allergy"}, 
{"Row" : 40, "Column" : 1, "Text" : "metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]"}, 
{"Row" : 42, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 44, "Column" : 1, "Text" : "[R,DI] <AND> metronidazole 500 mg PO q8h, two doses post-operatively ($) [DI]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Severe infections or unable to take oral medications"}, 
{"Row" : 47, "Column" : 1, "Text" : "Note: ceftriaxone does not require redosing due to it's long half-live"}, 
{"Row" : 50, "Column" : 1, "Text" : "Penicillin allergy and severe infections or unable to take oral medications"}, 
{"Row" : 52, "Column" : 1, "Text" : "metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]"}, 
{"Row" : 54, "Column" : 1, "Text" : "MRSA risk factors and severe infections or unable to take oral medications"}, 
{"Row" : 55, "Column" : 1, "Text" : "< ADD > to one of the above IV regimens for operations involving axilla or"}, 
{"Row" : 56, "Column" : 1, "Text" : "perineum"}, 
{"Row" : 59, "Column" : 1, "Text" : "Continuation of pre-operative antibiotics that are not listed above", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Note: azithromycin and ceftriaxone do not require redosing due to their long"}, 
{"Row" : 61, "Column" : 1, "Text" : "half-lives"}, 
{"Row" : 63, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 65, "Column" : 1, "Text" : "[R,DI] < AND > Penicillin VK 500 mg PO TID, 2 doses post-operatively ($) [R]"}, 
{"Row" : 66, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 68, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 72, "Column" : 1, "Text" : "References: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283"}, 
{"Row" : 75, "Column" : 1, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185"}, 
{"Row" : 76, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 77, "Column" : 1, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44"}, 
{"Row" : 78, "Column" : 1, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52"}, 
{"Row" : 79, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site"}, 
{"Row" : 80, "Column" : 1, "Text" : "infection in adults"}, 
{"Row" : 81, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 82, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 83, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 84, "Column" : 1, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754"}, 
{"Row" : 85, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}
]},
{"Name" : "ORZID2 GMENU ABX DERM PROPHYLAXIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "ANTIMICROBIAL PROPHYLAXIS AND DERMATOLOGIC SURGERY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Antibiotics are used to prevent infections in patients undergoing surgery in"}, 
{"Row" :5, "Column" : 1, "Text" : "certain well-defined circumstances. They are used to prevent surgical site"}, 
{"Row" :6, "Column" : 1, "Text" : "infection or to prevent endocarditis in circumstances where the risk of"}, 
{"Row" :7, "Column" : 1, "Text" : "endocarditis is high. For many low-risk surgeries, the risks associated with"}, 
{"Row" :8, "Column" : 1, "Text" : "antibiotic use, which can be severe or cause death, outweigh the benefits. The"}, 
{"Row" :9, "Column" : 1, "Text" : "following recommendations are consistent with guidelines published by the"}, 
{"Row" : 10, "Column" : 1, "Text" : "American Heart Association and Infectious Disease Society of America."}, 
{"Row" : 12, "Column" : 1, "Text" : "In general, antibiotics are used to prevent post-operative wound infection"}, 
{"Row" : 13, "Column" : 1, "Text" : "in clean-contaminated surgery. Most dermatological surgery involves clean"}, 
{"Row" : 14, "Column" : 1, "Text" : "sites, and the risks of antibiotics outweigh potential benefits. Antibiotics"}, 
{"Row" : 15, "Column" : 1, "Text" : "are used to prevent endocarditis and hematogenous joint infection in procedures"}, 
{"Row" : 16, "Column" : 1, "Text" : "involving infected skin structures. Antibitic prophylaxis is also"}, 
{"Row" : 17, "Column" : 1, "Text" : "recommended to prevent surgical site infections in procedures involving high"}, 
{"Row" : 18, "Column" : 1, "Text" : "risk surgical sites and conditions."}, 
{"Row" : 20, "Column" : 1, "Text" : "When they are used, prophylactic oral antimicrobial agents should be"}, 
{"Row" : 21, "Column" : 1, "Text" : "administered 30-60 minutes before the first tissue manipulation or incision."}, 
{"Row" : 22, "Column" : 1, "Text" : "Intravenous antimicrobials should be administered 60 minutes (120 minutes for"}, 
{"Row" : 23, "Column" : 1, "Text" : "vancomycin) prior to procedure."}, 
{"Row" : 25, "Column" : 1, "Text" : "Antimicrobials should not be used to prevent infections in patients with"}, 
{"Row" : 26, "Column" : 1, "Text" : "vascular grafts or orthopedic prostheses because the risk of bacteremia or"}, 
{"Row" : 27, "Column" : 1, "Text" : "infection of these devices is tiny and antibiotic risks outweigh any theoretical"}, 
{"Row" : 28, "Column" : 1, "Text" : "benefit."}, 
{"Row" : 30, "Column" : 1, "Text" : "A full course of antibiotics should be used to treat skin infections where"}, 
{"Row" : 31, "Column" : 1, "Text" : "infection is already present at the time of surgery."}, 
{"Row" : 33, "Column" : 1, "Text" : "Suggested antibiotic prophylaxis regimens should be targeted against the typical"}, 
{"Row" : 34, "Column" : 1, "Text" : "pathogens likely to be present. A risk-based approach for coverage of MRSA"}, 
{"Row" : 35, "Column" : 1, "Text" : "should be taken in patients with specific risk factors for MRSA."}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283"}, 
{"Row" : 41, "Column" : 1, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185"}, 
{"Row" : 42, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 43, "Column" : 1, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44"}, 
{"Row" : 44, "Column" : 1, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site"}, 
{"Row" : 46, "Column" : 1, "Text" : "infection in adults"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 48, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 50, "Column" : 1, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754"}, 
{"Row" : 51, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}
]},
{"Name" : "ORZID2 GMENU ABX DERM SURGICAL INFECTION" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP CEFADROXIL 1000MG PO Q12H METRON 500MG PO Q8H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Text" : "", "Mnemonic" : "14"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CIPROF 500MG PO BID METRO 500MG PO TID", "Text" : "Ciprofloxacin 50O mg PO q12h ($) [R,DI] <AND> metronidazole 500 mg PO q8h ($", "Mnemonic" : "16"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX OP TMP 1 DS TAB PO BID METRO 500MG PO TID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI] <AND> metronidazole", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI] <AND> metronidazole", "Mnemonic" : "18"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "20"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($", "Mnemonic" : "22"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "DERMATOLOGIC SURGICAL SITE INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If an infection develops, obtain a gram stain and/or culture. Suture removal,"}, 
{"Row" :6, "Column" : 1, "Text" : "incision and drainage is recommended. Antimicrobials may be beneficial in"}, 
{"Row" :7, "Column" : 1, "Text" : "surgical site infections with significant systemic response (i.e induration"}, 
{"Row" :8, "Column" : 1, "Text" : "greater than 5cm from wound edge, fever, tachycardia and leukocytosis)."}, 
{"Row" :9, "Column" : 1, "Text" : "In general, most post-op infections develop greater than 48 hours after surgery."}, 
{"Row" : 10, "Column" : 1, "Text" : "Start on antibiotics as below until culture result is available and then switch"}, 
{"Row" : 11, "Column" : 1, "Text" : "antibiotics, if indicated."}, 
{"Row" : 13, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treat for 5-7 days"}, 
{"Row" : 18, "Column" : 1, "Text" : "Operations involving trunk or extremity away from axilla or perineum", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Penicillin allergy or MRSA risk factors"}, 
{"Row" : 24, "Column" : 1, "Text" : "Severe infections or unable to take oral medications"}, 
{"Row" : 27, "Column" : 1, "Text" : "Penicillin allergy or MRSA risk factors and severe infection or unable to take"}, 
{"Row" : 28, "Column" : 1, "Text" : "oral medications"}, 
{"Row" : 31, "Column" : 1, "Text" : "Operations involving the axilla, gastrointestinal tract, or perineum, or female", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "genital tract", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Penicillin allergy"}, 
{"Row" : 37, "Column" : 1, "Text" : "[DI]"}, 
{"Row" : 39, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 41, "Column" : 1, "Text" : "500 mg PO TID ($) [DI]"}, 
{"Row" : 43, "Column" : 1, "Text" : "Severe infections or unable to take oral medications"}, 
{"Row" : 46, "Column" : 1, "Text" : "Penicillin allergy and severe infections or unable to take oral medications"}, 
{"Row" : 48, "Column" : 1, "Text" : "[DI]"}, 
{"Row" : 50, "Column" : 1, "Text" : "MRSA risk factors and severe infections or unable to take oral medications"}, 
{"Row" : 51, "Column" : 1, "Text" : "< ADD > to one of the above IV regimens for operations involving axilla or"}, 
{"Row" : 52, "Column" : 1, "Text" : "perineum"}, 
{"Row" : 56, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 60, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations " , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM PROPHYLAXIS", "Text" : "Antimicrobial Prophylaxis and Dermatologic Surgery", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "DisplayText" : "Prevention of Bacterial Endocarditis", "Text" : "[click here] for inpatients", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "DisplayText" : "Prevention of bacterial endocarditis (Outpatient)", "Text" : "[click here] for outpatients", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "DisplayText" : "Prevention of prosthetic joint infection before dental procedures", "Text" : "Oral mucosa or surgical site with high risk of hematogenous prosthetic joint", "Mnemonic" : "8"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "DisplayText" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS", "Text" : "Infected skin surgical site with high risk of hematogenous prosthetic joint", "Mnemonic" : "10"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM HIGH RISK SITE PROPHYLAXIS", "DisplayText" : "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS", "Text" : "Other high risk surgical sites and conditions", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX PHOTODYNAMIC THERAPY HSV-1", "DisplayText" : "Photodynamic therapy for HSV-1 prophylaxis", "Text" : "[click here] for inpatients", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX PHOTODYNAMIC THERAPY HSV-1", "DisplayText" : "Photodynamic therapy for HSV-1 prophylaxis", "Text" : "[click here] for outpatients", "Mnemonic" : "16"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM POST-OP INFECTIONS", "Text" : "Post-operative prophylaxis recommendations", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM SURGICAL INFECTION", "Text" : "Management of Post-Operative infections", "Mnemonic" : "20"},
{"Row" :2, "Column" : 1, "Text" : "DERMATOLOGICAL GUIDELINES", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Background information on antibiotic prophylaxis in dermatologic surgery: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Specific antibiotic prophylaxis recommendations in dermatologic surgery: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Oral mucosa or infected skin surgical site with high risk of infective"}, 
{"Row" :9, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 14, "Column" : 1, "Text" : "infection"}, 
{"Row" : 17, "Column" : 1, "Text" : "infection"}, 
{"Row" : 20, "Column" : 1, "Text" : "*Menu contains outpatient PO orders"}, 
{"Row" : 22, "Column" : 1, "Text" : "Photodynamic therapy and laser skin resurfacing HSV-1 prophylaxis"}, 
{"Row" : 27, "Column" : 1, "Text" : "*Menu contains outpatient PO orders"}, 
{"Row" : 29, "Column" : 1, "Text" : "Dermatologic surgical site infection recommendations: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "*Menu contains outpatient PO orders"}
]},
{"Name" : "ORZID2 GMENU ABX DERMATOLOGY MAIN" , "Term1" : "Dermatological Infections section " , "Term2" : "Skin Infections section", "DisplayText" : "Dermatological Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPETIGO", "DisplayText" : "Impetigo", "Text" : "Impetigo", "Mnemonic" : "5"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU FOLLICULITIS", "DisplayText" : "Folliculitis", "Text" : "Folliculitis", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas", "Text" : "Erysipelas", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and carbuncles", "Text" : "Furuncles and carbuncles", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "DisplayText" : "Cellulitis", "Text" : "Cellulitis", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Necrotizing infections", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ECTHYMA GANGRENOSUM", "DisplayText" : "Ecthyma Gangrenosum", "Text" : "Ecthyma gangrenosum", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU STAPH SCALDED SYNDROME", "DisplayText" : "Staphylococcal Scalded Skin Syndrom (Ritter's Disease)", "Text" : "Scalded Skin Syndrome", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "DisplayText" : "Hidradenitis Suppurativa", "Text" : "Hidradenitis Suppurativa", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome", "Text" : "Toxic Shock Syndrome", "Mnemonic" : "22"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ERYTHRASMA", "DisplayText" : "Erythrasma", "Text" : "Erythrasma", "Mnemonic" : "24"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELOID", "DisplayText" : "Erysipeloid", "Text" : "Erysipeloid", "Mnemonic" : "26"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU CAT-SCATCH DISEASE", "DisplayText" : "Cat-Scratch Disease", "Text" : "Cat-scratch disease", "Mnemonic" : "28"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU LEISHMANIASIS", "DisplayText" : "Leishmaniasis", "Text" : "Leishmaniasis", "Mnemonic" : "30"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ROCKY MTN SPOT FEVER", "DisplayText" : "Rocky Mountain Spotted Fever", "Text" : "Rocky Mountain Spotted Fever", "Mnemonic" : "32"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatology Post-Op Infection", "Mnemonic" : "34"},
{"Row" :3, "Column" : 1, "Text" : "++DERMATOLOGICAL INFECTIONS ++", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Section reviewed January 2018", "Header" : 1}, 
{"Row" :5, "Column" : 2, "Item" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS", "DisplayText" : "Cutaneous Candidiasis", "Text" : "Candidiasis", "Mnemonic" : "40"},
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU PARONYCHIA", "DisplayText" : "Paronychia", "Text" : "Paronychia", "Mnemonic" : "42"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera)", "Text" : "Bed bugs (hemiptera)", "Mnemonic" : "44"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis)", "Text" : "Head lice (Pediculosis Capitis)", "Mnemonic" : "46"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis)", "Text" : "Body lice (Pediculosis corporis)", "Mnemonic" : "48"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)", "Text" : "Pubic lice (Pediculosis pubis)", "Mnemonic" : "50"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU SCABIES", "DisplayText" : "Scabies", "Text" : "Scabies", "Mnemonic" : "52"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease", "Mnemonic" : "54"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "DisplayText" : "Blastomyces dermatidis", "Text" : "Blastomycosis", "Mnemonic" : "56"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU SPOROTRICHOSIS", "DisplayText" : "Sporotrichosis", "Text" : "Sporotrichosis", "Mnemonic" : "58"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections", "Mnemonic" : "60"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)", "Text" : "Herpes Whitlow (digit/hand cellulitis)", "Mnemonic" : "62"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "DisplayText" : "Orolabial Herpes", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Mnemonic" : "64"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm)", "Text" : "Tinea capitis (ringworm)", "Mnemonic" : "66"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Tinea unguium (onychomycosis)", "Mnemonic" : "68"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris", "Text" : "Tinea pedis, Tinea corporis, Tinea cruris", "Mnemonic" : "70"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU TINEA VERSICOLOR", "DisplayText" : "Tinea Versicolor", "Text" : "Tinea versicolor", "Mnemonic" : "72"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox)", "Text" : "Varicella/Chickenpox (primary infection)", "Mnemonic" : "74"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")", "Text" : "Zoster/Shingles (reactivation)", "Mnemonic" : "76"},
{"Row" : 17, "Column" : 2, "Text" : "Herpes simplex virus infections", "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Text" : "Tinea fungal infections", "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Text" : "Varicella-Zoster virus infections", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX ACNE", "DisplayText" : "Acne", "Text" : "Acne", "Mnemonic" : "3"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX ROSACEA", "DisplayText" : "Rosacea", "Text" : "Rosacea", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS" , "Term1" : "Device-related infections", "DisplayText" : "Device-related infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Intravascular catheter-related infection", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "DisplayText" : "Prosthetic Valve Endocarditis--Empicaral Therapy", "Text" : "Prosthetic-valve endocarditis - Empirical therapy", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "DisplayText" : "Prosthetic Valve Endocarditis--Selected Pathogens", "Text" : "Prosthetic-valve endocarditis - Selected pathogens", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "DisplayText" : "Infections involves cardiovascular devices (excluding valves)", "Text" : "Infections involving cardiovascular devices (except valves)", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "++DEVICE-RELATED INFECTIONS++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If the desired syndrome is not listed below, return to the main menu and refer"}, 
{"Row" :6, "Column" : 1, "Text" : "to the pertinent organ-system."}, 
{"Row" : 14, "Column" : 1, "Text" : "Last reviewed 11/17", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX DEXAMETHASONE FOR COVID" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 11, "Column" : 1, "Text" : "Indications: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "COVID with hypoxia (<89% O2 at rest for more than an hour, not just a transient"}, 
{"Row" : 13, "Column" : 1, "Text" : "episode or nocturnal hypoxia due to sleep apnea). May be discontinued early"}, 
{"Row" : 14, "Column" : 1, "Text" : "if patient is no longer hypoxic."}, 
{"Row" : 16, "Column" : 1, "Text" : "Contraindications: Lack of hypoxia", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Dexamethasone (PO/IV): ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID DEXAMETHASONE 6MG PO QDAY FOR 10DAYS COVID", "DisplayText" : "Dexamethasone 6 MG PO q24h for up to 10 days", "Text" : "Dexamethasone 6 MG PO q24h for up to 10 days", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 6MG IV QDAY FOR 10 DAYS COVID", "DisplayText" : "Dexamethasone 6 MG IV q24h for up to 10 days", "Text" : "Dexamethasone 6 MG IV q24h for up to 10 days", "Mnemonic" : "8"},
{"Row" :4, "Column" : 1, "Text" : "-Dexamethasone (for up to 10 days) decreases mortality in patients with severe"}, 
{"Row" :5, "Column" : 1, "Text" : "or critical COVID-19 (RECOVERY trial)."}, 
{"Row" :6, "Column" : 1, "Text" : "-Dexamethasone may increase mortality in patients with mild/moderate COVID."}, 
{"Row" :7, "Column" : 1, "Text" : "-Dexamethasone is the preferred steroid, but a meta-analysis supports the use of"}, 
{"Row" :8, "Column" : 1, "Text" : "other steroids (hydrocortisone, methylprednisolone, or hydrocortisone) if"}, 
{"Row" :9, "Column" : 1, "Text" : "dexamethasone is not available."}, 
{"Row" :3, "Column" : 1, "Text" : "DEXAMETHASONE (RECOVERY trial) for COVID-19", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "RECOVERY Collaborative Group, N Engl J Med. (2021) 384(8):693-704."}
]},
{"Name" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS" , "Term1" : "Endocarditis, diagnosis of", "DisplayText" : "Diagnosis of Endocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE CRITERIA", "DisplayText" : "Modified Duke Diagnostic Criteria", "Text" : "Modified Duke Diagnostic Criteria", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DIAGNOSIS OF ENDOCARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and management are complex. Cardiology, Infectious Disease, and"}, 
{"Row" :6, "Column" : 1, "Text" : "Surgery services should all be involved in diagnosis and management of infective"}, 
{"Row" :7, "Column" : 1, "Text" : "endocarditis."}, 
{"Row" :9, "Column" : 1, "Text" : "Endocarditis is the result of growth of microorganisms on endothelium of the"}, 
{"Row" : 10, "Column" : 1, "Text" : "heart. The integrity of the endothelial surface must be compromised in order to"}, 
{"Row" : 11, "Column" : 1, "Text" : "allow microorganisms to attach and proliferate. Often such lesions are caused by"}, 
{"Row" : 12, "Column" : 1, "Text" : "abnormal blood flow or thrombi resulting from heart valvular disease, prosthetic"}, 
{"Row" : 13, "Column" : 1, "Text" : "heart valves, or from foreign material or microorganisms introduced to the"}, 
{"Row" : 14, "Column" : 1, "Text" : "bloodstream as byproducts of illicit intravenous drug use."}, 
{"Row" : 16, "Column" : 1, "Text" : "Endocarditis should be considered a possible diagnosis in a patient with"}, 
{"Row" : 17, "Column" : 1, "Text" : "persistent bacteremia without an identifiable focal infection, especially when"}, 
{"Row" : 18, "Column" : 1, "Text" : "the patient has a structural heart abnormality, prosthesis, or has a recent"}, 
{"Row" : 19, "Column" : 1, "Text" : "history of intravenous illicit drug use."}, 
{"Row" : 21, "Column" : 1, "Text" : "Diagnosis of endocarditis can be based on several combinations of signs and"}, 
{"Row" : 22, "Column" : 1, "Text" : "symptoms. The Duke criteria help categorize cases as definite or possible"}, 
{"Row" : 23, "Column" : 1, "Text" : "endocarditis based on major and minor criteria. The Duke criteria also indicate"}, 
{"Row" : 24, "Column" : 1, "Text" : "when a diagnosis of endocarditis can be excluded."}, 
{"Row" : 28, "Column" : 1, "Text" : "Severity of Disease", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Endocarditis is categorized by time course and severity of symptoms of illness"}, 
{"Row" : 30, "Column" : 1, "Text" : "into acute and subacute. These classifications help suggest which pathogens may"}, 
{"Row" : 31, "Column" : 1, "Text" : "be more likely associated with symptoms."}, 
{"Row" : 33, "Column" : 1, "Text" : "Acute", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Acute endocarditis is a rapidly progressing illness that often causes fever. It"}, 
{"Row" : 35, "Column" : 1, "Text" : "can be associated with spread of infection to other parts of the body and can"}, 
{"Row" : 36, "Column" : 1, "Text" : "cause death within a matter of weeks. In patient with suspected acute"}, 
{"Row" : 37, "Column" : 1, "Text" : "endocarditis, three sets of blood cultures should be obtained with the first and"}, 
{"Row" : 38, "Column" : 1, "Text" : "last cultures separated by at least one hour. Empiric antimicrobial therapy"}, 
{"Row" : 39, "Column" : 1, "Text" : "should then be initiated as soon as possible."}, 
{"Row" : 41, "Column" : 1, "Text" : "Subacute", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Subacute endocarditis follows an indolent course. Generally, patients have had"}, 
{"Row" : 43, "Column" : 1, "Text" : "some symptoms for at least 2 weeks. Symptoms are more subtle and spread of"}, 
{"Row" : 44, "Column" : 1, "Text" : "infection to other systems is uncommon. In patients with suspected subacute"}, 
{"Row" : 45, "Column" : 1, "Text" : "endocarditis, every attempt should be made to identify a pathogen prior to"}, 
{"Row" : 46, "Column" : 1, "Text" : "initiating antimicrobial therapy. These patients should be observed carefully"}, 
{"Row" : 47, "Column" : 1, "Text" : "for signs of heart failure or embolic complications, and if signs are noted,"}, 
{"Row" : 48, "Column" : 1, "Text" : "surgery should be consulted immediately."}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 57, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ABX DIVERTICULITIS" , "Term1" : "Diverticulitis", "DisplayText" : "Diverticulitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 10 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX TRIMETH/SULFA DS Q12H METRO 1 GM PO Q12H", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400MG PO Q24H", "DisplayText" : "Moxifloxacin 400mg po q24h (Var)", "Text" : "Moxifloxacin 400 mg PO q24h for 7 to 10 days ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-Tazobactam 3.375g IV q6h for 7 to 10 days ($$) [R]", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h for 7 to 10 days ($$) [R,DI]", "Mnemonic" : "16"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "18"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h for 10-14 days ($$) [R]", "Mnemonic" : "20"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "22"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "DIVERTICULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in"}, 
{"Row" :6, "Column" : 1, "Text" : "the colon, causing pain and disturbed bowel function."}, 
{"Row" :8, "Column" : 1, "Text" : "Mild disease or Step-down treatment for completion of antimicrobial course", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "after initial intravenous treatment in patients who can tolerate oral therapy.", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Base selection on culture results.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "metronidazole 1000 mg PO q12h ($) [DI] for 7 to 10 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "q12h ($) [DI] for 7 to 10 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "Moderate disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "If symptoms fail to respond within 48 to 72 hours, consult General Surgery."}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "for 7 to 10 days"}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative for beta lactam allergy"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "($) [DI] for 7 to 10 days"}, 
{"Row" : 35, "Column" : 1, "Text" : "Severe, life-threatening disease", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Consult General Surgery."}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 43, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Diverticulitis and Typhlitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Diverticulitis"}, 
{"Row" : 50, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management"}
]},
{"Name" : "ORZID2 GMENU ABX DRUG ALLERGIES" , "Term1" : "Allergy information " , "Term2" : "Drug allergy information", "DisplayText" : "Drug allergies" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Link to penicillin desensitization protocol", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DRUG ALLERGIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Importance of history", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "The nature and circumstances of a possible previous reaction including the"}, 
{"Row" :7, "Column" : 1, "Text" : "timing should be considered. In many cases, previous reactions are clearly"}, 
{"Row" :8, "Column" : 1, "Text" : "not due to drug allergy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Types of reactions", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "*Immediate - within one hour of starting drug administration."}, 
{"Row" : 12, "Column" : 1, "Text" : "Type I reactions present with urticaria, hypotension, angioedema, bronchospasm,"}, 
{"Row" : 13, "Column" : 1, "Text" : "or anaphylaxis and occur within an hour of exposure. These reactions are"}, 
{"Row" : 14, "Column" : 1, "Text" : "immunoglobulin E (IgE) and mast cell and/or basophil mediated."}, 
{"Row" : 16, "Column" : 1, "Text" : "*Delayed - After one hour of starting administration (usually after 6 days)"}, 
{"Row" : 17, "Column" : 1, "Text" : "1) Type II reactions manifest as hemolytic anemia, thrombocytopenia and"}, 
{"Row" : 18, "Column" : 1, "Text" : "neutropenia. They are caused by antibody (usually IgG)- mediated cell"}, 
{"Row" : 19, "Column" : 1, "Text" : "destruction."}, 
{"Row" : 20, "Column" : 1, "Text" : "2) Type III reactions can manifest as serum sickness, vasculitis or Arthus"}, 
{"Row" : 21, "Column" : 1, "Text" : "reaction, and are caused by IgG:drug immune complex deposition and complement"}, 
{"Row" : 22, "Column" : 1, "Text" : "activation."}, 
{"Row" : 23, "Column" : 1, "Text" : "3) Type IV reactions typically manifest as contact dermatitis, morbilliform"}, 
{"Row" : 24, "Column" : 1, "Text" : "reactions, severe exfoliative dermatoses (Stevens-Johnson syndrome/toxic"}, 
{"Row" : 25, "Column" : 1, "Text" : "epidermal necrolysis) and other presentations. They are T-cell mediated."}, 
{"Row" : 27, "Column" : 1, "Text" : "Repeated exposures lead to reactions that are of the same type."}, 
{"Row" : 29, "Column" : 1, "Text" : "Beta-lactam allergies", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Approximately 10% of patients report a beta-lactam allergy. Up to 90% of these"}, 
{"Row" : 31, "Column" : 1, "Text" : "patients can tolerate penicillin and have been designated penicillin allergic"}, 
{"Row" : 32, "Column" : 1, "Text" : "unnecessarily. Patients allergic to cephalosporins will have a cross-reaction to"}, 
{"Row" : 33, "Column" : 1, "Text" : "penicillins 3% to 5% of the time. Overall, patients with a history of penicillin"}, 
{"Row" : 34, "Column" : 1, "Text" : "allergy can tolerate cephalosporins although there are rare reports to severe,"}, 
{"Row" : 35, "Column" : 1, "Text" : "sometimes fatal anaphylactic reactions. Neither penicillin- or cephalosporin-"}, 
{"Row" : 36, "Column" : 1, "Text" : "allergic patients will react to aztreonam. The degree of cross-reactivity of"}, 
{"Row" : 37, "Column" : 1, "Text" : "penicillins and cephalosporins with carbapenems appears to be low."}, 
{"Row" : 39, "Column" : 1, "Text" : "Therapeutic implications", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "If a patient has had an immediate reaction to a drug in the past, an allergy"}, 
{"Row" : 41, "Column" : 1, "Text" : "specialist should evaluate the patient before a drug of the same class is"}, 
{"Row" : 42, "Column" : 1, "Text" : "administered to the patient. Patients with delayed onset reactions causing"}, 
{"Row" : 43, "Column" : 1, "Text" : "fever, systemic symptoms or mucosal involvement should also be evaluated by an"}, 
{"Row" : 44, "Column" : 1, "Text" : "allergy specialist before a drug of the same class is administered."}, 
{"Row" : 46, "Column" : 1, "Text" : "Desensitization", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "A patient with previous Type I reaction to a beta-lactam can be desensitized and"}, 
{"Row" : 48, "Column" : 1, "Text" : "then receive therapeutic doses of the same class within a day. Severe"}, 
{"Row" : 49, "Column" : 1, "Text" : "reactions during desensitization are uncommon. Pharmacy service must be"}, 
{"Row" : 50, "Column" : 1, "Text" : "contacted for assistance and drug preparation. Infectious Disease consultation"}, 
{"Row" : 51, "Column" : 1, "Text" : "strongly recommended."}, 
{"Row" : 56, "Column" : 1, "Text" : "References"}, 
{"Row" : 58, "Column" : 1, "Text" : "JAMA 2001, 285: 249"}, 
{"Row" : 59, "Column" : 1, "Text" : "Joint Task Force on Practice Parameters: Drug Allergy - An Updated Practice"}, 
{"Row" : 60, "Column" : 1, "Text" : "Parameter (2010)"}, 
{"Row" : 61, "Column" : 1, "Text" : "Kelkar PS NEJM 2001, 345: 804"}, 
{"Row" : 62, "Column" : 1, "Text" : "Mayo Clinic Proc 1999, 74: 290"}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of"}, 
{"Row" : 64, "Column" : 1, "Text" : "cephalosporins and related antibiotics"}, 
{"Row" : 65, "Column" : 1, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features"}, 
{"Row" : 66, "Column" : 1, "Text" : "Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and"}, 
{"Row" : 67, "Column" : 1, "Text" : "related antibiotics. Clin Allergy 1988, 18:515"}
]},
{"Name" : "ORZID2 GMENU ABX DRUG INFO PAGE" , "Term1" : "Drug Information", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion," , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Acyclovir PO", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Acyclovir IV", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Albendazole PO", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Amantadine PO", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Amikacin IV", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Amoxicillin PO", "Mnemonic" : "12"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Amoxicillin-clavulanate PO", "Mnemonic" : "14"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Amphotericin B IV", "Mnemonic" : "16"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ampicillin IV", "Mnemonic" : "18"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ampicillin-sulbactam IV", "Mnemonic" : "20"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Atovaquone PO", "Mnemonic" : "22"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Azithromycin PO", "Mnemonic" : "24"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Azithromycin IV", "Mnemonic" : "26"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Aztreonam IV", "Mnemonic" : "28"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Benzathine penicillin IM", "Mnemonic" : "30"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Caspofungin IV", "Mnemonic" : "32"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefazolin IV", "Mnemonic" : "34"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefepime IV", "Mnemonic" : "36"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefixime PO", "Mnemonic" : "38"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefotetan IV", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefoxitin IV", "Mnemonic" : "42"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefpodoxime PO", "Mnemonic" : "44"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ceftazidime IV", "Mnemonic" : "46"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ceftriaxone IM", "Mnemonic" : "48"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ceftriaxone IV", "Mnemonic" : "50"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cefuroxime PO", "Mnemonic" : "52"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Cephalexin PO", "Mnemonic" : "54"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Chloramphenicol IV", "Mnemonic" : "56"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ciprofloxacin PO", "Mnemonic" : "58"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ciprofloxacin IV", "Mnemonic" : "60"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clarithromycin PO", "Mnemonic" : "62"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clindamycin PO", "Mnemonic" : "64"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clindamycin IV", "Mnemonic" : "66"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clindamycin Vaginal", "Mnemonic" : "68"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clotrimazole Topical", "Mnemonic" : "70"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Clotrimazole Vaginal", "Mnemonic" : "72"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Daptomycin IV", "Mnemonic" : "74"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Dicloxacillin PO", "Mnemonic" : "76"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Dolutegravir PO", "Mnemonic" : "78"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Doxycycline PO", "Mnemonic" : "80"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Doxycycline IV", "Mnemonic" : "82"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Emtricitabine/Tenofovir PO", "Mnemonic" : "84"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ertapenem IV", "Mnemonic" : "86"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Erythromycin Ophthalmic", "Mnemonic" : "88"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Erythromycin PO", "Mnemonic" : "90"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Erythromycin IV", "Mnemonic" : "92"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ethambutol PO", "Mnemonic" : "94"},
{"Row" :2, "Column" : 1, "Text" : "++ IMPORTANT DRUG PROPERTIES PAGE ++", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Select below for drug info from online database"}, 
{"Row" :5, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Fluconazole PO", "Mnemonic" : "98"},
{"Row" :6, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Fluconazole IV", "Mnemonic" : "100"},
{"Row" :7, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Flucytosine PO", "Mnemonic" : "102"},
{"Row" :8, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Foscarnet IV", "Mnemonic" : "104"},
{"Row" :9, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Fosfomycin PO", "Mnemonic" : "106"},
{"Row" : 10, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Ganciclovir IV", "Mnemonic" : "108"},
{"Row" : 11, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Gentamicin IV", "Mnemonic" : "110"},
{"Row" : 12, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Griseofulvin PO", "Mnemonic" : "112"},
{"Row" : 13, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Iodoquinol PO", "Mnemonic" : "114"},
{"Row" : 14, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Itraconazole PO", "Mnemonic" : "116"},
{"Row" : 15, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Itraconazole IV", "Mnemonic" : "118"},
{"Row" : 16, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Levofloxacin PO", "Mnemonic" : "120"},
{"Row" : 17, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Levofloxacin IV", "Mnemonic" : "122"},
{"Row" : 18, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Linezolid PO", "Mnemonic" : "124"},
{"Row" : 19, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Linezolid IV", "Mnemonic" : "126"},
{"Row" : 20, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Meropenem IV", "Mnemonic" : "128"},
{"Row" : 21, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Metronidazole PO", "Mnemonic" : "130"},
{"Row" : 22, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Metronidazole IV", "Mnemonic" : "132"},
{"Row" : 23, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Metronidazole Vaginal", "Mnemonic" : "134"},
{"Row" : 24, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Micafungin IV", "Mnemonic" : "136"},
{"Row" : 25, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Minocycline PO", "Mnemonic" : "138"},
{"Row" : 26, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Moxifloxacin Ophthalmic", "Mnemonic" : "140"},
{"Row" : 27, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Moxifloxacin PO", "Mnemonic" : "142"},
{"Row" : 28, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Moxifloxacin IV", "Mnemonic" : "144"},
{"Row" : 29, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Nafcillin IV", "Mnemonic" : "146"},
{"Row" : 30, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Neomycin PO", "Mnemonic" : "148"},
{"Row" : 31, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Nitazoxanide PO", "Mnemonic" : "150"},
{"Row" : 32, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Nitrofurantoin PO", "Mnemonic" : "152"},
{"Row" : 33, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Oseltamivir PO", "Mnemonic" : "154"},
{"Row" : 34, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Paromomycin PO", "Mnemonic" : "156"},
{"Row" : 35, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Penicillin PO", "Mnemonic" : "158"},
{"Row" : 36, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Penicillin IV", "Mnemonic" : "160"},
{"Row" : 37, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Piperacillin-tazobactam IV", "Mnemonic" : "162"},
{"Row" : 38, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Pyrimethamine PO", "Mnemonic" : "164"},
{"Row" : 39, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Quinupristin-dalfoprisin IV", "Mnemonic" : "166"},
{"Row" : 40, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Rifabutin PO", "Mnemonic" : "168"},
{"Row" : 41, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Rifampin IV", "Mnemonic" : "170"},
{"Row" : 42, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Rifaximin PO", "Mnemonic" : "172"},
{"Row" : 43, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Streptomycin IV", "Mnemonic" : "174"},
{"Row" : 44, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Sulfacetamide Ophthalmic", "Mnemonic" : "176"},
{"Row" : 45, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Sulfadiazine PO", "Mnemonic" : "178"},
{"Row" : 46, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Terconazole 0.4% Vaginal", "Mnemonic" : "180"},
{"Row" : 47, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Tetracycline PO", "Mnemonic" : "182"},
{"Row" : 48, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Tobramycin IV", "Mnemonic" : "184"},
{"Row" : 49, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Trimethoprim PO (does not contain sulfa)", "Mnemonic" : "186"},
{"Row" : 50, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Trimethoprim-sulfamethoxazole PO", "Mnemonic" : "188"},
{"Row" : 51, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Trimethoprim-sulfamethoxazole IV", "Mnemonic" : "190"},
{"Row" : 52, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Valacyclovir PO", "Mnemonic" : "192"},
{"Row" : 53, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Valganciclovir PO", "Mnemonic" : "194"},
{"Row" : 54, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Vancomycin IV", "Mnemonic" : "196"},
{"Row" : 55, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Voriconazole PO", "Mnemonic" : "198"},
{"Row" : 56, "Column" : 2, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Zanamivir INH", "Mnemonic" : "200"}
]},
{"Name" : "ORZID2 GMENU ABX DUKE CRITERIA", "DisplayText" : "Modified Duke Diagnostic Criteria " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE LISTING", "DisplayText" : "Duke Diagnostic Criteria Listing", "Text" : "Modified Duke Criteria Diagnostic Listing", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "MODIFIED DUKE DIAGNOSTIC CRITERIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The Modified Duke criteria are used to diagnose endocarditis on clinical"}, 
{"Row" :6, "Column" : 1, "Text" : "grounds. Endocarditis may also be diagnosed by pathology results."}, 
{"Row" : 10, "Column" : 1, "Text" : "Requirements for definite diagnosis of endocarditis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Two major criteria"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 13, "Column" : 1, "Text" : "One major criterion and three minor criteria"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Five minor criteria"}, 
{"Row" : 17, "Column" : 1, "Text" : "Requirements for possible diagnosis of endocarditis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "One major criterion and one minor criterion"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Three minor criteria"}, 
{"Row" : 22, "Column" : 1, "Text" : "Requirements for rejection of diagnosis of endocarditis", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Firm alternative diagnosis explaining evidence of endocarditis"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Resolution of endocarditis syndrome with antibiotic therapy for less than 4 days"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "No pathological evidence of endocarditis at surgery or autopsy, with antibiotic"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy for less than 4 days"}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Does not meet criteria for possible endocarditis as above."}, 
{"Row" : 32, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 39, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ABX DUKE LISTING", "DisplayText" : "Duke Diagnostic Criteria Listing" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MODIFIED DUKE CRITERIA DIAGNOSTIC LISTING", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Major criteria", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Blood culture positive", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "*Typical microorganisms consistent with IE from 2 separate blood cultures: "}, 
{"Row" :8, "Column" : 1, "Text" : "Viridans streptococci, Streptococcus bovis, HACEK group organisms (Haemophilus"}, 
{"Row" :9, "Column" : 1, "Text" : "species, Aggregatibacter species, Cardiobacterium species, Eikenella corrodens,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and Kingella species), Staphylococcus aureus, or community-acquired enterococci"}, 
{"Row" : 11, "Column" : 1, "Text" : "in the absence of a primary focus, or microorganisms consistent with IE from"}, 
{"Row" : 12, "Column" : 1, "Text" : "persistently positive blood cultures defined as follows: at least 2 positive"}, 
{"Row" : 13, "Column" : 1, "Text" : "cultures of blood samples drawn >12h apart or all 3 or a majority of >/= 4"}, 
{"Row" : 14, "Column" : 1, "Text" : "separate cultures of blood (with first and last sample drawn at least 1 h apart)"}, 
{"Row" : 16, "Column" : 1, "Text" : "*Single culture positive for Coxiella burnetii or anti-phase 1 IgG antibody"}, 
{"Row" : 17, "Column" : 1, "Text" : "titer greater than or equal to 1:800"}, 
{"Row" : 19, "Column" : 1, "Text" : "Echocardiogram positive for endocarditis", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "*Echocardiographic evidence for endocarditis, defined as: "}, 
{"Row" : 21, "Column" : 1, "Text" : "An echo dense, intracardiac mass attached to valve or supporting structures, in"}, 
{"Row" : 22, "Column" : 1, "Text" : "the path of regurgitant jets, or a mass present on implanted material in the"}, 
{"Row" : 23, "Column" : 1, "Text" : "absence of an alternative anatomic explanation"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Paravalvular abscess"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "New partial dehiscence of prosthetic valve or new valvular regurgitation"}, 
{"Row" : 28, "Column" : 1, "Text" : "(worsening or changing or preexisting murmur is not sufficient for a major"}, 
{"Row" : 29, "Column" : 1, "Text" : "criterion)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Note: Echocardiography should be performed in all patients suspected of having"}, 
{"Row" : 32, "Column" : 1, "Text" : "endocarditis. Transesophageal echocardiograph (TEE) is recommended for patients"}, 
{"Row" : 33, "Column" : 1, "Text" : "with prosthetic valves. Transthoracic echocardiograph (TTE) is often adequate"}, 
{"Row" : 34, "Column" : 1, "Text" : "for patients suspected of having native valve endocarditis, especially on the"}, 
{"Row" : 35, "Column" : 1, "Text" : "aortic valve, but TEE may be needed for these patients as well. Contact"}, 
{"Row" : 36, "Column" : 1, "Text" : "infectious diseases or cardiology for more information."}, 
{"Row" : 38, "Column" : 1, "Text" : "Minor criteria", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Predisposing heart condition or intravenous drug user", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Fever", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Temperature over 38 degrees Celsius (100.4 degrees Fahrenheit)"}, 
{"Row" : 44, "Column" : 1, "Text" : "Vascular phenomena", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Major arterial embolus, septic pulmonary infarcts, mycotic aneurysm,"}, 
{"Row" : 46, "Column" : 1, "Text" : "intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions"}, 
{"Row" : 48, "Column" : 1, "Text" : "Immunologic phenomena", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Glomerulonephritis, Osler's nodes, Roth's spots, or rheumatoid factor"}, 
{"Row" : 51, "Column" : 1, "Text" : "Microbiological evidence", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "A case with a positive blood culture, but with results that don't meet the major"}, 
{"Row" : 53, "Column" : 1, "Text" : "criterion blood culture criteria listed above or serological evidence of active"}, 
{"Row" : 54, "Column" : 1, "Text" : "infection with organism consistent with endocarditis. Microbiological evidence"}, 
{"Row" : 55, "Column" : 1, "Text" : "is not intended to include all positive blood cultures. For example, a single"}, 
{"Row" : 56, "Column" : 1, "Text" : "positive culture for coagulase-negative staphylococci or a culture yielding an"}, 
{"Row" : 57, "Column" : 1, "Text" : "organism that is not a cause of endocarditis would not support a diagnosis of"}, 
{"Row" : 58, "Column" : 1, "Text" : "endocarditis."}, 
{"Row" : 60, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "References: "}, 
{"Row" : 63, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 64, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 65, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 66, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 67, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ABX DURATION OF ABX THERAPY", "DisplayText" : "Duration of antimicrobial therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "DURATION OF ANTIMICROBIAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "In general, duration of therapy is based on multiple factors, including"}, 
{"Row" :6, "Column" : 1, "Text" : "infection severity, rapidity of improvement, and pathogen susceptibility. For a"}, 
{"Row" :7, "Column" : 1, "Text" : "few diseases guidelines are established based on available evidence and opinion."}, 
{"Row" :8, "Column" : 1, "Text" : "For many more diseases, guidelines have not been established."}, 
{"Row" : 10, "Column" : 1, "Text" : "For outpatient prescriptions, when a range is recommended by CDSS, the"}, 
{"Row" : 11, "Column" : 1, "Text" : "prescription order will default to the lowest dose and day supply. For inpatient"}, 
{"Row" : 12, "Column" : 1, "Text" : "orders, durations are listed in the recommendations but are not included in the"}, 
{"Row" : 13, "Column" : 1, "Text" : "quick order. The provider must select a duration, if desired, when completing an"}, 
{"Row" : 14, "Column" : 1, "Text" : "inpatient quick order."}, 
{"Row" : 15, "Column" : 1, "Text" : "For all cases clinical judgment is important. More information is given within"}, 
{"Row" : 16, "Column" : 1, "Text" : "specific diagnoses or syndromes sections."}
]},
{"Name" : "ORZID2 GMENU ABX E COLI INFECT" , "Term1" : "Escherichia coli diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Enterohemorrhagic E. coli " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "DisplayText" : "RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "Text" : "Rifaximin 200 mg q8h for 3 days ($$) [M]", "Mnemonic" : "8"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)", "Text" : "Link to Shigella/Enteroinvasive E. coli menu", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH ESCHERICHIA COLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Enterotoxigenic E. coli (ETEC)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "EAEC infection can cause watery diarrhea with mucus that is occasionally bloody."}, 
{"Row" :8, "Column" : 1, "Text" : "It is more common in patients with HIV and those who have traveled to developing"}, 
{"Row" :9, "Column" : 1, "Text" : "regions. EPEC infection is associated with severe acute watery diarrhea that is"}, 
{"Row" : 10, "Column" : 1, "Text" : "occasionally bloody. ETEC infection causes acute watery diarrhea that is"}, 
{"Row" : 11, "Column" : 1, "Text" : "occasionally severe. It is most common in travelers to tropical regions who are"}, 
{"Row" : 12, "Column" : 1, "Text" : "exposed to contaminated food and water."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antibiotic therapy is not required for mild to moderate disease caused by these"}, 
{"Row" : 15, "Column" : 1, "Text" : "organisms because diarrhea often resolves on its own. Do not use antimotility"}, 
{"Row" : 16, "Column" : 1, "Text" : "agents in patients with bloody stool."}, 
{"Row" : 18, "Column" : 1, "Text" : "Primary treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial treatment of severe diarrhea"}, 
{"Row" : 24, "Column" : 1, "Text" : "Antimicrobial treatment in patients with AIDS"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 30, "Column" : 1, "Text" : "Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "EHEC and STEC disease often presents as bloody diarrhea. It is more common in"}, 
{"Row" : 32, "Column" : 1, "Text" : "people who have consumed undercooked meats or poultry, fruits or unpasteurized"}, 
{"Row" : 33, "Column" : 1, "Text" : "fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include"}, 
{"Row" : 34, "Column" : 1, "Text" : "swimming in or drinking untreated fresh water and visiting a farm, petting zoo,"}, 
{"Row" : 35, "Column" : 1, "Text" : "healthcare facility, prison or childcare facility."}, 
{"Row" : 37, "Column" : 1, "Text" : "Treatment includes supportive measures such as volume repletion and"}, 
{"Row" : 38, "Column" : 1, "Text" : "administering appropriate nutrition. Do not use antimotility or antimicrobial"}, 
{"Row" : 39, "Column" : 1, "Text" : "agents as they can increase shiga-toxin release and increase the risk of"}, 
{"Row" : 40, "Column" : 1, "Text" : "hemolytic uremia syndrome (HUS)."}, 
{"Row" : 42, "Column" : 1, "Text" : "Enteroinvasive E. coli (EIEC)", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "EIEC disease typically presents as watery diarrhea, sometimes progressing to"}, 
{"Row" : 44, "Column" : 1, "Text" : "bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for"}, 
{"Row" : 45, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli"}, 
{"Row" : 53, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-to-Date article: Pathogenic Escherichia coli"}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment is complex, consult Infectious Diseases"}
]},
{"Name" : "ORZID2 GMENU ABX ELEMENTS OF CDSS ADVICE PAGE", "DisplayText" : "Elements of a CDSS Advice Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "ELEMENTS OF A CDSS ADVICE MENU", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Advice menus are comprised of the following elements: "}, 
{"Row" :7, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "TYPICALLY present on an advice menu", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "1) Diagnosis or condition label-at the top of each advice menu."}, 
{"Row" : 15, "Column" : 1, "Text" : "2) Treatment. Empirical treatment as well as treatment for selected pathogens"}, 
{"Row" : 16, "Column" : 1, "Text" : "is presented with links to antimicrobial quick orders unless stated otherwise."}, 
{"Row" : 17, "Column" : 1, "Text" : "In addition to the drug, dose, and route, each quick order text includes the"}, 
{"Row" : 18, "Column" : 1, "Text" : "drug's approximate cost per day and coding for important drug properties of"}, 
{"Row" : 19, "Column" : 1, "Text" : "note. Drugs clustered together are considered equivalent."}, 
{"Row" : 21, "Column" : 1, "Text" : "3) Help. At the top of each advice menu. There are links to a variety of"}, 
{"Row" : 22, "Column" : 1, "Text" : "resources (susceptibilities, important drug properties, section-specific"}, 
{"Row" : 23, "Column" : 1, "Text" : "consults, etc.)."}, 
{"Row" : 25, "Column" : 1, "Text" : "4) References. At the bottom on each advice menu. These are key references for"}, 
{"Row" : 26, "Column" : 1, "Text" : "the recommendations on the menu."}, 
{"Row" : 28, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "DISCRETIONARY advice menu components", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "1) (Treatment) Alternative. Following the (preferred) Treatment section with"}, 
{"Row" : 34, "Column" : 1, "Text" : "quick orders for common alternative antimicrobials. Antimicrobial listed under"}, 
{"Row" : 35, "Column" : 1, "Text" : "each alternative header are equivalents among those listed. A broader selection"}, 
{"Row" : 36, "Column" : 1, "Text" : "of medications can be accessed through the Need an alternative menu within the"}, 
{"Row" : 37, "Column" : 1, "Text" : "help section. For some conditions we recommend alternative antimicrobials when"}, 
{"Row" : 38, "Column" : 1, "Text" : "recommended drugs are not suitable for an individual patient. Unless otherwise"}, 
{"Row" : 39, "Column" : 1, "Text" : "stated drugs clustered together under Alternatives are considered equivalent."}, 
{"Row" : 41, "Column" : 1, "Text" : "If none of the recommended or alternative drugs is suitable you can find more"}, 
{"Row" : 42, "Column" : 1, "Text" : "drugs by clicking on the Need an alternative link at the top of the menu."}, 
{"Row" : 44, "Column" : 1, "Text" : "2) Consults. At the top of the menu, these are consultation requests pertinent"}, 
{"Row" : 45, "Column" : 1, "Text" : "to the clinical problem addressed by the menu. Links to context-specific"}, 
{"Row" : 46, "Column" : 1, "Text" : "consults can be found on advice menus, as appropriate. For example, the herpes"}, 
{"Row" : 47, "Column" : 1, "Text" : "simplex encephalitis menu contains a link to a request for neurology consult."}, 
{"Row" : 49, "Column" : 1, "Text" : "3) Resources. Pertinent to the clinical problem and addressed by the menu is"}, 
{"Row" : 50, "Column" : 1, "Text" : "provided for example. For some menus, supplemental resources have been"}, 
{"Row" : 51, "Column" : 1, "Text" : "identified (e.g., PORT score calculator for Community Acquired Pneumonia,"}, 
{"Row" : 52, "Column" : 1, "Text" : "diagnostic tools, Epidemiology, etc.) the information is included on the advice"}, 
{"Row" : 53, "Column" : 1, "Text" : "menu."}
]},
{"Name" : "ORZID2 GMENU ABX EMPYEMA" , "Term1" : "Empyema", "DisplayText" : "Empyema " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV Q24H ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($)[H,O]", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($)[H,O]", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Metronidazole 500 MG IV Q8H", "Text" : "Metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 1000MG PO Q12H", "DisplayText" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Text" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "EMPYEMA"}, 
{"Row" :4, "Column" : 1, "Text" : "Empyema is usually a complication of pneumonia.Blood cultures should be drawn"}, 
{"Row" :5, "Column" : 1, "Text" : "and whenever possible, diagnostic thoracentesis should be performed before"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials are begun to guide therapy.Drainage is essential, and a chest"}, 
{"Row" :7, "Column" : 1, "Text" : "tube is often required.Pulmonary or Infectious Diseases consultation is"}, 
{"Row" :8, "Column" : 1, "Text" : "essential."}, 
{"Row" :9, "Column" : 1, "Text" : "The duration of antibiotic therapy for bacterial empyema is determined on"}, 
{"Row" : 10, "Column" : 1, "Text" : "a patient-by-patient basis based on clinical and radiographic improvement."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Choose two antimicrobials, one from Group A and one from Group B."}, 
{"Row" : 15, "Column" : 1, "Text" : ">>Group A<<", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : ">>Group B <<", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 31, "Column" : 1, "Text" : "Harrison's chapter: Infections due to mixed organisms"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA" , "Term1" : "Entamoeba histolytica diarrhea/gastroenteritis", "DisplayText" : "Entoemeba histolytica " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX METRO 750MG PO Q8H PAROMOMYC 25-35MG/KG/DAY PO Q8H", "DisplayText" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Text" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ENTAMOEBA HISTOLYTICA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary treatment for gastroenteritis", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment for gastroenteritis or extraintestinal disease", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must"}, 
{"Row" : 10, "Column" : 1, "Text" : "be ordered by Infectious Diseases."}, 
{"Row" : 12, "Column" : 1, "Text" : "25-35 mg/kg/day PO q8h for 7 days ($) [M]"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica"}, 
{"Row" : 18, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis"}
]},
{"Name" : "ORZID2 GMENU ABX ENTERIC FEVER" , "Term1" : "Enteric fever " , "Term2" : "Paratyphoid fever " , "Term3" : "Typhoid fever", "DisplayText" : "Enteric Fever " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 7-10 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h for 7-10 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM ONCE THEN 500MG PO Q24H 5DAYS", "DisplayText" : "Azithromycin 1 gm PO once then 500 mg PO q24h for 5 days ($) [M]", "Text" : "Azithromycin 1 gm PO once then 500 mg PO q24h for 5 to 7 days ($) [M]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 7 to 14 days ($) [M]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Enteric fever is a systemic febrile illness caused by Salmonella enterica"}, 
{"Row" :6, "Column" : 1, "Text" : "serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever"}, 
{"Row" :7, "Column" : 1, "Text" : "and abdominal pain. Enteric fever typically occurs in patients who have traveled"}, 
{"Row" :8, "Column" : 1, "Text" : "to impoverished areas where the organisms are endemic, but can also be acquired"}, 
{"Row" :9, "Column" : 1, "Text" : "within the United States. Treatment is based on location of acquisition due to"}, 
{"Row" : 10, "Column" : 1, "Text" : "increasing rates of fluoroquinolone resistance in Asia."}, 
{"Row" : 12, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobial treatment for infection NOT acquired in Asia", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial treatment for infection acquired in Asia", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Typhoid Fever, Enteric Fever"}, 
{"Row" : 30, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of enteric (typhoid and"}, 
{"Row" : 32, "Column" : 1, "Text" : "paratyphoid) fever"}
]},
{"Name" : "ORZID2 GMENU ABX EPIDIDYMITIS" , "Term1" : "Epididymitis", "DisplayText" : "Epididymitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE LEVOFLOX 500MG PO Q24H", "DisplayText" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Mnemonic" : "6"},
{"Row" : 49, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "8"},
{"Row" : 51, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) for 10 days", "Mnemonic" : "10"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 10 days", "Mnemonic" : "12"},
{"Row" : 56, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "14"},
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE DOXY 100MG PO Q12H", "DisplayText" : "Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "16"},
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 1GM IM ONCE DOXY PO 100MG Q12H GONOCOCC", "DisplayText" : "Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "18"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "20"},
{"Row" : 70, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "22"},
{"Row" : 72, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV q24h ($) for 10 days", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Epididymitis is inflammation of the epididymis and when testicles are involved"}, 
{"Row" :6, "Column" : 1, "Text" : "is referred to as epididymo-orchitis. Acute epididymitis is the most common"}, 
{"Row" :7, "Column" : 1, "Text" : "cause of scrotal pain in adults. Other features include scrotal erythema and"}, 
{"Row" :8, "Column" : 1, "Text" : "edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually"}, 
{"Row" :9, "Column" : 1, "Text" : "unilateral. It is primarily caused by infection but can also result from trauma"}, 
{"Row" : 10, "Column" : 1, "Text" : "and autoimmune diseases. Testicular torsion should be ruled out before"}, 
{"Row" : 11, "Column" : 1, "Text" : "treatment. Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 12, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 13, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 are associated"}, 
{"Row" : 14, "Column" : 1, "Text" : "with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if"}, 
{"Row" : 15, "Column" : 1, "Text" : "the patient has been in the hospital for more than 48 hours or received a course"}, 
{"Row" : 16, "Column" : 1, "Text" : "of antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 17, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 19, "Column" : 1, "Text" : "A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be performed in all cases of suspected epididymitis before starting"}, 
{"Row" : 21, "Column" : 1, "Text" : "treatment to guide therapy: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 25, "Column" : 1, "Text" : "treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve"}, 
{"Row" : 29, "Column" : 1, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal"}, 
{"Row" : 30, "Column" : 1, "Text" : "pain and referral to a urologist should be considered."}, 
{"Row" : 32, "Column" : 1, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older men"}, 
{"Row" : 33, "Column" : 1, "Text" : "should have their residual urinary volume checked. If the residual volume is"}, 
{"Row" : 34, "Column" : 1, "Text" : "elevated, the patient should be seen by a urologist as epididymitis is unlikely"}, 
{"Row" : 35, "Column" : 1, "Text" : "to respond if the prostate is blocking the vas deferens."}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical treatment in men who practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "for 10 days ($) [R, DI]"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Empirical treatment in men who do not practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Age >/= 35 years or", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "biopsy, vasectomy): ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 58, "Column" : 1, "Text" : "Age < 35 years", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Patient weighing less than 300 lbs"}, 
{"Row" : 62, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 64, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater"}, 
{"Row" : 66, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 68, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 71, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 73, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 78, "Column" : 1, "Text" : "Sanford keyword: Epididymo-orchitis"}, 
{"Row" : 79, "Column" : 1, "Text" : "Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3"}, 
{"Row" : 80, "Column" : 1, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults"}, 
{"Row" : 81, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID2 GMENU ABX EPIGLOTTITIS" , "Term1" : "Epiglottitis", "DisplayText" : "Epiglottitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX CETRIAX 2G Q24H VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15 mg/kg IV q 12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 500MG QD VANCO 15MG/KG Q12", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "EPIGLOTTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Maintaining the airway is the key to management. Call ENT service and ask them"}, 
{"Row" :6, "Column" : 1, "Text" : "to see the patient immediately. Blood cultures and epiglottal cultures (in"}, 
{"Row" :7, "Column" : 1, "Text" : "intubated patients) should be used to direct antimicrobial therapy. Empirical"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy should be initiated prior to results of cultures as infection is life"}, 
{"Row" :9, "Column" : 1, "Text" : "threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin"}, 
{"Row" : 10, "Column" : 1, "Text" : "resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)"}, 
{"Row" : 12, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 15, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 20, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Epiglottitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Rafei et al., Pediatric Clinics 2006, 53.2, 215-242"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Epiglottitis, Supraglottis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-date article: Epiglottis (supraglottis): Management"}
]},
{"Name" : "ORZID2 GMENU ABX ESBL KPC ETC" , "Term1" : "Resistant bacteria, more about" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Gram-Negative Bacilli Drug Resistance", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "In some Gram-negative bacilli, potent bacterial enzymes have emerged that"}, 
{"Row" :6, "Column" : 1, "Text" : "inactive many newer broad-spectrum beta lactam drugs. These include extended-"}, 
{"Row" :7, "Column" : 1, "Text" : "spectrum beta-lactamases (ESBLs), serine carbapenemases, metallo-beta-"}, 
{"Row" :8, "Column" : 1, "Text" : "lactamases, AmpC beta-lactamases and oxacillinases. These enzymes are most"}, 
{"Row" :9, "Column" : 1, "Text" : "common in strains of Acinetobacter, Citrobacter, Enterobacter, Escherichia coli,"}, 
{"Row" : 10, "Column" : 1, "Text" : "Klebsiella, Proteus, Pseudomonas aeruginosa, Salmonella, and Serratia"}, 
{"Row" : 11, "Column" : 1, "Text" : "marcescens. The enzymes can be latent under many circumstances. However, in"}, 
{"Row" : 12, "Column" : 1, "Text" : "patients receiving beta lactam antibiotics, the enzymes can be expressed and"}, 
{"Row" : 13, "Column" : 1, "Text" : "contribute to treatment failure. Because of this, and since the enzymes continue"}, 
{"Row" : 14, "Column" : 1, "Text" : "to evolve, they are difficult to detect in clinical microbiology laboratories."}, 
{"Row" : 15, "Column" : 1, "Text" : "Bacteria carrying these enzymes are often also resistant to many other commonly"}, 
{"Row" : 16, "Column" : 1, "Text" : "used antimicrobials, including trimethoprim-sulfamethoxazole, quinolones, and"}, 
{"Row" : 17, "Column" : 1, "Text" : "others, through different mechanisms. Enterobacteriaceae, Pseudomonas and"}, 
{"Row" : 18, "Column" : 1, "Text" : "Acinetobacter are increasingly resistant to all antimicrobials."}, 
{"Row" : 20, "Column" : 1, "Text" : "Clinicians must be aware that these enzymes may not be detected in all strains"}, 
{"Row" : 21, "Column" : 1, "Text" : "that carry them. If a Gram-negative infection is not responding to therapy with"}, 
{"Row" : 22, "Column" : 1, "Text" : "a beta lactam drug, consider adding or switching to a drug that is not a beta"}, 
{"Row" : 23, "Column" : 1, "Text" : "lactam and appears active in the susceptibility report."}, 
{"Row" : 25, "Column" : 1, "Text" : "If a patient is suspected of having a Gram-negative infection and is likely to"}, 
{"Row" : 26, "Column" : 1, "Text" : "be colonized with bacteria carrying these enzymes, empirical therapy with"}, 
{"Row" : 27, "Column" : 1, "Text" : "alternative drugs that are not inactivated by them should be considered."}, 
{"Row" : 29, "Column" : 1, "Text" : "Risk factors for colonization or infection with resistant gram-negative bacilli", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Travel to Asia"}, 
{"Row" : 31, "Column" : 1, "Text" : "2. Central venous catheters and other indwelling tube and drains"}, 
{"Row" : 32, "Column" : 1, "Text" : "3. Recent surgical procedures"}, 
{"Row" : 33, "Column" : 1, "Text" : "4. Recent antibiotic therapy"}, 
{"Row" : 34, "Column" : 1, "Text" : "5. Long-term care facility residence"}, 
{"Row" : 35, "Column" : 1, "Text" : "6. Multiple, severe chronic illnesses"}, 
{"Row" : 36, "Column" : 1, "Text" : "7. Ventilator assistance"}, 
{"Row" : 37, "Column" : 1, "Text" : "8. Hemodialysis"}, 
{"Row" : 38, "Column" : 1, "Text" : "9. Long hospital or ICU stay."}, 
{"Row" : 40, "Column" : 1, "Text" : "AmpC beta-lactamases alternative antimicrobials", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Inactivate many cephalosporins, most penicillins, and beta-lactam inhibitor"}, 
{"Row" : 42, "Column" : 1, "Text" : "combinations. Alternatives include aminoglycosides, carbapenems, cefepime and"}, 
{"Row" : 43, "Column" : 1, "Text" : "colistin."}, 
{"Row" : 45, "Column" : 1, "Text" : "ESBLs alternative antimicrobials", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Inactivate most cephalosporins, monobactams, and penicillins. Alternatives"}, 
{"Row" : 47, "Column" : 1, "Text" : "include aminoglycosides, carbapenems and colistin."}, 
{"Row" : 49, "Column" : 1, "Text" : "Serine carbapenemases, metallo-beta-lactamases and oxacillinases alternative", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "antimicrobials", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Confer resistance to all beta-lactams. Most strains are also resistant to most"}, 
{"Row" : 52, "Column" : 1, "Text" : "other antibiotic classes. Alternatives include aminoglycosides and colistin."}, 
{"Row" : 53, "Column" : 1, "Text" : "Infectious Diseases consultation is recommended."}, 
{"Row" : 55, "Column" : 1, "Text" : "Additional alternative antimicrobials", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole and quinolones are non-beta-lactam alternative"}, 
{"Row" : 57, "Column" : 1, "Text" : "antimicrobials, especially useful for IV to PO conversion. Gram negative bacilli"}, 
{"Row" : 58, "Column" : 1, "Text" : "co-resistance to these antimicrobials is common however. Tigecycline (restricted"}, 
{"Row" : 59, "Column" : 1, "Text" : "to ID) and ceftazidime-avibactam (non-formulary) are also potential options for"}, 
{"Row" : 60, "Column" : 1, "Text" : "susceptible isolates. Infectious Diseases consultation is required for their"}, 
{"Row" : 61, "Column" : 1, "Text" : "use."}, 
{"Row" : 64, "Column" : 1, "Text" : "References"}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Molecular Mechanisms of Antibiotic Resistance in Bacteria"}, 
{"Row" : 67, "Column" : 1, "Text" : "Up-to-Date article: Extended-spectrum beta-lactamases"}, 
{"Row" : 68, "Column" : 1, "Text" : "Up-to-Date article: Overview of carbapenemase-producing gram-negative bacilli"}, 
{"Row" : 69, "Column" : 1, "Text" : "Rodrguez-Bano et al. Clinical microbiology reviews, 2018, 31(2): e00079-17"}, 
{"Row" : 70, "Column" : 1, "Text" : "Sanford guide keyword: Gram Negative Bacilli, Drug Resistance, Overview"}, 
{"Row" : 74, "Column" : 1, "Text" : "Last Reviewed 9/18", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ESOPHAGITIS" , "Term1" : "Esophagitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Candidiasis", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "DisplayText" : "CMV Colitis or Esophagistis", "Text" : "CMV Esophagitis", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes Simplex Esophagitis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ESOPHAGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Esophagitis is usually associated with non-infectious diseases like"}, 
{"Row" :6, "Column" : 1, "Text" : "gastroesophageal reflux disease, mucositis and pill-induced esophagitis."}, 
{"Row" :7, "Column" : 1, "Text" : "Esophageal infection occurs primarily in immunosuppressed individuals (e.g."}, 
{"Row" :8, "Column" : 1, "Text" : "chemotherapy, transplantation, HIV) and rarely in healthy individuals. The"}, 
{"Row" :9, "Column" : 1, "Text" : "majority of infectious esophagitis is caused by Candida albicans,"}, 
{"Row" : 10, "Column" : 1, "Text" : "cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the"}, 
{"Row" : 11, "Column" : 1, "Text" : "esophagus is common in HIV infection. HIV screening is recommneded."}, 
{"Row" : 17, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Esophagitis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford Keyword: Candidiasis"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date article: Herpes simplex virus infection of the esophagus"}
]},
{"Name" : "ORZID2 GMENU ABX EXCLUSIONS" , "Term1" : "Diseases and Syndromes not covered", "DisplayText" : "Exclusions" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact VISN23 Antimicrobial CDSS Program Staff", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DISEASES AND SYNDROMES NOT COVERED", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Our system provides advice for the treatment of most infectious diseases likely"}, 
{"Row" :6, "Column" : 1, "Text" : "to be encountered in our patient population. Diseases that do not require"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobial therapy are not included. For more information on a syndrome not"}, 
{"Row" :8, "Column" : 1, "Text" : "described in our system, please contact infectious diseases. If you feel that a"}, 
{"Row" :9, "Column" : 1, "Text" : "syndrome should be included in our system please contact us."}, 
{"Row" : 12, "Column" : 1, "Text" : "Erik Stensgard, PharmD: (612) 271-4121"}, 
{"Row" : 13, "Column" : 1, "Text" : "Bobbie Masoud, PharmD:(612) 719-6778"}
]},
{"Name" : "ORZID2 GMENU ABX FIRST RECURRENCE ABX ASSOC" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin taper and pulse dosing", "Text" : "Vancomycin Extended-Pulse Taper Regimen ($) [M]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "Select for Fulminant CDI", "Mnemonic" : "12"},
{"Row" :8, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if"}, 
{"Row" :9, "Column" : 1, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 27, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 28, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential."}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and"}, 
{"Row" : 39, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG Q12H 10D", "DisplayText" : "Fidaxomicin 200 mg po q12h for 10 days ($$) [M]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :5, "Column" : 1, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory"}, 
{"Row" :6, "Column" : 1, "Text" : "confirmed case of CDI within 12 weeks after a prior episode."}, 
{"Row" : 11, "Column" : 1, "Text" : "First Recurrence CDI: *The REGIMEN should be different from initial treatment.*", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO Q6H X10DAYS CDIFF", "DisplayText" : "Vancomycin 125mg PO q6h for 10 days for C.difficile infection. ($) [M]", "Text" : "Vancomycin 125 mg PO q6h for 10 days ($) [M]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 35, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID FIDAXAMICIN EXTENDED-PULSE REGIMEN", "DisplayText" : "Fidaxomicin Extended-Pulse Regimen ($$) [M]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)"}, 
{"Row" : 26, "Column" : 1, "Text" : "Fulminant CDI: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with"}, 
{"Row" : 23, "Column" : 1, "Text" : "125 mg po q12h for 7 days, then 125mg po qday for 7 days, then"}, 
{"Row" : 24, "Column" : 1, "Text" : "125mg every other day for 6 weeks)"}, 
{"Row" :3, "Column" : 1, "Text" : "FIRST RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX FUNGUS" , "Term1" : "Fungi section", "DisplayText" : "Fungi " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP.", "DisplayText" : "Aspergillus spp.", "Text" : "Aspergillus and other moulds", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "DisplayText" : "Blastomyces dermatidis", "Text" : "Blastomyces dermatitidis", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Candida albicans", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA", "DisplayText" : "Candida glabrata", "Text" : "Candida glabrata", "Mnemonic" : "10"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI", "DisplayText" : "Candida krusei", "Text" : "Candida krusei", "Mnemonic" : "12"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES", "DisplayText" : "Coccidioidomyces", "Text" : "Coccidioidomyces", "Mnemonic" : "14"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "DisplayText" : "Cryptococcus Neoformans", "Text" : "Cryptococcus neoformans", "Mnemonic" : "16"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM", "DisplayText" : "Histoplasma capsulatum", "Text" : "Histoplasma capsulatum", "Mnemonic" : "18"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis (considered a fungus)", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "++ FUNGI ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome section for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "Last reviewed 8/18", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX GASTROINTESTINAL" , "Term1" : "Gastrointestinal and Intraabdominal section", "DisplayText" : "Gastrointestinal and Intraabdominal " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Hepatic abscess", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "DisplayText" : "Secondary Peritonitis", "Text" : "Intraabdominal abscess", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "DisplayText" : "Secondary Peritonitis", "Text" : "Intraperitoneal abscess", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal/Anorectal abscess", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation", "Text" : "Appendicitis without perforation", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "DisplayText" : "Appendicitis with perforation", "Text" : "Appendicitis with perforation", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLECYSTITIS", "DisplayText" : "Cholecystitis", "Text" : "[click here]", "Mnemonic" : "16"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLANGITIS", "DisplayText" : "Cholangitis", "Text" : "[click here]", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Mild to moderate disease", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "Severe/life-threatening disease", "Mnemonic" : "22"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "[click here]", "Mnemonic" : "24"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIVERTICULITIS", "DisplayText" : "Diverticulitis", "Text" : "[click here]", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "++ GASTROINTESTINAL ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Abscess", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Appendicitis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Cholecystitis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Cholangitis", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Clostridium difficile disease", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "(shock, ileus and megacolon)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Diarrhea, infectious", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Diverticulitis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "SECTION LAST REVIEWED MAY 2018", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "[click here]", "Mnemonic" : "28"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection", "Text" : "[click here]", "Mnemonic" : "32"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A", "Text" : "Hepatitis A", "Mnemonic" : "34"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B", "Text" : "Hepatitis B", "Mnemonic" : "36"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C", "Text" : "Hepatitis C", "Mnemonic" : "38"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "DisplayText" : "Neutropenic Enterocolitis (Typhlitis)", "Text" : "[click here]", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU ABX PANCREATITIS", "DisplayText" : "Pancreatitis", "Text" : "[click here]", "Mnemonic" : "42"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Acute Spontaneous Bacterial Peritonitis (SBP)", "Mnemonic" : "44"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "DisplayText" : "Peritonitis associated with peritoneal dialysis", "Text" : "Peritonitis associated with", "Mnemonic" : "46"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "DisplayText" : "Secondary Peritonitis", "Text" : "Secondary peritonitis", "Mnemonic" : "48"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "[click here]", "Mnemonic" : "50"},
{"Row" : 12, "Column" : 2, "Text" : "Helicobacter pylori infection", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : "Hepatitis", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Neutropenic enterocolitis", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "(Typhlitis)", "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Text" : "Pancreatitis", "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Text" : "Peritonitis", "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Text" : "peritoneal dialysis"}, 
{"Row" : 33, "Column" : 2, "Text" : "Thrush", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "[click here]", "Mnemonic" : "15"},
{"Row" : 15, "Column" : 1, "Text" : "Asplenia (Fever Tx/Vaccines/Abx Prophylaxis)", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Esophagitis", "Header" : 1}, 
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Candidal", "Mnemonic" : "29"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Other", "Mnemonic" : "30"},
{"Row" :5, "Column" : 2, "Text" : "Enteric Fever", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help and Additional Information Menu", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN IP", "DisplayText" : "INPT CONSULTS MENU", "Text" : "Consult Menu - place consults to specialty service", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "DisplayText" : "Need an alternative antimicrobial? (inpatient)", "Text" : "Alternative Antimicrobials to CDSS Recommendations - select here", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact Information", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Antimicrobial Information", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important Drug Properties", "Mnemonic" : "14"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)", "Text" : "Antimicrobial Cost Information", "Mnemonic" : "16"},
{"Row" :1, "Column" : 1, "Text" : "GENERAL INFORMATION", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "LEGEND ________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[DI] = Important interactions between antimicrobial and other drugs"}, 
{"Row" : 15, "Column" : 1, "Text" : "[H] = Hepatic excretion of antimicrobial"}, 
{"Row" : 16, "Column" : 1, "Text" : "[M] = Minimal risk posed by antimicrobial"}, 
{"Row" : 17, "Column" : 1, "Text" : "[O] = Other important antimicrobial property"}, 
{"Row" : 18, "Column" : 1, "Text" : "[R] = Renal excretion of antimicrobial"}, 
{"Row" : 21, "Column" : 1, "Text" : "($) = <10 dollars per day"}, 
{"Row" : 22, "Column" : 1, "Text" : "($$) = 10-50 dollars per day"}, 
{"Row" : 23, "Column" : 1, "Text" : "($$$) = 51-100 dollars per day"}, 
{"Row" : 24, "Column" : 1, "Text" : "($$$$) = 101-400 dollars per day"}, 
{"Row" : 25, "Column" : 1, "Text" : "($$$$$) = >400 dollars per day"}, 
{"Row" :4, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "Infectious Diseases Consult", "Mnemonic" : "3"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "9"}
]},
{"Name" : "ORZID2 GMENU ABX GENITAL HERPES" , "Term1" : "Genital herpes " , "Term2" : "Herpes, genital " , "Term3" : "Sexually transmitted infection, genital warts", "DisplayText" : "Genital herpes" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 5 days ($) [R]", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO TID", "DisplayText" : "Acyclovir 800MG PO TID", "Text" : "Acyclovir 800 mg PO q8h for 2 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO BID", "DisplayText" : "Valacyclovir 500 mg PO q12h ($) [R]", "Text" : "Valacyclovir 500 mg PO q12h for 3 days ($) [R]", "Mnemonic" : "12"},
{"Row" : 53, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h ($) [R]", "Mnemonic" : "14"},
{"Row" : 56, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h ($) [R]", "Mnemonic" : "16"},
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "DisplayText" : "Acyclovir 5 mg/kg IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h ($$) [R]", "Mnemonic" : "18"},
{"Row" : 72, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "DisplayText" : "Acyclovir 400MG PO BID", "Text" : "Acyclovir 400 mg PO q12h ($) [R]", "Mnemonic" : "20"},
{"Row" : 75, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "DisplayText" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Text" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Mnemonic" : "22"},
{"Row" : 78, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1000 MG PO Q24H", "DisplayText" : "VALACYCLOVIR 1000 MG PO Q24h", "Text" : "Valacyclovir 1000 mg PO Q24h ($) [R]", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "GENITAL HERPES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment of the initial episode decreases the duration of pain, lesions, and"}, 
{"Row" : 13, "Column" : 1, "Text" : "viral shedding by 1 to 2 days. Treatment of the initial episode does not"}, 
{"Row" : 14, "Column" : 1, "Text" : "decrease likelihood of recurrent episodes."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Episodic therapy for relapses", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Treatment of recurrent episodes must be started within 24 hours of symptom"}, 
{"Row" : 27, "Column" : 1, "Text" : "onset. Treatment decreases the duration of pain and lesions, and viral shedding"}, 
{"Row" : 28, "Column" : 1, "Text" : "by 1 to 2 days. Consider suppressive treatment for patients with more than 6"}, 
{"Row" : 29, "Column" : 1, "Text" : "episodes per year."}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Immunocompromised patients in whom genital herpes simplex disease is often"}, 
{"Row" : 42, "Column" : 1, "Text" : "severe include: patients with HIV infection, organ transplants, malnourishment,"}, 
{"Row" : 43, "Column" : 1, "Text" : "eczema or severe burns, and in patients receiving immunosuppressive"}, 
{"Row" : 44, "Column" : 1, "Text" : "chemotherapy."}, 
{"Row" : 46, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Treat mild to moderate disease for 10 days. In severe disease, treat with"}, 
{"Row" : 48, "Column" : 1, "Text" : "intravenous acyclovir for 2 to 7 days based on clinical response, then treat"}, 
{"Row" : 49, "Column" : 1, "Text" : "with an oral antiviral for a total duration of 10 days."}, 
{"Row" : 51, "Column" : 1, "Text" : "Treatment for mild to moderate disease or after clinical improvement of severe", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "disease", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 58, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Infectious Diseases consult encouraged."}, 
{"Row" : 62, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "Chronic suppressive therapy", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Suppressive therapy is indicated in patients with more than 6 episodes per year."}, 
{"Row" : 68, "Column" : 1, "Text" : "Suppressive therapy is optional, and some patients may find episodic treatment"}, 
{"Row" : 69, "Column" : 1, "Text" : "more convenient. The frequency of recurrences usually decreases after 1 to 5"}, 
{"Row" : 70, "Column" : 1, "Text" : "years, and suppressive therapy should be stopped every few years to see if it is"}, 
{"Row" : 71, "Column" : 1, "Text" : "still needed."}, 
{"Row" : 74, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 77, "Column" : 1, "Text" : "For a patient with more than 9 episodes per year", "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Text" : "References: "}, 
{"Row" : 83, "Column" : 1, "Text" : "Center for Disease Control. MMWR 55(RR 11) 1-94"}, 
{"Row" : 84, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 85, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"}
]},
{"Name" : "ORZID2 GMENU ABX GENITOURINARY" , "Term1" : "Genitourinary section", "DisplayText" : "Genitourinary " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPROACH TO UTI", "DisplayText" : "Approach to Urinary Tract Infection (UTI)", "Text" : "Approach to Urinary Tract Infection (UTI)", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic Bacteriuria", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU UROSEPSIS", "DisplayText" : "Urosepsis", "Text" : "Bacteremia/sepsis urinary tract source, Urosepsis", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Candida Urinary Tract Infection", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "DisplayText" : "Complicated Cystitis", "Text" : "Complicated cystitis", "Mnemonic" : "12"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Pyelonephritis", "Mnemonic" : "14"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "DisplayText" : "Uncomplicated Cystitis", "Text" : "Uncomplicated cystitis", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "DisplayText" : "Acute Bacterial Prostatitis", "Text" : "Acute bacterial prostatitis", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX BALANITIS", "DisplayText" : "Balanitis and Balanoposthitis", "Text" : "Balanitis and Balanoposthitis", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS", "DisplayText" : "Chronic bacterial prostatitis", "Text" : "Chronic bacterial prostatitis", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "DisplayText" : "Chronic protatitis/Chronic pelvic pain syndrome", "Text" : "Chronic prostatitis/Chronic pelvic pain syndrome", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "DisplayText" : "Epididymitis", "Text" : "Epididymitis and Epididymo-Orchitis", "Mnemonic" : "26"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Urethritis", "Mnemonic" : "28"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX VAGINITIS", "DisplayText" : "Bacterial Vaginosis", "Text" : "Bacterial vaginosis", "Mnemonic" : "30"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida Vulvo-Vaginitis", "Text" : "Candida vulvovaginitis", "Mnemonic" : "32"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Cervicitis", "Mnemonic" : "34"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "36"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Trichomonas vaginitis", "Mnemonic" : "38"},
{"Row" :3, "Column" : 1, "Text" : "++ GENITOURINARY ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Urinary tract infections", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Male specific infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Female specific Infections", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Last updated July 2022", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Cervicitis", "Mnemonic" : "2"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Epididymitis", "Mnemonic" : "4"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Genital Herpes", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Gonorrhea infection with/without Chlamydia", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Syphilis", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Trichomonas Vaginitis", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Urethritis", "Mnemonic" : "18"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Necrotizing infection", "Mnemonic" : "20"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Surgical site infection", "Mnemonic" : "22"},
{"Row" :5, "Column" : 2, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" :7, "Column" : 2, "Text" : "Chlamydia (See Cervicitis or Urethritis)"}, 
{"Row" : 17, "Column" : 2, "Text" : "Necrotizing Infection (including Fournier gangrene)", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Surgical Site Infection", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX GI EUS-FNA ENDO PROCED" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 500MG PO QDAY 4DAYS PROCEDURE", "DisplayText" : "Levofloxacin 500 mg po qday for 4 days starting 60min before proce", "Text" : "Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 500MG PO ONCE THEN QDAY 3DAYS", "DisplayText" : "Levofloxacin 500 mg PO q24h for 4 days", "Text" : "Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "Antibiotic Prophylaxis for GI Endoscopic Ultrasound FNA Procedures", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the"}, 
{"Row" :6, "Column" : 1, "Text" : "risk of iatrogenic infectious complications."}, 
{"Row" :8, "Column" : 1, "Text" : "Cystic lesions along GI tract including mediastinum: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Antibiotic prophylaxis is recommended before a FNA for cystic lesions along"}, 
{"Row" : 10, "Column" : 1, "Text" : "the GI tract to prevent cyst infection."}, 
{"Row" : 11, "Column" : 1, "Text" : "Recommendation: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "INPATIENT: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "endoscopic procedure ($) [R,DI]"}, 
{"Row" : 15, "Column" : 1, "Text" : "OUTPATIENT: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "endoscopic procedure ($) [R,DI]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Solid Lesions along the upper or lower GI tract: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Antibiotic prophylaxis is not recommended before a diagnostic EUS or EUS-FNA"}, 
{"Row" : 21, "Column" : 1, "Text" : "of solid lesions along the upper or lower GI tract."}, 
{"Row" : 23, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal"}, 
{"Row" : 26, "Column" : 1, "Text" : "Endoscopy 2008, 67:791-795"}
]},
{"Name" : "ORZID2 GMENU ABX GIARDIA" , "Term1" : "Giardia lamblia diarrhea", "DisplayText" : "Diarrhea with Giardia lamblia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID NITAZOXANIDE 500MG PO Q12H", "DisplayText" : "Nitazoxanide 500mg po q12h", "Text" : "Nitazoxanide 500 mg PO q12h for 3 days ($$$)[M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 250 MG PO Q8H", "DisplayText" : "Metronidazole 250 mg PO q8h for 5 days($0.24/Day) [DI]", "Text" : "Metronidazole 250 mg PO q8h for 5 to 7 days ($) [DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Illness with Giardia is typically subacute but varies widely in its time course."}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment is necessary when the patient has symptomatic disease. Diarrhea,"}, 
{"Row" :7, "Column" : 1, "Text" : "abdominal pain, bloating, belching, flatus, nausea, and vomiting are present"}, 
{"Row" :8, "Column" : 1, "Text" : "acutely and after several days give way to flatus, loose stools, belching, and"}, 
{"Row" :9, "Column" : 1, "Text" : "weight loss."}, 
{"Row" : 11, "Column" : 1, "Text" : "Asymptomatic carriage of Giardia is common in household contacts of people who"}, 
{"Row" : 12, "Column" : 1, "Text" : "are infected with Giardia. Treatment of asymptomatic patients can be considered"}, 
{"Row" : 13, "Column" : 1, "Text" : "if they have contact with immunocompromised or pregnant people or live or work"}, 
{"Row" : 14, "Column" : 1, "Text" : "in settings where there is risk of spreading infection to others (e.g., food"}, 
{"Row" : 15, "Column" : 1, "Text" : "handlers, daycare, nursing home)."}, 
{"Row" : 17, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 20, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Minetti et al, BMJ, 2016, 355.i5369"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Giardiasis: Treatment and prevention"}
]},
{"Name" : "ORZID2 GMENU ABX GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" :8, "Column" : 1, "Text" : "Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "chlamydia."}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients weighing less than 300lbs: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Patients weighing 300lbs or greater: ", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "No reliable alternative treatments are available for pharyngeal gonorrhea."}, 
{"Row" : 46, "Column" : 1, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment"}, 
{"Row" : 47, "Column" : 1, "Text" : "of the reaction is recommended. For persons with an anaphylactic or other"}, 
{"Row" : 48, "Column" : 1, "Text" : "severe reaction to ceftriaxone, consult Infectious Disease for alternative"}, 
{"Row" : 49, "Column" : 1, "Text" : "treatment recommendation."}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 1GM IMX1 +DOXY 100MG BID X7D", "DisplayText" : "Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po bid x7days (", "Text" : "Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]", "Mnemonic" : "14"},
{"Row" :9, "Column" : 1, "Text" : "-If chlamydial infection has not been excluded, recommend to treat for"}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM X1 +DOXY 100MG PO BIDX7D GONOC", "DisplayText" : "Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO bidx7days ($) [DI]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 11, "Column" : 1, "Text" : "-A test-of-cure is unnecessary for uncomplicated urogenital or rectal"}, 
{"Row" : 12, "Column" : 1, "Text" : "gonorrhea for patients treated with the recommended or alternative regimen."}, 
{"Row" : 40, "Column" : 1, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment"}, 
{"Row" : 41, "Column" : 1, "Text" : "of the reaction is recommended."}, 
{"Row" : 52, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 240MG IM X1+AZITH 2000MG X1 GONOCOCCAL", "DisplayText" : "Gentamicin 240 MG IM Once ($) [R] <AND> Azithromycin 2000 mg PO Once ($) [DI]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 44, "Column" : 1, "Text" : "Alternative treatment for beta-lactam allergy for pharynx: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "-A test-of-cure is recommended for patients with pharyngeal gonorrhea."}, 
{"Row" : 14, "Column" : 1, "Text" : "Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial"}, 
{"Row" : 15, "Column" : 1, "Text" : "treatment, regardless of regimen used for pharyngeal gonorrhea."}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred treatment for patients and no chlamydial co-infection: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred treatment with chlamydial co-infection or chlamydial infection has", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "not been excluded: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Patient weighing less than 300lbs: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Patients weighing 300lbs or greater: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 500MG IM X1 GONOCOCCAL", "DisplayText" : "Ceftriaxone 500 MG IM x1 dose ($) [M]", "Text" : "", "Mnemonic" : "08"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IM X1 GONOCOCCAL", "DisplayText" : "Ceftriaxone 1 GM IM x1 dose ($) [M]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia Urethritis", "Text" : "[Click here] Chlamydial infection and no co-infection", "Mnemonic" : "06"},
{"Row" : 20, "Column" : 1, "Text" : "Chlamydial infection and no co-infection: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "_____________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "[Click here] Place order for gonorrhea/chlamydia lab NAAT test", "Mnemonic" : "04"},
{"Row" : 17, "Column" : 1, "Text" : "Lab test: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-When diagnosed with sexually transmitted disease, the patient's sexual"}, 
{"Row" :5, "Column" : 1, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually"}, 
{"Row" :6, "Column" : 1, "Text" : "transmitted infection."}, 
{"Row" :3, "Column" : 1, "Text" : "Gonococcal Infections: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX HEAD AND NECK" , "Term1" : "Ear, nose, throat (ENT)/Head and Neck section " , "Term2" : "Head and Neck/ENT section", "DisplayText" : "Head and Neck " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "DisplayText" : "Malignant Otitis Externa", "Text" : "Malignant Otitis Externa", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU MASTOIDITIS", "DisplayText" : "Mastoiditis", "Text" : "Mastoiditis", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU OTITIS EXTERNA", "DisplayText" : "Otitis Externa", "Text" : "Otitis Externa", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU OTITIS MEDIA", "DisplayText" : "Otitis Media", "Text" : "Otitis Media", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis", "Text" : "Conjunctivitis", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ENDOOPTHALMITIS", "DisplayText" : "Endophthalmitis", "Text" : "Endophthalmitis", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU KERATITIS", "DisplayText" : "Keratitis", "Text" : "Keratitis", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "DisplayText" : "Periocular Infections", "Text" : "Periocular Infections", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU PROPHYLAXIS OPTH SURG", "DisplayText" : "Prophylaxis for ophthalmic surgery", "Text" : "Prophylaxis for Ophthalmic Surgery", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "Retinitis", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU UVEITIS", "DisplayText" : "Uveitis", "Text" : "Uveitis", "Mnemonic" : "24"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "DisplayText" : "Bell's Palsy", "Text" : "Bell's Palsy", "Mnemonic" : "26"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal Cellulitis", "Text" : "Pre-septal Cellulitis", "Mnemonic" : "28"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal Cellulitis", "Text" : "Post-septal Cellulitis (Orbital Cellulitis)", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "++HEAD AND NECK++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ear/Otologic", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Eye/Ophthalmologic", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Facial", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Section last reviewed June 2021", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "DisplayText" : "Acute Sinusitis--Mild to Moderate Disease", "Text" : "Acute Sinusitis", "Mnemonic" : "34"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU CHRONIC SINUSITIS", "DisplayText" : "Chronic Sinusitis", "Text" : "Chronic Sinusitis", "Mnemonic" : "36"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Fungal Sinusitis", "Mnemonic" : "38"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU ABX NASAL PACKING", "DisplayText" : "Nasal Packing (to prevent infection)", "Text" : "Nasal Packing (to prevent infection)", "Mnemonic" : "40"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "DisplayText" : "Nosocomial Sinusitis", "Text" : "Nosocomial Sinusitis", "Mnemonic" : "42"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "DisplayText" : "Deep Oropharyngeal Infections", "Text" : "Deep Oropharyngeal Infections", "Mnemonic" : "44"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections", "Text" : "Dental Infections", "Mnemonic" : "46"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX EPIGLOTTITIS", "DisplayText" : "Epiglottitis", "Text" : "Epiglottitis", "Mnemonic" : "48"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Mnemonic" : "50"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "DisplayText" : "Laryngitis and Croup", "Text" : "Laryngitis", "Mnemonic" : "52"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX PAROTITIS", "DisplayText" : "Parotitis", "Text" : "Parotitis", "Mnemonic" : "54"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease", "Text" : "Periodontal Disease", "Mnemonic" : "56"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "DisplayText" : "Pertussis", "Text" : "Pertussis", "Mnemonic" : "58"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Pharyngitis", "Mnemonic" : "60"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Thrush", "Mnemonic" : "62"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Tonsillitis", "Mnemonic" : "64"},
{"Row" :5, "Column" : 2, "Text" : "Nasal/Sinus", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Throat/Oropharyngeal", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX HELP PAGE" , "Term1" : "Help", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "DisplayText" : "How to find an alternative antimicrobial", "Text" : "[Click Here]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "DisplayText" : "Antimicrobial Formulary Hyperlink", "Text" : "Formulary", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important drug properties", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category", "Text" : "Pregnancy and lactation risk", "Mnemonic" : "12"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Susceptibilities (Antibiogram)", "Mnemonic" : "14"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "DisplayText" : "RESOURCE QTC PROLONGATION FOR DRUGS", "Text" : "QTc prolongation drug resource", "Mnemonic" : "16"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions", "Mnemonic" : "18"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Additional assistance", "Mnemonic" : "20"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Clinical on call schedule (ID)", "Mnemonic" : "22"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or suggestions", "Mnemonic" : "24"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "DisplayText" : "Exclusions", "Text" : "[Click Here]", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "CDSS HELP AND ADDITIONAL INFORMATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Allergies", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Penicillin desensitization"}, 
{"Row" : 10, "Column" : 1, "Text" : "Alternative antimicrobials", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "When to use and how to find"}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobial information", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Contact Information", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Excluded diseases and syndromes", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "DisplayText" : "Home IV at the Minneapolis VAMC", "Text" : "[Click Here]", "Mnemonic" : "28"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO USE CDSS", "DisplayText" : "How to use the CDSS", "Text" : "[Click Here]", "Mnemonic" : "30"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "DisplayText" : "Infection Control", "Text" : "[Click Here]", "Mnemonic" : "32"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "[Click Here]", "Mnemonic" : "34"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABOUT THE CDSS", "DisplayText" : "About the CDSS", "Text" : "About the CDSS", "Mnemonic" : "36"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX ACKNOWLEDGEMENTS", "DisplayText" : "Acknowledgements", "Text" : "Acknowledgements", "Mnemonic" : "38"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX NEW UPDATES", "DisplayText" : "New Updates", "Text" : "New updates information", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "DisplayText" : "Lexicomp Online", "Text" : "Lexicomp online", "Mnemonic" : "42"},
{"Row" : 26, "Column" : 2, "Item" : "ORZ GTX ABX MANDELL", "DisplayText" : "Mandell Online", "Text" : "Mandell's online", "Mnemonic" : "44"},
{"Row" : 27, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "DisplayText" : "UP TO DATE WEB SITE", "Text" : "Up-to-date online", "Mnemonic" : "46"},
{"Row" : 28, "Column" : 2, "Item" : "ORZ GTX ABX SANFORD", "DisplayText" : "Sanford Guide Web Site", "Text" : "Sanford Guide online", "Mnemonic" : "48"},
{"Row" :5, "Column" : 2, "Text" : "Home IV Treatment Information", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "How to use the CDSS", "Header" : 1}, 
{"Row" :9, "Column" : 2, "Text" : "Navigation, adjusting regimens, menu"}, 
{"Row" : 10, "Column" : 2, "Text" : "elements"}, 
{"Row" : 13, "Column" : 2, "Text" : "Infection Control", "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Text" : "Contact info, links, precautions"}, 
{"Row" : 17, "Column" : 2, "Text" : "Restriction policy information", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Other/additional resources", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)", "Text" : "Cost Information", "Mnemonic" : "7"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam reaction assessment", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "History, types, implications,", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS A" , "Term1" : "Hepatitis A", "DisplayText" : "Hepatitis A " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "HEPATITIS A", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Disease Management", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Most acute disease is self-limited, and the virus does not cause chronic"}, 
{"Row" :7, "Column" : 1, "Text" : "disease. No specific antiviral therapy is available."}, 
{"Row" :9, "Column" : 1, "Text" : "Patients who appear to be developing fulminant hepatitis, including those with"}, 
{"Row" : 10, "Column" : 1, "Text" : "mental status changes should receive supportive treatment. Fulminant hepatitis"}, 
{"Row" : 11, "Column" : 1, "Text" : "is suggested by increased prothrombin time, cholestasis, ascites, decreased"}, 
{"Row" : 12, "Column" : 1, "Text" : "liver size, or decreasing serum albumin. Supportive treatment includes"}, 
{"Row" : 13, "Column" : 1, "Text" : "maintenance of fluid and electrolyte balance, monitoring and possible correction"}, 
{"Row" : 14, "Column" : 1, "Text" : "of coagulation defects, treatment of hepatic encephalopathy, and good nutrition"}, 
{"Row" : 15, "Column" : 1, "Text" : "with a low-protein diet."}, 
{"Row" : 17, "Column" : 1, "Text" : "Prevention for persons with continuing high risk of disease", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Vaccine should be offered to persons at high risk of hepatitis A infection: men"}, 
{"Row" : 19, "Column" : 1, "Text" : "who have sex with men, travelers to endemic areas likely to be exposed, illegal"}, 
{"Row" : 20, "Column" : 1, "Text" : "drug users, persons at occupational risk of disease, persons with chronic liver"}, 
{"Row" : 21, "Column" : 1, "Text" : "disease or clotting factor disorders."}, 
{"Row" : 23, "Column" : 1, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months"}, 
{"Row" : 25, "Column" : 1, "Text" : "Prevention for persons with a specific, defined exposure", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Post-exposure prophylaxis should be offered to persons with substantial exposure"}, 
{"Row" : 27, "Column" : 1, "Text" : "to hepatitis A. Specifically, persons exposed to acute hepatitis through"}, 
{"Row" : 28, "Column" : 1, "Text" : "household or sexual contact, persons who attend or work in a day care center"}, 
{"Row" : 29, "Column" : 1, "Text" : "with a recent case, or employee or patron of a restaurant with a food handler"}, 
{"Row" : 30, "Column" : 1, "Text" : "with hepatitis. Post exposure prophylaxis must be given within 2 weeks of"}, 
{"Row" : 31, "Column" : 1, "Text" : "exposure. Vaccine can be given at the same time as immune-globulin."}, 
{"Row" : 33, "Column" : 1, "Text" : "Immune globulin 0.02 ml/kg IM x 1 <AND>"}, 
{"Row" : 34, "Column" : 1, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months"}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Hepatitis A, Acute, Treatment"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-date article: Hepatitis A virus infections: Treatment and prevention"}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS B" , "Term1" : "Hepatitis B", "DisplayText" : "Hepatitis B " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B Vaccine Information Page", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "DisplayText" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Text" : "Hepatitis B Evaluation", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "HEPATITIS B", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute disease management", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Most acute hepatitis B disease is mild and self-limited. Patients who appear to"}, 
{"Row" :7, "Column" : 1, "Text" : "be developing fulminant hepatitis, including those with mental status changes"}, 
{"Row" :8, "Column" : 1, "Text" : "should receive supportive treatment. Fulminant hepatitis is suggested by"}, 
{"Row" :9, "Column" : 1, "Text" : "increased prothrombin time, cholestasis, ascites, decreased liver size, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "decreasing serum albumin. Supportive treatment includes maintenance of fluid"}, 
{"Row" : 11, "Column" : 1, "Text" : "and electrolyte balance, monitoring and possible correction of coagulation"}, 
{"Row" : 12, "Column" : 1, "Text" : "defects, treatment of hepatic encephalopathy, and good nutrition with a low-"}, 
{"Row" : 13, "Column" : 1, "Text" : "protein diet. Antiviral therapy is not indicated. Gastroenterology consult"}, 
{"Row" : 14, "Column" : 1, "Text" : "encouraged."}, 
{"Row" : 16, "Column" : 1, "Text" : "Chronic disease management", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Antiviral therapy for chronic hepatitis B is a complicated, highly specialized"}, 
{"Row" : 18, "Column" : 1, "Text" : "task. Consult with gastroenterology and infectious diseases."}, 
{"Row" : 20, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Vaccinate persons at high risk of disease including men who have sex with men,"}, 
{"Row" : 22, "Column" : 1, "Text" : "illegal drug users, and health care workers with substantial exposure to blood"}, 
{"Row" : 23, "Column" : 1, "Text" : "or body fluids."}, 
{"Row" : 26, "Column" : 1, "Text" : "Select below for Hepatitis B evaluation for patients receiving Anti-CD20", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Antibody Treatment", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Chronic viral hepatitis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-date article: Hepatitis B virus: Overview of management"}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS C" , "Term1" : "Hepatitis C", "DisplayText" : "Hepatitis C " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "HEPATITIS C", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment of acute disease", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Most acute disease is asymptomatic or mild. Patients with acute hepatitis C"}, 
{"Row" :7, "Column" : 1, "Text" : "should be referred to the Hepatitis C clinic. Treatment may be indicated for"}, 
{"Row" :8, "Column" : 1, "Text" : "disease that persists beyond 2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "Chronic disease treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Antiviral therapy for chronic hepatitis C is a complicated, highly specialized"}, 
{"Row" : 12, "Column" : 1, "Text" : "task"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Chronic viral hepatitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-to-date article: Overview of the management of chronic hepatitis C virus"}, 
{"Row" : 20, "Column" : 1, "Text" : "infection"}
]},
{"Name" : "ORZID2 GMENU ABX HERPES KERATITIS" , "Term1" : "Herpes keratitis", "DisplayText" : "HERPES KERATITIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO BID", "DisplayText" : "Valacyclovir 500 mg PO q12h ($) [R]", "Text" : "Valacyclovir 500 mg PO q12h for 7-10 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "DisplayText" : "Acyclovir 800MG PO 5x/d", "Text" : "Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1 gm PO q8h for 14-21 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "DisplayText" : "Acyclovir 400MG PO BID", "Text" : "Acyclovir 400 mg PO Q12h for 12 months ($) [R]", "Mnemonic" : "12"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "DisplayText" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Text" : "Valacyclovir 500 mg PO Q24h for 12 months ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "HERPES KERATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of"}, 
{"Row" :6, "Column" : 1, "Text" : "cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5"}, 
{"Row" :7, "Column" : 1, "Text" : "year period, less than that of oral or genital herpes. Ocular herpes is a"}, 
{"Row" :8, "Column" : 1, "Text" : "major cause of blindness and typically presents as infection of the epithelium"}, 
{"Row" :9, "Column" : 1, "Text" : "of the cornea but can also rarely involve the stroma and endothelium."}, 
{"Row" : 10, "Column" : 1, "Text" : "Ophthalmology consultation is recommended."}, 
{"Row" : 12, "Column" : 1, "Text" : "Involvement of the stroma or endothelium requires treatment with topical"}, 
{"Row" : 13, "Column" : 1, "Text" : "steroid and close monitoring. For these cases, start oral antiviral and consult"}, 
{"Row" : 14, "Column" : 1, "Text" : "ophthalmology for management."}, 
{"Row" : 16, "Column" : 1, "Text" : "Antiviral prophylaxis is recommended for patients with multiple recurrences,"}, 
{"Row" : 17, "Column" : 1, "Text" : "recurrent episodes with ulceration, recurrent inflammation with"}, 
{"Row" : 18, "Column" : 1, "Text" : "scar/vascularization approaching visual axis, patients who have had keratoplasty"}, 
{"Row" : 19, "Column" : 1, "Text" : "for HSV-related scarring/astigmatism, and patients who have had HSV keratitis"}, 
{"Row" : 20, "Column" : 1, "Text" : "while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed"}, 
{"Row" : 21, "Column" : 1, "Text" : "here. Please consult ophthalmology for more information."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of acute infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Without epithelial ulceration"}, 
{"Row" : 26, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 29, "Column" : 1, "Text" : "Ulceration of epithelium (Geographic ulcer)"}, 
{"Row" : 31, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 34, "Column" : 1, "Text" : "Infection prophylaxis for prevention of recurrence", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Reassess need for prophylaxis every 12 months"}, 
{"Row" : 37, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 41, "Column" : 1, "Text" : "References: "}, 
{"Row" : 43, "Column" : 1, "Text" : "Baratz, Arch Ophthalmology, (2012) 130.1: 108-110"}, 
{"Row" : 44, "Column" : 1, "Text" : "Guess et al, The Ocular Surface, (2007) 5.3:240-250"}, 
{"Row" : 45, "Column" : 1, "Text" : "Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898"}, 
{"Row" : 46, "Column" : 1, "Text" : "Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of"}, 
{"Row" : 47, "Column" : 1, "Text" : "Recurrent Herpes Simplex"}, 
{"Row" : 48, "Column" : 1, "Text" : "Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007"}, 
{"Row" : 49, "Column" : 1, "Text" : "144:547-551"}, 
{"Row" : 50, "Column" : 1, "Text" : "White et al, Ocular Microbiology and Immunology Group and American Academy of"}, 
{"Row" : 51, "Column" : 1, "Text" : "Ophthalmology, (2014)"}
]},
{"Name" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS" , "Term1" : "Herpes esophagitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO 5X/DAYS", "DisplayText" : "Acyclovir 400MG PO 5x/days", "Text" : "Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h (Cost $) [R]", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO 5X/DAYS", "DisplayText" : "Acyclovir 400MG PO 5x/days", "Text" : "Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h (Cost $) [R]", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "DisplayText" : "Acyclovir 5 mg/kg IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h (Cost $) [R]", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "HERPES SIMPLEX ESOPHAGITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "HSV infection of the esophagus usually occurs in patients who are"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompromised, typically solid organ and bone marrow transplant"}, 
{"Row" :7, "Column" : 1, "Text" : "recipients.In healthy patients HSV esophagitis occurs occasionally,"}, 
{"Row" :8, "Column" : 1, "Text" : "usually in men under the age of 40."}, 
{"Row" : 10, "Column" : 1, "Text" : "Patients usually present with odynophagia and dysphagia.Fever"}, 
{"Row" : 11, "Column" : 1, "Text" : "epigastric pain, nausea, vomiting, and heartburn are less frequent."}, 
{"Row" : 12, "Column" : 1, "Text" : "Some patients may have coexistent herpes labialis or oropharyngeal"}, 
{"Row" : 13, "Column" : 1, "Text" : "ulcers.Diagnosis is usually established with an upper endoscopy."}, 
{"Row" : 14, "Column" : 1, "Text" : "Suggestive findings may also be seen during a barium swallow."}, 
{"Row" : 16, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Spontaneous resolution usually occurs in immunocompetent patients after"}, 
{"Row" : 18, "Column" : 1, "Text" : "one to two weeks. Patients may respond more quickly if treated with a"}, 
{"Row" : 19, "Column" : 1, "Text" : "short course of oral acyclovir."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treat for 7-10 days"}, 
{"Row" : 25, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treat for 14-21 days"}, 
{"Row" : 34, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Treat for 7-14 days"}, 
{"Row" : 41, "Column" : 1, "Text" : "John Hopkin's Guides keyword: Herpes simplex virus"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Herpes simplex virus infection of the esophagitis"}
]},
{"Name" : "ORZID2 GMENU ABX HERPES WHITLOW" , "Term1" : "Cellulitis, herpes whitlow " , "Term2" : "Herpes whitlow (digit or hand cellulitis)", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 10 days ($) [R]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h for 10 days ($) [R]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "HERPES WHITLOW (DIGIT OR HAND CELLULITIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Alternative for easier compliance schedule", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Whitlow, herpetic"}
]},
{"Name" : "ORZID2 GMENU ABX HIV-AIDS" , "Term1" : "HIV infection, general", "DisplayText" : "HIV-AIDS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "ID consult", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "DisplayText" : "MRTC", "Text" : "MRTC consult", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "HIV", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "HIV infection and AIDS are associated with several host defense defects. Cell-"}, 
{"Row" :6, "Column" : 1, "Text" : "mediated immune defects render a patient more susceptible to opportunistic"}, 
{"Row" :7, "Column" : 1, "Text" : "infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis"}, 
{"Row" :8, "Column" : 1, "Text" : "carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare"}, 
{"Row" :9, "Column" : 1, "Text" : "complex, and Candida spp."}, 
{"Row" : 11, "Column" : 1, "Text" : "Contact ID or HIV (MRTC) service for assistance."}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Rich RR, et al, eds. Clinical Immunology"}, 
{"Row" : 20, "Column" : 1, "Text" : "Roitt l, et al, eds. Immunology"}
]},
{"Name" : "ORZID2 GMENU ABX HOME IV AT MPLS" , "Term1" : "Home IV therapy at MVAMC " , "Term2" : "Intravenous therapy at home, MVAMC", "DisplayText" : "Home IV at the Minneapolis VAMC " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "GMRCTZ HOME IV INFUSION COORDINATION", "DisplayText" : "HOME IV INFUSION COORDINATION", "Text" : "Home IV consult (or page 7253)", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "HOME IV AT THE MINNEAPOLIS VA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Minneapolis VA provides home IV therapy contracts with commercial providers. To"}, 
{"Row" :6, "Column" : 1, "Text" : "order home IV antimicrobials: "}, 
{"Row" :8, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Step 1", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "An Infectious Disease staff physician must approve outpatient IV antimicrobials"}, 
{"Row" : 14, "Column" : 1, "Text" : "in each case. Call x4185, or call the operator on off-tours to contact the ID"}, 
{"Row" : 15, "Column" : 1, "Text" : "staff member on-call. If the ID service has been consulted, you must request"}, 
{"Row" : 16, "Column" : 1, "Text" : "Home IV approval and recommendations from the ID staff on-call."}, 
{"Row" : 18, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Step 2", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Order a Home IV consult (click on quick order below). Note: Allow 24 hours for"}, 
{"Row" : 24, "Column" : 1, "Text" : "home IV service assessment, teaching, etc to occur."}
]},
{"Name" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "DisplayText" : "How to find an alternative antimicrobial" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "HOW TO FIND AN ALTERNATIVE ANTIMICROBIAL WITHIN THE CDSS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The CDSS has been developed locally with input from a broad, representative"}, 
{"Row" :6, "Column" : 1, "Text" : "group of clinicians. All antimicrobial recommendations within the Antimicrobial"}, 
{"Row" :7, "Column" : 1, "Text" : "CDSS are reviewed by a clinical pharmacist and an Infectious Diseases Medical"}, 
{"Row" :8, "Column" : 1, "Text" : "Specialist. Recommendations provided are based on local susceptibility patterns,"}, 
{"Row" :9, "Column" : 1, "Text" : "clinical evidence, local preferences, and national guidelines. In rare cases,"}, 
{"Row" : 10, "Column" : 1, "Text" : "the recommended antimicrobials and listed alternatives may not be preferred for"}, 
{"Row" : 11, "Column" : 1, "Text" : "the patient you are treating (e.g. isolate resistance, allergies, etc.). In"}, 
{"Row" : 12, "Column" : 1, "Text" : "these cases, a broader set of alternative antimicrobials may be ordered through"}, 
{"Row" : 13, "Column" : 1, "Text" : "the Antimicrobial CDSS. Like other antimicrobial orders in the CDSS,"}, 
{"Row" : 14, "Column" : 1, "Text" : "antimicrobials ordered through the Alternative Antimicrobials menu do on require"}, 
{"Row" : 15, "Column" : 1, "Text" : "a prior authorization or ID approval."}, 
{"Row" : 17, "Column" : 1, "Text" : "To access the Alternative Antimicrobials menu, navigate to the menu containing"}, 
{"Row" : 18, "Column" : 1, "Text" : "antimicrobial recommendations for the infectious disease you are treating."}, 
{"Row" : 25, "Column" : 1, "Text" : "The Alternative Antimicrobial menu contains antimicrobial regimens that have"}, 
{"Row" : 26, "Column" : 1, "Text" : "been deemed appropriate for use as alternatives to recommended antimicrobials by"}, 
{"Row" : 27, "Column" : 1, "Text" : "the Antimicrobial P&T Subcommittee. If the list does not contain the preferred"}, 
{"Row" : 28, "Column" : 1, "Text" : "antimicrobial, contact or consult Infectious Diseases."}, 
{"Row" : 30, "Column" : 1, "Text" : "The regimens provided in the Alternative Antimicrobial menu are not tailored for"}, 
{"Row" : 31, "Column" : 1, "Text" : "a specific infectious disease. The dose, frequency, and duration must be changed"}, 
{"Row" : 32, "Column" : 1, "Text" : "based on the infectious disease you are treating as well as for patient specific"}, 
{"Row" : 33, "Column" : 1, "Text" : "factors. The usage of alternative antimicrobials are monitored by the"}, 
{"Row" : 34, "Column" : 1, "Text" : "Antimicrobial CDSS team for appropriateness and to identify infectious diseases"}, 
{"Row" : 35, "Column" : 1, "Text" : "for addition to the system."}, 
{"Row" : 19, "Column" : 1, "Text" : "At the top of the menu, select: "}, 
{"Row" : 20, "Column" : 1, "Text" : "2 Help legend, allergy info, consults, alternative antimicrobials and more"}, 
{"Row" : 21, "Column" : 1, "Text" : "Then select- Alternative Antimicrobials to CDSS Recommendations"}, 
{"Row" : 22, "Column" : 1, "Text" : "Select the reason an alternative antimicrobial is required then the Alternative"}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrobial menu will display."}
]},
{"Name" : "ORZID2 GMENU ABX HOW TO USE CDSS", "DisplayText" : "How to use the CDSS " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX DURATION OF ABX THERAPY", "DisplayText" : "Duration of antimicrobial therapy", "Text" : "More information on duration of antimicrobial therapy", "Mnemonic" : "4"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU ABX ELEMENTS OF CDSS ADVICE PAGE", "DisplayText" : "Elements of a CDSS Advice Page", "Text" : "[Click Here]", "Mnemonic" : "6"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "DisplayText" : "Adjust existing antimicrobial therapy", "Text" : "Adjusting existing antimicrobial therapy", "Mnemonic" : "8"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "DisplayText" : "How to find an alternative antimicrobial", "Text" : "How to find an alternative antimicrobial within the CDSS", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "HOW TO USE THE CDSS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The CDSS has been designed to offer antimicrobial prescribing advice quickly and"}, 
{"Row" :6, "Column" : 1, "Text" : "efficiently. Since inpatient and outpatient drugs are ordered differently, the"}, 
{"Row" :7, "Column" : 1, "Text" : "CDSS has both and inpatient and outpatient versions for prescribing."}, 
{"Row" :9, "Column" : 1, "Text" : "The Antimicrobial CDSS is located within CPRS. When CPRS is open, click on the"}, 
{"Row" : 10, "Column" : 1, "Text" : "Orders tab at the bottom left hand side of the CPRS window."}, 
{"Row" : 12, "Column" : 1, "Text" : "For inpatients", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "On the left-hand side of the \"Orders\" tab, click on the \"Medicine Inpt Orders.\""}, 
{"Row" : 16, "Column" : 1, "Text" : "now be open."}, 
{"Row" : 18, "Column" : 1, "Text" : "For outpatients", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "On the left-hand side of the \"Orders\" tab, click on the \"Medicine Outpt Orders.\""}, 
{"Row" : 22, "Column" : 1, "Text" : "now be open."}, 
{"Row" : 24, "Column" : 1, "Text" : "Navigating Within the CDSS", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "*Using the decision tree"}, 
{"Row" : 26, "Column" : 1, "Text" : "The main menu of the Antimicrobial CDSS contains links to categories of"}, 
{"Row" : 27, "Column" : 1, "Text" : "infectious diseases based on syndrome/organ system (e.g. cardiovascular,"}, 
{"Row" : 28, "Column" : 1, "Text" : "genitourinary, etc.), organisms (e.g. gram-positive bacteria, gram-negative"}, 
{"Row" : 29, "Column" : 1, "Text" : "bacteria, viruses, etc.) and other special cases. To navigate to specific"}, 
{"Row" : 30, "Column" : 1, "Text" : "infectious disease, select the category the infectious disease is associated"}, 
{"Row" : 31, "Column" : 1, "Text" : "with. Within the category menu, select the specific infectious disease sub-menu"}, 
{"Row" : 32, "Column" : 1, "Text" : "for recommendations, quick orders and pertinent resources (e.g., section-"}, 
{"Row" : 33, "Column" : 1, "Text" : "specific consults, important drug properties, CDSS system help resources, etc.)."}, 
{"Row" : 36, "Column" : 1, "Text" : "*Using the Index"}, 
{"Row" : 37, "Column" : 1, "Text" : "The Index is in the main menu at the top of the left-hand column under the"}, 
{"Row" : 38, "Column" : 1, "Text" : "header Index of Antimicrobial CDSS content. The Index contains an alphabetized"}, 
{"Row" : 39, "Column" : 1, "Text" : "list of Antimicrobial CDSS content. Find the infectious disease, organism or"}, 
{"Row" : 40, "Column" : 1, "Text" : "other topic you are looking for by scrolling down the list. When you locate the"}, 
{"Row" : 41, "Column" : 1, "Text" : "term you are looking for, click on it to be linked to the menu containing"}, 
{"Row" : 42, "Column" : 1, "Text" : "specific recommendations, quick orders and pertinent resources."}, 
{"Row" : 44, "Column" : 1, "Text" : "Quick Orders", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Quick orders are preprogrammed with the usually recommended antimicrobial dose,"}, 
{"Row" : 46, "Column" : 1, "Text" : "frequency and solution for the specific infectious disease."}, 
{"Row" : 49, "Column" : 1, "Text" : "Quick orders are not tailored to specific patient factors such as renal"}, 
{"Row" : 50, "Column" : 1, "Text" : "insufficiency, comorbidities, contraindications, weight, allergies, etc. The"}, 
{"Row" : 51, "Column" : 1, "Text" : "provider must assess every patient closely for these factors and modify"}, 
{"Row" : 52, "Column" : 1, "Text" : "recommended antimicrobials if needed. To assist the provider, additional drug"}, 
{"Row" : 53, "Column" : 1, "Text" : "information is provided within specific infectious diseases recommendation menus"}, 
{"Row" : 54, "Column" : 1, "Text" : "and a link to more in depth information is provided at the top of these menus."}, 
{"Row" : 55, "Column" : 1, "Text" : "Alternatives to preferred antimicrobials quick orders are often provided in"}, 
{"Row" : 56, "Column" : 1, "Text" : "recommendations, a broader selection of alternative antimicrobials is provided"}, 
{"Row" : 57, "Column" : 1, "Text" : "in the Alternative Antimicrobial menu (see What if a Preferred Antimicrobial is"}, 
{"Row" : 58, "Column" : 1, "Text" : "not Provided in the Recommendations?)."}, 
{"Row" : 60, "Column" : 1, "Text" : "Elements of a CDSS Advice Page", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "If you need to modify existing therapy", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "If you need an alternative antimicrobial", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "option.In the right-hand column of the window that pops up, select \" 77"}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobials (CDSS).\". The main menu of the Inpatient Antimicrobial CDSS will"}, 
{"Row" : 20, "Column" : 1, "Text" : "option. In the right-hand column of the window that pops up, select \" 55"}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial (CDSS).\". The main menu of the Outpatient Antimicrobial CDSS will"}
]},
{"Name" : "ORZID2 GMENU ABX HSV ENCEPHALITIS" , "Term1" : "Encephalitis", "DisplayText" : "HSV Encephalitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "DisplayText" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI]", "Text" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI] for 14 to 21 days", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "HERPES SIMPLEX ENCEPHALITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Herpes simplex virus (HSV) type 1 is the leading cause of sporadic fatal"}, 
{"Row" :6, "Column" : 1, "Text" : "encephalitis worldwide and should be suspected in patients who have symptoms"}, 
{"Row" :7, "Column" : 1, "Text" : "unexplained by other causes. Typical symptoms include acute alteration of"}, 
{"Row" :8, "Column" : 1, "Text" : "consciousness for more than 24 hours, fever, new onset seizures and/or focal"}, 
{"Row" :9, "Column" : 1, "Text" : "neurologic deficits. Patients taking natalizumab are at increased risk of HSV"}, 
{"Row" : 10, "Column" : 1, "Text" : "encephalitis. Early diagnosis and treatment are essential to achieve resolution"}, 
{"Row" : 11, "Column" : 1, "Text" : "of infection and symptoms. If diagnosis is not certain and there is little"}, 
{"Row" : 12, "Column" : 1, "Text" : "likelihood of herniation, obtain cerebrospinal fluid (CSF) sample for HSV"}, 
{"Row" : 13, "Column" : 1, "Text" : "polymerase chain reaction (PCR). MRI without contrast nearly always show"}, 
{"Row" : 14, "Column" : 1, "Text" : "abnormal signs in patients with HSV encephalitis. Neurology and Infectious"}, 
{"Row" : 15, "Column" : 1, "Text" : "disease consultations are strongly encouraged."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment, Initiate Immediately When HSV Encephalitis is Suspected", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Rabinstein, Neurol Clin, 2017, 695-705"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Encephalitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date Article: Herpes simplex virus type 1 encephalitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "*If BMI > 35, use IBW to dose"}
]},
{"Name" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "DisplayText" : "Ciprofloxacin PO" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "________________________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Ciprofloxacin PO", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Usual dose: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "250-500 mg q12h"}, 
{"Row" : 10, "Column" : 1, "Text" : "Dose adjustments for renal or hepatic insufficiency: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Creatinine clearance (ml/min) Dose adjustment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< 30 250 mg q12h"}, 
{"Row" : 14, "Column" : 1, "Text" : "Hemodialysis250-500 mg q24h"}, 
{"Row" : 16, "Column" : 1, "Text" : "Drug Interactions: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Hypoglycemia that can lead to coma especially in diabetics taking"}, 
{"Row" : 18, "Column" : 1, "Text" : "oral hypoglycemic medicine or insulin."}, 
{"Row" : 20, "Column" : 1, "Text" : "Calcium, dairy products, iron, zinc, magnesium, aluminuminhibit the absorption"}, 
{"Row" : 21, "Column" : 1, "Text" : "of oral ciprofloxacin.Give ciprofloxacin 2 hours before or 6 hours after these"}, 
{"Row" : 22, "Column" : 1, "Text" : "drugs."}, 
{"Row" : 24, "Column" : 1, "Text" : "Increases effects of caffeine and theophylline by inhibitingmetabolism."}, 
{"Row" : 25, "Column" : 1, "Text" : "Monitor the patient for signs of agitation or anxiety."}, 
{"Row" : 27, "Column" : 1, "Text" : "Increases the effect of warfarin.Monitor international normalized ratio (INR)"}, 
{"Row" : 28, "Column" : 1, "Text" : "ratio (INR) frequently in patients taking warfarin."}, 
{"Row" : 30, "Column" : 1, "Text" : "Adverse Drug Reactions: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "FDA Drug Safety Communication", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "The U.S. Food and Drug Administration advised that the serious"}, 
{"Row" : 33, "Column" : 1, "Text" : "side effects associated with fluoroquinolone antibacterial drugs"}, 
{"Row" : 34, "Column" : 1, "Text" : "generally outweigh the benefits for patients with acute sinusitis, acute"}, 
{"Row" : 35, "Column" : 1, "Text" : "bronchitis, and uncomplicated urinary tract infections who have other"}, 
{"Row" : 36, "Column" : 1, "Text" : "treatment options. For patients with these conditions, fluoroquinolones should"}, 
{"Row" : 37, "Column" : 1, "Text" : "be reserved for those who do not have alternative treatment options."}, 
{"Row" : 39, "Column" : 1, "Text" : "An FDA safety review has shown that fluoroquinolones when used systemically"}, 
{"Row" : 40, "Column" : 1, "Text" : "are associated with disabling and potentially permanent serious side effects"}, 
{"Row" : 41, "Column" : 1, "Text" : "that can occur together. These side effects can involve the tendons,"}, 
{"Row" : 42, "Column" : 1, "Text" : "muscles, joints, nerves, and central nervous system."}, 
{"Row" : 44, "Column" : 1, "Text" : "FDA identified cases of hypoglycemic coma, resulting in death in some"}, 
{"Row" : 45, "Column" : 1, "Text" : "instances. Most pateints had risk factors for hypoglycemia such as older age,"}, 
{"Row" : 46, "Column" : 1, "Text" : "diabetes, renal insufficiency, and concomitant use of hypoglycemic drugs,"}, 
{"Row" : 47, "Column" : 1, "Text" : "especally sulfonylureas.FDA also identified reports of additional mental"}, 
{"Row" : 48, "Column" : 1, "Text" : "health side effects, and requires that all fluoroquinolones include six"}, 
{"Row" : 49, "Column" : 1, "Text" : "psychiatric adverse reactions (disturbance in attention, memory impairment,"}, 
{"Row" : 50, "Column" : 1, "Text" : "delirium, nervousness, agitation and disorientation)."}, 
{"Row" : 52, "Column" : 1, "Text" : "Other adverse reactions: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Nausea/vomiting, diarrhea, dizziness, confusion, CNS"}, 
{"Row" : 54, "Column" : 1, "Text" : "stimulation, rare seizures, rare QT interval prolongation, and"}, 
{"Row" : 55, "Column" : 1, "Text" : "tendinitis/tendon rupture. Six psychiatric adverse reactions"}, 
{"Row" : 56, "Column" : 1, "Text" : "including disturbance in attention, memory impairment, delirium,"}, 
{"Row" : 57, "Column" : 1, "Text" : "nervousness, agitation and disorientation."}, 
{"Row" : 58, "Column" : 1, "Text" : "Hypoglycemia that can lead to coma, occuring more frequently in"}, 
{"Row" : 59, "Column" : 1, "Text" : "the elderly and those with diabetes."}, 
{"Row" : 61, "Column" : 1, "Text" : "Pregnancy Risk Factor Category: C", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT" , "Term1" : "Immunocompromised Patients section", "DisplayText" : "Infections in Immunocompromised Patients" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "DisplayText" : "Basic concepts", "Text" : "Basic concepts", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY", "DisplayText" : "Complement deficiency", "Text" : "Complement deficiency", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Spleen absent or dysfunctional", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "DisplayText" : "Malnutrition", "Text" : "Malnutrition", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "DisplayText" : "Diabetes Mellitus", "Text" : "Diabetes Mellitus", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION", "DisplayText" : "Neurological dysfunction", "Text" : "Neurological dysfunction", "Mnemonic" : "14"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "DisplayText" : "Tobacco smoke", "Text" : "Tobacco smoke", "Mnemonic" : "16"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "DisplayText" : "Stress", "Text" : "Stress", "Mnemonic" : "18"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "DisplayText" : "Hypochlorhydria", "Text" : "Hypochlorhydria", "Mnemonic" : "20"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "DisplayText" : "Altered microbial flora", "Text" : "Altered microbial flora", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy", "Text" : "Malignancy", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "DisplayText" : "Neutropenia", "Text" : "Neutropenia", "Mnemonic" : "26"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "Neutropenic fever", "Mnemonic" : "28"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is a candidate for oral therapy", "Text" : "Oral therapy for neutropenic fever", "Mnemonic" : "30"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy", "Text" : "Empirical intravenous therapy for neutropenic fever", "Mnemonic" : "32"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "DisplayText" : "Modification to Neutropenic fever therapy", "Text" : "Modification to neutropenic fever therapy", "Mnemonic" : "34"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis", "Mnemonic" : "36"},
{"Row" :3, "Column" : 1, "Text" : "++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS ++", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Innate defects", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "HIV", "Mnemonic" : "40"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU CMI DEFECTS", "DisplayText" : "Cell-mediated immunity (CMI) defects", "Text" : "Cell-mediated immunity (CMI) defects", "Mnemonic" : "42"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU IG HIS DEFICIENCY", "DisplayText" : "Immunoglobulin (Humoral immune system) deficiency", "Text" : "Immunoglobulin (humoral immune system) deficiency", "Mnemonic" : "44"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU TRANSPLANTATION", "DisplayText" : "Transplantation", "Text" : "Transplantation", "Mnemonic" : "46"},
{"Row" :7, "Column" : 2, "Text" : "Immune defects", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX IMPETIGO" , "Term1" : "Impetigo", "DisplayText" : "Impetigo" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID MUPIROCIN 2% OINT TOP TO AFFECT AREA Q8H", "DisplayText" : "Mupirocin 2% ointment topical to affected area q8h", "Text" : "Mupirocin ointment to affected area q8h for 5 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100MG PO q12h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100MG PO q12h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "16"},
{"Row" :2, "Column" : 1, "Text" : "Impetigo and Ecthyma"}, 
{"Row" :4, "Column" : 1, "Text" : "Impetigo is a superficial skin infection that rarely causes systemic"}, 
{"Row" :5, "Column" : 1, "Text" : "symptoms. Ecthyma is a skin infection characterized by crusted sores"}, 
{"Row" :6, "Column" : 1, "Text" : "beneath which ulcers form. It is a deep form of impetigo, as the same"}, 
{"Row" :7, "Column" : 1, "Text" : "bacteria causing the infection are involved. Ecthyma causes deeper"}, 
{"Row" :8, "Column" : 1, "Text" : "erosions of the skin into the dermis."}, 
{"Row" : 10, "Column" : 1, "Text" : "Gram stain and culture of the pus or exudates from skin lesions of"}, 
{"Row" : 11, "Column" : 1, "Text" : "impetigo and ecthyma are recommended to help identify whether"}, 
{"Row" : 12, "Column" : 1, "Text" : "Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause."}, 
{"Row" : 14, "Column" : 1, "Text" : "Bullous and non-bullous impetigo can be treated with oral or topical"}, 
{"Row" : 15, "Column" : 1, "Text" : "antimicrobials, but oral therapy is recommended for patients with"}, 
{"Row" : 16, "Column" : 1, "Text" : "numerous lesions or in outbreaks affecting several people to help"}, 
{"Row" : 17, "Column" : 1, "Text" : "decrease transmission of infection. Treatment for ecthyma should be an"}, 
{"Row" : 18, "Column" : 1, "Text" : "oral antimicrobial."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment for impetigo with few lesions", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment for ecthyma and for impetigo with numerous lesions or", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "whose symptoms have not responded to topical treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treat orally for 7 days"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "IF MRSA confirmed or suspected: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 39, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014 59: 147"}, 
{"Row" : 40, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU ABX IMPORTANT BETA-LACTAM ALLERGY FACTS", "DisplayText" : "Important Beta-lactam Allergy Facts and Reaction History" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Important Beta-lactam Allergy Facts", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "1. 10% of patients report an allergy to penicillin."}, 
{"Row" :4, "Column" : 1, "Text" : "2. Less than 1% of patients are truly allergic to penicillin."}, 
{"Row" :5, "Column" : 1, "Text" : "3. 80% of patients who had an immediate allergic reaction (Type I,"}, 
{"Row" :6, "Column" : 1, "Text" : "Immunoglobulin E (IgE)-mediated) to penicillin lose sensitivity after 10"}, 
{"Row" :7, "Column" : 1, "Text" : "years."}, 
{"Row" :8, "Column" : 1, "Text" : "4. Cross-reactivity between penicillin and cephalosporins occurs in only 2% of"}, 
{"Row" :9, "Column" : 1, "Text" : "patients and most patients do not have clinically significant reactions."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtaining a Detailed Reaction History", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "- Locate documented reaction information within the Computerized Patient Record"}, 
{"Row" : 13, "Column" : 1, "Text" : "System (CPRS)"}, 
{"Row" : 14, "Column" : 1, "Text" : "> Reported reactions can be found in the Cover Sheet under Allergies/Adverse"}, 
{"Row" : 15, "Column" : 1, "Text" : "Reactions. Double click on the specific reaction for more information,"}, 
{"Row" : 16, "Column" : 1, "Text" : "including signs/symptoms and date of reaction."}, 
{"Row" : 17, "Column" : 1, "Text" : "> A reaction report can also be found here: Reports tab -> Clinical Reports -"}, 
{"Row" : 18, "Column" : 1, "Text" : "Allergies."}, 
{"Row" : 19, "Column" : 1, "Text" : "- Determine beta-lactam medication history. A list of all locally prescribed"}, 
{"Row" : 20, "Column" : 1, "Text" : "medications can be found here: Reports tab -> Clinical Reports -> Pharmacy ->"}, 
{"Row" : 21, "Column" : 1, "Text" : "All Medications."}, 
{"Row" : 22, "Column" : 1, "Text" : "- Interview the patient or family for details about the reaction. Questions to"}, 
{"Row" : 23, "Column" : 1, "Text" : "ask during the interview: "}, 
{"Row" : 24, "Column" : 1, "Text" : "> What medication were you taking when the reaction occurred? DO NOT accept"}, 
{"Row" : 25, "Column" : 1, "Text" : "Penicillin or Cephalosporin as an allergy, ensure specific offending"}, 
{"Row" : 26, "Column" : 1, "Text" : "medication is identified."}, 
{"Row" : 27, "Column" : 1, "Text" : "> How long after taking the medication did the reaction occur? Immediate"}, 
{"Row" : 28, "Column" : 1, "Text" : "reactions typically occur within 1 hour and up to 72 hours after"}, 
{"Row" : 29, "Column" : 1, "Text" : "administration. Delayed reactions occur after 72 hours."}, 
{"Row" : 30, "Column" : 1, "Text" : "> How long ago did the reaction occur? Did it occur over 10 years ago?"}, 
{"Row" : 31, "Column" : 1, "Text" : "> What kind of reaction occurred? Did the reaction require medical attention?"}, 
{"Row" : 32, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital"}, 
{"Row" : 36, "Column" : 1, "Text" : "Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625"}, 
{"Row" : 37, "Column" : 1, "Text" : "Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,"}, 
{"Row" : 38, "Column" : 1, "Text" : "2017"}, 
{"Row" : 39, "Column" : 1, "Text" : "Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-"}, 
{"Row" : 40, "Column" : 1, "Text" : "Reactivity. Pharmacy, 2019, 7(3)103"}, 
{"Row" : 41, "Column" : 1, "Text" : "Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart"}, 
{"Row" : 42, "Column" : 1, "Text" : "Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious"}, 
{"Row" : 44, "Column" : 1, "Text" : "Diseases, 2020"}, 
{"Row" : 45, "Column" : 1, "Text" : "Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved"}, 
{"Row" : 46, "Column" : 1, "Text" : "safely. BC Medical Journal, 2019, 61(9)350"}, 
{"Row" : 47, "Column" : 1, "Text" : "Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo"}, 
{"Row" : 48, "Column" : 1, "Text" : "the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?"}, 
{"Row" : 49, "Column" : 1, "Text" : "Clinical Infectious Diseases, 2019, 68(1)157"}, 
{"Row" : 50, "Column" : 1, "Text" : "Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,"}, 
{"Row" : 51, "Column" : 1, "Text" : "321(2)188"}, 
{"Row" : 53, "Column" : 1, "Text" : "Immunol. 2010, 105(4)259"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Drug Allergy, Beta-lactams"}, 
{"Row" : 55, "Column" : 1, "Text" : "Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-"}, 
{"Row" : 56, "Column" : 1, "Text" : "Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-"}, 
{"Row" : 57, "Column" : 1, "Text" : "1542"}, 
{"Row" : 58, "Column" : 1, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of"}, 
{"Row" : 59, "Column" : 1, "Text" : "cephalosporins and related antibiotics"}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features"}, 
{"Row" : 61, "Column" : 1, "Text" : "Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol"}, 
{"Row" : 62, "Column" : 1, "Text" : "Pract. 2018, 6(1)72"}, 
{"Row" : 52, "Column" : 1, "Text" : "Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma"}
]},
{"Name" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES" , "Term1" : "Drug properties, important " , "Term2" : "Important drug properties", "DisplayText" : "Important drug properties " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX UP TO DATE", "DisplayText" : "UP TO DATE WEB SITE", "Text" : "Up-to-Date online (Lexicomp)", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD", "DisplayText" : "Sanford Guide Web Site", "Text" : "Sanford online", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet: A-B (acyclovir-benzathine penicllin)", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet: C(caspofungin-clindamycin)", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet D-E-F(daptomycin-fosfomycin)", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet: G-H-I-J-K-L (ganciclovir-linezolid)", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet M-N-O(metronidazole-oseltamivir)", "Mnemonic" : "16"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet: P-Q-R-S (paromomycin-sulfadiazine)", "Mnemonic" : "18"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Alphabet: T-U-V-W-X-Y-Z (terconazole-zanamivir)", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "IMPORTANT DRUG PROPERTIES CODING", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Next to each drug quick order in CDSS, there are letters alerting the user to"}, 
{"Row" :6, "Column" : 1, "Text" : "important properties associated with that drug: "}, 
{"Row" :7, "Column" : 1, "Text" : "[DI]= clinically important drug interactions"}, 
{"Row" :8, "Column" : 1, "Text" : "[H] = may require dose adjustment in patients with hepatic dysfunction"}, 
{"Row" :9, "Column" : 1, "Text" : "[R] = may require dose adjustment in patients with renal dysfunction"}, 
{"Row" : 10, "Column" : 1, "Text" : "[O] = other important information"}, 
{"Row" : 11, "Column" : 1, "Text" : "[M] = minimal"}, 
{"Row" : 13, "Column" : 1, "Text" : "The Important Drug Properties menu contains valuable information on common or"}, 
{"Row" : 14, "Column" : 1, "Text" : "severe adverse effects, drug interactions and dose adjustments for hepatic and"}, 
{"Row" : 15, "Column" : 1, "Text" : "renal failure. This list is not comprehensive. Refer to Up-to-date, found in"}, 
{"Row" : 16, "Column" : 1, "Text" : "Clinical Online Resources under the Tools menu in CPRS, or click on the ling"}, 
{"Row" : 17, "Column" : 1, "Text" : "below for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "Infectious Diseases and Pharmacy Services can help with dose adjustments."}, 
{"Row" : 23, "Column" : 1, "Text" : "Important Drug Properties Menu Select by Alphabet of Generic Name", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Links to Sanford and Up-to-Date (Lexicomp) for drug information"}
]},
{"Name" : "ORZID2 GMENU ABX INDEX INPATIENT", "DisplayText" : "Inpatient Antimicrobial CDSS Index" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "DisplayText" : "Central Nervous System", "Text" : "Abscess, brain", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "DisplayText" : "Cranial epidural abscess", "Text" : "Abscess, cranial epidural", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess", "Text" : "Abscess, cutaneous", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Abscess, liver", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "DisplayText" : "Lung abscess", "Text" : "Abscess, lung", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Abscess, perianal/anorectal", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABSCESSES", "DisplayText" : "Abscesses:Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis", "Text" : "Abscess, skin and soft tissue", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "DisplayText" : "Spinal epidural abscess", "Text" : "Abscess, spinal epidural", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI", "DisplayText" : "Acinetobacter baumanni", "Text" : "Acinetobacter baumannii, general", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII", "DisplayText" : "Nosocomial pneumonia with Acinetobacter baumannii", "Text" : "Acinetobacter baumannii, nosocomial pneumonia", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "Acquired immunodeficiency syndrome (AIDS)", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.", "DisplayText" : "Actinomyces spp.", "Text" : "Actinomyces infections, general", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Adenovirus diarrhea/gastroenteritis", "Mnemonic" : "26"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "DisplayText" : "Large uniform rods in an aerobic bottle", "Text" : "Aerobic bottle, large uniform bacilli", "Mnemonic" : "28"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "DisplayText" : "Small pleomorphic rods in aerobic bottle", "Text" : "Aerobic bottle, small pleomorphic bacilli", "Mnemonic" : "30"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX AEROMONAS", "DisplayText" : "Diarrhea with Aeromonas", "Text" : "Aeromonas diarrhea/gastroenteritis", "Mnemonic" : "32"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Aggregatibacter native valve endocarditis", "Mnemonic" : "34"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Aggregatibacter prosthetic valve endocarditis", "Mnemonic" : "36"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Allergy information", "Mnemonic" : "38"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "DisplayText" : "Altered microbial flora", "Text" : "Altered microbial flora", "Mnemonic" : "40"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Amebic liver abscess", "Mnemonic" : "42"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "DisplayText" : "Large uniform rods in an anaerobic bottle", "Text" : "Anaerobic bottle, large uniform bacilli", "Mnemonic" : "44"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "DisplayText" : "Small pleomorphic rods in an anaerobic bottle", "Text" : "Anaerobic bottle, small pleomorphic bacilli", "Mnemonic" : "46"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "DisplayText" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Text" : "Anaerobic gram-positive cocci", "Mnemonic" : "48"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Text" : "Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)", "Mnemonic" : "50"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Anorectal abscess", "Mnemonic" : "52"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "DisplayText" : "Prevention of bacterial infection in a patient with malignancy", "Text" : "Antibacterial prophylaxis in malignancy", "Mnemonic" : "54"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram", "Mnemonic" : "56"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infections in a patient with malignancy", "Text" : "Antifungal prophylaxis in malignancy", "Mnemonic" : "58"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Antimicrobial interactions with warfarin", "Mnemonic" : "60"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Antimicrobial shortages updates", "Mnemonic" : "62"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antimicrobial susceptibilities", "Mnemonic" : "64"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis in malignancy", "Mnemonic" : "66"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "DisplayText" : "Appendicitis with perforation", "Text" : "Appendicitis with perforation", "Mnemonic" : "68"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation", "Text" : "Appendicitis without perforation", "Mnemonic" : "70"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU LYME ARTHRITIS", "DisplayText" : "Arthritis associated with Lyme disease", "Text" : "Arthritis associated with Lyme disease", "Mnemonic" : "72"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP.", "DisplayText" : "Aspergillus spp.", "Text" : "Aspergillus infections, general", "Mnemonic" : "74"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia", "Text" : "Aspiration pneumonia", "Mnemonic" : "76"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Asplenia [CLICK HERE], includes: ", "Mnemonic" : "78"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Astrovirus diarrhea/gastroenteritis", "Mnemonic" : "80"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "82"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Asymptomatic candiduria", "Mnemonic" : "84"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Asymptomatic pyuria", "Mnemonic" : "86"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU BABESIA SPP.", "DisplayText" : "Babesia species", "Text" : "Babesia infections, general", "Mnemonic" : "88"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)", "Text" : "Bacillary dysentery", "Mnemonic" : "90"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "DisplayText" : "Large uniform rods in an aerobic bottle", "Text" : "Bacilli, large uniform, aerobic bottle", "Mnemonic" : "92"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "DisplayText" : "Large uniform rods in an anaerobic bottle", "Text" : "Bacilli, large uniform, anaerobic bottle", "Mnemonic" : "94"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "DisplayText" : "Small pleomorphic rods in aerobic bottle", "Text" : "Bacilli, small pleomorphic, aerobic bottle", "Mnemonic" : "96"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "DisplayText" : "Small pleomorphic rods in an anaerobic bottle", "Text" : "Bacilli, small pleomorphic, anaerobic bottle", "Mnemonic" : "98"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "DisplayText" : "Bacillus species", "Text" : "Bacillus infections, general", "Mnemonic" : "100"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "DisplayText" : "Bacteremia", "Text" : "Bacteremia", "Mnemonic" : "102"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram-negative Bacteria", "Text" : "Bacteria, Gram-Negative section", "Mnemonic" : "104"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "DisplayText" : "Gram-positive bacteria", "Text" : "Bacteria, Gram-Positive section", "Mnemonic" : "106"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Bacteriuria", "Mnemonic" : "108"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (including Prevotella, Porphyromonas)", "Text" : "Bacteroides infections, general", "Mnemonic" : "110"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera)", "Text" : "Bed bugs", "Mnemonic" : "112"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "DisplayText" : "Bell's Palsy", "Text" : "Bell's palsy", "Mnemonic" : "114"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds", "Text" : "Bite wounds", "Mnemonic" : "116"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "DisplayText" : "Blastomyces dermatidis", "Text" : "Blastomycosis infections, general", "Mnemonic" : "118"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis)", "Text" : "Body lice", "Mnemonic" : "120"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "DisplayText" : "Soft tissue, muscle, bone and joint infections", "Text" : "Bone and Joint section", "Mnemonic" : "122"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Bone marrow transplant immunizations", "Mnemonic" : "124"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses", "Text" : "Bone prosthesis infection", "Mnemonic" : "126"},
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.", "DisplayText" : "Bordetella species", "Text" : "Bordetella infections, general", "Mnemonic" : "128"},
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "DisplayText" : "Brain abscess resulting from contiguous or hematogenous spread of infection", "Text" : "Brain abscess from contiguous or hematogenous spread", "Mnemonic" : "130"},
{"Row" : 77, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "DisplayText" : "Brain Abscess with Nocardia spp.", "Text" : "Brain abscess with Nocardia spp.", "Mnemonic" : "132"},
{"Row" : 78, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "DisplayText" : "Brain Abscess with Pseudomonas spp.", "Text" : "Brain abscess with Pseudomonas spp.", "Mnemonic" : "134"},
{"Row" : 79, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "DisplayText" : "Brain Abscess with Toxoplasma gondii", "Text" : "Brain abscess with Toxoplasma gondii", "Mnemonic" : "136"},
{"Row" : 80, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "DisplayText" : "Post-surgical or post-traumatic brain abscess", "Text" : "Brain abscess, post-surgical or post-traumatic", "Mnemonic" : "138"},
{"Row" : 81, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "Bronchitis", "Mnemonic" : "140"},
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis in otherwise healthy patient", "Mnemonic" : "142"},
{"Row" : 83, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella infections, general", "Mnemonic" : "144"},
{"Row" : 84, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella spp.", "Mnemonic" : "146"},
{"Row" : 85, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis", "Text" : "Bursitis, septic", "Mnemonic" : "148"},
{"Row" : 88, "Column" : 1, "Item" : "ORZID2 GMENU ABX CAMPYLOBACTER", "DisplayText" : "Diarrhea with Campylobacter", "Text" : "Campylobacter diarrhea/gastroenteritis", "Mnemonic" : "150"},
{"Row" : 89, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.", "DisplayText" : "Campylobacter spp.", "Text" : "Campylobacter, general", "Mnemonic" : "152"},
{"Row" : 90, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy", "Text" : "Cancer [CLICK HERE], includes: ", "Mnemonic" : "154"},
{"Row" : 92, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Candida albicans infections, general", "Mnemonic" : "156"},
{"Row" : 93, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA", "DisplayText" : "Candida glabrata", "Text" : "Candida glabrata infections, general", "Mnemonic" : "158"},
{"Row" : 94, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP", "DisplayText" : "Intravascular catheter-associated Candida Spp. infection", "Text" : "Candida intravascular catheter-associated infection", "Mnemonic" : "160"},
{"Row" : 95, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI", "DisplayText" : "Candida krusei", "Text" : "Candida krusei infections, general", "Mnemonic" : "162"},
{"Row" : 96, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "Candida retinitis", "Mnemonic" : "164"},
{"Row" : 97, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Candida urinary tract infection", "Mnemonic" : "166"},
{"Row" : 98, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida Vulvo-Vaginitis", "Text" : "Candida vulvo-vaginitis", "Mnemonic" : "168"},
{"Row" : 99, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "Candidemia", "Mnemonic" : "170"},
{"Row" :100, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS", "DisplayText" : "Cutaneous Candidiasis", "Text" : "Candidiasis", "Mnemonic" : "172"},
{"Row" :101, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Candiduria", "Mnemonic" : "174"},
{"Row" :102, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and carbuncles", "Text" : "Carbuncles", "Mnemonic" : "176"},
{"Row" :103, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease", "Text" : "Cardiac disease associated with Lyme disease", "Mnemonic" : "178"},
{"Row" :104, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Cardiobacterium native valve endocarditis", "Mnemonic" : "180"},
{"Row" :105, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Cardiobacterium prosthetic valve endocarditis", "Mnemonic" : "182"},
{"Row" :106, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "DisplayText" : "Infections involves cardiovascular devices (excluding valves)", "Text" : "Cardiovascular device infections (excluding valves)", "Mnemonic" : "184"},
{"Row" :108, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Catheter-associated infection, intravascular", "Mnemonic" : "186"},
{"Row" :109, "Column" : 1, "Item" : "ORZID2 GMENU CAT-SCATCH DISEASE", "DisplayText" : "Cat-Scratch Disease", "Text" : "Cat-scratch disease", "Mnemonic" : "188"},
{"Row" :110, "Column" : 1, "Item" : "ORZID2 GMENU CMI DEFECTS", "DisplayText" : "Cell-mediated immunity (CMI) defects", "Text" : "Cell-mediated immunity (CMI) defects", "Mnemonic" : "190"},
{"Row" :111, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "DisplayText" : "Cellulitis", "Text" : "Cellulitis", "Mnemonic" : "192"},
{"Row" :112, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)", "Text" : "Cellulitis, herpes whitlow", "Mnemonic" : "194"},
{"Row" :113, "Column" : 1, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal Cellulitis", "Text" : "Cellulitis, postseptal (orbital)", "Mnemonic" : "196"},
{"Row" :114, "Column" : 1, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal Cellulitis", "Text" : "Cellulitis, preseptal", "Mnemonic" : "198"},
{"Row" :115, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "DisplayText" : "Central Nervous System", "Text" : "Central Nervous System section", "Mnemonic" : "200"},
{"Row" :116, "Column" : 1, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Cervicitis associated with sexually transmitted diseases", "Mnemonic" : "202"},
{"Row" :117, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Chickenpox vaccination", "Mnemonic" : "204"},
{"Row" :118, "Column" : 1, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox)", "Text" : "Chickenpox, primary infection", "Mnemonic" : "206"},
{"Row" :119, "Column" : 1, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")", "Text" : "Chickenpox, reactivation of primary infection", "Mnemonic" : "208"},
{"Row" :120, "Column" : 1, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Chlamydia urethritis", "Mnemonic" : "210"},
{"Row" :121, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLANGITIS", "DisplayText" : "Cholangitis", "Text" : "Cholangitis", "Mnemonic" : "212"},
{"Row" :122, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLECYSTITIS", "DisplayText" : "Cholecystitis", "Text" : "Cholecystitis", "Mnemonic" : "214"},
{"Row" :123, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.", "DisplayText" : "Citrobacter spp.", "Text" : "Citrobacter infections, general", "Mnemonic" : "216"},
{"Row" :124, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Clostridium difficile suspected, sepsis", "Mnemonic" : "218"},
{"Row" :125, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile, mild to moderate disease", "Mnemonic" : "220"},
{"Row" :126, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "Clostridium difficile, severe/life-threatening disease", "Mnemonic" : "222"},
{"Row" :127, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.", "DisplayText" : "Clostridium spp.", "Text" : "Clostridium infections, general", "Mnemonic" : "224"},
{"Row" :128, "Column" : 1, "Item" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH", "DisplayText" : "Blood culture positive for coagulase negative staphylococci", "Text" : "Coagulase negative staphylococci, single blood culture positive", "Mnemonic" : "226"},
{"Row" :129, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "DisplayText" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Text" : "Coagulase-negative Staphylococci (CNS) bacteremia", "Mnemonic" : "228"},
{"Row" :130, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "DisplayText" : "Treatment for Coagulase negative Staphylococci", "Text" : "Coagulase-negative staphylococci, general", "Mnemonic" : "230"},
{"Row" :131, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "DisplayText" : "Intravascular catheter-associated coagulase-negative staphylococcus infection", "Text" : "Coagulase-negative staphylococci, intravascular catheter-associated infectio", "Mnemonic" : "232"},
{"Row" :132, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES", "DisplayText" : "Coccidioidomyces", "Text" : "Coccidioides infections, general", "Mnemonic" : "234"},
{"Row" :133, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "DisplayText" : "CMV Colitis or Esophagistis", "Text" : "Colitis, cytomegalovirus (CMV)", "Mnemonic" : "236"},
{"Row" :134, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR", "DisplayText" : "Colonized respiratory tract in patient with a ventilator", "Text" : "Colonized respiratory tract patient on a ventilator", "Mnemonic" : "238"},
{"Row" :135, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "DisplayText" : "Colonized wounds", "Text" : "Colonized wound", "Mnemonic" : "240"},
{"Row" :136, "Column" : 1, "Item" : "ORZID2 GMENU COMM ACQ DIARRHEA", "DisplayText" : "Community acquired diarrhea", "Text" : "Community-acquired diarrhea", "Mnemonic" : "242"},
{"Row" :137, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "244"},
{"Row" :138, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community-acquired pneumonia (CAP), inpatient treatment setting", "Mnemonic" : "246"},
{"Row" :139, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY", "DisplayText" : "Complement deficiency", "Text" : "Complement deficiency", "Mnemonic" : "248"},
{"Row" :140, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "DisplayText" : "Complicated Cystitis", "Text" : "Complicated cystitis", "Mnemonic" : "250"},
{"Row" :141, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT REQUIRED MAIN", "DisplayText" : "Antibiotics not required", "Text" : "Conditions not benefitted by antimicrobials", "Mnemonic" : "252"},
{"Row" :142, "Column" : 1, "Item" : "ORZID2 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis", "Text" : "Conjunctivitis", "Mnemonic" : "254"},
{"Row" :143, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Mnemonic" : "256"},
{"Row" :144, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "DisplayText" : "Brain abscess resulting from contiguous or hematogenous spread of infection", "Text" : "Contiguous or hematogenous spread brain abscess", "Mnemonic" : "258"},
{"Row" :145, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "COPD exacerbation", "Mnemonic" : "260"},
{"Row" :146, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "DisplayText" : "Azithromycin for Prevention of Exacerbations COPD", "Text" : "COPD, prevention of exacerbations", "Mnemonic" : "262"},
{"Row" :147, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.", "DisplayText" : "Corynebacterium spp.", "Text" : "Corynebacterium spp.", "Mnemonic" : "264"},
{"Row" :148, "Column" : 1, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)", "Text" : "Crabs", "Mnemonic" : "266"},
{"Row" :149, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "DisplayText" : "Cranial epidural abscess", "Text" : "Cranial epidural abscess", "Mnemonic" : "268"},
{"Row" :150, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "DisplayText" : "Cryptococcus Neoformans", "Text" : "Cryptococcus neoformans", "Mnemonic" : "270"},
{"Row" :151, "Column" : 1, "Item" : "ORZID2 GMENU ABX CRYPTOSPORIDIA", "DisplayText" : "Diarrhea with Cryptosporidium parvum", "Text" : "Cryptosporidium parvum diarrhea/gastroenteritis", "Mnemonic" : "272"},
{"Row" :152, "Column" : 1, "Item" : "ORZID2 GMENU ABX CYCLOSPORA", "DisplayText" : "Cyclospora cayetanensis", "Text" : "Cyclospora cayetanensis diarrhea/gastroenteritis", "Mnemonic" : "274"},
{"Row" :153, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "DisplayText" : "Complicated Cystitis", "Text" : "Cystitis, complicated", "Mnemonic" : "276"},
{"Row" :154, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "DisplayText" : "Uncomplicated Cystitis", "Text" : "Cystitis, uncomplicated", "Mnemonic" : "278"},
{"Row" :155, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV MAIN PAGE", "DisplayText" : "Cytomegalovirus (CMV) Main Page", "Text" : "Cytomegalovirus (CMV) [CLICK HERE], includes: ", "Mnemonic" : "280"},
{"Row" :160, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Decolonization of Staphylococcus aureus", "Mnemonic" : "282"},
{"Row" :161, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "DisplayText" : "Decubitus ulcers", "Text" : "Decubitus ulcers", "Mnemonic" : "284"},
{"Row" :162, "Column" : 1, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "DisplayText" : "Deep Oropharyngeal Infections", "Text" : "Deep oropharyngeal infections", "Mnemonic" : "286"},
{"Row" :163, "Column" : 1, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections", "Text" : "Dental infections", "Mnemonic" : "288"},
{"Row" :164, "Column" : 1, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "DisplayText" : "Stasis dermatitis", "Text" : "Dermatitis, stasis", "Mnemonic" : "290"},
{"Row" :165, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatological surgery guidelines", "Mnemonic" : "292"},
{"Row" :166, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "DisplayText" : "Dermatological Infections", "Text" : "Dermatological Infections section", "Mnemonic" : "294"},
{"Row" :167, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatology post-op infection", "Mnemonic" : "296"},
{"Row" :168, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Desensitization protocol, penicillin", "Mnemonic" : "298"},
{"Row" :169, "Column" : 1, "Item" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS", "DisplayText" : "Device-related infections", "Text" : "Device-related infections", "Mnemonic" : "300"},
{"Row" :170, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "DisplayText" : "Diabetes Mellitus", "Text" : "Diabetes Mellitus", "Mnemonic" : "302"},
{"Row" :171, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Diabetic foot ulcer", "Mnemonic" : "304"},
{"Row" :172, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "Diarrhea, infectious/gastroenteritis", "Mnemonic" : "306"},
{"Row" :173, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Diphtheria vaccination", "Mnemonic" : "308"},
{"Row" :174, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "DisplayText" : "Exclusions", "Text" : "Diseases and Syndromes not covered", "Mnemonic" : "310"},
{"Row" :175, "Column" : 1, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "DisplayText" : "Diskitis and Vertebral Osteomyelitis", "Text" : "Diskitis and vertebral osteomyelitis", "Mnemonic" : "312"},
{"Row" :176, "Column" : 1, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "DisplayText" : "Disseminated Mycobacterium avium disease treatment", "Text" : "Disseminated Mycobacterium avium", "Mnemonic" : "314"},
{"Row" :177, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIVERTICULITIS", "DisplayText" : "Diverticulitis", "Text" : "Diverticulitis", "Mnemonic" : "316"},
{"Row" :178, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Drug allergy information", "Mnemonic" : "318"},
{"Row" :179, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Drug Information", "Mnemonic" : "320"},
{"Row" :180, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Drug properties, important", "Mnemonic" : "322"},
{"Row" :1, "Column" : 1, "Text" : "INPATIENT ANTIMICROIBAL CDSS INDEX", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "A through F", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "A______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "antimicrobial prophylaxis, management of fever,"}, 
{"Row" : 47, "Column" : 1, "Text" : "patient initiated antibiotics, vaccines"}, 
{"Row" : 53, "Column" : 1, "Text" : "B______________________________________________________________________________", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "C______________________________________________________________________________", "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Text" : "antimicrobial prophylaxis, neutropenic fever"}, 
{"Row" :156, "Column" : 1, "Text" : "colitis, esophagitis, encephalitis, polyradiculopathy"}, 
{"Row" :157, "Column" : 1, "Text" : "retinitis, and pneumonia"}, 
{"Row" :159, "Column" : 1, "Text" : "D______________________________________________________________________________", "Header" : 1}, 
{"Row" :183, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "DisplayText" : "Head and Neck", "Text" : "Ear, nose, throat (ENT)/Head and Neck section", "Mnemonic" : "324"},
{"Row" :184, "Column" : 1, "Item" : "ORZID2 GMENU ECTHYMA GANGRENOSUM", "DisplayText" : "Ecthyma Gangrenosum", "Text" : "Ecthyma gangrenosum", "Mnemonic" : "326"},
{"Row" :185, "Column" : 1, "Item" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Mnemonic" : "328"},
{"Row" :186, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite wounds with Eikenella corrodens", "Text" : "Eikenella corrodens, bite wound", "Mnemonic" : "330"},
{"Row" :187, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Eikenella native valve endocarditis", "Mnemonic" : "332"},
{"Row" :188, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Eikenella prosthetic valve endocarditis", "Mnemonic" : "334"},
{"Row" :189, "Column" : 1, "Item" : "ORZID2 GMENU ABX EMPYEMA", "DisplayText" : "Empyema", "Text" : "Empyema", "Mnemonic" : "336"},
{"Row" :190, "Column" : 1, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "DisplayText" : "Subdural Empyema", "Text" : "Empyema, subdural", "Mnemonic" : "338"},
{"Row" :191, "Column" : 1, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "DisplayText" : "HSV Encephalitis", "Text" : "Encephalitis", "Mnemonic" : "340"},
{"Row" :192, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV ENCEPHALITIS", "DisplayText" : "CMV Encephalitis", "Text" : "Encephalitis, Cytomegalovirus (CMV)", "Mnemonic" : "342"},
{"Row" :193, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Endocarditis with sepsis", "Mnemonic" : "344"},
{"Row" :194, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS", "DisplayText" : "Approach to Endocarditis", "Text" : "Endocarditis, approach to", "Mnemonic" : "346"},
{"Row" :195, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS", "DisplayText" : "Diagnosis of Endocarditis", "Text" : "Endocarditis, diagnosis of", "Mnemonic" : "348"},
{"Row" :196, "Column" : 1, "Item" : "ORZID2 GMENU EC NV SEL PATH", "DisplayText" : "Native Valve Endocarditis--Selected Pathogens", "Text" : "Endocarditis, native valve [CLICK HERE], includes: ", "Mnemonic" : "350"},
{"Row" :200, "Column" : 1, "Item" : "ORZID2 GMENU EC NV EMP THERA", "DisplayText" : "Native Valve Endocarditis - Empirical Therapy", "Text" : "Endocarditis, native valve empirical therapy", "Mnemonic" : "352"},
{"Row" :201, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "DisplayText" : "Prosthetic Valve Endocarditis--Selected Pathogens", "Text" : "Endocarditis, prosthetic valve [CLICK HERE], includes: ", "Mnemonic" : "354"},
{"Row" :205, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "DisplayText" : "Prosthetic Valve Endocarditis--Empicaral Therapy", "Text" : "Endocarditis, prosthetic valve empirical therapy", "Mnemonic" : "356"},
{"Row" :206, "Column" : 1, "Item" : "ORZID2 GMENU ENDOOPTHALMITIS", "DisplayText" : "Endophthalmitis", "Text" : "Endophthalmitis", "Mnemonic" : "358"},
{"Row" :207, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA", "DisplayText" : "Entoemeba histolytica", "Text" : "Entamoeba histolytica diarrhea/gastroenteritis", "Mnemonic" : "360"},
{"Row" :208, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Enteric fever", "Mnemonic" : "362"},
{"Row" :209, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.", "DisplayText" : "Enterobacter spp.", "Text" : "Enterobacter species, general", "Mnemonic" : "364"},
{"Row" :210, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT", "DisplayText" : "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae", "Text" : "Enterobacteriaceae (ESBL+) nosocomial pneumonia", "Mnemonic" : "366"},
{"Row" :211, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI", "DisplayText" : "Enterococci", "Text" : "Enterococcal infections, general", "Mnemonic" : "368"},
{"Row" :212, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS", "DisplayText" : "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION", "Text" : "Enterococcal intravascular catheter-associated infection", "Mnemonic" : "370"},
{"Row" :213, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI", "DisplayText" : "Septic arthritis (Native joint) with Enterococci", "Text" : "Enterococcal native joint infection", "Mnemonic" : "372"},
{"Row" :214, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci", "Text" : "Enterococcal native valve endocarditis", "Mnemonic" : "374"},
{"Row" :215, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses", "Text" : "Enterococcal prosthetic bone/joint infection", "Mnemonic" : "376"},
{"Row" :216, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci", "Text" : "Enterococcal prosthetic valve endocarditis", "Mnemonic" : "378"},
{"Row" :217, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Enterococcal pyelonephritis", "Mnemonic" : "380"},
{"Row" :218, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "DisplayText" : "Epididymitis", "Text" : "Epididymitis", "Mnemonic" : "382"},
{"Row" :219, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "DisplayText" : "Cranial epidural abscess", "Text" : "Epidural abscess, cranial", "Mnemonic" : "384"},
{"Row" :220, "Column" : 1, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "DisplayText" : "Spinal epidural abscess", "Text" : "Epidural abscess, spinal", "Mnemonic" : "386"},
{"Row" :221, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIGLOTTITIS", "DisplayText" : "Epiglottitis", "Text" : "Epiglottitis", "Mnemonic" : "388"},
{"Row" :222, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas", "Text" : "Erysipelas", "Mnemonic" : "390"},
{"Row" :223, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELOID", "DisplayText" : "Erysipeloid", "Text" : "Erysipeloid", "Mnemonic" : "392"},
{"Row" :224, "Column" : 1, "Item" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease", "Text" : "Erythema migrans, Lyme disease", "Mnemonic" : "394"},
{"Row" :225, "Column" : 1, "Item" : "ORZID2 GMENU ERYTHRASMA", "DisplayText" : "Erythrasma", "Text" : "Erythrasma", "Mnemonic" : "396"},
{"Row" :226, "Column" : 1, "Item" : "ORZID2 GMENU ABX E COLI INFECT", "DisplayText" : "Diarrhea with Enterohemorrhagic E. coli", "Text" : "Escherichia coli diarrhea/gastroenteritis", "Mnemonic" : "398"},
{"Row" :227, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI", "DisplayText" : "Escherichia coli", "Text" : "Escherichia coli infections, general", "Mnemonic" : "400"},
{"Row" :228, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Escherichia coli meningitis", "Mnemonic" : "402"},
{"Row" :229, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Mnemonic" : "404"},
{"Row" :230, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "Exacerbation of COPD", "Mnemonic" : "406"},
{"Row" :231, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "DisplayText" : "Azithromycin for Prevention of Exacerbations COPD", "Text" : "Exacerbations of COPD, prevention of", "Mnemonic" : "408"},
{"Row" :234, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "Flu", "Mnemonic" : "410"},
{"Row" :235, "Column" : 1, "Item" : "ORZID2 GMENU FOLLICULITIS", "DisplayText" : "Folliculitis", "Text" : "Folliculitis", "Mnemonic" : "412"},
{"Row" :236, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Foot ulcer in patient with diabetes", "Mnemonic" : "414"},
{"Row" :237, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "DisplayText" : "Endocarditis with Fungi", "Text" : "Fungal native valve endocarditis", "Mnemonic" : "416"},
{"Row" :238, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "DisplayText" : "Endocarditis with Fungi", "Text" : "Fungal prosthetic valve endocarditis", "Mnemonic" : "418"},
{"Row" :239, "Column" : 1, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Fungal sinusitis", "Mnemonic" : "420"},
{"Row" :240, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "Fungemia associated with Candida spp.", "Mnemonic" : "422"},
{"Row" :241, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "DisplayText" : "Fungi", "Text" : "Fungi section", "Mnemonic" : "424"},
{"Row" :242, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and carbuncles", "Text" : "Furuncles", "Mnemonic" : "426"},
{"Row" :182, "Column" : 1, "Text" : "E______________________________________________________________________________", "Header" : 1}, 
{"Row" :197, "Column" : 1, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :198, "Column" : 1, "Text" : "gram-negative bacilli, streptococci, staphylococci,"}, 
{"Row" :199, "Column" : 1, "Text" : "and HACEK bacteria"}, 
{"Row" :202, "Column" : 1, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :203, "Column" : 1, "Text" : "gram-negative bacilli, Streptococcus bovis,"}, 
{"Row" :204, "Column" : 1, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci"}, 
{"Row" :233, "Column" : 1, "Text" : "F______________________________________________________________________________", "Header" : 1}, 
{"Row" :1, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Mnemonic" : "420"},
{"Row" :2, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help", "Mnemonic" : "422"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "Gastroenteritis/infectious diarrhea", "Mnemonic" : "424"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX GASTROINTESTINAL", "DisplayText" : "Gastrointestinal and Intraabdominal", "Text" : "Gastrointestinal and Intraabdominal section", "Mnemonic" : "426"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "DisplayText" : "Genital herpes", "Text" : "Genital herpes", "Mnemonic" : "428"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITOURINARY", "DisplayText" : "Genitourinary", "Text" : "Genitourinary section", "Mnemonic" : "430"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX GIARDIA", "DisplayText" : "Diarrhea with Giardia lamblia", "Text" : "Giardia lamblia diarrhea", "Mnemonic" : "432"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX GIARDIA", "DisplayText" : "Diarrhea with Giardia lamblia", "Text" : "Giardia lamblia infections, general", "Mnemonic" : "434"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Gonococcal urethritis", "Mnemonic" : "436"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GNB", "DisplayText" : "Interim report of Gram-negative bacilli", "Text" : "Gram-negative bacilli bacteremia", "Mnemonic" : "438"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU GN INT RS GNB", "DisplayText" : "Interim results:Gram-negative Bacilli", "Text" : "Gram-negative bacilli interim culture results", "Mnemonic" : "440"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVAS CATH GNB", "DisplayText" : "Intravascular catheter-associated Gram-negative Bacilli infection", "Text" : "Gram-negative bacilli intravascular catheter-associated infection", "Mnemonic" : "442"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GNB", "DisplayText" : "Bacterial meningitis with Gram negative bacilli", "Text" : "Gram-negative bacilli meningitis", "Mnemonic" : "444"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU EC GNB", "DisplayText" : "Endocarditis with Gram Negative Bacilli", "Text" : "Gram-negative bacilli, non-HACEK, native valve endocarditis", "Mnemonic" : "446"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU EC GNB", "DisplayText" : "Endocarditis with Gram Negative Bacilli", "Text" : "Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis", "Mnemonic" : "448"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOM WITH GNB", "DisplayText" : "Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas)", "Text" : "Gram-negative bacilli, non-pseudomonas, osteomyelitis", "Mnemonic" : "450"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU PROS B/J GNB", "DisplayText" : "Gram Negative Bacilli infections in bone or joint prostheses", "Text" : "Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection", "Mnemonic" : "452"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTH GNB", "DisplayText" : "Septic arthritis (Native joint) with Gram negative bacilli", "Text" : "Gram-negative bacilli, non-pseudomonas, native joint infection", "Mnemonic" : "454"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram-negative Bacteria", "Text" : "Gram-Negative Bacteria section", "Mnemonic" : "456"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GNC", "DisplayText" : "Interim report of Gram-negative cocci", "Text" : "Gram-negative cocci bacteremia", "Mnemonic" : "458"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GN INT RS GNC", "DisplayText" : "Interim results:Gram-negative cocci", "Text" : "Gram-negative cocci interim culture results", "Mnemonic" : "460"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "DisplayText" : "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis", "Text" : "Gram-negative diplococci meningitis", "Mnemonic" : "462"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Gram-positive bacilli bacteremia", "Mnemonic" : "464"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes", "Text" : "Gram-positive bacilli meningitis", "Mnemonic" : "466"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Gram-positive bacilli, interim culture results", "Mnemonic" : "468"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "DisplayText" : "Gram-positive bacteria", "Text" : "Gram-positive bacteria, section", "Mnemonic" : "470"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and chains", "Text" : "Gram-positive cocci in pairs and chains bacteremia", "Mnemonic" : "472"},
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and clusters", "Text" : "Gram-positive cocci in pairs and clusters bacteremia", "Mnemonic" : "474"},
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Gram-positive cocci in pairs bacteremia", "Mnemonic" : "476"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Gram-positive cocci in pairs interim culture results", "Mnemonic" : "478"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "DisplayText" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Text" : "Gram-positive cocci, anaerobic", "Mnemonic" : "480"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes", "Text" : "Gram-positive coccobacilli meningitis", "Mnemonic" : "482"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "DisplayText" : "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia", "Text" : "Gram-positive diplococci meningitis", "Mnemonic" : "484"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "DisplayText" : "Group A Streptococci (S. pyogenes)", "Text" : "Group A streptococci", "Mnemonic" : "486"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "DisplayText" : "Group B Streptococci (S. agalactiae)", "Text" : "Group B Streptococci", "Mnemonic" : "488"},
{"Row" : 40, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "DisplayText" : "Group D (S. bovis)", "Text" : "Group D Streptococci", "Mnemonic" : "490"},
{"Row" : 41, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "DisplayText" : "Streptococci Groups C, F, G", "Text" : "Groups C, F, G Streptococci", "Mnemonic" : "492"},
{"Row" : 44, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "HACEK bacteria native valve endocarditis", "Mnemonic" : "494"},
{"Row" : 45, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "HACEK bacteria prosthetic valve endocarditis", "Mnemonic" : "496"},
{"Row" : 46, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.", "DisplayText" : "Haemophilus spp.", "Text" : "Haemophilus infections, general", "Mnemonic" : "498"},
{"Row" : 47, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae B vaccination", "Mnemonic" : "500"},
{"Row" : 48, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Haemophilus native valve endocarditis", "Mnemonic" : "502"},
{"Row" : 49, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Haemophilus prosthetic valve endocarditis", "Mnemonic" : "504"},
{"Row" : 50, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "DisplayText" : "Head and Neck", "Text" : "Head and Neck/ENT section", "Mnemonic" : "506"},
{"Row" : 51, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis)", "Text" : "Head lice", "Mnemonic" : "508"},
{"Row" : 52, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection", "Text" : "Helicobacter pylori", "Mnemonic" : "510"},
{"Row" : 53, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help", "Mnemonic" : "512"},
{"Row" : 54, "Column" : 2, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera)", "Text" : "Hemiptera", "Mnemonic" : "514"},
{"Row" : 55, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Hemodialysis immunizations", "Mnemonic" : "516"},
{"Row" : 56, "Column" : 2, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Hepatic abscess", "Mnemonic" : "518"},
{"Row" : 57, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Hepatic disease immunizations", "Mnemonic" : "520"},
{"Row" : 58, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A", "Text" : "Hepatitis A", "Mnemonic" : "522"},
{"Row" : 59, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A vaccination", "Mnemonic" : "524"},
{"Row" : 60, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A/Hepatitis B vaccination", "Mnemonic" : "526"},
{"Row" : 61, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B", "Text" : "Hepatitis B", "Mnemonic" : "528"},
{"Row" : 62, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B vaccination", "Mnemonic" : "530"},
{"Row" : 63, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C", "Text" : "Hepatitis C", "Mnemonic" : "532"},
{"Row" : 64, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes esophagitis", "Mnemonic" : "534"},
{"Row" : 65, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Herpes keratitis", "Mnemonic" : "536"},
{"Row" : 66, "Column" : 2, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "Herpes retinitis", "Mnemonic" : "538"},
{"Row" : 67, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)", "Text" : "Herpes whitlow (digit or hand cellulitis)", "Mnemonic" : "540"},
{"Row" : 68, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "DisplayText" : "Genital herpes", "Text" : "Herpes, genital", "Mnemonic" : "542"},
{"Row" : 69, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "DisplayText" : "Orolabial Herpes", "Text" : "Herpes, orolabial", "Mnemonic" : "544"},
{"Row" : 70, "Column" : 2, "Item" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "DisplayText" : "Hidradenitis Suppurativa", "Text" : "Hidradenitis suppurativa", "Mnemonic" : "546"},
{"Row" : 71, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM", "DisplayText" : "Histoplasma capsulatum", "Text" : "Histoplasma capsulatum", "Mnemonic" : "548"},
{"Row" : 72, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "HIV patient immunization", "Mnemonic" : "550"},
{"Row" : 73, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "HIV infection, general", "Mnemonic" : "552"},
{"Row" : 74, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "DisplayText" : "Home IV at the Minneapolis VAMC", "Text" : "Home IV therapy at MVAMC", "Mnemonic" : "554"},
{"Row" : 75, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Hospital-acquired pneumonia (HAP)", "Mnemonic" : "556"},
{"Row" : 76, "Column" : 2, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "HSCT immunizations", "Mnemonic" : "558"},
{"Row" : 77, "Column" : 2, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papilloma virus vaccination", "Mnemonic" : "560"},
{"Row" : 78, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "DisplayText" : "Hypochlorhydria", "Text" : "Hypochlorhydria", "Mnemonic" : "562"},
{"Row" : 81, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "DisplayText" : "Immunization of Immunocompromised Patients", "Text" : "Immunization of immunocompromised patients (except HIV)", "Mnemonic" : "564"},
{"Row" : 82, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Immunization of patients at high-risk of rabies exposure", "Mnemonic" : "566"},
{"Row" : 83, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Immunization of patients in kidney failure/HD", "Mnemonic" : "568"},
{"Row" : 84, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Immunization of patients with asplenia", "Mnemonic" : "570"},
{"Row" : 85, "Column" : 2, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Immunization of patients with bone marrow transplant", "Mnemonic" : "572"},
{"Row" : 86, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Immunization of patients with chronic liver disease", "Mnemonic" : "574"},
{"Row" : 87, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "Immunization of patients with HIV", "Mnemonic" : "576"},
{"Row" : 88, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Immunization of patients with pregnancy", "Mnemonic" : "578"},
{"Row" : 89, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "DisplayText" : "CDC Recommended Adult Immunizations", "Text" : "Immunization, adult [CLICK HERE], includes: ", "Mnemonic" : "580"},
{"Row" : 94, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "DisplayText" : "Basic concepts", "Text" : "Immunocompromised patients basic concepts", "Mnemonic" : "582"},
{"Row" : 95, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT", "DisplayText" : "Infections in Immunocompromised Patients", "Text" : "Immunocompromised Patients section", "Mnemonic" : "584"},
{"Row" : 96, "Column" : 2, "Item" : "ORZID2 GMENU IG HIS DEFICIENCY", "DisplayText" : "Immunoglobulin (Humoral immune system) deficiency", "Text" : "Immunoglobulin (Humoral immune system) deficiency", "Mnemonic" : "586"},
{"Row" : 97, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPETIGO", "DisplayText" : "Impetigo", "Text" : "Impetigo", "Mnemonic" : "588"},
{"Row" : 98, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important drug properties", "Mnemonic" : "590"},
{"Row" : 99, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "DisplayText" : "Infection Control", "Text" : "Infection control department information", "Mnemonic" : "592"},
{"Row" :100, "Column" : 2, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "DisplayText" : "Prevention of Infection", "Text" : "Infection Prevention section", "Mnemonic" : "594"},
{"Row" :101, "Column" : 2, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "Infectious diarrhea/gastroenteritis", "Mnemonic" : "596"},
{"Row" :102, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "Influenza", "Mnemonic" : "598"},
{"Row" :103, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Intravascular catheter-associated infection", "Mnemonic" : "600"},
{"Row" :104, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "DisplayText" : "Home IV at the Minneapolis VAMC", "Text" : "Intravenous therapy at home, MVAMC", "Mnemonic" : "602"},
{"Row" :105, "Column" : 2, "Item" : "ORZID2 GMENU ABX ISOSPORA", "DisplayText" : "Diarrhea with Isospora belli", "Text" : "Isospora diarrhea/gastroenteritis", "Mnemonic" : "604"},
{"Row" :108, "Column" : 2, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "DisplayText" : "Soft tissue, muscle, bone and joint infections", "Text" : "Joint and Bone section", "Mnemonic" : "606"},
{"Row" :109, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native joint)", "Text" : "Joint infection, native [CLICK HERE], includes: ", "Mnemonic" : "608"},
{"Row" :113, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Joint infection, prosthetic [CLICK HERE], includes: ", "Mnemonic" : "610"},
{"Row" :119, "Column" : 2, "Item" : "ORZID2 GMENU KERATITIS", "DisplayText" : "Keratitis", "Text" : "Keratitis", "Mnemonic" : "612"},
{"Row" :120, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Kidney failure immunizations", "Mnemonic" : "614"},
{"Row" :121, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Kingella native valve endocarditis", "Mnemonic" : "616"},
{"Row" :122, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "Kingella prosthetic valve endocarditis", "Mnemonic" : "618"},
{"Row" :123, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.", "DisplayText" : "Klebsiella spp.", "Text" : "Klebsiella infections, general", "Mnemonic" : "620"},
{"Row" :126, "Column" : 2, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "DisplayText" : "Large uniform rods in an aerobic bottle", "Text" : "Large uniform bacilli, aerobic bottle", "Mnemonic" : "622"},
{"Row" :127, "Column" : 2, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "DisplayText" : "Large uniform rods in an anaerobic bottle", "Text" : "Large uniform bacilli, anaerobic bottle", "Mnemonic" : "624"},
{"Row" :128, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "DisplayText" : "Laryngitis and Croup", "Text" : "Laryngitis", "Mnemonic" : "626"},
{"Row" :129, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.", "DisplayText" : "Legionella spp.", "Text" : "Legionella infections, general", "Mnemonic" : "628"},
{"Row" :130, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA", "DisplayText" : "Nosocomial pneumonia with Legionella pneumophila", "Text" : "Legionella pneumophila nosocomial pneumonia", "Mnemonic" : "630"},
{"Row" :131, "Column" : 2, "Item" : "ORZID2 GMENU LEISHMANIASIS", "DisplayText" : "Leishmaniasis", "Text" : "Leishmaniasis", "Mnemonic" : "632"},
{"Row" :132, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "DisplayText" : "Leukocytosis", "Text" : "Leukocytosis", "Mnemonic" : "634"},
{"Row" :133, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis)", "Text" : "Lice, body", "Mnemonic" : "636"},
{"Row" :134, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis)", "Text" : "Lice, head", "Mnemonic" : "638"},
{"Row" :135, "Column" : 2, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)", "Text" : "Lice, pubic", "Mnemonic" : "640"},
{"Row" :136, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.", "DisplayText" : "Listeria spp.", "Text" : "Listeria infections, general", "Mnemonic" : "642"},
{"Row" :137, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "DisplayText" : "Bacteremia associated with Listeria monocytogenes", "Text" : "Listeria monocytogenes bacteremia", "Mnemonic" : "644"},
{"Row" :138, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "DisplayText" : "Bacterial meningitis with L. monocytogenes", "Text" : "Listeria monocytogenes meningitis", "Mnemonic" : "646"},
{"Row" :139, "Column" : 2, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Liver abscess", "Mnemonic" : "648"},
{"Row" :140, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Liver disease immunizations", "Mnemonic" : "650"},
{"Row" :141, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Liver disease, prevention of spontaneous bacterial peritonitis", "Mnemonic" : "652"},
{"Row" :142, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "DisplayText" : "Lung abscess", "Text" : "Lung abscess", "Mnemonic" : "654"},
{"Row" :143, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "DisplayText" : "Lung and Mediastinum", "Text" : "Lungs and Mediastinum section", "Mnemonic" : "656"},
{"Row" :144, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease [CLICK HERE], includes: ", "Mnemonic" : "658"},
{"Row" :149, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy", "Text" : "Malignancy [CLICK HERE], includes: ", "Mnemonic" : "660"},
{"Row" :151, "Column" : 2, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "DisplayText" : "Malignant Otitis Externa", "Text" : "Malignant otitis externa", "Mnemonic" : "662"},
{"Row" :152, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "DisplayText" : "Malnutrition", "Text" : "Malnutrition", "Mnemonic" : "664"},
{"Row" :153, "Column" : 2, "Item" : "ORZID2 GMENU MASTOIDITIS", "DisplayText" : "Mastoiditis", "Text" : "Mastoiditis", "Mnemonic" : "666"},
{"Row" :154, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles vaccination", "Mnemonic" : "668"},
{"Row" :155, "Column" : 2, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "DisplayText" : "Mediastinitis", "Text" : "Mediastinitis", "Mnemonic" : "670"},
{"Row" :156, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "DisplayText" : "Lung and Mediastinum", "Text" : "Mediastinum and Lung section", "Mnemonic" : "672"},
{"Row" :157, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "DisplayText" : "Bacterial meningitis associated with trauma or nosocomial infection", "Text" : "Meningitis associated with trauma or nosocomial infection", "Mnemonic" : "674"},
{"Row" :158, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Meningitis with E. coli, Pseudomonas or other organism", "Mnemonic" : "676"},
{"Row" :159, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Meningitis with Escherichia coli", "Mnemonic" : "678"},
{"Row" :160, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GNB", "DisplayText" : "Bacterial meningitis with Gram negative bacilli", "Text" : "Meningitis with gram-negative bacilli", "Mnemonic" : "680"},
{"Row" :161, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "DisplayText" : "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis", "Text" : "Meningitis with gram-negative diplococci", "Mnemonic" : "682"},
{"Row" :162, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes", "Text" : "Meningitis with gram-positive bacilli/coccobacilli", "Mnemonic" : "684"},
{"Row" :163, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "DisplayText" : "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia", "Text" : "Meningitis with gram-positive diplococci", "Mnemonic" : "686"},
{"Row" :164, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "DisplayText" : "Bacterial meningitis with L. monocytogenes", "Text" : "Meningitis with Listeria monocytogenes", "Mnemonic" : "688"},
{"Row" :165, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "DisplayText" : "Bacterial meningitis with N. meningitidis", "Text" : "Meningitis with Neisseria meningitidis", "Mnemonic" : "690"},
{"Row" :166, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Meningitis with pseudomonas", "Mnemonic" : "692"},
{"Row" :167, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Meningitis with sepsis", "Mnemonic" : "694"},
{"Row" :168, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "DisplayText" : "Bacterial meningitis with S. pneumoniae", "Text" : "Meningitis with Streptococcus pneumoniae", "Mnemonic" : "696"},
{"Row" :169, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "DisplayText" : "Bacterial meningitis without Gram stain results", "Text" : "Meningitis without gram stain results", "Mnemonic" : "698"},
{"Row" :170, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Meningitis, other organism", "Mnemonic" : "700"},
{"Row" :171, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal conjugate (MENACWY) vaccination", "Mnemonic" : "702"},
{"Row" :172, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MENB) vaccination", "Mnemonic" : "704"},
{"Row" :173, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "DisplayText" : "Bite wounds with Staphylococcus aureus", "Text" : "Methicillin-resistant Staphylococcus aureus bite wounds", "Mnemonic" : "706"},
{"Row" :174, "Column" : 2, "Item" : "ORZID2 GMENU ABX MICROSPORIDIA", "DisplayText" : "Microsporidia", "Text" : "Microsporidia diarrhea/gastroenteritis", "Mnemonic" : "708"},
{"Row" :175, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis", "Text" : "Moraxella catarrhalis infections, general", "Mnemonic" : "710"},
{"Row" :176, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "DisplayText" : "Bite wounds with Staphylococcus aureus", "Text" : "MRSA bite wounds", "Mnemonic" : "712"},
{"Row" :177, "Column" : 2, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "MRSA risk factors", "Mnemonic" : "714"},
{"Row" :178, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "DisplayText" : "Bite wounds with Staphylococcus aureus", "Text" : "MSSA bite wounds", "Mnemonic" : "716"},
{"Row" :179, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Mumps vaccination", "Mnemonic" : "718"},
{"Row" :180, "Column" : 2, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "DisplayText" : "Soft tissue, muscle, bone and joint infections", "Text" : "Muscle and Soft Tissue section", "Mnemonic" : "720"},
{"Row" :181, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM INTRACELLULARE", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a MAI or MAC)", "Text" : "Mycobacterium avium intracellular complex (MAI or MAC)", "Mnemonic" : "722"},
{"Row" :182, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia", "Text" : "Mycobacterium avium pneumonia", "Mnemonic" : "724"},
{"Row" :183, "Column" : 2, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "DisplayText" : "Prophylaxis against Mycobacterium avium disease...", "Text" : "Mycobacterium avium prophylaxis", "Mnemonic" : "726"},
{"Row" :184, "Column" : 2, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "DisplayText" : "Disseminated Mycobacterium avium disease treatment", "Text" : "Mycobacterium avium, disseminated", "Mnemonic" : "728"},
{"Row" :185, "Column" : 2, "Item" : "ORZID2 GMENU M. TUBERCULOSIS", "DisplayText" : "Mycobacterium tuberculosis", "Text" : "Mycobacterium tuberculosis", "Mnemonic" : "730"},
{"Row" :186, "Column" : 2, "Item" : "ORZID2 GMENU M. PNEUMONIAE", "DisplayText" : "Mycoplasma pneumoniae", "Text" : "Mycoplasma pneumonia infections, general", "Mnemonic" : "732"},
{"Row" :187, "Column" : 2, "Item" : "ORZID2 GMENU ABX MYOCARDITIS", "DisplayText" : "Myocarditis", "Text" : "Myocarditis", "Mnemonic" : "734"},
{"Row" :4, "Column" : 2, "Text" : "G through Pn", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Text" : "G______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Text" : "H______________________________________________________________________________", "Header" : 1}, 
{"Row" : 80, "Column" : 2, "Text" : "I______________________________________________________________________________", "Header" : 1}, 
{"Row" : 90, "Column" : 2, "Text" : "diphtheria, Haemophilus influenza B, Hepatitis A and B,"}, 
{"Row" : 91, "Column" : 2, "Text" : "human papilloma virus, influenza, measles, mumps,"}, 
{"Row" : 92, "Column" : 2, "Text" : "meningococcal, pneumococcal, pertussis, rubella,"}, 
{"Row" : 93, "Column" : 2, "Text" : "tetanus, varicella, zoster"}, 
{"Row" :107, "Column" : 2, "Text" : "J______________________________________________________________________________", "Header" : 1}, 
{"Row" :110, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :111, "Column" : 2, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" :112, "Column" : 2, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :114, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :115, "Column" : 2, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" :116, "Column" : 2, "Text" : "and streptococcus"}, 
{"Row" :118, "Column" : 2, "Text" : "K______________________________________________________________________________", "Header" : 1}, 
{"Row" :125, "Column" : 2, "Text" : "L______________________________________________________________________________", "Header" : 1}, 
{"Row" :145, "Column" : 2, "Text" : "arthritis, carditis, erythema migrans,"}, 
{"Row" :146, "Column" : 2, "Text" : "neurological complications, prophylaxis"}, 
{"Row" :148, "Column" : 2, "Text" : "M______________________________________________________________________________", "Header" : 1}, 
{"Row" :150, "Column" : 2, "Text" : "antimicrobial prophylaxis, neutropenic fever"}, 
{"Row" :190, "Column" : 2, "Item" : "ORZID2 GMENU ABX NASAL PACKING", "DisplayText" : "Nasal Packing (to prevent infection)", "Text" : "Nasal packing", "Mnemonic" : "744"},
{"Row" :191, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native joint)", "Text" : "Native joint infection [CLICK HERE], includes: ", "Mnemonic" : "746"},
{"Row" :195, "Column" : 2, "Item" : "ORZID2 GMENU EC NV SEL PATH", "DisplayText" : "Native Valve Endocarditis--Selected Pathogens", "Text" : "Native valve endocarditis [CLICK HERE], includes: ", "Mnemonic" : "748"},
{"Row" :199, "Column" : 2, "Item" : "ORZID2 GMENU EC NV EMP THERA", "DisplayText" : "Native Valve Endocarditis - Empirical Therapy", "Text" : "Native valve endocarditis empirical therapy", "Mnemonic" : "750"},
{"Row" :200, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Native valve endocarditis with sepsis", "Mnemonic" : "752"},
{"Row" :201, "Column" : 2, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Necrotizing infections", "Mnemonic" : "754"},
{"Row" :202, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae", "Text" : "Neisseria gonorrhoeae infections, general", "Mnemonic" : "756"},
{"Row" :203, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE", "DisplayText" : "Septic arthritis (Native joint) with N. gonorrhoeae", "Text" : "Neisseria gonorrhoeae native joint infection", "Mnemonic" : "758"},
{"Row" :204, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis", "Text" : "Neisseria meningitidis infections, general", "Mnemonic" : "760"},
{"Row" :205, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "DisplayText" : "Bacterial meningitis with N. meningitidis", "Text" : "Neisseria meningitidis meningitis", "Mnemonic" : "762"},
{"Row" :206, "Column" : 2, "Item" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE", "DisplayText" : "Acute neurological disease associated with Lyme disease", "Text" : "Neurological disease associated with Lyme disease", "Mnemonic" : "764"},
{"Row" :207, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION", "DisplayText" : "Neurological dysfunction", "Text" : "Neurological dysfunction", "Mnemonic" : "766"},
{"Row" :208, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "DisplayText" : "Neutropenia", "Text" : "Neutropenia", "Mnemonic" : "768"},
{"Row" :209, "Column" : 2, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "DisplayText" : "Neutropenic Enterocolitis (Typhlitis)", "Text" : "Neutropenic enterocolitis", "Mnemonic" : "770"},
{"Row" :210, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "Neutropenic fever", "Mnemonic" : "772"},
{"Row" :211, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Neutropenic fever with sepsis", "Mnemonic" : "774"},
{"Row" :212, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "DisplayText" : "Brain Abscess with Nocardia spp.", "Text" : "Nocardia spp. brain abscess", "Mnemonic" : "776"},
{"Row" :213, "Column" : 2, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation", "Text" : "Non-perforated appendicitis", "Mnemonic" : "778"},
{"Row" :214, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Non-streptococcal pharyngitis", "Mnemonic" : "780"},
{"Row" :215, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Nosocomial pneumonia", "Mnemonic" : "782"},
{"Row" :216, "Column" : 2, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "DisplayText" : "Nosocomial Sinusitis", "Text" : "Nosocomial sinusitis", "Mnemonic" : "784"},
{"Row" :219, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Occupational post-exposure prophylaxis", "Mnemonic" : "786"},
{"Row" :220, "Column" : 2, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Onychomycosis", "Mnemonic" : "788"},
{"Row" :221, "Column" : 2, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal Cellulitis", "Text" : "Orbital cellulitis", "Mnemonic" : "790"},
{"Row" :222, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "DisplayText" : "Orolabial Herpes", "Text" : "Orolabial herpes", "Mnemonic" : "792"},
{"Row" :223, "Column" : 2, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "DisplayText" : "Deep Oropharyngeal Infections", "Text" : "Oropharyngeal infections, deep", "Mnemonic" : "794"},
{"Row" :224, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis", "Text" : "Osteomyelitis [CLICK HERE], includes: ", "Mnemonic" : "796"},
{"Row" :227, "Column" : 2, "Item" : "ORZID2 GMENU OTHER PATHOGENS", "DisplayText" : "Other pathogens", "Text" : "Other Pathogens section", "Mnemonic" : "798"},
{"Row" :228, "Column" : 2, "Item" : "ORZID2 GMENU OTITIS EXTERNA", "DisplayText" : "Otitis Externa", "Text" : "Otitis externa", "Mnemonic" : "800"},
{"Row" :229, "Column" : 2, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "DisplayText" : "Malignant Otitis Externa", "Text" : "Otitis externa, malignant", "Mnemonic" : "802"},
{"Row" :230, "Column" : 2, "Item" : "ORZID2 GMENU OTITIS MEDIA", "DisplayText" : "Otitis Media", "Text" : "Otitis media", "Mnemonic" : "804"},
{"Row" :233, "Column" : 2, "Item" : "ORZID2 GMENU ABX PANCREATITIS", "DisplayText" : "Pancreatitis", "Text" : "Pancreatitis", "Mnemonic" : "806"},
{"Row" :234, "Column" : 2, "Item" : "ORZID2 GMENU ABX PARAINFLUENZA", "DisplayText" : "Parainfluenza", "Text" : "Parainfluenza", "Mnemonic" : "808"},
{"Row" :235, "Column" : 2, "Item" : "ORZID2 GMENU PARASITES", "DisplayText" : "Parasites", "Text" : "Parasites", "Mnemonic" : "810"},
{"Row" :236, "Column" : 2, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Paratyphoid fever", "Mnemonic" : "812"},
{"Row" :237, "Column" : 2, "Item" : "ORZID2 GMENU PARONYCHIA", "DisplayText" : "Paronychia", "Text" : "Paronychia", "Mnemonic" : "814"},
{"Row" :238, "Column" : 2, "Item" : "ORZID2 GMENU ABX PAROTITIS", "DisplayText" : "Parotitis", "Text" : "Parotitis", "Mnemonic" : "816"},
{"Row" :239, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite wounds with Pasteurella multocida", "Text" : "Pasteurella multocida bite wounds", "Mnemonic" : "818"},
{"Row" :240, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA", "DisplayText" : "Pasteurella multocida", "Text" : "Pasteurella multocida infections, general", "Mnemonic" : "820"},
{"Row" :241, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis)", "Text" : "Pediculosis corporis", "Mnemonic" : "822"},
{"Row" :242, "Column" : 2, "Item" : "ORZID2 GMENU ABX PID", "DisplayText" : "Pelvic Inflammatory Disease", "Text" : "Pelvic inflammatory disease (PID)", "Mnemonic" : "824"},
{"Row" :243, "Column" : 2, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "DisplayText" : "Chronic protatitis/Chronic pelvic pain syndrome", "Text" : "Pelvic pain syndrome/prostatitis, chronic", "Mnemonic" : "826"},
{"Row" :244, "Column" : 2, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Penicillin desensitization protocol", "Mnemonic" : "828"},
{"Row" :245, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "DisplayText" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Text" : "Peptostreptococcus infections, general", "Mnemonic" : "830"},
{"Row" :246, "Column" : 2, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "DisplayText" : "Appendicitis with perforation", "Text" : "Perforated appendicitis", "Mnemonic" : "832"},
{"Row" :247, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal abscess", "Mnemonic" : "834"},
{"Row" :248, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERICARDITIS", "DisplayText" : "Pericarditis", "Text" : "Pericarditis", "Mnemonic" : "836"},
{"Row" :249, "Column" : 2, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "DisplayText" : "Periocular Infections", "Text" : "Periocular infections", "Mnemonic" : "838"},
{"Row" :250, "Column" : 2, "Item" : "ORZID2 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease", "Text" : "Periodontal disease", "Mnemonic" : "840"},
{"Row" :251, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "DisplayText" : "Peritonitis associated with peritoneal dialysis", "Text" : "Peritoneal dialysis peritonitis", "Mnemonic" : "842"},
{"Row" :252, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Peritonitis, acute spontaneous bacterial", "Mnemonic" : "844"},
{"Row" :253, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "DisplayText" : "Peritonitis associated with peritoneal dialysis", "Text" : "Peritonitis, peritoneal dialysis associated", "Mnemonic" : "846"},
{"Row" :254, "Column" : 2, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "DisplayText" : "Secondary Peritonitis", "Text" : "Peritonitis, secondary", "Mnemonic" : "848"},
{"Row" :255, "Column" : 2, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis", "Text" : "Persistent or recurrent urethritis", "Mnemonic" : "850"},
{"Row" :256, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "DisplayText" : "Pertussis", "Text" : "Pertussis", "Mnemonic" : "852"},
{"Row" :257, "Column" : 2, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "DisplayText" : "Prevention of Pertussis", "Text" : "Pertussis post-exposure prophylaxis", "Mnemonic" : "854"},
{"Row" :258, "Column" : 2, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Pertussis vaccination", "Mnemonic" : "856"},
{"Row" :259, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Pharyngitis, non-streptococcal", "Mnemonic" : "858"},
{"Row" :260, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Pharyngitis, streptococcal", "Mnemonic" : "860"},
{"Row" :261, "Column" : 2, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal vaccination", "Mnemonic" : "862"},
{"Row" :262, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis", "Mnemonic" : "864"},
{"Row" :263, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis prophylaxis", "Mnemonic" : "866"},
{"Row" :264, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMONIA", "DisplayText" : "Pneumonia", "Text" : "Pneumonia", "Mnemonic" : "868"},
{"Row" :265, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Pneumonia with sepsis", "Mnemonic" : "870"},
{"Row" :266, "Column" : 2, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia", "Text" : "Pneumonia, aspiration", "Mnemonic" : "872"},
{"Row" :267, "Column" : 2, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Pneumonia, community-acquired (CAP)", "Mnemonic" : "876"},
{"Row" :268, "Column" : 2, "Item" : "ORZID2 GMENU ABX CMV PNEUMONIA", "DisplayText" : "CMV Pneumonia", "Text" : "Pneumonia, Cytomegalovirus (CMV)", "Mnemonic" : "878"},
{"Row" :269, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia", "Text" : "Pneumonia, Mycobacterium avium", "Mnemonic" : "880"},
{"Row" :270, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Pneumonia, nosocomial [CLICK HERE], includes: ", "Mnemonic" : "882"},
{"Row" :189, "Column" : 2, "Text" : "N______________________________________________________________________________", "Header" : 1}, 
{"Row" :192, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :193, "Column" : 2, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" :194, "Column" : 2, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :196, "Column" : 2, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :197, "Column" : 2, "Text" : "gram-negative bacilli, streptococci, staphylococci,"}, 
{"Row" :198, "Column" : 2, "Text" : "and HACEK bacteria"}, 
{"Row" :218, "Column" : 2, "Text" : "O______________________________________________________________________________", "Header" : 1}, 
{"Row" :225, "Column" : 2, "Text" : "empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,"}, 
{"Row" :226, "Column" : 2, "Text" : "Staphylococcus aureus, and streptococci"}, 
{"Row" :232, "Column" : 2, "Text" : "Pa-Pn__________________________________________________________________________", "Header" : 1}, 
{"Row" :271, "Column" : 2, "Text" : "72 hour re-evaluation, Acinetobacter baumannii,"}, 
{"Row" :272, "Column" : 2, "Text" : "empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,"}, 
{"Row" :273, "Column" : 2, "Text" : "Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP"}, 
{"Row" :1, "Column" : 3, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Drug Information", "Mnemonic" : "884"},
{"Row" :7, "Column" : 3, "Item" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY", "DisplayText" : "CMV Polyradiculopathy", "Text" : "Polyradiculopathy, Cytomegalovirus (CMV)", "Mnemonic" : "886"},
{"Row" :8, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (including Prevotella, Porphyromonas)", "Text" : "Porphyromonas infections, general", "Mnemonic" : "888"},
{"Row" :9, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Post-exposure prophylaxis, occupational", "Mnemonic" : "890"},
{"Row" : 10, "Column" : 3, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "DisplayText" : "Prevention of Pertussis", "Text" : "Post-exposure prophylaxis, pertussis", "Mnemonic" : "892"},
{"Row" : 13, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Post-operative antimicrobial prophylaxis", "Mnemonic" : "896"},
{"Row" : 14, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Post-operative dermatology infection", "Mnemonic" : "898"},
{"Row" : 15, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Post-operative wound infection", "Mnemonic" : "900"},
{"Row" : 16, "Column" : 3, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal Cellulitis", "Text" : "Postseptal cellulitis", "Mnemonic" : "902"},
{"Row" : 17, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "DisplayText" : "Post-surgical or post-traumatic brain abscess", "Text" : "Post-surgical or post-traumatic brain abscess", "Mnemonic" : "904"},
{"Row" : 18, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy immunizations", "Mnemonic" : "906"},
{"Row" : 19, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category", "Text" : "Pregnancy risk factors for antimicrobials", "Mnemonic" : "908"},
{"Row" : 20, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Pre-operative antimicrobial prophylaxis", "Mnemonic" : "910"},
{"Row" : 21, "Column" : 3, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal Cellulitis", "Text" : "Preseptal cellulitis", "Mnemonic" : "912"},
{"Row" : 22, "Column" : 3, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "DisplayText" : "Azithromycin for Prevention of Exacerbations COPD", "Text" : "Prevention of COPD exacerbations", "Mnemonic" : "914"},
{"Row" : 23, "Column" : 3, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "DisplayText" : "Prevention of Infection", "Text" : "Prevention of Infection section", "Mnemonic" : "916"},
{"Row" : 24, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (including Prevotella, Porphyromonas)", "Text" : "Prevotella infections, general", "Mnemonic" : "918"},
{"Row" : 25, "Column" : 3, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "DisplayText" : "Prevention of bacterial infection in a patient with malignancy", "Text" : "Prophylactic antibiotics in malignancy", "Mnemonic" : "920"},
{"Row" : 26, "Column" : 3, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infections in a patient with malignancy", "Text" : "Prophylactic antifungals in malignancy", "Mnemonic" : "922"},
{"Row" : 27, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Prophylactic antimicrobials for asplenia", "Mnemonic" : "924"},
{"Row" : 28, "Column" : 3, "Item" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis", "Text" : "Prophylactic antimicrobials for Lyme disease", "Mnemonic" : "926"},
{"Row" : 29, "Column" : 3, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "DisplayText" : "Prophylaxis against Mycobacterium avium disease...", "Text" : "Prophylactic antimicrobials for Mycobacterium avium", "Mnemonic" : "928"},
{"Row" : 30, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Prophylactic antimicrobials for occupational post-exposure", "Mnemonic" : "930"},
{"Row" : 31, "Column" : 3, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Prophylactic antimicrobials for Pneumocystis", "Mnemonic" : "932"},
{"Row" : 32, "Column" : 3, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "DisplayText" : "Prevention of Pertussis", "Text" : "Prophylactic antimicrobials for post-exposure pertussis", "Mnemonic" : "934"},
{"Row" : 33, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Prophylactic antimicrobials for spontaneous bacterial peritonitis", "Mnemonic" : "936"},
{"Row" : 34, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Prophylactic antimicrobials, post-operative", "Mnemonic" : "938"},
{"Row" : 35, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Prophylactic antimicrobials, pre-operative", "Mnemonic" : "940"},
{"Row" : 36, "Column" : 3, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prophylactic antivirals in malignancy", "Mnemonic" : "942"},
{"Row" : 39, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.", "DisplayText" : "Propionibacterium spp.", "Text" : "Propionibacterium infections, general", "Mnemonic" : "946"},
{"Row" : 40, "Column" : 3, "Item" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "DisplayText" : "Acute Bacterial Prostatitis", "Text" : "Prostatitis, acute", "Mnemonic" : "948"},
{"Row" : 41, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS", "DisplayText" : "Chronic bacterial prostatitis", "Text" : "Prostatitis, chronic", "Mnemonic" : "950"},
{"Row" : 42, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "DisplayText" : "Chronic protatitis/Chronic pelvic pain syndrome", "Text" : "Prostatitis/pelvic pain syndrome, chronic", "Mnemonic" : "952"},
{"Row" : 43, "Column" : 3, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Prosthetic bone/joint infection [CLICK HERE], includes: ", "Mnemonic" : "954"},
{"Row" : 47, "Column" : 3, "Item" : "ORZID2 GMENU EC PV SEL PATH", "DisplayText" : "Prosthetic Valve Endocarditis--Selected Pathogens", "Text" : "Prosthetic valve endocarditis [CLICK HERE], includes: ", "Mnemonic" : "956"},
{"Row" : 51, "Column" : 3, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "DisplayText" : "Prosthetic Valve Endocarditis--Empicaral Therapy", "Text" : "Prosthetic valve endocarditis empirical therapy", "Mnemonic" : "958"},
{"Row" : 52, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Prosthetic valve endocarditis with sepsis", "Mnemonic" : "960"},
{"Row" : 53, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.", "DisplayText" : "Proteus spp.", "Text" : "Proteus infections, general", "Mnemonic" : "962"},
{"Row" : 54, "Column" : 3, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Protocol for Penicillin Desensitization", "Mnemonic" : "964"},
{"Row" : 55, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA", "DisplayText" : "Septic arthritis (Native joint) with Pseudomonas aeruginosa", "Text" : "Pseudomonas aeruginosa native joint infection", "Mnemonic" : "966"},
{"Row" : 56, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA", "DisplayText" : "Nosocomial pneumonia with Pseudomonas aeruginosa", "Text" : "Pseudomonas aeruginosa nosocomial pneumonia", "Mnemonic" : "968"},
{"Row" : 57, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa", "Text" : "Pseudomonas aeruginosa osteomyelitis", "Mnemonic" : "970"},
{"Row" : 58, "Column" : 3, "Item" : "ORZID2 GMENU PROS B/J P. AERUGINOSA", "DisplayText" : "Pseudomonas aeruginosa infections in bone or joint prostheses", "Text" : "Pseudomonas aeruginosa prosthetic bone/joint infection", "Mnemonic" : "972"},
{"Row" : 59, "Column" : 3, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Pseudomonas aeruginosa pyelonephritis", "Mnemonic" : "974"},
{"Row" : 60, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.", "DisplayText" : "Pseudomonas spp.", "Text" : "Pseudomonas infections, general", "Mnemonic" : "976"},
{"Row" : 61, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism", "Text" : "Pseudomonas meningitis", "Mnemonic" : "978"},
{"Row" : 62, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "DisplayText" : "Brain Abscess with Pseudomonas spp.", "Text" : "Pseudomonas spp. brain abscess", "Mnemonic" : "980"},
{"Row" : 63, "Column" : 3, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)", "Text" : "Pubic lice", "Mnemonic" : "982"},
{"Row" : 64, "Column" : 3, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "DisplayText" : "Pyelonephritis", "Text" : "Pyelonephritis [CLICK HERE], includes: ", "Mnemonic" : "984"},
{"Row" : 66, "Column" : 3, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Pyogenic liver abscess", "Mnemonic" : "986"},
{"Row" : 67, "Column" : 3, "Item" : "ORZID2 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis", "Mnemonic" : "988"},
{"Row" : 68, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Pyuria", "Mnemonic" : "990"},
{"Row" : 75, "Column" : 3, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Rabies vaccination", "Mnemonic" : "994"},
{"Row" : 76, "Column" : 3, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis", "Text" : "Recurrent or persistent urethritis", "Mnemonic" : "996"},
{"Row" : 77, "Column" : 3, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Renal failure immunizations", "Mnemonic" : "998"},
{"Row" : 78, "Column" : 3, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "Resistant bacteria, more about", "Mnemonic" : "1000"},
{"Row" : 79, "Column" : 3, "Item" : "ORZID2 GMENU ABX RSV", "DisplayText" : "RSV", "Text" : "Respiratory syncytial virus (RSV)", "Mnemonic" : "1004"},
{"Row" : 80, "Column" : 3, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "Restrictions on antimicrobials", "Mnemonic" : "1006"},
{"Row" : 81, "Column" : 3, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "Retinitis [CLICK HERE], includes: ", "Mnemonic" : "1008"},
{"Row" : 83, "Column" : 3, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm)", "Text" : "Ringworm", "Mnemonic" : "1010"},
{"Row" : 84, "Column" : 3, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "Risk factors for MRSA", "Mnemonic" : "1012"},
{"Row" : 85, "Column" : 3, "Item" : "ORZID2 GMENU ROCKY MTN SPOT FEVER", "DisplayText" : "Rocky Mountain Spotted Fever", "Text" : "Rocky mountain spotted fever", "Mnemonic" : "1014"},
{"Row" : 86, "Column" : 3, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Rubella vaccination", "Mnemonic" : "1016"},
{"Row" : 89, "Column" : 3, "Item" : "ORZID2 GMENU ABX SALMONELLA SPECIES", "DisplayText" : "Diarrhea with Salmonella", "Text" : "Salmonella diarrhea/gastroenteritis", "Mnemonic" : "1018"},
{"Row" : 90, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.", "DisplayText" : "Salmonella spp.", "Text" : "Salmonella infections, general", "Mnemonic" : "1020"},
{"Row" : 91, "Column" : 3, "Item" : "ORZID2 GMENU SCABIES", "DisplayText" : "Scabies", "Text" : "Scabies", "Mnemonic" : "1022"},
{"Row" : 92, "Column" : 3, "Item" : "ORZID2 GMENU STAPH SCALDED SYNDROME", "DisplayText" : "Staphylococcal Scalded Skin Syndrom (Ritter's Disease)", "Text" : "Scalded skin syndrome", "Mnemonic" : "1024"},
{"Row" : 93, "Column" : 3, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "Seasonal influenza", "Mnemonic" : "1026"},
{"Row" : 94, "Column" : 3, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "DisplayText" : "Secondary Peritonitis", "Text" : "Secondary peritonitis", "Mnemonic" : "1028"},
{"Row" : 95, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Sepsis and septic shock", "Mnemonic" : "1030"},
{"Row" : 96, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native joint)", "Text" : "Septic arthritis, native joint [CLICK HERE], includes: ", "Mnemonic" : "1032"},
{"Row" :100, "Column" : 3, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Septic arthritis, prosthetic joint [CLICK HERE], includes: ", "Mnemonic" : "1034"},
{"Row" :104, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis", "Text" : "Septic bursitis", "Mnemonic" : "1036"},
{"Row" :105, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.", "DisplayText" : "Serratia spp.", "Text" : "Serratia infections, general", "Mnemonic" : "1038"},
{"Row" :106, "Column" : 3, "Item" : "ORZID2 GMENU ABX VAGINITIS", "DisplayText" : "Bacterial Vaginosis", "Text" : "Sexually transmitted infection, bacterial vaginitis", "Mnemonic" : "1040"},
{"Row" :107, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, cervicitis", "Mnemonic" : "1042"},
{"Row" :108, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, chlamydia cervicitis", "Mnemonic" : "1044"},
{"Row" :109, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Sexually transmitted infection, chlamydia urethritis", "Mnemonic" : "1046"},
{"Row" :110, "Column" : 3, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "DisplayText" : "Genital herpes", "Text" : "Sexually transmitted infection, genital warts", "Mnemonic" : "1048"},
{"Row" :111, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, gonorrhea cervicitis", "Mnemonic" : "1050"},
{"Row" :112, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Sexually transmitted infection, gonorrhea urethritis", "Mnemonic" : "1052"},
{"Row" :113, "Column" : 3, "Item" : "ORZID2 GMENU ABX PID", "DisplayText" : "Pelvic Inflammatory Disease", "Text" : "Sexually transmitted infection, pelvic inflammatory disease", "Mnemonic" : "1054"},
{"Row" :114, "Column" : 3, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)", "Text" : "Sexually transmitted infection, pubic lice (crabs)", "Mnemonic" : "1056"},
{"Row" :115, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Sexually transmitted infection, syphilis", "Mnemonic" : "1058"},
{"Row" :116, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "DisplayText" : "Trichomonas Vaginitis", "Text" : "Sexually transmitted infection, trichomoniasis", "Mnemonic" : "1060"},
{"Row" :117, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Sexually transmitted infection, urethritis", "Mnemonic" : "1062"},
{"Row" :118, "Column" : 3, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)", "Text" : "Shigella diarrhea/gastroenteritis", "Mnemonic" : "1064"},
{"Row" :119, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN SHIGELLA SPP.", "DisplayText" : "Shigella spp. (bacillary dysentery)", "Text" : "Shigella infections, general", "Mnemonic" : "1066"},
{"Row" :120, "Column" : 3, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")", "Text" : "Shingles", "Mnemonic" : "1068"},
{"Row" :121, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Shingles vaccination", "Mnemonic" : "1070"},
{"Row" :122, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of antimicrobials updates", "Mnemonic" : "1072"},
{"Row" :123, "Column" : 3, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "DisplayText" : "Acute Sinusitis--Mild to Moderate Disease", "Text" : "Sinusitis, acute", "Mnemonic" : "1074"},
{"Row" :124, "Column" : 3, "Item" : "ORZID2 GMENU CHRONIC SINUSITIS", "DisplayText" : "Chronic Sinusitis", "Text" : "Sinusitis, chronic", "Mnemonic" : "1076"},
{"Row" :125, "Column" : 3, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Sinusitis, fungal", "Mnemonic" : "1078"},
{"Row" :126, "Column" : 3, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "DisplayText" : "Nosocomial Sinusitis", "Text" : "Sinusitis, nosocomial", "Mnemonic" : "1080"},
{"Row" :127, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Skin and soft tissue infection with sepsis", "Mnemonic" : "1082"},
{"Row" :128, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "DisplayText" : "Dermatological Infections", "Text" : "Skin Infections section", "Mnemonic" : "1084"},
{"Row" :129, "Column" : 3, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "DisplayText" : "Small pleomorphic rods in aerobic bottle", "Text" : "Small pleomorphic bacilli, aerobic bottle", "Mnemonic" : "1086"},
{"Row" :130, "Column" : 3, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "DisplayText" : "Small pleomorphic rods in an anaerobic bottle", "Text" : "Small pleomorphic bacilli, anaerobic bottle", "Mnemonic" : "1088"},
{"Row" :131, "Column" : 3, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "DisplayText" : "Soft tissue, muscle, bone and joint infections", "Text" : "Soft Tissue and Muscle section", "Mnemonic" : "1090"},
{"Row" :132, "Column" : 3, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "DisplayText" : "Introduction to Specific Pathogen section", "Text" : "Specific pathogen introduction", "Mnemonic" : "1092"},
{"Row" :133, "Column" : 3, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "DisplayText" : "Spinal epidural abscess", "Text" : "Spinal epidural abscess", "Mnemonic" : "1094"},
{"Row" :134, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Spleen absent or dysfunctional [CLICK HERE], includes: ", "Mnemonic" : "1096"},
{"Row" :137, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Spontaneous bacterial peritonitis prevention", "Mnemonic" : "1098"},
{"Row" :138, "Column" : 3, "Item" : "ORZID2 GMENU SPOROTRICHOSIS", "DisplayText" : "Sporotrichosis", "Text" : "Sporotrichosis infections, general", "Mnemonic" : "1100"},
{"Row" :139, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI", "DisplayText" : "Staphylococci", "Text" : "Staphylococcal infections, general", "Mnemonic" : "1102"},
{"Row" :140, "Column" : 3, "Item" : "ORZID2 GMENU EC NV STAPHYLOCOCCI", "DisplayText" : "Native Valve Endocarditis with Staphylococci", "Text" : "Staphylococcal native valve endocarditis", "Mnemonic" : "1104"},
{"Row" :141, "Column" : 3, "Item" : "ORZID2 GMENU EC PV STAPHYLOCOCCI", "DisplayText" : "Prosthetic Valve Endocarditis with Staphylococci", "Text" : "Staphylococcal prosthetic valve endocarditis", "Mnemonic" : "1106"},
{"Row" :142, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome", "Text" : "Staphylococcal toxic shock syndrome", "Mnemonic" : "1108"},
{"Row" :143, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "DisplayText" : "Treatment for Coagulase negative Staphylococci", "Text" : "Staphylococci, coagulase-negative", "Mnemonic" : "1110"},
{"Row" :144, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS", "DisplayText" : "Treatment for Staphyloccus aureus", "Text" : "Staphylococcus aureus infections, general", "Mnemonic" : "1112"},
{"Row" :145, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA", "DisplayText" : "STAPHYLOCOCCUS AUREUS PNEUMONIA", "Text" : "Staphylococcus aureus nosocomial pneumonia", "Mnemonic" : "1114"},
{"Row" :146, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS", "DisplayText" : "Osteomyelitis with Staphylococcus aureus", "Text" : "Staphylococcus aureus osteomyelitis", "Mnemonic" : "1116"},
{"Row" :147, "Column" : 3, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "DisplayText" : "Bacteremia associated with Staphylococcus aureus", "Text" : "Staphylococcus aureus bacteremia", "Mnemonic" : "1118"},
{"Row" :148, "Column" : 3, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Staphylococcus aureus decolonization", "Mnemonic" : "1120"},
{"Row" :149, "Column" : 3, "Item" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS", "DisplayText" : "Intravascular catheter-associated Staphyloccus aureus infection", "Text" : "Staphylococcus aureus intravascular catheter-associated infection", "Mnemonic" : "1122"},
{"Row" :150, "Column" : 3, "Item" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses", "Text" : "Staphylococcus aureus prosthetic bone/joint infection", "Mnemonic" : "1124"},
{"Row" :151, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS", "DisplayText" : "Septic arthritis (Native joint) with Staphylococcus aureus", "Text" : "Staphylococcus aureus, native joint infection", "Mnemonic" : "1126"},
{"Row" :152, "Column" : 3, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "DisplayText" : "Bacteremia associated with Staphylococcus lugdunensis", "Text" : "Staphylococcus lugdunensis bacteremia", "Mnemonic" : "1128"},
{"Row" :153, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS", "DisplayText" : "Staphylococcis Lugdunensis", "Text" : "Staphylococcus lugdunensis infections, general", "Mnemonic" : "1130"},
{"Row" :154, "Column" : 3, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "DisplayText" : "Stasis dermatitis", "Text" : "Stasis dermatitis", "Mnemonic" : "1132"},
{"Row" :155, "Column" : 3, "Item" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite wounds with Streptococci", "Text" : "Streptococcal bite wounds", "Mnemonic" : "1134"},
{"Row" :156, "Column" : 3, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci", "Text" : "Streptococcal native valve endocarditis (highly resistant isolate)", "Mnemonic" : "1136"},
{"Row" :157, "Column" : 3, "Item" : "ORZID2 GMENU EC NV STREPTOCOCCI", "DisplayText" : "Native Valve Endocarditis with Streptococci", "Text" : "Streptococcal native valve endocarditis (sensitive isolate)", "Mnemonic" : "1138"},
{"Row" :158, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI", "DisplayText" : "Osteomyelitis with Streptococci", "Text" : "Streptococcal osteomyelitis", "Mnemonic" : "1140"},
{"Row" :159, "Column" : 3, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Streptococcal pharyngitis", "Mnemonic" : "1142"},
{"Row" :160, "Column" : 3, "Item" : "ORZID2 GMENU PROS B/J STREPTOCOCCI", "DisplayText" : "Streptococcal infections in bone or joint prostheses", "Text" : "Streptococcal prosthetic bone/joint infection", "Mnemonic" : "1144"},
{"Row" :161, "Column" : 3, "Item" : "ORZID2 GMENU EC PV VGS/S. BOVIS", "DisplayText" : "Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis", "Text" : "Streptococcal prosthetic valve endocarditis", "Mnemonic" : "1146"},
{"Row" :162, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome", "Text" : "Streptococcal toxic shock syndrome", "Mnemonic" : "1148"},
{"Row" :163, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "DisplayText" : "Streptococci Groups C, F, G", "Text" : "Streptococci Groups C, F, G infections, general", "Mnemonic" : "1150"},
{"Row" :164, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)", "Text" : "Streptococci viridans infections, general [CLICK HERE], includes: ", "Mnemonic" : "1152"},
{"Row" :166, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "DisplayText" : "Group B Streptococci (S. agalactiae)", "Text" : "Streptococcus agalactiae (Group B)", "Mnemonic" : "1154"},
{"Row" :167, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS", "DisplayText" : "Streptococcus anginosus (formerly S. milleri)", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Mnemonic" : "1156"},
{"Row" :168, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "DisplayText" : "Group D (S. bovis)", "Text" : "Streptococcus bovis (Group D)", "Mnemonic" : "1158"},
{"Row" :169, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI", "DisplayText" : "Septic arthritis (Native joint) with Streptococci", "Text" : "Streptococcus native joint infection", "Mnemonic" : "1160"},
{"Row" :170, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE", "DisplayText" : "Streptococcus pneumoniae", "Text" : "Streptococcus pneumoniae infections, general", "Mnemonic" : "1162"},
{"Row" :171, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "DisplayText" : "Bacterial meningitis with S. pneumoniae", "Text" : "Streptococcus pneumoniae meningitis", "Mnemonic" : "1164"},
{"Row" :172, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "DisplayText" : "Group A Streptococci (S. pyogenes)", "Text" : "Streptococcus pyogenes (Group A) infections, general", "Mnemonic" : "1166"},
{"Row" :173, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "DisplayText" : "Stress", "Text" : "Stress", "Mnemonic" : "1168"},
{"Row" :174, "Column" : 3, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "DisplayText" : "Subdural Empyema", "Text" : "Subdural empyema", "Mnemonic" : "1170"},
{"Row" :175, "Column" : 3, "Item" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH", "DisplayText" : "Suppurative intracranial thrombophlebitis", "Text" : "Suppurative intracranial thrombophlebitis", "Mnemonic" : "1172"},
{"Row" :176, "Column" : 3, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections", "Text" : "Suppurative odontic infections", "Mnemonic" : "1174"},
{"Row" :177, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "DisplayText" : "Suppurative Thrombophlebitis--Empirical Therapy", "Text" : "Suppurative thrombophlebitis", "Mnemonic" : "1176"},
{"Row" :178, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Surgical site infection", "Mnemonic" : "1178"},
{"Row" :179, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Susceptibilities, antimicrobial", "Mnemonic" : "1180"},
{"Row" :180, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "Suspected bacteremia, blood cultures not yet positive", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Mnemonic" : "1182"},
{"Row" :181, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Syphilis", "Mnemonic" : "1184"},
{"Row" :182, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES", "DisplayText" : "Systemic Infectious Diseases", "Text" : "Systemic Infections section", "Mnemonic" : "1186"},
{"Row" :4, "Column" : 3, "Text" : "Po through Z", "Header" : 1}, 
{"Row" :6, "Column" : 3, "Text" : "Po-Py__________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" : 45, "Column" : 3, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" : 46, "Column" : 3, "Text" : "and streptococcus"}, 
{"Row" : 48, "Column" : 3, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" : 49, "Column" : 3, "Text" : "gram-negative bacilli, Streptococcus bovis,"}, 
{"Row" : 50, "Column" : 3, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci"}, 
{"Row" : 65, "Column" : 3, "Text" : "empiric therapy, enterococcus, pseudomonas"}, 
{"Row" : 70, "Column" : 3, "Text" : "Q______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 3, "Text" : "R______________________________________________________________________________", "Header" : 1}, 
{"Row" : 82, "Column" : 3, "Text" : "candida, Cytomegalovirus, herpes, zoster, and others"}, 
{"Row" : 88, "Column" : 3, "Text" : "S______________________________________________________________________________", "Header" : 1}, 
{"Row" : 97, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" : 98, "Column" : 3, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" : 99, "Column" : 3, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :101, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :102, "Column" : 3, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" :103, "Column" : 3, "Text" : "and streptococcus"}, 
{"Row" :135, "Column" : 3, "Text" : "antimicrobial prophylaxis, management of fever,"}, 
{"Row" :136, "Column" : 3, "Text" : "patient initiated antibiotics, vaccines"}, 
{"Row" :165, "Column" : 3, "Text" : "S. mutans, S. mitis, S. sanguis"}, 
{"Row" :185, "Column" : 3, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus vaccination", "Mnemonic" : "1188"},
{"Row" :186, "Column" : 3, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "DisplayText" : "Candida albicans", "Text" : "Thrush", "Mnemonic" : "1190"},
{"Row" :188, "Column" : 3, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm)", "Text" : "Tinea capitis", "Mnemonic" : "1192"},
{"Row" :189, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris", "Text" : "Tinea corporis", "Mnemonic" : "1194"},
{"Row" :190, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris", "Text" : "Tinea cruris", "Mnemonic" : "1196"},
{"Row" :191, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris", "Text" : "Tinea pedis", "Mnemonic" : "1198"},
{"Row" :192, "Column" : 3, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Tinea unguium", "Mnemonic" : "1200"},
{"Row" :193, "Column" : 3, "Item" : "ORZID2 GMENU TINEA VERSICOLOR", "DisplayText" : "Tinea Versicolor", "Text" : "Tinea versicolor", "Mnemonic" : "1202"},
{"Row" :194, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "DisplayText" : "Tobacco smoke", "Text" : "Tobacco smoke", "Mnemonic" : "1204"},
{"Row" :195, "Column" : 3, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Tonsillitis", "Mnemonic" : "1206"},
{"Row" :196, "Column" : 3, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections", "Text" : "Tooth abscess and other suppurative odontic infections", "Mnemonic" : "1208"},
{"Row" :197, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome", "Text" : "Toxic shock syndrome", "Mnemonic" : "1210"},
{"Row" :198, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "DisplayText" : "Brain Abscess with Toxoplasma gondii", "Text" : "Toxoplasma gondii brain abscess", "Mnemonic" : "1212"},
{"Row" :199, "Column" : 3, "Item" : "ORZID2 GMENU TOXOPLASMA SPP.", "DisplayText" : "Toxoplasma spp.", "Text" : "Toxoplasma infections, general", "Mnemonic" : "1214"},
{"Row" :200, "Column" : 3, "Item" : "ORZID2 GMENU TRANSPLANTATION", "DisplayText" : "Transplantation", "Text" : "Transplantation", "Mnemonic" : "1216"},
{"Row" :201, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "DisplayText" : "Bacterial meningitis associated with trauma or nosocomial infection", "Text" : "Trauma or nosocomial infection associated meningitis", "Mnemonic" : "1218"},
{"Row" :202, "Column" : 3, "Item" : "ORZID2 GMENU TRAVELERS DIARRHEA", "DisplayText" : "Traveler's Diarrhea", "Text" : "Traveler's diarrhea", "Mnemonic" : "1220"},
{"Row" :203, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "DisplayText" : "Trichomonas Vaginitis", "Text" : "Trichomonas vaginitis", "Mnemonic" : "1222"},
{"Row" :204, "Column" : 3, "Item" : "ORZID2 GMENU ABX TUBERCULOSIS", "DisplayText" : "Tuberculosis", "Text" : "Tuberculosis", "Mnemonic" : "1224"},
{"Row" :205, "Column" : 3, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "DisplayText" : "Neutropenic Enterocolitis (Typhlitis)", "Text" : "Typhlitis", "Mnemonic" : "1226"},
{"Row" :206, "Column" : 3, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Typhoid fever", "Mnemonic" : "1228"},
{"Row" :209, "Column" : 3, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "DisplayText" : "Decubitus ulcers", "Text" : "Ulcer, decubitus", "Mnemonic" : "1230"},
{"Row" :210, "Column" : 3, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Ulcer, diabetic foot", "Mnemonic" : "1232"},
{"Row" :211, "Column" : 3, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "DisplayText" : "Uncomplicated Cystitis", "Text" : "Uncomplicated cystitis", "Mnemonic" : "1234"},
{"Row" :212, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Updates on antimicrobial shortages", "Mnemonic" : "1236"},
{"Row" :213, "Column" : 3, "Item" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)", "DisplayText" : "Upper respiratory infections (URI)", "Text" : "Upper respiratory infections (URI)", "Mnemonic" : "1238"},
{"Row" :214, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Urethritis associated with STIs [CLICK HERE], includes: ", "Mnemonic" : "1240"},
{"Row" :216, "Column" : 3, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis", "Text" : "Urethritis, recurrent or persistent", "Mnemonic" : "1242"},
{"Row" :217, "Column" : 3, "Item" : "ORZID2 GMENU ABX APPROACH TO UTI", "DisplayText" : "Approach to Urinary Tract Infection (UTI)", "Text" : "Urinary tract infection (UTI), bacterial", "Mnemonic" : "1244"},
{"Row" :218, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Urinary tract infection (UTI), candida", "Mnemonic" : "1246"},
{"Row" :219, "Column" : 3, "Item" : "ORZID2 GMENU UROSEPSIS", "DisplayText" : "Urosepsis", "Text" : "Urinary tract infection with sepsis", "Mnemonic" : "1248"},
{"Row" :220, "Column" : 3, "Item" : "ORZID2 GMENU UROSEPSIS", "DisplayText" : "Urosepsis", "Text" : "Urosepsis", "Mnemonic" : "1250"},
{"Row" :221, "Column" : 3, "Item" : "ORZID2 GMENU UVEITIS", "DisplayText" : "Uveitis", "Text" : "Uveitis", "Mnemonic" : "1252"},
{"Row" :225, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida Vulvo-Vaginitis", "Text" : "Vaginitis, Candida", "Mnemonic" : "1254"},
{"Row" :226, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "DisplayText" : "Trichomonas Vaginitis", "Text" : "Vaginitis, Trichomonas", "Mnemonic" : "1256"},
{"Row" :227, "Column" : 3, "Item" : "ORZID2 GMENU ABX VAGINITIS", "DisplayText" : "Bacterial Vaginosis", "Text" : "Vaginosis, bacterial", "Mnemonic" : "1258"},
{"Row" :228, "Column" : 3, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox)", "Text" : "Varicella", "Mnemonic" : "1260"},
{"Row" :229, "Column" : 3, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella vaccination", "Mnemonic" : "1262"},
{"Row" :230, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Ventilator-associated pneumonia (VAP)", "Mnemonic" : "1264"},
{"Row" :231, "Column" : 3, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "DisplayText" : "Diskitis and Vertebral Osteomyelitis", "Text" : "Vertebral osteomyelitis and diskitis", "Mnemonic" : "1266"},
{"Row" :232, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHOLERA", "DisplayText" : "Diarrhea with Cholera (Vibrio cholera)", "Text" : "Vibrio cholerae diarrhea/gastroenteritis", "Mnemonic" : "1268"},
{"Row" :233, "Column" : 3, "Item" : "ORZID2 GMENU ABX NON-CHOLERA", "DisplayText" : "Vibrio non-cholera", "Text" : "Vibrio non-cholerae, diarrhea/gastroenteritis", "Mnemonic" : "1270"},
{"Row" :234, "Column" : 3, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Viral diarrhea/gastroenteritis", "Mnemonic" : "1272"},
{"Row" :235, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)", "Text" : "Viridans streptococci", "Mnemonic" : "1274"},
{"Row" :236, "Column" : 3, "Item" : "ORZID2 GMENU ABX VIRUSES", "DisplayText" : "Viruses", "Text" : "Viruses section", "Mnemonic" : "1276"},
{"Row" :237, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida Vulvo-Vaginitis", "Text" : "Vulvo-vaginitis, candida", "Mnemonic" : "1278"},
{"Row" :240, "Column" : 3, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions with antimicrobials", "Mnemonic" : "1280"},
{"Row" :241, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Wound infection, post-op", "Mnemonic" : "1282"},
{"Row" :242, "Column" : 3, "Item" : "ORZID2 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds", "Text" : "Wound, bite", "Mnemonic" : "1284"},
{"Row" :243, "Column" : 3, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "DisplayText" : "Colonized wounds", "Text" : "Wound, colonized", "Mnemonic" : "1286"},
{"Row" :248, "Column" : 3, "Item" : "ORZID2 GMENU INT RPT YEAST", "DisplayText" : "Interim report of yeast", "Text" : "Yeast bacteremia", "Mnemonic" : "1288"},
{"Row" :249, "Column" : 3, "Item" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA", "DisplayText" : "Diarrhea with Yersinia enterocolitica", "Text" : "Yersinia enterocolitica diarrhea/gastroenteritis", "Mnemonic" : "1290"},
{"Row" :252, "Column" : 3, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")", "Text" : "Zoster", "Mnemonic" : "1292"},
{"Row" :253, "Column" : 3, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "Zoster retinitis", "Mnemonic" : "1294"},
{"Row" :254, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Zoster vaccination", "Mnemonic" : "1296"},
{"Row" :184, "Column" : 3, "Text" : "T______________________________________________________________________________", "Header" : 1}, 
{"Row" :208, "Column" : 3, "Text" : "U______________________________________________________________________________", "Header" : 1}, 
{"Row" :215, "Column" : 3, "Text" : "chlamydia and gonococcal"}, 
{"Row" :223, "Column" : 3, "Text" : "V______________________________________________________________________________", "Header" : 1}, 
{"Row" :224, "Column" : 3, "Text" : "Vaccination: see immunization, specific organism or condition"}, 
{"Row" :239, "Column" : 3, "Text" : "W______________________________________________________________________________", "Header" : 1}, 
{"Row" :245, "Column" : 3, "Text" : "X______________________________________________________________________________", "Header" : 1}, 
{"Row" :247, "Column" : 3, "Text" : "Y______________________________________________________________________________", "Header" : 1}, 
{"Row" :251, "Column" : 3, "Text" : "Z______________________________________________________________________________", "Header" : 1}, 
{"Row" : 73, "Column" : 3, "Text" : "Rabies post-exposure prophylaxis - see Emergency"}, 
{"Row" : 74, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" : 37, "Column" : 3, "Text" : "Prophylaxis for post-exposure, Rabies - see Emergency"}, 
{"Row" : 38, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" : 11, "Column" : 3, "Text" : "Post-exposure prophylaxis, Rabies - see Emergency"}, 
{"Row" : 12, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" :107, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "DisplayText" : "Cardiovascular", "Text" : "Cardiovascular Section", "Mnemonic" : "185"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Bite, tick", "Mnemonic" : "115"},
{"Row" :187, "Column" : 3, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Tick Bite", "Mnemonic" : "1191"}
]},
{"Name" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES" , "Term1" : "Cardiovascular device infections (excluding valves)", "DisplayText" : "Infections involves cardiovascular devices (excluding valves) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO+RIFAMP 300MG PO Q8H", "DisplayText" : "VANCO 15MG/KG IV Q12H RIFAMPIN 300 MG PO Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> rifampin 300 mg PO/NG q8h ($)", "Mnemonic" : "6"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 1 MG/KG IV Q8H", "DisplayText" : "Gentamicin 1 mg/kg IV Q8H", "Text" : "< ADD > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "INFECTIONS INVOLVING CARDIOVASCULAR DEVICES (EXCLUDING VALVES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most infections are associated with Staphylococcus aureus and coagulase-negative"}, 
{"Row" :6, "Column" : 1, "Text" : "staphylococci.Many of these staphylococci are resistant to methicillin, so"}, 
{"Row" :7, "Column" : 1, "Text" : "initial empiric therapy with vancomycin is required. Consultation with"}, 
{"Row" :8, "Column" : 1, "Text" : "Infectious Diseases is encouraged for patients with severe allergies to"}, 
{"Row" :9, "Column" : 1, "Text" : "vancomycin or for those who have vancomycin-resistant infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "At least 3 blood cultures should be drawn prior to the initiation of empirical"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobial. Modify antimicrobial regimen and narrow coverage based on results"}, 
{"Row" : 13, "Column" : 1, "Text" : "of culture and susceptibility tests Infectious Disease and Cardiothoracic"}, 
{"Row" : 14, "Column" : 1, "Text" : "surgery consultations are encouraged."}, 
{"Row" : 16, "Column" : 1, "Text" : "Device removal is necessary for cure in most cases.However, it may be"}, 
{"Row" : 17, "Column" : 1, "Text" : "difficult depending on the nature of the device and specific clinical"}, 
{"Row" : 18, "Column" : 1, "Text" : "circumstances.Device removal should be discussed with Cardiology, Infectious"}, 
{"Row" : 19, "Column" : 1, "Text" : "Disease, or Cardiothoracic surgery consultants."}, 
{"Row" : 21, "Column" : 1, "Text" : "If the device removal is not possible add rifampin."}, 
{"Row" : 23, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Duration of therapy should be determined in concert with Cardiology, Infectious"}, 
{"Row" : 25, "Column" : 1, "Text" : "Disease, or Cardiothoracic surgery consultants."}, 
{"Row" : 27, "Column" : 1, "Text" : "Empiric treatment in cases where device removal is planned", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Empiric treatment in cases where surgery cannot be performed", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "[DI,O]"}, 
{"Row" : 34, "Column" : 1, "Text" : "For hemodynamically unstable patients, add gentamicin to one of the above", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "treatment regimens", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Baddour et al., Circulation 2010, 121.458-477"}, 
{"Row" : 42, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 43, "Column" : 1, "Text" : "Kusumoto et al., Heart Rhythm 2017, 14.15"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Pacemaker/Defibrillator Infections"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Infections of Nonvalvular Cardiovascular Devices"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Infections involving cardiac implantable electronic devices: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Treatment and prevention"}, 
{"Row" : 48, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ABX INFECTION CTRL" , "Term1" : "Infection control department information", "DisplayText" : "Infection Control " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX MVAMC INTRANET INFECT CTRL", "DisplayText" : "Minneapolis SharePoint Infection Control website", "Text" : "[Click here] Minneapolis VAMC Infection Prevention & Control SharePoint site", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX CDC WEBSITE", "DisplayText" : "CDC website for the Infectious Diseases", "Text" : "[Click here] CDC website", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "[Click here] Consult Infectious Diseases (inpatient)", "Mnemonic" : "8"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX ISOLATION SIGNS", "DisplayText" : "Minneapolis VAMC Isolation Precautions", "Text" : "[Click here] Minneapolis VAMC Isolation Precautions", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INFECTION CONTROL", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Minneapolis VAMC infection control policies and practices are designed to"}, 
{"Row" :6, "Column" : 1, "Text" : "prevent infection and infectious diseases among patients, employees, visitors,"}, 
{"Row" :7, "Column" : 1, "Text" : "families and friends. This section briefly summarizes key infection control"}, 
{"Row" :8, "Column" : 1, "Text" : "practices."}, 
{"Row" :9, "Column" : 1, "Text" : "____________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "For more information", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "____________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : ">> Infection Prevention is available via phone (612-467-6888) during"}, 
{"Row" : 15, "Column" : 1, "Text" : "duty hours Monday to Friday. (Internal extension 31-6888)"}, 
{"Row" : 17, "Column" : 1, "Text" : ">> During nights, weekends, and holidays, contact the on-call person for"}, 
{"Row" : 18, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 21, "Column" : 1, "Text" : ">> Minneapolis VAMC Infection Prevention and Control SharePoint site"}, 
{"Row" : 24, "Column" : 1, "Text" : ">> CDC web site (www.cdc.gov)"}, 
{"Row" : 30, "Column" : 1, "Text" : "____________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Standard and special precautions", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "____________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "[Click here] Consult Infectious Diseases (outpatient)", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Text" : ">> Place consults for ID"}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "[Click here] Minneapolis Clinical On-Call Schedule", "Mnemonic" : "2"}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIVIRAL TREATMENT", "DisplayText" : "ANTIVIRAL TREATMENT", "Text" : "Antiviral Treatment Recommendations", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA CHEMOPROPHYLAXIS", "DisplayText" : "Early treatment as alternative to chemoprophylaxis: ", "Text" : "Chemoprophylaxis Recommendations", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GMENU LAB NASOPHARYNGEAL TESTING MAIN", "DisplayText" : "Nasopharyngeal Testing Menu", "Text" : "Lab Influenza Testing Menu", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "Seasonal Influenza", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Last reviewed September 2022", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza vaccination recommendations", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA CHEMOPROPHYLAXIS", "DisplayText" : "Early treatment as alternative to chemoprophylaxis: ", "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "Early treatment as alternative to chemoprophylaxis: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "In most cases, if a person is suspected of having been exposed to influenza,"}, 
{"Row" :5, "Column" : 1, "Text" : "early treatment should signs or symptoms develop is preferred rather than"}, 
{"Row" :6, "Column" : 1, "Text" : "chemoprophylaxis."}, 
{"Row" :8, "Column" : 1, "Text" : "The provider should explain the early signs and symptoms of influenza to the"}, 
{"Row" :9, "Column" : 1, "Text" : "patient and advise the patient to immediately contact a health care provider"}, 
{"Row" : 10, "Column" : 1, "Text" : "for evaluation and possible early treatment if these symptoms or signs"}, 
{"Row" : 11, "Column" : 1, "Text" : "develop. Influenza-like symptoms or signs include fever, cough, sore throat,"}, 
{"Row" : 12, "Column" : 1, "Text" : "runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and"}, 
{"Row" : 13, "Column" : 1, "Text" : "diarrhea. Influenza can present without fever."}, 
{"Row" : 15, "Column" : 1, "Text" : "Health care providers should use clinical judgment regarding situations where"}, 
{"Row" : 16, "Column" : 1, "Text" : "early recognition of illness and treatment might be an appropriate"}, 
{"Row" : 17, "Column" : 1, "Text" : "alternative to chemoprophylaxis."}, 
{"Row" : 19, "Column" : 1, "Text" : "Early treatment alternative or chemoprophylaxis may be considered: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "*Persons who are part of a high-risk group and are household or close"}, 
{"Row" : 21, "Column" : 1, "Text" : "contacts of someone with influenza-like illness"}, 
{"Row" : 24, "Column" : 1, "Text" : "Chemoprophylaxis recommended: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Chemoprophylaxis considered: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "*Atypical situations (such as case clusters). Contact state health department"}, 
{"Row" : 34, "Column" : 1, "Text" : "for consultation."}, 
{"Row" : 42, "Column" : 1, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such"}, 
{"Row" : 43, "Column" : 1, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have"}, 
{"Row" : 44, "Column" : 1, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using"}, 
{"Row" : 45, "Column" : 1, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the"}, 
{"Row" : 46, "Column" : 1, "Text" : "bronchodilator."}, 
{"Row" : 47, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Zanamivir 2 inhalations (2 x 5 mg)daily ($) [O]"}, 
{"Row" : 51, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Centers for Disease Control (CDC) (Accessed 9/8/22)"}, 
{"Row" : 25, "Column" : 1, "Text" : "*For control of outbreaks in institutional settings (long-term care"}, 
{"Row" : 26, "Column" : 1, "Text" : "facilities and hospitals)"}, 
{"Row" : 36, "Column" : 1, "Text" : "Antiviral Prophylaxis Recommendations: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID OSELTAMIVIR 75 MG PO DAILY PROPHY", "DisplayText" : "Oseltamivir 75 mg po q daily($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 49, "Column" : 1, "Text" : "(See information above for length of prophylaxis)"}, 
{"Row" : 39, "Column" : 1, "Text" : "(See information above for length of prophylaxis)"}, 
{"Row" : 22, "Column" : 1, "Text" : "Chemoprophylaxis duration: 7 days after last known exposure"}, 
{"Row" : 27, "Column" : 1, "Text" : "Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week"}, 
{"Row" : 28, "Column" : 1, "Text" : "after the last known case identified."}, 
{"Row" : 29, "Column" : 1, "Text" : "Note: Antiviral chemoprophylaxis is recommended for all residents, including"}, 
{"Row" : 30, "Column" : 1, "Text" : "those who have received influenza vaccination."}, 
{"Row" : 37, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative treatment: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm"}, 
{"Row" : 54, "Column" : 1, "Text" : "UpToDate Seasonal influenza in adults: Role of antiviral prophylaxis for"}, 
{"Row" : 55, "Column" : 1, "Text" : "prevention"}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA EGG ALLERGY ACIP", "DisplayText" : "Information on Influenza Vaccinations for patients with egg allergies " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Influenza Vaccine for Patients with Egg Allergies", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Previously the ACIP had recommended that persons with serious egg allergies"}, 
{"Row" :5, "Column" : 1, "Text" : "receive the egg-free influenza vaccine- i.e FluBlok. In 2016-2017 the ACIP"}, 
{"Row" :6, "Column" : 1, "Text" : "changed the recommendation for persons with egg-allergies to state that"}, 
{"Row" :7, "Column" : 1, "Text" : "all persons should receive any formulation of age-appropriate flu vaccine"}, 
{"Row" :8, "Column" : 1, "Text" : "regardless of egg allergy."}, 
{"Row" : 10, "Column" : 1, "Text" : "This change was based on data from large studies of greater than 4000 egg"}, 
{"Row" : 11, "Column" : 1, "Text" : "allergic patients with 500 of them having severe egg allergy who received"}, 
{"Row" : 12, "Column" : 1, "Text" : "the influenza vaccine with no anaphylactic reactions. Egg-allergic patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "should be monitored just like everyone else for 15 minutes after influenza"}, 
{"Row" : 14, "Column" : 1, "Text" : "vaccine receipt."}, 
{"Row" : 16, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2021, 70(5):1-28"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-to-date online: Influenza vaccination in individuals with egg allergy"}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Text" : "Annual influenza vaccination is recommended for all persons aged 6"}, 
{"Row" :8, "Column" : 1, "Text" : "months and older without a specific contraindication."}, 
{"Row" : 13, "Column" : 1, "Text" : "B viruses."}, 
{"Row" : 37, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Minneapolis VAHCS Influenza Commitee 2022-2023"}, 
{"Row" : 38, "Column" : 1, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2022, 71(1):1-28"}, 
{"Row" : 24, "Column" : 1, "Text" : "Adults aged >/= 65 years: Adjuvanted vaccine (Flu-Ad) quadrivalent once"}, 
{"Row" : 25, "Column" : 1, "Text" : "Adults aged <65 years: standard quadrivalent vaccine once"}, 
{"Row" :9, "Column" : 1, "Text" : "Adjuvanted influenza vaccines - an ingredient is added to help create a"}, 
{"Row" : 10, "Column" : 1, "Text" : "stronger immune response."}, 
{"Row" : 11, "Column" : 1, "Text" : "Quadrivalent influenza vaccine - made up of the four flu strains most likely"}, 
{"Row" : 12, "Column" : 1, "Text" : "to cause the flu during the upcoming season (H1N1, H3N2, and two group"}, 
{"Row" : 15, "Column" : 1, "Text" : "Eggs and latex allergies are NOT considered contraindications to receiving"}, 
{"Row" : 16, "Column" : 1, "Text" : "the vaccine, the only contraindication to the flu vaccination is severe"}, 
{"Row" : 17, "Column" : 1, "Text" : "allergic reaction (i.e. Anaphylactic reactions)."}, 
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX INFLUENZA INPATIENT", "DisplayText" : "Influenza Inpatient", "Text" : "[Click here] Inpatient Influenza Vaccine Guidelines", "Mnemonic" : "4"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZ INFLUENZA VACCINE ONCE ON ADMIT FLUAD HIGH 2022", "DisplayText" : "Adjuvanted influenza vaccine for OVER 65 years old only", "Text" : "*For Inpts Age >/= 65 Use Only* Adjuvanted influenza vaccine (Flu-Ad) once", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZ INFLUENZA VACCINE ONCE ON ADMIT STANDARD 2022", "DisplayText" : "Standard influenza vaccine", "Text" : "*For Inpts Age <65 Use Only* Standard quadrivalent influenza vaccine once", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Text" : "Outpatient Vaccination: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Administer via standing order protocol - no patient specific order needed"}, 
{"Row" : 30, "Column" : 1, "Text" : "Inpatient Vaccination: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Influenza 2022-2023 Vaccination Recommendations: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Influenza orders are part of admission order set. For those who require an order"}, 
{"Row" : 32, "Column" : 1, "Text" : "due to admission order being discontinued/expired or if patient was admitted"}, 
{"Row" : 33, "Column" : 1, "Text" : "prior to influenza season, use orders below: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Recommend observing all patients for 15 minutes after receipt of any", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "influenza vaccine. A previous severe allergic reaction to influenza vaccine,", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "regardless of the component suspected of being responsible for the reaction,", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "is a contraindication to future receipt of ANY influenza vaccine.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "MVAHCS Vaccination Recommendations Inpatient and Outpatient: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX INI EPI ABX ASSOC COLITIS", "DisplayText" : "Initial Episode of Antibiotic Associated Colitis... " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO Q6H X10DAYS CDIFF", "DisplayText" : "Vancomycin 125mg PO q6h for 10 days for C.difficile infection. ($) [M]", "Text" : "Vancomycin 125mg PO q6h for 10 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "Select for Fulminant CDI", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 23, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 24, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential."}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical"}, 
{"Row" : 35, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG PO Q12H 10DAYS", "DisplayText" : "Fidaxomicin 200 mg PO bid for 10 days ($$) [M]", "Text" : "Fidaxomicin 200 mg PO q12h for 10 days ($$) [M]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Text" : "Patient at increased risk of CDI recurrence: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,"}, 
{"Row" : 16, "Column" : 1, "Text" : "and/or immunosuppression)"}, 
{"Row" : 19, "Column" : 1, "Text" : "Patient not meeting criteria above for increased risk of CDI recurrence: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patient with clinical symptom onset (e.g. 3 or more unformed stools in 24 hours"}, 
{"Row" :7, "Column" : 1, "Text" : "after discontinuation of laxatives) and laboratory confirmation of CDI."}, 
{"Row" : 30, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 31, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" : 12, "Column" : 1, "Text" : "Initial Episode Non-Severe", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Fulminant CDI", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "INITIAL EPISODE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "<Click here> Information on C. difficile lab testing", "Mnemonic" : "3"}
]},
{"Name" : "ORZID2 GMENU ABX INPT MAIN", "DisplayText" : "Inpatient Antimicrobial Computer Decision Support System (CDSS) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX INDEX INPATIENT", "DisplayText" : "Inpatient Antimicrobial CDSS Index", "Text" : "[CLICK HERE]", "Mnemonic" : "7"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "DisplayText" : "Central Nervous System", "Text" : "Central Nervous System", "Mnemonic" : "11"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "DisplayText" : "Head and Neck", "Text" : "Head and Neck", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "DisplayText" : "Lung and Mediastinum", "Text" : "Lungs & Mediastinum", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "[b] Influenza Seasonal 2022-2023"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA", "DisplayText" : "Pneumonia", "Text" : "[c] Pneumonia"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "DisplayText" : "Cardiovascular", "Text" : "Cardiovascular", "Mnemonic" : "20"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX GASTROINTESTINAL", "DisplayText" : "Gastrointestinal and Intraabdominal", "Text" : "GI & Intraabdominal", "Mnemonic" : "22"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[a] C. difficile Colitis Mild/Moderate"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENITOURINARY", "DisplayText" : "Genitourinary", "Text" : "Urogenital", "Mnemonic" : "26"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "[a] Sexually Transmitted Infections (STI)"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "DisplayText" : "Soft tissue, muscle, bone and joint infections", "Text" : "Soft Tissue, Muscle, Bone and Joint Infection", "Mnemonic" : "30"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "DisplayText" : "Dermatological Infections", "Text" : "Skin", "Mnemonic" : "32"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES", "DisplayText" : "Systemic Infectious Diseases", "Text" : "Systemic Infections", "Mnemonic" : "34"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "DisplayText" : "Bacteremia", "Text" : "[a] Bacteremia"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "[b] Sepsis and Septic Shock"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "[c] Neutropenic Fever"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "DisplayText" : "Introduction to Specific Pathogen section", "Text" : "Introduction to Specific Pathogen", "Mnemonic" : "42"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram-negative Bacteria", "Text" : "Gram-negative Bacteria", "Mnemonic" : "44"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "DisplayText" : "Gram-positive bacteria", "Text" : "Gram-positive Bacteria", "Mnemonic" : "46"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX VIRUSES", "DisplayText" : "Viruses", "Text" : "Viruses", "Mnemonic" : "48"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "DisplayText" : "Fungi", "Text" : "Fungi", "Mnemonic" : "50"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU PARASITES", "DisplayText" : "Parasites", "Text" : "Parasites", "Mnemonic" : "52"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU OTHER PATHOGENS", "DisplayText" : "Other pathogens", "Text" : "Other Pathogens", "Mnemonic" : "54"},
{"Row" :107, "Column" : 1, "Item" : "ORZID2 GMENU ABX TESTING INPATIENT MENU", "DisplayText" : "CDSS INPATIENT TESTING MENU", "Text" : "Inpatient Testing Menu", "Mnemonic" : "56"},
{"Row" :4, "Column" : 1, "Text" : "*******************************************************"}, 
{"Row" :5, "Column" : 1, "Text" : "* ANTIMICROBIAL DECISION SUPPORT *"}, 
{"Row" :6, "Column" : 1, "Text" : "* >>>>>>>>INPATIENT<<<<<<<<<*"}, 
{"Row" :7, "Column" : 1, "Text" : "*******************************************************"}, 
{"Row" :8, "Column" : 1, "Text" : "Welcome.Please click on the"}, 
{"Row" :9, "Column" : 1, "Text" : "diagnosis or syndrome you wish to treat."}, 
{"Row" : 17, "Column" : 1, "Text" : "Index of Antimicrobial CDSS content", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Syndromes and diseases, by body systems", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Specific organisms", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Medicine is an inexact and rapidly"}, 
{"Row" : 53, "Column" : 1, "Text" : "changing discipline.The developers of"}, 
{"Row" : 54, "Column" : 1, "Text" : "this system have made every effort to"}, 
{"Row" : 55, "Column" : 1, "Text" : "provide current, accurate information."}, 
{"Row" : 56, "Column" : 1, "Text" : "However, in view of the possibility of"}, 
{"Row" : 57, "Column" : 1, "Text" : "human error or changes in medical"}, 
{"Row" : 58, "Column" : 1, "Text" : "service, readers are encouraged to"}, 
{"Row" : 59, "Column" : 1, "Text" : "confirm the information contained"}, 
{"Row" : 60, "Column" : 1, "Text" : "herein with other sources.In"}, 
{"Row" : 61, "Column" : 1, "Text" : "particular, readers are encouraged to"}, 
{"Row" : 62, "Column" : 1, "Text" : "check the product information for"}, 
{"Row" : 63, "Column" : 1, "Text" : "antimicrobials to be certain that"}, 
{"Row" : 64, "Column" : 1, "Text" : "information in this system is accurate"}, 
{"Row" : 65, "Column" : 1, "Text" : "and current, especially for new or"}, 
{"Row" : 66, "Column" : 1, "Text" : "infrequently used drugs."}, 
{"Row" :2, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact CDSS & ASP Staff", "Mnemonic" : "58"},
{"Row" :3, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page...", "Mnemonic" : "60"},
{"Row" :4, "Column" : 2, "Item" : "ORZ GTX ABX CDSS FAQ", "DisplayText" : "CDSS FAQ", "Text" : "Frequently Asked questions (FAQ)", "Mnemonic" : "62"},
{"Row" :5, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or Suggestions about this CDSS", "Mnemonic" : "64"},
{"Row" :9, "Column" : 2, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "DisplayText" : "Antimicrobial Formulary Hyperlink", "Text" : "Antimicrobial Formulary (Restricted)", "Mnemonic" : "68"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "Restrictions on Antimicrobials", "Mnemonic" : "70"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "DisplayText" : "Adjust existing antimicrobial therapy", "Text" : "Adjust Existing Antimicrobial Therapy", "Mnemonic" : "72"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "DisplayText" : "How to find an alternative antimicrobial", "Text" : "How to Find Alternative Antimicrobials", "Mnemonic" : "74"},
{"Row" : 13, "Column" : 2, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Clinical On-Call Schedule (Infectious Disease)", "Mnemonic" : "76"},
{"Row" : 14, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "DisplayText" : "UP TO DATE WEB SITE", "Text" : "Up-to-date Online (Clinical Resource)", "Mnemonic" : "78"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "DisplayText" : "Infection Control", "Text" : "Infection Control/Prevention Information", "Mnemonic" : "80"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatological Guidelines", "Mnemonic" : "82"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS", "DisplayText" : "Device-related infections", "Text" : "Device-related Infections", "Mnemonic" : "84"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "DisplayText" : "Prevention of Infection", "Text" : "Prevention of Infection", "Mnemonic" : "86"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "HIV-AIDS", "Mnemonic" : "88"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT", "DisplayText" : "Infections in Immunocompromised Patients", "Text" : "Immunocompromised Patients", "Mnemonic" : "90"},
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Antimicrobial Prophylaxis Pre-op", "Mnemonic" : "92"},
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Antimicrobial Prophylaxis Post-op", "Mnemonic" : "94"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Surgical Site Infections", "Mnemonic" : "96"},
{"Row" : 42, "Column" : 2, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Important Drug (Abx) Properties", "Mnemonic" : "99"},
{"Row" : 43, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "DisplayText" : "Lexicomp Online", "Text" : "Lexicomp Online Drug Information", "Mnemonic" : "100"},
{"Row" : 44, "Column" : 2, "Item" : "ORZ GTX ABX RESOURCE QTC", "DisplayText" : "RESOURCE QTC PROLONGATION FOR DRUGS", "Text" : "QT Prolongation Drug Resource", "Mnemonic" : "102"},
{"Row" : 45, "Column" : 2, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "DDI Warfarin and Antimicrobials", "Mnemonic" : "104"},
{"Row" : 46, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category", "Text" : "Pregnancy Risk Factors for Antibiotics", "Mnemonic" : "106"},
{"Row" : 47, "Column" : 2, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of Antimicrobials", "Mnemonic" : "108"},
{"Row" : 50, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT REQUIRED MAIN", "DisplayText" : "Antibiotics not required", "Text" : "Conditions NOT benefitted by antibiotics", "Mnemonic" : "110"},
{"Row" : 51, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "ESBLs, Amp-C beta-lactamases and Carbapenemases", "Mnemonic" : "112"},
{"Row" :1, "Column" : 2, "Text" : "HELP", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "General", "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Text" : "Surgical: Antimicrobial Prophylaxis and Site Infections", "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Text" : "Drug Information Links", "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Text" : "Miscellaneous/Emerging Topics", "Header" : 1}, 
{"Row" :106, "Column" : 1, "Item" : "ORZID2 GMENU ABX CDSS VERSION", "DisplayText" : "CDSS VERSION", "Text" : "", "Mnemonic" : "999"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "[b] C. difficile Fulminant (severe/complicated)"},
{"Row" : 14, "Column" : 1, "Text" : "CDSS-MicroGuide Web and Mobile App", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "DisplayText" : "MicroGuide Mobile App Instructions", "Text" : "[CLICK HERE]", "Mnemonic" : "4"},
{"Row" : 91, "Column" : 1, "Text" : "TESTING MENU ONLY- DO NOT USE TO PLACE ORDERS", "Header" : 1}, 
{"Row" :104, "Column" : 1, "Item" : "LRTZ SET PAN CULTURE", "DisplayText" : "Pan Culture", "Text" : "", "Mnemonic" : "140"},
{"Row" :105, "Column" : 1, "Item" : "ORZ SET LOWER EXTREMITY BYPASS PREOP VASCULAR SURGERY", "DisplayText" : "L/E Bypass Preop Set", "Text" : "", "Mnemonic" : "150"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPROACH TO UTI", "DisplayText" : "Approach to Urinary Tract Infection (UTI)", "Text" : "[b] Urinary Tract Infections"},
{"Row" : 87, "Column" : 1, "Text" : "Testing Menu:Restricted to ID/ED", "Header" : 1}, 
{"Row" :102, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting", "Text" : "COVID-19 Vaccine Inpt Testing Menu", "Mnemonic" : "55"},
{"Row" :103, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE CLC", "DisplayText" : "CLC COVID VACCINE (PFIZER-BIONTECH)", "Text" : "CLC COVID-19 VACCINES", "Mnemonic" : "999"},
{"Row" :101, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "DisplayText" : "Tocilizumab for treatment of COVID-19", "Text" : "Tocilizumab COVID-19 Treatment", "Mnemonic" : "xx"},
{"Row" :2, "Column" : 1, "Text" : "Call Ext 31-3144 to expedite URGENT Outpatient prescriptions", "Header" : 1}, 
{"Row" : 52, "Column" : 2, "Item" : "ORZID2 GMENU ABX VANCO + MRSA NARES INFORMATION", "DisplayText" : "Information on Vancomycin IV New Starts and MRSA Nares Testing", "Text" : "MRSA Nares Screening-Vanco New Start", "Mnemonic" : "116"},
{"Row" : 21, "Column" : 1, "Text" : "(List starts at top and goes down body systems)"}, 
{"Row" :109, "Column" : 1, "Item" : "PSJIZID TEST QOA", "DisplayText" : "TST", "Text" : "TEST", "Mnemonic" : "190"},
{"Row" :110, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 8MG/KG IV X1 COVID-19 DOSE 2", "DisplayText" : "Tocilizumab 8 mg/kg IV x1 dose 2 for COVID-19", "Text" : "TESTING DOSE 2 TOCI", "Mnemonic" : "220"},
{"Row" : 89, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOTROVIMAB EUA", "DisplayText" : "Sotrovimab (EUA) Orders", "Text" : "Sotrovimab (EUA) Menu/orders", "Mnemonic" : "200"},
{"Row" : 83, "Column" : 1, "Item" : "PSJZID2 NIRMATRELVIR 150MG RITONAVIR 100MG PO BID 5D", "DisplayText" : "Paxlovid (nirmatrelvir-ritonavir) 150 mg - 100 mg PO BID for 5 days", "Text" : "Inpatient Paxlovid Renally Dosed UD Order", "Mnemonic" : "118"},
{"Row" : 84, "Column" : 1, "Item" : "PSJZID2 MOLNUPIRAVIR 800 MG PO BID 5DS", "DisplayText" : "Molnupiravir 800 mg PO BID for 5 days Inpt", "Text" : "Inpatient Molnupiravir UD Order", "Mnemonic" : "120"},
{"Row" : 82, "Column" : 1, "Text" : "**FOR INPATIENT PHARMACY USE ONLY**", "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "Emergency Use Authorization (EUA) SharePoint Site", "Mnemonic" : "121"},
{"Row" :100, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINE", "DisplayText" : "Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines", "Text" : "COVID-19 Inpt Treatment Guidelines Edits", "Mnemonic" : "999"},
{"Row" :112, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "", "Mnemonic" : "500"},
{"Row" : 99, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU TESTING", "DisplayText" : "Epididymitis", "Text" : "Lab menu test - epididymitis", "Mnemonic" : "test"},
{"Row" : 97, "Column" : 1, "Item" : "ORZID2 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*FOR ID USE ONLY* Monkeypox Treatment with TPOXX", "Mnemonic" : "Inpt"},
{"Row" : 98, "Column" : 1, "Item" : "ORZID3 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*FOR ID USE ONLY* Monkeypox Treatment with TPOXX", "Mnemonic" : "Opt"},
{"Row" : 88, "Column" : 1, "Item" : "ORZ GTX ABX TESTING ORDER DIALOG", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "TEST", "Mnemonic" : "TEST"},
{"Row" : 95, "Column" : 1, "Item" : "SD RTC", "DisplayText" : "Return To Clinic", "Text" : "GO RTC", "Mnemonic" : "TEST"},
{"Row" : 96, "Column" : 1, "Item" : "SDZ RTC 3D ID INJECTION", "DisplayText" : "3D ID Injection", "Text" : "QUICK ORDER RTC", "Mnemonic" : "TEST"},
{"Row" : 94, "Column" : 1, "Item" : "SDZ RTC ID VACCINE ADMIN", "DisplayText" : "Return to clinic for vaccine administration", "Text" : "CDSS RTC VACCCINE", "Mnemonic" : "TEST"},
{"Row" : 77, "Column" : 1, "Text" : "Vaccine Order Testing", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZ SET ABX OP VACCINE TESTING", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A vaccine order set test", "Mnemonic" : "Test"},
{"Row" : 79, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting", "Text" : "Bivalent COVID-19 Vaccine Testing", "Mnemonic" : "Test"},
{"Row" : 80, "Column" : 1, "Item" : "ORZ GTX ABX MONKEYPOX VACCINE NURSING TEXT ORDER", "DisplayText" : "Nursing Vaccine Administration Text Order", "Text" : "Monkeypox nursing text order", "Mnemonic" : "Test"},
{"Row" :7, "Column" : 2, "Text" : "Important Antimicrobial Information", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "**************"}, 
{"Row" : 36, "Column" : 2, "Text" : "Monkeypox", "Header" : 1}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZ GTX ABX MONKEYPOX SHAREPOINT SITE", "DisplayText" : "Monkeypox SharePoint Link", "Text" : "", "Mnemonic" : "98a"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*ID Providers Only*Monkeypox Treatment", "Mnemonic" : "98b"},
{"Row" : 39, "Column" : 2, "Text" : "Monkeypox vaccine - see Outpatient CDSS"}, 
{"Row" : 74, "Column" : 1, "Text" : "Amoxicillin Challenge Testing", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU ABX AMOXICILLIN CHALLENGE ALLERGY", "DisplayText" : "Amoxicillin Challenge", "Text" : "", "Mnemonic" : "200"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram (Susceptibilities)", "Mnemonic" : "66"},
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact CDSS & ASP Staff", "Mnemonic" : "411"},
{"Row" : 17, "Column" : 2, "Text" : "Beta-lactam Reaction Assessment", "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "", "Mnemonic" : "81a"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Text Version", "Mnemonic" : "81b"},
{"Row" : 28, "Column" : 2, "Text" : "Immunization Information and Vaccine Orders", "Header" : 1}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU ABX RECOMMENDED IMMUNIZATIONS", "DisplayText" : "CDC Recommended Adult Immunizations", "Text" : "Recommended Adult Immunizations", "Mnemonic" : "91"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MAIN MENU", "DisplayText" : "COVID-19", "Text" : "[a] COVID-19"},
{"Row" : 70, "Column" : 1, "Text" : "TEST: C diff 2-step lab testing", "Header" : 1}, 
{"Row" : 92, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "VANCO NOW MRSA SCREEN ORDER SET", "Mnemonic" : "TEST"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "C difficile 2-step Testing", "Mnemonic" : "300"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "Information C diff 2-step lab testing", "Mnemonic" : "2"},
{"Row" : 72, "Column" : 1, "Item" : "ORZ SET ABX C DIFF 2-STEP LAB ORDER + SYMPTOMS CONFIRMATION", "DisplayText" : "C. difficile 2-step lab order", "Text" : "C. difficile 2-step lab order + symptoms confirmation", "Mnemonic" : "301"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "[d] Lyme disease"},
{"Row" : 76, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H X 2DOSES", "DisplayText" : "Cefazolin 2gm IVPB q8h x 2doses post-op ($) [R]", "Text" : "CEFAZOLIN TEST IVPB 2GM", "Mnemonic" : "202"},
{"Row" : 73, "Column" : 1, "Item" : "ORZ GTX ABX WEIGHT FOR ABX DOSING", "DisplayText" : "Last recorded weight", "Text" : "TESTING", "Mnemonic" : "100"},
{"Row" : 11, "Column" : 1, "Text" : "C diff 2-step testing", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGY NEW", "DisplayText" : "Urological procedures", "Text" : "TEST Urology Preop", "Mnemonic" : "200"},
{"Row" : 68, "Column" : 1, "Text" : "TESTING MENU- Do NOT use", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ISOSPORA" , "Term1" : "Isospora diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Isospora belli" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO Q12H for 7 to 10 days ($)", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 75MG PO Q24H LEUCOVORIN 25MG PO Q24H", "DisplayText" : "Pyrimethamine 75 mg PO q24h for 21-28 days ($$) [DI,O] <AND> leucovorin 25", "Text" : "Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg q24h ($) for", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB PO Q6H", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS q6h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS q6h for 10 days ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 75MG PO Q24H LEUCOVORIN 25MG PO Q24H", "DisplayText" : "Pyrimethamine 75 mg PO q24h for 21-28 days ($$) [DI,O] <AND> leucovorin 25", "Text" : "Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg PO q24h ($)", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB Q72H", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO q72h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO QOD ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 25MG PO Q24H LEUCOVORIN 10MG PO Q24H", "DisplayText" : "Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> leucovorin 10 mg q24h ($)", "Text" : "Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> leucovorin PO mg PO q24h ($)", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompetent persons."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial treatment of persons without HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[R,DI]"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 18, "Column" : 1, "Text" : "for 21-28 days"}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial treatment of persons with HIV/AIDS", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Infectious Diseases involvement is essential. Initial treatment of acute"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection is followed by secondary prophylaxis until CD4 count is >200 for >6"}, 
{"Row" : 24, "Column" : 1, "Text" : "months in response to ART without evidence of active C. belli."}, 
{"Row" : 25, "Column" : 1, "Text" : "Initial treatment", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 30, "Column" : 1, "Text" : "for 21 to 28 days"}, 
{"Row" : 32, "Column" : 1, "Text" : "Secondary prophylaxis", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 39, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 42, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Cystoisospora belli"}, 
{"Row" : 44, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-to-Date article: Management of Cystoisospora (Isospora) infections"}
]},
{"Name" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture", "Text" : "Urine culture", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "ANTIMICROBIAL CDSS LAB MENU", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Urogenital lab orders", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Item" : "LRTZID URINE ANALYSIS", "DisplayText" : "Urine analysis", "Text" : "Urinalysis", "Mnemonic" : "4"},
{"Row" :5, "Column" : 1, "Item" : "LRTZID BLOOD CULTURE", "DisplayText" : "Blood culture", "Text" : "Blood culture", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC RECTAL SWAB", "DisplayText" : "Chlamydia/GC Rectal Swab", "Text" : "Rectal swab", "Mnemonic" : "7"},
{"Row" : 11, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC THROAT SWAB", "DisplayText" : "Chlamydia/GC Throat Swab", "Text" : "Throat swab", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "Urine NAAT", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Text" : "Gonorrhea and chlamydia lab orders"}
]},
{"Name" : "ORZID2 GMENU ABX LAB MENU TESTING", "DisplayText" : "Epididymitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE LEVOFLOX 500MG PO Q24H", "DisplayText" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Mnemonic" : "6"},
{"Row" : 49, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "8"},
{"Row" : 51, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) for 10 days", "Mnemonic" : "10"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 10 days", "Mnemonic" : "12"},
{"Row" : 56, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "14"},
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE DOXY 100MG PO Q12H", "DisplayText" : "Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "16"},
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 1GM IM ONCE DOXY PO 100MG Q12H GONOCOCC", "DisplayText" : "Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "18"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "20"},
{"Row" : 70, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "22"},
{"Row" : 72, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV q24h ($) for 10 days", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Epididymitis is inflammation of the epididymis and when testicles are involved"}, 
{"Row" :6, "Column" : 1, "Text" : "is referred to as epididymo-orchitis. Acute epididymitis is the most common"}, 
{"Row" :7, "Column" : 1, "Text" : "cause of scrotal pain in adults. Other features include scrotal erythema and"}, 
{"Row" :8, "Column" : 1, "Text" : "edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually"}, 
{"Row" :9, "Column" : 1, "Text" : "unilateral. It is primarily caused by infection but can also result from trauma"}, 
{"Row" : 10, "Column" : 1, "Text" : "and autoimmune diseases. Testicular torsion should be ruled out before"}, 
{"Row" : 11, "Column" : 1, "Text" : "treatment. Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 12, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 13, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 are associated"}, 
{"Row" : 14, "Column" : 1, "Text" : "with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if"}, 
{"Row" : 15, "Column" : 1, "Text" : "the patient has been in the hospital for more than 48 hours or received a course"}, 
{"Row" : 16, "Column" : 1, "Text" : "of antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 17, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 19, "Column" : 1, "Text" : "A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be performed in all cases of suspected epididymitis before starting"}, 
{"Row" : 21, "Column" : 1, "Text" : "treatment to guide therapy: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 25, "Column" : 1, "Text" : "treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve"}, 
{"Row" : 29, "Column" : 1, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal"}, 
{"Row" : 30, "Column" : 1, "Text" : "pain and referral to a urologist should be considered."}, 
{"Row" : 32, "Column" : 1, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older men"}, 
{"Row" : 33, "Column" : 1, "Text" : "should have their residual urinary volume checked. If the residual volume is"}, 
{"Row" : 34, "Column" : 1, "Text" : "elevated, the patient should be seen by a urologist as epididymitis is unlikely"}, 
{"Row" : 35, "Column" : 1, "Text" : "to respond if the prostate is blocking the vas deferens."}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical treatment in men who practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "for 10 days ($) [R, DI]"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Empirical treatment in men who do not practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Age >/= 35 years or", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "biopsy, vasectomy): ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 58, "Column" : 1, "Text" : "Age < 35 years", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Patient weighing less than 300 lbs"}, 
{"Row" : 62, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 64, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater"}, 
{"Row" : 66, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 68, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 71, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 73, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 78, "Column" : 1, "Text" : "Sanford keyword: Epididymo-orchitis"}, 
{"Row" : 79, "Column" : 1, "Text" : "Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3"}, 
{"Row" : 80, "Column" : 1, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults"}, 
{"Row" : 81, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP" , "Term1" : "Laryngitis", "DisplayText" : "Laryngitis and Croup" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LARYNGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,"}, 
{"Row" :6, "Column" : 1, "Text" : "coronavirus). Treatment is based on symptomatic therapy alone."}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Mandell chapter: Acute laryngitis"}, 
{"Row" : 12, "Column" : 1, "Text" : "Up-To-Date article: Hoarseness in adults"}
]},
{"Name" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS" , "Term1" : "Amebic liver abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX METRO 750MG PO Q8H PAROMOMYC 25-35MG/KG/DAY PO Q8H", "DisplayText" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Text" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "AMEBIC LIVER ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Serological testing for amoebiasis should be obtained in all patients with"}, 
{"Row" :6, "Column" : 1, "Text" : "suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood"}, 
{"Row" :7, "Column" : 1, "Text" : "cultures should also be obtained prior to starting antibiotics to exclude"}, 
{"Row" :8, "Column" : 1, "Text" : "pyogenic liver abscess, which is a much more common cause of liver abscess."}, 
{"Row" :9, "Column" : 1, "Text" : "Serologic testing can be negative in a small number of patients with acute"}, 
{"Row" : 10, "Column" : 1, "Text" : "presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat"}, 
{"Row" : 11, "Column" : 1, "Text" : "serological testing is negative for amoebiasis or patient does not respond to"}, 
{"Row" : 12, "Column" : 1, "Text" : "treatment of amebic liver abscess, patient should have further diagnostic"}, 
{"Row" : 13, "Column" : 1, "Text" : "testing completed to exclude pyogenic liver abscess."}, 
{"Row" : 15, "Column" : 1, "Text" : "Drainage of amebic liver abscess should be considered in patients with large"}, 
{"Row" : 16, "Column" : 1, "Text" : "lesions at risk of rupture."}, 
{"Row" : 18, "Column" : 1, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation"}, 
{"Row" : 19, "Column" : 1, "Text" : "is recommended in all patients with liver abscess."}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of patients with confirmed or suspected amebic liver abscess (obtain", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "blood cultures prior to starting in suspected cases)", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Paromomycin is nonformulary and must be ordered by Infectious Diseases."}, 
{"Row" : 25, "Column" : 1, "Text" : "25-35 mg/kg/day PO q8h for 7 days ($) [M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica"}, 
{"Row" : 32, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis"}
]},
{"Name" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS" , "Term1" : "Abscess, liver " , "Term2" : "Hepatic abscess " , "Term3" : "Liver abscess " , "Term4" : "Pyogenic liver abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Link to Amebic Liver Abscess menu", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 39, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "LIVER ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Liver abscess should be suspected in all patients with fever, leukocytosis, and"}, 
{"Row" :6, "Column" : 1, "Text" : "a space-occupying liver lesion. Liver abscesses fall broadly into two"}, 
{"Row" :7, "Column" : 1, "Text" : "categories: pyogenic and amebic. In the United States, pyogenic liver abscess is"}, 
{"Row" :8, "Column" : 1, "Text" : "much more common. Amebic liver abscess occurs almost exclusively in travelers"}, 
{"Row" :9, "Column" : 1, "Text" : "and immigrants. If amebic liver abscess is suspected, select the link below."}, 
{"Row" : 12, "Column" : 1, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation is"}, 
{"Row" : 13, "Column" : 1, "Text" : "recommended in patients with pyogenic liver abscess."}, 
{"Row" : 14, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of pyogenic liver abscess", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "A typical course for pyogenic liver abscess is 4 to 6 weeks."}, 
{"Row" : 21, "Column" : 1, "Text" : "Initial treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for patients with mild to moderate disease and beta lactam allergy"}, 
{"Row" : 28, "Column" : 1, "Text" : "[DI]"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for patients with severe disease and beta lactam allergy"}, 
{"Row" : 32, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 34, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Hepatic Abscess"}, 
{"Row" : 49, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-to-Date article: Pyogenic liver abscess"}
]},
{"Name" : "ORZID2 GMENU ABX LUNG ABSCESS" , "Term1" : "Abscess, lung " , "Term2" : "Lung abscess", "DisplayText" : "Lung abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] < OR >", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($) [H,O]< OR >", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "16"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "LUNG ABSCESS"}, 
{"Row" :4, "Column" : 1, "Text" : "Pulmonary and/or Infectious Diseases consultations are strongly encouraged for"}, 
{"Row" :5, "Column" : 1, "Text" : "all cases.Obtain samples for gram stain and culture from fine needle"}, 
{"Row" :6, "Column" : 1, "Text" : "aspiration whenever possible.Sputum culture is less helpful because it will be"}, 
{"Row" :7, "Column" : 1, "Text" : "contaminated with upper respiratory flora.Classically, lung abscess is a"}, 
{"Row" :8, "Column" : 1, "Text" : "complication of mixed anaerobic and aerobic pulmonary infection. The initial"}, 
{"Row" :9, "Column" : 1, "Text" : "infection may or may not be clinically apparent.Malaise, weight loss, fever,"}, 
{"Row" : 10, "Column" : 1, "Text" : "chills, and malodorous sputum typically develop over a period of weeks."}, 
{"Row" : 12, "Column" : 1, "Text" : "Cavitation and/or abscess can occur in cases of pneumonia from a single"}, 
{"Row" : 13, "Column" : 1, "Text" : "pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobial treatment should be directed against the specific pathogen."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treat for 6 to 8 weeks and adjust treatment based on clinical response.Oral"}, 
{"Row" : 17, "Column" : 1, "Text" : "medications should be used in patients who can take them."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred intravenous treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Preferred oral treatment", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternatives for patient with severe penicillin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "If Staphloccus aureus MRSA suspected: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Bartlett JG Anaerobe 2012, 18:235"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword lung abscess"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 39, "Column" : 1, "Text" : "Harrison's chapter: Infections due to mixed organisms"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM" , "Term1" : "Lungs and Mediastinum section " , "Term2" : "Mediastinum and Lung section", "DisplayText" : "Lung and Mediastinum" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "Bronchitis", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX EMPYEMA", "DisplayText" : "Empyema", "Text" : "Empyema", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "Exacerbation of chronic obstructive pulmonary disease (COPD)", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "Influenza Seasonal", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "DisplayText" : "Lung abscess", "Text" : "Lung abscess", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "DisplayText" : "Mediastinitis", "Text" : "Mediastinitis", "Mnemonic" : "14"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "DisplayText" : "Pertussis", "Text" : "Pertussis", "Mnemonic" : "16"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX TUBERCULOSIS", "DisplayText" : "Tuberculosis", "Text" : "Tuberculosis", "Mnemonic" : "18"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "DisplayText" : "Azithromycin for Prevention of Exacerbations COPD", "Text" : "Azithromycin for prevention of COPD exacerbations", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "++LUNGS AND MEDIASTINUM++", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia", "Text" : "Aspiration pneumonia", "Mnemonic" : "24"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "26"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Nosocomial pneumonia (including HAP and VAP)", "Mnemonic" : "28"},
{"Row" :5, "Column" : 2, "Text" : "Pneumonia", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX LYME DISEASE" , "Term1" : "Lyme disease", "DisplayText" : "Lyme disease" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis", "Text" : "Lyme Disease Prophylaxis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease", "Text" : "Erythema migrans associated with Lyme disease", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE", "DisplayText" : "Acute neurological disease associated with Lyme disease", "Text" : "Acute neurological disease associated with Lyme disease", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU LYME ARTHRITIS", "DisplayText" : "Arthritis associated with Lyme disease", "Text" : "Arthritis associated with Lyme disease", "Mnemonic" : "10"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease", "Text" : "Cardiac disease associated with Lyme disease", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an"}, 
{"Row" :6, "Column" : 1, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30"}, 
{"Row" :7, "Column" : 1, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness."}, 
{"Row" :8, "Column" : 1, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and"}, 
{"Row" :9, "Column" : 1, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick"}, 
{"Row" : 10, "Column" : 1, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not"}, 
{"Row" : 11, "Column" : 1, "Text" : "be treated with antimicrobials."}, 
{"Row" : 13, "Column" : 1, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who"}, 
{"Row" : 14, "Column" : 1, "Text" : "have been bitten while in endemic areas."}, 
{"Row" : 17, "Column" : 1, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged."}, 
{"Row" : 26, "Column" : 1, "Text" : "References"}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 29, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 30, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}
]},
{"Name" : "ORZID2 GMENU ABX MANAGEMENT OF FEBRILE EPISODE ASPLENIA", "DisplayText" : "Management of an Episode of Fever in an Asplenic Patient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOXACIN 400MG IV Q24H VANCO IV Q12H", "DisplayText" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "DisplayText" : "Bacterial meningitis with S. pneumoniae", "Text" : "Bacterial meningitis with S. pneumoniae", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "Fever in an Asplenic Patient", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Patients with impaired splenic function are at risk for severe and"}, 
{"Row" :4, "Column" : 1, "Text" : "and overwhelming infection with encapsulated bacteria. Streptococcus"}, 
{"Row" :5, "Column" : 1, "Text" : "pneumoniae is the most common cause of fulminant sepsis in patients with"}, 
{"Row" :6, "Column" : 1, "Text" : "impaired splenic function, followed by Haemophilus influenzae and Neisseria"}, 
{"Row" :7, "Column" : 1, "Text" : "meningitidis."}, 
{"Row" :9, "Column" : 1, "Text" : "If fever develops in an asplenic patient, immediate administration of an"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobial agent is indicated, because fever can be the initial"}, 
{"Row" : 11, "Column" : 1, "Text" : "manifestation of a fulminant infection and prompt administration of an"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobial agent may prevent the development of clinical sepsis."}, 
{"Row" : 14, "Column" : 1, "Text" : "Administration of antibiotics should not be delayed in order to perform"}, 
{"Row" : 15, "Column" : 1, "Text" : "diagnostic studies, including lumbar punture."}, 
{"Row" : 17, "Column" : 1, "Text" : "Recommended Empiric Therapy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for penicillin/beta lactam allergy: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Streptococcus pneumoniae meningitis suspected: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Rubin LG, N Engl J Med 2014, 371:349-356"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-date online"}
]},
{"Name" : "ORZID2 GMENU ABX MEDIASTINITIS" , "Term1" : "Mediastinitis", "DisplayText" : "Mediastinitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2 gm Iv q8h ($$)[R] <AND> Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> Vancomycin 15 mg/kg IV q12h ($)[R]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600mg IV q8h ($$) [H,O]< OR >", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU Q4H METRONIDAZOLE 500 MGM IV Q8H", "DisplayText" : "Penicillin G 4MU Q4H and Metronidazole 500 MG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($) [R] <AND> metronidazole 500 mg", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG IV Q24H METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "DisplayText" : "Bacillus species", "Text" : "Anthrax section", "Mnemonic" : "16"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "MEDIASTINITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Mediastinitis occurs after cardiothoracic procedures or less commonly after"}, 
{"Row" :5, "Column" : 1, "Text" : "esophageal perforation.Rarely, infectious diseases of the head, neck or thorax"}, 
{"Row" :6, "Column" : 1, "Text" : "spread into the mediastinum.Surgical drainage and antimicrobial therapy are"}, 
{"Row" :7, "Column" : 1, "Text" : "both essential.Specific management depends on the source of infection.Obtain"}, 
{"Row" :8, "Column" : 1, "Text" : "aerobic and anaerobic cultures in all cases."}, 
{"Row" : 10, "Column" : 1, "Text" : "Inhalational anthrax (due to Bacillus anthracis) typically presents as"}, 
{"Row" : 11, "Column" : 1, "Text" : "mediastinitis with cough productive of hemorrhagic secretions.This disease"}, 
{"Row" : 12, "Column" : 1, "Text" : "should be considered in a patient without typical risk factors for mediastinitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "or in the setting of suspected or confirmed bioterrorism.If anthrax is"}, 
{"Row" : 14, "Column" : 1, "Text" : "suspected, page the Infectious Diseases service."}, 
{"Row" : 16, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment AFTER CARDIOTHORACIC SURGERY", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 2 to 3 weeks: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment associated WITH MOUTH/THROAT INFECTION", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Mixed aerobic/anaerobic infection is often present."}, 
{"Row" : 32, "Column" : 1, "Text" : "IV q8h ($) [DI]"}, 
{"Row" : 34, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Treatment AFTER ESOPHAGEAL PERFORATION OR RUPTURE", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Mixed aerobic/anaerobic infection is often present."}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "q8h ($) [DI]"}, 
{"Row" : 44, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Treatment if B. anthracis is suspected", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Intravenous antimicrobials should be used initially for treatment.Contact"}, 
{"Row" : 48, "Column" : 1, "Text" : "infectious diseases immediately."}, 
{"Row" : 56, "Column" : 1, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases."}
]},
{"Name" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "DisplayText" : "CV Surgery Delayed Order Antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU ABX DELAYED STANDARD ABX CV SURG", "DisplayText" : "Standard (Non PCN allergic)", "Text" : "Standard (Non PCN allergic)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU DELAYED PCN ALLERGIC CV SURG", "DisplayText" : "Severly PCN allergic", "Text" : "Severly PCN allergic", "Mnemonic" : "4"},
{"Row" :1, "Column" : 1, "Text" : "Delayed Antibiotic Orders CV Surgery", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Minneapolis VA facility specific recommendations for open-heart surgery"}
]},
{"Name" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "DisplayText" : "MicroGuide Mobile App Instructions" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "DIRECTIONS TO INSTALL MICROGUIDE ON MOBILE DEVICE", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Within the Apple or Google app store on your mobile device, search for the term"}, 
{"Row" :7, "Column" : 1, "Text" : "\"MicroGuide\" and download the app. When opening the app, you will be prompted to"}, 
{"Row" :8, "Column" : 1, "Text" : "submit information about yourself and institution (this is for tracking usage of"}, 
{"Row" :9, "Column" : 1, "Text" : "the system by CDSS personal). Select the Minneapolis VA Health Care System as"}, 
{"Row" : 10, "Column" : 1, "Text" : "your institution. You will then be prompted to download the Minneapolis VA"}, 
{"Row" : 11, "Column" : 1, "Text" : "Health Care System CDSS specific guide content."}, 
{"Row" : 13, "Column" : 1, "Text" : "When updates to the CDSS MicroGuide are made, you will be prompted to update"}, 
{"Row" : 14, "Column" : 1, "Text" : "the content on your mobile device when opening the app."}, 
{"Row" :3, "Column" : 1, "Item" : "ORZ GTX ABX MICROGUIDE WEB APP", "DisplayText" : "MicroGuide Web App Link", "Text" : "[CLICK HERE]", "Mnemonic" : "2"},
{"Row" :2, "Column" : 1, "Text" : "MicroGuide Web App Link", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX MICROSPORIDIA" , "Term1" : "Microsporidia diarrhea/gastroenteritis", "DisplayText" : "Microsporidia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID ALBENDAZOLE 400MG PO Q12H", "DisplayText" : "Albendazole 400mg po q12h", "Text" : "Albendazole 400 mg PO q12h for 7 to 14 days ($$) [O]", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID ALBENDAZOLE 400MG PO Q12H", "DisplayText" : "Albendazole 400mg po q12h", "Text" : "Albendazole 400 mg PO q12h ($$) [O]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH MICROSPORIDIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "In patients without HIV/AIDs, antimicrobial treatment may not be necessary"}, 
{"Row" :6, "Column" : 1, "Text" : "because symptoms can resolve without antimicrobial therapy. In persons with"}, 
{"Row" :7, "Column" : 1, "Text" : "AIDS, highly active anti-retroviral therapy (HAART) is beneficial because"}, 
{"Row" :8, "Column" : 1, "Text" : "recovery of host defenses helps to control microsporidial disease. Treatment"}, 
{"Row" :9, "Column" : 1, "Text" : "must include dietary supplementation for weight loss. Infectious Diseases"}, 
{"Row" : 10, "Column" : 1, "Text" : "involvement is essential in patients with HIV/AIDS."}, 
{"Row" : 12, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobial treatment of persons without HIV/AIDS", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Antimicrobial treatment of persons with HIV/AIDS", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Continue treatment until CD4 count is >200 for >6 months after initiation of"}, 
{"Row" : 20, "Column" : 1, "Text" : "ART."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 27, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Microsporidiosis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Microsporidiosis"}
]},
{"Name" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "DisplayText" : "More about Nosocomial pneumonia..." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Mnemonic" : "4"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "MORE ABOUT NOSOCOMIAL PNEUMONIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Types of nosocomial pneumonia", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Hospital acquired pneumonia (HAP): "}, 
{"Row" :7, "Column" : 1, "Text" : "Development of pneumonia 48 hours or more after hospital admission."}, 
{"Row" :9, "Column" : 1, "Text" : "Ventilator-associated pneumonia (VAP): "}, 
{"Row" : 10, "Column" : 1, "Text" : "Pneumonia occurring 48 hours or more after endotracheal intubation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Criteria for diagnosis of pneumonia", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "1.Presence of new or progressive infiltrate <AND>"}, 
{"Row" : 14, "Column" : 1, "Text" : "2.At least two of the following: "}, 
{"Row" : 15, "Column" : 1, "Text" : "> Fever greater than 38 C (100.4 F)"}, 
{"Row" : 16, "Column" : 1, "Text" : "> Leukocytosis or leukopenia"}, 
{"Row" : 17, "Column" : 1, "Text" : "> Purulent bronchial secretions"}, 
{"Row" : 19, "Column" : 1, "Text" : "HAP OR VAP suspected: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Gram stain and culture of lower respiratory tract secretions and blood"}, 
{"Row" : 21, "Column" : 1, "Text" : "cultures are important for guiding therapy. If a patient with no change in"}, 
{"Row" : 22, "Column" : 1, "Text" : "antimicrobial therapy during the previous 72 hours has few bacteria on gram"}, 
{"Row" : 23, "Column" : 1, "Text" : "stain of secretions, bacterial pneumonia is unlikely."}, 
{"Row" : 27, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 29, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 30, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 31, "Column" : 1, "Text" : "culture and susceptibility tests."}, 
{"Row" : 32, "Column" : 1, "Text" : "Longer duration of therapy is recommended for more resistant organisms"}, 
{"Row" : 33, "Column" : 1, "Text" : "(e.g. Pseudomonas aeruginosa , Acinetobacter baumanni, and"}, 
{"Row" : 34, "Column" : 1, "Text" : "Legonella pneumophila)."}, 
{"Row" : 38, "Column" : 1, "Text" : "Kalil AC Clin Infect Dis 2016, 63:1"}, 
{"Row" : 39, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 40, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 41, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 42, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}
]},
{"Name" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Term" : "MRSA Risk Factors", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "MRSA RISK FACTORS", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Patients with one or more of the following risk factors are at increased risk of"}, 
{"Row" :4, "Column" : 1, "Text" : "MRSA infection: "}, 
{"Row" :5, "Column" : 1, "Text" : "1. Recent hospitalization"}, 
{"Row" :6, "Column" : 1, "Text" : "2. Residence in a long-term care facility"}, 
{"Row" :7, "Column" : 1, "Text" : "3. Recent surgery"}, 
{"Row" :8, "Column" : 1, "Text" : "4. Hemodialysis"}, 
{"Row" :9, "Column" : 1, "Text" : "5. History of MRSA colonization or infection within the last year"}, 
{"Row" : 10, "Column" : 1, "Text" : "6. Recent antibiotic use"}, 
{"Row" : 11, "Column" : 1, "Text" : "7. Human immunodeficiency virus (HIV) infection"}, 
{"Row" : 12, "Column" : 1, "Text" : "8. Injection drug use"}, 
{"Row" : 13, "Column" : 1, "Text" : "9. Contact with person colonized with MRSA"}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in"}, 
{"Row" : 19, "Column" : 1, "Text" : "adults: Epidemiology"}
]},
{"Name" : "ORZID2 GMENU ABX MYOCARDITIS" , "Term1" : "Myocarditis", "DisplayText" : "Myocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MYOCARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Myocarditis is most commonly associated with enterovirus or coxsackie virus"}, 
{"Row" :6, "Column" : 1, "Text" : "infection. Less common pathogens include pyogenic bacteria, rickettsia,"}, 
{"Row" :7, "Column" : 1, "Text" : "toxoplasmosis, and fungi."}, 
{"Row" :9, "Column" : 1, "Text" : "Empirical antimicrobial treatment is not indicated. Supportive care and"}, 
{"Row" : 10, "Column" : 1, "Text" : "treatment of CHF are essential. Consult Cardiology and/or Infectious Diseases"}, 
{"Row" : 11, "Column" : 1, "Text" : "for more assistance."}, 
{"Row" : 13, "Column" : 1, "Text" : "Avoid non-steroidal anti-inflammatory drugs (NSAIDS) and corticosteroids in"}, 
{"Row" : 14, "Column" : 1, "Text" : "these patients, as the use of NSAIDs in myocarditis has been associated with"}, 
{"Row" : 15, "Column" : 1, "Text" : "worse outcomes."}, 
{"Row" : 17, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Myocarditis and Pericarditis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-To-Date article: Treatment and prognosis of myocarditis in adults"}
]},
{"Name" : "ORZID2 GMENU ABX NASAL PACKING" , "Term1" : "Nasal packing", "DisplayText" : "Nasal Packing (to prevent infection)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in"}, 
{"Row" :6, "Column" : 1, "Text" : "patients with nasal packing is not recommended. Antibiotics increase the risk of"}, 
{"Row" :7, "Column" : 1, "Text" : "adverse events in patients with nasal packing with no proven effectiveness in"}, 
{"Row" :8, "Column" : 1, "Text" : "preventing infection."}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Cohn, Annals of emergency medicine 2015, 1.65, 109-111"}, 
{"Row" : 14, "Column" : 1, "Text" : "Kucik et al, Am Fam Physician 2005, 71.2, 305-311"}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-to-Date article: Approach to the adult with epistaxis"}
]},
{"Name" : "ORZID2 GMENU ABX NEW UPDATES", "DisplayText" : "New Updates " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "NEW UPDATES INFORMATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Section titles that are labeled with *New Updates* have been recently updated"}, 
{"Row" :6, "Column" : 1, "Text" : "according to current literature and guidelines. All updates are reviewed by a"}, 
{"Row" :7, "Column" : 1, "Text" : "Minneapolis VAHCS Infectious Diseases staff physician and a clinical pharmacist."}, 
{"Row" :9, "Column" : 1, "Text" : "If you have any questions or concerns please contact the VISN23 CDSS team: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "[Click here] Contact the CDSS Team", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "DisplayText" : "Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19 Inpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PATIENT EUA FACT SHEET", "DisplayText" : "Paxlovid EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PROVIDER FACT SHEET EUA", "DisplayText" : "Paxlovid EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Paxlovid", "Mnemonic" : "8"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID INPT AND OPT ORDERS", "DisplayText" : "PAXLOVID INPT AND OPT ORDERS", "Text" : "INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PAXLOVID (EUA)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use"}, 
{"Row" :6, "Column" : 1, "Text" : "Authorization (EUA) for treating patients that meet specific criteria. Paxlovid"}, 
{"Row" :7, "Column" : 1, "Text" : "is not an FDA approved drug."}, 
{"Row" :9, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 17, "Column" : 1, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "receive: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19"}, 
{"Row" : 20, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be"}, 
{"Row" : 21, "Column" : 1, "Text" : "hospitalized for some other reason."}, 
{"Row" : 22, "Column" : 1, "Text" : "4) Administration will begin within 5 days of symptom onset."}, 
{"Row" : 23, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to Paxlovid or components."}, 
{"Row" : 26, "Column" : 1, "Text" : "Contraindications, NONE of the following must be met for patient to receive: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "1) Severe renal impairment (eGFR <30 mL/min)."}, 
{"Row" : 28, "Column" : 1, "Text" : "2) Severe hepatic impairment (Child-Pugh Class C)."}, 
{"Row" : 29, "Column" : 1, "Text" : "3) History of clinically significant hypersensitivity reactions to the active"}, 
{"Row" : 30, "Column" : 1, "Text" : "ingredients (nirmatrelvir or ritonavir) or any other components."}, 
{"Row" : 31, "Column" : 1, "Text" : "4) Co-administration with drugs highly dependent on CYP3A for clearance and for"}, 
{"Row" : 32, "Column" : 1, "Text" : "which elevated concentrations are associated with serious and/or"}, 
{"Row" : 33, "Column" : 1, "Text" : "life-threatening reactions."}, 
{"Row" : 34, "Column" : 1, "Text" : "5) Co-administration with potent CYP3A inducers where significantly reduced"}, 
{"Row" : 35, "Column" : 1, "Text" : "nirmatrelvir or ritonavir plasma concentrations may be associated with the"}, 
{"Row" : 36, "Column" : 1, "Text" : "potential for loss of virologic response and possible resistance."}, 
{"Row" : 38, "Column" : 1, "Text" : "Warnings and Precautions: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "1) The concomitant use of PAXLOVID and certain other drugs may result in"}, 
{"Row" : 40, "Column" : 1, "Text" : "potentially significant drug interactions. Consult the full prescribing"}, 
{"Row" : 41, "Column" : 1, "Text" : "information prior to and during treatment for potential drug interactions."}, 
{"Row" : 42, "Column" : 1, "Text" : "2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and"}, 
{"Row" : 43, "Column" : 1, "Text" : "jaundice have occurred in patients receiving ritonavir."}, 
{"Row" : 44, "Column" : 1, "Text" : "3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing"}, 
{"Row" : 45, "Column" : 1, "Text" : "resistance to HIV protease inhibitors in individuals with uncontrolled or"}, 
{"Row" : 46, "Column" : 1, "Text" : "undiagnosed HIV-1 infection."}, 
{"Row" : 48, "Column" : 1, "Text" : "If all above criteria above are met and there are no contraindications, place", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "medication order: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "*Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min): 150 mg"}, 
{"Row" : 54, "Column" : 1, "Text" : "nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), with"}, 
{"Row" : 55, "Column" : 1, "Text" : "both tablets taken together twice daily for 5 days."}, 
{"Row" : 57, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 58, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing"}, 
{"Row" : 59, "Column" : 1, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent"}, 
{"Row" : 60, "Column" : 1, "Text" : "handwashing) according to CDC guidelines."}, 
{"Row" : 24, "Column" : 1, "Text" : "6) Patient must be able to take PO and swallow tablets whole"}, 
{"Row" : 51, "Column" : 1, "Text" : "**Place medication orders for inpatient and outpatient (included in order set)"}
]},
{"Name" : "ORZID2 GMENU ABX NON-CHOLERA" , "Term1" : "Vibrio non-cholerae, diarrhea/gastroenteritis", "DisplayText" : "Vibrio non-cholera" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg BID for 3-5 days ($) [DI]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 3-5 days ($) [M]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q24H DOXY IV 100MG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM DOXI 100MG PO", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h for 7 to 14 days ($) [R,DI]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "NON-CHOLERA VIBRIO", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound"}, 
{"Row" :6, "Column" : 1, "Text" : "infections. Vibrio vulnificans infections are acquired from contact with"}, 
{"Row" :7, "Column" : 1, "Text" : "seawater or seafood, especially raw oysters. V. vulnificans cases are more"}, 
{"Row" :8, "Column" : 1, "Text" : "severe than cases with other species. V. parahaemolyticus causes"}, 
{"Row" :9, "Column" : 1, "Text" : "gastroenteritis and milder wound infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobials do not shorten the course of disease in immunocompetent patients"}, 
{"Row" : 12, "Column" : 1, "Text" : "with mild gastroenteritis."}, 
{"Row" : 14, "Column" : 1, "Text" : "Primary treatment for gastroenteritis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 17, "Column" : 1, "Text" : "Antimicrobial treatment of minor wound infection, severe gastroenteritis or", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "immunocompromised patient with gastroenteritis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative for patient intolerant of fluoroquinolones"}, 
{"Row" : 24, "Column" : 1, "Text" : "For patients who are hospitalized or unable to take oral medications"}, 
{"Row" : 27, "Column" : 1, "Text" : "Antimicrobial treatment of severe wound infection or septicemia", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Consult Infectious Diseases for advice on duration of treatment."}, 
{"Row" : 30, "Column" : 1, "Text" : "for 7 to 14 days"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "for 7 to 14 days"}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 39, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Vibrio parahaemolyticus"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Vibrio parahaemolyticus infections"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-to-Date article: Vibrio vulnificus infections"}
]},
{"Name" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW" , "Term1" : "Hospital-acquired pneumonia (HAP) " , "Term2" : "Nosocomial pneumonia " , "Term3" : "Pneumonia, nosocomial " , "Term4" : "Ventilator-associated pneumonia (VAP)", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "DisplayText" : "More about Nosocomial pneumonia...", "Text" : "More about Nosocomial pneumonia...", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "DisplayText" : "PNEUMONIA HAP", "Text" : "Hospital Acquired Pneumonia (HAP)", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA VAP", "DisplayText" : "PNEUMONIA VAP", "Text" : "VENTILATOR ASSOCIATED PNEUMONIA (VAP)", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII", "DisplayText" : "Nosocomial pneumonia with Acinetobacter baumannii", "Text" : "Acinetobacter baumannii", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT", "DisplayText" : "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae", "Text" : "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA", "DisplayText" : "Nosocomial pneumonia with Legionella pneumophila", "Text" : "Legionella pneumophila", "Mnemonic" : "16"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA", "DisplayText" : "Nosocomial pneumonia with Pseudomonas aeruginosa", "Text" : "Pseudomonas aeruginosa", "Mnemonic" : "18"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA", "DisplayText" : "STAPHYLOCOCCUS AUREUS PNEUMONIA", "Text" : "Staphylococcus aureus", "Mnemonic" : "20"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA"}, 
{"Row" :7, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" : 11, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" : 16, "Column" : 1, "Text" : "Empirical therapy must be re-evaluated at 72 hours.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Duration of Therapy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 21, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 22, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 23, "Column" : 1, "Text" : "culture and susceptibility tests."}, 
{"Row" : 25, "Column" : 1, "Text" : "Pathogen-specific treatment", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Certain respiratory pathogens that are usually treated in unique ways are listed"}, 
{"Row" : 28, "Column" : 1, "Text" : "here.Other respiratory pathogens are treated with drugs effective for"}, 
{"Row" : 29, "Column" : 1, "Text" : "pneumonia and active against identified organisms."}, 
{"Row" : 30, "Column" : 1, "Text" : "Recommended duration of therapy for more resistant pathogens"}, 
{"Row" : 31, "Column" : 1, "Text" : "(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment."}, 
{"Row" : 32, "Column" : 1, "Text" : "Refer to pathogen-specific treatment regimen below for recommendation."}, 
{"Row" : 34, "Column" : 1, "Text" : "Pathogen-specific nosocomial pneumonia treatment regimens", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 44, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 45, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676"}, 
{"Row" : 46, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 48, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII" , "Term1" : "Acinetobacter baumannii, nosocomial pneumonia", "DisplayText" : "Nosocomial pneumonia with Acinetobacter baumannii " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA WITH ACINETOBACTER BAUMANNII"}, 
{"Row" :4, "Column" : 1, "Text" : "Infectious Diseases consultation is essential for cases with Acinetobacter which"}, 
{"Row" :5, "Column" : 1, "Text" : "are often resistant to most therapies."}, 
{"Row" :7, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of therapy is unclear and should be guided by clinical response."}, 
{"Row" : 14, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 15, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 16, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 17, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 19, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT" , "Term1" : "Enterobacteriaceae (ESBL+) nosocomial pneumonia", "DisplayText" : "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,O]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA WITH EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING (ESBL+)"}, 
{"Row" :3, "Column" : 1, "Text" : "ENTEROBACTERIACEAE"}, 
{"Row" :5, "Column" : 1, "Text" : "The microbiology laboratory tests for ESBL production in all E. coli and"}, 
{"Row" :6, "Column" : 1, "Text" : "Klebsiella isolates. Proteus isolated from blood samples are also tested for"}, 
{"Row" :7, "Column" : 1, "Text" : "ESBL production.Other Enterobacteriaceae produce ESBL less commonly but"}, 
{"Row" :8, "Column" : 1, "Text" : "practical tests are not available for these. If ESBL is suspected regardless of"}, 
{"Row" :9, "Column" : 1, "Text" : "testing, consult Infectious Diseases and/or the microbiology laboratory for more"}, 
{"Row" : 10, "Column" : 1, "Text" : "information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 19, "Column" : 1, "Text" : "Craven DE Infect Dis Clin N Am 2004, 18: 939"}, 
{"Row" : 20, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 21, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 22, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2003,37: 1405"}, 
{"Row" : 23, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 24, "Column" : 1, "Text" : "Singh N Am J Resp Crit Care Med 2000, 162: 505"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 26, "Column" : 1, "Text" : "AnonymousAm J Respir Crit Care Med 2005, 171: 388"}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA" , "Term1" : "Legionella pneumophila nosocomial pneumonia", "DisplayText" : "Nosocomial pneumonia with Legionella pneumophila" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "DisplayText" : "Azithromycin 500 mg IV q24h ($) [O]", "Text" : "Azithromycin 500 mg IV q24h ($) [M]< OR >", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h ($) [M]< OR >", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA WITH LEGIONELLA PNEUMOPHILA"}, 
{"Row" :4, "Column" : 1, "Text" : "Intravenous therapy preferred initially until signs and symptoms improve."}, 
{"Row" :6, "Column" : 1, "Text" : "Treat for 7 to 10 days. Consider longer courses of therapy in"}, 
{"Row" :7, "Column" : 1, "Text" : "immunocompromised patients with severe illness."}, 
{"Row" :9, "Column" : 1, "Text" : "Recommend to start with parenteral therapy: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Switch to oral to complete therapy: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2007, 44: S27"}, 
{"Row" : 19, "Column" : 1, "Text" : "Phin N Lancet Infectious Diseases 2014, 14:1011"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford: Pneumonia Legionella"}, 
{"Row" : 21, "Column" : 1, "Text" : "Stout JE, Yu VL: Legionellosis. N Engl J Med 337:682, 1997"}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA" , "Term1" : "Pseudomonas aeruginosa nosocomial pneumonia", "DisplayText" : "Nosocomial pneumonia with Pseudomonas aeruginosa" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZIDIME 2GM IV Q8H GENT 5MG IV QD", "DisplayText" : "CEFTAZIDIME 2GM IV Q8H GENT 5MG IV QD", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> gentamicin 5mg/kg IV q24h", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CIP 400MG IV Q8H GENT 5MG IV QD", "DisplayText" : "CIPROFL 400MG IV Q8H GENT 5MG IV QD", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> gentamicin 5mg/kg IV q24h", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin 5", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTA 2GM IV Q8H CIPRO 400MG IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> Ciprofloxacin 400 mg", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]< OR >", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA WITH PSEUDOMONAS AERUGINOSA"}, 
{"Row" :5, "Column" : 1, "Text" : "Single drug therapy is as effective as combination therapy once susceptibility"}, 
{"Row" :6, "Column" : 1, "Text" : "results are known."}, 
{"Row" :8, "Column" : 1, "Text" : "Empiric Treatment: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 11, "Column" : 1, "Text" : "($) [R,O]< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "($) [R,O] < OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "mg/kg IV q24h ($) [R,O] < OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "IV q8h ($) [R,DI]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Narrow therapy to single active antibiotic once susceptibility results are", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "available: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 29, "Column" : 1, "Text" : "Oral therapy (usually given after several days of intravenous therapy)", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "if isolate known sensitive to fluoroquinolone: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 36, "Column" : 1, "Text" : "Craven DE Infect Dis Clin N Am 2004, 18: 939"}, 
{"Row" : 37, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 38, "Column" : 1, "Text" : "Garnacho-Montero J Crit Care Med. 2007, 35:1888"}, 
{"Row" : 39, "Column" : 1, "Text" : "Kalil AC Clin Infect Dis 2016 63:1"}, 
{"Row" : 40, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 41, "Column" : 1, "Text" : "Singh N Am J Resp Crit Care Med 2000, 162: 505"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA" , "Term1" : "Staphylococcus aureus nosocomial pneumonia", "DisplayText" : "STAPHYLOCOCCUS AUREUS PNEUMONIA " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcilin 2 gm IV q4h ($$) [DI]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI] < OR >", "Mnemonic" : "20"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] < OR >", "Mnemonic" : "22"},
{"Row" : 39, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "24"},
{"Row" :2, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA WITH STAPHYLOCOCCUS AUREUS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Known Methicillin-SUSCEPTIBLE Staphylococcus aureus pneumonia", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Duration of therapy 7-14 days."}, 
{"Row" : 10, "Column" : 1, "Text" : "Oral therapy (usually given after several days of intravenous therapy): ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "A patient who is substantially improved, without fever for at least 2 days"}, 
{"Row" : 12, "Column" : 1, "Text" : "can be treated with an oral agent to which the isolate is susceptible."}, 
{"Row" : 16, "Column" : 1, "Text" : "_________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Methicillin-RESISTANT or Susceptibilities Unknown Staphylococcus aureus", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "In patients with MRSA pneumonia complicated by empyema, antimicrobial therapy"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be used in conjunction with drainage procedures."}, 
{"Row" : 22, "Column" : 1, "Text" : "NOTE: A prospective trial comparing Linezolid to Vancomycin for MRSA"}, 
{"Row" : 23, "Column" : 1, "Text" : "pneumonia, including ventilator-associated pneumonia, showed higher clinical"}, 
{"Row" : 24, "Column" : 1, "Text" : "cure rate (p=0.042) for linezolid (95/165, 57.6%) than for vancomycin"}, 
{"Row" : 25, "Column" : 1, "Text" : "(81/174, 46.6%) but no difference in mortality (15.7% for linezolid vs. 17%"}, 
{"Row" : 26, "Column" : 1, "Text" : "for vancomycin).Other factors to consider are the drug-drug interactions"}, 
{"Row" : 27, "Column" : 1, "Text" : "associated with linezolid and cost."}, 
{"Row" : 29, "Column" : 1, "Text" : "Duration of therapy 7-14 days"}, 
{"Row" : 33, "Column" : 1, "Text" : "Oral therapy (usually given after several days of intravenous therapy: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "In cases when a patient has substantially improved and has not had a fever"}, 
{"Row" : 35, "Column" : 1, "Text" : "for at least 2 days, it may be appropriate to treat with an oral agent to"}, 
{"Row" : 36, "Column" : 1, "Text" : "which the isolate is susceptible to complete therapy."}, 
{"Row" : 41, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Liu C, Clin Infect Dis. 2011:52:285"}, 
{"Row" : 43, "Column" : 1, "Text" : "Wunderink RG, Clin Infect Dis. 2012: 54:621"}, 
{"Row" : 44, "Column" : 1, "Text" : "Rybak MJ, Clin Infect 2009: Dis 49:325"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford Keyword:Staphlococcus aureus pneumonia"}, 
{"Row" : 46, "Column" : 1, "Text" : "John Hopkins Antimicrobial Guidewww.johnhopkinsguides.com"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :7, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS" , "Term1" : "Non-streptococcal pharyngitis " , "Term2" : "Pharyngitis, non-streptococcal", "DisplayText" : "Not Benefited by Abx Pharyngitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References: ", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "PHARYNGITIS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Acute pharyngitis is common, accounting for 2 percent of all"}, 
{"Row" :5, "Column" : 1, "Text" : "ambulatory visits in the United States.The major treatable pathogen, group"}, 
{"Row" :6, "Column" : 1, "Text" : "A streptococcus (GAS), is the cause of pharyngitis in only approximately 10"}, 
{"Row" :7, "Column" : 1, "Text" : "percent of adults who seek medical care.The vast majority of patients"}, 
{"Row" :8, "Column" : 1, "Text" : "receive presumptive antibiotic therapy for pharyngitis which in most cases is"}, 
{"Row" :9, "Column" : 1, "Text" : "unnecessary and results in adverse effects including death, increases costs,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and adds to pressure on antimicrobial resistance.Typical causes of"}, 
{"Row" : 11, "Column" : 1, "Text" : "pharyngitis include viruses in about , beta-hemolytic streptococci other"}, 
{"Row" : 12, "Column" : 1, "Text" : "than group A in 18%, Mycoplasma pneumoniae in 10%, Chlamydophila pneumoniae"}, 
{"Row" : 13, "Column" : 1, "Text" : "in 8%, Group A streptococci in 5%, and no microbe identified in 1/3."}, 
{"Row" : 15, "Column" : 1, "Text" : "Rheumatic fever is rare in the United States, especially in adults, so"}, 
{"Row" : 16, "Column" : 1, "Text" : "that some authorities recommend no treatment even if GAS is a potential cause"}, 
{"Row" : 17, "Column" : 1, "Text" : "of pharyngitis. Others feel it is important to detect GASsince antibiotic"}, 
{"Row" : 18, "Column" : 1, "Text" : "therapy can slightly shorten the acute illness, prevent acute rheumatic fever"}, 
{"Row" : 19, "Column" : 1, "Text" : "and possibly prevent suppurative sequelae.Other potential causes of"}, 
{"Row" : 20, "Column" : 1, "Text" : "pharyngitis that should be considered and diagnosed if likely include"}, 
{"Row" : 21, "Column" : 1, "Text" : "Epstein-Barr virus (EBV) mononucleosis, primary HIV infection, influenza,"}, 
{"Row" : 22, "Column" : 1, "Text" : "gonococcal pharyngitis, diphtheria, and suppurative pharyngeal infections."}, 
{"Row" : 24, "Column" : 1, "Text" : "The Centor criteria are used to predict whether GAS pharyngitis is present."}, 
{"Row" : 26, "Column" : 1, "Text" : "*Tonsillar exudates"}, 
{"Row" : 27, "Column" : 1, "Text" : "*Tender anterior cervical adenopathy"}, 
{"Row" : 28, "Column" : 1, "Text" : "*Fever by history"}, 
{"Row" : 29, "Column" : 1, "Text" : "*Absence of cough"}, 
{"Row" : 31, "Column" : 1, "Text" : "If three or four of these criteria are met, the positive predictive value is"}, 
{"Row" : 32, "Column" : 1, "Text" : "40 to 60 percent.If fewer than three criteria are present, the likelihood"}, 
{"Row" : 33, "Column" : 1, "Text" : "GAS is causing pharyngitis is less than 20 percent.If 3 or > Centor criteria"}, 
{"Row" : 34, "Column" : 1, "Text" : "are met, obtain a throat culture for group A streptococcus.Treat"}, 
{"Row" : 35, "Column" : 1, "Text" : "empirically for GAS if the patient has severe symptoms or treat later for GAS"}, 
{"Row" : 36, "Column" : 1, "Text" : "if the throat culture is positive."}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}
]},
{"Name" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA" , "Term1" : "Asymptomatic bacteriuria " , "Term2" : "Asymptomatic candiduria " , "Term3" : "Asymptomatic pyuria " , "Term4" : "Bacteriuria " , "Term5" : "Candiduria " , "Term6" : "Pyuria", "DisplayText" : "Bacteruria, Candiduria, and Pyuria" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic Bacteriuria", "Text" : "Treatment of Asymptomatic Bacteriuria", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Treatment of Candida Urinary Tract Infections", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIURIA, CANDIDURIA, AND PYURIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in"}, 
{"Row" :6, "Column" : 1, "Text" : "middle aged and older people, especially those who have chronic medical"}, 
{"Row" :7, "Column" : 1, "Text" : "conditions. Pyuria is common in persons with bacteriuria and individuals with"}, 
{"Row" :8, "Column" : 1, "Text" : "indwelling catheters in place. By itself, the presence of pyuria is not"}, 
{"Row" :9, "Column" : 1, "Text" : "sufficient to diagnose bacteriuria, and the presence or absence of pyuria does"}, 
{"Row" : 10, "Column" : 1, "Text" : "not differentiate symptomatic from asymptomatic urinary infection. Candiduria is"}, 
{"Row" : 11, "Column" : 1, "Text" : "less common than bacteriuria, but the implications of candiduria are similar to"}, 
{"Row" : 12, "Column" : 1, "Text" : "those of bacteriuria."}, 
{"Row" : 14, "Column" : 1, "Text" : "Many studies, including randomized clinical trials have shown that"}, 
{"Row" : 15, "Column" : 1, "Text" : "treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is"}, 
{"Row" : 16, "Column" : 1, "Text" : "of no benefit, except in certain well-defined circumstances. Antimicrobial"}, 
{"Row" : 17, "Column" : 1, "Text" : "therapy is always accompanied by risk of harms, including drug reactions,"}, 
{"Row" : 18, "Column" : 1, "Text" : "Clostridium difficile colitis, anaphylaxis and death. Except in circumstances"}, 
{"Row" : 19, "Column" : 1, "Text" : "specified below, it is best to not order urinalysis or urine culture in"}, 
{"Row" : 20, "Column" : 1, "Text" : "asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an"}, 
{"Row" : 21, "Column" : 1, "Text" : "asymptomatic person for some reason, antimicrobial therapy should not be given"}, 
{"Row" : 22, "Column" : 1, "Text" : "except as specified below."}, 
{"Row" : 24, "Column" : 1, "Text" : "Pregnant women or patients undergoing urological procedures with bacteriuria", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Patients undergoing urological procedures or neutropenic patients with", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "candiduria", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References"}, 
{"Row" : 34, "Column" : 1, "Text" : "Pappas et al, Clin Infect Dis, 2016, 62.409"}, 
{"Row" : 35, "Column" : 1, "Text" : "Nicolle et al, Clin Infect Dis, 2005, 40:643"}
]},
{"Name" : "ORZID2 GMENU ABX NOT REQUIRED MAIN" , "Term1" : "Conditions not benefitted by antimicrobials", "DisplayText" : "Antibiotics not required" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)", "DisplayText" : "Upper respiratory infections (URI)", "Text" : "Upper Respiratory Infections (URI)", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR", "DisplayText" : "Colonized respiratory tract in patient with a ventilator", "Text" : "Colonized Respiratory Tract in a Patient on a Ventilator", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "DisplayText" : "Stasis dermatitis", "Text" : "Stasis Dermatitis", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "DisplayText" : "Colonized wounds", "Text" : "Colonized Wounds", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "DisplayText" : "Bacteruria, Candiduria, and Pyuria", "Text" : "Asymptomatic Bacteriuria, cadiduria and pyuria", "Mnemonic" : "12"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH", "DisplayText" : "Blood culture positive for coagulase negative staphylococci", "Text" : "Blood culture positive for coagulase negative staphylococci", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Several common conditions associated with inflammation or"}, 
{"Row" :6, "Column" : 1, "Text" : "microorganisms do not benefit from antibiotic therapy in most or all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Yet, antimicrobials are frequently prescribed for these conditions leading to"}, 
{"Row" :8, "Column" : 1, "Text" : "unnecessary toxicity and costs, rare deaths, and the relentless increase in"}, 
{"Row" :9, "Column" : 1, "Text" : "antimicrobial resistance. Please review these conditions and do not give"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials for these conditions unless there are extraordinary"}, 
{"Row" : 11, "Column" : 1, "Text" : "circumstances that make your situation different. If you have any questions,"}, 
{"Row" : 12, "Column" : 1, "Text" : "please contact the infectious disease physician on call."}, 
{"Row" : 14, "Column" : 1, "Text" : "Lungs and Mediastinum", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Skin and Soft Tissue", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Genitourinary", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Miscellaneous", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Last reviewed 9-2018", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Pharyngitis, non-streptococcal", "Mnemonic" : "3"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis in an Otherwise Healthy Patient", "Mnemonic" : "5"}
]},
{"Name" : "ORZID2 GMENU ABX OROLABIAL HERPES" , "Term1" : "Herpes, orolabial " , "Term2" : "Orolabial herpes", "DisplayText" : "Orolabial Herpes" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 5 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 2GM PO Q12H 1 DAY", "DisplayText" : "Valacyclovir 2 gm q12h for 1 day ($) [R]", "Text" : "Valacyclovir 2 gm q12h for 1 day ($) [R]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "DisplayText" : "Acyclovir 400MG PO q8h", "Text" : "Acyclovir 400 mg PO q8h for 7-14 days($) [R]", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm q12h for 7-14 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "DisplayText" : "Acyclovir 5 mg/kg IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h for 7-14 days ($$) [R]", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "DisplayText" : "Acyclovir 400MG PO BID", "Text" : "Acyclovir 400 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 48, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "DisplayText" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Text" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "OROLABIAL HERPES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Antiviral therapy is not beneficial after formation of vesicles. However, when"}, 
{"Row" : 11, "Column" : 1, "Text" : "started as soon as prodromal symptoms of burning or tingling occur, antivirals"}, 
{"Row" : 12, "Column" : 1, "Text" : "reduce duration of pain and lesions."}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Immunocompromised patients in whom herpes simplex infections can be more severe"}, 
{"Row" : 24, "Column" : 1, "Text" : "include: patients with HIV infection, organ transplant recipients, patients"}, 
{"Row" : 25, "Column" : 1, "Text" : "undergoing chemotherapy, malnourished patients, and those with compromised skin"}, 
{"Row" : 26, "Column" : 1, "Text" : "integrity."}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Chronic suppressive therapy", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Indicated for patients with greater than 6 recurrences or severe recurrences,"}, 
{"Row" : 42, "Column" : 1, "Text" : "immunocompromised patients or as adjunct to prevent transmission. Suppressive"}, 
{"Row" : 43, "Column" : 1, "Text" : "therapy is optional, and some patients may find episodic treatment more"}, 
{"Row" : 44, "Column" : 1, "Text" : "convenient. Patients should be reassessed every few years to evaluate if chronic"}, 
{"Row" : 45, "Column" : 1, "Text" : "suppressive therapy is still necessary."}, 
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-To-Date article: Treatment of herpes simplex virus type 1 infection in"}, 
{"Row" : 56, "Column" : 1, "Text" : "immunocompetent patients"}
]},
{"Name" : "ORZID2 GMENU ABX PANCREATITIS" , "Term1" : "Pancreatitis", "DisplayText" : "Pancreatitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "6"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG IV Q24H METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h", "Mnemonic" : "10"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 48, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] < AND > metronidazole 1 gm PO q12h", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "PANCREATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobials are not indicated for uncomplicated pancreatitis."}, 
{"Row" :7, "Column" : 1, "Text" : "In cases of necrotizing pancreatitis without infection, antimicrobial"}, 
{"Row" :8, "Column" : 1, "Text" : "prophylaxis does not improve patient outcomes. Antimicrobials increase the risk"}, 
{"Row" :9, "Column" : 1, "Text" : "of fungal superinfection and should not be used."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobials are indicated for cases with pancreatic abscess, infected"}, 
{"Row" : 12, "Column" : 1, "Text" : "pancreatic pseudocyst, or infected necrotic pancreas (phlegmon). The diagnosis"}, 
{"Row" : 13, "Column" : 1, "Text" : "of infection can be difficult and may require aspiration. Consultation with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases is encouraged."}, 
{"Row" : 16, "Column" : 1, "Text" : "Uncomplicated pancreatitis", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "No antimicrobials are indicated."}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Cases with necrosis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "In cases with necrosis, aspirate necrotic material (fine needle under CT or"}, 
{"Row" : 22, "Column" : 1, "Text" : "ultrasound guidance) for smear and culture. Uninfected cases should not receive"}, 
{"Row" : 23, "Column" : 1, "Text" : "antimicrobials."}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Pancreatic abscess, infected pancreatic pseudocyst, or infected necrotic", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "pancreas (phlegmon)", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Total duration of antimicrobial therapy is typically 2 to 4 weeks"}, 
{"Row" : 32, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Alternative for beta-lactam allergy in patients with mild or moderate disease"}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 43, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "on culture results.", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 54, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Mandell chapter: Pancreatic Infection"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford Guide keyword: Pancreatitis"}, 
{"Row" : 58, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date article: Management of acute pancreatitis"}
]},
{"Name" : "ORZID2 GMENU ABX PARAINFLUENZA" , "Term1" : "Parainfluenza", "DisplayText" : "Parainfluenza " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PARAINFLUENZA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "more information on management of this disease."}, 
{"Row" :9, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Sanford keyword: Parainfluenza virus"}
]},
{"Name" : "ORZID2 GMENU ABX PAROTITIS" , "Term1" : "Parotitis", "DisplayText" : "Parotitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PAROTITIS MORE INFORMATION", "DisplayText" : "More Information on Parotitis", "Text" : "More information on Parotitis", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG PO Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG Q12 METRON 500 MG Q8", "DisplayText" : "VANCO 15 MG/KG Q12 METRON 500 MG Q8", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG Q12H METRO 500MG PO Q8H", "DisplayText" : "VANCO 15 MG/KG Q12H METRO 500MG PO Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "PAROTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection of salivary tissue is a relatively common disease. It is usually"}, 
{"Row" :6, "Column" : 1, "Text" : "caused by a stone in the parotid duct, dehydration, or a viral infection."}, 
{"Row" :7, "Column" : 1, "Text" : "Sialolithiasis in elderly patients often leads to ductal obstruction and"}, 
{"Row" :8, "Column" : 1, "Text" : "secondary infection. Other predisposing factors for ductal occlusion include"}, 
{"Row" :9, "Column" : 1, "Text" : "dehydration, anticholinergic medications such as tricyclics and diphenhydramine,"}, 
{"Row" : 10, "Column" : 1, "Text" : "general disability and trauma. Once culture results are available adjust"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial therapy based on specific etiologic organism."}, 
{"Row" : 13, "Column" : 1, "Text" : "For more information click on the link below"}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Therapy duration varies based on clinical response to treatment and is typically"}, 
{"Row" : 18, "Column" : 1, "Text" : "10-14 days."}, 
{"Row" : 20, "Column" : 1, "Text" : "Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Immunocompetent Patient", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "If MRSA suspected or alternative to above: "}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "Immunocompromised Patient", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 40, "Column" : 1, "Text" : "Viral Parotitis", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender"}, 
{"Row" : 42, "Column" : 1, "Text" : "swelling of the parotid glands. For mumps parotitis treat with warm compresses"}, 
{"Row" : 43, "Column" : 1, "Text" : "and analgesics and maintain good hydration to prevent secondary bacterial"}, 
{"Row" : 44, "Column" : 1, "Text" : "infection. Other viral causes of parotitis include influenza and enteroviruses."}, 
{"Row" : 46, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "References: "}, 
{"Row" : 49, "Column" : 1, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888"}, 
{"Row" : 50, "Column" : 1, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 51, "Column" : 1, "Text" : "Sanford keyword: Parotitis"}, 
{"Row" : 52, "Column" : 1, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults"}
]},
{"Name" : "ORZID2 GMENU ABX PAROTITIS MORE INFORMATION", "DisplayText" : "More Information on Parotitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MORE ABOUT PAROTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,"}, 
{"Row" :6, "Column" : 1, "Text" : "malnourished, dehydrated or post-operative patients. Symptoms include fever,"}, 
{"Row" :7, "Column" : 1, "Text" : "toxicity, and tender swelling along the mandible with purulent drainage from the"}, 
{"Row" :8, "Column" : 1, "Text" : "parotid duct. Suppurative parotitis is usually unilateral whereas viral"}, 
{"Row" :9, "Column" : 1, "Text" : "parotitis is usually bilateral. Pain is intense and aggressive, analgesic"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy is required. Progression of infection may lead to massive swelling of"}, 
{"Row" : 11, "Column" : 1, "Text" : "the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent"}, 
{"Row" : 12, "Column" : 1, "Text" : "facial bones. Empiric antibiotics are required for coverage of Staphylococcus"}, 
{"Row" : 13, "Column" : 1, "Text" : "aureus if bacterial, and surgical drainage is usually necessary."}, 
{"Row" : 15, "Column" : 1, "Text" : "Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations."}, 
{"Row" : 16, "Column" : 1, "Text" : "Chronic, low-grade bacterial infection results in functional destruction of the"}, 
{"Row" : 17, "Column" : 1, "Text" : "salivary gland. It may be confused with Sjogren's syndrome, a noninfectious"}, 
{"Row" : 18, "Column" : 1, "Text" : "illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be"}, 
{"Row" : 19, "Column" : 1, "Text" : "required for patients with long-standing infection."}, 
{"Row" : 21, "Column" : 1, "Text" : "Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling"}, 
{"Row" : 22, "Column" : 1, "Text" : "of one or both parotid glands within 2 to 3 weeks after exposure to the mumps"}, 
{"Row" : 23, "Column" : 1, "Text" : "virus. Mumps usually involves both parotid glands whereas bacterial parotitis is"}, 
{"Row" : 24, "Column" : 1, "Text" : "unilateral. Other viral causes of parotitis include influenza and enteroviruses."}, 
{"Row" : 25, "Column" : 1, "Text" : "Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide"}, 
{"Row" : 26, "Column" : 1, "Text" : "symptomatic relief of pain and fever and maintain hydration to prevent secondary"}, 
{"Row" : 27, "Column" : 1, "Text" : "bacterial infection."}, 
{"Row" : 29, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Parotitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults"}
]},
{"Name" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PCV20 MUST BE ADMINISTERED THROUGH CLINICAL REMINDER", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "PCV20 orders are currently not availble in CDSS. Please contact Erik Stensgard,"}, 
{"Row" :9, "Column" : 1, "Text" : "PharmD, more information (email: erik.stensgard@va.gov)."}, 
{"Row" :5, "Column" : 1, "Text" : "Use the Pneumococcal Conjugate Vaccine (PCV15/PCV20) Nursing Clinical"}, 
{"Row" :6, "Column" : 1, "Text" : "Reminder on the Cover Sheet for administration of this vaccine."}
]},
{"Name" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL" , "Term1" : "Desensitization protocol, penicillin " , "Term2" : "Penicillin desensitization protocol " , "Term3" : "Protocol for Penicillin Desensitization", "DisplayText" : "Penicillin Desensitization Protocol " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "PENICILLIN DESENSITIZATION PROTOCOL", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pharmacy Service must be involved. Contact satellite pharmacist at ext. 2040 or"}, 
{"Row" :6, "Column" : 1, "Text" : "menu 648-6746. Infectious Diseases Consult strongly recommended."}, 
{"Row" :8, "Column" : 1, "Text" : "When penicillin is the drug of choice for an infectious disease in a patient"}, 
{"Row" :9, "Column" : 1, "Text" : "with Type I penicillin allergy, one option is to desensitize the patient."}, 
{"Row" : 10, "Column" : 1, "Text" : "Severe reactions cannot be predicted accurately with skin testing in the"}, 
{"Row" : 11, "Column" : 1, "Text" : "clinical setting."}, 
{"Row" : 13, "Column" : 1, "Text" : "Penicillin Desensitization", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "> Perform in an ICU or similar setting."}, 
{"Row" : 15, "Column" : 1, "Text" : "> Discontinue all beta-adrenergic antagonists."}, 
{"Row" : 16, "Column" : 1, "Text" : "> Have IV line in place and EKG and spirometer ready."}, 
{"Row" : 17, "Column" : 1, "Text" : "> Once desensitization has been accomplished, therapy with this drug must not"}, 
{"Row" : 18, "Column" : 1, "Text" : "lapse or the risk of allergic reactions increases."}, 
{"Row" : 19, "Column" : 1, "Text" : "> A history of Stevens Johnson syndrome, exfoliative dermatitis, or erythroderma"}, 
{"Row" : 20, "Column" : 1, "Text" : "are nearly absolute contraindications to desensitization."}, 
{"Row" : 22, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "ORAL ROUTE", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Oral route is preferred if oral preparation is available and GI tract is"}, 
{"Row" : 28, "Column" : 1, "Text" : "functional. 1/3 of patients will develop transient reaction, usually mild."}, 
{"Row" : 30, "Column" : 1, "Text" : "[Step, 15 minute intervals] concentration, volume", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "[1] 0.5mg/ml, 0.1ml"}, 
{"Row" : 32, "Column" : 1, "Text" : "[2] 0.5mg/ml, 0.2ml"}, 
{"Row" : 33, "Column" : 1, "Text" : "[3] 0.5mg/ml, 0.4ml"}, 
{"Row" : 34, "Column" : 1, "Text" : "[4] 0.5mg/ml, 0.8ml"}, 
{"Row" : 35, "Column" : 1, "Text" : "[5] 0.5mg/ml, 1.6ml"}, 
{"Row" : 36, "Column" : 1, "Text" : "[6] 0.5mg/ml, 3.2ml"}, 
{"Row" : 37, "Column" : 1, "Text" : "[7] 0.5mg/ml, 6.4ml"}, 
{"Row" : 38, "Column" : 1, "Text" : "[8] 5mg/ml, 1.2ml"}, 
{"Row" : 39, "Column" : 1, "Text" : "[9] 5mg/ml, 2.4ml"}, 
{"Row" : 40, "Column" : 1, "Text" : "[10] 5mg/ml, 4.8ml"}, 
{"Row" : 41, "Column" : 1, "Text" : "[11] 50mg/ml, 1ml"}, 
{"Row" : 42, "Column" : 1, "Text" : "[12] 50mg/ml, 2ml"}, 
{"Row" : 43, "Column" : 1, "Text" : "[13] 50mg/ml, 4ml"}, 
{"Row" : 44, "Column" : 1, "Text" : "[14] 50mg/ml, 8ml"}, 
{"Row" : 46, "Column" : 1, "Text" : "After step 14, observe 30 minutes. If no reaction, give 1 gm IV."}, 
{"Row" : 48, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "PARENTERAL ROUTE", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "[Step, 15 minute intervals] concentration, volume", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "[1] 0.1mg/ml, 0.1ml"}, 
{"Row" : 56, "Column" : 1, "Text" : "[2] 0.1mg/ml, 0.2ml"}, 
{"Row" : 57, "Column" : 1, "Text" : "[3] 0.1mg/ml, 0.4ml"}, 
{"Row" : 58, "Column" : 1, "Text" : "[4] 0.1mg/ml, 0.8ml"}, 
{"Row" : 59, "Column" : 1, "Text" : "[5] 1mg/ml, 0.16ml"}, 
{"Row" : 60, "Column" : 1, "Text" : "[6] 1mg/ml, 0.32ml"}, 
{"Row" : 61, "Column" : 1, "Text" : "[7] 1mg/ml, 0.64ml"}, 
{"Row" : 62, "Column" : 1, "Text" : "[8] 10mg/ml, 0.12ml"}, 
{"Row" : 63, "Column" : 1, "Text" : "[9] 10mg/ml, 0.24ml"}, 
{"Row" : 64, "Column" : 1, "Text" : "[10] 10mg/ml, 0.48ml"}, 
{"Row" : 65, "Column" : 1, "Text" : "[11] 100mg/ml, 0.1ml"}, 
{"Row" : 66, "Column" : 1, "Text" : "[12] 100mg/ml, 0.2ml"}, 
{"Row" : 67, "Column" : 1, "Text" : "[13] 100mg/ml, 0.4ml"}, 
{"Row" : 68, "Column" : 1, "Text" : "[14] 100mg/ml, 0.8ml"}, 
{"Row" : 69, "Column" : 1, "Text" : "[15] 1000mg/ml, 0.16ml"}, 
{"Row" : 70, "Column" : 1, "Text" : "[16] 1000mg/ml, 0.32ml"}, 
{"Row" : 71, "Column" : 1, "Text" : "[17] 1000mg/ml, 0.64ml"}, 
{"Row" : 73, "Column" : 1, "Text" : "After step 17, observe 30 minutes. If no reaction, give 1 gm IV."}, 
{"Row" : 76, "Column" : 1, "Text" : "References"}, 
{"Row" : 78, "Column" : 1, "Text" : "Sanford key term: allergy"}, 
{"Row" : 79, "Column" : 1, "Text" : "Allergy: Principles and Practice 1993, p1726"}, 
{"Row" : 80, "Column" : 1, "Text" : "Curr Clin Topics Inf Dis 1993, 13:131"}
]},
{"Name" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "DisplayText" : "Peritonitis associated with peritoneal dialysis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 82, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q48H", "DisplayText" : "Fluconazole 200 mg PO q48h ($) [R,DI]", "Text" : "Fluconazole 200 mg PO every other day ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 84, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 100MG PO Q24H", "DisplayText" : "Fluconazole 100 mg q24h ($) [R,DI]", "Text" : "Fluconazole 100 mg PO q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "DisplayText" : "Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H AND GENT 0.6MG/KG Q24H", "DisplayText" : "Cefazolin and gentamicin PD order menu", "Text" : "Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h", "Mnemonic" : "10"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1GM Q24H VANCO 15-30MG/KG Q5-7D", "DisplayText" : "Cefepime and Vancomycin Treatment of Peritonitis Associated with PD", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Mnemonic" : "12"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D AND GENT 0.6MG/KG Q24H", "DisplayText" : "Vancomycin and gentamicin PD order menu", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Mnemonic" : "14"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "DisplayText" : "Cefazolin PD order menu", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Mnemonic" : "16"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "DisplayText" : "Vancomycin PD order menu", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Mnemonic" : "18"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "DisplayText" : "Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Mnemonic" : "20"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Gentamicin PD order menu", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Mnemonic" : "22"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "DisplayText" : "Cefazolin PD order menu", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Mnemonic" : "24"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFTAZIDIME 1GM Q24H", "DisplayText" : "Ceftazidime PD order menu", "Text" : "Ceftazidime 1 gm PD q24h ($) [R]", "Mnemonic" : "26"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFTRIAXONE 1GM Q24H", "DisplayText" : "Ceftriaxone PD order menu", "Text" : "Ceftriaxone 1 gm PD q24h ($) [M]", "Mnemonic" : "28"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Gentamicin PD order menu", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Mnemonic" : "30"},
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "DisplayText" : "Vancomycin PD order menu", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Mnemonic" : "32"},
{"Row" :3, "Column" : 1, "Text" : "PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Peritonitis associated with peritoneal dialysis usually presents with abdominal"}, 
{"Row" :6, "Column" : 1, "Text" : "pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte"}, 
{"Row" :7, "Column" : 1, "Text" : "concentration is greater than 100 cells/microliter of dialysate, with more than"}, 
{"Row" :8, "Column" : 1, "Text" : "50% neutrophils."}, 
{"Row" : 10, "Column" : 1, "Text" : "Obtain Gram stain, culture, and cell count with differential of dialysate before"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials are given. Nephrology consultation is essential. If cultures"}, 
{"Row" : 12, "Column" : 1, "Text" : "show Gram-negative or mixed bacterial infection, a gastrointestinal tract"}, 
{"Row" : 13, "Column" : 1, "Text" : "infectious source is more likely. Gram-positive organisms like staphylococci"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually result from external contamination. Fungal peritonitis is rare and"}, 
{"Row" : 15, "Column" : 1, "Text" : "requires immediate catheter removal."}, 
{"Row" : 17, "Column" : 1, "Text" : "**Antimicrobial recommendations are for empirical therapy only. Regimens should"}, 
{"Row" : 18, "Column" : 1, "Text" : "be tailored according to patient response and microbiology results in"}, 
{"Row" : 19, "Column" : 1, "Text" : "consultation with Nephrology and/or Infectious Diseases for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin"}, 
{"Row" : 22, "Column" : 1, "Text" : "per dialysis bag each day until one day after the dialysate is clear."}, 
{"Row" : 24, "Column" : 1, "Text" : "If vancomycin is used, trough serum concentrations should be kept above 15"}, 
{"Row" : 25, "Column" : 1, "Text" : "mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be"}, 
{"Row" : 26, "Column" : 1, "Text" : "given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more"}, 
{"Row" : 27, "Column" : 1, "Text" : "information."}, 
{"Row" : 77, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "Antifungal prophylaxis: ", "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Text" : "Antifungal prophylaxis may be used for the duration of antimicrobial therapy to"}, 
{"Row" : 80, "Column" : 1, "Text" : "possibly reduce the risk of fungal peritonitis."}, 
{"Row" : 83, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Antimicrobial therapy", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Duration of therapy depends on the pathogen identified. Treat staphylococcal and"}, 
{"Row" : 35, "Column" : 1, "Text" : "streptococcal infections for 2 weeks and all other gram-positive infections for"}, 
{"Row" : 36, "Column" : 1, "Text" : "3 weeks. In patients who have Staphylococcus isolated and had a previous"}, 
{"Row" : 37, "Column" : 1, "Text" : "staphylococcal infection, treat for 3 weeks"}, 
{"Row" : 39, "Column" : 1, "Text" : "All antimicrobials below are administered via peritoneal dialysate bag over 6", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "hours with the option to include heparin 1000 units.", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Empirical treatment while waiting for results of gram stain", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 47, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 49, "Column" : 1, "Text" : "cefepime 1 gm PD q24h ($) [R]"}, 
{"Row" : 51, "Column" : 1, "Text" : "Alternative for severe penicillin or cephalosporin allergy"}, 
{"Row" : 53, "Column" : 1, "Text" : "gentamicin 0.6 mg/kg PD q24h ($) [R,O]"}, 
{"Row" : 55, "Column" : 1, "Text" : "Gram positive organism", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 60, "Column" : 1, "Text" : "Gram negative organism", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Alternative for severe penicillin allergy"}, 
{"Row" : 66, "Column" : 1, "Text" : "Alternative treatments for narrowing coverage based on isolate susceptibilities", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 70, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 72, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 74, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 88, "Column" : 1, "Text" : "References: "}, 
{"Row" : 90, "Column" : 1, "Text" : "De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15"}, 
{"Row" : 91, "Column" : 1, "Text" : "Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508"}, 
{"Row" : 92, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" : 93, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Dialysis (CAPD) Associated"}, 
{"Row" : 94, "Column" : 1, "Text" : "Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal"}, 
{"Row" : 95, "Column" : 1, "Text" : "dialysis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Consult Nephrology in all cases.", "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS" , "Term1" : "Abscess, perianal/anorectal " , "Term2" : "Anorectal abscess " , "Term3" : "Perianal abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "DisplayText" : "Prevention of Bacterial Endocarditis", "Text" : "High risk of infective endocarditis", "Mnemonic" : "4"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX TRIMETH/SULFA DS Q12H METRO 1 GM PO Q12H", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Mnemonic" : "8"},
{"Row" : 44, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "12"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-Tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 55, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Mnemonic" : "18"},
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "20"},
{"Row" : 61, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "22"},
{"Row" : 63, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "24"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "PERIANAL/ANORECTAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary therapy: abscess drainage", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Prompt surgical drainage is important. Antibiotics have a limited role in the"}, 
{"Row" :8, "Column" : 1, "Text" : "treatment of uncomplicated anorectal abscess. In general, the addition of"}, 
{"Row" :9, "Column" : 1, "Text" : "antibiotics to routine incision and drainage of uncomplicated anorectal abscess"}, 
{"Row" : 10, "Column" : 1, "Text" : "does not improve healing time or reduce recurrences. Antibiotics may be"}, 
{"Row" : 11, "Column" : 1, "Text" : "considered in patients with significant cellulitis, underlying"}, 
{"Row" : 12, "Column" : 1, "Text" : "immunosuppression, concomitant systemic illness, or failure to improve with"}, 
{"Row" : 13, "Column" : 1, "Text" : "drainage alone."}, 
{"Row" : 15, "Column" : 1, "Text" : "Antibiotic prophylaxis for prevention of infective endocarditis is recommended"}, 
{"Row" : 16, "Column" : 1, "Text" : "for procedures involving infected skin or skin structures in patients with"}, 
{"Row" : 17, "Column" : 1, "Text" : "underlying cardiac conditions. Click on link below for list of conditions and"}, 
{"Row" : 18, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 21, "Column" : 1, "Text" : "Although culture of abscess fluid in patients who undergo drainage is rarely"}, 
{"Row" : 22, "Column" : 1, "Text" : "helpful, it may be considered in patients who will be treated with adjunctive"}, 
{"Row" : 23, "Column" : 1, "Text" : "antibiotic treatment, recurrent infection or nonhealing wounds, substantial host"}, 
{"Row" : 24, "Column" : 1, "Text" : "defense deficiency, and patients with MRSA risk factors."}, 
{"Row" : 26, "Column" : 1, "Text" : "Duration of adjunctive antimicrobial therapy", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "After adequate drainage, 5-14 days of antibiotic coverage is indicated for those"}, 
{"Row" : 28, "Column" : 1, "Text" : "who receive adjunctive antimicrobial therapy, with duration in part based on"}, 
{"Row" : 29, "Column" : 1, "Text" : "resolution of fever and leukocytosis, severity of infection, and additional"}, 
{"Row" : 30, "Column" : 1, "Text" : "indicators of clinical response."}, 
{"Row" : 31, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Adjunctive antibiotic treatment for drained perirectal abscess in patients with", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "significant cellulitis, underlying immunosuppression, concomitant systemic", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "illness, or failure to improve with drainage alone", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Mild disease", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 42, "Column" : 1, "Text" : "metronidazole 1000 mg PO q12h ($) [DI]"}, 
{"Row" : 43, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 49, "Column" : 1, "Text" : "Moderate disease", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 54, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy"}, 
{"Row" : 56, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 58, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 60, "Column" : 1, "Text" : "Severe, life-threatening disease", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 65, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy"}, 
{"Row" : 67, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 70, "Column" : 1, "Text" : "References: "}, 
{"Row" : 72, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 73, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 74, "Column" : 1, "Text" : "Steele et al, Dis Colon Rectum 54(12):1465-74, 2011"}, 
{"Row" : 75, "Column" : 1, "Text" : "Wilson et al, Circulation 116:1736, 2007"}, 
{"Row" : 76, "Column" : 1, "Text" : "Up-to-date article: Perianal and perirectal abscess"}, 
{"Row" : 77, "Column" : 1, "Text" : "Up-to-date article: Cellulitis and skin abscess in adults: Treatment"}
]},
{"Name" : "ORZID2 GMENU ABX PERICARDITIS" , "Term1" : "Pericarditis", "DisplayText" : "Pericarditis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "DisplayText" : "VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> piperacillin-tazobactam 4.5 gm", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "PERICARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases arise from non-infectious causes or are associated with viruses."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobial therapy is not indicated unless pericardial fluid is purulent. If"}, 
{"Row" :7, "Column" : 1, "Text" : "fluid is purulent, pericardial drainage is required in most cases. Modify"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial regimen and narrow coverage based on results of culture and"}, 
{"Row" :9, "Column" : 1, "Text" : "susceptibility tests."}, 
{"Row" : 10, "Column" : 1, "Text" : "Cardiology consultation is essential for management of therapy. Infectious"}, 
{"Row" : 11, "Column" : 1, "Text" : "Diseases consultation is recommended if an infectious origin is suspected."}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration is based on patient specific factors such as resolution of fever and"}, 
{"Row" : 15, "Column" : 1, "Text" : "clinical signs of infection. Generally, duration is 2 to 4 weeks depending on"}, 
{"Row" : 16, "Column" : 1, "Text" : "how adequacyof drainage of pericardial fluid and susceptibility of infectious"}, 
{"Row" : 17, "Column" : 1, "Text" : "organism."}, 
{"Row" : 19, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 26, "Column" : 1, "Text" : "IV q6h ($$) [R]"}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Adler et al., European Heart Journal 2015, 36.2921-2964"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Myocarditis and Pericarditis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Pericarditis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Purulent pericarditis"}
]},
{"Name" : "ORZID2 GMENU ABX PERTUSSIS" , "Term1" : "Pertussis", "DisplayText" : "Pertussis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "DisplayText" : "Diagnosis of Pertussis", "Text" : "Diagnosis of pertussis", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "DisplayText" : "Prevention of Pertussis", "Text" : "Prevention of pertussis", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 then 250 mg QD for 4 days ($)[M]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "PERTUSSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Pertussis is associated with persistent cough in adolescents and adults."}, 
{"Row" :6, "Column" : 1, "Text" : "Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1"}, 
{"Row" :7, "Column" : 1, "Text" : "to 2 weeks of disease resembles viral upper respiratory infection.After this,"}, 
{"Row" :8, "Column" : 1, "Text" : "the characteristic cough with whoop is present for 1 to 6 weeks, followed by a"}, 
{"Row" :9, "Column" : 1, "Text" : "2 to 3 week period of gradual resolution."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for macrolide intolerant or allergic patients", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Kline et al, Am Fam Physician (2013) 88.8, 507-514"}, 
{"Row" : 24, "Column" : 1, "Text" : "Langley et al, Pediatrics (2004), e96-e101"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Pertussis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Bordetella species"}
]},
{"Name" : "ORZID2 GMENU ABX PHARYNGITIS" , "Term1" : "Pharyngitis, streptococcal " , "Term2" : "Streptococcal pharyngitis", "DisplayText" : "Pharyngitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment of Gonorrheal Infections", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "DisplayText" : "HIV, Rapid", "Text" : "HIV Rapid Test", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU MORE ABOUT PHARYNGITIS", "DisplayText" : "More about Pharyngitis...", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "DisplayText" : "Strep A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500 MG PO Q12H", "DisplayText" : "Penicillin V 500mg po q12h", "Text" : "Penicillin V 500 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "12"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID BENZATHINE PENICILLIN 1.2MU IM ONCE", "DisplayText" : "Benzathine penicillin 1.2MU IM once", "Text" : "Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "16"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO q24h for 4 days ($)", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "PHARYNGITIS AND TONSILLITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and"}, 
{"Row" :6, "Column" : 1, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal"}, 
{"Row" :7, "Column" : 1, "Text" : "pharyngitis, use link below for recommendations."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider HIV screening for patients with pharyngitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcal Pharyngitis and Tonsillitis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by"}, 
{"Row" : 15, "Column" : 1, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk"}, 
{"Row" : 16, "Column" : 1, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for"}, 
{"Row" : 17, "Column" : 1, "Text" : "Modified Centor score criteria and for more details."}, 
{"Row" : 21, "Column" : 1, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Antimicrobials are not indicated"}, 
{"Row" : 24, "Column" : 1, "Text" : "GAS Pharyngitis and Tonsillitis Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: "}, 
{"Row" : 36, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Streptococcal Pharyngitis"}, 
{"Row" : 44, "Column" : 1, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis"}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "Cefadroxil 1000 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "18"}
]},
{"Name" : "ORZID2 GMENU ABX PHOTODYNAMIC THERAPY HSV-1", "DisplayText" : "Photodynamic therapy for HSV-1 prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "PHOTODYNAMIC THERAPY AND LASER SKIN RESURFACING HSV-1 PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Recommended in patients with history of HSV-1 infection. Initiate prophylaxis"}, 
{"Row" :6, "Column" : 1, "Text" : "24-48 hours prior to surgery and continue for 3-7 days."}, 
{"Row" :8, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "DisplayText" : "Acyclovir 400MG PO BID", "Text" : "Acyclovir 400 mg PO BID for 5 days ($) [R]", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Mandell chapter: Herpes Simplex Virus"}, 
{"Row" : 14, "Column" : 1, "Text" : "Up-To-Date article: Prevention of herpes simplex virus type 1 infection in"}, 
{"Row" : 15, "Column" : 1, "Text" : "immunocompetent patients"}
]},
{"Name" : "ORZID2 GMENU ABX PID" , "Term1" : "Pelvic inflammatory disease (PID) " , "Term2" : "Sexually transmitted infection, pelvic inflammatory disease", "DisplayText" : "Pelvic Inflammatory Disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 500MG IM DOXYC 100MG PO METRO 500MG PO", "DisplayText" : "Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg q12h for 14", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg q12h for 14", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEF 500MG IM ONCE DOXYCL 100MG PO Q12H", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg PO q12h for 7", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 500MG IM ONCE AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "CEFTRIAX 500MG IM ONCE AZITHROMYCIN 1GM PO ONCE", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > azithromycin 1 gm PO once ($) [M]", "Mnemonic" : "8"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX CEFOTETAN 2GM IV Q12H DOXYCL 100MG PO Q12H", "DisplayText" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFOT 2GM IV Q12H DOXYCL 100MG IV Q12H", "DisplayText" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg IV q12h ($) [DI]", "Text" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg IV q12h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG IV Q8H GENT 5 MG/KG QD", "DisplayText" : "Clindamycin 900 mg IV q8h ($$) [H,O] < AND > gentamicin 5 mg/kg q24h ($) [R,", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O] < AND > gentamicin 5 mg/kg q24h ($) [R,", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "PELVIC INFLAMMATORY DISEASE (PID)", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Pelvic inflammatory disease (PID) refers to bacterial infection of the upper"}, 
{"Row" :7, "Column" : 1, "Text" : "female reproductive tract. Likely bacterial pathogens include Neisseria"}, 
{"Row" :8, "Column" : 1, "Text" : "gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and"}, 
{"Row" :9, "Column" : 1, "Text" : "Streptococcus agalactiae. PID should be considered in sexually active women"}, 
{"Row" : 10, "Column" : 1, "Text" : "with pelvic tenderness and signs of lower genital tract inflammation. Signs and"}, 
{"Row" : 11, "Column" : 1, "Text" : "symptoms may be mild or non-specific, and providers should have a low threshold"}, 
{"Row" : 12, "Column" : 1, "Text" : "to initiate treatment. All women who are diagnosed with acute PID should be"}, 
{"Row" : 13, "Column" : 1, "Text" : "tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of"}, 
{"Row" : 14, "Column" : 1, "Text" : "patients with PID should be examined and treated (see below) if they had sexual"}, 
{"Row" : 15, "Column" : 1, "Text" : "contact within the 60 days before onset of the patient's symptoms."}, 
{"Row" : 17, "Column" : 1, "Text" : "Judge severity of infection based on clinical signs and symptoms, including"}, 
{"Row" : 18, "Column" : 1, "Text" : "blood pressure, pulse, mental status, and degree of fever."}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 24, "Column" : 1, "Text" : "days ($) [DI] < OPTIONAL > metronidazole 500 mg PO q12h ($) [DI]"}, 
{"Row" : 26, "Column" : 1, "Text" : "For patients who cannot take ceftriaxone and doxycycline, call ID", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment of sex partner who is a veteran", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treat for both Chlamydia and Gonorrhea"}, 
{"Row" : 31, "Column" : 1, "Text" : "days ($) [DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 43, "Column" : 1, "Text" : "O]"}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3"}, 
{"Row" : 49, "Column" : 1, "Text" : "Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Pelvic inflammatory disease"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Pelvic inflammatory disease"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS" , "Term1" : "Pneumocystis prophylaxis " , "Term2" : "Prophylactic antimicrobials for Pneumocystis", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po q24h", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q day ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA SS Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO q24h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 SS tablet q day ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID DAPSONE 100MG PO QDAY PCP PROPHLAXIS", "DisplayText" : "Dapsone 100 mg PO qd for PCP prophylaxis", "Text" : "Dapsone 100mg PO q day ($) [DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PNEUMOCYSTIS JIROVECII PROPHYLAXIS (PCP Prophylaxis)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Indications for primary prophylaxis of P. jirovecii include: "}, 
{"Row" :6, "Column" : 1, "Text" : "1) HIV/AIDS patients with CD4 count <200 cells/microliter"}, 
{"Row" :7, "Column" : 1, "Text" : "2) Hematopoietic or organ transplantation patients during immunosuppression"}, 
{"Row" :8, "Column" : 1, "Text" : "3) Patients receiving Alemtuzumab, temozolomide or fludarabine"}, 
{"Row" :9, "Column" : 1, "Text" : "4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month"}, 
{"Row" : 10, "Column" : 1, "Text" : "5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving"}, 
{"Row" : 11, "Column" : 1, "Text" : "immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe"}, 
{"Row" : 12, "Column" : 1, "Text" : "combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM"}, 
{"Row" : 15, "Column" : 1, "Text" : "Dose and duration of prophylaxis varies with the indication. Please contact"}, 
{"Row" : 16, "Column" : 1, "Text" : "Infectious Diseases or Hematology/Oncology for more information."}, 
{"Row" : 18, "Column" : 1, "Text" : "Prophylaxis should be discontinued when host defenses are restored. In persons"}, 
{"Row" : 19, "Column" : 1, "Text" : "with AIDS on highly active antiretroviral therapy, Prophylaxis should be"}, 
{"Row" : 20, "Column" : 1, "Text" : "discontinued when the CD4 cell concentrations remain over 200 cells/microliter"}, 
{"Row" : 21, "Column" : 1, "Text" : "for 3 to 6 months in patients, except that prophylaxis should be continued for"}, 
{"Row" : 22, "Column" : 1, "Text" : "life in those who have had P. jirovecii disease."}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "References"}, 
{"Row" : 55, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 56, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2018)"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford keyword: Pneumocystis pneumonia, Adult"}, 
{"Row" : 58, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-"}, 
{"Row" : 59, "Column" : 1, "Text" : "uninfected patients"}, 
{"Row" : 24, "Column" : 1, "Text" : "Recommended FIRST-LINE prophylaxis: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)"}, 
{"Row" : 31, "Column" : 1, "Text" : "deficiency before starting dapsone. Individuals deficient in G6-PD"}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID ATOVAQUONE 1500MG QDAY PCP PROPHYLAXIS", "DisplayText" : "Atovaquone 1500mg qday for PCP prophylaxis", "Text" : "Atovaquone 1500mg q day for PCP prophylaxis ($$) [DI]", "Mnemonic" : "12"},
{"Row" : 40, "Column" : 1, "Text" : "Atovaquone is alternative for patient for clinical reason: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "(e.g. patients with SLE, hematologic concerns, G6PD deficiency)"}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative to the above preferred regimens: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "LRTZ G6-PD SCREEN", "DisplayText" : "G6-PD Screen", "Text" : "[Click here] G6-PD Screen Lab Order", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Text" : "syndrome)"}, 
{"Row" : 32, "Column" : 1, "Text" : "show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic"}, 
{"Row" : 33, "Column" : 1, "Text" : "anemia."}, 
{"Row" : 34, "Column" : 1, "Text" : "G6-PD lab test are resulted the same day or next day. May be add on lab."}, 
{"Row" : 35, "Column" : 1, "Text" : "G6-PD lab result should be \"normal\" to start dapsone therapy."}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404"}, 
{"Row" : 54, "Column" : 1, "Text" : "Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9"}, 
{"Row" : 44, "Column" : 1, "Text" : "Alternative to the above regimens: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB INPT", "DisplayText" : "Pentamidine inhalation order set", "Text" : "Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%", "Mnemonic" : "14"},
{"Row" : 48, "Column" : 1, "Text" : "inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN"}, 
{"Row" : 49, "Column" : 1, "Text" : "appointment)"}, 
{"Row" : 45, "Column" : 1, "Text" : "Due to efficacy and complicated logistics for administration, alternative"}, 
{"Row" : 46, "Column" : 1, "Text" : "when above recommendations not appropriate for patient."}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA" , "Term1" : "Pneumonia", "DisplayText" : "Pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia", "Text" : "Aspiration Pneumonia", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "DisplayText" : "Nosocomial pneumonia (including HAP, AND VAP)", "Text" : "Nosocomial pneumonia (including HAP, AND VAP)", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "++ PNEUMONIA - INPATIENT ++", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019"}, 
{"Row" :8, "Column" : 1, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA"}, 
{"Row" :9, "Column" : 1, "Text" : "and/or P. aeruginosa are used to guide whether to start"}, 
{"Row" : 10, "Column" : 1, "Text" : "appropriate coverage empirically. (See CAP above)"}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "DisplayText" : "PNEUMONIA HAP " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM IV Q6H VANCO 15MG/KG IV Q12H", "DisplayText" : "Piperacillin/tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Text" : "15 mg/kg IV q12h ($) [R] < OR >"}, 
{"Row" :3, "Column" : 1, "Text" : "EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "20"},
{"Row" : 34, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative for penicillin allergy: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "References: "}, 
{"Row" : 49, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1."}, 
{"Row" : 51, "Column" : 1, "Text" : "Chastre J. JAMA 2003. 290:2588."}, 
{"Row" : 52, "Column" : 1, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371."}, 
{"Row" : 53, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676."}, 
{"Row" : 54, "Column" : 1, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119."}, 
{"Row" :9, "Column" : 1, "Text" : "Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s): ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Prior intravenous antibiotic use within 90 days"}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 23, "Column" : 1, "Text" : "Empiric Treatment: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 16, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 17, "Column" : 1, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no"}, 
{"Row" : 18, "Column" : 1, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal"}, 
{"Row" : 19, "Column" : 1, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for"}, 
{"Row" : 20, "Column" : 1, "Text" : "MRSA."}, 
{"Row" :7, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" :6, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" :4, "Column" : 1, "Text" : "Development of pneumonia 48 hours or more after hospital admission."}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Text" : "", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Text" : "Conditions that increase risk for Pseudomonas infections: "}, 
{"Row" : 38, "Column" : 1, "Text" : ">Bronchiectasis or Bronchomalacia"}, 
{"Row" : 39, "Column" : 1, "Text" : ">Lung Cancer"}, 
{"Row" : 40, "Column" : 1, "Text" : ">Pneumonectomy"}, 
{"Row" : 41, "Column" : 1, "Text" : ">Bronchoesophageal fistula"}, 
{"Row" : 42, "Column" : 1, "Text" : ">Cystic Fibrosis"}, 
{"Row" : 43, "Column" : 1, "Text" : ">Chronic pleural effusions with chest tubes"}, 
{"Row" : 44, "Column" : 1, "Text" : ">Severe obstructive Lung Disease with FEV1%<31"}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "", "Mnemonic" : "22"},
{"Row" : 45, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "If no risk factors for pseudomonas: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "If risk factors for Pseudomonas *ADD* additional coverage to above regimens: ", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA VAP", "DisplayText" : "PNEUMONIA VAP " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TZ 4.5 GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin 5", "Mnemonic" : "10"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM GENT 5M/KG VANCO 15MG/KG Q12H", "DisplayText" : "Cefepime Gentamicin Vancomycin", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> gentamicin 5", "Mnemonic" : "12"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) <AND> gentamicin 5 mg/kg IV", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG GENT 5M/KG VANCO 15MG/KG Q12H", "DisplayText" : "Levofloxacin 750 mg Gentamicin 5 mg/kg Vancomycin 15 mg/kg", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h ($)", "Mnemonic" : "16"},
{"Row" :2, "Column" : 1, "Text" : "EMPIRIC TREATMENT: Ventilator Associated Pneumonia (VAP)", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumonia occurring 48 hours or more after endotracheal intubation"}, 
{"Row" :5, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" :6, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "Risk factors for Multi-Drug Resistant VAP: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Prior intravenous antibiotic use within 90 days"}, 
{"Row" : 10, "Column" : 1, "Text" : "Septic shock at the time of VAP"}, 
{"Row" : 11, "Column" : 1, "Text" : "ARDS preceding VAP"}, 
{"Row" : 12, "Column" : 1, "Text" : "5 or more days of hospitalization prior to the occurrence of VAP"}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute renal replacement therapy prior to VAP onset"}, 
{"Row" : 14, "Column" : 1, "Text" : "Local resistance pattern"}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 18, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 20, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 21, "Column" : 1, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no"}, 
{"Row" : 22, "Column" : 1, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal"}, 
{"Row" : 23, "Column" : 1, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for"}, 
{"Row" : 24, "Column" : 1, "Text" : "MRSA."}, 
{"Row" : 26, "Column" : 1, "Text" : "Empiric Treatment: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "No Risk of MDR Pathogen(s): ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 32, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative for Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 38, "Column" : 1, "Text" : "Risk of MDR Pathogens: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 44, "Column" : 1, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative for penicillin allergy: "}, 
{"Row" : 48, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 51, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 53, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1."}, 
{"Row" : 55, "Column" : 1, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163"}, 
{"Row" : 56, "Column" : 1, "Text" : "Chastre J. JAMA 2003. 290:2588."}, 
{"Row" : 57, "Column" : 1, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371."}, 
{"Row" : 58, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676."}, 
{"Row" : 59, "Column" : 1, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119."}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH" , "Term1" : "Coagulase negative staphylococci, single blood culture positive", "DisplayText" : "Blood culture positive for coagulase negative staphylococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "DisplayText" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Text" : "Treatment of CNS Bacteremia", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "DisplayText" : "Intravascular catheter-associated coagulase-negative staphylococcus infection", "Text" : "Treatment of CNS Infected Intravascular Catheters", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "CNS are the most common contaminants isolated from blood cultures. When CNS"}, 
{"Row" :6, "Column" : 1, "Text" : "isolated from blood cultures represent true bacteremia, the blood is usually"}, 
{"Row" :7, "Column" : 1, "Text" : "obtained from a patient with plastic or metal in the body. The most common"}, 
{"Row" :8, "Column" : 1, "Text" : "source of coagulase negative staphylococcal bacteremia is an infected"}, 
{"Row" :9, "Column" : 1, "Text" : "intravascular catheter."}, 
{"Row" : 11, "Column" : 1, "Text" : "When CNS are isolated from blood, the physician should carefully assess the"}, 
{"Row" : 12, "Column" : 1, "Text" : "patient to decide whether the isolation represents disease or colonization."}, 
{"Row" : 13, "Column" : 1, "Text" : "Colonization is more likely if a single bottle is positive or both bottles from"}, 
{"Row" : 14, "Column" : 1, "Text" : "a single blood draw are positive. If multiple bottles are positive from separate"}, 
{"Row" : 15, "Column" : 1, "Text" : "blood draws, it is more likely that the isolates reflect disease or colonization"}, 
{"Row" : 16, "Column" : 1, "Text" : "of an intravascular device. Isolates from contaminated bottles often take"}, 
{"Row" : 17, "Column" : 1, "Text" : "several days to become positive. If the patient has risk factors for true"}, 
{"Row" : 18, "Column" : 1, "Text" : "coagulase negative staphylococcal bacteremia, catheter-related blood stream"}, 
{"Row" : 19, "Column" : 1, "Text" : "infection and/or the patient is severely ill, antimicrobials should be given"}, 
{"Row" : 20, "Column" : 1, "Text" : "(see below). If there is a plastic or metal prosthesis in the body, the"}, 
{"Row" : 21, "Column" : 1, "Text" : "physician should evaluate the site for possible infection. If the isolates are"}, 
{"Row" : 22, "Column" : 1, "Text" : "likely to represent contamination and the patient does not seem ill with CNS,"}, 
{"Row" : 23, "Column" : 1, "Text" : "antimicrobial therapy would not be helpful and should not be given."}, 
{"Row" : 29, "Column" : 1, "Text" : "References"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative"}, 
{"Row" : 32, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mermel et al, Clin Infect Dis, 2009, 49"}
]},
{"Name" : "ORZID2 GMENU ABX PREVENTION OF INFECTION" , "Term1" : "Infection Prevention section " , "Term2" : "Prevention of Infection section", "DisplayText" : "Prevention of Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "DisplayText" : "Prevention of Bacterial Endocarditis", "Text" : "Prevention of bacterial endocarditis", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "DisplayText" : "Prevention of prosthetic joint infection before dental procedures", "Text" : "Before dental procedures", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "DisplayText" : "Prevention of bacterial infection in a patient with malignancy", "Text" : "Antibacterial prophylaxis", "Mnemonic" : "10"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infections in a patient with malignancy", "Text" : "Antifungal prophylaxis", "Mnemonic" : "12"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP)", "Text" : "Spontaneous bacterial peritonitis", "Mnemonic" : "16"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis jirovecii prophylaxis", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Click Here", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "++PREVENTION OF INFECTION++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prevention of bacterial endocarditis", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Prevention of prosthetic joint infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Prevention of infection in patient with malignancy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Prevention of infection in patients with liver disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Prevention of Pneumocystis infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Prevention of recurrent Staphylococcus aureus skin infection", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Section reviewed January 2019"}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "DisplayText" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS", "Text" : "Before procedures involving infected skin, skin structures or musculoskeletal", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Text" : "tissue"}
]},
{"Name" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX" , "Term1" : "Chickenpox, primary infection " , "Term2" : "Varicella", "DisplayText" : "Primary infection (Chickenpox)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "DisplayText" : "Acyclovir 800MG PO 5x/d", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "DisplayText" : "Acyclovir 800MG PO 5x/d", "Text" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R]", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 44, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "DisplayText" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI]", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "PRIMARY INFECTION (CHICKENPOX)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Vaccinate all adults without evidence of immunity except for pregnant women."}, 
{"Row" : 12, "Column" : 1, "Text" : "Test antibody first in adults who have uncertain history of chickenpox or"}, 
{"Row" : 13, "Column" : 1, "Text" : "vaccination."}, 
{"Row" : 14, "Column" : 1, "Text" : "Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Therapy must be started within 24 hrs onset of rash."}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Therapy must be started within 24 hrs onset of rash."}, 
{"Row" : 24, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Immunocompromised patients without prior immunity to varicella who are at risk"}, 
{"Row" : 31, "Column" : 1, "Text" : "for disease include: patients with malignancy, current immunosuppressive"}, 
{"Row" : 32, "Column" : 1, "Text" : "therapy, or HIV infection. Vaccination is not recommended while patients are"}, 
{"Row" : 33, "Column" : 1, "Text" : "immunocompromised."}, 
{"Row" : 35, "Column" : 1, "Text" : "Contact Infectious Diseases for more information."}, 
{"Row" : 37, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "Treatment for severe disease, or if mild to moderate disease doesn't improve on", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "above therapy", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "References: "}, 
{"Row" : 49, "Column" : 1, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Varicella-Zoster Virus"}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)"}
]},
{"Name" : "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES", "DisplayText" : "Drugs for procedures that involve infected skin, skin structures" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "DisplayText" : "Cefazolin 1gm iv once", "Text" : "Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID TRIMETHOPRIM/SULFA 1 DS PO (PRE-OP)", "DisplayText" : "Trimethoprim/Sulfa 1 DS table PO (Pre-Op)", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100 MG PO (PRE-OP)", "DisplayText" : "Minocycline 100 mg PO 1 hour before incision (Pre-Op)", "Text" : "Minocycline 100 mg PO 1 hour before incision ($) [DI]", "Mnemonic" : "10"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15mg/kg IV over 60 minutes, beginning 120 minutes before incision", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Patients unable to take oral medications", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 13, "Column" : 1, "Text" : "Suspected MRSA", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "($) [R,DI]"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283"}, 
{"Row" : 26, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 27, "Column" : 1, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site"}, 
{"Row" : 29, "Column" : 1, "Text" : "infection in adults"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 31, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}, 
{"Row" : 32, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}, 
{"Row" :7, "Column" : 1, "Item" : "PSJZID CEFADROXIL 2GM PO ONCE 'C'", "DisplayText" : "Cefadroxil 2 GM PO 1 hour before procedure ($) [R]", "Text" : "", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU ABX PYELONEPHRITIS" , "Term1" : "Pyelonephritis", "DisplayText" : "Pyelonephritis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "16"},
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 64, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Mnemonic" : "20"},
{"Row" : 66, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 14 days", "Mnemonic" : "22"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "24"},
{"Row" : 70, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "26"},
{"Row" : 81, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days", "Mnemonic" : "28"},
{"Row" : 83, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] for 14 days", "Mnemonic" : "30"},
{"Row" : 86, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "32"},
{"Row" : 89, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R] for 14 days", "Mnemonic" : "34"},
{"Row" : 93, "Column" : 1, "Item" : "PSJIZID AMPICIL 2GM IV Q6H", "DisplayText" : "Ampicillin 2 gm IV q6h ($$) [R]", "Text" : "Ampicillin 2 gm IV q6h ($$) [R] for 14 days", "Mnemonic" : "36"},
{"Row" : 95, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "DisplayText" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R] for 14 days", "Mnemonic" : "38"},
{"Row" : 98, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "40"},
{"Row" : 99, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 14 days", "Mnemonic" : "42"},
{"Row" :101, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Mnemonic" : "44"},
{"Row" :103, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O] for 14 days", "Mnemonic" : "46"},
{"Row" :3, "Column" : 1, "Text" : "PYELONEPHRITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Features of pyelonephritis include fever/other signs of systemic infection,"}, 
{"Row" :6, "Column" : 1, "Text" : "flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most"}, 
{"Row" :7, "Column" : 1, "Text" : "cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "and Pseudomonas, are more likely if the patient is elderly, has been in the"}, 
{"Row" :9, "Column" : 1, "Text" : "hospital for more than 48 hours, or received a course of antibiotics."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobial therapy: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Drugs active against enterococci (ampicillin, piperacillin) or staphylococci"}, 
{"Row" : 16, "Column" : 1, "Text" : "needn't be used if Gram-negative bacilli predominate on the smear. Broad"}, 
{"Row" : 17, "Column" : 1, "Text" : "spectrum antimicrobials are needed if patient is at risk of having a multi-drug"}, 
{"Row" : 18, "Column" : 1, "Text" : "resistant (MDR) organism."}, 
{"Row" : 20, "Column" : 1, "Text" : "Judge severity of infection based on clinical signs and symptoms, including"}, 
{"Row" : 21, "Column" : 1, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever."}, 
{"Row" : 22, "Column" : 1, "Text" : "Oral regimens are preferred over IV if severity is mild or moderate and patient"}, 
{"Row" : 23, "Column" : 1, "Text" : "can tolerate oral antibiotics. In patients with severe or persistent disease,"}, 
{"Row" : 24, "Column" : 1, "Text" : "new renal failure, or suspected urinary obstruction, obtain a renal ultrasound"}, 
{"Row" : 25, "Column" : 1, "Text" : "to rule out obstruction or other complicating condition. Consult urology if"}, 
{"Row" : 26, "Column" : 1, "Text" : "abnormalities are found."}, 
{"Row" : 28, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 29, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 30, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 32, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical"}, 
{"Row" : 34, "Column" : 1, "Text" : "response, 7 days of treatment may be adequate. A longer duration may be required"}, 
{"Row" : 35, "Column" : 1, "Text" : "in severe infection, resistant organisms, presence of obstruction, underlying"}, 
{"Row" : 36, "Column" : 1, "Text" : "renal disease, immunosuppression, neurologic or structural abnormality, and men"}, 
{"Row" : 37, "Column" : 1, "Text" : "in some cases. A 7-day course of ciprofloxacin has been shown to be as effective"}, 
{"Row" : 38, "Column" : 1, "Text" : "as a 14-day course."}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "History of Pseudomonas or ESBL isolate", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 56, "Column" : 1, "Text" : "History of MRSA, add to intravenous therapy above", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 65, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 68, "Column" : 1, "Text" : "Alternative or isolate resistant to preferred antimicrobials: "}, 
{"Row" : 71, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 73, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" : 75, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" : 76, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" : 77, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 79, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 82, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 85, "Column" : 1, "Text" : "Isolate resistant to preferred antimicrobials: "}, 
{"Row" : 87, "Column" : 1, "Text" : "for 14 days"}, 
{"Row" : 88, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 91, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" : 92, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 94, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 97, "Column" : 1, "Text" : "Resistant isolate or alternative to preferred antimicrobials: "}, 
{"Row" :100, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :102, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :104, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :107, "Column" : 1, "Text" : "References: "}, 
{"Row" :108, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :109, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :110, "Column" : 1, "Text" : "Sanford keyword: Pyelonephritis, Acute"}, 
{"Row" :111, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis"}, 
{"Row" :112, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :113, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :114, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}
]},
{"Name" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "DisplayText" : "Re-evaluate Nosocomial pneumonia at 72 hours" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "RE-EVALUATE NOSOCOMIAL PNEUMONIA AT 72 HOURS"}, 
{"Row" :5, "Column" : 1, "Text" : "_____________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Step 1.Evaluate the patient", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_____________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Assess for favorable clinical response indicated by improvement in one or more"}, 
{"Row" : 10, "Column" : 1, "Text" : "of the following: fever, mental status, appetite, ability to eat, oxygenation,"}, 
{"Row" : 11, "Column" : 1, "Text" : "blood pressure, pulse, leukopenia.If the patient has improved, continue to"}, 
{"Row" : 12, "Column" : 1, "Text" : "step 2."}, 
{"Row" : 14, "Column" : 1, "Text" : "If the patient has not improved, consider the following"}, 
{"Row" : 15, "Column" : 1, "Text" : "1. The patient has pneumonia with a pathogen resistant to empirical"}, 
{"Row" : 16, "Column" : 1, "Text" : "antimicrobials (e.g., resistant bacteria, fungi, mycobacteria)"}, 
{"Row" : 17, "Column" : 1, "Text" : "2. The patient does not have bacterial pneumonia.Consider alternative"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnoses including pulmonary edema, atelectasis, pulmonary embolus, ARDS,"}, 
{"Row" : 19, "Column" : 1, "Text" : "pulmonary hemorrhage, underlying disease, and neoplasm."}, 
{"Row" : 20, "Column" : 1, "Text" : "3. The patient has infectious disease outside the lungs."}, 
{"Row" : 21, "Column" : 1, "Text" : "4. The patient has one or more complications of pneumonia (e.g., empyema, lung"}, 
{"Row" : 22, "Column" : 1, "Text" : "abscess, mediastinitis, or pericarditis)"}, 
{"Row" : 23, "Column" : 1, "Text" : "5. The patient has an adverse drug event"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infectious Disease or Pulmonary consult is strongly encouraged for patients who"}, 
{"Row" : 26, "Column" : 1, "Text" : "do not respond to initial therapy.If bacterial pneumonia is still considered"}, 
{"Row" : 27, "Column" : 1, "Text" : "likely, continue to step 2."}, 
{"Row" : 28, "Column" : 1, "Text" : "____________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Step 2.Evaluate microbiology results", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "____________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Decide whether a likely pathogen has been identified from respiratory secretions"}, 
{"Row" : 33, "Column" : 1, "Text" : "or blood.The clinician must decide whether any organisms identified on smear"}, 
{"Row" : 34, "Column" : 1, "Text" : "or culture of respiratory tract secretions reflect disease, colonization, or"}, 
{"Row" : 35, "Column" : 1, "Text" : "contamination based on clinical and microbiological information."}, 
{"Row" : 37, "Column" : 1, "Text" : "The quality of a respiratory secretion sample must be evaluated.Sputum samples"}, 
{"Row" : 38, "Column" : 1, "Text" : "with fewer than 25 polymorphonuclear leukocytes per high power field (hpf) are"}, 
{"Row" : 39, "Column" : 1, "Text" : "unlikely to be from a site of bacterial infection unless the patient is"}, 
{"Row" : 40, "Column" : 1, "Text" : "profoundly neutropenic.Sputum samples with more than 10 epithelial cells/hpf"}, 
{"Row" : 41, "Column" : 1, "Text" : "are likely to be contaminated with upper respiratory tract secretions."}, 
{"Row" : 43, "Column" : 1, "Text" : "In cases of bacterial pneumonia, a gram stain of a high quality respiratory"}, 
{"Row" : 44, "Column" : 1, "Text" : "tract secretion usually contains 3+ or 4+ of bacteria with morphology and"}, 
{"Row" : 45, "Column" : 1, "Text" : "staining characteristics consistent with the pathogen.Culture of the"}, 
{"Row" : 46, "Column" : 1, "Text" : "respiratory tract secretion indicates the species and susceptibilities of the"}, 
{"Row" : 47, "Column" : 1, "Text" : "bacteria seen on gram stain."}, 
{"Row" : 48, "Column" : 1, "Text" : "_____________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Step 3.Adjust or discontinue antimicrobial therapy", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "_____________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Decide whether to continue, modify, or discontinue antimicrobials.If an"}, 
{"Row" : 53, "Column" : 1, "Text" : "organism likely to be a respiratory pathogen is isolated from a patient thought"}, 
{"Row" : 54, "Column" : 1, "Text" : "to have bacterial pneumonia, adjust therapy if necessary to treat this pathogen."}, 
{"Row" : 55, "Column" : 1, "Text" : "If the patient does not have convincing evidence for bacterial pneumonia and/or"}, 
{"Row" : 56, "Column" : 1, "Text" : "a likely pathogen has not been isolated from respiratory secretions then stop"}, 
{"Row" : 57, "Column" : 1, "Text" : "antimicrobials for pneumonia."}, 
{"Row" : 62, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290: 2588"}, 
{"Row" : 63, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 64, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1"}, 
{"Row" : 65, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 66, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}, 
{"Row" : 67, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER" , "Term1" : "Chickenpox, reactivation of primary infection " , "Term2" : "Shingles " , "Term3" : "Zoster", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID PREDNISONE TAPER HERPES ZOSTER TX", "DisplayText" : "PREDNISONE TAPER HERPES ZOSTER TX", "Text" : "Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg", "Mnemonic" : "6"},
{"Row" : 56, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Mnemonic" : "8"},
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "DisplayText" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI]", "Text" : "Acyclovir 10 mg/kg IV q8h for 7-14 days ($$) [R]", "Mnemonic" : "10"},
{"Row" : 64, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 7.5 MG/KG IV Q8H", "DisplayText" : "Acyclovir 7.5 mg/kg iv q8h", "Text" : "Acyclovir 7.5 mg/kg IV q8h for 7-14 days($$) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Zoster represents reactivation of varicella-zoster virus. After primary"}, 
{"Row" :6, "Column" : 1, "Text" : "infection, virus remains latent in the sensory dorsal root ganglia."}, 
{"Row" :7, "Column" : 1, "Text" : "Reactivation syndrome is characterized by painful, unilateral, vesicular,"}, 
{"Row" :8, "Column" : 1, "Text" : "dermatomal rash."}, 
{"Row" : 10, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Vaccinate all adults greater than or equal to 50 years of age with the"}, 
{"Row" : 12, "Column" : 1, "Text" : "recombinant zoster vaccine regardless of past episode or receipt of the live"}, 
{"Row" : 13, "Column" : 1, "Text" : "zoster vaccine."}, 
{"Row" : 14, "Column" : 1, "Text" : "Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first"}, 
{"Row" : 15, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment in persons <50 years", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment is not beneficial, none is recommended."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment in persons >=50 years", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment with antivirals can shorten duration of pain and rash in patients over"}, 
{"Row" : 26, "Column" : 1, "Text" : "50 years old. Treatment must be started within 72 hours of onset."}, 
{"Row" : 30, "Column" : 1, "Text" : "There is evidence that addition of corticosteroids to antiviral"}, 
{"Row" : 31, "Column" : 1, "Text" : "therapy decreases pain and duration of rash and improves quality of life"}, 
{"Row" : 32, "Column" : 1, "Text" : "modestly during the acute shingles episode. Corticosteroids do not decrease the"}, 
{"Row" : 33, "Column" : 1, "Text" : "incidence of post-herpetic neuralgia. Some authorities recommend addition of"}, 
{"Row" : 34, "Column" : 1, "Text" : "corticosteroid therapy to antiviral therapy for patients over age 50 years."}, 
{"Row" : 35, "Column" : 1, "Text" : "Corticosteroids are not recommended for patients at greater risk for steroid"}, 
{"Row" : 36, "Column" : 1, "Text" : "toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic"}, 
{"Row" : 37, "Column" : 1, "Text" : "ulcer disease) or for immunocompromised patients."}, 
{"Row" : 39, "Column" : 1, "Text" : "Optional Recommendation: "}, 
{"Row" : 41, "Column" : 1, "Text" : "daily for 7 days. ($)"}, 
{"Row" : 43, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Immunocompromised patients at increased risk for complications of VZV disease"}, 
{"Row" : 50, "Column" : 1, "Text" : "include: patients with malignancy, current immunosuppressive therapy, or HIV"}, 
{"Row" : 51, "Column" : 1, "Text" : "infection. Treatment with antivirals shortens duration of symptoms and reduces"}, 
{"Row" : 52, "Column" : 1, "Text" : "incidence of complications. In immunocompromised patients, treatment is"}, 
{"Row" : 53, "Column" : 1, "Text" : "recommended to be started at any point during an active infection."}, 
{"Row" : 55, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Treatment for severe disease or progression from mild to moderate disease in", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "patients <=65 years", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Treatment for severe disease or progression from mild to moderate disease in", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "patients >65 years", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "References: "}, 
{"Row" : 69, "Column" : 1, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220"}, 
{"Row" : 70, "Column" : 1, "Text" : "Sanford keyword: Varicella-Zoster Virus"}, 
{"Row" : 71, "Column" : 1, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)"}
]},
{"Name" : "ORZID2 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Relcalcitrant Acne and Rosacea" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSJZID2 TMP/SULFA 12WKS 1DS PO Q12H", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID2 CEPHALEXIN 12WKS 500MG Q12H", "DisplayText" : "Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks", "Text" : "Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID2 AMOX/CLAV 500/125MG 12WKS PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks", "Text" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID2 AZITHROMYCIN 12WKS 500MG PO Q8H", "DisplayText" : "Azithromycin 500 mg three times weekly ($) [O] for 12 weeks", "Text" : "Azithromycin 500 mg three times weekly ($) [O] for 12 weeks", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO BID ($) [DI]", "Text" : "Doxycycline 50 mg PO BID ($) [DI] prolonged therapy", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "DERMATOLOGY SERVICE ORDER MENU FOR RECALCITRANT ACNE AND ROSACEA", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Recalcitrant Acne and Rosacea Treatment: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Refractory Severe Rosacea Treatment: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "**For dermatology use only, requires dermatology consult prior to treatment**", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Term" : "CDC Recommended Adult Immunizations", "DisplayText" : "CDC Recommended Adult Immunizations " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "[Click Here] for vaccination history including link to Joint Legacy Viewer", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "[Click Here] for link to PDF of CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting", "Text" : "COVID-19 (Comirnaty, Spikevax, Janssen)", "Mnemonic" : "8"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Flu (seasonal influenza)", "Mnemonic" : "10"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Functional or Anatomical Asplenia", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND INPATIENT VACCINE ORDERS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patient Vaccine History: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "(See Outpatient CDSS for complete list of vaccinations with clinic orders.)"}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}, 
{"Row" : 11, "Column" : 1, "Text" : "Inpatient Vaccine Information and Orders", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (A-C)", "DisplayText" : "Journal References (Author Lastname: A-C) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Anonymous.Antibiotic prophylaxis for urological patients with total joint"}, 
{"Row" :4, "Column" : 1, "Text" : "replacement.Advisory statement, American Urological Association And"}, 
{"Row" :5, "Column" : 1, "Text" : "American Academy Of Orthopaedic Surgeons.J Urol 2003, 169: 1796"}, 
{"Row" :6, "Column" : 1, "Text" : "Anonymous.Antifungal drugs.Med Letter Treatment Guidelines 2005, 3: 7"}, 
{"Row" :7, "Column" : 1, "Text" : "Anonymous.Antimicrobial prophylaxis in surgery.Med Lett 2001, 43: 92"}, 
{"Row" :8, "Column" : 1, "Text" : "Anonymous.ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery."}, 
{"Row" :9, "Column" : 1, "Text" : "Am J Health-Syst Pharm 1999, 56: 1839"}, 
{"Row" : 10, "Column" : 1, "Text" : "Anonymous.Choice of antibacterial drugs.Med Letter Treatment Guidelines"}, 
{"Row" : 11, "Column" : 1, "Text" : "2004, 2: 13"}, 
{"Row" : 12, "Column" : 1, "Text" : "Anonymous.Guidelines for the management of adults with hospital-acquired,"}, 
{"Row" : 13, "Column" : 1, "Text" : "ventilator-associated, and healthcare-associated pneumonia.Am J Respir"}, 
{"Row" : 14, "Column" : 1, "Text" : "Crit Care Med 2005, 171: 388"}, 
{"Row" : 15, "Column" : 1, "Text" : "Anonymous.Prevention of wound infection and sepsis in surgical patients.Med"}, 
{"Row" : 16, "Column" : 1, "Text" : "Lett 2001, 43: 92"}, 
{"Row" : 17, "Column" : 1, "Text" : "Baddour et al. Infective endocarditis: diagnosis, antimicrobial therapy, and"}, 
{"Row" : 18, "Column" : 1, "Text" : "management of complications.AHA scientific statement.Circulation 2005,"}, 
{"Row" : 19, "Column" : 1, "Text" : "111: e394-e433."}, 
{"Row" : 20, "Column" : 1, "Text" : "Baddour LM, et al.Nonvalvular cardiovascular device-related infections.AHA"}, 
{"Row" : 21, "Column" : 1, "Text" : "Scientific Statement.Circulation 2003, 108: 2015-31."}, 
{"Row" : 22, "Column" : 1, "Text" : "Bartlett JG.Antibiotic-associated diarrhea.NEJM 2002, 346:334"}, 
{"Row" : 23, "Column" : 1, "Text" : "Baum J.Infections of the eye.Clin Infect Dis 1995, 21: 479"}, 
{"Row" : 24, "Column" : 1, "Text" : "Beutner KR, et al.Valacyclovir compared with acyclovir for improved therapy"}, 
{"Row" : 25, "Column" : 1, "Text" : "for herpes zoster in immunocompetent adults.Antimicrob Ag Chemother 1995,"}, 
{"Row" : 26, "Column" : 1, "Text" : "39:1546."}, 
{"Row" : 27, "Column" : 1, "Text" : "Bisno AL , et al.Practice guidelines for the diagnosis and management of group"}, 
{"Row" : 28, "Column" : 1, "Text" : "A streptococcal pharyngitis.Clin Infect Dis 2002, 35: 113"}, 
{"Row" : 29, "Column" : 1, "Text" : "Boivin G, et al.Predicting influenza infections during epidemics with use of a"}, 
{"Row" : 30, "Column" : 1, "Text" : "clinical case definition. Clin Infect Dis 2000, 31: 1166."}, 
{"Row" : 31, "Column" : 1, "Text" : "Bratzler, DW, et al.Antimicrobial prophylaxis for surgery: an advisory"}, 
{"Row" : 32, "Column" : 1, "Text" : "statement from the national surgical infection prevention project.Clin"}, 
{"Row" : 33, "Column" : 1, "Text" : "Infect Dis 2004, 38: 1706"}, 
{"Row" : 34, "Column" : 1, "Text" : "Byl B, et al.Antibiotic prophylaxis for infectious complications after"}, 
{"Row" : 35, "Column" : 1, "Text" : "therapeutic endoscopic retrograde cholangiopancreatography: a randomized,"}, 
{"Row" : 36, "Column" : 1, "Text" : "double-blind, placebo-controlled study.Clin Infect Dis 1995, 20: 1236"}, 
{"Row" : 37, "Column" : 1, "Text" : "Calderone RR, et al.Overview and classification of spinal infections.Ortho"}, 
{"Row" : 38, "Column" : 1, "Text" : "Clin N Amer 1996, 27: 1"}, 
{"Row" : 39, "Column" : 1, "Text" : "Casburn-Jones AC, et al.Management of infectious diarrhea.Gut 2004, 53:296-"}, 
{"Row" : 40, "Column" : 1, "Text" : "305"}, 
{"Row" : 41, "Column" : 1, "Text" : "Center for Disease Control.MMWR 2002, 51: 73-6"}, 
{"Row" : 42, "Column" : 1, "Text" : "Center for Disease Control and Prevention. Sexually transmitted diseases"}, 
{"Row" : 43, "Column" : 1, "Text" : "treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002, 51(No. RR-6):1"}, 
{"Row" : 44, "Column" : 1, "Text" : "Chastre J et al.Comparison of 8 vs 15 days of antibiotic therapy for"}, 
{"Row" : 45, "Column" : 1, "Text" : "ventilator-associated pneumonia in adults.JAMA 2003, 290: 2588"}, 
{"Row" : 46, "Column" : 1, "Text" : "Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of"}, 
{"Row" : 47, "Column" : 1, "Text" : "prophylactic administration of antibiotics and the risk of surgical-wound"}, 
{"Row" : 48, "Column" : 1, "Text" : "infection. New England Journal of Medicine. 1992,326(5):281-286"}, 
{"Row" : 49, "Column" : 1, "Text" : "Cohen JI, et al.Recent advances in varicella-zoster infection.Ann Intern Med"}, 
{"Row" : 50, "Column" : 1, "Text" : "1999,130:922."}, 
{"Row" : 51, "Column" : 1, "Text" : "Couch RB.Prevention and treatment of influenza.N Engl J Med 2000, 343: 1778."}, 
{"Row" : 52, "Column" : 1, "Text" : "Cox NJ, Subbaro K. Influenza.Lancet 354:1277, 1999."}, 
{"Row" : 53, "Column" : 1, "Text" : "Craven DE et al.Healthcare-associated pneumonia in adults: management"}, 
{"Row" : 54, "Column" : 1, "Text" : "principles to improve outcomes. Infect Dis Clin N Am 2004, 18:939"}, 
{"Row" : 55, "Column" : 1, "Text" : "Cunha BA.Osteomyelitis in elderly patients.Clin Infect Dis 2002, 35: 287"}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: A-C)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (D-J)", "DisplayText" : "Journal References (Author Lastname: D-J) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Delzell JE et alUrinary tract infections during pregnancy.Am Fam Physician"}, 
{"Row" :4, "Column" : 1, "Text" : "2000, 61: 713"}, 
{"Row" :5, "Column" : 1, "Text" : "Dennesen PJ et al.Resolution of infectious parameters after antimicrobial"}, 
{"Row" :6, "Column" : 1, "Text" : "therapy in patients with ventilator-associated pneumonia.Am J Respir Crit"}, 
{"Row" :7, "Column" : 1, "Text" : "Care Med 2001, 163: 1371"}, 
{"Row" :8, "Column" : 1, "Text" : "Dryden MS, et al.Empirical treatment of severe community-acquired diarrhea"}, 
{"Row" :9, "Column" : 1, "Text" : "with ciprofloxacin.Clin Infect Dis 1996, 22: 1019"}, 
{"Row" : 10, "Column" : 1, "Text" : "Dupont HL, et al.Persistent diarrhea in travelers.Clin Infect Dis 1996,"}, 
{"Row" : 11, "Column" : 1, "Text" : "22:124"}, 
{"Row" : 12, "Column" : 1, "Text" : "Dupont HL, et al.Rifaximin versus ciprofloxacin for the treatment of"}, 
{"Row" : 13, "Column" : 1, "Text" : "traveler's diarrhea.Clin Infect Dis 2001, 33: 1807"}, 
{"Row" : 14, "Column" : 1, "Text" : "Dworkin RH.Prevention of postherpetic neuralgia.Lancet 1999, 353:1636."}, 
{"Row" : 15, "Column" : 1, "Text" : "Frazee LA, et al.Long-term prophylaxis of spontaneous bacterial peritonitis in"}, 
{"Row" : 16, "Column" : 1, "Text" : "patients with cirrhosis.Ann Pharmacother 2005, 39: 908"}, 
{"Row" : 17, "Column" : 1, "Text" : "Gerding D, et al.Clostridium-difficile associated diarrhea and colitis.Inf"}, 
{"Row" : 18, "Column" : 1, "Text" : "Cont Hosp Epi 1995, 16:459"}, 
{"Row" : 19, "Column" : 1, "Text" : "Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients"}, 
{"Row" : 20, "Column" : 1, "Text" : "undergoing common surgical procedures in a community teaching hospital: the"}, 
{"Row" : 21, "Column" : 1, "Text" : "chaos continues. World Journal of Surgery. 1999,23(5):429-432, discussion"}, 
{"Row" : 22, "Column" : 1, "Text" : "433."}, 
{"Row" : 23, "Column" : 1, "Text" : "Gould IM. A review of the role of antimicrobial policies in the control of"}, 
{"Row" : 24, "Column" : 1, "Text" : "antibiotic resistance. Journal of Antimicrobial Chemotherapy. 1999,43:459-"}, 
{"Row" : 25, "Column" : 1, "Text" : "465."}, 
{"Row" : 26, "Column" : 1, "Text" : "Guerrant RL, et al.Practice guidelines for the management of infectious"}, 
{"Row" : 27, "Column" : 1, "Text" : "diarrhea.Clin Infect Dis 2001, 32: 331"}, 
{"Row" : 28, "Column" : 1, "Text" : "Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and"}, 
{"Row" : 29, "Column" : 1, "Text" : "after hip arthroplasty. Clinical Orthopaedics & Related Research."}, 
{"Row" : 30, "Column" : 1, "Text" : "1999(369):124-138."}, 
{"Row" : 31, "Column" : 1, "Text" : "Harris A, et al.Meta-analysis of antibiotic prophylaxis in endoscopic"}, 
{"Row" : 32, "Column" : 1, "Text" : "retrograde cholangiopancreatography (ERCP).Endoscopy 1999, 31: 718"}, 
{"Row" : 33, "Column" : 1, "Text" : "Hewlett EL, et al.Pertussis - not just for kids.NEJM 2005, 352: 1215"}, 
{"Row" : 34, "Column" : 1, "Text" : "Hooton et al.Acute uncomplicated cystitis in an era of increasing antibiotic"}, 
{"Row" : 35, "Column" : 1, "Text" : "resistance: a proposed approach to empiric therapy.Clin Infect Dis"}, 
{"Row" : 36, "Column" : 1, "Text" : "2004:39:75"}, 
{"Row" : 37, "Column" : 1, "Text" : "Hughes WT, et al.2002 guidelines for the use of antimicrobial agents in"}, 
{"Row" : 38, "Column" : 1, "Text" : "neutropenic patients with cancer.Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 39, "Column" : 1, "Text" : "Interagency Task Force on Antimicrobial Resistance. A public health action plan"}, 
{"Row" : 40, "Column" : 1, "Text" : "to combat antimicrobial resistance.Part I:Domestic issues. Centers for"}, 
{"Row" : 41, "Column" : 1, "Text" : "Disease Control and Prevention, Atlanta, Georgia. 2000."}, 
{"Row" : 42, "Column" : 1, "Text" : "Jaeckel et al.Treatment of acute hepatitis C with interferon alfa-2b.NEJM"}, 
{"Row" : 43, "Column" : 1, "Text" : "2001, 345: 1452."}, 
{"Row" : 44, "Column" : 1, "Text" : "Jensen L et al.Oral antivirals for the acute treatment of recurrent herpes"}, 
{"Row" : 45, "Column" : 1, "Text" : "labialis.Ann Pharmacother 2004, 38:705."}, 
{"Row" : 46, "Column" : 1, "Text" : "Johnson RT.Acute encephalitis. Clin Infect Dis 1996, 23:219."}, 
{"Row" : 47, "Column" : 1, "Text" : "Joshi N, et al.Infections in patients with diabetes mellitus.New Eng J Med"}, 
{"Row" : 48, "Column" : 1, "Text" : "1999, 341: 1906."}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: D-J)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (K-N)", "DisplayText" : "Journal References (Author Lastname: K-N) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Lew DP, et al.Osteomyelitis.Lancet 2004, 364: 369"}, 
{"Row" :4, "Column" : 1, "Text" : "Lipsky BA et al.Diagnosis and treatment of diabetic foot infections.Clin"}, 
{"Row" :5, "Column" : 1, "Text" : "Infect Dis 2004, 39: 885"}, 
{"Row" :6, "Column" : 1, "Text" : "Little P et al.Information leaflet and antibiotic prescribing strategies for"}, 
{"Row" :7, "Column" : 1, "Text" : "acute lower respiratory tract infection.JAMA 2005, 293: 3029"}, 
{"Row" :8, "Column" : 1, "Text" : "Ljungman P, et al.Treatment of interstitial pneumonitis due to cytomegalovirus"}, 
{"Row" :9, "Column" : 1, "Text" : "with ganciclovir and intravenous immune globulin: experience of European"}, 
{"Row" : 10, "Column" : 1, "Text" : "bone marrow donor transplant group.Clin Infect Dis 1992 14:831-5."}, 
{"Row" : 11, "Column" : 1, "Text" : "Luna CM, et al.Resolution of ventilator-associated pneumonia: prospective"}, 
{"Row" : 12, "Column" : 1, "Text" : "evaluation of the clinical pulmonary infection score as an early clinical"}, 
{"Row" : 13, "Column" : 1, "Text" : "predictor of outcome.Crit Care Med 2003, 31: 676"}, 
{"Row" : 14, "Column" : 1, "Text" : "Madigosky WS.Does acyclovir help herpes simplex virus cold sores if treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "is delayed?J Fam Prac 2004, 53: 923."}, 
{"Row" : 16, "Column" : 1, "Text" : "Magnus G.Perioperative antibiotic prophylaxis in urology.Curr Opin Urol"}, 
{"Row" : 17, "Column" : 1, "Text" : "2001, 11: 81"}, 
{"Row" : 18, "Column" : 1, "Text" : "Maki DG, Schuna AA. A study of antimicrobial misuse in a university hospital."}, 
{"Row" : 19, "Column" : 1, "Text" : "American Journal of the Medical Sciences. 1978,275:271-282."}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell LA, Bartlett JG, Dowell SF, et al, Update of practice guidelines for the"}, 
{"Row" : 21, "Column" : 1, "Text" : "management of community-acquired pneumonia in immunocompetent adults., Clin"}, 
{"Row" : 22, "Column" : 1, "Text" : "Infect Dis 2003,37:1405"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mangram AJ, et al.Guideline for Prevention of Surgical Site Infection, Infect"}, 
{"Row" : 24, "Column" : 1, "Text" : "Control Hosp Epidemiol 1999, 20: 247"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention"}, 
{"Row" : 26, "Column" : 1, "Text" : "of Surgical Site Infection, 1999. Infection Control and Hospital"}, 
{"Row" : 27, "Column" : 1, "Text" : "Epidemiology. 1999,20(4):250-278."}, 
{"Row" : 28, "Column" : 1, "Text" : "Mathisen GE, et al.Brain abscess.Clin Infect Dis 1997, 25: 763."}, 
{"Row" : 29, "Column" : 1, "Text" : "McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose"}, 
{"Row" : 30, "Column" : 1, "Text" : "antimicrobial prophylaxis for major surgery:a systematic review."}, 
{"Row" : 31, "Column" : 1, "Text" : "Australia & New Zealand Journal of Surgery. 1998,68:388-396."}, 
{"Row" : 32, "Column" : 1, "Text" : "McGowan JE, Jr. Do intensive hospital antibiotic control programs prevent the"}, 
{"Row" : 33, "Column" : 1, "Text" : "spread of antibiotic resistance? Infection Control & Hospital Epidemiology."}, 
{"Row" : 34, "Column" : 1, "Text" : "1994,7:478-483."}, 
{"Row" : 35, "Column" : 1, "Text" : "Merrill et al Treating postoperative mediastinitis.Ann Thorac Surg 2004, 78: "}, 
{"Row" : 36, "Column" : 1, "Text" : "608-12."}, 
{"Row" : 37, "Column" : 1, "Text" : "Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination and"}, 
{"Row" : 38, "Column" : 1, "Text" : "fitness. [Review] 70. Current Opinion in Microbiology. 1998,1(5):524-529."}, 
{"Row" : 39, "Column" : 1, "Text" : "Mulhern JG, et al.Trough serum vancomycin levels predict the relapse of gram-"}, 
{"Row" : 40, "Column" : 1, "Text" : "positive peritonitis in peritoneal dialysis patients.Am J Kidney Dis"}, 
{"Row" : 41, "Column" : 1, "Text" : "1995, 25: 611"}, 
{"Row" : 42, "Column" : 1, "Text" : "Murphy TF, et al.The role of bacteria in exacerbations of COPD.Chest 2000,"}, 
{"Row" : 43, "Column" : 1, "Text" : "118:204"}, 
{"Row" : 44, "Column" : 1, "Text" : "Naber et al. Chronic prostatitis - an infectious disease?JAC 2000, 46:157"}, 
{"Row" : 45, "Column" : 1, "Text" : "Nathens AB et al.Management of the critically ill patient with severe acute"}, 
{"Row" : 46, "Column" : 1, "Text" : "pancreatitis.Crit Care Med 2004, 32: 2524-2536"}, 
{"Row" : 47, "Column" : 1, "Text" : "Nichols RL. Preventing surgical site infections: a surgeon's perspective."}, 
{"Row" : 48, "Column" : 1, "Text" : "Emerging Infectious Diseases. 2001,7(2):220-224."}, 
{"Row" : 49, "Column" : 1, "Text" : "Nicolle et al IDSA guidelines for the diagnosis and treatment of asymptomatic"}, 
{"Row" : 50, "Column" : 1, "Text" : "bacteriuria in adults.Clin Infect Dis 2005, 40: 643"}, 
{"Row" : 51, "Column" : 1, "Text" : "Novella M, et al.Continuous versus inpatient prophylaxis of the first episode"}, 
{"Row" : 52, "Column" : 1, "Text" : "of spontaneous bacterial peritonitis with norfloxacin.Hepatol 1997, 25: "}, 
{"Row" : 53, "Column" : 1, "Text" : "532"}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: K-N)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (P-R)", "DisplayText" : "Journal References (Author Lastname: P-R) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Pappas PG, et al.Guidelines for treatment of candidiasis.Clin Infect Dis"}, 
{"Row" :4, "Column" : 1, "Text" : "2004, 38: 161"}, 
{"Row" :5, "Column" : 1, "Text" : "Parish LC et al.Controversies about the decubitus ulcer.Dermatol Clin 2004,"}, 
{"Row" :6, "Column" : 1, "Text" : "22: 87."}, 
{"Row" :7, "Column" : 1, "Text" : "Parsi MA, et al.Spontaneous bacterial peritonitis: recent data on incidence"}, 
{"Row" :8, "Column" : 1, "Text" : "and treatment.Clev Clin J Med 2004, 71: 569"}, 
{"Row" :9, "Column" : 1, "Text" : "Payne TH. Computer decision support systems. Chest. 2000,118:47S-52S."}, 
{"Row" : 10, "Column" : 1, "Text" : "Peterson LR.Penicillins for treatment of pneumococcal pneumonia: does in vitro"}, 
{"Row" : 11, "Column" : 1, "Text" : "resistance really matter?Clin Infect Dise 2006, 42: 224"}, 
{"Row" : 12, "Column" : 1, "Text" : "Pharmacy Benefits Management-Medical Advisory Panel. The Pharmacologic"}, 
{"Row" : 13, "Column" : 1, "Text" : "Management of Helicobacter pylori in Peptic Ulcer Disease and Dyspepsia."}, 
{"Row" : 14, "Column" : 1, "Text" : "VHA PBM-SHG Publication No. 98-0009.Hines, IL: Pharmacy Benefits"}, 
{"Row" : 15, "Column" : 1, "Text" : "Management Strategic Health Group, Veterans Health Administration,"}, 
{"Row" : 16, "Column" : 1, "Text" : "Department of Veterans Affairs. February 1998."}, 
{"Row" : 17, "Column" : 1, "Text" : "Piraino B, et al.Peritoneal dialysis-related infections recommendations: 2005"}, 
{"Row" : 18, "Column" : 1, "Text" : "update.Perit Dial Int 2005, 25: 107."}, 
{"Row" : 19, "Column" : 1, "Text" : "Ray S, et al.Neuroretinitis.Int Ophth Clin 2001, 41: 83."}, 
{"Row" : 20, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology.2nd ed.London, UK: Mosby"}, 
{"Row" : 21, "Column" : 1, "Text" : "International Limited 2001."}, 
{"Row" : 22, "Column" : 1, "Text" : "Roig J, et al.Legionnaire's disease: a rational approach to therapy.J"}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrob Chemother 2003, 51: 1119-29"}, 
{"Row" : 24, "Column" : 1, "Text" : "Roitt I, Brostoff J, Male D, eds.Immunology.5th ed.London, UK: Mosby"}, 
{"Row" : 25, "Column" : 1, "Text" : "International Limited 1998."}, 
{"Row" : 26, "Column" : 1, "Text" : "Rolston KVI.The infectious diseases society of America 2002 guidelines for the"}, 
{"Row" : 27, "Column" : 1, "Text" : "use of antimicrobial agents in neutropenic patients with cancer and"}, 
{"Row" : 28, "Column" : 1, "Text" : "neutropenia: salient features and comments.Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 29, "Column" : 1, "Text" : "Ronald A The etiology of urinary tract infection: traditional and emerging"}, 
{"Row" : 30, "Column" : 1, "Text" : "pathogens.Dis Mon 2003, 49: 71"}, 
{"Row" : 31, "Column" : 1, "Text" : "Runyon BA, et al.Short course versus long course antibiotic treatment of"}, 
{"Row" : 32, "Column" : 1, "Text" : "spontaneous bacterial peritonitis.Gastroenterol 1991, 100: 1737"}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: P-R)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (S-V)", "DisplayText" : "Journal References (Author Lastname: S-V) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Saag MS, et al.Practice guidelines for the management of cryptococcal disease."}, 
{"Row" :4, "Column" : 1, "Text" : "Clin Infect Dis 2000, 30: 710"}, 
{"Row" :5, "Column" : 1, "Text" : "Sapico FL.Microbiology and antimicrobial therapy of spinal infections.Ortho"}, 
{"Row" :6, "Column" : 1, "Text" : "Clin N Amer 1996, 27:9"}, 
{"Row" :7, "Column" : 1, "Text" : "Scheid DC, et al.Acute bacterial rhinosinusitis in adults.Am Fam Phys 2004,"}, 
{"Row" :8, "Column" : 1, "Text" : "70: 1697"}, 
{"Row" :9, "Column" : 1, "Text" : "Scher KS. Studies on the duration of antibiotic administration for surgical"}, 
{"Row" : 10, "Column" : 1, "Text" : "prophylaxis. The American Surgeon. 1997,63:59-63."}, 
{"Row" : 11, "Column" : 1, "Text" : "Schwartz MN.Cellulitis.New Eng J Med 2004, 350: 904"}, 
{"Row" : 12, "Column" : 1, "Text" : "Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of"}, 
{"Row" : 13, "Column" : 1, "Text" : "America and Infectious Diseases Society of American Joint Committee on the"}, 
{"Row" : 14, "Column" : 1, "Text" : "prevention of antimicrobial resistance:guidelines for the prevention of"}, 
{"Row" : 15, "Column" : 1, "Text" : "antimicrobial resistance in hospitals. Infection Control & Hospital"}, 
{"Row" : 16, "Column" : 1, "Text" : "Epidemiology. 1997,18:275-291."}, 
{"Row" : 17, "Column" : 1, "Text" : "Singh N et al.Short-course empiric antibiotic therapy for patients with"}, 
{"Row" : 18, "Column" : 1, "Text" : "pulmonary infiltrates in the intensive care unit.Am J Resp Crit Care Med"}, 
{"Row" : 19, "Column" : 1, "Text" : "2000, 162: 505"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sipsas NV, et al.Perspectives for the management of febrile neutropenic"}, 
{"Row" : 21, "Column" : 1, "Text" : "patients with cancer in the 21st century.Cancer 2005, 103: 1103."}, 
{"Row" : 22, "Column" : 1, "Text" : "Snow V, et al. Principles of appropriate antibiotic use for acute sinusitis in"}, 
{"Row" : 23, "Column" : 1, "Text" : "adults. Ann Intern Med 2001, 1234: 495"}, 
{"Row" : 24, "Column" : 1, "Text" : "Snow V, et al.Principles of appropriate antibiotic use for acute pharyngitis"}, 
{"Row" : 25, "Column" : 1, "Text" : "for adults.Ann Intern Med 2001, 134: 506"}, 
{"Row" : 26, "Column" : 1, "Text" : "Soares-Weiser K, et al.Antibiotic prophylaxis for cirrhotic patients with"}, 
{"Row" : 27, "Column" : 1, "Text" : "gastrointestinal bleeding.Cochrane Database of Systematic Reviews 3, 2005"}, 
{"Row" : 28, "Column" : 1, "Text" : "Solomkin JS, et al.Guidelines for the selection of anti-infective agents for"}, 
{"Row" : 29, "Column" : 1, "Text" : "complicated intra-abdominal infections.Clin Infect Dis 2003, 37: 997"}, 
{"Row" : 30, "Column" : 1, "Text" : "Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic"}, 
{"Row" : 31, "Column" : 1, "Text" : "review of randomized controlled trials. British Journal of Surgery."}, 
{"Row" : 32, "Column" : 1, "Text" : "1998,85(9):1232-1241."}, 
{"Row" : 33, "Column" : 1, "Text" : "Stevens DL, et al.Practice guidelines for the diagnosis and management of skin"}, 
{"Row" : 34, "Column" : 1, "Text" : "and soft-tissue infections.Clin Infect Dis 2005, 41: 1373."}, 
{"Row" : 35, "Column" : 1, "Text" : "Strader DB, et al.Diagnosis, management, and treatment of hepatitis C."}, 
{"Row" : 36, "Column" : 1, "Text" : "Hepatology 2004, 39:1147-71."}, 
{"Row" : 37, "Column" : 1, "Text" : "Stulberg DL, et al.Common bacterial skin infections.Am Fam Phys 2002, 66: "}, 
{"Row" : 38, "Column" : 1, "Text" : "119"}, 
{"Row" : 39, "Column" : 1, "Text" : "Such J et al.Spontaneous bacterial peritonitis.Clin Infect Dis 1998, 27: 669"}, 
{"Row" : 40, "Column" : 1, "Text" : "Tay BK et al.Spinal infections.J Amer Acad Ortho Surg 2002, 10: 188"}, 
{"Row" : 41, "Column" : 1, "Text" : "Thielman, NM.Acute infectious diarrhea.NEJM 2004, 350: 38"}, 
{"Row" : 42, "Column" : 1, "Text" : "Tunkel et al.Practice guidelines for the management of bacterial meningitis."}, 
{"Row" : 43, "Column" : 1, "Text" : "Clin Infect Dis 2004, 39: 1267-84."}, 
{"Row" : 44, "Column" : 1, "Text" : "Van der Valk P et al.Clinical predictors of bacterial involvement in"}, 
{"Row" : 45, "Column" : 1, "Text" : "exacerbations of chronic obstructive pulmonary disease.CID 2004, 39: 980"}, 
{"Row" : 46, "Column" : 1, "Text" : "Vincent MT, et al.Pharyngitis.Am Fam Phys 2004, 69: 1465"}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: S-V)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (W-Z)", "DisplayText" : "Journal References (Author Lastname: W-Z) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Weinstein L, et al.Gas gangrene.New Eng J Med 1973, 289: 1129"}, 
{"Row" :4, "Column" : 1, "Text" : "Westphal JF.Biliary tract infections.Drugs 1999, 57: 81-91."}, 
{"Row" :5, "Column" : 1, "Text" : "Wheat J, et al.Practice guidelines for the management of patients with"}, 
{"Row" :6, "Column" : 1, "Text" : "Histoplasmosis.Clin Infect Dis 2000, 30: 688"}, 
{"Row" :7, "Column" : 1, "Text" : "Whitely RJ, et al.Herpes simplex virus infections.Lancet 2001, 357: 1513."}, 
{"Row" :8, "Column" : 1, "Text" : "Whitely RJ, et al.Herpes zoster: risk categories for persistent pain.J"}, 
{"Row" :9, "Column" : 1, "Text" : "Infect Dis 1999,179:9."}, 
{"Row" : 10, "Column" : 1, "Text" : "Wald A.New therapies and prevention strategies for genital herpes.Clin"}, 
{"Row" : 11, "Column" : 1, "Text" : "Infect Dis 1999, 28(Suppl 1):S4."}, 
{"Row" : 12, "Column" : 1, "Text" : "Wallace MR, et al.Treatment of adult varicella with acyclovir.Ann Int Med"}, 
{"Row" : 13, "Column" : 1, "Text" : "1992, 117:358."}, 
{"Row" : 14, "Column" : 1, "Text" : "Warren et al.Guidelines for antimicrobial treatment of uncomplicated acute"}, 
{"Row" : 15, "Column" : 1, "Text" : "bacterial cystitis and acute pyelonephritis in women.Clin Infect Dis"}, 
{"Row" : 16, "Column" : 1, "Text" : "1999, 29:745"}, 
{"Row" : 17, "Column" : 1, "Text" : "Woods RK, et al.Current guidelines for antibiotic prophylaxis of surgical"}, 
{"Row" : 18, "Column" : 1, "Text" : "wounds.Am Fam Phys 1998, 57:2731"}, 
{"Row" : 19, "Column" : 1, "Text" : "Wormser GP, et al.Duration of antibiotic therapy for early Lyme disease.Ann"}, 
{"Row" : 20, "Column" : 1, "Text" : "Intern Med 2003, 138: 697."}, 
{"Row" : 21, "Column" : 1, "Text" : "Wormser GP, et al.Practice guidelines for the treatment of Lyme disease.Clin"}, 
{"Row" : 22, "Column" : 1, "Text" : "Infect Dis 2000, 31 (Supp 1): S1"}, 
{"Row" : 23, "Column" : 1, "Text" : "Zimmerli W, et al.Prosthetic-joint infections.New Eng J Med 2004, 351:1645"}, 
{"Row" :1, "Column" : 1, "Text" : "CDSS Journal References (Author Lastname: W-Z)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES BOOK", "DisplayText" : "Book References", "Text" : "Book references", "Mnemonic" : "02"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES WEBSITE", "DisplayText" : "Website References", "Text" : "Website references", "Mnemonic" : "04"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES JOURNAL", "DisplayText" : "Journal References", "Text" : "Journal references", "Mnemonic" : "06"}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES BOOK", "DisplayText" : "Book References " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "CDSS Book References (common to most CDSS guidelines)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to"}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobial Therapy. 35th ed. Hyde Park, VT: Antimicrobial Therapy Inc,"}, 
{"Row" :7, "Column" : 1, "Text" : "2005."}, 
{"Row" : 10, "Column" : 1, "Text" : "Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison's Principles of Internal"}, 
{"Row" : 11, "Column" : 1, "Text" : "Medicine. 16th ed. Mcgraw-Hill, 2005."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious"}, 
{"Row" : 13, "Column" : 1, "Text" : "Diseases. 6th ed. Philadelphia, PA: Churchill-Livingston, 2005."}, 
{"Row" :8, "Column" : 1, "Text" : "Johns Hopkins Point of Care Information Technology (POC-IT): ABX Guide."}, 
{"Row" :9, "Column" : 1, "Text" : "www.hopkins-abxguide.org"}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES JOURNAL", "DisplayText" : "Journal References" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "CDSS Journal References", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (A-C)", "DisplayText" : "Journal References (Author Lastname: A-C)", "Text" : "Go to CDSS Journal References (Author Lastname: A-C)", "Mnemonic" : "02"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (D-J)", "DisplayText" : "Journal References (Author Lastname: D-J)", "Text" : "Go to CDSS Journal References (Author Lastname: D-J)", "Mnemonic" : "04"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (K-N)", "DisplayText" : "Journal References (Author Lastname: K-N)", "Text" : "Go to CDSS Journal References (Author Lastname: K-N)", "Mnemonic" : "06"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (P-R)", "DisplayText" : "Journal References (Author Lastname: P-R)", "Text" : "Go to CDSS Journal References (Author Lastname: P-R)", "Mnemonic" : "08"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (S-V)", "DisplayText" : "Journal References (Author Lastname: S-V)", "Text" : "Go to CDSS Journal References (Author Lastname: S-V)", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (W-Z)", "DisplayText" : "Journal References (Author Lastname: W-Z)", "Text" : "Go to CDSS Journal References (Author Lastname: W-Z)", "Mnemonic" : "12"}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES WEBSITE", "DisplayText" : "Website References" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "Up-to-date (view up-to-date web site)www.uptodate.com"}, 
{"Row" :3, "Column" : 1, "Text" : "CDSS Website References (common to most CDSS guidelines)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REMDESIVER FOR TREATMENT OF COVID-19", "DisplayText" : "Remdesivir for treatment of COVID-19" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Select here for help, legend, consults, alternative antimicrobials and more (Ip)", "Mnemonic" : "2"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX REMDESIVIR 200MG LOAD THEN 100MG Q24H 5DAYS", "DisplayText" : "Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 4 days", "Text" : "Remdesivir 200mg IV once on day 1, then 100mg IV daily for 4 additional days", "Mnemonic" : "12"},
{"Row" : 47, "Column" : 1, "Text" : "Note: Consult Infectious Disease for approval to extend therapy beyond 5 days"}, 
{"Row" : 36, "Column" : 1, "Text" : "1. Requirement: PCR-confirmed COVID-19"}, 
{"Row" : 48, "Column" : 1, "Text" : "(maximum 10 days total therapy)"}, 
{"Row" : 35, "Column" : 1, "Text" : "Remdesivir is FDA approved for treatment of COVID-19 in hospitalized patients: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Monitoring required for Remdesivir: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "***If above requirements are met, place order for labs and Remdesivir***", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "1. Daily laboratory monitoring includes: "}, 
{"Row" :5, "Column" : 1, "Text" : "See below for full prescribing information including WARNINGS and PRECAUTIONS"}, 
{"Row" : 27, "Column" : 1, "Text" : "Relative contraindications: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "2. Consider discontinuing drug if ALT levels increase to greater than 10 times"}, 
{"Row" : 23, "Column" : 1, "Text" : "upper limit of normal"}, 
{"Row" : 24, "Column" : 1, "Text" : "3. Discontinue drug if ALT elevation is accompanied by signs or symptoms of"}, 
{"Row" : 25, "Column" : 1, "Text" : "liver inflammation"}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Hepatic impairment (pharmacokinetics and need for dose adjustment unclear)"}, 
{"Row" : 33, "Column" : 1, "Text" : "3. Pregnancy (maternal and fetal risks unknown)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Note: Consult Infectious Disease for COVID-19 negative patients, but"}, 
{"Row" : 38, "Column" : 1, "Text" : "clinically very consistent with COVID-19"}, 
{"Row" : 28, "Column" : 1, "Text" : "Use not recommended unless potential benefit outweighs potential risk."}, 
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX URL REMDESIVIR PI", "DisplayText" : "Remdesivir PI", "Text" : "[Link] Remdesivir Package Insert (FDA approved Oct 2020)", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Text" : "Comprehensive Metabolic Profile, CBC with Diff, and INR"}, 
{"Row" : 29, "Column" : 1, "Text" : "Note: Discuss with Infectious Disease patients with these contraindications: "}, 
{"Row" : 31, "Column" : 1, "Text" : "2. Renal impairment: not recommended in patients with eGFR less than 30ml/min"}, 
{"Row" :9, "Column" : 1, "Text" : "-Remdesivir can shorten COVID symptom duration but does not affect mortality. It"}, 
{"Row" : 10, "Column" : 1, "Text" : "appears most effective for patients needing supplemental oxygen but not"}, 
{"Row" : 11, "Column" : 1, "Text" : "receiving mechanical ventilation. It has little benefit for patients not"}, 
{"Row" : 12, "Column" : 1, "Text" : "requiring oxygen."}, 
{"Row" : 15, "Column" : 1, "Text" : "considering an extension of therapy beyond 5 days."}, 
{"Row" :8, "Column" : 1, "Text" : "Please Note: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "REMDESIVIR COVID-19 REGIMEN", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "-Remdesivir may be discontinued early in patients who are minimally symptomatic"}, 
{"Row" : 17, "Column" : 1, "Text" : "and ready for discharge."}, 
{"Row" : 13, "Column" : 1, "Text" : "-The default duration of therapy is 5 days and DOES NOT require Infectious"}, 
{"Row" : 14, "Column" : 1, "Text" : "Disease approval, extending therapy is of minimal benefit. Contact ID if"}, 
{"Row" : 32, "Column" : 1, "Text" : "Note: May be given to patients on dialysis at recommended dose."}, 
{"Row" : 42, "Column" : 1, "Text" : "Monitor Labs Daily: Comprehensive Metabolic Profile, CBC with Diff, and INR", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Place medication order: ", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : "LRTZ SET REMDESIVIR X5 DAYS", "DisplayText" : "Remdesivir Labs", "Text" : "[Click here] Place lab orders for Remdesivir daily x 5 days", "Mnemonic" : "10"}
]},
{"Name" : "ORZID2 GMENU ABX ROSACEA", "DisplayText" : "Rosacea " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 0.75% CREAM TOPICALLY Q24H", "DisplayText" : "Metronidazole 0.75% cream topically q24h ($) [DI]", "Text" : "Metronidazole 0.75% cream topically q24h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID2 DOXYCYCLINE 12WKS 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID2 MINOCYLCINE 12WKS 50MG PO Q12H", "DisplayText" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Relcalcitrant Acne and Rosacea", "Text" : "Recalcitrant Rosacea", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ROSACEA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Rosacea is an inflammatory skin condition resulting in erythema and"}, 
{"Row" :6, "Column" : 1, "Text" : "telangiectasia of nose, cheeks, eyelids, and forehead. It typically occurs in"}, 
{"Row" :7, "Column" : 1, "Text" : "mid-life and the etiology is unknown. Erythematous rosacea is the early stage of"}, 
{"Row" :8, "Column" : 1, "Text" : "the disease and usually manifests with flushing reactions and persistently"}, 
{"Row" :9, "Column" : 1, "Text" : "erythematous skin. Late-stage disease is known as papulopustular rosace."}, 
{"Row" : 10, "Column" : 1, "Text" : "Symptoms include papular, pustular, cysts and nodules. Severe disease results in"}, 
{"Row" : 11, "Column" : 1, "Text" : "tissue atrophy and rhinophyma (bulbus nose)."}, 
{"Row" : 13, "Column" : 1, "Text" : "The goal of treatment is control of symptoms, not cure. General treatment"}, 
{"Row" : 14, "Column" : 1, "Text" : "measures include avoiding triggers (e.g. spicy food, alcohol), skin care (e.g."}, 
{"Row" : 15, "Column" : 1, "Text" : "moisturizing, gentle cleansing, avoiding topical irritants) and using sun"}, 
{"Row" : 16, "Column" : 1, "Text" : "screen. Medical treatment includes topical agents as first line therapy and oral"}, 
{"Row" : 17, "Column" : 1, "Text" : "treatment for refractory disease."}, 
{"Row" : 19, "Column" : 1, "Text" : "Papulopustular rosacea", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 29, "Column" : 1, "Text" : "**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**"}, 
{"Row" : 31, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Acne Rosacea"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date Article: Rosacea: Pathogenesis, clinical features, and diagnosis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date Article: Management of rosacea"}, 
{"Row" : 38, "Column" : 1, "Text" : "van Zuuren EJ et al., N Engl J Med, 2017, 377(18)1754-1764"}, 
{"Row" : 39, "Column" : 1, "Text" : ""}
]},
{"Name" : "ORZID2 GMENU ABX RSV" , "Term1" : "Respiratory syncytial virus (RSV)", "DisplayText" : "RSV " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "RESPIRATORY SYNCYTIAL VIRUS (RSV)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "more information on management of this disease."}, 
{"Row" :9, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Sanford keyword: Respiratory Syncytial Virus"}
]},
{"Name" : "ORZID2 GMENU ABX SALMONELLA SPECIES" , "Term1" : "Salmonella diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Salmonella" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Link to Enteric Fever Menu", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 7 days ($) [M]", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 7 days ($) [M]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 14 days ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 14 days ($) [M]", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 14 days ($) [M]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH SALMONELLA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever"}, 
{"Row" :6, "Column" : 1, "Text" : "Menu: "}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment is not recommended for mild or moderately severe disease in otherwise"}, 
{"Row" : 10, "Column" : 1, "Text" : "healthy individuals <50 years old, because the disease is self-limiting and"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials can prolong the carrier state and increase the risk of relapse."}, 
{"Row" : 12, "Column" : 1, "Text" : "By contrast, treatment should be considered for severe disease, and if the"}, 
{"Row" : 13, "Column" : 1, "Text" : "patient is > 50 years old, is immunocompromised, or has another debilitating"}, 
{"Row" : 14, "Column" : 1, "Text" : "underlying disease."}, 
{"Row" : 16, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 19, "Column" : 1, "Text" : "Antimicrobial treatment of immunocompetent patients", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones"}, 
{"Row" : 25, "Column" : 1, "Text" : "For patients who are hospitalized or unable to take oral medications"}, 
{"Row" : 28, "Column" : 1, "Text" : "Antimicrobial treatment of immunocompromised patients", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones"}, 
{"Row" : 34, "Column" : 1, "Text" : "For patients who are hospitalized or unable to take oral medications"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Salmonella: Non-typhi"}, 
{"Row" : 41, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and"}, 
{"Row" : 43, "Column" : 1, "Text" : "carriage"}
]},
{"Name" : "ORZID2 GMENU ABX SECOND PERITONITIS" , "Term1" : "Peritonitis, secondary " , "Term2" : "Secondary peritonitis", "DisplayText" : "Secondary Peritonitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 43, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Secondary peritonitis occurs after spillage of colonic flora into the peritoneum"}, 
{"Row" :6, "Column" : 1, "Text" : "due to ruptured viscus, perforated appendicitis, gastrointestinal trauma, or"}, 
{"Row" :7, "Column" : 1, "Text" : "diverticulitis."}, 
{"Row" :9, "Column" : 1, "Text" : "Intraperitoneal or intraabdominal abscess can complicate secondary or primary"}, 
{"Row" : 10, "Column" : 1, "Text" : "peritonitis. Abscess location is generally related to primary disease site."}, 
{"Row" : 12, "Column" : 1, "Text" : "Primary therapy: abscess drainage", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "CT or US-guided percutaneous or surgical drainage should be considered in all"}, 
{"Row" : 14, "Column" : 1, "Text" : "cases for diagnostic confirmation, microbiologic evaluation, and therapy."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "After adequate drainage, 4 days of antibiotic coverage is indicated, with"}, 
{"Row" : 18, "Column" : 1, "Text" : "duration in part based on resolution of fever, leukocytosis, ileus severity of"}, 
{"Row" : 19, "Column" : 1, "Text" : "infection, and additional indicators of clinical response. Inadequately drained"}, 
{"Row" : 20, "Column" : 1, "Text" : "abscess with residual fluid may require prolonged therapy with follow-up imaging"}, 
{"Row" : 21, "Column" : 1, "Text" : "to ensure resolution."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "Treatment of severe disease (typically necessitating ICU admission)", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 37, "Column" : 1, "Text" : "< AND > vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 39, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results.", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Secondary: rupture, perforation, abscess"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sawyer et al, N Engl J Med, 2015, 372:1996-2005"}, 
{"Row" : 54, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial approach to intra-abdominal infections in"}, 
{"Row" : 56, "Column" : 1, "Text" : "adults"}
]},
{"Name" : "ORZID2 GMENU ABX SECOND RECUR ABX ASSOC COLITIS", "DisplayText" : "ORZID2 GMENU SECOND RECURRENCE ABX ASSOC COLITIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin taper and pulse dosing", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "Select for Fulminant CDI", "Mnemonic" : "12"},
{"Row" :5, "Column" : 1, "Text" : "Patients with more than one recurrence of C. difficile infection are complex and"}, 
{"Row" :6, "Column" : 1, "Text" : "difficult."}, 
{"Row" :9, "Column" : 1, "Text" : "Discontinue any antibiotics if possible and avoid high-risk antibiotic if"}, 
{"Row" : 10, "Column" : 1, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 12, "Column" : 1, "Text" : "Second Recurrence: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 27, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential."}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and"}, 
{"Row" : 38, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG Q12H 10D", "DisplayText" : "Fidaxomicin 200 mg po q12h for 10 days ($$) [M]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID FIDAXAMICIN EXTENDED-PULSE REGIMEN", "DisplayText" : "Fidaxomicin Extended-Pulse Regimen ($$) [M]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)"}, 
{"Row" : 19, "Column" : 1, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with"}, 
{"Row" : 20, "Column" : 1, "Text" : "125 mg po q12h for 7 days, then 125mg po qday for 7 days, then"}, 
{"Row" : 21, "Column" : 1, "Text" : "125mg every other day for 6 weeks)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 34, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" :7, "Column" : 1, "Text" : "*Infectious Disease or Gastroenterology consultation is recommended*"}, 
{"Row" : 25, "Column" : 1, "Text" : "Fulminant CDI: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Third or more recurrence: Consult Gastroenterology or Infectious Disease", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SECOND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "14"},
{"Row" :5, "Column" : 1, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity"}, 
{"Row" :3, "Column" : 1, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP."}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "DisplayText" : "Epididymitis", "Text" : "", "Mnemonic" : "28"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX PID", "DisplayText" : "Pelvic Inflammatory Disease", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "32"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Cervicitis", "Mnemonic" : "26"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "DisplayText" : "Genital herpes", "Text" : "", "Mnemonic" : "30"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases", "Text" : "Urethritis", "Mnemonic" : "34"},
{"Row" : 24, "Column" : 1, "Text" : "Sexually Transmitted Infections (STIs)", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "38"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "42"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "40"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "DisplayText" : "Trichomonas Vaginitis", "Text" : "Trichomonas Vaginitis, Urethritis and Male Sex Partners", "Mnemonic" : "36"},
{"Row" :6, "Column" : 1, "Text" : "that could result in HIV exposure. Recommendation is for the provider to"}, 
{"Row" :7, "Column" : 1, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "HIV acquisition.If the patient is interested, the provider should place a"}, 
{"Row" : 11, "Column" : 1, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have"}, 
{"Row" : 12, "Column" : 1, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by"}, 
{"Row" : 13, "Column" : 1, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or"}, 
{"Row" : 14, "Column" : 1, "Text" : "injection drug use, these medicines can work to keep the virus from"}, 
{"Row" : 15, "Column" : 1, "Text" : "establishing a permanent infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "When taken daily, PrEP is highly effective for preventing HIV. Studies"}, 
{"Row" : 18, "Column" : 1, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about"}, 
{"Row" : 19, "Column" : 1, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently."}, 
{"Row" : 20, "Column" : 1, "Text" : "As PrEP only protects against HIV, condoms are important for the protection"}, 
{"Row" : 21, "Column" : 1, "Text" : "against other STIs. Condoms are also an important prevention strategy"}, 
{"Row" : 22, "Column" : 1, "Text" : "if PrEP is not taken consistently."}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia Urethritis", "Text" : "Chlamydia", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Gonorrhea", "Mnemonic" : "22"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Syphilis", "Mnemonic" : "24"}
]},
{"Name" : "ORZID2 GMENU ABX SHIGELLA SPECIES" , "Term1" : "Bacillary dysentery " , "Term2" : "Shigella diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Shigellosis is generally a self-limited infection lasting 5-7 days."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobial resistance is common and continues to rise for all recommended"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobials. Treatment should be reserved for patients who are"}, 
{"Row" :8, "Column" : 1, "Text" : "immunocompromised, or who develop severe illness (e.g., requiring"}, 
{"Row" :9, "Column" : 1, "Text" : "hospitalization, invasive, or with complications) or live or work in settings"}, 
{"Row" : 10, "Column" : 1, "Text" : "where there is risk of spreading infection to others (e.g., food handlers,"}, 
{"Row" : 11, "Column" : 1, "Text" : "daycare, nursing home)."}, 
{"Row" : 13, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 16, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 22, "Column" : 1, "Text" : "For patients who are hospitalized or unable to take oral medications"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "CDC advisory: https://emergency.cdc.gov/han/han00401.asp"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Shigella"}, 
{"Row" : 30, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Shigella infection: Treatment and prevention in adults"}
]},
{"Name" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE" , "Term1" : "Bone and Joint section " , "Term2" : "Joint and Bone section " , "Term3" : "Muscle and Soft Tissue section " , "Term4" : "Soft Tissue and Muscle section", "DisplayText" : "Soft tissue, muscle, bone and joint infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds", "Text" : "Bite wounds", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis", "Text" : "Septic bursitis", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABSCESSES", "DisplayText" : "Abscesses:Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis", "Text" : "Abscesses", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess", "Text" : "Cutaneous abscess", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal/Anorectal Abscess", "Mnemonic" : "12"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis", "Mnemonic" : "14"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "DisplayText" : "Decubitus ulcers", "Text" : "Decubitus ulcers", "Mnemonic" : "16"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "DisplayText" : "Surgical Site Infection", "Text" : "Surgical wound infections", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "++ SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS++", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Section reviewed Dec 2018"}, 
{"Row" :5, "Column" : 2, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Foot ulcer in patient with diabetes mellitus", "Mnemonic" : "22"},
{"Row" :7, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis", "Text" : "Osteomyelitis", "Mnemonic" : "24"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "DisplayText" : "Diskitis and Vertebral Osteomyelitis", "Text" : "Diskitis and vertebral osteomylitis", "Mnemonic" : "26"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "28"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native joint)", "Text" : "Septic arthritis (Native joint)", "Mnemonic" : "30"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Prosthetic joint", "Mnemonic" : "32"},
{"Row" : 11, "Column" : 2, "Text" : "Septic arthritis", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SOTROVIMAB EUA", "DisplayText" : "Sotrovimab (EUA) Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "", "Mnemonic" : "02"},
{"Row" : 45, "Column" : 1, "Text" : "If above requirements are met, place medication order: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid"}, 
{"Row" : 51, "Column" : 1, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and"}, 
{"Row" : 52, "Column" : 1, "Text" : "frequent handwashing) according to CDC guidelines."}, 
{"Row" : 54, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Monitor patient during infusion and 1 hour after infusion completed."}, 
{"Row" : 20, "Column" : 1, "Text" : "Inclusion Criteria", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "ALL of the following criteria must be met for a patient to receive: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19."}, 
{"Row" : 26, "Column" : 1, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an"}, 
{"Row" : 27, "Column" : 1, "Text" : "increase in baseline oxygen flow rate due to COVID-19."}, 
{"Row" : 28, "Column" : 1, "Text" : "4) Administration will begin within 7 days of symptom onset."}, 
{"Row" : 29, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to sotrovimab or components."}, 
{"Row" : 35, "Column" : 1, "Text" : "The provider has communicated with the patient/caregiver regarding"}, 
{"Row" : 36, "Column" : 1, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/"}, 
{"Row" : 37, "Column" : 1, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an"}, 
{"Row" : 38, "Column" : 1, "Text" : "unapproved drug that is authorized for use under an EUA, given information"}, 
{"Row" : 39, "Column" : 1, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver"}, 
{"Row" : 40, "Column" : 1, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)"}, 
{"Row" : 22, "Column" : 1, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19."}, 
{"Row" : 34, "Column" : 1, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA"}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Mnemonic" : "04"},
{"Row" : 12, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX INV-SOTROVIMAB NURSING INST", "DisplayText" : "Inv-Sotrovimab 500 mg IVPB Once + Nursing Text Order", "Text" : "INV-Sotrovimab 500mg IVPB ONCE", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Text" : "including hospitalization or death."}, 
{"Row" : 30, "Column" : 1, "Text" : "6) Patient has at least one risk factor for progression to severe disease"}, 
{"Row" : 32, "Column" : 1, "Text" : "See link below for complete list: "}, 
{"Row" : 16, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Note: patient may be hospitalized for some other reason."}, 
{"Row" :3, "Column" : 1, "Text" : "Sotrovimab (EUA)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Sotrovimab Emergency Use Authorization (EUA)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-Sotrovimab is available via FDA Emergency Use Authorization (EUA)"}, 
{"Row" :5, "Column" : 1, "Text" : "for treating patients that meet specific criteria. Sotrovimab is"}, 
{"Row" :6, "Column" : 1, "Text" : "not FDA approved drug."}, 
{"Row" :7, "Column" : 1, "Text" : "-Sotrovimab EUA does NOT include post-exposure prophylaxis."}, 
{"Row" : 49, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PATIENT EUA FACT SHEET", "DisplayText" : "Sotrovimab EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab", "Mnemonic" : "06"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Sotrovimab EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab", "Mnemonic" : "08"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Sotrovimab EUA Provider Fact Sheet", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Mnemonic" : "12"},
{"Row" : 42, "Column" : 1, "Text" : "Exclusion Criteria", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID."}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY CHART", "DisplayText" : "Splenectomy Vaccines" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Text" : "Functional or Anatomical Asplenia", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Item" : "PSJZID MENINGOCOCCAL B VACCINE ONE DOSE", "DisplayText" : "Meningococcal B vaccine one dose", "Text" : "", "Mnemonic" : "08"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE ONE DOSE", "DisplayText" : "Meningococcal Oligosaccharide conj (MenACWY) one dose", "Text" : "", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Text" : "Repeat every 5 years: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Item" : "PSJZID PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE", "DisplayText" : "Pneumococcal 20-valent conjugate vaccine one dose", "Text" : "", "Mnemonic" : "06"},
{"Row" : 10, "Column" : 1, "Text" : "(Note: 2 dose series- order 2nd dose in 4 weeks in Outpatient CDSS)"}, 
{"Row" : 13, "Column" : 1, "Text" : "(Note: 2 dose series- order 2nd dose in 8 weeks in Outpatient CDSS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Note: Please select EACH of the recommended 4 vaccines to place orders", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Revaccination (booster): (Order in Outpatient CDSS)", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Meningococcal Oligosaccharide conj (MenACWY) one dose"}, 
{"Row" : 18, "Column" : 1, "Text" : "Repeat 1 year after completing the primary series and every 2 to 3 years", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "thereafter: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Meningococcal B vaccine one dose"}, 
{"Row" :5, "Column" : 1, "Item" : "PSJZID HAEMOPHILUS B new VACCINE ONE DOSE", "DisplayText" : "Haemophilus B vaccine one dose", "Text" : "", "Mnemonic" : "04"}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY DAILY ANTIBIOTICS", "DisplayText" : "Asplenic Empiric Antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO BID FOR DAILY PROPHY ASPLENIA", "DisplayText" : "Amoxicillin 500MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Text" : "Amoxicillin 500MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 250MG PO BID FOR DAILY PROPHY ASPLENIA", "DisplayText" : "Cephalexin 250MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Text" : "Cephalexin 250MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 250MG PO QDAY DAILY PROPHY ASPLENIA", "DisplayText" : "Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($) [DI]", "Text" : "Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($) [DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "Daily Antibiotic Prophylaxis for Asplenia", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "The need for daily antibiotic prophylaxis and its duration is typically"}, 
{"Row" :5, "Column" : 1, "Text" : "determined individually based on patient age, immune status, history of"}, 
{"Row" :6, "Column" : 1, "Text" : "infection, potential for adverse drug reactions and other factors."}, 
{"Row" :8, "Column" : 1, "Text" : "Consider Prophylaxis: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "1) Approximately 1 year prophylaxis for all patients following splenectomy."}, 
{"Row" : 10, "Column" : 1, "Text" : "2) Lifelong prophylaxis for patients with history of sepsis or other severe"}, 
{"Row" : 11, "Column" : 1, "Text" : "infections caused by encapsulated organisms."}, 
{"Row" : 12, "Column" : 1, "Text" : "3) Prophylaxis for as long as the patient is immunocompromised or for life"}, 
{"Row" : 13, "Column" : 1, "Text" : "for patients with concurrent immunocompromising conditions (e.g. hematologic"}, 
{"Row" : 14, "Column" : 1, "Text" : "malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver"}, 
{"Row" : 15, "Column" : 1, "Text" : "disease, or HIV infection)."}, 
{"Row" : 17, "Column" : 1, "Text" : "Daily antibiotic prophylaxis is in addition to the emergency supply.", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for penicillin and beta lactam allergy: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date online"}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX MANAGEMENT OF FEBRILE EPISODE ASPLENIA", "DisplayText" : "Management of an Episode of Fever in an Asplenic Patient", "Text" : "Management of an Episode of Fever in an Asplenic Patient", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY CHART", "DisplayText" : "Splenectomy Vaccines", "Text" : "[click here] Place Order for specific vaccines for asplenia", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY DAILY ANTIBIOTICS", "DisplayText" : "Asplenic Empiric Antibiotics", "Text" : "Daily Antibiotic Prophylaxis INPATIENT", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "DisplayText" : "Asplenic Empiric Antibiotics", "Text" : "Self-medicate Empiric Antibiotics", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "Asplenia Functional or Anatomical", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Following a splenectomy there is considerably increased risk of developing"}, 
{"Row" :4, "Column" : 1, "Text" : "septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,"}, 
{"Row" :5, "Column" : 1, "Text" : "Haemophilus inluenza type b and meningococcus. Key measures to prevent"}, 
{"Row" :6, "Column" : 1, "Text" : "such infections include education, vaccination, prophylactic antimicrobial"}, 
{"Row" :7, "Column" : 1, "Text" : "therapy in selected patients, and early empirical therapy for febrile"}, 
{"Row" :8, "Column" : 1, "Text" : "epsisodes. It is critically important to educate patients regarding the"}, 
{"Row" :9, "Column" : 1, "Text" : "lifelong risk of postsplenectomy sepsis, the importance of vaccinations,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and the need for urgent action in response to a febrile episode."}, 
{"Row" : 12, "Column" : 1, "Text" : "Management of an Episode of Fever in an Asplenic Patient", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Initiation of vaccine regimen: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Ideally splenectomy vaccinations should be given 10 to 12 weeks before"}, 
{"Row" : 22, "Column" : 1, "Text" : "elective splenectomy.Where this is not possible they can be given up to"}, 
{"Row" : 23, "Column" : 1, "Text" : "two weeks before or at least two weeks post-splenectomy."}, 
{"Row" : 27, "Column" : 1, "Text" : "Use of Antibiotic Prophylaxis for Asplenia: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Use of antibiotic prophylaxis, in addition to vaccination, further reduces"}, 
{"Row" : 29, "Column" : 1, "Text" : "the risk of infection and poor outcomes."}, 
{"Row" : 31, "Column" : 1, "Text" : "Daily Antibiotic Prophylaxis: (in addition to emergency supply)", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "**OUTPATIENT ORDERS**", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References"}, 
{"Row" : 39, "Column" : 1, "Text" : "MMWR Morb Mortal Wkly Rep 2022, 71(7):229"}, 
{"Row" : 40, "Column" : 1, "Text" : "Clin Infect Dis 2014, 58:e44-100"}, 
{"Row" : 17, "Column" : 1, "Text" : "See CDSS immunization section to order, if needed."}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX URL ASPLENIA VACCINATION RECOMMENDATIONS", "DisplayText" : "Vaccinations for Adults without a Spleen", "Text" : "[click here] Recommendations: Vaccinations for Adults without a Spleen", "Mnemonic" : "6"},
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date: Prevention of infection in patients with impaired splenic function"}, 
{"Row" : 16, "Column" : 1, "Text" : "ROUTINE VACCINATIONS SHOULD BE UP TO DATE."}, 
{"Row" : 20, "Column" : 1, "Text" : "Specific Asplenia Vaccines: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SPON BACT PERITONITIS" , "Term1" : "Liver disease, prevention of spontaneous bacterial peritonitis " , "Term2" : "Peritonitis, acute spontaneous bacterial " , "Term3" : "Prophylactic antimicrobials forspontaneous bacterial peritonitis " , "Term4" : "Spontaneous bacterial peritonitis prevention", "DisplayText" : "Acute spontaneous bacterial peritonitis (SBP) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h for 5 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po q24h", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg PO qday for prophylaxis ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 48, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" : 53, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po q24h", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h until discharge from", "Mnemonic" : "20"},
{"Row" : 56, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg PO qday for prophylaxis ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q24h until discharge from hospital ($) [R,DI]", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or"}, 
{"Row" :6, "Column" : 1, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease"}, 
{"Row" :7, "Column" : 1, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250"}, 
{"Row" :8, "Column" : 1, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens"}, 
{"Row" :9, "Column" : 1, "Text" : "are isolated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first"}, 
{"Row" : 12, "Column" : 1, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with"}, 
{"Row" : 13, "Column" : 1, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1"}, 
{"Row" : 14, "Column" : 1, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients"}, 
{"Row" : 15, "Column" : 1, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more"}, 
{"Row" : 16, "Column" : 1, "Text" : "information."}, 
{"Row" : 18, "Column" : 1, "Text" : "SBP", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Prophylaxis in a patient with a previous SBP episode", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Treat initially with an intravenous antimicrobial then step down to an oral"}, 
{"Row" : 34, "Column" : 1, "Text" : "antimicrobial when the patient can tolerate oral treatment."}, 
{"Row" : 36, "Column" : 1, "Text" : "Duration of antimicrobial therapy"}, 
{"Row" : 37, "Column" : 1, "Text" : "Treat for a total of 7 days (intravenous and oral)"}, 
{"Row" : 39, "Column" : 1, "Text" : "Preffered initial treatment"}, 
{"Row" : 42, "Column" : 1, "Text" : "Initial treatment, alternative for beta-lactam allergy"}, 
{"Row" : 45, "Column" : 1, "Text" : "Step down treatment"}, 
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 49, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "(less than 1 gm/dL peritoneal fluid)", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "hospital ($) [R,DI]"}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 59, "Column" : 1, "Text" : "References: "}, 
{"Row" : 61, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" : 62, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial"}, 
{"Row" : 63, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 64, "Column" : 1, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and"}, 
{"Row" : 65, "Column" : 1, "Text" : "prophylaxis"}
]},
{"Name" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION" , "Term1" : "Decolonization of Staphylococcus aureus " , "Term2" : "Staphylococcus aureus decolonization" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically q12h ($) [M] <AND> chlorhexidine 4% liquid", "Text" : "Mupirocin 2% ointment topically q12h ($) [M] <AND> chlorhexidine 4% liquid", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "From 10% to 40% of adults are colonized with Staphylococcus aureus, and the"}, 
{"Row" :6, "Column" : 1, "Text" : "anterior nares is the most common site of colonization. The great majority of"}, 
{"Row" :7, "Column" : 1, "Text" : "people never have disease with S. aureus, but a tiny fraction of people develop"}, 
{"Row" :8, "Column" : 1, "Text" : "clinical infections with the S. aureus that has colonized their skin or anterior"}, 
{"Row" :9, "Column" : 1, "Text" : "nares. Steps to decolonize the skin and anterior nares can transiently diminish"}, 
{"Row" : 10, "Column" : 1, "Text" : "or eradicate S. aureus colonization and can prevent post-operative wound"}, 
{"Row" : 11, "Column" : 1, "Text" : "infection in certain high-risk circumstances. For people who have other forms"}, 
{"Row" : 12, "Column" : 1, "Text" : "of recurrent S. aureus disease, not associated with an operation, results with"}, 
{"Row" : 13, "Column" : 1, "Text" : "decolonization have been disappointing, and decolonization is not routinely"}, 
{"Row" : 14, "Column" : 1, "Text" : "recommended. Colonization typically reappears in most patients within a few"}, 
{"Row" : 15, "Column" : 1, "Text" : "days or weeks after decolonization has been attempted. Clinicians occasionlly"}, 
{"Row" : 16, "Column" : 1, "Text" : "wish to attempt decolonization for patients with frequent, troublesome"}, 
{"Row" : 17, "Column" : 1, "Text" : "recurrences. The procedure here is one of several that have been studied, but"}, 
{"Row" : 18, "Column" : 1, "Text" : "none have been particularly effective over the long run."}, 
{"Row" : 20, "Column" : 1, "Text" : "Consultation with Infectious Diseases is recommended."}, 
{"Row" : 22, "Column" : 1, "Text" : "Inpatient Decolonization Order Set: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "topically q24h nursing text order ($) [M] for 5 days"}, 
{"Row" : 26, "Column" : 1, "Text" : "Outpatient Decolonization Order Set: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Order if patient is being discharged within 5 days"}, 
{"Row" : 29, "Column" : 1, "Text" : "topically qday ($) [M] for 5 days"}, 
{"Row" : 31, "Column" : 1, "Text" : "Instructions", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "* Patient must wear clean clothes after bathing to prevent recontaminat"}, 
{"Row" : 33, "Column" : 1, "Text" : "* Bedding and linens must be changed/cleaned daily until the end of the"}, 
{"Row" : 34, "Column" : 1, "Text" : "decolonization protocol."}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Bradley S Clin Infect Dis 2007, 44: 186"}, 
{"Row" : 40, "Column" : 1, "Text" : "Lonneke G NEJM 2010, 362: 9"}, 
{"Row" : 41, "Column" : 1, "Text" : "Schweizer et al, JAMA 2015, 313.212:162-2171"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in"}, 
{"Row" : 43, "Column" : 1, "Text" : "adults: Prevention and control"}
]},
{"Name" : "ORZID2 GMENU ABX STASIS DERMATITIS" , "Term1" : "Dermatitis, stasis " , "Term2" : "Stasis dermatitis", "DisplayText" : "Stasis dermatitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "DisplayText" : "Cellulitis", "Text" : "Bacterial Cellulitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "STASIS DERMATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Stasis dermatitis is a common condition that is often confused with"}, 
{"Row" :6, "Column" : 1, "Text" : "bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial"}, 
{"Row" :7, "Column" : 1, "Text" : "therapy. It is important to distinguish between the two. The provider"}, 
{"Row" :8, "Column" : 1, "Text" : "should be mindful of the fact that bacterial cellulitis can occur on skin"}, 
{"Row" :9, "Column" : 1, "Text" : "with underlying stasis dermatitis. (See link below for bacterial cellulitis)"}, 
{"Row" : 11, "Column" : 1, "Text" : "Common risk factors for venous stasis include advancing age, family"}, 
{"Row" : 12, "Column" : 1, "Text" : "history of venous disease, increased body mass index, smoking, a history of"}, 
{"Row" : 13, "Column" : 1, "Text" : "trauma, prior venous thrombosis and pregnancy. Chronic venous disease and"}, 
{"Row" : 14, "Column" : 1, "Text" : "arterial vascular disease have some common risk factors (eg, smoking,"}, 
{"Row" : 15, "Column" : 1, "Text" : "obesity) and pathophysiological processes. The most common symptoms reported"}, 
{"Row" : 16, "Column" : 1, "Text" : "by patients with chronic venous disease are limb discomfort (tired, heavy"}, 
{"Row" : 17, "Column" : 1, "Text" : "legs), pain, and limb swelling. Swelling is often worse with prolonged"}, 
{"Row" : 18, "Column" : 1, "Text" : "standing and improves with leg elevation and walking. The skin of the"}, 
{"Row" : 19, "Column" : 1, "Text" : "anterior surfaces of the lower legs often has brown or blue-grey"}, 
{"Row" : 20, "Column" : 1, "Text" : "hyperpigmentation."}, 
{"Row" : 22, "Column" : 1, "Text" : "People with venous stasis are prone to develop stasis dermatitis which"}, 
{"Row" : 23, "Column" : 1, "Text" : "is one of the most common and earliest dermatologic signs of chronic venous"}, 
{"Row" : 24, "Column" : 1, "Text" : "insufficiency. Stasis dermatitis is an inflammatory process that presents as"}, 
{"Row" : 25, "Column" : 1, "Text" : "an eczematous rash characterized by itching, erythema, scaling, weeping,"}, 
{"Row" : 26, "Column" : 1, "Text" : "erosions, and crusting. Longstanding cases may develop lipodermatosclerosis"}, 
{"Row" : 27, "Column" : 1, "Text" : "a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis"}, 
{"Row" : 28, "Column" : 1, "Text" : "typically starts with a firm area of induration at the medial ankle. As the"}, 
{"Row" : 29, "Column" : 1, "Text" : "process progresses, the entire leg lower leg can become involved with"}, 
{"Row" : 30, "Column" : 1, "Text" : "extension up to the mid leg in more advanced cases. The skin overlying the"}, 
{"Row" : 31, "Column" : 1, "Text" : "panniculitis is typically heavily pigmented and bound down to the"}, 
{"Row" : 32, "Column" : 1, "Text" : "subcutaneous tissues. Brawny edema above the fibrotic area and on the foot"}, 
{"Row" : 33, "Column" : 1, "Text" : "below is seen in advanced cases. Leukocytosis and fever are common in people"}, 
{"Row" : 34, "Column" : 1, "Text" : "with stasis dermatitis."}, 
{"Row" : 36, "Column" : 1, "Text" : "Chronic venous disease is the most common cause of leg ulcers. They"}, 
{"Row" : 37, "Column" : 1, "Text" : "are usually found low on the medial ankle over a perforating vein, or along"}, 
{"Row" : 38, "Column" : 1, "Text" : "the course of the great or small saphenous veins. They occur more proximally"}, 
{"Row" : 39, "Column" : 1, "Text" : "if precipitated by trauma. Venous ulcers are not found on the forefoot or"}, 
{"Row" : 40, "Column" : 1, "Text" : "above the level of the knee. Venous ulcers can be multiple or single, and"}, 
{"Row" : 41, "Column" : 1, "Text" : "can be exquisitely tender, shallow, exudative and have a granulation base."}, 
{"Row" : 42, "Column" : 1, "Text" : "The ulcer borders are usually irregular but not undermined. They can extend"}, 
{"Row" : 43, "Column" : 1, "Text" : "circumferentially around the leg if left untreated."}, 
{"Row" : 45, "Column" : 1, "Text" : "Arterial ulcers are typically painful, and punched out or stellate. The"}, 
{"Row" : 46, "Column" : 1, "Text" : "surrounding skin is red and taut. Some arterial ulcers are pale - others have"}, 
{"Row" : 47, "Column" : 1, "Text" : "a black or yellow eschar. They are often associated with trauma and commonly"}, 
{"Row" : 48, "Column" : 1, "Text" : "occur on the foot over pressure points. There may be other signs of arterial"}, 
{"Row" : 49, "Column" : 1, "Text" : "insufficiency on the lower limb including thin atrophic or hairless skin,"}, 
{"Row" : 50, "Column" : 1, "Text" : "poor pedal pulses, diminished capillary refill, or hypertrophic deformed"}, 
{"Row" : 51, "Column" : 1, "Text" : "nails."}, 
{"Row" : 53, "Column" : 1, "Text" : "Patients with stasis or lipodermatosclerosis are prone to bouts of"}, 
{"Row" : 54, "Column" : 1, "Text" : "bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated"}, 
{"Row" : 55, "Column" : 1, "Text" : "streptococci. Typically, stasis dermatitis develops slowly, over a week or"}, 
{"Row" : 56, "Column" : 1, "Text" : "more. It is often bilateral. The onset of bacterial cellulitis is usually"}, 
{"Row" : 57, "Column" : 1, "Text" : "abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often"}, 
{"Row" : 58, "Column" : 1, "Text" : "starts in one area and spreads to adjacent areas. Bacterial cellulitis is"}, 
{"Row" : 59, "Column" : 1, "Text" : "unilateral. Both can present with fever and leukocytosis."}, 
{"Row" : 61, "Column" : 1, "Text" : "In a patient with stasis and cellulitis and the physician is uncertain"}, 
{"Row" : 62, "Column" : 1, "Text" : "about whether bacterial cellulitis is present, the physician should consider"}, 
{"Row" : 63, "Column" : 1, "Text" : "a trial of bed rest, leg elevation, and if there is fluid overload, diuresis"}, 
{"Row" : 64, "Column" : 1, "Text" : "If the cellulitis improves in 24-48 hours, antibacterial therapy and the"}, 
{"Row" : 65, "Column" : 1, "Text" : "attendant adverse reactions can be avoided. If it is clear that bacterial"}, 
{"Row" : 66, "Column" : 1, "Text" : "cellulitis has occurred, antimicrobial therapy should be given."}, 
{"Row" : 71, "Column" : 1, "Text" : "References"}, 
{"Row" : 73, "Column" : 1, "Text" : "Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52"}, 
{"Row" : 74, "Column" : 1, "Text" : "Up-to-Date article: Stasis dermatitis"}
]},
{"Name" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY" , "Term1" : "Suppurative thrombophlebitis", "DisplayText" : "Suppurative Thrombophlebitis--Empirical Therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX VANC 15 mg/kg IV Q12H CEFTRIAX 2 GM IV Q24H", "DisplayText" : "VANCO 1 GM IV Q12H CEFTRIAX 2 GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "DisplayText" : "vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg IV q24h ($)", "Mnemonic" : "8"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SUPPURATIVE THROMBOPHLEBITIS - EMPIRICAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Obtain blood cultures before starting empirical antimicrobials."}, 
{"Row" :7, "Column" : 1, "Text" : "Peripheral vein suppurative thrombophlebitis may require surgical intervention"}, 
{"Row" :8, "Column" : 1, "Text" : "in addition to antimicrobial therapy. The usual treatment for jugular vein"}, 
{"Row" :9, "Column" : 1, "Text" : "suppurative thrombophlebitis (Lemierre's syndrome) and vena cava suppurative"}, 
{"Row" : 10, "Column" : 1, "Text" : "thrombophlebitis is prolonged antimicrobial therapy, with or without"}, 
{"Row" : 11, "Column" : 1, "Text" : "radiological or thrombolytic clot removal. Consult Infectious Diseases and"}, 
{"Row" : 12, "Column" : 1, "Text" : "Vascular Surgery for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Modify antimicrobial regimen and narrow coverage based on results of culture and"}, 
{"Row" : 15, "Column" : 1, "Text" : "susceptibility tests."}, 
{"Row" : 17, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "A minimum of 4 to 6 weeks of antimicrobial therapy is appropriate and may be"}, 
{"Row" : 19, "Column" : 1, "Text" : "abbreviated in peripheral vein infections based on patient specific factors."}, 
{"Row" : 20, "Column" : 1, "Text" : "Antimicrobial therapy should be continued until there is definite clinical"}, 
{"Row" : 21, "Column" : 1, "Text" : "response and oral antimicrobial therapy may be used after completion of initial"}, 
{"Row" : 22, "Column" : 1, "Text" : "course of intravenous therapy."}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical treatment for peripheral vein infections and central vein infections", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "associated with a venous catheter", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 32, "Column" : 1, "Text" : "[R,O]"}, 
{"Row" : 34, "Column" : 1, "Text" : "Empirical treatment for jugular vein infection (also known as Lemierre's) or", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "suppurative pelvic vein infection", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Consultation with Surgery and Infectious Diseases is encouraged."}, 
{"Row" : 37, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 43, "Column" : 1, "Text" : "For catheter-associated infection, add vancomycin to one of the above treatment", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "regimens", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Suppurative Thrombophlebitis"}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 52, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 2009, 49.1-45"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-To-date article: Suppurative (septic) thrombophlebitis"}
]},
{"Name" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)" , "Term1" : "Antibiogram " , "Term2" : "Antimicrobial susceptibilities " , "Term3" : "Susceptibilities, antimicrobial", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX MPLS VAMC ABX SENSITIVITIES", "DisplayText" : "Mpls VAMC Antibiotic Susceptibilities", "Text" : "[Click here] to go directly to the Antibiotic Susceptibilities.", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX ANTIBIOGRAM", "DisplayText" : "MDH antibiogram", "Text" : "Please Click Here For the MDH website", "Mnemonic" : "6"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD", "DisplayText" : "Sanford Guide Web Site", "Text" : "Click Here for link to Sanford Guide online access", "Mnemonic" : "8"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ GTX ABX MANDELL", "DisplayText" : "Mandell Online", "Text" : "Click Here for link to Principles and Practice of Infectious Diseases online", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "ANTIMICROBIAL SUSCEPTIBILITIES", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Antimicrobial selection should be based on likely susceptibilities of"}, 
{"Row" :5, "Column" : 1, "Text" : "anticipated or proven pathogens. Clinicians should be aware of local, regional,"}, 
{"Row" :6, "Column" : 1, "Text" : "and national susceptibility patterns. Several sources for susceptibility"}, 
{"Row" :7, "Column" : 1, "Text" : "patterns are listed below."}, 
{"Row" :9, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "LOCAL", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Minneapolis VAMC Network W-Drive", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "W:\\LABORATORY\\MICROBIOL INFO FOR CLINICIANS-Lab\\Antibiotic Susceptibilities"}, 
{"Row" : 20, "Column" : 1, "Text" : "Minneapolis VAMC Microbiology Laboratory", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Call (ext. 31-2408) or visit (room BB-127) the Microbiology Laboratory"}, 
{"Row" : 24, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "REGIONAL", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Minnesota Department of Health", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "NATIONAL", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "_____________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford Guide", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Gilbert DN et al: The Sanford Guide to Antimicrobial Therapy, published"}, 
{"Row" : 40, "Column" : 1, "Text" : "annually by Antimicrobial Therapy, Inc., Hyde Park, VT."}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell, Douglas, and Bennett Textbook", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "access"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell et al: Principles and Practice of Infectious Diseases, Churchill"}, 
{"Row" : 46, "Column" : 1, "Text" : "Livingstone"}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobial Susceptibilities Pathway: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "[ OR ]", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "and ask for the most recent summary."}, 
{"Row" : 19, "Column" : 1, "Text" : "[ OR ]", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS" , "Term1" : "Suspected bacteremia, blood cultures not yet positive", "DisplayText" : "Suspected bacteremia, blood cultures not yet positive " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Intravascular Catheter-Associated Infection", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "DisplayText" : "VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) <AND> vancomycin 15 mg/kg IV q12h", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "DisplayText" : "vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Text" : "vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If blood cultures are positive, return to the previous menu and make a selection"}, 
{"Row" :6, "Column" : 1, "Text" : "based on the interim results."}, 
{"Row" :8, "Column" : 1, "Text" : "Choice of antimicrobials", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Select antimicrobials active against any suspected site of infection that may be"}, 
{"Row" : 10, "Column" : 1, "Text" : "present. Return to main menu and refer to the source infection's page within"}, 
{"Row" : 11, "Column" : 1, "Text" : "the Antimicrobial CDSS."}, 
{"Row" : 13, "Column" : 1, "Text" : "For patients with an intravascular catheter, refer to the intravascular-", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "associated infection page", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Empirical therapy for mild to moderate infection, focal infection not found", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Empirical therapy for severe infection", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical therapy for immunosuppressed patients", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "For patients with penicillin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References"}, 
{"Row" : 33, "Column" : 1, "Text" : "Medical Letter Treatment Guidelines 2010, 8: 94"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Enterococci"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Staphylococci"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Streptococci"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID2 GMENU ABX SYPHILIS" , "Term1" : "Sexually transmitted infection, syphilis " , "Term2" : "Syphilis", "DisplayText" : "Syphilis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "LRTZ SYPHILIS AB W/REFLEX TO RPR W/TITER", "DisplayText" : "Syphilis AB w/reflex to RPR w/titer", "Text" : "Syphilis antibody test with reflex to rapid plasma reagin (RPR)", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSJZID BENZATHINE PENICILLIN 2.4MU IM ONCE", "DisplayText" : "Benzathine Penicillin 2.4 million units IM one time dose (Cost $$$) [M]", "Text" : "Benzathine Penicillin 2.4 million units IM once ($$$) [M]", "Mnemonic" : "10"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 14 days", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "PSJZID2 BENZATHINE PENICILLIN 2.4MU IM QWEEK X3 SYPHILIS", "DisplayText" : "Benzathine Penicillin 2.4 million units IM qweek x3 ($$$)[M]", "Text" : "Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses", "Mnemonic" : "16"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "18"},
{"Row" : 54, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 28 days", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "SYPHILIS", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Syphilis is a sexually transmitted disease caused by the spirochete Treponema"}, 
{"Row" : 10, "Column" : 1, "Text" : "pallidum that can manifest as a variety of signs or symptoms. Primary syphilis"}, 
{"Row" : 11, "Column" : 1, "Text" : "typically consists of painless ulcers or chancre at the site of infection with"}, 
{"Row" : 12, "Column" : 1, "Text" : "regional adenopathy. Secondary syphilis often includes a skin rash (disseminated"}, 
{"Row" : 13, "Column" : 1, "Text" : "and/or including the palms and soles), fever, malaise, mucocutaneous lesions and"}, 
{"Row" : 14, "Column" : 1, "Text" : "lymphadenopathy. Tertiary syphilis includes those with cardiovascular or"}, 
{"Row" : 15, "Column" : 1, "Text" : "gummatous disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Latent syphilis is a period of disease when a patient does not have symptoms but"}, 
{"Row" : 18, "Column" : 1, "Text" : "is found to be infected through serologic testing. Early latent syphilis refers"}, 
{"Row" : 19, "Column" : 1, "Text" : "to latent syphilis acquired within the preceding year and late latent syphilis"}, 
{"Row" : 20, "Column" : 1, "Text" : "refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or"}, 
{"Row" : 21, "Column" : 1, "Text" : "Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g."}, 
{"Row" : 22, "Column" : 1, "Text" : "meningitis, stroke, vision or hearing loss) occurring within the first months to"}, 
{"Row" : 23, "Column" : 1, "Text" : "years of infection and late manifestations (e.g. dementia, tabes dorsalis)"}, 
{"Row" : 24, "Column" : 1, "Text" : "occurring after 10-30 years."}, 
{"Row" : 26, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "A presumptive diagnosis is made through use of a nontreponemal or serologic test"}, 
{"Row" : 28, "Column" : 1, "Text" : "(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent"}, 
{"Row" : 29, "Column" : 1, "Text" : "treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield"}, 
{"Row" : 30, "Column" : 1, "Text" : "microscopy and direct fluorescent antibody (DFA) must be used for definitive"}, 
{"Row" : 31, "Column" : 1, "Text" : "diagnosis since T. pallidum cannot be cultured."}, 
{"Row" : 35, "Column" : 1, "Text" : "Management of sex partners", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Persons with sexual contact with a person with primary, secondary or early"}, 
{"Row" : 37, "Column" : 1, "Text" : "latent syphilis within the last 90 days should be presumptively treated even if"}, 
{"Row" : 38, "Column" : 1, "Text" : "serologic test is negative."}, 
{"Row" : 40, "Column" : 1, "Text" : "Primary, Secondary and Early Latent Syphilis", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 44, "Column" : 1, "Text" : "Secondary treatment for patients who are not pregnant"}, 
{"Row" : 48, "Column" : 1, "Text" : "Tertiary and Late Latent Syphilis", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 52, "Column" : 1, "Text" : "Secondary treatment for patients who are not pregnant"}, 
{"Row" : 56, "Column" : 1, "Text" : "Neurosyphilis, Ocular syphilis or Otosyphilis", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Consult Infectious Disease for treatment"}, 
{"Row" : 59, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "References: "}, 
{"Row" : 62, "Column" : 1, "Text" : "CDC STD Treatment Guidelines MMWR (2021) 70.4"}, 
{"Row" : 63, "Column" : 1, "Text" : "Mandell Chapter: Syphilis (Treponema pallidum)"}, 
{"Row" : 64, "Column" : 1, "Text" : "Sanford keyword: Syphilis"}, 
{"Row" : 65, "Column" : 1, "Text" : "Up-To-Date article: Syphilis: Screening and diagnostic testing"}, 
{"Row" : 66, "Column" : 1, "Text" : "Up-To-Date article: Syphilis: Treatment and monitoring"}, 
{"Row" :7, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. Evaluation and management are complex.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES" , "Term1" : "Systemic Infections section", "DisplayText" : "Systemic Infectious Diseases" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "DisplayText" : "Approach to bacteremia", "Text" : "Approach to bacteremia", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "DisplayText" : "Suspected bacteremia, blood cultures not yet positive", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "DisplayText" : "Interim report of Gram-negative cocci", "Text" : "Interim report of Gram-negative cocci", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "DisplayText" : "Interim report of Gram-negative bacilli", "Text" : "Interim report of Gram-negative bacilli", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Interim report of Gram-positive cocci in pairs", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and chains", "Text" : "Interim report of Gram-positive cocci in pairs and chains", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "DisplayText" : "Interim report of Gram-positive cocci in pairs and clusters", "Text" : "Interim report of Gram-positive cocci in pairs and clusters", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Interim report of Gram-positive bacilli", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "DisplayText" : "Interim report of yeast", "Text" : "Interim report of yeast", "Mnemonic" : "20"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "DisplayText" : "Bacteremia associated with Staphylococcus aureus", "Text" : "Bacteremia associated with Staphylococcus aureus", "Mnemonic" : "22"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "DisplayText" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Text" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Mnemonic" : "24"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "DisplayText" : "Bacteremia associated with Staphylococcus lugdunensis", "Text" : "Bacteremia associated with Staphylococcus lugdunensis", "Mnemonic" : "26"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "DisplayText" : "Bacteremia associated with Listeria monocytogenes", "Text" : "Bacteremia associated with Listeria monocytogenes", "Mnemonic" : "28"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "Fungemia associated with Candida spp.", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "++SYSTEMIC INFECTIOUS DISEASES++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Bacteremia", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Bacteremia, preliminary results", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Bacteremia, final results (specific pathogens)", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Last reviewed July 2017", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection", "Text" : "Intravascular catheter-associated infection", "Mnemonic" : "34"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Sepsis and septic shock", "Mnemonic" : "36"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "DisplayText" : "Leukocytosis", "Text" : "Leukocytosis", "Mnemonic" : "38"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU FEVER OF UNK ORIGIN", "DisplayText" : "Fever of unknown origin", "Text" : "Fever of unknown origin", "Mnemonic" : "40"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "Neutropenic fever", "Mnemonic" : "42"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease", "Mnemonic" : "44"},
{"Row" :9, "Column" : 2, "Text" : "Other systemic diseases", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX TESTING INPATIENT MENU", "DisplayText" : "CDSS INPATIENT TESTING MENU " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Item" : "ORZ GTX ABX THERADOC HYPERLINK", "DisplayText" : "TheraDoc Link", "Text" : "CLICK HERE FOR THERADOC", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINARY CATHETER", "DisplayText" : "Urinary Catheter Decision Tree", "Text" : "Urinary catheters", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties A-B", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP C SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties C", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP D-E-F SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties D-E-F", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Propertie G-L", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP M-N-O SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties M-N-O", "Mnemonic" : "14"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties P-Q-R-S", "Mnemonic" : "16"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "Important Drug Properties T-U-V-W-X-Y-Z", "Mnemonic" : "18"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "testing drug info", "Mnemonic" : "20"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "MENINGOCOCCAL VACCINE INFO PAGE", "Mnemonic" : "30"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX POST SCT VACCINATIONS BLOOD 2016", "DisplayText" : "Post SCT Vaccinations Blood 2016", "Text" : "Test Post SCT Blood", "Mnemonic" : "34"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX URL ANTIMICROBIAL CDSS WEBSITE LINK", "DisplayText" : "CDC website for the Infectious Diseases", "Text" : "Antimicrobial CDSS Website Link", "Mnemonic" : "40"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "DisplayText" : "Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections", "Text" : "TEST ortho", "Mnemonic" : "42"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX URL IDP A-B SANFORD OR LEXI LINKS", "DisplayText" : "IDP SANFORD OR LEXI LINK", "Text" : "SANFORD LINKS", "Mnemonic" : "44"},
{"Row" :1, "Column" : 1, "Text" : "CDSS TESTING ONLY BELOWS", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "THERADOC: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "DisplayText" : "PNEUMONIA HAP", "Text" : "Pneumonia HAP (new page Pseudomonas)", "Mnemonic" : "RRx"}
]},
{"Name" : "ORZID2 GMENU ABX TESTING MENU" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TZ 4.5 GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin 5", "Mnemonic" : "10"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM GENT 5M/KG VANCO 15MG/KG Q12H", "DisplayText" : "Cefepime Gentamicin Vancomycin", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> gentamicin 5", "Mnemonic" : "12"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) <AND> gentamicin 5 mg/kg IV", "Mnemonic" : "14"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG GENT 5M/KG VANCO 15MG/KG Q12H", "DisplayText" : "Levofloxacin 750 mg Gentamicin 5 mg/kg Vancomycin 15 mg/kg", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h ($)", "Mnemonic" : "16"},
{"Row" :2, "Column" : 1, "Text" : "EMPIRIC TREATMENT: Ventilator Associated Pneumonia (VAP)", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumonia occurring 48 hours or more after endotracheal intubation"}, 
{"Row" :5, "Column" : 1, "Text" : "Local facility antibiogram and patient risk factors for multi-drug"}, 
{"Row" :6, "Column" : 1, "Text" : "resistant pathogens guide antimicrobial therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "Risk factors for Multi-Drug Resistant VAP: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Prior intravenous antibiotic use within 90 days"}, 
{"Row" : 10, "Column" : 1, "Text" : "Septic shock at the time of VAP"}, 
{"Row" : 11, "Column" : 1, "Text" : "ARDS preceding VAP"}, 
{"Row" : 12, "Column" : 1, "Text" : "5 or more days of hospitalization prior to the occurrence of VAP"}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute renal replacement therapy prior to VAP onset"}, 
{"Row" : 14, "Column" : 1, "Text" : "Local resistance pattern"}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy"}, 
{"Row" : 18, "Column" : 1, "Text" : "covered the pathogen and the patient is clinically responding."}, 
{"Row" : 20, "Column" : 1, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of"}, 
{"Row" : 21, "Column" : 1, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no"}, 
{"Row" : 22, "Column" : 1, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal"}, 
{"Row" : 23, "Column" : 1, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for"}, 
{"Row" : 24, "Column" : 1, "Text" : "MRSA."}, 
{"Row" : 26, "Column" : 1, "Text" : "Empiric Treatment: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "No Risk of MDR Pathogen(s): ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 32, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative for Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 38, "Column" : 1, "Text" : "Risk of MDR Pathogens: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 44, "Column" : 1, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative for penicillin allergy: "}, 
{"Row" : 48, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>"}, 
{"Row" : 51, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 53, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1."}, 
{"Row" : 55, "Column" : 1, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163"}, 
{"Row" : 56, "Column" : 1, "Text" : "Chastre J. JAMA 2003. 290:2588."}, 
{"Row" : 57, "Column" : 1, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371."}, 
{"Row" : 58, "Column" : 1, "Text" : "Luna CM. Crit Care Med 2003. 31:676."}, 
{"Row" : 59, "Column" : 1, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119."}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "DisplayText" : "Tocilizumab for treatment of COVID-19 " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 800MG IV X1 COVID-19 DOSE 1", "DisplayText" : "Tocilizumab 800 mg IV x1 dose 1 for COVID-19", "Text" : "Tocilizumab 800 mg IV x 1 ($$$$) [DI,O]", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 600MG IV X1 COVID-19 DOSE 1", "DisplayText" : "Tocilizumab 600 mg IV x1 dose 1 for COVID-19", "Text" : "Tocilizumab 600 mg IV x 1 ($$$$) [DI,O]", "Mnemonic" : "7"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 400MG IV X1 COVID-19 DOSE 1", "DisplayText" : "Tocilizumab 400 mg IV x1 dose 1 for COVID-19", "Text" : "Tocilizumab 400 mg IV x 1 ($$$$) [DI,O]", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 8MG/KG IV X1 COVID-19 DOSE 1", "DisplayText" : "Tocilizumab 8 mg/kg x1 dose 1 for COVID-19", "Text" : "Tocilizumab 8 mg/kg IV x 1 ($$$$) [DI,O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "TOCILIZUMAB (IL- 6 RECEPTOR BLOCKER) FOR TREATMENT OF COVID-19", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Inclusion Criteria: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "o Confirmed COVID-19 <AND>"}, 
{"Row" :7, "Column" : 1, "Text" : "o Hospitalized <AND>"}, 
{"Row" :8, "Column" : 1, "Text" : "o Clinical evidence of progressive COVID-19 (supplemental oxygen, high-flow"}, 
{"Row" :9, "Column" : 1, "Text" : "oxygen, or noninvasive or invasive ventilation) <AND>"}, 
{"Row" : 12, "Column" : 1, "Text" : "Exclusion Criteria: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "o Outpatient"}, 
{"Row" : 14, "Column" : 1, "Text" : "o Current documented or suspected bacterial or fungal infection"}, 
{"Row" : 15, "Column" : 1, "Text" : "o Active tuberculosis"}, 
{"Row" : 16, "Column" : 1, "Text" : "o ANC < 1000/mm3, platelet count < 50,000/mm3, ALT/AST> 10x ULN"}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "**1ST DOSE**", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "If all the above inclusion criteria are met and no exclusion criteria, the 1st", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "dose of tocilizumab may be ordered below based on patient's weight.", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Patient weight >/= 90 kg", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Patient weight >/= 65 kg and < 90 kg", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Patient weight >/= 40 kg and < 65 kg", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Patient weight < 40 kg", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "**2ND DOSE**", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "If the patient's condition has not improved in 12-24 hours after receiving the", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "1st dose, a second dose may be considered in select patients. Please page ID for", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Horby, Peter W., et al. Tocilizumab in patients admitted to hospital with"}, 
{"Row" : 45, "Column" : 1, "Text" : "COVID-19 (RECOVERY): preliminary results of a randomized, controlled, open-"}, 
{"Row" : 46, "Column" : 1, "Text" : "label, platform trial. Medrxiv (2021)."}, 
{"Row" : 10, "Column" : 1, "Text" : "o Patient does not have a known hypersensitivity to tocilizumab"}, 
{"Row" : 40, "Column" : 1, "Text" : "discussion of 2nd dose.", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "o GI perforation"}
]},
{"Name" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX METRONIDAZOLE 500MG IV Q8H VANCO 500MG CAPS PO Q6H", "DisplayText" : "Metronidazole IV Vanco 500mg Caps Vanco Enema", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]", "Mnemonic" : "4"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8h VANCO 500MG PO/NG Q6H", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG soln q6h ($)", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8H VANCO CAP 500MG Q6H W/O ENEMA", "DisplayText" : "Metronidazole IV Vanco 500mg Caps", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]", "Mnemonic" : "8"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8H VANCO 500MG NG Q6H W/O ENEMA", "DisplayText" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG q6h ($$) [R]", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG q6h ($) [M]", "Mnemonic" : "10"},
{"Row" :7, "Column" : 1, "Text" : "Discontinue any antibiotics if possible and avoid high risk antibiotic if", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "An enteral dose of 125mg of vancomycin results in colonic vancomycin", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "concentrations hundreds of times greater than needed to inhibit Clostridium", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "difficile. Only with toxic megacolon or ileus is a higher dose of vancomycin", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "(500mg) administered by enteral route.", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Antimicrobial therapy should be continued for 10 days but may be prolonged"}, 
{"Row" : 20, "Column" : 1, "Text" : "considering clinical circumstances. In patients being treated with antibiotics"}, 
{"Row" : 21, "Column" : 1, "Text" : "for predisposing infections, continue treatment for 7 days after completion of"}, 
{"Row" : 22, "Column" : 1, "Text" : "those antibiotics. If patient is being treated for C. difficile recurrence,"}, 
{"Row" : 23, "Column" : 1, "Text" : "pulse taper therapy is indicated after resolution of severe disease. Refer to"}, 
{"Row" : 24, "Column" : 1, "Text" : "mild to moderate C. difficile treatment menu for recommendations."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment if ileus is present", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Deliver antimicrobials by intravenous, oral, and rectal routes."}, 
{"Row" : 32, "Column" : 1, "Text" : "<AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]"}, 
{"Row" : 34, "Column" : 1, "Text" : "**ONLY for Vancomycin NG administration**"}, 
{"Row" : 36, "Column" : 1, "Text" : "[M] <AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]"}, 
{"Row" : 37, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment if ileus is not present", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential."}, 
{"Row" : 44, "Column" : 1, "Text" : "**ONLY for Vancomycin NG administration**"}, 
{"Row" : 48, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 52, "Column" : 1, "Text" : "McDonald et al, Clin Inf Dis, 2018, (00)1-48"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical"}, 
{"Row" :4, "Column" : 1, "Text" : "Definition of fulminant CDI is supported by: "}, 
{"Row" :5, "Column" : 1, "Text" : "Hypotension or shock, ileus, megacolon"}, 
{"Row" : 28, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential."}, 
{"Row" : 50, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis,2021,73(5):e1029-e1044"}, 
{"Row" : 55, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 10, "Column" : 1, "Text" : "Note: There are no available data supporting the use of fidaxomicin for", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "treatment of fulminant CDI.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX TPOXX DOCUMENTS LINK", "DisplayText" : "TPOXX SharePoint Link", "Text" : "[CLICK HERE] for link to required documents (Monkeypox Taskforce Teams group)", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX INV-TECOVIRIMAT 600 MG ORALLY Q12H 14 DAYS", "DisplayText" : "INV-TECOVIRIMAT 600 MG ORALLY Q12H 14 DAYS", "Text" : "INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days", "Mnemonic" : "6"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX INV-TECOVIRIMAT 600 MG ORALLY Q8H 14 DAYS", "DisplayText" : "INV-TECOVIRIMAT 600 MG ORALLY Q8H 14 DAYS", "Text" : "INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days", "Mnemonic" : "8"},
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX INV-TECOVIRIMAT 200MG IV Q12H X14 DAYS", "DisplayText" : "INV-TECOVIRIMAT 200MG IV Q12H X14 DAYS", "Text" : "INV-Tecovirimat 200 mg IV q12h over 6 hours for 14 days", "Mnemonic" : "10"},
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX INV-TECOVIRIMAT 300MG IV Q12H X14 DAYS", "DisplayText" : "INV-TECOVIRIMAT 300MG IV Q12H X14 DAYS", "Text" : "INV-Tecovirimat 300 mg IV q12h over 6 hours for 14 days", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CDC MONKEYPOX TREATMENT WITH TPOXX", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Eligibility: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "o Consent: Must have documented consent by patient or legally authorized"}, 
{"Row" :7, "Column" : 1, "Text" : "representative in paper or i-Med consent"}, 
{"Row" :8, "Column" : 1, "Text" : "o Primary/empiric treatment: Confirmed diagnosis or suspected infection based"}, 
{"Row" :9, "Column" : 1, "Text" : "on exposure and/or symptoms while testing is pending."}, 
{"Row" : 10, "Column" : 1, "Text" : "o Secondary Treatment: Complications from replication competent vaccinia"}, 
{"Row" : 11, "Column" : 1, "Text" : "infection from vaccination, secondary transmission, or other exposure. TPOXX may"}, 
{"Row" : 12, "Column" : 1, "Text" : "be used after VIGIV treatment or in conjunction with VIGIV and/or with other"}, 
{"Row" : 13, "Column" : 1, "Text" : "therapies based on clinical judgement."}, 
{"Row" : 14, "Column" : 1, "Text" : "o Post-exposure prophylaxis (PEP): May be considered on a case-by-case basis in"}, 
{"Row" : 15, "Column" : 1, "Text" : "consultation with the CDC. Eligibility for PEP use depends on high risk exposure"}, 
{"Row" : 16, "Column" : 1, "Text" : "confirmed or probable case and alternative or complement to PEP vaccination"}, 
{"Row" : 17, "Column" : 1, "Text" : "is needed based on clinical judgment (e.g. vaccine allergy, immunocompromise)."}, 
{"Row" : 18, "Column" : 1, "Text" : "o Dosage and duration: Weight based dosing for 14 days. But it may be longer"}, 
{"Row" : 19, "Column" : 1, "Text" : "based on clinical progress but not to exceed 90 days. Oral tecovirimat capsule"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be taken by mouth with a full glass of water within 30 minutes after"}, 
{"Row" : 21, "Column" : 1, "Text" : "eating a full meal of moderate or high fat (ideally about 600 calories and 25"}, 
{"Row" : 22, "Column" : 1, "Text" : "grams of fat)."}, 
{"Row" : 23, "Column" : 1, "Text" : "o CDC Case Reports Forms:To be completed and returned to CDC by treating"}, 
{"Row" : 24, "Column" : 1, "Text" : "physicians per IND protocol."}, 
{"Row" : 28, "Column" : 1, "Text" : "Exclusions: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "o Patient or legally authorized representative unwilling to sign an informed"}, 
{"Row" : 30, "Column" : 1, "Text" : "consent and refuse tecovirimat treatment"}, 
{"Row" : 31, "Column" : 1, "Text" : "oKnown allergy to tecovirimat and/or excipients of tecovirimat"}, 
{"Row" : 32, "Column" : 1, "Text" : "oUpon negative test results for orthopoxvirus whose treatment was initiated"}, 
{"Row" : 33, "Column" : 1, "Text" : "based on clinical manifestations prior to laboratory results."}, 
{"Row" : 34, "Column" : 1, "Text" : "o For IV tecovirimat only: patients with severe renal impairment (creatinine"}, 
{"Row" : 35, "Column" : 1, "Text" : "clearance <30 mL/min)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Oral Treatment: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Patients 40kg to < 120 kg"}, 
{"Row" : 40, "Column" : 1, "Text" : "*Places medication orders for inpatient and outpatient (included in order set)"}, 
{"Row" : 42, "Column" : 1, "Text" : "Patients 120 kg and Above"}, 
{"Row" : 44, "Column" : 1, "Text" : "*Places medication orders for inpatient and outpatient (included in order set)"}, 
{"Row" : 46, "Column" : 1, "Text" : "Intravenous Treatment: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "o Very ill hospitalized patients who are unable to take oral therapy or for whom"}, 
{"Row" : 48, "Column" : 1, "Text" : "there is a concern that oral drug absorption may be altered."}, 
{"Row" : 49, "Column" : 1, "Text" : "o IV tecovirimat should not be administered in patients with severe renal"}, 
{"Row" : 50, "Column" : 1, "Text" : "impairment (creatinine clearance <30 mL/min) and should be used with caution in"}, 
{"Row" : 51, "Column" : 1, "Text" : "patients with moderate (creatinine clearance 30-49 mL/min) or mild (creatinine"}, 
{"Row" : 52, "Column" : 1, "Text" : "clearance 50-80 mL/min) renal impairment."}, 
{"Row" : 53, "Column" : 1, "Text" : "o IV tecovirimat should be switched to the oral formulation as soon as patients"}, 
{"Row" : 54, "Column" : 1, "Text" : "can take oral medications and/or gastrointestinal disfunction impacting"}, 
{"Row" : 55, "Column" : 1, "Text" : "absorption has resolved."}, 
{"Row" : 57, "Column" : 1, "Text" : "Patients 35 kg to < 120 kg"}, 
{"Row" : 62, "Column" : 1, "Text" : "Patients 120 kg and Above"}, 
{"Row" : 59, "Column" : 1, "Text" : "*Places medication orders for 2 seperate INV-tecovirimat IV 100mg q12h orders"}, 
{"Row" : 64, "Column" : 1, "Text" : "*Places medication orders for 2 seperate INV-tecovirimat IV 150 mg q12h orders"}, 
{"Row" : 60, "Column" : 1, "Text" : "for a total of 400 mg over 24hrs via slow infusion."}, 
{"Row" : 65, "Column" : 1, "Text" : "for a total of 600 mg over 24hrs via slow infusion."}
]},
{"Name" : "ORZID2 GMENU ABX TRICH VAGINITIS" , "Term1" : "Sexually transmitted infection, trichomoniasis " , "Term2" : "Trichomonas vaginitis " , "Term3" : "Vaginitis, Trichomonas", "DisplayText" : "Trichomonas Vaginitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "DisplayText" : "Metronidazole 500MG PO q12h", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "DisplayText" : "Metronidazole 500MG PO q12h", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 2GM PO Q24H", "DisplayText" : "Metronidazole 2 gm PO q24h for 7 days ($) [DI]", "Text" : "Metronidazole 2 gm PO q24h for 7 days ($) [DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "TRICHOMONAS VAGINITIS AND URETHRITIS", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Male sexual partners of women with trichomonas vaginitis will not have symptoms"}, 
{"Row" :8, "Column" : 1, "Text" : "but should be treated to prevent recurrent vaginitis in the female sexual"}, 
{"Row" :9, "Column" : 1, "Text" : "partner."}, 
{"Row" : 11, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "The discharge is purulent, malodorous, and thin. The vaginal pH is greater"}, 
{"Row" : 13, "Column" : 1, "Text" : "than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved"}, 
{"Row" : 14, "Column" : 1, "Text" : "sensitivities and specifities compared to wet mount."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of Initial Episode in Men and Woman", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pregnant women with trichomonas infection may be treated with metronidazole"}, 
{"Row" : 18, "Column" : 1, "Text" : "during any trimester."}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Referred to Non-VA Care)", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "1st failure"}, 
{"Row" : 26, "Column" : 1, "Text" : "2nd failure"}, 
{"Row" : 29, "Column" : 1, "Text" : "3rd failure"}, 
{"Row" : 30, "Column" : 1, "Text" : "Consult Infectious Disease"}, 
{"Row" : 31, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Trichomoniasis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 37, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2021) 70.4"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-To-Date article: Trichomoniasis"}
]},
{"Name" : "ORZID2 GMENU ABX TUBERCULOSIS" , "Term1" : "Tuberculosis", "DisplayText" : "Tuberculosis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "TUBERCULOSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Evaluation and management are complex.Consult pulmonary and/or infectious"}, 
{"Row" :6, "Column" : 1, "Text" : "diseases."}, 
{"Row" :8, "Column" : 1, "Text" : "Patients with suspected or proven pulmonary tuberculosis must be in respiratory"}, 
{"Row" :9, "Column" : 1, "Text" : "isolation."}, 
{"Row" : 14, "Column" : 1, "Text" : "Centers for Disease Control (CDC). Tuberculosis"}
]},
{"Name" : "ORZID2 GMENU ABX TYPHLITIS" , "Term1" : "Neutropenic enterocolitis " , "Term2" : "Typhlitis", "DisplayText" : "Neutropenic Enterocolitis (Typhlitis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile infection", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q8H METRONIDAZOLE 500 MG IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($35/day) [R] <AND> metronidazole 500 mg IV q8h", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "patients, especially in those with acute leukemia. Send stool for C. difficile"}, 
{"Row" :8, "Column" : 1, "Text" : "PCR testing to exclude of C. difficile infection."}, 
{"Row" : 11, "Column" : 1, "Text" : "Hematology-oncology, Infectious Diseases and general surgery consults"}, 
{"Row" : 12, "Column" : 1, "Text" : "are essential."}, 
{"Row" : 14, "Column" : 1, "Text" : "Broad spectrum antimicrobials that include anaerobic coverage should be"}, 
{"Row" : 15, "Column" : 1, "Text" : "initiated promptly."}, 
{"Row" : 17, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Continue antimicrobial therapy until normalization of body temperature, recovery"}, 
{"Row" : 19, "Column" : 1, "Text" : "of neutropenia and thrombocytopenia, return of normal gastrointestinal function"}, 
{"Row" : 20, "Column" : 1, "Text" : "and resolution of bacteremia if initially present."}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative for beta-lactam allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< AND > Vancomycin 15 mg/kg ($)[R]"}, 
{"Row" : 33, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results.", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Diverticulitis and typhlitis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Nesher and Rolston, Clinical Infectious Diseases, 2013, 56(5):711-7"}, 
{"Row" : 47, "Column" : 1, "Text" : "Sanford keyword: Neutropenic Enterocolitis, Typhlitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Up-to-Date article: Neutropenic enterocolitis (typhlitis)"}, 
{"Row" : 49, "Column" : 1, "Text" : "Freifeld AG Clin Infect Dis 2011, 52: e56"}, 
{"Row" :5, "Column" : 1, "Text" : "Neutropenic enterocolitis, also known as \"typhlitis\" or \"necrotizing"}, 
{"Row" :6, "Column" : 1, "Text" : "enterocolitis\", is a severe intraabdominal infection that occurs in neutropenic"}
]},
{"Name" : "ORZID2 GMENU ABX UNCOMP CYSTITIS" , "Term1" : "Cystitis, uncomplicated " , "Term2" : "Uncomplicated cystitis", "DisplayText" : "Uncomplicated Cystitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "DisplayText" : "Complicated Cystitis", "Text" : "Complicated cystitis", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic Bacteriuria", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days", "Mnemonic" : "8"},
{"Row" : 44, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "12"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 5 days", "Mnemonic" : "16"},
{"Row" : 55, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 5 days", "Mnemonic" : "18"},
{"Row" : 58, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 3 days", "Mnemonic" : "20"},
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3 GM PO ONCE", "DisplayText" : "FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3GM sachet PO ($$)[M] once", "Mnemonic" : "22"},
{"Row" : 64, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "24"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "26"},
{"Row" : 68, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 3 days", "Mnemonic" : "28"},
{"Row" : 73, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1/2 SS Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]", "Mnemonic" : "30"},
{"Row" : 75, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 SS TAB ONCE POST-COITUS", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]", "Mnemonic" : "32"},
{"Row" : 77, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100MG PO QHS", "DisplayText" : "Nitrofurantoin SA 100 mg PO QHS ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min", "Mnemonic" : "34"},
{"Row" : 79, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO X1 POST COITUS", "DisplayText" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min", "Mnemonic" : "36"},
{"Row" :3, "Column" : 1, "Text" : "UNCOMPLICATED CYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Uncomplicated cystitis is defined as symptomatic bladder inflammation caused by"}, 
{"Row" :6, "Column" : 1, "Text" : "bacterial infections in people with structurally and neurogenically normal"}, 
{"Row" :7, "Column" : 1, "Text" : "urinary tract. Symptoms usually include dysuria, lower abdominal pain, and"}, 
{"Row" :8, "Column" : 1, "Text" : "urgency. Most cases of uncomplicated cystitis occur in pre-menopausal,"}, 
{"Row" :9, "Column" : 1, "Text" : "non-pregnant, sexually active young women and is commonly associated with"}, 
{"Row" : 10, "Column" : 1, "Text" : "Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S."}, 
{"Row" : 11, "Column" : 1, "Text" : "saprophyticus."}, 
{"Row" : 13, "Column" : 1, "Text" : "Cystitis is considered complicated when it occurs in pregnant women, people"}, 
{"Row" : 14, "Column" : 1, "Text" : "with abnormalities of the urinary tract, immunocompromised individuals and those"}, 
{"Row" : 15, "Column" : 1, "Text" : "who have persistent, recurrent, or relapsed infections, or treatment failure are"}, 
{"Row" : 16, "Column" : 1, "Text" : "considered complicated. Diagnosis and treatment of complicated cystitis is"}, 
{"Row" : 17, "Column" : 1, "Text" : "discussed elsewhere."}, 
{"Row" : 20, "Column" : 1, "Text" : "The presence of pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine"}, 
{"Row" : 21, "Column" : 1, "Text" : "nitrate, or urine bacteria is not a sufficient indication for antibiotic"}, 
{"Row" : 22, "Column" : 1, "Text" : "treatment. Asymptomatic bacteriuria occurs in patients who have bacteria in the"}, 
{"Row" : 23, "Column" : 1, "Text" : "urine with no symptoms of cystitis, and with few exceptions, should not be"}, 
{"Row" : 24, "Column" : 1, "Text" : "treated. Diagnosis and treatment of asymptomatic bacteriuria is further"}, 
{"Row" : 25, "Column" : 1, "Text" : "discussed elsewhere: "}, 
{"Row" : 28, "Column" : 1, "Text" : "The prevalence of antimicrobial resistance among bacteria associated with"}, 
{"Row" : 29, "Column" : 1, "Text" : "uncomplicated cystitis has increased. A urine culture should be considered in a"}, 
{"Row" : 30, "Column" : 1, "Text" : "patient who has had substantial involvement with healthcare or exposure to"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobials. If a patient fails to respond to therapy, a urine culture should"}, 
{"Row" : 32, "Column" : 1, "Text" : "be done."}, 
{"Row" : 34, "Column" : 1, "Text" : "For women with recurrent uncomplicated cystitis (2 episodes in 6 months or 3 or"}, 
{"Row" : 35, "Column" : 1, "Text" : "more episodes in 12 months), suppressive therapy is indicated after infection is"}, 
{"Row" : 36, "Column" : 1, "Text" : "eradicated and non-antimicrobial prevention methods, such as increased fluid"}, 
{"Row" : 37, "Column" : 1, "Text" : "intake and avoiding spermicide, are considered. Consider consulting Women's"}, 
{"Row" : 38, "Column" : 1, "Text" : "Clinic for treatment recommendations."}, 
{"Row" : 40, "Column" : 1, "Text" : "Men, empirical treatment", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 43, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 49, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Women, empirical treatment", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 56, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 57, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 59, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 61, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 63, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 66, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 70, "Column" : 1, "Text" : "Women, suppression", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 72, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 74, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 76, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 78, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 80, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 83, "Column" : 1, "Text" : "References: "}, 
{"Row" : 84, "Column" : 1, "Text" : "Drekonja et al., JAMA, 2021, 326(4)324-331"}, 
{"Row" : 85, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" : 86, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" : 87, "Column" : 1, "Text" : "Sanford keyword: UTI, Acute, Uncomplicated, Adult, Female"}, 
{"Row" : 88, "Column" : 1, "Text" : "Sanford keyword: UTI, Adult, Male"}, 
{"Row" : 89, "Column" : 1, "Text" : "Sanford keyword: Prevention of Recurrent UTI, Female"}, 
{"Row" : 90, "Column" : 1, "Text" : "Up-To-Date article: Acute simple cystitis in men"}, 
{"Row" : 91, "Column" : 1, "Text" : "Up-To-Date article: Acute simple cystitis in women"}, 
{"Row" : 92, "Column" : 1, "Text" : "Up-To-Date article: Recurrent simple cystitis in women"}
]},
{"Name" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)" , "Term1" : "Upper respiratory infections (URI)", "DisplayText" : "Upper respiratory infections (URI)" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "DisplayText" : "Consider Antibiotic", "Text" : "Bronchitis", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "DisplayText" : "Acute Sinusitis--Mild to Moderate Disease", "Text" : "Sinusitis", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "DisplayText" : "Pharyngitis", "Text" : "Pharyngitis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "UPPER RESPIRATORY INFECTION (URI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Upper respiratory infections include several common syndromes including"}, 
{"Row" :6, "Column" : 1, "Text" : "the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis"}, 
{"Row" :7, "Column" : 1, "Text" : "(see below). Most are caused by viruses and there is no benefit from"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial therapy. If a patient presents with a URI, consider specific"}, 
{"Row" :9, "Column" : 1, "Text" : "infections that do respond to antimicrobial therapy like herpes simplex"}, 
{"Row" : 10, "Column" : 1, "Text" : "stomatitis, pertussis or thrush. If no condition that benefits from"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial therapy is present, antimicrobials will almost certainly not help"}, 
{"Row" : 12, "Column" : 1, "Text" : "but will likely select for antimicrobial resistance and may lead to other"}, 
{"Row" : 13, "Column" : 1, "Text" : "adverse effects."}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 22, "Column" : 1, "Text" : "Kogawa et al, General medicine, 2009, 10:7-15"}
]},
{"Name" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted diseases" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "Chlamydia & GC PCR/LCR test", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis", "Text" : "Treatment of recurrent or persistent urethritis", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment for gonococcal urethritis", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia Urethritis", "Text" : "Treatment for chlamydial or non-gonococcal urethritis", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "The main differential in a person who presents with dysuria is between cystitis"}, 
{"Row" :8, "Column" : 1, "Text" : "and urethritis. Bacterial urethritis is more likely in people with mild"}, 
{"Row" :9, "Column" : 1, "Text" : "dysuria, onset over a few days, or recent sexual contact."}, 
{"Row" : 10, "Column" : 1, "Text" : "The two most common sexually transmitted urethritis pathogens are Neisseria"}, 
{"Row" : 11, "Column" : 1, "Text" : "gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for"}, 
{"Row" : 12, "Column" : 1, "Text" : "these pathogens are more sensitive than culture and should be used for patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "at risk for sexually transmitted urethritis."}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients who have recently been treated for urethritis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "When dysuria is from a sexually transmitted disease, the patient's sexual"}, 
{"Row" : 20, "Column" : 1, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually"}, 
{"Row" : 21, "Column" : 1, "Text" : "transmitted infection."}, 
{"Row" : 22, "Column" : 1, "Text" : "If diagnostic tests for the cause of urethritis are not feasible, therapy for"}, 
{"Row" : 23, "Column" : 1, "Text" : "both N. gonorrhoeae and C. trachomatis should be given to partners."}, 
{"Row" : 25, "Column" : 1, "Text" : "Initial treatment of patients and sex partners", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C."}, 
{"Row" : 27, "Column" : 1, "Text" : "trachomatis. Treat for both pathogens unless one is ruled out by lab test."}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"},
{"Row" : 33, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}
]},
{"Name" : "ORZID2 GMENU ABX URINARY CATHETER", "DisplayText" : "Urinary Catheter Decision Tree" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 28, "Column" : 1, "Text" : "1) Urinary blockage due to clots"}, 
{"Row" : 30, "Column" : 1, "Text" : "2) Urinary blockage due to urinary obstruction (not clots)"}, 
{"Row" : 32, "Column" : 1, "Text" : "3) Urinary retention due to neurological condition"}, 
{"Row" : 34, "Column" : 1, "Text" : "4) Urinary incontinence"}, 
{"Row" : 36, "Column" : 1, "Text" : "5) Prolonged surgical procedure"}, 
{"Row" : 38, "Column" : 1, "Text" : "6) Monitoring of urinary output"}, 
{"Row" : 40, "Column" : 1, "Text" : "7) Open sacral wound"}, 
{"Row" : 42, "Column" : 1, "Text" : "8) Suprapubic catheter"}, 
{"Row" : 44, "Column" : 1, "Text" : "9) Nephrostomy tubes present"}, 
{"Row" :2, "Column" : 1, "Item" : "GMRCTZ UROLOGY INPT", "DisplayText" : "UROLOGY INPT", "Text" : "Consult Urology (inpatient)", "Mnemonic" : "02"},
{"Row" :1, "Column" : 1, "Text" : "HELP, additional information: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Urinary Catheters: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Bladder catheters are used for urinary drainage, or as a means to collect"}, 
{"Row" :7, "Column" : 1, "Text" : "urine for measurement. Many clinical situations are appropriate for the"}, 
{"Row" :8, "Column" : 1, "Text" : "placement of catheters, BUT too frequently they are used without proper"}, 
{"Row" :9, "Column" : 1, "Text" : "indication or continued longer than needed.Unwarranted urinary catheters"}, 
{"Row" : 12, "Column" : 1, "Text" : "Daily evaluation of the ongoing need for the catheter is essential to reduce"}, 
{"Row" : 13, "Column" : 1, "Text" : "complications including catheter-assosciated urinary tract infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternatives to indwelling urethral catheterization should be considered"}, 
{"Row" : 18, "Column" : 1, "Text" : "and include intermittent catheterization, external sheath (ie,condom)"}, 
{"Row" : 19, "Column" : 1, "Text" : "catheters, suprapubic catheters, and in some cases, supportive management"}, 
{"Row" : 20, "Column" : 1, "Text" : "with protective garments."}, 
{"Row" : 14, "Column" : 1, "Text" : "Hospital-acquired urinary tract infection is the most common type of"}, 
{"Row" : 15, "Column" : 1, "Text" : "nosocomial infection."}, 
{"Row" : 10, "Column" : 1, "Text" : "are placed in 21 to 50 percent of hospitalized patients."}, 
{"Row" : 24, "Column" : 1, "Text" : "Indications for Catheterization: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU URINARY CATHETER DUE TO IMMOBILIZATION", "Text" : "Management of immobilized patients (eg, stroke, pelvic fracture)", "Mnemonic" : "06"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINARY CATHETER NEUROGENIC BLADDER", "DisplayText" : "Management of patients with neurogenic bladder/spinal cord injury", "Text" : "", "Mnemonic" : "08"},
{"Row" : 22, "Column" : 1, "Text" : "04 Description of types of catheters and insertion", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX URINARY CATHETER NEUROGENIC BLADDER", "DisplayText" : "Management of patients with neurogenic bladder/spinal cord injury " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "Management of patients with neurogenic bladder/spinal cord injury", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The goal of an SCI bladder program is to preserve renal function while"}, 
{"Row" :6, "Column" : 1, "Text" : "eliminating urine at regular and socially acceptable times, avoiding high"}, 
{"Row" :7, "Column" : 1, "Text" : "bladder pressures, retention, incontinence, and infection."}, 
{"Row" :9, "Column" : 1, "Text" : "Clean intermittent catheterization, which is the removal of the catheter"}, 
{"Row" : 10, "Column" : 1, "Text" : "immediately after bladder decompression with recatheterization on a scheduled"}, 
{"Row" : 16, "Column" : 1, "Text" : "Clean technique intermittent catheterization has a lower infection rate"}, 
{"Row" : 17, "Column" : 1, "Text" : "compared with with the use of indwelling catheters."}, 
{"Row" : 11, "Column" : 1, "Text" : "basis ispreferred. Clean intermittent catheterization is performed at regular"}, 
{"Row" : 12, "Column" : 1, "Text" : "intervals, usually every 4 hours. A bladder volume of less than 500 mls"}, 
{"Row" : 13, "Column" : 1, "Text" : "of urine is targeted in order to avoid bladder distention, pressure, and reflux"}, 
{"Row" : 14, "Column" : 1, "Text" : "as well as to reduce the incidence of infections."}, 
{"Row" :2, "Column" : 1, "Item" : "GMRCTZ UROLOGY INPT", "DisplayText" : "UROLOGY INPT", "Text" : "Urology Consult (Inpatient)", "Mnemonic" : "02"},
{"Row" :1, "Column" : 1, "Text" : "HELP, additional information: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "08 Order forIntermittent Catheterization Q4Hours", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Intermittent urinary incontinence is expected. Condom catheters (for men)"}, 
{"Row" : 21, "Column" : 1, "Text" : "and adult diapers are important short-term interventions. Recommend rule"}, 
{"Row" : 22, "Column" : 1, "Text" : "out infection and adjust the frequency of intermittent catheterization"}, 
{"Row" : 23, "Column" : 1, "Text" : "and fluid intake."}, 
{"Row" : 24, "Column" : 1, "Text" : "10 Order for condom catheter for men", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "12 Order for adult diapers", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 28, "Column" : 1, "Text" : "available caregivers, a chronic indwelling catheter may be necessary."}, 
{"Row" : 29, "Column" : 1, "Text" : "The indwelling catheter should be changed each month to minimize infections."}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "13 Order for indwelling catheter", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "For admitted patients who normally use chronic indwelling catheter: "}, 
{"Row" : 27, "Column" : 1, "Text" : "For patients unable to perform intermittent catheterization and without"}
]},
{"Name" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "URINE CULTURE MAIN ORDER MENU", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "-Cloudy urine"}, 
{"Row" :7, "Column" : 1, "Text" : "-Malodorous urine"}, 
{"Row" :8, "Column" : 1, "Text" : "-Discolored urine"}, 
{"Row" :9, "Column" : 1, "Text" : "-When a urinary catheter is placed"}, 
{"Row" : 10, "Column" : 1, "Text" : "-Automatic on admission"}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (FEVER/SEPSIS NO OTHER CAUSE)", "DisplayText" : "Fever or sepsis with no other identifiable cause", "Text" : "", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (DYSURIA,FREQ,URG)", "DisplayText" : "Dysuria, frequency, or urgency", "Text" : "", "Mnemonic" : "12"},
{"Row" : 22, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PAIN:FLANK,SUPRAPUBIC,PELVIC", "DisplayText" : "Flank, suprapubic, or pelvic pain", "Text" : "", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (CVA tenderness)", "DisplayText" : "CVA tenderness", "Text" : "", "Mnemonic" : "16"},
{"Row" :5, "Column" : 1, "Text" : "Urine Culture is NOT indicated for the following conditions alone: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (ACUTE HEMATURIA)", "DisplayText" : "Acute hematuria", "Text" : "", "Mnemonic" : "18"},
{"Row" : 28, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PRE-0P SCREENING UROLOGIC)", "DisplayText" : "Pre-operative screening for urologic procedure", "Text" : "PRE-OPERATIVE SCREENING for urologic procedure", "Mnemonic" : "20"},
{"Row" : 30, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PREGNANT SCREENING)", "DisplayText" : "Pregnant and due for screening", "Text" : "", "Mnemonic" : "22"},
{"Row" : 32, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (SCI OR NEUROGENIC BLADDER)", "DisplayText" : "Increased bladder spasticity or autonomic dysreflexia in patients with", "Text" : "", "Mnemonic" : "24"},
{"Row" : 13, "Column" : 1, "Text" : "Urine cultures should be ordered in patients with symptoms of a urinary tract", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "infection, during pregnancy at appropriate screening intervals, and prior", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "to an invasive urologic procedure.", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Select indication for urine culture your patient has to place lab order: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "-End of therapy re-testing"}, 
{"Row" : 35, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (ALTERED MENTAL STATUS)", "DisplayText" : "Altered mental status with no other identifiable cause", "Text" : "", "Mnemonic" : "26"},
{"Row" : 36, "Column" : 1, "Text" : "(note that UC not usually indicated, call ID with questions)"}, 
{"Row" :3, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Minneapolis Clinical On-Call Schedule (Infectious Disease)", "Mnemonic" : "02"},
{"Row" : 33, "Column" : 1, "Text" : "spinal cord injury or neurologic deficit"}, 
{"Row" : 38, "Column" : 1, "Item" : "LRTZ SET OR/IR STERILE ASPIRATE COLLECTION ONLY 2", "DisplayText" : "OR/IR Sterile Aspirate Collection Only", "Text" : "", "Mnemonic" : "28"}
]},
{"Name" : "ORZID2 GMENU ABX VAGINITIS" , "Term1" : "Sexually transmitted infection, bacterial vaginitis " , "Term2" : "Vaginosis, bacterial", "DisplayText" : "Bacterial Vaginosis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "DisplayText" : "Metronidazole 500MG PO q12h", "Text" : "Metronidazole 500 mg PO q12h ($) [DI] for 7 days", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 0.75% GEL VAGINAL QHS", "Text" : "Metronidazole vaginal gel 0.75%, contents of 1 applicator intravaginally qhs ($)", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q12H", "DisplayText" : "Clindamycin 300MG PO q12h", "Text" : "Clindamycin 300 mg PO q12h ($) [H,O] for 7 days", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 2% CRM VAG 1APPLFUL CREAM QHS", "Text" : "Clindamycin phosphate vaginal cream 2%, contents of 1 applicator", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL VAGINOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Vaginitis usually presents with discharge, itching, irritation, odor, or pain."}, 
{"Row" :6, "Column" : 1, "Text" : "Bacterial vaginosis is the most common form of vaginitis. Normal hydrogen"}, 
{"Row" :7, "Column" : 1, "Text" : "peroxide and lactic acid producing vaginal flora, including Lactobacillus"}, 
{"Row" :8, "Column" : 1, "Text" : "species, is reduced and high concentrations of anaerobic bacterial pathogens are"}, 
{"Row" :9, "Column" : 1, "Text" : "present. Pathogenic bacteria commonly include Gardnerella vaginalis, Mycoplasma"}, 
{"Row" : 10, "Column" : 1, "Text" : "hominis, Nobiluncus, Prevotella and other Gram-negative anaerobes."}, 
{"Row" : 11, "Column" : 1, "Text" : "Vaginal pH should be measured, and the specimen should be examined under the"}, 
{"Row" : 12, "Column" : 1, "Text" : "microscope for identification of clue cells (epithelial cell coated with"}, 
{"Row" : 13, "Column" : 1, "Text" : "bacteria). In bacterial vaginosis the vaginal pH is high (> 4.5), the discharge"}, 
{"Row" : 14, "Column" : 1, "Text" : "is homogenous and gray-white, and the specimen has a positive amine or whiff"}, 
{"Row" : 15, "Column" : 1, "Text" : "test characterized by a fishy odor before or after addition of 10% KOH."}, 
{"Row" : 16, "Column" : 1, "Text" : "Bacterial vaginosis nucleic acid amplification tests are available for common"}, 
{"Row" : 17, "Column" : 1, "Text" : "pathogens to aide in identification of pathogen(s)."}, 
{"Row" : 19, "Column" : 1, "Text" : "Bacterial vaginosis may be transmitted sexually. Patients at risk of sexually"}, 
{"Row" : 20, "Column" : 1, "Text" : "transmitted infections should be assessed for treatment."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "[DI] for 5 days"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "intravaginally qhs ($) [H,O] for 7 days"}, 
{"Row" : 35, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Bacterial Vaginosis"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date article: Bacterial vaginosis: Clinical manifestations and diagnosis"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date article: Bacterial Vaginosis: Treatment"}, 
{"Row" : 43, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID2 GMENU ABX VANCO + MRSA NARES INFORMATION", "DisplayText" : "Information on Vancomycin IV New Starts and MRSA Nares Testing" , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "MRSA nares screening will be ordered on all new IV Vancomycin starts."}, 
{"Row" :6, "Column" : 1, "Text" : "MRSA nares may be a helpful tool in identifying patients with low risk of"}, 
{"Row" :7, "Column" : 1, "Text" : "MRSA infection in whom empiric vancomycin may not be required."}, 
{"Row" :9, "Column" : 1, "Text" : "A negative MRSA nares does not definitively rule out the presence of MRSA"}, 
{"Row" : 10, "Column" : 1, "Text" : "elsewhere and is one factor to consider in the de-escalation of vancomycin"}, 
{"Row" : 11, "Column" : 1, "Text" : "(and other anti-MRSA antimicrobials)."}, 
{"Row" : 13, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The Clinical Utility of"}, 
{"Row" : 15, "Column" : 1, "Text" : "Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule"}, 
{"Row" : 16, "Column" : 1, "Text" : "Out MRSA Pneumonia: A Diagnostic Meta-analysis With AntimicrobialStewardship"}, 
{"Row" : 17, "Column" : 1, "Text" : "Implications. Clin Infect Dis. (2018) 67(1):1-7"}, 
{"Row" : 18, "Column" : 1, "Text" : "doi: 10.1093/cid/ciy024. PMID: 29340593."}, 
{"Row" : 20, "Column" : 1, "Text" : "Jones BE, Ying J, Stevens V, et al. Empirical Anti-MRSA vs Standard Antibiotic"}, 
{"Row" : 21, "Column" : 1, "Text" : "Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia."}, 
{"Row" : 22, "Column" : 1, "Text" : "JAMA Intern Med. (2020) 180(4):552-560. doi:10.1001/jamainternmed.2019.7495"}, 
{"Row" :2, "Column" : 1, "Text" : "Information on adding MRSA nares screening with new IV Vancomycin starts: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX VIRUSES" , "Term1" : "Viruses section", "DisplayText" : "Viruses " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV MAIN PAGE", "DisplayText" : "Cytomegalovirus (CMV) Main Page", "Text" : "[click here]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "[click here]", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A", "Text" : "Hepatitis A", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B", "Text" : "Hepatitis B", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C", "Text" : "Hepatitis C", "Mnemonic" : "12"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "DisplayText" : "Bell's Palsy", "Text" : "Bell's palsy", "Mnemonic" : "14"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "DisplayText" : "HSV Encephalitis", "Text" : "Encephalitis", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Genital herpes", "Mnemonic" : "18"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)", "Text" : "Herpes Whitlow (digit or hand", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Keratitis", "Mnemonic" : "22"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "DisplayText" : "Orolabial Herpes", "Text" : "Oral lesions: Mouth,Lips (Cold sores)", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "++ VIRUSES ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Diarrhea, viral", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Hepatitis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Herpes Simplex", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "cellulitis)"}, 
{"Row" : 27, "Column" : 1, "Text" : "Last reviewed 8/2018", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "[click here]", "Mnemonic" : "28"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "[click here]", "Mnemonic" : "30"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX PARAINFLUENZA", "DisplayText" : "Parainfluenza", "Text" : "[click here]", "Mnemonic" : "32"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX RSV", "DisplayText" : "RSV", "Text" : "[click here]", "Mnemonic" : "34"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "DisplayText" : "Bell's Palsy", "Text" : "Bell's palsy", "Mnemonic" : "36"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox)", "Text" : "Varicella/Chickenpox (primary infection)", "Mnemonic" : "38"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\")", "Text" : "Zoster/Shingles (reactivation)", "Mnemonic" : "40"},
{"Row" :5, "Column" : 2, "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Influenza, Seasonal", "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Text" : "Parainfluenza", "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Text" : "Respiratory Syncytial Virus (RSV)", "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Text" : "Varicella-zoster", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ACUTE SINUSITIS" , "Term1" : "Sinusitis, acute", "DisplayText" : "Acute Sinusitis--Mild to Moderate Disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU MILD TO MOD SINUSITIS", "DisplayText" : "Mild to Moderate Sinusitis", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis", "Mnemonic" : "4"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU SEVERE SINUSITIS", "DisplayText" : "Severe Sinusitis", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be"}, 
{"Row" :7, "Column" : 1, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute"}, 
{"Row" :8, "Column" : 1, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2"}, 
{"Row" :9, "Column" : 1, "Text" : "minor symptoms."}, 
{"Row" : 10, "Column" : 1, "Text" : "Major Symptoms", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "1. Purulent anterior nasal discharge"}, 
{"Row" : 12, "Column" : 1, "Text" : "2. Purulent or discolored posterior nasal discharge"}, 
{"Row" : 13, "Column" : 1, "Text" : "3. Nasal congestion or fullness"}, 
{"Row" : 14, "Column" : 1, "Text" : "4. Facial pain or pressure"}, 
{"Row" : 15, "Column" : 1, "Text" : "5. Hyposmia or anosmia"}, 
{"Row" : 16, "Column" : 1, "Text" : "6. Fever"}, 
{"Row" : 17, "Column" : 1, "Text" : "Minor Symptoms", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "1. Headache"}, 
{"Row" : 19, "Column" : 1, "Text" : "2. Ear pain, pressure or fullness"}, 
{"Row" : 20, "Column" : 1, "Text" : "3. Halitosis"}, 
{"Row" : 21, "Column" : 1, "Text" : "4. Dental pain"}, 
{"Row" : 22, "Column" : 1, "Text" : "5. Cough"}, 
{"Row" : 23, "Column" : 1, "Text" : "6. Fatigue"}, 
{"Row" : 25, "Column" : 1, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials"}, 
{"Row" : 26, "Column" : 1, "Text" : "according to the following criteria for mild to moderate or severe bacterial"}, 
{"Row" : 27, "Column" : 1, "Text" : "sinusitis."}, 
{"Row" : 29, "Column" : 1, "Text" : "Mild to moderate bacterial sinusitis", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Symptoms persisting beyond 10 days"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection"}, 
{"Row" : 33, "Column" : 1, "Text" : "initially improving for 5-6 days then worsening with new development of fever,"}, 
{"Row" : 34, "Column" : 1, "Text" : "headache or increased nasal discharge."}, 
{"Row" : 37, "Column" : 1, "Text" : "Severe bacterial sinusitis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39"}, 
{"Row" : 39, "Column" : 1, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial"}, 
{"Row" : 40, "Column" : 1, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness."}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 49, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 52, "Column" : 1, "Text" : "manifestations and diagnosis"}
]},
{"Name" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM" , "Term1" : "Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h for 10 days ($) [DI]", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h for 10 days ($$) [DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 11, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis"}, 
{"Row" : 14, "Column" : 1, "Text" : "MMWR RR. 2016, 65 (2) 1-44"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Ehrlichia sp., Anaplasma sp."}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis"}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "DisplayText" : "Acyclovir 800 MG PO q12h ($) [R]", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "DisplayText" : "Acyclovir 800 MG PO q12h ($) [R]", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Severly Immunosuppressive Chemo-immunotherapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Purine Analogues", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Chemotherapy with purine analogues such as fludarabine, cladribine, or"}, 
{"Row" :8, "Column" : 1, "Text" : "pentostatin results in major cellular-immunodeficiency that may outlast the"}, 
{"Row" :9, "Column" : 1, "Text" : "exposure by months and enhances the risk for viral infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "Recommend antiviral prophylaxis for patients treated with purine analogues,"}, 
{"Row" : 12, "Column" : 1, "Text" : "if at least one of the following risk factors is present: "}, 
{"Row" : 13, "Column" : 1, "Text" : "a) Second-line chemotherapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "b) Treatment with corticosteroids"}, 
{"Row" : 15, "Column" : 1, "Text" : "c) CD4 cell count <50/ul"}, 
{"Row" : 16, "Column" : 1, "Text" : "d) Age >65 years"}, 
{"Row" : 17, "Column" : 1, "Text" : "e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /"}, 
{"Row" : 18, "Column" : 1, "Text" : "L (Grade III neutropenia) OR Moderate: <500 Neutrophils/L"}, 
{"Row" : 19, "Column" : 1, "Text" : "(Grade IV neutropenia)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Duration: Antiviral prophylaxis should be initiated in the first week of"}, 
{"Row" : 22, "Column" : 1, "Text" : "therapy and continued until 2 months after completion of therapy."}, 
{"Row" : 25, "Column" : 1, "Text" : "Alemtuzumab Therapy: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Alemtuzumab is a potent reactivator of latent intracellular pathogens,"}, 
{"Row" : 27, "Column" : 1, "Text" : "including CMV. Chemotherapy with alemtuzumab results in major cellular-"}, 
{"Row" : 28, "Column" : 1, "Text" : "immunodeficiency that may outlast the exposure by months and enhances the"}, 
{"Row" : 29, "Column" : 1, "Text" : "risk for viral infections. The risk of viral disease increases with the"}, 
{"Row" : 30, "Column" : 1, "Text" : "intensity and duration of functional T-cell suppression experienced with"}, 
{"Row" : 31, "Column" : 1, "Text" : "recipients of alemtuzumab."}, 
{"Row" : 32, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and"}, 
{"Row" : 34, "Column" : 1, "Text" : "continue therapy for at least 2 months after last dose or until CD4 counts"}, 
{"Row" : 35, "Column" : 1, "Text" : "are greater than or equal to 200 cells/ul, whichever is later."}, 
{"Row" : 38, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology 2018, 36:3043"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 41, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sandherr M Annals of Oncology 2006, 17:1051"}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY", "Text" : "Select for recommendations for antiviral prophylaxis", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2022-2023", "DisplayText" : "Influenza Seasonal 2022-2023", "Text" : "Seasonal Influenza Recommendations", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Mnemonic" : "8"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "DisplayText" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Text" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Prophylaxis for Influenza and Other Respiratory Viruses", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Yearly influenza vaccination with inactivated vaccine is recommended for all"}, 
{"Row" :9, "Column" : 1, "Text" : "patients receiving chemotherapy for malignancy and all family and household"}, 
{"Row" : 10, "Column" : 1, "Text" : "contacts and health care providers."}, 
{"Row" : 12, "Column" : 1, "Text" : "Optimal timing of vaccination for patients being treated for cancer is not"}, 
{"Row" : 13, "Column" : 1, "Text" : "established, but serologic responses may be best between chemotherapy cycles"}, 
{"Row" : 14, "Column" : 1, "Text" : "(greater than 7 days after the last treatment) or greater than 2 weeks"}, 
{"Row" : 15, "Column" : 1, "Text" : "before chemotherapy starts."}, 
{"Row" : 17, "Column" : 1, "Text" : "Patients with active malignant disease are at higher risk for upper"}, 
{"Row" : 18, "Column" : 1, "Text" : "respiratory infections due to influenza, parainfluenza or respiratory"}, 
{"Row" : 19, "Column" : 1, "Text" : "syncytial virus (RSV). Although response to vaccination with the attenuated"}, 
{"Row" : 20, "Column" : 1, "Text" : "influenza vaccine in patients on chemotherapy is variable, ranging"}, 
{"Row" : 21, "Column" : 1, "Text" : "from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended for"}, 
{"Row" : 22, "Column" : 1, "Text" : "patients with active malignant disease or chemotherapy, lymphoproliferative"}, 
{"Row" : 23, "Column" : 1, "Text" : "disease, or multiple myeloma. In areas and seasons where influenza is"}, 
{"Row" : 24, "Column" : 1, "Text" : "endemic, chemoprophylaxis can be considered in addition to vaccination in"}, 
{"Row" : 25, "Column" : 1, "Text" : "exposed patients with a high risk of influenza complications."}, 
{"Row" : 26, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Prophylaxis for Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Prophylaxis and monitoring for CMV reactivation is not recommended unless the"}, 
{"Row" : 31, "Column" : 1, "Text" : "patient has received an allogeneic HSCT. Usually the recommendations for"}, 
{"Row" : 32, "Column" : 1, "Text" : "surveillance and prophylaxis of CMV infections from the institution"}, 
{"Row" : 33, "Column" : 1, "Text" : "performing the HSCT will be followed."}, 
{"Row" : 34, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Prophylaxis for Chronic Hepatitis B", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Reactivation of chronic hepatitis B in patients undergoing immunosuppressive"}, 
{"Row" : 39, "Column" : 1, "Text" : "or antineoplastic treatment is a severe complication. Patients with positive"}, 
{"Row" : 40, "Column" : 1, "Text" : "HBsAg, chronic hepatitis B infection, or a previous episode of HBV"}, 
{"Row" : 41, "Column" : 1, "Text" : "reactivation who will receive immunosuppressive therapy should receive"}, 
{"Row" : 42, "Column" : 1, "Text" : "prophylaxis."}, 
{"Row" : 43, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab"}, 
{"Row" : 44, "Column" : 1, "Text" : "(Anti-CD20 antibody) therapy in patients."}, 
{"Row" : 45, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 51, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 52, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology 2018, 36:3043"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sandherr M Annals of Oncology 2006, 17: 1051"}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY" , "Term1" : "Antiviral prophylaxis in malignancy " , "Term2" : "Prophylactic antivirals in malignancy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Text" : "Solid Tumors, Acute Leukemia, or Lymphoma", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY", "Text" : "Purine analogues or Alemtuzumab", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Stem cell transplant recipients (autologous or allogeneic)", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Rituximab therapy", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Influenza and Other Respiratory Viruses", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Cytomegalovirus (CMV)", "Mnemonic" : "16"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Hepatitis B", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF VIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Viral infections reactivate in a small percentage of people with malignancy."}, 
{"Row" :5, "Column" : 1, "Text" : "Most viral infections in patients with hematologic malignancies or solid"}, 
{"Row" :6, "Column" : 1, "Text" : "tumors result from reactivation of asymptomatic latent infections,"}, 
{"Row" :7, "Column" : 1, "Text" : "predominantly of herpes viruses, including herpes simplex virus (HSV),"}, 
{"Row" :8, "Column" : 1, "Text" : "varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous"}, 
{"Row" :9, "Column" : 1, "Text" : "respiratory tract infections caused by influenza, parainfluenza"}, 
{"Row" : 10, "Column" : 1, "Text" : "or respiratory syncytial virus (RSV) are less common."}, 
{"Row" : 12, "Column" : 1, "Text" : "The main risk factor for clinically relevant reactivation is profound"}, 
{"Row" : 13, "Column" : 1, "Text" : "disruption of cellular immune response, usually due to chemotherapy."}, 
{"Row" : 14, "Column" : 1, "Text" : "The duration and severity of neutropenia are of lesser importance."}, 
{"Row" : 15, "Column" : 1, "Text" : "The risk of viral disease increases with the intensity and duration"}, 
{"Row" : 16, "Column" : 1, "Text" : "of functional T-cell suppression. Patients receiving conventionally"}, 
{"Row" : 17, "Column" : 1, "Text" : "dosed chemotherapy regimens for solid tumors experience no major"}, 
{"Row" : 18, "Column" : 1, "Text" : "T-cell suppression and do not have a higher incidence of"}, 
{"Row" : 19, "Column" : 1, "Text" : "invasive viral infections."}, 
{"Row" : 21, "Column" : 1, "Text" : "This section is organized mainly by type of malignancy.", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "There are separate sections for purine analogues (fludarabine,"}, 
{"Row" : 23, "Column" : 1, "Text" : "cladribine, pentostatin), alemtuzumab and rituximab."}, 
{"Row" : 24, "Column" : 1, "Text" : "Select below for recommended antiviral prophylaxis: "}, 
{"Row" : 31, "Column" : 1, "Text" : "This section is organized by virus.", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Select below for recommended antiviral prophylaxis: "}, 
{"Row" : 38, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 41, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sandherr M Annals of Oncology 2006, 17:1051"}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Select for Hepatitis B recommendations", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "**Stem cell transplant recipients (autologous or allogeneic)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Usually the standard prophylaxis and monitoring strategies recommended"}, 
{"Row" :6, "Column" : 1, "Text" : "by the institution performing the stem cell transplant will be"}, 
{"Row" :7, "Column" : 1, "Text" : "followed."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult Hematology-Oncology or Infectious Disease for recommendations.", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Rituximab Therapy", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B prior to initiating treatment"}, 
{"Row" : 12, "Column" : 1, "Text" : "with Rituximab."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)"}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL TYPE OF MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "DisplayText" : "Acyclovir 800 MG PO q12h ($) [R]", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B", "Text" : "Hepatitis B information page", "Mnemonic" : "6"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "DisplayText" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Text" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "**Solid Tumors**", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Solid tumors do not significantly compromise the cellular immune system."}, 
{"Row" :7, "Column" : 1, "Text" : "Therefore, patients are at low risk for opportunistic viral infections."}, 
{"Row" :8, "Column" : 1, "Text" : "Documented invasive viral infections are very rare. Coincidental"}, 
{"Row" :9, "Column" : 1, "Text" : "mucocutaneous infections by herpes simplex are easily treated and do not"}, 
{"Row" : 10, "Column" : 1, "Text" : "result in life-threatening invasive infections. Reactivation of"}, 
{"Row" : 11, "Column" : 1, "Text" : "Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed."}, 
{"Row" : 13, "Column" : 1, "Text" : "**Acute Leukemia**", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Herpes simplex virus-seronegative patients", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended"}, 
{"Row" : 16, "Column" : 1, "Text" : "In patients with acute leukemia, treatment is highly aggressive and consists"}, 
{"Row" : 17, "Column" : 1, "Text" : "of a combination of various cytotoxic agents administered in sequential"}, 
{"Row" : 18, "Column" : 1, "Text" : "cycles as induction, consolidation and maintenance therapy. Persistent, i.e."}, 
{"Row" : 19, "Column" : 1, "Text" : ">10 days and profound neutropenia (<500 neutrophils) regularly occurs and"}, 
{"Row" : 20, "Column" : 1, "Text" : "correlates with the risk of developing fever and infections. Almost all viral"}, 
{"Row" : 21, "Column" : 1, "Text" : "infections during neutropenia constitute reactivations of herpes viruses."}, 
{"Row" : 22, "Column" : 1, "Text" : "None of the available studies demonstrated an effect of antiviral prophylaxis"}, 
{"Row" : 23, "Column" : 1, "Text" : "on the initiation of antibiotic treatment, number of febrile days, duration"}, 
{"Row" : 24, "Column" : 1, "Text" : "of antibiotic treatment, and onset of opportunistic infections. Therefore, no"}, 
{"Row" : 25, "Column" : 1, "Text" : "recommendation for antiviral prophylaxis in patients with acute leukemia can"}, 
{"Row" : 26, "Column" : 1, "Text" : "be given."}, 
{"Row" : 28, "Column" : 1, "Text" : "Herpes simplex virus-seropostive patients", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Patients undergoing leukemia induction therapy should receive prophylaxis."}, 
{"Row" : 31, "Column" : 1, "Text" : "**Lymphoma**", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Rituximab is a monoclonal anti-CD-20 antibody used for treatment of"}, 
{"Row" : 34, "Column" : 1, "Text" : "lymphomas. It leads to a profound depletion of circulating B-cells. B-cells"}, 
{"Row" : 35, "Column" : 1, "Text" : "recover usually within 3-6 months after treatment. Prolonged administration"}, 
{"Row" : 36, "Column" : 1, "Text" : "of rituximab (e.g., maintenance treatment >12 months) may result in a"}, 
{"Row" : 37, "Column" : 1, "Text" : "significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-"}, 
{"Row" : 38, "Column" : 1, "Text" : "papovavirus infections have been reported with maintenance rituximab therapy,"}, 
{"Row" : 39, "Column" : 1, "Text" : "but drugs that would prevent these infections are not available. There is no"}, 
{"Row" : 40, "Column" : 1, "Text" : "substantial increase in risk of reactivation of herpes viruses (including"}, 
{"Row" : 41, "Column" : 1, "Text" : "HSV, VZV, and CMV)."}, 
{"Row" : 42, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B virus prior to initiating Rituximab"}, 
{"Row" : 43, "Column" : 1, "Text" : "therapy in patients."}, 
{"Row" : 47, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 49, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-to-Date"}, 
{"Row" : 51, "Column" : 1, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006"}
]},
{"Name" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION" , "Term1" : "Appendicitis without perforation " , "Term2" : "Non-perforated appendicitis", "DisplayText" : "Appendicitis without perforation" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "DisplayText" : "Appendicitis with perforation", "Text" : "Link to appendicitis with perforation menu", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFAZ 2GM IVPB X1 METRO 500MG IV X1", "DisplayText" : "metronidazole 500 mg IV over 30 minutes <AND> Cefazolin 2gm IVPB over 30 mins", "Text" : "Cefazolin 2 gm IV ($) [R] <AND> metronidazole 500 mg IV ($) [DI] both given", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H METRONIDAZOLE 1000MG PO Q12H", "DisplayText" : "CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H METRONIDAZOLE 1000MG PO Q12H", "DisplayText" : "CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITHOUT PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with an acutely inflamed appendix and no gangrene or perforation are"}, 
{"Row" :6, "Column" : 1, "Text" : "considered to have uncomplicated appendicitis. Patients with gangrene,"}, 
{"Row" :7, "Column" : 1, "Text" : "perforation, peritonitis, or abscess have complicated appendicitis. Treatment"}, 
{"Row" :8, "Column" : 1, "Text" : "with antibiotics is an option for patients who are unfit for surgery or refuse"}, 
{"Row" :9, "Column" : 1, "Text" : "surgery. Treatment with antibiotics should not be used routinely as an"}, 
{"Row" : 10, "Column" : 1, "Text" : "alternative to surgery."}, 
{"Row" : 12, "Column" : 1, "Text" : "Select for treatment of complicated appendicitis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment of uncomplicated appendicitis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Administer prophylaxis regimen below prior to surgery. After surgery, treat for"}, 
{"Row" : 17, "Column" : 1, "Text" : "3-5 days with one of the oral post-surgical treatment options below. For"}, 
{"Row" : 18, "Column" : 1, "Text" : "patients who will not be undergoing surgery for source control, refer to the"}, 
{"Row" : 19, "Column" : 1, "Text" : "recommendations below."}, 
{"Row" : 21, "Column" : 1, "Text" : "Surgical prophylaxis: "}, 
{"Row" : 23, "Column" : 1, "Text" : "over 30 minutes beginning 60 minutes before incision"}, 
{"Row" : 25, "Column" : 1, "Text" : "Post-post surgical treatment: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Treat for 3-5 days after surgery"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "Treatment of patients without surgical intervention", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Treat fo 10 days total"}, 
{"Row" : 35, "Column" : 1, "Text" : "Initial treatment"}, 
{"Row" : 38, "Column" : 1, "Text" : "Step down treatment after completion of initial intravenous treatment"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "CODA Collaborative, N Engl J Med, 2020, 383:1907-1919"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Appendicitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Salminen et al, JAMA, 2015, 313(23):2340-2348"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Appendicitis"}, 
{"Row" : 51, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 52, "Column" : 1, "Text" : "Up-to-Date article: Management of acute appendicitis in adults"}
]},
{"Name" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION" , "Term1" : "Appendicitis with perforation " , "Term2" : "Perforated appendicitis", "DisplayText" : "Appendicitis with perforation " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "8"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "10"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H METRONIDAZOLE 1000MG PO Q12H", "DisplayText" : "CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITH PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treat until source control or clinical improvement"}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 17, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results.", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR>"}, 
{"Row" : 29, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Appendicitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Appendicitis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date article: Management of acute appendicitis in adults"}
]},
{"Name" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "DisplayText" : "Approach to foot ulcers with infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO FOOT ULCER WITH INFECTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Whenever possible, material should be obtained for Gram stain and culture."}, 
{"Row" :6, "Column" : 1, "Text" : "Specimens from deep ulcer biopsy, aspiration, or bone biopsy are superior to"}, 
{"Row" :7, "Column" : 1, "Text" : "wound swab or drainage.Pathogen identification is especially important because"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy is often given for weeks."}, 
{"Row" : 10, "Column" : 1, "Text" : "While foot ulcers in patients with diabetes typically have many bacterial"}, 
{"Row" : 11, "Column" : 1, "Text" : "species on the surface, disease is usually caused by only one or two.When"}, 
{"Row" : 12, "Column" : 1, "Text" : "Staphylococcus aureus is present in a surface culture, it is usually a pathogen"}, 
{"Row" : 13, "Column" : 1, "Text" : "in the deeper tissues.Therapy can usually be directed against the predominant"}, 
{"Row" : 14, "Column" : 1, "Text" : "or virulent organisms found on surface cultures and need not be active against"}, 
{"Row" : 15, "Column" : 1, "Text" : "every isolate.To reduce uncertainty it is better to obtain deeper cultures."}, 
{"Row" : 17, "Column" : 1, "Text" : "Bacteria that are most likely to be responsible for invasive infection include"}, 
{"Row" : 18, "Column" : 1, "Text" : "S. aureus, streptococci, enteric gram-negative bacilli, Pseudomonas aeruginosa,"}, 
{"Row" : 19, "Column" : 1, "Text" : "and anaerobes typical of the human enteric flora.When there is no evidence"}, 
{"Row" : 20, "Column" : 1, "Text" : "that would direct therapy to any single organism, empirical therapy should be"}, 
{"Row" : 21, "Column" : 1, "Text" : "directed against these organisms."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 26, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}
]},
{"Name" : "ORZID2 GMENU APPRO INTRAVAS CATH-ASSOC INFECT", "DisplayText" : "Approach to Intravascular catheter-associated infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "DisplayText" : "Suppurative Thrombophlebitis--Empirical Therapy", "Text" : "Suppurative thrombophlebitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO INTRAVASCULAR CATHETER-ASSOCIATED INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The likelihood of colonization of an intravenous catheter increases with time,"}, 
{"Row" :6, "Column" : 1, "Text" : "increasing noticeably after 3 days. Patients whose catheters become colonized"}, 
{"Row" :7, "Column" : 1, "Text" : "may or may not develop local or systemic signs or symptoms. All types of"}, 
{"Row" :8, "Column" : 1, "Text" : "catheters are associated with risk of local and catheter-associated bacteremia."}, 
{"Row" :9, "Column" : 1, "Text" : "Since central catheters are usually used for more days than peripheral"}, 
{"Row" : 10, "Column" : 1, "Text" : "catheters, central catheters have a greater risk of catheter-associated"}, 
{"Row" : 11, "Column" : 1, "Text" : "bacteremia."}, 
{"Row" : 13, "Column" : 1, "Text" : "When catheter-related bacteremia is suspected, draw blood cultures from both the"}, 
{"Row" : 14, "Column" : 1, "Text" : "catheter and a peripheral vein. Growth rate between the two cultures may be used"}, 
{"Row" : 15, "Column" : 1, "Text" : "to determine if the source of bacteremia is likely catheter-associated. If the"}, 
{"Row" : 16, "Column" : 1, "Text" : "catheter obtained culture's time to positivity is 2 hours or more before the"}, 
{"Row" : 17, "Column" : 1, "Text" : "peripheral vein obtained culture's time to positivity, this suggests catheter-"}, 
{"Row" : 18, "Column" : 1, "Text" : "associated infection. Sample any exudate at the catheter site for gram stain and"}, 
{"Row" : 19, "Column" : 1, "Text" : "culture."}, 
{"Row" : 21, "Column" : 1, "Text" : "Suppurative thrombophlebitis presents with inflammation in and around a vein."}, 
{"Row" : 22, "Column" : 1, "Text" : "There may be local thrombosis and/or bacteremia. Cases may be life-threatening"}, 
{"Row" : 23, "Column" : 1, "Text" : "and can require surgical drainage."}, 
{"Row" : 26, "Column" : 1, "Text" : "For patients with catheter-associated bacteremia with virulent pathogens like"}, 
{"Row" : 27, "Column" : 1, "Text" : "Staphylococcus aureus, gram-negative bacilli, or candida, catheter removal is"}, 
{"Row" : 28, "Column" : 1, "Text" : "almost always necessary. For mild or moderate cases with less virulent"}, 
{"Row" : 29, "Column" : 1, "Text" : "organisms like coagulase-negative staphylococci, antimicrobial therapy is"}, 
{"Row" : 30, "Column" : 1, "Text" : "successful without catheter removal about half of the time. The decision about"}, 
{"Row" : 31, "Column" : 1, "Text" : "whether to remove the catheter depends on severity of illness, the need for the"}, 
{"Row" : 32, "Column" : 1, "Text" : "catheter, and how difficult catheter replacement would be."}, 
{"Row" : 34, "Column" : 1, "Text" : "Antimicrobial lock therapy", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "For cases in which an infected catheter is not removed, the success rate is"}, 
{"Row" : 36, "Column" : 1, "Text" : "improved when the infected catheter is filled with an antimicrobial solution"}, 
{"Row" : 37, "Column" : 1, "Text" : "during periods when the catheter is not used. Consult Infectious Diseases or"}, 
{"Row" : 38, "Column" : 1, "Text" : "Pharmacy for information."}, 
{"Row" : 40, "Column" : 1, "Text" : "In Staphylococcus aureus cases, document that bacteremia has cleared during"}, 
{"Row" : 41, "Column" : 1, "Text" : "antimicrobial therapy. Infectious Disease consultation is required for all"}, 
{"Row" : 42, "Column" : 1, "Text" : "cases of S. aureus bacteremia."}, 
{"Row" : 44, "Column" : 1, "Text" : "For a patient whose blood cultures remain positive for more than 3 days or with"}, 
{"Row" : 45, "Column" : 1, "Text" : "a catheter tunnel abscess or who has a prosthetic device, contact Infectious"}, 
{"Row" : 46, "Column" : 1, "Text" : "diseases."}, 
{"Row" : 49, "Column" : 1, "Text" : "References"}, 
{"Row" : 51, "Column" : 1, "Text" : "Gaur et al., Clinical infectious diseases 2003, 37.4"}, 
{"Row" : 52, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 53, "Column" : 1, "Text" : "Mandell chapter Sepsis, Severe Sepsis and Septic Shock"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-to-Date article: Prevention of Intravascular Catheter Associated Infection"}
]},
{"Name" : "ORZID2 GMENU APPROACH TO BRAIN ABSCESS", "DisplayText" : "Approach to Brain Abscess " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "DisplayText" : "Brain abscess resulting from contiguous or hematogenous spread of infection", "Text" : "Brain abscess from contiguous or hematogenous spread of infection", "Mnemonic" : "4"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "DisplayText" : "Post-surgical or post-traumatic brain abscess", "Text" : "Post-surgical or post-traumatic brain abscess", "Mnemonic" : "6"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "DisplayText" : "Brain Abscess with Nocardia spp.", "Text" : "Nocardia spp.", "Mnemonic" : "8"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "DisplayText" : "Brain Abscess with Pseudomonas spp.", "Text" : "Pseudomonas spp.", "Mnemonic" : "10"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "DisplayText" : "Brain Abscess with Toxoplasma gondii", "Text" : "Toxoplasma gondii", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO BRAIN ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Brain abscess is a focal infection of the brain parenchyma. Symptoms often"}, 
{"Row" :6, "Column" : 1, "Text" : "include headache, fever, altered mental status, seizures, and focal neural"}, 
{"Row" :7, "Column" : 1, "Text" : "deficits. Pathogens vary based on primary site of infection and patient's immune"}, 
{"Row" :8, "Column" : 1, "Text" : "status. Bacteria cause most infections in immunocompetent patients whereas a"}, 
{"Row" :9, "Column" : 1, "Text" : "wider array of pathogens, including fungi, cause infection in immunocompromised"}, 
{"Row" : 10, "Column" : 1, "Text" : "patients."}, 
{"Row" : 12, "Column" : 1, "Text" : "Streptococci are the most isolated pathogen, often isolated from mixed"}, 
{"Row" : 13, "Column" : 1, "Text" : "infections. Bacteroides are also commonly isolated in mixed cultures. Enteric"}, 
{"Row" : 14, "Column" : 1, "Text" : "gram-negative bacilli are typically isolated in patients with otitic foci,"}, 
{"Row" : 15, "Column" : 1, "Text" : "bacteremia, or post-neurosurgery. Staphylococcus aureus is commonly isolated in"}, 
{"Row" : 16, "Column" : 1, "Text" : "a pure culture and in patients with endocarditis or cranial trauma. Brain"}, 
{"Row" : 17, "Column" : 1, "Text" : "abscess caused by Listeria and Nocardia may occur in patients who are"}, 
{"Row" : 18, "Column" : 1, "Text" : "immunocompromised."}, 
{"Row" : 20, "Column" : 1, "Text" : "Magnetic resonance imaging (MRI) should be obtained in all patients with"}, 
{"Row" : 21, "Column" : 1, "Text" : "suspected brain abscess for diagnosis and determining number of lesions. Prior"}, 
{"Row" : 22, "Column" : 1, "Text" : "to beginning antimicrobial therapy, when possible, computed topographic (CT) -"}, 
{"Row" : 23, "Column" : 1, "Text" : "guided aspiration or surgery should be performed to obtain abscess material for"}, 
{"Row" : 24, "Column" : 1, "Text" : "determination of infectious pathogen."}, 
{"Row" : 26, "Column" : 1, "Text" : "Solitary brain abscesses usually result from the spread of focal ear, sinus, or"}, 
{"Row" : 27, "Column" : 1, "Text" : "dental infection (contiguous source). Cases with multiple abscesses often result"}, 
{"Row" : 28, "Column" : 1, "Text" : "from hematogenous spread from infections such as endocarditis, abdominal"}, 
{"Row" : 29, "Column" : 1, "Text" : "infection, or lung abscess."}, 
{"Row" : 31, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Empiric Treatment After Obtaining Abscess Sample, When Possible", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Treatment Based on Isolated Pathogen", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "When infectious organism is identified, adjust antimicrobials to optimize"}, 
{"Row" : 39, "Column" : 1, "Text" : "therapy"}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Brain Abscess"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Brain Abscess"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of"}, 
{"Row" : 52, "Column" : 1, "Text" : "brain abscess"}
]},
{"Name" : "ORZID2 GMENU BABESIA SPP." , "Term1" : "Babesia infections, general", "DisplayText" : "Babesia species " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 500 THEN 250 Q24H ATOVAQUONE 750 Q12H", "Text" : "Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO q24h ($) [M] for 6", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 500MG IV Q24H ATOVA 750MG PO Q12H", "DisplayText" : "AZITHRO 500MG IV Q24H ATOVA 750MG PO Q12H", "Text" : "Azithromycin 500 IV q24h ($) [M] <AND> atovaquone 750 mg PO q12h ($) [M]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "BABESIA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6"}, 
{"Row" :9, "Column" : 1, "Text" : "weeks including 2 weeks after babesia are no longer detected in blood smear."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "days <AND> atovaquone 750 mg PO q12h ($) [M] for 7 days"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "*Consult Infectious Diseases, requires NF consult for quinine."}, 
{"Row" : 17, "Column" : 1, "Text" : "Clindamycin 600 mg PO q8h <AND> quinine 650 mg PO q8h"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 23, "Column" : 1, "Text" : "*Consult Infectious diseases, requires NF consult for quinine."}, 
{"Row" : 24, "Column" : 1, "Text" : "Clindamycin 600mg IV q6h <AND> quinine 650 mg PO q8h"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Babesia Species"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Babesiosis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Babesiosis: Treatment and prevention"}, 
{"Row" : 31, "Column" : 1, "Text" : "Vannier et al. N Engl J Med. 2012 (366)2397-407"}
]},
{"Name" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO" , "Term1" : "Gram-positive bacilli meningitis " , "Term2" : "Gram-positive coccobacilli meningitis " , "Term3" : "Meningitis with gram-positive bacilli/coccobacilli", "DisplayText" : "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID GENT 2MG/KG IV ONCE THEN 1.7MG/KG IV Q8H", "DisplayText" : "Gentamicin 2 mg/kg iv once then 1.7 mg/kg iv q8h", "Text" : "Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "DisplayText" : "Trimeth/sulfa 5-25 mg/kg iv q6h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH GRAM-POSITIVE BACILLI/COCCOBACILLI SUGGESTING LISTERI", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "MONOCYTOGENES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :8, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :9, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" : 10, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 11, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 13, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 18, "Column" : 1, "Text" : "< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 30, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 32, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 34, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 35, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA" , "Term1" : "Meningitis associated with trauma or nosocomial infection " , "Term2" : "Trauma or nosocomial infection associated meningitis", "DisplayText" : "Bacterial meningitis associated with trauma or nosocomial infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2gm IV q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R] for 10-14", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R] for", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS ASSOCIATED WITH TRAUMA OR NOSOCOMIAL INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Neurosurgery and Infectious Diseases", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Removal of Infected Shunt, Drain, and Other Hardware is Required for Source", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Control", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment duration is typically 10-14 days depending on infection type,"}, 
{"Row" : 19, "Column" : 1, "Text" : "organism, severity, and source control.A shorter duration may be used in"}, 
{"Row" : 20, "Column" : 1, "Text" : "infections caused by P. acnes, coagulase-negative staphylococci, diptheroids,"}, 
{"Row" : 21, "Column" : 1, "Text" : "and infections with minimal CSF abnormalities."}, 
{"Row" : 23, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 26, "Column" : 1, "Text" : "days"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 31, "Column" : 1, "Text" : "10-14 days"}, 
{"Row" : 32, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 38, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 39, "Column" : 1, "Text" : "Tunkel et al., Clinical Infectious Diseases, 2017, 64(6)e34-e65"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 41, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 43, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 44, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS" , "Term1" : "Escherichia coli meningitis " , "Term2" : "Meningitis with E. coli, Pseudomonas or other organism " , "Term3" : "Meningitis with Escherichia coli " , "Term4" : "Meningitis withpseudomonas " , "Term5" : "Meningitis, other organism " , "Term6" : "Pseudomonas meningitis", "DisplayText" : "Bacterial meningitis with E. Coli, Pseudomonas, or other organism " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH E. COLI, PSEUDOMONAS, OR ANOTHER ORGANISM", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment is complicated and non-standardized. Consult Infectious Diseases to"}, 
{"Row" :6, "Column" : 1, "Text" : "assist in treatment in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 13, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 14, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 15, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 17, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 18, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING GNB" , "Term1" : "Gram-negative bacilli meningitis " , "Term2" : "Meningitis with gram-negative bacilli", "DisplayText" : "Bacterial meningitis with Gram negative bacilli " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H GENT 2MG/KG X1 1.7MG/KG IV Q8H", "DisplayText" : "CEFEPIME 2GM IV Q8H GENT 2MG/KG X1 1.7MG/KG IV Q8H", "Text" : "Cefepime 2gm IV q8h ($$) [R] <AND> gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH GRAM-NEGATIVE BACILLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 17, "Column" : 1, "Text" : "q8h ($) [R,O]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Gram-negative Bacilli"}, 
{"Row" : 29, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 31, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 33, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 34, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING" , "Term1" : "Gram-negative diplococci meningitis " , "Term2" : "Meningitis with gram-negative diplococci", "DisplayText" : "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH GRAM-NEGATIVE DIPLOCOCCI SUGGESTING NEISSERIA", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "MENINGITIDIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :8, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :9, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" : 10, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 11, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 13, "Column" : 1, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be"}, 
{"Row" : 14, "Column" : 1, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for"}, 
{"Row" : 15, "Column" : 1, "Text" : "advice and assistance."}, 
{"Row" : 17, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 32, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 34, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 36, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 37, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO" , "Term1" : "Gram-positive diplococci meningitis " , "Term2" : "Meningitis with gram-positive diplococci", "DisplayText" : "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IVPB Q6H", "DisplayText" : "Dexamethasone 10 MG IV q6h", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH GRAM-POSITIVE DIPLOCOCCI SUGGESTING STREPTOCOCCUS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "PNEUMONIAE", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :8, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :9, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" : 10, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 11, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 13, "Column" : 1, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all"}, 
{"Row" : 15, "Column" : 1, "Text" : "community acquired cases that might be associated with S. pneumoniae."}, 
{"Row" : 16, "Column" : 1, "Text" : "Dexamethasone must be given before (1 to 20 minutes) with antimicrobials."}, 
{"Row" : 18, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Step 1 of Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Step 2 of Treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical Antimicrobials", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 31, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 37, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 39, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 41, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 42, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES" , "Term1" : "Listeria monocytogenes meningitis " , "Term2" : "Meningitis with Listeria monocytogenes", "DisplayText" : "Bacterial meningitis with L. monocytogenes" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] for 21 days", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID GENT 2MG/KG IV ONCE THEN 1.7MG/KG IV Q8H", "DisplayText" : "Gentamicin 2 mg/kg iv once then 1.7 mg/kg iv q8h", "Text" : "Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O] for 7 days", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "DisplayText" : "Trimeth/sulfa 5-25 mg/kg iv q6h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH L. MONOCYTOGENES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for a total duration of 21 days. If gentamicin is added for synergy, treat"}, 
{"Row" : 16, "Column" : 1, "Text" : "for at least 1 week. May be extended for up to 3 weeks in those who are poor"}, 
{"Row" : 17, "Column" : 1, "Text" : "responders and do not have signs of toxicity."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 22, "Column" : 1, "Text" : "< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Listeria monocytogenes"}, 
{"Row" : 35, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 37, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 39, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 40, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS" , "Term1" : "Meningitis with Neisseria meningitidis " , "Term2" : "Neisseria meningitidis meningitis", "DisplayText" : "Bacterial meningitis with N. meningitidis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Penicillin MIC <0.1 mcg/mL: Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Penicillin MIC 0.1-1.0 mcg/mL: Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH N. MENINGITIDIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Meningococcal disease prophylaxis should be given to close contacts. Contact"}, 
{"Row" : 13, "Column" : 1, "Text" : "Infectious Diseases/Epidemiology for advice and assistance."}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for a total duration of 7 days."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred treatment: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Neisseria meningitidis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 37, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 39, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 40, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE" , "Term1" : "Meningitis with Streptococcus pneumoniae " , "Term2" : "Streptococcus pneumoniae meningitis", "DisplayText" : "Bacterial meningitis with S. pneumoniae " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IVPB Q6H", "DisplayText" : "Dexamethasone 10 MG IV q6h", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "10"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "12"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "14"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R]", "Mnemonic" : "16"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 52, "Column" : 1, "Item" : "PSJZID RIFAMPIN 600MG PO Q24H", "DisplayText" : "Rifampin 600 mg PO Q24h ($) [DI,O]", "Text" : "< ADD > Rifampin 600 mg PO q24h to above ($) [DI,O]", "Mnemonic" : "20"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID RIFAMPIN 600MG IV Q24H", "DisplayText" : "Rifampin 600 mg IV q24h to above ($$$$) [DI,O]", "Text" : "< ADD > Rifampin 600 mg IV q24h to above ($$$$) [DI,O]", "Mnemonic" : "22"},
{"Row" : 57, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "24"},
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOXACIN 400MG IV Q24H VANCO IV Q12H", "DisplayText" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS WITH S. PNEUMONIAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all"}, 
{"Row" : 14, "Column" : 1, "Text" : "community acquired cases that might be associated with S. pneumoniae."}, 
{"Row" : 15, "Column" : 1, "Text" : "Dexamethasone must be given before (1 to 20 minutes) with antimicrobials."}, 
{"Row" : 17, "Column" : 1, "Text" : "If Initiating Therapy, Give: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Note: Antimicrobials depend on S. pneumoniae MIC results. In most cases results"}, 
{"Row" : 23, "Column" : 1, "Text" : "will usually be known only after 2 or 3 days of therapy."}, 
{"Row" : 25, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Treat for a total duration of 10-14 days."}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment if Penicillin MIC < or = 0.1 mcg/mL", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC < or = 0.5", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "mcg/mL", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC > 0.5 mcg/mL", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Treat as listed below, and obtain another CSF specimen in 24 to 48 hours."}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Ceftriaxone MIC < 2 mcg/mL"}, 
{"Row" : 51, "Column" : 1, "Text" : "Ceftriaxone MIC >/= 2 mcg/mL"}, 
{"Row" : 53, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 56, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 59, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "References: "}, 
{"Row" : 63, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 64, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 65, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Streptococcus pneumoniae"}, 
{"Row" : 66, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 67, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 68, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 69, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 70, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 71, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES" , "Term1" : "Meningitis without gram stain results", "DisplayText" : "Bacterial meningitis without Gram stain results " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IVPB Q6H", "DisplayText" : "Dexamethasone 10 MG IV q6h", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN+CEFTRIAX+VANCOMYCIN", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M] <AND>", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M] <AND>", "Mnemonic" : "12"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "14"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOX IV Q24H VANCO IV Q12H TMP/SULFA IV Q6H", "DisplayText" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15mg/kg q12h ($) [R]", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15mg/kg q12h ($) [R]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,"}, 
{"Row" :6, "Column" : 1, "Text" : "antimicrobials should be initiated as soon as possible. Two blood cultures"}, 
{"Row" :7, "Column" : 1, "Text" : "should be drawn. Lumbar puncture (LP) should be performed in nearly all patients"}, 
{"Row" :8, "Column" : 1, "Text" : "to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining"}, 
{"Row" :9, "Column" : 1, "Text" : "infectious organism/susceptibility. Adjust antimicrobial regimen to optimize"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy and treatment duration based on pathogen once isolated."}, 
{"Row" : 12, "Column" : 1, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all"}, 
{"Row" : 14, "Column" : 1, "Text" : "community acquired cases that might be associated with S. pneumoniae."}, 
{"Row" : 15, "Column" : 1, "Text" : "Dexamethasone must be given before (1 to 20 minutes) with antimicrobials."}, 
{"Row" : 17, "Column" : 1, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be"}, 
{"Row" : 18, "Column" : 1, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for"}, 
{"Row" : 19, "Column" : 1, "Text" : "advice and assistance."}, 
{"Row" : 21, "Column" : 1, "Text" : "Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Step 1 of Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "(Discontinue if isolated pathogen is not S. pneumoniae)"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Step 2 of Treatment, Select One of the Following: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Any Other Condition Associated with Impaired Cellular Immunity.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 42, "Column" : 1, "Text" : "vancomycin 15mg/kg q12h ($) [R]"}, 
{"Row" : 44, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 47, "Column" : 1, "Text" : "<AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]"}, 
{"Row" : 48, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Mandell chapter: Acute meningitis"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Age > 50 years"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Meningitis, Age 1 mo to 50 years"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain"}, 
{"Row" : 56, "Column" : 1, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84"}, 
{"Row" : 57, "Column" : 1, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial"}, 
{"Row" : 58, "Column" : 1, "Text" : "meningitis in adults"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific"}, 
{"Row" : 60, "Column" : 1, "Text" : "pathogens in adults"}, 
{"Row" : 61, "Column" : 1, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62"}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP." , "Term1" : "Candidemia " , "Term2" : "Fungemia associated with Candida spp.", "DisplayText" : "Bacteremia associated with Candida spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "DisplayText" : "Micafungin 100 mg IV q24h", "Text" : "Micafungin 100 mg IV q24h ($$$) [DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "FUNGEMIA ASSOCIATED WITH CANDIDA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases. Antifungal treatment is indicated for all cases of"}, 
{"Row" :6, "Column" : 1, "Text" : "candidemia. Treat until 14 days after the last positive blood culture."}, 
{"Row" :8, "Column" : 1, "Text" : "Most Candida can be treated with fluconazole. If the patient is critically ill,"}, 
{"Row" :9, "Column" : 1, "Text" : "if the patient has recently taken an azole antifungal, or if Candida krusei or"}, 
{"Row" : 10, "Column" : 1, "Text" : "C. glabrata are present, micafungin should be used initially."}, 
{"Row" : 12, "Column" : 1, "Text" : "If the patient has substantial renal disease, but is not dialysis-dependent,"}, 
{"Row" : 13, "Column" : 1, "Text" : "consider micafungin. Call Infectious Diseases for advice."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment for Candida albicans, Candida parapsilosis and", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Candida tropicalis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients who cannot take oral medication"}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment for Candida glabrata and Candida krusei", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References"}, 
{"Row" : 28, "Column" : 1, "Text" : "Andes et al, Clinical Infectious Diseases 2012, 54.8"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 30, "Column" : 1, "Text" : "Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Candidiasis"}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH" , "Term1" : "Coagulase-negative Staphylococci (CNS) bacteremia", "DisplayText" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "DisplayText" : "Bacteremia associated with Staphylococcus lugdunensis", "Text" : "Bacteremia associated with Staphylococcus lugdunensis", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA ASSOCIATED WITH COAGULASE-NEGATIVE STAPHYLOCOCCI (CNS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S."}, 
{"Row" :6, "Column" : 1, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S."}, 
{"Row" :7, "Column" : 1, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S."}, 
{"Row" :8, "Column" : 1, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S."}, 
{"Row" :9, "Column" : 1, "Text" : "warneri and S. xylosus."}, 
{"Row" : 11, "Column" : 1, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer"}, 
{"Row" : 12, "Column" : 1, "Text" : "to Bacteremia Associated S. lugdunensis page for treatment."}, 
{"Row" : 15, "Column" : 1, "Text" : "CNS are present in 50% of positive blood cultures, and 90% are contaminants. In"}, 
{"Row" : 16, "Column" : 1, "Text" : "a patient without signs or symptoms of infection, a single positive blood"}, 
{"Row" : 17, "Column" : 1, "Text" : "culture for CNS often represents contamination and not infection. CNS are more"}, 
{"Row" : 18, "Column" : 1, "Text" : "likely to be pathogens in patients with a prosthetic device. Contact Infectious"}, 
{"Row" : 19, "Column" : 1, "Text" : "Diseases for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "For patients with catheter-related bacteremia or those with suspected"}, 
{"Row" : 22, "Column" : 1, "Text" : "endocarditis, please return to the main menu and proceed to the appropriate"}, 
{"Row" : 23, "Column" : 1, "Text" : "advice page."}, 
{"Row" : 25, "Column" : 1, "Text" : "Most isolates are methicillin-resistant. Use vancomycin empirically, but switch"}, 
{"Row" : 26, "Column" : 1, "Text" : "to the more effective beta-lactam antimicrobials if the isolate is susceptible."}, 
{"Row" : 28, "Column" : 1, "Text" : "Empirical treatment of coagulase-negative staphylococci", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Treatment for methicillin-susceptible staphylococci", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 37, "Column" : 1, "Text" : "Treatment for methicillin-resistant staphylococci or for patients with severe", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "penicillin allergy", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "References"}, 
{"Row" : 44, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus, Coagulase-negative species"}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA LISTERIA" , "Term1" : "Listeria monocytogenes bacteremia", "DisplayText" : "Bacteremia associated with Listeria monocytogenes " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "DisplayText" : "Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA ASSOCIATED WITH LISTERIA MONOCYTOGENES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment of listeria infection", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "For immunocompromised patients and for patients with meningitis or endocarditis", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 14, "Column" : 1, "Text" : "For patients with penicillin allergy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "References"}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Listeria Monocytogenes"}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Listeria monocytogenes"}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA S. AUREUS" , "Term1" : "Staphylococcus aureus bacteremia", "DisplayText" : "Bacteremia associated with Staphylococcus aureus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "DisplayText" : "Cardiovascular", "Text" : "CARDIOVASCULAR", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS AUREUS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. Empirical therapy should cover"}, 
{"Row" :6, "Column" : 1, "Text" : "methicillin-resistant Staphylococcus aureus. If an isolate susceptible to"}, 
{"Row" :7, "Column" : 1, "Text" : "beta-lactams is identified, use one of these drugs because they are more"}, 
{"Row" :8, "Column" : 1, "Text" : "effective."}, 
{"Row" : 10, "Column" : 1, "Text" : "If there is an easily removable or drainable focus (e.g. infected intravenous"}, 
{"Row" : 11, "Column" : 1, "Text" : "catheter, minor abscess, urinary cystitis, or mild to moderate pneumonia), and"}, 
{"Row" : 12, "Column" : 1, "Text" : "this focus has been treated, give parenteral antimicrobials for 2 weeks."}, 
{"Row" : 13, "Column" : 1, "Text" : "Consider echocardiogram to assess for associated endocarditis, which would"}, 
{"Row" : 14, "Column" : 1, "Text" : "require 4-6 weeks of therapy. Consult Cardiology or Infectious Diseases for more"}, 
{"Row" : 15, "Column" : 1, "Text" : "information."}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to cardiovascular section for suspected endocarditis"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment for methicillin-susceptible staphylococci", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment for methicillin-resistant staphylococci", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Antimicrobial Therapy"}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS" , "Term1" : "Staphylococcus lugdunensis bacteremia", "DisplayText" : "Bacteremia associated with Staphylococcus lugdunensis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "DisplayText" : "Cardiovascular", "Text" : "CARDIOVASCULAR", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS LUGDUNENSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Severity of S. lugdenensis infections vary from moderate to severe."}, 
{"Row" :6, "Column" : 1, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin"}, 
{"Row" :7, "Column" : 1, "Text" : "resistance is uncommon. Since optimal duration of therapy has not been"}, 
{"Row" :8, "Column" : 1, "Text" : "established, treat until patient is clearly improved and has been free of"}, 
{"Row" :9, "Column" : 1, "Text" : "symptoms or signs of S. lugdunensis infection for several days."}, 
{"Row" : 11, "Column" : 1, "Text" : "Refer to cardiovascular section for suspected endocarditis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment for methicillin-susceptible S. lugdunensis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for methicillin-resistant S. lugdunensis", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative"}, 
{"Row" : 26, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-To-Date article: Staphylococcus lugdunensis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus lugdunensis"}
]},
{"Name" : "ORZID2 GMENU BED BUGS (HEMIPTERA)" , "Term1" : "Bed bugs " , "Term2" : "Hemiptera", "DisplayText" : "Bed Bugs (Hemiptera)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSJZID TRIAMCINOLONE 0.1% CRM TOP BID PRN", "DisplayText" : "Triamcinolone 0.1% cream topical bid prn", "Text" : "Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID HYDROXYZINE PAMOATE 25MG PO TID", "DisplayText" : "Hydroxyzine pamoate 25mg po tid then 25mg po tid prn (Var)", "Text" : "Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "BED BUGS (HEMIPTERA)"}, 
{"Row" :4, "Column" : 1, "Text" : "Antimicrobial treatment is not indicated.Treat itching with topical"}, 
{"Row" :5, "Column" : 1, "Text" : "corticosteroids or systemic antihistamines."}, 
{"Row" : 10, "Column" : 1, "Text" : "TID PRN for itching ($) [H]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS" , "Term1" : "Eikenella corrodens, bite wound", "DisplayText" : "Bite wounds with Eikenella corrodens" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100MG PO Q12H", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Bites"}, 
{"Row" : 16, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}
]},
{"Name" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA" , "Term1" : "Pasteurella multocida bite wounds", "DisplayText" : "Bite wounds with Pasteurella multocida" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100mg PO q12h ($) [DI] < OR >", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100mg IV q12h ($$) [DI]", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA"}, 
{"Row" :4, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Sanford keyword: Bites"}, 
{"Row" : 15, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 16, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}
]},
{"Name" : "ORZID2 GMENU BITE WNDS S. AUREUS" , "Term1" : "Methicillin-resistant Staphylococcus aureus bite wounds " , "Term2" : "MRSA bite wounds " , "Term3" : "MSSA bite wounds", "DisplayText" : "Bite wounds with Staphylococcus aureus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]OR >", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Mnemonic" : "16"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]< OR >", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH STAPHYLOCOCCUS AUREUS"}, 
{"Row" :5, "Column" : 1, "Text" : "_________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Methicillin-SUSCEPTIBLE S. aureus", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Methicillin-RESISTANT S. aureus", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Bites"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI" , "Term1" : "Streptococcal bite wounds", "DisplayText" : "Bite wounds with Streptococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 MU IV q4h ($) [R]< OR >", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH STREPTOCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for penicillin allergic patients: "}, 
{"Row" : 16, "Column" : 1, "Text" : "References"}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Bites"}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :7, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU BITE WOUNDS" , "Term1" : "Bite wounds " , "Term2" : "Wound, bite", "DisplayText" : "Bite wounds " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Mnemonic" : "4"},
{"Row" : 49, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]< OR >", "Mnemonic" : "6"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 53, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400MG PO Q24H", "DisplayText" : "Moxifloxacin 400mg po q24h (Var)", "Text" : "Moxifloxacin 400mg po q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 58, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "DisplayText" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Mnemonic" : "16"},
{"Row" : 61, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "DisplayText" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite wounds with Pasteurella multocida", "Text" : "Bite wounds with Pasteurella multocida", "Mnemonic" : "20"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite wounds with Eikenella corrodens", "Text" : "Bite wounds with Eikenella corrodens", "Mnemonic" : "22"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "DisplayText" : "Bite wounds with Staphylococcus aureus", "Text" : "Bite wounds with Staphylococcus aureus", "Mnemonic" : "24"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite wounds with Streptococci", "Text" : "Bite wounds with Streptococci", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS"}, 
{"Row" :5, "Column" : 1, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried"}, 
{"Row" :6, "Column" : 1, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually"}, 
{"Row" :7, "Column" : 1, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites,"}, 
{"Row" :8, "Column" : 1, "Text" : "streptococci and staphylococci."}, 
{"Row" : 10, "Column" : 1, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic"}, 
{"Row" : 11, "Column" : 1, "Text" : "and debride non-viable tissue."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult orthopedic surgery for all bite wounds involving the hand."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antibiotic Prophylaxis Indications: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,"}, 
{"Row" : 16, "Column" : 1, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,"}, 
{"Row" : 17, "Column" : 1, "Text" : "Advanced liver disease"}, 
{"Row" : 19, "Column" : 1, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients"}, 
{"Row" : 20, "Column" : 1, "Text" : "with superficial wounds with no puncture that do not involve the face/"}, 
{"Row" : 21, "Column" : 1, "Text" : "genitals/hands is not recommended."}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrobial Treatment: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empiric treatment for suspected or established infection following bite wound."}, 
{"Row" : 25, "Column" : 1, "Text" : "In these cases, therapy should be directed against pathogen identified"}, 
{"Row" : 26, "Column" : 1, "Text" : "by Gram stain and culture whenever possible."}, 
{"Row" : 28, "Column" : 1, "Text" : "Rabies Prophylaxis: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases."}, 
{"Row" : 30, "Column" : 1, "Text" : "Contact infectious diseases for assistance."}, 
{"Row" : 32, "Column" : 1, "Text" : "Consider tetanus immunization status: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus."}, 
{"Row" : 34, "Column" : 1, "Text" : "If immunization is lacking, and: "}, 
{"Row" : 35, "Column" : 1, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td"}, 
{"Row" : 36, "Column" : 1, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)"}, 
{"Row" : 38, "Column" : 1, "Text" : "Select below for Tetanus vaccination information page: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection."}, 
{"Row" : 43, "Column" : 1, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat"}, 
{"Row" : 44, "Column" : 1, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,"}, 
{"Row" : 45, "Column" : 1, "Text" : "treat 14 to 21 days."}, 
{"Row" : 47, "Column" : 1, "Text" : "Prophylaxis: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Duration 3 to 5 days: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy: "}, 
{"Row" : 55, "Column" : 1, "Text" : "Empiric treatment for suspected or estabished infection: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Duration 7 to 14 days: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy: ", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Pathogen directed bite wound therapy: ", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 70, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 71, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 72, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 73, "Column" : 1, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85"}
]},
{"Name" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)" , "Term1" : "Body lice " , "Term2" : "Lice, body " , "Term3" : "Pediculosis corporis", "DisplayText" : "Body Lice (Pediculosis Corporis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "DisplayText" : "Permethrin 1% lotion to the affected area for 10 minutes", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "BODY LICE (PEDICULOSIS CORPORIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "Body lice proliferate in places where crowding of persons with poor hygiene is"}, 
{"Row" :6, "Column" : 1, "Text" : "common, especially homeless persons."}, 
{"Row" :7, "Column" : 1, "Text" : "Infested clothing and bed linen should be heat washed or discarded."}, 
{"Row" :9, "Column" : 1, "Text" : "Itching is the most common symptom, but some patients present only with"}, 
{"Row" : 10, "Column" : 1, "Text" : "excoriations and inflammation on the neck and trunk."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "A repeat application may be used if live lice are seen 7-10 days after"}, 
{"Row" : 14, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 17, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT" , "Term1" : "Brain abscess from contiguous or hematogenous spread " , "Term2" : "Contiguous or hematogenous spread brain abscess", "DisplayText" : "Brain abscess resulting from contiguous or hematogenous spread of infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H", "DisplayText" : "CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "8"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "10"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO500MGIVQ8H VANCO15MG/KGIVQ12H", "DisplayText" : "CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "14"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "BRAIN ABSCESS FROM CONTIGUOUS OR HEMATOGENOUS SPREAD OF INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic"}, 
{"Row" :6, "Column" : 1, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess"}, 
{"Row" :7, "Column" : 1, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen"}, 
{"Row" :8, "Column" : 1, "Text" : "to optimize therapy and treatment duration to optimize therapy based on pathogen"}, 
{"Row" :9, "Column" : 1, "Text" : "once isolated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Broad spectrum empiric antimicrobials are indicated initially for brain abscess."}, 
{"Row" : 12, "Column" : 1, "Text" : "Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more"}, 
{"Row" : 13, "Column" : 1, "Text" : "effective than vancomycin for susceptible Staphylococci. If Staphylococcus is"}, 
{"Row" : 14, "Column" : 1, "Text" : "isolated, once methicillin- resistance is ruled out, switch to an"}, 
{"Row" : 15, "Column" : 1, "Text" : "anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen"}, 
{"Row" : 16, "Column" : 1, "Text" : "in post-surgical patients, and those who are known to be colonized with"}, 
{"Row" : 17, "Column" : 1, "Text" : "Pseudomonas."}, 
{"Row" : 19, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Duration is typically 6-8 weeks, with the shorter duration for those with"}, 
{"Row" : 23, "Column" : 1, "Text" : "cerebritis only or drained abscess, longer for undrained or encapsulated"}, 
{"Row" : 24, "Column" : 1, "Text" : "abscesses, multiple or loculated abscesses, abscess in an immunocompromised"}, 
{"Row" : 25, "Column" : 1, "Text" : "host."}, 
{"Row" : 27, "Column" : 1, "Text" : "Empiric Treatment for Solitary Brain Abscess from Contiguous Source", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Empiric Treatment for Solitary Brain Abscess from Unknown Source, From", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Hematogenous Spread, Multiple Brain Abscesses or History of MRSA Infection or", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Colonization", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Preferred if Pseudomonas is not likely: "}, 
{"Row" : 40, "Column" : 1, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 42, "Column" : 1, "Text" : "Preferred if Pseudomonas is likely: "}, 
{"Row" : 44, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 49, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Brain Abscess"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Brain Abscess"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess"}, 
{"Row" : 57, "Column" : 1, "Text" : "Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of"}, 
{"Row" : 58, "Column" : 1, "Text" : "brain abscess"}
]},
{"Name" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP" , "Term1" : "Brain abscess with Nocardia spp." , "Term2" : "Nocardia spp. brain abscess", "DisplayText" : "Brain Abscess with Nocardia spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX TMP-SMZ 15-75MG/KG IV Q8H IMIPENEM 1GM IV Q8H", "DisplayText" : "TMP-SMZ 15-75MG/KG IV Q8H IMIPENEM 1GM IV Q8H", "Text" : "Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX TMP-SMZ 25-75MG/KG IV Q8H CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>", "Text" : "Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID AMIKACIN 7.5 MG/KG IV Q12H", "DisplayText" : "Amikacin 7.5 mg/kg q12h ($$)", "Text" : "< ADD > Amikacin 7.5 mg/kg q12h ($$)", "Mnemonic" : "8"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LINEZOLID 600MG IV Q12H IMIPENEM 1GM IV Q8H", "DisplayText" : "LINEZOLID 600MG IV Q12H IMIPENEM 1GM IV Q8H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O] < AND > imipenem 1 gm q8h ($$) [R]", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 2DS PO Q12H", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 2 DS PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100mg q12h($) [DI]", "Mnemonic" : "14"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "BRAIN ABSCESS WITH NOCARDIA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Magnetic resonance imaging (MRI) should be obtained in all patients with"}, 
{"Row" :6, "Column" : 1, "Text" : "suspected brain abscess for diagnosis and determining number of lesions. Prior"}, 
{"Row" :7, "Column" : 1, "Text" : "to beginning antimicrobial therapy, when possible, computed topographic (CT) -"}, 
{"Row" :8, "Column" : 1, "Text" : "guided aspiration or surgery should be performed to obtain abscess material for"}, 
{"Row" :9, "Column" : 1, "Text" : "determination of infectious pathogen."}, 
{"Row" : 11, "Column" : 1, "Text" : "Nocardia brain abscesses typically occur in immunocompromised patients and is"}, 
{"Row" : 12, "Column" : 1, "Text" : "often concomitant with disseminated or pulmonary infection. May occur with"}, 
{"Row" : 13, "Column" : 1, "Text" : "meningitis and/or ventriculitis."}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat with IV therapy for total duration of 3-6 weeks in immunocompetent and 6"}, 
{"Row" : 19, "Column" : 1, "Text" : "weeks in immunocompromised patients. Switch to oral antimicrobials after"}, 
{"Row" : 20, "Column" : 1, "Text" : "completing IV therapy and treat for an additional 3 months or more (longer for"}, 
{"Row" : 21, "Column" : 1, "Text" : "meningitis, immunocompromise or extensive disease)."}, 
{"Row" : 23, "Column" : 1, "Text" : "Initial IV Therapy", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "imipenem 1000 mg q8h ($$) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "If Nocardia isolate is susceptible to third generation cephalosporins"}, 
{"Row" : 29, "Column" : 1, "Text" : "ceftriaxone 2 gm IV q12h ($) [M]"}, 
{"Row" : 31, "Column" : 1, "Text" : "If multiorgan or rapidly progressive disease, in addition to above therapy"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 37, "Column" : 1, "Text" : "Oral Therapy, After Completing IV Therapy Above", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "For immunocompetent patients, treat with one of the below PO antimicrobials for"}, 
{"Row" : 39, "Column" : 1, "Text" : "at least 3 months after initial IV treatment. For immunocompromised patients,"}, 
{"Row" : 40, "Column" : 1, "Text" : "Treat with 2 of the below antimicrobials for at least one year."}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Brain Abscess"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Brain Abscess"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-to-Date article: Treatment of Nocardiosis"}
]},
{"Name" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC" , "Term1" : "Brain abscess, post-surgical or post-traumatic " , "Term2" : "Post-surgical or post-traumatic brain abscess", "DisplayText" : "Post-surgical or post-traumatic brain abscess " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15mg/kg IV Q12H CEFT 2GM IV Q12H", "DisplayText" : "Vancomycin 15mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "14"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "POST-SURGICAL OR POST-TRAUMATIC BRAIN ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic"}, 
{"Row" :6, "Column" : 1, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess"}, 
{"Row" :7, "Column" : 1, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen"}, 
{"Row" :8, "Column" : 1, "Text" : "to optimize therapy based on pathogen once isolated."}, 
{"Row" : 10, "Column" : 1, "Text" : "Broad spectrum empiric antimicrobials are indicated initially for brain abscess."}, 
{"Row" : 11, "Column" : 1, "Text" : "Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more"}, 
{"Row" : 12, "Column" : 1, "Text" : "effective than vancomycin for susceptible Staphylococci. If Staphylococcus is"}, 
{"Row" : 13, "Column" : 1, "Text" : "isolated, once methicillin- resistance is ruled out, switch to an"}, 
{"Row" : 14, "Column" : 1, "Text" : "anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen"}, 
{"Row" : 15, "Column" : 1, "Text" : "in post-surgical patients, and those who are known to be colonized with"}, 
{"Row" : 16, "Column" : 1, "Text" : "Pseudomonas."}, 
{"Row" : 18, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Post-Surgical Empiric Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Post Traumatic Empiric Treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred if pseudomonas is not suspected and paranasal sinuses are not"}, 
{"Row" : 30, "Column" : 1, "Text" : "involved: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Preferred if Pseudomonas is suspected and paranasal sinuses are not involved: "}, 
{"Row" : 36, "Column" : 1, "Text" : "If paranasal sinuses are involved or alternative: "}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "References: "}, 
{"Row" : 43, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 44, "Column" : 1, "Text" : "Mandell chapter: Brain Abscess"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Brain Abscess, Post-traumatic or Post-surgical"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess"}
]},
{"Name" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP." , "Term1" : "Brain abscess with Pseudomonas spp." , "Term2" : "Pseudomonas spp. brain abscess", "DisplayText" : "Brain Abscess with Pseudomonas spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime 2gm IV Q8h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BRAIN ABSCESS WITH PSEUDOMONAS SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic"}, 
{"Row" :6, "Column" : 1, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess"}, 
{"Row" :7, "Column" : 1, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen"}, 
{"Row" :8, "Column" : 1, "Text" : "to optimize therapy based on pathogen once isolated."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for a total duration of 6-8 weeks"}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Brain abscess"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date Article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" : 31, "Column" : 1, "Text" : "tract, gastrointestinal tract and central nervous system"}
]},
{"Name" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII" , "Term1" : "Brain abscess with Toxoplasma gondii " , "Term2" : "Toxoplasma gondii brain abscess", "DisplayText" : "Brain Abscess with Toxoplasma gondii" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H", "DisplayText" : "PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO x 1 then 75 mg po daily ($$$$$) [DI,O] <AND>", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETH 200MG PO SULFAD 1GM LEUCOVORIN 10MG", "DisplayText" : "Pyrimethamine 200 mg PO x 1 ($$$$$) [DI,O] then 50 mg PO QD ($$$$$)", "Text" : "Pyrimethamine 200 mg PO x 1 then 50 mg PO daily ($$$$$) [DI,O] <AND>", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 75MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H", "DisplayText" : "PYRIM 75MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 75 mg PO q24h ($$$$$) [DI,O] <AND> clindamycin 600 mg PO q6h", "Mnemonic" : "8"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 50MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H", "DisplayText" : "PYRIM 50MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 50 mg PO q24h ($$$$$) [DI,O] <AND> clindamycin 600 mg PO q6h", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "DisplayText" : "Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Mnemonic" : "12"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "BRAIN ABSCESS WITH TOXOPLASMA GONDII", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic"}, 
{"Row" :6, "Column" : 1, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess"}, 
{"Row" :7, "Column" : 1, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen"}, 
{"Row" :8, "Column" : 1, "Text" : "to optimize therapy based on pathogen once isolated."}, 
{"Row" : 10, "Column" : 1, "Text" : "Central nervous system toxoplasmosis occurs mostly in HIV-infected patients."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Continue treatment for a minimum of 6 weeks after resolution of signs/symptoms,"}, 
{"Row" : 16, "Column" : 1, "Text" : "followed by suppressive therapy until sustained immune reconstitution occurs."}, 
{"Row" : 17, "Column" : 1, "Text" : "Suppression can be discontinued if CD4 count >200 for 6 months."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Patient weight >/= 60 kg"}, 
{"Row" : 23, "Column" : 1, "Text" : "sulfadiazine 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10 to 25 mg po daily ($)"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Patient weight < 60 kg"}, 
{"Row" : 27, "Column" : 1, "Text" : "sulfadiazine 1 gm po q6h ($$) [DI,O] <AND> leucovorin 10 to 25 mg po daily ($)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Patient weight >/= 60 kg"}, 
{"Row" : 32, "Column" : 1, "Text" : "($) [H,O] <AND> leucovorin 10 to 25 mg po daily ($)"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "Patient weight < 60 kg"}, 
{"Row" : 36, "Column" : 1, "Text" : "($) [H,O] <AND> leucovorin 10 to 25 mg po daily ($)"}, 
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Brain Abscess"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Brain Abscess, Toxoplasmosis"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date article: Toxoplasmosis"}
]},
{"Name" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING" , "Term1" : "Community-acquired pneumonia (CAP), inpatient treatment setting", "DisplayText" : "CAP SEVERE treated in an ICU setting" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "DisplayText" : "Stepdown empiric treatment for CAP with oral antibiotics", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Mnemonic" : "4"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET LAB SPUTUM CULT & GRAM STAIN", "DisplayText" : "Sputum Culture and Gram Stain", "Text" : "Lab Order: Sputum Culture & Gram Stain", "Mnemonic" : "6"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET LAB BLOOD CULTURE X2", "DisplayText" : "Blood Culture x2", "Text" : "Lab order: Blood culture x2", "Mnemonic" : "8"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX PNA CEF 2GM IV AND AZITHROMYCIN 500MG IV", "Text" : "Ceftriaxone 2 gm IV q24h($) [M] <AND> azithromycin 500 mg IV once", "Mnemonic" : "10"},
{"Row" : 64, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "12"},
{"Row" : 65, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 67, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 72, "Column" : 1, "Item" : "ORZ SET ABX VANCO PNA NEW START + MRSA NARES", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV q12h (PNA) ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 78, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPERACILLIN-TAZO AND AZITHROMYCIN 500/250 IV", "DisplayText" : "PIPERACILLIN-TAZO 4.5 AND AZITH 500/250 BOTH IV", "Text" : "Piperacillin-tazobactam 4.5 gm IV Q6H ($$) [R] <AND> Azithromycin 500 mg IV", "Mnemonic" : "20"},
{"Row" : 81, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME AND AZITHROMYCIN IV", "DisplayText" : "Cefepime and Azithromycin IV for pna pseudomonas", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> Azithromycin 500 mg IV x1 on day 1,", "Mnemonic" : "22"},
{"Row" : 85, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "24"},
{"Row" : 86, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "26"},
{"Row" : 88, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Mnemonic" : "28"},
{"Row" :3, "Column" : 1, "Text" : "SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Criteria for Defining SEVERE Community-acquired Pneumonia", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Validated definition includes either one major or three or more minor criteria"}, 
{"Row" :7, "Column" : 1, "Text" : "MAJOR CRITERIA: "}, 
{"Row" :8, "Column" : 1, "Text" : "Septic shock with need for vasopressors"}, 
{"Row" :9, "Column" : 1, "Text" : "Respiratory failure requiring mechanical ventilation"}, 
{"Row" : 10, "Column" : 1, "Text" : "MINOR CRITERIA: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Respiratory rate greater than or equal to 30 breaths/minute"}, 
{"Row" : 12, "Column" : 1, "Text" : "PaO2/FiO2 ratio less than or equal to 250"}, 
{"Row" : 13, "Column" : 1, "Text" : "Multilobar infiltrates"}, 
{"Row" : 14, "Column" : 1, "Text" : "Confusion/disorientation"}, 
{"Row" : 15, "Column" : 1, "Text" : "Uremia (blood urea nitrogen level greater than 20 mg/dl)"}, 
{"Row" : 16, "Column" : 1, "Text" : "Leukopenia* (WBC less than 4,000 cells/microliter)"}, 
{"Row" : 17, "Column" : 1, "Text" : "*Due to infection alone (i.e., not chemotherapy induced)"}, 
{"Row" : 18, "Column" : 1, "Text" : "Thrombocytopenia (platelet count less than 100,000 microliters)"}, 
{"Row" : 19, "Column" : 1, "Text" : "Hypothermia (core temperature less than 36 degrees C)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Hypotension requiring aggressive fluid resuscitation"}, 
{"Row" : 22, "Column" : 1, "Text" : "Recommendation for duration of antibiotic therapy for CAP: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be"}, 
{"Row" : 24, "Column" : 1, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-"}, 
{"Row" : 25, "Column" : 1, "Text" : "associated sign of clinical instability before discontinuation"}, 
{"Row" : 26, "Column" : 1, "Text" : "of therapy."}, 
{"Row" : 27, "Column" : 1, "Text" : "Criteria for clinical stability: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Temperature less than/equal to 100 degrees F"}, 
{"Row" : 29, "Column" : 1, "Text" : "Heart rate less than/equal to 100 beats/minute"}, 
{"Row" : 30, "Column" : 1, "Text" : "Respiratory rate less than/equal to 24 breaths/minute"}, 
{"Row" : 31, "Column" : 1, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg"}, 
{"Row" : 32, "Column" : 1, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--"}, 
{"Row" : 33, "Column" : 1, "Text" : "PO2 greater than/equal to 60 mm Hg on room air"}, 
{"Row" : 34, "Column" : 1, "Text" : "Ability to maintain oral intake"}, 
{"Row" : 35, "Column" : 1, "Text" : "Normal mental status"}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment on INTENSIVE CARE UNIT (ICU)", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "(Specific therapy should be guided by culture results.)"}, 
{"Row" : 44, "Column" : 1, "Text" : "Recommend blood and lower respiratory tract specimen cultures for all patients", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "with Severe CAP.", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or"}, 
{"Row" : 52, "Column" : 1, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below"}, 
{"Row" : 54, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Prior Respiratory Isolation of P. aeruginosa in the last 12 months: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "COVER for P. aeruginosa. Obtain cultures to allow deescalation or"}, 
{"Row" : 57, "Column" : 1, "Text" : "confirmation of need for continued therapy. SEE P. aeruginosa section below"}, 
{"Row" : 59, "Column" : 1, "Text" : "Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "on day 1, then 250 mg IV Q24H for 4 days ($) [M]"}, 
{"Row" : 63, "Column" : 1, "Text" : "Alternative Standard Regimen: ", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 69, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "Prior respiratory isolation of P. aeruginosa in the last 12 months: ", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "SELECT REGIMEN BELOW: ", "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Text" : "on day 1, then 250 mg IV Q24H for 4 days ($) [M]"}, 
{"Row" : 80, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 82, "Column" : 1, "Text" : "then 250 mg IV Q24H for 4days ($) [M]"}, 
{"Row" : 84, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 90, "Column" : 1, "Text" : "References: "}, 
{"Row" : 91, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45"}, 
{"Row" : 92, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 93, "Column" : 1, "Text" : "Sanford website"}, 
{"Row" : 37, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "DisplayText" : "CAP NON-SEVERE treated in an Inpatient Ward setting " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "DisplayText" : "Stepdown empiric treatment for CAP with oral antibiotics", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Mnemonic" : "16"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM IV QD AND AZITHROMYCIN 500MG PO", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M] <AND> azithromycin 500 mg PO x1", "Mnemonic" : "18"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "20"},
{"Row" : 53, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750MG PO Q24H X5DAYS", "DisplayText" : "Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]", "Mnemonic" : "22"},
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPERACILLIN-TAZO AND AZITHROMYCIN 500/250 PO", "DisplayText" : "Piperacillin-tazo 4.5 PO q6h and azith 500/250 iv", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> Azithromycin", "Mnemonic" : "26"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME 2GM Q8H AND AZITH 500/250 PO", "DisplayText" : "Cefepime 2 gm IV Q8H ($$) [R] <AND> Azithromycin PO 500/250", "Text" : "Cefepime 2 gm IV Q8H ($$) [R] <AND> Azithromycin 500 mg PO x1 on", "Mnemonic" : "28"},
{"Row" : 69, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "30"},
{"Row" : 70, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO Q24H ($) [R,DI]", "Mnemonic" : "32"},
{"Row" :3, "Column" : 1, "Text" : "NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA TREATED IN AN INPATIENT SETTING", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Be sure of the diagnosis.Careful reviews have shown that over half of"}, 
{"Row" :6, "Column" : 1, "Text" : "people treated for community-acquired pneumonia do not in fact have"}, 
{"Row" :7, "Column" : 1, "Text" : "pneumonia.Pneumonia is likely in persons with 3 or more signs or symptoms"}, 
{"Row" :8, "Column" : 1, "Text" : "including a) new infiltrate (or, no prior film for comparison) b) new"}, 
{"Row" :9, "Column" : 1, "Text" : "crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills"}, 
{"Row" : 10, "Column" : 1, "Text" : "e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea"}, 
{"Row" : 11, "Column" : 1, "Text" : "or tachypnea, and no likely alternative explanation for the presentation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Common alternative explanations include heart failure, thromboembolic"}, 
{"Row" : 13, "Column" : 1, "Text" : "disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or"}, 
{"Row" : 14, "Column" : 1, "Text" : "tumor. Most of the latter conditions do NOT benefit from antimicrobials."}, 
{"Row" : 16, "Column" : 1, "Text" : "Recommendation for duration of antibiotic therapy for CAP: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be"}, 
{"Row" : 18, "Column" : 1, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-"}, 
{"Row" : 19, "Column" : 1, "Text" : "associated sign of clinical instability before discontinuation"}, 
{"Row" : 20, "Column" : 1, "Text" : "of therapy."}, 
{"Row" : 21, "Column" : 1, "Text" : "Criteria for clinical stability: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Temperature less than/equal to 100 degrees F"}, 
{"Row" : 23, "Column" : 1, "Text" : "Heart rate less than/equal to 100 beats/minute"}, 
{"Row" : 24, "Column" : 1, "Text" : "Respiratory rate less than/equal to 24 breaths/minute"}, 
{"Row" : 25, "Column" : 1, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg"}, 
{"Row" : 26, "Column" : 1, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--"}, 
{"Row" : 27, "Column" : 1, "Text" : "PO2 greater than/equal to 60 mm Hg on room air"}, 
{"Row" : 28, "Column" : 1, "Text" : "Ability to maintain oral intake"}, 
{"Row" : 29, "Column" : 1, "Text" : "Normal mental status"}, 
{"Row" : 30, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Inpatient, non-severe CAP (NOTE: DURATION of therapy)", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Note: These regimens may also be used to convert patients to oral medications"}, 
{"Row" : 36, "Column" : 1, "Text" : "prior to discharge."}, 
{"Row" : 38, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage"}, 
{"Row" : 40, "Column" : 1, "Text" : "positive for MRSA. (See below for prior respiratory isolation of MRSA)"}, 
{"Row" : 42, "Column" : 1, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa: ", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures"}, 
{"Row" : 44, "Column" : 1, "Text" : "are positive for P. aeruginosa. (See below for prior respiratory isolation"}, 
{"Row" : 45, "Column" : 1, "Text" : "of P. aeruginosa)"}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "on day 1, then 250 mg PO Q24H for 4 days ($) [M]< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal Regimen below: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "Select regimen below for P.aeruginosa, obtain cultures to allow deescalation"}, 
{"Row" : 62, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "500mg PO x1 on day 1, then 250 mg PO Q24H for 4 days ($) [M]"}, 
{"Row" : 65, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 67, "Column" : 1, "Text" : "day 1, then 250 mg PO Q24H for 4 days ($) [M]"}, 
{"Row" : 68, "Column" : 1, "Text" : "Alternative for P. aeruginosa: ", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "References: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45"}, 
{"Row" : 75, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 76, "Column" : 1, "Text" : "Sanford website"}, 
{"Row" : 57, "Column" : 1, "Text" : "Obtain cultures/nasal PCR to allow for deescalation."}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX VANCO PNA NEW START + MRSA NARES", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV q12h (PNA) ($) [R]", "Text" : "", "Mnemonic" : "24"}
]},
{"Name" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "DisplayText" : "Stepdown empiric treatment for CAP with oral antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID2 PNA DOXYCYCLINE 100MG PO Q12H X5DAYS", "DisplayText" : "Doxycycline 100 mg PO Q12H for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO Q12H for 5 days ($) [DI]", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID2 PNA AMOXICILLIN 1000MG PO Q8H X5DAYS", "DisplayText" : "Amoxicillin 1000 mg PO Q8H for 5 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO Q8H for 5 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PNA AMOX-CLAV 875 PO Q12H AZITH 500MG PO THEN 250MG", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] <AND> Azithromycin", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFDINIR 300MG BIDX5D AZITH 500MG PO THEN 250MG", "DisplayText" : "Cefdinir 300 mg PO Q12H ($) [R] <AND> Azithromycin 500mg PO", "Text" : "Cefdinir 300 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX PNA AMOX-CLAV 875 PO Q12H DOXY 100MG PO Q12H 5DAYS", "DisplayText" : "Amox-clav 875 mg po q12h and doxy 100 mg po q12h both 5days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Doxycycline", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFDINIR 300MG PO BID DOXY 100MG PO Q12H 5DAYS", "DisplayText" : "Cefdinir 300 mg po bid and Doxycycline 100 mg po q12h 5 days", "Text" : "Cefdinir 300 mg PO q12h for 5 days ($) [R] <AND> Doxycycline", "Mnemonic" : "14"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750MG PO Q24H X5DAYS", "DisplayText" : "Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h for 5 days ($) [DI]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED WITH ORAL ANTIBIOTICS"}, 
{"Row" :5, "Column" : 1, "Text" : "NOTE: These are INPATIENT orders.To transfer these orders to outpatient for", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "discharge, highlight the order in the MEDS tab of CPRS, click on the", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "heading ACTION then click on Transfer to Outpatient.", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred oral treatment for PREVIOUSLY HEALTHY PATIENTS: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,"}, 
{"Row" : 11, "Column" : 1, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing"}, 
{"Row" : 12, "Column" : 1, "Text" : "conditions, or use of immunosuppressing drugs)"}, 
{"Row" : 14, "Column" : 1, "Text" : "No comorbidities: (Note: duration of therapy)", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred oral treatment for PATIENTS WITH COMORBIDITIES: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure, congestive"}, 
{"Row" : 21, "Column" : 1, "Text" : "heart failure, malignancy, alcoholism, asplenia, immunosuppressing conditions"}, 
{"Row" : 22, "Column" : 1, "Text" : "or use of immunosuppressing drugs)"}, 
{"Row" : 24, "Column" : 1, "Text" : "Comorbidities: (Note: duration of therapy)", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 27, "Column" : 1, "Text" : "po once on day 1, then 250 mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "once on day 1, then 250 mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "100 mg PO Q12H for 5 days ($) [DI]"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "100 mg PO Q12H for 5 days ($) [DI]"}, 
{"Row" : 38, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "References: "}, 
{"Row" : 43, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford: Community Acquired Pneumonia"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU CAT-SCATCH DISEASE" , "Term1" : "Cat-scratch disease", "DisplayText" : "Cat-Scratch Disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "CAT-SCRATCH DISEASE"}, 
{"Row" :4, "Column" : 1, "Text" : "Cat-scratch disease occurs when a cat infected with Bartonella henselae"}, 
{"Row" :5, "Column" : 1, "Text" : "scratches or bites a person or licks a person's open wound.A local pustule"}, 
{"Row" :6, "Column" : 1, "Text" : "develops followed by lymphadenopathy, typically on the same side of the body as"}, 
{"Row" :7, "Column" : 1, "Text" : "the scratch or bite."}, 
{"Row" :9, "Column" : 1, "Text" : "Infections associated with other pathogens such as Francisella tularemia,"}, 
{"Row" : 10, "Column" : 1, "Text" : "Coxiella burnetiid and other slow-growing bacteria may present with similar"}, 
{"Row" : 11, "Column" : 1, "Text" : "symptoms.Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "About 10% of cases of cat-scratch disease present atypically with symptoms"}, 
{"Row" : 14, "Column" : 1, "Text" : "involving the eye, nervous system, or lungs.Consult Infectious Diseases in"}, 
{"Row" : 15, "Column" : 1, "Text" : "these cases."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Bartonella, including cat-scratch disease"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: cat-scratch disease"}, 
{"Row" : 28, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 21, "Column" : 1, "Text" : "Consult Infectious Diseases"}
]},
{"Name" : "ORZID2 GMENU CHRONIC SINUSITIS" , "Term1" : "Sinusitis, chronic", "DisplayText" : "Chronic Sinusitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SEVERE SINUSITIS", "DisplayText" : "Severe Sinusitis", "Text" : "Severe Sinusitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4"}, 
{"Row" :6, "Column" : 1, "Text" : "cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires"}, 
{"Row" :7, "Column" : 1, "Text" : "objective evidence of mucosal inflammation using nasal endoscopy and/or CT"}, 
{"Row" :8, "Column" : 1, "Text" : "imaging. The initial therapy for chronic sinusitis is treatment with intranasal"}, 
{"Row" :9, "Column" : 1, "Text" : "corticosteroids and saline. For patients with severe nasal blockage by polyps,"}, 
{"Row" : 10, "Column" : 1, "Text" : "treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3"}, 
{"Row" : 11, "Column" : 1, "Text" : "months of intranasal therapy or after completion of glucocorticoid therapy. If"}, 
{"Row" : 12, "Column" : 1, "Text" : "signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases"}, 
{"Row" : 13, "Column" : 1, "Text" : "as treatment is complex."}, 
{"Row" : 14, "Column" : 1, "Text" : "Acute exacerbations of chronic sinusitis can be caused by discontinuing medical"}, 
{"Row" : 15, "Column" : 1, "Text" : "therapy, viral infections, allergens, noxious inhalants and bacterial or fungal"}, 
{"Row" : 16, "Column" : 1, "Text" : "infections. Bacterial infections should be suspected when the patient has"}, 
{"Row" : 17, "Column" : 1, "Text" : "increased signs/symptoms persisting for more than 10 days. Refer to Severe"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sinusitis recommendations for choice of antimicrobial therapy in these patients."}, 
{"Row" : 19, "Column" : 1, "Text" : "Repeated use of the same agent should be avoided to prevent promotion of drug"}, 
{"Row" : 20, "Column" : 1, "Text" : "resistant bacteria or increased fungal colonization."}, 
{"Row" : 23, "Column" : 1, "Text" : "Cardinal Signs/Symptoms of Chronic Sinusitis", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "1. Anterior and/or posterior nasal mucopurulent drainage"}, 
{"Row" : 25, "Column" : 1, "Text" : "2. Nasal obstruction/nasal blockage/congestion"}, 
{"Row" : 26, "Column" : 1, "Text" : "3. Facial pain, pressure, and/or fullness"}, 
{"Row" : 27, "Column" : 1, "Text" : "4. Reduction or loss of sense of smell"}, 
{"Row" : 29, "Column" : 1, "Text" : "Objective Evidence mucosal inflammation", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions"}, 
{"Row" : 31, "Column" : 1, "Text" : "2. Polyps in the nasal cavity or the middle meatus"}, 
{"Row" : 32, "Column" : 1, "Text" : "3. Radiographic imaging demonstrating mucosal thickening or partial or complete"}, 
{"Row" : 33, "Column" : 1, "Text" : "opacification of the paranasal sinuses"}, 
{"Row" : 35, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 41, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 42, "Column" : 1, "Text" : "Rudmik et al., JAMA. 2015, 314(9) 926-939"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Chronic"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,"}, 
{"Row" : 45, "Column" : 1, "Text" : "pathophysiology, and diagnosis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic"}, 
{"Row" : 47, "Column" : 1, "Text" : "rhinosinusitis"}
]},
{"Name" : "ORZID2 GMENU CMI DEFECTS" , "Term1" : "Cell-mediated immunity (CMI) defects", "DisplayText" : "Cell-mediated immunity (CMI) defects" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CELL-MEDIATED IMMUNITY (CMI) DEFECTS"}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with reduced CMI include those with HIV/AIDS, hematologic malignancies,"}, 
{"Row" :6, "Column" : 1, "Text" : "cytotoxic chemotherapy, and congenital abnormalities.Patients with cell-"}, 
{"Row" :7, "Column" : 1, "Text" : "mediated immune defects are more susceptible to infections from ubiquitous"}, 
{"Row" :8, "Column" : 1, "Text" : "microorganisms that do not usually cause infection in healthy patients.The"}, 
{"Row" :9, "Column" : 1, "Text" : "specific organisms that are more likely to be associated with disease vary"}, 
{"Row" : 10, "Column" : 1, "Text" : "depending on the specific type of immune defect present, but include: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Pneumocystis jirovecii (formerly Pneumocystis carinii), Mycobacterium avium,"}, 
{"Row" : 12, "Column" : 1, "Text" : "Mycobacterium tuberculosis, Salmonella spp., Candida spp., Aspergillus spp.,"}, 
{"Row" : 13, "Column" : 1, "Text" : "Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,"}, 
{"Row" : 14, "Column" : 1, "Text" : "and Cryptosporidium parvum."}, 
{"Row" : 16, "Column" : 1, "Text" : "These infectious diseases usually have a subacute or chronic presentation.The"}, 
{"Row" : 17, "Column" : 1, "Text" : "best approach in most circumstances is for the clinician to conduct a methodical"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnostic workup to identify the specific pathogen and guide therapy."}, 
{"Row" : 19, "Column" : 1, "Text" : "Empirical antimicrobials are not indicated for patients with CMI defects who"}, 
{"Row" : 20, "Column" : 1, "Text" : "present only with fever.Contact Infectious Disease for more information."}, 
{"Row" : 25, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 26, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU COMM ACQ DIARRHEA" , "Term1" : "Community-acquired diarrhea", "DisplayText" : "Community acquired diarrhea " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Mnemonic" : "8"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Acute diarrhea (< 14 days of symptoms)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Empirical antimicrobials should be given only in cases of severe acute disease"}, 
{"Row" :9, "Column" : 1, "Text" : "or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion"}, 
{"Row" : 10, "Column" : 1, "Text" : "requiring hospitalization, severe abdominal pain, immune compromise, cardiac"}, 
{"Row" : 11, "Column" : 1, "Text" : "disease, >/= 70 years old."}, 
{"Row" : 13, "Column" : 1, "Text" : "If in the preceding two months the patient has taken a PPI or has been"}, 
{"Row" : 14, "Column" : 1, "Text" : "hospitalized for three or more days, consider Clostridium difficile infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 19, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 20, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 21, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 22, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 23, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 24, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 25, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 26, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 28, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 31, "Column" : 1, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Subacute or chronic (>/= 14 days of symptoms)", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Primary treatment is hydration and electrolyte replacement. Empiric"}, 
{"Row" : 42, "Column" : 1, "Text" : "antimicrobial therapy is not indicated. Investigate for the cause of diarrhea."}, 
{"Row" : 43, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases involvement is encouraged."}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 50, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich"}, 
{"Row" : 52, "Column" : 1, "Text" : "settings"}
]},
{"Name" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS" , "Term1" : "Adenovirus diarrhea/gastroenteritis " , "Term2" : "Astrovirus diarrhea/gastroenteritis " , "Term3" : "Viral diarrhea/gastroenteritis", "DisplayText" : "Viral Diarrhea" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "VIRAL GASTROENTERITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,"}, 
{"Row" :6, "Column" : 1, "Text" : "Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes"}, 
{"Row" :7, "Column" : 1, "Text" : "supportive measures such as oral rehydration and unrestricted nutrition."}, 
{"Row" :8, "Column" : 1, "Text" : "Antiviral therapy is not recommended and for most viruses is unavailable."}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimotility agents may be used for one or two days in patients with mild to"}, 
{"Row" : 11, "Column" : 1, "Text" : "moderate volume depletion. Antiemetic agents may be used for one or two days in"}, 
{"Row" : 12, "Column" : 1, "Text" : "patients with vomiting."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 19, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-To-Date article: Acute viral gastroenteritis in adults"}
]},
{"Name" : "ORZID2 GMENU CONJUNCTIVITIS" , "Term1" : "Conjunctivitis", "DisplayText" : "Conjunctivitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H", "Text" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID X5D", "Text" : "Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "CONJUNCTIVITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Conjunctivitis is associated with viral or bacterial pathogens. Viral"}, 
{"Row" :6, "Column" : 1, "Text" : "conjunctivitis presents with watery discharge. Bacterial infections are more"}, 
{"Row" :7, "Column" : 1, "Text" : "likely to present with thick exudate and conjunctival injection. Allergic"}, 
{"Row" :8, "Column" : 1, "Text" : "conjunctivitis typically presents with stringy mucus. If there is pus"}, 
{"Row" :9, "Column" : 1, "Text" : "(hypopion), corneal involvement, possible bacterial conjunctivitis, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "keratitis, consult ophthalmology."}, 
{"Row" : 12, "Column" : 1, "Text" : "Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited"}, 
{"Row" : 13, "Column" : 1, "Text" : "and antivirals provide no benefit. Symptomatic treatment with ophthalmic"}, 
{"Row" : 14, "Column" : 1, "Text" : "antihistamine/decongestants and warm or cool compresses may relieve symptoms."}, 
{"Row" : 16, "Column" : 1, "Text" : "Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,"}, 
{"Row" : 17, "Column" : 1, "Text" : "Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,"}, 
{"Row" : 18, "Column" : 1, "Text" : "Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is"}, 
{"Row" : 19, "Column" : 1, "Text" : "generally self-limited, but topical antimicrobials reduce duration of symptoms"}, 
{"Row" : 20, "Column" : 1, "Text" : "and limit person-to-person spread of infection. If symptoms do not improve after"}, 
{"Row" : 21, "Column" : 1, "Text" : "2 days of antimicrobial therapy, the patient should be seen by an"}, 
{"Row" : 22, "Column" : 1, "Text" : "ophthalmologist."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment for acute bacterial conjunctivitis", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "q3h for 7 days ($) [M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for severe cases of bacterial conjunctivitis involving suppuration or", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "contact lens wearers", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Consult ophthalmology and begin topical antimicrobials."}, 
{"Row" : 32, "Column" : 1, "Text" : "days then 2 drops QID for 5 days ($) [M]"}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Azari eta al, JAMA (2013) 1721-1730"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Microbial conjunctivitis"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date Article: Conjunctivitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Conjunctivitis, Bacterial"}
]},
{"Name" : "ORZID2 GMENU CONTACT CDSS STAFF" , "Term1" : "Contact CDSS staff" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "DisplayText" : "Exclusions", "Text" : "Exclusions- recommendations for additions to CDSS", "Mnemonic" : "4"},
{"Row" :1, "Column" : 1, "Text" : "The CDSS Project Team can be contacted in Outlook using the"}, 
{"Row" :2, "Column" : 1, "Text" : "group Email: VISN23AntimicrobialCDSS@va.gov"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact CDSS Team", "Mnemonic" : "2"}
]},
{"Name" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS" , "Term1" : "Abscess, cranial epidural " , "Term2" : "Cranial epidural abscess " , "Term3" : "Epidural abscess, cranial", "DisplayText" : "Cranial epidural abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO500MGIVQ8H VANCO15MG/KGIVQ12H", "DisplayText" : "CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "CRANIAL EPIDURAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment involves source control by drainage procedure and antimicrobial"}, 
{"Row" :6, "Column" : 1, "Text" : "therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "Beta-lactam antibiotics are more effective than vancomycin against susceptible"}, 
{"Row" :9, "Column" : 1, "Text" : "Staphylococci. If Staphylococcus is isolated, once methicillin-resistance is"}, 
{"Row" : 10, "Column" : 1, "Text" : "ruled out, switch to an anti-staphylococcal beta-lactam antibiotic. Pseudomonas"}, 
{"Row" : 11, "Column" : 1, "Text" : "is a potential pathogen in post-surgical patients or patients with known"}, 
{"Row" : 12, "Column" : 1, "Text" : "Pseudomonas colonization."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat for 6 weeks after surgical drainage. In patients with associated"}, 
{"Row" : 18, "Column" : 1, "Text" : "osteomyelitis, patients in whom surgical drainage did not occur, and patients in"}, 
{"Row" : 19, "Column" : 1, "Text" : "whom the response to therapy has been slow, treat for 6 to 8 weeks."}, 
{"Row" : 21, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred if Pseudomonas is not suspected: "}, 
{"Row" : 24, "Column" : 1, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred if Pseudomonas is suspected: "}, 
{"Row" : 28, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Treatment if methicillin-sensitive S. aureus is isolated", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative"}, 
{"Row" : 43, "Column" : 1, "Text" : "Intracranial Thrombophlebitis"}, 
{"Row" : 44, "Column" : 1, "Text" : "Pradilla et al, Lancet Neurol, 2009, 8(3)292-300"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-To-Date Article: Intracranial Epidural Abscess"}
]},
{"Name" : "ORZID2 GMENU CUTANEOUS ABSCESS" , "Term1" : "Abscess, cutaneous", "DisplayText" : "Cutaneous abscess " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "CUTANEOUS ABSCESS"}, 
{"Row" :5, "Column" : 1, "Text" : "Incise and drain then cover the site with a dry dressing. For small abscesses,"}, 
{"Row" :6, "Column" : 1, "Text" : "systemic antimicrobial therapy is rarely necessary."}, 
{"Row" :8, "Column" : 1, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or"}, 
{"Row" :9, "Column" : 1, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases for assistance."}, 
{"Row" : 12, "Column" : 1, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Mild to Moderate Cases: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Moderate or high suspicion of MRSA", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Low suspicion of MRSA", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "For SEVERE cases empiric coverage with MRSA agent", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "For Perirectal/Anorectal Abscess Select Below", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword:Skin infections"}, 
{"Row" : 36, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS" , "Term1" : "Candidiasis", "DisplayText" : "Cutaneous Candidiasis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CREAM TOPICAL BID", "DisplayText" : "Clotrimazole 1% cream topical bid", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID NYSTATIN CREAM BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M]", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "CUTANEOUS CANDIDIASIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Cutaneous candidiasis is a superficial fungal infection of the epidermis."}, 
{"Row" :5, "Column" : 1, "Text" : "Presents with red, erythematous patches, often in areas where skin contacts"}, 
{"Row" :6, "Column" : 1, "Text" : "skin, including axillae, groin, and abdominal folds."}, 
{"Row" :8, "Column" : 1, "Text" : "Keep affected areas dry and clean."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 4 weeks."}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford: Cutaneous Candidiasis"}
]},
{"Name" : "ORZID2 GMENU DECUBITUS ULCERS" , "Term1" : "Decubitus ulcers " , "Term2" : "Ulcer, decubitus", "DisplayText" : "Decubitus ulcers" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "DisplayText" : "Cellulitis", "Text" : "Cellulitis", "Mnemonic" : "16"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis", "Text" : "Osteomyelitis", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "DECUBITUS ULCERS"}, 
{"Row" :5, "Column" : 1, "Text" : "Relieve pressure and friction, provide good nutrition, and debride the ulcer."}, 
{"Row" :7, "Column" : 1, "Text" : "Decubitus ulcers are colonized with bacteria.Antimicrobial therapy is"}, 
{"Row" :8, "Column" : 1, "Text" : "unnecessary unless the patient has infection of surrounding tissues signified by"}, 
{"Row" :9, "Column" : 1, "Text" : "erythema, warmth, local tenderness, or purulent discharge.Rectal or groin"}, 
{"Row" : 10, "Column" : 1, "Text" : "decubitus ulcers with surrounding infection need broad spectrum antimicrobials."}, 
{"Row" : 11, "Column" : 1, "Text" : "Ulcers located in other sites are usually treated with antimicrobials for"}, 
{"Row" : 12, "Column" : 1, "Text" : "staphylococci and streptococci."}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of therapy usually 7-14 days, but adjust to clinical response", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For deep abscesses away from the rectal area, obtain material for Gram stain an", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "culture to guide therapy.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "For severe cases", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "For deep PERIRECTAL ABSCESSES that need a systemic antimicrobial SELECT BELOW: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the"}, 
{"Row" : 31, "Column" : 1, "Text" : "advice page for the appropriate syndrome.Contact the ET nurse, Infectious"}, 
{"Row" : 32, "Column" : 1, "Text" : "Diseases, Dietician, or Vascular surgery for more information."}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 40, "Column" : 1, "Text" : "Parish LC Dermatol Clin 2004, 22: 87"}, 
{"Row" : 41, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU DEEP OROPHAR INFECT" , "Term1" : "Deep oropharyngeal infections " , "Term2" : "Oropharyngeal infections, deep", "DisplayText" : "Deep Oropharyngeal Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h for 7 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "MRSA risk factors", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "< ADD > vancomycin 15 mg/kg IV q12 hours ($) [R]", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "DisplayText" : "Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R] < AND > vancomycin 15 mg/kg IV q 12 hours ($) [R]", "Mnemonic" : "16"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "DEEP OROPHARYNGEAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Deep oropharyngeal infections may threaten life and must be treated immediately."}, 
{"Row" :6, "Column" : 1, "Text" : "Assess the risk of airway compromise and monitor the airway if it is threatened."}, 
{"Row" :7, "Column" : 1, "Text" : "These infections are more common in people with diabetes mellitus and are caused"}, 
{"Row" :8, "Column" : 1, "Text" : "by mixed organisms including streptococcus sp., Staphylococcus aureus and"}, 
{"Row" :9, "Column" : 1, "Text" : "anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases"}, 
{"Row" : 10, "Column" : 1, "Text" : "consults are essential."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "If the patient's condition worsens or does not improve during the first 48 hours"}, 
{"Row" : 14, "Column" : 1, "Text" : "of antimicrobial therapy, surgical drainage is indicated. If surgical drainage"}, 
{"Row" : 15, "Column" : 1, "Text" : "is done, antimicrobials are usually continued for 48 hours after the procedure."}, 
{"Row" : 16, "Column" : 1, "Text" : "If surgical drainage is not done, 2 weeks of antimicrobial therapy until"}, 
{"Row" : 17, "Column" : 1, "Text" : "clinical improvement is observed (e.g. resolution of fever and leukocytosis) is"}, 
{"Row" : 18, "Column" : 1, "Text" : "appropriate."}, 
{"Row" : 20, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative: Assessment of Beta-lactam Reaction"}, 
{"Row" : 27, "Column" : 1, "Text" : "Risk factors for MRSA or gram-positive cocci in clusters on gram stain, in", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "addition to one of the above antimicrobial regimens", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Immunocompromised patient or severe infection", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Immunocompromised patients require additional coverage for Staphylococcus aureus"}, 
{"Row" : 34, "Column" : 1, "Text" : "and Pseudomonas aeruginosa."}, 
{"Row" : 35, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 37, "Column" : 1, "Text" : "< AND > vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 42, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 44, "Column" : 1, "Text" : "Step-down treatment after initial intravenous therapy. Adjust duration based on", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "criteria above.", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 52, "Column" : 1, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head"}, 
{"Row" : 53, "Column" : 1, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252"}, 
{"Row" : 54, "Column" : 1, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date article: Submandibular space infections (Ludwig's angina)"}
]},
{"Name" : "ORZID2 GMENU DELAYED PCN ALLERGIC CV SURG", "DisplayText" : "Severly PCN allergic" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE", "DisplayText" : "VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE OPEN HEART", "Text" : "Vancomycin 1500mg PREOPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750 MG DELAYED ORDER", "DisplayText" : "Levofloxacin 750mg IV once Pre-Op Delayed Order", "Text" : "Levofloxacin 750mg IV once Pre-op Delayed Order", "Mnemonic" : "4"},
{"Row" :1, "Column" : 1, "Text" : "Severly PCN Allergic Pre-op Antibiotic Delayed Order", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "DisplayText" : "Diagnosis of Pertussis" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Td/Tdap Immunization Menu", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ LAB MICROBIOLOGY", "DisplayText" : "MICRO ORDER", "Text" : "Obtain nasopharyngeal sample for PCR", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ LAB MICROBIOLOGY", "DisplayText" : "MICRO ORDER", "Text" : "Obtain nasopharyngeal sample for PCR", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "LRTZID IGG ABY BORDETELLA PERTUSSIS", "DisplayText" : "Igg antibodies for Bordetella pertussis", "Text" : "Obtain serum sample for IgG antibodies to Bordetella pertussis", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "LRTZID IGG ABY BORDETELLA PERTUSSIS", "DisplayText" : "Igg antibodies for Bordetella pertussis", "Text" : "Obtain serum sample for IgG antibodies to Bordetella pertussis", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "DIAGNOSIS OF PERTUSSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Laboratory testing is recommended to confirm a clinical diagnosis of pertussis."}, 
{"Row" :6, "Column" : 1, "Text" : "Nasopharyngeal samples should be obtained with calcium alginate swabs.The"}, 
{"Row" :7, "Column" : 1, "Text" : "appropriate diagnostic strategy depends upon the duration of coughing symptoms."}, 
{"Row" :9, "Column" : 1, "Text" : "For previously unvaccinated individuals, the three-dose serious of Td/Tdap"}, 
{"Row" : 10, "Column" : 1, "Text" : "should be administered. A Tdap booster should be administered every 10 years"}, 
{"Row" : 11, "Column" : 1, "Text" : "after completion of the series."}, 
{"Row" : 14, "Column" : 1, "Text" : ">>During the first 2 weeks of coughing", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : ">>Between 2 and 4 weeks of coughing", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : ">>More than 4 weeks of coughing", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "References"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Pertussis infection in adolescents and adults: Clinic"}, 
{"Row" : 28, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Pertussis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Bordetella species"}
]},
{"Name" : "ORZID2 GMENU DISSEMINATED M. AVIUM" , "Term1" : "Disseminated Mycobacterium avium " , "Term2" : "Mycobacterium avium, disseminated", "DisplayText" : "Disseminated Mycobacterium avium disease treatment" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN 500 PO Q12H EHTAMBUTOL 15 Q24H", "Text" : "Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 250MG PO Q24H ETHAMBUTOL 15 PO Q24H", "Text" : "Azithromycin 250 mg PO q24h ($) [M] <AND> ethambutol 15 mg/kg PO q24h [R]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN, ETHAMBUTOL, RIFABUTIN", "Text" : "Clarithromycin 500 mg PO q12h($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AZITH 250, ETHAMBUTOL, RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Many of these patients have HIV/AIDS. Management is complex. Consult"}, 
{"Row" :6, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" :8, "Column" : 1, "Text" : "Rifabutin is optional for disseminated disease. Rifabutin can improve cure"}, 
{"Row" :9, "Column" : 1, "Text" : "rates, but may decrease blood concentrations of many drugs. Consult Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases or Pharmacy for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment is continued for 12 months and until CD4 count is >100 cells per"}, 
{"Row" : 14, "Column" : 1, "Text" : "microliter for at least 6 months."}, 
{"Row" : 16, "Column" : 1, "Text" : "Two-drug treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "($$) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 24, "Column" : 1, "Text" : "Three-drug treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 27, "Column" : 1, "Text" : "($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]"}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 31, "Column" : 1, "Text" : "<AND> rifabutin 300 mg q24h ($$) [R,DI]"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 37, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium complex"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected"}, 
{"Row" : 41, "Column" : 1, "Text" : "patients"}
]},
{"Name" : "ORZID2 GMENU DRUG PT UNDERGO DENTAL PROC", "DisplayText" : "Drugs for patients undergoing dental, oral, or esophageal procedures" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 2GM PO ONCE 'C'", "DisplayText" : "Amoxicillin 2gm po once (Var)", "Text" : "Amoxicillin 2 gm PO 1 hour before procedure ($) [R]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV ONCE 'C'", "DisplayText" : "Ampicillin 2gm iv once", "Text" : "Ampicillin 2 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "DisplayText" : "Cefazolin 1gm iv once", "Text" : "Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]", "Mnemonic" : "12"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500 MG PO ONCE 'C'", "DisplayText" : "Azithromycin 500mg po once (Var)", "Text" : "Azithromycin 500mg PO 1 hour before procedure ($) [M]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "BACTERIAL ENDOCARDITIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Preferred", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 11, "Column" : 1, "Text" : "Primary Alternative", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Secondary Alternative, after assessment of beta-lactam reaction above", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 24, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 25, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CEFADROXIL 2GM PO ONCE 'C'", "DisplayText" : "Cefadroxil 2 GM PO 1 hour before procedure ($) [R]", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID2 GMENU EC CX NEG", "DisplayText" : "Endocarditis with Negative Culture" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "ENDOCARDITIS WITH CULTURE-NEGATIVE RESULTS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cultures are often negative in cases of infection with fastidious organisms like"}, 
{"Row" :6, "Column" : 1, "Text" : "Abiotrophia (formerly nutritionally variant Streptococci), Bartonella, Coxiella,"}, 
{"Row" :7, "Column" : 1, "Text" : "Chlamydia, Legionella spp., or Trophyrema or when antimicrobials are given"}, 
{"Row" :8, "Column" : 1, "Text" : "before blood cultures are obtained. Consult Infectious Diseases and Cardiology."}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 17, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2GM IV Q4H CEFTRIAXONE 2G Q12H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV", "Text" : "Penicillin G 4 MU IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($)", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2GM IV Q4H CEFTRIAXONE 2G Q12H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX VANC Q12H 15MG/KG GENT 1MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($)", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI] for 6 weeks", "Mnemonic" : "14"},
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 10-12MG/KG Q24H", "DisplayText" : "Daptomycin 10-12 mg/kg IV q24h ($$$$) [R,DI]", "Text" : "Daptomycin 10-12 mg/kg IV q24h ($$$$) [R,DI] for 6 weeks", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "ENDOCARDITIS WITH ENTEROCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious diseases and cardiology should be consulted in all cases"}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Native valve endocarditis (NVE): "}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of therapy depends on duration of symptoms, susceptibility of the"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterococcus isolate to antimicrobials, and the effectiveness of the"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials that can be used. For patients who have experienced symptoms for"}, 
{"Row" : 12, "Column" : 1, "Text" : "less than 3 months and who can be treated with ampicillin or penicillin plus"}, 
{"Row" : 13, "Column" : 1, "Text" : "gentamicin, treat for 4. Treat all other patients including any patient"}, 
{"Row" : 14, "Column" : 1, "Text" : "receiving vancomycin for at least 6 weeks. Duration should be determined with"}, 
{"Row" : 15, "Column" : 1, "Text" : "input from Infectious Diseases."}, 
{"Row" : 17, "Column" : 1, "Text" : "Prosthetic Valve endocarditis (PVE): "}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for at least 6 weeks, duration should be determined with input from"}, 
{"Row" : 19, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 21, "Column" : 1, "Text" : "Organism Susceptibility", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Isolate is susceptible to penicillin (MIC </= 16 mcg/mL) and high concentration", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "gentamicin (MIC </= 500 mcg/mL)", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "weeks"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "[R,O] for 4 to 6 weeks (NVE) for 6 weeks (PVE)"}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "for 4 to 6 weeks (NVE) for 6 weeks (PVE)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Isolate is resistant to gentamicin (MIC > 500 mcg/mL)", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "weeks"}, 
{"Row" : 37, "Column" : 1, "Text" : "Isolate is penicillin-resistant (MIC > 16 mcg/mL)", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "[R,O] for 6 weeks"}, 
{"Row" : 41, "Column" : 1, "Text" : "Isolate is penicillin resistant (MIC > 16 mcg/mL), gentamicin resistant (MIC >", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "500 mcg/mL) and vancomycin resistant", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 51, "Column" : 1, "Text" : "Fernandez-Hidalgo, Clinical Infectious Diseases 2013, 56: 1261"}, 
{"Row" : 52, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 55, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC FUNGI", "DisplayText" : "Endocarditis with Fungi " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "ENDOCARDITIS WITH FUNGI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases, Cardiology, and Cardiothoracic surgery."}, 
{"Row" :7, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "References: "}, 
{"Row" : 10, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 11, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 14, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC GNB", "DisplayText" : "Endocarditis with Gram Negative Bacilli " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 6 weeks", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime2 gm IV q8h ($$) [R] for 6 weeks", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ENDOCARDITIS WITH GRAM NEGATIVE BACILLI OTHER THAN HACEK ORGANISMS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pseudomonas aeruginosa and various Enterobacteriaceae are uncommon endocarditis"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogens. Risk factors include cirrhosis, IV drug use and prosthetic valve."}, 
{"Row" :7, "Column" : 1, "Text" : "Choice of agents should be based on in vitro susceptibilities."}, 
{"Row" : 13, "Column" : 1, "Text" : "Consult Infectious Diseases and Cardiothoracic surgery in all cases."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment for Enterobacteriaceae", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment for Pseudomonas", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Most cases of pseudomonas endocarditis occur in IV drug users."}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 29, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}, 
{"Row" :9, "Column" : 1, "Text" : "Begin treatment with a beta-lactam agent, and when appropriate, Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases will initiate treatment with add-on aminoglycoside or fluroquinolone"}, 
{"Row" : 11, "Column" : 1, "Text" : "agent for additional coverage."}
]},
{"Name" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks (NVE) or 6 weeks (PVE)", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] for 4 weeks (NVE) or 6 weeks (PVE)", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ENDOCARDITIS WITH HACEK BACTERIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "HACEK bacteria are the fastidious Gram-negative bacilli, including Haemophilus"}, 
{"Row" :6, "Column" : 1, "Text" : "parainfluenzae, Haemophilus paraphrophilus, Haemophilus influenzae,"}, 
{"Row" :7, "Column" : 1, "Text" : "Aggregatibacter aphrophilus (Haemophilus aphrophilus), Actinobacillus"}, 
{"Row" :8, "Column" : 1, "Text" : "actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella"}, 
{"Row" :9, "Column" : 1, "Text" : "kingae and Kingella denitrificans. It may take up three weeks for the"}, 
{"Row" : 10, "Column" : 1, "Text" : "microbiology laboratory to isolate these organisms."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment options are limited for patients with allergies to beta-lactam"}, 
{"Row" : 13, "Column" : 1, "Text" : "antibiotics. Consult Infectious Diseases for advice."}, 
{"Row" : 15, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Native valve endocarditis (NVE): 4 weeks"}, 
{"Row" : 17, "Column" : 1, "Text" : "Prosthetic valve endocarditis (PVE): 6 weeks"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Isolate is susceptible to ampicillin", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 32, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC NV EMP THERA" , "Term1" : "Endocarditis, native valve empirical therapy " , "Term2" : "Native valve endocarditis empirical therapy", "DisplayText" : "Native Valve Endocarditis - Empirical Therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "DisplayText" : "VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($)", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "DisplayText" : "VANCO 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "DisplayText" : "VANCO 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NATIVE VALVE ENDOCARDITIS--EMPIRICAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Empirical treatment in a non-intravenous drug user", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Wait for identification of pathogen before initiating antimicrobial therapy in"}, 
{"Row" :7, "Column" : 1, "Text" : "most cases. If empiric antimicrobial treatment is necessary, due to hemodynamic"}, 
{"Row" :8, "Column" : 1, "Text" : "instability or other severe disease, use: "}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 12, "Column" : 1, "Text" : "[R,O]"}, 
{"Row" : 14, "Column" : 1, "Text" : "Empirical treatment in an intravenous drug user", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Staphylococcus aureus is the most likely pathogen, followed by streptococci and"}, 
{"Row" : 16, "Column" : 1, "Text" : "enterococci. However, gram negative pathogens are often associated with"}, 
{"Row" : 17, "Column" : 1, "Text" : "endocarditis in these patients. Culture results are key for appropriate therapy."}, 
{"Row" : 18, "Column" : 1, "Text" : "Consult Cardiology and Infectious Diseases for more information."}, 
{"Row" : 20, "Column" : 1, "Text" : "[R,O]"}, 
{"Row" : 22, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 29, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC NV SEL PATH" , "Term1" : "Endocarditis, native valve " , "Term2" : "Native valve endocarditis", "DisplayText" : "Native Valve Endocarditis--Selected Pathogens " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU EC CX NEG", "DisplayText" : "Endocarditis with Negative Culture", "Text" : "Culture-negative endocarditis", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci", "Text" : "Enterococci", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "DisplayText" : "Endocarditis with Fungi", "Text" : "Fungi", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC GNB", "DisplayText" : "Endocarditis with Gram Negative Bacilli", "Text" : "Gram negative bacilli (other than HACEK organisms)", "Mnemonic" : "10"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "HACEK bacteria", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC NV STAPHYLOCOCCI", "DisplayText" : "Native Valve Endocarditis with Staphylococci", "Text" : "Staphylococci", "Mnemonic" : "14"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU EC NV STREPTOCOCCI", "DisplayText" : "Native Valve Endocarditis with Streptococci", "Text" : "Streptococci", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "NATIVE VALVE ENDOCARDITIS--SELECTED PATHOGENS", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU EC NV STAPHYLOCOCCI" , "Term1" : "Staphylococcal native valve endocarditis", "DisplayText" : "Native Valve Endocarditis with Staphylococci" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI] for 6 weeks", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "DisplayText" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Text" : "Daptomycin 8-12mg/kg q24h ($$$$) [R,DI] for 6 weeks", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "NATIVE VALVE ENDOCARDITIS WITH STAPHYLOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are"}, 
{"Row" :6, "Column" : 1, "Text" : "treated similarly."}, 
{"Row" :8, "Column" : 1, "Text" : "Retrospective studies show that patients with native valve staphylococcal"}, 
{"Row" :9, "Column" : 1, "Text" : "endocarditis treated with valve replacement and antimicrobials have a lower"}, 
{"Row" : 10, "Column" : 1, "Text" : "mortality rate than those treated with antimicrobials alone. Consult"}, 
{"Row" : 11, "Column" : 1, "Text" : "cardiothoracic surgery for all patients with staphylococcal endocarditis."}, 
{"Row" : 13, "Column" : 1, "Text" : "Most patients need 6 weeks of antimicrobial treatment. For vancomycin-resistant"}, 
{"Row" : 14, "Column" : 1, "Text" : "strains Infectious Disease consultation is recommended."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment for methicillin-susceptible strains", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment for methicillin-resistant strains", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 40, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "5"},
{"Row" : 22, "Column" : 1, "Text" : "Treat for 6 weeks: "}
]},
{"Name" : "ORZID2 GMENU EC NV STREPTOCOCCI" , "Term1" : "Streptococcal native valve endocarditis (sensitive isolate)", "DisplayText" : "Native Valve Endocarditis with Streptococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "DisplayText" : "Penicillin G 3 million units IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R] for 4 weeks", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 3MU IV Q4H GENT 3 MG/KG ONCE DAILY", "DisplayText" : "PENICILLIN 3MU IV Q4H GENT 3 MG/KG ONCE DAILY", "Text" : "Penicillin G 3 million units IV q4h ($$) [R] for 2 weeks <AND> gentamicin", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "DisplayText" : "CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 2 weeks <AND> gentamicin 3 mg/kg IV once", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 4 weeks", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "DisplayText" : "PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 4 weeks <AND> gentamicin", "Mnemonic" : "18"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "DisplayText" : "CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 4 weeks <AND> gentamicin 3 mg/kg IV q24h", "Mnemonic" : "20"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Mnemonic" : "22"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h", "Mnemonic" : "24"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "26"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "28"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "NATIVE VALVE ENDOCARDITIS WITH STREPTOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Selection is based on susceptibility to penicillin."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment of highly susceptible viridians streptococci or Streptococcus", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "The addition of gentamicin provides a synergistic effect and is reasonable to"}, 
{"Row" : 10, "Column" : 1, "Text" : "add in patients with uncomplicated endocarditis, rapid response to therapy and"}, 
{"Row" : 11, "Column" : 1, "Text" : "no underlying renal disease"}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "3 mg/kg IV q24h ($) [R,O] for 2 weeks"}, 
{"Row" : 18, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "daily ($) [R,O] for 2 weeks"}, 
{"Row" : 25, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment of relatively resistant viridians streptococci or S. gallolyticus", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "For ceftriaxone susceptible isolates (MIC < 0.5 mcg/mL): "}, 
{"Row" : 33, "Column" : 1, "Text" : "For ceftriaxone resistant isolates (MIC >/= 0.5 mcg/mL): "}, 
{"Row" : 35, "Column" : 1, "Text" : "3 mg/kg IV q24h ($) [R,O] for first 2 weeks"}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "($) [R,O] for first 2 weeks"}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "(penicillin MIC greater than or equal to 0.5 mcg/mL)", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 48, "Column" : 1, "Text" : "($) [R,O] for 4 weeks"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR>"}, 
{"Row" : 51, "Column" : 1, "Text" : "for 4 weeks"}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 57, "Column" : 1, "Text" : "Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "and G beta-hemolytic streptococci", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Treatment is non-standardized and must be tailored to each patient. Consult"}, 
{"Row" : 60, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 62, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "References: "}, 
{"Row" : 65, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 67, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 68, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 69, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "21"}
]},
{"Name" : "ORZID2 GMENU EC PV EMP THERAPY" , "Term1" : "Endocarditis, prosthetic valve empirical therapy " , "Term2" : "Prosthetic valve endocarditis empirical therapy", "DisplayText" : "Prosthetic Valve Endocarditis--Empicaral Therapy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG IV Q12H RIFAMP 300MG PO GENT 1MG/KG", "DisplayText" : "Vanco 15 MG/KG IV Q12H Rifamp 300MG PO Q8H Gent 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PROSTHETIC VALVE ENDOCARDITIS--EMPIRICAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Early surgical consultation is essential."}, 
{"Row" :7, "Column" : 1, "Text" : "If a patient is hemodynamically stable and the diagnosis is uncertain,"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial therapy can safely be withheld until the diagnosis is clear and"}, 
{"Row" :9, "Column" : 1, "Text" : "blood culture results are available to guide therapy. In all cases, be sure"}, 
{"Row" : 10, "Column" : 1, "Text" : "adequate numbers of blood cultures are obtained before antimicrobials are given."}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[R,O] <AND> rifampin 300 mg PO/NG q8h ($) [DI,O]"}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 23, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC PV SEL PATH" , "Term1" : "Endocarditis, prosthetic valve " , "Term2" : "Prosthetic valve endocarditis", "DisplayText" : "Prosthetic Valve Endocarditis--Selected Pathogens " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU EC CX NEG", "DisplayText" : "Endocarditis with Negative Culture", "Text" : "Culture-negative endocarditis", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "DisplayText" : "Endocarditis with Enterococci", "Text" : "Enterococci", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "DisplayText" : "Endocarditis with Fungi", "Text" : "Fungi", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC GNB", "DisplayText" : "Endocarditis with Gram Negative Bacilli", "Text" : "Gram negative bacilli (other than HACEK organisms)", "Mnemonic" : "10"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "DisplayText" : "Endocarditis with \"HACEK\" bacteria", "Text" : "HACEK bacteria", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC PV STAPHYLOCOCCI", "DisplayText" : "Prosthetic Valve Endocarditis with Staphylococci", "Text" : "Staphylococci", "Mnemonic" : "14"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU EC PV VGS/S. BOVIS", "DisplayText" : "Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis", "Text" : "Streptococci", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "PROSTHETIC VALVE ENDOCARDITIS--SELECTED PATHOGEN", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU EC PV STAPHYLOCOCCI" , "Term1" : "Staphylococcal prosthetic valve endocarditis", "DisplayText" : "Prosthetic Valve Endocarditis with Staphylococci" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX NAFCIL 2GM IV Q4H RIFAMP 300MG Q8H GENT 1MG/KG Q8H", "DisplayText" : "NAFCILLIN 2GM IV Q4H RIFAMPIN 300MG PO Q8H GENT 1MG/KG Q8H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI] x 6 weeks <AND> rifampin 300 mg PO/NG q8h", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG IV Q12H RIFAMP 300MG PO GENT 1MG/KG", "DisplayText" : "Vanco 15 MG/KG IV Q12H Rifamp 300MG PO Q8H Gent 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] x 6 weeks <AND> rifampin 300 mg PO/NG", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "PROSTHETIC VALVE ENDOCARDITIS WITH STAPHYLOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are"}, 
{"Row" :6, "Column" : 1, "Text" : "treated similarly. Surgery is required frequently in these patients."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment for methicillin-susceptible strains", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "($) [DI,O] for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial 2"}, 
{"Row" : 11, "Column" : 1, "Text" : "weeks"}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment for methicillin-resistant strains", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "($) [DI,O] q8h for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial"}, 
{"Row" : 16, "Column" : 1, "Text" : "2 weeks"}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 22, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 25, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU EC PV VGS/S. BOVIS" , "Term1" : "Streptococcal prosthetic valve endocarditis", "DisplayText" : "Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "DisplayText" : "PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks <AND> gentamicin", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 6 weeks", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "DisplayText" : "CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 6 weeks <AND> gentamicin 3 mg/kg IV q24h", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Mnemonic" : "14"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "DisplayText" : "PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "DisplayText" : "CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) <AND> gentamicin 1 mg/kg IV QD($) R,O] both", "Mnemonic" : "18"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "20"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Mnemonic" : "22"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "24"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Mnemonic" : "26"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Mnemonic" : "28"},
{"Row" :3, "Column" : 1, "Text" : "PROSTHETIC VALVE ENDOCARDITIS WITH STREPTOCOCCUS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment of highly susceptible viridians streptococci or Streptococcus", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Addition of gentamicin to penicillin or ceftriaxone is optional, as combination"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy has not demonstrated superior outcomes. Contact Infectious Diseases for"}, 
{"Row" :9, "Column" : 1, "Text" : "more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "3 mg/kg IV q24h($) [R,O] for 2 weeks"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "($) [R,O] for 2 weeks"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment of relatively resistant viridians streptococci or S. gallolyticus", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 29, "Column" : 1, "Text" : "($) [R,O] both drugs for 6 weeks"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "drugs for 6 weeks"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "(penicillin MIC greater than or equal to 0.5 mcg/mL)", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 41, "Column" : 1, "Text" : "($) [R,O] for 6 weeks"}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR>"}, 
{"Row" : 44, "Column" : 1, "Text" : "for 6 weeks"}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "and G beta-hemolytic streptococci", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Treatment is non-standardized and must be tailored to each patient. Consult"}, 
{"Row" : 53, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 55, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Baddour et al., Circulation 2015, 132:1-52"}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and intravascular infections"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Endocarditis"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults"}, 
{"Row" : 62, "Column" : 1, "Text" : "Wang et al., JAMA 2018, 320.1:72-83"}
]},
{"Name" : "ORZID2 GMENU ECTHYMA GANGRENOSUM" , "Term1" : "Ecthyma gangrenosum", "DisplayText" : "Ecthyma Gangrenosum " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CIP 400MG IV Q8H GENT 5MG IV QD", "DisplayText" : "CIPROFL 400MG IV Q8H GENT 5MG IV QD", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] < AND > gentamicin 5 mg/kg", "Mnemonic" : "12"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "ECTHYMA GANGRENOSUM"}, 
{"Row" :4, "Column" : 1, "Text" : "Ecthyma gangrenosum lesions commonly begin as painless red macules which"}, 
{"Row" :5, "Column" : 1, "Text" : "rapidly evolve into areas of induration that develop into pustules and-or"}, 
{"Row" :6, "Column" : 1, "Text" : "bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions"}, 
{"Row" :7, "Column" : 1, "Text" : "typically progress rapidly within 12 to 18 hours. They are often associated"}, 
{"Row" :8, "Column" : 1, "Text" : "with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients."}, 
{"Row" :9, "Column" : 1, "Text" : "Recommend blood cultures and culture of skin exudates."}, 
{"Row" : 10, "Column" : 1, "Text" : "Infectious disease consult is suggested."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consider combination therapy in patients with severe infections."}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 7 days."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for severe infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "5 mg/kg IV q24h ($) [R,O]"}, 
{"Row" : 25, "Column" : 1, "Text" : "IV q24h ($) [R,O]"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Pseudomonas aeruginosa"}, 
{"Row" : 32, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 33, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS" , "Term1" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treat for at least 5 to 7 days, up to 10 days may be required for more severe or"}, 
{"Row" :7, "Column" : 1, "Text" : "complicated cases"}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis"}, 
{"Row" : 18, "Column" : 1, "Text" : "MMWR RR. 2016, 65 (2) 1-44"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis"}
]},
{"Name" : "ORZID2 GMENU EMP INTRAV W/ VANCO", "DisplayText" : "Empirical intravenous regimens WITH vancomycin" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($6/day) [R] <AND> cefepime 2 gm IV q8h", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> vancomycin 15mg/kg", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TZ 4.5 GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2GM Q8H VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN"}, 
{"Row" :5, "Column" : 1, "Text" : "Discontinue vancomycin after 3 days unless culture results indicate that"}, 
{"Row" :6, "Column" : 1, "Text" : "continued therapy is needed.Gentamicin is optional.Contact Hematology-"}, 
{"Row" :7, "Column" : 1, "Text" : "Oncology or Infectious Diseases for advice."}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "($35/DAY) [R]"}, 
{"Row" : 16, "Column" : 1, "Text" : "IV q12h ($6.00/day) [R] < OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "mg/kg IV q24h ($3/day) [R] <AND> vancomycin 15mg/kg q12h ($6.00/day) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "($6/day) [R] < OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]"}, 
{"Row" : 31, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 32, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU EMP INTRAV W/O VANCO", "DisplayText" : "Empirical intravenous regimens WITHOUT vancomycin " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime 2 gm IV q8h ($35/day) [R]< OR >", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] < OR >", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2GM Q8H VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN"}, 
{"Row" :5, "Column" : 1, "Text" : "Gentamicin is optional.Contact Hematology-Oncology or Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "advice."}, 
{"Row" : 13, "Column" : 1, "Text" : "mg/kg IV q24h ($3/day) [R]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Vancomycin must be added to aztreonam for coverage of Gram-positive organisms."}, 
{"Row" : 18, "Column" : 1, "Text" : "($6/day) [R] < OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730"}, 
{"Row" : 27, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU ENDOOPTHALMITIS" , "Term1" : "Endophthalmitis", "DisplayText" : "Endophthalmitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO 1MG INTRA INJ CEFTAZ 2.25MG INTRA INJ", "DisplayText" : "Vancomycin 1mg intravitreous inject Ceftazidime 2.25mg intrav inj", "Text" : "Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > ceftazidime", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX VANCO 1MG INTRAVITREOUS AMIK 0.4MG INTR INJ", "DisplayText" : "Vancomycin 1mg intravitreous inj Amikacin 0.4mg intravitreous inj", "Text" : "Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > amikacin 0.4", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID AMPHO B 5MCG INTRAVITREOUS INJECTION ONCE", "DisplayText" : "Amphotericin B 5mcg/0.1mL intravitreal injection STAT", "Text" : "Amphotericin B 5mcg/0.1mL intravitreal injection STAT ($$$) [R,O]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 100MCG INTRAVITREOUS INJECTION ONCE", "DisplayText" : "Voriconazole 100 mcg/0.1 mL intravitreal injection STAT", "Text" : "Voriconazole 100 mcg/0.1mL intravitreal injection STAT ($$$$) [R,H,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ENDOPHTHALMITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Endophthalmitis is a medical emergency and presents with eye pain and visual"}, 
{"Row" :6, "Column" : 1, "Text" : "loss. It may be associated with gram positive or gram-negative bacteria,"}, 
{"Row" :7, "Column" : 1, "Text" : "including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or"}, 
{"Row" :9, "Column" : 1, "Text" : "vitreous fluid sample for gram stain and culture and begin intravitreal"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment with intravitreal antimicrobials", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "2.25 mg/0.1 mL intravitreal injection STAT ($$) [M]"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "mg/0.1 mL intravitreal injection STAT ($$) [M]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Fungal endophthalmitis", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment"}, 
{"Row" : 21, "Column" : 1, "Text" : "is complicated. Ophthalmology and Infectious Diseases involvement is essential."}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Endophthalmitis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Endophthalmitis, Hematogenous or Endogenous"}, 
{"Row" : 31, "Column" : 1, "Text" : "Tranos et al., Advances in therapy. 2016, 33(5)727-746"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Bacterial endophthalmitis"}
]},
{"Name" : "ORZID2 GMENU ERYSIPELAS" , "Term1" : "Erysipelas", "DisplayText" : "Erysipelas" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 250 - 500 mg PO q6h ($) [R]", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 500MG PO Q6H", "DisplayText" : "Erythromycin 500MG PO q6h", "Text" : "Erythromycin 500 mg po q6h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID PENICILLIN 3 MILLION UNITS IV Q6H", "DisplayText" : "Penicillin 3 million units iv q6h", "Text" : "Penicillin 3 million units IV q6h ($) [R]", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($) [H,O]", "Mnemonic" : "16"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "ERYSIPELAS"}, 
{"Row" :4, "Column" : 1, "Text" : "In contrast to cellulitis, erysipelas has sharply demarcated borders and a"}, 
{"Row" :5, "Column" : 1, "Text" : "characteristic raised, orange-peel appearance.Most cases are associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "streptococcus.In a minority of cases, especially those involving the face,"}, 
{"Row" :7, "Column" : 1, "Text" : "Staphylococcus aureus is also a potential pathogen.In severe cases,"}, 
{"Row" :8, "Column" : 1, "Text" : "methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided"}, 
{"Row" :9, "Column" : 1, "Text" : "until microbiology results are available."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 5 to 10days, longer if patient is bacteremic."}, 
{"Row" : 12, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Facial", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Sudden onset of rapidly spreading red edematous tender plaque-like skin on the"}, 
{"Row" : 16, "Column" : 1, "Text" : "face in an otherwise healthy host."}, 
{"Row" : 17, "Column" : 1, "Text" : "If erysipelas-like on the face treat as if MRSA is present: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Non-facial", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "MILD TO MODERATE disease", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "SEVERE disease", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative for penicillin allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Erysipelas"}, 
{"Row" : 43, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID2 GMENU ERYSIPELOID" , "Term1" : "Erysipeloid", "DisplayText" : "Erysipeloid " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin V 500 mg PO QID ($) [R]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 500MG PO Q6H", "DisplayText" : "Erythromycin 500MG PO q6h", "Text" : "Erythromycin 500 mg PO QID ($) [DI]", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 GM IV q24h ($$) [M]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "DisplayText" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)"}, 
{"Row" :4, "Column" : 1, "Text" : "Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae."}, 
{"Row" :5, "Column" : 1, "Text" : "It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by"}, 
{"Row" :6, "Column" : 1, "Text" : "direct animal contact, most commonly with fish, but also with other animals"}, 
{"Row" :7, "Column" : 1, "Text" : "(e.g., swine). It usually affects the hand or fingers and is characterized by"}, 
{"Row" :8, "Column" : 1, "Text" : "throbbing pain and a red rash with a purple center and an elevated border."}, 
{"Row" :9, "Column" : 1, "Text" : "Localized infections can be treated with oral antimicrobials."}, 
{"Row" : 11, "Column" : 1, "Text" : "Severe, diffuse cutaneous infections or systemic infections with E."}, 
{"Row" : 12, "Column" : 1, "Text" : "rhusopathiae occur rarely after ingestion of undercooked pork or contaminated"}, 
{"Row" : 13, "Column" : 1, "Text" : "seafood in immunosuppressed individuals.These infections are treated"}, 
{"Row" : 14, "Column" : 1, "Text" : "initially with intravenous antimicrobials."}, 
{"Row" : 16, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of localized infection (erysipeloid)", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 7 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "___________________________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment of systemic or severe diffuse cutaneous infection with E.", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "rhusopathiae.", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "___________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment duration is at least 4 weeks. Infectious Disease Consult recommended.", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Erysipelothrix"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 41, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 42, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID2 GMENU ERYTHRASMA" , "Term1" : "Erythrasma", "DisplayText" : "Erythrasma" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 1% TOPICAL SOLN Q12H", "DisplayText" : "Clindamycin 1% topical solution apply twice daily", "Text" : "Clindamycin 1% topical solution apply twice daily ($) [M]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CLARITHROMYCIN 500MG PO Q12H", "DisplayText" : "Clarithromycin 500mg po q12h", "Text" : "Clarithromycin 500 mg PO q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "ERYTHRASMA"}, 
{"Row" :4, "Column" : 1, "Text" : "Erythrasma presents as brownish-red, well circumscribed, irregularly shaped"}, 
{"Row" :5, "Column" : 1, "Text" : "patches in or near skin folds.Patches in the groin often itch."}, 
{"Row" :7, "Column" : 1, "Text" : "Most cases respond to topical therapy.Systemic antibiotics are used for more"}, 
{"Row" :8, "Column" : 1, "Text" : "severe cases or those that do not respond to topical therapy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: erythrasma"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 22, "Column" : 1, "Text" : "Holdiness MR Drugs 2002, 62:1131"}
]},
{"Name" : "ORZID2 GMENU FEVER OF UNK ORIGIN", "DisplayText" : "Fever of unknown origin " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "NEUTROPENIC FEVER", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "FEVER OF UNKNOWN ORIGIN", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fever of unknown origin (FUO) is the occurrence of several episodes of fever"}, 
{"Row" :6, "Column" : 1, "Text" : "greater than 101 degrees Fahrenheit over a time period of at least 3 weeks"}, 
{"Row" :7, "Column" : 1, "Text" : "despite 1 week of hospital evaluation. Cases with FUO are often classified in"}, 
{"Row" :8, "Column" : 1, "Text" : "four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever"}, 
{"Row" :9, "Column" : 1, "Text" : "in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated"}, 
{"Row" : 10, "Column" : 1, "Text" : "in patients with FUO."}, 
{"Row" : 12, "Column" : 1, "Text" : "Note that FUO in neutropenic patients refers to persistent fever that has"}, 
{"Row" : 13, "Column" : 1, "Text" : "remained undiagnosed after extensive diagnostic work and empirical antimicrobial"}, 
{"Row" : 14, "Column" : 1, "Text" : "therapy. New fever in patients with profound neutropenia is a different"}, 
{"Row" : 15, "Column" : 1, "Text" : "syndrome and does require empirical antimicrobial therapy. Infectious Diseases"}, 
{"Row" : 16, "Column" : 1, "Text" : "should be involved in any case where empirical treatment for fever of unknown"}, 
{"Row" : 17, "Column" : 1, "Text" : "origin is being considered."}, 
{"Row" : 22, "Column" : 1, "Text" : "References"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell Chapter: Fever of Unknown Origin"}
]},
{"Name" : "ORZID2 GMENU FOLLICULITIS" , "Term1" : "Folliculitis", "DisplayText" : "Folliculitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID MUPIROCIN 2% OINT TOP TO AFFECT AREA Q8H", "DisplayText" : "Mupirocin 2% ointment topical to affected area q8h", "Text" : "Mupirocin ointment to affected area q8h for 7 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CRM TOP Q8H", "DisplayText" : "Clotrimazole 1% cream top to affected area q8h", "Text" : "Clotrimazole cream q8h for 7 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "FOLLICULITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Folliculitis is an infection of the hair follicle with purulent exudate in the"}, 
{"Row" :5, "Column" : 1, "Text" : "epidermis. It is usually associated with Staphylococcus aureus.In patients"}, 
{"Row" :6, "Column" : 1, "Text" : "exposed to swimming pools or hot tubs, folliculitis may be associated with"}, 
{"Row" :7, "Column" : 1, "Text" : "Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients"}, 
{"Row" :8, "Column" : 1, "Text" : "receiving antimicrobials and/or corticosteroids. For folliculitis in patients"}, 
{"Row" :9, "Column" : 1, "Text" : "with severe acne, consult Dermatology.For extensive folliculitis or in"}, 
{"Row" : 10, "Column" : 1, "Text" : "patients with HIV, consult Infectious Diseases."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Usually self-limiting. For most cases, treat with daily saline compresses until"}, 
{"Row" : 14, "Column" : 1, "Text" : "symptoms resolve."}, 
{"Row" : 16, "Column" : 1, "Text" : "For moderate to severe cases associated with Staphylococcus aureus: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "For cases associated with Candida albicans", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Folliculitis"}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER W/ INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITH infection of surrounding tissues " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "DisplayText" : "Approach to foot ulcers with infection", "Text" : "Approach to foot ulcers with infection", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 1DS PO Q12", "DisplayText" : "Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 1DS q12h", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] <AND> Trimethoprim-", "Mnemonic" : "18"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "21"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX AMPI/SULB 3GM IV Q6H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV", "Mnemonic" : "22"},
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg", "Mnemonic" : "26"},
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)", "Mnemonic" : "28"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES"}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation."}, 
{"Row" :9, "Column" : 1, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved."}, 
{"Row" : 10, "Column" : 1, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe."}, 
{"Row" : 11, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Mild: ulcer with superficial inflammation", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Oral therapy, no MRSA coverage: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Oral therapy, MRSA coverage: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Moderate: Ulcer with inflammation, extension into fascia", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks"}, 
{"Row" : 34, "Column" : 1, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen"}, 
{"Row" : 35, "Column" : 1, "Text" : "is reasonable following clinical improvement."}, 
{"Row" : 37, "Column" : 1, "Text" : "Oral therapy with MRSA coverage: (MRSA coverage until ruled out)", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "sulfamethoxazole 1 DS tablet po q12h ($) [R,DI]"}, 
{"Row" : 44, "Column" : 1, "Text" : "Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "q12h ($) [R,DI]"}, 
{"Row" : 50, "Column" : 1, "Text" : "Severe: Extensive local inflammation plus systemic toxicity", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Intravenous regimens for SEVERE (limb-threatening) infections", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Duration: treat to resolution of symptoms usually 2-4 weeks"}, 
{"Row" : 56, "Column" : 1, "Text" : "A switch to an oral regimen is reasonable following clinical improvement."}, 
{"Row" : 60, "Column" : 1, "Text" : "IV q12h ($) [R]"}, 
{"Row" : 63, "Column" : 1, "Text" : "[R] <AND> metronidazole 500 mg IV q8h ($) [DI]"}, 
{"Row" : 67, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 70, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 71, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 61, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks"}, 
{"Row" : 32, "Column" : 1, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial"}, 
{"Row" : 33, "Column" : 1, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data."}, 
{"Row" : 65, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CEFADROXIL 500MG PO BID", "DisplayText" : "Cefadroxil 500 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX AMOX CLAV 875 Q12H + DOXYCYCLINE 100MG Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] <AND> Doxycycline 100 mg", "Text" : "", "Mnemonic" : "20"},
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "PO BID for 14 days ($) [DI]"}, 
{"Row" : 54, "Column" : 1, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial"}, 
{"Row" : 55, "Column" : 1, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data."}, 
{"Row" : 58, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITHOUT infection of surrounding tissues" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES"}, 
{"Row" :5, "Column" : 1, "Text" : "Clinically uninfected wounds do not need antibiotic treatment."}, 
{"Row" :6, "Column" : 1, "Text" : "Topical antimicrobials are not helpful, are associated with allergic reactions,"}, 
{"Row" :7, "Column" : 1, "Text" : "and select for resistant organisms.In general, local treatment should consist"}, 
{"Row" :8, "Column" : 1, "Text" : "of dressings with frequent changes, soaks, and debridement. Patients with"}, 
{"Row" :9, "Column" : 1, "Text" : "edema or impaired venous return should keep the limb elevated.Wound care and"}, 
{"Row" : 10, "Column" : 1, "Text" : "improved control of diabetes can improve outcomes of infection and prevent"}, 
{"Row" : 11, "Column" : 1, "Text" : "future complications."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2004, 39: 885"}, 
{"Row" : 17, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER WITH DM" , "Term1" : "Diabetic foot ulcer " , "Term2" : "Foot ulcer in patient with diabetes " , "Term3" : "Ulcer, diabetic foot", "DisplayText" : "Foot ulcer in patient with diabetes mellitus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITHOUT infection of surrounding tissues", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/ INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITH infection of surrounding tissues", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS"}, 
{"Row" :5, "Column" : 1, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobials should not be used to treat colonization."}, 
{"Row" :8, "Column" : 1, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local"}, 
{"Row" :9, "Column" : 1, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain"}, 
{"Row" : 10, "Column" : 1, "Text" : "may not be present in patients with neuropathy.In patients with substantial"}, 
{"Row" : 11, "Column" : 1, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues"}, 
{"Row" : 12, "Column" : 1, "Text" : "will be dusky, mottled, or cool.Capillary refill may be impaired.Patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "with diabetes and ulcers are at risk for gangrenous infections.If there is any"}, 
{"Row" : 14, "Column" : 1, "Text" : "suggestion of gangrene, consult surgery immediately."}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 23, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}
]},
{"Name" : "ORZID2 GMENU FUNGAL SINUSITIS" , "Term1" : "Fungal sinusitis " , "Term2" : "Sinusitis, fungal", "DisplayText" : "Fungal Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "FUNGAL SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fungal sinusitis mainly affects immunocompromised patients, but occasionally it"}, 
{"Row" :6, "Column" : 1, "Text" : "occurs in immunocompetent hosts. Drainage is essential. Consult ENT and"}, 
{"Row" :7, "Column" : 1, "Text" : "Infectious Disease."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "References: "}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Up-to-Date article: Fungal rhinosinusitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}
]},
{"Name" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP." , "Term1" : "Aspergillus infections, general", "DisplayText" : "Aspergillus spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "DisplayText" : "Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses", "Text" : "Voriconazole 6 mg/kg IV q12h for 2 doses, then 4 mg/kg IV q12h ($$$$) [R,H,", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 200MG PO BID", "DisplayText" : "Voriconazole 200mg po bid (Var)", "Text" : "Voriconazole 200 mg PO q12h ($$) [R,H,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ASPERGILLUS SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For localized disease (fungus ball), antifungal therapy is ineffective."}, 
{"Row" :6, "Column" : 1, "Text" : "Consult Surgery and Pulmonary for cases of localized disease without systemic"}, 
{"Row" :7, "Column" : 1, "Text" : "infection. Consult Infectious Diseases in all cases."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat invasive disease with intravenous antifungals initially, then"}, 
{"Row" : 11, "Column" : 1, "Text" : "switch to oral antifungals for a total duration of therapy of 6-12"}, 
{"Row" : 12, "Column" : 1, "Text" : "weeks dependent on the degree and duration of immunosuppression, site of disease"}, 
{"Row" : 13, "Column" : 1, "Text" : "and evidence of disease improvement."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred intravenous therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative intravenous therapy for patients intolerant to voriconazole", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Oral therapy after disease has stabilized", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell Chapter: Aspergillus Species"}, 
{"Row" : 28, "Column" : 1, "Text" : "Patterson et al. Clinical Infectious Diseases. 2016, 63(4): e1-60"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Aspergillosis, Invasive"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of invasive aspergillosis"}
]},
{"Name" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS" , "Term1" : "Blastomycosis infections, general", "DisplayText" : "Blastomyces dermatidis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200 BID", "DisplayText" : "Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6-12 months", "Text" : "Itraconazole 200 mg PO q8h for 3 days then q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400-800 mg PO q24h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "14"},
{"Row" : 43, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO Q24H", "DisplayText" : "Fluconazole 800 mg PO q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg PO q24h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "BLASTOMYCES DERMATITIDIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be"}, 
{"Row" :6, "Column" : 1, "Text" : "required in immunosuppressed patients if immunosuppression cannot be reversed."}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Disease outside of the central nervous system", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for 6-12 months. It is recommended that immunocompromised patients be"}, 
{"Row" : 15, "Column" : 1, "Text" : "treated with at least 1-2 weeks of intravenous treatment and a total treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "duration of 12 months."}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Change to oral itraconazole after the patient's condition has stabilized."}, 
{"Row" : 25, "Column" : 1, "Text" : "Oral therapy after disease has stabilized", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Central nervous system infection", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Treat with intravenous therapy for 4-6 weeks followed by oral azole for at least"}, 
{"Row" : 37, "Column" : 1, "Text" : "12 months."}, 
{"Row" : 39, "Column" : 1, "Text" : "Initial intravenous treatment", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Oral therapy after disease has stabilized", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Blastomycosis"}, 
{"Row" : 53, "Column" : 1, "Text" : "Up-to-Date article: Treatment of blastomycosis"}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS" , "Term1" : "Candida albicans infections, general", "DisplayText" : "Candida albicans" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID NYSTATIN SWISH AND SWALLOW 5ML Q6H", "DisplayText" : "Nystatin swish and swallow 500", "Text" : "Nystatin swish and swallow q6h for 7-14 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE TROCHE 10MG PO 5X/DAY", "DisplayText" : "Clotrimazolel troche 10mg po 5x/day", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q24H", "DisplayText" : "Fluconazole 200 mg po q24h ($0.20) [R", "Text" : "Fluconazole 200 mg PO q24h for 7-14 days ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg PO q24h for 14-21 days ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h", "Text" : "Fluconazole 400 IV q24h for 14-21 days ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "Liposomal amphotericin (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O]", "Mnemonic" : "18"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "DisplayText" : "Micafungin 100 mg IV q24h", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA ALBICANS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Avoid using fluconazole empirically to treat candidal infections in patients who"}, 
{"Row" :6, "Column" : 1, "Text" : "have received an imidazole in the previous year."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of thrush or oropharyngeal candidiasis", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white"}, 
{"Row" : 10, "Column" : 1, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with"}, 
{"Row" : 11, "Column" : 1, "Text" : "dentures), or as pseudomembranes."}, 
{"Row" : 12, "Column" : 1, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult MRTC"}, 
{"Row" : 13, "Column" : 1, "Text" : "clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for"}, 
{"Row" : 14, "Column" : 1, "Text" : "more information on treatment of recurrent infection."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild disease."}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "Moderate to severe disease"}, 
{"Row" : 24, "Column" : 1, "Text" : "Esophageal candidiasis", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Esophageal infection requires systemic therapy."}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for patient who cannot swallow tablets"}, 
{"Row" : 33, "Column" : 1, "Text" : "Systemic candidal infection", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Fluconazole is preferred empirical therapy in most cases. Amphotericin B should"}, 
{"Row" : 35, "Column" : 1, "Text" : "be used empirically in patients who have received an azole antifungal drug"}, 
{"Row" : 36, "Column" : 1, "Text" : "recently, or in patients who are critically ill."}, 
{"Row" : 38, "Column" : 1, "Text" : "Duration of antimicrobial therapy"}, 
{"Row" : 39, "Column" : 1, "Text" : "Duration of therapy is dependent upon location, severity of infection,"}, 
{"Row" : 40, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 42, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "Recent azole antifungal treatment"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 55, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 56, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 58, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA" , "Term1" : "Candida glabrata infections, general", "DisplayText" : "Candida glabrata" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "DisplayText" : "Micafungin 100 mg IV q24h", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "DisplayText" : "Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses", "Text" : "Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 400MG PO Q12H THEN 200MG Q12H", "DisplayText" : "Voriconazole 400mg po q12h for 2 doses then 200mg po q12h", "Text" : "Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA GLABRATA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. glabrata is often resistant to fluconazole and occasionally has some degree"}, 
{"Row" :6, "Column" : 1, "Text" : "of resistance to amphotericin. Higher doses of amphotericin are recommended due"}, 
{"Row" :7, "Column" : 1, "Text" : "to delayed killing effects against Candida glabrata."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 11, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "*150mg q24h for esophageal candidiasis, 100mg q24h for other indications"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative for susceptible isolates", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 28, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI" , "Term1" : "Candida krusei infections, general", "DisplayText" : "Candida krusei" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "DisplayText" : "Micafungin 100 mg IV q24h", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "DisplayText" : "Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses", "Text" : "Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 400MG PO Q12H THEN 200MG Q12H", "DisplayText" : "Voriconazole 400mg po q12h for 2 doses then 200mg po q12h", "Text" : "Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA KRUSEI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. krusei is resistant to fluconazole, and often has some degree of resistance"}, 
{"Row" :6, "Column" : 1, "Text" : "to amphotericin. Higher doses of amphotericin are recommended for treatment of"}, 
{"Row" :7, "Column" : 1, "Text" : "C. krusei due to decreased susceptibility."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 11, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "*150mg q24h for esophageal candidiasis, 100mg q24h for other indications"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 29, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES" , "Term1" : "Coccidioides infections, general", "DisplayText" : "Coccidioidomyces" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h", "Text" : "Fluconazole 400-800 mg IV q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "COCCIDIOIDOMYCES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pulmonary and Infectious Diseases consultations are essential for diagnosis and"}, 
{"Row" :6, "Column" : 1, "Text" : "treatment."}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate disease", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Observation alone is indicated for some cases. Consult Infectious Diseases for"}, 
{"Row" : 14, "Column" : 1, "Text" : "more information. If antifungal treatment is indicated: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 22, "Column" : 1, "Text" : "Severe disease (diffuse pneumonia, rapid progression or central nervous system", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "infection)", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell Chapter: Coccidioidomycosis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford guide keyword: Coccidioidomycosis"}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS" , "Term1" : "Cryptococcus neoformans", "DisplayText" : "Cryptococcus Neoformans " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "CRYPTOCOCCUS NEOFORMANS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases."}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" :9, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate infection outside of the central nervous system", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "or step-down treatment once disease has stabilized", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment of central nervous system infection or severe infection outside", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "central nervous system", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases, recommended combination therapy"}, 
{"Row" : 22, "Column" : 1, "Text" : "with flucytosine requires ID approval"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus"}, 
{"Row" : 30, "Column" : 1, "Text" : "gattii)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Cryptococcus"}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Text" : "Amphotericin B Liposomal (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O] <AND>"}, 
{"Row" : 24, "Column" : 1, "Text" : "flucytosine 25 mg/kg PO q6h ($$$$$) [R,O]"}, 
{"Row" : 25, "Column" : 1, "Text" : "(Reminder: for Ampho B add NS 500 ml hydration BEFORE & AFTER.)"}
]},
{"Name" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM" , "Term1" : "Histoplasma capsulatum", "DisplayText" : "Histoplasma capsulatum" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : "", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400-800 mg PO q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "HISTOPLASMA CAPSULATUM", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Intravenous antifungals are indicated initially for severe or progressive"}, 
{"Row" :6, "Column" : 1, "Text" : "disease. After disease has stabilized, oral antifungals may be used to complete"}, 
{"Row" :7, "Column" : 1, "Text" : "the course. Contact Infectious Diseases and Pulmonary services for advice."}, 
{"Row" :8, "Column" : 1, "Text" : "Contact HIV expert for advice on cases involving patients with HIV."}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 12, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred initial therapy for meningitis, severe pulmonary or disseminated", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "disease", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment after disease has stabilized", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Itraconazole is more effective than fluconazole, but fluconazole may be used in"}, 
{"Row" : 20, "Column" : 1, "Text" : "patients who cannot tolerate itraconazole."}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Histoplasma capsulatum (Histoplasmosis)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Histoplasmosis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Diagnosis and treatment of pulmonary histoplasmosis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Wheat et al. Clinical Infectious Diseases. 2007 (45) 807-25"}
]},
{"Name" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES" , "Term1" : "Carbuncles " , "Term2" : "Furuncles", "DisplayText" : "Furuncles and carbuncles" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg po q12h ($) [DI]", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "FURUNCLES AND CARBUNCLES"}, 
{"Row" :5, "Column" : 1, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous"}, 
{"Row" :6, "Column" : 1, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is an"}, 
{"Row" :7, "Column" : 1, "Text" : "inflamed nodule that usually develops as a complication of folliculitis.A"}, 
{"Row" :8, "Column" : 1, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous"}, 
{"Row" :9, "Column" : 1, "Text" : "tissue.Contact a wound care nurse for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous"}, 
{"Row" : 12, "Column" : 1, "Text" : "abscesses, and large furuncles."}, 
{"Row" : 14, "Column" : 1, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct"}, 
{"Row" : 15, "Column" : 1, "Text" : "to incision and drainage should be made based on the presence of systemic"}, 
{"Row" : 16, "Column" : 1, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired"}, 
{"Row" : 17, "Column" : 1, "Text" : "host defenses."}, 
{"Row" : 19, "Column" : 1, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "recommended consider a decolonization regimen.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Mild infection: Purulent infection without systemic signs of infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Recommend incision and drainage. No antibiotic indicated."}, 
{"Row" : 26, "Column" : 1, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Recommend incision and drainage. Culture material and use results to guide"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 29, "Column" : 1, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time."}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Severe Infections: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Patients who have failed incision and drainage along with oral antibiotics"}, 
{"Row" : 45, "Column" : 1, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished"}, 
{"Row" : 46, "Column" : 1, "Text" : "neutrophil function."}, 
{"Row" : 47, "Column" : 1, "Text" : "Recommend incision and drainage. Culture material and use results to guide"}, 
{"Row" : 48, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 49, "Column" : 1, "Text" : "Treat for 5 days. Reevaluate patient and extend or modify treatment if not"}, 
{"Row" : 50, "Column" : 1, "Text" : "improved in this time."}, 
{"Row" : 54, "Column" : 1, "Text" : "References: "}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 56, "Column" : 1, "Text" : "Sanford keyword: Furuncle, carbuncle"}, 
{"Row" : 57, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 58, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "", "Mnemonic" : "20"}
]},
{"Name" : "ORZID2 GMENU GI ENDOSCOPIC PROCEDURES" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU SURG ERCP", "DisplayText" : "Endoscopic Retrograde Cholangiopancreatography (ERCP)", "Text" : "Endoscopic Retrograde Cholangiopancreatography (ERCP)-Inpatient", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX GI EUS-FNA ENDO PROCED", "Text" : "Endoscopic Ultrasound-FNA Gastrointestinal Tract", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU GI PEG TUBE PLACEMENT", "Text" : "Placement of Percutaneous Gastrostomy (PEG) Tube", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ANTIBIOTIC PROPHYLAXIS FOR GI ENDOSCOPIC PROCEDURES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the"}, 
{"Row" :6, "Column" : 1, "Text" : "risk of iatrogenic infectious complications."}
]},
{"Name" : "ORZID2 GMENU GI PEG TUBE PLACEMENT" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV ONCE 'C'", "DisplayText" : "Clindamycin 600mg iv once", "Text" : "Clindamycin 600 mg IV over 30 minutes beginning 60 minutes", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "Antibiotic Prophylaxis for Placement of Percutaneous Gastrostomy (PEG) Tube", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antibiotics are recommended for all patients prior to placement of PEG tube"}, 
{"Row" :6, "Column" : 1, "Text" : "to reduce the risk of peristomal wound infection."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred Prophylaxis: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative for patient with severe penicillin allergy: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "before incision ($$) [H,O]"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 17, "Column" : 1, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal"}, 
{"Row" : 18, "Column" : 1, "Text" : "Endoscopy 2008, 67:791-795"}
]},
{"Name" : "ORZID2 GMENU GN INT RS GNB" , "Term1" : "Gram-negative bacilli interim culture results", "DisplayText" : "Interim results:Gram-negative Bacilli " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE BACILLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can"}, 
{"Row" :6, "Column" : 1, "Text" : "show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and"}, 
{"Row" :7, "Column" : 1, "Text" : "Prevotella spp. usually grow anaerobically (but can show up in an aerobic"}, 
{"Row" :8, "Column" : 1, "Text" : "bottle). Most other gram-negative bacilli are facultative, i.e. they can grow"}, 
{"Row" :9, "Column" : 1, "Text" : "in aerobic or anaerobic culture conditions."}, 
{"Row" : 11, "Column" : 1, "Text" : "Some antimicrobial combinations are synergistic in vitro against some Gram-"}, 
{"Row" : 12, "Column" : 1, "Text" : "negative bacilli. Combination therapy has not been shown to improve outcomes"}, 
{"Row" : 13, "Column" : 1, "Text" : "in most circumstances. Single drug therapy is used in most cases. Contact"}, 
{"Row" : 14, "Column" : 1, "Text" : "Infectious Diseases for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Use susceptibility information to select an antimicrobial when a pathogen is"}, 
{"Row" : 17, "Column" : 1, "Text" : "identified."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment before pathogen is identified", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment if Pseudomonas is suspected", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative for critically ill patients", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "IV q24h ($) [R,O]"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford Keyword: Antibacterial Activity Spectra"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford Keyword: Pseudomonas aeruginosa"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas"}, 
{"Row" : 38, "Column" : 1, "Text" : "aeruginosa infections"}
]},
{"Name" : "ORZID2 GMENU GN INT RS GNC" , "Term1" : "Gram-negative cocci interim culture results", "DisplayText" : "Interim results:Gram-negative cocci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 3-4 million units IV q4 hr ($$) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE COCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or Moraxella. This"}, 
{"Row" :6, "Column" : 1, "Text" : "page recommends empirical therapy before the final identification of the"}, 
{"Row" :7, "Column" : 1, "Text" : "pathogen,based on the clinical situation."}, 
{"Row" :9, "Column" : 1, "Text" : "If meningococci are suspected", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "If gonoccoci are suspected", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "If Moraxella is suspected", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Neisseria meningitidis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Neisseia gonorrhoeae"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Moraxella catarrhalis"}
]},
{"Name" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA" , "Term1" : "Bacteria, Gram-Negative section " , "Term2" : "Gram-Negative Bacteria section", "DisplayText" : "Gram-negative Bacteria" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU GN INT RS GNB", "DisplayText" : "Interim results:Gram-negative Bacilli", "Text" : "Gram-negative bacilli", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU GN INT RS GNC", "DisplayText" : "Interim results:Gram-negative cocci", "Text" : "Gram-negative cocci", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "++ GRAM-NEGATIVE BACTERIA ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome,"}, 
{"Row" :6, "Column" : 1, "Text" : "site of infection, penetration of"}, 
{"Row" :7, "Column" : 1, "Text" : "drug(s)into site, and whether"}, 
{"Row" :8, "Column" : 1, "Text" : "organism is pathogen, colonizer, or"}, 
{"Row" :9, "Column" : 1, "Text" : "contaminant. See disease/syndrome"}, 
{"Row" : 10, "Column" : 1, "Text" : "section for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Interim culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "++ MULTIDRUG RESTANT ORGANISMS ++", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ESBLS, Amp-C beta-lactamases, and", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Carbapenemases", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Consider whether patient is at risk"}, 
{"Row" : 22, "Column" : 1, "Text" : "for or has evidence of infection with"}, 
{"Row" : 23, "Column" : 1, "Text" : "Gram-negative bacilli carrying"}, 
{"Row" : 24, "Column" : 1, "Text" : "extended-spectrum beta-lactamases"}, 
{"Row" : 25, "Column" : 1, "Text" : "(ESBLs), AmpC beta-lactamases, or"}, 
{"Row" : 26, "Column" : 1, "Text" : "carbapenemases."}, 
{"Row" : 29, "Column" : 1, "Text" : "lactamases, and carbapenemases."}, 
{"Row" : 32, "Column" : 1, "Text" : "Last Reviewed December 2017", "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI", "DisplayText" : "Acinetobacter baumanni", "Text" : "Acinetobacter baumanni", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.", "DisplayText" : "Citrobacter spp.", "Text" : "Citrobacter spp.", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.", "DisplayText" : "Enterobacter spp.", "Text" : "Enterobacter spp.", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI", "DisplayText" : "Escherichia coli", "Text" : "Escherichia coli", "Mnemonic" : "22"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.", "DisplayText" : "Klebsiella spp.", "Text" : "Klebsiella spp.", "Mnemonic" : "28"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.", "DisplayText" : "Proteus spp.", "Text" : "Proteus spp.", "Mnemonic" : "34"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.", "DisplayText" : "Serratia spp.", "Text" : "Serratia spp.", "Mnemonic" : "40"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.", "DisplayText" : "Bordetella species", "Text" : "Bordetella spp.", "Mnemonic" : "12"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella spp.", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.", "DisplayText" : "Campylobacter spp.", "Text" : "Campylobacter spp.", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.", "DisplayText" : "Haemophilus spp.", "Text" : "Haemophilus spp.", "Mnemonic" : "24"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection", "Text" : "Helicobacter pylori", "Mnemonic" : "26"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.", "DisplayText" : "Legionella spp.", "Text" : "Legionella spp.", "Mnemonic" : "30"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA", "DisplayText" : "Pasteurella multocida", "Text" : "Pasteurella multocida", "Mnemonic" : "32"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.", "DisplayText" : "Pseudomonas spp.", "Text" : "Pseudomonas spp.", "Mnemonic" : "36"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.", "DisplayText" : "Salmonella spp.", "Text" : "Salmonella spp.", "Mnemonic" : "38"},
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)", "Text" : "Shigella spp (bacillary dysentery)", "Mnemonic" : "42"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis", "Text" : "Neisseria meningitidis", "Mnemonic" : "50"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae", "Text" : "Neisseria gonorrhoeae", "Mnemonic" : "48"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis", "Text" : "Moraxella catarrhalis", "Mnemonic" : "46"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (including Prevotella, Porphyromonas)", "Text" : "Bacteriodes, Porphyromonas,", "Mnemonic" : "44"},
{"Row" : 11, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Final culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : ">> Gram-negative bacilli <<", "Header" : 1}, 
{"Row" : 34, "Column" : 2, "Text" : ">> Gram-negative cocci <<", "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Text" : "Prevotella"}
]},
{"Name" : "ORZID2 GMENU GRAM POS BACTERIA" , "Term1" : "Bacteria, Gram-Positive section " , "Term2" : "Gram-positive bacteria, section", "DisplayText" : "Gram-positive bacteria" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs", "Text" : "Gram-positive cocci", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "DisplayText" : "Interim report of Gram-positive rods", "Text" : "Gram-positive bacilli", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "++ GRAM-POSTITIVE BACTERIA ++", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Always consider disease or syndrome,"}, 
{"Row" :7, "Column" : 1, "Text" : "site of infection, penetration of"}, 
{"Row" :8, "Column" : 1, "Text" : "drug(s) into site, and whether"}, 
{"Row" :9, "Column" : 1, "Text" : "organism is pathogen, colonizer, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "contaminant. See disease/syndrome"}, 
{"Row" : 11, "Column" : 1, "Text" : "section for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Interim culture results", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Last Reviewed December 2017", "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI", "DisplayText" : "Staphylococci", "Text" : "Staphylococci", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "DisplayText" : "Group A Streptococci (S. pyogenes)", "Text" : "Group A (S. pyogenes)", "Mnemonic" : "12"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "DisplayText" : "Group B Streptococci (S. agalactiae)", "Text" : "Group B (S. agalactiae)", "Mnemonic" : "14"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "DisplayText" : "Streptococci Groups C, F, G", "Text" : "Groups C, F, G", "Mnemonic" : "16"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "DisplayText" : "Group D (S. bovis)", "Text" : "Group D (S. bovis)", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)", "Text" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE", "DisplayText" : "Streptococcus pneumoniae", "Text" : "Streptococcus pneumoniae", "Mnemonic" : "22"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS", "DisplayText" : "Streptococcus anginosus (formerly S. milleri)", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Mnemonic" : "24"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "DisplayText" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Text" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Mnemonic" : "26"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI", "DisplayText" : "Enterococci", "Text" : "Enterococci", "Mnemonic" : "28"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "DisplayText" : "Bacillus species", "Text" : "Bacillus spp.", "Mnemonic" : "30"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.", "DisplayText" : "Clostridium spp.", "Text" : "Clostridium spp.", "Mnemonic" : "32"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.", "DisplayText" : "Corynebacterium spp.", "Text" : "Corynebacteriium spp.", "Mnemonic" : "34"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.", "DisplayText" : "Propionibacterium spp.", "Text" : "Cutibacterium (formerly Propionibacterium) spp.", "Mnemonic" : "36"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.", "DisplayText" : "Actinomyces spp.", "Text" : "Actinomyces spp.", "Mnemonic" : "38"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.", "DisplayText" : "Listeria spp.", "Text" : "Listeria spp.", "Mnemonic" : "40"},
{"Row" : 12, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "Final culture results", "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Text" : ">> Gram-positive cocci <<", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Streptococci", "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Text" : ">> Gram-positive bacilli <<", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP." , "Term1" : "Bacteroides infections, general " , "Term2" : "Porphyromonas infections, general " , "Term3" : "Prevotella infections, general", "DisplayText" : "Bacteroides spp. (including Prevotella, Porphyromonas)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 1000MG PO Q12H", "DisplayText" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Text" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 1000MG IV Q12H", "DisplayText" : "METRONIDAZOLE 1000MG IV Q12H", "Text" : "Metronidazole 1000 mg IV q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "These bacteria are strict anaerobes and will only grow in anaerobic media."}, 
{"Row" :7, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :8, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Bacteriodes sp., Overview"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-To-Date article: Anaerobic bacterial infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP." , "Term1" : "Campylobacter, general", "DisplayText" : "Campylobacter spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "DisplayText" : "Azithromycin 500 mg IV q24h ($) [O]", "Text" : "Azithromycin 500 mg IV q24h ($) [O]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "CAMPYLOBACTER SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal Optimal therapy depends on both the disease or syndrome and the"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogen. See diagnosis/syndrome section for more information. Drugs"}, 
{"Row" :7, "Column" : 1, "Text" : "recommended below are best for most cases. If susceptibility results or other"}, 
{"Row" :8, "Column" : 1, "Text" : "factors make these inappropriate for this case, click need an alternative"}, 
{"Row" : 11, "Column" : 1, "Text" : "For information on gastroenteritis (usually involving C. jejuni), refer to the"}, 
{"Row" : 12, "Column" : 1, "Text" : "Gastrointestinal and Intraabdominal infection section."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment of extraintestinal infectious not involving the central nervous", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "system infections", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment of central nervous system infections", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Campylobacter jejuni, Campylobacter coli"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 35, "Column" : 1, "Text" : "Campylobacter infection"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP." , "Term1" : "Enterobacter species, general", "DisplayText" : "Enterobacter spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TAZO 3.375 Q6H GENT 5MG/KG Q24H", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 IV Q12H GENT 5MG/KG IV Q24H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROBACTER SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "q24h ($) [R,O]"}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Enterobacter sp."}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS" , "Term1" : "Moraxella catarrhalis infections, general", "DisplayText" : "Moraxella catarrhalis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "MORAXELLA CATARRHALIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Moraxella catarrhalis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date article: Moracella catarrhalis infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE" , "Term1" : "Neisseria gonorrhoeae infections, general", "DisplayText" : "Neisseria gonorrhoeae " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NEISSERIA GONORRHOEAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen."}, 
{"Row" :6, "Column" : 1, "Text" : "See diagnosis/syndrome section for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred treatment for disseminated gonococcal infection: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-To-Date article: Disseminated gonococcal infection"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Neisseria gonorrhoeae"}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for at least 7 days. Need susceptibility testing of the bloodstream"}, 
{"Row" : 13, "Column" : 1, "Text" : "isolate to guide potential switch to an oral medication."}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment"}, 
{"Row" : 18, "Column" : 1, "Text" : "of the reaction is recommended."}, 
{"Row" : 19, "Column" : 1, "Text" : "-Consult Infectious Disease to determine best alternative to cephalosporin."}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "04"},
{"Row" : 24, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916"}, 
{"Row" :8, "Column" : 1, "Text" : "All gonorrhea patients should be tested for HIV, syphilis, and Chlamydia"}, 
{"Row" :9, "Column" : 1, "Text" : "trachomatis. Sexual partners should be evaluated."}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS" , "Term1" : "Neisseria meningitidis infections, general", "DisplayText" : "Neisseria meningitidis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "DisplayText" : "Penicillin G 3 million units IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 1 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CHLORAMPHENICOL 12.5 MG/KG IV Q6H", "DisplayText" : "Chloramphenicol 12.5 mg/kg IV q6h ($$) [O]", "Text" : "Chloramphenicol 12.5 mg/kg IV q6h ($$) [O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "NEISSERIA MENINGITIDIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Central nervous system infections require higher doses of antimicrobials."}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment for infections outside of the central nervous system", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment for central nervous system infections", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 20, "Column" : 1, "Text" : "For patients intolerant to cephalosporins"}, 
{"Row" : 22, "Column" : 1, "Text" : "Call pharmacy, chloramphenicol is not regularly stocked and will need to be"}, 
{"Row" : 23, "Column" : 1, "Text" : "special ordered."}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Neisseria meningitidis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-To-Date article: Treatment and prevention of meningococcal infection"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA" , "Term1" : "Pasteurella multocida infections, general", "DisplayText" : "Pasteurella multocida " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PASTEURELLA MULTOCIDA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Pasteurella multocida"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date article: Pasteurella infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP." , "Term1" : "Pseudomonas infections, general", "DisplayText" : "Pseudomonas spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM Q6H TOBRA 5MG/KG Q24H", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > tobramycin 5 mg/kg IV", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > tobramycin 5 mg/kg IV", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM Q8H TOBRA 5MG/KG Q24H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R] < AND > tobramycin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] < AND > tobramycin 5 mg/kg IV q24h ($) [R,O", "Mnemonic" : "14"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2G Q8H TOBRA 5MG/KG Q24H", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R] < AND > tobramycin 5 mg/kg IV q24h ($)", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] < AND > tobramycin 5 mg/kg IV q24h ($)", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "PSEUDOMONAS SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "In severe cases, addition of an aminoglycoside to a beta"}, 
{"Row" : 11, "Column" : 1, "Text" : "lactam may be beneficial. Aminoglycoside monotherapy is effective only in"}, 
{"Row" : 12, "Column" : 1, "Text" : "treatment of UTI. Refer to genitourinary section for treatment of UTI due to"}, 
{"Row" : 13, "Column" : 1, "Text" : "pseudomonas. Consult Infectious Diseases for more information."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Oral treatment for mild infections"}, 
{"Row" : 23, "Column" : 1, "Text" : "For patients with Beta-lactam allergy"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for severe infections", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "q24h ($) [R,O]"}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "For patients with Beta-lactam allergy"}, 
{"Row" : 34, "Column" : 1, "Text" : "[R,O]"}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas"}, 
{"Row" : 42, "Column" : 1, "Text" : "aeruginosa infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP." , "Term1" : "Salmonella infections, general", "DisplayText" : "Salmonella spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SALMONELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis antimicrobials are not usually indicated. Please refer to"}, 
{"Row" : 11, "Column" : 1, "Text" : "the Gastrointestinal and Intra-abdominal infections section for more"}, 
{"Row" : 12, "Column" : 1, "Text" : "information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 15, "Column" : 1, "Text" : "salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 16, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 20, "Column" : 1, "Text" : "For localized or systemic extraintestinal infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Salmonella sp."}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN SHIGELLA SPP." , "Term1" : "Shigella infections, general", "DisplayText" : "Shigella spp. (bacillary dysentery) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "SHIGELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal"}, 
{"Row" : 11, "Column" : 1, "Text" : "infections section for more information. antibiotic resistance is increasing,"}, 
{"Row" : 12, "Column" : 1, "Text" : "especially among men who have sex with men. Drug selection should be based on"}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial susceptibility tests."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment for systemic infections", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 29, "Column" : 1, "Text" : "MMWR (2015) 64.318"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Shigella Sp."}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-To-Date article: Shigella infection: Treatment and prevention in adults"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI" , "Term1" : "Acinetobacter baumannii, general", "DisplayText" : "Acinetobacter baumanni" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases.", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM Q8H AMIK 7.5 MG/KG Q12H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> amikacin 7.5 mg/kg IV q12h ($$) [R,O]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> amikacin 7.5 mg/kg IV q12h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "ACINETOBACTER BAUMANNII", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Isolation of Acinetobacter baumannii from a culture often represents"}, 
{"Row" :6, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" :7, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Many isolates are resistant to multiple antimicrobials. If susceptibilities are"}, 
{"Row" : 13, "Column" : 1, "Text" : "not known, start therapy with imipenem or amikacin."}, 
{"Row" : 14, "Column" : 1, "Text" : "If susceptibities are known, use appropriate antimicrobial."}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 17, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 18, "Column" : 1, "Text" : "Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 19, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sulbactam is active against some strains of ESBLs", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Acinetobacter baumannii"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Acinetobacter infection: Treatment and prevention"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP." , "Term1" : "Bordetella infections, general", "DisplayText" : "Bordetella species" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "DisplayText" : "Azithromycin 500mg IV once then 250 mg IV q24h x 4days", "Text" : "Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "DisplayText" : "Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "BORDETELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Bordetella pertussis"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP." , "Term1" : "Brucella infections, general " , "Term2" : "Brucella spp.", "DisplayText" : "Brucella spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX DOXYCY 100MG PO Q12H RIFAMP 600MG PO Q24H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI] < AND > rifampin 600 mg PO", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] < AND > rifampin 600 mg PO q24h ($)", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "BRUCELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for non-localizing disease only. Consult Infectious Diseases for"}, 
{"Row" :7, "Column" : 1, "Text" : "specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,"}, 
{"Row" :8, "Column" : 1, "Text" : "endocarditis, etc.)"}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat with both drugs for 45 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "[DI,O]"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford keyword: Brucellosis"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 20, "Column" : 1, "Text" : "brucellosis"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP." , "Term1" : "Citrobacter infections, general", "DisplayText" : "Citrobacter spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CITROBACTER SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Citrobacter sp."}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI" , "Term1" : "Escherichia coli infections, general", "DisplayText" : "Escherichia coli" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3 GM PO ONCE", "DisplayText" : "FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] once", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "16"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "18"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "20"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "22"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3GM PO QOD 3 DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "24"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "26"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3GM PO QOD 3 DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "28"},
{"Row" :3, "Column" : 1, "Text" : "ESCHERICHIA COLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal"}, 
{"Row" : 11, "Column" : 1, "Text" : "infections section."}, 
{"Row" : 13, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 14, "Column" : 1, "Text" : "E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 15, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 19, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "E. coli carrying ESBL: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "E. coli carrying carbapenemase: ", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "References: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford keyword: Escherichia coli"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP." , "Term1" : "Haemophilus infections, general", "DisplayText" : "Haemophilus spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "DisplayText" : "Azithromycin 500mg IV once then 250 mg IV q24h x 4days", "Text" : "Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "HAEMOPHILUS SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Haemophilus influenzae"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-To-Date article: "}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP." , "Term1" : "Klebsiella infections, general", "DisplayText" : "Klebsiella spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "DisplayText" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "10"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX FOSFOMYCIN 3 GM PO ONCE", "DisplayText" : "FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] once", "Mnemonic" : "14"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "16"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "18"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "KLEBSIELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 11, "Column" : 1, "Text" : "klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 12, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Klebsiella sp."}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP." , "Term1" : "Legionella infections, general", "DisplayText" : "Legionella spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "DisplayText" : "Azithromycin 500 mg IV q24h ($) [O]", "Text" : "Azithromycin 500 mg IV q24h ($) [O]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "LEGIONELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Consider treating for up to 21 days in immunosuppressed patients who are"}, 
{"Row" :9, "Column" : 1, "Text" : "severely ill upon presentation."}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for 10 days"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for patients intolerant to macrolides"}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for 10 days"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Legionella sp."}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-To-Date article: Treatment and prevention of Legionella infection"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP." , "Term1" : "Proteus infections, general", "DisplayText" : "Proteus spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "DisplayText" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "14"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "PROTEUS SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 11, "Column" : 1, "Text" : "proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 12, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "Allergy to penicillin"}, 
{"Row" : 24, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Proteus sp."}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP." , "Term1" : "Serratia infections, general", "DisplayText" : "Serratia spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "DisplayText" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "SERRATIA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Serratia marcescens"}, 
{"Row" : 26, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-To-Date article: Infections due to Serratia species"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP." , "Term1" : "Actinomyces infections, general", "DisplayText" : "Actinomyces spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Mnemonic" : "12"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "14"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "ACTINOMYCES SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Actinomycosis"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI" , "Term1" : "Anaerobic gram-positive cocci " , "Term2" : "Gram-positive cocci, anaerobic " , "Term3" : "Peptostreptococcus infections, general", "DisplayText" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "DisplayText" : "Penicillin G 3 million units IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AMPICIL 2GM IV Q6H", "DisplayText" : "Ampicillin 2 gm IV q6h ($$) [R]", "Text" : "Ampicillin 2 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "ANAEROBIC GRAM-POSITIVE COCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Anaerobic Gram-positive cocci, including peptostreptococci, are often involved"}, 
{"Row" :6, "Column" : 1, "Text" : "in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and"}, 
{"Row" :7, "Column" : 1, "Text" : "penicillin) and clindamycin are the drugs of choice against anaerobic gram-"}, 
{"Row" :8, "Column" : 1, "Text" : "positive cocci. Beta-lactam/beta-lactamase inhibitors are active against"}, 
{"Row" :9, "Column" : 1, "Text" : "peptostreptococci, so no additional anaerobic antimicrobials are needed"}, 
{"Row" : 10, "Column" : 1, "Text" : "specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam"}, 
{"Row" : 11, "Column" : 1, "Text" : "or piperacillin-tazobactam are used."}, 
{"Row" : 13, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 14, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating"}, 
{"Row" : 32, "Column" : 1, "Text" : "Bacilli"}, 
{"Row" : 33, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Peptostreptococcus sp."}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP." , "Term1" : "Bacillus infections, general", "DisplayText" : "Bacillus species" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 Q8H MERO 2 Q8H LINEZOLID 600 Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG IV Q8H CLINDA 900MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "BACILLUS SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "B. cereus", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "If isolate is clindamycin-susceptable"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "B. anthracis", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Start combination therapy and contact Infectious Diseases immediately."}, 
{"Row" : 19, "Column" : 1, "Text" : "If meningitis has not been ruled out", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treat for 6 weeks"}, 
{"Row" : 22, "Column" : 1, "Text" : "($$) [R,O] < AND > linezolid 600 mg IV q12h ($$$$) [DI]"}, 
{"Row" : 24, "Column" : 1, "Text" : "If meningitis has been ruled out", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "If isolate is penicillin-susceptible"}, 
{"Row" : 27, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 29, "Column" : 1, "Text" : "Isolate is not penicillin susceptible or susceptibility unknown"}, 
{"Row" : 31, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2"}, 
{"Row" : 37, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP." , "Term1" : "Clostridium infections, general", "DisplayText" : "Clostridium spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile disease", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "DisplayText" : "Penicillin G 3 million units IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "12"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "DisplayText" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "CLOSTRIDIUM SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For Clostridium difficile disease refer to"}, 
{"Row" :8, "Column" : 1, "Text" : "Mild to moderate infections may be treated with oral antimicrobials. For"}, 
{"Row" :9, "Column" : 1, "Text" : "neutropenic enterocolitis, gas gangrene, or other necrotizing infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : "intravenous therapy is indicated. Combination therapy may be preferred. Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to the appropriate section of the CDSS or contact Infectious Diseases for more"}, 
{"Row" : 12, "Column" : 1, "Text" : "information."}, 
{"Row" : 14, "Column" : 1, "Text" : "C. perfringens food poisoning is treated with supportive care. Diarrhea resolves"}, 
{"Row" : 15, "Column" : 1, "Text" : "within 24 hours."}, 
{"Row" : 17, "Column" : 1, "Text" : "For severe infection with Clostridium spp. other than perfringens, septicum or"}, 
{"Row" : 18, "Column" : 1, "Text" : "sordellii, call Infectious Diseases."}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred empirical treatment for mild to moderate infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative for beta-lactam allergic patients"}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred empirical therapy for severe infections", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "Alternative for beta-lactam allergic patients"}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford Table 2: Recommended antimicrobial agents"}, 
{"Row" : 43, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP." , "Term1" : "Corynebacterium spp.", "DisplayText" : "Corynebacterium spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 6 MG/KG IV Q24H", "DisplayText" : "Daptomycin 6 mg/kg iv q24h", "Text" : "Daptomycin 4-6 mg/kg IV q24h ($$$$) [R]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID ERYTHROM 500MG PO Q8H", "DisplayText" : "Erythromycin 500 mg PO q8h ($$) [DI]", "Text" : "Erythromycin 500 mg PO q8h ($$) [DI]", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID ERYTHROMYCIN 500MG IV Q6H", "DisplayText" : "Erythromycin 500 mg IV q6h ($$) [DI]", "Text" : "Erythromycin 500 mg IV q6h ($$) [DI]", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 500,000 UNITS IV Q4H", "DisplayText" : "Penicillin G 500,000 units IV q4h ($$) [R]", "Text" : "Penicillin G 500,000 units IV q4h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID PENICILLIN VK 250MG PO Q6H", "DisplayText" : "Penicillin VK 250 mg PO q6h ($) [R]", "Text" : "Penicillin VK 250 mg PO q6h ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "CORYNEBACTERIUM SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Corynebacterium jeikeium", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patients intolerant of vancomycin"}, 
{"Row" : 15, "Column" : 1, "Text" : "Corynebacterium diphtheriae", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Diphtheria is usually severe and often fatal. Antitoxin is the most important"}, 
{"Row" : 17, "Column" : 1, "Text" : "treatment. Contact Infectious Diseases immediately."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for patients intolerant of erythromycin"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium diptheriae"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium jeikeium"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 36, "Column" : 1, "Text" : "diptheria"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI" , "Term1" : "Enterococcal infections, general", "DisplayText" : "Enterococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI TREAT ENTEROCOCCI", "DisplayText" : "Treatment for Enterococcal infections", "Text" : "Treatment for enterococcal infections", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The important human pathogens are Enterococcus faecium and Enterococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "faecalis. The antimicrobial susceptibilities that are reported for enterococci"}, 
{"Row" :7, "Column" : 1, "Text" : "depend on the site of the sample. For all enterococci the microbiology"}, 
{"Row" :8, "Column" : 1, "Text" : "laboratory reports susceptibility for ampicillin and vancomycin. Additionally"}, 
{"Row" :9, "Column" : 1, "Text" : "the lab reports fluoroquinolone susceptibility for urinary isolates and"}, 
{"Row" : 10, "Column" : 1, "Text" : "susceptibility to gentamicin synergy for bloodstream isolates. For more"}, 
{"Row" : 11, "Column" : 1, "Text" : "information on culture and susceptibilities, contact the microbiology laboratory"}, 
{"Row" : 13, "Column" : 1, "Text" : "Ampicillin is the drug of choice for enterococcal infections. Piperacillin is"}, 
{"Row" : 14, "Column" : 1, "Text" : "also active against enterococcus. Cephalosporins are ineffective as single"}, 
{"Row" : 15, "Column" : 1, "Text" : "agents for enterococcal infections. For patients who are allergic to penicillin"}, 
{"Row" : 16, "Column" : 1, "Text" : "or infected with penicillin-resistant enterococcus, vancomycin is the preferred"}, 
{"Row" : 17, "Column" : 1, "Text" : "drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid"}, 
{"Row" : 18, "Column" : 1, "Text" : "must be reserved for cases where no other drug can be used as it has many side"}, 
{"Row" : 19, "Column" : 1, "Text" : "effects and drug interactions, is expensive, is bacteriostatic rather than"}, 
{"Row" : 20, "Column" : 1, "Text" : "bactericidal, and its use promotes resistance."}, 
{"Row" : 22, "Column" : 1, "Text" : "Combination regimens include a primary anti-enterococcal agent (ampicillin or"}, 
{"Row" : 23, "Column" : 1, "Text" : "vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are"}, 
{"Row" : 24, "Column" : 1, "Text" : "needed for severe infections like endocarditis or prosthetic joint infections."}, 
{"Row" : 25, "Column" : 1, "Text" : "See relevant disease/syndrome sections for more information. Milder diseases"}, 
{"Row" : 26, "Column" : 1, "Text" : "like cystitis or wound infection can usually be treated with a single drug. For"}, 
{"Row" : 27, "Column" : 1, "Text" : "more information on treatment of enterococcal infections, contact Infectious"}, 
{"Row" : 28, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and"}, 
{"Row" : 37, "Column" : 1, "Text" : "Leuconostoc Species"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecalis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infection"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP." , "Term1" : "Listeria infections, general", "DisplayText" : "Listeria spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "DisplayText" : "Trimeth/sulfa 5-25 mg/kg iv q6h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "LISTERIA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :7, "Column" : 1, "Text" : "For meningitis, please refer to the meningitis section for treatment advice."}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy or intolerant of gentamicin", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Listeria monocytogenes"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-To-Date article: Treatment, prognosis, and prevention of Listeria"}, 
{"Row" : 21, "Column" : 1, "Text" : "monocytogenes infection"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP." , "Term1" : "Propionibacterium infections, general", "DisplayText" : "Propionibacterium spp." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "DisplayText" : "Penicillin 2 million units iv q4h", "Text" : "Penicillin G 2 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Isolation of Propionibacterium species from a culture often represents"}, 
{"Row" :6, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" :7, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)"}, 
{"Row" : 25, "Column" : 1, "Text" : "infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS" , "Term1" : "Streptococcus anginosus (formerly S. milleri)", "DisplayText" : "Streptococcus anginosus (formerly S. milleri) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Mnemonic" : "12"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Ceftriaxone or penicillin are preferred for central nervous system infection."}, 
{"Row" :9, "Column" : 1, "Text" : "Cefazolin or penicillin are preferred for infection outside of the central"}, 
{"Row" : 10, "Column" : 1, "Text" : "nervous system."}, 
{"Row" : 12, "Column" : 1, "Text" : "Central nervous system infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Contact Infectious Diseases for advice."}, 
{"Row" : 21, "Column" : 1, "Text" : "Infections outside of the central nervous system", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 28, "Column" : 1, "Text" : "If isolate is clindamycin-susceptable"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Streptococcus anginosus group"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Streptococcus anginosus group"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus"}, 
{"Row" : 39, "Column" : 1, "Text" : "milleri) group"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE" , "Term1" : "Streptococcus pneumoniae infections, general", "DisplayText" : "Streptococcus pneumoniae" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "DisplayText" : "Central Nervous System", "Text" : "Central Nervous System section", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "DisplayText" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "12"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCUS PNEUMONIAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Refer to Central Nervous System section for treatment of meningitis"}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred treatment for infections outside of the central nervous system", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy, or when beta-lactam resistance"}, 
{"Row" : 23, "Column" : 1, "Text" : "is suspected or proved"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Streptococcus pneumoniae"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pneumoniae"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections"}, 
{"Row" : 35, "Column" : 1, "Text" : "and bacteremia"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI TREAT ENTEROCOCCI", "DisplayText" : "Treatment for Enterococcal infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "DisplayText" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Text" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR ENTEROCOCCAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Isolation of enterococci in wounds often represents colonization rather than"}, 
{"Row" :9, "Column" : 1, "Text" : "infection. When colonization is suspected, enterococci need not be treated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment for urinary tract infections", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for systemic infections", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for resistant organisms"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for patients unable to take vancomycin or vancomycin resistant"}, 
{"Row" : 27, "Column" : 1, "Text" : "enterococci"}, 
{"Row" : 28, "Column" : 1, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and"}, 
{"Row" : 29, "Column" : 1, "Text" : "promotes bacterial resistance. It should only be used in cases where other"}, 
{"Row" : 30, "Column" : 1, "Text" : "options are not feasible. Contact Infectious Diseases for assistance."}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus"}, 
{"Row" : 41, "Column" : 1, "Text" : "gallolyticus Group, and Leuconostoc Species"}, 
{"Row" : 42, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecalis"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH" , "Term1" : "Coagulase-negative staphylococci, general " , "Term2" : "Staphylococci, coagulase-negative", "DisplayText" : "Treatment for Coagulase negative Staphylococci" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS", "DisplayText" : "Staphylococcis Lugdunensis", "Text" : "Treatment for Staphylococcus lugdunensis", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "DisplayText" : "Penicillin G 3 million units IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 39, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "20"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "22"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Mnemonic" : "26"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "28"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S."}, 
{"Row" :6, "Column" : 1, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S."}, 
{"Row" :7, "Column" : 1, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S."}, 
{"Row" :8, "Column" : 1, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S."}, 
{"Row" :9, "Column" : 1, "Text" : "warneri and S. xylosus"}, 
{"Row" : 10, "Column" : 1, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to S. lugdunensis page for treatment."}, 
{"Row" : 14, "Column" : 1, "Text" : "Isolation of coagulase-negative staphylococci from a culture often represents"}, 
{"Row" : 15, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" : 16, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" : 18, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" : 19, "Column" : 1, "Text" : "drugs."}, 
{"Row" : 24, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Preferred treatment for urinary tract infection associated with S. saprophyticu", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 48, "Column" : 1, "Text" : "References: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative"}, 
{"Row" : 51, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 52, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus sp., Coagulase-negative"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus epidermidis"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment"}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "31"},
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "If not, use drug for resistant organisms empirically until final culture"}, 
{"Row" : 22, "Column" : 1, "Text" : "and susceptibilities available."}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS" , "Term1" : "Staphylococcus aureus infections, general", "DisplayText" : "Treatment for Staphyloccus aureus " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR STAPHYLOCOCCUS AUREUS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" :6, "Column" : 1, "Text" : "drugs."}, 
{"Row" :7, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus aureus"}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus aureus"}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "If susceptibility results are not known, empirically select one of the"}, 
{"Row" : 15, "Column" : 1, "Text" : "following drugs until final culture and susceptibilities available."}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS" , "Term1" : "Group D Streptococci " , "Term2" : "Streptococcus bovis (Group D)", "DisplayText" : "Group D (S. bovis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID AMPICIL 2GM IV Q6H", "DisplayText" : "Ampicillin 2 gm IV q6h ($$) [R]", "Text" : "Ampicillin 2 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "GROUP D STREPTOCOCCI (S. BOVIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Bacteremia with Streptococcus bovis is associated with malignancy of the colon."}, 
{"Row" : 10, "Column" : 1, "Text" : "Resistance to penicillin is uncommon. Vancomycin should only be used in a"}, 
{"Row" : 11, "Column" : 1, "Text" : "patient with beta-lactam allergy, or if beta-lactam resistance is strongly"}, 
{"Row" : 12, "Column" : 1, "Text" : "suspected."}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 30, "Column" : 1, "Text" : "infections due to group D streptococci (Streptococcus bovis/Streptococcus"}, 
{"Row" : 31, "Column" : 1, "Text" : "equinus complex)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES" , "Term1" : "Group A streptococci " , "Term2" : "Streptococcus pyogenes (Group A) infections, general", "DisplayText" : "Group A Streptococci (S. pyogenes)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PENICILLIN VK 250MG PO Q6H", "DisplayText" : "Penicillin VK 250 mg PO q6h ($) [R]", "Text" : "Penicillin VK 250 mg PO q6h ($) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q12H CLINDAMYCIN 900MG IV Q8H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "18"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 15MG/KG IV Q12H CLINDAMYCIN 900MG IV Q8H", "DisplayText" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> clindamycin 900 mg IV q8h ($$)", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> clindamycin 900 mg IV q8h ($$)", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "GROUP A STREPTOCOCCI (S. PYOGENES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Group A streptococcus (Streptococcus pyogenes) is the most virulent"}, 
{"Row" :6, "Column" : 1, "Text" : "streptococcal species. Important syndromes include pharyngitis, cellulitis,"}, 
{"Row" :7, "Column" : 1, "Text" : "streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic"}, 
{"Row" :8, "Column" : 1, "Text" : "fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on"}, 
{"Row" :9, "Column" : 1, "Text" : "both the disease or syndrome and the pathogen. See diagnosis/syndrome section"}, 
{"Row" : 10, "Column" : 1, "Text" : "for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate infections (non-necrotizing)", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 22, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "Bacteremia, toxic shock syndrome and necrotizing infections", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 29, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "[H,O]"}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Streptococcus pyogenes"}, 
{"Row" : 43, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G"}, 
{"Row" : 45, "Column" : 1, "Text" : "Strep"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in"}, 
{"Row" : 47, "Column" : 1, "Text" : "adults"}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS" , "Term1" : "Staphylococcus lugdunensis infections, general", "DisplayText" : "Staphylococcis Lugdunensis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Severity of S. lugdunensis infections vary from moderate to severe."}, 
{"Row" :6, "Column" : 1, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin"}, 
{"Row" :7, "Column" : 1, "Text" : "resistance is uncommon."}, 
{"Row" :9, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" : 10, "Column" : 1, "Text" : "drugs. If not, use vancomycin empirically until final culture and"}, 
{"Row" : 11, "Column" : 1, "Text" : "susceptibilities are available."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for patients unable to take vancomycin", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative"}, 
{"Row" : 37, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus lugdunensis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-To-Date article: Staphylococcus lugdunensis"}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI" , "Term1" : "Staphylococcal infections, general", "DisplayText" : "Staphylococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS", "DisplayText" : "Treatment for Staphyloccus aureus", "Text" : "for Staphylococcus aureus", "Mnemonic" : "4"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "DisplayText" : "Treatment for Coagulase negative Staphylococci", "Text" : "for coagulase-negative staphylococci", "Mnemonic" : "6"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Click Here", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends"}, 
{"Row" :6, "Column" : 1, "Text" : "to relapse. Optimal therapy often involves intravenous therapy for defined"}, 
{"Row" :7, "Column" : 1, "Text" : "durations. See sections on specific syndromes (e.g., bacteremia or"}, 
{"Row" :8, "Column" : 1, "Text" : "endocarditis) for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "Coagulase-negative staphylococci, including Staphylococcus epidermidis and"}, 
{"Row" : 11, "Column" : 1, "Text" : "several less common species, are less virulent than S. aureus and are most"}, 
{"Row" : 12, "Column" : 1, "Text" : "commonly pathogenic when they colonize plastic or metal devices in a patient"}, 
{"Row" : 13, "Column" : 1, "Text" : "(e.g., intravenous catheters, prosthetic joints or heart valves). S."}, 
{"Row" : 14, "Column" : 1, "Text" : "lugdunensis is an uncommon but virulent coagulase-negative staphylococcus"}, 
{"Row" : 15, "Column" : 1, "Text" : "species. S. saprophyticus is associated with urinary tract infections in women."}, 
{"Row" : 17, "Column" : 1, "Text" : "Beta-lactam antimicrobials are the most active drugs against beta-lactam"}, 
{"Row" : 18, "Column" : 1, "Text" : "susceptible staphylococci. Penicillin is superior for penicillin-susceptible"}, 
{"Row" : 19, "Column" : 1, "Text" : "staphylococci, but most strains are resistant. Nafcillin and oxacillin are"}, 
{"Row" : 20, "Column" : 1, "Text" : "nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are"}, 
{"Row" : 21, "Column" : 1, "Text" : "next best. Vancomycin, a glycopeptide, is less active than the beta-lactams."}, 
{"Row" : 23, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective"}, 
{"Row" : 24, "Column" : 1, "Text" : "than beta-lactams for treatment of methicillin-susceptible staphylococcal"}, 
{"Row" : 25, "Column" : 1, "Text" : "infections, but may be useful in patients with severe penicillin allergy. For"}, 
{"Row" : 26, "Column" : 1, "Text" : "methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,"}, 
{"Row" : 27, "Column" : 1, "Text" : "minocycline, and clindamycin are useful alternatives to to vancomycin, as they"}, 
{"Row" : 28, "Column" : 1, "Text" : "are inexpensive and available in both intravenous and oral formulations. They"}, 
{"Row" : 29, "Column" : 1, "Text" : "are preferred over linezolid in most circumstances because linezolid is"}, 
{"Row" : 30, "Column" : 1, "Text" : "expensive, toxic with long-term use, and needed for treatment of highly"}, 
{"Row" : 31, "Column" : 1, "Text" : "resistant bacteria like vancomycin-resistant enterococci."}, 
{"Row" : 33, "Column" : 1, "Text" : "Combination regimens include a primary anti-staphylococcal agent (beta-lactam or"}, 
{"Row" : 34, "Column" : 1, "Text" : "vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or"}, 
{"Row" : 35, "Column" : 1, "Text" : "rifampin) often synergistic against staphylococci in vitro, but there is no"}, 
{"Row" : 36, "Column" : 1, "Text" : "evidence that combination therapy improves outcomes in staphylococcal infections"}, 
{"Row" : 37, "Column" : 1, "Text" : "in humans. Combination therapy has become the community standard for treatment"}, 
{"Row" : 38, "Column" : 1, "Text" : "of prosthetic-valve staphylococcal endocarditis based on experimental models and"}, 
{"Row" : 39, "Column" : 1, "Text" : "limited clinical data that combination therapy is superior (see endocarditis"}, 
{"Row" : 40, "Column" : 1, "Text" : "section for details)."}, 
{"Row" : 42, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Decolonization", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "References: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Baddour, et al. Circulation 2015, 132.15"}, 
{"Row" : 53, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and Intravascular Infections"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus aureus"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G" , "Term1" : "Groups C, F, G Streptococci " , "Term2" : "Streptococci Groups C, F, G infections, general", "DisplayText" : "Streptococci Groups C, F, G " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCI GROUPS C, F, G", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,"}, 
{"Row" : 33, "Column" : 1, "Text" : "Groups C and G Streptococci, and Other Related Organisms"}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G"}, 
{"Row" : 36, "Column" : 1, "Text" : "Strep"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-To-Date article: Group C and group G streptococcal infection"}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "12"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP" , "Term1" : "Streptococci viridans infections, general " , "Term2" : "Viridans streptococci", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "DisplayText" : "Cardiovascular", "Text" : "Cardiovascular", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "VIRIDANS STREPTOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Viridans streptococci are a heterogeneous group defined by their production of"}, 
{"Row" :6, "Column" : 1, "Text" : "green pigment on blood agar. Clinically important members of this group include"}, 
{"Row" :7, "Column" : 1, "Text" : "S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and"}, 
{"Row" :8, "Column" : 1, "Text" : "Streptococcus bovis are described separately. Viridans streptococci are"}, 
{"Row" :9, "Column" : 1, "Text" : "important, common pathogens in endocarditis and can also be contaminants in"}, 
{"Row" : 10, "Column" : 1, "Text" : "cultures of blood and other specimens. Consult Infectious Diseases for more"}, 
{"Row" : 11, "Column" : 1, "Text" : "information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to Cardiovascular Section for diagnosis and treatment of endocarditis"}, 
{"Row" : 17, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred treatment is penicillin or cefazolin. Vancomycin should be used only"}, 
{"Row" : 21, "Column" : 1, "Text" : "in patients with beta-lactam allergy, or if beta-lactam resistance is strongly"}, 
{"Row" : 22, "Column" : 1, "Text" : "suspected. For serious disease, consider addition of gentamicin for synergy."}, 
{"Row" : 23, "Column" : 1, "Text" : "Contact Infectious Diseases for more information."}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "q8h ($) [R,O]"}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative for patient with penicillin allergy, or if beta-lactam resistance", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "is suspected", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,"}, 
{"Row" : 43, "Column" : 1, "Text" : "Groups C and G Streptococci, and Other Related Organisms"}, 
{"Row" : 44, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Streptococci, viridans group"}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE" , "Term1" : "Group B Streptococci " , "Term2" : "Streptococcus agalactiae (Group B)", "DisplayText" : "Group B Streptococci (S. agalactiae)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "GROUP B STREPTOCOCCI (S. AGALACTIAE)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Group B streptococci (Streptococcus agalactiae) are associated most commonly"}, 
{"Row" :6, "Column" : 1, "Text" : "with bacteremia and meningitis in infants and bacteremia and urinary tract"}, 
{"Row" :7, "Column" : 1, "Text" : "infections in elderly people and people with diabetes mellitus."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 24, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Streptococcus agalactiae, Group B Strep"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-To-Date article: Group B streptococcal infections in nonpregnant adults"}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "", "Mnemonic" : "12"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU H. PYLORI INFECT" , "Term1" : "Helicobacter pylori", "DisplayText" : "Helicobacter pylori infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX BIS SUBSAL METRO TCN OMEP H PYLORI", "DisplayText" : "BIS SUBSAL METRO TCN OMEP H PYLORI", "Text" : "Bismuth subsalicylate 524 mg PO PO q6h <AND> Tetracycline 500 mg q6h ($) [DI]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "HELICOBACTER PYLORI INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "H. pylori infection is associated with peptic ulcers, gastritis, gastric"}, 
{"Row" :6, "Column" : 1, "Text" : "adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to"}, 
{"Row" :7, "Column" : 1, "Text" : "patients with confirmed H. pylori infection. Antisecretory therapy should be"}, 
{"Row" :8, "Column" : 1, "Text" : "given concurrently. Contact Gastroenterology for more information or"}, 
{"Row" : 13, "Column" : 1, "Text" : "<AND> metronidazole 250mg PO q6h ($) [DI] <AND> omeprazole 20 mg PO q12h"}, 
{"Row" : 14, "Column" : 1, "Text" : "Take all for 14 days."}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Treatment regimens for Helicobacter pylori"}, 
{"Row" : 24, "Column" : 1, "Text" : "Chey et al, Am J Gastroenterol, 2017,112:212-239"}, 
{"Row" :9, "Column" : 1, "Text" : "treatment failures to first line."}, 
{"Row" : 11, "Column" : 1, "Text" : "First line treatment: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CLARITH AMOX METRO OMEPRO H PYLORI", "DisplayText" : "CLARITH AMOX METRO OMEPRO H PYLORI", "Text" : "Clarithromycin 500 mg PO q12h ($)[R,DI] <AND> Amoxicillin 1000 mg PO q12h", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Text" : "($)[R] <AND> metronidazole 500 mg PO q12h ($) [DI] <AND> omeprazole 20 mg"}, 
{"Row" : 20, "Column" : 1, "Text" : "PO q12h. Take all for 14 days."}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Resistance to clarithromycin is increasing, do not use for patients with"}, 
{"Row" : 17, "Column" : 1, "Text" : "prior exposure to macrolides: "}
]},
{"Name" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)" , "Term1" : "Head lice " , "Term2" : "Lice, head", "DisplayText" : "Head Lice (Pediculosis Capitis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX TREAT HEAD LICE URL", "DisplayText" : "Treating Head Lice URL", "Text" : "https://www.cdc.gov/parasites/lice/head/index.html", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "DisplayText" : "Permethrin 1% lotion to the affected area for 10 minutes", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "HEAD LICE (PEDICULOSIS CAPITIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse"}, 
{"Row" :6, "Column" : 1, "Text" : "living on the scalp.Dead nits may remain for months after successful"}, 
{"Row" :7, "Column" : 1, "Text" : "treatment.Dead nits are usually located more than 6 mm from the scalp."}, 
{"Row" :9, "Column" : 1, "Text" : "Lice are often transmitted by infected clothing and bedclothes but not by"}, 
{"Row" : 10, "Column" : 1, "Text" : "ordinary furniture that is not typically in contact with hair or scalp.Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to the following for advice on household cleaning for lice infestations: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Repeat if live lice are seen 7-10 days after treatment."}, 
{"Row" : 19, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA" , "Term1" : "Hidradenitis suppurativa", "DisplayText" : "Hidradenitis Suppurativa" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID CHLORHEXIDINE GLUCONATE WASH QDAY", "DisplayText" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]", "Text" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "DisplayText" : "Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]", "Text" : "Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 1% TOPICAL SOLN Q12H", "DisplayText" : "Clindamycin 1% topical solution apply twice daily", "Text" : "Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]", "Mnemonic" : "8"},
{"Row" : 45, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "12"},
{"Row" : 50, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q12H", "DisplayText" : "Clindamycin 300MG PO q12h", "Text" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]", "Mnemonic" : "14"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX MOXI400MGPOQ24H METRO500MGPOQ8H RIFAMP300MGPOQ12H", "DisplayText" : "MOXI 400MG PO Q24H METRO 500MG PO Q8H RIFAMPIN 300MG PO Q12H", "Text" : "Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "HIDRADENITIS SUPPURATIVA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A chronic inflammatory condition that typically involves occlusion, rupture,"}, 
{"Row" :6, "Column" : 1, "Text" : "abscess formation and infection of hair follicles as well as secondary infection"}, 
{"Row" :7, "Column" : 1, "Text" : "of apocrine glands/surrounding tissues. Lesions most often occur in the"}, 
{"Row" :8, "Column" : 1, "Text" : "intertriginous areas (axillae, inguinal and anogenital) in is associated with"}, 
{"Row" :9, "Column" : 1, "Text" : "smoking and obesity. There is a 40% genetic predisposition for hidradenitis"}, 
{"Row" : 10, "Column" : 1, "Text" : "suppurativa (HS) and is often accompanied by pain, malodor, and drainage."}, 
{"Row" : 11, "Column" : 1, "Text" : "Cultures are negative 50% of the time and often are polymicrobial with S."}, 
{"Row" : 12, "Column" : 1, "Text" : "epidermidis and S. aureus most isolated. The Hurley Staging System is often used"}, 
{"Row" : 13, "Column" : 1, "Text" : "to determine severity of HS."}, 
{"Row" : 15, "Column" : 1, "Text" : "Therapy generally consists of treatment of comorbidities that can exacerbate HS,"}, 
{"Row" : 16, "Column" : 1, "Text" : "avoidance of triggers, pain management, wound care, and topical/oral"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be"}, 
{"Row" : 18, "Column" : 1, "Text" : "used to treat certain patients. Biologics may be considered in Stage II-III HS."}, 
{"Row" : 20, "Column" : 1, "Text" : "Consult Dermatology in all cases", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Hurley Staging System: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Stage I: recurrent nodules and abscesses with minimal scarring"}, 
{"Row" : 24, "Column" : 1, "Text" : "Stage II: limited number of sinuses and/or scarring within a body region"}, 
{"Row" : 25, "Column" : 1, "Text" : "Stage III: multiple or extensive sinuses and/or scarring"}, 
{"Row" : 27, "Column" : 1, "Text" : "Duration of Therapy: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment is typically for 12 weeks but may require longer durations in certain"}, 
{"Row" : 29, "Column" : 1, "Text" : "cases. Metronidazole should only be used for a maximum of 6 weeks to avoid"}, 
{"Row" : 30, "Column" : 1, "Text" : "neurologic toxicity."}, 
{"Row" : 32, "Column" : 1, "Text" : "Interventions for All Patients: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Smoking cessation, weight loss, avoidance of triggers, and pain management"}, 
{"Row" : 34, "Column" : 1, "Text" : "should be part of all treatment plans. Consult Dermatology for use of hormonal"}, 
{"Row" : 35, "Column" : 1, "Text" : "agents, steroids, retinoids, and surgery."}, 
{"Row" : 37, "Column" : 1, "Text" : "Optional Topical Treatment, May be Used in Addition to Oral Therapies Below: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>"}, 
{"Row" : 44, "Column" : 1, "Text" : "Stage I-II Initial Treatment: ", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 49, "Column" : 1, "Text" : "Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline: ", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Stage II-III Failure of Oral Clindamycin: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12"}, 
{"Row" : 55, "Column" : 1, "Text" : "weeks"}, 
{"Row" : 57, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019): "}, 
{"Row" : 61, "Column" : 1, "Text" : "76-90"}, 
{"Row" : 62, "Column" : 1, "Text" : "John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa"}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Management"}, 
{"Row" : 64, "Column" : 1, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,"}, 
{"Row" : 65, "Column" : 1, "Text" : "and diagnosis"}
]},
{"Name" : "ORZID2 GMENU IG HIS DEFICIENCY" , "Term1" : "Immunoglobulin (Humoral immune system) deficiency", "DisplayText" : "Immunoglobulin (Humoral immune system) deficiency " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($5.71/day) [M]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)"}, 
{"Row" :5, "Column" : 1, "Text" : "Antibody deficiency typically leads to recurrent, severe respiratory tract"}, 
{"Row" :6, "Column" : 1, "Text" : "infections associated with encapsulated bacteria, especially Streptococcus"}, 
{"Row" :7, "Column" : 1, "Text" : "pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes."}, 
{"Row" :9, "Column" : 1, "Text" : "Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "rotavirus is also common in some patients."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred empirical treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for severe penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Chloramphenicol is not currently available.Contact Infectious Diseases for"}, 
{"Row" : 17, "Column" : 1, "Text" : "advice."}, 
{"Row" : 22, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 23, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA" , "Term1" : "Altered microbial flora", "DisplayText" : "Altered microbial flora " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ALTERED MICROBIAL FLORA"}, 
{"Row" :5, "Column" : 1, "Text" : "A rich, diverse microbial flora lives on or in skin, mucosal surfaces, and"}, 
{"Row" :6, "Column" : 1, "Text" : "respiratory and gastrointestinal tracts of healthy people.This flora prevents"}, 
{"Row" :7, "Column" : 1, "Text" : "disease by inhibiting the growth of potential pathogens.Disruption of the"}, 
{"Row" :8, "Column" : 1, "Text" : "normal flora, usually by antimicrobial therapy, reduces this barrier and"}, 
{"Row" :9, "Column" : 1, "Text" : "increases the risk of infectious disease.Patients exposed to broad-spectrum"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials are at greater risk for colonization with resistant bacteria,"}, 
{"Row" : 11, "Column" : 1, "Text" : "fungal infections, and Clostridium difficile colitis.During hospitalization,"}, 
{"Row" : 12, "Column" : 1, "Text" : "many patients become colonized with more resistant organisms like methicillin-"}, 
{"Row" : 13, "Column" : 1, "Text" : "resistant Staphylococcus aureus and resistant Gram-negative bacilli."}, 
{"Row" : 18, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 19, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS" , "Term1" : "Immunocompromised patients basic concepts", "DisplayText" : "Basic concepts" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "BASIC CONCEPTS"}, 
{"Row" :5, "Column" : 1, "Text" : "Humans are protected by a broad array of host defenses that fall into two major"}, 
{"Row" :6, "Column" : 1, "Text" : "categories: innate and immune host defenses.Innate defense operate"}, 
{"Row" :7, "Column" : 1, "Text" : "continuously without specific antigenic stimulation and immune defenses are"}, 
{"Row" :8, "Column" : 1, "Text" : "primed by and respond to antigenic stimulation."}, 
{"Row" : 10, "Column" : 1, "Text" : "Each type of host defense protects against a specific set of organisms.As a"}, 
{"Row" : 11, "Column" : 1, "Text" : "result, infectious diseases more common because of host defense defects in an"}, 
{"Row" : 12, "Column" : 1, "Text" : "individual patient are usually predictable from that patient's host defense"}, 
{"Row" : 13, "Column" : 1, "Text" : "defects.For example, antibody or complement deficiencies predispose patients"}, 
{"Row" : 14, "Column" : 1, "Text" : "to disease with encapsulated organisms but not fungi.Defects in cell-mediated"}, 
{"Row" : 15, "Column" : 1, "Text" : "immunity predispose patients to infections with mycobacteria or cytomegalovirus"}, 
{"Row" : 16, "Column" : 1, "Text" : "but not Escherichia coli or influenza virus.Suspected cases of infectious"}, 
{"Row" : 17, "Column" : 1, "Text" : "disease must be evaluated in the context of the patient's host defects."}, 
{"Row" : 18, "Column" : 1, "Text" : "Management, including possible antimicrobial therapy, should be initiated on the"}, 
{"Row" : 19, "Column" : 1, "Text" : "basis of the most likely offending pathogens."}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY" , "Term1" : "Complement deficiency", "DisplayText" : "Complement deficiency " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($5.71/day) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "COMPLEMENT DEFICIENCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Complement deficiency can be inherited or acquired.Acquired defects are"}, 
{"Row" :6, "Column" : 1, "Text" : "usually a consequence of other diseases like systemic lupus erythematosus."}, 
{"Row" :7, "Column" : 1, "Text" : "Complement deficiency leads to increased rates of infections, usually of the"}, 
{"Row" :8, "Column" : 1, "Text" : "upper respiratory tract, but also occasionally with bacteremia or meningitis."}, 
{"Row" :9, "Column" : 1, "Text" : "Pathogens are usually Streptococcus pneumoniae, Neisseria meningitidis, and"}, 
{"Row" : 10, "Column" : 1, "Text" : "Neisseria gonorrhea."}, 
{"Row" : 12, "Column" : 1, "Text" : "Patients presenting with fever or other symptoms suggesting systemic bacterial"}, 
{"Row" : 13, "Column" : 1, "Text" : "infection should be treated immediately with antimicrobials active against these"}, 
{"Row" : 14, "Column" : 1, "Text" : "pathogens."}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred empirical treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative for severe penicillin allergy", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Chloramphenicol is not currently available.Contact Infectious Diseases for"}, 
{"Row" : 21, "Column" : 1, "Text" : "advice."}, 
{"Row" : 26, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 27, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS" , "Term1" : "Diabetes Mellitus", "DisplayText" : "Diabetes Mellitus " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DIABETES MELLITUS"}, 
{"Row" :5, "Column" : 1, "Text" : "Hyperglycemia increases the risk of infectious diseases in diabetic patients,"}, 
{"Row" :6, "Column" : 1, "Text" : "and increased blood glucose slows infection resolution.Diabetic patients are"}, 
{"Row" :7, "Column" : 1, "Text" : "prone to a variety of infections including urinary tract infections,"}, 
{"Row" :8, "Column" : 1, "Text" : "cholecystitis, and bacteremia.Peripheral neuropathy and arterial insufficiency"}, 
{"Row" :9, "Column" : 1, "Text" : "predispose to infections of skin, soft tissue, and bone infection in the lower"}, 
{"Row" : 10, "Column" : 1, "Text" : "legs and feet."}, 
{"Row" : 15, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 16, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}, 
{"Row" : 17, "Column" : 1, "Text" : "Joshi NNew Eng J Med 1999, 341: 1906"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA" , "Term1" : "Hypochlorhydria", "DisplayText" : "Hypochlorhydria " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "HYPOCHLORHYDRIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Diminished gastric acid allows increased numbers of bacteria in the stomach and"}, 
{"Row" :6, "Column" : 1, "Text" : "predisposes to infection with several potentially pathogenic bacterial species."}, 
{"Row" :7, "Column" : 1, "Text" : "These changes increase the risk of nosocomial pneumonia and possibly the risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "community-acquired respiratory infections.However, interventions to"}, 
{"Row" :9, "Column" : 1, "Text" : "decontaminate the upper gastrointestinal tract do not prevent infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "disease."}, 
{"Row" : 15, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 16, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY" , "Term1" : "Cancer " , "Term2" : "Malignancy", "DisplayText" : "Malignancy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "DisplayText" : "Neutropenic fever", "Text" : "Neutropenic fever", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "DisplayText" : "Prevention of bacterial infection in a patient with malignancy", "Text" : "Prevention of bacterial infections in a patient with malignancy", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infections in a patient with malignancy", "Text" : "Prevention of fungal infections in a patient with malignancy", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prevention of viral infection in a patient with malignancy", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Malignancies affect host defenses in many ways.Hematogenous malignancies can"}, 
{"Row" :6, "Column" : 1, "Text" : "diminish the effectiveness of neutrophils and other cells involved in host"}, 
{"Row" :7, "Column" : 1, "Text" : "defense.Tumors often disrupt mucous membranes or blood vessels and allow"}, 
{"Row" :8, "Column" : 1, "Text" : "contaminating organisms into hollow cavities or the bloodstream.Chemotherapy"}, 
{"Row" :9, "Column" : 1, "Text" : "used to treat these malignancies often impairs mucus membranes and suppresses"}, 
{"Row" : 10, "Column" : 1, "Text" : "neutrophil production and function."}, 
{"Row" : 12, "Column" : 1, "Text" : "Ordinarily, empirical antimicrobials are not indicated for patients with"}, 
{"Row" : 13, "Column" : 1, "Text" : "malignancy and fever unless they have neutropenia or a specific infectious"}, 
{"Row" : 14, "Column" : 1, "Text" : "disease."}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 24, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION" , "Term1" : "Malnutrition", "DisplayText" : "Malnutrition" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "MALNUTRITION"}, 
{"Row" :5, "Column" : 1, "Text" : "Adequate nutrition is necessary for optimal host defense function.A few days"}, 
{"Row" :6, "Column" : 1, "Text" : "of malnutrition can decrease host defenses, mainly cell-mediated immunity. The"}, 
{"Row" :7, "Column" : 1, "Text" : "degree of compromised immunity increases with the duration of malnutrition."}, 
{"Row" :8, "Column" : 1, "Text" : "However, nutritional replacement has not been shown to improve outcomes in"}, 
{"Row" :9, "Column" : 1, "Text" : "patients with mild-moderate malnutrition.Enteral nutritional replacement is"}, 
{"Row" : 10, "Column" : 1, "Text" : "far superior to and safer than intravenous hyperalimentation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Empirical antimicrobials are not indicated for malnourished patients with fever"}, 
{"Row" : 14, "Column" : 1, "Text" : "but without evidence of a specific infectious disease."}, 
{"Row" : 19, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 20, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION" , "Term1" : "Neurological dysfunction", "DisplayText" : "Neurological dysfunction" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia", "Text" : "Aspiration pneumonia", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "NEUROLOGICAL DYSFUNCTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Several types of neurological dysfunction predispose patients to infectious"}, 
{"Row" :6, "Column" : 1, "Text" : "diseases.Comatose patients are unable to keep weight off dependent tissues,"}, 
{"Row" :7, "Column" : 1, "Text" : "predisposing them to decubitus ulcers and pressure necrosis.Atelectasis is"}, 
{"Row" :8, "Column" : 1, "Text" : "common in obtunded patients who cannot cough or breathe deeply.When patients"}, 
{"Row" :9, "Column" : 1, "Text" : "require artificial ventilation, intubation compounds the risk of respiratory"}, 
{"Row" : 10, "Column" : 1, "Text" : "infection."}, 
{"Row" : 12, "Column" : 1, "Text" : "Neurological dysfunction of the bladder can interfere with normal bladder"}, 
{"Row" : 13, "Column" : 1, "Text" : "emptying and predisposes patients to bacteriuria.The risk of bacteruria"}, 
{"Row" : 14, "Column" : 1, "Text" : "increases if patients are catheterized.Antimicrobial treatment is not"}, 
{"Row" : 15, "Column" : 1, "Text" : "indicated for asymptomatic bacteriuria.It provides no benefit and increases"}, 
{"Row" : 16, "Column" : 1, "Text" : "risk of colonization with resistant organisms."}, 
{"Row" : 18, "Column" : 1, "Text" : "Neurological dysfunction predisposes patients to aspiration of oropharyngeal or"}, 
{"Row" : 19, "Column" : 1, "Text" : "gastric contents.Aspiration causes fever, inflammation, and/or pulmonary"}, 
{"Row" : 20, "Column" : 1, "Text" : "infiltrate, but does not require antimicrobial treatment. Bacterial pneumonia"}, 
{"Row" : 21, "Column" : 1, "Text" : "occurs in a minority of patients who experience significant aspiration,"}, 
{"Row" : 22, "Column" : 1, "Text" : "typically about 3 days later.Typically, the patient improves for the first 2"}, 
{"Row" : 23, "Column" : 1, "Text" : "days and then worsens as bacterial pneumonia develops with increased fever, new"}, 
{"Row" : 24, "Column" : 1, "Text" : "or progressive infiltrates, leukocytosis, and newly purulent sputum."}, 
{"Row" : 31, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 32, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER" , "Term1" : "Neutropenic fever", "DisplayText" : "Neutropenic fever " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is a candidate for oral therapy", "Text" : "If patient IS a candidate for oral therapy", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy", "Text" : "If patient is NOT a candidate for oral therapy", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "DisplayText" : "Modification to Neutropenic fever therapy", "Text" : "Modification to neutropenic fever therapy", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER"}, 
{"Row" :5, "Column" : 1, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute"}, 
{"Row" :6, "Column" : 1, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500"}, 
{"Row" :7, "Column" : 1, "Text" : "cells/microliter.The risk increases dramatically when the ANC is <100"}, 
{"Row" :8, "Column" : 1, "Text" : "cells/microliter.Because of these risks, patients with fever and neutropenia"}, 
{"Row" :9, "Column" : 1, "Text" : "to this degree should receive empirical antimicrobial therapy immediately."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000"}, 
{"Row" : 11, "Column" : 1, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter"}, 
{"Row" : 12, "Column" : 1, "Text" : "within the next 48 hours.For this purpose, fever is defined as a single"}, 
{"Row" : 13, "Column" : 1, "Text" : "temperature greater than 38.3 degrees Celsius."}, 
{"Row" : 15, "Column" : 1, "Text" : "Initial therapy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined"}, 
{"Row" : 18, "Column" : 1, "Text" : "above.Vancomycin should only be given when there are clear indications for its"}, 
{"Row" : 19, "Column" : 1, "Text" : "use."}, 
{"Row" : 21, "Column" : 1, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who"}, 
{"Row" : 22, "Column" : 1, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of"}, 
{"Row" : 23, "Column" : 1, "Text" : "severe disease, like hypotension.Outpatient antimicrobials for neutropenic"}, 
{"Row" : 24, "Column" : 1, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Modifcation to therapy", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730"}, 
{"Row" : 39, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA" , "Term1" : "Neutropenia", "DisplayText" : "Neutropenia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with neutropenia are at risk of infection from pyogenic organisms"}, 
{"Row" :6, "Column" : 1, "Text" : "including Staphylococcus aureus, streptococci, Gram-negative bacilli,"}, 
{"Row" :7, "Column" : 1, "Text" : "Pseudomonas aeruginosa, candida, and certain filamentous fungi, most notably"}, 
{"Row" :8, "Column" : 1, "Text" : "Aspergillus and the zygomycetes.The risk is inversely related to the absolute"}, 
{"Row" :9, "Column" : 1, "Text" : "neutrophil count (ANC), the disease or condition associated with neutropenia,"}, 
{"Row" : 10, "Column" : 1, "Text" : "duration of neutropenia, and the presence of other host defense defects or"}, 
{"Row" : 11, "Column" : 1, "Text" : "underlying diseases."}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM STRESS" , "Term1" : "Stress", "DisplayText" : "Stress" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "STRESS"}, 
{"Row" :5, "Column" : 1, "Text" : "Acute psychological stress is associated with immune stimulation and increased"}, 
{"Row" :6, "Column" : 1, "Text" : "cellular host defenses.However, chronic stress decrease humoral and cell-"}, 
{"Row" :7, "Column" : 1, "Text" : "mediated immunity.Chronic stress has been correlated with increased risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "respiratory tract infection."}, 
{"Row" : 10, "Column" : 1, "Text" : "Critically ill patients are usually profoundly stressed.The risk of infection"}, 
{"Row" : 11, "Column" : 1, "Text" : "is subtle and the defects are non-specific."}, 
{"Row" : 16, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 17, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE" , "Term1" : "Tobacco smoke", "DisplayText" : "Tobacco smoke " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "TOBACCO SMOKE"}, 
{"Row" :5, "Column" : 1, "Text" : "Active or passive exposure to tobacco smoke is associated with increased"}, 
{"Row" :6, "Column" : 1, "Text" : "susceptibility to respiratory infectious diseases and several systemic"}, 
{"Row" :7, "Column" : 1, "Text" : "infectious diseases with bacterial and viral pathogens.Compounds found in"}, 
{"Row" :8, "Column" : 1, "Text" : "tobacco or tobacco smoke interfere with several host defense mechanisms in the"}, 
{"Row" :9, "Column" : 1, "Text" : "respiratory tract and elsewhere in the body."}, 
{"Row" : 14, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 15, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO" , "Term1" : "Diarrhea, infectious/gastroenteritis " , "Term2" : "Gastroenteritis/infectious diarrhea " , "Term3" : "Infectious diarrhea/gastroenteritis", "DisplayText" : "Infectious diarrhea/Gastroenteritis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU COMM ACQ DIARRHEA", "DisplayText" : "Community acquired diarrhea", "Text" : "Community acquired diarrhea (no recent travel)", "Mnemonic" : "4"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU TRAVELERS DIARRHEA", "DisplayText" : "Traveler's Diarrhea", "Text" : "Traveler's diarrhea", "Mnemonic" : "6"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX AEROMONAS", "DisplayText" : "Diarrhea with Aeromonas", "Text" : "Aeromonas", "Mnemonic" : "8"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Adenovirus", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Astrovirus", "Mnemonic" : "12"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX CAMPYLOBACTER", "DisplayText" : "Diarrhea with Campylobacter", "Text" : "Campylobacter", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[CLICK HERE] for mild to moderate disease", "Mnemonic" : "16"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXIC MEGACOLON", "DisplayText" : "Severe disease - Ileus/Toxic megacolon", "Text" : "[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)", "Mnemonic" : "18"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX ISOSPORA", "DisplayText" : "Diarrhea with Isospora belli", "Text" : "Cystoisospora belli", "Mnemonic" : "20"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX CRYPTOSPORIDIA", "DisplayText" : "Diarrhea with Cryptosporidium parvum", "Text" : "Cryptosporidium parvum", "Mnemonic" : "22"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX CYCLOSPORA", "DisplayText" : "Cyclospora cayetanensis", "Text" : "Cyclospora cayetanensis", "Mnemonic" : "24"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA", "DisplayText" : "Entoemeba histolytica", "Text" : "Entamoeba histolytica", "Mnemonic" : "26"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU ABX E COLI INFECT", "DisplayText" : "Diarrhea with Enterohemorrhagic E. coli", "Text" : "Escherichia coli [CLICK HERE], including varieties listed below: ", "Mnemonic" : "28"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX GIARDIA", "DisplayText" : "Diarrhea with Giardia lamblia", "Text" : "Giardia duodenalis", "Mnemonic" : "30"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROSPORIDIA", "DisplayText" : "Microsporidia", "Text" : "Microsporidia", "Mnemonic" : "32"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Norovirus", "Mnemonic" : "34"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Rotavirus", "Mnemonic" : "36"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Sapovirus", "Mnemonic" : "38"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU ABX SALMONELLA SPECIES", "DisplayText" : "Diarrhea with Salmonella", "Text" : "Salmonella", "Mnemonic" : "40"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "DisplayText" : "Diarrhea with Shigella species (bacillary dysentery)", "Text" : "Shigella", "Mnemonic" : "42"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLERA", "DisplayText" : "Diarrhea with Cholera (Vibrio cholera)", "Text" : "Vibrio cholerae", "Mnemonic" : "44"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU ABX NON-CHOLERA", "DisplayText" : "Vibrio non-cholera", "Text" : "Vibrio non-cholerae", "Mnemonic" : "46"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA", "DisplayText" : "Diarrhea with Yersinia enterocolitica", "Text" : "Yersinia enterocolitica", "Mnemonic" : "48"},
{"Row" :3, "Column" : 1, "Text" : "INFECTIOUS DIARRHEA / GASTROENTERITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most episodes of acute diarrhea are self limited and do not need to be evaluated"}, 
{"Row" :6, "Column" : 1, "Text" : "or treated. In most mild to moderate cases, antimicrobial therapy does not"}, 
{"Row" :7, "Column" : 1, "Text" : "provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is"}, 
{"Row" :8, "Column" : 1, "Text" : "detrimental in cases involving enterohemorrhagic Escherichia coli."}, 
{"Row" : 10, "Column" : 1, "Text" : "The decision for whether to test stool depends on illness severity and duration,"}, 
{"Row" : 11, "Column" : 1, "Text" : "the likelihood of specific infectious agents and the severity of any underlying"}, 
{"Row" : 12, "Column" : 1, "Text" : "diseases. Send stool sample for enteric pathogen PCR testing if the patient has"}, 
{"Row" : 13, "Column" : 1, "Text" : "volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24"}, 
{"Row" : 14, "Column" : 1, "Text" : "hours, temperature >38.4 C, or severe abdominal pain or signs of sepsis, or is"}, 
{"Row" : 15, "Column" : 1, "Text" : ">/= 70 years old or substantially immunocompromised. Replace fluid losses and"}, 
{"Row" : 16, "Column" : 1, "Text" : "correct electrolyte imbalances. Patients with diarrhea who were potentially"}, 
{"Row" : 17, "Column" : 1, "Text" : "exposed during a community outbreak of infectious diarrhea should be tested for"}, 
{"Row" : 18, "Column" : 1, "Text" : "the suspected bacterial, viral, and parasitic agents regardless of symptom"}, 
{"Row" : 19, "Column" : 1, "Text" : "severity."}, 
{"Row" : 21, "Column" : 1, "Text" : "Obtain blood cultures if patients have signs of septicemia, suspected enteric"}, 
{"Row" : 22, "Column" : 1, "Text" : "fever (e.g., fever plus recent travel to an endemic area or contact with someone"}, 
{"Row" : 23, "Column" : 1, "Text" : "who has enteric fever), other systemic symptoms, immune compromise, or other"}, 
{"Row" : 24, "Column" : 1, "Text" : "high-risk conditions."}, 
{"Row" : 26, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 29, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 30, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 32, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 33, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 34, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 35, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 37, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 40, "Column" : 1, "Text" : "Empirical antimicrobial treatment of diarrhea", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Treatment of diarrhea caused by specific bacteria, parasites, and viruses", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Clostridium difficile: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),"}, 
{"Row" : 61, "Column" : 1, "Text" : "Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),"}, 
{"Row" : 62, "Column" : 1, "Text" : "Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)"}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 78, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 79, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 80, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 81, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich"}, 
{"Row" : 82, "Column" : 1, "Text" : "settings"}
]},
{"Name" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT" , "Term1" : "Anaerobic bottle, large uniform bacilli " , "Term2" : "Bacilli, large uniform, anaerobic bottle " , "Term3" : "Large uniform bacilli, anaerobic bottle", "DisplayText" : "Large uniform rods in an anaerobic bottle " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$)[R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin G 4 million units IV q4h (Cost $$) [R] <AND> clindamycin 900 mg", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a"}, 
{"Row" :6, "Column" : 1, "Text" : "potentially severe pathogen. Combination therapy is recommended for necrotizing"}, 
{"Row" :7, "Column" : 1, "Text" : "infections as clindamycin has the theoretical benefit of inhibiting toxin"}, 
{"Row" :8, "Column" : 1, "Text" : "production."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical treatment of mild to moderate infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients with severe penicillin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "Empirical treatment of severe or necrotizing infection", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "IV q8h (Cost $$) [H,O]"}, 
{"Row" : 24, "Column" : 1, "Text" : "References"}, 
{"Row" : 26, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Clostridium perfingens"}, 
{"Row" : 28, "Column" : 1, "Text" : "Stevens et al., Clinical Infectious Diseases 2014 59.2"}
]},
{"Name" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT" , "Term1" : "Aerobic bottle, large uniform bacilli " , "Term2" : "Bacilli, large uniform, aerobic bottle " , "Term3" : "Large uniform bacilli, aerobic bottle", "DisplayText" : "Large uniform rods in an aerobic bottle " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 Q8H MERO 2 Q8H LINEZOLID 600 Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h", "Text" : "Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> Meropenem 2 gm IV q8h", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin 4 million units IV q4H (Cost $$) [R,DI] <AND> clindamycin 900mg", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG IV Q8H CLINDA 900MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h", "Text" : "Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> clindamycin 900mg IV q8h", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Large uniform bacilli in an aerobic bottle usually suggest Bacillus species."}, 
{"Row" :6, "Column" : 1, "Text" : "Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but"}, 
{"Row" :7, "Column" : 1, "Text" : "usually pathogenic. If Bacillus anthracis is suspected or isolated contact"}, 
{"Row" :8, "Column" : 1, "Text" : "Infectious Diseases immediately."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical treatment of suspected non-anthracis Bacillus spp. associated with", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "disease", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Empirical treatment of suspected Bacillus anthracis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Start combination therapy and contact Infectious Diseases immediately.", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "If meningitis has not been ruled out", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for 6 weeks"}, 
{"Row" : 20, "Column" : 1, "Text" : "(Cost $$) [R,O] < AND > linezolid 600 mg IV q12h (Cost $$$$) [DI]"}, 
{"Row" : 22, "Column" : 1, "Text" : "If meningitis has been ruled out", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Isolate is penicillin-susceptible"}, 
{"Row" : 25, "Column" : 1, "Text" : "IV q8h (Cost $$) [H,O]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Isolate is not penicillin susceptible or susceptibility unknown"}, 
{"Row" : 29, "Column" : 1, "Text" : "(Cost $$) [H,O]"}, 
{"Row" : 32, "Column" : 1, "Text" : "References"}, 
{"Row" : 34, "Column" : 1, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2"}, 
{"Row" : 35, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species"}
]},
{"Name" : "ORZID2 GMENU INT RPT GNB" , "Term1" : "Gram-negative bacilli bacteremia", "DisplayText" : "Interim report of Gram-negative bacilli " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h (Cost $$) [R]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime 2 gm IV q8h (Cost $$) [R]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Text" : "Aztreonam 2 gm IV q8h (Cost $$$$) [R]", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Gentamicin 5 mg/kg IV q24h (Cost $) [R,O] <AND> piperacillin-tazobactam", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-NEGATIVE BACILLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most Gram-negative bacilli grow in aerobic or anaerobic bottles. Pseudomonas"}, 
{"Row" :6, "Column" : 1, "Text" : "nearly always grows in aerobic bottles. One drug is sufficient to treat Gram-"}, 
{"Row" :7, "Column" : 1, "Text" : "negative bacillus bacteremia, unless the patient is critically ill."}, 
{"Row" :9, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Empirical treatment if pseudomonas is suspected", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients with severe penicillin allergy"}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical treatment for critically ill patients or resistant organism likely", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "4.5 gm q6h (Cost $$) [R]"}, 
{"Row" : 28, "Column" : 1, "Text" : "References"}, 
{"Row" : 30, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Gram-negative bacillary bacteremia in adults"}
]},
{"Name" : "ORZID2 GMENU INT RPT GNC" , "Term1" : "Gram-negative cocci bacteremia", "DisplayText" : "Interim report of Gram-negative cocci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$) [R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "DisplayText" : "Azithromycin 500 mg IV q24h ($) [O]", "Text" : "Azithromycin 500mg IV q24h (Cost $) [O]", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis", "Text" : "NEISSERIA MENINGITIDIS", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae", "Text" : "NEISSERIA GONORRHOEAE", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis", "Text" : "MORAXELLA CATARRHALIS", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-NEGATIVE COCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or moraxella. Based"}, 
{"Row" :6, "Column" : 1, "Text" : "on the clinical situation, select from following possibilities: "}, 
{"Row" :9, "Column" : 1, "Text" : "Empirical treatment if meningococci are suspected", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical treatment if gonococci, moraxella are suspected or if unknown", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "suspected organism", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For suspected meningococci or gonococci and severe penicillin allergy"}, 
{"Row" : 17, "Column" : 1, "Text" : "Consult Infectious Diseases"}, 
{"Row" : 19, "Column" : 1, "Text" : "For suspected moraxella and severe penicillin allergy"}, 
{"Row" : 22, "Column" : 1, "Text" : "Refer to specific organism page when final culture results are available", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References"}, 
{"Row" : 30, "Column" : 1, "Text" : "Warkowski et al, MMWR Recomm Rep 2015, 64.3"}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Neisseria Meningitidis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Neisseria Meningitidis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Neisseria Gonorrhoeae"}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC IN PAIRS" , "Term1" : "Gram-positive cocci in pairs bacteremia " , "Term2" : "Gram-positive cocci in pairs interim culture results", "DisplayText" : "Interim report of Gram-positive cocci in pairs" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "DisplayText" : "Penicillin 2 million units iv q4h", "Text" : "Penicillin G 2 million units IV q4h (Cost $) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A preliminary report of gram-positive cocci in pairs suggests staphylococci,"}, 
{"Row" :6, "Column" : 1, "Text" : "streptococci, or enterococci. If the patient is severely ill, is likely"}, 
{"Row" :7, "Column" : 1, "Text" : "colonized with resistant organisms, or if staphylococci or enterococci are"}, 
{"Row" :8, "Column" : 1, "Text" : "likely, treat with vancomycin until susceptibility results are known."}, 
{"Row" :9, "Column" : 1, "Text" : "Cephalosporins are not active against enterococci or methicillin-resistant"}, 
{"Row" : 10, "Column" : 1, "Text" : "Staphylococcus aureus."}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical treatment of suspected streptococci", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 18, "Column" : 1, "Text" : "For severe disease, resistance to beta lactams likely or patient with severe", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "penicillin allergy", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical treatment of suspected enterococci", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "For severe disease, resistance to beta-lactams likely or patient with", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "penicillin allergy", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Empirical treatment of suspected staphylococci", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References"}, 
{"Row" : 37, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Enterococci"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Staphylococci"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Streptococci"}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS" , "Term1" : "Gram-positive cocci in pairs and clusters bacteremia", "DisplayText" : "Interim report of Gram-positive cocci in pairs and clusters " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CLUSTERS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "This suggests staphylococci. Empirical therapy should cover methicillin-"}, 
{"Row" :6, "Column" : 1, "Text" : "resistant Staphylococcus aureus. If a susceptible isolate is identified, beta-"}, 
{"Row" :7, "Column" : 1, "Text" : "lactam antimicrobials should be used as they are most effective at killing"}, 
{"Row" :8, "Column" : 1, "Text" : "staphylococci. When a final pathogen is identified, treatment depends on which"}, 
{"Row" :9, "Column" : 1, "Text" : "specific bacterium is identified."}, 
{"Row" : 11, "Column" : 1, "Text" : "Empirical treatment of suspected staphylococcus infection", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References"}, 
{"Row" : 17, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford keyword: Staphylococci"}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS" , "Term1" : "Gram-positive cocci in pairs and chains bacteremia", "DisplayText" : "Interim report of Gram-positive cocci in pairs and chains " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "DisplayText" : "Penicillin 2 million units iv q4h", "Text" : "Penicillin G 2 million units IV q4h (Cost $) [R]", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CHAINS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If chains are reported, streptococci are likely. If short chains are"}, 
{"Row" :6, "Column" : 1, "Text" : "reported, enterococci are likely. Beta-lactam antimicrobials are more effective"}, 
{"Row" :7, "Column" : 1, "Text" : "than vancomycin in killing susceptible streptococci and enterococci, so"}, 
{"Row" :8, "Column" : 1, "Text" : "penicillin or ampicillin should be used if resistance is unlikely."}, 
{"Row" : 10, "Column" : 1, "Text" : "If the patient is severely ill or is likely to be colonized with resistant"}, 
{"Row" : 11, "Column" : 1, "Text" : "organisms, treat with vancomycin until susceptibility results are known."}, 
{"Row" : 13, "Column" : 1, "Text" : "Empirical treatment of suspected streptococcus infection", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients with severe-penicillin allergy"}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical treatment of suspected enterococcal infection", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "For patients with severe disease, resistance to beta-lactams is likely or", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "patient with penicillin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References"}, 
{"Row" : 33, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Enterococci"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Streptococci"}
]},
{"Name" : "ORZID2 GMENU INT RPT GPR" , "Term1" : "Gram-positive bacilli bacteremia " , "Term2" : "Gram-positive bacilli, interim culture results", "DisplayText" : "Interim report of Gram-positive rods" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "DisplayText" : "Large uniform rods in an aerobic bottle", "Text" : "LARGE UNIFORM BACILLI in an AEROBIC bottle", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "DisplayText" : "Large uniform rods in an anaerobic bottle", "Text" : "LARGE UNIFORM BACILLI in an ANAEROBIC bottle", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "DisplayText" : "Small pleomorphic rods in aerobic bottle", "Text" : "SMALL PLEOMORPHIC BACILLI in AEROBIC bottle", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "DisplayText" : "Small pleomorphic rods in an anaerobic bottle", "Text" : "SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE BACILLI"}, 
{"Row" :5, "Column" : 1, "Text" : "There are three typical morphologies (1)large and regular, (2)medium sized and"}, 
{"Row" :6, "Column" : 1, "Text" : "variable, and (3)small and pleomorphic.The large, uniformly rod-shaped Gram-"}, 
{"Row" :7, "Column" : 1, "Text" : "positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species"}, 
{"Row" :8, "Column" : 1, "Text" : "(anaerobic).Bacillus spp. include Bacillus subtilis (usually a contaminant),"}, 
{"Row" :9, "Column" : 1, "Text" : "Bacillus cereus, and Bacillus anthracis.Medium-sized Gram-positive bacilli are"}, 
{"Row" : 10, "Column" : 1, "Text" : "usually Lactobacilli (anaerobic).Small and pleomorphic bacilli are usually"}, 
{"Row" : 11, "Column" : 1, "Text" : "Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and"}, 
{"Row" : 12, "Column" : 1, "Text" : "Corynebacteria (aerobic)."}
]},
{"Name" : "ORZID2 GMENU INT RPT YEAST" , "Term1" : "Yeast bacteremia", "DisplayText" : "Interim report of yeast " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "DisplayText" : "Fungi", "Text" : "Fungi", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "DisplayText" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "DisplayText" : "Micafungin 100 mg IV q24h", "Text" : "Micafungin 100 mg IV q24h ($$$) [DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF YEAST", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. If the yeast appear to be or are"}, 
{"Row" :6, "Column" : 1, "Text" : "known to be Candida species treat as follows. If other yeasts (e.g."}, 
{"Row" :7, "Column" : 1, "Text" : "Cryptococcus, Histoplasma) are suspected, contact Infectious Diseases for"}, 
{"Row" :8, "Column" : 1, "Text" : "treatment advice."}, 
{"Row" : 10, "Column" : 1, "Text" : "Refer to specific organism for yeasts other than candida"}, 
{"Row" : 13, "Column" : 1, "Text" : "Most Candida can be treated with fluconazole. If the patient is critically ill"}, 
{"Row" : 14, "Column" : 1, "Text" : "or neutropenic or has recently taken an azole antifungal, or if Candida krusei"}, 
{"Row" : 15, "Column" : 1, "Text" : "or C. glabrata are suspected, micafungin should be used initially. Removal of"}, 
{"Row" : 16, "Column" : 1, "Text" : "central venous catheter is associated with decreased mortality. Call Infectious"}, 
{"Row" : 17, "Column" : 1, "Text" : "Diseases for advice."}, 
{"Row" : 19, "Column" : 1, "Text" : "Empirical treatment for patients with mild to moderate illness who have no", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "prior azole antifungal therapy", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "For patients who cannot take oral medication"}, 
{"Row" : 26, "Column" : 1, "Text" : "Empirical treatment for critically ill patients, neutropenic patients, patients", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "who have recently taken azole antifungals, or if C. glabrata or C. krusei are", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "suspected", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References"}, 
{"Row" : 34, "Column" : 1, "Text" : "Andes et al, Clinical Infectious Diseases 2012, 54.8"}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 36, "Column" : 1, "Text" : "Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Candidiasis"}
]},
{"Name" : "ORZID2 GMENU INT SM RODS AEROBIC BOT" , "Term1" : "Aerobic bottle, small pleomorphic bacilli " , "Term2" : "Bacilli, small pleomorphic, aerobic bottle " , "Term3" : "Small pleomorphic bacilli, aerobic bottle", "DisplayText" : "Small pleomorphic rods in aerobic bottle" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R] and gentamicin 1.7 mg/kg IV q8h (Cost", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "DisplayText" : "Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h (Cost $$$) [R,DI]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are"}, 
{"Row" :6, "Column" : 1, "Text" : "usually contaminants. Uncommonly such organisms prove to be Listeria"}, 
{"Row" :7, "Column" : 1, "Text" : "monocytogenes, which when present in a blood culture is likely a pathogen."}, 
{"Row" :8, "Column" : 1, "Text" : "Listeria is more likely in patients with impaired cell-mediated immunity,"}, 
{"Row" :9, "Column" : 1, "Text" : "pregnant women, elderly and patients on immunosuppressive therapy for"}, 
{"Row" : 10, "Column" : 1, "Text" : "transplantation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical treatment if there is a strong suspicion of listeria", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "For immunocompromised, meningitis or endocarditis"}, 
{"Row" : 17, "Column" : 1, "Text" : "$) [R,O]"}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients with penicillin allergy"}, 
{"Row" : 22, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empirical treatment if therapy is indicated and listeria is not suspected", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Listeria Monocytogenes"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci"}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Listeria monocytogenes"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium"}
]},
{"Name" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT" , "Term1" : "Anaerobic bottle, small pleomorphic bacilli " , "Term2" : "Bacilli, small pleomorphic, anaerobic bottle " , "Term3" : "Small pleomorphic bacilli, anaerobic bottle", "DisplayText" : "Small pleomorphic rods in an anaerobic bottle " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$)[R]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria."}, 
{"Row" :6, "Column" : 1, "Text" : "These are often contaminants."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment if therapy is indicated", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "For penicillin allergy"}, 
{"Row" : 14, "Column" : 1, "Text" : "For severe penicillin allergy"}, 
{"Row" : 18, "Column" : 1, "Text" : "References"}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci"}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium"}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP" , "Term1" : "Candida intravascular catheter-associated infection", "DisplayText" : "Intravascular catheter-associated Candida Spp. infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "DisplayText" : "Bacteremia associated with Candida spp.", "Text" : "FUNGEMIA ASSOCIATED WITH CANDIDA SPP.", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED CANDIDA SPP. INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Remove catheter and Consult Infectious Diseases"}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Refer to candidemia page for antifungal choice and duration of treatment"}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH" , "Term1" : "Coagulase-negative staphylococci, intravascular catheter-associated infection", "DisplayText" : "Intravascular catheter-associated coagulase-negative staphylococcus infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO 2GM Q8H CEFAZ ABX LOCK THERAPY", "DisplayText" : "Cefazolin 2 gm IVPB q8h ($) [R] <AND> cefazolin antibiotic lock therapy", "Text" : "", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG Q12H VANCO ABX LOCK THERAPY", "DisplayText" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED COAGULASE-NEGATIVE STAPHYLOCOCCUS INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Catheter removal is optional."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment if the catheter is removed", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 7 days."}, 
{"Row" :9, "Column" : 1, "Text" : "Methicillin-susceptible isolate", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "For patients with non-severe penicillin allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "Methicillin-resistant isolate or alternative for patients with severe", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "penicillin allergy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment if the catheter is retained", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treat concurrently with systemic therapy and antibiotic lock therapy for 10 to"}, 
{"Row" : 22, "Column" : 1, "Text" : "14 days."}, 
{"Row" : 23, "Column" : 1, "Text" : "Methicillin susceptible isolate", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Methicillin resistant isolate or alternative for patients with", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "penicillin/cephalosporin allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-date article: Treatment of Intravascular Catheter-Related Infections"}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS" , "Term1" : "Enterococcal intravascular catheter-associated infection", "DisplayText" : "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "DisplayText" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI]", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "DisplayText" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Text" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H AMPICIL ABX LOCK THERAPY", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ampicillin antibiotic lock therapy", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ampicillin antibiotic lock therapy", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG Q12H VANCO ABX LOCK THERAPY", "DisplayText" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Remove catheter and treat for 7-14 days for uncomplicated catheter-associated"}, 
{"Row" :6, "Column" : 1, "Text" : "bacteremia. Document that bacteremia clears on therapy. If there is evidence of"}, 
{"Row" :7, "Column" : 1, "Text" : "deep-seated infection or endocarditis refer to pertinent sections."}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment if the catheter is removed (preferred)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for 7-14 days"}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment for ampicillin-resistant isolates or alternative for patients with"}, 
{"Row" : 16, "Column" : 1, "Text" : "penicillin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for ampicillin and vancomycin resistant isolate"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treat for 6 weeks"}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Treatment if catheter removal is not possible (less desirable)", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Use concurrent systemic AND antibiotic lock therapy, both for 14 days."}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment for ampicillin resistant isolates or alternative for patients with"}, 
{"Row" : 31, "Column" : 1, "Text" : "penicillin allergy"}, 
{"Row" : 34, "Column" : 1, "Text" : "Treatment for ampicillin and vancomycin resistant isolate"}, 
{"Row" : 35, "Column" : 1, "Text" : "If catheter removal is not possible, discuss options with Infectious Diseases"}, 
{"Row" : 38, "Column" : 1, "Text" : "References"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections"}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH GNB" , "Term1" : "Gram-negative bacilli intravascular catheter-associated infection", "DisplayText" : "Intravascular catheter-associated Gram-negative Bacilli infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "DisplayText" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 Q6H GENT ABX LOCK THERAPY", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin antibiotic", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin antibiotic", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED GRAM-NEGATIVE BACILLI INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Adjust initial antibiotics to narrow spectrum when cultures and susceptibility"}, 
{"Row" :6, "Column" : 1, "Text" : "data are available."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment if the catheter is removed (preferred)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 to 14 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patients with non-severe penicillin allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for patients with severe penicillin allergy"}, 
{"Row" : 18, "Column" : 1, "Text" : "Critically ill patient or resistant organism likely", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "IV q24h ($) [R,O]"}, 
{"Row" : 21, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment if catheter removal is not possible (less desirable)", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Use concurrent systemic AND antibiotic lock therapy, both for 14 days."}, 
{"Row" : 26, "Column" : 1, "Text" : "lock therapy"}, 
{"Row" : 29, "Column" : 1, "Text" : "References"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-Date article gram-negative bacillary bacteremia in adults"}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS" , "Term1" : "Staphylococcus aureus intravascular catheter-associated infection", "DisplayText" : "Intravascular catheter-associated Staphyloccus aureus infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED STAPHYLOCOCCUS AUREUS INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Remove catheter and treat for 2 weeks. Duration should be extended to 4 to 6"}, 
{"Row" :6, "Column" : 1, "Text" : "weeks in complicated cases. Document that bacteremia clears on therapy. If"}, 
{"Row" :7, "Column" : 1, "Text" : "there is evidence of deep-seated infection or endocarditis refer to pertinent"}, 
{"Row" :8, "Column" : 1, "Text" : "sections."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult infectious Diseases in all cases.", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment for methicillin-susceptible isolates", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Methicillin resistant isolate or alternative for patient with severe penicillin", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "allergy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections"}
]},
{"Name" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT" , "Term1" : "Catheter-associated infection, intravascular " , "Term2" : "Intravascular catheter-associated infection", "DisplayText" : "Intravascular catheter-associated infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO INTRAVAS CATH-ASSOC INFECT", "DisplayText" : "Approach to Intravascular catheter-associated infection", "Text" : "Approach to intravascular catheter-associated infection and antimicrobial", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg IV", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "DisplayText" : "vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "DisplayText" : "Intravascular catheter-associated coagulase-negative staphylococcus infection", "Text" : "Coagulase-negative staph. intravascular catheter-associated infection", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS", "DisplayText" : "Intravascular catheter-associated Staphyloccus aureus infection", "Text" : "Staphyloccus aureus intravascular catheter-associated infection", "Mnemonic" : "14"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS", "DisplayText" : "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION", "Text" : "Enterococcus intravascular catheter-associated infection", "Mnemonic" : "16"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH GNB", "DisplayText" : "Intravascular catheter-associated Gram-negative Bacilli infection", "Text" : "Gram-negative Bacilli intravascular catheter-associated infection", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP", "DisplayText" : "Intravascular catheter-associated Candida Spp. infection", "Text" : "Candida Spp. intravascular catheter-associated infection", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED INFECTION", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "lock therapy"}, 
{"Row" :8, "Column" : 1, "Text" : "When catheter-related bacteremia is suspected, draw blood cultures from both the"}, 
{"Row" :9, "Column" : 1, "Text" : "catheter and a peripheral vein. If patient is seriously ill (hypotension,"}, 
{"Row" : 10, "Column" : 1, "Text" : "hypoperfusion, signs and symptoms of organ failure) remove catheter and culture"}, 
{"Row" : 11, "Column" : 1, "Text" : "tip. In patients who are moderately ill (e.g. hypotension, organ failure),"}, 
{"Row" : 12, "Column" : 1, "Text" : "remove catheter and culture tip if patient has a prosthetic valve, pacemaker or"}, 
{"Row" : 13, "Column" : 1, "Text" : "vascular graft. Start empirical antibiotics while awaiting culture results."}, 
{"Row" : 14, "Column" : 1, "Text" : "Narrow therapeutic spectrum based on sensitivities of cultured pathogens."}, 
{"Row" : 15, "Column" : 1, "Text" : "Empirical therapy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Empirical therapy for immunosuppressed patients", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "q12h ($) [R]"}, 
{"Row" : 22, "Column" : 1, "Text" : "For patients with penicillin allergy"}, 
{"Row" : 25, "Column" : 1, "Text" : "Pathogen-directed therapy", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "References"}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-date article: Treatment of Intravascular Catheter-Related Infections"}
]},
{"Name" : "ORZID2 GMENU INTRO SPEC PATHOGEN" , "Term1" : "Specific pathogen introduction", "DisplayText" : "Introduction to Specific Pathogen section " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX MANDELL", "DisplayText" : "Mandell Online", "Text" : "Mandell's Principles and Practice of Infectious Disease Online Access", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "INTRODUCTION TO SPECIFIC PATHOGEN SECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "This section gives brief advice on antimicrobial treatment for specific"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogens. Colonization by pathogens in most non-sterile sites rarely requires"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobial therapy. If there is a question about whether an isolate should"}, 
{"Row" :8, "Column" : 1, "Text" : "be treated, contact Infectious Diseases."}, 
{"Row" : 10, "Column" : 1, "Text" : "If culture and susceptibility results are available, use them to select"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial therapy. If culture and susceptibility results are not available,"}, 
{"Row" : 12, "Column" : 1, "Text" : "use clinical judgment to decide the appropriate spectrum of coverage. If you"}, 
{"Row" : 13, "Column" : 1, "Text" : "need advice on a disease or syndrome, return to the main menu and proceed to"}, 
{"Row" : 14, "Column" : 1, "Text" : "that disease or syndrome. In most cases, culture and susceptibility results"}, 
{"Row" : 15, "Column" : 1, "Text" : "should be used when they become available to select antimicrobials. This"}, 
{"Row" : 16, "Column" : 1, "Text" : "section gives the most common drugs to treat most microorganisms. Contact"}, 
{"Row" : 17, "Column" : 1, "Text" : "Infectious Diseases or consult a textbook such as Mandell's Principles and"}, 
{"Row" : 18, "Column" : 1, "Text" : "Practice of Infectious Disease for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "Microbiology results often become available in stages. Interim reports"}, 
{"Row" : 22, "Column" : 1, "Text" : "typically indicate the morphology and staining properties of an organism before"}, 
{"Row" : 23, "Column" : 1, "Text" : "final identification and susceptibility reports are available. Use an interim"}, 
{"Row" : 24, "Column" : 1, "Text" : "report along with the patient's presenting syndrome to refine the empirical"}, 
{"Row" : 25, "Column" : 1, "Text" : "therapy regimen pending final results. Use this section to adjust antimicrobial"}, 
{"Row" : 26, "Column" : 1, "Text" : "therapy based on an interim report."}
]},
{"Name" : "ORZID2 GMENU KERATITIS" , "Term1" : "Keratitis", "DisplayText" : "Keratitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Herpes keratitis", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 0.5% OPTH 1 DROP Q1H", "DisplayText" : "Moxifloxacin 0.5% opth 1 drop q1h", "Text" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFZ 50MG/ML OPH GENT 15MG/ML OPH Q1H", "DisplayText" : "Cefazolin 50 mg/mL oph Gentamicin 15 mg/mL oph q1h", "Text" : "Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "KERATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Keratitis is an emergency requiring prompt treatment to prevent vision loss."}, 
{"Row" :6, "Column" : 1, "Text" : "Contact Ophthalmology immediately."}, 
{"Row" :8, "Column" : 1, "Text" : "Keratitis is associated with viral or bacterial infection, trauma, foreign"}, 
{"Row" :9, "Column" : 1, "Text" : "bodies, or allergies. About half of cases of infectious keratitis are caused by"}, 
{"Row" : 10, "Column" : 1, "Text" : "bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and"}, 
{"Row" : 11, "Column" : 1, "Text" : "gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites"}, 
{"Row" : 12, "Column" : 1, "Text" : "have also been associated with corneal infection. Obtain corneal scrapings for"}, 
{"Row" : 13, "Column" : 1, "Text" : "gram stain and bacterial and viral cultures and start empirical therapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "immediately."}, 
{"Row" : 16, "Column" : 1, "Text" : "Link to herpes keratitis page"}, 
{"Row" : 19, "Column" : 1, "Text" : "If bacterial keratitis is likely, contact ophthalmology to obtain a corneal"}, 
{"Row" : 20, "Column" : 1, "Text" : "scraping and give empirical antibacterial drops immediately. Modify therapy"}, 
{"Row" : 21, "Column" : 1, "Text" : "based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic"}, 
{"Row" : 22, "Column" : 1, "Text" : "corticosteroids are contraindicated in patients with keratitis."}, 
{"Row" : 24, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment should be continued until ulcer and other signs of infectious"}, 
{"Row" : 26, "Column" : 1, "Text" : "keratitis have resolved. A minimum of two weeks and in rare cases, up to a month"}, 
{"Row" : 27, "Column" : 1, "Text" : "of therapy may be required."}, 
{"Row" : 29, "Column" : 1, "Text" : "Mild to moderate bacterial keratitis empirical treatment", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Severe (vision-threatening) bacterial keratitis empirical treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)"}, 
{"Row" : 36, "Column" : 1, "Text" : "Suspected MRSA", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin"}, 
{"Row" : 38, "Column" : 1, "Text" : "eye drops. Vancomycin eye drops must be specially compounded and managed by"}, 
{"Row" : 39, "Column" : 1, "Text" : "Ophthalmology."}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Lin et al., Ophthalmology. 2019,126(1):1-55"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Microbial keratitis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Keratitis"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date article:Complications of contact lenses"}
]},
{"Name" : "ORZID2 GMENU LEISHMANIASIS" , "Term1" : "Leishmaniasis", "DisplayText" : "Leishmaniasis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LEISHMANIASIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and treatment are complex.Consult Infectious Diseases and/or"}, 
{"Row" :6, "Column" : 1, "Text" : "Dermatology in all cases."}
]},
{"Name" : "ORZID2 GMENU LEUKOCYTOSIS" , "Term1" : "Leukocytosis", "DisplayText" : "Leukocytosis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LEUKOCYTOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The majority of leukocytosis cases are due to infection but a sizable minority"}, 
{"Row" :6, "Column" : 1, "Text" : "are associated with physiological stress, inflammation, medications (e.g"}, 
{"Row" :7, "Column" : 1, "Text" : "glucosteroids), and hematological conditions. In a review of 100 cases of"}, 
{"Row" :8, "Column" : 1, "Text" : "extreme leukocytosis (more than 25000 leukocytes per microliter with more than"}, 
{"Row" :9, "Column" : 1, "Text" : "50% granulocytes) at the Minneapolis VA, only 48 were from infectious problems."}, 
{"Row" : 11, "Column" : 1, "Text" : "Infection should be considered as a possible stimulus for leukocytosis in a"}, 
{"Row" : 12, "Column" : 1, "Text" : "patient with leukocytosis. Antimicrobials should be administered if the patient"}, 
{"Row" : 13, "Column" : 1, "Text" : "has a syndrome or disease that calls for antimicrobials. Antimicrobials should"}, 
{"Row" : 14, "Column" : 1, "Text" : "not be administered solely to treat a patient with leukocytosis and no other"}, 
{"Row" : 15, "Column" : 1, "Text" : "sign or symptom of infection."}, 
{"Row" : 18, "Column" : 1, "Text" : "References"}, 
{"Row" : 20, "Column" : 1, "Text" : "Wanahita et al., Clinical Infectious Diseases (2002), 34.1585-92"}, 
{"Row" : 21, "Column" : 1, "Text" : "Reding et al., The American Journal of Medicine (1998), 104.12-16"}
]},
{"Name" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE" , "Term1" : "Neurological disease associated with Lyme disease", "DisplayText" : "Acute neurological disease associated with Lyme disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more"}, 
{"Row" :6, "Column" : 1, "Text" : "extensive neurological disease with intravenous antimicrobials."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 14 to 21 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of neurological disease other than Bell palsy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat for 14 to 28 days."}, 
{"Row" : 21, "Column" : 1, "Text" : "References"}, 
{"Row" : 23, "Column" : 1, "Text" : "Halperin et. al., Neurology (2007) 69.91-102"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 26, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID2 GMENU LYME ARTHRITIS" , "Term1" : "Arthritis associated with Lyme disease", "DisplayText" : "Arthritis associated with Lyme disease" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ARTHRITIS ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases respond to a 28 day course of oral antimicrobials. If symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "persist or recur, Consult Infectious Diseases or Rheumatology."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "References"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 19, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID2 GMENU LYME CARDIAC DISEASE" , "Term1" : "Cardiac disease associated with Lyme disease", "DisplayText" : "Cardiac disease associated with Lyme disease" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment of first degree or second degree heart block", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment of third degree heart block or other manifestation", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "References"}, 
{"Row" : 19, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 21, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS" , "Term1" : "Prophylactic antimicrobials for Lyme disease", "DisplayText" : "Lyme Disease Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "DisplayText" : "IXODES IDENTIFACTION LINK", "Text" : "Ixodes scapularis identification", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX TICKBORNE RISK MAP", "DisplayText" : "TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 200MG PO ONCE", "DisplayText" : "Doxyclycline PO 200mg once ($) [DI] (Var)", "Text" : "Doxyclycline PO 200mg once ($) [DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-"}, 
{"Row" :6, "Column" : 1, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis"}, 
{"Row" :7, "Column" : 1, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%"}, 
{"Row" :8, "Column" : 1, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease."}, 
{"Row" :9, "Column" : 1, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease"}, 
{"Row" : 10, "Column" : 1, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes"}, 
{"Row" : 11, "Column" : 1, "Text" : "scapularis tick."}, 
{"Row" : 13, "Column" : 1, "Text" : "All following criteria must be met to be considered for prophylactic treatment: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)"}, 
{"Row" : 15, "Column" : 1, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes"}, 
{"Row" : 16, "Column" : 1, "Text" : "scalpularis. Follow link below for identification guide: "}, 
{"Row" : 18, "Column" : 1, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of"}, 
{"Row" : 19, "Column" : 1, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area."}, 
{"Row" : 20, "Column" : 1, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed."}, 
{"Row" : 21, "Column" : 1, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes"}, 
{"Row" : 22, "Column" : 1, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota"}, 
{"Row" : 23, "Column" : 1, "Text" : "counties where there is high risk of tickborne disease are shown in the"}, 
{"Row" : 24, "Column" : 1, "Text" : "following link: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the"}, 
{"Row" : 27, "Column" : 1, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B."}, 
{"Row" : 28, "Column" : 1, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed."}, 
{"Row" : 29, "Column" : 1, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick"}, 
{"Row" : 30, "Column" : 1, "Text" : "bite in New England or Mid-Atlantic States."}, 
{"Row" : 32, "Column" : 1, "Text" : "Prophylactic treatment if all above criteria are met", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}, 
{"Row" : 39, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 40, "Column" : 1, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)"}, 
{"Row" : 41, "Column" : 1, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html"}, 
{"Row" : 42, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)"}, 
{"Row" : 43, "Column" : 1, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf"}, 
{"Row" : 44, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)"}, 
{"Row" : 45, "Column" : 1, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf"}
]},
{"Name" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS" , "Term1" : "Erythema migrans, Lyme disease", "DisplayText" : "Erythema migrans associated with Lyme disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases."}, 
{"Row" :6, "Column" : 1, "Text" : "It is typically an erythematous circular rash, 5cm or larger in diameter, with"}, 
{"Row" :7, "Column" : 1, "Text" : "induration and central clearing (although other patterns occur). It usually"}, 
{"Row" :8, "Column" : 1, "Text" : "develops at the site of the bite and/or in one or more distant locations. The"}, 
{"Row" :9, "Column" : 1, "Text" : "rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days"}, 
{"Row" : 10, "Column" : 1, "Text" : "after a tick bite are not from Lyme disease."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 16, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat for 14 days"}, 
{"Row" : 21, "Column" : 1, "Text" : "References"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 25, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID2 GMENU M. AVIUM INTRACELLULARE" , "Term1" : "Mycobacterium avium intracellular complex (MAI or MAC)", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a MAI or MAC) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia", "Text" : "Treatment for pneumonia", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "DisplayText" : "Disseminated Mycobacterium avium disease treatment", "Text" : "Treatment for disseminated disease", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "DisplayText" : "Prophylaxis against Mycobacterium avium disease...", "Text" : "Prophylaxis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "MAI colonization in patients with chronic lung disease is common. These"}, 
{"Row" :6, "Column" : 1, "Text" : "patients should not be treated with antimicrobials."}, 
{"Row" :8, "Column" : 1, "Text" : "Occasionally, MAI causes pulmonary disease in patients who are not"}, 
{"Row" :9, "Column" : 1, "Text" : "immunosuppressed. Diagnosis and management are complex. Consult Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases and/or Pulmonary."}, 
{"Row" : 12, "Column" : 1, "Text" : "MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these"}, 
{"Row" : 13, "Column" : 1, "Text" : "cases do not involve the lungs. After treatment, long-term prophylaxis is"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually given. Consult Infectious Diseases in all cases."}
]},
{"Name" : "ORZID2 GMENU M. AVIUM PNEUMONIA" , "Term1" : "Mycobacterium avium pneumonia " , "Term2" : "Pneumonia, Mycobacterium avium", "DisplayText" : "Mycobacterium avium pneumonia " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN, ETHAMBUTOL, RIFABUTIN", "Text" : "Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AZITH 250, ETHAMBUTOL, RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM AVIUM PNEUMONIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are"}, 
{"Row" :6, "Column" : 1, "Text" : "usually recommended, but two drug regimens may be sufficient in some cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Consult Infectious Diseases and/or Pulmonary in all cases."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment is continued until sputum cultures are consecutively negative for 12"}, 
{"Row" : 11, "Column" : 1, "Text" : "months."}, 
{"Row" : 13, "Column" : 1, "Text" : "Three-drug regimens", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 20, "Column" : 1, "Text" : "<AND> rifabutin 300 mg q24h ($$) [R,DI]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Four-drug regimens may be recommended for advanced (severe) or previously", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "treated disease-Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium Complex"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in"}, 
{"Row" : 31, "Column" : 1, "Text" : "adults"}
]},
{"Name" : "ORZID2 GMENU M. PNEUMONIAE" , "Term1" : "Mycoplasma pneumonia infections, general", "DisplayText" : "Mycoplasma pneumoniae " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h for 5 days ($) [R,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "MYCOPLASMA PNEUMONIAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 14, "Column" : 1, "Text" : "Intolerance to doxycycline and azithromycin"}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford keyword: Mycoplasma pneumoniae"}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-to-Date article: Mycoplasma pneumoniae infection in adults"}
]},
{"Name" : "ORZID2 GMENU M. TUBERCULOSIS" , "Term1" : "Mycobacterium tuberculosis", "DisplayText" : "Mycobacterium tuberculosis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM TUBERCULOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Management of tuberculosis is complex. Contact Infectious Diseases and/or"}, 
{"Row" :6, "Column" : 1, "Text" : "Pulmonary service for more information."}
]},
{"Name" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA" , "Term1" : "Malignant otitis externa " , "Term2" : "Otitis externa, malignant", "DisplayText" : "Malignant Otitis Externa" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h for 6 weeks ($$) [R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q8h for 6 weeks ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "MALIGNANT OTITIS EXTERNA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Those who are elderly, diabetic, immunocompromised and debilitated are at"}, 
{"Row" :6, "Column" : 1, "Text" : "highest risk. Most cases are associated with Pseudomonas aeruginosa, but other"}, 
{"Row" :7, "Column" : 1, "Text" : "pathogens can be involved. Obtain culture to identify etiologic agent and"}, 
{"Row" :8, "Column" : 1, "Text" : "susceptibilities. Obtain a CT scan to determine whether osteomyelitis is"}, 
{"Row" :9, "Column" : 1, "Text" : "present. ENT and Infectious Disease consultations are recommended."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "for 6 weeks"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment of early infection or step-down treatment after initial intravenous", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "therapy.", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell"}, 
{"Row" : 28, "Column" : 1, "Text" : "chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Otitis Externa"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Malignant (necrotizing) external otitis"}
]},
{"Name" : "ORZID2 GMENU MASTOIDITIS" , "Term1" : "Mastoiditis", "DisplayText" : "Mastoiditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "DisplayText" : "Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q 12 hours ($) [R] < AND > cefepime 2 gm IV q12h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEFUROXIME 500MG Q12H", "Text" : "Cefuroxime 500mg PO q12h for 7 days ($) [R]", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN/DEXAMETHASONE OTIC 4 DRPS BID", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)", "Mnemonic" : "16"},
{"Row" : 55, "Column" : 1, "Item" : "PSJZID NEOMYCIN/POLYMIXIN/HC OTIC 4 DRPS QID", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "MASTOIDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Mastoiditis", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Acute mastoiditis most commonly occurs as a suppurative complication of acute"}, 
{"Row" :7, "Column" : 1, "Text" : "otitis media. Diagnosis is supported by CT or MRI imaging and culture of"}, 
{"Row" :8, "Column" : 1, "Text" : "drainage. Antibiotics and drainage of middle ear are sufficient treatment in"}, 
{"Row" :9, "Column" : 1, "Text" : "most cases. Mastoidectomy is necessary if abscess has formed in the mastoid"}, 
{"Row" : 10, "Column" : 1, "Text" : "bone. If complication of first episode of acute otitis media, etiologies"}, 
{"Row" : 11, "Column" : 1, "Text" : "typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,"}, 
{"Row" : 12, "Column" : 1, "Text" : "or Staphylococcus aureus. If secondary to chronic otitis media, etiologies"}, 
{"Row" : 13, "Column" : 1, "Text" : "typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually too ill for outpatient therapy. ENT consultation recommended. Obtain"}, 
{"Row" : 15, "Column" : 1, "Text" : "cultures of auditory canal or middle ear fluid (preferred)."}, 
{"Row" : 17, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 20, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q 12 hours ($) [R] for 7 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results. Adjust for a", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "total duration of 7 days of antimicrobial therapy.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Chronic Mastoiditis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Chronic mastoiditis is usually the result of chronic otitis media with"}, 
{"Row" : 39, "Column" : 1, "Text" : "perforation of the tympanic membrane. There is often associated formation of a"}, 
{"Row" : 40, "Column" : 1, "Text" : "cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and"}, 
{"Row" : 41, "Column" : 1, "Text" : "culture of drainage. Long term treatment with topical antimicrobials is first"}, 
{"Row" : 42, "Column" : 1, "Text" : "line therapy. Infection is often polymicrobial, including Staphylococcus aureus,"}, 
{"Row" : 43, "Column" : 1, "Text" : "Pseudomonas aeruginosa and anaerobes. Treatment should be managed in"}, 
{"Row" : 44, "Column" : 1, "Text" : "collaboration with otolaryngology and includes topical antimicrobials, care of"}, 
{"Row" : 45, "Column" : 1, "Text" : "external auditory canal, and is some cases mastoidectomy. If possible, withhold"}, 
{"Row" : 46, "Column" : 1, "Text" : "therapy until a pathogen is identified by culture of drainage to direct therapy."}, 
{"Row" : 47, "Column" : 1, "Text" : "Specific drug choice dictated by culture results."}, 
{"Row" : 49, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 52, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 54, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 56, "Column" : 1, "Text" : "weeks ($) [M]"}, 
{"Row" : 58, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "References: "}, 
{"Row" : 61, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 62, "Column" : 1, "Text" : "Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104."}, 
{"Row" : 63, "Column" : 1, "Text" : "Sanford keyword: Mastoiditis"}, 
{"Row" : 64, "Column" : 1, "Text" : "Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in"}, 
{"Row" : 65, "Column" : 1, "Text" : "adults"}
]},
{"Name" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials..." , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYL GENRL INFO", "DisplayText" : "Surgical prophylaxis general information", "Text" : "Surgical prophylaxis general information", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "DisplayText" : "Surgical wound classification and antimicrobial prophylaxis...", "Text" : "Surgical wound classification and prophylaxis recommendations", "Mnemonic" : "4"},
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU SURG TIMING DOSING PROPHYL ABX", "DisplayText" : "Timing and dosing (including re-dosing) of prophylatic antimicrobials", "Text" : "Timing of prophylactic antibiotics", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "DisplayText" : "Doses and Redosing of prophylactic antibiotics", "Text" : "CHART: Doses and Redosing Interval for NORMAL renal function", "Mnemonic" : "8"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU SURG ANTIBIOTIC RENAL REDOSING", "DisplayText" : "Redosing Interval for renal fxn normal vs esrd", "Text" : "CHART: Redosing Interval for Normal and ESRD renal function", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX SURGICAL PROPHYLAXIS", "DisplayText" : "Surgical Prophylaxis Guidelines", "Text" : "<Hyperlink> Surgical Antimicrobial Prophylaxis Guidelines 2013", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "14"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "DisplayText" : "Prevention of Bacterial Endocarditis", "Text" : "Inpatient status", "Mnemonic" : "16"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "DisplayText" : "Prevention of bacterial endocarditis (Outpatient)", "Text" : "Outpatient status", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "DisplayText" : "Neurosurgery", "Text" : "Neurosurgery", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "DisplayText" : "Head and neck surgery", "Text" : "Head and neck surgery (See Thoracic for esophageal procedures)", "Mnemonic" : "22"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU SURG OPHTHALMIC SURG", "DisplayText" : "Ophthalmic surgery", "Text" : "Ophthalmology Surgery- Moxifloxacin Intracameral for Cataract Surgery", "Mnemonic" : "24"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "DisplayText" : "CV Surgery Delayed Order Antibiotics", "Text" : "CV Surgery (open heart)", "Mnemonic" : "26"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU SURG CARDIAC SURG", "DisplayText" : "Cardiac surgery and implantation of pacemaker", "Text" : "Cardiac Procedures", "Mnemonic" : "28"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED PREOP", "DisplayText" : "CIED Pre Op", "Text" : "Cardiac Implantable Electronic Devices Surgery", "Mnemonic" : "30"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG THORACIC SURGERY", "DisplayText" : "Thoracic surgery", "Text" : "Thoracic surgery (See CV surgery for heart)", "Mnemonic" : "32"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX CARD SURGERY DECOLON", "Text" : "Cardiovascular surgery decolonization", "Mnemonic" : "34"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU SURG GASTRODUODENAL SURG", "DisplayText" : "Gastroduodenal Surgery", "Text" : "Gastroduodenal surgery", "Mnemonic" : "36"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU GI ENDOSCOPIC PROCEDURES", "Text" : "GI Endoscopic Procedures", "Mnemonic" : "38"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU SURG VASCULAR SURG", "DisplayText" : "Vascular surgery", "Text" : "Vascular surgery", "Mnemonic" : "40"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation", "Text" : "Appendectomy", "Mnemonic" : "42"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU SURG BILIARY", "DisplayText" : "Biliary Surgery", "Text" : "Biliary surgery", "Mnemonic" : "44"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "DisplayText" : "Bowel/Colo-rectal Surgery", "Text" : "Colon and rectal surgery", "Mnemonic" : "46"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU SURG HERNIA REPAIR", "DisplayText" : "Hernia repair surgery with abdominal mesh", "Text" : "Hernia repair surgery with abdominal mesh", "Mnemonic" : "48"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU SURG GYNECOL SURG", "DisplayText" : "Gynecological surgery", "Text" : "Gynecological surgery", "Mnemonic" : "50"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "DisplayText" : "Urological procedures", "Text" : "Urological Procedures", "Mnemonic" : "52"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO SURG JOINT ARTHRO", "DisplayText" : "Orthopedic surgery, including joint arthroplasty", "Text" : "Orthopedic surgery,including joint arthroplasty", "Mnemonic" : "54"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "DisplayText" : "Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections", "Text" : "Orthopedic surgery ALBC Joint Infections", "Mnemonic" : "56"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatologic surgery", "Mnemonic" : "58"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU SURG PLASTIC SURGERY", "Text" : "Plastic surgery", "Mnemonic" : "60"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU SURG OTHER PROCEDURES", "DisplayText" : "Other Procedures", "Text" : "Other procedures", "Mnemonic" : "62"},
{"Row" :1, "Column" : 1, "Text" : "++Surgical Prophylaxis++", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "For the complete guideline follow the link below: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Endocarditis Prophylaxis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Patients receiving preop antibiotics to prevent an SSI generally"}, 
{"Row" : 16, "Column" : 1, "Text" : "do NOT need additional antibiotics for endocarditis prophylaxis."}, 
{"Row" : 20, "Column" : 1, "Text" : "Antimicrobial Surgical Prophylaxis Specific Surgeries", "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Text" : "__Oral Medications and Nasal Spray__", "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Text" : "Do NOT use Delayed Orders"}, 
{"Row" : 25, "Column" : 2, "Text" : "Go to Surgery Outpt Orders"}, 
{"Row" : 26, "Column" : 2, "Text" : "then56 Pre Op Clinic Medications"}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU SURG SPINAL CORD STIMULATOR TRIAL", "DisplayText" : "Spinal Cord Stimulator Trial Procedure Antimicrobial Prophylaxis", "Text" : "Pain Clinic-Spinal Cord Stim Trial", "Mnemonic" : "64"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU SURG PODIATRY", "DisplayText" : "Podiatry Antimicrobial Surgical Prophylaxis Orders", "Text" : "", "Mnemonic" : "57"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU SURG INTERVENTIONAL RADIOLOGY", "DisplayText" : "Interventional Radiology", "Text" : "Interventional Radiology", "Mnemonic" : "39"}
]},
{"Name" : "ORZID2 GMENU MILD TO MOD SINUSITIS", "DisplayText" : "Mild to Moderate Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 5 days", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "MILD TO MODERATE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,"}, 
{"Row" :7, "Column" : 1, "Text" : "Staphylococcus aureus and anaerobes are isolated less frequently."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment for first 10 days of illness", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat with decongestants, analgesics, and nasal saline spray."}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment of cases that have not improved in 10 days despite", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "treatment with decongestants, analgesics, and nasal saline.", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment Failure", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "If symptoms worsen despite 72 hours orfail to improve after 3-5 days of"}, 
{"Row" : 26, "Column" : 1, "Text" : "initial empirical antimicrobial therapy, broaden coverage, switch to different"}, 
{"Row" : 27, "Column" : 1, "Text" : "antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there"}, 
{"Row" : 28, "Column" : 1, "Text" : "is no improvement after 3-5 more days of treatment, obtain CT to investigate"}, 
{"Row" : 29, "Column" : 1, "Text" : "non-infectious or suppurative causes. ENT consultation is recommended. If"}, 
{"Row" : 30, "Column" : 1, "Text" : "sinuses are aspirated, specimens should be cultured."}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 38, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 39, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 42, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "5"}
]},
{"Name" : "ORZID2 GMENU MORE ABOUT CELLULITIS", "DisplayText" : "The approach to cellulitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas", "Text" : "Erysipelas", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus", "Text" : "Foot ulcer in patient with diabetes mellitus", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "THE APPROACH TO CELLULITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments"}, 
{"Row" :6, "Column" : 1, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the"}, 
{"Row" :7, "Column" : 1, "Text" : "affected limb reduces swelling.Heat reduces discomfort."}, 
{"Row" :9, "Column" : 1, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry.In patients with"}, 
{"Row" : 10, "Column" : 1, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence"}, 
{"Row" : 11, "Column" : 1, "Text" : "of recurrent infection."}, 
{"Row" : 13, "Column" : 1, "Text" : "In many cases of cellulitis, the affected area is usually not well-"}, 
{"Row" : 14, "Column" : 1, "Text" : "differeniated from unaffected areas of the skin. Erysipelas is a special case"}, 
{"Row" : 15, "Column" : 1, "Text" : "with typically a well-defined border and raised, orange-peel appearance."}, 
{"Row" : 19, "Column" : 1, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with"}, 
{"Row" : 20, "Column" : 1, "Text" : "advanced diabetes."}, 
{"Row" : 27, "Column" : 1, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Cellulitis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID2 GMENU MORE ABOUT PHARYNGITIS", "DisplayText" : "More about Pharyngitis... " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "As most cases are of viral origin, antimicrobials are not indicated in these"}, 
{"Row" :6, "Column" : 1, "Text" : "cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief"}, 
{"Row" :7, "Column" : 1, "Text" : "of throat pain. Five to 10% of cases are caused by group A Streptococcus."}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment reduces symptoms by one day, prevents suppurative"}, 
{"Row" :9, "Column" : 1, "Text" : "complications and prevents acute rheumatic fever, an uncommon disease in US"}, 
{"Row" : 10, "Column" : 1, "Text" : "adults."}, 
{"Row" : 12, "Column" : 1, "Text" : "Streptococcal pharyngitis or tonsillitis should be suspected when patients have"}, 
{"Row" : 13, "Column" : 1, "Text" : "fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,"}, 
{"Row" : 14, "Column" : 1, "Text" : "nasal congestion, or runny nose that suggest viral infection or common cold. If"}, 
{"Row" : 15, "Column" : 1, "Text" : "streptococcal pharyngitis is suspected in adults, perform PCR testing for group"}, 
{"Row" : 16, "Column" : 1, "Text" : "A streptococci and treat only if positive."}, 
{"Row" : 18, "Column" : 1, "Text" : "Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be"}, 
{"Row" : 19, "Column" : 1, "Text" : "considered for patients with risk factors for sexually transmitted diseases. N."}, 
{"Row" : 20, "Column" : 1, "Text" : "gonorrhoeae infections must be reported to the state health department and this"}, 
{"Row" : 21, "Column" : 1, "Text" : "will be done by Infection Control if the culture is positive."}, 
{"Row" : 23, "Column" : 1, "Text" : "The Modified Centor score", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Used to estimate the likelihood that a patient with sore throat has"}, 
{"Row" : 25, "Column" : 1, "Text" : "streptococcal pharyngitis and whether rapid PCR testing should be performed."}, 
{"Row" : 27, "Column" : 1, "Text" : "1) Absence of cough = 1 point"}, 
{"Row" : 28, "Column" : 1, "Text" : "2) Swollen and tender anterior cervical nodes = 1 point"}, 
{"Row" : 29, "Column" : 1, "Text" : "3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1"}, 
{"Row" : 30, "Column" : 1, "Text" : "point"}, 
{"Row" : 31, "Column" : 1, "Text" : "4) Tonsillar exudates or swelling = 1 point"}, 
{"Row" : 32, "Column" : 1, "Text" : "5) Age: 3-14 years = 1 point"}, 
{"Row" : 33, "Column" : 1, "Text" : "15-44 years = 0 points"}, 
{"Row" : 34, "Column" : 1, "Text" : "45 years and older = -1 point"}, 
{"Row" : 36, "Column" : 1, "Text" : "Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic"}, 
{"Row" : 37, "Column" : 1, "Text" : "treatment are not indicated. Patients with a score of 2 to 4 are at moderate to"}, 
{"Row" : 38, "Column" : 1, "Text" : "high risk. PCR testing should be obtained in these patients to determine if GAS"}, 
{"Row" : 39, "Column" : 1, "Text" : "is present. In patients with a score of 4 or greater, consider empiric"}, 
{"Row" : 40, "Column" : 1, "Text" : "antibiotic treatment."}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390"}, 
{"Row" : 46, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}, 
{"Row" : 47, "Column" : 1, "Text" : "Sanford keyword: Streptococcal Pharyngitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis"}
]},
{"Name" : "ORZID2 GMENU NECROT INFECT DIRECT THERAPY", "DisplayText" : "Pathogen-directed therapy of necrotizing infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "DisplayText" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "DisplayText" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h", "Mnemonic" : "16"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "18"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV", "Mnemonic" : "20"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h", "Mnemonic" : "22"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "24"},
{"Row" :2, "Column" : 1, "Text" : "NECROTIZING INFECTIONS--PATHOGEN-DIRECTED THERAPY"}, 
{"Row" :4, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Clostridial infections", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "IV q8h ($$) [H,O]"}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "_______________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Group A Streptococcal infections (S. pyogenes)", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "IV q8h ($$) [H,O]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "______________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Polymicrobial infections", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "______________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "These are more common in injection drug users, or in patients who have had"}, 
{"Row" : 32, "Column" : 1, "Text" : "recent abdominal surgery or trauma, vulvo-vaginal infection, or genital or"}, 
{"Row" : 33, "Column" : 1, "Text" : "rectal abscess."}, 
{"Row" : 35, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R] < OR >"}, 
{"Row" : 45, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 57, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 58, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 59, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID2 GMENU NECROT INFECT EMP THERAPY", "DisplayText" : "Empirical therapy for Necrotizing infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h ($$)", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 1gm IV q8h ($$) <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV", "Mnemonic" : "10"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "EMPIRICAL THERAPY FOR NECROTIZING INFECTIONS"}, 
{"Row" :4, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" :7, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 10, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternatives for penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 28, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 29, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID2 GMENU NECROTIZING INFECTIONS" , "Term1" : "Necrotizing infections", "DisplayText" : "Necrotizing infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU NECROT INFECT EMP THERAPY", "DisplayText" : "Empirical therapy for Necrotizing infections", "Text" : "Empirical therapy of necrotizing infections", "Mnemonic" : "4"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU NECROT INFECT DIRECT THERAPY", "DisplayText" : "Pathogen-directed therapy of necrotizing infections", "Text" : "Pathogen-directed therapy of necrotizing infections", "Mnemonic" : "6"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NECROTIZING INFECTIONS"}, 
{"Row" :5, "Column" : 1, "Text" : "Call Surgery immediately and consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Necrotizing infections involve tissues skin and/or deeper structures, including"}, 
{"Row" :8, "Column" : 1, "Text" : "fascia and muscle.These infections destroy tissue, often rapidly, and are"}, 
{"Row" :9, "Column" : 1, "Text" : "often fatal if not treated promptly and appropriately.Necrotizing infections"}, 
{"Row" : 10, "Column" : 1, "Text" : "usually result from trauma, surgery, and/or ischemia.These infections can be"}, 
{"Row" : 11, "Column" : 1, "Text" : "monomicrobial (e.g., with streptococci or clostridia) or polymicrobial (usually"}, 
{"Row" : 12, "Column" : 1, "Text" : "with a mixture of aerobes and anaerobes).Fournier gangrene is usually"}, 
{"Row" : 13, "Column" : 1, "Text" : "associated with mixed infection.Myonecrosis is most commonly associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Clostridium species."}, 
{"Row" : 16, "Column" : 1, "Text" : "Necrotizing infections differ from cellulitis in several ways.Necrotic"}, 
{"Row" : 17, "Column" : 1, "Text" : "infections typically have one or more of the following: (1) severe, constant"}, 
{"Row" : 18, "Column" : 1, "Text" : "pain, (2) bullae, (3) bruising or necrosis of overlying skin, (4) gas in tissues"}, 
{"Row" : 19, "Column" : 1, "Text" : "which can be felt or seen on images, (5) edema that extends beyond areas of"}, 
{"Row" : 20, "Column" : 1, "Text" : "erythema, (6) local anesthesia, and (7) signs of systemic toxicity, such as"}, 
{"Row" : 21, "Column" : 1, "Text" : "fever, leukocytosis, delirium, or renal failure."}, 
{"Row" : 23, "Column" : 1, "Text" : "Necrotizing infections must be treated with both antimicrobial therapy and"}, 
{"Row" : 24, "Column" : 1, "Text" : "surgical procedures (excision and/or drainage).Call surgery to see the patient"}, 
{"Row" : 25, "Column" : 1, "Text" : "immediately in all cases.Obtain tissue and blood cultures and begin empirical"}, 
{"Row" : 26, "Column" : 1, "Text" : "antimicrobials.For several necrotic diseases and/or pathogens, a combination"}, 
{"Row" : 27, "Column" : 1, "Text" : "of two antimicrobials is recommended including a bactericidal antimicrobial"}, 
{"Row" : 28, "Column" : 1, "Text" : "active at the cell wall or membrane (e.g., beta-lactam or glycopeptide) and an"}, 
{"Row" : 29, "Column" : 1, "Text" : "antimicrobial that rapidly inhibits protein synthesis and thus inhibits toxin"}, 
{"Row" : 30, "Column" : 1, "Text" : "production, typically clindamycin."}, 
{"Row" : 31, "Column" : 1, "Text" : "Repeat debridement should be performed daily until no further debridement is"}, 
{"Row" : 32, "Column" : 1, "Text" : "necessary. Antibiotic therapy should be tailored as soon as culture results"}, 
{"Row" : 33, "Column" : 1, "Text" : "become available."}, 
{"Row" : 35, "Column" : 1, "Text" : "Administer antibiotics until further debridement is no longer necessary, the"}, 
{"Row" : 36, "Column" : 1, "Text" : "patient has improved clinically, and fever has been absent for 48-72 hours."}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical antimicrobials", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Pathogen-directed treatment regimens", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Gas gangrene"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 49, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 50, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU EMP INTRAV W/O VANCO", "DisplayText" : "Empirical intravenous regimens WITHOUT vancomycin", "Text" : "Empirical intravenous regimens WITHOUT vancomycin", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EMP INTRAV W/ VANCO", "DisplayText" : "Empirical intravenous regimens WITH vancomycin", "Text" : "Empirical intravenous regimens WITH vancomycin", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "Vancomycin is not recommended as a standard part of the initial antibiotic"}, 
{"Row" :6, "Column" : 1, "Text" : "regimen.Consider adding Vancomycin for specific clinical indications: "}, 
{"Row" :8, "Column" : 1, "Text" : ">>Suspected catheter-related infection,"}, 
{"Row" :9, "Column" : 1, "Text" : ">>Skin or soft-tissue infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : ">>Pneumonia,"}, 
{"Row" : 11, "Column" : 1, "Text" : ">>Hemodynamic instability"}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 21, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is a candidate for oral therapy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 500MG Q12H AMOX-CLAV 875/125 Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> amoxicillin-clavulanate", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOX 500MG PO BID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Ciprofloxacin 500mg PO q12h ($) [R,DI] <AND> Clindamycin 300mg po q6h ($) [H,O]", "Text" : "Ciprofloxacin 500mg PO q12h ($) [R,DI] <AND> Clindamycin 300mg po q6h ($) [H,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "Can the patient be treated with oral therapy?", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 11, "Column" : 1, "Text" : "875/125 mg PO q12h ($) [R]"}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Freifeld AG Clinical Infectious Disease 2011, 52: 427-431"}, 
{"Row" : 17, "Column" : 1, "Text" : "Taplitz RA, J Clin Oncol 2018, 36: 1443-1453"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford: Neutropenia, Febrile, Low-Risk"}, 
{"Row" : 19, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 20, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "DisplayText" : "Modification to Neutropenic fever therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER PT BECOME AFEBRILE", "DisplayText" : "Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment", "Text" : "Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER PT FEVER PERSISTS", "DisplayText" : "Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment", "Text" : "Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "MODIFICATION TO NEUTROPENIC FEVER THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "Determine efficacy of the initial regimen during the first 3 to 5 days."}, 
{"Row" :6, "Column" : 1, "Text" : "Decisions about therapy should be made based on (1) whether an infectious"}, 
{"Row" :7, "Column" : 1, "Text" : "disease has been diagnosed (e.g., pneumonia or cellulitis), (2) whether the"}, 
{"Row" :8, "Column" : 1, "Text" : "fever has resolved, and (3) the clinical course."}, 
{"Row" : 10, "Column" : 1, "Text" : "If a specific infectious disease and/or pathogen is identified, ensure that the"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial regimen is adequate to treat that pathogen or disease, and"}, 
{"Row" : 12, "Column" : 1, "Text" : "continue broad-spectrum antimicrobial therapy."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 22, "Column" : 1, "Text" : "(www.journals.uchicago.edu/doi/pdf/10.1086/339215)"}, 
{"Row" : 23, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER PT BECOME AFEBRILE", "DisplayText" : "Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Scoring tool to identify low risk febrile neutropenic patients", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 500MG Q12H AMOX-CLAV 875/125 Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h($0.18/day) [R,DI] <AND> amoxicillin-", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "PATIENTS WITH NEUTROPENIC FEVER WHO BECOME AFEBRILE IN THE FIRST 3 TO 5 DAYS OF"}, 
{"Row" :4, "Column" : 1, "Text" : "TREATMENT"}, 
{"Row" :6, "Column" : 1, "Text" : ">>Treatment if an INFECTIOUS CAUSE WAS IDENTIFIED and has resolved", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(The infectious disease associated with the fever has resolved, the pathogen has"}, 
{"Row" :8, "Column" : 1, "Text" : "been controlled or eradicated, and the patient seems well)"}, 
{"Row" :9, "Column" : 1, "Text" : "Stop antimicrobials after treatment for pathogen/disease is completed, often"}, 
{"Row" : 10, "Column" : 1, "Text" : "after 7 days."}, 
{"Row" : 12, "Column" : 1, "Text" : ">>Treatment if infectious cause of fever WAS NOT identified", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "To determine a patients risk level refer to"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment for low risk patients", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Consider a change to oral therapy"}, 
{"Row" : 19, "Column" : 1, "Text" : "clavulanate 875/125 mg PO q12h($1.56/day) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for high risk patients", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Continue same antimicrobials for 7 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 28, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER PT FEVER PERSISTS", "DisplayText" : "Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PATIENTS WITH NEUTROPENIC FEVER WHOSE FEVER PERSISTS THROUGHOUT THE FIRST 3 TO 5"}, 
{"Row" :4, "Column" : 1, "Text" : "DAYS OF TREATMENT"}, 
{"Row" :6, "Column" : 1, "Text" : "If no infectious disease has been diagnosed but the patient is clinically"}, 
{"Row" :7, "Column" : 1, "Text" : "stable, continue the current regimen.If vancomycin was part of initial therapy"}, 
{"Row" :8, "Column" : 1, "Text" : "but culture results have not yielded a pathogen that must be treated with"}, 
{"Row" :9, "Column" : 1, "Text" : "vancomycin, discontinue it to minimize development of resistance."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consider adding amphotericin B for empirical antifungal therapy.Hematology-"}, 
{"Row" : 12, "Column" : 1, "Text" : "oncology or Infectious Diseases may recommend another antifungal like"}, 
{"Row" : 13, "Column" : 1, "Text" : "micafungin or voriconazole.Contact Infectious Diseases for more information."}, 
{"Row" : 15, "Column" : 1, "Text" : "If the patient is receiving prophylactic fluconazole, stop it when empirical"}, 
{"Row" : 16, "Column" : 1, "Text" : "antifungals are started."}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 23, "Column" : 1, "Text" : "Rolston KVIClin Infect Dis 2004, 39: S44"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sipsas NVCancer 2005, 103: 1103"}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "DisplayText" : "Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio", "Text" : ""},
{"Row" : 21, "Column" : 1, "Text" : "References: "}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "MASCC RISK INDEX FOR FEBRILE NEUTROPENIA", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SCORING TOOL TO IDENTIFY LOW RISK FEBRILE NEUTROPENIC PATIENTS"}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with minimal risk of severe or rapidly progressive infection can be"}, 
{"Row" :6, "Column" : 1, "Text" : "treated with oral antimicrobials safely.Many can be treated as outpatients."}, 
{"Row" :7, "Column" : 1, "Text" : "Use the scoring index to identify febrile neutropenic patients who at"}, 
{"Row" :8, "Column" : 1, "Text" : "sufficiently low risk for severe infections and can be treated with outpatient"}, 
{"Row" :9, "Column" : 1, "Text" : "oral antimicrobials."}, 
{"Row" : 11, "Column" : 1, "Text" : "SCORING INDEX", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "CharacteristicScore", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Severity of symptoms of illness (choose one only)"}, 
{"Row" : 15, "Column" : 1, "Text" : "No symptoms or mild symptoms 5"}, 
{"Row" : 16, "Column" : 1, "Text" : "Moderate symptoms3"}, 
{"Row" : 17, "Column" : 1, "Text" : "No hypotension 5"}, 
{"Row" : 18, "Column" : 1, "Text" : "No chronic obstructive pulmonary disease4"}, 
{"Row" : 19, "Column" : 1, "Text" : "Solid tumor or no previous fungal infection4"}, 
{"Row" : 20, "Column" : 1, "Text" : "No dehydration 3"}, 
{"Row" : 21, "Column" : 1, "Text" : "Outpatient status at onset of fever3"}, 
{"Row" : 22, "Column" : 1, "Text" : "Age less than 60 years2"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sum total __"}, 
{"Row" : 26, "Column" : 1, "Text" : "Interpretation", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "The highest possible score is 26. A risk index score of 21 or greater indicates"}, 
{"Row" : 28, "Column" : 1, "Text" : "that the patient is likely to be at LOW RISK for complications and morbidity."}, 
{"Row" : 29, "Column" : 1, "Text" : "This is a guide.Always use clinical judgement."}, 
{"Row" : 34, "Column" : 1, "Text" : "Klastersky, J Clin Oncol 2000, 18: 3038"}
]},
{"Name" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS" , "Term1" : "Nosocomial sinusitis " , "Term2" : "Sinusitis, nosocomial", "DisplayText" : "Nosocomial Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Nasogastric tubes increase the risk of bacterial sinus infection associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "Staphylococcus aureus, streptococcus, and gram-negative bacilli, including"}, 
{"Row" :7, "Column" : 1, "Text" : "Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial therapy. Adequate sinus drainage is vital to treatment."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical antimicrobial treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 18, "Column" : 1, "Text" : "MRSA suggestive on gram-stain", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 27, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Intubation Associated"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-To-Date article: Complications of the endotracheal tube following initial"}, 
{"Row" : 30, "Column" : 1, "Text" : "placement: Prevention and management in adult intensive care unit patients"}
]},
{"Name" : "ORZID2 GMENU OSTEOM EMPIRICAL THERAPY", "DisplayText" : "Empirical therapy for Osteomyelitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 500MG PO Q24H RIFAMPIN 600 MG PO Q24H", "DisplayText" : "Levofloxacin 500mg po q24h ($0.19/day) [R", "Text" : "Levofloxacin 500mg po q24h ($) [R] <AND> Rifampin 600 mg po", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL THERAPY FOR OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Therapy should be modified when culture results and patient response to therapy"}, 
{"Row" :6, "Column" : 1, "Text" : "are known.If cultures cannot be obtained, the oral regimens listed below can"}, 
{"Row" :7, "Column" : 1, "Text" : "be used for empirical therapy or to complete a treatment course after the"}, 
{"Row" :8, "Column" : 1, "Text" : "patient's disease has improved. Consult Infectious Diseases for more"}, 
{"Row" :9, "Column" : 1, "Text" : "information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of treatment 4 to 6 weeks."}, 
{"Row" : 12, "Column" : 1, "Text" : "ORAL treatment for MILD disease or for completion of treatment course", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "q24h ($) [DI,O]"}, 
{"Row" : 18, "Column" : 1, "Text" : "INTRAVENOUS treatment for MODERATE to SEVERE disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford: key term: Osteomyelitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell Chapter: Osteomyelitis"}, 
{"Row" : 27, "Column" : 1, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26"}, 
{"Row" : 28, "Column" : 1, "Text" : "Calhoun JH Infect Dis Clin North AM 2005, 19:765"}, 
{"Row" : 29, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:393"}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH GNB" , "Term1" : "Gram-negative bacilli, non-pseudomonas, osteomyelitis", "DisplayText" : "Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]< OR >", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]< OR >", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]< OR >", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 16, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA" , "Term1" : "Pseudomonas aeruginosa osteomyelitis", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 16, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}, 
{"Row" :7, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <OR>", "Mnemonic" : "6"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacilin-tazobactam 4.5 gm IV q6h ($$) [R]<OR>", "Mnemonic" : "4"}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI" , "Term1" : "Streptococcal osteomyelitis", "DisplayText" : "Osteomyelitis with Streptococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]< OR >", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH STREPTOCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 16, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" :8, "Column" : 1, "Text" : "Oral treatment: "}
]},
{"Name" : "ORZID2 GMENU OSTEOMYELITIS" , "Term1" : "Osteomyelitis", "DisplayText" : "Osteomyelitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM EMPIRICAL THERAPY", "DisplayText" : "Empirical therapy for Osteomyelitis", "Text" : "Empirical therapy for osteomyelitis", "Mnemonic" : "4"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS", "DisplayText" : "Osteomyelitis with Staphylococcus aureus", "Text" : "Osteomyelitis with Staphylococcus aureus", "Mnemonic" : "6"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI", "DisplayText" : "Osteomyelitis with Streptococci", "Text" : "Osteomyelitis with Streptococci", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH GNB", "DisplayText" : "Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas)", "Text" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas)", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa", "Text" : "Osteomyelitis with Pseudomonas aeruginosa", "Mnemonic" : "12"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "14"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "DisplayText" : "Mediastinitis", "Text" : "Mediastinitis", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "In acute osteomyelitis, symptoms have been present for several days to weeks."}, 
{"Row" :6, "Column" : 1, "Text" : "Chronic osteomyelitis is characterized by a longer duration of symptoms,"}, 
{"Row" :7, "Column" : 1, "Text" : "sometimes months or years, and often dead, necrotic bone is present.There is"}, 
{"Row" :8, "Column" : 1, "Text" : "considerable overlap between the syndromes of acute and chronic osteomyelitis."}, 
{"Row" :9, "Column" : 1, "Text" : "Symptom duration may be unreliable in a patient with neuropathy."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtain material for gram stain and culture before initiating antimicrobials."}, 
{"Row" : 12, "Column" : 1, "Text" : "Blood and bone cultures are ideal.Sinus tracts are often colonized with"}, 
{"Row" : 13, "Column" : 1, "Text" : "multiple species and usually only one or two are pathogens in bone.If"}, 
{"Row" : 14, "Column" : 1, "Text" : "Staphylococcus aureus is present, it is likely to be a pathogen in bone."}, 
{"Row" : 16, "Column" : 1, "Text" : "Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,"}, 
{"Row" : 17, "Column" : 1, "Text" : "but necrotic bone must often be removed for cure of chronic osteomyelitis.If"}, 
{"Row" : 18, "Column" : 1, "Text" : "complete debridement is not possible, long-term suppressive antimicrobials may"}, 
{"Row" : 19, "Column" : 1, "Text" : "be needed.Consult Infectious Diseases for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "The most important pathogens are S. aureus and streptococci.Gram negative"}, 
{"Row" : 22, "Column" : 1, "Text" : "bacilli are common pathogens in osteomyelitis associated with diabetic foot"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection."}, 
{"Row" : 25, "Column" : 1, "Text" : "Duration of treatment and route will vary with differences in location of"}, 
{"Row" : 26, "Column" : 1, "Text" : "infection, infecting organism, and host comorbidities.In general treat"}, 
{"Row" : 27, "Column" : 1, "Text" : "for 4 to 6 weeks.For difficult location (e.g. spine) or difficult bacteria"}, 
{"Row" : 28, "Column" : 1, "Text" : "(e.g. staphylococcus, pseudomonas) give intravenous therapy for 4 to 6 weeks."}, 
{"Row" : 29, "Column" : 1, "Text" : "For moderate cases, give intravenous therapy for 1 to 2 weeks followed"}, 
{"Row" : 30, "Column" : 1, "Text" : "by oral therapy for the balance of 4 to 6 weeks.For mild cases, start with"}, 
{"Row" : 31, "Column" : 1, "Text" : "intravenous therapy for only a few days followed by oral therapy for the"}, 
{"Row" : 32, "Column" : 1, "Text" : "balance of 4 to 6 weeks."}, 
{"Row" : 34, "Column" : 1, "Text" : "Empirical treatment regimens", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Pathogen-directed treatment regimens", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry"}, 
{"Row" : 44, "Column" : 1, "Text" : "(for foot infections), and Infectious Diseases consults."}, 
{"Row" : 46, "Column" : 1, "Text" : "Treat for 4 to 6 weeks.Do not place a long-term intravascular access device"}, 
{"Row" : 47, "Column" : 1, "Text" : "(e.g. a PICC line) until it is clear the patient will need long-term intravenous"}, 
{"Row" : 48, "Column" : 1, "Text" : "therapy.Consult Infectious Diseases or Orthopedic Surgery for more"}, 
{"Row" : 49, "Column" : 1, "Text" : "information."}, 
{"Row" : 51, "Column" : 1, "Text" : ">>For patients with infections associated with prosthetic materials see"}, 
{"Row" : 54, "Column" : 1, "Text" : ">>For patients with sternal infection associated with chest surgery see"}, 
{"Row" : 58, "Column" : 1, "Text" : "References: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 60, "Column" : 1, "Text" : "Lipsky BA Clin Infect Disease 2012, 54:393"}
]},
{"Name" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS" , "Term1" : "Staphylococcus aureus osteomyelitis", "DisplayText" : "Osteomyelitis with Staphylococcus aureus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($) [DI] < OR >", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Mnemonic" : "14"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Mnemonic" : "16"},
{"Row" : 22, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS"}, 
{"Row" :5, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Methicillin-SUSCEPTIBLE S. aureus", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Methicillin-RESISTANT S. aureus", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 27, "Column" : 1, "Text" : "Spellberg B Clin Infect Dis 2012, 54:393"}, 
{"Row" : 28, "Column" : 1, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26"}, 
{"Row" : 29, "Column" : 1, "Text" : "Calhoun JH Infect Dis Clin North Am 2005,19:765"}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Text" : "Oral treatment: "}
]},
{"Name" : "ORZID2 GMENU OTHER PATHOGENS" , "Term1" : "Other Pathogens section", "DisplayText" : "Other pathogens " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Text" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU M. TUBERCULOSIS", "DisplayText" : "Mycobacterium tuberculosis", "Text" : "Mycobacterium tuberculosis", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU M. AVIUM INTRACELLULARE", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a MAI or MAC)", "Text" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)", "Mnemonic" : "12"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU M. PNEUMONIAE", "DisplayText" : "Mycoplasma pneumoniae", "Text" : "Mycoplasma pneumonia", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "++ OTHER PATHOGENS ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or"}, 
{"Row" :7, "Column" : 1, "Text" : "contaminant. See disease/syndrome section for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Coxiella and Ehrlichia", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Lyme Disease", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Mycobacteria", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Mycoplasma", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Pneumocystis infection", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU OTITIS EXTERNA" , "Term1" : "Otitis externa", "DisplayText" : "Otitis Externa" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and carbuncles", "Text" : "Furuncles and Carbuncles", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID NEOMYCIN/POLYMIXIN/HC OTIC 4 DRPS QID", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN/DEXAMETHASONE OTIC 4 DRPS BID", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CIPROFL 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500mg po q12h (Var)", "Text" : "< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "OTITIS EXTERNA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Localized Disease", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus."}, 
{"Row" :7, "Column" : 1, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep"}, 
{"Row" :8, "Column" : 1, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed."}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to the Furuncles and Carbuncles page for antibiotic recommendations."}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute diffuse and chronic otitis externa", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and"}, 
{"Row" : 15, "Column" : 1, "Text" : "Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and"}, 
{"Row" : 16, "Column" : 1, "Text" : "purulent material which can improve effectiveness of topical antibiotics. Avoid"}, 
{"Row" : 17, "Column" : 1, "Text" : "products that contain neomycin if the tympanic membrane is perforated."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment if tympanic membrane is intact", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "for 7 days ($) [M]"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Complicated Cases", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "For cases resistant to topical therapy alone, patients with poorly controlled"}, 
{"Row" : 30, "Column" : 1, "Text" : "diabetes mellitus, immunocompromised patients, cases where infection has spread"}, 
{"Row" : 31, "Column" : 1, "Text" : "beyond ear canal and in those where topical therapy cannot be delivered"}, 
{"Row" : 32, "Column" : 1, "Text" : "effectively. Culture secretions to guide therapy."}, 
{"Row" : 33, "Column" : 1, "Text" : "In addition to topical therapy above"}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Otitis Externa"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-To-Date article: External otitis: Treatment"}
]},
{"Name" : "ORZID2 GMENU OTITIS MEDIA" , "Term1" : "Otitis media", "DisplayText" : "Otitis Media" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "DisplayText" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h for 10 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir 300 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "DisplayText" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Text" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "OTITIS MEDIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are"}, 
{"Row" :6, "Column" : 1, "Text" : "the most common bacteria to cause otitis media."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Patient has NOT received antibiotics in the prior month"}, 
{"Row" : 12, "Column" : 1, "Text" : "Patient has received antibiotics in the prior month"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternatives", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Harmes et al, American Family Physician. 2013, 88(7)435-440"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Otitis media"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date Online: Acute otitis media in adults"}
]},
{"Name" : "ORZID2 GMENU PARASITES" , "Term1" : "Parasites", "DisplayText" : "Parasites " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU BABESIA SPP.", "DisplayText" : "Babesia species", "Text" : "Babesia spp.", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "DisplayText" : "Infectious diarrhea/Gastroenteritis", "Text" : "Diarrhea, parasitic", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocyctis Jirovecii Prophylaxis", "Text" : "Pneumocystis", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU TOXOPLASMA SPP.", "DisplayText" : "Toxoplasma spp.", "Text" : "Toxoplasma", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "++ PARASITES ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome section for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PARONYCHIA" , "Term1" : "Paronychia", "DisplayText" : "Paronychia" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CLOTRIM 1% CREAM TOPICAL QDAY", "DisplayText" : "Clotrimazole 1% cream topical qday", "Text" : "Clotrimazole 1% apply to affected area once daily ($) [M]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID NYSTATIN CREAM BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M]", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "DisplayText" : "Herpes Whitlow (digit/hand cellulitis)", "Text" : "Link to Herpes whitlow", "Mnemonic" : "12"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "PARONYCHIA"}, 
{"Row" :4, "Column" : 1, "Text" : "Cutaneous infection of the hand, cuticle or fingers usually occurring near OR"}, 
{"Row" :5, "Column" : 1, "Text" : "around the nail."}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment depends on etiology.Candida spp. are commonly involved when the"}, 
{"Row" :7, "Column" : 1, "Text" : "patient has extensive exposure to water (e.g. dishwashers).Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "aureus is more commonly after manicures or nail biting.Herpes simplex"}, 
{"Row" :9, "Column" : 1, "Text" : "(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "anesthetists)."}, 
{"Row" : 11, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment for paronychia associated with Candida", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for 14 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for paronychia associated with Staphylococcus", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treat for 10 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Treatment for paronychia associated with Herpes whitlow", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: paronychia"}
]},
{"Name" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "DisplayText" : "Cefazolin PD order menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PD CEFAZOLIN 15MG/KG Q24H", "DisplayText" : "Cefazolin 1 gm PD q24h", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD CEFAZOLIN 15MG/KG Q24H HEP", "DisplayText" : "Cefazolin 1 gm PD q24h with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFAZOLIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cefazolin 15 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}
]},
{"Name" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H AND GENT 0.6MG/KG Q24H", "DisplayText" : "Cefazolin and gentamicin PD order menu" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD CEFAZ 1GM Q24H GENT Q24H", "DisplayText" : "Cefaz 1 gm PD q24h and gent PD 24h", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID PD CEFAZ 1GM Q24H GENT Q24H HEP", "DisplayText" : "Cefaz 1 gm PD q24h and gent PD 24h with hep", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFAZOLIN AND GENTAMICIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cefazolin 15 mg/kg PD q24h and gentamicin 0.6 mg/kg PD q24h in 2000 mL"}, 
{"Row" :6, "Column" : 1, "Text" : "2.5% dextrose diaslyate solution (low mag)"}, 
{"Row" : 11, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "DisplayText" : "Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PD CEFEPIME 1GM Q24H", "DisplayText" : "Cefepime 1 gm PD q24h", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD CEFEPIME 1GM Q24H HEP", "DisplayText" : "Cefepime 1 gm PD q24h with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFIPIME", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cefepime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}
]},
{"Name" : "ORZID2 GMENU PD CEFEPIME 1GM Q24H VANCO 15-30MG/KG Q5-7D", "DisplayText" : "Cefepime and Vancomycin Treatment of Peritonitis Associated with PD " , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX PD CEFEPIME AND VANCO LOW MAG 2.5%", "DisplayText" : "Cefepime PD q24h and vanco q5-7d in low mag 1.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX PD CEFEPIME AND VANCO HEP LOW MAG 2.5%", "DisplayText" : "Cefepime PD q24h and vanco q5-7d in low mag 1.5% with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFIPIME AND VANCOMYCIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cefepime 1 gm PD q24h and vancomycin 30 mg/kg PD loading dose followed by 15"}, 
{"Row" :6, "Column" : 1, "Text" : "mg/kg PD every 3 to 7 days in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}, 
{"Row" : 11, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD CEFTAZIDIME 1GM Q24H", "DisplayText" : "Ceftazidime PD order menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PD CEFTAZIDIME 1GM Q24H", "DisplayText" : "Ceftazidime 1 gm PD q24h", "Text" : "Low Mag 2.5%", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD CEFTAZIDIME 1GM Q24H HEP", "DisplayText" : "Ceftazidime 1 gm PD q24h with heparin", "Text" : "Low Mag 2.5% with heparin 1000 units daily", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFTAZIDIME", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ceftazidime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}
]},
{"Name" : "ORZID2 GMENU PD CEFTRIAXONE 1GM Q24H", "DisplayText" : "Ceftriaxone PD order menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PD CEFTRIAXONE 1GM Q24H", "DisplayText" : "Ceftriaxone 1 gm PD q24h", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD CEFTRIAXONE 1GM Q24H HEP", "DisplayText" : "Ceftriaxone 1 gm PD q24h with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFTRIAXONE", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ceftriaxone 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}
]},
{"Name" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Gentamicin PD order menu" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PD GENT 0.6MG/KG Q24H", "DisplayText" : "Gentamicin 0.6 mg/kg PD q24h", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID PD GENT 0.6MG/KG Q24H HEP", "DisplayText" : "Gentamicin 0.6 mg/kg PD q24h with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "GENTAMICIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low ma"}, 
{"Row" : 10, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "DisplayText" : "Vancomycin PD order menu" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO 30MG/KG-15MG/KG Q5-7D LOW MAG 2.5%", "DisplayText" : "Vanco 30mg/kg PD LD 15mg/kg q5-7d in in low mag 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO 30MG/KG-15MG/KG Q5-7D HEP LOW MAG 2.5%", "DisplayText" : "Vanco 30mg/kg PD LD 15mg/kg q5-7d in low mag 2.5% with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "VANCOMYCIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days"}, 
{"Row" :6, "Column" : 1, "Text" : "in 2000 mL 2.5% dextrose diaslyate solution (low mag)"}, 
{"Row" : 11, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D AND GENT 0.6MG/KG Q24H", "DisplayText" : "Vancomycin and gentamicin PD order menu " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO AND GENTAMICIN LOW MAG 2.5%", "DisplayText" : "Vanco PD q5-7d and gent PD q24h in low mag 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO AND GENTAMICIN HEP LOW MAG 2.5%", "DisplayText" : "Vanco PD q5-7d and gent PD q24h in low mag 2.5% with heparin", "Text" : "[Click Here] to order WITH heparin", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "VANCOMYCIN AND GENTAMICIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days"}, 
{"Row" :6, "Column" : 1, "Text" : "and gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution"}, 
{"Row" :7, "Column" : 1, "Text" : "(low mag)"}, 
{"Row" : 12, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PERIOCULAR INFECTIONS" , "Term1" : "Periocular infections", "DisplayText" : "Periocular Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PERIOCULAR INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Eyelid infections", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patients with moderate or severe eyelid infections should be referred to"}, 
{"Row" :7, "Column" : 1, "Text" : "ophthalmology."}, 
{"Row" :8, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Blepharitis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Wash margins with baby shampoo daily and use warm compresses daily."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobials have no benefit."}, 
{"Row" : 13, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Hordeolum (stye)", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For external disease (involving the gland of Zeis), daily hot pack massage"}, 
{"Row" : 17, "Column" : 1, "Text" : "encourages drainage and relieves symptoms. For internal disease (involving"}, 
{"Row" : 18, "Column" : 1, "Text" : "Meibomian glands) ophthalmology consult is encouraged, as the infection seldom"}, 
{"Row" : 19, "Column" : 1, "Text" : "drains without intervention."}, 
{"Row" : 20, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Lacrimal infections", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Refer cases of lacrimal infection to ophthalmology, including infections of the"}, 
{"Row" : 24, "Column" : 1, "Text" : "lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts"}, 
{"Row" : 25, "Column" : 1, "Text" : "(canaliculitis)."}, 
{"Row" : 27, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-To-Date article: Blepharitis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-To-Date article: Eyelid lesions"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Blepharitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Hordeolum, Stye"}
]},
{"Name" : "ORZID2 GMENU PERIODENTAL DISEASE" , "Term1" : "Periodontal disease", "DisplayText" : "Periodental disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CHLORHEXIDINE 0.12% ORAL SWISH BID", "DisplayText" : "Chlorhexidine 0.12% oral rinse swish for 30 secs then spint 15ml 2x/daily", "Text" : "Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PERIODONTAL DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Periodontal disease, including gingivitis and periodontitis, may progress into"}, 
{"Row" :6, "Column" : 1, "Text" : "more severe disease or cause hematogenous spreading of bacteria if left"}, 
{"Row" :7, "Column" : 1, "Text" : "untreated. All patients with periodontal disease should be referred to the"}, 
{"Row" :8, "Column" : 1, "Text" : "dental service for assessment and direction of treatment. In the presence of"}, 
{"Row" :9, "Column" : 1, "Text" : "gingivitis, the most commonly isolated subgingival flora includes Prevotella"}, 
{"Row" : 10, "Column" : 1, "Text" : "intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the"}, 
{"Row" : 11, "Column" : 1, "Text" : "presence of periodontitis, flora increases in complexity to most commonly"}, 
{"Row" : 12, "Column" : 1, "Text" : "include Porphyromonas gingivalis, P. intermedia, Aggregatibacter"}, 
{"Row" : 13, "Column" : 1, "Text" : "actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consult Dental Service", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Non-severe periodontitis or acute simple gingivitis treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "daily for 7 days ($) [M]"}, 
{"Row" : 20, "Column" : 1, "Text" : "Severe periodontitis or acute complicated gingivitis (ulceration, rapidly", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "advancing disease, severe pain, patients with immunocompromising conditions)", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Consult Dental Service"}, 
{"Row" : 25, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandel Chapter: Infections of the Oral Cavity, Neck and Head"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-To-Date article: Complications, diagnosis, and treatment of odontogenic"}, 
{"Row" : 31, "Column" : 1, "Text" : "infections"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-To-Date article: Overview of gingivitis and periodontitis in adults"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Vincent's Angina"}, 
{"Row" : 34, "Column" : 1, "Text" : "Slots et al., Periodontology. 2002, 28(1)106-176"}, 
{"Row" : 35, "Column" : 1, "Text" : "Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172."}
]},
{"Name" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "DisplayText" : "CIED Post Op", "Text" : "CIED Surgery Post-op Prophylaxis", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU SURG CV POSTOP", "DisplayText" : "CV POSTOPERATIVE PROPHYLAXIS", "Text" : "CV Surgery (Open Heart) Postoperative Prophylaxis", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG THORACIC POSTOP", "DisplayText" : "THORACIC POSTOPERATIVE PROPHYLAXIS", "Text" : "Thoracic Surgery Postoperative Prophylaxis", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU POSTSEPTAL CELLULITIS" , "Term1" : "Cellulitis, postseptal (orbital) " , "Term2" : "Orbital cellulitis " , "Term3" : "Postseptal cellulitis", "DisplayText" : "Postseptal Cellulitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM Q24H METRO 500GM Q8H VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q24h metronidazole 500 mg q8h vancomycin 15 mg/kg q12h", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 2DS PO Q12", "DisplayText" : "Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 2DS q12h", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >", "Mnemonic" : "10"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "12"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H TMP/SMX 2DS PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h and trimethoprim-sulfamethoxazole 2DS PO q12h", "Text" : "Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and"}, 
{"Row" :6, "Column" : 1, "Text" : "requires immediate consultation with otolaryngology and ophthalmology. Urgent"}, 
{"Row" :7, "Column" : 1, "Text" : "surgical drainage may be necessary. The most common pathogenic organisms in"}, 
{"Row" :8, "Column" : 1, "Text" : "adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus"}, 
{"Row" :9, "Column" : 1, "Text" : "aureus. Broad-spectrum empirical antimicrobials should be used until a pathogen"}, 
{"Row" : 10, "Column" : 1, "Text" : "can be identified from the drainage fluid."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Orbital cellulitis should be treated until all signs of infection have resolved."}, 
{"Row" : 14, "Column" : 1, "Text" : "Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and"}, 
{"Row" : 15, "Column" : 1, "Text" : "complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of"}, 
{"Row" : 16, "Column" : 1, "Text" : "sinus) should be treated for at least 4 weeks."}, 
{"Row" : 18, "Column" : 1, "Text" : "Empiric treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 21, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 26, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 28, "Column" : 1, "Text" : "Step-down treatment after initial intravenous therapy. Base selection on cultur", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "results.Adjust duration based on criteria above.", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 32, "Column" : 1, "Text" : "trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 37, "Column" : 1, "Text" : "q12h ($) [R,DI] for 7 days"}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 43, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Orbital Cellulitis"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Orbital cellulitis"}
]},
{"Name" : "ORZID2 GMENU PRESEPTAL CELLULITIS" , "Term1" : "Cellulitis, preseptal " , "Term2" : "Preseptal cellulitis", "DisplayText" : "Preseptal Cellulitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM Q24H METRO 500GM Q8H VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q24h metronidazole 500 mg q8h vancomycin 15 mg/kg q12h", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 2DS PO Q12", "DisplayText" : "Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 2DS q12h", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>", "Mnemonic" : "10"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H TMP/SMX 2DS PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h and trimethoprim-sulfamethoxazole 2DS PO q12h", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 2 DS PO", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "PRESEPTAL CELLULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Preseptal cellulitis involves soft tissues in front of the orbital septum and"}, 
{"Row" :6, "Column" : 1, "Text" : "the eyelids and is often preceded by sinusitis. Infection does not involve the"}, 
{"Row" :7, "Column" : 1, "Text" : "orbital contents. The most common pathogenic organisms in adults are"}, 
{"Row" :8, "Column" : 1, "Text" : "streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat under the guidance of ophthalmology and/or otolaryngology. Intravenous"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials are indicated initially for treatment of moderate to severe"}, 
{"Row" : 12, "Column" : 1, "Text" : "disease. Switch to oral antimicrobials when the patient's symptoms improve and"}, 
{"Row" : 13, "Column" : 1, "Text" : "the patient can tolerate oral medications."}, 
{"Row" : 15, "Column" : 1, "Text" : "Moderate to severe infection or failure of oral antibiotics", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Transition to oral antibiotics can be considered if significant improvement"}, 
{"Row" : 17, "Column" : 1, "Text" : "within 24-48 hours."}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 20, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R] for 5 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of mild disease or step-down treatment after initial intravenous", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy. Treat for a total duration of 5 days.", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 5 days"}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 36, "Column" : 1, "Text" : "BID ($) [R,DI] for 5 days"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 43, "Column" : 1, "Text" : "Johns Hopkins website"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-date article: Preseptal cellulitis"}
]},
{"Name" : "ORZID2 GMENU PREV INFECT BACT PROPHYL" , "Term1" : "Antibacterial prophylaxis in malignancy " , "Term2" : "Prophylactic antibiotics in malignancy", "DisplayText" : "Prevention of bacterial infection in a patient with malignancy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h($) [R,DI] < OR >", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "DisplayText" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis is often given to patients likely to have profound,"}, 
{"Row" :6, "Column" : 1, "Text" : "prolonged neutropenia.Profound neutropenia is less than 100 neutrophils and"}, 
{"Row" :7, "Column" : 1, "Text" : "bands per microliter, and such neutropenia is considered prolonged when it is"}, 
{"Row" :8, "Column" : 1, "Text" : "expected to last more than 7 days.Most patients who should receive prophylaxis"}, 
{"Row" :9, "Column" : 1, "Text" : "have received stem cell transplants or are undergoing induction chemotherapy for"}, 
{"Row" : 10, "Column" : 1, "Text" : "acute leukemia."}, 
{"Row" : 12, "Column" : 1, "Text" : "If antibacterial prophylaxis is indicated", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of therapy: During period of expected neutropenia"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter:Prophylaxis and Empirical Therapy for Infection in Cancer"}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients"}, 
{"Row" : 25, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 26, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}
]},
{"Name" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL" , "Term1" : "Antifungal prophylaxis in malignancy " , "Term2" : "Prophylactic antifungals in malignancy", "DisplayText" : "Prevention of fungal infections in a patient with malignancy" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "DisplayText" : "Fluconazole 400mg po q24h", "Text" : "Fluconazole 400 mg po q24h ($) [R,DI]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antifungal chemoprophylaxis is often given to patients undergoing induction"}, 
{"Row" :6, "Column" : 1, "Text" : "chemotherapy for acute leukemia expected to have profound neutropenia (less than"}, 
{"Row" :7, "Column" : 1, "Text" : "100 neutrophils and bands per milliliter) for more than 10 days and for patients"}, 
{"Row" :8, "Column" : 1, "Text" : "receiving allogeneic stem cell transplantation.For most other patients the"}, 
{"Row" :9, "Column" : 1, "Text" : "expected benefits do not outweigh the risks of adverse effects and selection of"}, 
{"Row" : 10, "Column" : 1, "Text" : "resistant fungi."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antifungal is usually given until the absolute neutrophil concentration"}, 
{"Row" : 13, "Column" : 1, "Text" : "increases to more than 500 cells/microliter in patients undergoing induction"}, 
{"Row" : 14, "Column" : 1, "Text" : "chemotherapy for leukemia.Duration is 100 days for patients undergoing stem"}, 
{"Row" : 15, "Column" : 1, "Text" : "cell transplantation.Some physicians continue prevention after 100 days if"}, 
{"Row" : 16, "Column" : 1, "Text" : "corticosteroids are part of the immunosuppressive regimen."}, 
{"Row" : 17, "Column" : 1, "Text" : "Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia."}, 
{"Row" : 18, "Column" : 1, "Text" : "Contact Hematology Oncology or Infectious Disease for more information."}, 
{"Row" : 20, "Column" : 1, "Text" : "Patients who have had invasive fungal infection in the recent past and who are"}, 
{"Row" : 21, "Column" : 1, "Text" : "about to become neutropenic may require chemoprophylaxis.Contact Hematology-"}, 
{"Row" : 22, "Column" : 1, "Text" : "Oncology or Infectious Disease for more information."}, 
{"Row" : 24, "Column" : 1, "Text" : "If antifungal prophylaxis is indicated: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Duration of therapy: during period of expected neutropenia"}, 
{"Row" : 28, "Column" : 1, "Text" : "For patients being treated for AML: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Requires Infectious Disease approval: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on"}, 
{"Row" : 31, "Column" : 1, "Text" : "day 2 and thereafter. Continue for 7 days after the neutrophil count"}, 
{"Row" : 32, "Column" : 1, "Text" : "rises above 500/mm3. ($$$$) [DI]"}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043"}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Prophylaxis and empirical therapy for infection in cancer"}, 
{"Row" : 38, "Column" : 1, "Text" : "patients"}, 
{"Row" : 39, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 40, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}
]},
{"Name" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "DisplayText" : "Prevention of Bacterial Endocarditis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX DENTAL ABX PPX SOP", "DisplayText" : "DENTAL ABX PPX SOP", "Text" : "SOP for dental surgery antimicrobial prophylaxis", "Mnemonic" : "4"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU DRUG PT UNDERGO DENTAL PROC", "DisplayText" : "Drugs for patients undergoing dental, oral, or esophageal procedures", "Text" : "Patients undergoing dental or oral mucosa procedures", "Mnemonic" : "6"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "DisplayText" : "Head and neck surgery", "Text" : "Patients undergoing procedures on the respiratory tract that involve incision or", "Mnemonic" : "8"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES", "DisplayText" : "Drugs for procedures that involve infected skin, skin structures", "Text" : "Patients undergoing procedures for infected skin, skin structures, or infected", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF BACTERIAL ENDOCARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Bacteremia occurs several times a day during daily activities like eating and"}, 
{"Row" :6, "Column" : 1, "Text" : "brushing teeth and rarely results in endocarditis, even in people with abnormal"}, 
{"Row" :7, "Column" : 1, "Text" : "valves.While bacteremia might occur following dental or other procedures, most"}, 
{"Row" :8, "Column" : 1, "Text" : "cases of endocarditis are from the millions more episodes of transient"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteremia a person experiences per year from ordinary daily activities.There"}, 
{"Row" : 10, "Column" : 1, "Text" : "is no evidence that antimicrobial prophylaxis prevents endocarditis after"}, 
{"Row" : 11, "Column" : 1, "Text" : "procedures.The best available evidence suggests that prophylactic"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobials confer more risks than benefits in most situations.A decision"}, 
{"Row" : 13, "Column" : 1, "Text" : "about whether to administer antimicrobial prophylaxis should be based on both"}, 
{"Row" : 14, "Column" : 1, "Text" : "the risk of endocarditis conferred by the patient's cardiac defect and the risk"}, 
{"Row" : 15, "Column" : 1, "Text" : "of bacteremia from a planned dental or surgical procedure."}, 
{"Row" : 17, "Column" : 1, "Text" : "Minneapolis VAHCS SOP antimicrobial prophylaxis for dental surgery: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Determine the need for prophylaxis through the 2-step process outlined", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "below.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Step 1.Assess the risk of endocarditis for your patient", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Prophylaxis is recommended if a patient has any of the following conditions: "}, 
{"Row" : 25, "Column" : 1, "Text" : "oProsthetic cardiac valve or material including: Presence of cardiac"}, 
{"Row" : 26, "Column" : 1, "Text" : "prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR"}, 
{"Row" : 27, "Column" : 1, "Text" : "cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left"}, 
{"Row" : 28, "Column" : 1, "Text" : "ventricular assist devices or implantable heart"}, 
{"Row" : 29, "Column" : 1, "Text" : "oA history of infective endocarditis"}, 
{"Row" : 30, "Column" : 1, "Text" : "oCertain specific congenital heart conditions - refer to the full SOP"}, 
{"Row" : 31, "Column" : 1, "Text" : "(link above) or consult Cardiology for more detailed recommendations"}, 
{"Row" : 32, "Column" : 1, "Text" : "oCardiac transplant that develops a problem in the heart valve"}, 
{"Row" : 34, "Column" : 1, "Text" : "Step 2.Assess the risk of bacteremia from the planned procedure", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Prophylaxis is indicated for these procedures: "}, 
{"Row" : 36, "Column" : 1, "Text" : "oAll dental procedures that involve manipulation of gingival tissue or the"}, 
{"Row" : 37, "Column" : 1, "Text" : "periapical region of teeth or perforation of the oral mucosa."}, 
{"Row" : 38, "Column" : 1, "Text" : "oProcedures on the respiratory tract that involve incision or biopsy of the"}, 
{"Row" : 39, "Column" : 1, "Text" : "respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is"}, 
{"Row" : 40, "Column" : 1, "Text" : "recommended for bronchoscopy when procedure involves incision of the respira"}, 
{"Row" : 41, "Column" : 1, "Text" : "tract mucosa."}, 
{"Row" : 42, "Column" : 1, "Text" : "oProcedures that involve incision through infected skin, skin structures, or"}, 
{"Row" : 43, "Column" : 1, "Text" : "musculoskeletal tissue."}, 
{"Row" : 44, "Column" : 1, "Text" : "oDermatologic procedures that breach the oral mucosa."}, 
{"Row" : 46, "Column" : 1, "Text" : "Prophylactic Antimicrobials select below: ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "biopsy of the respiratory mucosa"}, 
{"Row" : 51, "Column" : 1, "Text" : "musculoskeletal tissues"}, 
{"Row" : 52, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 57, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 58, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}
]},
{"Name" : "ORZID2 GMENU PREV OF PERTUSSIS" , "Term1" : "Pertussis post-exposure prophylaxis " , "Term2" : "Post-exposure prophylaxis, pertussis " , "Term3" : "Prophylactic antimicrobials for post-exposure pertussis", "DisplayText" : "Prevention of Pertussis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF PERTUSSIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Immunization", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in"}, 
{"Row" :6, "Column" : 1, "Text" : "adults regardless of interval between most recent Td vaccine. One dose of Tdap"}, 
{"Row" :7, "Column" : 1, "Text" : "vaccine is given to pregnant women during each pregnancy."}, 
{"Row" :9, "Column" : 1, "Text" : "Postexposure prophylaxis in adults", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Household contacts with symptomatic coughing should be treated as if they have"}, 
{"Row" : 11, "Column" : 1, "Text" : "pertussis. Consult Infectious Diseases for all suspected cases of pertussis and"}, 
{"Row" : 12, "Column" : 1, "Text" : "exposure to pertussis."}, 
{"Row" : 14, "Column" : 1, "Text" : "CDC recommends postexposure prophylaxis in household contacts within 21 days"}, 
{"Row" : 15, "Column" : 1, "Text" : "after exposure to pertussis regardless of immunization history. Non-household"}, 
{"Row" : 16, "Column" : 1, "Text" : "contacts who are at high risk of severe illness or who have close contact with"}, 
{"Row" : 17, "Column" : 1, "Text" : "high risk individuals should receive post exposure prophylaxis within 21 days of"}, 
{"Row" : 18, "Column" : 1, "Text" : "exposure. Those at high risk of severe illness are infants less than one year of"}, 
{"Row" : 19, "Column" : 1, "Text" : "age, women in third trimester of pregnancy and those with preexisting health"}, 
{"Row" : 20, "Column" : 1, "Text" : "conditions that may be exacerbated by pertussis (e.g. immunosuppressed and"}, 
{"Row" : 21, "Column" : 1, "Text" : "asthmatic individuals). A single dose of Tdap should be administered in those"}, 
{"Row" : 22, "Column" : 1, "Text" : "who are not up to date."}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for macrolide intolerant or allergic patients"}, 
{"Row" : 31, "Column" : 1, "Text" : "CDC:Pertussis https://www.cdc.gov/pertussis/outbreaks/pep.html"}, 
{"Row" : 32, "Column" : 1, "Text" : "Kim et al, Annals of internal medicine (2016) 184-194"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Pertussis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Bordetella species"}
]},
{"Name" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "DisplayText" : "Prevention of prosthetic joint infection before dental procedures " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE DENTAL PROCEDURES", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Dental procedures are not associated with an increased risk of prosthetic joint"}, 
{"Row" :5, "Column" : 1, "Text" : "infection. The routine use of antimicrobial prophylaxis before dental procedures"}, 
{"Row" :6, "Column" : 1, "Text" : "in patients with prosthetic joints is not recommended. Good dental health should"}, 
{"Row" :7, "Column" : 1, "Text" : "be maintained in patients with prosthetic joints and dental infections should be"}, 
{"Row" :8, "Column" : 1, "Text" : "treated promptly."}, 
{"Row" : 10, "Column" : 1, "Text" : "For more information contact Infectious Diseases."}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic"}, 
{"Row" : 17, "Column" : 1, "Text" : "hardware infection"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sollecito et al., J Am Dent Assoc, 2015, 146(1):11-16"}, 
{"Row" : 18, "Column" : 1, "Text" : "Rethman et al., J Am Acad Orthop Surg, 2013, 21:180-189"}
]},
{"Name" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM" , "Term1" : "Mycobacterium avium prophylaxis " , "Term2" : "Prophylactic antimicrobials for Mycobacterium avium", "DisplayText" : "Prophylaxis against Mycobacterium avium disease..." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1200MG PO Q WEEK", "DisplayText" : "Azithromycin 1200mg po q week (Var)", "Text" : "Azithromycin 1200 mg PO q week ($) [M]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID CLARITHROMYCIN 500MG PO Q12H", "DisplayText" : "Clarithromycin 500mg po q12h", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious Diseases should be involved in all cases. Patients with CD4 count <"}, 
{"Row" :6, "Column" : 1, "Text" : "50 cells per microliter, after ruling out disseminated MC disease, should"}, 
{"Row" :7, "Column" : 1, "Text" : "receive prophylaxis until CD4 count is >100 for at least 3 months in response to"}, 
{"Row" :8, "Column" : 1, "Text" : "antiretroviral therapy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 20, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 21, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium complex"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected"}, 
{"Row" : 24, "Column" : 1, "Text" : "patients"}
]},
{"Name" : "ORZID2 GMENU PROPHYLAXIS OPTH SURG", "DisplayText" : "Prophylaxis for ophthalmic surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PROPHYLAXIS FOR OPHTHALMIC SURGERY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before"}, 
{"Row" :6, "Column" : 1, "Text" : "procedures."}
]},
{"Name" : "ORZID2 GMENU PROS B/J ENTEROCOCCI" , "Term1" : "Bone prosthesis infection " , "Term2" : "Enterococcal prosthetic bone/joint infection", "DisplayText" : "Enterococci infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100mg PO q12h ($) [DI]", "Mnemonic" : "14"},
{"Row" : 35, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. For severe infections, add an aminoglycoside for"}, 
{"Row" :7, "Column" : 1, "Text" : "synergy during the first weeks of therapy. Mild infections can be treated with"}, 
{"Row" :8, "Column" : 1, "Text" : "oral antibiotics only."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Treatement", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 14, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 16, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative for penicillin allergy or resistant organism"}, 
{"Row" : 22, "Column" : 1, "Text" : "Optional Addition to Above IV Treatment < ADD >", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Allergy to penicillin"}, 
{"Row" : 34, "Column" : 1, "Text" : "For resistant isolates only"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 41, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID2 GMENU PROS B/J GNB" , "Term1" : "Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection", "DisplayText" : "Gram Negative Bacilli infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "PROSTHESES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :7, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :8, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Treatement", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 14, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 16, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for penicillin or cephalosporin allergy"}, 
{"Row" : 26, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative Oral Treatment for Intolerance to Above Oral Antibiotics", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "For treatment of mild infections and continuation of therapy"}, 
{"Row" : 36, "Column" : 1, "Text" : "For Chronic Suppression"}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 43, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID2 GMENU PROS B/J P. AERUGINOSA" , "Term1" : "Pseudomonas aeruginosa prosthetic bone/joint infection", "DisplayText" : "Pseudomonas aeruginosa infections in bone or joint prostheses " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2g IV q12h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "DisplayText" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Text" : "Gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "8"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :7, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of Treatement", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 13, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 15, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "For cephalosporin allergy"}, 
{"Row" : 21, "Column" : 1, "Text" : "Optional addition to above IV antibiotic < ADD >", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, For Continuation of Therapy", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Oral Treatment for Chronic Suppression", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 34, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID2 GMENU PROS B/J STREPTOCOCCI" , "Term1" : "Streptococcal prosthetic bone/joint infection", "DisplayText" : "Streptococcal infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "DisplayText" : "Penicillin VK 500 mg PO q6h ($) [R]", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :7, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases for specific management advice.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of Treatement", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic suppression with oral"}, 
{"Row" : 15, "Column" : 1, "Text" : "antimicrobials may follow treatment based on individual patient circumstances."}, 
{"Row" : 17, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "Allergy to penicillin or cephalosporin"}, 
{"Row" : 25, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy or Chronic", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Allergy to penicillin or cephalosporin"}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 38, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS" , "Term1" : "Staphylococcus aureus prosthetic bone/joint infection", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX RIFAMPIN 600MG PO Q24H", "DisplayText" : "RIFAMPIN 600MG PO Q24H", "Text" : "Rifampin 600 mg PO q24h ($) [DI,O]", "Mnemonic" : "12"},
{"Row" : 55, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Mnemonic" : "18"},
{"Row" : 57, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100mg PO q12h ($) [DI]", "Mnemonic" : "22"},
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX RIFAMPIN 600MG PO Q24H", "DisplayText" : "RIFAMPIN 600MG PO Q24H", "Text" : "Rifampin 600 mg PO q24h ($) [DI,O]", "Mnemonic" : "24"},
{"Row" :4, "Column" : 1, "Text" : "STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment Following Debridement and Retention of Prosthesis", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of"}, 
{"Row" : 10, "Column" : 1, "Text" : "an oral antibiotic combined with rifampin (3 months in total hip, elbow,"}, 
{"Row" : 11, "Column" : 1, "Text" : "shoulder and ankle arthroplasty and 6 months in total knee arthroplasty)."}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Staged Reimplantation of Prosthesis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 6 weeks for all joint types."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment Following 1-Stage Exchange of Prosthesis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an"}, 
{"Row" : 19, "Column" : 1, "Text" : "oral antibiotic combined with rifampin for all joint types."}, 
{"Row" : 21, "Column" : 1, "Text" : "Rifampin Synergy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Rifampin is recommended for treatment with debridement and retention or one"}, 
{"Row" : 23, "Column" : 1, "Text" : "stage exchange. When rifampin is combined with a beta-lactam or vancomycin in"}, 
{"Row" : 24, "Column" : 1, "Text" : "vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial"}, 
{"Row" : 25, "Column" : 1, "Text" : "resistance develops rapidly. If patient does not tolerate rifampin it may be"}, 
{"Row" : 27, "Column" : 1, "Text" : "information."}, 
{"Row" : 29, "Column" : 1, "Text" : "Chronic Suppression", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Chronic suppression with oral antimicrobials may follow treatment based on"}, 
{"Row" : 31, "Column" : 1, "Text" : "individual patient circumstances."}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Oxacillin-susceptible: "}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 43, "Column" : 1, "Text" : "MRSA or allergy to penicillin and cephalosporins: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "In addition to IV treatment above < ADD >"}, 
{"Row" : 49, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Oral Treatment for Continuation of Therapy or Chronic Suppression", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "MRSA or allergy to penicillin or cephalosporin"}, 
{"Row" : 56, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 59, "Column" : 1, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Chronic Suppression)", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "In addition to PO treatment above < ADD >"}, 
{"Row" : 65, "Column" : 1, "Text" : "References: "}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 67, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 68, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 69, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Text" : "omitted from treatment regimen. Contact Infectious Diseases for more"}
]},
{"Name" : "ORZID2 GMENU PROS JOINT BONE INFECT" , "Term1" : "Joint infection, prosthetic " , "Term2" : "Prosthetic bone/joint infection " , "Term3" : "Septic arthritis, prosthetic joint", "DisplayText" : "Infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses", "Text" : "Staphylococcus aureus infections", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J STREPTOCOCCI", "DisplayText" : "Streptococcal infections in bone or joint prostheses", "Text" : "Streptococci infections", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses", "Text" : "Enterococci infections", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J GNB", "DisplayText" : "Gram Negative Bacilli infections in bone or joint prostheses", "Text" : "Gram negative bacilli (other than Pseudomonas) infections", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J P. AERUGINOSA", "DisplayText" : "Pseudomonas aeruginosa infections in bone or joint prostheses", "Text" : "Pseudomonas aeruginosa infections", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "DisplayText" : "Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]", "Text" : "Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($)[R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Common important pathogens include coagulase-negative staphylococci,"}, 
{"Row" :6, "Column" : 1, "Text" : "Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli."}, 
{"Row" :7, "Column" : 1, "Text" : "Obtain material for gram stain and culture and base antimicrobial therapy on"}, 
{"Row" :8, "Column" : 1, "Text" : "results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are"}, 
{"Row" :9, "Column" : 1, "Text" : "ideal specimens to culture. Sinus tracts are often colonized and isolates from"}, 
{"Row" : 10, "Column" : 1, "Text" : "drainage may not be pathogens. If Staphylococcus aureus is present,it is likely"}, 
{"Row" : 11, "Column" : 1, "Text" : "to be a pathogen in the bone."}, 
{"Row" : 13, "Column" : 1, "Text" : "Pathogen-directed Treatment Regimens", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Acute infections can often be cured with debridement with joint retention"}, 
{"Row" : 21, "Column" : 1, "Text" : "followed by antimicrobials. Infections with duration of symptoms greater then 3"}, 
{"Row" : 22, "Column" : 1, "Text" : "weeks or infection within 4 weeks of implantation require one or two stage"}, 
{"Row" : 23, "Column" : 1, "Text" : "remimplantation. Cases that are inoperable can be managed with long-term"}, 
{"Row" : 24, "Column" : 1, "Text" : "suppressive antimicrobial therapy or joint removal without replacement depending"}, 
{"Row" : 25, "Column" : 1, "Text" : "on patient's condition. Consult Infectious Diseases (inpatient) for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Infectious Disease and Orthopedics consultations are essential."}, 
{"Row" : 30, "Column" : 1, "Text" : "Empirical Therapy Before a Pathogen is Identified is Not Recommended.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "If patient has sepsis or is otherwise unstable, empiric treatment before culture"}, 
{"Row" : 32, "Column" : 1, "Text" : "results are obtained may be justified."}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 40, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)" , "Term1" : "Crabs " , "Term2" : "Lice, pubic " , "Term3" : "Pubic lice " , "Term4" : "Sexually transmitted infection, pubic lice (crabs)", "DisplayText" : "Pubic Lice (Pediculosis Pubis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "DisplayText" : "Permethrin 1% lotion to the affected area for 10 minutes", "Text" : "Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "PUBIC LICE (PEDICULOSIS PUBIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse"}, 
{"Row" :6, "Column" : 1, "Text" : "living in pubic hair."}, 
{"Row" :8, "Column" : 1, "Text" : "The presence of nits on a hair shaft, especially when they are located more"}, 
{"Row" :9, "Column" : 1, "Text" : "than 6 mm from the skin, does NOT indicate active infestation.Nits may remain"}, 
{"Row" : 10, "Column" : 1, "Text" : "present for months after successful treatment."}, 
{"Row" : 12, "Column" : 1, "Text" : "Household contacts and persons who may have come into contact with personal"}, 
{"Row" : 13, "Column" : 1, "Text" : "belongings of an infested individual should be examined for evidence of lice"}, 
{"Row" : 14, "Column" : 1, "Text" : "and discarded or cleaned if contaminated."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "A repeat application may be used if live lice are seen 7-10 days after"}, 
{"Row" : 18, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 21, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU PYOMYOSITIS" , "Term1" : "Pyomyositis", "DisplayText" : "Pyomyositis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15mg/kg IV q 12 hours ($) [R]", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "PYOMYOSITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Pyomyositis is the presence of pus in a muscle group.It occurs more often in"}, 
{"Row" :5, "Column" : 1, "Text" : "patients with HIV infection or diabetes, and is usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "Staphylococcus aureus."}, 
{"Row" :8, "Column" : 1, "Text" : "Early drainage of purulent material should be performed.Cultures"}, 
{"Row" :9, "Column" : 1, "Text" : "of blood and abscess material should be obtained to guide therapy."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antibiotics should be administered intravenously initially, but once"}, 
{"Row" : 12, "Column" : 1, "Text" : "the patient is clinically improved, oral antibiotics are appropriate"}, 
{"Row" : 13, "Column" : 1, "Text" : "for whom bacteremia cleared promptly and there is no evidence of endocarditis"}, 
{"Row" : 14, "Column" : 1, "Text" : "or metastatic abscess."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of treatment: 2 to 3 weeks", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Initial empirical therapy: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "ADD for immunocompromised patient or following open trauma to muscles: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: "}, 
{"Row" : 26, "Column" : 1, "Text" : "IF proven MSSA: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Myositis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS" , "Term1" : "Persistent or recurrent urethritis " , "Term2" : "Recurrent or persistent urethritis " , "Term3" : "Urethritis, recurrent or persistent", "DisplayText" : "Recurrent or persistent urethritis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX METRONIDAZOLE 2GM PO X1 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Metronidazole 2 gm PO ONCE ($) [DI] Azithromycin 1 gm PO ONCE ($) [M]", "Text" : "Metronidazole 2 gm PO ONCE ($) [DI] Azithromycin 1 gm PO ONCE ($) [M]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Retreat with initial treatment regimen if patient was non-compliant with initial"}, 
{"Row" :6, "Column" : 1, "Text" : "treatment regimen or re-exposed to an untreated sex partner. If infection is not"}, 
{"Row" :7, "Column" : 1, "Text" : "due to non-compliance with treatment regimen or re-exposure to an untreated sex"}, 
{"Row" :8, "Column" : 1, "Text" : "partner, infection is most commonly caused by M. genitalium and less commonly T."}, 
{"Row" :9, "Column" : 1, "Text" : "vaginalis."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment for persistent or recurrent urethritis and failure of initial", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "doxycycline treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Failure of above treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Consult Infectious Diseases (inpatient)"}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3"}, 
{"Row" : 22, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Urethritis, Recurrent/Persistent"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}
]},
{"Name" : "ORZID2 GMENU RETINITIS" , "Term1" : "Candida retinitis " , "Term2" : "Herpes retinitis " , "Term3" : "Retinitis " , "Term4" : "Zoster retinitis", "DisplayText" : "Retinitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "DisplayText" : "CMV Retinitis", "Text" : "Link to Treatment of CMV Retinitis and ARN", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "DisplayText" : "Acyclovir 800MG PO 5x/d", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "DisplayText" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI]", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]", "Mnemonic" : "8"},
{"Row" : 38, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG Q8H", "DisplayText" : "Acyclovir 400 mg q8h ($) [R]", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "DisplayText" : "Acyclovir 5 mg/kg IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h ($$) [R]", "Mnemonic" : "14"},
{"Row" : 46, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "DisplayText" : "Valacyclovir 1GM PO q12h", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Mnemonic" : "16"},
{"Row" : 58, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "DisplayText" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI]", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($) [R]", "Mnemonic" : "18"},
{"Row" : 59, "Column" : 1, "Item" : "PSJZID FOSCARNET 2.4MG INTRAVITREOUS INJECT ONCE", "DisplayText" : "Foscarnet 2.4 mg intravitreous injection", "Text" : "< Optional add-on therapy > Foscarnet 2.4mg/0.1 mL intravitreal injection STAT", "Mnemonic" : "20"},
{"Row" : 62, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "DisplayText" : "Valacyclovir 1 gm PO q8h ($) [R]", "Text" : "Valacyclovir 1 gm PO q8h for 42 days ($) [R]", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "RETINITIS AND ACUTE RETINAL NECROSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Retinitis is a subset of uveitis, is rare in immunocompetent people: in these"}, 
{"Row" :6, "Column" : 1, "Text" : "individuals it is usually caused by varicella-zoster virus (VZV) or herpes"}, 
{"Row" :7, "Column" : 1, "Text" : "simplex virus (HSV). Retinitis is more common in immunocompromised patients and"}, 
{"Row" :8, "Column" : 1, "Text" : "cytomegalovirus being the most common pathogen in these patients. Other"}, 
{"Row" :9, "Column" : 1, "Text" : "retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma"}, 
{"Row" : 10, "Column" : 1, "Text" : "capsulatum, and Treponema pallidum. In most cases, patients have other"}, 
{"Row" : 11, "Column" : 1, "Text" : "neurological symptoms or signs.Patients with candidemia may present with 1-3"}, 
{"Row" : 12, "Column" : 1, "Text" : "mm white punctate retinal lesions called cotton-wool spots. These may only be"}, 
{"Row" : 13, "Column" : 1, "Text" : "visible on fundus examination. Treatment of candidal retinitisis systemic"}, 
{"Row" : 14, "Column" : 1, "Text" : "antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for"}, 
{"Row" : 15, "Column" : 1, "Text" : "help."}, 
{"Row" : 17, "Column" : 1, "Text" : "VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small"}, 
{"Row" : 18, "Column" : 1, "Text" : "number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "that occurs primarily in immunocompetent people and can cause vision loss."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment with intravenous acyclovir or valacyclovir is essential to halt"}, 
{"Row" : 21, "Column" : 1, "Text" : "progression of ARN."}, 
{"Row" : 23, "Column" : 1, "Text" : "Ophthalmology and Infectious Diseases consultation is essential"}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment of Non-viral Retinitis or ARN", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Refer to specific pathogen treatment recommendations of the CDSS to treat"}, 
{"Row" : 27, "Column" : 1, "Text" : "underlying infection"}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment of Retinitis or ARN due to CMV: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Treatment of VZV Retinitis", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 40, "Column" : 1, "Text" : "Treatment of HSV Retinitis", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 45, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 48, "Column" : 1, "Text" : "Treatment of VZV and HSV Acute Retinal Necrosis", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Ophthalmologist involvement is essential for treatment including"}, 
{"Row" : 50, "Column" : 1, "Text" : "corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in"}, 
{"Row" : 51, "Column" : 1, "Text" : "addition to a systemic antiviral may provide added therapeutic efficacy."}, 
{"Row" : 53, "Column" : 1, "Text" : "Duration"}, 
{"Row" : 54, "Column" : 1, "Text" : "Treat with intravenous therapy for a minimum of 7 days until disease has"}, 
{"Row" : 55, "Column" : 1, "Text" : "stabilized then treat with or therapy for a minimum of 6 weeks"}, 
{"Row" : 57, "Column" : 1, "Text" : "Treatment"}, 
{"Row" : 60, "Column" : 1, "Text" : "($$$$) [R,O]"}, 
{"Row" : 61, "Column" : 1, "Text" : "< THEN >"}, 
{"Row" : 64, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "References: "}, 
{"Row" : 67, "Column" : 1, "Text" : "Lau et al, Ophthalmology. 2007, 114(4)756-762"}, 
{"Row" : 68, "Column" : 1, "Text" : "Mandell chapter: Infectious causes of uveitis"}, 
{"Row" : 69, "Column" : 1, "Text" : "Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392"}, 
{"Row" : 70, "Column" : 1, "Text" : "Sanford keyword: Acute Retinal Necrosis"}, 
{"Row" : 71, "Column" : 1, "Text" : "Sanford keyword: Herpes Simplex"}, 
{"Row" : 72, "Column" : 1, "Text" : "Sanford keyword: Retinitis"}, 
{"Row" : 73, "Column" : 1, "Text" : "Sanford keyword: Varicella-zoster Virus (Chickenpox)"}
]},
{"Name" : "ORZID2 GMENU ROCKY MTN SPOT FEVER" , "Term1" : "Rocky mountain spotted fever", "DisplayText" : "Rocky Mountain Spotted Fever" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "ROCKY MOUNTAIN SPOTTED FEVER"}, 
{"Row" :4, "Column" : 1, "Text" : "Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening"}, 
{"Row" :5, "Column" : 1, "Text" : "rickettsial disease. The highest incidence in the United States is in the"}, 
{"Row" :6, "Column" : 1, "Text" : "Southeastern and South-central states. Clinical diagnosis include fever in an"}, 
{"Row" :7, "Column" : 1, "Text" : "endemic area, known or possible tick bite, with or without rash. Rash typically"}, 
{"Row" :8, "Column" : 1, "Text" : "spreads from the extremities to the trunk."}, 
{"Row" : 10, "Column" : 1, "Text" : "Diagnosis is difficult, consult Infectious Diseases for assistance."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consider empirical therapy with doxycycline for a patient with an undiagnosed"}, 
{"Row" : 13, "Column" : 1, "Text" : "febrile illness and relevant tick exposure."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Treat for 7 days."}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Rocky mountain spotted fever"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 27, "Column" : 1, "Text" : "Masters EJ Arch Intern Med 2003, 163: 769"}
]},
{"Name" : "ORZID2 GMENU SCABIES" , "Term1" : "Scabies", "DisplayText" : "Scabies " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PERMETHRIN 5% CREAM APPLY FROM HEAD TO FEET", "DisplayText" : "Permethrin 5% cream apply from head to feet", "Text" : "Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "SCABIES"}, 
{"Row" :4, "Column" : 1, "Text" : "Scabies is an infestation of the skin by the mite Sarcoptes scabiei."}, 
{"Row" :5, "Column" : 1, "Text" : "It is transmitted by skin to skin contact. Outbreaks occur in nursing"}, 
{"Row" :6, "Column" : 1, "Text" : "homes, day care centers, and residential institutions.Scabies is highly"}, 
{"Row" :7, "Column" : 1, "Text" : "contagious and meticulous infection control is needed."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment is a single application of permethrin cream.Some experts recommend a"}, 
{"Row" : 10, "Column" : 1, "Text" : "second application 7-10 days after the first application if the patient is still"}, 
{"Row" : 11, "Column" : 1, "Text" : "symptomatic or if live mites are found at that time.Contact Dermatology or"}, 
{"Row" : 12, "Column" : 1, "Text" : "Infectious Diseases for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat family members and other close contacts to prevent spread and recurrence."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Repeat application 7-10 days after the first application if patient is still"}, 
{"Row" : 18, "Column" : 1, "Text" : "experiencing symptoms, or if lives mites are found."}, 
{"Row" : 21, "Column" : 1, "Text" : "wash cream off with soap and water ($) [M]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Scabies"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU SEPSIS AND SHOCK" , "Term1" : "Clostridium difficile suspected, sepsis " , "Term2" : "Endocarditis with sepsis " , "Term3" : "Meningitis with sepsis " , "Term4" : "Native valve endocarditis with sepsis Term5:Neutropenic fever with sepsis " , "Term6" : "Pneumonia with sepsis", "DisplayText" : "Sepsis and septic shock " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX SOFA ONLINE CALCULATOR", "DisplayText" : "SOFA Online Calculator", "Text" : "SOFA Online Calculator", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GMENU SEPSIS PROTOCOL MAIN INPT", "DisplayText" : "Sepsis ICU Orders", "Text" : "ICU sepsis order set", "Mnemonic" : "6"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET MEDICINE INPT SEPSIS LANDING PAGE", "DisplayText" : "Medicine Inpatient Time Zero Order", "Text" : "Ward sepsis order set", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GMENU UC/ED SEPSIS 2", "Text" : "ED sepsis order set", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS AND SEPTIC SHOCK", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Per the Sepsis-3 task force, sepsis is defined as life-threatening"}, 
{"Row" :6, "Column" : 1, "Text" : "organ dysfunction caused by dysregulated host response to infection."}, 
{"Row" :8, "Column" : 1, "Text" : "The Sequential Organ Failure Assessment (SOFA) score can be used to help"}, 
{"Row" :9, "Column" : 1, "Text" : "identify organ dysfunction. An acute increase of 2 or more points in a patient"}, 
{"Row" : 10, "Column" : 1, "Text" : "with sepsis is associated with in-hospital mortality greater than 10%. Neither"}, 
{"Row" : 11, "Column" : 1, "Text" : "the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the"}, 
{"Row" : 12, "Column" : 1, "Text" : "sole method of identifying sepsis related organ dysfunction."}, 
{"Row" : 16, "Column" : 1, "Text" : "Septic shock is a subset of sepsis in which profound circulatory, cellular and"}, 
{"Row" : 17, "Column" : 1, "Text" : "metabolic abnormalities occur. Septic shock is associated with in-hospital"}, 
{"Row" : 18, "Column" : 1, "Text" : "mortality greater than 40%."}, 
{"Row" : 20, "Column" : 1, "Text" : "Early intervention is crucial to prevention of death from sepsis. Antimicrobials"}, 
{"Row" : 21, "Column" : 1, "Text" : "active against likely pathogens and supportive treatment to maintain vascular"}, 
{"Row" : 22, "Column" : 1, "Text" : "perfusion should be initiated immediately."}, 
{"Row" : 24, "Column" : 1, "Text" : "Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture"}, 
{"Row" : 25, "Column" : 1, "Text" : "and susceptibility data are available."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of Sepsis or Septic Shock", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "References"}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock"}, 
{"Row" : 36, "Column" : 1, "Text" : "Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377"}, 
{"Row" : 37, "Column" : 1, "Text" : "Singer et al., JAMA (2016), 315(8) 801-810"}
]},
{"Name" : "ORZID2 GMENU SEPSIS EMPIRIC THERAPY SITE UNK", "DisplayText" : "Site Unknown Or Suspected Intraabdominal Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "DisplayText" : "PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] SEPSIS", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO 2GM Q8H METRO 1GM Q12H VANCO 15MG/KG", "DisplayText" : "AZTREO 2GM Q8H METRO 1GM Q12H VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 1 gm IV q12H ($) [DI] <AND>", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG X1 SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "DisplayText" : "Abdominal CT", "Text" : "Please Click Here To Order an Abdominal CT", "Mnemonic" : "12"},
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases"}, 
{"Row" :7, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 14, "Column" : 1, "Text" : "For Severe Penicillin Allergy: "}, 
{"Row" : 16, "Column" : 1, "Text" : "vancomycin 15 mg/kg IV q12H ($) [R]"}, 
{"Row" : 18, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose"}, 
{"Row" : 21, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 23, "Column" : 1, "Text" : "Consider abdominal CT", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH UNKNOWN INFECTIOUS SITE", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SEPSIS PNEUMONIA", "DisplayText" : "Community-Acquired Pneumonia" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "DisplayText" : "PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] SEPSIS", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO VANCO 15MG/KG AZITH", "DisplayText" : "Pip/Tazo, Vanco 15mg/kg, and Azithromycin", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Mnemonic" : "8"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG Q12H AZITH", "DisplayText" : "cefepime, Vanco 15mg/kg, and Azithromycin", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] <AND>", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS LEVOFLOXACIN 750MG IV Q24H VANCO 15MG/KG", "DisplayText" : "LEVOFLOXACIN 750MG IV Q24H VANCO 15MG/KG", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12H ($) [R]", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG X1 SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Mnemonic" : "14"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Nosocomial pneumonia preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 18, "Column" : 1, "Text" : "Community acquired pneumonia preferred treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "($) [R] <AND> Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 24, "Column" : 1, "Text" : "Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "For severe penicillin allergy in nosocomial and community acquired pneumonia", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose"}, 
{"Row" : 32, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 34, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED PNEUMONIA", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS PROTOCOL ANTIMICROBIALS", "DisplayText" : "Empirical Antimicrobials" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS EMPIRIC THERAPY SITE UNK", "DisplayText" : "Site Unknown Or Suspected Intraabdominal Infection", "Text" : "Unknown Infectious Site (see below for Intraabdominal infection)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS PNEUMONIA", "DisplayText" : "Community-Acquired Pneumonia", "Text" : "Suspected Pneumonia", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED MENINGITIS", "DisplayText" : "Suspected Meningitis, CNS Infection", "Text" : "Suspected Meningitis, CNS Infection", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP NATIVE VALVE ENDOCARD", "DisplayText" : "Suspected Native Valve Endocarditis", "Text" : "Suspected Native Valve Endocarditis", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP PROS VALVE ENDOCARD", "DisplayText" : "Suspected Prosthetic Valve Endocarditis", "Text" : "Suspected Prosthetic Valve Endocarditis", "Mnemonic" : "10"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Suspected Necrotizing Infection", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED SKIN SOFT TISSUE", "DisplayText" : "Sepsis Suspected Skin Soft Tissue", "Text" : "Suspected Skin Soft Tissue Infection", "Mnemonic" : "14"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED URO SEPSIS", "DisplayText" : "Suspected Urosepsis", "Text" : "Suspected Urinary Tract Infection (AKA urospesis)", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "DisplayText" : "Suspected Intraabdominal Infection", "Text" : "Suspected Intraabdominal Infection", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP C. DIFFICILE", "DisplayText" : "Suspected Severe Clostridium Difficile Infection", "Text" : "Suspected Severe Clostridium Difficile Infection", "Mnemonic" : "20"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy", "Text" : "Suspected Neutropenic Fever", "Mnemonic" : "22"},
{"Row" :1, "Column" : 1, "Text" : "Initial Empiric Antibiotic Guidelines for Sepsis: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP C. DIFFICILE", "DisplayText" : "Suspected Severe Clostridium Difficile Infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO QID SEPSIS", "DisplayText" : "Vancomycin 125MG PO QID (Var)", "Text" : "Vancomycin 125MG PO QID", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS METRONI 500MG IV Q6H VANCO ENEMA 500MG Q6H", "DisplayText" : "Metronidazole 500MG IV Q6H AND Vancomycin Enema 500MG PR Q6H", "Text" : "Metronidazole 500MG IV Q6H AND Vancomycin Enema 500MG PR Q6H", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "If No ileus: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "If ileus: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP NATIVE VALVE ENDOCARD", "DisplayText" : "Suspected Native Valve Endocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO GENT 1.5 MG/KG VANCO 15MG/KG IV", "DisplayText" : "6Please Click Here To Order This Set.", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO 2GM GENT 1.5 MG/KG VANCO 15MG/KG", "DisplayText" : "1Please Click Here To Order This Set.", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND"}, 
{"Row" : 14, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 18, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Aztreonam 2GM IV Q8H AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND"}, 
{"Row" : 21, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP PROS VALVE ENDOCARD", "DisplayText" : "Suspected Prosthetic Valve Endocarditis " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZ GENT 1.5 M/K VANC 15M/K RIFAMP 300MG", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO GENT VANCO RIFAMPIN 300MG", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND"}, 
{"Row" : 14, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 15, "Column" : 1, "Text" : "Rifampin 300MG IV Q8H"}, 
{"Row" : 19, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Aztreonam 2GM IV Q8H AND"}, 
{"Row" : 21, "Column" : 1, "Text" : "Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND"}, 
{"Row" : 22, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 23, "Column" : 1, "Text" : "Rifampin 300MG IV Q8H"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "DisplayText" : "Suspected Intraabdominal Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5GM IV Q6H SEPSIS", "DisplayText" : "Piperacillin/Tazobactam 4.5GM IV Q6H", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H METRO 1GM Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] and metronidazole 1gm q12h SEPSIS", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND>metronidazole 1 gm IV q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO 400MG IV Q12H METRO 1GM IV Q12H", "DisplayText" : "CIPRO 400MG IV Q12H METRO 1GM IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12H ($) [R,DI] <AND> metronidazole 1 gm IV q12h", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG X1 SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "DisplayText" : "Abdominal CT", "Text" : "Please Click Here To Order an Abdominal CT", "Mnemonic" : "12"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "For severe penicillin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "($) [DI]"}, 
{"Row" : 21, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose"}, 
{"Row" : 24, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 26, "Column" : 1, "Text" : "Consider Abdominal CT", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED MENINGITIS", "DisplayText" : "Suspected Meningitis, CNS Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFTRIAXONE 2GM IV VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFTRIAX 2GM VANCO 15MG/KG AMPICILLIN 2GM IV", "DisplayText" : "4Please Click Here To Order This Set.", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS TRIMETHO/SULFA 5 MG/KG VANCO 15MG/KG IV Q12H", "DisplayText" : "Please Click Here To Order This Set.", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "8"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Penicillin Allergy and Listeria is NOT a concern: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Ceftriaxone 2GM IV Q12H AND Vancomycin 15mg/kg IV Q12H"}, 
{"Row" : 13, "Column" : 1, "Text" : "(Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 17, "Column" : 1, "Text" : "No Penicillin Allergy and Listeria IS a concern (Patient with age > 50", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "yrs, alcoholism, or impaired cellular immunity: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Ceftriaxone 2GM IV Q12H AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND"}, 
{"Row" : 21, "Column" : 1, "Text" : "Ampicillin 2GM IV Q4H"}, 
{"Row" : 25, "Column" : 1, "Text" : "_________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern): ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV Q6H AND"}, 
{"Row" : 28, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED SKIN SOFT TISSUE", "DisplayText" : "Sepsis Suspected Skin Soft Tissue" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Necrotizing infections recommendations", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO, VANCO 15MG/KG IV Q12H", "DisplayText" : "8Please Click Here To Order This Set.", "Text" : "Please Click Here to Order This Set.", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "Aggressive surgical debridement is recommended.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "For necrotizing infections refer to those recommendations for treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H <AND>"}, 
{"Row" : 18, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 22, "Column" : 1, "Text" : "If Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "hypotension, etc.)", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Ciprofloxacin 400 MG IV Q12H <AND>"}, 
{"Row" : 25, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED URO SEPSIS", "DisplayText" : "Suspected Urosepsis" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO, VANCO 15MG/KG IV Q12H", "DisplayText" : "8Please Click Here To Order This Set.", "Text" : "Please Click Here To Order This Set.", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set", "Mnemonic" : "6"},
{"Row" :5, "Column" : 1, "Text" : "Site:Unless the specific site or etiologic agent is known with a high"}, 
{"Row" :6, "Column" : 1, "Text" : "level of probability strong consideration should be given:1) To"}, 
{"Row" :7, "Column" : 1, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the"}, 
{"Row" :8, "Column" : 1, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)"}, 
{"Row" :9, "Column" : 1, "Text" : "and 2) Strongly consider ID consult."}, 
{"Row" : 11, "Column" : 1, "Text" : "No Pencillin Allergy: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND"}, 
{"Row" : 13, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 14, "Column" : 1, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)"}, 
{"Row" : 18, "Column" : 1, "Text" : "If Penicillin Allergy: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Ciprofloxacin 400 mg IV q12H AND"}, 
{"Row" : 20, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)"}, 
{"Row" : 21, "Column" : 1, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Consider selecting alternative agents from separate drug class if", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "recently treated with any of the above antibiotics.", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "SEPSIS WITH SUSPECTED URINARY TRACT INFECTION", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "1"},
{"Row" : 25, "Column" : 1, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose"}, 
{"Row" : 28, "Column" : 1, "Text" : "*Pharmacy to follow"}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG X1 SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI" , "Term1" : "Enterococcal native joint infection", "DisplayText" : "Septic arthritis (Native joint) with Enterococci" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15MG/KG IV Q12 GENT 1MG/KG IV Q8H", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "For severe enterococcal infections, add an aminoglycoside for synergy during the"}, 
{"Row" :6, "Column" : 1, "Text" : "first 2-4 weeks of therapy.Consult Infectious Diseases for specific management"}, 
{"Row" :7, "Column" : 1, "Text" : "advice."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of treatment for 2-4 weeks, depending on response"}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment, MILD-MODERATE infections", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative for penicillin allergy or resistant organism", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment, SEVERE infections", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for penicillin allergy or resistant organism", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 27, "Column" : 1, "Text" : "Stevens DL Clin Inf Dis 2014, 59:e10-52"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH GNB" , "Term1" : "Gram-negative bacilli, non-pseudomonas, native joint infection", "DisplayText" : "Septic arthritis (Native joint) with Gram negative bacilli" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]< OR >", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "DisplayText" : "Levofloxacin 500 mg PO q24h ($) [R]", "Text" : "Levofloxacin 500 mg po q24h ($) [R,DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN"}, 
{"Row" :4, "Column" : 1, "Text" : "PSEUDOMONAS)"}, 
{"Row" :6, "Column" : 1, "Text" : "Administer parenteral therapy initially for approximately 1-2 weeks"}, 
{"Row" :7, "Column" : 1, "Text" : "then can be converted to appropriate oral therapy."}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 4 weeks", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Oral therapy to complete the course after intravenous therapy initially: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 22, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE" , "Term1" : "Neisseria gonorrhoeae native joint infection", "DisplayText" : "Septic arthritis (Native joint) with N. gonorrhoeae " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI] < OR >", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE"}, 
{"Row" :5, "Column" : 1, "Text" : "Treat presumptively also for Chlamydia trachomatis infection (asymptomatic"}, 
{"Row" :6, "Column" : 1, "Text" : "urethritis) and test for HIV.Infection control will report cases with N."}, 
{"Row" :7, "Column" : 1, "Text" : "gonorrhea isolated to the state department of health."}, 
{"Row" :8, "Column" : 1, "Text" : "Susceptibility results are required to guide potential switch to an oral medicat"}, 
{"Row" : 10, "Column" : 1, "Text" : "N. gonorrheae Treat for 1-2 weeks (Plus see below for Chlamydia treatment)", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative for severe penicillin allergy", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Consult Infectious Disease for alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Concomitant treatment for C. trachomatis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred treatment: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative treatment: "}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}, 
{"Row" : 27, "Column" : 1, "Text" : "MMWR Recommendations and Reports CDC 2015, 64:1-137"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA" , "Term1" : "Pseudomonas aeruginosa native joint infection", "DisplayText" : "Septic arthritis (Native joint) with Pseudomonas aeruginosa " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < OR >", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]< OR >", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA"}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 4 weeks", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS" , "Term1" : "Staphylococcus aureus, native joint infection", "DisplayText" : "Septic arthritis (Native joint) with Staphylococcus aureus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]< OR >", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI]", "Text" : "Minocycline 100 mg PO q12h ($) [DI]< OR >", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS"}, 
{"Row" :5, "Column" : 1, "Text" : "Administer parenteral therapy initially for approximately two weeks"}, 
{"Row" :6, "Column" : 1, "Text" : "then can be converted to appropriate oral therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Methicillin-SUSCEPTIBLE Staphylococcus aureus", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for 4-6 weeks depending on response", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Oral therapy to complete the course after intravenous therapy initially: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Methicillin-RESISTANT Staphylococcus aureus", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treat for 4-6 weeks depending on response", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Oral therapy to complete the course after intravenous therapy initially: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}, 
{"Row" : 35, "Column" : 1, "Text" : "Coakley G Rheumatology (Oxford) 2006, 45:1039"}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI" , "Term1" : "Streptococcus native joint infection", "DisplayText" : "Septic arthritis (Native joint) with Streptococci " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "DisplayText" : "PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "DisplayText" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Mnemonic" : "12"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "DisplayText" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Duration: treat for 2-4 weeks"}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative for beta-lactam allergy, or when beta-lactam resistance", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "is suspected or proved: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Oral step-down therapy to complete full course once sensitivities are known: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)" , "Term1" : "Joint infection, native " , "Term2" : "Native joint infection " , "Term3" : "Septic arthritis, native joint", "DisplayText" : "Septic arthritis (Native joint) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "DisplayText" : "Infections in bone or joint prostheses", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds", "Text" : "Bite wounds", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "DisplayText" : "Lyme disease", "Text" : "Lyme disease", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15mg/kg IV q 12 hours ($) [R]", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "DisplayText" : "Ampicillin 2 gm IV q4h ($$) [R]", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q24H AZITHRO 1GM PO ONCE", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > azithromycin 1 gm PO once ($) [O]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> Azithromycin 1 gm PO x1dose ($) [O]", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Mnemonic" : "16"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "20"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS", "DisplayText" : "Septic arthritis (Native joint) with Staphylococcus aureus", "Text" : "Staphylococcus aureus", "Mnemonic" : "22"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI", "DisplayText" : "Septic arthritis (Native joint) with Streptococci", "Text" : "Streptococci", "Mnemonic" : "24"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI", "DisplayText" : "Septic arthritis (Native joint) with Enterococci", "Text" : "Enterococci", "Mnemonic" : "26"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH GNB", "DisplayText" : "Septic arthritis (Native joint) with Gram negative bacilli", "Text" : "Gram negative bacilli (other than Pseudomonas)", "Mnemonic" : "28"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA", "DisplayText" : "Septic arthritis (Native joint) with Pseudomonas aeruginosa", "Text" : "Pseudomonas aeruginosa", "Mnemonic" : "30"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE", "DisplayText" : "Septic arthritis (Native joint) with N. gonorrhoeae", "Text" : "Neisseria gonorrhoeae", "Mnemonic" : "32"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT)"}, 
{"Row" :5, "Column" : 1, "Text" : ">>For arthritis associated with a PROSTHETIC JOINT see"}, 
{"Row" :8, "Column" : 1, "Text" : ">>For arthritis associated with a BITE WOUND see"}, 
{"Row" : 11, "Column" : 1, "Text" : ">>For arthritis associated with TICK EXPOSURE in an endemic area, consider"}, 
{"Row" : 14, "Column" : 1, "Text" : "Septic arthritis native joint: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Aspirate the joint for gram stain and culture."}, 
{"Row" : 16, "Column" : 1, "Text" : "Use the Gram stain of aspirated fluid to select initial therapy."}, 
{"Row" : 17, "Column" : 1, "Text" : "Use culture results to guide definitive therapy."}, 
{"Row" : 18, "Column" : 1, "Text" : "In addition to antimicrobial treatment, successful management of acute"}, 
{"Row" : 19, "Column" : 1, "Text" : "septic arthritis requires removal of intra-articular pus."}, 
{"Row" : 21, "Column" : 1, "Text" : "**Synovial fluid Gram stain with organisms: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Gram positive cocci in clusters: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Gram positive cocci in chains (streptococci): ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Gram negative diplococci (Neisseria) or STD risk and Gram stain negative: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "(one dose of azithromycin for possible concomitant C. trachomatis)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Gram negative rods: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "**Synovial fluid without organisms on Gram stain: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "*No MRSA risk factors: "}, 
{"Row" : 40, "Column" : 1, "Text" : "*MRSA risk factors, high risk of Gram negative infection (elderly,"}, 
{"Row" : 41, "Column" : 1, "Text" : "nursing home, hospitalized, cutaneous ulcers)"}, 
{"Row" : 44, "Column" : 1, "Text" : "Pathogen-specific septic arthritis treatment regimens", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Duration of therapy based on pathogen and clinical response. (See pathogen)"}, 
{"Row" : 48, "Column" : 1, "Text" : "If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of"}, 
{"Row" : 49, "Column" : 1, "Text" : "antimicrobials may be needed, depending on clinical response."}, 
{"Row" : 50, "Column" : 1, "Text" : "Consult Rheumatology for more information"}, 
{"Row" : 59, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 61, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 62, "Column" : 1, "Text" : "Sharff KA Curr Rheumatol Rep 2013 15:332"}, 
{"Row" : 63, "Column" : 1, "Text" : "Coakley G Lancet 2010, 375:846"}
]},
{"Name" : "ORZID2 GMENU SEPTIC BURSITIS" , "Term1" : "Bursitis, septic " , "Term2" : "Septic bursitis", "DisplayText" : "Septic bursitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]< OR >", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID($) [DI]", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "SEPTIC BURSITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Aspiration for treatment and diagnostic confirmation should be performed in all"}, 
{"Row" :5, "Column" : 1, "Text" : "cases. Obtain synovial fluid for gram stain and culture to guide therapy. Most"}, 
{"Row" :6, "Column" : 1, "Text" : "cases are associated with Staphylococcus aureus."}, 
{"Row" :8, "Column" : 1, "Text" : "Intravenous therapy is recommended. Some clinicians treat mild cases in"}, 
{"Row" :9, "Column" : 1, "Text" : "otherwise healthy individuals with intravenous therapy for part of the course"}, 
{"Row" : 10, "Column" : 1, "Text" : "and then switch to oral therapy. Other clinicians treat mild cases with oral"}, 
{"Row" : 11, "Column" : 1, "Text" : "therapy for the entire course. Drug selection should be based on microbiological"}, 
{"Row" : 12, "Column" : 1, "Text" : "results. Close clinical follow-up is needed for all cases"}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for 2 to 3 weeks."}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Mild cases in otherwise healthy adults", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Bursitis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 32, "Column" : 1, "Text" : "Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU SEVERE SINUSITIS", "DisplayText" : "Severe Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI]", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3gm IV q6h ($) [R] for 10 days", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 10 days", "Mnemonic" : "16"},
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R] for 10 days", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "SEVERE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A"}, 
{"Row" :7, "Column" : 1, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently."}, 
{"Row" :9, "Column" : 1, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees"}, 
{"Row" : 10, "Column" : 1, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4"}, 
{"Row" : 11, "Column" : 1, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the"}, 
{"Row" : 12, "Column" : 1, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses"}, 
{"Row" : 13, "Column" : 1, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT"}, 
{"Row" : 15, "Column" : 1, "Text" : "immediately. Closely monitor all patients who present with severe signs and"}, 
{"Row" : 16, "Column" : 1, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours."}, 
{"Row" : 18, "Column" : 1, "Text" : "Outpatient Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment of hospitalized patient", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment failure", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,"}, 
{"Row" : 38, "Column" : 1, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If"}, 
{"Row" : 39, "Column" : 1, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of"}, 
{"Row" : 40, "Column" : 1, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT"}, 
{"Row" : 41, "Column" : 1, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be"}, 
{"Row" : 42, "Column" : 1, "Text" : "cultured."}, 
{"Row" : 44, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 46, "Column" : 1, "Text" : "for 10 days"}, 
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 55, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 56, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 58, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 59, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Chronic"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic"}, 
{"Row" : 62, "Column" : 1, "Text" : "rhinosinusitis"}
]},
{"Name" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity"}, 
{"Row" :6, "Column" : 1, "Text" : "that could result in HIV exposure. Recommendation is for the provider to"}, 
{"Row" :7, "Column" : 1, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "HIV acquisition.If the patient is interested, the provider should place a"}, 
{"Row" :9, "Column" : 1, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP."}, 
{"Row" : 11, "Column" : 1, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have"}, 
{"Row" : 12, "Column" : 1, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by"}, 
{"Row" : 13, "Column" : 1, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or"}, 
{"Row" : 14, "Column" : 1, "Text" : "injection drug use, these medicines can work to keep the virus from"}, 
{"Row" : 15, "Column" : 1, "Text" : "establishing a permanent infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies"}, 
{"Row" : 18, "Column" : 1, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about"}, 
{"Row" : 19, "Column" : 1, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently."}, 
{"Row" : 20, "Column" : 1, "Text" : "As PrEP only protects against HIV, condoms are important for the protection"}, 
{"Row" : 21, "Column" : 1, "Text" : "against other STIs. Condoms are also an important prevention strategy"}, 
{"Row" : 22, "Column" : 1, "Text" : "if PrEP is not taken consistently."}
]},
{"Name" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS" , "Term1" : "Abscess, spinal epidural " , "Term2" : "Epidural abscess, spinal " , "Term3" : "Spinal epidural abscess", "DisplayText" : "Spinal epidural abscess " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Cefepime 2gm IV Q8h ($$) [R]< AND > vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SPINAL EPIDURAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are associated with Staphylococcus aureus. Others are associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "Gram-negative bacilli and streptococci. Beta-lactam antibiotics are more"}, 
{"Row" :7, "Column" : 1, "Text" : "effective than vancomycin against susceptible Staphylococci. If Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "is isolated, once methicillin-resistance is ruled out, switch to an anti-"}, 
{"Row" :9, "Column" : 1, "Text" : "staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in"}, 
{"Row" : 10, "Column" : 1, "Text" : "post-surgical patients or patients with known Pseudomonas colonization."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for 4 to 8 weeks. Shorter durations may be used in patients who have"}, 
{"Row" : 16, "Column" : 1, "Text" : "undergone surgical drainage and who have responded well to therapy."}, 
{"Row" : 18, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred if Pseudomonas is not suspected: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred if Pseudomonas is suspected: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment if methicillin-sensitive S. aureus is isolated", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Krishnamohan et al, Curr Infect Dis Rep, 2014, 16(11)1-6"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-To-Date Article: Spinal Epidural Abscess"}
]},
{"Name" : "ORZID2 GMENU SPOROTRICHOSIS" , "Term1" : "Sporotrichosis infections, general", "DisplayText" : "Sporotrichosis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "DisplayText" : "Itraconazole 200mg po q12h", "Text" : "Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "SPOROTRICHOSIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Sporotrichosis occurs most often in people who have had significant outdoor"}, 
{"Row" :5, "Column" : 1, "Text" : "exposure to soil.In immunocompetent people, disease is usually limited to the"}, 
{"Row" :6, "Column" : 1, "Text" : "skin.In people with decreased host defenses (eg, HIV/AIDS, alcoholism,"}, 
{"Row" :7, "Column" : 1, "Text" : "diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis"}, 
{"Row" :8, "Column" : 1, "Text" : "often disseminates to bones, joints, or lungs.Consult Infectious Diseases or"}, 
{"Row" :9, "Column" : 1, "Text" : "Dermatology"}, 
{"Row" : 11, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Cutaneous infection in a patient without HIV infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "resolved, usually for a total of 3-6 months ($) [DI]"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Consult Dermatology or Infectious Diseases."}, 
{"Row" : 21, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Extracutaneous infection or any infection in a patient with HIV/AIDS", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Consult Dermatology or Infectious Diseases."}, 
{"Row" : 30, "Column" : 1, "Text" : "Kaufman CA Clin Infect Dis 2000, 30: 684"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID2 GMENU STAPH SCALDED SYNDROME" , "Term1" : "Scalded skin syndrome", "DisplayText" : "Staphylococcal Scalded Skin Syndrom (Ritter's Disease)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)"}, 
{"Row" :4, "Column" : 1, "Text" : "Staphylococcal scalded skin syndrome (SSSS) presents with severe skin"}, 
{"Row" :5, "Column" : 1, "Text" : "blistering and exfoliation resulting from toxins produced by Staphylococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "aureus.SSSS is usually found in children and rarely in older adults.Obtain"}, 
{"Row" :7, "Column" : 1, "Text" : "a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis."}, 
{"Row" :9, "Column" : 1, "Text" : "Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empiric therapy active against both MRSA and MSSA until results available."}, 
{"Row" : 11, "Column" : 1, "Text" : "If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change"}, 
{"Row" : 12, "Column" : 1, "Text" : "to nafcillin or cefazolin for better antimicrobial activity."}, 
{"Row" : 14, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment if MSSA is isolated", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Staph. Scalded skin syndrome"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: The acutely ill patient with fever and rash"}, 
{"Row" : 27, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 28, "Column" : 1, "Text" : "Patel GK Am J Clin Dermatol 2003, 4:165"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU STAPH TOXIC SHOCK SYNDROME", "DisplayText" : "CDC criteria for diagnosis of Staphylococcal Toxic Shock Syndrome " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CDC CRITERIA FOR DIAGNOSIS OF STAPHYLOCOCCAL TOXIC SHOCK SYNDROME"}, 
{"Row" :5, "Column" : 1, "Text" : "These criteria were developed for epidemiological purposes.Treat cases when"}, 
{"Row" :6, "Column" : 1, "Text" : "fewer criteria are met if staphylococcal TSS seems likely."}, 
{"Row" :8, "Column" : 1, "Text" : "Definite:All 6 of the following criteria are met."}, 
{"Row" :9, "Column" : 1, "Text" : "Probable:Five of the 6 criteria are met."}, 
{"Row" : 11, "Column" : 1, "Text" : "Fever", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "T >38.9 degree Celsius (102.0 degree Fahrenheit)"}, 
{"Row" : 14, "Column" : 1, "Text" : "Hypotension", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Systolic blood pressure 90 mmHg, orthostatic drop in diastolic 15 mmHg,"}, 
{"Row" : 16, "Column" : 1, "Text" : "orthostatic syncope or dizziness"}, 
{"Row" : 18, "Column" : 1, "Text" : "Rash", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Diffuse macular erythroderma"}, 
{"Row" : 21, "Column" : 1, "Text" : "Desquamation", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Occurs 1 to 2 weeks after onset of illness and usually involving palms and"}, 
{"Row" : 23, "Column" : 1, "Text" : "soles"}, 
{"Row" : 25, "Column" : 1, "Text" : "Multisystem involvement (3 or more of the following organ systems)", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "GI", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Vomiting or diarrhea at onset of illness"}, 
{"Row" : 30, "Column" : 1, "Text" : "Muscular", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Severe myalgia or CPK elevation >2 times the normal upper limit"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mucous membranes", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Vaginal, oropharyngeal, or conjunctival hyperemia"}, 
{"Row" : 36, "Column" : 1, "Text" : "Renal", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "BUN or serum creatinine >2 times the normal upper limit, or pyuria (>5"}, 
{"Row" : 38, "Column" : 1, "Text" : "WBC/hpf)"}, 
{"Row" : 40, "Column" : 1, "Text" : "Hepatic", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Bilirubin or transaminases >2 times the normal upper limit"}, 
{"Row" : 43, "Column" : 1, "Text" : "Hematologic", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Platelets <100,000/microLiter"}, 
{"Row" : 46, "Column" : 1, "Text" : "Central nervous system", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Disorientation or alterations in consciousness without focal neurologic"}, 
{"Row" : 48, "Column" : 1, "Text" : "signs in the absence of fever and hypotension"}, 
{"Row" : 50, "Column" : 1, "Text" : "Negative results on the following tests, if obtained", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Blood, throat, or cerebrospinal fluid cultures for another pathogen (blood"}, 
{"Row" : 52, "Column" : 1, "Text" : "cultures may be positive for S. aureus)."}, 
{"Row" : 54, "Column" : 1, "Text" : "Serologic tests for Rocky Mountain spotted fever, leptospirosis, or measles"}, 
{"Row" : 59, "Column" : 1, "Text" : "MMWR 1990, 39(RR-13):1"}, 
{"Row" : 60, "Column" : 1, "Text" : "DeVries AS PLoS One 2011, 6(8):e22997"}
]},
{"Name" : "ORZID2 GMENU STREP TOXIC SHOCK SYNDROME", "DisplayText" : "Criteria for diagnosis of Streptococcal Toxic Shock Syndrome" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CRITERIA FOR DIAGNOSIS OF STREPTOCOCCAL TOXIC SHOCK SYNDROME"}, 
{"Row" :5, "Column" : 1, "Text" : "These criteria were developed for epidemiological purposes.Treat cases when"}, 
{"Row" :6, "Column" : 1, "Text" : "fewer criteria are met if streptococcal TSS seems likely."}, 
{"Row" :8, "Column" : 1, "Text" : "1.)Isolation of Group A Streptococcus from a normally sterile site (eg, blood"}, 
{"Row" :9, "Column" : 1, "Text" : "cerebrospinal, pleural, or peritoneal fluid, tissue biopsy, or surgical wound)"}, 
{"Row" : 11, "Column" : 1, "Text" : "< AND >"}, 
{"Row" : 13, "Column" : 1, "Text" : "2.)Hypotension (systolic blood pressure 90 mm Hg in adults"}, 
{"Row" : 15, "Column" : 1, "Text" : "< AND >"}, 
{"Row" : 17, "Column" : 1, "Text" : "3.)Two or more of the following: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Renal impairment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "(creatinine in adults, 2 mg/dL, in children, two-times upper limit of normal"}, 
{"Row" : 21, "Column" : 1, "Text" : "for age, in patients with pre-existing renal disease two-fold elevation over"}, 
{"Row" : 22, "Column" : 1, "Text" : "baseline)"}, 
{"Row" : 24, "Column" : 1, "Text" : "Coagulopathy", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "(eg, thrombocytopenia, disseminated intravascular coagulation)"}, 
{"Row" : 27, "Column" : 1, "Text" : "Liver involvement", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "(eg, two-times upper limit of normal for age of transaminases or bilirubin, in"}, 
{"Row" : 29, "Column" : 1, "Text" : "patients with pre-existing liver disease two-fold elevation over baseline)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Adult respiratory distress syndrome", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Erythematous macular rash", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "may desquamate"}, 
{"Row" : 36, "Column" : 1, "Text" : "Soft tissue necrosis (eg, necrotizing fasciitis, myositis, or gangrene)"}, 
{"Row" : 41, "Column" : 1, "Text" : "Working Group on Severe Streptococcal Infections JAMA 1993, 269:390"}
]},
{"Name" : "ORZID2 GMENU SUBDURAL EMPYEMA" , "Term1" : "Empyema, subdural " , "Term2" : "Subdural empyema", "DisplayText" : "Subdural Empyema" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H", "DisplayText" : "CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "10"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SUBDURAL EMPYEMA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases (60-90%) result from extension of sinusitis or otitis media"}, 
{"Row" :6, "Column" : 1, "Text" : "(contiguous sources). Surgical drainage is necessary. Obtain material for"}, 
{"Row" :7, "Column" : 1, "Text" : "culture. For patients with severe penicillin allergy consult Infectious"}, 
{"Row" :8, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 4-6 weeks"}, 
{"Row" : 15, "Column" : 1, "Text" : "Empiric Treatment for Infection from Contiguous Source", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Empiric Treatment for Unknown Source, History of MRSA Infection or Colonization", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative"}, 
{"Row" : 35, "Column" : 1, "Text" : "Intracranial Thrombophlebitis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Subdural empyema"}
]},
{"Name" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH" , "Term1" : "Suppurative intracranial thrombophlebitis", "DisplayText" : "Suppurative intracranial thrombophlebitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO500MGIVQ8H VANCO15MG/KGIVQ12H", "DisplayText" : "CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "DisplayText" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin 2 gm IV q8h ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "SUPPURATIVE INTRACRANIAL THROMBOPHLEBITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Adjust therapy from empirical regimens listed below after consultation with"}, 
{"Row" :6, "Column" : 1, "Text" : "Infectious Disease or Neurosurgery services. Beta-lactam antibiotics are more"}, 
{"Row" :7, "Column" : 1, "Text" : "effective than vancomycin against susceptible Staphylococci. If Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "is isolated, once methicillin-resistance is ruled out, switch to an anti-"}, 
{"Row" :9, "Column" : 1, "Text" : "staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in"}, 
{"Row" : 10, "Column" : 1, "Text" : "post-surgical patients or patients with known pseudomonas colonization."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consult Infectious Disease and Neurosurgery."}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of Therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for 3 to 6 weeks."}, 
{"Row" : 17, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred if Pseudomonas is not suspected: "}, 
{"Row" : 20, "Column" : 1, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred if Pseudomonas is suspected: "}, 
{"Row" : 24, "Column" : 1, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment if Methicillin-Sensitive S. Aureus is Isolated", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Kombogiorgas et al, British Journal of Neurosurgery, 2007, 21(6)603 - 609"}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative"}, 
{"Row" : 40, "Column" : 1, "Text" : "Intracranial Thrombophlebitis"}
]},
{"Name" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT" , "Term1" : "Dental infections " , "Term2" : "Suppurative odontic infections " , "Term3" : "Tooth abscess and other suppurative odontic infections", "DisplayText" : "Suppurative odontogenic infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "DisplayText" : "Amoxicillin 500 mg PO q8h ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h for 5 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 5 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "DisplayText" : "Cefdinir 300 mg PO q12h ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "10"},
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "DENTAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential. All"}, 
{"Row" :6, "Column" : 1, "Text" : "patients should be referred to the dental service for assessment and direction"}, 
{"Row" :7, "Column" : 1, "Text" : "of treatment. Empirical coverage for likely pathogens (streptococci,"}, 
{"Row" :8, "Column" : 1, "Text" : "Peptostreptococcus, Finegoldia, Bacteriodes and other oral anaerobes) is"}, 
{"Row" :9, "Column" : 1, "Text" : "required."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consult Dental Service", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "Primary alternative: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_______________________________________________________________________________"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 29, "Column" : 1, "Text" : "Lockhart et al. JADA. 2019, 150(11)906-921"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head"}, 
{"Row" : 31, "Column" : 1, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252"}, 
{"Row" : 32, "Column" : 1, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic"}, 
{"Row" : 35, "Column" : 1, "Text" : "Infections"}
]},
{"Name" : "ORZID2 GMENU SURG 48HRS AFTER PROC", "DisplayText" : "Patients with signs of infection 48 HOURS OR MORE after procedure " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "GMRCTZ WOCN OSTOMY INPT", "DisplayText" : "WOUND NURSE INPT", "Text" : "Wound care (ET) nurse consult", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "DisplayText" : "MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R] < OR >", "Mnemonic" : "8"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CIPROFL 400 MG IV Q12H CLINDA 600MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Clindamycin 600 mg IV", "Mnemonic" : "10"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX AMPI/SULB 3GM IV Q6H VANCO 15MG/KG IV Q12H", "DisplayText" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "14"},
{"Row" : 49, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) <AND> vancomycin 15 mg/kg", "Mnemonic" : "16"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX CIPROFL, METRONI, VANCO", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg", "Mnemonic" : "18"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "PATIENTS WITH SIGNS OF INFECTION MORE THAN 48 HOURS AFTER PROCEDURE"}, 
{"Row" :5, "Column" : 1, "Text" : "Most post-operative infections appear at least 4 days after the operation.If"}, 
{"Row" :6, "Column" : 1, "Text" : "the wound appears normal to examination surgical site infection is unlikely."}, 
{"Row" :7, "Column" : 1, "Text" : "Seek other source of fever.Consider opening wounds that show induration or"}, 
{"Row" :8, "Column" : 1, "Text" : "erythema.Obtain material for gram stain and culture whenever possible."}, 
{"Row" :9, "Column" : 1, "Text" : "Determine whether the patient has signs of invasive or systemic infection like"}, 
{"Row" : 10, "Column" : 1, "Text" : "erythema (diameter greater than 5 centimeters), temperature greater than 38.5"}, 
{"Row" : 11, "Column" : 1, "Text" : "degrees Celsius (101.3 degrees Fahrenheit) or heart rate higher than 100 beats"}, 
{"Row" : 12, "Column" : 1, "Text" : "per minute."}, 
{"Row" : 14, "Column" : 1, "Text" : "If there are no signs of invasive or systemic infection systemic antimicrobials"}, 
{"Row" : 15, "Column" : 1, "Text" : "are unnecessary.Dressing changes alone are indicated."}, 
{"Row" : 17, "Column" : 1, "Text" : "For wounds that require complicated care", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "If there are signs of invasive or systemic infection obtain blood cultures and"}, 
{"Row" : 21, "Column" : 1, "Text" : "wound Gram stain and cultures.Whenever possible select antimicrobial therapy"}, 
{"Row" : 22, "Column" : 1, "Text" : "based on the Gram stain.When the Gram stain cannot provide guidance give"}, 
{"Row" : 23, "Column" : 1, "Text" : "empirical therapy as indicated: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Empirical treatment of INFECTED WOUNDS AFTER CLEAN SURGERY or wounds on the", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "trunk, head, neck, arms or legs", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Vancomycin should be included in the initial regimen due to the prevalence of"}, 
{"Row" : 28, "Column" : 1, "Text" : "methicillin-resistant Staphylococcus aureus.However beta-lactam antibiotics"}, 
{"Row" : 29, "Column" : 1, "Text" : "are more effective for susceptible bacteria than is vancomycin.If methicillin-"}, 
{"Row" : 30, "Column" : 1, "Text" : "susceptible S. aureus is identified switch to an anti-staphylococcal beta-lactam"}, 
{"Row" : 31, "Column" : 1, "Text" : "antibiotic."}, 
{"Row" : 35, "Column" : 1, "Text" : "Preferred empirical treatment for INFECTED WOUNDS AFTER CLEAN-CONTAMINATED or", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "CONTAMINATED SURGERY", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "q8h ($$) [H]"}, 
{"Row" : 45, "Column" : 1, "Text" : "Alternative if methicillin-resistant Staphylococcus aureus is suspected", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "IV q12h ($) [R] < OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "IV q12h ($) [R] < OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "IV q8h ($) [DI] <AND> vancomycin 15mg/kg IV q12 ($) [R]"}, 
{"Row" : 57, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}
]},
{"Name" : "ORZID2 GMENU SURG ANTIBIOTIC RENAL REDOSING", "DisplayText" : "Redosing Interval for renal fxn normal vs esrd" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Recommended Redosing Interval", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Based on Normal and ESRD renal function", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Recommended redosing interval 2 times the half-life", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "ANTIMICROBIAL", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Ampicillin", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Ampicillin sulbactam", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Aztreonam", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Cefazolin", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Cefuroxime", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Cefoxitin", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Cefotetan", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Ceftriaxone", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Ciprofloxacin", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Clindamycin", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Gentamicin", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Levofloxacin", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Metronidazole", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Piperacilln Tazobactam", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Vancomycin", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Am J Health-Syst Pharm. 2013, 70: 195-283", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford Guide Online", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Text" : "REDOSING INTERVAL**", "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Text" : "NORMAL RENAL FXN", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Text" : "N/A", "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 45, "Column" : 2, "Text" : "Doses based on Dosing Weight (DW)*", "Header" : 1}, 
{"Row" : 46, "Column" : 2, "Text" : "*Calculate Dosing Weight (DW)", "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Text" : "DW = IBW + 0.4 (ABW - IBW)", "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Text" : "IBW=Ideal Body WtABW=Actual Body Wt", "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Text" : "Male IBW (kg)=50+2.3 * (Ht-60inches)", "Header" : 1}, 
{"Row" : 50, "Column" : 2, "Text" : "Female IBW (kg)=45.5+2.3 * (Ht-60inches)", "Header" : 1}, 
{"Row" :1, "Column" : 3, "Text" : "Antimicrobial Surgical Prophylaxis", "Header" : 1}, 
{"Row" : 10, "Column" : 3, "Text" : "REDOSING INTERVAL**", "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Text" : "END STAGE RENAL DISEASE", "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 15, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 17, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 19, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 21, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 23, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 25, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 27, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 31, "Column" : 3, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 33, "Column" : 3, "Text" : "Only give 3mg/kg preop ONCE*", "Header" : 1}, 
{"Row" : 39, "Column" : 3, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 41, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Text" : "based on typical case length, for", "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Text" : "unusually long procedures,", "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Text" : "redosing may be needed.", "Header" : 1}, 
{"Row" :5, "Column" : 3, "Text" : "**For those marked N/A --", "Header" : 1}, 
{"Row" :6, "Column" : 3, "Text" : "based on typical case length,", "Header" : 1}, 
{"Row" :7, "Column" : 3, "Text" : "unusually long procedures,", "Header" : 1}, 
{"Row" :8, "Column" : 3, "Text" : "redosing may be needed.", "Header" : 1}, 
{"Row" : 43, "Column" : 3, "Text" : "**For those marked N/A --", "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Text" : "Single dose only preop", "Header" : 1}, 
{"Row" : 29, "Column" : 2, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 29, "Column" : 3, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Text" : "12 hours", "Header" : 1}, 
{"Row" : 37, "Column" : 2, "Text" : "12 hours", "Header" : 1}, 
{"Row" : 37, "Column" : 3, "Text" : "12 hours", "Header" : 1}, 
{"Row" : 35, "Column" : 2, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "John Hopkins Antibiotic Guide.Online.Oct2021.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG BILIARY", "DisplayText" : "Biliary Surgery " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BILIARY SURGERY"}, 
{"Row" :5, "Column" : 1, "Text" : "Surgical prophylaxis is indicated for open procedures and high risk"}, 
{"Row" :6, "Column" : 1, "Text" : "laparoscopic procedures.Additional doses should not be given after"}, 
{"Row" :7, "Column" : 1, "Text" : "incisions are closed. Surgical prophylaxis is not indicated in elective"}, 
{"Row" :8, "Column" : 1, "Text" : "low risk laparoscopic procedures."}, 
{"Row" : 10, "Column" : 1, "Text" : "The risk of infectious complications after laparoscopic cholecystectomy is"}, 
{"Row" : 11, "Column" : 1, "Text" : "increased after emergent procedures, procedures lasting more than 120 minutes,"}, 
{"Row" : 12, "Column" : 1, "Text" : "intraoperative gall bladder rupture or bile spillage, conversion from"}, 
{"Row" : 13, "Column" : 1, "Text" : "laparoscopic to open cholecystectomy, and insertion of a prosthetic device."}, 
{"Row" : 15, "Column" : 1, "Text" : "The risk is increased in patients who have had an episode of colic or a"}, 
{"Row" : 16, "Column" : 1, "Text" : "biliary procedure within 30 days before the procedure, patients with acute"}, 
{"Row" : 17, "Column" : 1, "Text" : "cholecystitis or jaundice, patients with a nonfunctional gallbladder, patients"}, 
{"Row" : 18, "Column" : 1, "Text" : "with immunosuppression, pregnancy, diabetes, age greater than 70 years, or"}, 
{"Row" : 19, "Column" : 1, "Text" : "American Society of Anesthesiologists classification of 3 or greater."}, 
{"Row" : 21, "Column" : 1, "Text" : "If one of these risk factors exists, prophylaxis is indicated for laparoscopic"}, 
{"Row" : 22, "Column" : 1, "Text" : "cholecystectomy.If there is a substantial likelihood that one of these risk"}, 
{"Row" : 23, "Column" : 1, "Text" : "factors will develop during a procedure, the surgeon may elect to order"}, 
{"Row" : 24, "Column" : 1, "Text" : "prophylaxis."}, 
{"Row" : 26, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Open procedure or high-risk laparoscopic procedure: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternative in patients with beta lactam allergy", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 38, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}
]},
{"Name" : "ORZID2 GMENU SURG CARDIAC SURG", "DisplayText" : "Cardiac surgery and implantation of pacemaker " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED PREOP", "DisplayText" : "CIED Pre Op", "Text" : "Click here to go to CIED Surgery Prophylaxis", "Mnemonic" : "4"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "DisplayText" : "CV Surgery Delayed Order Antibiotics", "Text" : "Click here to go to CV (open heart) Surgery Prophylaxis", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "8"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "CARDIAC SURGERY"}, 
{"Row" :7, "Column" : 1, "Text" : "Antimicrobial prophylaxis is not indicated before cardiac catheterization"}, 
{"Row" :8, "Column" : 1, "Text" : "with or without stent placement or for transesophageal echocardiogram."}, 
{"Row" : 10, "Column" : 1, "Text" : "For patients undergoing cardiac procedures the recommended regimen is a"}, 
{"Row" : 11, "Column" : 1, "Text" : "single pre-incision dose of antibiotic with additional doses"}, 
{"Row" : 13, "Column" : 1, "Text" : "while incisions are open for long procedures."}, 
{"Row" : 14, "Column" : 1, "Text" : "Prophylaxis should not be continued beyond 24 hours"}, 
{"Row" : 15, "Column" : 1, "Text" : "even if drains or intravenous catheters remain in place."}, 
{"Row" : 17, "Column" : 1, "Text" : "Cefazolin is preferred for prophylaxis, as it is more active than vancomycin"}, 
{"Row" : 18, "Column" : 1, "Text" : "against methicillin-susceptible staphylococci.Vancomycin should"}, 
{"Row" : 19, "Column" : 1, "Text" : "be used when methicillin-resistant Staphylococcus aureus infection is likely."}, 
{"Row" : 20, "Column" : 1, "Text" : "Consult Cardiothoracic Surgery or Infectious Diseases for more information."}, 
{"Row" : 22, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Prophylaxis", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 36, "Column" : 1, "Text" : "in surrgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 37, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 38, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}, 
{"Row" : 39, "Column" : 1, "Text" : "Baddour LM, et al. Circulation 2010 Vol 121 pages 458-477"}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for beta-lactam allergy or IF MRSA likely: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "[Click here] Beta-lactam allergy assessment"}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "12"}
]},
{"Name" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3GM IVPB ONCE PREOP", "DisplayText" : "Cefazolin 3GM IVPB ONCE", "Text" : "", "Mnemonic" : "06"},
{"Row" :9, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE PREOP", "DisplayText" : "Cefazolin 2GM IVPB ONCE", "Text" : "", "Mnemonic" : "04"},
{"Row" :8, "Column" : 1, "Text" : "Weight <120 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Weight >/= 120 kg: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Preop dose administer over 30 minutes, beginning 60 minutes before incision."}, 
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX WEIGHT FOR ABX DOSING", "DisplayText" : "Last recorded weight", "Text" : "<Click here> Display last recorded patient weight (limited to 2 years)", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Text" : "Recommended Cefazolin Preop Dose based on patient weight: ", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Text" : "CEFAZOLIN: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG CIED POSTOP", "DisplayText" : "CIED Post Op" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB Q8H X 2DOSES", "DisplayText" : "Cefazolin 2gm IVPB q8h x 2doses post-op ($) [R]", "Text" : "", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3 GM POSTOP X2DOSES FOR WT GREATER THAN 120KG", "DisplayText" : "Cefazolin 3GM q8hours for 2 doses post-op ($) [R]", "Text" : "Cefazolin 3 GM q8h for 2 doses post-op ($) [R]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID VANCOM 15 MG/KG IV Q12H 2DOSES POSTOP", "DisplayText" : "Vancomycin 15 MG/KG iv q12h for 2 doses post-op ($) [R]", "Text" : "Vancomycin 15mg/kg for 2 doses post-op ($) [R]", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM + VANCO 15MG/KG 2DOSES POSTOP", "Text" : "Cefazolin 2 GM q8h x 2 doses post-op ($) [R] < AND >", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 3GM + VANCOMYCIN 15MG/KG POSTOP X2DOSES", "Text" : "Cefazolin 3 GM q8h x 2 doses post-op ($) [R] < AND >", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO BID X3DAYS CIED POSTOP", "DisplayText" : "Cephalexin 500MG PO bid for 3 days AFTER CIED PROCEDURE", "Text" : "Cephalexin 500MG PO bid for 3 days AFTER CIED PROCEDURE", "Mnemonic" : "14"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID X3DAYS CIED POSTOP", "DisplayText" : "Clindamycin 300MG po qid for 3 days AFTER CIED PROCEDURE", "Text" : "Clindamycin 300MG po qid for 3 days AFTER CIED PROCEDURE", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID X3DAYS CIED POSTOP", "DisplayText" : "Doxycycline 100MG PO bid for 3 days AFTER CIED PROCEDURE", "Text" : "Doxycycline 100MG PO bid for 3 days AFTER CIED PROCEDURE", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "Cardiac Implantable Electronic Device (CIED) Post-Op Prophylaxis Antibiotics", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Post-procedure CIED IV antibiotic prophylaxis: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Place post-op IV antimicrobial prophylaxis after admission."}, 
{"Row" :5, "Column" : 1, "Text" : "If new CIED implant, then give same antibiotic(s) as preop for 2 doses post-op"}, 
{"Row" :6, "Column" : 1, "Text" : "If generator replacement only, then no additional doses recommended."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred POST-PROCEDURE prophylaxis: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "For patients weight less than 120 kg: "}, 
{"Row" : 11, "Column" : 1, "Text" : "For patients weight equal to or greater than 120kg: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative in patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "MRSA Positive Patients Post-Procedure antibiotics: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients weight less than 120 kg: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]"}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients weight equal to or greater than 120 kg: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]"}, 
{"Row" : 23, "Column" : 1, "Text" : "__________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Post-procedure CIED ORAL TAKE HOME MEDICATIONS: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred POST-PROCEDURE prophylaxis: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "MRSA Positive Patients Post-Procedure antibiotics: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 35, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}
]},
{"Name" : "ORZID2 GMENU SURG CIED PREOP", "DisplayText" : "CIED Pre Op " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID MUPIROCIN 2% OINT DECOLON TOPICAL BID 5D", "DisplayText" : "Mupirocin 2% ointment topical to affected area tid for 5 days ($) [M]", "Text" : "Mupirocin Ointment applytopical to each nares bid for 5 days PRIOR TO", "Mnemonic" : "10"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN WT BASED + VANCOMYCIN 15MG/KG PREOP CIED", "DisplayText" : "Cefazolin weight based once + Vancomycin 15mg/kg once", "Text" : "", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "Cardiac Implantable Electronic Device (CIED) Pre-Op Prophylaxis Antibiotics", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Pre-procedure IV prophylaxis antibiotic recommendations: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Preferred prophylaxis: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Alternative in patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Recommended for MRSA Positive Patients: Decolonization AND Pre-op Antibiotics", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Decolonization for MRSA positive: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "PROCEDURE (ideally) ($) [M]"}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred prophylaxis for MRSA positive: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 19, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}
]},
{"Name" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "DisplayText" : "Bowel/Colo-rectal Surgery " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO WT BASED IV 30MIN METRON 500MG IV X1", "DisplayText" : "Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop", "Text" : "Cefazolin 2gm IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX GENTAM 5 MG/KG IV 30MIN METRO 500MG IV X1", "Text" : "Gentamicin 5 MG/KGIV over 30 minutes ($) [R,O] beginning 60 minutes", "Mnemonic" : "10"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG IV/LEVOFLOXACIN 500MG IV", "DisplayText" : "Clindamycin 900mg IV over 30min once and levofloxacin 500mg IV over 30 min once", "Text" : "Clindamycin 900mg IV over 30 minutes ($)[H,O] beginning 60 minutes", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "Bowel/Colo-rectal Surgery"}, 
{"Row" :5, "Column" : 1, "Text" : "Bowel preparation should be done for cases in which the colon should be cleansed"}, 
{"Row" :6, "Column" : 1, "Text" : "for surgical reasons."}, 
{"Row" :8, "Column" : 1, "Text" : "Systemic antimicrobials should provide coverage for aerobes and anaerobes."}, 
{"Row" : 19, "Column" : 1, "Text" : "Systemic antimicrobials", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "($) [R] <AND> metronidazole 500 mg IV over 30 minutes beginning 60"}, 
{"Row" : 23, "Column" : 1, "Text" : "minutes before incision ($) [DI]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative in patient with beta lactam allergy", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "before incision <AND> metronidazole 500 mg IV ($) [DI] over 30 minutes"}, 
{"Row" : 28, "Column" : 1, "Text" : "beginning 60 minutes before incision"}, 
{"Row" : 31, "Column" : 1, "Text" : "before incision <AND> levofloxacin 500mg IV over 60 minutes ($)[R,DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "beginning 60 minutes before incision."}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 36, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013, 70: 195-283"}, 
{"Row" : 37, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter 2012, 10: 73-77"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Prophylaxis"}, 
{"Row" : 10, "Column" : 1, "Text" : "Outpatient Orders for Bowel Prep Medications", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Inpatient Orders for Bowel Prep Medications", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZ SET GENERAL SURGERY BOWEL PREP", "DisplayText" : "General Surgery Bowel Prep Orders", "Text" : "Outpatient orders for Bowel Prep (Golytely+Neomycin PO+Erythromycin PO)", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSJZ METOCLOPRAMIDE 10MG PO PRE-GOLYTELY", "DisplayText" : "Reglan 10mg PO prior to Golytely", "Text" : "", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJZ GOLYTELY BOWEL PREP", "DisplayText" : "Golytely Bowel Prep", "Text" : "", "Mnemonic" : "8"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZ NEOMYCIN 1GM PO TID BOWEL PREP", "DisplayText" : "Neomycin 1GM TID day before surgery.", "Text" : "Neomycin 1000 mg PO TID day before surgery", "Mnemonic" : "10"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZ ERYTHROMYCIN 1GM PO TID BOWEL PREP", "DisplayText" : "Erythromycin 1GM TID day before surgery.", "Text" : "Erythromycin 1000 mg PO TID day before surgery", "Mnemonic" : "12"}
]},
{"Name" : "ORZID2 GMENU SURG CV POSTOP", "DisplayText" : "CV POSTOPERATIVE PROPHYLAXIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "DisplayText" : "CIED Post Op", "Text" : "CIED Surgery Postoperative Prophylaxis", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFUR 1.5G VANCO 15MG/KG POSTOP CARD", "Text" : "Cefuroxime 1.5 gm IV q8h x 1 dose post-op ($$) [R] <AND> vancomycin 15 mg/kg", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "DisplayText" : "VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg (pharmacy to dose) IV q12h x 1 dose post-op ($) [R]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CV SURGERY (OPEN HEART) MVAHCS POSTOPERATIVE PROPHYLAXIS RECOMMENDATIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Place post-op IV antimicrobial prophylaxis orders after admission to ward."}, 
{"Row" :6, "Column" : 1, "Text" : "Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations"}, 
{"Row" :7, "Column" : 1, "Text" : "longer than 24 hours have not been shown effective in preventing cardiothoracic"}, 
{"Row" :8, "Column" : 1, "Text" : "surgical site infections. There is no benefit to continuing antimicrobial"}, 
{"Row" :9, "Column" : 1, "Text" : "prophylaxis until all indwelling drains and intravascular catheters are removed."}, 
{"Row" : 11, "Column" : 1, "Text" : "For CIED surgery postoperative antimicrobial prophylaxis click link below: "}, 
{"Row" : 14, "Column" : 1, "Text" : "CV Surgery (including CAB and TAVR) Postoperative Prophylaxis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "(pharmacy to dose) IV q12h x 1 dose post-op ($) [R]"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative for patient with cephalosporin allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "Levofloxacin has a duration of action of 24 hours. If patient received a pre-op"}, 
{"Row" : 20, "Column" : 1, "Text" : "dose of levofloxacin, a post-op dose is not required."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in"}, 
{"Row" : 27, "Column" : 1, "Text" : "Surgery, Am J Health-Syst Pharm (2013) 70:195-283"}
]},
{"Name" : "ORZID2 GMENU SURG ERCP", "DisplayText" : "Endoscopic Retrograde Cholangiopancreatography (ERCP) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG ERCP INCOMP DRAINAGE", "DisplayText" : "Antimicrobial Prophylaxis After ERCP with Incomplete Drainage", "Text" : "Antimicrobial prophylaxis after ERCP with incomplete drainage", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM AND GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Ampicillin 2gram IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "Ampicillin 2 gm IV over 20 minutes ($) [R] < AND > gentamicin 5mg/kg", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFL 400MG IV ONCE SURG PREOP", "DisplayText" : "Ciprofloxacin 400mg IV ONCE Preop", "Text" : "Ciprofloxacin 400 mg IV over 60 minutes beginning 60 minutes before incision", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)"}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobials are not indicated in the absence of obstruction or intervention."}, 
{"Row" :6, "Column" : 1, "Text" : "If obstruction is present or intervention is likely antimicrobial prophylaxis"}, 
{"Row" :7, "Column" : 1, "Text" : "is recommended.Use of gentamicin is optional.Contact Gastroenterology for"}, 
{"Row" :8, "Column" : 1, "Text" : "more information.If drainage is incomplete, prophylactic antimicrobials after"}, 
{"Row" :9, "Column" : 1, "Text" : "ERCP may be indicated."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "over 20 minutes ($) [R,O] both beginning 60 minutes before incision"}, 
{"Row" : 16, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 18, "Column" : 1, "Text" : "($) [R,DI]"}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< AND > gentamicin 5mg/kg ($) [R,O] over 20 minutes beginning 60"}, 
{"Row" : 23, "Column" : 1, "Text" : "minutes before incision"}, 
{"Row" : 25, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford website: Surgical Prophylaxis Gastroduodenal, Biliary"}, 
{"Row" : 28, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial"}, 
{"Row" : 29, "Column" : 1, "Text" : "Prophylaxis in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 31, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter 2012 vol 10 pages 73-77"}, 
{"Row" : 34, "Column" : 1, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal"}, 
{"Row" : 35, "Column" : 1, "Text" : "Endoscopy 2008 vol 67 pages 791-795"}
]},
{"Name" : "ORZID2 GMENU SURG ERCP INCOMP DRAINAGE", "DisplayText" : "Antimicrobial Prophylaxis After ERCP with Incomplete Drainage " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "DisplayText" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Text" : "Amoxicillin-clavulante 875/125 mg PO q12h ($) [R]", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIAL PROPHYLAXIS AFTER ERCP WITH INCOMPLETE DRAINAGE"}, 
{"Row" :5, "Column" : 1, "Text" : "The risk of symptomatic infection is increased when drainage of the common bile"}, 
{"Row" :6, "Column" : 1, "Text" : "duct is incomplete or if dye is trapped in the biliary tract.In such cases,"}, 
{"Row" :7, "Column" : 1, "Text" : "give antimicrobials for 5 days."}, 
{"Row" : 13, "Column" : 1, "Text" : "Up to date website"}, 
{"Row" : 15, "Column" : 1, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal"}, 
{"Row" : 16, "Column" : 1, "Text" : "Endoscopy 2008, vol 67 pages 791-795"}
]},
{"Name" : "ORZID2 GMENU SURG GASTRODUODENAL SURG", "DisplayText" : "Gastroduodenal Surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "GASTRODUODENAL SURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "Prophylaxis is indicated in procedures involving entry into lumen of"}, 
{"Row" :5, "Column" : 1, "Text" : "gastrointestinal tract."}, 
{"Row" :6, "Column" : 1, "Text" : "For procedures without entry into gastrointestinal tract, prophylaxis"}, 
{"Row" :7, "Column" : 1, "Text" : "is indicated only in patients with unusual risk for infection."}, 
{"Row" :8, "Column" : 1, "Text" : ">>Patients with high gastric pH or acid-suppression therapy,"}, 
{"Row" :9, "Column" : 1, "Text" : ">>Patients with decreased gastroduodenal motility due to obstruction,"}, 
{"Row" : 10, "Column" : 1, "Text" : "hemorrhage, gastric ulcer, malignancy, or diabetic gastroparesis, or"}, 
{"Row" : 11, "Column" : 1, "Text" : ">>Obese patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Prophylaxis", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 30, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 32, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 33, "Column" : 1, "Text" : "Medical Letter 2012 vol 10 pages 73-77"}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG<AND> CIPROFLO 400 GASTRICPREOP", "DisplayText" : "Clindamycin 900mg and Ciprofloxacin 400 mg IVPB Preop Gastroduodenal", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Text" : "($) [H,O] < AND > Ciprofloxacin 400 mg IV over 60 minutes beginning 120 minutes"}, 
{"Row" : 26, "Column" : 1, "Text" : "before incision ($) [R,O]"}, 
{"Row" : 21, "Column" : 1, "Text" : "For a patient with a history of anaphylactic shock or severe allergy to", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "penicillin OR beta-lactam antibiotic please order: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 240 MG IVPB DOSE LESS 50KG PREOP", "DisplayText" : "Gentamicin 240 mg IV ONCE", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 300 MG IVPB DOSE 50-75KG PREOP", "DisplayText" : "Gentamicin 300 mg IV ONCE", "Text" : "", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 400 MG IVPB DOSE 75-100KG PREOP", "DisplayText" : "Gentamicin 400 mg IV ONCE", "Text" : "", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 500 MG IVPB DOSE 100-125KG PREOP", "DisplayText" : "Gentamicin 500 mg IV ONCE", "Text" : "", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 600 MG IVPB 100-125 KG PREOP", "DisplayText" : "Gentamicin 600 mg IV ONCE", "Text" : "", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Text" : "Weight >/= 120 kg: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX WEIGHT FOR ABX DOSING", "DisplayText" : "Last recorded weight", "Text" : "<Click here> Display last recorded patient weight", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Text" : "Preop dose administer beginning 60 minutes before incision: "}, 
{"Row" :3, "Column" : 1, "Text" : "Recommended Gentamicin Preop Dose based on patient weight: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Weight >/= 50 kg and < 75 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Weight >/= 75 kg and < 100 kg: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Weight < 50 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Weight >/= 100 kg and < 120 kg: ", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Text" : "GENTAMICIN: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG GYNECOL SURG", "DisplayText" : "Gynecological surgery " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "GYNECOLOGICAL SURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "Prophylaxis is indicated for abdominal or vaginal hysterectomy with either open"}, 
{"Row" :5, "Column" : 1, "Text" : "or laparoscopic approach.Antimicrobials are not indicated after incisions are"}, 
{"Row" :6, "Column" : 1, "Text" : "closed."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative in patients with beta lactam allergy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 17, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "6"}
]},
{"Name" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "DisplayText" : "Head and neck surgery " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE PREOP", "DisplayText" : "Ampicillin-Sulbactam 3 GM IV once pre-op", "Text" : "Ampicillin-sulbactam 3 gm IV over 30 minutes beginning 60 minutes before", "Mnemonic" : "12"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO WT BASED IV 30MIN METRON 500MG IV X1", "DisplayText" : "Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop", "Text" : "", "Mnemonic" : "14"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "HEAD AND NECK SURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "Clean procedures include thyroidectomy and lymph node excisions."}, 
{"Row" :5, "Column" : 1, "Text" : "Clean-contaminated procedures include all procedures involving an incision"}, 
{"Row" :6, "Column" : 1, "Text" : "through the oral or pharyngeal mucosa. Clean-contaminated procedures include"}, 
{"Row" :7, "Column" : 1, "Text" : "esophagectomy."}, 
{"Row" :9, "Column" : 1, "Text" : "Clean procedures, no prosthesis:No antimicrobial prophylaxis recommended.", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Clean, prosthesis inserted: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Post-op doses are not indicated."}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Post-op doses are not indicated."}, 
{"Row" : 24, "Column" : 1, "Text" : "Clean-contaminated procedures** including cancer surgery: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "incision. ($) [R]"}, 
{"Row" : 28, "Column" : 1, "Text" : "Prophylaxis recommendations includes q6h for 3 doses post-op."}, 
{"Row" : 29, "Column" : 1, "Text" : "Please place post-op antimicrobial prophylaxis order after admission."}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op."}, 
{"Row" : 34, "Column" : 1, "Text" : "Please place post-op antimicrobial prophylaxis orders after admission."}, 
{"Row" : 36, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 40, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}, 
{"Row" : 41, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order after admission."}, 
{"Row" : 43, "Column" : 1, "Text" : "**Prophylaxis not indicated for tonsillectomy or functional endoscopic sinus"}, 
{"Row" : 44, "Column" : 1, "Text" : "procedures."}, 
{"Row" : 46, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 48, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Text" : "Each over 30 minutes beginning 60 minutes before incision"}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU SURG HERNIA REPAIR", "DisplayText" : "Hernia repair surgery with abdominal mesh " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "HERNIA REPAIR SURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "Surgical prophylaxis is recommended for hernioplasty and herniorrhaphy.For"}, 
{"Row" :5, "Column" : 1, "Text" : "patients known to be colonized with MRSA, add a single dose of vancomycin"}, 
{"Row" :6, "Column" : 1, "Text" : "to the preferred agent (cefazolin)."}, 
{"Row" :7, "Column" : 1, "Text" : "Antimicrobials are not indicated after incisions are closed."}, 
{"Row" : 11, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "For patients colonized with MRSA *ADD* Vancomycin in addition to cefazolin: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for patient with beta lactam allergy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 24, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" :9, "Column" : 1, "Item" : "ORZ GMENU DVT PROPHYLAXIS", "DisplayText" : "DVT Prophylaxis", "Text" : "DVT prophylaxis orders", "Mnemonic" : "3"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU SURG INTERVENTIONAL RADIOLOGY", "DisplayText" : "Interventional Radiology" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "NEUROSURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy or IF MRSA concern: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "References"}, 
{"Row" : 16, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 17, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 18, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}, 
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophy"}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU SURG NEUROSURGERY", "DisplayText" : "Neurosurgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "NEUROSURGERY"}, 
{"Row" :4, "Column" : 1, "Text" : "Risk factors for postoperative infections following neurologic procedures"}, 
{"Row" :5, "Column" : 1, "Text" : "include diabetes, procedure duration longer than two to four hours, placement"}, 
{"Row" :6, "Column" : 1, "Text" : "of a foreign body, repeat surgery, emergency surgery, cerebrospinal fluid"}, 
{"Row" :7, "Column" : 1, "Text" : "(CSF) leak, postoperative intracranial pressure monitoring or presence of a"}, 
{"Row" :8, "Column" : 1, "Text" : "ventricular drain for more than five days postoperatively, and concurrent or"}, 
{"Row" :9, "Column" : 1, "Text" : "prior infection of an incision or shunt."}, 
{"Row" : 11, "Column" : 1, "Text" : "In spinal surgery, the infection rate after conventional lumbar discectomy is"}, 
{"Row" : 12, "Column" : 1, "Text" : "low, but due to the severe consequences of postoperative infection at this site"}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial prophylaxis is recommended. Infection rates are higher after"}, 
{"Row" : 14, "Column" : 1, "Text" : "prolonged spinal surgery or spinal procedures involving fusion or insertion of"}, 
{"Row" : 15, "Column" : 1, "Text" : "foreign material, and antimicrobial prophylaxis is also recommended."}, 
{"Row" : 17, "Column" : 1, "Text" : "Antimicrobial prophylaxis is warranted for patients undergoing clean craniotomy"}, 
{"Row" : 18, "Column" : 1, "Text" : "CSF shunt procedures, or intrathecal pump placement."}, 
{"Row" : 20, "Column" : 1, "Text" : "For all other neurosurgical procedures, antimicrobial prophylaxis is not"}, 
{"Row" : 21, "Column" : 1, "Text" : "indicated."}, 
{"Row" : 23, "Column" : 1, "Text" : "Cefazolin is preferred for most patients as it penetrates into the cerebrospinal"}, 
{"Row" : 24, "Column" : 1, "Text" : "fluid and is more active than vancomycin against susceptible staphylococci."}, 
{"Row" : 25, "Column" : 1, "Text" : "Vancomycin should be used when the patient is colonized or has been recently"}, 
{"Row" : 26, "Column" : 1, "Text" : "infected with methicillin-resistant Staphylococcus aureus.Consult Neurosurgery"}, 
{"Row" : 27, "Column" : 1, "Text" : "or Infectious Diseases for more information."}, 
{"Row" : 29, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy or IF MRSA concern: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "References"}, 
{"Row" : 41, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 42, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 43, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 40, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophy"}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "[Click here] Beta-lactam allergy assessment", "Mnemonic" : "8"}
]},
{"Name" : "ORZID2 GMENU SURG OPHTHALMIC SURG", "DisplayText" : "Ophthalmic surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN (VIGAMOX) 0.5% EYE DROPS CATARACT SURGERY", "DisplayText" : "Moxifloxacin 0.5% Eye Drops Cataract Surgery (Dose: 0.5mg/0.1ml)", "Text" : "Moxifloxacin 0.5% Eye Drops INTRACAMERAL for Cataract Surgery (0.5mg/0.1ml)", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "OPHTHALMIC SURGERY"}, 
{"Row" :5, "Column" : 1, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before"}, 
{"Row" :6, "Column" : 1, "Text" : "procedures."}, 
{"Row" :8, "Column" : 1, "Text" : "Cataract Surgery", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Intracameral moxifloxacin is recommended for use to reduce the risk of"}, 
{"Row" : 10, "Column" : 1, "Text" : "post-operative endophthalmitis after cataract surgery only in those patients"}, 
{"Row" : 11, "Column" : 1, "Text" : "at highest risk of infection, including the following: "}, 
{"Row" : 12, "Column" : 1, "Text" : "* Patients with prior intravitreal injections"}, 
{"Row" : 13, "Column" : 1, "Text" : "* Immunosuppressed patients"}, 
{"Row" : 14, "Column" : 1, "Text" : "* Patients with significant ocular surface eyelid disease"}, 
{"Row" : 15, "Column" : 1, "Text" : "* Complication occurs during surgery (i.e. capusle rupture, vitreous loss)"}, 
{"Row" : 16, "Column" : 1, "Text" : "* Other possible high risk situations as they arise but not listed above"}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Arshinoff S., J Cataract Refract Surg, (2016) 42:1730-1741"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"}
]},
{"Name" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "DisplayText" : "Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX VANCO + CEFUROXIME ALBC SPACER ORTHO", "Text" : "Cefuroxime and vancomycin ALBC order set", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX VANCO + AZTREONAM ALBC SPACER ORTHO", "Text" : "Aztreonam and vancomycin ALBC order set", "Mnemonic" : "6"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX ALBC ORTHOPEDIC HYPERLINK", "DisplayText" : "Orthopedic ALBC protocol", "Text" : "Select here for full protocol", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "MVAHCS Protocol for Antibiotic Loaded Bone Cement (ALBC) for", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Treatment of Periprosthetic Hip and Knee Joint Infections", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patient Classification: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "No beta-lactam allergy: gram-positive and/or non-pseudomonas"}, 
{"Row" :8, "Column" : 1, "Text" : "gram-negative infection"}, 
{"Row" : 11, "Column" : 1, "Text" : "Patient Classification: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Beta-lactam allergy, any infecting organism OR No beta-lactam allergy,"}, 
{"Row" : 13, "Column" : 1, "Text" : "but with documented pseudomonas infection"}, 
{"Row" : 16, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "MVAHCS Protocol for Use of Antibiotic Loaded Cement (ALBC) for Treatment of"}, 
{"Row" : 18, "Column" : 1, "Text" : "Periprosthetic Hip and Knee Joint Infections at The Minneapolis VA"}, 
{"Row" : 19, "Column" : 1, "Text" : "Medical Center, July 2017"}
]},
{"Name" : "ORZID2 GMENU SURG ORTHO SURG JOINT ARTHRO", "DisplayText" : "Orthopedic surgery, including joint arthroplasty" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "12"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "14"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "18"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "20"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "22"},
{"Row" : 78, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "26"},
{"Row" : 84, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "28"},
{"Row" : 92, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "30"},
{"Row" : 98, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "34"},
{"Row" :104, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "36"},
{"Row" :3, "Column" : 1, "Text" : "ORTHOPAEDIC SURGERY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis is not recommended for most clean procedures,"}, 
{"Row" :6, "Column" : 1, "Text" : "including knee, hand or foot procedures, arthroscopy, or other procedures"}, 
{"Row" :7, "Column" : 1, "Text" : "without implantation of foreign materials."}, 
{"Row" :9, "Column" : 1, "Text" : "Prophylaxis is indicated for joint replacement, internal fixation, or hip"}, 
{"Row" : 10, "Column" : 1, "Text" : "fracture repair.Open fractures should be treated as infected."}, 
{"Row" : 12, "Column" : 1, "Text" : "Cefazolin is preferred for prophylaxis, as it is more active than vancomycin"}, 
{"Row" : 13, "Column" : 1, "Text" : "against susceptible staphylococci, the most common surgical pathogens."}, 
{"Row" : 14, "Column" : 1, "Text" : "Vancomycin should be used when methicillin-resistant Staphylococcus aureus"}, 
{"Row" : 15, "Column" : 1, "Text" : "infection, in patients who are colonized or were recently infected with"}, 
{"Row" : 16, "Column" : 1, "Text" : "methicillin-resistant Staphylococcus aureus."}, 
{"Row" : 18, "Column" : 1, "Text" : "Prophylaxis beyond 24 hours is not supported by current data and guidelines."}, 
{"Row" : 19, "Column" : 1, "Text" : "Longer durations provide no additional benefit and are associated with"}, 
{"Row" : 20, "Column" : 1, "Text" : "side effects, increased costs, and bacterial resistance."}, 
{"Row" : 21, "Column" : 1, "Text" : "Also, there is no evidence of benefit of antimicrobial administration until"}, 
{"Row" : 22, "Column" : 1, "Text" : "all drains or catheters are removed."}, 
{"Row" : 24, "Column" : 1, "Text" : "Clean operations involving hand, knee, or foot and NOT involving implantation", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "of foreign materials: (Select below)", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Prophylaxis for Total Joint Replacement", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}, 
{"Row" : 32, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 33, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 39, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 40, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 42, "Column" : 1, "Text" : "Known MRSA colonization: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 45, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 46, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 48, "Column" : 1, "Text" : "Prophylaxis for Hip Fracture Repair: ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}, 
{"Row" : 52, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 53, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 55, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 59, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 60, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 62, "Column" : 1, "Text" : "Known MRSA colonization: "}, 
{"Row" : 64, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 65, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 66, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 68, "Column" : 1, "Text" : "Prophylaxis for Implantation of Internal Fixation Devices (e.g. nails, screws,", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "plates, wires): ", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 72, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}, 
{"Row" : 73, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 74, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 76, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 79, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 80, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 81, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 83, "Column" : 1, "Text" : "Known MRSA colonization: "}, 
{"Row" : 85, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 86, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 87, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 89, "Column" : 1, "Text" : "Prophylaxis for Orthopedic Spinal Procedures with and without instrumentation", "Header" : 1}, 
{"Row" : 90, "Column" : 1, "Text" : "(e.g. rods, plates): ", "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 93, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}, 
{"Row" : 94, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" : 95, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" : 97, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 99, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" :100, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" :101, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" :103, "Column" : 1, "Text" : "Known MRSA colonization: "}, 
{"Row" :105, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" :106, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders"}, 
{"Row" :107, "Column" : 1, "Text" : "AFTER patient is admitted."}, 
{"Row" :109, "Column" : 1, "Text" : "References: "}, 
{"Row" :110, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" :111, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013, vol 70 pages 195-283"}
]},
{"Name" : "ORZID2 GMENU SURG OTHER PROCEDURES", "DisplayText" : "Other Procedures" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "OTHER PROCEDURES"}, 
{"Row" :5, "Column" : 1, "Text" : "In view of the small number of wound infections that would be prevented by"}, 
{"Row" :6, "Column" : 1, "Text" : "systemic antimicrobial prophylaxis the risks outweigh benefits for patients who"}, 
{"Row" :7, "Column" : 1, "Text" : "will have cardiac catheterization, varicose vein surgery, most dermatologic and"}, 
{"Row" :8, "Column" : 1, "Text" : "plastic surgery, arterial puncture, thoracentesis, paracentesis, repair of"}, 
{"Row" :9, "Column" : 1, "Text" : "simple lacerations, outpatient treatment of burns, dental extractions, or root"}, 
{"Row" : 10, "Column" : 1, "Text" : "canal therapy."}, 
{"Row" : 12, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 17, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}
]},
{"Name" : "ORZID2 GMENU SURG PLASTIC SURGERY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PLASTIC SURGERY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis is not recommended for most clean procedures in"}, 
{"Row" :6, "Column" : 1, "Text" : "patients without additional postoperative infection risk factors."}, 
{"Row" :7, "Column" : 1, "Text" : "Risk factors that increase the risk of postoperative infectious complications"}, 
{"Row" :8, "Column" : 1, "Text" : "for plastic surgery procedures include implants, skin irradiation before the"}, 
{"Row" :9, "Column" : 1, "Text" : "procedure, and procedures below the waist."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial prophylaxis is recommended for clean-contaminated procedures,"}, 
{"Row" : 12, "Column" : 1, "Text" : "breast cancer procedures, and clean procedures with risk factors. A single"}, 
{"Row" : 13, "Column" : 1, "Text" : "preoperative dose is recommended."}, 
{"Row" : 15, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Clean with risk factors or clean-contaminated: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred Prophylaxis: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "($) [R]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 28, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 30, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 32, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 33, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}
]},
{"Name" : "ORZID2 GMENU SURG PODIATRY", "DisplayText" : "Podiatry Antimicrobial Surgical Prophylaxis Orders" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "[Select here] No antimicrobial prophylaxis recommended for procedure/surgery", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "8"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "12"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "14"},
{"Row" : 10, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 21, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 22, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 24, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 25, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}, 
{"Row" :3, "Column" : 1, "Text" : "Podiatry Surgery", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Known MRSA colonization: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "DisplayText" : "Surgical wound classification and antimicrobial prophylaxis...", "Text" : "[Select here] Surgical wound classification and prophlaxis recommendations", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE PODIATRY ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR PODIATRY ABX", "Text" : "[Select here] No antimicrobial prophylaxis, already on concurrent antimicrobials", "Mnemonic" : "7"},
{"Row" :6, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select appropriate order below: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG POST-OP WND INFECT", "DisplayText" : "Post-operative wound infection" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG W/I 48HRS PROCEDURE", "DisplayText" : "Patients with signs of infection WITHIN 48 HOURS of procedure", "Text" : "Patients with signs of infection WITHIN 48 HOURS of procedure", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU SURG 48HRS AFTER PROC", "DisplayText" : "Patients with signs of infection 48 HOURS OR MORE after procedure", "Text" : "Patients with signs of infection 48 HOURS OR MORE after procedure", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "POST-OPERATIVE WOUND INFECTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Surgical site infections are categorized by the extent of tissues involved."}, 
{"Row" :6, "Column" : 1, "Text" : "Superficial incisional infections involve only the subcutaneous space and occur"}, 
{"Row" :7, "Column" : 1, "Text" : "within 30 days of operation.Deep incisional infections involve deep layers of"}, 
{"Row" :8, "Column" : 1, "Text" : "soft tissue, such as fascia and muscle, and occur within 30 days of operation,"}, 
{"Row" :9, "Column" : 1, "Text" : "or within 1 year of operation if prosthetic material was inserted.Organ/space"}, 
{"Row" : 10, "Column" : 1, "Text" : "infections involve anatomical areas other than the incisional wound that were"}, 
{"Row" : 11, "Column" : 1, "Text" : "opened or manipulated during operation.Organ/space infections should be"}, 
{"Row" : 12, "Column" : 1, "Text" : "treated as infections of the relevant area of the anatomy.Return to the main"}, 
{"Row" : 13, "Column" : 1, "Text" : "page and choose the pertinent organ system for advice on management of these"}, 
{"Row" : 14, "Column" : 1, "Text" : "infections."}, 
{"Row" : 16, "Column" : 1, "Text" : "Post-operative wound infections usually occur between 2 and 30 days after the"}, 
{"Row" : 17, "Column" : 1, "Text" : "operation.Infections within 48 hours of the surgery are uncommon, but are"}, 
{"Row" : 18, "Column" : 1, "Text" : "serious when they do occur.Symptoms commonly begin to appear no sooner than 5"}, 
{"Row" : 19, "Column" : 1, "Text" : "days after the operation and may take up to 2 weeks to appear."}
]},
{"Name" : "ORZID2 GMENU SURG PROPHYL GENRL INFO", "DisplayText" : "Surgical prophylaxis general information" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SURGICAL PROPHYLAXIS COMMON PRINCIPLES"}, 
{"Row" :6, "Column" : 1, "Text" : "Potential pathogens are introduced into normally sterile areas of the body"}, 
{"Row" :7, "Column" : 1, "Text" : "during most surgical procedures.The purpose of antimicrobial prophylaxis is to"}, 
{"Row" :8, "Column" : 1, "Text" : "reduce the intraoperative microbial burden so that local host defenses can"}, 
{"Row" :9, "Column" : 1, "Text" : "eliminate microorganisms and prevent disease.Prophylaxis cannot be expected to"}, 
{"Row" : 10, "Column" : 1, "Text" : "sterilize tissues."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial agent for surgical prophylaxis should be: "}, 
{"Row" : 13, "Column" : 1, "Text" : "1. active against the pathogens most likely to contaminate the surgical site"}, 
{"Row" : 14, "Column" : 1, "Text" : "2. given in an appropriate dosage and at a time that ensures adequate serum"}, 
{"Row" : 15, "Column" : 1, "Text" : "and tissue concentrations during the period of potential contamination"}, 
{"Row" : 16, "Column" : 1, "Text" : "3. safe, and"}, 
{"Row" : 17, "Column" : 1, "Text" : "4. administered for the shortest effective period to minimize adverse"}, 
{"Row" : 18, "Column" : 1, "Text" : "effects, the development of resistance, and costs."}, 
{"Row" : 20, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 22, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 24, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter 2012 Vol 10 pages 73-77"}
]},
{"Name" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "DisplayText" : "Doses and Redosing of prophylactic antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Recommended Doses and Redosing Interval", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Existing renal or hepatic dysfunction: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "for single dose, no modification usually necessary."}, 
{"Row" :9, "Column" : 1, "Text" : "ANTIMICROBIAL", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Ampicillin", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Ampicillin sulbactam", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Aztreonam", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Cefazolin", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Cefuroxime", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Cefoxitin", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Cefotetan", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Ceftriaxone", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Ciprofloxacin", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Clindamycin", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Gentamicin", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Levofloxacin", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Metronidazole", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Piperacilln Tazobactam", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Vancomycin", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Am J Health-Syst Pharm. 2013, 70: 195-283", "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "Select for Gentamicin doses", "Mnemonic" : "2"},
{"Row" : 42, "Column" : 2, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Select for Vancomycin doses", "Mnemonic" : "4"},
{"Row" :9, "Column" : 2, "Text" : "RECOMMENDED DOSE", "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "3 grams", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Text" : "Recommend 3gm dose patients >=120kg", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "1.5 grams", "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 26, "Column" : 2, "Text" : "2 grams", "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Text" : "400 mg", "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Text" : "900 mg", "Header" : 1}, 
{"Row" : 32, "Column" : 2, "Text" : "5mg/kg based on dosing wt*", "Header" : 1}, 
{"Row" : 35, "Column" : 2, "Text" : "500 mg", "Header" : 1}, 
{"Row" : 37, "Column" : 2, "Text" : "500 mg", "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Text" : "3.375 grams", "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Text" : "15mg/kg based on dosing wt", "Header" : 1}, 
{"Row" : 45, "Column" : 2, "Text" : "Doses based on Dosing Weight (DW)*", "Header" : 1}, 
{"Row" : 46, "Column" : 2, "Text" : "*Calculate Dosing Weight (DW)", "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Text" : "DW = IBW + 0.4 (ABW - IBW)", "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Text" : "IBW=Ideal Body WtABW=Actual Body Wt", "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Text" : "Male IBW (kg)=50+2.3 * (Ht-60inches)", "Header" : 1}, 
{"Row" : 50, "Column" : 2, "Text" : "Female IBW (kg)=45.5+2.3 * (Ht-60inches)", "Header" : 1}, 
{"Row" :1, "Column" : 3, "Text" : "Antimicrobial Surgical Prophylaxis", "Header" : 1}, 
{"Row" :9, "Column" : 3, "Text" : "REDOSING INTERVAL**", "Header" : 1}, 
{"Row" : 10, "Column" : 3, "Text" : "(from initiation of preop dose)", "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 15, "Column" : 3, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 17, "Column" : 3, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 20, "Column" : 3, "Text" : "4 hours", "Header" : 1}, 
{"Row" : 22, "Column" : 3, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 24, "Column" : 3, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 26, "Column" : 3, "Text" : "N/A", "Header" : 1}, 
{"Row" : 28, "Column" : 3, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 30, "Column" : 3, "Text" : "6 hours", "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Text" : "Do not redose", "Header" : 1}, 
{"Row" : 37, "Column" : 3, "Text" : "12 hours", "Header" : 1}, 
{"Row" : 39, "Column" : 3, "Text" : "2 hours", "Header" : 1}, 
{"Row" : 41, "Column" : 3, "Text" : "12 hours", "Header" : 1}, 
{"Row" : 43, "Column" : 3, "Text" : "**For those marked N/A--", "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Text" : "based on typical case length, for", "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Text" : "unusually long procedures,", "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Text" : "redosing may be needed.", "Header" : 1}, 
{"Row" : 32, "Column" : 3, "Text" : "Do not redose", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "**For those marked N/A -", "Header" : 1}, 
{"Row" :5, "Column" : 3, "Text" : "based on typical case length, for", "Header" : 1}, 
{"Row" :6, "Column" : 3, "Text" : "unusually long procedures,", "Header" : 1}, 
{"Row" :7, "Column" : 3, "Text" : "redosing may be needed.", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "John Hopkins Antibiotic Guide Online Oct2021", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG SPINAL CORD STIMULATOR TRIAL", "DisplayText" : "Spinal Cord Stimulator Trial Procedure Antimicrobial Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB ONCE PRE-PROCEDURE PAIN CLINIC", "DisplayText" : "Cefazolin 2 GM IVPB Once administer 60 minutes prior to procedure ($) [R]", "Text" : "", "Mnemonic" : "6"},
{"Row" :6, "Column" : 1, "Text" : "Preferred Prophylaxis: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patient with beta lactam allergy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 22, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 24, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter 2012 vol 10 pages 73-77"}, 
{"Row" :7, "Column" : 1, "Text" : "For patients weight < 120 kg: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "For patients weight >/= 120 kg: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Pain Clinic Antimicrobial Prophylaxis Pre-procedure Orders", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Spinal Cord Stimulator Trial"}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3GM IV ONCE PRE-PROCEDURE PAIN CLINIC", "DisplayText" : "Cefazolin 3 GM IVPB Once administer 60 minutes prior to procedure($) [R]", "Text" : "", "Mnemonic" : "8"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin Weight Based Dosing IVPB x1 Dose", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "10"},
{"Row" : 17, "Column" : 1, "Text" : "ADD Vancomycin with Cefazolin (above) for MRSA positive nares + risk factors", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin Weight Based Dosing IVPB x1 Dose", "Mnemonic" : "14"},
{"Row" : 16, "Column" : 1, "Text" : "MRSA positive nares + risk factors: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG SURGICAL SITE INFECT" , "Term1" : "Post-operative wound infection " , "Term2" : "Surgical site infection " , "Term3" : "Wound infection, post-op", "DisplayText" : "Surgical Site Infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU SURG POST-OP WND INFECT", "DisplayText" : "Post-operative wound infection", "Text" : "Post-operative wound infection", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "DisplayText" : "Mediastinitis", "Text" : "Mediastinitis", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatologic Infections", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "++SURGICAL SITE INFECTION++", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "++SURGICAL PROPHYLAXIS FOR DERMATOLGY/POST-OP SKIN INFECTION++", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG THORACIC POSTOP", "DisplayText" : "THORACIC POSTOPERATIVE PROPHYLAXIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "DisplayText" : "CIED Post Op", "Text" : "CIED Surgery Postoperative Prophylaxis", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU SURG CV POSTOP", "DisplayText" : "CV POSTOPERATIVE PROPHYLAXIS", "Text" : "CV Surgery Postoperative Prophylaxis", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM METRONIDAZOLE 500MG 2 DOSES POST OP", "DisplayText" : "Cefazolin 2gm IVPB Metronidazole 500mg IV 2 doses post op", "Text" : "Cefazolin 2 gm IV q8h x 2 doses post-op ($) [R] <AND> metronidazole 500 mg IV", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CLINDAM 900MG IV Q8H X2DOSES POSTOP", "DisplayText" : "Clindamycin 900mg IV q8h x2doses postop", "Text" : "Clindamycin 900 mg IV q8h x 2 doses post-op ($$)", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "DisplayText" : "VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV (pharmacy to dose) q12h x 1 dose post-op ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "THORACIC SURGERY POST-OPERATIVE ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Place post-op IV antimicrobial prophylaxis orders after admission to ward."}, 
{"Row" :6, "Column" : 1, "Text" : "Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations"}, 
{"Row" :7, "Column" : 1, "Text" : "longer than 24 hours have not been shown effective in preventing cardiothoracic"}, 
{"Row" :8, "Column" : 1, "Text" : "surgical site infections. There is no benefit to continuing antimicrobial"}, 
{"Row" :9, "Column" : 1, "Text" : "prophylaxis until all indwelling drains and intravascular catheters are removed."}, 
{"Row" : 11, "Column" : 1, "Text" : "For CIED surgery postoperative antimicrobial prophylaxis click link below: "}, 
{"Row" : 14, "Column" : 1, "Text" : "For CV surgery (Open Heart) postoperative prophylaxis click link below: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Esophageal Surgical Procedures Postoperative Prophylaxis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "q8h x 2 doses post-op ($) [R]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative for patient with cephalosporin allergy"}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for patient colonized or recently infected with MRSA"}, 
{"Row" : 27, "Column" : 1, "Text" : "Non-Esophageal Thoracic Procedures Postoperative Prophylaxis", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures"}, 
{"Row" : 29, "Column" : 1, "Text" : "including lobectomy, pneumonectomy, lung resection and thoracotomy."}, 
{"Row" : 30, "Column" : 1, "Text" : "No postoperative antibiotic prophylaxis is recommended"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in"}, 
{"Row" : 36, "Column" : 1, "Text" : "Surgery, Am J Health-Syst Pharm (2013) 70:195-283"}
]},
{"Name" : "ORZID2 GMENU SURG THORACIC SURGERY", "DisplayText" : "Thoracic surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO WT BASED IV 30MIN METRON 500MG IV X1", "DisplayText" : "Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop", "Text" : "", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "THORACIC SURGERY (INCLUDES SECTION ON ESOPHAGEAL PROCEDURES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Esophageal Surgical Procedures: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Prophylaxis: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op."}, 
{"Row" : 10, "Column" : 1, "Text" : "Please place post-op antimicrobial prophylaxis orders after admission."}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "($) [H,O]"}, 
{"Row" : 15, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op."}, 
{"Row" : 16, "Column" : 1, "Text" : "Please place post-op antimicrobial prophylaxis order after admission."}, 
{"Row" : 17, "Column" : 1, "Text" : "___________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Thoracic surgery (except for esophageal procedures): ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures,"}, 
{"Row" : 20, "Column" : 1, "Text" : "including lobectomy, pneumonectomy, lung resection and thoracotomy."}, 
{"Row" : 21, "Column" : 1, "Text" : "No post-operative doses are recommended.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Prophylaxis", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "($) [H,O]"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for patient colonized or recently infected with MRSA", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 36, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 38, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical"}, 
{"Row" : 39, "Column" : 1, "Text" : "Letter 2012 Vol 10 pages 73-77"}, 
{"Row" :8, "Column" : 1, "Text" : "beginning 60 minutes before incision"}
]},
{"Name" : "ORZID2 GMENU SURG TIMING DOSING PROPHYL ABX", "DisplayText" : "Timing and dosing (including re-dosing) of prophylatic antimicrobials " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "DisplayText" : "Doses and Redosing of prophylactic antibiotics", "Text" : "Doses and Redosing Recommendations for Common Antimicrobials", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "TIMING AND DOSING (INCLUDING RE-DOSING) OF PROPHYLACTIC ANTIMICROBIALS"}, 
{"Row" :5, "Column" : 1, "Text" : "For optimal prevention, antimicrobial concentrations should be above the minimal"}, 
{"Row" :6, "Column" : 1, "Text" : "inhibitory concentration (MIC) of potential pathogens from initial incision"}, 
{"Row" :7, "Column" : 1, "Text" : "until closure."}, 
{"Row" :9, "Column" : 1, "Text" : "There is no advantage to giving post-operative doses. Despite a lack of"}, 
{"Row" : 10, "Column" : 1, "Text" : "demonstrated benefit, post-operative doses are sometimes given in clinical"}, 
{"Row" : 11, "Column" : 1, "Text" : "practice.If post-operative doses are given, they should be discontinued by 24"}, 
{"Row" : 12, "Column" : 1, "Text" : "hours after closure of the incision."}, 
{"Row" : 14, "Column" : 1, "Text" : "When prophylaxis consists of a single dose as should be the case in the majority"}, 
{"Row" : 15, "Column" : 1, "Text" : "of procedures, adjustment for renal or hepatic dysfunction is not necessary."}, 
{"Row" : 17, "Column" : 1, "Text" : "The optimal time for administration of preoperative doses is 30 to"}, 
{"Row" : 18, "Column" : 1, "Text" : "60 minutes before surgical incision for most antimicrobials."}, 
{"Row" : 19, "Column" : 1, "Text" : "Infusions of drugs like fluoroquinolones and vancomycin that require longer"}, 
{"Row" : 20, "Column" : 1, "Text" : "infusion times should begin 60 to 120 minutes before first incision."}, 
{"Row" : 22, "Column" : 1, "Text" : "During procedures that last so long that concentrations might fall below the"}, 
{"Row" : 23, "Column" : 1, "Text" : "MICs of potential pathogens, repeated doses of antimicrobials should be given."}, 
{"Row" : 24, "Column" : 1, "Text" : "Re-dosing may also be warranted if prolonged or excessive bleeding"}, 
{"Row" : 25, "Column" : 1, "Text" : "occurs."}, 
{"Row" : 30, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 31, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 33, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter 2012 Vol 10 pages 73-77"}
]},
{"Name" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "DisplayText" : "Urological procedures " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX AUA SURGERY PROPHYL", "DisplayText" : "<Click here> AUA Surgery Prophylaxis Guidelines", "Text" : "<Hyperlink> AUA Surgical Prophylaxis Guidelines", "Mnemonic" : "4"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Text" : "Nitrofurantoin SA 100 MG po Q12H ($) [R,O]-INPATIENT ORDER", "Mnemonic" : "6"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]-OUTPATIENT ORDER", "Mnemonic" : "8"},
{"Row" : 47, "Column" : 1, "Item" : "PSJZID CIPROFL 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500mg po q12h (Var)", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]-INPATIENT ORDER", "Mnemonic" : "14"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]-OUTPATIENT ORDER**ADJUST QUANTITY**", "Mnemonic" : "16"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida urinary tract infection", "Text" : "Candida urinary tract infection- INPATIENT", "Mnemonic" : "18"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Candida urinary tract infection- OUTPATIENT", "Mnemonic" : "20"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "22"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY", "Text" : "Link to prophylaxis for TRUSP procedure", "Mnemonic" : "26"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGY SURGERY (OPEN,ROBOTIC,LAP)", "Text" : "Link to Urology Surgery Antimicrobial Prophylaxis (OPEN,ROBOTIC,LAP)", "Mnemonic" : "28"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "30"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "32"},
{"Row" : 80, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "34"},
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "36"},
{"Row" : 88, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "38"},
{"Row" : 90, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "40"},
{"Row" : 96, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "42"},
{"Row" : 98, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "44"},
{"Row" :104, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "46"},
{"Row" :106, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "48"},
{"Row" :112, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "50"},
{"Row" :114, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Mnemonic" : "52"},
{"Row" :3, "Column" : 1, "Text" : "UROLOGICAL PROCEDURES"}, 
{"Row" :5, "Column" : 1, "Text" : "Though uncommon, most post-operative infections after urological surgery occur"}, 
{"Row" :6, "Column" : 1, "Text" : "when 1) a procedure is done in a person with significant bacteriuria and the"}, 
{"Row" :7, "Column" : 1, "Text" : "urinary mucosa is cut, 2) fecal flora enter tissues when the colon or rectal"}, 
{"Row" :8, "Column" : 1, "Text" : "mucosa is cut, or 3) skin flora enter tissues when the skin is cut."}, 
{"Row" :9, "Column" : 1, "Text" : "Antimicrobial prophylaxis is given to prevent symptomatic infection after"}, 
{"Row" : 10, "Column" : 1, "Text" : "procedures with these characteristics."}, 
{"Row" : 11, "Column" : 1, "Text" : "Patient-related factors affecting host response to surgical infections", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "In situations when the risk benefit ratio supporting antimicrobial"}, 
{"Row" : 13, "Column" : 1, "Text" : "prophylaxis is not clear, certain risk factors may tip the balance in favor"}, 
{"Row" : 14, "Column" : 1, "Text" : "of prophylaxis. These risk factors include: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Advanced age: Anatomic anomalies of the urinary tract: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Smoking: Chronic corticosteroid use: Immunodeficiency: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Externalized catheters: Colonized endogenous - exogenous material: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Distant coexistent infection: Prolonged hospitalization"}, 
{"Row" : 20, "Column" : 1, "Text" : "When surgical prophylaxis is recommended, a single dose of the appropriate"}, 
{"Row" : 21, "Column" : 1, "Text" : "antibiotic should be administered prior to the urological procedure"}, 
{"Row" : 22, "Column" : 1, "Text" : "UNLESS otherwise noted."}, 
{"Row" : 23, "Column" : 1, "Text" : "The recommended antimicrobial prophylaxis is based on the incision site.An"}, 
{"Row" : 24, "Column" : 1, "Text" : "antimicrobial active against pathogens likely to be present at the site and"}, 
{"Row" : 25, "Column" : 1, "Text" : "to cause post-operative wound infection is needed."}, 
{"Row" : 27, "Column" : 1, "Text" : "Recommendations are based on AUA guidelines", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Obtain urine culture for invasive or complex urological procedures: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "For invasive or complex urological procedures, whenever possible,"}, 
{"Row" : 32, "Column" : 1, "Text" : "please obtain an urine culture a few days before the procedure."}, 
{"Row" : 34, "Column" : 1, "Text" : "If bacteriuria or fungiuria is present, select an antimicrobial that will be"}, 
{"Row" : 35, "Column" : 1, "Text" : "be effective against organisms that have been isolated."}, 
{"Row" : 36, "Column" : 1, "Text" : "If prosthetic material is to be placed, test of cure recommended."}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment of bacteriuria before procedures in which urinary mucosa will be cut", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Treat for 3 to 7 days."}, 
{"Row" : 46, "Column" : 1, "Text" : "If known susceptibility to a fluoroquinolone: "}, 
{"Row" : 50, "Column" : 1, "Text" : "Treatment of funguria before procedures in which urinary mucosa will be cut", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Prevention of Prosthetic Joint Infection Before Genitourinary Procedures", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "Recommended prophylaxis TRUSP (transrectal ultrasound biopsy prostate)", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Recommended antimicrobial prophylaxis for Urology Surgery (Open,Robotic,Lap)", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "Recommended antimicrobial prophylaxis for Lower Tract Instrumentation", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Procedure: Removal of external urinary catheter", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "Prophylaxis indicated for patients with higher risk of developing urinary"}, 
{"Row" : 69, "Column" : 1, "Text" : "retention, such as BPH, or neurogenic bladder."}, 
{"Row" : 70, "Column" : 1, "Text" : "Also could be considered if risk factors."}, 
{"Row" : 71, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 73, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 75, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 77, "Column" : 1, "Text" : "Procedure: Cystography, urodynamic study, or simple cystourethrosocpy", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "Prophylaxis not usually indicated, could consider if risk factors."}, 
{"Row" : 79, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 81, "Column" : 1, "Text" : "Alternative for patients with beta lactam allergy: "}, 
{"Row" : 83, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 85, "Column" : 1, "Text" : "Procedure: Cystourethroscopy with manipulation OR Ureteroscopy", "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Text" : "Prophylaxis indicated for all procedures."}, 
{"Row" : 87, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 89, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" : 91, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" : 93, "Column" : 1, "Text" : "Procedure: Prostate brachytherapy or cyrotherapy", "Header" : 1}, 
{"Row" : 94, "Column" : 1, "Text" : "Prophylaxis indicated uncertain, assess individual case."}, 
{"Row" : 95, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 97, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" : 99, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" :101, "Column" : 1, "Text" : "Procedure: Shock-wave lithotripsy", "Header" : 1}, 
{"Row" :102, "Column" : 1, "Text" : "Prophylaxis indicated IF risk factors."}, 
{"Row" :103, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :105, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" :107, "Column" : 1, "Text" : "($) [R,O]"}, 
{"Row" :109, "Column" : 1, "Text" : "Procedure: Percutaneous renal surgery", "Header" : 1}, 
{"Row" :110, "Column" : 1, "Text" : "Prophylaxis indicated for all procedures."}, 
{"Row" :111, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :113, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" :115, "Column" : 1, "Text" : "($) [H,O] <AND> Gentamicin 5 mg/kg IV over 30 minutes beginning 60"}, 
{"Row" :116, "Column" : 1, "Text" : "minutes before incision ($) [R,O]"}, 
{"Row" :118, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" :119, "Column" : 1, "Text" : "Lightner DJ, et al. Best Practice Statement on Urologic Procedures"}, 
{"Row" :120, "Column" : 1, "Text" : "and Antimicrobial Prophylaxis, The Journal of Urology (2019)"}, 
{"Row" :122, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" :123, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "24"},
{"Row" : 43, "Column" : 1, "Item" : "PSJZID CEFADROXIL 1000MG PO Q12H", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R]", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] -INPATIENT ORDER", "Mnemonic" : "10"},
{"Row" : 44, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Cefadroxil 1000 mg PO BID ($) [R] -OUTPATIENT ORDER**ADJUST QUANTITY**", "Mnemonic" : "12"}
]},
{"Name" : "ORZID2 GMENU SURG UROLOGY NEW", "DisplayText" : "Urological procedures " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX AUA SURGERY PROPHYL", "DisplayText" : "<Click here> AUA Surgery Prophylaxis Guidelines", "Text" : "", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended order", "Mnemonic" : "6"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY", "Text" : "Link to outpatient menu", "Mnemonic" : "42"},
{"Row" : 54, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Lightner DJ, et al. Best Practice Statement on Urologic Procedures"}, 
{"Row" : 56, "Column" : 1, "Text" : "and Antimicrobial Prophylaxis, The Journal of Urology (2019)"}, 
{"Row" : 58, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 59, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 50, "Column" : 1, "Text" : "TRUSP Biopsy: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Implants: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Endoscopic procedures: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "If no prophylaxis recommended, enter order: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Urological Procedures", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Open/Robotic procedures: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "24"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Text" : "**Additional single agents: "}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING", "DisplayText" : "Gentamicin 5mg/kg Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "16"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN WT BASED IVPB GENTAMICIN 5MG/KG IV PREOP", "DisplayText" : "Cefazolin Weight Based IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "34"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG + GENTAMICIN 5MG/KG IV PREOP", "DisplayText" : "Vancomycin 15mg/kg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "38"},
{"Row" : 31, "Column" : 1, "Text" : "Alternative for cephalosporin allergy: "}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM AND GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Ampicillin 2gram IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CIPROFL 400MG IV ONCE SURG PREOP", "DisplayText" : "Ciprofloxacin 400mg IV ONCE Preop", "Text" : "", "Mnemonic" : "18"},
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV ONCE PREOP", "DisplayText" : "Fluconazole 400mg IV ONCE Preop", "Text" : "", "Mnemonic" : "22"},
{"Row" : 47, "Column" : 1, "Text" : "Soak Solution for Penile Implant prior to implantation in OR", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 50MG RIFAMPIN 500MG PENILE IMPLANT SOAK", "DisplayText" : "Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation", "Text" : "", "Mnemonic" : "40"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID CEFOXITIN 2GM IV ONCE PREOP", "DisplayText" : "Cefoxitin 2 gram IV ONCE Preop", "Text" : "", "Mnemonic" : "30"},
{"Row" : 35, "Column" : 1, "Text" : "Cystectomy/large bowel/vaginal procedures: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Text" : "Alternative for allergy to penicillin/cephalosporin: "}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "", "Mnemonic" : "26"},
{"Row" : 43, "Column" : 1, "Text" : "Alternative for cephalosporin allergy: "}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "", "Mnemonic" : "36"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "DisplayText" : "Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "28"},
{"Row" : 24, "Column" : 1, "Item" : "PSCZID CIPROFLOXACIN 500MG X1 GIVEN IN CLINIC", "DisplayText" : "Ciprofloxacin 500 mg po x1 give in clinic", "Text" : "", "Mnemonic" : "20"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 500MG IV ONCE SURG-PREOP", "DisplayText" : "Metronidazole 500mg IV ONCE Preop", "Text" : "", "Mnemonic" : "32"},
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID2 GMENU SURG UROLOGY SURGERY (OPEN,ROBOTIC,LAP)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophlaxis recommended", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN WT BASED IVPB GENTAMICIN 5MG/KG IV PREOP", "DisplayText" : "Cefazolin Weight Based IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop", "Text" : "", "Mnemonic" : "14"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 50MG RIFAMPIN 500MG PENILE IMPLANT SOAK", "DisplayText" : "Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation", "Text" : "Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation", "Mnemonic" : "18"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "DisplayText" : "Bowel/Colo-rectal Surgery", "Text" : "Link to Bowel Surgery", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "Urology Surgery Open, Robotic or Laparoscopic", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Surgery through skin without opening urinary tract", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Prophylaxis indicated IF risk factors."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" : 14, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 16, "Column" : 1, "Text" : "Vaginal surgery includes urethral sling procedures", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Prophylaxis indicated for all surgeries."}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy: "}, 
{"Row" : 22, "Column" : 1, "Text" : "($$) [H,O]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Surgery involving implanted prosthesis including penile prosthesis", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Prophylaxis indicated for all surgeries."}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy or history of MRSA: "}, 
{"Row" : 30, "Column" : 1, "Text" : "< AND > gentamicin 5mg/kg ($) [R,O] over 30 minutes beginning 60"}, 
{"Row" : 31, "Column" : 1, "Text" : "minutes before incision"}, 
{"Row" : 33, "Column" : 1, "Text" : "Soak Solution for Penile Implant prior to implantation in OR", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Urologic surgery with entry into bowel/intestines", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "(Note: updated order 7/2022 per OR pharmacist DM)"}
]},
{"Name" : "ORZID2 GMENU SURG VANCOMYCIN POST-OP SPECIFIC DOSING" , "Version" : "Minneapolis", "Contents" : [
{"Row" :5, "Column" : 1, "Text" : "Recommended Vancomycin Doses based on patient weight: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Weight less than 70 kg: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Weight equal/greater 70 kg and equal/less than 100 kg: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Weight greater than 100 kg: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1000MG POSTOP DOSE LESS 70KG", "DisplayText" : "Vancomycin 1000 mg IV q12h x1 dose post-op if allergy to PCN/Ceph/MRSA+", "Text" : "", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID VANCOMCYIN 1500 MG POSTOP DOSE 70-100KG", "DisplayText" : "Vancomycin 1500 mg IVq12h x1 dose post-op if allergy to PCN/Ceph/MRSA+", "Text" : "", "Mnemonic" : "12"},
{"Row" :4, "Column" : 1, "Text" : "POSTOP DOSE", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 2000 MG POSTOP DOSE GREATER 100KG", "DisplayText" : "Vancomycin 2000 mg IV q12h x1 dose post-op if allergy to PCN/Ceph/MRSA+", "Text" : "", "Mnemonic" : "14"}
]},
{"Name" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop" , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1000 MG IVPB DOSE LESS 70KG PREOP", "DisplayText" : "Vancomycin 1000 mg IV ONCE", "Text" : "", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1500 MG IVPB DOSE 70-100KG PREOP", "DisplayText" : "Vancomycin 1500 mg IV ONCE", "Text" : "", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 2000MG IVPB DOSE GREATER 100KG PREOP", "DisplayText" : "Vancomycin 2000 mg IV ONCE", "Text" : "", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "Recommended Vancomycin Preop Dose based on patient weight: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Weight <70 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Weight >100 kg: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Preop dose administer beginning 120 minutes before incision: "}, 
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX WEIGHT FOR ABX DOSING", "DisplayText" : "Last recorded weight", "Text" : "<Click here> Display patients last recorded weight", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Text" : "Weight 70-100 kg: ", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Text" : "VANCOMYCIN: ", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG VASCULAR SURG", "DisplayText" : "Vascular surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "DisplayText" : "NURSE GENERIC ORDER FOR ABX", "Text" : "*No antimicrobial prophylaxis recommended", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "DisplayText" : "Clindamycin 900mg iv once", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Mnemonic" : "8"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING", "DisplayText" : "Vancomycin Weight Based Dosing Preop", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "14"},
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID RIFAMPIN 600 MG VIAL FOR VASCULAR SURGERY", "DisplayText" : "Rifampin 600 mg & Sterile Water VIALS for Vascular Surgery for Vascular Surgery", "Text" : "Rifampin Vascular Graft Soak (600mg)", "Mnemonic" : "16"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Mnemonic" : "20"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "VASCULAR SURGERY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis is not recommended for some procedures, including"}, 
{"Row" :6, "Column" : 1, "Text" : "brachiocephalic procedures (e.g., carotid endarterectomy, brachial artery"}, 
{"Row" :7, "Column" : 1, "Text" : "repair) without implantation of prosthetic material."}, 
{"Row" :9, "Column" : 1, "Text" : "Antimicrobial prophylaxis is recommended in vascular procedures that involve"}, 
{"Row" : 10, "Column" : 1, "Text" : "implantation of prosthetic material and procedures for which there is greater"}, 
{"Row" : 11, "Column" : 1, "Text" : "risk of infection, such as aneurysm repair, thromboendarterectomy and vein"}, 
{"Row" : 12, "Column" : 1, "Text" : "bypass. Longer duration of antimicrobial prophylaxis therapy is warranted for"}, 
{"Row" : 13, "Column" : 1, "Text" : "graft placement."}, 
{"Row" : 15, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Prophylaxis for vascular procedures OTHER THAN graft placement* and procedures", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "involving the groin** (SEE BELOW FOR * AND **): ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "($$) [R]"}, 
{"Row" : 27, "Column" : 1, "Text" : "*Prophylaxis for graft placement procedures: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis orders."}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternative for beta lactam allergy or MRSA concern: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place"}, 
{"Row" : 36, "Column" : 1, "Text" : "post-op antimicrobial prophylaxis order."}, 
{"Row" : 38, "Column" : 1, "Text" : "Rifampin vascular graft soak for INFECTED graft", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "**Prophylaxis for procedures that involve the abdominal aorta or groin incision", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "due to the potential for gastrointestinal flora: ", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Alternative for beta lactam allergy or MRSA concern: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "<AND> gentamicin 5 mg/kg IV over 30 minutes ($) [R,O] beginning 60"}, 
{"Row" : 49, "Column" : 1, "Text" : "minutes before incision"}, 
{"Row" : 52, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis"}, 
{"Row" : 53, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283"}, 
{"Row" : 55, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 56, "Column" : 1, "Text" : "Medical Letter 2012 vol 10 pages 73-77"}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING", "DisplayText" : "Cefazolin Weight Based Dosing Preop", "Text" : "", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place"}
]},
{"Name" : "ORZID2 GMENU SURG W/I 48HRS PROCEDURE", "DisplayText" : "Patients with signs of infection WITHIN 48 HOURS of procedure " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections", "Text" : "Necrotizing infections", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "PATIENTS WITH SIGNS OF INFECTION WITHIN 48 HOURS OF PROCEDURE"}, 
{"Row" :5, "Column" : 1, "Text" : "Fever within 48 hours of procedure is usually due to anesthesia or other non-"}, 
{"Row" :6, "Column" : 1, "Text" : "infectious factors but Clostridium species and Streptococcus pyogenes can cause"}, 
{"Row" :7, "Column" : 1, "Text" : "early infections.Examine the wound of any patient with systemic signs of"}, 
{"Row" :8, "Column" : 1, "Text" : "infection, like fever, within 48 hours of surgery.If there are signs of"}, 
{"Row" :9, "Column" : 1, "Text" : "infection consider opening the wound.Obtain a STAT Gram stain and culture of"}, 
{"Row" : 10, "Column" : 1, "Text" : "any drainage. If the Gram stain shows evidence of streptococci or clostridia"}, 
{"Row" : 11, "Column" : 1, "Text" : "refer to the section on necrotizing infections.If signs of wound infection are"}, 
{"Row" : 12, "Column" : 1, "Text" : "absent seek an alternative source of the fever."}
]},
{"Name" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "DisplayText" : "Surgical wound classification and antimicrobial prophylaxis..." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "SURGICAL WOUND CLASSIFICATION AND ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS"}, 
{"Row" :5, "Column" : 1, "Text" : ">>Clean<<", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "A wound resulting from a procedure in which no inflammation or infection was"}, 
{"Row" :7, "Column" : 1, "Text" : "encountered and the respiratory, alimentary, genital, or uninfected urinary"}, 
{"Row" :8, "Column" : 1, "Text" : "tract was not entered.Clean wounds are closed at the end of surgery and if"}, 
{"Row" :9, "Column" : 1, "Text" : "drainage is necessary wounds are closed with drains in place."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial prophylaxis is usually not indicated.Exceptions are procedures"}, 
{"Row" : 12, "Column" : 1, "Text" : "in which prosthetic material will be inserted or for operations in which a"}, 
{"Row" : 13, "Column" : 1, "Text" : "surgical site infection would be catastrophic.These exceptions include most"}, 
{"Row" : 14, "Column" : 1, "Text" : "cardiac operations, joint replacement, revascularization procedures in legs, and"}, 
{"Row" : 15, "Column" : 1, "Text" : "most neurosurgical operations."}, 
{"Row" : 17, "Column" : 1, "Text" : ">>Clean contaminated<<", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Clean-contaminated wounds are those in which the respiratory, alimentary,"}, 
{"Row" : 19, "Column" : 1, "Text" : "genital, or urinary tracts are entered but there is no evidence of infection and"}, 
{"Row" : 20, "Column" : 1, "Text" : "there is no major break in technique.These include operations on the biliary"}, 
{"Row" : 21, "Column" : 1, "Text" : "tract, appendix, vagina, and oropharynx."}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrobial prophylaxis is indicated for most of these procedures."}, 
{"Row" : 25, "Column" : 1, "Text" : ">>Contaminated<<", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Contaminated wounds include an open, fresh, accidental wound, or operations with"}, 
{"Row" : 27, "Column" : 1, "Text" : "major breaks in sterile technique, gross spillage from the gastrointestinal"}, 
{"Row" : 28, "Column" : 1, "Text" : "tract, or incisions in which acute, non-purulent inflammation is encountered."}, 
{"Row" : 30, "Column" : 1, "Text" : "Antimicrobials are therapeutic and not prophylactic."}, 
{"Row" : 32, "Column" : 1, "Text" : ">>Dirty-Infected<<", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Dirty-infected wounds are old traumatic wounds with devitalized tissue and those"}, 
{"Row" : 34, "Column" : 1, "Text" : "that involve existing infection or perforated viscera.The organisms usually"}, 
{"Row" : 35, "Column" : 1, "Text" : "have been present in the operative field since before the operation."}, 
{"Row" : 37, "Column" : 1, "Text" : "Antimicrobials are therapeutic and not prophylactic."}, 
{"Row" : 41, "Column" : 1, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial"}, 
{"Row" : 42, "Column" : 1, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283"}, 
{"Row" : 44, "Column" : 1, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The"}, 
{"Row" : 45, "Column" : 1, "Text" : "Medical Letter 2012 Vol 10 pages 73-77"}
]},
{"Name" : "ORZID2 GMENU TEST", "DisplayText" : "TESTING " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "TEST1"}
]},
{"Name" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)" , "Term1" : "Ringworm " , "Term2" : "Tinea capitis", "DisplayText" : "Tinea Capitis (Ringworm)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "DisplayText" : "Terbinafine 250mg po qday", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "TINEA CAPITIS (RINGWORM)"}, 
{"Row" :4, "Column" : 1, "Text" : "Tinea capitis is a common fungal infection of the scalp and hair. It is"}, 
{"Row" :5, "Column" : 1, "Text" : "characterized by itchy, red, raised, scaly patches often sharply defined. The"}, 
{"Row" :6, "Column" : 1, "Text" : "redder margins than centers create impression of ring. Tinea capitis primarily"}, 
{"Row" :7, "Column" : 1, "Text" : "affects prepubescent children, but can affect people of any age."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat for 4 weeks."}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Tinea"}
]},
{"Name" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)" , "Term1" : "Tinea corporis " , "Term2" : "Tinea cruris " , "Term3" : "Tinea pedis", "DisplayText" : "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CREAM TOPICAL BID", "DisplayText" : "Clotrimazole 1% cream topical bid", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID TERBINAFINE 1% CREAM TOP BID", "DisplayText" : "Terbinafine 1% cream topical bid", "Text" : "Terbinafine 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO QWEEK", "DisplayText" : "Fluconazole 150mg po qweek", "Text" : "Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "DisplayText" : "Terbinafine 250mg po qday", "Text" : "Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "Dermatophyte (tinea) Infections", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Dermatophyte fungal infections are common worldwide. Dermatophytes"}, 
{"Row" :6, "Column" : 1, "Text" : "metabolize and subsist upon keratin in the skin, hair, and nails."}, 
{"Row" :7, "Column" : 1, "Text" : "Most tinea infections can often be cured with topical therapy alone.Systemic"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy is reserved for severe or refractory infection, recurrent infection, or"}, 
{"Row" :9, "Column" : 1, "Text" : "in immunocompromised patients."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 4 weeks"}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Systemic treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Tinea"}
]},
{"Name" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)" , "Term1" : "Onychomycosis " , "Term2" : "Tinea unguium", "DisplayText" : "Tinea Unguium (Onychomycosis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "DisplayText" : "Terbinafine 250mg po qday", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "TINEA UNGUIUM (ONYCHOMYCOSIS)"}, 
{"Row" : 36, "Column" : 1, "Text" : "Treat fingernail infections for 6 weeks"}, 
{"Row" : 61, "Column" : 1, "Text" : "Sanford keyword: Tinea"}, 
{"Row" : 59, "Column" : 1, "Text" : "Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299"}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-date website: Onychomycosis Management"}, 
{"Row" : 38, "Column" : 1, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine"}, 
{"Row" : 37, "Column" : 1, "Text" : "Treat toenail infections for 12 weeks"}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative oral therapy: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Preferred Terbinafine first-line oral: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Treat fingernail infections for 3 months"}, 
{"Row" : 43, "Column" : 1, "Text" : "Treat toenail infections for 6 months"}, 
{"Row" : 44, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 300MG PO QWEEK FOR NAIL INFECTION", "DisplayText" : "Fluconazole 300 mg PO q week for fungal nail infection ($) [R,DI]", "Text" : "", "Mnemonic" : "6"},
{"Row" : 46, "Column" : 1, "Text" : "Topical Treatment: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Ciclopirox is a topical first-line treatment for both fingernails and toenails"}, 
{"Row" : 48, "Column" : 1, "Text" : "Complete resolution occurs in approximately 7 percent of patients treated"}, 
{"Row" : 49, "Column" : 1, "Text" : "daily for 48 weeks.Ciclopirox is a well-tolerated treatment. Potential side"}, 
{"Row" : 50, "Column" : 1, "Text" : "effects include temporary nail changes and local skin irritation."}, 
{"Row" : 54, "Column" : 1, "Text" : "See accompanying medication pamphlet for specific instructions."}, 
{"Row" : 55, "Column" : 1, "Text" : "Treatment is continued until nail clearance or up to 48 weeks."}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJZID CICLOPIROX 8% NAIL LACQUER QDAY REMOVE Q7DAYS", "DisplayText" : "Ciclopirox 8% nail lacquer: Apply once daily to affected nail(s)", "Text" : "", "Mnemonic" : "8"},
{"Row" : 53, "Column" : 1, "Text" : "Remove with rubbing alcohol every 7 days. ($) [M]"}, 
{"Row" :5, "Column" : 1, "Text" : "Onychomycosis is a fungal infection of the nail that presents with yellow,"}, 
{"Row" :6, "Column" : 1, "Text" : "thick, or crumbling nails. Obtain a fungal stain of nail sample prior to"}, 
{"Row" :7, "Column" : 1, "Text" : "initiating treatment. Using large nail clippers, remove as much of the"}, 
{"Row" :8, "Column" : 1, "Text" : "unattached dystrophic nail as possible. Place the piece of clipped nail plate"}, 
{"Row" :9, "Column" : 1, "Text" : "in formalin jar and send to pathology for fungal stain (PAS). Treatment should"}, 
{"Row" : 10, "Column" : 1, "Text" : "only be initiated if stain is positive for fungal elements. Fungal culture is"}, 
{"Row" : 11, "Column" : 1, "Text" : "NOT recommended."}, 
{"Row" : 13, "Column" : 1, "Text" : "Cure is unlikely if the entire nail is involved, or if a portion of the lunula"}, 
{"Row" : 14, "Column" : 1, "Text" : "is involved. Sometimes after treatment the fungus is cured, but the nail"}, 
{"Row" : 15, "Column" : 1, "Text" : "still does not appear normal because once nail dystrophy occurs, that"}, 
{"Row" : 16, "Column" : 1, "Text" : "is not reversible."}, 
{"Row" : 18, "Column" : 1, "Text" : "Systemic therapy is most likely to achieve a cure, especially with more nail"}, 
{"Row" : 19, "Column" : 1, "Text" : "involvement. If <25% involvement topical therapy may be considered. If"}, 
{"Row" : 20, "Column" : 1, "Text" : ">50-75% involvement systemic therapy should be considered."}, 
{"Row" : 27, "Column" : 1, "Text" : "Terbinafine works about 70% of the time to cure the fungus, and reinfection"}, 
{"Row" : 28, "Column" : 1, "Text" : "is common, so many patients will need to do more than one course"}, 
{"Row" : 29, "Column" : 1, "Text" : "of treatment.Fluconazole pulse dosing response rate is approximately 50%."}, 
{"Row" : 30, "Column" : 1, "Text" : "May consider retreatment with oral therapy after one year."}, 
{"Row" : 32, "Column" : 1, "Text" : "Recommend Dermatology Consult for retreatment after failure of 2 courses of"}, 
{"Row" : 33, "Column" : 1, "Text" : "terbinafine or fluconazole."}, 
{"Row" : 26, "Column" : 1, "Text" : "Oral Treatment: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Toenails take 12-18 months to grow out completely, so improvement should not"}, 
{"Row" : 23, "Column" : 1, "Text" : "be expected to be observed for at least 6-9 months.Continued improvement can"}, 
{"Row" : 24, "Column" : 1, "Text" : "be experienced following treatment completion."}
]},
{"Name" : "ORZID2 GMENU TINEA VERSICOLOR" , "Term1" : "Tinea versicolor", "DisplayText" : "Tinea Versicolor" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSJZID KETOCONAZOLE 2% CREAM TOP QDAY", "DisplayText" : "Ketoconazole 2% cream topical qday", "Text" : "Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TERBINAFINE 1% CRM TOP QDAY", "DisplayText" : "Terbinafine 1% cream topical qday", "Text" : "Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "PSJZID SELENIUM SULFIDE LOT 2.5% 10MIN", "DisplayText" : "Selenium sulfide lotion 2.5% to affected area for 10 minutes", "Text" : "Selenium sulfide lotion 2.5% apply to affected area, leave on for 10", "Mnemonic" : "8"},
{"Row" : 25, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "DisplayText" : "Fluconazole 300 MG PO weekly for 2 weeks ($) [R,DI]", "Text" : "Fluconazole 300 MG PO weekly for 2 weeks ($) [R,DI]", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "TINEA VERSICOLOR"}, 
{"Row" :4, "Column" : 1, "Text" : "Pityriasis or tinea versicolor is a common superficial fungal infection."}, 
{"Row" :5, "Column" : 1, "Text" : "Patients often present with erythematous, hypo- or hyperpigmented patches,"}, 
{"Row" :6, "Column" : 1, "Text" : "usually on the trunk or extremities."}, 
{"Row" :8, "Column" : 1, "Text" : "Topical antifungals can be used for limited disease.For disease that involves"}, 
{"Row" :9, "Column" : 1, "Text" : "nails or does not respond to topical therapy, use oral antifungals."}, 
{"Row" : 11, "Column" : 1, "Text" : "Oily skin products or exposure to hot environments often lead to recurrences."}, 
{"Row" : 13, "Column" : 1, "Text" : "Return of normal skin color often takes several weeks after the treatment"}, 
{"Row" : 14, "Column" : 1, "Text" : "course is finished."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment limited disease: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment extensive disease: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Tinea"}, 
{"Row" : 31, "Column" : 1, "Text" : "AK Gupta AK, J Cutan Med Surg. 2014, 18:79"}
]},
{"Name" : "ORZID2 GMENU TOXIC SHOCK SYNDROME" , "Term1" : "Staphylococcal toxic shock syndrome " , "Term2" : "Streptococcal toxic shock syndrome " , "Term3" : "Toxic shock syndrome", "DisplayText" : "Toxic Shock Syndrome" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU STREP TOXIC SHOCK SYNDROME", "DisplayText" : "Criteria for diagnosis of Streptococcal Toxic Shock Syndrome", "Text" : "Link to Diagnosis of Streptococcal toxic shock syndrome", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU STAPH TOXIC SHOCK SYNDROME", "DisplayText" : "CDC criteria for diagnosis of Staphylococcal Toxic Shock Syndrome", "Text" : "Link to Diagnosis of Staphylococcal toxic shock syndrome", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "DisplayText" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Mnemonic" : "8"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG AND CLINDA 900MG IV Q8H", "DisplayText" : "Vanco 15mg/kg and Clindamycin 900 mg q8h IV", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG AND CLINDA 900MG IV Q8H", "DisplayText" : "Vanco 15mg/kg and Clindamycin 900 mg q8h IV", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "12"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX NAFCIL 2GM IV Q4H CLINDA 900MG Q8H", "DisplayText" : "Nafcillin 2 gm IV q4h ($$) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Nafcillin 2 gm IV q4h ($$) [H,O]) [R] <AND> Clindamycin 900 mg IV q8h ($$", "Mnemonic" : "14"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM Q8H AND CLINDA 900MG Q8H IV", "DisplayText" : "Cefazolin 2 gm IVPB ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Text" : "Cefazolin 2 gm IV q8h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Mnemonic" : "16"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "TOXIC SHOCK SYNDROME"}, 
{"Row" :4, "Column" : 1, "Text" : "Toxic shock syndrome (TSS) can be associated with either staphylococci or"}, 
{"Row" :5, "Column" : 1, "Text" : "streptococci.Antimicrobial treatment and supportive care is urgent.Click one"}, 
{"Row" :6, "Column" : 1, "Text" : "of the links below for diagnostic criteria."}, 
{"Row" : 11, "Column" : 1, "Text" : "_________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment of Streptococcal Toxic Shock Syndrome", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "_________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "IV q8h ($$) [H,O]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "q8h ($$) [H,O]"}, 
{"Row" : 23, "Column" : 1, "Text" : "_________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment of Staphylococcal Toxic Shock Syndrome", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Use vancomycin initially in case methicillin-resistant Staphylococcus aureus is"}, 
{"Row" : 28, "Column" : 1, "Text" : "present.If cultures reveal methicillin-susceptible Staphylococcus aureus"}, 
{"Row" : 29, "Column" : 1, "Text" : "(MSSA), change to nafcillin or cefazolin for better antimicrobial activity."}, 
{"Row" : 31, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Treatment if MSSA is isolated", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "MMWR 1990, 39(RR-13):1"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford: Staphylococcal toxic shock"}, 
{"Row" : 44, "Column" : 1, "Text" : "Lappin E, Lancet Infect Dis 2009, 9:281"}, 
{"Row" : 45, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}
]},
{"Name" : "ORZID2 GMENU TOXOPLASMA SPP." , "Term1" : "Toxoplasma infections, general", "DisplayText" : "Toxoplasma spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN50MGQ24H SULFDIAZ1GMQ6H LEUCO10MGQ24H", "DisplayText" : "PYRIM200MGTHEN50MGQ24H SULFDIAZ1GMQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H", "DisplayText" : "PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN50MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "DisplayText" : "PYRIM200MGTHEN50MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "DisplayText" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "DisplayText" : "Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg IV q12h ($$) [R,DI]", "Mnemonic" : "12"},
{"Row" : 40, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "DisplayText" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 50MG Q24H SULFADIAZ 0.5GM Q6H LEUCO 10MG Q24H", "DisplayText" : "PYRIM 50MG Q24H SULFADIAZ 0.5GM Q6H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO q6h", "Mnemonic" : "16"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 50MG Q24H CLINDA 600MG Q8H LEUCO 10MG Q24H", "DisplayText" : "PYRIM 50MG Q24H CLINDA 600MG Q8H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> clindamycin 600 mg PO q8h ($)", "Mnemonic" : "18"},
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX PYRIME 25MG Q24H ATOVA 750MG Q12H LEUCO 10MG Q24H", "DisplayText" : "PYRIME 25MG Q24H ATOVA 750MG Q12H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> atovaquone 750-1500 mg PO", "Mnemonic" : "20"},
{"Row" : 62, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po q24h", "Text" : "Trimethoprim sulfamethoxazole 1DS tablet PO q24h ($) [R,DI]", "Mnemonic" : "22"},
{"Row" : 64, "Column" : 1, "Item" : "PSJZID ATOVAQUONE 750MG PO Q12H", "DisplayText" : "Atovaquone 750mg po q12h", "Text" : "Atovaquone 750-1500 mg PO q12h ($) [M]", "Mnemonic" : "24"},
{"Row" : 75, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "DisplayText" : "PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "Text" : "Pyrimethamine 50 mg q12h for 2 days, then 50 mg PO q24h ($$) [DI,O] <AND>", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "TOXOPLASMA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If patient is immunocompetent and not pregnant, treatment is usually not needed"}, 
{"Row" :6, "Column" : 1, "Text" : "as disease is usually self-limited. Patients who are immunocompromised, pregnant"}, 
{"Row" :7, "Column" : 1, "Text" : "or have severe disease should be treated. Consult Infectious Diseases in all"}, 
{"Row" :8, "Column" : 1, "Text" : "cases."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Non-pregnant patients", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients"}, 
{"Row" : 16, "Column" : 1, "Text" : "for 6 weeks or longer if radiologic disease is extensive or response is"}, 
{"Row" : 17, "Column" : 1, "Text" : "incomplete at 6 weeks."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Patients weighing <60 kg"}, 
{"Row" : 22, "Column" : 1, "Text" : "sulfadiazine 1 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients weighing >60kg"}, 
{"Row" : 26, "Column" : 1, "Text" : "sulfadiazine 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "Preferred alternative for sulfa allergy", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Patients weighing <60 kg"}, 
{"Row" : 31, "Column" : 1, "Text" : "clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]"}, 
{"Row" : 33, "Column" : 1, "Text" : "Patients weighing >60 kg"}, 
{"Row" : 35, "Column" : 1, "Text" : "clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]"}, 
{"Row" : 37, "Column" : 1, "Text" : "Secondary alternatives", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Chronic Maintenance therapy for immunocompromised patients", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >"}, 
{"Row" : 48, "Column" : 1, "Text" : "200 cells per microliter."}, 
{"Row" : 50, "Column" : 1, "Text" : "Maintenance therapy", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "($$) <AND> leucovorin 10-25 mg PO q24h ($) [M]"}, 
{"Row" : 54, "Column" : 1, "Text" : "Preferred alternative for sulfa allergy", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "[H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]"}, 
{"Row" : 58, "Column" : 1, "Text" : "Secondary alternatives", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "q12h ($) [M] <AND> leucovorin 10-25 mg PO q24h ($) [M]"}, 
{"Row" : 61, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 63, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 65, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Pregnant patients", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "Patient diagnosed <16-18 weeks of gestation", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "*Contact Infectious Diseases, non-formulary consult is required for spiramycin"}, 
{"Row" : 72, "Column" : 1, "Text" : "Spiramycin 1 gm po q8h until week 18 of gestation"}, 
{"Row" : 74, "Column" : 1, "Text" : "Patient diagnosed >16-18 weeks of gestation", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "sulfadiazine 75mg/kg once, then 50mg/kg q12h ($$) [DI,O] <AND> leucovorin 10-25"}, 
{"Row" : 77, "Column" : 1, "Text" : "mg PO q24h ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence"}, 
{"Row" : 78, "Column" : 1, "Text" : "of fetal distress"}, 
{"Row" : 80, "Column" : 1, "Text" : "References: "}, 
{"Row" : 82, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 83, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 84, "Column" : 1, "Text" : "Mandell chapter: Toxoplasma gondii"}, 
{"Row" : 85, "Column" : 1, "Text" : "Sanford keyword: Toxoplasmosis"}, 
{"Row" : 86, "Column" : 1, "Text" : "Up-to-Date article: Toxoplasmosis in immunocompetent hosts"}
]},
{"Name" : "ORZID2 GMENU TRANSPLANTATION" , "Term1" : "Transplantation", "DisplayText" : "Transplantation " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "TRANSPLANTATION"}, 
{"Row" :5, "Column" : 1, "Text" : "Organ transplantation is associated with many host defense defects.Early on,"}, 
{"Row" :6, "Column" : 1, "Text" : "surgical wounds may become infected.Preparation for transplantation and anti-"}, 
{"Row" :7, "Column" : 1, "Text" : "rejection drugs can induce neutropenia.Later, CMI defects predominate."}, 
{"Row" :8, "Column" : 1, "Text" : "Patients become infected with exogenous pathogens and also endogenous pathogens"}, 
{"Row" :9, "Column" : 1, "Text" : "like cytomegalovirus that might have been present in latent or subclinical form."}, 
{"Row" : 11, "Column" : 1, "Text" : "Cell-mediated immune defects caused by anti-rejection drugs cause patients to be"}, 
{"Row" : 12, "Column" : 1, "Text" : "especially susceptible to infections with organisms that infrequently cause"}, 
{"Row" : 13, "Column" : 1, "Text" : "disease in healthy people.They include: Pneumocystis jirovecii (formerly"}, 
{"Row" : 14, "Column" : 1, "Text" : "Pneumocystis carinii), mycobacteria, salmonella, candida, aspergillus,"}, 
{"Row" : 15, "Column" : 1, "Text" : "Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,"}, 
{"Row" : 16, "Column" : 1, "Text" : "and cryptosporidia."}, 
{"Row" : 18, "Column" : 1, "Text" : "The approach to fever or other signs or symptoms suggesting the possibility of"}, 
{"Row" : 19, "Column" : 1, "Text" : "an infectious disease depends on the specific defects present in the patient,"}, 
{"Row" : 20, "Column" : 1, "Text" : "the nature of the presenting signs and symptoms and a bedside assessment of the"}, 
{"Row" : 21, "Column" : 1, "Text" : "severity of illness.Empirical antimicrobials are usually not indicated for"}, 
{"Row" : 22, "Column" : 1, "Text" : "fever alone unless the patient has a host defense defect that predisposes to"}, 
{"Row" : 23, "Column" : 1, "Text" : "rapid progression of illness like severe neutropenia or splenectomy.Contact"}, 
{"Row" : 24, "Column" : 1, "Text" : "Infectious Diseases for more information."}, 
{"Row" : 29, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 30, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID2 GMENU TRAVELERS DIARRHEA" , "Term1" : "Traveler's diarrhea", "DisplayText" : "Traveler's Diarrhea " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Text" : "Azithromycin 1000 mg PO one time dose ($) [M]", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "DisplayText" : "Azithromycin 500 mg PO q24h ($) [M]", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 3 days ($) [R,DI]", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "DisplayText" : "RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "Text" : "Rifaximin 200 mg q8h for 3 days ($$) [M]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "TRAVELER'S DIARRHEA", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Acute non-bloody diarrhea (< 14 days of symptoms)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Most cases are mild and self-limited. Reserve antimicrobial therapy for"}, 
{"Row" :8, "Column" : 1, "Text" : "patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or"}, 
{"Row" :9, "Column" : 1, "Text" : "diarrhea that is incapacitating."}, 
{"Row" : 11, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 13, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 14, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 15, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 16, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 17, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 18, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 19, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 20, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 22, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 25, "Column" : 1, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 32, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Subacute diarrhea (>/= 14 days of symptoms)", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Primary treatment is hydration and electrolyte replacement. Empirical"}, 
{"Row" : 38, "Column" : 1, "Text" : "antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for"}, 
{"Row" : 39, "Column" : 1, "Text" : "example, enteric pathogen PCR testing, Clostridium difficile testing in those"}, 
{"Row" : 40, "Column" : 1, "Text" : "who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and"}, 
{"Row" : 41, "Column" : 1, "Text" : "endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present"}, 
{"Row" : 42, "Column" : 1, "Text" : "the case should be evaluated by Gastroenterology and/or Infectious Diseases."}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Travelers Diarrhea"}, 
{"Row" : 49, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and"}, 
{"Row" : 51, "Column" : 1, "Text" : "treatment"}
]},
{"Name" : "ORZID2 GMENU UROSEPSIS" , "Term1" : "Urinary tract infection with sepsis " , "Term2" : "Urosepsis", "DisplayText" : "Urosepsis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "DisplayText" : "Sepsis and septic shock", "Text" : "Sepsis and septic shock", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "DisplayText" : "Bacteremia", "Text" : "Bacteremia", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "DisplayText" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "DisplayText" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "DisplayText" : "Cefepime 2 gm IV q12h ($$) [R]", "Text" : "Cefepime 2 gm IV q12h ($$) [R]", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA OR SEPSIS WITH URINARY TRACT SOURCE (AKA UROSEPSIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients with signs and symptoms of sepsis, like multiple organ system"}, 
{"Row" :6, "Column" : 1, "Text" : "dysfunction, shock and/or acute renal failure, should be treated as outlined in"}, 
{"Row" :7, "Column" : 1, "Text" : "the sepsis pathway. Early intervention is crucial to prevention of death from"}, 
{"Row" :8, "Column" : 1, "Text" : "sepsis."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment for patients with signs and/or symptoms of sepsis", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Bacteremia with a urinary source", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Obtain blood cultures before starting antibiotics when signs or symptoms suggest"}, 
{"Row" : 16, "Column" : 1, "Text" : "bacteremia. Obtain 2 or 3 blood culture sets from different venipuncture sites"}, 
{"Row" : 17, "Column" : 1, "Text" : "within a 24-hour period. When suspicion is strong and the patient's signs and"}, 
{"Row" : 18, "Column" : 1, "Text" : "symptoms have not responded, obtain 2 blood culture sets the next day."}, 
{"Row" : 19, "Column" : 1, "Text" : "Bacteremia is discussed in more detail elsewhere: "}, 
{"Row" : 22, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 23, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 24, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 26, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Antimicrobial treatment duration is based on pathogen isolated from blood"}, 
{"Row" : 28, "Column" : 1, "Text" : "cultures and patient response to therapy, typically 7-14 days."}, 
{"Row" : 30, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331"}, 
{"Row" : 46, "Column" : 1, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Cystitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated urinary tract infection (including"}, 
{"Row" : 50, "Column" : 1, "Text" : "pyelonephritis) in adults"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Gram-negative bacillary bacteremia in adults"}
]},
{"Name" : "ORZID2 GMENU UVEITIS" , "Term1" : "Uveitis", "DisplayText" : "Uveitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "DisplayText" : "Retinitis", "Text" : "VZV or HSV retinitis and ARN", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "DisplayText" : "CMV Retinitis", "Text" : "CMV retinitis and ARN", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "UVEITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are non-infectious. Most infectious cases are associated with a"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogen causing systemic or central nervous system infection. Diagnosis of"}, 
{"Row" :7, "Column" : 1, "Text" : "uveitis usually must be made presumptively due to the technical difficulty of"}, 
{"Row" :8, "Column" : 1, "Text" : "sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and"}, 
{"Row" :9, "Column" : 1, "Text" : "protozoa like Toxoplasma gondii."}, 
{"Row" : 11, "Column" : 1, "Text" : "For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of uveitis involves treating the underlying infection and is usually", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "systemic. Refer to specific pathogen recommendations for treatment of underlyin", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "infection. Contact Ophthalmology and/or Infectious Diseases for assistance.", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell chapter: Infectious causes of uveitis"}
]},
{"Name" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM" , "Term1" : "Diskitis and vertebral osteomyelitis " , "Term2" : "Vertebral osteomyelitis and diskitis", "DisplayText" : "Diskitis and Vertebral Osteomyelitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "DisplayText" : "VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Ceftriaxone 2GM IV", "Mnemonic" : "4"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 mg/kg IV Q12H CIPRO 400 MG IV Q12H", "DisplayText" : "VANCO 15 mg/kg IV Q12H CIPRO 400 MG IV Q12H", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R] <AND> Ciprofloxacin 400mg IV q12h ($) [R,DI]", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "DISKITIS AND VERTEBRAL OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "About half of cases of diskitis are culture negative, and many of those appear"}, 
{"Row" :6, "Column" : 1, "Text" : "to be uninfected.Infectious cases often result from a surgical procedure near"}, 
{"Row" :7, "Column" : 1, "Text" : "the disk or back trauma.Vertebral osteomyelitis usually results from"}, 
{"Row" :8, "Column" : 1, "Text" : "hematogenous seeding or directly from nearby organs.Patients usually present"}, 
{"Row" :9, "Column" : 1, "Text" : "with subacute or chronic pain which is often attributed initially to other"}, 
{"Row" : 10, "Column" : 1, "Text" : "conditions including osteoarthritis, trauma, and malignancy."}, 
{"Row" : 12, "Column" : 1, "Text" : "When possible obtain diagnostic cultures before starting empiric therapy."}, 
{"Row" : 13, "Column" : 1, "Text" : "Obtain blood cultures and image guided aspirates or surgical bone biopsy."}, 
{"Row" : 14, "Column" : 1, "Text" : "Definitive therapy based on culture and susceptibility test results."}, 
{"Row" : 16, "Column" : 1, "Text" : "The most common causes of vertebral osteomyelitis are staphylococci,"}, 
{"Row" : 17, "Column" : 1, "Text" : "streptococci, and gram-negative bacilli. Anaerobes are uncommon pathogens."}, 
{"Row" : 18, "Column" : 1, "Text" : "If cultures are negative but infection is suspected, direct empirical"}, 
{"Row" : 19, "Column" : 1, "Text" : "therapy against the most common pathogens."}, 
{"Row" : 21, "Column" : 1, "Text" : "Surgical intervention and spinal stabilization may be required."}, 
{"Row" : 22, "Column" : 1, "Text" : "Surgery and Infectious Diseases consultations are essential."}, 
{"Row" : 24, "Column" : 1, "Text" : "Recommended duration of therapy: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treat for 6 to 8 weeks for low risk infections."}, 
{"Row" : 26, "Column" : 1, "Text" : "Treat for at least 8 weeks of pathogen-directed IV/PO therapy for high risk"}, 
{"Row" : 27, "Column" : 1, "Text" : "including MRSA infection, ESRD, or undrained abscess or device implantation."}, 
{"Row" : 29, "Column" : 1, "Text" : "Once culture and susceptibility testing is available switch to"}, 
{"Row" : 30, "Column" : 1, "Text" : "pathogen directed therapy."}, 
{"Row" : 32, "Column" : 1, "Text" : "Empiric therapy: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Recommended: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "q24h ($) [M]"}, 
{"Row" : 37, "Column" : 1, "Text" : "Alternative for allergy to penicillin: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date online"}, 
{"Row" : 43, "Column" : 1, "Text" : "Park KH Clin Infect Dis 2016, 62:1262"}, 
{"Row" : 44, "Column" : 1, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26"}
]},
{"Name" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA" , "Term1" : "Yersinia enterocolitica diarrhea/gastroenteritis", "DisplayText" : "Diarrhea with Yersinia enterocolitica " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "DisplayText" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h for 5 days ($) [R,DI]", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 5 days ($) [R,DI]", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2G Q24H GENT 5MG/KG Q24H", "DisplayText" : "CEFTRIAXONE 2G Q24H GENT 5MG/KG Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> gentamicin 5 mg/kg IV q24h ($) [R,O]", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "YERSINIA ENTEROCOLITICA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobials are indicated only for patients with severe disease or immune"}, 
{"Row" :6, "Column" : 1, "Text" : "compromise.For patients with extra-intestinal disease, consult Infectious"}, 
{"Row" :7, "Column" : 1, "Text" : "Diseases or Gastroenterology for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Primary treatment of gastroenteritis", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial treatment of severe gastroenteritis or immunocompromised patient", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative for fluoroquinolone intolerant patients"}, 
{"Row" : 18, "Column" : 1, "Text" : "Antimicrobial treatment of extra-intestinal infection", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "for 2-3 weeks"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Yersinia enterocolitica"}, 
{"Row" : 26, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and"}, 
{"Row" : 28, "Column" : 1, "Text" : "Yersinia pseudotuberculosis infection"}
]},
{"Name" : "ORZID2 GO DIAGNOSIS UTI 3", "DisplayText" : "Diagnosis: Uncomplicated Cystitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1.0, "Item" : "OR GTX WORD PROCESSING 1", "DisplayText" : "Comments: ", "Text" : "Uncomplicated Cystitis"}
]},
{"Name" : "ORZID3 GMENU ABSCESSES", "DisplayText" : "Abscesses (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess (Outpatient)", "Text" : "Cutaneous abscess", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Perirectal abscess", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient)", "Text" : "Furuncles and carbuncles", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, AND CARBUNCLE"}, 
{"Row" :5, "Column" : 1, "Text" : "This section describes management of skin and soft tissue infections.For"}, 
{"Row" :6, "Column" : 1, "Text" : "information on abscesses in other areas, please return to the main CDSS menu and"}, 
{"Row" :7, "Column" : 1, "Text" : "choose the appropriate organ system."}
]},
{"Name" : "ORZID3 GMENU ABX ACNE", "DisplayText" : "Acne" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 1% LOTION TOPICALLY Q12H", "DisplayText" : "Clindamycin 1% lotion topically q12h ($) [M]", "Text" : "Clindamycin 1% lotion topically q12h ($) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID ERYTHROMYCIN 2% GEL TOPICALLY Q12H", "DisplayText" : "Erythromycin 2% gel topically q12h ($) [DI]", "Text" : "Erythromycin 2% gel topically q12h ($) [DI]", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID ERYTHROMYCIN 2% GEL TOPICALLY Q12H", "DisplayText" : "Erythromycin 2% gel topically q12h ($) [DI]", "Text" : "Erythromycin 2% gel topically q12h ($) [DI]", "Mnemonic" : "8"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 12WKS 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 MINOCYLCINE 12WKS 50MG PO Q12H", "DisplayText" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "DisplayText" : "DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "Text" : "Doxycycline 100 mg PO q12h($) [DI] for 12 weeks <AND> erythromycin 2% gel", "Mnemonic" : "14"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "DisplayText" : "MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks <AND> erythromycin 2% gel", "Mnemonic" : "16"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Acne and Rosacea Dermatology Orders", "Text" : "Recalcitrant acne", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "ACNE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acne is an inflammatory skin condition caused by excess sebum production, gland"}, 
{"Row" :6, "Column" : 1, "Text" : "obstruction and infection with Cutibacterum acnes. Early disease manifests with"}, 
{"Row" :7, "Column" : 1, "Text" : "black heads and white heads and little inflammation. Small papules and pustules"}, 
{"Row" :8, "Column" : 1, "Text" : "are present in mild disease. Severe disease occurs when comedones, papules,"}, 
{"Row" :9, "Column" : 1, "Text" : "pustules and less often cysts are present."}, 
{"Row" : 11, "Column" : 1, "Text" : "The goal of treatment is prevention and reeducation of new comedones and"}, 
{"Row" : 12, "Column" : 1, "Text" : "creating an environment that is inhibitory for C. acnes. General skin care"}, 
{"Row" : 13, "Column" : 1, "Text" : "treatment measures include utilizing gentle skin cleansers, avoiding aggressive"}, 
{"Row" : 14, "Column" : 1, "Text" : "scrubbing, using non-comedogenic skin products, and avoiding picking of lesions."}, 
{"Row" : 15, "Column" : 1, "Text" : "Diet's role in therapy remains uncertain."}, 
{"Row" : 17, "Column" : 1, "Text" : "Non-Antimicrobial therapy includes benzoyl peroxide topical/wash, salicylic acid"}, 
{"Row" : 18, "Column" : 1, "Text" : "topical, and tretinoin topical. These agents can be used as monotherapy in early"}, 
{"Row" : 19, "Column" : 1, "Text" : "disease and in addition to antimicrobial treatment in mild to severe disease."}, 
{"Row" : 21, "Column" : 1, "Text" : "Early Disease: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mild Disease: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Severe Disease: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "topically q12h"}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "topically q12h"}, 
{"Row" : 39, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 43, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Sanford keyword: Acne Vulgaris"}, 
{"Row" : 48, "Column" : 1, "Text" : "Up-to-Date Article: Pathogenesis, clinical manifestations, and diagnosis of acne"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-to-Date Article: Acne vulgaris: Overview of management"}, 
{"Row" : 50, "Column" : 1, "Text" : "Zaenglein et al., N Engl J Med, 2018, 379(14)1343-1352"}, 
{"Row" : 51, "Column" : 1, "Text" : "Zaenglein et al., J Am Acad Dermatol, 2016, 74(5)945-73.e33"}, 
{"Row" : 41, "Column" : 1, "Text" : "**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX APPROACH TO UTI", "DisplayText" : "APPROACH TO URINARY TRACT INFECTION (UTI) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic bacteriuria (Outpatient)", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Candida urinary tract infections", "Mnemonic" : "8"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient)", "Text" : "Uncomplicated cystitis", "Mnemonic" : "10"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient)", "Text" : "Complicated cystitis", "Mnemonic" : "12"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Pyelonephritis", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "APPROACH TO URINARY TRACT INFECTION (UTI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Urinary tract infections (UTI) occur in patients with symptoms of infection in"}, 
{"Row" :6, "Column" : 1, "Text" : "the lower urinary tract (cystitis) and/or the upper urinary tract"}, 
{"Row" :7, "Column" : 1, "Text" : "(pyelonephritis). Cystitis refers to infection of the urinary bladder, but"}, 
{"Row" :8, "Column" : 1, "Text" : "inflammation often extends into the urethra. Typical signs and symptoms include"}, 
{"Row" :9, "Column" : 1, "Text" : "dysuria, increased urinary frequency, urgency, and/or suprapubic tenderness."}, 
{"Row" : 11, "Column" : 1, "Text" : "Uncomplicated cystitis occurs in people with structurally and neurogenically"}, 
{"Row" : 12, "Column" : 1, "Text" : "normal urinary tract. Most cases of uncomplicated cystitis occur in"}, 
{"Row" : 13, "Column" : 1, "Text" : "pre-menopausal, non-pregnant, sexually active young women and is associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S."}, 
{"Row" : 15, "Column" : 1, "Text" : "saprophyticus. Complicated cystitis occurs in the conditions listed below and is"}, 
{"Row" : 16, "Column" : 1, "Text" : "associated with Enterobacteriaceae, but more resistant pathogens occur,"}, 
{"Row" : 17, "Column" : 1, "Text" : "including the Gram-positive pathogens staphylococci and enterococci. Features of"}, 
{"Row" : 18, "Column" : 1, "Text" : "pyelonephritis include fever/other signs of systemic infection, flank pain,"}, 
{"Row" : 19, "Column" : 1, "Text" : "costovertebral tenderness, and pelvic or perianal pain in men. In rare and"}, 
{"Row" : 20, "Column" : 1, "Text" : "severe cases, urinary tract infections can also present with bacteremia, sepsis,"}, 
{"Row" : 21, "Column" : 1, "Text" : "multiple organ system dysfunction, shock and/or acute renal failure."}, 
{"Row" : 23, "Column" : 1, "Text" : "When a patient presents with symptoms of cystitis, like dysuria, increased"}, 
{"Row" : 24, "Column" : 1, "Text" : "frequency, and suprapubic pain, perform a urine culture. Antimicrobial therapy"}, 
{"Row" : 25, "Column" : 1, "Text" : "is not indicated for pyuria in the absence of symptoms. Patients with signs and"}, 
{"Row" : 26, "Column" : 1, "Text" : "symptoms of pyelonephritis should have a urinary culture and susceptibility"}, 
{"Row" : 27, "Column" : 1, "Text" : "obtained and a urine Gram-stain performed prior to starting empirical"}, 
{"Row" : 28, "Column" : 1, "Text" : "antimicrobials to guide therapy. Patients presenting with bacteremia, sepsis,"}, 
{"Row" : 29, "Column" : 1, "Text" : "multiorgan dysfunction, shock and/or acute renal failure should be treated"}, 
{"Row" : 30, "Column" : 1, "Text" : "accordingly with urinary tract as the foci of infection."}, 
{"Row" : 32, "Column" : 1, "Text" : "Asymptomatic bacteriuria occurs in patients who have bacteria in the urine but"}, 
{"Row" : 33, "Column" : 1, "Text" : "do not have symptoms of a urinary tract infection. Asymptomatic bacteriuria is"}, 
{"Row" : 34, "Column" : 1, "Text" : "further discussed elsewhere: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 38, "Column" : 1, "Text" : "treatment: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Candida urinary tract infections are discussed elsewhere: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Complicating conditions", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Cystitis is considered complicated when one or more of the following is present: "}, 
{"Row" : 46, "Column" : 1, "Text" : "o Pregnant women"}, 
{"Row" : 47, "Column" : 1, "Text" : "o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter"}, 
{"Row" : 48, "Column" : 1, "Text" : "or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)"}, 
{"Row" : 49, "Column" : 1, "Text" : "o Immunocompromise"}, 
{"Row" : 50, "Column" : 1, "Text" : "o Persistent infection, relapse, recurrence, or treatment failure"}, 
{"Row" : 51, "Column" : 1, "Text" : "o In some cases, men and patients admitted to health care settings may be"}, 
{"Row" : 52, "Column" : 1, "Text" : "considered complicated"}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "*Bacteremia or sepsis with urinary tract source (aka urosepsis) - refer to inpt"}, 
{"Row" : 61, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "References: "}, 
{"Row" : 65, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" : 66, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infection"}
]},
{"Name" : "ORZID3 GMENU ABX BALANITIS", "DisplayText" : "Balanitis and Balanoposthitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "Text" : "Clotrimazole 1% cream topically q12h ($) [M] for 7 days", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 NYSTATIN CREAM 100,000 UNITS/G CREAM TOPICALLY Q12H 7D", "DisplayText" : "Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days", "Text" : "Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days", "Mnemonic" : "8a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 NYSTATIN CREAM 100,000 UNITS/G CREAM TOPICALLY Q12H 7D", "DisplayText" : "Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days (non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150mg po once", "Text" : "Fluconazole 150 mg PO once ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150mg po once Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 0.75% CREAM TOPICALLY BID 7D", "DisplayText" : "Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days", "Text" : "Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days", "Mnemonic" : "12a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 0.75% CREAM TOPICALLY BID 7D", "DisplayText" : "Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days", "Text" : "Metronidazole 500 mg PO q12h ($) [DI] for 7 days", "Mnemonic" : "14a"},
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "BALANITIS AND BALANOPOSTHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Balanitis is inflammation of the glans penis and is often associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "erythema and pruritis. When the foreskin is also involved, the condition is"}, 
{"Row" :7, "Column" : 1, "Text" : "known as balanoposthitis (also referred to as balanitis in this discussion)."}, 
{"Row" :8, "Column" : 1, "Text" : "There are a variety of causes of balanitis, but most are due to poor hygiene of"}, 
{"Row" :9, "Column" : 1, "Text" : "the foreskin in uncircumcised men resulting in candida infection. Other, less"}, 
{"Row" : 10, "Column" : 1, "Text" : "common causes, include bacterial infection (typically sexually transmitted or"}, 
{"Row" : 11, "Column" : 1, "Text" : "anaerobic bacteria), dermatologic conditions, malignancy as well as others. Men"}, 
{"Row" : 12, "Column" : 1, "Text" : "with Candidal balanitis often have a white curd-like exudate compared to a thick"}, 
{"Row" : 13, "Column" : 1, "Text" : "foul-smelling purulent exudate in menu with anaerobic bacterial balanitis."}, 
{"Row" : 15, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 16, "Column" : 1, "Text" : "treatment: "}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Candidal balanitis empirical treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Mild to moderate cases", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Severe cases", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Bacterial balanitis empirical treatment", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Mild cases"}, 
{"Row" : 41, "Column" : 1, "Text" : "Moderate to severe cases"}, 
{"Row" : 44, "Column" : 1, "Text" : "___________________________________________________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Edwards et al., International Journal of STD & AIDS, 2014, 25(9)615-526"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Balanitis"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-to-Date article: Balanitis in Adults"}, 
{"Row" : 51, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID3 GMENU ABX BEBTELOVIMAB EUA", "DisplayText" : "Bebtelovimab (EUA) Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "DisplayText" : "Bebtelovimab EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Bebtelovimab EUA Provider Fact Sheet", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "Bebtelovimab (EUA)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)"}, 
{"Row" :5, "Column" : 1, "Text" : "for treating patients that meet specific criteria. bebtelovimab is"}, 
{"Row" :6, "Column" : 1, "Text" : "not FDA approved drug."}, 
{"Row" :7, "Column" : 1, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis."}, 
{"Row" :9, "Column" : 1, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 20, "Column" : 1, "Text" : "Inclusion Criteria", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "ALL of the following criteria must be met for a patient to receive: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19 and is diagnosed with mild to"}, 
{"Row" : 24, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "Note: patient may be hospitalized for some other reason."}, 
{"Row" : 26, "Column" : 1, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19."}, 
{"Row" : 27, "Column" : 1, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an"}, 
{"Row" : 28, "Column" : 1, "Text" : "increase in baseline oxygen flow rate due to COVID-19."}, 
{"Row" : 29, "Column" : 1, "Text" : "4) Administration will begin within 7 days of symptom onset."}, 
{"Row" : 30, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components."}, 
{"Row" : 31, "Column" : 1, "Text" : "6) Patient has at least one risk factor for progression to severe disease"}, 
{"Row" : 32, "Column" : 1, "Text" : "including hospitalization or death."}, 
{"Row" : 33, "Column" : 1, "Text" : "See link below for complete list: "}, 
{"Row" : 35, "Column" : 1, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA"}, 
{"Row" : 36, "Column" : 1, "Text" : "The provider has communicated with the patient/caregiver regarding"}, 
{"Row" : 37, "Column" : 1, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/"}, 
{"Row" : 38, "Column" : 1, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an"}, 
{"Row" : 39, "Column" : 1, "Text" : "unapproved drug that is authorized for use under an EUA, given information"}, 
{"Row" : 40, "Column" : 1, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver"}, 
{"Row" : 41, "Column" : 1, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)"}, 
{"Row" : 43, "Column" : 1, "Text" : "Exclusion Criteria", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID."}, 
{"Row" : 46, "Column" : 1, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available. Click", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 53, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid"}, 
{"Row" : 54, "Column" : 1, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and"}, 
{"Row" : 55, "Column" : 1, "Text" : "frequent handwashing) according to CDC guidelines."}, 
{"Row" : 48, "Column" : 1, "Text" : "text order below to complete order form for ED administration.", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Note: order does not contain medication order. ED provider will order.", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : "GMRCTZ COVID-19 BEBTELOVIMAB INFO", "DisplayText" : "COVID-19 Bebtelovimab Emergency Department Information", "Text" : "ED text order for administration of INV-Bebtelovimab 175 mg IV Push ONCE", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Text" : "moderate illness."}
]},
{"Name" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE ALLOGENIC", "DisplayText" : "Seattle and Nashville Allogenic Bone Marrow Transplant Vaccinations", "Text" : "Allogenic", "Mnemonic" : "6"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE AUTOLOGOUS", "DisplayText" : "Seattle and Nashville Autologous Bone Marrow Transplant Vaccinations", "Text" : "Autologous", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "BONE MARROW POST-TRANSPLANT VACCINATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Seasonal influenza vaccination should be administered yearly. Patient should be"}, 
{"Row" :6, "Column" : 1, "Text" : "administered COVID-19 vaccinations to be up-to-date per current CDC guidelines."}, 
{"Row" :7, "Column" : 1, "Text" : "Influenza and COVID-19 vaccinations may be administered via nursing standing"}, 
{"Row" :8, "Column" : 1, "Text" : "orders."}, 
{"Row" : 10, "Column" : 1, "Text" : "Order sets are available below for other post-transplant vaccine regimens."}, 
{"Row" : 11, "Column" : 1, "Text" : "Choose vaccine regimen based on location where transplant was performed and"}, 
{"Row" : 12, "Column" : 1, "Text" : "type of transplantation."}, 
{"Row" : 14, "Column" : 1, "Text" : "Mayo Clinic", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Seattle or Nashville", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "University of Minnesota (U of M)", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : ">>Under construction"}, 
{"Row" : 22, "Column" : 1, "Text" : ">>Under construction"}
]},
{"Name" : "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE ALLOGENIC", "DisplayText" : "Seattle and Nashville Allogenic Bone Marrow Transplant Vaccinations " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB HPV MCCONJ PCV20 POLIO", "DisplayText" : "DTaP, Hib, Hep B, HPV, Meningicoccal conj, PCV20, and polio vaccines", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "4"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 20-VALENT VACCINE ONCE", "DisplayText" : "PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 20 valent", "Mnemonic" : "6"},
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB HPV PCV20 POLIO", "DisplayText" : "DTAP HIB HEPB HPV PCV20 POLIO VACCINES", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "8"},
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB POLIO", "DisplayText" : "DTaP, Hib, Hep B, and polio vaccines", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "10"},
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX OP HPV PPSV23 MCCONJ ZOSTER", "DisplayText" : "HPV PPSV23 MCCONJ ZOSTER VACCINES", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "12"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE ONE DOSE", "DisplayText" : "ZOSTER RECOMBINANT VACCINE ONE DOSE", "Text" : "Zoster recombinant - 2 of 2", "Mnemonic" : "14"},
{"Row" : 69, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "MMR (If not on active myelosuppressive treatment)", "Mnemonic" : "16"},
{"Row" : 70, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 20-VALENT VACCINE ONCE", "DisplayText" : "PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 20 valent (only if GVHD negative)", "Mnemonic" : "18"},
{"Row" : 72, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "DisplayText" : "PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 23 valent (only if GVHD negative)", "Mnemonic" : "20"},
{"Row" : 76, "Column" : 1, "Item" : "ORZ SET ABX OP HAEMOPHILUS B VACCINE ONE DOSE", "DisplayText" : "HAEMOPHILUS B VACCINE ONE DOSE", "Text" : "Hib (if titers negative - check yearly until positive)", "Mnemonic" : "22"},
{"Row" : 77, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE ONE DOSE", "DisplayText" : "HEPATITIS B VACCINE ONE DOSE", "Text" : "Hepatitis B (if titers negative - check yearly until positive)", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "SEATTLE OR NASHVILLE ALLOGENIC POST-TRANSPLANT VACCINATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Select below vaccine order sets based on time from transplant. Only doses that"}, 
{"Row" :6, "Column" : 1, "Text" : "are due will be placed. Follow up vaccine doses in series will need to be"}, 
{"Row" :7, "Column" : 1, "Text" : "ordered, using the below order sets, when they are due. Vaccinations that should"}, 
{"Row" :8, "Column" : 1, "Text" : "be ordered via nursing standing orders are listed as such."}, 
{"Row" : 10, "Column" : 1, "Text" : "Certain vaccinations are only indicated in those who are a certain age or have"}, 
{"Row" : 11, "Column" : 1, "Text" : "other co-morbidities. These indications are noted within parentheses in the"}, 
{"Row" : 12, "Column" : 1, "Text" : "below order sets. If the patient does not meet these criteria, cancel the order"}, 
{"Row" : 13, "Column" : 1, "Text" : "after selecting the order set."}, 
{"Row" : 15, "Column" : 1, "Text" : "COVID-19 vaccination changes rapidly. Refer to CDC for most up to date"}, 
{"Row" : 16, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 18, "Column" : 1, "Text" : "3 months", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : ">>Administer 1st COVID-19 vaccine via standing orders"}, 
{"Row" : 21, "Column" : 1, "Text" : "4 months", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : ">>Administer 2nd COVID-19 vaccine and influenza vaccine via standing orders"}, 
{"Row" : 24, "Column" : 1, "Text" : "5 months", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : ">>Administer 3rd COVID-19 vaccine via standing orders"}, 
{"Row" : 27, "Column" : 1, "Text" : "6 months", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "DTaP - 1 of 3"}, 
{"Row" : 29, "Column" : 1, "Text" : "Hib - 1 of 3"}, 
{"Row" : 30, "Column" : 1, "Text" : "Hepatitis B - 1 of 3"}, 
{"Row" : 31, "Column" : 1, "Text" : "HPV - 1 of 3 (for those under 45)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Meningococcal conj - 1 of 2 (For those with splenectomy, HIV, or those at risk)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Pneumococcal 20 valent"}, 
{"Row" : 34, "Column" : 1, "Text" : "Polio - 1 of 3"}, 
{"Row" : 37, "Column" : 1, "Text" : "7 Months", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "8 months", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : ">>Administer 4th COVID-19 vaccine via standing orders"}, 
{"Row" : 42, "Column" : 1, "Text" : "DTap - 2 of 3"}, 
{"Row" : 43, "Column" : 1, "Text" : "Hib - 2 of 3"}, 
{"Row" : 44, "Column" : 1, "Text" : "Hepatitis B - 2 of 3"}, 
{"Row" : 45, "Column" : 1, "Text" : "HPV - 2 of 3 (for those under 45)"}, 
{"Row" : 46, "Column" : 1, "Text" : "Pneumococcal 20 valent"}, 
{"Row" : 47, "Column" : 1, "Text" : "Polio - 2 of 3"}, 
{"Row" : 50, "Column" : 1, "Text" : "10 months", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "DTaP - 3 of 3"}, 
{"Row" : 52, "Column" : 1, "Text" : "Hib - 3 of 3"}, 
{"Row" : 53, "Column" : 1, "Text" : "Hepatitis B - 3 of 3"}, 
{"Row" : 54, "Column" : 1, "Text" : "Polio - 3 of 3"}, 
{"Row" : 57, "Column" : 1, "Text" : "12 months", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : ">>OPTIONAL - administer 4th COVID-19 vaccine via standing orders"}, 
{"Row" : 59, "Column" : 1, "Text" : "HPV - 3 of 3 (for those under 45)"}, 
{"Row" : 60, "Column" : 1, "Text" : "Pneumococcal 23 valent (if GVHD postive - give PCV20 instead of PPSV23)"}, 
{"Row" : 61, "Column" : 1, "Text" : "Meningococcal conj - 2 of 2 (For those with splenectomy, HIV, or those at risk)"}, 
{"Row" : 62, "Column" : 1, "Text" : "Zoster recombinant - 1 of 2"}, 
{"Row" : 65, "Column" : 1, "Text" : "14 months", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "24 Months", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 74, "Column" : 1, "Text" : "Annually", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : ">> Administer seasonal influenza and COVID-19 via standing orders per CDC recs"}
]},
{"Name" : "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE AUTOLOGOUS", "DisplayText" : "Seattle and Nashville Autologous Bone Marrow Transplant Vaccinations" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB HPV MCCONJ PCV20 POLIO", "DisplayText" : "DTaP, Hib, Hep B, HPV, Meningicoccal conj, PCV20, and polio vaccines", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "4"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB PCV23 POLIO", "DisplayText" : "DTaP, Hib, Hep B, PCV23, and polio vaccines", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "6"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX OP DTAP HIB HEPB POLIO", "DisplayText" : "DTaP, Hib, Hep B, and polio vaccines", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "8"},
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX OP HPV MCCONJ ZOSTER RECOMB", "DisplayText" : "HPV, MENINGOCOCCAL CONJ, ZOSTER RECOMBINANT Vaccination", "Text" : "[CLICK HERE] to order above vaccine orders", "Mnemonic" : "10"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE ONE DOSE", "DisplayText" : "ZOSTER RECOMBINANT VACCINE ONE DOSE", "Text" : "Zoster recombinant - 2 of 2", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "SEATTLE OR NASHVILLE AUTOLOGOUS POST-TRANSPLANT VACCINATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Select below vaccine order sets based on time from transplant. Only doses that"}, 
{"Row" :6, "Column" : 1, "Text" : "are due will be placed. Follow up vaccine doses in series will need to be"}, 
{"Row" :7, "Column" : 1, "Text" : "ordered, using the below order sets, when they are due. Vaccinations that should"}, 
{"Row" :8, "Column" : 1, "Text" : "be ordered via nursing standing orders are listed as such."}, 
{"Row" : 10, "Column" : 1, "Text" : "Certain vaccinations are only indicated in those who are a certain age or have"}, 
{"Row" : 11, "Column" : 1, "Text" : "other co-morbidities. These indications are noted within parentheses in the"}, 
{"Row" : 12, "Column" : 1, "Text" : "below order sets. If the patient does not meet these criteria, cancel the order"}, 
{"Row" : 13, "Column" : 1, "Text" : "after selecting the order set."}, 
{"Row" : 15, "Column" : 1, "Text" : "COVID-19 vaccination changes rapidly. Refer to CDC for most up to date"}, 
{"Row" : 16, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 18, "Column" : 1, "Text" : "3 months", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : ">>Administer 1st COVID-19 vaccine and influenza vaccine via standing orders"}, 
{"Row" : 21, "Column" : 1, "Text" : "4 months", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : ">>Administer 2nd COVID-19 vaccine via standing orders"}, 
{"Row" : 24, "Column" : 1, "Text" : "5 months", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : ">>Administer 3rd COVID-19 vaccine via standing orders"}, 
{"Row" : 27, "Column" : 1, "Text" : "6 months", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "DTaP - 1 of 3"}, 
{"Row" : 29, "Column" : 1, "Text" : "Hib - 1 of 3"}, 
{"Row" : 30, "Column" : 1, "Text" : "Hepatitis B - 1 of 3"}, 
{"Row" : 31, "Column" : 1, "Text" : "HPV - 1 of 2 (for those under 45)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Meningococcal conj - 1 of 2 (For those with splenectomy, HIV, or those at risk)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Pneumococcal 20 valent"}, 
{"Row" : 34, "Column" : 1, "Text" : "Polio - 1 of 3"}, 
{"Row" : 37, "Column" : 1, "Text" : "8 months", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : ">>Administer 4th COVID-19 vaccine via standing orders"}, 
{"Row" : 39, "Column" : 1, "Text" : "DTap - 2 of 3"}, 
{"Row" : 40, "Column" : 1, "Text" : "Hib - 2 of 3"}, 
{"Row" : 41, "Column" : 1, "Text" : "Hepatitis B - 2 of 3"}, 
{"Row" : 42, "Column" : 1, "Text" : "Pneumococcal 23 valent"}, 
{"Row" : 43, "Column" : 1, "Text" : "Polio - 2 of 3"}, 
{"Row" : 46, "Column" : 1, "Text" : "10 months", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "DTaP - 3 of 3"}, 
{"Row" : 48, "Column" : 1, "Text" : "Hib - 3 of 3"}, 
{"Row" : 49, "Column" : 1, "Text" : "Hepatitis B - 3 of 3"}, 
{"Row" : 50, "Column" : 1, "Text" : "Polio - 3 of 3"}, 
{"Row" : 53, "Column" : 1, "Text" : "12 months", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "HPV - 2 of 2 (for those under 45)"}, 
{"Row" : 55, "Column" : 1, "Text" : "Meningococcal conj - 2 of 2 (For those with splenectomy, HIV, or those at risk))"}, 
{"Row" : 56, "Column" : 1, "Text" : "Zoster recombinant - 1 of 2"}, 
{"Row" : 59, "Column" : 1, "Text" : "14 months", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Annually", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Seasonal influenza and COVID-19 per CDC recommendations"}
]},
{"Name" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 400MG PO QDAY 6DAYS", "DisplayText" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI]", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 3 days before and 3 days", "Mnemonic" : "4a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 400MG PO QDAY 6DAYS", "DisplayText" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 200MG QDAY 14 DAYS", "DisplayText" : "FLUCONAZOLE 200MG QDAY 14 DAYS", "Text" : "Fluconazole 200 mg (3 mg/kg) PO q24h ($) [R,DI] for 14 days", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 200MG QDAY 14 DAYS", "DisplayText" : "FLUCONAZOLE 200MG QDAY 14 DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "DisplayText" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 14 days", "Mnemonic" : "8a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "DisplayText" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA URINARY TRACT INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A positive urine culture for candida usually reflects colonization. Treat"}, 
{"Row" :6, "Column" : 1, "Text" : "cystitis only if the patient has symptoms of urinary tract infection (e.g."}, 
{"Row" :7, "Column" : 1, "Text" : "dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient"}, 
{"Row" :8, "Column" : 1, "Text" : "will undergo invasive urological manipulation"}, 
{"Row" : 10, "Column" : 1, "Text" : "Asymptomatic candiduria in a patient with a urinary catheter should not be"}, 
{"Row" : 11, "Column" : 1, "Text" : "treated without an additional indication. Removal of catheter is strongly"}, 
{"Row" : 12, "Column" : 1, "Text" : "recommended. Contact Infectious Diseases for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Neutropenic patients with asymptomatic candiduria should be assessed for"}, 
{"Row" : 15, "Column" : 1, "Text" : "candidemia because they are at risk of dissemination. Obtain blood cultures and"}, 
{"Row" : 16, "Column" : 1, "Text" : "assess potential sources of candidemia such as central venous catheters. Refer"}, 
{"Row" : 17, "Column" : 1, "Text" : "to fungemia page in the Inpatient Antimicrobialc CDSS for treatment"}, 
{"Row" : 18, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Patient undergoing invasive urological manipulation: "}, 
{"Row" : 23, "Column" : 1, "Text" : "after procedure"}, 
{"Row" : 26, "Column" : 1, "Text" : "Symptomatic candida cystitis: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Pyelonephritis: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Resistant candida: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Consult Infectious Diseases for treatment options"}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Pappas et al., Clinical Infectious Diseases, 2016, 62(4)e1-e50"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infections"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-To-Date article: Candida Infections of the Bladder and Kidneys"}, 
{"Row" : 43, "Column" : 1, "Text" : "Up-To Date article: Candidemia in adults: Epidemiology, microbiology, and"}, 
{"Row" : 44, "Column" : 1, "Text" : "pathogenesis"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Urinary Tract Infections"}
]},
{"Name" : "ORZID3 GMENU ABX CARD SURGERY DECOLON" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET ABX CHLORHEX MUPIRO DECOLON CARDIOTHOR", "DisplayText" : "CHLORHEXADINE MUPIROCIN DECOLINIZATION", "Text" : "Chlorhexidine 4% liquid topically Q24h ($) [M] < AND > Mupirocin 2%", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX INPT CHLORHEX MUPIRO DECOLON CARDIOTHOR", "DisplayText" : "CHLOHEX MUPIR ORDER SET", "Text" : "Chlorhexidine 4% liquid topically Q24h ($) [M] nursing text order", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "Cardiac Surgery MRSA/MSSA Decolonization Protocol Pre-Op", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Outpatient", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "ointment topically Q12h ($) [M]"}, 
{"Row" :8, "Column" : 1, "Text" : "Inpatient", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "If patient is discharged prior to surgery, place outpatient orders as well"}, 
{"Row" : 11, "Column" : 1, "Text" : "< AND > Mupirocin 2% ointment topically Q12h ($) [M]"}, 
{"Row" : 14, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in"}, 
{"Row" : 16, "Column" : 1, "Text" : "adults: Prevention and control"}
]},
{"Name" : "ORZID3 GMENU ABX CMV MAIN PAGE", "DisplayText" : "Cytomegalovirus (CMV) Main Page (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "DisplayText" : "CMV colitis or esophagitis (Outpatient)", "Text" : "Colitis or esophagitis", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU CMV ENCEPHALITIS", "DisplayText" : "CMV encephalitis (Outpatient)", "Text" : "Encephalitis", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "DisplayText" : "CMV polyradiculopathy (Outpatient)", "Text" : "Polyradiculopathy", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "DisplayText" : "CMV retinitis (Outpatient)", "Text" : "Retinitis", "Mnemonic" : "10"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU CMV PNEUMONIA", "DisplayText" : "CMV pneumonia (Outpatient)", "Text" : "Pneumonia", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CYTOMEGALOVIRUS (CMV)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antiviral toxicity information", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "The major toxicities of both ganciclovir and valganciclovir are neutropenia."}, 
{"Row" :7, "Column" : 1, "Text" : "Nephrotoxicity is the major toxicity associated with foscarnet, which may be"}, 
{"Row" :8, "Column" : 1, "Text" : "reduced by concomitant saline administration (generally 0.5-1L)."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Immunocompetent patient", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Infection is rare and usually associated with minimal or no symptoms."}, 
{"Row" : 13, "Column" : 1, "Text" : "Mononucleosis can be associated with CMV, but is more commonly associated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "Epstein Barr virus. Antiviral treatment is not usually necessary as most"}, 
{"Row" : 15, "Column" : 1, "Text" : "patients recover without intervention."}, 
{"Row" : 16, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Immunocompromised patient", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Patients in whom the risk for CMV disease is increased include solid organ and"}, 
{"Row" : 20, "Column" : 1, "Text" : "bone marrow transplant recipients, persons receiving prolonged immunosuppressive"}, 
{"Row" : 21, "Column" : 1, "Text" : "chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of"}, 
{"Row" : 22, "Column" : 1, "Text" : "less than 50 cells/microliter."}, 
{"Row" : 24, "Column" : 1, "Text" : "CMV treatment recommendations", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 35, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 39, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "DisplayText" : "Colonized Respiratory Tract in a Patient on a Ventilator (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The respiratory tracts of persons who are intubated, have a"}, 
{"Row" :6, "Column" : 1, "Text" : "tracheostomy, or have other abnormalities of the larynx or trachea are"}, 
{"Row" :7, "Column" : 1, "Text" : "usually colonized with bacteria and often fungi. The bacteria can be of"}, 
{"Row" :8, "Column" : 1, "Text" : "relatively low virulence (e.g. coagulase negative staphylococci, streptococci,"}, 
{"Row" :9, "Column" : 1, "Text" : "candida) or of potentially greater virulence (Staphylococcus aureus,"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterobacteriaceae, pseudomonas). Candida and enterococci are common"}, 
{"Row" : 11, "Column" : 1, "Text" : "respiratory tract colonizers and they almost never cause pneumonia. There is"}, 
{"Row" : 12, "Column" : 1, "Text" : "no benefit from treatment of patients with systemic antimicrobials simply"}, 
{"Row" : 13, "Column" : 1, "Text" : "because the respiratory tract is colonized with a potential pathogen and there"}, 
{"Row" : 14, "Column" : 1, "Text" : "is no evidence of an infiltrate. Systemic antimicrobial therapy will select for"}, 
{"Row" : 15, "Column" : 1, "Text" : "resistant organisms and may lead to other adverse effects."}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for ventilator-associated pneumonia"}, 
{"Row" : 18, "Column" : 1, "Text" : "treatment recommendations in patients with a new or progressive infiltrate and"}, 
{"Row" : 19, "Column" : 1, "Text" : "at least one of the following: fever greater than 100.4F, leukocytosis,"}, 
{"Row" : 20, "Column" : 1, "Text" : "leukopenia or purulent bronchial secretions."}, 
{"Row" : 23, "Column" : 1, "Text" : "References"}, 
{"Row" : 25, "Column" : 1, "Text" : "Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111."}
]},
{"Name" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "DisplayText" : "Colonized Wounds (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "DisplayText" : "Decubitis ulcers (Outpatient)", "Text" : "Decubitus ulcers", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Diabetic foot ulcers", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "COLONIZED WOUNDS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Open wounds are usually colonized with bacteria and often fungi. This is true of"}, 
{"Row" :6, "Column" : 1, "Text" : "ulcers (see below), post-operative wounds, traumatic wounds, and others. Then"}, 
{"Row" :7, "Column" : 1, "Text" : "bacteria can be of relatively low virulence (eg, coagulase negative"}, 
{"Row" :8, "Column" : 1, "Text" : "staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus"}, 
{"Row" :9, "Column" : 1, "Text" : "aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds"}, 
{"Row" : 10, "Column" : 1, "Text" : "that are moist or covered. There is no need to treat patients with systemic"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials simply because a wound culture is positive for a potential"}, 
{"Row" : 12, "Column" : 1, "Text" : "pathogen. Topical antimicrobials are not effective in nearly all circumstances"}, 
{"Row" : 13, "Column" : 1, "Text" : "and can select for resistant organisms or lead to other adverse effects."}, 
{"Row" : 14, "Column" : 1, "Text" : "Systemic antimicrobial therapy may be indicated if there are signs of infection."}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 22, "Column" : 1, "Text" : "Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-Date article: Clinical assessment of chronic wounds"}
]},
{"Name" : "ORZID3 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINES OPT", "DisplayText" : "Outpatient COVID-19 Antimicrobial Treatment Guidelines" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "DisplayText" : "Minneapolis COVID-19 SharePoint Site", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Minneapolis On-Call Schedule - Infectious Disease", "Mnemonic" : "8"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 MONOCLONAL ANTIBODY SOP", "DisplayText" : "Monocolonal Antibody Allocation SOP", "Text" : "Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID PHARMACY INFO", "DisplayText" : "Paxlovid EUA", "Text" : "Paxlovid (Nirmatrelvir 300 mg and ritonavir 100 mg) BID for 5 days", "Mnemonic" : "10"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX MOLNUPIRAVIR PHARMACY INFO", "DisplayText" : "Molnupiravir EUA", "Text" : "Molnupiravir 800 mg PO BID for 5 days", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "OUTPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info."}, 
{"Row" :8, "Column" : 1, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies an", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should b", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "discussed with the infectious diseases service. ***", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "If you have any questions on the selection of therapy, please contact Infectious"}, 
{"Row" : 18, "Column" : 1, "Text" : "Disease."}, 
{"Row" : 14, "Column" : 1, "Text" : "DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "ORAL COVID-19 ANTIVIRALS: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Please contact Pharmacy to determine supply and availability."}, 
{"Row" : 25, "Column" : 1, "Text" : "Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144"}, 
{"Row" : 26, "Column" : 1, "Text" : "Inpatient Pharmacy - Off-Tours: 31-3128"}, 
{"Row" : 29, "Column" : 1, "Text" : "documentation, address medication questions and determine the best method of"}, 
{"Row" : 30, "Column" : 1, "Text" : "delivery."}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "DisplayText" : "COVID-19 Medication Interaction Check", "Text" : "Interaction checker for COVID-19 medications website link", "Mnemonic" : "9"},
{"Row" : 34, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "*Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min): "}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID RENAL DOSING PHARMACY INFO", "DisplayText" : "Paxlovid EUA", "Text" : "Paxlovid (Nirmatrelvir 150 mg and ritonavir 100 mg) PO BID for 5 days", "Mnemonic" : "11"},
{"Row" : 28, "Column" : 1, "Text" : "*Please be ready to spend time on the phone with the pharmacist to complete"}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX DENTAL SOP ANTIBIOTIC CHOICE", "DisplayText" : "Dental SOP - Antibiotic choice" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Dental SOP for Antibiotic Prophylaxis", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "a. See links below for recommendations"}, 
{"Row" :7, "Column" : 1, "Text" : "b. Amoxicillin is preferred over Penicillin as it is more effective against"}, 
{"Row" :8, "Column" : 1, "Text" : "gram negative anaerobes and is associated with lower incidence of GI"}, 
{"Row" :9, "Column" : 1, "Text" : "adverse effects."}, 
{"Row" : 10, "Column" : 1, "Text" : "c. If a patient reports a Penicillin allergy, conduct an allergy assessment"}, 
{"Row" : 11, "Column" : 1, "Text" : "to determine if it is a true allergy. If not, consider prescribing"}, 
{"Row" : 12, "Column" : 1, "Text" : "Cephalexin."}, 
{"Row" : 13, "Column" : 1, "Text" : "d. In the unusual case where a patient cannot take Penicillin or Cephalexin,"}, 
{"Row" : 14, "Column" : 1, "Text" : "Doxycycline or Azithromycin would be first choice. Clindamycin is no longer"}, 
{"Row" : 15, "Column" : 1, "Text" : "recommended by the ADA, due to the side effects--it increases the risk"}, 
{"Row" : 16, "Column" : 1, "Text" : "of developing Clostridioides difficile Infection (CDI), even after a"}, 
{"Row" : 17, "Column" : 1, "Text" : "single dose. Clindamycin also gives suboptimal prophylactic coverage."}, 
{"Row" : 18, "Column" : 1, "Text" : "e. If patient is taking an antibiotic with the same spectrum as the one"}, 
{"Row" : 19, "Column" : 1, "Text" : "indicated for antibiotic prophylaxis, additional antibiotics do not need"}, 
{"Row" : 20, "Column" : 1, "Text" : "to be prescribed."}, 
{"Row" : 21, "Column" : 1, "Text" : "f. Consider intramuscular antibiotic therapy for patients with GI disorders."}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Dental Infections", "Mnemonic" : "04"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease (Outpatient)", "Text" : "Periodontal Disease", "Mnemonic" : "06"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Tooth Abscess and other Suppurative Odonotogenic Infections", "Mnemonic" : "08"},
{"Row" :5, "Column" : 1, "Text" : "Antibiotic choice considerations: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Select indication below for recommendations: ", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX DENTAL SOP BACKGROUND INFORMATION", "DisplayText" : "[Click here] Background Information " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "a. Compared to previous recommendations, there are currently few patient"}, 
{"Row" :5, "Column" : 1, "Text" : "subpopulations who would benefit from antibiotic prophylaxis prior to"}, 
{"Row" :6, "Column" : 1, "Text" : "designated dental procedures."}, 
{"Row" :7, "Column" : 1, "Text" : "b. Cumulative, low grade bacteremias (triggered by normal daily activities,"}, 
{"Row" :8, "Column" : 1, "Text" : "such as tooth brushing, flossing and chewing) are a greater risk factor in"}, 
{"Row" :9, "Column" : 1, "Text" : "developing Infective Endocarditis (IE), more so than sporadic, high grade"}, 
{"Row" : 10, "Column" : 1, "Text" : "bacteremias (caused by invasive dental procedures). Maintenance of oral"}, 
{"Row" : 11, "Column" : 1, "Text" : "health to reduce bacteremia from daily activities is more important than"}, 
{"Row" : 12, "Column" : 1, "Text" : "antibiotic prophylaxis."}, 
{"Row" : 13, "Column" : 1, "Text" : "c. Adverse events associated with inappropriate antibiotic use include"}, 
{"Row" : 14, "Column" : 1, "Text" : "antimicrobial resistance, C. difficile associated disease (CDI), allergic"}, 
{"Row" : 15, "Column" : 1, "Text" : "reactions and disruptions in normal flora."}, 
{"Row" : 16, "Column" : 1, "Text" : "d. Some conditions that may warrant antibiotic prophylaxis are: "}, 
{"Row" : 17, "Column" : 1, "Text" : "i. Heart conditions (risk of developing IE)"}, 
{"Row" : 18, "Column" : 1, "Text" : "1. Artificial heart valve"}, 
{"Row" : 19, "Column" : 1, "Text" : "2. History of IE"}, 
{"Row" : 20, "Column" : 1, "Text" : "3. Certain specific congenital heart conditions--highly recommend"}, 
{"Row" : 21, "Column" : 1, "Text" : "Cardiology consult"}, 
{"Row" : 22, "Column" : 1, "Text" : "4. Cardiac transplant that develops a problem in the heart valve"}, 
{"Row" : 23, "Column" : 1, "Text" : "ii. These conditions are NOT recommended for prophylaxis: "}, 
{"Row" : 24, "Column" : 1, "Text" : "1. Coronary artery stents, history of coronary artery bypass"}, 
{"Row" : 25, "Column" : 1, "Text" : "graft (CABG)."}, 
{"Row" : 26, "Column" : 1, "Text" : "e. Presence of prosthetic joints is no longer an indication to provide"}
]},
{"Name" : "ORZID3 GMENU ABX DENTAL SOP MAIN", "DisplayText" : "Antibiotic Propylaxis for Dental Procedures " , "Version" : "Minneapolis", "Contents" : [
{"Row" :6, "Column" : 1, "Text" : "Purpose: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "To establish guidelines that can be used by dentists or dental specialists"}, 
{"Row" :8, "Column" : 1, "Text" : "to determine if antibiotic prophylaxis is necessary for their patients prior"}, 
{"Row" :9, "Column" : 1, "Text" : "to undergoing dental procedures, while being cognizant of the VA Antimicrobial"}, 
{"Row" : 10, "Column" : 1, "Text" : "Stewardship Program (ASP)."}, 
{"Row" : 12, "Column" : 1, "Text" : "Responsibility and Authority: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "The dental team is responsible for management of their patients, including"}, 
{"Row" : 14, "Column" : 1, "Text" : "the use of antibiotic prophylaxis where applicable."}, 
{"Row" :2, "Column" : 1, "Text" : "Guidance pertaining to making an informed decision about Antibiotic Prophylaxis", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "before dental procedures", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Procedure: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "[Click here] Procedure"}, 
{"Row" : 22, "Column" : 1, "Text" : "Antibiotic choice considerations: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Minneapolis VA Health Care System, Service Line: Specialty Care, Dental SOP"}, 
{"Row" : 26, "Column" : 1, "Text" : "Reference: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Background information: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZ GTX ABX URL DENTAL SOP", "DisplayText" : "Dental SOP Antibiotic Prophylaxis", "Text" : "[Click here] Review Dental SOP for Antibiotic Prophylaxis Document", "Mnemonic" : "04"},
{"Row" : 28, "Column" : 1, "Text" : "(Revised: Feb 2023, to be reviewed annually)"}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX URL DENTAL SOP", "DisplayText" : "Dental SOP Antibiotic Prophylaxis", "Text" : "[Click here] Dental SOP Antibiotic Prophylaxis Document", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU ABX DENTAL SOP ANTIBIOTIC CHOICE", "DisplayText" : "Dental SOP - Antibiotic choice", "Text" : "[Click here] Antibiotic choice considerations", "Mnemonic" : "10"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ABX DENTAL SOP BACKGROUND INFORMATION", "DisplayText" : "[Click here] Background Information", "Text" : "", "Mnemonic" : "06"}
]},
{"Name" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Term" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS", "DisplayText" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE INFECTED SKIN, SKIN STRUCTURES", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "OR MUSKULOSKELETAL TISSUE PROCEDURES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "There is a lack of evidence supporting antimicrobial prophylaxis to prevent"}, 
{"Row" :6, "Column" : 1, "Text" : "prosthetic joint infections in patients undergoing procedures on infected skin,"}, 
{"Row" :7, "Column" : 1, "Text" : "skin structures or musculoskeletal tissue procedures."}, 
{"Row" :9, "Column" : 1, "Text" : "For more information contact Infectious Diseases."}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________"}, 
{"Row" : 14, "Column" : 1, "Text" : "References: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic"}, 
{"Row" : 16, "Column" : 1, "Text" : "hardware infection"}
]},
{"Name" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 7-10 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 AZITHRO 1000MG ONCE THEN 500MG PO QDAY 5DS", "DisplayText" : "Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 days ($) [M]", "Text" : "Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 to 7 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 AZITHRO 1000MG ONCE THEN 500MG PO QDAY 5DS", "DisplayText" : "Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Enteric fever is a systemic febrile illness caused by Salmonella enterica"}, 
{"Row" :6, "Column" : 1, "Text" : "serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever"}, 
{"Row" :7, "Column" : 1, "Text" : "and abdominal pain. Enteric fever typically occurs in patients who have traveled"}, 
{"Row" :8, "Column" : 1, "Text" : "to impoverished areas where the organisms are endemic, but can also be acquired"}, 
{"Row" :9, "Column" : 1, "Text" : "within the United States. Treatment is based on location of acquisition due to"}, 
{"Row" : 10, "Column" : 1, "Text" : "increasing rates of fluoroquinolone resistance in Asia."}, 
{"Row" : 12, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobial treatment for infection NOT acquired in Asia", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 20, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 22, "Column" : 1, "Text" : "Antimicrobial treatment for infection acquired in Asia", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 27, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Typhoid Fever, Enteric Fever"}, 
{"Row" : 33, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of enteric (typhoid and"}, 
{"Row" : 35, "Column" : 1, "Text" : "paratyphoid) fever"}
]},
{"Name" : "ORZID3 GMENU ABX ESOPHAGITIS", "DisplayText" : "Esophagitis (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Candidiasis", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "DisplayText" : "CMV colitis or esophagitis (Outpatient)", "Text" : "CMV Esophagitis", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "DisplayText" : "Herpes Simplex Esophagitis (Outpatient)", "Text" : "Herpes Simplex Esophagitis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ESOPHAGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Esophagitis is usually associated with non-infectious diseases like"}, 
{"Row" :6, "Column" : 1, "Text" : "gastroesophageal reflux disease, mucositis and pill-induced esophagitis."}, 
{"Row" :7, "Column" : 1, "Text" : "Esophageal infection occurs primarily in immunosuppressed individuals (e.g."}, 
{"Row" :8, "Column" : 1, "Text" : "chemotherapy, transplantation, HIV) and rarely in healthy individuals. The"}, 
{"Row" :9, "Column" : 1, "Text" : "majority of infectious esophagitis is caused by Candida albicans,"}, 
{"Row" : 10, "Column" : 1, "Text" : "cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the"}, 
{"Row" : 11, "Column" : 1, "Text" : "esophagus is common in HIV infection. HIV screening is recommneded."}, 
{"Row" : 17, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Mandell chapter: Esophagitis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford Keyword: Candidiasis"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date article: Herpes simplex virus infection of the esophagus"}
]},
{"Name" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help and Additional Information Menu", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN OP", "DisplayText" : "OUTPT CONSULT MENU", "Text" : "Consult Menu - place consults to specialty service", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "DisplayText" : "Need an alternative antimicrobial? (outpatient)", "Text" : "Alternative Antimicrobials to CDSS Recommendations - select here", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact Information", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Antimicrobial Information", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important Drug Properties", "Mnemonic" : "14"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)", "Text" : "Antimicrobial Cost Information", "Mnemonic" : "16"},
{"Row" :1, "Column" : 1, "Text" : "GENERAL INFORMATION", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "LEGEND ________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[DI] = Important interactions between antimicrobial and other drugs"}, 
{"Row" : 15, "Column" : 1, "Text" : "[H] = Hepatic excretion of antimicrobial"}, 
{"Row" : 16, "Column" : 1, "Text" : "[M] = Minimal risk posed by antimicrobial"}, 
{"Row" : 17, "Column" : 1, "Text" : "[O] = Other important antimicrobial property"}, 
{"Row" : 18, "Column" : 1, "Text" : "[R] = Renal excretion of antimicrobial"}, 
{"Row" : 21, "Column" : 1, "Text" : "($) = <10 dollars per day"}, 
{"Row" : 22, "Column" : 1, "Text" : "($$) = 10-50 dollars per day"}, 
{"Row" : 23, "Column" : 1, "Text" : "($$$) = 51-100 dollars per day"}, 
{"Row" : 24, "Column" : 1, "Text" : "($$$$) = 101-400 dollars per day"}, 
{"Row" : 25, "Column" : 1, "Text" : "($$$$$) = >400 dollars per day"}, 
{"Row" :4, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "Infectious Diseases Consult", "Mnemonic" : "3"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "9"}
]},
{"Name" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient HepA orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "HEPATITIS A VACCINE INJ,SUSP"}, 
{"Row" : 12, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Havrix"}, 
{"Row" : 15, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Hepatitis A"}, 
{"Row" : 17, "Column" : 1, "Text" : "(HepA)"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 23, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 24, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 25, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 27, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 28, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 29, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*All adults who want to be"}, 
{"Row" :5, "Column" : 2, "Text" : "protected from hepatitis A"}, 
{"Row" :6, "Column" : 2, "Text" : "virus (HAV) infection."}, 
{"Row" :8, "Column" : 2, "Text" : "*People who travel or work"}, 
{"Row" :9, "Column" : 2, "Text" : "anywhere EXCEPT the U.S.,"}, 
{"Row" : 10, "Column" : 2, "Text" : "most, but not all of"}, 
{"Row" : 11, "Column" : 2, "Text" : "Western Europe, New"}, 
{"Row" : 12, "Column" : 2, "Text" : "Zealand, Australia,"}, 
{"Row" : 13, "Column" : 2, "Text" : "Canada, and Japan."}, 
{"Row" : 15, "Column" : 2, "Text" : "*People with chronic liver"}, 
{"Row" : 16, "Column" : 2, "Text" : "disease, injecting and"}, 
{"Row" : 17, "Column" : 2, "Text" : "non-injecting drug users,"}, 
{"Row" : 18, "Column" : 2, "Text" : "people who have HIV"}, 
{"Row" : 19, "Column" : 2, "Text" : "infection, men who have"}, 
{"Row" : 20, "Column" : 2, "Text" : "sex with men, people who"}, 
{"Row" : 21, "Column" : 2, "Text" : "are homeless or live in"}, 
{"Row" : 22, "Column" : 2, "Text" : "temporary housing (e.g., a"}, 
{"Row" : 23, "Column" : 2, "Text" : "shelter), people who work"}, 
{"Row" : 24, "Column" : 2, "Text" : "with HAV in lab settings."}, 
{"Row" : 26, "Column" : 2, "Text" : "*People who anticipate"}, 
{"Row" : 27, "Column" : 2, "Text" : "close personal contact"}, 
{"Row" : 28, "Column" : 2, "Text" : "with an international"}, 
{"Row" : 29, "Column" : 2, "Text" : "adoptee from"}, 
{"Row" : 30, "Column" : 2, "Text" : "a country of high or"}, 
{"Row" : 31, "Column" : 2, "Text" : "intermediate endemicity"}, 
{"Row" : 32, "Column" : 2, "Text" : "during the first 60d"}, 
{"Row" : 33, "Column" : 2, "Text" : "following the adoptee's"}, 
{"Row" : 34, "Column" : 2, "Text" : "arrival in the U.S."}, 
{"Row" : 36, "Column" : 2, "Text" : "*Postexposure: adults with"}, 
{"Row" : 37, "Column" : 2, "Text" : "recent (within 2wks)"}, 
{"Row" : 38, "Column" : 2, "Text" : "exposure to HAV, give"}, 
{"Row" : 39, "Column" : 2, "Text" : "HepA. Vaccine may be used"}, 
{"Row" : 40, "Column" : 2, "Text" : "in conjunction with IG at"}, 
{"Row" : 41, "Column" : 2, "Text" : "the provider's discretion"}, 
{"Row" : 42, "Column" : 2, "Text" : "in adults older than age"}, 
{"Row" : 43, "Column" : 2, "Text" : "40 or immunocompromised"}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 2 doses, spaced 6-"}, 
{"Row" :5, "Column" : 3, "Text" : "12 months apart."}, 
{"Row" :7, "Column" : 3, "Text" : "*If dose2 is delayed, do"}, 
{"Row" :8, "Column" : 3, "Text" : "not repeat dose1. Just"}, 
{"Row" :9, "Column" : 3, "Text" : "give dose2."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "4 dose series", "Mnemonic" : "6"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient HepA/B orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Rapid schedule: "}, 
{"Row" : 12, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "HEPATITIS A/HEPATITIS B"}, 
{"Row" : 14, "Column" : 1, "Text" : "VACCINE INJ,SUSP"}, 
{"Row" : 16, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Twinrix"}, 
{"Row" : 19, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Hepatitis A/B Recombinant"}, 
{"Row" : 21, "Column" : 1, "Text" : "(HepA/HepB)"}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 27, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 28, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 29, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 31, "Column" : 1, "Text" : "Murthy et al. Annals"}, 
{"Row" : 32, "Column" : 1, "Text" : "internal medicine, 2022,"}, 
{"Row" : 33, "Column" : 1, "Text" : "175(3)432-443"}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*All adults who want to be"}, 
{"Row" :5, "Column" : 2, "Text" : "protected from hepatitis A"}, 
{"Row" :6, "Column" : 2, "Text" : "and hepatitis B virus"}, 
{"Row" :7, "Column" : 2, "Text" : "infection."}, 
{"Row" :9, "Column" : 2, "Text" : "HepA Specific: ", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Text" : "*People who travel or work"}, 
{"Row" : 11, "Column" : 2, "Text" : "anywhere EXCEPT the U.S.,"}, 
{"Row" : 12, "Column" : 2, "Text" : "most, but not all of"}, 
{"Row" : 13, "Column" : 2, "Text" : "Western Europe, New"}, 
{"Row" : 14, "Column" : 2, "Text" : "Zealand, Australia,"}, 
{"Row" : 15, "Column" : 2, "Text" : "Canada, and Japan."}, 
{"Row" : 17, "Column" : 2, "Text" : "*People with chronic liver"}, 
{"Row" : 18, "Column" : 2, "Text" : "disease, injecting and"}, 
{"Row" : 19, "Column" : 2, "Text" : "non-injecting drug users,"}, 
{"Row" : 20, "Column" : 2, "Text" : "people who have HIV"}, 
{"Row" : 21, "Column" : 2, "Text" : "infection, men who have"}, 
{"Row" : 22, "Column" : 2, "Text" : "sex with men, people who"}, 
{"Row" : 23, "Column" : 2, "Text" : "are homeless or live in"}, 
{"Row" : 24, "Column" : 2, "Text" : "temporary housing (e.g., a"}, 
{"Row" : 25, "Column" : 2, "Text" : "shelter), people who work"}, 
{"Row" : 26, "Column" : 2, "Text" : "with HAV in lab settings."}, 
{"Row" : 28, "Column" : 2, "Text" : "*People who anticipate"}, 
{"Row" : 29, "Column" : 2, "Text" : "close personal contact"}, 
{"Row" : 30, "Column" : 2, "Text" : "with an international"}, 
{"Row" : 31, "Column" : 2, "Text" : "adoptee from"}, 
{"Row" : 32, "Column" : 2, "Text" : "a country of high or"}, 
{"Row" : 33, "Column" : 2, "Text" : "intermediate endemicity"}, 
{"Row" : 34, "Column" : 2, "Text" : "during the first 60d"}, 
{"Row" : 35, "Column" : 2, "Text" : "following the adoptee's"}, 
{"Row" : 36, "Column" : 2, "Text" : "arrival in the U.S."}, 
{"Row" : 38, "Column" : 2, "Text" : "*Postexposure: adults with"}, 
{"Row" : 39, "Column" : 2, "Text" : "recent (within 2wks)"}, 
{"Row" : 40, "Column" : 2, "Text" : "exposure to HAV, give"}, 
{"Row" : 41, "Column" : 2, "Text" : "HepA. Vaccine may be used"}, 
{"Row" : 42, "Column" : 2, "Text" : "in conjunction with IG at"}, 
{"Row" : 43, "Column" : 2, "Text" : "the provider's discretion"}, 
{"Row" : 44, "Column" : 2, "Text" : "in adults older than age"}, 
{"Row" : 45, "Column" : 2, "Text" : "40 or immunocompromised"}, 
{"Row" : 47, "Column" : 2, "Text" : "HepB Specific", "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Text" : "*People age 19-59yrs"}, 
{"Row" : 50, "Column" : 2, "Text" : "*People age 60yrs and older"}, 
{"Row" : 51, "Column" : 2, "Text" : "who want to be protected"}, 
{"Row" : 52, "Column" : 2, "Text" : "from hepatitis B virus"}, 
{"Row" : 53, "Column" : 2, "Text" : "infection and those who are"}, 
{"Row" : 54, "Column" : 2, "Text" : "at risk for hepatitis B"}, 
{"Row" : 55, "Column" : 2, "Text" : "virus infection: "}, 
{"Row" : 56, "Column" : 2, "Text" : "o Chronic liver disease"}, 
{"Row" : 57, "Column" : 2, "Text" : "(e.g., persons with"}, 
{"Row" : 58, "Column" : 2, "Text" : "hepatitis C, cirrhosis,"}, 
{"Row" : 59, "Column" : 2, "Text" : "fatty liver disease,"}, 
{"Row" : 60, "Column" : 2, "Text" : "alcoholic liver disease,"}, 
{"Row" : 61, "Column" : 2, "Text" : "autoimmune hepatitis,"}, 
{"Row" : 62, "Column" : 2, "Text" : "alanine aminotransferase"}, 
{"Row" : 63, "Column" : 2, "Text" : "[ALT] or aspartate"}, 
{"Row" : 64, "Column" : 2, "Text" : "aminotransferase [AST]"}, 
{"Row" : 65, "Column" : 2, "Text" : "level greater than twice"}, 
{"Row" : 66, "Column" : 2, "Text" : "upper limit of normal)"}, 
{"Row" : 67, "Column" : 2, "Text" : "o HIV infection"}, 
{"Row" : 68, "Column" : 2, "Text" : "o Sexual exposure risk"}, 
{"Row" : 69, "Column" : 2, "Text" : "(e.g., sex partners of"}, 
{"Row" : 70, "Column" : 2, "Text" : "hepatitis B surface"}, 
{"Row" : 71, "Column" : 2, "Text" : "antigen [HBsAg]-positive"}, 
{"Row" : 72, "Column" : 2, "Text" : "persons: sexually active"}, 
{"Row" : 73, "Column" : 2, "Text" : "persons not in mutually"}, 
{"Row" : 74, "Column" : 2, "Text" : "monogamous relationships: "}, 
{"Row" : 75, "Column" : 2, "Text" : "persons seeking evaluation"}, 
{"Row" : 76, "Column" : 2, "Text" : "or treatment for a"}, 
{"Row" : 77, "Column" : 2, "Text" : "sexually transmitted"}, 
{"Row" : 78, "Column" : 2, "Text" : "infection: men who have"}, 
{"Row" : 79, "Column" : 2, "Text" : "sex with men)"}, 
{"Row" : 80, "Column" : 2, "Text" : "o Current or recent"}, 
{"Row" : 81, "Column" : 2, "Text" : "injection drug use"}, 
{"Row" : 82, "Column" : 2, "Text" : "o Percutaneous or mucosal"}, 
{"Row" : 83, "Column" : 2, "Text" : "risk for exposure to blood"}, 
{"Row" : 84, "Column" : 2, "Text" : "(e.g., household contacts"}, 
{"Row" : 85, "Column" : 2, "Text" : "of HBsAg-positive persons: "}, 
{"Row" : 86, "Column" : 2, "Text" : "residents and staff of"}, 
{"Row" : 87, "Column" : 2, "Text" : "facilities for"}, 
{"Row" : 88, "Column" : 2, "Text" : "developmentally disabled"}, 
{"Row" : 89, "Column" : 2, "Text" : "persons: health care and"}, 
{"Row" : 90, "Column" : 2, "Text" : "public safety personnel"}, 
{"Row" : 91, "Column" : 2, "Text" : "with reasonably"}, 
{"Row" : 92, "Column" : 2, "Text" : "anticipated risk for"}, 
{"Row" : 93, "Column" : 2, "Text" : "exposure to blood or"}, 
{"Row" : 94, "Column" : 2, "Text" : "blood-contaminated body"}, 
{"Row" : 95, "Column" : 2, "Text" : "fluids: hemodialysis,"}, 
{"Row" : 96, "Column" : 2, "Text" : "peritoneal dialysis, home"}, 
{"Row" : 97, "Column" : 2, "Text" : "dialysis, and predialysis"}, 
{"Row" : 98, "Column" : 2, "Text" : "patients: patients with"}, 
{"Row" : 99, "Column" : 2, "Text" : "diabetes)"}, 
{"Row" :100, "Column" : 2, "Text" : "o Incarcerated persons"}, 
{"Row" :101, "Column" : 2, "Text" : "o Travel in countries with"}, 
{"Row" :102, "Column" : 2, "Text" : "high or intermediate"}, 
{"Row" :103, "Column" : 2, "Text" : "endemic hepatitis B"}, 
{"Row" :104, "Column" : 2, "Text" : "patient is chronically"}, 
{"Row" :105, "Column" : 2, "Text" : "infected, assure"}, 
{"Row" :106, "Column" : 2, "Text" : "appropriate disease"}, 
{"Row" :107, "Column" : 2, "Text" : "management. For sex"}, 
{"Row" :108, "Column" : 2, "Text" : "partners and household"}, 
{"Row" :109, "Column" : 2, "Text" : "contacts of HBsAg-positive"}, 
{"Row" :110, "Column" : 2, "Text" : "people, provide serologic"}, 
{"Row" :111, "Column" : 2, "Text" : "screening and administer"}, 
{"Row" :112, "Column" : 2, "Text" : "initial dose of HepB"}, 
{"Row" :113, "Column" : 2, "Text" : "vaccine at same visit."}, 
{"Row" :115, "Column" : 2, "Text" : "*Serologic testing is"}, 
{"Row" :116, "Column" : 2, "Text" : "recommended 1 to 2 months"}, 
{"Row" :117, "Column" : 2, "Text" : "after the final dose of"}, 
{"Row" :118, "Column" : 2, "Text" : "the primary vaccine series"}, 
{"Row" :119, "Column" : 2, "Text" : "and annually to determine"}, 
{"Row" :120, "Column" : 2, "Text" : "the need for booster"}, 
{"Row" :121, "Column" : 2, "Text" : "doses. Persons with anti-"}, 
{"Row" :122, "Column" : 2, "Text" : "HBs concentrations of <10"}, 
{"Row" :123, "Column" : 2, "Text" : "milliunits/mL should"}, 
{"Row" :124, "Column" : 2, "Text" : "receive a booster dose"}, 
{"Row" :126, "Column" : 2, "Text" : "NOTE: Provide serologic"}, 
{"Row" :127, "Column" : 2, "Text" : "screening for immigrants"}, 
{"Row" :128, "Column" : 2, "Text" : "from endemic areas. If"}, 
{"Row" :129, "Column" : 2, "Text" : "patient is chronically"}, 
{"Row" :130, "Column" : 2, "Text" : "infected, assure"}, 
{"Row" :131, "Column" : 2, "Text" : "appropriate disease"}, 
{"Row" :132, "Column" : 2, "Text" : "management. For sex"}, 
{"Row" :133, "Column" : 2, "Text" : "partners and household"}, 
{"Row" :134, "Column" : 2, "Text" : "contacts of HBsAg-positive"}, 
{"Row" :135, "Column" : 2, "Text" : "people, provide serologic"}, 
{"Row" :136, "Column" : 2, "Text" : "screening and administer"}, 
{"Row" :137, "Column" : 2, "Text" : "initial dose of HepB"}, 
{"Row" :138, "Column" : 2, "Text" : "vaccine at same visit."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Standard Schedule: Give 3"}, 
{"Row" :5, "Column" : 3, "Text" : "doses on a 0, 1, 6-month"}, 
{"Row" :6, "Column" : 3, "Text" : "schedule."}, 
{"Row" :8, "Column" : 3, "Text" : "*Rapid Schedule: Give 4"}, 
{"Row" :9, "Column" : 3, "Text" : "doses on a 0, 1wk, 3wks,"}, 
{"Row" : 10, "Column" : 3, "Text" : "and 1yr schedule. Must"}, 
{"Row" : 11, "Column" : 3, "Text" : "receive all dose for long"}, 
{"Row" : 12, "Column" : 3, "Text" : "term protection."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Text" : "HEPATITIS A", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Disease Management", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Most acute disease is self-limited, and the virus does not cause chronic"}, 
{"Row" :8, "Column" : 1, "Text" : "disease. No specific antiviral therapy is available."}, 
{"Row" : 10, "Column" : 1, "Text" : "Patients who appear to be developing fulminant hepatitis, including those with"}, 
{"Row" : 11, "Column" : 1, "Text" : "mental status changes should receive supportive treatment. Fulminant hepatitis"}, 
{"Row" : 12, "Column" : 1, "Text" : "is suggested by increased prothrombin time, cholestasis, ascites, decreased"}, 
{"Row" : 13, "Column" : 1, "Text" : "liver size, or decreasing serum albumin. Supportive treatment includes"}, 
{"Row" : 14, "Column" : 1, "Text" : "maintenance of fluid and electrolyte balance, monitoring and possible correction"}, 
{"Row" : 15, "Column" : 1, "Text" : "of coagulation defects, treatment of hepatic encephalopathy, and good nutrition"}, 
{"Row" : 16, "Column" : 1, "Text" : "with a low-protein diet."}, 
{"Row" : 18, "Column" : 1, "Text" : "Prevention for persons with continuing high risk of disease", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Vaccine should be offered to persons at high risk of hepatitis A infection: men"}, 
{"Row" : 20, "Column" : 1, "Text" : "who have sex with men, travelers to endemic areas likely to be exposed, illegal"}, 
{"Row" : 21, "Column" : 1, "Text" : "drug users, persons at occupational risk of disease, persons with chronic liver"}, 
{"Row" : 22, "Column" : 1, "Text" : "disease or clotting factor disorders."}, 
{"Row" : 24, "Column" : 1, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months"}, 
{"Row" : 26, "Column" : 1, "Text" : "Prevention for persons with a specific, defined exposure", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Post-exposure prophylaxis should be offered to persons with substantial exposure"}, 
{"Row" : 28, "Column" : 1, "Text" : "to hepatitis A. Specifically, persons exposed to acute hepatitis through"}, 
{"Row" : 29, "Column" : 1, "Text" : "household or sexual contact, persons who attend or work in a day care center"}, 
{"Row" : 30, "Column" : 1, "Text" : "with a recent case, or employee or patron of a restaurant with a food handler"}, 
{"Row" : 31, "Column" : 1, "Text" : "with hepatitis. Post exposure prophylaxis must be given within 2 weeks of"}, 
{"Row" : 32, "Column" : 1, "Text" : "exposure. Vaccine can be given at the same time as immune-globulin."}, 
{"Row" : 34, "Column" : 1, "Text" : "Immune globulin 0.02 ml/kg IM x 1 <AND>"}, 
{"Row" : 35, "Column" : 1, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Hepatitis A, Acute, Treatment"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-date article: Hepatitis A virus infections: Treatment and prevention"}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "DisplayText" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Text" : "Hepatitis B Evaluation", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "HEPATITIS B", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute disease management", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Most acute hepatitis B disease is mild and self-limited. Patients who appear to"}, 
{"Row" :7, "Column" : 1, "Text" : "be developing fulminant hepatitis, including those with mental status changes"}, 
{"Row" :8, "Column" : 1, "Text" : "should receive supportive treatment. Fulminant hepatitis is suggested by"}, 
{"Row" :9, "Column" : 1, "Text" : "increased prothrombin time, cholestasis, ascites, decreased liver size, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "decreasing serum albumin. Supportive treatment includes maintenance of fluid"}, 
{"Row" : 11, "Column" : 1, "Text" : "and electrolyte balance, monitoring and possible correction of coagulation"}, 
{"Row" : 12, "Column" : 1, "Text" : "defects, treatment of hepatic encephalopathy, and good nutrition with a low-"}, 
{"Row" : 13, "Column" : 1, "Text" : "protein diet. Antiviral therapy is not indicated. Gastroenterology consult"}, 
{"Row" : 14, "Column" : 1, "Text" : "encouraged."}, 
{"Row" : 16, "Column" : 1, "Text" : "Chronic disease management", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Antiviral therapy for chronic hepatitis B is a complicated, highly specialized"}, 
{"Row" : 18, "Column" : 1, "Text" : "task. Consult with gastroenterology and infectious diseases."}, 
{"Row" : 20, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Vaccinate persons at high risk of disease including men who have sex with men,"}, 
{"Row" : 22, "Column" : 1, "Text" : "illegal drug users, and health care workers with substantial exposure to blood"}, 
{"Row" : 23, "Column" : 1, "Text" : "or body fluids."}, 
{"Row" : 24, "Column" : 1, "Text" : "Give Hepatitis B vaccine 1 dose IM in deltoid at 0, then 1 or 2 months, and"}, 
{"Row" : 25, "Column" : 1, "Text" : "again at 4 to 6 months."}, 
{"Row" : 27, "Column" : 1, "Text" : "Select below for Hepatitis B evaluation for patients receiving Anti-CD20", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Antibody Treatment", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Chronic viral hepatitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-date article: Hepatitis B virus: Overview of management"}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "HEPATITIS C", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment of acute disease", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Most acute disease is asymptomatic or mild. Patients with acute hepatitis C"}, 
{"Row" :7, "Column" : 1, "Text" : "should be referred to the Hepatitis C clinic. Treatment may be indicated for"}, 
{"Row" :8, "Column" : 1, "Text" : "disease that persists beyond 2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "Chronic disease treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Antiviral therapy for chronic hepatitis C is a complicated, highly specialized"}, 
{"Row" : 12, "Column" : 1, "Text" : "task"}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Acute viral hepatitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Chronic viral hepatitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-to-date article: Overview of the management of chronic hepatitis C virus"}, 
{"Row" : 20, "Column" : 1, "Text" : "infection"}
]},
{"Name" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "4 dose series", "Mnemonic" : "6"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient HepB orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "*Hemodialysis pts only: "}, 
{"Row" : 12, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "HEPATITIS B INJ"}, 
{"Row" : 15, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Engerix-B"}, 
{"Row" : 18, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Hepatitis B"}, 
{"Row" : 20, "Column" : 1, "Text" : "(HepB)"}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 26, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 27, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 28, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 30, "Column" : 1, "Text" : "Murthy et al. Annals"}, 
{"Row" : 31, "Column" : 1, "Text" : "internal medicine, 2022,"}, 
{"Row" : 32, "Column" : 1, "Text" : "175(3)432-443"}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People age 19-59yrs"}, 
{"Row" :6, "Column" : 2, "Text" : "*People age 60yrs and older"}, 
{"Row" :7, "Column" : 2, "Text" : "who want to be protected"}, 
{"Row" :8, "Column" : 2, "Text" : "from hepatitis B virus"}, 
{"Row" :9, "Column" : 2, "Text" : "infection and those who are"}, 
{"Row" : 10, "Column" : 2, "Text" : "at risk for hepatitis B"}, 
{"Row" : 11, "Column" : 2, "Text" : "virus infection: "}, 
{"Row" : 12, "Column" : 2, "Text" : "o Chronic liver disease"}, 
{"Row" : 13, "Column" : 2, "Text" : "(e.g., persons with"}, 
{"Row" : 14, "Column" : 2, "Text" : "hepatitis C, cirrhosis,"}, 
{"Row" : 15, "Column" : 2, "Text" : "fatty liver disease,"}, 
{"Row" : 16, "Column" : 2, "Text" : "alcoholic liver disease,"}, 
{"Row" : 17, "Column" : 2, "Text" : "autoimmune hepatitis,"}, 
{"Row" : 18, "Column" : 2, "Text" : "alanine aminotransferase"}, 
{"Row" : 19, "Column" : 2, "Text" : "[ALT] or aspartate"}, 
{"Row" : 20, "Column" : 2, "Text" : "aminotransferase [AST]"}, 
{"Row" : 21, "Column" : 2, "Text" : "level greater than twice"}, 
{"Row" : 22, "Column" : 2, "Text" : "upper limit of normal)"}, 
{"Row" : 23, "Column" : 2, "Text" : "o HIV infection"}, 
{"Row" : 24, "Column" : 2, "Text" : "o Sexual exposure risk"}, 
{"Row" : 25, "Column" : 2, "Text" : "(e.g., sex partners of"}, 
{"Row" : 26, "Column" : 2, "Text" : "hepatitis B surface"}, 
{"Row" : 27, "Column" : 2, "Text" : "antigen [HBsAg]-positive"}, 
{"Row" : 28, "Column" : 2, "Text" : "persons: sexually active"}, 
{"Row" : 29, "Column" : 2, "Text" : "persons not in mutually"}, 
{"Row" : 30, "Column" : 2, "Text" : "monogamous relationships: "}, 
{"Row" : 31, "Column" : 2, "Text" : "persons seeking evaluation"}, 
{"Row" : 32, "Column" : 2, "Text" : "or treatment for a"}, 
{"Row" : 33, "Column" : 2, "Text" : "sexually transmitted"}, 
{"Row" : 34, "Column" : 2, "Text" : "infection: men who have"}, 
{"Row" : 35, "Column" : 2, "Text" : "sex with men)"}, 
{"Row" : 36, "Column" : 2, "Text" : "o Current or recent"}, 
{"Row" : 37, "Column" : 2, "Text" : "injection drug use"}, 
{"Row" : 38, "Column" : 2, "Text" : "o Percutaneous or mucosal"}, 
{"Row" : 39, "Column" : 2, "Text" : "risk for exposure to blood"}, 
{"Row" : 40, "Column" : 2, "Text" : "(e.g., household contacts"}, 
{"Row" : 41, "Column" : 2, "Text" : "of HBsAg-positive persons: "}, 
{"Row" : 42, "Column" : 2, "Text" : "residents and staff of"}, 
{"Row" : 43, "Column" : 2, "Text" : "facilities for"}, 
{"Row" : 44, "Column" : 2, "Text" : "developmentally disabled"}, 
{"Row" : 45, "Column" : 2, "Text" : "persons: health care and"}, 
{"Row" : 46, "Column" : 2, "Text" : "public safety personnel"}, 
{"Row" : 47, "Column" : 2, "Text" : "with reasonably"}, 
{"Row" : 48, "Column" : 2, "Text" : "anticipated risk for"}, 
{"Row" : 49, "Column" : 2, "Text" : "exposure to blood or"}, 
{"Row" : 50, "Column" : 2, "Text" : "blood-contaminated body"}, 
{"Row" : 51, "Column" : 2, "Text" : "fluids: hemodialysis,"}, 
{"Row" : 52, "Column" : 2, "Text" : "peritoneal dialysis, home"}, 
{"Row" : 53, "Column" : 2, "Text" : "dialysis, and predialysis"}, 
{"Row" : 54, "Column" : 2, "Text" : "patients: patients with"}, 
{"Row" : 55, "Column" : 2, "Text" : "diabetes)"}, 
{"Row" : 56, "Column" : 2, "Text" : "o Incarcerated persons"}, 
{"Row" : 57, "Column" : 2, "Text" : "o Travel in countries with"}, 
{"Row" : 58, "Column" : 2, "Text" : "high or intermediate"}, 
{"Row" : 59, "Column" : 2, "Text" : "endemic hepatitis B"}, 
{"Row" : 60, "Column" : 2, "Text" : "patient is chronically"}, 
{"Row" : 61, "Column" : 2, "Text" : "infected, assure"}, 
{"Row" : 62, "Column" : 2, "Text" : "appropriate disease"}, 
{"Row" : 63, "Column" : 2, "Text" : "management. For sex"}, 
{"Row" : 64, "Column" : 2, "Text" : "partners and household"}, 
{"Row" : 65, "Column" : 2, "Text" : "contacts of HBsAg-positive"}, 
{"Row" : 66, "Column" : 2, "Text" : "people, provide serologic"}, 
{"Row" : 67, "Column" : 2, "Text" : "screening and administer"}, 
{"Row" : 68, "Column" : 2, "Text" : "initial dose of HepB"}, 
{"Row" : 69, "Column" : 2, "Text" : "vaccine at same visit."}, 
{"Row" : 71, "Column" : 2, "Text" : "*Serologic testing is"}, 
{"Row" : 72, "Column" : 2, "Text" : "recommended 1 to 2 months"}, 
{"Row" : 73, "Column" : 2, "Text" : "after the final dose of"}, 
{"Row" : 74, "Column" : 2, "Text" : "the primary vaccine series"}, 
{"Row" : 75, "Column" : 2, "Text" : "and annually to determine"}, 
{"Row" : 76, "Column" : 2, "Text" : "the need for booster"}, 
{"Row" : 77, "Column" : 2, "Text" : "doses. Persons with anti-"}, 
{"Row" : 78, "Column" : 2, "Text" : "HBs concentrations of <10"}, 
{"Row" : 79, "Column" : 2, "Text" : "milliunits/mL should"}, 
{"Row" : 80, "Column" : 2, "Text" : "receive a booster dose"}, 
{"Row" : 82, "Column" : 2, "Text" : "NOTE: Provide serologic"}, 
{"Row" : 83, "Column" : 2, "Text" : "screening for immigrants"}, 
{"Row" : 84, "Column" : 2, "Text" : "from endemic areas. If"}, 
{"Row" : 85, "Column" : 2, "Text" : "patient is chronically"}, 
{"Row" : 86, "Column" : 2, "Text" : "infected, assure"}, 
{"Row" : 87, "Column" : 2, "Text" : "appropriate disease"}, 
{"Row" : 88, "Column" : 2, "Text" : "management. For sex"}, 
{"Row" : 89, "Column" : 2, "Text" : "partners and household"}, 
{"Row" : 90, "Column" : 2, "Text" : "contacts of HBsAg-positive"}, 
{"Row" : 91, "Column" : 2, "Text" : "people, provide serologic"}, 
{"Row" : 92, "Column" : 2, "Text" : "screening and administer"}, 
{"Row" : 93, "Column" : 2, "Text" : "initial dose of HepB"}, 
{"Row" : 94, "Column" : 2, "Text" : "vaccine at same visit."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 3 doses on a 0, 1, 6-"}, 
{"Row" :5, "Column" : 3, "Text" : "month schedule."}, 
{"Row" :6, "Column" : 3, "Text" : "There must be at least"}, 
{"Row" :7, "Column" : 3, "Text" : "4wks between doses1 and"}, 
{"Row" :8, "Column" : 3, "Text" : "2, and at least 8wks"}, 
{"Row" :9, "Column" : 3, "Text" : "between doses2 and3."}, 
{"Row" : 10, "Column" : 3, "Text" : "Overall, there must be at"}, 
{"Row" : 11, "Column" : 3, "Text" : "least 16wks between doses"}, 
{"Row" : 12, "Column" : 3, "Text" : "1 and3."}, 
{"Row" : 13, "Column" : 3, "Text" : "[Alternative timing"}, 
{"Row" : 14, "Column" : 3, "Text" : "Options for vaccination"}, 
{"Row" : 15, "Column" : 3, "Text" : "include: "}, 
{"Row" : 16, "Column" : 3, "Text" : "1) 0, 2, 4 months"}, 
{"Row" : 17, "Column" : 3, "Text" : "2) 0, 1, 4 months"}, 
{"Row" : 18, "Column" : 3, "Text" : "3) 0, 1, 2, 12 months]"}, 
{"Row" : 20, "Column" : 3, "Text" : "*For adults on"}, 
{"Row" : 21, "Column" : 3, "Text" : "hemodialysis or with other"}, 
{"Row" : 22, "Column" : 3, "Text" : "conditions, give 2 doses"}, 
{"Row" : 23, "Column" : 3, "Text" : "of 20 micrograms/mL"}, 
{"Row" : 24, "Column" : 3, "Text" : "simultaneously at 0, 1, 2,"}, 
{"Row" : 25, "Column" : 3, "Text" : "6 months"}, 
{"Row" : 27, "Column" : 3, "Text" : "*Schedule for those who"}, 
{"Row" : 28, "Column" : 3, "Text" : "have fallen behind: If the"}, 
{"Row" : 29, "Column" : 3, "Text" : "series is delayed between"}, 
{"Row" : 30, "Column" : 3, "Text" : "doses, DO NOT start the"}, 
{"Row" : 31, "Column" : 3, "Text" : "series over. Continue from"}, 
{"Row" : 32, "Column" : 3, "Text" : "where the schedule was"}, 
{"Row" : 33, "Column" : 3, "Text" : "interrupted."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R]", "Text" : "Acyclovir 400 mg PO TID for 7-10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 500MG BID 7D", "DisplayText" : "Valacyclovir 500 mg PO BID ($) [R] for 7 days", "Text" : "Valacyclovir 500 mg PO BID for 7-10 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 500MG BID 7D", "DisplayText" : "Valacyclovir 500 mg PO BID ($) [R] for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 800MG 5X/DAY 14D", "DisplayText" : "Acyclovir 800 mg PO 5 times per day ($) [R] for 14 days", "Text" : "Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 800MG 5X/DAY 14D", "DisplayText" : "Acyclovir 800 mg PO 5 times per day ($) [R] for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1GM TID 14D", "DisplayText" : "Valacyclovir 1 gm PO TID ($) [R] for 14 days", "Text" : "Valacyclovir 1 gm PO TID for 14-21 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1GM TID 14D", "DisplayText" : "Valacyclovir 1 gm PO TID ($) [R] for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 400MG BID 1YR", "DisplayText" : "Acyclovir 400 mg PO BID ($) [R] for 1 year", "Text" : "Acyclovir 400 mg PO BID for 12 months ($) [R]", "Mnemonic" : "12a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG BID 1YR", "DisplayText" : "Acyclovir 400 mg PO BID ($) [R] for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year", "Text" : "Valacyclovir 500 mg PO QDay for 12 months ($) [R]", "Mnemonic" : "14a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "HERPES KERATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of"}, 
{"Row" :6, "Column" : 1, "Text" : "cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5"}, 
{"Row" :7, "Column" : 1, "Text" : "year period, less than that of oral or genital herpes. Ocular herpes is a"}, 
{"Row" :8, "Column" : 1, "Text" : "major cause of blindness and typically presents as infection of the epithelium"}, 
{"Row" :9, "Column" : 1, "Text" : "of the cornea but can also rarely involve the stroma and endothelium."}, 
{"Row" : 10, "Column" : 1, "Text" : "Ophthalmology consultation is recommended."}, 
{"Row" : 12, "Column" : 1, "Text" : "Involvement of the stroma or endothelium requires treatment with topical"}, 
{"Row" : 13, "Column" : 1, "Text" : "steroid and close monitoring. For these cases, start oral antiviral and consult"}, 
{"Row" : 14, "Column" : 1, "Text" : "ophthalmology for management."}, 
{"Row" : 16, "Column" : 1, "Text" : "Antiviral prophylaxis is recommended for patients with multiple recurrences,"}, 
{"Row" : 17, "Column" : 1, "Text" : "recurrent episodes with ulceration, recurrent inflammation with"}, 
{"Row" : 18, "Column" : 1, "Text" : "scar/vascularization approaching visual axis, patients who have had keratoplasty"}, 
{"Row" : 19, "Column" : 1, "Text" : "for HSV-related scarring/astigmatism, and patients who have had HSV keratitis"}, 
{"Row" : 20, "Column" : 1, "Text" : "while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed"}, 
{"Row" : 21, "Column" : 1, "Text" : "here. Please consult ophthalmology for more information."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of acute infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Without epithelial ulceration"}, 
{"Row" : 27, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 31, "Column" : 1, "Text" : "Ulceration of epithelium (Geographic ulcer)"}, 
{"Row" : 34, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 38, "Column" : 1, "Text" : "Infection prophylaxis for prevention of recurrence", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Reassess need for prophylaxis every 12 months"}, 
{"Row" : 42, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 47, "Column" : 1, "Text" : "References: "}, 
{"Row" : 49, "Column" : 1, "Text" : "Baratz, Arch Ophthalmology, (2012) 130.1: 108-110"}, 
{"Row" : 50, "Column" : 1, "Text" : "Guess et al, The Ocular Surface, (2007) 5.3:240-250"}, 
{"Row" : 51, "Column" : 1, "Text" : "Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898"}, 
{"Row" : 52, "Column" : 1, "Text" : "Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of"}, 
{"Row" : 53, "Column" : 1, "Text" : "Recurrent Herpes Simplex"}, 
{"Row" : 54, "Column" : 1, "Text" : "Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007"}, 
{"Row" : 55, "Column" : 1, "Text" : "144:547-551"}, 
{"Row" : 56, "Column" : 1, "Text" : "White et al, Ocular Microbiology and Immunology Group and American Academy of"}, 
{"Row" : 57, "Column" : 1, "Text" : "Ophthalmology, (2014)"}
]},
{"Name" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "DisplayText" : "Herpes Simplex Esophagitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 400MG PO 5X/DAY 7D", "DisplayText" : "Acyclovir 400 mg PO 5x/day for 7 days ($) [R]", "Text" : "Acyclovir 400 mg PO 5x/day for 7 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 400MG PO 5X/DAY 7D", "DisplayText" : "Acyclovir 400 mg PO 5x/day for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Text" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 14DS 400MG PO 5X/D", "DisplayText" : "Acyclovir 400 mg PO 5x/day for 14 days ($) [R]", "Text" : "Acyclovir 400 mg PO 5x/day for 14 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 14DS 400MG PO 5X/D", "DisplayText" : "Acyclovir 400 mg PO 5x/day for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID VALCYCLOVIR 1GM PO BID 14D", "DisplayText" : "Valacyclovir 1 gm PO BID for 14 days ($) [R]", "Text" : "Valacyclovir 1 gm PO BID for 14 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID VALCYCLOVIR 1GM PO BID 14D", "DisplayText" : "Valacyclovir 1 gm PO BID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "HERPES SIMPLEX ESOPHAGITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "HSV infection of the esophagus usually occurs in patients who are"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompromised, typically solid organ and bone marrow transplant"}, 
{"Row" :7, "Column" : 1, "Text" : "recipients. In healthy patients HSV esophagitis occurs occasionally,"}, 
{"Row" :8, "Column" : 1, "Text" : "usually in men under the age of 40."}, 
{"Row" : 10, "Column" : 1, "Text" : "Patients usually present with odynophagia and dysphagia. Fever"}, 
{"Row" : 11, "Column" : 1, "Text" : "epigastric pain, nausea, vomiting, and heartburn are less frequent."}, 
{"Row" : 12, "Column" : 1, "Text" : "Some patients may have coexistent herpes labialis or oropharyngeal"}, 
{"Row" : 13, "Column" : 1, "Text" : "ulcers. Diagnosis is usually established with an upper endoscopy."}, 
{"Row" : 14, "Column" : 1, "Text" : "Suggestive findings may also be seen during a barium swallow."}, 
{"Row" : 16, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Spontaneous resolution usually occurs in immunocompetent patients after"}, 
{"Row" : 18, "Column" : 1, "Text" : "one to two weeks. Patients may respond more quickly if treated with a"}, 
{"Row" : 19, "Column" : 1, "Text" : "short course of oral acyclovir."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treat for 7-10 days"}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Treat for 14-21 days"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 42, "Column" : 1, "Text" : "References"}, 
{"Row" : 44, "Column" : 1, "Text" : "John Hopkin's Guides keyword: Herpes simplex virus"}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date article: Herpes simplex virus infection of the esophagitis"}
]},
{"Name" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP HAEMOPHILUS B VACCINE ONE DOSE", "DisplayText" : "HAEMOPHILUS B VACCINE ONE DOSE", "Text" : "One dose", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP HAEMOPHILUS B VACCINE 3 DOSE SERIES", "DisplayText" : "HAEMOPHILUS B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Mnemonic" : "4"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient Hib orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "HSCT Pts only: "}, 
{"Row" : 12, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "HAEMOPHILUS B VACCINE"}, 
{"Row" : 14, "Column" : 1, "Text" : "INJ,LYPHL"}, 
{"Row" : 16, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Hiberix"}, 
{"Row" : 19, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Haemophilus influenzae"}, 
{"Row" : 21, "Column" : 1, "Text" : "type b"}, 
{"Row" : 22, "Column" : 1, "Text" : "(Hib)"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 28, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 29, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 30, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 32, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 33, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 34, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*Not routinely recommended"}, 
{"Row" :5, "Column" : 2, "Text" : "for healthy adults."}, 
{"Row" :7, "Column" : 2, "Text" : "*Those adults at highest"}, 
{"Row" :8, "Column" : 2, "Text" : "risk of serious Hib"}, 
{"Row" :9, "Column" : 2, "Text" : "disease include people who"}, 
{"Row" : 10, "Column" : 2, "Text" : "1) have anatomic or"}, 
{"Row" : 11, "Column" : 2, "Text" : "functional asplenia,"}, 
{"Row" : 12, "Column" : 2, "Text" : "2) are undergoing an"}, 
{"Row" : 13, "Column" : 2, "Text" : "elective splenectomy, or"}, 
{"Row" : 14, "Column" : 2, "Text" : "3) are recipients of"}, 
{"Row" : 15, "Column" : 2, "Text" : "hematopoietic stem cell"}, 
{"Row" : 16, "Column" : 2, "Text" : "transplant (HSCT)."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 1 dose to adults in"}, 
{"Row" :5, "Column" : 3, "Text" : "categories 1 or 2 (see 2nd"}, 
{"Row" :6, "Column" : 3, "Text" : "bullet in column to left)"}, 
{"Row" :7, "Column" : 3, "Text" : "if no history of previous"}, 
{"Row" :8, "Column" : 3, "Text" : "Hib vaccine."}, 
{"Row" : 10, "Column" : 3, "Text" : "*For HSCT patients,"}, 
{"Row" : 11, "Column" : 3, "Text" : "regardless of Hib vacci-"}, 
{"Row" : 12, "Column" : 3, "Text" : "nation history, give 3"}, 
{"Row" : 13, "Column" : 3, "Text" : "doses, at least 4wks"}, 
{"Row" : 14, "Column" : 3, "Text" : "apart, beginning 6-12"}, 
{"Row" : 15, "Column" : 3, "Text" : "months after transplant."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "ID consult", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "DisplayText" : "MRTC", "Text" : "MRTC consult", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "HIV", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "HIV infection and AIDS are associated with several host defense defects. Cell-"}, 
{"Row" :6, "Column" : 1, "Text" : "mediated immune defects render a patient more susceptible to opportunistic"}, 
{"Row" :7, "Column" : 1, "Text" : "infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis"}, 
{"Row" :8, "Column" : 1, "Text" : "carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare"}, 
{"Row" :9, "Column" : 1, "Text" : "complex, and Candida spp."}, 
{"Row" : 11, "Column" : 1, "Text" : "Contact ID or HIV (MRTC) service for assistance."}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Rich RR, et al, eds. Clinical Immunology"}, 
{"Row" : 20, "Column" : 1, "Text" : "Roitt l, et al, eds. Immunology"}
]},
{"Name" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient HPV orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "PAPILLOMAVIRUS HUMAN"}, 
{"Row" : 11, "Column" : 1, "Text" : "VACCINE INJ,SUSP"}, 
{"Row" : 13, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Gardasil 9"}, 
{"Row" : 16, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Human papillomavirus"}, 
{"Row" : 18, "Column" : 1, "Text" : "(HPV)"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 24, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 25, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 28, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 29, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 30, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*For unvaccinated or"}, 
{"Row" :5, "Column" : 2, "Text" : "partially vaccinated"}, 
{"Row" :6, "Column" : 2, "Text" : "adults through age 26yrs: "}, 
{"Row" :7, "Column" : 2, "Text" : "Complete a 3-dose series"}, 
{"Row" :8, "Column" : 2, "Text" : "of HPV."}, 
{"Row" : 10, "Column" : 2, "Text" : "*Unvaccinated adults age"}, 
{"Row" : 11, "Column" : 2, "Text" : "27 through 45yrs may be"}, 
{"Row" : 12, "Column" : 2, "Text" : "vaccinated based on"}, 
{"Row" : 13, "Column" : 2, "Text" : "shared clinical decision-"}, 
{"Row" : 14, "Column" : 2, "Text" : "making."}, 
{"Row" : 16, "Column" : 2, "Text" : "*Other guidance: Pregnancy"}, 
{"Row" : 17, "Column" : 2, "Text" : "is neither a"}, 
{"Row" : 18, "Column" : 2, "Text" : "contraindication nor a"}, 
{"Row" : 19, "Column" : 2, "Text" : "precaution"}, 
{"Row" : 20, "Column" : 2, "Text" : "to HPV vaccine."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 3 doses on a 0, 1-2,"}, 
{"Row" :5, "Column" : 3, "Text" : "6-month schedule."}, 
{"Row" :7, "Column" : 3, "Text" : "*There must be at least"}, 
{"Row" :8, "Column" : 3, "Text" : "4wks between doses1 and"}, 
{"Row" :9, "Column" : 3, "Text" : "2 and at least 12wks"}, 
{"Row" : 10, "Column" : 3, "Text" : "between doses2 and3."}, 
{"Row" : 11, "Column" : 3, "Text" : "Overall, there must be at"}, 
{"Row" : 12, "Column" : 3, "Text" : "least 5 months between"}, 
{"Row" : 13, "Column" : 3, "Text" : "doses1 and3"}, 
{"Row" : 15, "Column" : 3, "Text" : "*If the type of HPV"}, 
{"Row" : 16, "Column" : 3, "Text" : "vaccine previously given"}, 
{"Row" : 17, "Column" : 3, "Text" : "is not known or not"}, 
{"Row" : 18, "Column" : 3, "Text" : "available, any available"}, 
{"Row" : 19, "Column" : 3, "Text" : "HPV vaccine should be used"}, 
{"Row" : 20, "Column" : 3, "Text" : "to complete the series."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "DisplayText" : "Immunization of Patients Age 65 Years or Greater" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis", "Mnemonic" : "16"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series.", "Mnemonic" : "18"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "20"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "22"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk", "Mnemonic" : "24"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "26"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "28"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those w/additional risk factor or another.", "Mnemonic" : "30"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "32"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "34"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "36"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "38"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "40"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "42"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "44"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "46"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "48"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "50"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "52"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "54"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "56"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS AGE 65 YEARS OR GREATER", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients age 65 years or greater: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 25, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 31, "Column" : 1, "Text" : "Human papillomavirus: not indicated."}, 
{"Row" : 35, "Column" : 1, "Text" : "Measles, mumps, and rubella: not indicated"}, 
{"Row" : 38, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 39, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 40, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 43, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 70, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "DisplayText" : "Immunization of Patients Age 19-26 Years" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series.", "Mnemonic" : "18"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "20"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "22"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "24"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "26"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk", "Mnemonic" : "28"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "30"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "32"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "34"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "36"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "38"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "40"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "42"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "44"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "46"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "48"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "50"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "52"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "54"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "56"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "58"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS AGE 19-26 YEARS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients age 19-26 years: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 28, "Column" : 1, "Text" : "Herpes zoster: not indicated."}, 
{"Row" : 37, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 40, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 41, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 42, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 45, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 48, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 49, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 53, "Column" : 1, "Text" : "Varicella: not indicated."}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "References: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series for age 27-45yrs based on shared clinical", "Mnemonic" : "18"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "20"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "22"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "24"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "26"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose for those w/additional risk factor or another", "Mnemonic" : "28"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "30"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "32"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those born 1980 or later.", "Mnemonic" : "34"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "36"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "38"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "40"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "42"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "44"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "46"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "48"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "50"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "52"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "54"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "56"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "58"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "60"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS AGE 27-49 YEARS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients age 27-49 years: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 28, "Column" : 1, "Text" : "Herpes zoster: not indicated."}, 
{"Row" : 31, "Column" : 1, "Text" : "decision making."}, 
{"Row" : 38, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 41, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 42, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 43, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 46, "Column" : 1, "Text" : "indication."}, 
{"Row" : 49, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 50, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 55, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "References: "}, 
{"Row" : 75, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "DisplayText" : "Immunization of Patients Age 50-64 Years" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "20"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "22"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "24"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "26"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose for those w/additional risk factor or another", "Mnemonic" : "28"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "30"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "32"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those w/additional risk factor or another.", "Mnemonic" : "34"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "36"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "38"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "40"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "42"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "44"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "46"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "48"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "50"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "52"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "54"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "56"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "58"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "60"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS AGE 50-64 YEARS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients age 50-64 years: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 30, "Column" : 1, "Text" : "Human papillomavirus: not indicated."}, 
{"Row" : 37, "Column" : 1, "Text" : "nor another indication."}, 
{"Row" : 40, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 41, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 42, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 45, "Column" : 1, "Text" : "indication."}, 
{"Row" : 48, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 49, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "References: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "DisplayText" : "Immunization of Patients with Heart/Lung Disease or Alcoholism" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "24"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "26"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "28"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "30"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "32"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "34"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "36"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "38"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "40"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "42"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "44"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "46"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "48"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "50"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "52"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "54"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "56"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "58"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "60"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "62"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WITH HEART/LUNG DISEASE OR ALCOHOLISM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients with heart/lung disease or alcoholism: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 31, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 38, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 41, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 42, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 43, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 46, "Column" : 1, "Text" : "indication."}, 
{"Row" : 53, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "References: "}, 
{"Row" : 73, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE" , "Term1" : "Hepatic disease immunizations " , "Term2" : "Immunization of patients with chronic liver disease " , "Term3" : "Liver disease immunizations", "DisplayText" : "Immunization in Chronic Liver Disease " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series.", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series.", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis", "Mnemonic" : "16"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "24"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "26"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "28"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "30"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose prior to age 65.", "Mnemonic" : "32"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "34"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "36"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "38"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "40"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "42"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "44"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "46"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "48"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "50"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "52"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "54"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "56"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "58"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "60"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "62"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WITH CHRONIC LIVER DISEASE", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See specific immunization information pages located at the bottom of this page"}, 
{"Row" :7, "Column" : 1, "Text" : "for other indications, contraindications, and one-time dose orders to listed"}, 
{"Row" :8, "Column" : 1, "Text" : "vaccines."}, 
{"Row" : 13, "Column" : 1, "Text" : "Specific vaccine orders for patients with chronic liver disease: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 16, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 17, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 30, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 37, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 40, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 41, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 42, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 45, "Column" : 1, "Text" : "indication."}, 
{"Row" : 52, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "References: "}, 
{"Row" : 72, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "DisplayText" : "Immunization of Patients with Diabetes" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "24"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "26"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "28"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "30"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "32"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "34"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "36"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "38"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "40"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "42"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "44"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "46"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "48"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "50"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "52"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "54"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "56"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "58"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "60"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "62"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WITH DIABETES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients with diabetes: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 31, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 38, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 41, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 42, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 43, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 46, "Column" : 1, "Text" : "indication."}, 
{"Row" : 53, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "References: "}, 
{"Row" : 73, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "DisplayText" : "Immunization of Patients who are Health Care Personnel" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "24"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "26"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "28"},
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "30"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "32"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "34"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "36"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "38"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "40"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "42"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "44"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "46"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "48"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "50"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "52"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "54"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "56"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "58"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "60"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "62"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WHO ARE HEALTH CARE PERSONNEL", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients who are health care personnel: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 19, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 31, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 38, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 41, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 42, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 43, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 46, "Column" : 1, "Text" : "indication."}, 
{"Row" : 49, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 50, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 55, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "References: "}, 
{"Row" : 75, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series.", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series.", "Mnemonic" : "12"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose", "Mnemonic" : "24"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC 2 DOSE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "Meningococcal A, C, W and Y: 2 dose primary series, booster every 5yrs.", "Mnemonic" : "26"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "28"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "30"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "32"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose series.", "Mnemonic" : "34"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "36"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "38"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "40"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "42"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "44"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "46"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "48"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "50"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "52"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "54"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "56"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "58"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "60"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WITH HIV", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See specific immunization information pages located at the bottom of this page"}, 
{"Row" :7, "Column" : 1, "Text" : "for other indications, contraindications, and one-time dose orders to listed"}, 
{"Row" :8, "Column" : 1, "Text" : "vaccines."}, 
{"Row" : 13, "Column" : 1, "Text" : "Specific vaccine orders for patients with HIV: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 16, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 17, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 30, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 35, "Column" : 1, "Text" : "series."}, 
{"Row" : 40, "Column" : 1, "Text" : "indication."}, 
{"Row" : 47, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "References: "}, 
{"Row" : 67, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD" , "Term1" : "Hemodialysis immunizations " , "Term2" : "Immunization of patients in kidney failure/HD " , "Term3" : "Kidney failure immunizations " , "Term4" : "Renal failure immunizations", "DisplayText" : "Immunization of patient with renal failure on hemodialysis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series.", "Mnemonic" : "12"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "14"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "18"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "20"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "22"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "24"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "26"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "28"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "30"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "32"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "34"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "36"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "38"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "40"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "42"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "44"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "46"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "48"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "50"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "52"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "54"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "56"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "58"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PATIENTS WITH END STAGE RENAL DISEASE OR ON HEMODIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for patients with end stage renal disease or on", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "hemodialysis: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 16, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 17, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 20, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 22, "Column" : 1, "Text" : "Hepatitis A/B: refer to hepatitis A vaccine series above and high dose hepatitis"}, 
{"Row" : 23, "Column" : 1, "Text" : "vaccine series below."}, 
{"Row" : 25, "Column" : 1, "Text" : "Hepatitis B: give high dose series below."}, 
{"Row" : 32, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 39, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 42, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 43, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 44, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 47, "Column" : 1, "Text" : "indication."}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "References: "}, 
{"Row" : 74, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "DisplayText" : "Immunization of Men who Have Sex with Men " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series", "Mnemonic" : "12"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Mnemonic" : "18"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Mnemonic" : "20"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "22"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Mnemonic" : "24"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Mnemonic" : "26"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "28"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "30"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "32"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Mnemonic" : "34"},
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Mnemonic" : "36"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "38"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "40"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "42"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "44"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "46"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "48"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "50"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "52"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "54"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "56"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "58"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "60"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "62"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF MEN WHO HAVE SEX WITH MEN", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See immunization information pages located at the bottom of this page for other"}, 
{"Row" :7, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 12, "Column" : 1, "Text" : "Specific vaccine orders for men who have sex with men: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 15, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 16, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 29, "Column" : 1, "Text" : "based on shared clinical decision making."}, 
{"Row" : 36, "Column" : 1, "Text" : "or another indication."}, 
{"Row" : 39, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 40, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 41, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 44, "Column" : 1, "Text" : "indication."}, 
{"Row" : 47, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 48, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 53, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "References: "}, 
{"Row" : 73, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "DisplayText" : "Immunization of Immunocompromised Patients" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Mnemonic" : "10"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs", "Mnemonic" : "18"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs", "Mnemonic" : "20"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually", "Mnemonic" : "22"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "24"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Mnemonic" : "26"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "Pneumococcal 20-valent: one dose.", "Mnemonic" : "28"},
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs", "Mnemonic" : "30"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "32"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "34"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "36"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "38"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "40"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "42"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "44"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "46"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "48"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "50"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "52"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "54"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "56"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF IMMUNOCOMPROMISED PATIENTS (EXCLUDING HIV and HSCT)", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "See specific immunization information pages located at the bottom of this page"}, 
{"Row" :7, "Column" : 1, "Text" : "for other indications, contraindications, and one-time dose orders to listed"}, 
{"Row" :8, "Column" : 1, "Text" : "vaccines."}, 
{"Row" : 13, "Column" : 1, "Text" : "Specific vaccine orders for immunocompromised patients: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 16, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 17, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 20, "Column" : 1, "Text" : "factor or another indication."}, 
{"Row" : 23, "Column" : 1, "Text" : "risk factor or another indication."}, 
{"Row" : 35, "Column" : 1, "Text" : "Measles, mumps, and rubella *CONTRAINDICATED*"}, 
{"Row" : 38, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 39, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 40, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 43, "Column" : 1, "Text" : "indication"}, 
{"Row" : 49, "Column" : 1, "Text" : "Varicella: *CONTRAINDICATED*"}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 70, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATIONS SPECIALTY CLINICS", "DisplayText" : "Immunizations-Administered in Clinic" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A 2 Dose Series", "Mnemonic" : "14"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B 3 Dose Series", "Mnemonic" : "16"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) 3 Dose Series", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) Accelerated 4 Dose Series", "Mnemonic" : "22"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster (Shingrix) 2 dose series", "Mnemonic" : "24"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B Vaccine 2 Dose Series", "Mnemonic" : "34"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC 2 DOSE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "Meningococcal Conjugate (MenACWY) Vaccine 2 dose series", "Mnemonic" : "36"},
{"Row" : 30, "Column" : 1, "Item" : "ORZSET ABX OP PNEUMOCOCCAL 13-VALENT VACCINE ONE DOSE", "DisplayText" : "PNEUMOCOCCAL 13-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 13-valent vaccine ONCE", "Mnemonic" : "38"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "DisplayText" : "PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 23-valent vaccine ONCE", "Mnemonic" : "40"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Tetanus Diptheria Vaccine booster", "Mnemonic" : "50"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tetanus/Diphteria/Pertussis (TDAP) Vaccine booster", "Mnemonic" : "52"},
{"Row" : 21, "Column" : 1, "Text" : "Vaccines - Administered in Clinic (select vaccine to place order)", "Header" : 1}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "Recommended Immunization Schedules and Outpatient Vaccine Orders", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "DisplayText" : "CDC Recommended Adult Immunizations", "Text" : "[Click Here] Main CDSS Recommended Immunizations Page", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Text" : "Patient Vaccine History: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "[Click Here] for vaccination history including link to Joint Legacy Viewer", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Text" : "Below are links to immunization information and outpatient vaccine orders: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "[Click Here] for links to PDFs of CDC Adult Immunization Schedules", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Text" : "Please note: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "*A vaccine series does not need to be restarted, regardless of the time"}, 
{"Row" : 14, "Column" : 1, "Text" : "that has elapsed between doses."}, 
{"Row" : 15, "Column" : 1, "Text" : "*For the purpose of calculating intervals between doses, 4 weeks = 28 days."}, 
{"Row" : 16, "Column" : 1, "Text" : "Intervals of 4 months or greater are determined by calendar months."}, 
{"Row" : 17, "Column" : 1, "Text" : "*Any vaccine can be given with another unless otherwise noted on the"}, 
{"Row" : 18, "Column" : 1, "Text" : "specific vaccine page. (See link above for Main CDSS Immunization page)"}, 
{"Row" : 19, "Column" : 1, "Text" : "*Mild illness is not a contraindication to receiving any vaccine."}
]},
{"Name" : "ORZID3 GMENU ABX INDEX OUTPATIENT", "Term" : "Outpatient Antimicrobial CDSS Index", "DisplayText" : "Outpatient Antimicrobial CDSS Index " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Abscess, brain", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Abscess, cranial epidural", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess (Outpatient)", "Text" : "Abscess, cutaneous", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Abscess, liver", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "DisplayText" : "Lung abscess (Outpatient)", "Text" : "Abscess, lung", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Abscess, perianal/anorectal", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABSCESSES", "DisplayText" : "Abscesses (Outpatient)", "Text" : "Abscess, skin and soft tissue", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Abscess, spinal epidural", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "DisplayText" : "Acinetobacter baumanni (Outpatient)", "Text" : "Acinetobacter baumannii, general", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Acinetobacter baumannii, nosocomial pneumonia", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "Acquired immunodeficiency syndrome (AIDS)", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "DisplayText" : "Actinomyces spp. (Outpatient)", "Text" : "Actinomyces infections, general", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Adenovirus diarrhea/gastroenteritis", "Mnemonic" : "26"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "DisplayText" : "Large uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Aerobic bottle, large uniform bacilli", "Mnemonic" : "28"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "DisplayText" : "Small uniform bacillin in an aerobic bottle (Outpatient)", "Text" : "Aerobic bottle, small pleomorphic bacilli", "Mnemonic" : "30"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA AEROMONAS", "DisplayText" : "Diarrhea with Aeromonas (Outpatient)", "Text" : "Aeromonas diarrhea/gastroenteritis", "Mnemonic" : "32"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Aggregatibacter native valve endocarditis", "Mnemonic" : "34"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Aggregatibacter prosthetic valve endocarditis", "Mnemonic" : "36"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Allergy information", "Mnemonic" : "38"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "DisplayText" : "Altered microbial flora", "Text" : "Altered microbial flora", "Mnemonic" : "40"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "DisplayText" : "Amebic Liver Abscess", "Text" : "Amebic liver abscess", "Mnemonic" : "42"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "DisplayText" : "Large uniform bacilli in an aerobic bottle (Outpatient)", "Text" : "Anaerobic bottle, large uniform bacilli", "Mnemonic" : "44"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "DisplayText" : "Small uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Anaerobic bottle, small pleomorphic bacilli", "Mnemonic" : "46"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "DisplayText" : "Anaerobic Gram-positive cocci (Outpatient)", "Text" : "Anaerobic gram-positive cocci", "Mnemonic" : "48"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient", "Text" : "Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)", "Mnemonic" : "50"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Anorectal abscess", "Mnemonic" : "52"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "DisplayText" : "Prevention of infection in a patient with malignancy (Outpatient)", "Text" : "Antibacterial prophylaxis in malignancy", "Mnemonic" : "54"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram", "Mnemonic" : "56"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infection in a patient with malignancy", "Text" : "Antifungal prophylaxis in malignancy", "Mnemonic" : "58"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Antimicrobial interactions with warfarin", "Mnemonic" : "60"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Antimicrobial shortages updates", "Mnemonic" : "62"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antimicrobial susceptibilities", "Mnemonic" : "64"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis in malignancy", "Mnemonic" : "66"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "DisplayText" : "Appendicitis with perforation (Outpatient)", "Text" : "Appendicitis with perforation", "Mnemonic" : "68"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation (Outpatient)", "Text" : "Appendicitis without perforation", "Mnemonic" : "70"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "DisplayText" : "Arthritis associated with Lyme disease (Outpatient)", "Text" : "Arthritis associated with Lyme disease", "Mnemonic" : "72"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "DisplayText" : "Aspergillus spp. (Outpatient)", "Text" : "Aspergillus infections, general", "Mnemonic" : "74"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient)", "Text" : "Aspiration pneumonia", "Mnemonic" : "76"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Asplenia [CLICK HERE], includes: ", "Mnemonic" : "78"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Astrovirus diarrhea/gastroenteritis", "Mnemonic" : "80"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "82"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Asymptomatic candiduria", "Mnemonic" : "84"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Asymptomatic pyuria", "Mnemonic" : "86"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE BABESIA SPP.", "DisplayText" : "Babesia spp. (Outpatient)", "Text" : "Babesia infections, general", "Mnemonic" : "88"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient)", "Text" : "Bacillary dysentery", "Mnemonic" : "90"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "DisplayText" : "Large uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Bacilli, large uniform, aerobic bottle", "Mnemonic" : "92"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "DisplayText" : "Large uniform bacilli in an aerobic bottle (Outpatient)", "Text" : "Bacilli, large uniform, anaerobic bottle", "Mnemonic" : "94"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "DisplayText" : "Small uniform bacillin in an aerobic bottle (Outpatient)", "Text" : "Bacilli, small pleomorphic, aerobic bottle", "Mnemonic" : "96"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "DisplayText" : "Small uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Bacilli, small pleomorphic, anaerobic bottle", "Mnemonic" : "98"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "DisplayText" : "Bacilli species (Outpatient)", "Text" : "Bacillus infections, general", "Mnemonic" : "100"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Bacteremia", "Mnemonic" : "102"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram negative bacteria (Outpatient)", "Text" : "Bacteria, Gram-Negative section", "Mnemonic" : "104"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Bacteria, Gram-Positive section", "Mnemonic" : "106"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Bacteriuria", "Mnemonic" : "108"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (Outpatient)", "Text" : "Bacteroides infections, general", "Mnemonic" : "110"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera) - Outpatient", "Text" : "Bed bugs", "Mnemonic" : "112"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient)", "Text" : "Bell's palsy", "Mnemonic" : "114"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)", "Text" : "Bite wounds", "Mnemonic" : "116"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "DisplayText" : "Blastomyces dermatitidis (Outpatient)", "Text" : "Blastomycosis infections, general", "Mnemonic" : "118"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis) - Outpatient", "Text" : "Body lice", "Mnemonic" : "120"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)", "Text" : "Bone and Joint section", "Mnemonic" : "122"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Bone marrow transplant immunizations", "Mnemonic" : "124"},
{"Row" : 74, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses (Outpatient)", "Text" : "Bone prosthesis infection", "Mnemonic" : "126"},
{"Row" : 75, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "DisplayText" : "Bordetella spp. (Outpatient)", "Text" : "Bordetella infections, general", "Mnemonic" : "128"},
{"Row" : 76, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Brain abscess from contiguous or hematogenous spread", "Mnemonic" : "130"},
{"Row" : 77, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Brain abscess with Nocardia spp.", "Mnemonic" : "132"},
{"Row" : 78, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Brain abscess with Pseudomonas spp.", "Mnemonic" : "134"},
{"Row" : 79, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Brain abscess with Toxoplasma gondii", "Mnemonic" : "136"},
{"Row" : 80, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Brain abscess, post-surgical or post-traumatic", "Mnemonic" : "138"},
{"Row" : 81, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "Bronchitis", "Mnemonic" : "140"},
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis in otherwise healthy patient", "Mnemonic" : "142"},
{"Row" : 83, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella infections, general", "Mnemonic" : "144"},
{"Row" : 84, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella spp.", "Mnemonic" : "146"},
{"Row" : 85, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis (Outpatient)", "Text" : "Bursitis, septic", "Mnemonic" : "148"},
{"Row" : 88, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "DisplayText" : "Diarrhea with Campylobacter (Outpatient)", "Text" : "Campylobacter diarrhea/gastroenteritis", "Mnemonic" : "150"},
{"Row" : 89, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "DisplayText" : "Campylobacter spp. (Outpatient)", "Text" : "Campylobacter, general", "Mnemonic" : "152"},
{"Row" : 90, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy (Outpatient)", "Text" : "Cancer [CLICK HERE], includes: ", "Mnemonic" : "154"},
{"Row" : 92, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Candida albicans infections, general", "Mnemonic" : "156"},
{"Row" : 93, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. GLABRATA", "DisplayText" : "Candida glabrata (Outpatient)", "Text" : "Candida glabrata infections, general", "Mnemonic" : "158"},
{"Row" : 94, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Candida intravascular catheter-associated infection", "Mnemonic" : "160"},
{"Row" : 95, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. KRUSEI", "DisplayText" : "Candida krusei (Outpatient)", "Text" : "Candida krusei infections, general", "Mnemonic" : "162"},
{"Row" : 96, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "Candida retinitis", "Mnemonic" : "164"},
{"Row" : 97, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Candida urinary tract infection", "Mnemonic" : "166"},
{"Row" : 98, "Column" : 1, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida vulvo-vaginitis (Outpatient)", "Text" : "Candida vulvo-vaginitis", "Mnemonic" : "168"},
{"Row" : 99, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Candidemia", "Mnemonic" : "170"},
{"Row" :100, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "DisplayText" : "Cutaneous Candidiasis (Outpatient)", "Text" : "Candidiasis", "Mnemonic" : "172"},
{"Row" :101, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Candiduria", "Mnemonic" : "174"},
{"Row" :102, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient)", "Text" : "Carbuncles", "Mnemonic" : "176"},
{"Row" :103, "Column" : 1, "Item" : "ORZID3 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease (Outpatient)", "Text" : "Cardiac disease associated with Lyme disease", "Mnemonic" : "178"},
{"Row" :104, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Cardiobacterium native valve endocarditis", "Mnemonic" : "180"},
{"Row" :105, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Cardiobacterium prosthetic valve endocarditis", "Mnemonic" : "182"},
{"Row" :106, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Cardiovascular device infections (excluding valves)", "Mnemonic" : "184"},
{"Row" :108, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Catheter-associated infection, intravascular", "Mnemonic" : "186"},
{"Row" :109, "Column" : 1, "Item" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "DisplayText" : "Cat-Scratch Disease (Outpatient)", "Text" : "Cat-scratch disease", "Mnemonic" : "188"},
{"Row" :110, "Column" : 1, "Item" : "ORZID2 GMENU CMI DEFECTS", "DisplayText" : "Cell-mediated immunity (CMI) defects", "Text" : "Cell-mediated immunity (CMI) defects", "Mnemonic" : "190"},
{"Row" :111, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "DisplayText" : "Cellulitis (Outpatient)", "Text" : "Cellulitis", "Mnemonic" : "192"},
{"Row" :112, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Text" : "Cellulitis, herpes whitlow", "Mnemonic" : "194"},
{"Row" :113, "Column" : 1, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal cellulitis (Orbital cellulitis) - Outpatient", "Text" : "Cellulitis, postseptal (orbital)", "Mnemonic" : "196"},
{"Row" :114, "Column" : 1, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal cellulitis (Outpatient)", "Text" : "Cellulitis, preseptal", "Mnemonic" : "198"},
{"Row" :115, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Central Nervous System section", "Mnemonic" : "200"},
{"Row" :116, "Column" : 1, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Cervicitis associated with sexually transmitted diseases", "Mnemonic" : "202"},
{"Row" :117, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Chickenpox vaccination", "Mnemonic" : "204"},
{"Row" :118, "Column" : 1, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox) - Outpatient", "Text" : "Chickenpox, primary infection", "Mnemonic" : "206"},
{"Row" :119, "Column" : 1, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient", "Text" : "Chickenpox, reactivation of primary infection", "Mnemonic" : "208"},
{"Row" :120, "Column" : 1, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Chlamydia urethritis", "Mnemonic" : "210"},
{"Row" :121, "Column" : 1, "Item" : "ORZID3 GMENU CHOLANGITIS", "DisplayText" : "Cholangitis (Outpatient)", "Text" : "Cholangitis", "Mnemonic" : "212"},
{"Row" :122, "Column" : 1, "Item" : "ORZID3 GMENU CHOLECYSTITIS", "DisplayText" : "Cholecystitis (Outpatient)", "Text" : "Cholecystitis", "Mnemonic" : "214"},
{"Row" :123, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "DisplayText" : "Citrobacter spp. (Outpatient)", "Text" : "Citrobacter infections, general", "Mnemonic" : "216"},
{"Row" :124, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Clostridium difficile suspected, sepsis", "Mnemonic" : "218"},
{"Row" :125, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile, mild to moderate disease", "Mnemonic" : "220"},
{"Row" :126, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "DisplayText" : "Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)", "Text" : "Clostridium difficile, severe/life-threatening disease", "Mnemonic" : "222"},
{"Row" :127, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "DisplayText" : "Clostridium spp. (Outpatient)", "Text" : "Clostridium infections, general", "Mnemonic" : "224"},
{"Row" :128, "Column" : 1, "Item" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "DisplayText" : "Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient)", "Text" : "Coagulase negative staphylococci, single blood culture positive", "Mnemonic" : "226"},
{"Row" :129, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Coagulase-negative Staphylococci (CNS) bacteremia", "Mnemonic" : "228"},
{"Row" :130, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "DisplayText" : "Treatment for Coagulase Negative Staphylococci (Outpatient)", "Text" : "Coagulase-negative staphylococci, general", "Mnemonic" : "230"},
{"Row" :131, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Coagulase-negative staphylococci, intravascular catheter-associated infectio", "Mnemonic" : "232"},
{"Row" :132, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "DisplayText" : "Coccidioidomyces (Outpatient)", "Text" : "Coccidioides infections, general", "Mnemonic" : "234"},
{"Row" :133, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "DisplayText" : "CMV colitis or esophagitis (Outpatient)", "Text" : "Colitis, cytomegalovirus (CMV)", "Mnemonic" : "236"},
{"Row" :134, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "DisplayText" : "Colonized Respiratory Tract in a Patient on a Ventilator (outpatient)", "Text" : "Colonized respiratory tract patient on a ventilator", "Mnemonic" : "238"},
{"Row" :135, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "DisplayText" : "Colonized Wounds (outpatient)", "Text" : "Colonized wound", "Mnemonic" : "240"},
{"Row" :136, "Column" : 1, "Item" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "DisplayText" : "Community acquired diarrhea (no recent travel) - Outpatient", "Text" : "Community-acquired diarrhea", "Mnemonic" : "242"},
{"Row" :137, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "244"},
{"Row" :138, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "DisplayText" : "Community-acquired pneumonia (CAP)", "Text" : "Community-acquired pneumonia (CAP), inpatient treatment setting", "Mnemonic" : "246"},
{"Row" :139, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "DisplayText" : "Complement Deficiency (Outpatient)", "Text" : "Complement deficiency", "Mnemonic" : "248"},
{"Row" :140, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient)", "Text" : "Complicated cystitis", "Mnemonic" : "250"},
{"Row" :141, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "DisplayText" : "Conditions Not Benefited by Antimicrobial Therapy (outpatient)", "Text" : "Conditions not benefitted by antimicrobials", "Mnemonic" : "252"},
{"Row" :142, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis (Outpatient)", "Text" : "Conjunctivitis", "Mnemonic" : "254"},
{"Row" :143, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Mnemonic" : "256"},
{"Row" :144, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Contiguous or hematogenous spread brain abscess", "Mnemonic" : "258"},
{"Row" :145, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "COPD exacerbation", "Mnemonic" : "260"},
{"Row" :146, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "COPD, prevention of exacerbations", "Mnemonic" : "262"},
{"Row" :147, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "DisplayText" : "Corynebacterium spp. (Outpatient)", "Text" : "Corynebacterium spp.", "Mnemonic" : "264"},
{"Row" :148, "Column" : 1, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient", "Text" : "Crabs", "Mnemonic" : "266"},
{"Row" :149, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Cranial epidural abscess", "Mnemonic" : "268"},
{"Row" :150, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "DisplayText" : "Cyptococcus Neoformans (outpatient)", "Text" : "Cryptococcus neoformans", "Mnemonic" : "270"},
{"Row" :151, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. PARVUM", "DisplayText" : "Diarrhea with Crytosporidium parvum (Outpatient)", "Text" : "Cryptosporidium parvum diarrhea/gastroenteritis", "Mnemonic" : "272"},
{"Row" :152, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "DisplayText" : "Diarrhea with Cyclospora cayetanensis (Outpatient)", "Text" : "Cyclospora cayetanensis diarrhea/gastroenteritis", "Mnemonic" : "274"},
{"Row" :153, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient)", "Text" : "Cystitis, complicated", "Mnemonic" : "276"},
{"Row" :154, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient)", "Text" : "Cystitis, uncomplicated", "Mnemonic" : "278"},
{"Row" :155, "Column" : 1, "Item" : "ORZID3 GMENU ABX CMV MAIN PAGE", "DisplayText" : "Cytomegalovirus (CMV) Main Page (outpatient)", "Text" : "Cytomegalovirus (CMV) [CLICK HERE], includes: ", "Mnemonic" : "280"},
{"Row" :160, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Decolonization of Staphylococcus aureus", "Mnemonic" : "282"},
{"Row" :161, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "DisplayText" : "Decubitis ulcers (Outpatient)", "Text" : "Decubitus ulcers", "Mnemonic" : "284"},
{"Row" :162, "Column" : 1, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "DisplayText" : "Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient", "Text" : "Deep oropharyngeal infections", "Mnemonic" : "286"},
{"Row" :163, "Column" : 1, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Dental infections", "Mnemonic" : "288"},
{"Row" :164, "Column" : 1, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "DisplayText" : "Stasis Dermatitis (outpatient)", "Text" : "Dermatitis, stasis", "Mnemonic" : "290"},
{"Row" :165, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatological surgery guidelines", "Mnemonic" : "292"},
{"Row" :166, "Column" : 1, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "DisplayText" : "Dermatology Infections (Outpatient)", "Text" : "Dermatological Infections section", "Mnemonic" : "294"},
{"Row" :167, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatology post-op infection", "Mnemonic" : "296"},
{"Row" :168, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Desensitization protocol, penicillin", "Mnemonic" : "298"},
{"Row" :169, "Column" : 1, "Item" : "ORZID3 GMENU DEVICE-RELATED INFECT", "DisplayText" : "Device-related infections (Outpatient)", "Text" : "Device-related infections", "Mnemonic" : "300"},
{"Row" :170, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "DisplayText" : "Diabetes Mellitus", "Text" : "Diabetes Mellitus", "Mnemonic" : "302"},
{"Row" :171, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Diabetic foot ulcer", "Mnemonic" : "304"},
{"Row" :172, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "Diarrhea, infectious/gastroenteritis", "Mnemonic" : "306"},
{"Row" :173, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Diphtheria vaccination", "Mnemonic" : "308"},
{"Row" :174, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "DisplayText" : "Exclusions", "Text" : "Diseases and Syndromes not covered", "Mnemonic" : "310"},
{"Row" :175, "Column" : 1, "Item" : "ORZID3 GMENU DISKITIS", "DisplayText" : "Diskitis and vertebral osteomyelitis (Outpatient)", "Text" : "Diskitis and vertebral osteomyelitis", "Mnemonic" : "312"},
{"Row" :176, "Column" : 1, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "DisplayText" : "Disseminated Mycobacterium avium disease (Outpatient)", "Text" : "Disseminated Mycobacterium avium", "Mnemonic" : "314"},
{"Row" :177, "Column" : 1, "Item" : "ORZID3 GMENU DIVERTICULITIS", "DisplayText" : "Diverticulitis (Outpatient)", "Text" : "Diverticulitis", "Mnemonic" : "316"},
{"Row" :178, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Drug allergy information", "Mnemonic" : "318"},
{"Row" :179, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Drug Information", "Mnemonic" : "320"},
{"Row" :180, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Drug properties, important", "Mnemonic" : "322"},
{"Row" :1, "Column" : 1, "Text" : "OUTPATIENT ANTIMICROIBAL CDSS INDEX", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "A______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "antimicrobial prophylaxis, management of fever,"}, 
{"Row" : 47, "Column" : 1, "Text" : "patient initiated antibiotics, vaccines"}, 
{"Row" : 53, "Column" : 1, "Text" : "B______________________________________________________________________________", "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Text" : "C______________________________________________________________________________", "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Text" : "antimicrobial prophylaxis, neutropenic fever"}, 
{"Row" :156, "Column" : 1, "Text" : "colitis, esophagitis, encephalitis, polyradiculopathy"}, 
{"Row" :157, "Column" : 1, "Text" : "retinitis, and pneumonia"}, 
{"Row" :159, "Column" : 1, "Text" : "D______________________________________________________________________________", "Header" : 1}, 
{"Row" :183, "Column" : 1, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "DisplayText" : "Head and Neck / ENT (Outpatient)", "Text" : "Ear, nose, throat (ENT)/Head and Neck section", "Mnemonic" : "324"},
{"Row" :184, "Column" : 1, "Item" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "DisplayText" : "Ecthyma Gangrenosum (Outpatient)", "Text" : "Ecthyma gangrenosum", "Mnemonic" : "326"},
{"Row" :185, "Column" : 1, "Item" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Mnemonic" : "328"},
{"Row" :186, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite wounds with Eikenella corrodens (Outpatient)", "Text" : "Eikenella corrodens, bite wound", "Mnemonic" : "330"},
{"Row" :187, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Eikenella native valve endocarditis", "Mnemonic" : "332"},
{"Row" :188, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Eikenella prosthetic valve endocarditis", "Mnemonic" : "334"},
{"Row" :189, "Column" : 1, "Item" : "ORZID3 GMENU EMPYEMA", "DisplayText" : "Empyema (Outpatient)", "Text" : "Empyema", "Mnemonic" : "336"},
{"Row" :190, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Empyema, subdural", "Mnemonic" : "338"},
{"Row" :191, "Column" : 1, "Item" : "ORZID3 GMENU HSV ENCEPHALITIS", "DisplayText" : "HSV encephalitis (Outpatient)", "Text" : "Encephalitis", "Mnemonic" : "340"},
{"Row" :192, "Column" : 1, "Item" : "ORZID3 GMENU CMV ENCEPHALITIS", "DisplayText" : "CMV encephalitis (Outpatient)", "Text" : "Encephalitis, Cytomegalovirus (CMV)", "Mnemonic" : "342"},
{"Row" :193, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Endocarditis with sepsis", "Mnemonic" : "344"},
{"Row" :194, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, approach to", "Mnemonic" : "346"},
{"Row" :195, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, diagnosis of", "Mnemonic" : "348"},
{"Row" :196, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, native valve [CLICK HERE], includes: ", "Mnemonic" : "350"},
{"Row" :200, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, native valve empirical therapy", "Mnemonic" : "352"},
{"Row" :201, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, prosthetic valve [CLICK HERE], includes: ", "Mnemonic" : "354"},
{"Row" :205, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Endocarditis, prosthetic valve empirical therapy", "Mnemonic" : "356"},
{"Row" :206, "Column" : 1, "Item" : "ORZID3 GMENU ENDOPHTHALMITIS", "DisplayText" : "Endophthalmitis (Outpatient)", "Text" : "Endophthalmitis", "Mnemonic" : "358"},
{"Row" :207, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "DisplayText" : "Diarrhea with Entamoeba histolytica (Outpatient)", "Text" : "Entamoeba histolytica diarrhea/gastroenteritis", "Mnemonic" : "360"},
{"Row" :208, "Column" : 1, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Enteric fever", "Mnemonic" : "362"},
{"Row" :209, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "DisplayText" : "Enterobacter spp. (Outpatient)", "Text" : "Enterobacter species, general", "Mnemonic" : "364"},
{"Row" :210, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Enterobacteriaceae (ESBL+) nosocomial pneumonia", "Mnemonic" : "366"},
{"Row" :211, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "DisplayText" : "Enterococci (Outpatient)", "Text" : "Enterococcal infections, general", "Mnemonic" : "368"},
{"Row" :212, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Enterococcal intravascular catheter-associated infection", "Mnemonic" : "370"},
{"Row" :213, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Enterococci - Outpatient", "Text" : "Enterococcal native joint infection", "Mnemonic" : "372"},
{"Row" :214, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Enterococcal native valve endocarditis", "Mnemonic" : "374"},
{"Row" :215, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses (Outpatient)", "Text" : "Enterococcal prosthetic bone/joint infection", "Mnemonic" : "376"},
{"Row" :216, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Enterococcal prosthetic valve endocarditis", "Mnemonic" : "378"},
{"Row" :217, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Enterococcal pyelonephritis", "Mnemonic" : "380"},
{"Row" :218, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "DisplayText" : "Epididymitis (Outpatient)", "Text" : "Epididymitis", "Mnemonic" : "382"},
{"Row" :219, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Epidural abscess, cranial", "Mnemonic" : "384"},
{"Row" :220, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Epidural abscess, spinal", "Mnemonic" : "386"},
{"Row" :221, "Column" : 1, "Item" : "ORZID3 GMENU EPIGLOTTITIS", "DisplayText" : "Epiglottitis (Outpatient)", "Text" : "Epiglottitis", "Mnemonic" : "388"},
{"Row" :222, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas (Outpatient)", "Text" : "Erysipelas", "Mnemonic" : "390"},
{"Row" :223, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELOID", "DisplayText" : "Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient", "Text" : "Erysipeloid", "Mnemonic" : "392"},
{"Row" :224, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease (Outpatient)", "Text" : "Erythema migrans, Lyme disease", "Mnemonic" : "394"},
{"Row" :225, "Column" : 1, "Item" : "ORZID3 GMENU ERYTHRASMA", "DisplayText" : "Erythrasma (Outpatient)", "Text" : "Erythrasma", "Mnemonic" : "396"},
{"Row" :226, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "DisplayText" : "Diarrhea with enterohemorrhagic E. Coli (Outpatient)", "Text" : "Escherichia coli diarrhea/gastroenteritis", "Mnemonic" : "398"},
{"Row" :227, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG E. COLI", "DisplayText" : "Escherichia coli (Outpatient)", "Text" : "Escherichia coli infections, general", "Mnemonic" : "400"},
{"Row" :228, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Escherichia coli meningitis", "Mnemonic" : "402"},
{"Row" :229, "Column" : 1, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "DisplayText" : "Esophagitis (outpatient)", "Text" : "Esophagitis", "Mnemonic" : "404"},
{"Row" :230, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "Exacerbation of COPD", "Mnemonic" : "406"},
{"Row" :231, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Exacerbations of COPD, prevention of", "Mnemonic" : "408"},
{"Row" :234, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "Flu", "Mnemonic" : "410"},
{"Row" :235, "Column" : 1, "Item" : "ORZID3 GMENU FOLLICULITIS", "DisplayText" : "Folliculitis (Outpatient)", "Text" : "Folliculitis", "Mnemonic" : "412"},
{"Row" :236, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Foot ulcer in patient with diabetes", "Mnemonic" : "414"},
{"Row" :237, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Fungal native valve endocarditis", "Mnemonic" : "416"},
{"Row" :238, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Fungal prosthetic valve endocarditis", "Mnemonic" : "418"},
{"Row" :239, "Column" : 1, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Fungal sinusitis", "Mnemonic" : "420"},
{"Row" :240, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Fungemia associated with Candida spp.", "Mnemonic" : "422"},
{"Row" :241, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI", "DisplayText" : "Fungi (Outpatient)", "Text" : "Fungi section", "Mnemonic" : "424"},
{"Row" :242, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient)", "Text" : "Furuncles", "Mnemonic" : "426"},
{"Row" :182, "Column" : 1, "Text" : "E______________________________________________________________________________", "Header" : 1}, 
{"Row" :197, "Column" : 1, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :198, "Column" : 1, "Text" : "gram-negative bacilli, streptococci, staphylococci,"}, 
{"Row" :199, "Column" : 1, "Text" : "and HACEK bacteria"}, 
{"Row" :202, "Column" : 1, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :203, "Column" : 1, "Text" : "gram-negative bacilli, Streptococcus bovis,"}, 
{"Row" :204, "Column" : 1, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci"}, 
{"Row" :233, "Column" : 1, "Text" : "F______________________________________________________________________________", "Header" : 1}, 
{"Row" :1, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Mnemonic" : "428"},
{"Row" :2, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help", "Mnemonic" : "430"},
{"Row" :7, "Column" : 2, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "Gastroenteritis/infectious diarrhea", "Mnemonic" : "432"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "DisplayText" : "Gastrointestinal (Outpatient)", "Text" : "Gastrointestinal and Intraabdominal section", "Mnemonic" : "434"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient)", "Text" : "Genital herpes", "Mnemonic" : "436"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU GENITOURINARY", "DisplayText" : "Genitourinary (Outpatient)", "Text" : "Genitourinary section", "Mnemonic" : "438"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "DisplayText" : "Diarrhea with Giardia lamblia (Outpatient)", "Text" : "Giardia lamblia diarrhea", "Mnemonic" : "440"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "DisplayText" : "Diarrhea with Giardia lamblia (Outpatient)", "Text" : "Giardia lamblia infections, general", "Mnemonic" : "442"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Gonococcal urethritis", "Mnemonic" : "444"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-negative bacilli bacteremia", "Mnemonic" : "446"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "DisplayText" : "Interim results:Gram-negative bacilli (Outpatient)", "Text" : "Gram-negative bacilli interim culture results", "Mnemonic" : "448"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Gram-negative bacilli intravascular catheter-associated infection", "Mnemonic" : "450"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Gram-negative bacilli meningitis", "Mnemonic" : "452"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Gram-negative bacilli, non-HACEK, native valve endocarditis", "Mnemonic" : "454"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis", "Mnemonic" : "456"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOM GNB", "DisplayText" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient", "Text" : "Gram-negative bacilli, non-pseudomonas, osteomyelitis", "Mnemonic" : "458"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU PROS B/J GNB", "DisplayText" : "Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses", "Text" : "Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection", "Mnemonic" : "460"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTH GNB", "DisplayText" : "Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient", "Text" : "Gram-negative bacilli, non-pseudomonas, native joint infection", "Mnemonic" : "462"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram negative bacteria (Outpatient)", "Text" : "Gram-Negative Bacteria section", "Mnemonic" : "464"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-negative cocci bacteremia", "Mnemonic" : "466"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "DisplayText" : "Iterim report of Gram-negative cocci (Outpatient)", "Text" : "Gram-negative cocci interim culture results", "Mnemonic" : "468"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Gram-negative diplococci meningitis", "Mnemonic" : "470"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-positive bacilli bacteremia", "Mnemonic" : "472"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Gram-positive bacilli meningitis", "Mnemonic" : "474"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "DisplayText" : "Interim report of Gram-positive Bacilli (Outpatient)", "Text" : "Gram-positive bacilli, interim culture results", "Mnemonic" : "476"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Gram-positive bacteria, section", "Mnemonic" : "478"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-positive cocci in pairs and chains bacteremia", "Mnemonic" : "480"},
{"Row" : 32, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-positive cocci in pairs and clusters bacteremia", "Mnemonic" : "482"},
{"Row" : 33, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Gram-positive cocci in pairs bacteremia", "Mnemonic" : "484"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs (Outpatient)", "Text" : "Gram-positive cocci in pairs interim culture results", "Mnemonic" : "486"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "DisplayText" : "Anaerobic Gram-positive cocci (Outpatient)", "Text" : "Gram-positive cocci, anaerobic", "Mnemonic" : "488"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Gram-positive coccobacilli meningitis", "Mnemonic" : "490"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Gram-positive diplococci meningitis", "Mnemonic" : "492"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "DisplayText" : "Group A (S. pyogenes) - Outpatient", "Text" : "Group A streptococci", "Mnemonic" : "494"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "DisplayText" : "Group B (S. agalactiae) - Outpatient", "Text" : "Group B Streptococci", "Mnemonic" : "496"},
{"Row" : 40, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "DisplayText" : "Group D Streptococci (S. bovis) - Outpatient", "Text" : "Group D Streptococci", "Mnemonic" : "498"},
{"Row" : 41, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "DisplayText" : "Streptococci Groups C, F, G (Outpatient)", "Text" : "Groups C, F, G Streptococci", "Mnemonic" : "500"},
{"Row" : 44, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "HACEK bacteria native valve endocarditis", "Mnemonic" : "502"},
{"Row" : 45, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "HACEK bacteria prosthetic valve endocarditis", "Mnemonic" : "504"},
{"Row" : 46, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "DisplayText" : "Haemophilus spp. (Outpatient)", "Text" : "Haemophilus infections, general", "Mnemonic" : "506"},
{"Row" : 47, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae B vaccination", "Mnemonic" : "508"},
{"Row" : 48, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Haemophilus native valve endocarditis", "Mnemonic" : "510"},
{"Row" : 49, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Haemophilus prosthetic valve endocarditis", "Mnemonic" : "512"},
{"Row" : 50, "Column" : 2, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "DisplayText" : "Head and Neck / ENT (Outpatient)", "Text" : "Head and Neck/ENT section", "Mnemonic" : "514"},
{"Row" : 51, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis) - Outpatient", "Text" : "Head lice", "Mnemonic" : "516"},
{"Row" : 52, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection (Outpatient)", "Text" : "Helicobacter pylori", "Mnemonic" : "518"},
{"Row" : 53, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help", "Mnemonic" : "520"},
{"Row" : 54, "Column" : 2, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera) - Outpatient", "Text" : "Hemiptera", "Mnemonic" : "522"},
{"Row" : 55, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Hemodialysis immunizations", "Mnemonic" : "524"},
{"Row" : 56, "Column" : 2, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Hepatic abscess", "Mnemonic" : "526"},
{"Row" : 57, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Hepatic disease immunizations", "Mnemonic" : "528"},
{"Row" : 58, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A (outpatient)", "Text" : "Hepatitis A", "Mnemonic" : "530"},
{"Row" : 59, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A vaccination", "Mnemonic" : "532"},
{"Row" : 60, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A/Hepatitis B vaccination", "Mnemonic" : "534"},
{"Row" : 61, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B (outpatient)", "Text" : "Hepatitis B", "Mnemonic" : "536"},
{"Row" : 62, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B vaccination", "Mnemonic" : "538"},
{"Row" : 63, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C (outpatient)", "Text" : "Hepatitis C", "Mnemonic" : "540"},
{"Row" : 64, "Column" : 2, "Item" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "DisplayText" : "Herpes Simplex Esophagitis (Outpatient)", "Text" : "Herpes esophagitis", "Mnemonic" : "542"},
{"Row" : 65, "Column" : 2, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Herpes keratitis", "Mnemonic" : "544"},
{"Row" : 66, "Column" : 2, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "Herpes retinitis", "Mnemonic" : "546"},
{"Row" : 67, "Column" : 2, "Item" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Text" : "Herpes whitlow (digit or hand cellulitis)", "Mnemonic" : "548"},
{"Row" : 68, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient)", "Text" : "Herpes, genital", "Mnemonic" : "550"},
{"Row" : 69, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "DisplayText" : "Orolabial herpes (Outpatient)", "Text" : "Herpes, orolabial", "Mnemonic" : "552"},
{"Row" : 70, "Column" : 2, "Item" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "DisplayText" : "Hidradenitis Suppurativa (Outpatient)", "Text" : "Hidradenitis suppurativa", "Mnemonic" : "554"},
{"Row" : 71, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "DisplayText" : "Histoplasma capsulatum (Outpatient)", "Text" : "Histoplasma capsulatum", "Mnemonic" : "556"},
{"Row" : 72, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "HIV patient immunization", "Mnemonic" : "558"},
{"Row" : 73, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS (outpatient)", "Text" : "HIV infection, general", "Mnemonic" : "560"},
{"Row" : 74, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "DisplayText" : "Home IV at the Minneapolis VAMC", "Text" : "Home IV therapy at MVAMC", "Mnemonic" : "562"},
{"Row" : 75, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Hospital-acquired pneumonia (HAP)", "Mnemonic" : "564"},
{"Row" : 76, "Column" : 2, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "HSCT immunizations", "Mnemonic" : "566"},
{"Row" : 77, "Column" : 2, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papilloma virus vaccination", "Mnemonic" : "568"},
{"Row" : 78, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "DisplayText" : "Hypochlorhydria", "Text" : "Hypochlorhydria", "Mnemonic" : "570"},
{"Row" : 81, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "DisplayText" : "Immunization of Immunocompromised Patients", "Text" : "Immunization of immunocompromised patients (except HIV)", "Mnemonic" : "572"},
{"Row" : 82, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Immunization of patients at high-risk of rabies exposure", "Mnemonic" : "574"},
{"Row" : 83, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Immunization of patients in kidney failure/HD", "Mnemonic" : "576"},
{"Row" : 84, "Column" : 2, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Immunization of patients with asplenia", "Mnemonic" : "578"},
{"Row" : 85, "Column" : 2, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Immunization of patients with bone marrow transplant", "Mnemonic" : "580"},
{"Row" : 86, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Immunization of patients with chronic liver disease", "Mnemonic" : "582"},
{"Row" : 87, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "Immunization of patients with HIV", "Mnemonic" : "584"},
{"Row" : 88, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Immunization of patients with pregnancy", "Mnemonic" : "586"},
{"Row" : 89, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "DisplayText" : "CDC Recommended Adult Immunizations", "Text" : "Immunization, adult [CLICK HERE], includes: ", "Mnemonic" : "588"},
{"Row" : 94, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "DisplayText" : "Basic concepts", "Text" : "Immunocompromised patients basic concepts", "Mnemonic" : "590"},
{"Row" : 95, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "DisplayText" : "Infections in Immunocompromised patients (Outpatient)", "Text" : "Immunocompromised Patients section", "Mnemonic" : "592"},
{"Row" : 96, "Column" : 2, "Item" : "ORZID3 GMENU IG DEFICIENCY HIS", "DisplayText" : "Immunoglobulin deficiency (Humoral immune system) - Outpatient", "Text" : "Immunoglobulin (Humoral immune system) deficiency", "Mnemonic" : "594"},
{"Row" : 97, "Column" : 2, "Item" : "ORZID3 GMENU IMPETIGO", "DisplayText" : "Impetigo (Outpatient)", "Text" : "Impetigo", "Mnemonic" : "596"},
{"Row" : 98, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "DisplayText" : "Important drug properties", "Text" : "Important drug properties", "Mnemonic" : "598"},
{"Row" : 99, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "DisplayText" : "Infection Control", "Text" : "Infection control department information", "Mnemonic" : "600"},
{"Row" :100, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "DisplayText" : "Prevention of Infection - Outpatient", "Text" : "Infection Prevention section", "Mnemonic" : "602"},
{"Row" :101, "Column" : 2, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "Infectious diarrhea/gastroenteritis", "Mnemonic" : "604"},
{"Row" :102, "Column" : 2, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "Influenza", "Mnemonic" : "606"},
{"Row" :103, "Column" : 2, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Intravascular catheter-associated infection", "Mnemonic" : "608"},
{"Row" :104, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "DisplayText" : "Home IV at the Minneapolis VAMC", "Text" : "Intravenous therapy at home, MVAMC", "Mnemonic" : "610"},
{"Row" :105, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "DisplayText" : "Diarrhea with Isospora belli (Outpatient)", "Text" : "Isospora diarrhea/gastroenteritis", "Mnemonic" : "612"},
{"Row" :108, "Column" : 2, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)", "Text" : "Joint and Bone section", "Mnemonic" : "614"},
{"Row" :109, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native Joint) - Outpatient", "Text" : "Joint infection, native [CLICK HERE], includes: ", "Mnemonic" : "616"},
{"Row" :113, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Joint infection, prosthetic [CLICK HERE], includes: ", "Mnemonic" : "618"},
{"Row" :119, "Column" : 2, "Item" : "ORZID3 GMENU KERATITIS", "DisplayText" : "Keratitis (Outpatient)", "Text" : "Keratitis", "Mnemonic" : "620"},
{"Row" :120, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Kidney failure immunizations", "Mnemonic" : "622"},
{"Row" :121, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Kingella native valve endocarditis", "Mnemonic" : "624"},
{"Row" :122, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Kingella prosthetic valve endocarditis", "Mnemonic" : "626"},
{"Row" :123, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "DisplayText" : "Klebsiella spp. (Outpatient)", "Text" : "Klebsiella infections, general", "Mnemonic" : "628"},
{"Row" :126, "Column" : 2, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "DisplayText" : "Large uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Large uniform bacilli, aerobic bottle", "Mnemonic" : "630"},
{"Row" :127, "Column" : 2, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "DisplayText" : "Large uniform bacilli in an aerobic bottle (Outpatient)", "Text" : "Large uniform bacilli, anaerobic bottle", "Mnemonic" : "632"},
{"Row" :128, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "DisplayText" : "Laryngitis and Croup", "Text" : "Laryngitis", "Mnemonic" : "634"},
{"Row" :129, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "DisplayText" : "Legionella spp. (Outpatient)", "Text" : "Legionella infections, general", "Mnemonic" : "636"},
{"Row" :130, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Legionella pneumophila nosocomial pneumonia", "Mnemonic" : "638"},
{"Row" :131, "Column" : 2, "Item" : "ORZID3 GMENU LEISHMANIASIS", "DisplayText" : "Leishmaniasis", "Text" : "Leishmaniasis", "Mnemonic" : "640"},
{"Row" :132, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "DisplayText" : "Leukocytosis", "Text" : "Leukocytosis", "Mnemonic" : "642"},
{"Row" :133, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis) - Outpatient", "Text" : "Lice, body", "Mnemonic" : "644"},
{"Row" :134, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis) - Outpatient", "Text" : "Lice, head", "Mnemonic" : "646"},
{"Row" :135, "Column" : 2, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient", "Text" : "Lice, pubic", "Mnemonic" : "648"},
{"Row" :136, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "DisplayText" : "Listeria spp. (Outpatient)", "Text" : "Listeria infections, general", "Mnemonic" : "650"},
{"Row" :137, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Listeria monocytogenes bacteremia", "Mnemonic" : "652"},
{"Row" :138, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Listeria monocytogenes meningitis", "Mnemonic" : "654"},
{"Row" :139, "Column" : 2, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Liver abscess", "Mnemonic" : "656"},
{"Row" :140, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Liver disease immunizations", "Mnemonic" : "658"},
{"Row" :141, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Liver disease, prevention of spontaneous bacterial peritonitis", "Mnemonic" : "660"},
{"Row" :142, "Column" : 2, "Item" : "ORZID3 GMENU LUNG ABSCESS", "DisplayText" : "Lung abscess (Outpatient)", "Text" : "Lung abscess", "Mnemonic" : "662"},
{"Row" :143, "Column" : 2, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "DisplayText" : "Lungs and Mediastinum (Outpatient)", "Text" : "Lungs and Mediastinum section", "Mnemonic" : "664"},
{"Row" :144, "Column" : 2, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme disease [CLICK HERE], includes: ", "Mnemonic" : "666"},
{"Row" :149, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy (Outpatient)", "Text" : "Malignancy [CLICK HERE], includes: ", "Mnemonic" : "668"},
{"Row" :151, "Column" : 2, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "DisplayText" : "Malignant otitis externa (Outpatient)", "Text" : "Malignant otitis externa", "Mnemonic" : "670"},
{"Row" :152, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "DisplayText" : "Malnutrition", "Text" : "Malnutrition", "Mnemonic" : "672"},
{"Row" :153, "Column" : 2, "Item" : "ORZID3 GMENU MASTOIDITIS", "DisplayText" : "Mastoiditis (Outpatient)", "Text" : "Mastoiditis", "Mnemonic" : "674"},
{"Row" :154, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles vaccination", "Mnemonic" : "676"},
{"Row" :155, "Column" : 2, "Item" : "ORZID3 GMENU MEDIASTINITIS", "DisplayText" : "Mediastinitis (Outpatient)", "Text" : "Mediastinitis", "Mnemonic" : "678"},
{"Row" :156, "Column" : 2, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "DisplayText" : "Lungs and Mediastinum (Outpatient)", "Text" : "Mediastinum and Lung section", "Mnemonic" : "680"},
{"Row" :157, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis associated with trauma or nosocomial infection", "Mnemonic" : "682"},
{"Row" :158, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with E. coli, Pseudomonas or other organism", "Mnemonic" : "684"},
{"Row" :159, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with Escherichia coli", "Mnemonic" : "686"},
{"Row" :160, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with gram-negative bacilli", "Mnemonic" : "688"},
{"Row" :161, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with gram-negative diplococci", "Mnemonic" : "690"},
{"Row" :162, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with gram-positive bacilli/coccobacilli", "Mnemonic" : "692"},
{"Row" :163, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with gram-positive diplococci", "Mnemonic" : "694"},
{"Row" :164, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with Listeria monocytogenes", "Mnemonic" : "696"},
{"Row" :165, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with Neisseria meningitidis", "Mnemonic" : "698"},
{"Row" :166, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with pseudomonas", "Mnemonic" : "700"},
{"Row" :167, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Meningitis with sepsis", "Mnemonic" : "702"},
{"Row" :168, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis with Streptococcus pneumoniae", "Mnemonic" : "704"},
{"Row" :169, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis without gram stain results", "Mnemonic" : "706"},
{"Row" :170, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Meningitis, other organism", "Mnemonic" : "708"},
{"Row" :171, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal conjugate (MENACWY) vaccination", "Mnemonic" : "710"},
{"Row" :172, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MENB) vaccination", "Mnemonic" : "712"},
{"Row" :173, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-resistant S. aureus (Outpatient)", "Text" : "Methicillin-resistant Staphylococcus aureus bite wounds", "Mnemonic" : "714"},
{"Row" :174, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "DisplayText" : "Diarrhea with Microsporidia (Outpatient)", "Text" : "Microsporidia diarrhea/gastroenteritis", "Mnemonic" : "716"},
{"Row" :175, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis (Outpatient)", "Text" : "Moraxella catarrhalis infections, general", "Mnemonic" : "718"},
{"Row" :176, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-resistant S. aureus (Outpatient)", "Text" : "MRSA bite wounds", "Mnemonic" : "720"},
{"Row" :177, "Column" : 2, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "MRSA risk factors", "Mnemonic" : "722"},
{"Row" :178, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient)", "Text" : "MSSA bite wounds", "Mnemonic" : "724"},
{"Row" :179, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Mumps vaccination", "Mnemonic" : "726"},
{"Row" :180, "Column" : 2, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)", "Text" : "Muscle and Soft Tissue section", "Mnemonic" : "728"},
{"Row" :181, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient", "Text" : "Mycobacterium avium intracellular complex (MAI or MAC)", "Mnemonic" : "730"},
{"Row" :182, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia (Outpatient)", "Text" : "Mycobacterium avium pneumonia", "Mnemonic" : "732"},
{"Row" :183, "Column" : 2, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "DisplayText" : "Prophylaxis against Mycobacterium avium disease... (Outpatient)", "Text" : "Mycobacterium avium prophylaxis", "Mnemonic" : "734"},
{"Row" :184, "Column" : 2, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "DisplayText" : "Disseminated Mycobacterium avium disease (Outpatient)", "Text" : "Mycobacterium avium, disseminated", "Mnemonic" : "736"},
{"Row" :185, "Column" : 2, "Item" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "DisplayText" : "Mycobacterium tuberculosis (Outpatient)", "Text" : "Mycobacterium tuberculosis", "Mnemonic" : "738"},
{"Row" :186, "Column" : 2, "Item" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "DisplayText" : "Mycoplasma pneumonia (Outpatient)", "Text" : "Mycoplasma pneumonia infections, general", "Mnemonic" : "740"},
{"Row" :187, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Myocarditis", "Mnemonic" : "742"},
{"Row" :4, "Column" : 2, "Text" : "G through Pn", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Text" : "G______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Text" : "H______________________________________________________________________________", "Header" : 1}, 
{"Row" : 80, "Column" : 2, "Text" : "I______________________________________________________________________________", "Header" : 1}, 
{"Row" : 90, "Column" : 2, "Text" : "diphtheria, Haemophilus influenza B, Hepatitis A and B,"}, 
{"Row" : 91, "Column" : 2, "Text" : "human papilloma virus, influenza, measles, mumps,"}, 
{"Row" : 92, "Column" : 2, "Text" : "meningococcal, pneumococcal, pertussis, rubella,"}, 
{"Row" : 93, "Column" : 2, "Text" : "tetanus, varicella, zoster"}, 
{"Row" :107, "Column" : 2, "Text" : "J______________________________________________________________________________", "Header" : 1}, 
{"Row" :110, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :111, "Column" : 2, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" :112, "Column" : 2, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :114, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :115, "Column" : 2, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" :116, "Column" : 2, "Text" : "and streptococcus"}, 
{"Row" :118, "Column" : 2, "Text" : "K______________________________________________________________________________", "Header" : 1}, 
{"Row" :125, "Column" : 2, "Text" : "L______________________________________________________________________________", "Header" : 1}, 
{"Row" :145, "Column" : 2, "Text" : "arthritis, carditis, erythema migrans,"}, 
{"Row" :146, "Column" : 2, "Text" : "neurological complications, prophylaxis"}, 
{"Row" :148, "Column" : 2, "Text" : "M______________________________________________________________________________", "Header" : 1}, 
{"Row" :150, "Column" : 2, "Text" : "antimicrobial prophylaxis, neutropenic fever"}, 
{"Row" :190, "Column" : 2, "Item" : "ORZID3 GMENU NASAL PACKING", "DisplayText" : "Prevention of infection in patients with nasal packing (Outpatient)", "Text" : "Nasal packing", "Mnemonic" : "744"},
{"Row" :191, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native Joint) - Outpatient", "Text" : "Native joint infection [CLICK HERE], includes: ", "Mnemonic" : "746"},
{"Row" :195, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Native valve endocarditis [CLICK HERE], includes: ", "Mnemonic" : "748"},
{"Row" :199, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Native valve endocarditis empirical therapy", "Mnemonic" : "750"},
{"Row" :200, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Native valve endocarditis with sepsis", "Mnemonic" : "752"},
{"Row" :201, "Column" : 2, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections (Outpatient)", "Text" : "Necrotizing infections", "Mnemonic" : "754"},
{"Row" :202, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae (Outpatient)", "Text" : "Neisseria gonorrhoeae infections, general", "Mnemonic" : "756"},
{"Row" :203, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "DisplayText" : "Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient", "Text" : "Neisseria gonorrhoeae native joint infection", "Mnemonic" : "758"},
{"Row" :204, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis (Outpatient)", "Text" : "Neisseria meningitidis infections, general", "Mnemonic" : "760"},
{"Row" :205, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Neisseria meningitidis meningitis", "Mnemonic" : "762"},
{"Row" :206, "Column" : 2, "Item" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "DisplayText" : "Acute neurological disease associated with Lyme disease (Outpatient)", "Text" : "Neurological disease associated with Lyme disease", "Mnemonic" : "764"},
{"Row" :207, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "DisplayText" : "Neurologial Dysfunction (Outpatient)", "Text" : "Neurological dysfunction", "Mnemonic" : "766"},
{"Row" :208, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "DisplayText" : "Neutropenia", "Text" : "Neutropenia", "Mnemonic" : "768"},
{"Row" :209, "Column" : 2, "Item" : "ORZID3 GMENU TYPHLITIS", "DisplayText" : "Neutropenic enterocolitis (Typhlitis) - Outpatient", "Text" : "Neutropenic enterocolitis", "Mnemonic" : "770"},
{"Row" :210, "Column" : 2, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)", "Text" : "Neutropenic fever", "Mnemonic" : "772"},
{"Row" :211, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Neutropenic fever with sepsis", "Mnemonic" : "774"},
{"Row" :212, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Nocardia spp. brain abscess", "Mnemonic" : "776"},
{"Row" :213, "Column" : 2, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation (Outpatient)", "Text" : "Non-perforated appendicitis", "Mnemonic" : "778"},
{"Row" :214, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Non-streptococcal pharyngitis", "Mnemonic" : "780"},
{"Row" :215, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Nosocomial pneumonia", "Mnemonic" : "782"},
{"Row" :216, "Column" : 2, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "DisplayText" : "Nosocomial sinusitis (Outpatient)", "Text" : "Nosocomial sinusitis", "Mnemonic" : "784"},
{"Row" :219, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Occupational post-exposure prophylaxis", "Mnemonic" : "786"},
{"Row" :220, "Column" : 2, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Onychomycosis", "Mnemonic" : "788"},
{"Row" :221, "Column" : 2, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal cellulitis (Orbital cellulitis) - Outpatient", "Text" : "Orbital cellulitis", "Mnemonic" : "790"},
{"Row" :222, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "DisplayText" : "Orolabial herpes (Outpatient)", "Text" : "Orolabial herpes", "Mnemonic" : "792"},
{"Row" :223, "Column" : 2, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "DisplayText" : "Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient", "Text" : "Oropharyngeal infections, deep", "Mnemonic" : "794"},
{"Row" :224, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis (Outpatient)", "Text" : "Osteomyelitis [CLICK HERE], includes: ", "Mnemonic" : "796"},
{"Row" :227, "Column" : 2, "Item" : "ORZID3 GMENU OTHER PATHOGENS", "DisplayText" : "Other Pathogens (Outpatient)", "Text" : "Other Pathogens section", "Mnemonic" : "798"},
{"Row" :228, "Column" : 2, "Item" : "ORZID3 GMENU OTITIS EXTERNA", "DisplayText" : "Otitis externa (Outpatient)", "Text" : "Otitis externa", "Mnemonic" : "800"},
{"Row" :229, "Column" : 2, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "DisplayText" : "Malignant otitis externa (Outpatient)", "Text" : "Otitis externa, malignant", "Mnemonic" : "802"},
{"Row" :230, "Column" : 2, "Item" : "ORZID3 GMENU OTITIS MEDIA", "DisplayText" : "Otitis media (Outpatient)", "Text" : "Otitis media", "Mnemonic" : "804"},
{"Row" :233, "Column" : 2, "Item" : "ORZID3 GMENU PANCREATITIS", "DisplayText" : "Pancreatitis (Outpatient)", "Text" : "Pancreatitis", "Mnemonic" : "806"},
{"Row" :234, "Column" : 2, "Item" : "ORZID3 GMENU ABX PARAINFLUENZA", "DisplayText" : "Parainfluenza (outpatient)", "Text" : "Parainfluenza", "Mnemonic" : "808"},
{"Row" :235, "Column" : 2, "Item" : "ORZID3 GMENU PARASITES MAIN", "DisplayText" : "Parasites (Outpatient)", "Text" : "Parasites", "Mnemonic" : "810"},
{"Row" :236, "Column" : 2, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Paratyphoid fever", "Mnemonic" : "812"},
{"Row" :237, "Column" : 2, "Item" : "ORZID3 GMENU PARONYCHIA", "DisplayText" : "Paronychia (Outpatient)", "Text" : "Paronychia", "Mnemonic" : "814"},
{"Row" :238, "Column" : 2, "Item" : "ORZID3 GMENU ABX PAROTITIS", "DisplayText" : "Parotitis (outpatient)", "Text" : "Parotitis", "Mnemonic" : "816"},
{"Row" :239, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite wounds with Pasteurella multocida (Outpatient)", "Text" : "Pasteurella multocida bite wounds", "Mnemonic" : "818"},
{"Row" :240, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "DisplayText" : "Pasteurella multocida (Outpatient)", "Text" : "Pasteurella multocida infections, general", "Mnemonic" : "820"},
{"Row" :241, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis) - Outpatient", "Text" : "Pediculosis corporis", "Mnemonic" : "822"},
{"Row" :242, "Column" : 2, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "DisplayText" : "Pelvic inflammatory disorder (PID) - Outpatient", "Text" : "Pelvic inflammatory disease (PID)", "Mnemonic" : "824"},
{"Row" :243, "Column" : 2, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "DisplayText" : "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)", "Text" : "Pelvic pain syndrome/prostatitis, chronic", "Mnemonic" : "826"},
{"Row" :244, "Column" : 2, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Penicillin desensitization protocol", "Mnemonic" : "828"},
{"Row" :245, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "DisplayText" : "Anaerobic Gram-positive cocci (Outpatient)", "Text" : "Peptostreptococcus infections, general", "Mnemonic" : "830"},
{"Row" :246, "Column" : 2, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "DisplayText" : "Appendicitis with perforation (Outpatient)", "Text" : "Perforated appendicitis", "Mnemonic" : "832"},
{"Row" :247, "Column" : 2, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Perianal abscess", "Mnemonic" : "834"},
{"Row" :248, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Pericarditis", "Mnemonic" : "836"},
{"Row" :249, "Column" : 2, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "DisplayText" : "Periocular Infections", "Text" : "Periocular infections", "Mnemonic" : "838"},
{"Row" :250, "Column" : 2, "Item" : "ORZID3 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease (Outpatient)", "Text" : "Periodontal disease", "Mnemonic" : "840"},
{"Row" :251, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "DisplayText" : "Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...", "Text" : "Peritoneal dialysis peritonitis", "Mnemonic" : "842"},
{"Row" :252, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Peritonitis, acute spontaneous bacterial", "Mnemonic" : "844"},
{"Row" :253, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "DisplayText" : "Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...", "Text" : "Peritonitis, peritoneal dialysis associated", "Mnemonic" : "846"},
{"Row" :254, "Column" : 2, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)", "Text" : "Peritonitis, secondary", "Mnemonic" : "848"},
{"Row" :255, "Column" : 2, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient)", "Text" : "Persistent or recurrent urethritis", "Mnemonic" : "850"},
{"Row" :256, "Column" : 2, "Item" : "ORZID3 GMENU PERTUSSIS", "DisplayText" : "Pertussis (Outpatient)", "Text" : "Pertussis", "Mnemonic" : "852"},
{"Row" :257, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "DisplayText" : "Prevention of pertussis (Outpatient)", "Text" : "Pertussis post-exposure prophylaxis", "Mnemonic" : "854"},
{"Row" :258, "Column" : 2, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Pertussis vaccination", "Mnemonic" : "856"},
{"Row" :259, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Pharyngitis, non-streptococcal", "Mnemonic" : "858"},
{"Row" :260, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Pharyngitis, streptococcal", "Mnemonic" : "860"},
{"Row" :261, "Column" : 2, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal vaccination", "Mnemonic" : "862"},
{"Row" :262, "Column" : 2, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient)", "Text" : "Pneumocystis", "Mnemonic" : "864"},
{"Row" :263, "Column" : 2, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocystis Jirovecii Prophylaxis", "Text" : "Pneumocystis prophylaxis", "Mnemonic" : "866"},
{"Row" :264, "Column" : 2, "Item" : "ORZID3 GMENU COMM INFECT PNEUMO", "DisplayText" : "Pneumonia (Outpatient)", "Text" : "Pneumonia", "Mnemonic" : "868"},
{"Row" :265, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Pneumonia with sepsis", "Mnemonic" : "870"},
{"Row" :266, "Column" : 2, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient)", "Text" : "Pneumonia, aspiration", "Mnemonic" : "872"},
{"Row" :267, "Column" : 2, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient)", "Text" : "Pneumonia, community-acquired (CAP)", "Mnemonic" : "876"},
{"Row" :268, "Column" : 2, "Item" : "ORZID3 GMENU CMV PNEUMONIA", "DisplayText" : "CMV pneumonia (Outpatient)", "Text" : "Pneumonia, Cytomegalovirus (CMV)", "Mnemonic" : "878"},
{"Row" :269, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia (Outpatient)", "Text" : "Pneumonia, Mycobacterium avium", "Mnemonic" : "880"},
{"Row" :270, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Pneumonia, nosocomial [CLICK HERE], includes: ", "Mnemonic" : "882"},
{"Row" :189, "Column" : 2, "Text" : "N______________________________________________________________________________", "Header" : 1}, 
{"Row" :192, "Column" : 2, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :193, "Column" : 2, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" :194, "Column" : 2, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :196, "Column" : 2, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" :197, "Column" : 2, "Text" : "gram-negative bacilli, streptococci, staphylococci,"}, 
{"Row" :198, "Column" : 2, "Text" : "and HACEK bacteria"}, 
{"Row" :218, "Column" : 2, "Text" : "O______________________________________________________________________________", "Header" : 1}, 
{"Row" :225, "Column" : 2, "Text" : "empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,"}, 
{"Row" :226, "Column" : 2, "Text" : "Staphylococcus aureus, and streptococci"}, 
{"Row" :232, "Column" : 2, "Text" : "Pa-Pn__________________________________________________________________________", "Header" : 1}, 
{"Row" :271, "Column" : 2, "Text" : "72 hour re-evaluation, Acinetobacter baumannii,"}, 
{"Row" :272, "Column" : 2, "Text" : "empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,"}, 
{"Row" :273, "Column" : 2, "Text" : "Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP"}, 
{"Row" :1, "Column" : 3, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Drug Information", "Mnemonic" : "884"},
{"Row" :7, "Column" : 3, "Item" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "DisplayText" : "CMV polyradiculopathy (Outpatient)", "Text" : "Polyradiculopathy, Cytomegalovirus (CMV)", "Mnemonic" : "886"},
{"Row" :8, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (Outpatient)", "Text" : "Porphyromonas infections, general", "Mnemonic" : "888"},
{"Row" :9, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Post-exposure prophylaxis, occupational", "Mnemonic" : "890"},
{"Row" : 10, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "DisplayText" : "Prevention of pertussis (Outpatient)", "Text" : "Post-exposure prophylaxis, pertussis", "Mnemonic" : "892"},
{"Row" : 13, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Post-operative antimicrobial prophylaxis", "Mnemonic" : "896"},
{"Row" : 14, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Post-operative dermatology infection", "Mnemonic" : "898"},
{"Row" : 15, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "Post-operative wound infection", "Mnemonic" : "900"},
{"Row" : 16, "Column" : 3, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal cellulitis (Orbital cellulitis) - Outpatient", "Text" : "Postseptal cellulitis", "Mnemonic" : "902"},
{"Row" : 17, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Post-surgical or post-traumatic brain abscess", "Mnemonic" : "904"},
{"Row" : 18, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy immunizations", "Mnemonic" : "906"},
{"Row" : 19, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category", "Text" : "Pregnancy risk factors for antimicrobials", "Mnemonic" : "908"},
{"Row" : 20, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Pre-operative antimicrobial prophylaxis", "Mnemonic" : "910"},
{"Row" : 21, "Column" : 3, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal cellulitis (Outpatient)", "Text" : "Preseptal cellulitis", "Mnemonic" : "912"},
{"Row" : 22, "Column" : 3, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Prevention of COPD exacerbations", "Mnemonic" : "914"},
{"Row" : 23, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "DisplayText" : "Prevention of Infection - Outpatient", "Text" : "Prevention of Infection section", "Mnemonic" : "916"},
{"Row" : 24, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (Outpatient)", "Text" : "Prevotella infections, general", "Mnemonic" : "918"},
{"Row" : 25, "Column" : 3, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "DisplayText" : "Prevention of infection in a patient with malignancy (Outpatient)", "Text" : "Prophylactic antibiotics in malignancy", "Mnemonic" : "920"},
{"Row" : 26, "Column" : 3, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infection in a patient with malignancy", "Text" : "Prophylactic antifungals in malignancy", "Mnemonic" : "922"},
{"Row" : 27, "Column" : 3, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Prophylactic antimicrobials for asplenia", "Mnemonic" : "924"},
{"Row" : 28, "Column" : 3, "Item" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis", "Text" : "Prophylactic antimicrobials for Lyme disease", "Mnemonic" : "926"},
{"Row" : 29, "Column" : 3, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "DisplayText" : "Prophylaxis against Mycobacterium avium disease... (Outpatient)", "Text" : "Prophylactic antimicrobials for Mycobacterium avium", "Mnemonic" : "928"},
{"Row" : 30, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "Prophylactic antimicrobials for occupational post-exposure", "Mnemonic" : "930"},
{"Row" : 31, "Column" : 3, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocystis Jirovecii Prophylaxis", "Text" : "Prophylactic antimicrobials for Pneumocystis", "Mnemonic" : "932"},
{"Row" : 32, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "DisplayText" : "Prevention of pertussis (Outpatient)", "Text" : "Prophylactic antimicrobials for post-exposure pertussis", "Mnemonic" : "934"},
{"Row" : 33, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Prophylactic antimicrobials for spontaneous bacterial peritonitis", "Mnemonic" : "936"},
{"Row" : 34, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Prophylactic antimicrobials, post-operative", "Mnemonic" : "938"},
{"Row" : 35, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Prophylactic antimicrobials, pre-operative", "Mnemonic" : "940"},
{"Row" : 36, "Column" : 3, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prophylactic antivirals in malignancy", "Mnemonic" : "942"},
{"Row" : 39, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "DisplayText" : "Propionibacterium species (Outpatient)", "Text" : "Propionibacterium infections, general", "Mnemonic" : "946"},
{"Row" : 40, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "DisplayText" : "Acute bacterial prostatitis (Outpatient)", "Text" : "Prostatitis, acute", "Mnemonic" : "948"},
{"Row" : 41, "Column" : 3, "Item" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "DisplayText" : "Chronic bacterial prostatitis (Outpatient)", "Text" : "Prostatitis, chronic", "Mnemonic" : "950"},
{"Row" : 42, "Column" : 3, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "DisplayText" : "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)", "Text" : "Prostatitis/pelvic pain syndrome, chronic", "Mnemonic" : "952"},
{"Row" : 43, "Column" : 3, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Prosthetic bone/joint infection [CLICK HERE], includes: ", "Mnemonic" : "954"},
{"Row" : 47, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Prosthetic valve endocarditis [CLICK HERE], includes: ", "Mnemonic" : "956"},
{"Row" : 51, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Prosthetic valve endocarditis empirical therapy", "Mnemonic" : "958"},
{"Row" : 52, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Prosthetic valve endocarditis with sepsis", "Mnemonic" : "960"},
{"Row" : 53, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "DisplayText" : "Proteus spp. (Outpatient)", "Text" : "Proteus infections, general", "Mnemonic" : "962"},
{"Row" : 54, "Column" : 3, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "DisplayText" : "Penicillin Desensitization Protocol", "Text" : "Protocol for Penicillin Desensitization", "Mnemonic" : "964"},
{"Row" : 55, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "DisplayText" : "Septic arthritis (Native Joint) with P. aeruginosa - Outpatient", "Text" : "Pseudomonas aeruginosa native joint infection", "Mnemonic" : "966"},
{"Row" : 56, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Pseudomonas aeruginosa nosocomial pneumonia", "Mnemonic" : "968"},
{"Row" : 57, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa (Outpatient)", "Text" : "Pseudomonas aeruginosa osteomyelitis", "Mnemonic" : "970"},
{"Row" : 58, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "DisplayText" : "Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient)", "Text" : "Pseudomonas aeruginosa prosthetic bone/joint infection", "Mnemonic" : "972"},
{"Row" : 59, "Column" : 3, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Pseudomonas aeruginosa pyelonephritis", "Mnemonic" : "974"},
{"Row" : 60, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "DisplayText" : "Pseudomonas spp. (Outpatient)", "Text" : "Pseudomonas infections, general", "Mnemonic" : "976"},
{"Row" : 61, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Pseudomonas meningitis", "Mnemonic" : "978"},
{"Row" : 62, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Pseudomonas spp. brain abscess", "Mnemonic" : "980"},
{"Row" : 63, "Column" : 3, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient", "Text" : "Pubic lice", "Mnemonic" : "982"},
{"Row" : 64, "Column" : 3, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Pyelonephritis [CLICK HERE], includes: ", "Mnemonic" : "984"},
{"Row" : 66, "Column" : 3, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Pyogenic liver abscess", "Mnemonic" : "986"},
{"Row" : 67, "Column" : 3, "Item" : "ORZID3 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis", "Mnemonic" : "988"},
{"Row" : 68, "Column" : 3, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Pyuria", "Mnemonic" : "990"},
{"Row" : 75, "Column" : 3, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Rabies vaccination", "Mnemonic" : "994"},
{"Row" : 76, "Column" : 3, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient)", "Text" : "Recurrent or persistent urethritis", "Mnemonic" : "996"},
{"Row" : 77, "Column" : 3, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Renal failure immunizations", "Mnemonic" : "998"},
{"Row" : 78, "Column" : 3, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "Resistant bacteria, more about", "Mnemonic" : "1000"},
{"Row" : 79, "Column" : 3, "Item" : "ORZID3 GMENU ABX RSV", "DisplayText" : "Respiratory Syncytial Virus (RSV) (outpatient)", "Text" : "Respiratory syncytial virus (RSV)", "Mnemonic" : "1004"},
{"Row" : 80, "Column" : 3, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "Restrictions on antimicrobials", "Mnemonic" : "1006"},
{"Row" : 81, "Column" : 3, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "Retinitis [CLICK HERE], includes: ", "Mnemonic" : "1008"},
{"Row" : 83, "Column" : 3, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm) - Outpatient", "Text" : "Ringworm", "Mnemonic" : "1010"},
{"Row" : 84, "Column" : 3, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "Risk factors for MRSA", "Mnemonic" : "1012"},
{"Row" : 85, "Column" : 3, "Item" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "DisplayText" : "Rocky Mountain Spotted Fever (Outpatient)", "Text" : "Rocky mountain spotted fever", "Mnemonic" : "1014"},
{"Row" : 86, "Column" : 3, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Rubella vaccination", "Mnemonic" : "1016"},
{"Row" : 89, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA SALMONELLA", "DisplayText" : "Diarrhea with Salmonella (Outpatient)", "Text" : "Salmonella diarrhea/gastroenteritis", "Mnemonic" : "1018"},
{"Row" : 90, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "DisplayText" : "Salmonella spp. (Outpatient)", "Text" : "Salmonella infections, general", "Mnemonic" : "1020"},
{"Row" : 91, "Column" : 3, "Item" : "ORZID3 GMENU SCABIES", "DisplayText" : "Scabies (Outpatient)", "Text" : "Scabies", "Mnemonic" : "1022"},
{"Row" : 92, "Column" : 3, "Item" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "DisplayText" : "Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient", "Text" : "Scalded skin syndrome", "Mnemonic" : "1024"},
{"Row" : 93, "Column" : 3, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "Seasonal influenza", "Mnemonic" : "1026"},
{"Row" : 94, "Column" : 3, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)", "Text" : "Secondary peritonitis", "Mnemonic" : "1028"},
{"Row" : 95, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Sepsis and septic shock", "Mnemonic" : "1030"},
{"Row" : 96, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native Joint) - Outpatient", "Text" : "Septic arthritis, native joint [CLICK HERE], includes: ", "Mnemonic" : "1032"},
{"Row" :100, "Column" : 3, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Septic arthritis, prosthetic joint [CLICK HERE], includes: ", "Mnemonic" : "1034"},
{"Row" :104, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis (Outpatient)", "Text" : "Septic bursitis", "Mnemonic" : "1036"},
{"Row" :105, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "DisplayText" : "Serratia spp. (Outpatient)", "Text" : "Serratia infections, general", "Mnemonic" : "1038"},
{"Row" :106, "Column" : 3, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "DisplayText" : "Bacterial vaginosis (Outpatient)", "Text" : "Sexually transmitted infection, bacterial vaginitis", "Mnemonic" : "1040"},
{"Row" :107, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, cervicitis", "Mnemonic" : "1042"},
{"Row" :108, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, chlamydia cervicitis", "Mnemonic" : "1044"},
{"Row" :109, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Sexually transmitted infection, chlamydia urethritis", "Mnemonic" : "1046"},
{"Row" :110, "Column" : 3, "Item" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient)", "Text" : "Sexually transmitted infection, genital warts", "Mnemonic" : "1048"},
{"Row" :111, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Sexually transmitted infection, gonorrhea cervicitis", "Mnemonic" : "1050"},
{"Row" :112, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Sexually transmitted infection, gonorrhea urethritis", "Mnemonic" : "1052"},
{"Row" :113, "Column" : 3, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "DisplayText" : "Pelvic inflammatory disorder (PID) - Outpatient", "Text" : "Sexually transmitted infection, pelvic inflammatory disease", "Mnemonic" : "1054"},
{"Row" :114, "Column" : 3, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient", "Text" : "Sexually transmitted infection, pubic lice (crabs)", "Mnemonic" : "1056"},
{"Row" :115, "Column" : 3, "Item" : "ORZID3 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Sexually transmitted infection, syphilis", "Mnemonic" : "1058"},
{"Row" :116, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "DisplayText" : "Trichomonas vaginitis (Outpatient)", "Text" : "Sexually transmitted infection, trichomoniasis", "Mnemonic" : "1060"},
{"Row" :117, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Sexually transmitted infection, urethritis", "Mnemonic" : "1062"},
{"Row" :118, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient)", "Text" : "Shigella diarrhea/gastroenteritis", "Mnemonic" : "1064"},
{"Row" :119, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SHIGELLA SPP.", "DisplayText" : "Shigella spp. (Outpatient)", "Text" : "Shigella infections, general", "Mnemonic" : "1066"},
{"Row" :120, "Column" : 3, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient", "Text" : "Shingles", "Mnemonic" : "1068"},
{"Row" :121, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Shingles vaccination", "Mnemonic" : "1070"},
{"Row" :122, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of antimicrobials updates", "Mnemonic" : "1072"},
{"Row" :123, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "DisplayText" : "ACUTE SINUSITIS", "Text" : "Sinusitis, acute", "Mnemonic" : "1074"},
{"Row" :124, "Column" : 3, "Item" : "ORZID3 GMENU CHRONIC SINUSITIS", "DisplayText" : "Chronic sinusitis (Outpatient)", "Text" : "Sinusitis, chronic", "Mnemonic" : "1076"},
{"Row" :125, "Column" : 3, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Sinusitis, fungal", "Mnemonic" : "1078"},
{"Row" :126, "Column" : 3, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "DisplayText" : "Nosocomial sinusitis (Outpatient)", "Text" : "Sinusitis, nosocomial", "Mnemonic" : "1080"},
{"Row" :127, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Skin and soft tissue infection with sepsis", "Mnemonic" : "1082"},
{"Row" :128, "Column" : 3, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "DisplayText" : "Dermatology Infections (Outpatient)", "Text" : "Skin Infections section", "Mnemonic" : "1084"},
{"Row" :129, "Column" : 3, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "DisplayText" : "Small uniform bacillin in an aerobic bottle (Outpatient)", "Text" : "Small pleomorphic bacilli, aerobic bottle", "Mnemonic" : "1086"},
{"Row" :130, "Column" : 3, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "DisplayText" : "Small uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "Small pleomorphic bacilli, anaerobic bottle", "Mnemonic" : "1088"},
{"Row" :131, "Column" : 3, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)", "Text" : "Soft Tissue and Muscle section", "Mnemonic" : "1090"},
{"Row" :132, "Column" : 3, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "DisplayText" : "Introduction to Specific Pathogen section", "Text" : "Specific pathogen introduction", "Mnemonic" : "1092"},
{"Row" :133, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Spinal epidural abscess", "Mnemonic" : "1094"},
{"Row" :134, "Column" : 3, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Spleen absent or dysfunctional [CLICK HERE], includes: ", "Mnemonic" : "1096"},
{"Row" :137, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Spontaneous bacterial peritonitis prevention", "Mnemonic" : "1098"},
{"Row" :138, "Column" : 3, "Item" : "ORZID3 GMENU SPOROTRICHOSIS", "DisplayText" : "Sporotrichosis (Outpatient)", "Text" : "Sporotrichosis infections, general", "Mnemonic" : "1100"},
{"Row" :139, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "DisplayText" : "Staphylococci (Outpatient)", "Text" : "Staphylococcal infections, general", "Mnemonic" : "1102"},
{"Row" :140, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Staphylococcal native valve endocarditis", "Mnemonic" : "1104"},
{"Row" :141, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Staphylococcal prosthetic valve endocarditis", "Mnemonic" : "1106"},
{"Row" :142, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome (Outpatient)", "Text" : "Staphylococcal toxic shock syndrome", "Mnemonic" : "1108"},
{"Row" :143, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "DisplayText" : "Treatment for Coagulase Negative Staphylococci (Outpatient)", "Text" : "Staphylococci, coagulase-negative", "Mnemonic" : "1110"},
{"Row" :144, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "DisplayText" : "Treatment for Staphylococcus aureus (Outpatient)", "Text" : "Staphylococcus aureus infections, general", "Mnemonic" : "1112"},
{"Row" :145, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Staphylococcus aureus nosocomial pneumonia", "Mnemonic" : "1114"},
{"Row" :146, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "DisplayText" : "Osteomyelitis with Staphylococcus aureus (Outpatient)", "Text" : "Staphylococcus aureus osteomyelitis", "Mnemonic" : "1116"},
{"Row" :147, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Staphylococcus aureus bacteremia", "Mnemonic" : "1118"},
{"Row" :148, "Column" : 3, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Staphylococcus aureus decolonization", "Mnemonic" : "1120"},
{"Row" :149, "Column" : 3, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Staphylococcus aureus intravascular catheter-associated infection", "Mnemonic" : "1122"},
{"Row" :150, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J S. AUREUS", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses (Outpatient)", "Text" : "Staphylococcus aureus prosthetic bone/joint infection", "Mnemonic" : "1124"},
{"Row" :151, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "DisplayText" : "Septic arthristis (Native Joint) with S. aureus - Outpatient", "Text" : "Staphylococcus aureus, native joint infection", "Mnemonic" : "1126"},
{"Row" :152, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Staphylococcus lugdunensis bacteremia", "Mnemonic" : "1128"},
{"Row" :153, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "DisplayText" : "Treatment for Staphylococcus lugdunensis", "Text" : "Staphylococcus lugdunensis infections, general", "Mnemonic" : "1130"},
{"Row" :154, "Column" : 3, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "DisplayText" : "Stasis Dermatitis (outpatient)", "Text" : "Stasis dermatitis", "Mnemonic" : "1132"},
{"Row" :155, "Column" : 3, "Item" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite wounds with Streptococci (Outpatient)", "Text" : "Streptococcal bite wounds", "Mnemonic" : "1134"},
{"Row" :156, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Streptococcal native valve endocarditis (highly resistant isolate)", "Mnemonic" : "1136"},
{"Row" :157, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Streptococcal native valve endocarditis (sensitive isolate)", "Mnemonic" : "1138"},
{"Row" :158, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "DisplayText" : "Osteomyelitis with Streptococci (Outpatient)", "Text" : "Streptococcal osteomyelitis", "Mnemonic" : "1140"},
{"Row" :159, "Column" : 3, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Streptococcal pharyngitis", "Mnemonic" : "1142"},
{"Row" :160, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "DisplayText" : "Streptococci infections in bone or joint prostheses (Outpatient)", "Text" : "Streptococcal prosthetic bone/joint infection", "Mnemonic" : "1144"},
{"Row" :161, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Streptococcal prosthetic valve endocarditis", "Mnemonic" : "1146"},
{"Row" :162, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome (Outpatient)", "Text" : "Streptococcal toxic shock syndrome", "Mnemonic" : "1148"},
{"Row" :163, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "DisplayText" : "Streptococci Groups C, F, G (Outpatient)", "Text" : "Streptococci Groups C, F, G infections, general", "Mnemonic" : "1150"},
{"Row" :164, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient", "Text" : "Streptococci viridans infections, general [CLICK HERE], includes: ", "Mnemonic" : "1152"},
{"Row" :166, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "DisplayText" : "Group B (S. agalactiae) - Outpatient", "Text" : "Streptococcus agalactiae (Group B)", "Mnemonic" : "1154"},
{"Row" :167, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "DisplayText" : "Streptococcus anginosus (formerly S. milleri) - Outpatient", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Mnemonic" : "1156"},
{"Row" :168, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "DisplayText" : "Group D Streptococci (S. bovis) - Outpatient", "Text" : "Streptococcus bovis (Group D)", "Mnemonic" : "1158"},
{"Row" :169, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Streptococci - Outpatient", "Text" : "Streptococcus native joint infection", "Mnemonic" : "1160"},
{"Row" :170, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "DisplayText" : "Streptococcus pneumoniae (Outpatient)", "Text" : "Streptococcus pneumoniae infections, general", "Mnemonic" : "1162"},
{"Row" :171, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Streptococcus pneumoniae meningitis", "Mnemonic" : "1164"},
{"Row" :172, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "DisplayText" : "Group A (S. pyogenes) - Outpatient", "Text" : "Streptococcus pyogenes (Group A) infections, general", "Mnemonic" : "1166"},
{"Row" :173, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "DisplayText" : "Stress", "Text" : "Stress", "Mnemonic" : "1168"},
{"Row" :174, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Subdural empyema", "Mnemonic" : "1170"},
{"Row" :175, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Suppurative intracranial thrombophlebitis", "Mnemonic" : "1172"},
{"Row" :176, "Column" : 3, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Suppurative odontic infections", "Mnemonic" : "1174"},
{"Row" :177, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Suppurative thrombophlebitis", "Mnemonic" : "1176"},
{"Row" :178, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "Surgical site infection", "Mnemonic" : "1178"},
{"Row" :179, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Susceptibilities, antimicrobial", "Mnemonic" : "1180"},
{"Row" :180, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Mnemonic" : "1182"},
{"Row" :181, "Column" : 3, "Item" : "ORZID3 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Syphilis", "Mnemonic" : "1184"},
{"Row" :182, "Column" : 3, "Item" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "DisplayText" : "Systemic Infectious Diseases (Outpatient)", "Text" : "Systemic Infections section", "Mnemonic" : "1186"},
{"Row" :4, "Column" : 3, "Text" : "Po through Z", "Header" : 1}, 
{"Row" :6, "Column" : 3, "Text" : "Po-Py__________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" : 45, "Column" : 3, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" : 46, "Column" : 3, "Text" : "and streptococcus"}, 
{"Row" : 48, "Column" : 3, "Text" : "culture negative, enterococci, fungi,"}, 
{"Row" : 49, "Column" : 3, "Text" : "gram-negative bacilli, Streptococcus bovis,"}, 
{"Row" : 50, "Column" : 3, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci"}, 
{"Row" : 65, "Column" : 3, "Text" : "empiric therapy, enterococcus, pseudomonas"}, 
{"Row" : 70, "Column" : 3, "Text" : "Q______________________________________________________________________________", "Header" : 1}, 
{"Row" : 72, "Column" : 3, "Text" : "R______________________________________________________________________________", "Header" : 1}, 
{"Row" : 82, "Column" : 3, "Text" : "candida, Cytomegalovirus, herpes, zoster, and others"}, 
{"Row" : 88, "Column" : 3, "Text" : "S______________________________________________________________________________", "Header" : 1}, 
{"Row" : 97, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" : 98, "Column" : 3, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,"}, 
{"Row" : 99, "Column" : 3, "Text" : "Staphylococcus aureus, streptococcus"}, 
{"Row" :101, "Column" : 3, "Text" : "empirical therapy, enterococci, gram-negative bacilli,"}, 
{"Row" :102, "Column" : 3, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,"}, 
{"Row" :103, "Column" : 3, "Text" : "and streptococcus"}, 
{"Row" :135, "Column" : 3, "Text" : "antimicrobial prophylaxis, management of fever,"}, 
{"Row" :136, "Column" : 3, "Text" : "patient initiated antibiotics, vaccines"}, 
{"Row" :165, "Column" : 3, "Text" : "S. mutans, S. mitis, S. sanguis"}, 
{"Row" :185, "Column" : 3, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus vaccination", "Mnemonic" : "1188"},
{"Row" :186, "Column" : 3, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Thrush", "Mnemonic" : "1190"},
{"Row" :188, "Column" : 3, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm) - Outpatient", "Text" : "Tinea capitis", "Mnemonic" : "1192"},
{"Row" :189, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot) - Outpatient", "Text" : "Tinea corporis", "Mnemonic" : "1194"},
{"Row" :190, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot) - Outpatient", "Text" : "Tinea cruris", "Mnemonic" : "1196"},
{"Row" :191, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot) - Outpatient", "Text" : "Tinea pedis", "Mnemonic" : "1198"},
{"Row" :192, "Column" : 3, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Tinea unguium", "Mnemonic" : "1200"},
{"Row" :193, "Column" : 3, "Item" : "ORZID3 GMENU TINEA VERSICOLOR", "DisplayText" : "Tinea Versicolor (Outpatient)", "Text" : "Tinea versicolor", "Mnemonic" : "1202"},
{"Row" :194, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "DisplayText" : "Tobacco smoke", "Text" : "Tobacco smoke", "Mnemonic" : "1204"},
{"Row" :195, "Column" : 3, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Tonsillitis", "Mnemonic" : "1206"},
{"Row" :196, "Column" : 3, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Tooth abscess and other suppurative odontic infections", "Mnemonic" : "1208"},
{"Row" :197, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome (Outpatient)", "Text" : "Toxic shock syndrome", "Mnemonic" : "1210"},
{"Row" :198, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Toxoplasma gondii brain abscess", "Mnemonic" : "1212"},
{"Row" :199, "Column" : 3, "Item" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "DisplayText" : "Toxoplasma spp. (Outpatient)", "Text" : "Toxoplasma infections, general", "Mnemonic" : "1214"},
{"Row" :200, "Column" : 3, "Item" : "ORZID2 GMENU TRANSPLANTATION", "DisplayText" : "Transplantation", "Text" : "Transplantation", "Mnemonic" : "1216"},
{"Row" :201, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Trauma or nosocomial infection associated meningitis", "Mnemonic" : "1218"},
{"Row" :202, "Column" : 3, "Item" : "ORZID3 GMENU TRAVELER DIARRHEA", "DisplayText" : "Traveler's diarrhea", "Text" : "Traveler's diarrhea", "Mnemonic" : "1220"},
{"Row" :203, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "DisplayText" : "Trichomonas vaginitis (Outpatient)", "Text" : "Trichomonas vaginitis", "Mnemonic" : "1222"},
{"Row" :204, "Column" : 3, "Item" : "ORZID3 GMENU TUBERCULOSIS", "DisplayText" : "Tuberculosis (Outpatient)", "Text" : "Tuberculosis", "Mnemonic" : "1224"},
{"Row" :205, "Column" : 3, "Item" : "ORZID3 GMENU TYPHLITIS", "DisplayText" : "Neutropenic enterocolitis (Typhlitis) - Outpatient", "Text" : "Typhlitis", "Mnemonic" : "1226"},
{"Row" :206, "Column" : 3, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Typhoid fever", "Mnemonic" : "1228"},
{"Row" :209, "Column" : 3, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "DisplayText" : "Decubitis ulcers (Outpatient)", "Text" : "Ulcer, decubitus", "Mnemonic" : "1230"},
{"Row" :210, "Column" : 3, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Ulcer, diabetic foot", "Mnemonic" : "1232"},
{"Row" :211, "Column" : 3, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient)", "Text" : "Uncomplicated cystitis", "Mnemonic" : "1234"},
{"Row" :212, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Updates on antimicrobial shortages", "Mnemonic" : "1236"},
{"Row" :213, "Column" : 3, "Item" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "DisplayText" : "Upper Respiratory Infections (outpatient)", "Text" : "Upper respiratory infections (URI)", "Mnemonic" : "1238"},
{"Row" :214, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Urethritis associated with STIs [CLICK HERE], includes: ", "Mnemonic" : "1240"},
{"Row" :216, "Column" : 3, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient)", "Text" : "Urethritis, recurrent or persistent", "Mnemonic" : "1242"},
{"Row" :217, "Column" : 3, "Item" : "ORZID3 GMENU ABX APPROACH TO UTI", "DisplayText" : "APPROACH TO URINARY TRACT INFECTION (UTI)", "Text" : "Urinary tract infection (UTI), bacterial", "Mnemonic" : "1244"},
{"Row" :218, "Column" : 3, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Urinary tract infection (UTI), candida", "Mnemonic" : "1246"},
{"Row" :219, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Urinary tract infection with sepsis", "Mnemonic" : "1248"},
{"Row" :220, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Urosepsis", "Mnemonic" : "1250"},
{"Row" :221, "Column" : 3, "Item" : "ORZID2 GMENU UVEITIS", "DisplayText" : "Uveitis", "Text" : "Uveitis", "Mnemonic" : "1252"},
{"Row" :225, "Column" : 3, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida vulvo-vaginitis (Outpatient)", "Text" : "Vaginitis, Candida", "Mnemonic" : "1254"},
{"Row" :226, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "DisplayText" : "Trichomonas vaginitis (Outpatient)", "Text" : "Vaginitis, Trichomonas", "Mnemonic" : "1256"},
{"Row" :227, "Column" : 3, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "DisplayText" : "Bacterial vaginosis (Outpatient)", "Text" : "Vaginosis, bacterial", "Mnemonic" : "1258"},
{"Row" :228, "Column" : 3, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox) - Outpatient", "Text" : "Varicella", "Mnemonic" : "1260"},
{"Row" :229, "Column" : 3, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella vaccination", "Mnemonic" : "1262"},
{"Row" :230, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Ventilator-associated pneumonia (VAP)", "Mnemonic" : "1264"},
{"Row" :231, "Column" : 3, "Item" : "ORZID3 GMENU DISKITIS", "DisplayText" : "Diskitis and vertebral osteomyelitis (Outpatient)", "Text" : "Vertebral osteomyelitis and diskitis", "Mnemonic" : "1266"},
{"Row" :232, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "DisplayText" : "Diarrhea with Vibrio cholera (Outpatient)", "Text" : "Vibrio cholerae diarrhea/gastroenteritis", "Mnemonic" : "1268"},
{"Row" :233, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "DisplayText" : "Diarrhea with non-cholera vibrio (Outpatient)", "Text" : "Vibrio non-cholerae, diarrhea/gastroenteritis", "Mnemonic" : "1270"},
{"Row" :234, "Column" : 3, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Viral diarrhea/gastroenteritis", "Mnemonic" : "1272"},
{"Row" :235, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient", "Text" : "Viridans streptococci", "Mnemonic" : "1274"},
{"Row" :236, "Column" : 3, "Item" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "DisplayText" : "Viruses (Outpatient)", "Text" : "Viruses section", "Mnemonic" : "1276"},
{"Row" :237, "Column" : 3, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida vulvo-vaginitis (Outpatient)", "Text" : "Vulvo-vaginitis, candida", "Mnemonic" : "1278"},
{"Row" :240, "Column" : 3, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions with antimicrobials", "Mnemonic" : "1280"},
{"Row" :241, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "Wound infection, post-op", "Mnemonic" : "1282"},
{"Row" :242, "Column" : 3, "Item" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)", "Text" : "Wound, bite", "Mnemonic" : "1284"},
{"Row" :243, "Column" : 3, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "DisplayText" : "Colonized wounds", "Text" : "Wound, colonized", "Mnemonic" : "1286"},
{"Row" :248, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Yeast bacteremia", "Mnemonic" : "1288"},
{"Row" :249, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "DisplayText" : "Diarrhea with Yersinia enterocolitica (Outpatient)", "Text" : "Yersinia enterocolitica diarrhea/gastroenteritis", "Mnemonic" : "1290"},
{"Row" :252, "Column" : 3, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient", "Text" : "Zoster", "Mnemonic" : "1292"},
{"Row" :253, "Column" : 3, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "Zoster retinitis", "Mnemonic" : "1294"},
{"Row" :254, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Zoster vaccination", "Mnemonic" : "1296"},
{"Row" :184, "Column" : 3, "Text" : "T______________________________________________________________________________", "Header" : 1}, 
{"Row" :208, "Column" : 3, "Text" : "U______________________________________________________________________________", "Header" : 1}, 
{"Row" :215, "Column" : 3, "Text" : "chlamydia and gonococcal"}, 
{"Row" :223, "Column" : 3, "Text" : "V______________________________________________________________________________", "Header" : 1}, 
{"Row" :224, "Column" : 3, "Text" : "Vaccination: see immunization, specific organism or condition"}, 
{"Row" :239, "Column" : 3, "Text" : "W______________________________________________________________________________", "Header" : 1}, 
{"Row" :245, "Column" : 3, "Text" : "X______________________________________________________________________________", "Header" : 1}, 
{"Row" :247, "Column" : 3, "Text" : "Y______________________________________________________________________________", "Header" : 1}, 
{"Row" :251, "Column" : 3, "Text" : "Z______________________________________________________________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "A through F", "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Text" : "Post-exposure prophylaxis, Rabies - see Emergency"}, 
{"Row" : 12, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" : 37, "Column" : 3, "Text" : "Prophylaxis for post-exposure, Rabies - see Emergency"}, 
{"Row" : 38, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" : 73, "Column" : 3, "Text" : "Rabies post-exposure prophylaxis - see Emergency"}, 
{"Row" : 74, "Column" : 3, "Text" : "Department CDSS or contact ID for more information"}, 
{"Row" :107, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Cardiovascular Section", "Mnemonic" : "185"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Bite, Tick", "Mnemonic" : "117"},
{"Row" :187, "Column" : 3, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Tick bite", "Mnemonic" : "1191"}
]},
{"Name" : "ORZID3 GMENU ABX LARYNGITIS AND CROUP", "DisplayText" : "Laryngitis and Croup" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LARYNGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,"}, 
{"Row" :6, "Column" : 1, "Text" : "coronavirus). Treatment is based on symptomatic therapy alone."}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Mandell chapter: Acute laryngitis"}, 
{"Row" : 12, "Column" : 1, "Text" : "Up-To-Date article: Hoarseness in adults"}
]},
{"Name" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "DisplayText" : "Amebic Liver Abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 750MG TID PAROMOMYCIN 25-35MG/KG/DAY TID", "DisplayText" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Text" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "AMEBIC LIVER ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Serological testing for amoebiasis should be obtained in all patients with"}, 
{"Row" :6, "Column" : 1, "Text" : "suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood"}, 
{"Row" :7, "Column" : 1, "Text" : "cultures should also be obtained prior to starting antibiotics to exclude"}, 
{"Row" :8, "Column" : 1, "Text" : "pyogenic liver abscess, which is a much more common cause of liver abscess."}, 
{"Row" :9, "Column" : 1, "Text" : "Serologic testing can be negative in a small number of patients with acute"}, 
{"Row" : 10, "Column" : 1, "Text" : "presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat"}, 
{"Row" : 11, "Column" : 1, "Text" : "serological testing is negative for amoebiasis or patient does not respond to"}, 
{"Row" : 12, "Column" : 1, "Text" : "treatment of amebic liver abscess, patient should have further diagnostic"}, 
{"Row" : 13, "Column" : 1, "Text" : "testing completed to exclude pyogenic liver abscess."}, 
{"Row" : 15, "Column" : 1, "Text" : "Drainage of amebic liver abscess should be considered in patients with large"}, 
{"Row" : 16, "Column" : 1, "Text" : "lesions at risk of rupture."}, 
{"Row" : 18, "Column" : 1, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation"}, 
{"Row" : 19, "Column" : 1, "Text" : "is recommended in all patients with liver abscess."}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of patients with confirmed or suspected amebic liver abscess (obtain", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "blood cultures prior to starting in suspected cases)", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Paromomycin is nonformulary and must be ordered by Infectious Diseases."}, 
{"Row" : 25, "Column" : 1, "Text" : "25-35 mg/kg/day PO TID for 7 days ($) [M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica"}, 
{"Row" : 32, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis"}
]},
{"Name" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC 2 DOSE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient MenACWY orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "MENINGOCOCCAL"}, 
{"Row" : 11, "Column" : 1, "Text" : "OLIGOSACCHARIDE"}, 
{"Row" : 12, "Column" : 1, "Text" : "CONJ. VACC INJ,SUSP"}, 
{"Row" : 14, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Menveo"}, 
{"Row" : 17, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Meningococcal conjugate"}, 
{"Row" : 19, "Column" : 1, "Text" : "(MenACWY)"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 25, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 26, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 27, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 29, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 30, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 31, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People with anatomic or"}, 
{"Row" :5, "Column" : 2, "Text" : "functional asplenia, HIV"}, 
{"Row" :6, "Column" : 2, "Text" : "infection, or persistent"}, 
{"Row" :7, "Column" : 2, "Text" : "complement component"}, 
{"Row" :8, "Column" : 2, "Text" : "deficiency, or complement"}, 
{"Row" :9, "Column" : 2, "Text" : "inhibitor use."}, 
{"Row" : 11, "Column" : 2, "Text" : "*People who travel to or"}, 
{"Row" : 12, "Column" : 2, "Text" : "reside in countries in"}, 
{"Row" : 13, "Column" : 2, "Text" : "which meningococcal"}, 
{"Row" : 14, "Column" : 2, "Text" : "disease is hyperendemic or"}, 
{"Row" : 15, "Column" : 2, "Text" : "epidemic (e.g., the"}, 
{"Row" : 16, "Column" : 2, "Text" : "meningitis belt of Sub-"}, 
{"Row" : 17, "Column" : 2, "Text" : "Saharan Africa)."}, 
{"Row" : 19, "Column" : 2, "Text" : "*Microbiologists routinely"}, 
{"Row" : 20, "Column" : 2, "Text" : "exposed to isolates of N."}, 
{"Row" : 21, "Column" : 2, "Text" : "meningitidis."}, 
{"Row" : 23, "Column" : 2, "Text" : "*For first year college"}, 
{"Row" : 24, "Column" : 2, "Text" : "students living in a"}, 
{"Row" : 25, "Column" : 2, "Text" : "residence hall, regardless"}, 
{"Row" : 26, "Column" : 2, "Text" : "of age,"}, 
{"Row" : 27, "Column" : 2, "Text" : ">> if unvaccinated, give 1"}, 
{"Row" : 28, "Column" : 2, "Text" : "dose."}, 
{"Row" : 29, "Column" : 2, "Text" : ">> if history of 1 dose"}, 
{"Row" : 30, "Column" : 2, "Text" : "given when younger than"}, 
{"Row" : 31, "Column" : 2, "Text" : "age 16, give dose2."}, 
{"Row" : 32, "Column" : 2, "Text" : ">> if most recent dose"}, 
{"Row" : 33, "Column" : 2, "Text" : "given after 16th birthday"}, 
{"Row" : 34, "Column" : 2, "Text" : "and more than 5 years"}, 
{"Row" : 35, "Column" : 2, "Text" : "have elapsed, give 1 dose."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 2 initial doses of"}, 
{"Row" :5, "Column" : 3, "Text" : "MenACWY separated by 2m to"}, 
{"Row" :6, "Column" : 3, "Text" : "adults with risk factors"}, 
{"Row" :7, "Column" : 3, "Text" : "listed in 1st bullet in"}, 
{"Row" :8, "Column" : 3, "Text" : "column to left."}, 
{"Row" : 10, "Column" : 3, "Text" : "*Give 1 initial dose of"}, 
{"Row" : 11, "Column" : 3, "Text" : "MenACWY to all other"}, 
{"Row" : 12, "Column" : 3, "Text" : "adults with risk factors"}, 
{"Row" : 13, "Column" : 3, "Text" : "(see 2nd-4th bullets in"}, 
{"Row" : 14, "Column" : 3, "Text" : "column to left)."}, 
{"Row" : 16, "Column" : 3, "Text" : "*Give booster doses of"}, 
{"Row" : 17, "Column" : 3, "Text" : "MenACWY every 5yrs to"}, 
{"Row" : 18, "Column" : 3, "Text" : "adults with continuing"}, 
{"Row" : 19, "Column" : 3, "Text" : "risk (see the 1st-3rd"}, 
{"Row" : 20, "Column" : 3, "Text" : "bullets in column to"}, 
{"Row" : 21, "Column" : 3, "Text" : "left)."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}
]},
{"Name" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient MenB orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "MENINGOCOCCAL B VACCINE"}, 
{"Row" : 11, "Column" : 1, "Text" : "INJ,SUSP"}, 
{"Row" : 13, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Bexsero"}, 
{"Row" : 16, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Meningococcal serogroup B"}, 
{"Row" : 18, "Column" : 1, "Text" : "(MenB)"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 24, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 25, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 28, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 29, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 30, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People with anatomic or"}, 
{"Row" :5, "Column" : 2, "Text" : "functional asplenia or"}, 
{"Row" :6, "Column" : 2, "Text" : "persistent complement"}, 
{"Row" :7, "Column" : 2, "Text" : "component deficiency."}, 
{"Row" :9, "Column" : 2, "Text" : "*Microbiologists routinely"}, 
{"Row" : 10, "Column" : 2, "Text" : "exposed to isolates of N."}, 
{"Row" : 11, "Column" : 2, "Text" : "meningitidis."}, 
{"Row" : 13, "Column" : 2, "Text" : "*People identified as at"}, 
{"Row" : 14, "Column" : 2, "Text" : "a serogroup B"}, 
{"Row" : 15, "Column" : 2, "Text" : "meningococcal disease"}, 
{"Row" : 16, "Column" : 2, "Text" : "outbreak."}, 
{"Row" : 18, "Column" : 2, "Text" : "*Young adults through age"}, 
{"Row" : 19, "Column" : 2, "Text" : "23yrs may be vaccinated"}, 
{"Row" : 20, "Column" : 2, "Text" : "routinely."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 2 doses spaced 1"}, 
{"Row" :5, "Column" : 3, "Text" : "month apart"}, 
{"Row" :7, "Column" : 3, "Text" : "*For people with continuing"}, 
{"Row" :8, "Column" : 3, "Text" : "risk (see 1st-3rd bullets"}, 
{"Row" :9, "Column" : 3, "Text" : "in column to left), give a"}, 
{"Row" : 10, "Column" : 3, "Text" : "booster 1 year after"}, 
{"Row" : 11, "Column" : 3, "Text" : "completing the primary"}, 
{"Row" : 12, "Column" : 3, "Text" : "series, followed by a"}, 
{"Row" : 13, "Column" : 3, "Text" : "booster every 2-3 years as"}, 
{"Row" : 14, "Column" : 3, "Text" : "long as risk continues."}, 
{"Row" : 15, "Column" : 3, "Text" : "Booster doses must be same"}, 
{"Row" : 16, "Column" : 3, "Text" : "brand as primary series."}, 
{"Row" : 18, "Column" : 3, "Text" : "*MenB vaccine may be given"}, 
{"Row" : 19, "Column" : 3, "Text" : "concomitantly with MenACWY"}, 
{"Row" : 20, "Column" : 3, "Text" : "vaccine"}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "*Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 14, "Column" : 4, "Text" : "without fever."}, 
{"Row" : 16, "Column" : 4, "Text" : "*Pregnancy"}
]},
{"Name" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "One dose", "Mnemonic" : "4"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: Subcutaneous", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient MMR orders: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "MEASLES/MUMPS/RUBELLA"}, 
{"Row" : 12, "Column" : 1, "Text" : "VIRUS VACCINE INJ"}, 
{"Row" : 14, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "M-M-R II"}, 
{"Row" : 17, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Measles, mumps, rubella"}, 
{"Row" : 19, "Column" : 1, "Text" : "(MMR)"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 25, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 26, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 27, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 29, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 30, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 31, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People born in 1957 or"}, 
{"Row" :5, "Column" : 2, "Text" : "later (especially those"}, 
{"Row" :6, "Column" : 2, "Text" : "born outside the U.S.)"}, 
{"Row" :7, "Column" : 2, "Text" : "should receive at least 1"}, 
{"Row" :8, "Column" : 2, "Text" : "dose of MMR if they have"}, 
{"Row" :9, "Column" : 2, "Text" : "no laboratory evidence of"}, 
{"Row" : 10, "Column" : 2, "Text" : "immunity to each of the 3"}, 
{"Row" : 11, "Column" : 2, "Text" : "diseases or documentation"}, 
{"Row" : 12, "Column" : 2, "Text" : "of a dose given on or"}, 
{"Row" : 13, "Column" : 2, "Text" : "after the first birthday."}, 
{"Row" : 15, "Column" : 2, "Text" : "*People in high-risk"}, 
{"Row" : 16, "Column" : 2, "Text" : "groups, such as healthcare"}, 
{"Row" : 17, "Column" : 2, "Text" : "personnel (paid, unpaid,"}, 
{"Row" : 18, "Column" : 2, "Text" : "or volunteer), students"}, 
{"Row" : 19, "Column" : 2, "Text" : "entering college and other"}, 
{"Row" : 20, "Column" : 2, "Text" : "post-high school"}, 
{"Row" : 21, "Column" : 2, "Text" : "educational institutions,"}, 
{"Row" : 22, "Column" : 2, "Text" : "and international"}, 
{"Row" : 23, "Column" : 2, "Text" : "travelers, should receive"}, 
{"Row" : 24, "Column" : 2, "Text" : "a total of 2 doses."}, 
{"Row" : 26, "Column" : 2, "Text" : "*HIV infection with CD4"}, 
{"Row" : 27, "Column" : 2, "Text" : "count >/=200 cells/mm3 for"}, 
{"Row" : 28, "Column" : 2, "Text" : "at least 6 months and no"}, 
{"Row" : 29, "Column" : 2, "Text" : "evidence of immunity to"}, 
{"Row" : 30, "Column" : 2, "Text" : "measles, mumps, or rubella"}, 
{"Row" : 31, "Column" : 2, "Text" : "should receive a total of"}, 
{"Row" : 32, "Column" : 2, "Text" : "2 doses. MMR"}, 
{"Row" : 33, "Column" : 2, "Text" : "contraindicated for HIV"}, 
{"Row" : 34, "Column" : 2, "Text" : "infection with CD4 count"}, 
{"Row" : 35, "Column" : 2, "Text" : "<200 cells/mm3"}, 
{"Row" : 37, "Column" : 2, "Text" : "*People born before 1957"}, 
{"Row" : 38, "Column" : 2, "Text" : "are usually considered"}, 
{"Row" : 39, "Column" : 2, "Text" : "immune, but evidence of"}, 
{"Row" : 40, "Column" : 2, "Text" : "immunity (serology or"}, 
{"Row" : 41, "Column" : 2, "Text" : "documented history of 2"}, 
{"Row" : 42, "Column" : 2, "Text" : "doses of MMR) should be"}, 
{"Row" : 43, "Column" : 2, "Text" : "considered for healthcare"}, 
{"Row" : 44, "Column" : 2, "Text" : "personnel."}, 
{"Row" : 46, "Column" : 2, "Text" : "*Women of childbearing age"}, 
{"Row" : 47, "Column" : 2, "Text" : "who do not have acceptable"}, 
{"Row" : 48, "Column" : 2, "Text" : "evidence of rubella"}, 
{"Row" : 49, "Column" : 2, "Text" : "immunity or vaccination."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 1 or 2 doses (see"}, 
{"Row" :5, "Column" : 3, "Text" : "criteria in 1st and 2nd"}, 
{"Row" :6, "Column" : 3, "Text" : "bullets in box to left)."}, 
{"Row" :8, "Column" : 3, "Text" : "*If dose2 is"}, 
{"Row" :9, "Column" : 3, "Text" : "recommended, give it no"}, 
{"Row" : 10, "Column" : 3, "Text" : "sooner than 4wks after"}, 
{"Row" : 11, "Column" : 3, "Text" : "dose1."}, 
{"Row" : 13, "Column" : 3, "Text" : "*If woman of childbearing-"}, 
{"Row" : 14, "Column" : 3, "Text" : "age is found to be rubella"}, 
{"Row" : 15, "Column" : 3, "Text" : "susceptible and is not"}, 
{"Row" : 16, "Column" : 3, "Text" : "pregnant, give 1 dose of"}, 
{"Row" : 17, "Column" : 3, "Text" : "MMR. If she is pregnant,"}, 
{"Row" : 18, "Column" : 3, "Text" : "the dose should be given"}, 
{"Row" : 19, "Column" : 3, "Text" : "postpartum. This includes"}, 
{"Row" : 20, "Column" : 3, "Text" : "women who have already"}, 
{"Row" : 21, "Column" : 3, "Text" : "received 1 or 2 doses of"}, 
{"Row" : 22, "Column" : 3, "Text" : "rubella-containing"}, 
{"Row" : 23, "Column" : 3, "Text" : "vaccine."}, 
{"Row" : 25, "Column" : 3, "Text" : "*If 2 or more of the"}, 
{"Row" : 26, "Column" : 3, "Text" : "following live virus"}, 
{"Row" : 27, "Column" : 3, "Text" : "vaccines are to be given -"}, 
{"Row" : 28, "Column" : 3, "Text" : "MMR, LAIV, Var, ZVL,"}, 
{"Row" : 29, "Column" : 3, "Text" : "and/or yellow fever - they"}, 
{"Row" : 30, "Column" : 3, "Text" : "should be given on the"}, 
{"Row" : 31, "Column" : 3, "Text" : "same day. If they are not"}, 
{"Row" : 32, "Column" : 3, "Text" : "given on the same day,"}, 
{"Row" : 33, "Column" : 3, "Text" : "space them by at least 28d"}, 
{"Row" : 34, "Column" : 3, "Text" : "(30d for yellow fever)."}, 
{"Row" : 35, "Column" : 3, "Text" : "May use as post-exposure"}, 
{"Row" : 36, "Column" : 3, "Text" : "prophylaxis if given"}, 
{"Row" : 37, "Column" : 3, "Text" : "within 3d of exposure."}, 
{"Row" : 35, "Column" : 4, "Item" : "ORZ GTX ABX URL ACIP BEST PRACTICES GUIDANCE", "DisplayText" : "ACIP's Best Practices Guidance", "Text" : "Best Practices Guidance", "Mnemonic" : "8"},
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "*History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "*Pregnancy or possibility"}, 
{"Row" : 12, "Column" : 4, "Text" : "of pregnancy within 4wks."}, 
{"Row" : 14, "Column" : 4, "Text" : "*Severe immunodeficiency"}, 
{"Row" : 15, "Column" : 4, "Text" : "(e.g., hematologic and"}, 
{"Row" : 16, "Column" : 4, "Text" : "solid tumors, receiving"}, 
{"Row" : 17, "Column" : 4, "Text" : "chemotherapy, congenital"}, 
{"Row" : 18, "Column" : 4, "Text" : "immunodeficiency, long-"}, 
{"Row" : 19, "Column" : 4, "Text" : "term immunosuppressive"}, 
{"Row" : 20, "Column" : 4, "Text" : "therapy, people with human"}, 
{"Row" : 21, "Column" : 4, "Text" : "immunodeficiency virus"}, 
{"Row" : 22, "Column" : 4, "Text" : "(HIV) infection who are"}, 
{"Row" : 23, "Column" : 4, "Text" : "severely"}, 
{"Row" : 24, "Column" : 4, "Text" : "immunocompromised (CD4"}, 
{"Row" : 25, "Column" : 4, "Text" : "count <200 cells/mm3).)"}, 
{"Row" : 27, "Column" : 4, "Text" : "Precautions", "Header" : 1}, 
{"Row" : 28, "Column" : 4, "Text" : "*Moderate or severe acute"}, 
{"Row" : 29, "Column" : 4, "Text" : "illness with or without"}, 
{"Row" : 30, "Column" : 4, "Text" : "fever."}, 
{"Row" : 32, "Column" : 4, "Text" : "*If blood, plasma, and/or"}, 
{"Row" : 33, "Column" : 4, "Text" : "immune globulin were given"}, 
{"Row" : 34, "Column" : 4, "Text" : "in past 11m, see ACIP's"}, 
{"Row" : 36, "Column" : 4, "Text" : "regarding time to wait"}, 
{"Row" : 37, "Column" : 4, "Text" : "before vaccinating."}, 
{"Row" : 39, "Column" : 4, "Text" : "*History of"}, 
{"Row" : 40, "Column" : 4, "Text" : "thrombocytopenia or"}, 
{"Row" : 41, "Column" : 4, "Text" : "thrombocytopenic purpura."}, 
{"Row" : 43, "Column" : 4, "Text" : "*Need for tuberculin skin"}, 
{"Row" : 44, "Column" : 4, "Text" : "testing (TST) or"}, 
{"Row" : 45, "Column" : 4, "Text" : "interferon-gamma release"}, 
{"Row" : 46, "Column" : 4, "Text" : "assay (IGRA) testing."}, 
{"Row" : 47, "Column" : 4, "Text" : "note: If TST or IGRA and"}, 
{"Row" : 48, "Column" : 4, "Text" : "MMR are both needed but"}, 
{"Row" : 49, "Column" : 4, "Text" : "not given on same day,"}, 
{"Row" : 50, "Column" : 4, "Text" : "delay TST or IGRA for at"}, 
{"Row" : 51, "Column" : 4, "Text" : "least 4wks after MMR."}
]},
{"Name" : "ORZID3 GMENU ABX MOLNUPIRAVIR EUA", "DisplayText" : "Molnupiravir for treatment of COVID-19" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX URL MOLNUPIRAVIR PATIENT EUA FACT SHEET", "DisplayText" : "Molnupiravir EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Molnupiravir", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL MOLNUPIRAVIR PROVIDER FACT SHEET EUA", "DisplayText" : "Molnupiravir EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Molnupiravir", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "MOLNUPIRAVIR (EUA)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Molnupiravir is available via FDA Emergency Use Authorization (EUA) for treating"}, 
{"Row" :6, "Column" : 1, "Text" : "patients that meet specific criteria. Molnupiravir is not an FDA approved drug."}, 
{"Row" :8, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 16, "Column" : 1, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "receive: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19."}, 
{"Row" : 19, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be"}, 
{"Row" : 20, "Column" : 1, "Text" : "hospitalized for some other reason."}, 
{"Row" : 21, "Column" : 1, "Text" : "4) Administration will begin within 5 days of symptom onset."}, 
{"Row" : 22, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to Molnupiravir or components."}, 
{"Row" : 24, "Column" : 1, "Text" : "Contraindications: None", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Warnings and Precautions: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "1) Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during"}, 
{"Row" : 28, "Column" : 1, "Text" : "pregnancy."}, 
{"Row" : 29, "Column" : 1, "Text" : "2) Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in"}, 
{"Row" : 30, "Column" : 1, "Text" : "patients less than 18 years of age because it may affect bone and cartilage"}, 
{"Row" : 31, "Column" : 1, "Text" : "growth."}, 
{"Row" : 33, "Column" : 1, "Text" : "If above requirements are met, place medication order: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 37, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing"}, 
{"Row" : 38, "Column" : 1, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent"}, 
{"Row" : 39, "Column" : 1, "Text" : "handwashing) according to CDC guidelines."}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX MOLNUPIRAVIR PHARMACY INFO", "DisplayText" : "Molnupiravir EUA", "Text" : "INV-Molnupiravir 800 mg PO BID for 5 days", "Mnemonic" : "8"}
]},
{"Name" : "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "DisplayText" : "Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19 " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PATIENT EUA FACT SHEET", "DisplayText" : "Paxlovid EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PROVIDER FACT SHEET EUA", "DisplayText" : "Paxlovid EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Paxlovid", "Mnemonic" : "8"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID PHARMACY INFO", "DisplayText" : "Paxlovid EUA", "Text" : "INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PAXLOVID (EUA)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use"}, 
{"Row" :6, "Column" : 1, "Text" : "Authorization (EUA) for treating patients that meet specific criteria. Paxlovid"}, 
{"Row" :7, "Column" : 1, "Text" : "is not an FDA approved drug."}, 
{"Row" :9, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 17, "Column" : 1, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "receive: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "1) Patient has tested positive for COVID-19"}, 
{"Row" : 20, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be"}, 
{"Row" : 21, "Column" : 1, "Text" : "hospitalized for some other reason."}, 
{"Row" : 22, "Column" : 1, "Text" : "4) Administration will begin within 5 days of symptom onset."}, 
{"Row" : 23, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to Paxlovid or components."}, 
{"Row" : 26, "Column" : 1, "Text" : "Contraindications, NONE of the following must be met for patient to receive: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "1) Severe renal impairment (eGFR <30 mL/min)."}, 
{"Row" : 28, "Column" : 1, "Text" : "2) Severe hepatic impairment (Child-Pugh Class C)."}, 
{"Row" : 29, "Column" : 1, "Text" : "3) History of clinically significant hypersensitivity reactions to the active"}, 
{"Row" : 30, "Column" : 1, "Text" : "ingredients (nirmatrelvir or ritonavir) or any other components."}, 
{"Row" : 31, "Column" : 1, "Text" : "4) Co-administration with drugs highly dependent on CYP3A for clearance and for"}, 
{"Row" : 32, "Column" : 1, "Text" : "which elevated concentrations are associated with serious and/or"}, 
{"Row" : 33, "Column" : 1, "Text" : "life-threatening reactions."}, 
{"Row" : 34, "Column" : 1, "Text" : "5) Co-administration with potent CYP3A inducers where significantly reduced"}, 
{"Row" : 35, "Column" : 1, "Text" : "nirmatrelvir or ritonavir plasma concentrations may be associated with the"}, 
{"Row" : 36, "Column" : 1, "Text" : "potential for loss of virologic response and possible resistance."}, 
{"Row" : 38, "Column" : 1, "Text" : "Warnings and Precautions: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "1) The concomitant use of PAXLOVID and certain other drugs may result in"}, 
{"Row" : 40, "Column" : 1, "Text" : "potentially significant drug interactions. Consult the full prescribing"}, 
{"Row" : 41, "Column" : 1, "Text" : "information prior to and during treatment for potential drug interactions."}, 
{"Row" : 42, "Column" : 1, "Text" : "2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and"}, 
{"Row" : 43, "Column" : 1, "Text" : "jaundice have occurred in patients receiving ritonavir."}, 
{"Row" : 44, "Column" : 1, "Text" : "3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing"}, 
{"Row" : 45, "Column" : 1, "Text" : "resistance to HIV protease inhibitors in individuals with uncontrolled or"}, 
{"Row" : 46, "Column" : 1, "Text" : "undiagnosed HIV-1 infection."}, 
{"Row" : 48, "Column" : 1, "Text" : "If all above criteria above are met and there are no contraindications, place", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "medication order: ", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 56, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing"}, 
{"Row" : 57, "Column" : 1, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent"}, 
{"Row" : 58, "Column" : 1, "Text" : "handwashing) according to CDC guidelines."}, 
{"Row" : 24, "Column" : 1, "Text" : "6) Patient must be able to take PO and swallow tablets whole"}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID RENAL DOSING PHARMACY INFO", "DisplayText" : "Paxlovid EUA", "Text" : "INV-Nirmatrelvir 150 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Mnemonic" : "12"},
{"Row" : 52, "Column" : 1, "Text" : "Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min): ", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX NON-VA ORDER INFORMATION", "DisplayText" : "Non-VA orders are available below each prescription order for CBOC use" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Non-VA orders are available below each prescription order for CBOC use", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic bacteriuria (Outpatient)", "Text" : "Treatment of Asymptomatic Bacteriuria", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Treatment of Candida Urinary Tract Infections", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIURIA, CANDIDURIA, AND PYURIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in"}, 
{"Row" :6, "Column" : 1, "Text" : "middle aged and older people, especially those who have chronic medical"}, 
{"Row" :7, "Column" : 1, "Text" : "conditions. Pyuria is common in persons with bacteriuria and individuals with"}, 
{"Row" :8, "Column" : 1, "Text" : "indwelling catheters in place. By itself, the presence of pyuria is not"}, 
{"Row" :9, "Column" : 1, "Text" : "sufficient to diagnose bacteriuria, and the presence or absence of pyuria does"}, 
{"Row" : 10, "Column" : 1, "Text" : "not differentiate symptomatic from asymptomatic urinary infection. Candiduria is"}, 
{"Row" : 11, "Column" : 1, "Text" : "less common than bacteriuria, but the implications of candiduria are similar to"}, 
{"Row" : 12, "Column" : 1, "Text" : "those of bacteriuria."}, 
{"Row" : 14, "Column" : 1, "Text" : "Many studies, including randomized clinical trials have shown that"}, 
{"Row" : 15, "Column" : 1, "Text" : "treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is"}, 
{"Row" : 16, "Column" : 1, "Text" : "of no benefit, except in certain well-defined circumstances. Antimicrobial"}, 
{"Row" : 17, "Column" : 1, "Text" : "therapy is always accompanied by risk of harms, including drug reactions,"}, 
{"Row" : 18, "Column" : 1, "Text" : "Clostridium difficile colitis, anaphylaxis and death. Except in circumstances"}, 
{"Row" : 19, "Column" : 1, "Text" : "specified below, it is best to not order urinalysis or urine culture in"}, 
{"Row" : 20, "Column" : 1, "Text" : "asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an"}, 
{"Row" : 21, "Column" : 1, "Text" : "asymptomatic person for some reason, antimicrobial therapy should not be given"}, 
{"Row" : 22, "Column" : 1, "Text" : "except as specified below."}, 
{"Row" : 24, "Column" : 1, "Text" : "Pregnant women or patients undergoing urological procedures with bacteriuria", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Patients undergoing urological procedures or neutropenic patients with", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "candiduria", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References"}, 
{"Row" : 34, "Column" : 1, "Text" : "Pappas et al, Clin Infect Dis, 2016, 62.409"}, 
{"Row" : 35, "Column" : 1, "Text" : "Nicolle et al, Clin Infect Dis, 2005, 40:643"}
]},
{"Name" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "DisplayText" : "Conditions Not Benefited by Antimicrobial Therapy (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "DisplayText" : "Upper Respiratory Infections (outpatient)", "Text" : "Upper Respiratory Infections (URI)", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "DisplayText" : "Colonized Respiratory Tract in a Patient on a Ventilator (outpatient)", "Text" : "Colonized Respiratory Tract in a Patient on a Ventilator", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "DisplayText" : "Stasis Dermatitis (outpatient)", "Text" : "Stasis Dermatitis", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "DisplayText" : "Colonized Wounds (outpatient)", "Text" : "Colonized Wounds", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "DisplayText" : "Bacteriuria, Candiduria and Pyuria (outpatient)", "Text" : "Asymptomatic Bacteriuria, cadiduria and pyuria", "Mnemonic" : "12"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "DisplayText" : "Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient)", "Text" : "Blood culture positive for coagulase negative staphylococci", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Several common conditions associated with inflammation or"}, 
{"Row" :6, "Column" : 1, "Text" : "microorganisms do not benefit from antibiotic therapy in most or all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Yet, antimicrobials are frequently prescribed for these conditions leading to"}, 
{"Row" :8, "Column" : 1, "Text" : "unnecessary toxicity and costs, rare deaths, and the relentless increase in"}, 
{"Row" :9, "Column" : 1, "Text" : "antimicrobial resistance. Please review these conditions and do not give"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials for these conditions unless there are extraordinary"}, 
{"Row" : 11, "Column" : 1, "Text" : "circumstances that make your situation different. If you have any questions,"}, 
{"Row" : 12, "Column" : 1, "Text" : "please contact the infectious disease physician on call."}, 
{"Row" : 14, "Column" : 1, "Text" : "Lungs and Mediastinum", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Skin and Soft Tissue", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Genitourinary", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Miscellaneous", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "`Last reviewed 9-2018", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis in and Otherwise Healthy Patient", "Mnemonic" : "5"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "DisplayText" : "Not Benefited by Abx Pharyngitis", "Text" : "Pharyngitis, non-streptococcal", "Mnemonic" : "3"}
]},
{"Name" : "ORZID3 GMENU ABX OUTPT MAIN", "DisplayText" : "Outpatient Antimicrobial Computer Decision Support System (CDSS)" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient)", "Text" : "Central Nervous System (CNS)", "Mnemonic" : "11"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "DisplayText" : "Head and Neck / ENT (Outpatient)", "Text" : "Head and Neck", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "DisplayText" : "Lungs and Mediastinum (Outpatient)", "Text" : "Lungs & Mediastinum", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "[b] Influenza Seasonal 2022-2023"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU COMM INFECT PNEUMO", "DisplayText" : "Pneumonia (Outpatient)", "Text" : "[c] Pneumonia"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "DisplayText" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Text" : "[d] Acute Respiratory Infection (ARI) Symptomatic Therapy"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Cardiovascular", "Mnemonic" : "22"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "DisplayText" : "Gastrointestinal (Outpatient)", "Text" : "GI & Intraabdominal", "Mnemonic" : "24"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[a] C. difficile colitis Mild/Moderate"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU GENITOURINARY", "DisplayText" : "Genitourinary (Outpatient)", "Text" : "Urogenital", "Mnemonic" : "28"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "[a] Sexually Transmitted Infections (STI)"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)", "Text" : "Soft Tissue, Bone and Joint Infections", "Mnemonic" : "32"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "DisplayText" : "Dermatology Infections (Outpatient)", "Text" : "Skin", "Mnemonic" : "34"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "DisplayText" : "Systemic Infectious Diseases (Outpatient)", "Text" : "Systemic Infections", "Mnemonic" : "36"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "[a] Bacteremia"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "[b] Sepsis and Septic Shock"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "DisplayText" : "Introduction to Specific Pathogen section", "Text" : "Introduction to Specific Pathogen", "Mnemonic" : "42"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram negative bacteria (Outpatient)", "Text" : "Gram-negative Bacteria", "Mnemonic" : "44"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Gram-positive Bacteria", "Mnemonic" : "46"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "DisplayText" : "Viruses (Outpatient)", "Text" : "Viruses", "Mnemonic" : "48"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI", "DisplayText" : "Fungi (Outpatient)", "Text" : "Fungi", "Mnemonic" : "50"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU PARASITES MAIN", "DisplayText" : "Parasites (Outpatient)", "Text" : "Parasites", "Mnemonic" : "52"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU OTHER PATHOGENS", "DisplayText" : "Other Pathogens (Outpatient)", "Text" : "Other Pathogens", "Mnemonic" : "54"},
{"Row" :4, "Column" : 1, "Text" : "*******************************************************"}, 
{"Row" :5, "Column" : 1, "Text" : "* ANTIMICROBIAL DECISION SUPPORT*"}, 
{"Row" :6, "Column" : 1, "Text" : "* >>>>>>>>OUTPATIENT<<<<<<<<< *"}, 
{"Row" :7, "Column" : 1, "Text" : "*******************************************************"}, 
{"Row" :8, "Column" : 1, "Text" : "Welcome.Please click on the"}, 
{"Row" :9, "Column" : 1, "Text" : "diagnosis or syndrome you wish to treat."}, 
{"Row" : 10, "Column" : 1, "Text" : "**********************"}, 
{"Row" : 21, "Column" : 1, "Text" : "Syndromes and diseases, by body systems", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Specific organisms", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Medicine is an inexact and rapidly"}, 
{"Row" : 53, "Column" : 1, "Text" : "changing discipline.The developers of"}, 
{"Row" : 54, "Column" : 1, "Text" : "this system have made every effort to"}, 
{"Row" : 55, "Column" : 1, "Text" : "provide current, accurate information."}, 
{"Row" : 56, "Column" : 1, "Text" : "However, in view of the possibility of"}, 
{"Row" : 57, "Column" : 1, "Text" : "human error or changes in medical"}, 
{"Row" : 58, "Column" : 1, "Text" : "service, readers are encouraged to"}, 
{"Row" : 59, "Column" : 1, "Text" : "confirm the information contained"}, 
{"Row" : 60, "Column" : 1, "Text" : "herein with other sources.In"}, 
{"Row" : 61, "Column" : 1, "Text" : "particular, readers are encouraged to"}, 
{"Row" : 62, "Column" : 1, "Text" : "check the product information for"}, 
{"Row" : 63, "Column" : 1, "Text" : "antimicrobials to be certain that"}, 
{"Row" : 64, "Column" : 1, "Text" : "information in this system is accurate"}, 
{"Row" : 65, "Column" : 1, "Text" : "and current, especially for new or"}, 
{"Row" : 66, "Column" : 1, "Text" : "infrequently used drugs."}, 
{"Row" :2, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact CDSS & ASP Staff", "Mnemonic" : "58"},
{"Row" :3, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page...", "Mnemonic" : "60"},
{"Row" :4, "Column" : 2, "Item" : "ORZ GTX ABX CDSS FAQ", "DisplayText" : "CDSS FAQ", "Text" : "Frequently Asked Questions (FAQ)", "Mnemonic" : "62"},
{"Row" :5, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or Suggestions about this CDSS", "Mnemonic" : "64"},
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "DisplayText" : "Antimicrobial susceptibilities (Antibiogram)", "Text" : "Antibiogram (Susceptibilities)", "Mnemonic" : "66"},
{"Row" :9, "Column" : 2, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "DisplayText" : "Antimicrobial Formulary Hyperlink", "Text" : "Antimicrobial Formulary (Restricted)", "Mnemonic" : "68"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "DisplayText" : "Antimicrobial restriction policy", "Text" : "Restrictions on Antimicrobials", "Mnemonic" : "70"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "DisplayText" : "Adjust existing antimicrobial therapy", "Text" : "Adjust Existing Antimicrobial Therapy", "Mnemonic" : "72"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "DisplayText" : "How to find an alternative antimicrobial", "Text" : "How to Find Alternative Antimicrobials", "Mnemonic" : "74"},
{"Row" : 13, "Column" : 2, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Clinical On-Call Schedule (Infectious Disease)", "Mnemonic" : "76"},
{"Row" : 14, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "DisplayText" : "UP TO DATE WEB SITE", "Text" : "UpToDate Online (Clinical Resource)", "Mnemonic" : "78"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "DisplayText" : "Infection Control", "Text" : "Infection Control/Prevention Information", "Mnemonic" : "80"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatologic Guidelines", "Mnemonic" : "82"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU DEVICE-RELATED INFECT", "DisplayText" : "Device-related infections (Outpatient)", "Text" : "Device-Related Infections", "Mnemonic" : "84"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "DisplayText" : "Prevention of Infection - Outpatient", "Text" : "Prevention of Infection", "Mnemonic" : "86"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "HIV-AIDS", "Mnemonic" : "88"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "DisplayText" : "Infections in Immunocompromised patients (Outpatient)", "Text" : "Immunocompromised Patients", "Mnemonic" : "90"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids", "Mnemonic" : "100"},
{"Row" : 40, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE", "Text" : "NON-OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids", "Mnemonic" : "101"},
{"Row" : 48, "Column" : 2, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "Important Drug (Abx) Properties", "Mnemonic" : "103"},
{"Row" : 49, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "DisplayText" : "Lexicomp Online", "Text" : "Lexicomp Online Drug Information", "Mnemonic" : "104"},
{"Row" : 50, "Column" : 2, "Item" : "ORZ GTX ABX RESOURCE QTC", "DisplayText" : "RESOURCE QTC PROLONGATION FOR DRUGS", "Text" : "QTc Prolongation Drug Resource", "Mnemonic" : "106"},
{"Row" : 51, "Column" : 2, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "DDI Warfarin and Antimicrobials", "Mnemonic" : "108"},
{"Row" : 52, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category", "Text" : "Pregnancy Risk Factors for Antibiotics", "Mnemonic" : "110"},
{"Row" : 53, "Column" : 2, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of Antimicrobials", "Mnemonic" : "112"},
{"Row" : 56, "Column" : 2, "Item" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "DisplayText" : "Conditions Not Benefited by Antimicrobial Therapy (outpatient)", "Text" : "Conditions NOT benefitted by antibiotics", "Mnemonic" : "114"},
{"Row" : 57, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "ESBLs, Amp-C beta-lactamases, and Carbapenemases", "Mnemonic" : "116"},
{"Row" :1, "Column" : 2, "Text" : "HELP", "Header" : 1}, 
{"Row" :7, "Column" : 2, "Text" : "Important Antimicrobial Information", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "General", "Header" : 1}, 
{"Row" : 38, "Column" : 2, "Text" : "Post-Exposure Prophylaxis (PEP)", "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Text" : "Drug Information Links", "Header" : 1}, 
{"Row" : 55, "Column" : 2, "Text" : "Miscellaneous/Emerging Topics", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ABX APPROACH TO UTI", "DisplayText" : "APPROACH TO URINARY TRACT INFECTION (UTI)", "Text" : "[b] Urinary Tract Infections"},
{"Row" :2, "Column" : 1, "Text" : "Call Ext 31-3144 to expedite URGENT medications only", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "(List starts at top and goes down body systems)"}, 
{"Row" : 83, "Column" : 1, "Item" : "PSCZID TICK-BORNE ENCEPHALITIS VACCINE ONCE", "DisplayText" : "Tick-Borne Encephalitis Vaccine Once", "Text" : "Tick-Borne Encephalitis Vaccine Once", "Mnemonic" : "test"},
{"Row" : 84, "Column" : 1, "Item" : "PSCZID TICK-BORNE ENCEPHALITIS VACCINE 3 DOSE SERIES", "DisplayText" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Text" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Mnemonic" : "test"},
{"Row" : 80, "Column" : 1, "Item" : "ORZID TESTING", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B Vaccine Update", "Mnemonic" : "test"},
{"Row" : 81, "Column" : 1, "Item" : "ORZID3 GMENU ABX ACNE", "DisplayText" : "Acne", "Text" : "Acne", "Mnemonic" : "test"},
{"Row" : 82, "Column" : 1, "Item" : "ORZID3 GMENU ABX ROSACEA", "DisplayText" : "Rosacea", "Text" : "Rosacea", "Mnemonic" : "test"},
{"Row" : 89, "Column" : 1, "Item" : "ORZ GTX ABX VACCINE 3 DOSE SERIES NURSING TEXT ORDER", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "VACC 3 TEST", "Mnemonic" : "TEST"},
{"Row" : 86, "Column" : 1, "Item" : "ORZ GTX ABX VACCINE 1 DOSE NURSING TEXT ORDER", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "VACC 1 TEST", "Mnemonic" : "TEST"},
{"Row" : 87, "Column" : 1, "Item" : "ORZ GTX ABX VACCINE 2 DOSE SERIES NURSING TEXT ORDER", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "VACC 2 TEST", "Mnemonic" : "TEST"},
{"Row" : 88, "Column" : 1, "Item" : "ORZ GTX ABX VACCINE 4 DOSE SERIES NURSING TEXT ORDER", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "VACC 4 TEST", "Mnemonic" : "TEST"},
{"Row" : 90, "Column" : 1, "Item" : "ORZ GTX ABX VACCINE 3 DOSE SERIES NURSING TEXT ORDER", "DisplayText" : "Vaccine Nursing Text Order", "Text" : "VACC 3 TEST 2", "Mnemonic" : "TEST"},
{"Row" : 79, "Column" : 1, "Item" : "ORZ SET ABX REMDESIVIR 200MG IV LOAD THEN 100MG Q24HH 3DAYS", "DisplayText" : "Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 2 days", "Text" : "Remedesivir 200mg load followed by 100mg q24h for 3 days", "Mnemonic" : "test"},
{"Row" : 78, "Column" : 1, "Item" : "ORZID3 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*FOR ID USE ONLY* Monkeypox Treatment with TPOXX", "Mnemonic" : "Opt"},
{"Row" : 77, "Column" : 1, "Item" : "ORZID2 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*FOR ID USE ONLY* Monkeypox Treatment with TPOXX", "Mnemonic" : "Inpt"},
{"Row" : 73, "Column" : 1, "Text" : "Dr. Waisbren Testing", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZ SET ABX HERNIA REPAIR", "DisplayText" : "HERNIA REPAIR ORDER SET", "Text" : "HERNIA ORDER SET", "Mnemonic" : "TEST"},
{"Row" : 75, "Column" : 1, "Item" : "ORZ AP SURGICAL PATHOLOGY WAISBREN", "DisplayText" : "Surgical Pathology", "Text" : "Waisbren AP Order", "Mnemonic" : "TEST"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Bone Marrow Transplant Vaccinations", "Mnemonic" : "TEST"},
{"Row" : 42, "Column" : 2, "Text" : "Monkeypox", "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Item" : "ORZ GTX ABX MONKEYPOX SHAREPOINT SITE", "DisplayText" : "Monkeypox SharePoint Link", "Text" : "", "Mnemonic" : "102a"},
{"Row" : 44, "Column" : 2, "Item" : "ORZID3 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment", "Text" : "*ID Providers Only*Monkeypox Treatment", "Mnemonic" : "102b"},
{"Row" : 45, "Column" : 2, "Item" : "ORZ GTX ABX MONKEYPOX VACCINE NURSING TEXT ORDER", "DisplayText" : "Nursing Vaccine Administration Text Order", "Text" : "Monkeypox vaccine nursing text order", "Mnemonic" : "102c"},
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact CDSS & ASP Staff", "Mnemonic" : "411"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "DisplayText" : "CDC Recommended Adult Immunizations", "Text" : "By Organism/Vaccine", "Mnemonic" : "92a"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE", "DisplayText" : "CDC Recommended Adult Immunizations by Age", "Text" : "By Age", "Mnemonic" : "92b"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION", "DisplayText" : "CDC Recommended Adult Immunizations by Indication", "Text" : "By Indication", "Mnemonic" : "92c"},
{"Row" : 28, "Column" : 2, "Text" : "Immunization Information and Vaccine Orders", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINES OPT", "DisplayText" : "Outpatient COVID-19 Antimicrobial Treatment Guidelines", "Text" : "[a] COVID-19"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ABX INDEX OUTPATIENT", "DisplayText" : "Outpatient Antimicrobial CDSS Index", "Text" : "[CLICK HERE]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Text" : "Index of Antimicrobial CDSS contents", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "CDSS-MicroGuide Web and Mobile App", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "DisplayText" : "MicroGuide Mobile App Instructions", "Text" : "[CLICK HERE]", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 2, "Text" : "Beta-lactam Allergy Assessment", "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "DisplayText" : "[Click here] Beta-lactam allergy assessment", "Text" : "PDF version *Preferred", "Mnemonic" : "81a"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Text version", "Mnemonic" : "81b"},
{"Row" : 33, "Column" : 2, "Text" : "Surgical Prophylaxis & Infections", "Header" : 1}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "DisplayText" : "Pre-Op Antimicrobials...", "Text" : "Pre-op Prophylaxis", "Mnemonic" : "94"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "DisplayText" : "Antimicrobial Prophylaxis Post-op", "Text" : "Post-op Prophylaxis", "Mnemonic" : "96"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "", "Mnemonic" : "98"},
{"Row" : 85, "Column" : 1, "Item" : "ORZID3 GMENU ABX DENTAL SOP MAIN", "DisplayText" : "Antibiotic Propylaxis for Dental Procedures", "Text" : "Dental SOP Antibiotic Prophylaxis", "Mnemonic" : "199"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "Information for C difficile 2-step lab testing", "Mnemonic" : "2"},
{"Row" : 71, "Column" : 1, "Item" : "ORZ SET ABX PCN SKIN TESTING", "DisplayText" : "Penicillin skin testing", "Text" : "PCN SKIN TESTING", "Mnemonic" : "TEST"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "[d] Lyme disease"},
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM LIDOCAINE 2.1 ML 1% IM ONCE", "DisplayText" : "Ceftriaxone 1 GM IM ONCE ($) [M] Lidocaine 2.1 ML 1% IM ONCE", "Text" : "Ceftriaxone 1gm Lidocaine 1% IM ONCE", "Mnemonic" : "TEST"},
{"Row" : 11, "Column" : 1, "Text" : "C diff 2-step testing", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX PARAINFLUENZA", "DisplayText" : "Parainfluenza (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PARAINFLUENZA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "more information on management of this disease."}, 
{"Row" :9, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Sanford keyword: Parainfluenza virus"}
]},
{"Name" : "ORZID3 GMENU ABX PAROTITIS", "DisplayText" : "Parotitis (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX PAROTITIS MORE INFORMATION", "DisplayText" : "More Information on Parotitis (outpatient)", "Text" : "More information on Parotitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PAROTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection of salivary tissue is a relatively common disease. It is usually"}, 
{"Row" :6, "Column" : 1, "Text" : "caused by a stone in the parotid duct, dehydration, or a viral infection."}, 
{"Row" :7, "Column" : 1, "Text" : "Sialolithiasis in elderly patients often leads to ductal obstruction and"}, 
{"Row" :8, "Column" : 1, "Text" : "secondary infection. Other predisposing factors for ductal occlusion include"}, 
{"Row" :9, "Column" : 1, "Text" : "dehydration, anticholinergic medications such as tricyclics and diphenhydramine,"}, 
{"Row" : 10, "Column" : 1, "Text" : "general disability and trauma. Once culture results are available adjust"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial therapy based on specific etiologic organism."}, 
{"Row" : 13, "Column" : 1, "Text" : "For more information click on the link below"}, 
{"Row" : 16, "Column" : 1, "Text" : "Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 20, "Column" : 1, "Text" : "Viral Parotitis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender"}, 
{"Row" : 22, "Column" : 1, "Text" : "swelling of the parotid glands. For mumps parotitis treat with warm compresses"}, 
{"Row" : 23, "Column" : 1, "Text" : "and analgesics and maintain good hydration to prevent secondary bacterial"}, 
{"Row" : 24, "Column" : 1, "Text" : "infection. Other viral causes of parotitis include influenza and enteroviruses."}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Parotitis"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults"}
]},
{"Name" : "ORZID3 GMENU ABX PAROTITIS MORE INFORMATION", "DisplayText" : "More Information on Parotitis (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MORE ABOUT PAROTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,"}, 
{"Row" :6, "Column" : 1, "Text" : "malnourished, dehydrated or post-operative patients. Symptoms include fever,"}, 
{"Row" :7, "Column" : 1, "Text" : "toxicity, and tender swelling along the mandible with purulent drainage from the"}, 
{"Row" :8, "Column" : 1, "Text" : "parotid duct. Suppurative parotitis is usually unilateral whereas viral"}, 
{"Row" :9, "Column" : 1, "Text" : "parotitis is usually bilateral. Pain is intense and aggressive, analgesic"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy is required. Progression of infection may lead to massive swelling of"}, 
{"Row" : 11, "Column" : 1, "Text" : "the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent"}, 
{"Row" : 12, "Column" : 1, "Text" : "facial bones. Empiric antibiotics are required for coverage of Staphylococcus"}, 
{"Row" : 13, "Column" : 1, "Text" : "aureus if bacterial, and surgical drainage is usually necessary."}, 
{"Row" : 15, "Column" : 1, "Text" : "Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations."}, 
{"Row" : 16, "Column" : 1, "Text" : "Chronic, low-grade bacterial infection results in functional destruction of the"}, 
{"Row" : 17, "Column" : 1, "Text" : "salivary gland. It may be confused with Sjogren's syndrome, a noninfectious"}, 
{"Row" : 18, "Column" : 1, "Text" : "illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be"}, 
{"Row" : 19, "Column" : 1, "Text" : "required for patients with long-standing infection."}, 
{"Row" : 21, "Column" : 1, "Text" : "Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling"}, 
{"Row" : 22, "Column" : 1, "Text" : "of one or both parotid glands within 2 to 3 weeks after exposure to the mumps"}, 
{"Row" : 23, "Column" : 1, "Text" : "virus. Mumps usually involves both parotid glands whereas bacterial parotitis is"}, 
{"Row" : 24, "Column" : 1, "Text" : "unilateral. Other viral causes of parotitis include influenza and enteroviruses."}, 
{"Row" : 25, "Column" : 1, "Text" : "Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide"}, 
{"Row" : 26, "Column" : 1, "Text" : "symptomatic relief of pain and fever and maintain hydration to prevent secondary"}, 
{"Row" : 27, "Column" : 1, "Text" : "bacterial infection."}, 
{"Row" : 29, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Parotitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults"}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GTX ABX POST EXPOSURE PROPHYLAXIS NON-OCCUP HYPERLINK", "DisplayText" : "POST EXPOSURE PROPHYLAXIS NON-OCCUPATIONAL HYPERLINK", "Text" : "< SELECT HERE > Post-Exposure Prophylaxis Non-occup Protocol", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NONOCCUP RISK TABLE BY EXPOSURE ACT", "DisplayText" : "< SELECT HERE> FOR TABLE", "Text" : "< SELECT HERE > FOR TABLE", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL LABORATORY ORDERS", "DisplayText" : "NON-OCCUPATIONAL nPEP Laboratory orders", "Text" : "< SELECT HERE > INITIAL LABORATORY ORDERS", "Mnemonic" : "8"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL DRUG TX", "DisplayText" : "ANTIRETROVIRAL TREATMENT RECOMMENDATIONS for nPEP", "Text" : "< SELECT HERE > ANTIRETROVIRAL RECOMMENDATIONS for nPEP", "Mnemonic" : "10"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP LABS 4WEEK FOLLOW-UP FOR PEP NON-OCCUP", "DisplayText" : "< SELECT HERE> Order 4 week follow-up labs + RTC Order", "Text" : "< SELECT HERE > ORDER FOLLOW-UP FOR BOTH LABS AND RTC ID PHARMACY", "Mnemonic" : "12"},
{"Row" : 41, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "DisplayText" : "MRTC", "Text" : "< SELECT HERE> Consult MRTC", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "Non-occupational: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "for HIV (sexual, injection drug use, or other substantial non-occupational"}, 
{"Row" :5, "Column" : 1, "Text" : "HIV exposure)"}, 
{"Row" :7, "Column" : 1, "Text" : "Please review and follow the Post-Exposure Prophylaxis (nPEP) Protocol: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Eligibility for nPEP requires ALL: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "1.Less than 72 hours since exposure < AND >"}, 
{"Row" : 12, "Column" : 1, "Text" : "2.High-risk anatomic site of exposure < AND >"}, 
{"Row" : 15, "Column" : 1, "Text" : "3.High-risk type of fluid < AND >"}, 
{"Row" : 18, "Column" : 1, "Text" : "4.Known (or strongly suspected) HIV-positive source"}, 
{"Row" : 25, "Column" : 1, "Text" : "Estimated per-act risk for acquiring HIV from infected source, by exposure act: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "****** Complete/assess all four items below for nPEP: ******", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "For initial laboratory orders for assessment: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "For nPEP drug treatment recommendations: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "For Follow-up Laboratory Orders and Schedule Return to Clinic Appointment: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "IF risk factors for HIV persist place MRTC consult: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "If risk factors for HIV persist, place a consult to MRTC clinic for"}, 
{"Row" : 40, "Column" : 1, "Text" : "consideration of PreP prior to the 28 days of nPEP ending."}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "CDC Guidelines 2016"}, 
{"Row" : 45, "Column" : 1, "Text" : "https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf"}, 
{"Row" : 13, "Column" : 1, "Text" : "(vagina, rectum, eye, mouth or other mucous membrane, nonintact skin,"}, 
{"Row" : 14, "Column" : 1, "Text" : "percutaneous inoculation)"}, 
{"Row" : 16, "Column" : 1, "Text" : "(blood, semen, vaginal secretions, rectal secretions, breast milk,"}, 
{"Row" : 17, "Column" : 1, "Text" : "any body fluid visibly contaminated with blood)"}, 
{"Row" : 19, "Column" : 1, "Text" : "When source HIV status is unknown, recommend erring on the side of providing"}, 
{"Row" : 20, "Column" : 1, "Text" : "antivirals for nPEP given the safety and tolerability of these medications,"}, 
{"Row" : 21, "Column" : 1, "Text" : "while including the patient in shared decision making."}, 
{"Row" : 23, "Column" : 1, "Text" : "**ID on-call is availble if there are any questions.**", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL DRUG TX", "DisplayText" : "ANTIRETROVIRAL TREATMENT RECOMMENDATIONS for nPEP " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP DOLUTEGRAVIR+Descovy CRCL >/=30", "DisplayText" : "Emtricitabine 200MG/Tenofov AF 25mg PO qday + Dolutegravir 50mg PO qday [R,O]", "Text" : "Emtricitabine 200MG/Tenofov AF 25MG Tab 1 po qday ($$)[R,DI] < AND >", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days"}, 
{"Row" :4, "Column" : 1, "Text" : "Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days"}, 
{"Row" :3, "Column" : 1, "Text" : "Non-Occupational: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "All persons offered nPEP should be prescribed a 28-day course of a 3-drug"}, 
{"Row" :8, "Column" : 1, "Text" : "antiretroviral regimen."}, 
{"Row" : 10, "Column" : 1, "Text" : "* These medications may be taken with or without food"}, 
{"Row" : 11, "Column" : 1, "Text" : "* Side effects of these medications are infrequent but may include: "}, 
{"Row" : 12, "Column" : 1, "Text" : "nausea, vomiting, diarrha, rash, fever, headaches, insomnia, arthralgias,"}, 
{"Row" : 13, "Column" : 1, "Text" : "fatigue, abdominal pain, hepatitis, renal dysfunction, rare lactic acidosis"}, 
{"Row" :9, "Column" : 1, "Text" : "* IMPORTANT- First dose should be given as soon as possible after exposure"}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment recommendations: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Select appropriate treatment below based on patient renal function: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-Date Online"}, 
{"Row" : 36, "Column" : 1, "Text" : "CDC Guidelines 2016"}, 
{"Row" : 29, "Column" : 1, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Text" : "Creatinine clearance >/= 30 ml/min: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Note: Dolutegravir is now a recommended agent to be used for HIV treatment"}, 
{"Row" : 32, "Column" : 1, "Text" : "and prevention in pregnancy (updated 2023)."}, 
{"Row" : 27, "Column" : 1, "Text" : "ESRD dialysis: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Creatinine clearance < 30 ml/min not on dialysis*: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP DOLUTEGRAVIR+DESCOVY DIALYSIS", "DisplayText" : "Emtricitabine 200MG+Tenofov AF 25MG + Dolutegravir", "Text" : "Emtricitabine 200MG/Tenofov AF 25MG Tab 1 PO qday ($$) [R,DI] < AND >", "Mnemonic" : "18"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID TRUVADA Q72H NPEP CRCL <30", "DisplayText" : "Emtricitabine 200mg/Tenofovir 300mg po q72h nPEP crcl <30", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q3days ($$) [R,DI]", "Mnemonic" : "16"},
{"Row" : 24, "Column" : 1, "Text" : "*Optimal dosing is uncertain. Follow-up with ID in 1-2 weeks is recommended"}, 
{"Row" : 25, "Column" : 1, "Text" : "to individualize dosing if needed."}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL LABORATORY ORDERS", "DisplayText" : "NON-OCCUPATIONAL nPEP Laboratory orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 25, "Column" : 1, "Text" : "C) Hepatitis B and Hepatitis C labs to assess status: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "DisplayText" : "GI Liver", "Text" : "Consult Gastroenterology Liver Outpatient for Hep B or Hep C Positive patients", "Mnemonic" : "18"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET ABX LRTZ COMPREHENSIVE METABOLIC AND CBC WITH DIFF", "Text" : "Labs: Comprehensive Metabolic AND CBC with Diff", "Mnemonic" : "04"},
{"Row" :4, "Column" : 1, "Text" : "A) Baseline labs: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "D) For females of child-bearing years: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "LRTZ PREGNANCY TEST", "DisplayText" : "Urine Pregnancy Test", "Text" : "Labs: Pregnancy Screen", "Mnemonic" : "24"},
{"Row" : 36, "Column" : 1, "Text" : "E) For all persons considered for or prescribed nPEP for sexual exposure: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Recommended laboratory assessments of exposed persons prior to providing nPEP: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "CDC Guidelines 2016"}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP LABS CHLAMYDIA+GONORRHEA AND SYPHILIS", "DisplayText" : "STD LABS: Chlamydia, Gonorrhea, and Syphilis", "Text" : "Labs: Chlamydia, Gonorrhea, and Syphilis", "Mnemonic" : "26"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP LAB HEP B SEROLOGY + HEP C ANTIBODY", "DisplayText" : "Labs: Hepatitis B Serology and Hepatitis C Antibody", "Text" : "", "Mnemonic" : "16"},
{"Row" : 40, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHEA THROAT", "DisplayText" : "Throat Chlamydia with Gonorrhea", "Text" : "Lab: Throatswab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Mnemonic" : "28"},
{"Row" : 41, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHEA RECTAL", "DisplayText" : "Rectal Chlamydia with Gonorrhea", "Text" : "Lab: Rectalswab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Mnemonic" : "30"},
{"Row" : 31, "Column" : 1, "Text" : "For women of reproductive capacity who have had genital exposure to semen"}, 
{"Row" : 32, "Column" : 1, "Text" : "and a negative pregnancy test when evaluated for possible nPEP, current"}, 
{"Row" : 33, "Column" : 1, "Text" : "contraception use should be assessed, and if a risk for pregnancy exists,"}, 
{"Row" : 34, "Column" : 1, "Text" : "emergency contraception should be discussed with the patient."}, 
{"Row" : 16, "Column" : 1, "Text" : "NEGATIVE HIV Ag/Ab Test: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "POSITIVE HIV Ag/Ab Test: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "___________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "_____________________________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "B) HIV Testing", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "**ADD Labs** below for relevant exposure: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHOEAE VAGINAL", "DisplayText" : "C.TRACHOMATIS/N.GONORRHEA DNA Vaginal (submit ONLY ONE SWAB in transport media)", "Text" : "Lab: Vaginal swab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Mnemonic" : "32"},
{"Row" : 39, "Column" : 1, "Text" : "Call Lab x2400 for APTIMA Unisex Swab Specimen Collection Kit"}, 
{"Row" :8, "Column" : 1, "Text" : "Order HIV Ag/Ab to assess status for all persons: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Item" : "LRTZ HIV AG/AB", "DisplayText" : "HIV AG/AB", "Text" : "Lab: HIV Ag/Ab", "Mnemonic" : "06"},
{"Row" : 10, "Column" : 1, "Text" : "Note:Negative result reported in approximately 1 hour"}, 
{"Row" : 11, "Column" : 1, "Text" : "Preliminary positive result sent out to Quest for confirmation"}, 
{"Row" : 12, "Column" : 1, "Text" : "(may take 3-5 days for confirmation)"}, 
{"Row" : 14, "Column" : 1, "Text" : "Next steps in assessment depends on if HIV Ag/Ab result is positive or negative: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "IF HIV Ag/Ab result is NEGATIVE, continue with assessment for nPEP."}, 
{"Row" : 19, "Column" : 1, "Text" : "IF HIV Ag/Ab inhouse preliminary result is POSITIVE, this may indicate"}, 
{"Row" : 20, "Column" : 1, "Text" : "pre-existing HIV infection (pending confirmation from send out lab)."}, 
{"Row" : 21, "Column" : 1, "Text" : "Please PAGE INPATIENT INFECTIOUS DISEASE on all such patients."}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Mpls ON-CALL Schedule", "Mnemonic" : "08"}
]},
{"Name" : "ORZID3 GMENU ABX PEP NONOCCUP RISK TABLE BY EXPOSURE ACT", "DisplayText" : "< SELECT HERE> FOR TABLE" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Text" : "Parenteral", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Parenteral", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Blood Transfusion"}, 
{"Row" :9, "Column" : 2, "Text" : "9,250"}, 
{"Row" : 10, "Column" : 1, "Text" : "Needle sharing during injection drug use"}, 
{"Row" : 10, "Column" : 2, "Text" : "63"}, 
{"Row" : 11, "Column" : 1, "Text" : "Percutaneous (needlestick)"}, 
{"Row" : 12, "Column" : 2, "Text" : ""}, 
{"Row" :5, "Column" : 1, "Text" : "EXPOSURE TYPE", "Header" : 1}, 
{"Row" :5, "Column" : 2, "Text" : "Rate for HIV acquisition", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Text" : "per 10,000 exposures", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Sexual", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "Sexual", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Receptive anal intercourse"}, 
{"Row" : 14, "Column" : 2, "Text" : "138"}, 
{"Row" : 11, "Column" : 2, "Text" : "23"}, 
{"Row" : 15, "Column" : 1, "Text" : "Receptive penile-vaginal intercourse"}, 
{"Row" : 15, "Column" : 2, "Text" : "8"}, 
{"Row" : 16, "Column" : 1, "Text" : "Insertive anal intercourse"}, 
{"Row" : 16, "Column" : 2, "Text" : "11"}, 
{"Row" : 17, "Column" : 1, "Text" : "Insertive penile-vaginal intercourse"}, 
{"Row" : 17, "Column" : 2, "Text" : "4"}, 
{"Row" : 18, "Column" : 2, "Text" : "Low"}, 
{"Row" : 18, "Column" : 1, "Text" : "Receptive oral intercourse"}, 
{"Row" : 19, "Column" : 1, "Text" : "Insertive oral intercourse"}, 
{"Row" : 19, "Column" : 2, "Text" : "Low"}, 
{"Row" : 21, "Column" : 1, "Text" : "OTHER: ", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "OTHER: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Biting"}, 
{"Row" : 22, "Column" : 2, "Text" : "Negligible"}, 
{"Row" : 23, "Column" : 2, "Text" : "Negligible"}, 
{"Row" : 23, "Column" : 1, "Text" : "Spitting"}, 
{"Row" : 24, "Column" : 1, "Text" : "Throwing body fluids (including semen or saliva)"}, 
{"Row" : 24, "Column" : 2, "Text" : "Negligible"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sharing sex toys"}, 
{"Row" : 25, "Column" : 2, "Text" : "Negligible"}, 
{"Row" :2, "Column" : 1, "Text" : "Estimated per-act risk for qcquiring HIV", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "from an infected source, by exposure act", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX POST EXPOSURE PROPHYLAXIS OCCUP HYPERLINK", "DisplayText" : "POST EXPOSURE PROPHYLAXIS OCCUPATIONAL", "Text" : "Post-Exposure Prophylaxis Protocol", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZ GMENU OCC HEALTH BBP LABS MAIN", "DisplayText" : "Blood Borne Pathogen Labs...", "Text" : "Blood Borne Pathogen Labs", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ GMENU LAB ED PEP CBC LFT BASIC METABOLIC", "DisplayText" : "ED LABS FOR POST-EXPOSURE PROPHYLAXIS (PEP)", "Text" : "Select to place order for labs [CBC, LFTs, Basic Metabolic(SMA-7)]", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP PEP OCCUP (DOLUTEGRAVIR EMTRICITABINE TENOFIR)", "DisplayText" : "POST EXPOSURE PROPHYLAXIS OCCUPATIONAL HIV", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q day($$)[R,DI,O] < AND >", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "Post-Exposure Prophylaxis (PEP) for Exposure to Blood or Body Fluids", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "A.Please review and follow the Post-Exposure Prophylaxis Protocol: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "B.Order the following laboratory tests for the source patient and employee: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "C.Evaluate employee for post-exposure prophylaxis antiviral medications: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "If the source patient is known or suspected of having HIV infection, you are"}, 
{"Row" : 12, "Column" : 1, "Text" : "strongly encouraged to call the infectious diseases staff physician"}, 
{"Row" : 13, "Column" : 1, "Text" : "on call for advice any time, day or night."}, 
{"Row" : 15, "Column" : 1, "Text" : "If there has been a significant known or potential exposure to blood or"}, 
{"Row" : 16, "Column" : 1, "Text" : "body fluids from a patient with HIV infection, the employee must be seen"}, 
{"Row" : 17, "Column" : 1, "Text" : "in Occupational Health by the end of the next business day.Post-exposure"}, 
{"Row" : 18, "Column" : 1, "Text" : "prophylaxis (PEP) medications should be recommended to the employee.If"}, 
{"Row" : 19, "Column" : 1, "Text" : "acceptable to the employee, medications should be started within two hours of"}, 
{"Row" : 20, "Column" : 1, "Text" : "of exposure and should be taken for up to 28 days.To get the medications"}, 
{"Row" : 21, "Column" : 1, "Text" : "started, order a 5-day supply of antiviral medications here (see link below)."}, 
{"Row" : 22, "Column" : 1, "Text" : "Additional medications can only be ordered by Occupational Health personnel"}, 
{"Row" : 23, "Column" : 1, "Text" : "after the employee is seen."}, 
{"Row" : 25, "Column" : 1, "Text" : "If the employee accepts PEP, employee baseline labs CBC, LFTs,", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Basic Metabolic(SMA-7) should be drawn: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Select below to order 5 day emergency supply of PEP antiviral medications: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$)[O]"}
]},
{"Name" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "DisplayText" : "Prevention of bacterial endocarditis (Outpatient)", "Text" : "High risk of infective endocarditis", "Mnemonic" : "4"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Mnemonic" : "6"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS TAB BID METRON 1GM BID PO 5DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Mnemonic" : "10"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX NV TMP/SMX 1DS TAB BID METRON 1GM BID PO 5DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Mnemonic" : "14"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500MG PO BID METRON 1GM PO BID 5DS", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO BID", "Mnemonic" : "18"},
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500MG PO BID METRON 1GM PO BID 5DS", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "PERIANAL/ANORECTAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary therapy: abscess drainage", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Prompt surgical drainage is important. Antibiotics have a limited role in the"}, 
{"Row" :8, "Column" : 1, "Text" : "treatment of uncomplicated anorectal abscess. In general, the addition of"}, 
{"Row" :9, "Column" : 1, "Text" : "antibiotics to routine incision and drainage of uncomplicated anorectal abscess"}, 
{"Row" : 10, "Column" : 1, "Text" : "does not improve healing time or reduce recurrences. Antibiotics may be"}, 
{"Row" : 11, "Column" : 1, "Text" : "considered in patients with significant cellulitis, underlying"}, 
{"Row" : 12, "Column" : 1, "Text" : "immunosuppression, concomitant systemic illness, or failure to improve with"}, 
{"Row" : 13, "Column" : 1, "Text" : "drainage alone."}, 
{"Row" : 15, "Column" : 1, "Text" : "Antibiotic prophylaxis for prevention of infective endocarditis is recommended"}, 
{"Row" : 16, "Column" : 1, "Text" : "for procedures involving infected skin or skin structures in patients with"}, 
{"Row" : 17, "Column" : 1, "Text" : "underlying cardiac conditions. Click on link below for list of conditions and"}, 
{"Row" : 18, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 21, "Column" : 1, "Text" : "Although culture of abscess fluid in patients who undergo drainage is rarely"}, 
{"Row" : 22, "Column" : 1, "Text" : "helpful, it may be considered in patients who will be treated with adjunctive"}, 
{"Row" : 23, "Column" : 1, "Text" : "antibiotic treatment, recurrent infection or nonhealing wounds, substantial host"}, 
{"Row" : 24, "Column" : 1, "Text" : "defense deficiency, and patients with MRSA risk factors."}, 
{"Row" : 26, "Column" : 1, "Text" : "Duration of adjunctive antimicrobial therapy", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "After adequate drainage, 5-14 days of antibiotic coverage is indicated for those"}, 
{"Row" : 28, "Column" : 1, "Text" : "who receive adjunctive antimicrobial therapy, with duration in part based on"}, 
{"Row" : 29, "Column" : 1, "Text" : "resolution of fever and leukocytosis, severity of infection, and additional"}, 
{"Row" : 30, "Column" : 1, "Text" : "indicators of clinical response."}, 
{"Row" : 31, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Adjunctive antibiotic treatment for drained perirectal abscess in patients with", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "significant cellulitis, underlying immunosuppression, concomitant systemic", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "illness, or failure to improve with drainage alone", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Mild disease", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 43, "Column" : 1, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 5 days"}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 48, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "($) [DI] for 5 days"}, 
{"Row" : 53, "Column" : 1, "Text" : "Moderate to severe disease", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford Keyword: Perirectal abscess"}, 
{"Row" : 61, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 62, "Column" : 1, "Text" : "Steele et al, Dis Colon Rectum 54(12):1465-74, 2011"}, 
{"Row" : 63, "Column" : 1, "Text" : "Wilson et al, Circulation 116:1736, 2007"}, 
{"Row" : 64, "Column" : 1, "Text" : "Up-to-date article: Perianal and perirectal abscess"}, 
{"Row" : 65, "Column" : 1, "Text" : "Up-to-date article: Cellulitis and skin abscess in adults: Treatment"}
]},
{"Name" : "ORZID3 GMENU ABX PHOTODYNAMIC THERAPY HSV-1", "DisplayText" : "Photodynamic therapy for HSV-1 prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "PHOTODYNAMIC THERAPY AND LASER SKIN RESURFACING HSV-1 PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Recommended in patients with history of HSV-1 infection. Initiate prophylaxis"}, 
{"Row" :6, "Column" : 1, "Text" : "24-48 hours prior to surgery and continue for 3-7 days."}, 
{"Row" :8, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG BID", "DisplayText" : "Acyclovir 400 mg PO BID for 5 days ($) [R]", "Text" : "Acyclovir 400 mg PO BID for 5 days ($) [R]", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Mandell chapter: Herpes Simplex Virus"}, 
{"Row" : 14, "Column" : 1, "Text" : "Up-To-Date article: Prevention of herpes simplex virus type 1 infection in"}, 
{"Row" : 15, "Column" : 1, "Text" : "immunocompetent patients"}
]},
{"Name" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "DisplayText" : "PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "PPSV23 one dose", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "IM (PCV20 and PPSV23)"}, 
{"Row" :6, "Column" : 1, "Text" : "Subcutaneous (PPSV23 only)"}, 
{"Row" :8, "Column" : 1, "Text" : "Outpatient orders: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "*for those who received"}, 
{"Row" : 12, "Column" : 1, "Text" : "prior dose of PCV13: "}, 
{"Row" : 15, "Column" : 1, "Text" : "CPRS names: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "PNEUMOCOCCAL 20-VALENT"}, 
{"Row" : 17, "Column" : 1, "Text" : "CONJUGATE VACCINE INJ"}, 
{"Row" : 18, "Column" : 1, "Text" : "(PCV20)"}, 
{"Row" : 20, "Column" : 1, "Text" : "PNEUMOCOCCAL 23-VALENT"}, 
{"Row" : 21, "Column" : 1, "Text" : "CONJUGATE VACCINE INJ"}, 
{"Row" : 22, "Column" : 1, "Text" : "(PPSV23)"}, 
{"Row" : 24, "Column" : 1, "Text" : "Stocked brand names: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Prevnar 20 (PCV20)"}, 
{"Row" : 26, "Column" : 1, "Text" : "Pneumovax 23 (PPSV23)"}, 
{"Row" : 28, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Pneumococcal conjugate"}, 
{"Row" : 30, "Column" : 1, "Text" : "(PCV20)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Pneumococcal"}, 
{"Row" : 33, "Column" : 1, "Text" : "polysaccharide"}, 
{"Row" : 34, "Column" : 1, "Text" : "(PPSV23)"}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 39, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 40, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 41, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 43, "Column" : 1, "Text" : "Murthy et al. Annals"}, 
{"Row" : 44, "Column" : 1, "Text" : "internal medicine, 2022,"}, 
{"Row" : 45, "Column" : 1, "Text" : "175(3)432-443"}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People age 65yrs or older."}, 
{"Row" :6, "Column" : 2, "Text" : "*People younger than age"}, 
{"Row" :7, "Column" : 2, "Text" : "65yrs with certain"}, 
{"Row" :8, "Column" : 2, "Text" : "underlying medical"}, 
{"Row" :9, "Column" : 2, "Text" : "conditions: "}, 
{"Row" : 10, "Column" : 2, "Text" : "alcoholism, chronic"}, 
{"Row" : 11, "Column" : 2, "Text" : "heart/liver/lung disease,"}, 
{"Row" : 12, "Column" : 2, "Text" : "chronic renal failure,"}, 
{"Row" : 13, "Column" : 2, "Text" : "cigarette smoking,"}, 
{"Row" : 14, "Column" : 2, "Text" : "cochlear implant,"}, 
{"Row" : 15, "Column" : 2, "Text" : "congenital or acquired"}, 
{"Row" : 16, "Column" : 2, "Text" : "asplenia, CSF leak,"}, 
{"Row" : 17, "Column" : 2, "Text" : "diabetes mellitus,"}, 
{"Row" : 18, "Column" : 2, "Text" : "generalized malignancy,"}, 
{"Row" : 19, "Column" : 2, "Text" : "HIV, Hodgkin disease,"}, 
{"Row" : 20, "Column" : 2, "Text" : "immunodeficiency,"}, 
{"Row" : 21, "Column" : 2, "Text" : "iatrogenic"}, 
{"Row" : 22, "Column" : 2, "Text" : "immunosuppression,"}, 
{"Row" : 23, "Column" : 2, "Text" : "leukemia, lymphoma,"}, 
{"Row" : 24, "Column" : 2, "Text" : "multiple myeloma,"}, 
{"Row" : 25, "Column" : 2, "Text" : "nephrotic syndrome, solid"}, 
{"Row" : 26, "Column" : 2, "Text" : "organ transplants, or"}, 
{"Row" : 27, "Column" : 2, "Text" : "sickle cell disease or"}, 
{"Row" : 28, "Column" : 2, "Text" : "other hemoglobinopathies."}, 
{"Row" : 29, "Column" : 2, "Text" : "public health authorities"}, 
{"Row" : 30, "Column" : 2, "Text" : "if increased risk exists"}, 
{"Row" : 31, "Column" : 2, "Text" : "in their community."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*When recommended (see"}, 
{"Row" :5, "Column" : 3, "Text" : "column 2), give PCV20 if"}, 
{"Row" :6, "Column" : 3, "Text" : "unvaccinated or if"}, 
{"Row" :7, "Column" : 3, "Text" : "previous vaccination"}, 
{"Row" :8, "Column" : 3, "Text" : "history is unknown."}, 
{"Row" : 10, "Column" : 3, "Text" : "*If patient received PCV13"}, 
{"Row" : 11, "Column" : 3, "Text" : "previously, give one dose"}, 
{"Row" : 12, "Column" : 3, "Text" : "of PPSV23 at least 1 year"}, 
{"Row" : 13, "Column" : 3, "Text" : "after PSV13. A minimum"}, 
{"Row" : 14, "Column" : 3, "Text" : "of 8 weeks may be"}, 
{"Row" : 15, "Column" : 3, "Text" : "considered in patients"}, 
{"Row" : 16, "Column" : 3, "Text" : "with immunocompromising"}, 
{"Row" : 17, "Column" : 3, "Text" : "conditions: "}, 
{"Row" : 18, "Column" : 3, "Text" : "Chronic renal failure,"}, 
{"Row" : 19, "Column" : 3, "Text" : "nephrotic syndrome,"}, 
{"Row" : 20, "Column" : 3, "Text" : "immunodeficiency,"}, 
{"Row" : 21, "Column" : 3, "Text" : "iatrogenic"}, 
{"Row" : 22, "Column" : 3, "Text" : "immunosuppression,"}, 
{"Row" : 23, "Column" : 3, "Text" : "generalized malignancy,"}, 
{"Row" : 24, "Column" : 3, "Text" : "human immunodeficiency"}, 
{"Row" : 25, "Column" : 3, "Text" : "virus, Hodgkin disease,"}, 
{"Row" : 26, "Column" : 3, "Text" : "leukemia, lymphoma,"}, 
{"Row" : 27, "Column" : 3, "Text" : "multiple myeloma, solid"}, 
{"Row" : 28, "Column" : 3, "Text" : "organ transplants,"}, 
{"Row" : 29, "Column" : 3, "Text" : "congenital or acquired"}, 
{"Row" : 30, "Column" : 3, "Text" : "asplenia, sickle cell"}, 
{"Row" : 31, "Column" : 3, "Text" : "disease, or other"}, 
{"Row" : 32, "Column" : 3, "Text" : "hemoglobinopathies."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications: ", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "History of severe allergic"}, 
{"Row" :6, "Column" : 4, "Text" : "reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component including (for"}, 
{"Row" : 11, "Column" : 4, "Text" : "PCV13) to any diphtheria"}, 
{"Row" : 12, "Column" : 4, "Text" : "toxoid containing vaccine,"}, 
{"Row" : 13, "Column" : 4, "Text" : "or to any of its"}, 
{"Row" : 14, "Column" : 4, "Text" : "components, including"}, 
{"Row" : 15, "Column" : 4, "Text" : "yeast."}, 
{"Row" : 17, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 18, "Column" : 4, "Text" : "Moderate or severe acute"}, 
{"Row" : 19, "Column" : 4, "Text" : "illness with or"}, 
{"Row" : 20, "Column" : 4, "Text" : "without fever."}, 
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE", "DisplayText" : "PCV20 Quick Orders Not Currently Available", "Text" : "PCV20 one dose", "Mnemonic" : "1"}
]},
{"Name" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "DisplayText" : "Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "CNS are the most common contaminants isolated from blood cultures. When CNS"}, 
{"Row" :6, "Column" : 1, "Text" : "isolated from blood cultures represent true bacteremia, the blood is usually"}, 
{"Row" :7, "Column" : 1, "Text" : "obtained from a patient with plastic or metal in the body. The most common"}, 
{"Row" :8, "Column" : 1, "Text" : "source of coagulase negative staphylococcal bacteremia is an infected"}, 
{"Row" :9, "Column" : 1, "Text" : "intravascular catheter."}, 
{"Row" : 11, "Column" : 1, "Text" : "When CNS are isolated from blood, the physician should carefully assess the"}, 
{"Row" : 12, "Column" : 1, "Text" : "patient to decide whether the isolation represents disease or colonization."}, 
{"Row" : 13, "Column" : 1, "Text" : "Colonization is more likely if a single bottle is positive or both bottles from"}, 
{"Row" : 14, "Column" : 1, "Text" : "a single blood draw are positive. If multiple bottles are positive from separate"}, 
{"Row" : 15, "Column" : 1, "Text" : "blood draws, it is more likely that the isolates reflect disease or colonization"}, 
{"Row" : 16, "Column" : 1, "Text" : "of an intravascular device. Isolates from contaminated bottles often take"}, 
{"Row" : 17, "Column" : 1, "Text" : "several days to become positive. If the patient has risk factors for true"}, 
{"Row" : 18, "Column" : 1, "Text" : "coagulase negative staphylococcal bacteremia, catheter-related blood stream"}, 
{"Row" : 19, "Column" : 1, "Text" : "infection and/or the patient is severely ill, antimicrobials should be given. If"}, 
{"Row" : 20, "Column" : 1, "Text" : "there is a plastic or metal prosthesis in the body, the physician should"}, 
{"Row" : 21, "Column" : 1, "Text" : "evaluate the site for possible infection. If the isolates are likely to"}, 
{"Row" : 22, "Column" : 1, "Text" : "represent contamination and the patient does not seem ill with CNS,"}, 
{"Row" : 23, "Column" : 1, "Text" : "antimicrobial therapy would not be helpful and should not be given."}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for treatment CNS bacteremia and infected"}, 
{"Row" : 26, "Column" : 1, "Text" : "intravascular catheters treatment recommendations"}, 
{"Row" : 29, "Column" : 1, "Text" : "References"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative"}, 
{"Row" : 32, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mermel et al, Clin Infect Dis, 2009, 49"}
]},
{"Name" : "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 2000MG PO ONCE", "DisplayText" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Text" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TAB PO ONCE PREOP", "DisplayText" : "TRIMETH/SULFA 1 DS TAB PO ONCE PREOP", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO ONCE", "DisplayText" : "Minocycline 100 mg PO 1 hour before incision ($1.20/day)[DI] < OR >", "Text" : "Minocycline 100 mg PO 1 hour before incision ($) [DI]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS OR", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "PROSTHETIC JOINT INFECTION", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Patients unable to take oral medications", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Suspected MRSA", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "($) [R,DI]"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis"}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283"}, 
{"Row" : 25, "Column" : 1, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63"}, 
{"Row" : 26, "Column" : 1, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site"}, 
{"Row" : 28, "Column" : 1, "Text" : "infection in adults"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications"}, 
{"Row" : 31, "Column" : 1, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73"}, 
{"Row" : 30, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}
]},
{"Name" : "ORZID3 GMENU ABX RABIES HIGH RISK GROUPS", "DisplayText" : "Rabies High Risk Groups " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Text" : "RABIES HIGH RISK GROUPS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Occupational", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "1. Veterinarians and their staff (e.g. students and technicians)"}, 
{"Row" :8, "Column" : 1, "Text" : "2. Laboratory workers working with rabies virus or specimens that may contain"}, 
{"Row" :9, "Column" : 1, "Text" : "rabies virus"}, 
{"Row" : 10, "Column" : 1, "Text" : "3. Other people with occupations or activities that bring them in to contact"}, 
{"Row" : 11, "Column" : 1, "Text" : "with animal species at risk for rabies (e.g. animal control officers and cavers)"}, 
{"Row" : 13, "Column" : 1, "Text" : "Travel", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "1. Travelers who will be working with or around potentially rabid animals"}, 
{"Row" : 15, "Column" : 1, "Text" : "2. People who will be in areas where dog-rabies is common and who won't be in an"}, 
{"Row" : 16, "Column" : 1, "Text" : "area where safe and effective biologics are readily available within a few days"}, 
{"Row" : 17, "Column" : 1, "Text" : "after exposure"}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 24, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 25, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 27, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 28, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 29, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 30, "Column" : 1, "Text" : "9"}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Post-exposure Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX MDH ANIMAL BITES AND RABIES RISK", "DisplayText" : "MDH Health Guide on Animal Bites and Rabies Risk", "Text" : "Minnesota Department of Health Guide on Animal Bites and Rabies Risk", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "DisplayText" : "Minneapolis Clinical On-Call Schedule", "Text" : "Infectious Diseases On-Call Schedule", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "PSCZID POVIDINE-IODINE SOLN WOUND CLEANSE ONE TIME DOSE", "DisplayText" : "Povidine-iodine solution wound cleanse", "Text" : "Povidine-iodine irrigation solution", "Mnemonic" : "8"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES IGG AND VACCINE SERIES", "DisplayText" : "Rabies immune globulin and vaccine series", "Text" : "Rabies immune globulin STAT < AND > rabies vaccine STAT", "Mnemonic" : "10"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES STAT AND VACCINE SERIES", "DisplayText" : "Rabies vaccine stat and 2nd dose", "Text" : "Rabies vaccine STAT", "Mnemonic" : "12"},
{"Row" : 49, "Column" : 1, "Item" : "PSCZID TETANUS/DIPTHERIA VACCINE ONE DOSE STAT", "DisplayText" : "Tetanus/diptheria vaccine one dose stat", "Text" : "Tetanus and Diphtheria (Td) vaccine booster dose STAT", "Mnemonic" : "14"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)", "Text" : "Bite wounds recommendations (outpatient)", "Mnemonic" : "16"},
{"Row" :4, "Column" : 1, "Text" : "RABIES POST-EXPOSURE PROPHYLAXIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patients are given post-exposure prophylaxis based upon their risk including"}, 
{"Row" :7, "Column" : 1, "Text" : "type of exposure, epidemiology of rabies in the area where contact occurred,"}, 
{"Row" :8, "Column" : 1, "Text" : "circumstances of the exposure incident, species and the availability of animal"}, 
{"Row" :9, "Column" : 1, "Text" : "involved. The Minnesota Department of Health has staff available 24/7 to consult"}, 
{"Row" : 10, "Column" : 1, "Text" : "health care providers on risk-status of individuals. They can be contacted by"}, 
{"Row" : 11, "Column" : 1, "Text" : "phone at 651-201-5414. Refer to link below for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Discussion with Infectious Diseases inpatient attending by phone is highly"}, 
{"Row" : 15, "Column" : 1, "Text" : "recommended. Use the link below to obtain the pager number for on-call staff."}, 
{"Row" : 18, "Column" : 1, "Text" : "Wound cleansing", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "All post-exposure prophylaxis should begin with immediate thorough cleansing of"}, 
{"Row" : 20, "Column" : 1, "Text" : "all wounds with soap and water. After cleansing, use povidine-iodine solution to"}, 
{"Row" : 21, "Column" : 1, "Text" : "irrigate the wounds."}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients without history of rabies vaccination", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "After wound cleansing, administer rabies immune globulin and first dose of"}, 
{"Row" : 26, "Column" : 1, "Text" : "rabies vaccine series immediately."}, 
{"Row" : 29, "Column" : 1, "Text" : "Administer second, third and fourth doses of rabies vaccine series on days 3, 7,"}, 
{"Row" : 30, "Column" : 1, "Text" : "and 14. An additional dose is given on day 28 for immunocompromised patients."}, 
{"Row" : 32, "Column" : 1, "Text" : "Patients with history of rabies vaccination", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Patients with a history of complete pre-exposure vaccination regimen and a"}, 
{"Row" : 34, "Column" : 1, "Text" : "documented antibody response to the rabies virus, do not require rabies immune"}, 
{"Row" : 35, "Column" : 1, "Text" : "globulin administration. If the patient does not meet these criteria, treat as a"}, 
{"Row" : 36, "Column" : 1, "Text" : "patient without history of rabies vaccination above. If patient does meet these"}, 
{"Row" : 37, "Column" : 1, "Text" : "criteria, after wound cleansing, administer first dose of rabies vaccine series."}, 
{"Row" : 40, "Column" : 1, "Text" : "Administer second dose of rabies vaccine series on day 3."}, 
{"Row" : 42, "Column" : 1, "Text" : "Tetanus Prophylaxis", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "In bite wounds that break the skin, tetanus vaccine is indicated if patient has"}, 
{"Row" : 44, "Column" : 1, "Text" : "received <3 doses of tetanus vaccine or immunization history is unknown. Tetanus"}, 
{"Row" : 45, "Column" : 1, "Text" : "immune globulin is also indicated in these patients if they have a tetanus prone"}, 
{"Row" : 46, "Column" : 1, "Text" : "wound. For patients with 3 or more documented tetanus vaccine doses, tetanus"}, 
{"Row" : 47, "Column" : 1, "Text" : "vaccine is indicated if >5 years since last booster in tetanus prone wounds and"}, 
{"Row" : 48, "Column" : 1, "Text" : "indicated if >10 years since last booster in non-tetanus-prone wounds."}, 
{"Row" : 51, "Column" : 1, "Text" : "Treatment of infection", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 59, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 60, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 62, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 63, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 64, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 65, "Column" : 1, "Text" : "9"}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINATED PATIENTS", "DisplayText" : "Rabies Post-exposure Vaccinated Patients" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE 2ND DOSE OF 2 DOSE SERIES", "DisplayText" : "Rabies vaccine clinic order", "Text" : "[CLICK HERE] to place clinic order for second dose", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX CBOC INFO", "DisplayText" : "CBOC Information Link", "Text" : "[CLICK HERE] for CBOC open hours and contact information", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES VACCINE POST EXP DOSE 2 OF 2 DOSE SERIES", "DisplayText" : "RABIES VACCINE POST EXPOSURE DOSE CBOC 2 SERIES", "Text" : "[CLICK HERE] to place clinic order and RTC order", "Mnemonic" : "8"},
{"Row" :4, "Column" : 1, "Text" : "ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "A second dose of the rabies vaccine is required on day 3 for patients with a"}, 
{"Row" :7, "Column" : 1, "Text" : "history of documented rabies vaccination. To order the second dose of the rabies"}, 
{"Row" :8, "Column" : 1, "Text" : "vaccination, follow these two steps: "}, 
{"Row" :9, "Column" : 1, "Text" : "1) Select vaccine series below based on administration location", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "2) Click the [Next] button at the top right of this window when finished", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "If second dose will be administered at MVAMC ED", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "If second dose will be administered at a CBOC", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Complete the following 4 steps: "}, 
{"Row" : 19, "Column" : 1, "Text" : "1) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and"}, 
{"Row" : 20, "Column" : 1, "Text" : "attach patient's primary care provider for follow up."}, 
{"Row" : 22, "Column" : 1, "Text" : "2) Ensure the CBOC is open on day 3."}, 
{"Row" : 25, "Column" : 1, "Text" : "3) Order vaccine dose and place return to clinic (RTC) order."}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 35, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 36, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 38, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 39, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 40, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 41, "Column" : 1, "Text" : "9"}, 
{"Row" : 28, "Column" : 1, "Text" : "4) Call inpatient pharmacy at ext 31-3128 to ensure vaccine dose is mailed over"}, 
{"Row" : 29, "Column" : 1, "Text" : "night to the CBOC for administration."}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINE NAIVE PATIENTS", "DisplayText" : "Rabies Post-Exposure Vaccine Naive Patients " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE 2-4 SERIES", "DisplayText" : "Rabies vaccine immunocompetent patients doses 2-4", "Text" : "[CLICK HERE] for immunocompetent patients", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE 2-5 SERIES", "DisplayText" : "Rabies vaccine immunocompromised patient dose 2-5", "Text" : "[CLICK HERE] for immunocompromised patients", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX CBOC INFO", "DisplayText" : "CBOC Information Link", "Text" : "[CLICK HERE] for CBOC open hours and contact information", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES POST EXPOSURE VACCINE 2-4 SERIES", "DisplayText" : "RABIES POST EXPOSURE VACCINE 2-4 SERIES", "Text" : "[CLICK HERE] for immunocompetent patients", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES POST EXPOSURE VACCINE 2-5 SERIES", "DisplayText" : "RABIES POST EXPOSURE VACCINE 2-5 SERIES", "Text" : "[CLICK HERE] for immunocompromised patients", "Mnemonic" : "12"},
{"Row" :4, "Column" : 1, "Text" : "ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "In patients without documented rabies vaccination, subsequent doses of the"}, 
{"Row" :7, "Column" : 1, "Text" : "rabies vaccine are required on days 3, 7, and 14. An additional dose is given on"}, 
{"Row" :8, "Column" : 1, "Text" : "day 28 for immunocompromised patients. To order subsequent rabies vaccinations,"}, 
{"Row" :9, "Column" : 1, "Text" : "follow these two steps: "}, 
{"Row" : 10, "Column" : 1, "Text" : "1) Select vaccine series below based on administration location and immune", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "status", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "2) Click the [Next] button at the top right of this window when finished", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "If all subsequent rabies vaccine doses will be administered at the MVAMC ED", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "If at least one subsequent rabies vaccine dose will be administered at a CBOC", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Complete the following 4 steps: "}, 
{"Row" : 22, "Column" : 1, "Text" : "1) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and"}, 
{"Row" : 23, "Column" : 1, "Text" : "attach patient's primary care provider for follow up."}, 
{"Row" : 25, "Column" : 1, "Text" : "2) Ensure CBOC is open on days when vaccine is scheduled to be given there. The"}, 
{"Row" : 26, "Column" : 1, "Text" : "rabies vaccine is given on a 3, 7, 14-day schedule, an additional dose is given"}, 
{"Row" : 27, "Column" : 1, "Text" : "on day 28 for immunocompromised patients"}, 
{"Row" : 30, "Column" : 1, "Text" : "3) Order vaccine doses and return to clinic (RTC) order"}, 
{"Row" : 37, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 42, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 43, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 45, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 46, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 47, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 48, "Column" : 1, "Text" : "9"}, 
{"Row" : 34, "Column" : 1, "Text" : "4) Call inpatient pharmacy at ext 31-3128 to ensure vaccine dose is mailed over"}, 
{"Row" : 35, "Column" : 1, "Text" : "night to the CBOC for administration."}
]},
{"Name" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Post-exposure Prophylaxis", "Text" : "Rabies Post-Exposure Prophylaxis", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES HIGH RISK GROUPS", "DisplayText" : "Rabies High Risk Groups", "Text" : "Rabies high risk groups", "Mnemonic" : "6"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES VACCINE 2 DOSE SERIES", "DisplayText" : "RABIES VACCINE 2 DOSE SERIES", "Text" : "Rabies vaccine, 2 dose series", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES RISK CATEGORIES", "DisplayText" : "Rabies Risk Categories", "Text" : "Rabies risk categories", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "LRTZID RABIES VIRUS RAPID FLUORESCENT INHIBITION TEST", "DisplayText" : "Rabies virus rapid fluorescent inhibition test", "Text" : "Rabies virus rapid fluorescent focus inhibition test", "Mnemonic" : "12"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES BOOSTER VACCINE ONE DOSE", "DisplayText" : "RABIES BOOSTER VACCINE ONE DOSE", "Text" : "Rabies booster vaccine", "Mnemonic" : "14"},
{"Row" :4, "Column" : 1, "Text" : "RABIES PRE-EXPOSURE PROPHYLAXIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "For patients exposed to a rabid animal, refer to the Rabies-Post Exposure"}, 
{"Row" :7, "Column" : 1, "Text" : "Prophylaxis recommendations in the emergency department CDSS."}, 
{"Row" : 10, "Column" : 1, "Text" : "Rabies Vaccination", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "People who are in high-risk groups should be vaccinated against rabies."}, 
{"Row" : 15, "Column" : 1, "Text" : "Rabies Booster", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "People with continuous risk of rabies exposure should be tested for rabies virus"}, 
{"Row" : 17, "Column" : 1, "Text" : "neutralizing antibody every six months. Those with frequent risk of rabies"}, 
{"Row" : 18, "Column" : 1, "Text" : "exposure should be tested every two years."}, 
{"Row" : 21, "Column" : 1, "Text" : "A booster vaccination should be administered if the serum titer falls to"}, 
{"Row" : 22, "Column" : 1, "Text" : "maintain a value of at least complete virus neutralization at a 1:5 serum"}, 
{"Row" : 23, "Column" : 1, "Text" : "dilution by the rapid fluorescent focus inhibition test."}, 
{"Row" : 27, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 34, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 35, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 37, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 38, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 39, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 40, "Column" : 1, "Text" : "9"}, 
{"Row" : 31, "Column" : 1, "Text" : "Briggs et. al., MMWR Morb Mortal Wkly Rep, 2022, 71:619-627"}
]},
{"Name" : "ORZID3 GMENU ABX RABIES RISK CATEGORIES", "DisplayText" : "Rabies Risk Categories" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Text" : "RABIES RISK CATEGORIES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Continuous", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Rabies research laboratory workers, rabies biologics production workers"}, 
{"Row" :9, "Column" : 1, "Text" : "Frequent", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Rabies diagnostic laboratory workers, cavers, veterinarians and staff and"}, 
{"Row" : 11, "Column" : 1, "Text" : "animal-control and wildlife workers in areas where rabies is enzootic. All"}, 
{"Row" : 12, "Column" : 1, "Text" : "persons who frequently handle bats."}, 
{"Row" : 14, "Column" : 1, "Text" : "Infrequent", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Veterinarians and animal-control staff working with terrestrial animals in areas"}, 
{"Row" : 16, "Column" : 1, "Text" : "where rabies is uncommon to rare. Veterinary students. Travelers visiting areas"}, 
{"Row" : 17, "Column" : 1, "Text" : "where rabies is enzootic and immediate access to appropriate medical care"}, 
{"Row" : 18, "Column" : 1, "Text" : "including biologics is limited."}, 
{"Row" : 20, "Column" : 1, "Text" : "Rare", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "U.S. population at large, including persons in areas where rabies is epizootic."}, 
{"Row" : 23, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United"}, 
{"Row" : 28, "Column" : 1, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization"}, 
{"Row" : 29, "Column" : 1, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1."}, 
{"Row" : 31, "Column" : 1, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for"}, 
{"Row" : 32, "Column" : 1, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the"}, 
{"Row" : 33, "Column" : 1, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-"}, 
{"Row" : 34, "Column" : 1, "Text" : "9"}
]},
{"Name" : "ORZID3 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Acne and Rosacea Dermatology Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 12WKS 1DS PO Q12H", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 12WKS 500MG Q12H", "DisplayText" : "Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks", "Text" : "Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 500/125MG 12WKS PO Q12H", "DisplayText" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks", "Text" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 12WKS 500MG PO Q8H", "DisplayText" : "Azithromycin 500 mg three times weekly ($) [O] for 12 weeks", "Text" : "Azithromycin 500 mg three times weekly ($) [O] for 12 weeks", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO BID ($) [DI]", "Text" : "Doxycycline 50 mg PO BID ($) [DI] prolonged therapy", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "DERMATOLOGY SERVICE ORDER MENU FOR RECALCITRANT ACNE AND ROSACEA", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Recalcitrant Acne and Rosacea Treatment: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 10, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 15, "Column" : 1, "Text" : "Refractory Severe Rosacea Treatment: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "**For dermatology use only, requires dermatology consult prior to treatment**", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Term" : "CDC Recommended Adult Immunizations", "DisplayText" : "CDC Recommended Adult Immunizations " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "[Click Here] for vaccination history including link to Joint Legacy Viewer", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "[Click Here] for link to PDF of CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Chickenpox (Varivax, VAR)", "Mnemonic" : "8"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "DisplayText" : "TEsting", "Text" : "COVID-19 *Inpatient orders only* (Comirnaty, Spikevax, Janssen)", "Mnemonic" : "10"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Diphtheria (Tenivac, Td / Boostrix, Tdap)", "Mnemonic" : "12"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Flu (seasonal influenza)", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hiberix, Hib)", "Mnemonic" : "16"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (Havrix, HepA)", "Mnemonic" : "18"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (Engerix-B, HepB)", "Mnemonic" : "20"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (Twinrix, HepA/B)", "Mnemonic" : "22"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (Shingrix, RZV)", "Mnemonic" : "24"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (Gardasil 9, HPV)", "Mnemonic" : "26"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza (seasonal influenza)", "Mnemonic" : "28"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles (M-M-R II, MMR)", "Mnemonic" : "30"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (Menveo, MenACWY)", "Mnemonic" : "32"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (Bexsero, MenB)", "Mnemonic" : "34"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Mumps (M-M-R II, MMR)", "Mnemonic" : "36"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Pertussis (Boostrix, Tdap)", "Mnemonic" : "38"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcus (PCV20, Prevnar20 / PPSV23, Pneumovax 23)", "Mnemonic" : "40"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Rabies (Imovax) - for post-exposure prophylaxis, refer to ED Antimicrobial CDSS", "Mnemonic" : "42"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Rubella (M-M-R II, MMR)", "Mnemonic" : "44"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Shingles (Shingrix, RZV)", "Mnemonic" : "46"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus (Tenivac, Td / Boostrix, Tdap)", "Mnemonic" : "48"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Whooping cough (Boostrix, Tdap)", "Mnemonic" : "50"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Zoster (Shingrix, RZV)", "Mnemonic" : "52"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "DisplayText" : "Immunization of Patients Age 19-26 Years", "Text" : "19-26 years", "Mnemonic" : "54"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS", "Text" : "27-49 years", "Mnemonic" : "56"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "DisplayText" : "Immunization of Patients Age 50-64 Years", "Text" : "50-64 years", "Mnemonic" : "58"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "DisplayText" : "Immunization of Patients Age 65 Years or Greater", "Text" : ">/= 65 years", "Mnemonic" : "60"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)", "Mnemonic" : "62"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Chronic Liver Disease", "Mnemonic" : "64"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "DisplayText" : "Immunization of Patients with Diabetes", "Text" : "Diabetes", "Mnemonic" : "66"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Functional or Anatomical Asplenia - Outpatient Orders", "Mnemonic" : "68"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Functional or Anatomical Asplenia - Inpatient Orders", "Mnemonic" : "70"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "DisplayText" : "Immunization of Patients who are Health Care Personnel", "Text" : "Health Care Personnel", "Mnemonic" : "72"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "DisplayText" : "Immunization of Patients with Heart/Lung Disease or Alcoholism", "Text" : "Heart/Lung Disease or Alcoholism", "Mnemonic" : "74"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "HIV", "Mnemonic" : "76"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "DisplayText" : "Immunization of Immunocompromised Patients", "Text" : "Immunocompromised (not including HIV and HSCT)", "Mnemonic" : "78"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Kidney Failure or on Hemodialysis", "Mnemonic" : "80"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "DisplayText" : "Immunization of Men who Have Sex with Men", "Text" : "Men who Have Sex with Men", "Mnemonic" : "82"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy", "Mnemonic" : "84"},
{"Row" :3, "Column" : 1, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patient Vaccine History: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Please note: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "*A vaccine series does not need to be restarted, regardless of the time that has"}, 
{"Row" : 13, "Column" : 1, "Text" : "elapsed between doses."}, 
{"Row" : 14, "Column" : 1, "Text" : "*For calculating intervals between doses, 4 weeks = 28 days. Intervals of 4"}, 
{"Row" : 15, "Column" : 1, "Text" : "months or greater are determined by calendar months."}, 
{"Row" : 16, "Column" : 1, "Text" : "*Any vaccine can be given with another unless otherwise noted on the specific"}, 
{"Row" : 17, "Column" : 1, "Text" : "vaccine page."}, 
{"Row" : 18, "Column" : 1, "Text" : "*Mild illness is not a contraindication to receiving any vaccine."}, 
{"Row" : 20, "Column" : 1, "Text" : "Vaccine information and orders - listed alphabetically below by organism name", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "*see below for immunization based on age or indication"}, 
{"Row" : 23, "Column" : 1, "Text" : "Cholera (Vaxchora) - refer to Travel Clinic"}, 
{"Row" : 34, "Column" : 1, "Text" : "Japanese encephalitis (Ixiaro) - refer to Travel Clinic"}, 
{"Row" : 42, "Column" : 1, "Text" : "Poliovirus (IPOL) - refer to Travel Clinic"}, 
{"Row" : 47, "Column" : 1, "Text" : "Tick-Borne Encephalitis (Ticovac) - refer to Travel Clinic"}, 
{"Row" : 48, "Column" : 1, "Text" : "Typhoid (Typhim Vi) - refer to Travel Clinic"}, 
{"Row" : 49, "Column" : 1, "Text" : "Varicella-zoster: refer to chickenpox for prevention of primary infection or"}, 
{"Row" : 50, "Column" : 1, "Text" : "herpes zoster/shingles/zoster for prevention of viral reactivation"}, 
{"Row" : 52, "Column" : 1, "Text" : "Yellow fever (YF-VAX) - refer to Travel Clinic"}, 
{"Row" : 55, "Column" : 1, "Text" : "By Age", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "By Indication", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "References: "}, 
{"Row" : 79, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX ABX MONKEYPOX VACCINE NURSING TEXT ORDER", "DisplayText" : "Nursing Vaccine Administration Text Order", "Text" : "Monkeypox (Jynneos)", "Mnemonic" : "35"}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE", "DisplayText" : "CDC Recommended Adult Immunizations by Age" , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "DisplayText" : "Immunization of Patients Age 19-26 Years", "Text" : "19-26 years", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS", "Text" : "27-49 years", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "DisplayText" : "Immunization of Patients Age 50-64 Years", "Text" : "50-64 years", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "DisplayText" : "Immunization of Patients Age 65 Years or Greater", "Text" : ">/= 65 years", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY AGE", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION", "DisplayText" : "CDC Recommended Adult Immunizations by Indication " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY INDICATION", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS", "DisplayText" : "Bone Marrow Post-Transplant Vaccinations", "Text" : "Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "DisplayText" : "Immunization in Chronic Liver Disease", "Text" : "Chronic Liver Disease", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "DisplayText" : "Immunization of Patients with Diabetes", "Text" : "Diabetes", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Functional or Anatomical Asplenia - Outpatient Orders", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx INPATIENT", "Text" : "Functional or Anatomical Asplenia - Inpatient Orders", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "DisplayText" : "Immunization of Patients who are Health Care Personnel", "Text" : "Health Care Personnel", "Mnemonic" : "14"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "DisplayText" : "Immunization of Patients with Heart/Lung Disease or Alcoholism", "Text" : "Heart/Lung Disease or Alcoholism", "Mnemonic" : "16"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "DisplayText" : "Immunization of patients with HIV", "Text" : "HIV", "Mnemonic" : "18"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "DisplayText" : "Immunization of Immunocompromised Patients", "Text" : "Immunocompromised (not including HIV and HSCT)", "Mnemonic" : "20"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "DisplayText" : "Immunization of patient with renal failure on hemodialysis", "Text" : "Kidney Failure or on Hemodialysis", "Mnemonic" : "22"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "DisplayText" : "Immunization of Men who Have Sex with Men", "Text" : "Men who Have Sex with Men", "Mnemonic" : "24"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy", "Mnemonic" : "26"}
]},
{"Name" : "ORZID3 GMENU ABX RESPIRATORY PAPILLOMATOSIS" , "Term1" : "Respiratory papillomatosis", "DisplayText" : "Respiratory papillomatosis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIDOFOVIR 5MG/ML INJECTION", "DisplayText" : "Cidofovir 5 mg/ml for mucosal injection ($525/75mg Vial) [M]", "Text" : "Cidofovir 5 mg/ml for mucosal injection ($525/75mg Vial) [M]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "RESPIRATORY PAPILLOMATOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Respiratory papillomas are usually associated with human papillomavirus"}, 
{"Row" :6, "Column" : 1, "Text" : "infection. The papillomas are found in the pharynx, usually in the"}, 
{"Row" :7, "Column" : 1, "Text" : "larynx.They can be surgically removed, but they often recur."}, 
{"Row" :8, "Column" : 1, "Text" : "Cidofovir is injected into the respiratory mucosa after papillomas are"}, 
{"Row" :9, "Column" : 1, "Text" : "removed to prevent recurrences."}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Elina Kiverniti o Nick Sevdalis oAnastasia Rachmanidou-Doran:A"}, 
{"Row" : 15, "Column" : 1, "Text" : "systematic review on recurrent respiratory papillomatosis:clinical"}, 
{"Row" : 16, "Column" : 1, "Text" : "effect and duration of benefit of different treatment modalities, Oncol"}, 
{"Row" : 17, "Column" : 1, "Text" : "Rev (2010) 4:35-42"}
]},
{"Name" : "ORZID3 GMENU ABX ROSACEA", "DisplayText" : "Rosacea " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID METRONIDAZOLE 0.75% CREAM TOPICALLY Q24H", "DisplayText" : "Metronidazole 0.75% cream topically q24h ($) [DI]", "Text" : "Metronidazole 0.75% cream topically q24h ($) [DI]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 12WKS 50MG PO Q12H", "DisplayText" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 MINOCYLCINE 12WKS 50MG PO Q12H", "DisplayText" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Minocycline 50 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECALCITRANT ACNE AND ROSACEA", "DisplayText" : "Acne and Rosacea Dermatology Orders", "Text" : "Recalcitrant Rosacea", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ROSACEA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Rosacea is an inflammatory skin condition resulting in erythema and"}, 
{"Row" :6, "Column" : 1, "Text" : "telangiectasia of nose, cheeks, eyelids, and forehead. It typically occurs in"}, 
{"Row" :7, "Column" : 1, "Text" : "mid-life and the etiology is unknown. Erythematous rosacea is the early stage of"}, 
{"Row" :8, "Column" : 1, "Text" : "the disease and usually manifests with flushing reactions and persistently"}, 
{"Row" :9, "Column" : 1, "Text" : "erythematous skin. Late-stage disease is known as papulopustular rosace."}, 
{"Row" : 10, "Column" : 1, "Text" : "Symptoms include papular, pustular, cysts and nodules. Severe disease results in"}, 
{"Row" : 11, "Column" : 1, "Text" : "tissue atrophy and rhinophyma (bulbus nose)."}, 
{"Row" : 13, "Column" : 1, "Text" : "The goal of treatment is control of symptoms, not cure. General treatment"}, 
{"Row" : 14, "Column" : 1, "Text" : "measures include avoiding triggers (e.g. spicy food, alcohol), skin care (e.g."}, 
{"Row" : 15, "Column" : 1, "Text" : "moisturizing, gentle cleansing, avoiding topical irritants) and using sun"}, 
{"Row" : 16, "Column" : 1, "Text" : "screen. Medical treatment includes topical agents as first line therapy and oral"}, 
{"Row" : 17, "Column" : 1, "Text" : "treatment for refractory disease."}, 
{"Row" : 19, "Column" : 1, "Text" : "Papulopustular rosacea", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 29, "Column" : 1, "Text" : "**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**"}, 
{"Row" : 31, "Column" : 1, "Text" : "________________________________________________________________________________"}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Acne Rosacea"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date Article: Rosacea: Pathogenesis, clinical features, and diagnosis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date Article: Management of rosacea"}, 
{"Row" : 38, "Column" : 1, "Text" : "van Zuuren EJ et al., N Engl J Med, 2017, 377(18)1754-1764"}, 
{"Row" : 39, "Column" : 1, "Text" : ""}
]},
{"Name" : "ORZID3 GMENU ABX RSV", "DisplayText" : "Respiratory Syncytial Virus (RSV) (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "RESPIRATORY SYNCYTIAL VIRUS (RSV)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for"}, 
{"Row" :6, "Column" : 1, "Text" : "more information on management of this disease."}, 
{"Row" :9, "Column" : 1, "Text" : "References: "}, 
{"Row" : 11, "Column" : 1, "Text" : "Sanford keyword: Respiratory Syncytial Virus"}
]},
{"Name" : "ORZID3 GMENU ABX SA DECOLONIZATION" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Mnemonic" : "4a"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Mnemonic" : "6a"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX NV CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "DisplayText" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "From 10% to 40% of adults are colonized with Staphylococcus aureus, and the"}, 
{"Row" :6, "Column" : 1, "Text" : "anterior nares is the most common site of colonization. The great majority of"}, 
{"Row" :7, "Column" : 1, "Text" : "people never have disease with S. aureus, but a tiny fraction of people develop"}, 
{"Row" :8, "Column" : 1, "Text" : "clinical infections with the S. aureus that has colonized their skin or anterior"}, 
{"Row" :9, "Column" : 1, "Text" : "nares. Steps to decolonize the skin and anterior nares can transiently diminish"}, 
{"Row" : 10, "Column" : 1, "Text" : "or eradicate S. aureus colonization and can prevent post-operative wound"}, 
{"Row" : 11, "Column" : 1, "Text" : "infection in certain high-risk circumstances. For people who have other forms"}, 
{"Row" : 12, "Column" : 1, "Text" : "of recurrent S. aureus disease, not associated with an operation, results with"}, 
{"Row" : 13, "Column" : 1, "Text" : "decolonization have been disappointing, and decolonization is not routinely"}, 
{"Row" : 14, "Column" : 1, "Text" : "recommended. Colonization typically reappears in most patients within a few"}, 
{"Row" : 15, "Column" : 1, "Text" : "days or weeks after decolonization has been attempted. Clinicians occasionlly"}, 
{"Row" : 16, "Column" : 1, "Text" : "wish to attempt decolonization for patients with frequent, troublesome"}, 
{"Row" : 17, "Column" : 1, "Text" : "recurrences. The procedure here is one of several that have been studied, but"}, 
{"Row" : 18, "Column" : 1, "Text" : "none have been particularly effective over the long run."}, 
{"Row" : 20, "Column" : 1, "Text" : "Consultation with Infectious Diseases is recommended."}, 
{"Row" : 22, "Column" : 1, "Text" : "Inpatient Decolonization Order Set: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "topically QDAY nursing text order ($) [M] for 5 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Outpatient Decolonization Order Set: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Order if patient is being discharged within 5 days"}, 
{"Row" : 30, "Column" : 1, "Text" : "topically QDAY ($) [M] for 5 days"}, 
{"Row" : 33, "Column" : 1, "Text" : "Instructions", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "* Patient must wear clean clothes after bathing to prevent recontaminat"}, 
{"Row" : 35, "Column" : 1, "Text" : "* Bedding and linens must be changed/cleaned daily until the end of the"}, 
{"Row" : 36, "Column" : 1, "Text" : "decolonization protocol."}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Bradley S Clin Infect Dis 2007, 44: 186"}, 
{"Row" : 43, "Column" : 1, "Text" : "Lonneke G NEJM 2010, 362: 9"}, 
{"Row" : 44, "Column" : 1, "Text" : "Schweizer et al, JAMA 2015, 313.212:162-2171"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in"}, 
{"Row" : 46, "Column" : 1, "Text" : "adults: Prevention and control"}
]},
{"Name" : "ORZID3 GMENU ABX SOTROVIMAB EUA", "DisplayText" : "Sotrovimab (EUA) Information" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "", "Mnemonic" : "02"},
{"Row" : 42, "Column" : 1, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "infection control measures (wear mask, isolate, social distance, avoid"}, 
{"Row" : 47, "Column" : 1, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and"}, 
{"Row" : 48, "Column" : 1, "Text" : "frequent handwashing) according to CDC guidelines."}, 
{"Row" : 17, "Column" : 1, "Text" : "Inclusion Criteria", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ALL of the following criteria must be met for a patient to receive: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "2) Patient is not hospitalized due to COVID-19."}, 
{"Row" : 22, "Column" : 1, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19."}, 
{"Row" : 23, "Column" : 1, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an"}, 
{"Row" : 24, "Column" : 1, "Text" : "increase in baseline oxygen flow rate due to COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "4) Administration will begin within 7 days of symptom onset."}, 
{"Row" : 26, "Column" : 1, "Text" : "5) Patient does not have known hypersensitivity to sotrovimab or components."}, 
{"Row" : 32, "Column" : 1, "Text" : "The provider has communicated with the patient/caregiver regarding"}, 
{"Row" : 33, "Column" : 1, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/"}, 
{"Row" : 34, "Column" : 1, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an"}, 
{"Row" : 35, "Column" : 1, "Text" : "unapproved drug that is authorized for use under an EUA, given information"}, 
{"Row" : 36, "Column" : 1, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver"}, 
{"Row" : 37, "Column" : 1, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)"}, 
{"Row" : 19, "Column" : 1, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19."}, 
{"Row" : 31, "Column" : 1, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA"}, 
{"Row" :9, "Column" : 1, "Text" : "Printable Fact Sheets", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "ID available to discuss if needed."}, 
{"Row" : 28, "Column" : 1, "Text" : "including hospitalization or death."}, 
{"Row" : 27, "Column" : 1, "Text" : "6) Patient has at least one risk factor for progression to severe disease"}, 
{"Row" : 29, "Column" : 1, "Text" : "See link below for complete list: "}, 
{"Row" : 13, "Column" : 1, "Text" : "**Treatment:**", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Note: patient may be hospitalized for some other reason."}, 
{"Row" :3, "Column" : 1, "Text" : "Sotrovimab (EUA) Information", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-Sotrovimab is available via FDA Emergency Use Authorization (EUA)"}, 
{"Row" :5, "Column" : 1, "Text" : "for treating patients that meet specific criteria. Sotrovimab is"}, 
{"Row" :6, "Column" : 1, "Text" : "not FDA approved drug."}, 
{"Row" :7, "Column" : 1, "Text" : "-Sotrovimab EUA does NOT include post-exposure prophylaxis."}, 
{"Row" : 45, "Column" : 1, "Text" : "*Patients treated with this drug should continue to self-isolate and use"}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PATIENT EUA FACT SHEET", "DisplayText" : "Sotrovimab EUA Patient Information", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab", "Mnemonic" : "06"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Sotrovimab EUA Provider Fact Sheet", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab", "Mnemonic" : "08"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "DisplayText" : "Sotrovimab EUA Provider Fact Sheet", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Mnemonic" : "12"},
{"Row" : 39, "Column" : 1, "Text" : "Exclusion Criteria", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID."}, 
{"Row" : 43, "Column" : 1, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available.", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "DisplayText" : "Stasis Dermatitis (outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "DisplayText" : "Cellulitis (Outpatient)", "Text" : "Bacterial Cellulitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "STASIS DERMATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Stasis dermatitis is a common condition that is often confused with"}, 
{"Row" :6, "Column" : 1, "Text" : "bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial"}, 
{"Row" :7, "Column" : 1, "Text" : "therapy. It is important to distinguish between the two. The provider"}, 
{"Row" :8, "Column" : 1, "Text" : "should be mindful of the fact that bacterial cellulitis can occur on skin"}, 
{"Row" :9, "Column" : 1, "Text" : "with underlying stasis dermatitis. (See link below for bacterial cellulitis)"}, 
{"Row" : 11, "Column" : 1, "Text" : "Common risk factors for venous stasis include advancing age, family"}, 
{"Row" : 12, "Column" : 1, "Text" : "history of venous disease, increased body mass index, smoking, a history of"}, 
{"Row" : 13, "Column" : 1, "Text" : "trauma, prior venous thrombosis and pregnancy. Chronic venous disease and"}, 
{"Row" : 14, "Column" : 1, "Text" : "arterial vascular disease have some common risk factors (eg, smoking,"}, 
{"Row" : 15, "Column" : 1, "Text" : "obesity) and pathophysiological processes. The most common symptoms reported"}, 
{"Row" : 16, "Column" : 1, "Text" : "by patients with chronic venous disease are limb discomfort (tired, heavy"}, 
{"Row" : 17, "Column" : 1, "Text" : "legs), pain, and limb swelling. Swelling is often worse with prolonged"}, 
{"Row" : 18, "Column" : 1, "Text" : "standing and improves with leg elevation and walking. The skin of the"}, 
{"Row" : 19, "Column" : 1, "Text" : "anterior surfaces of the lower legs often has brown or blue-grey"}, 
{"Row" : 20, "Column" : 1, "Text" : "hyperpigmentation."}, 
{"Row" : 22, "Column" : 1, "Text" : "People with venous stasis are prone to develop stasis dermatitis which"}, 
{"Row" : 23, "Column" : 1, "Text" : "is one of the most common and earliest dermatologic signs of chronic venous"}, 
{"Row" : 24, "Column" : 1, "Text" : "insufficiency. Stasis dermatitis is an inflammatory process that presents as"}, 
{"Row" : 25, "Column" : 1, "Text" : "an eczematous rash characterized by itching, erythema, scaling, weeping,"}, 
{"Row" : 26, "Column" : 1, "Text" : "erosions, and crusting. Longstanding cases may develop lipodermatosclerosis"}, 
{"Row" : 27, "Column" : 1, "Text" : "a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis"}, 
{"Row" : 28, "Column" : 1, "Text" : "typically starts with a firm area of induration at the medial ankle. As the"}, 
{"Row" : 29, "Column" : 1, "Text" : "process progresses, the entire leg lower leg can become involved with"}, 
{"Row" : 30, "Column" : 1, "Text" : "extension up to the mid leg in more advanced cases. The skin overlying the"}, 
{"Row" : 31, "Column" : 1, "Text" : "panniculitis is typically heavily pigmented and bound down to the"}, 
{"Row" : 32, "Column" : 1, "Text" : "subcutaneous tissues. Brawny edema above the fibrotic area and on the foot"}, 
{"Row" : 33, "Column" : 1, "Text" : "below is seen in advanced cases. Leukocytosis and fever are common in people"}, 
{"Row" : 34, "Column" : 1, "Text" : "with stasis dermatitis."}, 
{"Row" : 36, "Column" : 1, "Text" : "Chronic venous disease is the most common cause of leg ulcers. They"}, 
{"Row" : 37, "Column" : 1, "Text" : "are usually found low on the medial ankle over a perforating vein, or along"}, 
{"Row" : 38, "Column" : 1, "Text" : "the course of the great or small saphenous veins. They occur more proximally"}, 
{"Row" : 39, "Column" : 1, "Text" : "if precipitated by trauma. Venous ulcers are not found on the forefoot or"}, 
{"Row" : 40, "Column" : 1, "Text" : "above the level of the knee. Venous ulcers can be multiple or single, and"}, 
{"Row" : 41, "Column" : 1, "Text" : "can be exquisitely tender, shallow, exudative and have a granulation base."}, 
{"Row" : 42, "Column" : 1, "Text" : "The ulcer borders are usually irregular but not undermined. They can extend"}, 
{"Row" : 43, "Column" : 1, "Text" : "circumferentially around the leg if left untreated."}, 
{"Row" : 45, "Column" : 1, "Text" : "Arterial ulcers are typically painful, and punched out or stellate. The"}, 
{"Row" : 46, "Column" : 1, "Text" : "surrounding skin is red and taut. Some arterial ulcers are pale - others have"}, 
{"Row" : 47, "Column" : 1, "Text" : "a black or yellow eschar. They are often associated with trauma and commonly"}, 
{"Row" : 48, "Column" : 1, "Text" : "occur on the foot over pressure points. There may be other signs of arterial"}, 
{"Row" : 49, "Column" : 1, "Text" : "insufficiency on the lower limb including thin atrophic or hairless skin,"}, 
{"Row" : 50, "Column" : 1, "Text" : "poor pedal pulses, diminished capillary refill, or hypertrophic deformed"}, 
{"Row" : 51, "Column" : 1, "Text" : "nails."}, 
{"Row" : 53, "Column" : 1, "Text" : "Patients with stasis or lipodermatosclerosis are prone to bouts of"}, 
{"Row" : 54, "Column" : 1, "Text" : "bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated"}, 
{"Row" : 55, "Column" : 1, "Text" : "streptococci. Typically, stasis dermatitis develops slowly, over a week or"}, 
{"Row" : 56, "Column" : 1, "Text" : "more. It is often bilateral. The onset of bacterial cellulitis is usually"}, 
{"Row" : 57, "Column" : 1, "Text" : "abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often"}, 
{"Row" : 58, "Column" : 1, "Text" : "starts in one area and spreads to adjacent areas. Bacterial cellulitis is"}, 
{"Row" : 59, "Column" : 1, "Text" : "unilateral. Both can present with fever and leukocytosis."}, 
{"Row" : 61, "Column" : 1, "Text" : "In a patient with stasis and cellulitis and the physician is uncertain"}, 
{"Row" : 62, "Column" : 1, "Text" : "about whether bacterial cellulitis is present, the physician should consider"}, 
{"Row" : 63, "Column" : 1, "Text" : "a trial of bed rest, leg elevation, and if there is fluid overload, diuresis"}, 
{"Row" : 64, "Column" : 1, "Text" : "If the cellulitis improves in 24-48 hours, antibacterial therapy and the"}, 
{"Row" : 65, "Column" : 1, "Text" : "attendant adverse reactions can be avoided. If it is clear that bacterial"}, 
{"Row" : 66, "Column" : 1, "Text" : "cellulitis has occurred, antimicrobial therapy should be given."}, 
{"Row" : 71, "Column" : 1, "Text" : "References"}, 
{"Row" : 73, "Column" : 1, "Text" : "Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52"}, 
{"Row" : 74, "Column" : 1, "Text" : "Up-to-Date article: Stasis dermatitis"}
]},
{"Name" : "ORZID3 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "LRTZ SYPHILIS AB W/REFLEX TO RPR W/TITER", "DisplayText" : "Syphilis AB w/reflex to RPR w/titer", "Text" : "Syphilis antibody test with reflex to rapid plasma reagin (RPR)", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSCZID BENZATHINE PENICILLIN 2.4MU IM ONCE", "DisplayText" : "Benzathine Penicillin 2.4 million units IM once (Cost $$$) [M]", "Text" : "Benzathine Penicillin 2.4 million units IM once ($$$) [M]", "Mnemonic" : "10"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "12"},
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 14 days", "Mnemonic" : "14a"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 54, "Column" : 1, "Item" : "PSCZID2 BENZATHINE PENICILLIN 2.4MU IM QWEEK X3 SYPHILIS", "DisplayText" : "Benzathine Penicillin 2.4 million units IM qweek x3 ($$$)[M]", "Text" : "Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses", "Mnemonic" : "16"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Beta-lactam Reaction Assessment", "Mnemonic" : "18"},
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 28DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 28 days ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 28 days", "Mnemonic" : "20a"},
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 28DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 28 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" :3, "Column" : 1, "Text" : "SYPHILIS", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. Evaluation and management are complex.", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Syphilis is a sexually transmitted disease caused by the spirochete Treponema"}, 
{"Row" : 10, "Column" : 1, "Text" : "pallidum that can manifest as a variety of signs or symptoms. Primary syphilis"}, 
{"Row" : 11, "Column" : 1, "Text" : "typically consists of painless ulcers or chancre at the site of infection with"}, 
{"Row" : 12, "Column" : 1, "Text" : "regional adenopathy. Secondary syphilis often includes a skin rash (disseminated"}, 
{"Row" : 13, "Column" : 1, "Text" : "and/or including the palms and soles), fever, malaise, mucocutaneous lesions and"}, 
{"Row" : 14, "Column" : 1, "Text" : "lymphadenopathy. Tertiary syphilis includes those with cardiovascular or"}, 
{"Row" : 15, "Column" : 1, "Text" : "gummatous disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Latent syphilis is a period of disease when a patient does not have symptoms but"}, 
{"Row" : 18, "Column" : 1, "Text" : "is found to be infected through serologic testing. Early latent syphilis refers"}, 
{"Row" : 19, "Column" : 1, "Text" : "to latent syphilis acquired within the preceding year and late latent syphilis"}, 
{"Row" : 20, "Column" : 1, "Text" : "refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or"}, 
{"Row" : 21, "Column" : 1, "Text" : "Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g."}, 
{"Row" : 22, "Column" : 1, "Text" : "meningitis, stroke, vision or hearing loss) occurring within the first months to"}, 
{"Row" : 23, "Column" : 1, "Text" : "years of infection and late manifestations (e.g. dementia, tabes dorsalis)"}, 
{"Row" : 24, "Column" : 1, "Text" : "occurring after 10-30 years."}, 
{"Row" : 26, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "A presumptive diagnosis is made through use of a nontreponemal or serologic test"}, 
{"Row" : 28, "Column" : 1, "Text" : "(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent"}, 
{"Row" : 29, "Column" : 1, "Text" : "treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield"}, 
{"Row" : 30, "Column" : 1, "Text" : "microscopy and direct fluorescent antibody (DFA) must be used for definitive"}, 
{"Row" : 31, "Column" : 1, "Text" : "diagnosis since T. pallidum cannot be cultured."}, 
{"Row" : 35, "Column" : 1, "Text" : "Management of sex partners", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Persons with sexual contact with a person with primary, secondary or early"}, 
{"Row" : 37, "Column" : 1, "Text" : "latent syphilis within the last 90 days should be presumptively treated even if"}, 
{"Row" : 38, "Column" : 1, "Text" : "serologic test is negative."}, 
{"Row" : 40, "Column" : 1, "Text" : "Primary, Secondary and Early Latent Syphilis", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 44, "Column" : 1, "Text" : "Secondary treatment for patients who are not pregnant"}, 
{"Row" : 49, "Column" : 1, "Text" : "Tertiary and Late Latent Syphilis", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 51, "Column" : 1, "Text" : "*Outpatient treatment requires a follow up appointment on day 7 and day 14 to"}, 
{"Row" : 52, "Column" : 1, "Text" : "administer 2nd and 3rd dose respectfully. Ensure these appointments are made"}, 
{"Row" : 53, "Column" : 1, "Text" : "when ordering this treatment regimen."}, 
{"Row" : 56, "Column" : 1, "Text" : "Secondary treatment for patients who are not pregnant"}, 
{"Row" : 61, "Column" : 1, "Text" : "Neurosyphilis, Ocular syphilis or Otosyphilis", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Consult Infectious Disease for treatment"}, 
{"Row" : 64, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "References: "}, 
{"Row" : 67, "Column" : 1, "Text" : "CDC STD Treatment Guidelines MMWR (2021) 70.4"}, 
{"Row" : 68, "Column" : 1, "Text" : "Mandell Chapter: Syphilis (Treponema pallidum)"}, 
{"Row" : 69, "Column" : 1, "Text" : "Sanford keyword: Syphilis"}, 
{"Row" : 70, "Column" : 1, "Text" : "Up-To-Date article: Syphilis: Screening and diagnostic testing"}, 
{"Row" : 71, "Column" : 1, "Text" : "Up-To-Date article: Syphilis: Treatment and monitoring"}
]},
{"Name" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Td/Tdap 3 dose series", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Td", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tdap", "Mnemonic" : "6"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM (Td and Tdap)", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient orders: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "CPRS names: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "TETANUS/DIPHTERIA VACCINE"}, 
{"Row" : 15, "Column" : 1, "Text" : "INJ (Td)"}, 
{"Row" : 17, "Column" : 1, "Text" : "DIPHTHERIA/TETANUS/"}, 
{"Row" : 18, "Column" : 1, "Text" : "PERTUSSIS VACCINE INJ,SUSP"}, 
{"Row" : 19, "Column" : 1, "Text" : "(Tdap)"}, 
{"Row" : 21, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Tenivac (Td)"}, 
{"Row" : 23, "Column" : 1, "Text" : "Boostrix (Tdap)"}, 
{"Row" : 25, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Tetanus, diphtheria and"}, 
{"Row" : 27, "Column" : 1, "Text" : "acellular pertussis"}, 
{"Row" : 28, "Column" : 1, "Text" : "(Td, Tdap)"}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 34, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 35, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 36, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 38, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 39, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 40, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*All people who lack"}, 
{"Row" :5, "Column" : 2, "Text" : "written documentation of a"}, 
{"Row" :6, "Column" : 2, "Text" : "primary series consisting"}, 
{"Row" :7, "Column" : 2, "Text" : "of at least 3 doses of"}, 
{"Row" :8, "Column" : 2, "Text" : "tetanus- and diphtheria-"}, 
{"Row" :9, "Column" : 2, "Text" : "toxoid-containing vaccine."}, 
{"Row" : 11, "Column" : 2, "Text" : "*A booster dose of Td or"}, 
{"Row" : 12, "Column" : 2, "Text" : "Tdap may be needed for"}, 
{"Row" : 13, "Column" : 2, "Text" : "wound management, so"}, 
{"Row" : 14, "Column" : 2, "Text" : "consult ACIP"}, 
{"Row" : 15, "Column" : 2, "Text" : "recommendations."}, 
{"Row" : 17, "Column" : 2, "Text" : "*Adults who have not"}, 
{"Row" : 18, "Column" : 2, "Text" : "received Td or Tdap in the"}, 
{"Row" : 19, "Column" : 2, "Text" : "past 10 years or whose"}, 
{"Row" : 20, "Column" : 2, "Text" : "Tdap history is not known."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*For people who are"}, 
{"Row" :5, "Column" : 3, "Text" : "unvaccinated or behind,"}, 
{"Row" :6, "Column" : 3, "Text" : "complete a 3-dose series"}, 
{"Row" :7, "Column" : 3, "Text" : "with Tdap as the first"}, 
{"Row" :8, "Column" : 3, "Text" : "dose, followed by Td or"}, 
{"Row" :9, "Column" : 3, "Text" : "Tdap (observe intervals of"}, 
{"Row" : 10, "Column" : 3, "Text" : "1-2m between dose1 and"}, 
{"Row" : 11, "Column" : 3, "Text" : "2, and an interval of 6-"}, 
{"Row" : 12, "Column" : 3, "Text" : "12m between dose2 and"}, 
{"Row" : 13, "Column" : 3, "Text" : "3)."}, 
{"Row" : 15, "Column" : 3, "Text" : "*Give Tdap to pregnant"}, 
{"Row" : 16, "Column" : 3, "Text" : "women during each"}, 
{"Row" : 17, "Column" : 3, "Text" : "pregnancy (preferred"}, 
{"Row" : 18, "Column" : 3, "Text" : "during the early part of"}, 
{"Row" : 19, "Column" : 3, "Text" : "gestational weeks 27"}, 
{"Row" : 20, "Column" : 3, "Text" : "through 36), regardless of"}, 
{"Row" : 21, "Column" : 3, "Text" : "the interval since prior"}, 
{"Row" : 22, "Column" : 3, "Text" : "Td or Tdap."}, 
{"Row" : 24, "Column" : 3, "Text" : "*Give Td or Tdap booster"}, 
{"Row" : 25, "Column" : 3, "Text" : "every 10yrs after the"}, 
{"Row" : 26, "Column" : 3, "Text" : "primary series has been"}, 
{"Row" : 27, "Column" : 3, "Text" : "completed."}, 
{"Row" : 29, "Column" : 3, "Text" : "*If Tdap is indicated,"}, 
{"Row" : 30, "Column" : 3, "Text" : "Tdap should be given"}, 
{"Row" : 31, "Column" : 3, "Text" : "regardless of interval"}, 
{"Row" : 32, "Column" : 3, "Text" : "since previous Td."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "*History of severe"}, 
{"Row" :6, "Column" : 4, "Text" : "allergic reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or to a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "*For Tdap only, history of"}, 
{"Row" : 12, "Column" : 4, "Text" : "encephalopathy not"}, 
{"Row" : 13, "Column" : 4, "Text" : "attributable to an"}, 
{"Row" : 14, "Column" : 4, "Text" : "identifiable cause, within"}, 
{"Row" : 15, "Column" : 4, "Text" : "7d following DTP/DTaP, or"}, 
{"Row" : 16, "Column" : 4, "Text" : "Tdap."}, 
{"Row" : 18, "Column" : 4, "Text" : "Precautions", "Header" : 1}, 
{"Row" : 19, "Column" : 4, "Text" : "*Moderate or severe acute"}, 
{"Row" : 20, "Column" : 4, "Text" : "illness with or without"}, 
{"Row" : 21, "Column" : 4, "Text" : "fever."}, 
{"Row" : 24, "Column" : 4, "Text" : "syndrome within 6wks"}, 
{"Row" : 25, "Column" : 4, "Text" : "following previous dose of"}, 
{"Row" : 26, "Column" : 4, "Text" : "tetanus-toxoid containing"}, 
{"Row" : 27, "Column" : 4, "Text" : "vaccine."}, 
{"Row" : 29, "Column" : 4, "Text" : "*History of Arthus-type"}, 
{"Row" : 30, "Column" : 4, "Text" : "reaction following a prior"}, 
{"Row" : 31, "Column" : 4, "Text" : "dose of tetanus or"}, 
{"Row" : 32, "Column" : 4, "Text" : "diphtheria-toxoid"}, 
{"Row" : 33, "Column" : 4, "Text" : "containing vaccine"}, 
{"Row" : 34, "Column" : 4, "Text" : "(including MenACWY): defer"}, 
{"Row" : 35, "Column" : 4, "Text" : "vaccination until at least"}, 
{"Row" : 36, "Column" : 4, "Text" : "10yrs have elapsed since"}, 
{"Row" : 37, "Column" : 4, "Text" : "the last tetanus toxoid-"}, 
{"Row" : 38, "Column" : 4, "Text" : "containing vaccine."}, 
{"Row" : 40, "Column" : 4, "Text" : "*For pertussis-containing"}, 
{"Row" : 41, "Column" : 4, "Text" : "vaccines only, progressive"}, 
{"Row" : 42, "Column" : 4, "Text" : "or unstable neurologic"}, 
{"Row" : 43, "Column" : 4, "Text" : "disorder, uncontrolled"}, 
{"Row" : 44, "Column" : 4, "Text" : "seizures, or progressive"}, 
{"Row" : 45, "Column" : 4, "Text" : "encephalopathy until a"}, 
{"Row" : 46, "Column" : 4, "Text" : "treatment regimen has been"}, 
{"Row" : 47, "Column" : 4, "Text" : "established and the"}, 
{"Row" : 48, "Column" : 4, "Text" : "condition has stabilized."}, 
{"Row" :9, "Column" : 1, "Text" : "Booster doses"}, 
{"Row" : 23, "Column" : 4, "Text" : "*History of Guillain-Barre"}
]},
{"Name" : "ORZID3 GMENU ABX TPOXX MONKEYPOX TREATMENT", "DisplayText" : "TPOXX Monkeypox Treatment " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX TPOXX DOCUMENTS LINK", "DisplayText" : "TPOXX SharePoint Link", "Text" : "[CLICK HERE] for link to required documents (Monkeypox Taskforce Teams group)", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 INV-TECOVIRIMAT 600 MG ORALLY Q12H 14 DAYS", "DisplayText" : "INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days", "Text" : "INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 INV-TECOVIRIMAT 600 MG ORALLY Q8H 14 DAYS", "DisplayText" : "INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days", "Text" : "INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CDC MONKEYPOX TREATMENT WITH TPOXX", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Eligibility: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "o Consent: Must have documented consent by patient or legally authorized"}, 
{"Row" :7, "Column" : 1, "Text" : "representative in paper or i-Med consent"}, 
{"Row" :8, "Column" : 1, "Text" : "o Primary/empiric treatment: Confirmed diagnosis or suspected infection based"}, 
{"Row" :9, "Column" : 1, "Text" : "on exposure and/or symptoms while testing is pending."}, 
{"Row" : 10, "Column" : 1, "Text" : "o Secondary Treatment: Complications from replication competent vaccinia"}, 
{"Row" : 11, "Column" : 1, "Text" : "infection from vaccination, secondary transmission, or other exposure. TPOXX may"}, 
{"Row" : 12, "Column" : 1, "Text" : "be used after VIGIV treatment or in conjunction with VIGIV and/or with other"}, 
{"Row" : 13, "Column" : 1, "Text" : "therapies based on clinical judgement."}, 
{"Row" : 14, "Column" : 1, "Text" : "o Post-exposure prophylaxis (PEP): May be considered on a case-by-case basis in"}, 
{"Row" : 15, "Column" : 1, "Text" : "consultation with the CDC. Eligibility for PEP use depends on high risk exposure"}, 
{"Row" : 16, "Column" : 1, "Text" : "confirmed or probable case and alternative or complement to PEP vaccination"}, 
{"Row" : 17, "Column" : 1, "Text" : "is needed based on clinical judgment (e.g. vaccine allergy, immunocompromise)."}, 
{"Row" : 18, "Column" : 1, "Text" : "o Dosage and duration: Weight based dosing for 14 days. But it may be longer"}, 
{"Row" : 19, "Column" : 1, "Text" : "based on clinical progress but not to exceed 90 days. Oral tecovirimat capsule"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be taken by mouth with a full glass of water within 30 minutes after"}, 
{"Row" : 21, "Column" : 1, "Text" : "eating a full meal of moderate or high fat (ideally about 600 calories and 25"}, 
{"Row" : 22, "Column" : 1, "Text" : "grams of fat)."}, 
{"Row" : 23, "Column" : 1, "Text" : "o CDC Case Reports Forms:To be completed and returned to CDC by treating"}, 
{"Row" : 24, "Column" : 1, "Text" : "physicians per IND protocol."}, 
{"Row" : 28, "Column" : 1, "Text" : "Exclusions: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "o Patient or legally authorized representative unwilling to sign an informed"}, 
{"Row" : 30, "Column" : 1, "Text" : "consent and refuse tecovirimat treatment"}, 
{"Row" : 31, "Column" : 1, "Text" : "oKnown allergy to tecovirimat and/or excipients of tecovirimat"}, 
{"Row" : 32, "Column" : 1, "Text" : "oUpon negative test results for orthopoxvirus whose treatment was initiated"}, 
{"Row" : 33, "Column" : 1, "Text" : "based on clinical manifestations prior to laboratory results."}, 
{"Row" : 34, "Column" : 1, "Text" : "o For IV tecovirimat only: patients with severe renal impairment (creatinine"}, 
{"Row" : 35, "Column" : 1, "Text" : "clearance <30 mL/min)"}, 
{"Row" : 37, "Column" : 1, "Text" : "Oral Treatment: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Patients 40kg to < 120 kg"}, 
{"Row" : 41, "Column" : 1, "Text" : "Patients 120 kg and Above"}, 
{"Row" : 44, "Column" : 1, "Text" : "Intravenous Treatment: ", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "See Inpatient Antimicroibal CDSS for IV treatment recommendations."}
]},
{"Name" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "DisplayText" : "Upper Respiratory Infections (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "Bronchitis", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "DisplayText" : "ACUTE SINUSITIS", "Text" : "Sinusitis", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Pharyngitis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "UPPER RESPIRATORY INFECTION (URI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Upper respiratory infections include several common syndromes including"}, 
{"Row" :6, "Column" : 1, "Text" : "the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis"}, 
{"Row" :7, "Column" : 1, "Text" : "(see below). Most are caused by viruses and there is no benefit from"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial therapy. If a patient presents with a URI, consider specific"}, 
{"Row" :9, "Column" : 1, "Text" : "infections that do respond to antimicrobial therapy like herpes simplex"}, 
{"Row" : 10, "Column" : 1, "Text" : "stomatitis, pertussis or thrush. If no condition that benefits from"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobial therapy is present, antimicrobials will almost certainly not help"}, 
{"Row" : 12, "Column" : 1, "Text" : "but will likely select for antimicrobial resistance and may lead to other"}, 
{"Row" : 13, "Column" : 1, "Text" : "adverse effects."}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 22, "Column" : 1, "Text" : "Kogawa et al, General medicine, 2009, 10:7-15"}
]},
{"Name" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "ORZ SET ABX OP VARICELLA VACCINE 2 DOSE SERIES", "DisplayText" : "VARICELLA VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: Subcutaneous", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient VAR orders: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "VARICELLA VIRUS VACCINE"}, 
{"Row" : 11, "Column" : 1, "Text" : "INJ"}, 
{"Row" : 13, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Varivax"}, 
{"Row" : 16, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Varicella"}, 
{"Row" : 18, "Column" : 1, "Text" : "(Chickenpox, VAR)"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 24, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 25, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 28, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 29, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 30, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*All adults without"}, 
{"Row" :5, "Column" : 2, "Text" : "evidence of immunity."}, 
{"Row" :6, "Column" : 2, "Text" : "NOTE: Evidence of immunity"}, 
{"Row" :7, "Column" : 2, "Text" : "is defined as written"}, 
{"Row" :8, "Column" : 2, "Text" : "documentation"}, 
{"Row" :9, "Column" : 2, "Text" : "of 2 doses of varicella"}, 
{"Row" : 10, "Column" : 2, "Text" : "vaccine, a history of"}, 
{"Row" : 11, "Column" : 2, "Text" : "varicella disease or"}, 
{"Row" : 12, "Column" : 2, "Text" : "herpes zoster (shingles)"}, 
{"Row" : 13, "Column" : 2, "Text" : "based on healthcare-"}, 
{"Row" : 14, "Column" : 2, "Text" : "provider diagnosis,"}, 
{"Row" : 15, "Column" : 2, "Text" : "laboratory evidence of"}, 
{"Row" : 16, "Column" : 2, "Text" : "immunity or confirmation"}, 
{"Row" : 17, "Column" : 2, "Text" : "of disease, and/or birth"}, 
{"Row" : 18, "Column" : 2, "Text" : "in the U.S. before 1980,"}, 
{"Row" : 19, "Column" : 2, "Text" : "with the exceptions that"}, 
{"Row" : 20, "Column" : 2, "Text" : "follow: "}, 
{"Row" : 21, "Column" : 2, "Text" : ">>Healthcare personnel"}, 
{"Row" : 22, "Column" : 2, "Text" : "(HCP) born in the U.S."}, 
{"Row" : 23, "Column" : 2, "Text" : "before 1980 who do not"}, 
{"Row" : 24, "Column" : 2, "Text" : "meet any of the criteria"}, 
{"Row" : 25, "Column" : 2, "Text" : "above should be tested or"}, 
{"Row" : 26, "Column" : 2, "Text" : "given the 2-dose vaccine"}, 
{"Row" : 27, "Column" : 2, "Text" : "series. If testing"}, 
{"Row" : 28, "Column" : 2, "Text" : "indicates they are not"}, 
{"Row" : 29, "Column" : 2, "Text" : "immune, give the 1st dose"}, 
{"Row" : 30, "Column" : 2, "Text" : "of varicella vaccine"}, 
{"Row" : 31, "Column" : 2, "Text" : "immediately. Give the 2nd"}, 
{"Row" : 32, "Column" : 2, "Text" : "dose 4-8 wks later."}, 
{"Row" : 33, "Column" : 2, "Text" : ">>Pregnant women born in"}, 
{"Row" : 34, "Column" : 2, "Text" : "the U.S. before 1980 who"}, 
{"Row" : 35, "Column" : 2, "Text" : "do not meet any of the"}, 
{"Row" : 36, "Column" : 2, "Text" : "criteria above should"}, 
{"Row" : 37, "Column" : 2, "Text" : "either 1) be tested for"}, 
{"Row" : 38, "Column" : 2, "Text" : "susceptibility during"}, 
{"Row" : 39, "Column" : 2, "Text" : "pregnancy and if found"}, 
{"Row" : 40, "Column" : 2, "Text" : "susceptible, given the 1st"}, 
{"Row" : 41, "Column" : 2, "Text" : "dose of varicella vaccine"}, 
{"Row" : 42, "Column" : 2, "Text" : "postpartum before hospital"}, 
{"Row" : 43, "Column" : 2, "Text" : "discharge, or 2) not be"}, 
{"Row" : 44, "Column" : 2, "Text" : "tested for susceptibility"}, 
{"Row" : 45, "Column" : 2, "Text" : "and given the 1st dose of"}, 
{"Row" : 46, "Column" : 2, "Text" : "varicella vaccine post-"}, 
{"Row" : 47, "Column" : 2, "Text" : "partum before hospital"}, 
{"Row" : 48, "Column" : 2, "Text" : "discharge. Give the 2nd"}, 
{"Row" : 49, "Column" : 2, "Text" : "dose 4-8wks later."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 2 doses."}, 
{"Row" :6, "Column" : 3, "Text" : "*Dose2 is given 4-8wks"}, 
{"Row" :7, "Column" : 3, "Text" : "after dose1."}, 
{"Row" :9, "Column" : 3, "Text" : "*If dose2 is delayed, do"}, 
{"Row" : 10, "Column" : 3, "Text" : "not start over. Just give"}, 
{"Row" : 11, "Column" : 3, "Text" : "dose2."}, 
{"Row" : 13, "Column" : 3, "Text" : "*If 2 or more of the"}, 
{"Row" : 14, "Column" : 3, "Text" : "following live virus"}, 
{"Row" : 15, "Column" : 3, "Text" : "vaccines are to be given -"}, 
{"Row" : 16, "Column" : 3, "Text" : "MMR, LAIV, Var, ZVL,"}, 
{"Row" : 17, "Column" : 3, "Text" : "and/or yellow fever - they"}, 
{"Row" : 18, "Column" : 3, "Text" : "should be given on the"}, 
{"Row" : 19, "Column" : 3, "Text" : "same day. If they are not"}, 
{"Row" : 20, "Column" : 3, "Text" : "given on the same day,"}, 
{"Row" : 21, "Column" : 3, "Text" : "space them by at least 28d"}, 
{"Row" : 22, "Column" : 3, "Text" : "(30d for yellow fever)."}, 
{"Row" : 24, "Column" : 3, "Text" : "*May use as post exposure"}, 
{"Row" : 25, "Column" : 3, "Text" : "prophylaxis if given"}, 
{"Row" : 26, "Column" : 3, "Text" : "within 5d of exposure."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "*History of severe"}, 
{"Row" :6, "Column" : 4, "Text" : "allergic reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or to a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "*Pregnancy or possibility"}, 
{"Row" : 12, "Column" : 4, "Text" : "of pregnancy within 4wks."}, 
{"Row" : 14, "Column" : 4, "Text" : "*People on long-term"}, 
{"Row" : 15, "Column" : 4, "Text" : "immunosuppressive therapy"}, 
{"Row" : 16, "Column" : 4, "Text" : "or who are"}, 
{"Row" : 17, "Column" : 4, "Text" : "immunocompromised"}, 
{"Row" : 18, "Column" : 4, "Text" : "because of malignancy and"}, 
{"Row" : 19, "Column" : 4, "Text" : "primary or acquired"}, 
{"Row" : 20, "Column" : 4, "Text" : "immunodeficiency,"}, 
{"Row" : 21, "Column" : 4, "Text" : "including HIV/AIDS"}, 
{"Row" : 22, "Column" : 4, "Text" : "(although vaccination"}, 
{"Row" : 23, "Column" : 4, "Text" : "may be considered if CD4+"}, 
{"Row" : 24, "Column" : 4, "Text" : "T-lymphocyte counts are"}, 
{"Row" : 25, "Column" : 4, "Text" : "greater than or equal to"}, 
{"Row" : 26, "Column" : 4, "Text" : "200 cells/mm3)"}, 
{"Row" : 28, "Column" : 4, "Text" : "*People with isolated B-"}, 
{"Row" : 29, "Column" : 4, "Text" : "lymphocyte deficiency may"}, 
{"Row" : 30, "Column" : 4, "Text" : "receive varicella vaccine."}, 
{"Row" : 32, "Column" : 4, "Text" : "Precautions: ", "Header" : 1}, 
{"Row" : 33, "Column" : 4, "Text" : "*Moderate or severe acute"}, 
{"Row" : 34, "Column" : 4, "Text" : "illness with or without"}, 
{"Row" : 35, "Column" : 4, "Text" : "fever."}, 
{"Row" : 37, "Column" : 4, "Text" : "*If blood, plasma, and/or"}, 
{"Row" : 38, "Column" : 4, "Text" : "immune globulin (IG or"}, 
{"Row" : 39, "Column" : 4, "Text" : "VZIG) were given in past"}, 
{"Row" : 40, "Column" : 4, "Text" : "11m, see ACIP's Best"}, 
{"Row" : 41, "Column" : 4, "Text" : "Practices Guidance"}, 
{"Row" : 42, "Column" : 4, "Text" : "regarding time to wait"}, 
{"Row" : 43, "Column" : 4, "Text" : "before vaccinating."}, 
{"Row" : 45, "Column" : 4, "Text" : "*Receipt of specific"}, 
{"Row" : 46, "Column" : 4, "Text" : "antivirals (i.e.,"}, 
{"Row" : 47, "Column" : 4, "Text" : "acyclovir, famciclovir, or"}, 
{"Row" : 48, "Column" : 4, "Text" : "valacyclovir) 24hrs before"}, 
{"Row" : 49, "Column" : 4, "Text" : "vaccination, if possible."}, 
{"Row" : 50, "Column" : 4, "Text" : "Delay resumption of these"}, 
{"Row" : 51, "Column" : 4, "Text" : "antiviral drugs for 14d"}, 
{"Row" : 52, "Column" : 4, "Text" : "after vaccination."}, 
{"Row" : 54, "Column" : 4, "Text" : "*Use of aspirin or"}, 
{"Row" : 55, "Column" : 4, "Text" : "aspirin-containing"}, 
{"Row" : 56, "Column" : 4, "Text" : "products."}
]},
{"Name" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Mnemonic" : "2"},
{"Row" :1, "Column" : 1, "Text" : "Vaccine route, orders, names", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Route: IM", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Outpatient RZV (Shingrix)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Orders: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "CPRS name: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "ZOSTER VACCINE INJ,LYPHL"}, 
{"Row" : 13, "Column" : 1, "Text" : "Stocked brand name: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Shingrix"}, 
{"Row" : 16, "Column" : 1, "Text" : "Other names: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Zoster, Shingles"}, 
{"Row" : 18, "Column" : 1, "Text" : "(RZV)"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Immunization Action"}, 
{"Row" : 24, "Column" : 1, "Text" : "Coalition,"}, 
{"Row" : 25, "Column" : 1, "Text" : "Summary of Adult"}, 
{"Row" : 26, "Column" : 1, "Text" : "Immunizations, 2021, P2011"}, 
{"Row" : 28, "Column" : 1, "Text" : "Freedman et al., Annals of"}, 
{"Row" : 29, "Column" : 1, "Text" : "internal medicine, 2021,"}, 
{"Row" : 30, "Column" : 1, "Text" : "174(3)374-384."}, 
{"Row" :1, "Column" : 2, "Text" : "Recommended populations", "Header" : 1}, 
{"Row" :2, "Column" : 2, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Text" : "*People age 50yrs and"}, 
{"Row" :5, "Column" : 2, "Text" : "older"}, 
{"Row" :6, "Column" : 2, "Text" : ">>NOTE: Do not test people"}, 
{"Row" :7, "Column" : 2, "Text" : "age 50yrs or older for"}, 
{"Row" :8, "Column" : 2, "Text" : "varicella immunity prior"}, 
{"Row" :9, "Column" : 2, "Text" : "to zoster vaccination."}, 
{"Row" : 10, "Column" : 2, "Text" : "Persons born in the U.S."}, 
{"Row" : 11, "Column" : 2, "Text" : "prior to 1980 can be"}, 
{"Row" : 12, "Column" : 2, "Text" : "presumed to be immune to"}, 
{"Row" : 13, "Column" : 2, "Text" : "varicella for the purpose"}, 
{"Row" : 14, "Column" : 2, "Text" : "of zoster vaccination,"}, 
{"Row" : 15, "Column" : 2, "Text" : "regardless of their"}, 
{"Row" : 16, "Column" : 2, "Text" : "recollection of having had"}, 
{"Row" : 17, "Column" : 2, "Text" : "chickenpox."}, 
{"Row" :1, "Column" : 3, "Text" : "Administration Schedule", "Header" : 1}, 
{"Row" :2, "Column" : 3, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 3, "Text" : "*Give 2 doses of RZV,"}, 
{"Row" :5, "Column" : 3, "Text" : "separated by 2-6m,"}, 
{"Row" :6, "Column" : 3, "Text" : "regardless of previous"}, 
{"Row" :7, "Column" : 3, "Text" : "history of herpes zoster"}, 
{"Row" :8, "Column" : 3, "Text" : "(shingles) or chickenpox."}, 
{"Row" : 10, "Column" : 3, "Text" : "*If previously vaccinated"}, 
{"Row" : 11, "Column" : 3, "Text" : "with ZVL (Zostavax), give"}, 
{"Row" : 12, "Column" : 3, "Text" : "2 doses of RZV at least 2m"}, 
{"Row" : 13, "Column" : 3, "Text" : "after ZVL."}, 
{"Row" : 15, "Column" : 3, "Text" : "*A 1-time dose of ZVL may"}, 
{"Row" : 16, "Column" : 3, "Text" : "be given to previously"}, 
{"Row" : 17, "Column" : 3, "Text" : "unvaccinated"}, 
{"Row" : 18, "Column" : 3, "Text" : "immunocompetent adults age"}, 
{"Row" : 19, "Column" : 3, "Text" : "60y and older: however,"}, 
{"Row" : 20, "Column" : 3, "Text" : "RZV is preferred."}, 
{"Row" : 22, "Column" : 3, "Text" : "*If 2 or more of the"}, 
{"Row" : 23, "Column" : 3, "Text" : "following live virus"}, 
{"Row" : 24, "Column" : 3, "Text" : "vaccines are to be given -"}, 
{"Row" : 25, "Column" : 3, "Text" : "LAIV, MMR, Var, ZVL,"}, 
{"Row" : 26, "Column" : 3, "Text" : "and/or yellow fever - they"}, 
{"Row" : 27, "Column" : 3, "Text" : "should be given on the"}, 
{"Row" : 28, "Column" : 3, "Text" : "same day. If they are not,"}, 
{"Row" : 29, "Column" : 3, "Text" : "space them by at least 28d"}, 
{"Row" : 30, "Column" : 3, "Text" : "(30d for yellow fever)."}, 
{"Row" :1, "Column" : 4, "Text" : "Contraindications/Precautions", "Header" : 1}, 
{"Row" :2, "Column" : 4, "Text" : "__________________________", "Header" : 1}, 
{"Row" :4, "Column" : 4, "Text" : "Contraindications", "Header" : 1}, 
{"Row" :5, "Column" : 4, "Text" : "*History of severe"}, 
{"Row" :6, "Column" : 4, "Text" : "allergic reaction (e.g.,"}, 
{"Row" :7, "Column" : 4, "Text" : "anaphylaxis) to a previous"}, 
{"Row" :8, "Column" : 4, "Text" : "dose or to a vaccine"}, 
{"Row" :9, "Column" : 4, "Text" : "component."}, 
{"Row" : 11, "Column" : 4, "Text" : "Precautions", "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Text" : "*Moderate or severe acute"}, 
{"Row" : 13, "Column" : 4, "Text" : "illness with or without"}, 
{"Row" : 14, "Column" : 4, "Text" : "fever."}, 
{"Row" : 16, "Column" : 4, "Text" : "*Consider delaying"}, 
{"Row" : 17, "Column" : 4, "Text" : "vaccination in pregnant"}, 
{"Row" : 18, "Column" : 4, "Text" : "or lactating women"}
]},
{"Name" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "DisplayText" : "Acute bacterial prostatitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 DOXYC 14DS 100 PO BID", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "6a"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 DOXYC 14DS 100 PO BID", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) (Non-VA) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 1GM IM X1 DOXYC 14DS 100 PO BID", "DisplayText" : "Ceftriaxone 1gm IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "8a"},
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 1GM IM X1 DOXYC 14DS 100 PO BID", "DisplayText" : "Ceftriaxone 1gm IM x 1 ($) (Non-VA) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 14DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days", "Mnemonic" : "10a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 14DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 54, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "12a"},
{"Row" : 55, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE BACTERIAL PROSTATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute bacterial prostatitis typically presents with fever, dysuria, chills,"}, 
{"Row" :6, "Column" : 1, "Text" : "malaise, myalgia, pelvic or perianal pain. On exam, the prostate gland is tense,"}, 
{"Row" :7, "Column" : 1, "Text" : "boggy, and extremely tender. The urinalysis reveals pyuria, and the urine"}, 
{"Row" :8, "Column" : 1, "Text" : "culture is positive. Men with dysuria and fever but without pyuria and/or"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteriuria should be seen by a urologist. If there is any suspicion of abscess,"}, 
{"Row" : 10, "Column" : 1, "Text" : "especially in men older than 40 years, the patient should be seen by a urologist"}, 
{"Row" : 11, "Column" : 1, "Text" : "and transurethral prostate resection for drainage should be considered."}, 
{"Row" : 13, "Column" : 1, "Text" : "Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 14, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 15, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 and those who"}, 
{"Row" : 16, "Column" : 1, "Text" : "are at high risk of sexually transmitted infections are associated with N."}, 
{"Row" : 17, "Column" : 1, "Text" : "gonorrhoeae and C. trachomatis. Resistant organisms are more likely if the"}, 
{"Row" : 18, "Column" : 1, "Text" : "patient has been in the hospital for more than 48 hours or received a course of"}, 
{"Row" : 19, "Column" : 1, "Text" : "antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 20, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 22, "Column" : 1, "Text" : "A urine Gram stain and culture should be performed in all patients to guide"}, 
{"Row" : 23, "Column" : 1, "Text" : "antimicrobial therapy: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "There is limited data on duration of antimicrobial treatment for prostatitis. 14"}, 
{"Row" : 28, "Column" : 1, "Text" : "days minimum is required. 4 to 6 weeks may be necessary to completely eradicate"}, 
{"Row" : 29, "Column" : 1, "Text" : "bacteria in the prostate to ensure patient does not progress to chronic"}, 
{"Row" : 30, "Column" : 1, "Text" : "bacterial prostatitis."}, 
{"Row" : 31, "Column" : 1, "Text" : "_____________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Hydration, bed rest and analgesics are recommended along with antimicrobials"}, 
{"Row" : 35, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 37, "Column" : 1, "Text" : "Age < 35 years and those at high risk of sexually transmitted infections", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Patient weighing less than 300 lbs: "}, 
{"Row" : 40, "Column" : 1, "Text" : "14 days"}, 
{"Row" : 43, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater: "}, 
{"Row" : 45, "Column" : 1, "Text" : "14 days"}, 
{"Row" : 48, "Column" : 1, "Text" : "Age >/= 35 years", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 56, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652"}, 
{"Row" : 61, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 62, "Column" : 1, "Text" : "Sanford keyword: Prostatitis"}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-To-Date article: Acute Bacterial Prostatitis"}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "DisplayText" : "ACUTE SINUSITIS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "DisplayText" : "Acute sinusitis--mild to moderate disease (Outpatient)", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis", "Mnemonic" : "4"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "DisplayText" : "Acute sinusitis--Severe disease (Outpatient)", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be"}, 
{"Row" :7, "Column" : 1, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute"}, 
{"Row" :8, "Column" : 1, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2"}, 
{"Row" :9, "Column" : 1, "Text" : "minor symptoms."}, 
{"Row" : 10, "Column" : 1, "Text" : "Major Symptoms", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "1. Purulent anterior nasal discharge"}, 
{"Row" : 12, "Column" : 1, "Text" : "2. Purulent or discolored posterior nasal discharge"}, 
{"Row" : 13, "Column" : 1, "Text" : "3. Nasal congestion or fullness"}, 
{"Row" : 14, "Column" : 1, "Text" : "4. Facial pain or pressure"}, 
{"Row" : 15, "Column" : 1, "Text" : "5. Hyposmia or anosmia"}, 
{"Row" : 16, "Column" : 1, "Text" : "6. Fever"}, 
{"Row" : 17, "Column" : 1, "Text" : "Minor Symptoms", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "1. Headache"}, 
{"Row" : 19, "Column" : 1, "Text" : "2. Ear pain, pressure or fullness"}, 
{"Row" : 20, "Column" : 1, "Text" : "3. Halitosis"}, 
{"Row" : 21, "Column" : 1, "Text" : "4. Dental pain"}, 
{"Row" : 22, "Column" : 1, "Text" : "5. Cough"}, 
{"Row" : 23, "Column" : 1, "Text" : "6. Fatigue"}, 
{"Row" : 25, "Column" : 1, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials"}, 
{"Row" : 26, "Column" : 1, "Text" : "according to the following criteria for mild to moderate or severe bacterial"}, 
{"Row" : 27, "Column" : 1, "Text" : "sinusitis."}, 
{"Row" : 29, "Column" : 1, "Text" : "Mild to moderate bacterial sinusitis", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Symptoms persisting beyond 10 days"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection"}, 
{"Row" : 33, "Column" : 1, "Text" : "initially improving for 5-6 days then worsening with new development of fever,"}, 
{"Row" : 34, "Column" : 1, "Text" : "headache or increased nasal discharge."}, 
{"Row" : 37, "Column" : 1, "Text" : "Severe bacterial sinusitis", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39"}, 
{"Row" : 39, "Column" : 1, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial"}, 
{"Row" : 40, "Column" : 1, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness."}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 49, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 52, "Column" : 1, "Text" : "manifestations and diagnosis"}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "DisplayText" : "Acute sinusitis--mild to moderate disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "DisplayText" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Text" : "[CLICK HERE] to go to acute respiratory infection symptomatic treatment menu", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "8a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 5 days", "Mnemonic" : "10a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days", "Mnemonic" : "12a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "MILD TO MODERATE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,"}, 
{"Row" :7, "Column" : 1, "Text" : "Staphylococcus aureus and anaerobes are isolated less frequently."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment for first 10 days of illness", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat with decongestants, analgesics, and nasal saline spray."}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment of cases that have not improved in 10 days despite", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "treatment with decongestants, analgesics, and nasal saline.", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment Failure", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "If symptoms worsen despite 72 hours orfail to improve after 3-5 days of"}, 
{"Row" : 30, "Column" : 1, "Text" : "initial empirical antimicrobial therapy, broaden coverage, switch to different"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there"}, 
{"Row" : 32, "Column" : 1, "Text" : "is no improvement after 3-5 more days of treatment, obtain CT to investigate"}, 
{"Row" : 33, "Column" : 1, "Text" : "non-infectious or suppurative causes. ENT consultation is recommended. If"}, 
{"Row" : 34, "Column" : 1, "Text" : "sinuses are aspirated, specimens should be cultured."}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "References: "}, 
{"Row" : 41, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 44, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 47, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "7"}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "DisplayText" : "Acute sinusitis--Severe disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "8a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Mnemonic" : "10a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "SEVERE SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A"}, 
{"Row" :7, "Column" : 1, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently."}, 
{"Row" :9, "Column" : 1, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees"}, 
{"Row" : 10, "Column" : 1, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4"}, 
{"Row" : 11, "Column" : 1, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the"}, 
{"Row" : 12, "Column" : 1, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses"}, 
{"Row" : 13, "Column" : 1, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT"}, 
{"Row" : 15, "Column" : 1, "Text" : "immediately. Closely monitor all patients who present with severe signs and"}, 
{"Row" : 16, "Column" : 1, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours."}, 
{"Row" : 18, "Column" : 1, "Text" : "Outpatient Treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 27, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "Treatment of hospitalized patient", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 34, "Column" : 1, "Text" : "Treatment failure", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,"}, 
{"Row" : 36, "Column" : 1, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If"}, 
{"Row" : 37, "Column" : 1, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of"}, 
{"Row" : 38, "Column" : 1, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT"}, 
{"Row" : 39, "Column" : 1, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be"}, 
{"Row" : 40, "Column" : 1, "Text" : "cultured."}, 
{"Row" : 42, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 44, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 48, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 50, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 51, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy"}, 
{"Row" : 52, "Column" : 1, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical"}, 
{"Row" : 53, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Chronic"}, 
{"Row" : 55, "Column" : 1, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic"}, 
{"Row" : 56, "Column" : 1, "Text" : "rhinosinusitis"}
]},
{"Name" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg po qday ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO QDAY ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "DisplayText" : "Ciprofloxacin 500 mg po qday ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or"}, 
{"Row" :6, "Column" : 1, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease"}, 
{"Row" :7, "Column" : 1, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250"}, 
{"Row" :8, "Column" : 1, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens"}, 
{"Row" :9, "Column" : 1, "Text" : "are isolated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first"}, 
{"Row" : 12, "Column" : 1, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with"}, 
{"Row" : 13, "Column" : 1, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1"}, 
{"Row" : 14, "Column" : 1, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients"}, 
{"Row" : 15, "Column" : 1, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more"}, 
{"Row" : 16, "Column" : 1, "Text" : "information."}, 
{"Row" : 18, "Column" : 1, "Text" : "Acute SBP", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 21, "Column" : 1, "Text" : "Prophylaxis in a patient with a previous SBP episode", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 36, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 38, "Column" : 1, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "(less than 1 gm/dL peritoneal fluid)", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial"}, 
{"Row" : 47, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 48, "Column" : 1, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and"}, 
{"Row" : 49, "Column" : 1, "Text" : "prophylaxis"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 800 MG PO BID", "DisplayText" : "Acyclovir 800 MG po bid ($0.40/day) [R]", "Text" : "Acyclovir 800 MG PO BID ($0.40/day) [R]", "Mnemonic" : "4a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 800 MG PO BID", "DisplayText" : "Acyclovir 800 MG po bid ($0.40/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 36, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 800 MG PO BID", "DisplayText" : "Acyclovir 800 MG po bid ($0.40/day) [R]", "Text" : "Acyclovir 800 MG PO BID ($0.40/day) [R]", "Mnemonic" : "6a"},
{"Row" : 37, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 800 MG PO BID", "DisplayText" : "Acyclovir 800 MG po bid ($0.40/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Severly Immunosuppressive Chemo-immunotherapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Purine Analogues", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Chemotherapy with purine analogues such as fludarabine, cladribine, or"}, 
{"Row" :8, "Column" : 1, "Text" : "pentostatin results in major cellular-immunodeficiency that may outlast the"}, 
{"Row" :9, "Column" : 1, "Text" : "exposure by months and enhances the risk for viral infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "Recommend antiviral prophylaxis for patients treated with purine analogues"}, 
{"Row" : 12, "Column" : 1, "Text" : "if at least one of the following risk factors is present: "}, 
{"Row" : 13, "Column" : 1, "Text" : "a) Second-line chemotherapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "b) Treatment with corticosteroids"}, 
{"Row" : 15, "Column" : 1, "Text" : "c) CD4 cell count <50/ul"}, 
{"Row" : 16, "Column" : 1, "Text" : "d) Age >65 years"}, 
{"Row" : 17, "Column" : 1, "Text" : "e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /"}, 
{"Row" : 18, "Column" : 1, "Text" : "L (Grade III neutropenia) OR Moderate: <500 Neutrophils/L"}, 
{"Row" : 19, "Column" : 1, "Text" : "(Grade IV neutropenia)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Duration: Antiviral prophylaxis should be initiated in the first week of"}, 
{"Row" : 22, "Column" : 1, "Text" : "therapy and continued until 2 months after completion of therapy."}, 
{"Row" : 26, "Column" : 1, "Text" : "Alemtuzumab Therapy: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Alemtuzumab is a potent reactivator of latent intracellular pathogens,"}, 
{"Row" : 28, "Column" : 1, "Text" : "including CMV. Chemotherapy with alemtuzumab results in major cellular-"}, 
{"Row" : 29, "Column" : 1, "Text" : "immunodeficiency that may outlast the exposure by months and enhances the"}, 
{"Row" : 30, "Column" : 1, "Text" : "risk for viral infections. The risk of viral disease increases with the"}, 
{"Row" : 31, "Column" : 1, "Text" : "intensity and duration of functional T-cell suppression experienced with"}, 
{"Row" : 32, "Column" : 1, "Text" : "recipients of alemtuzumab."}, 
{"Row" : 33, "Column" : 1, "Text" : "Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and"}, 
{"Row" : 34, "Column" : 1, "Text" : "continue therapy for at least 2 months after last dose or until CD4 counts"}, 
{"Row" : 35, "Column" : 1, "Text" : "are greater than or equal to 200 cells/ul, whichever is later."}, 
{"Row" : 39, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 41, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date (accessed 6-10-12)"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY", "Text" : "Select for recommendations for antiviral prophylaxis", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "Seasonal Influenza", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Mnemonic" : "8"},
{"Row" : 37, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "DisplayText" : "INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Prophylaxis for Influenza and Other Respiratory Viruses", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Patients with active malignant disease are at higher risk for upper"}, 
{"Row" :9, "Column" : 1, "Text" : "respiratory infections due to influenza, parainfluenza or respiratory"}, 
{"Row" : 10, "Column" : 1, "Text" : "syncytial virus (RSV). Although response to vaccination with the attenuate"}, 
{"Row" : 11, "Column" : 1, "Text" : "influenza vaccine in patients on chemotherapy is variable, ranging"}, 
{"Row" : 12, "Column" : 1, "Text" : "from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended"}, 
{"Row" : 13, "Column" : 1, "Text" : "patients with active malignant disease or chemotherapy, lymphoproliferative"}, 
{"Row" : 14, "Column" : 1, "Text" : "disease, or multiple myeloma. In areas and seasons where influenza is"}, 
{"Row" : 15, "Column" : 1, "Text" : "endemic, chemoprophylaxis can be considered in addition to vaccination in"}, 
{"Row" : 16, "Column" : 1, "Text" : "exposed patients with a high risk of influenza complications."}, 
{"Row" : 17, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Prophylaxis for Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Prophylaxis and monitoring for CMV reactivation is not recommended unless"}, 
{"Row" : 22, "Column" : 1, "Text" : "patient has received an allogeneic HSCT. Usually the recommendations for"}, 
{"Row" : 23, "Column" : 1, "Text" : "surveillance and prophylaxis of CMV infections from the institution"}, 
{"Row" : 24, "Column" : 1, "Text" : "performing the HSCT will be followed."}, 
{"Row" : 25, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Prophylaxis for Chronic Hepatitis B", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Reactivation of chronic hepatitis B in patients undergoing immunosuppressive"}, 
{"Row" : 30, "Column" : 1, "Text" : "or antineoplastic treatment is a severe complication. Patients with positive"}, 
{"Row" : 31, "Column" : 1, "Text" : "HBsAg, chronic hepatitis B infection, or a previous episode of HBV"}, 
{"Row" : 32, "Column" : 1, "Text" : "reactivation who will receive immunosuppressive therapy should receive"}, 
{"Row" : 33, "Column" : 1, "Text" : "prophylaxis."}, 
{"Row" : 34, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab"}, 
{"Row" : 35, "Column" : 1, "Text" : "therapy in patients."}, 
{"Row" : 36, "Column" : 1, "Text" : "Recommendations: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 41, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 42, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sandherr, M et al, Annals of Oncology 17: 1051-1059, 2006"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Text" : "Solid Tumors, Acute Leukemia, or Lymphoma", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY", "Text" : "Purine analogues or Alemtuzumab", "Mnemonic" : "6"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Stem cell transplant recipients (autologous or allogeneic)", "Mnemonic" : "8"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Rituximab Therapy", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Mnemonic" : "12"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Influenza and Other Respiratory Viruses", "Mnemonic" : "14"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Cytomegalovirus (CMV)", "Mnemonic" : "16"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Hepatitis B", "Mnemonic" : "18"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Viral infections reactivate in a small percentage of people with malignancy"}, 
{"Row" :4, "Column" : 1, "Text" : "Most viral infections in patients with hematologic malignancies or solid"}, 
{"Row" :5, "Column" : 1, "Text" : "tumors result from reactivation of asymptomatic latent infections,"}, 
{"Row" :6, "Column" : 1, "Text" : "predominantly of herpes viruses, including herpes simplex virus (HSV),"}, 
{"Row" :7, "Column" : 1, "Text" : "varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous"}, 
{"Row" :8, "Column" : 1, "Text" : "respiratory tract infections caused by influenza, parainfluenza"}, 
{"Row" :9, "Column" : 1, "Text" : "or respiratory syncytial virus (RSV) are less common."}, 
{"Row" : 11, "Column" : 1, "Text" : "The main risk factor for clinically relevant reactivation is profound"}, 
{"Row" : 12, "Column" : 1, "Text" : "disruption of cellular immune response, usually due to chemotherapy."}, 
{"Row" : 13, "Column" : 1, "Text" : "The duration and severity of neutropenia are of lesser importance."}, 
{"Row" : 14, "Column" : 1, "Text" : "The risk of viral disease increases with the intensity and duration"}, 
{"Row" : 15, "Column" : 1, "Text" : "of functional T-cell suppression. Patients receiving conventionally"}, 
{"Row" : 16, "Column" : 1, "Text" : "dosed chemotherapy regimens for solid tumors experience no major"}, 
{"Row" : 17, "Column" : 1, "Text" : "T-cell suppression and do not have a higher incidence of"}, 
{"Row" : 18, "Column" : 1, "Text" : "invasive viral infections."}, 
{"Row" : 20, "Column" : 1, "Text" : "This section is organized mainly by type of malignancy.", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "There are separate sections for purine analogues (fludarabine,"}, 
{"Row" : 22, "Column" : 1, "Text" : "cladribine, pentostatin), alemtuzumab and rituximab."}, 
{"Row" : 23, "Column" : 1, "Text" : "Select below for recommended antiviral prophylaxis: "}, 
{"Row" : 30, "Column" : 1, "Text" : "This section is organized by virus.", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Select below for recommended antiviral prophylaxis: "}, 
{"Row" : 37, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 39, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 40, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL STEM CELL MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Select for Hepatitis B recommendations", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Stem cell transplant recipients (autologous or allogeneic)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Usually the standard prophylaxis and monitoring strategies recommended"}, 
{"Row" :6, "Column" : 1, "Text" : "by the institution performing the stem cell transplant will be"}, 
{"Row" :7, "Column" : 1, "Text" : "followed."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult Hematology-Oncology or Infectious Disease for recommendations.", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Rituximab Therapy", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B prior to initiating treatment"}, 
{"Row" : 12, "Column" : 1, "Text" : "with Rituximab."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "DisplayText" : "ANTIVIRAL TREATMENT OUTPATIENT" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 OSELTAMIVIR 75MG PO BID 5 DAYS TREAT", "DisplayText" : "Oseltamivir 75 mg po bid for 5 days ($12/day) [R]", "Text" : "Oseltamivir 75 mg po bid for 5 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID3 OSELTAMIVIR 75MG PO BID 5 DAYS TREAT", "DisplayText" : "Oseltamivir 75 mg po bid for 5 days ($12/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "Antiviral Therapy Recommendations: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Who to Treat: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "The decision to treat should be based on clinical symptoms and/or presence of"}, 
{"Row" :7, "Column" : 1, "Text" : "a high risk condition, and should NOT be delayed until laboratory test"}, 
{"Row" :8, "Column" : 1, "Text" : "results are available."}, 
{"Row" : 10, "Column" : 1, "Text" : "It is important to use antiviral drugs early to treat influenza in people who"}, 
{"Row" : 11, "Column" : 1, "Text" : "are very sick with influenza (for example hospitalized people) and people who"}, 
{"Row" : 12, "Column" : 1, "Text" : "are sick with influenza and have a greater chance of getting severe"}, 
{"Row" : 13, "Column" : 1, "Text" : "complications. If a patient is not in a high-risk group or is not hospitalized,"}, 
{"Row" : 14, "Column" : 1, "Text" : "healthcare providers should use clinical judgment to guide treatment decisions."}, 
{"Row" : 16, "Column" : 1, "Text" : "People who have a greater chance of serious influenza complications include: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "*Persons who have chronic pulmonary (including asthma) or cardiovascular"}, 
{"Row" : 19, "Column" : 1, "Text" : "(except isolated hypertension), renal, hepatic, hematologic, metabolic"}, 
{"Row" : 20, "Column" : 1, "Text" : "disorders (including diabetes mellitus), neurologic and"}, 
{"Row" : 22, "Column" : 1, "Text" : "*Persons who are immunocompromised due to any cause (including immunosuppresion"}, 
{"Row" : 23, "Column" : 1, "Text" : "caused by medications or by HIV infection)"}, 
{"Row" : 25, "Column" : 1, "Text" : "*Persons younger than 19 years of age who are receiving long-term aspirin-"}, 
{"Row" : 26, "Column" : 1, "Text" : "or salicylate-containing medications and who might be at risk for experiencing"}, 
{"Row" : 27, "Column" : 1, "Text" : "Reye syndrome after influenza virus infection"}, 
{"Row" : 28, "Column" : 1, "Text" : "*Residents of nursing homes and other long-term care facilities"}, 
{"Row" : 31, "Column" : 1, "Text" : "*Persons who are extremely obese (BMI greater than or equal to 40)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Antiviral Treatment: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "If indicated, antivirals should be started as soon as possible.Maximal"}, 
{"Row" : 35, "Column" : 1, "Text" : "benefit occurs when started within 48 hours of symptom onset.However,"}, 
{"Row" : 36, "Column" : 1, "Text" : "antivirals should not be withheld if symptoms began more than 48 hours prior"}, 
{"Row" : 37, "Column" : 1, "Text" : "and the patient meets criteria for treatment and remains severely ill."}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment Dosing: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such"}, 
{"Row" : 41, "Column" : 1, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have"}, 
{"Row" : 42, "Column" : 1, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using"}, 
{"Row" : 43, "Column" : 1, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the"}, 
{"Row" : 44, "Column" : 1, "Text" : "bronchodilator."}, 
{"Row" : 49, "Column" : 1, "Text" : "Recommended: ", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]"}, 
{"Row" : 64, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "*Adults aged 65 years and older"}, 
{"Row" : 21, "Column" : 1, "Text" : "neuro-developmental disorders"}, 
{"Row" : 57, "Column" : 1, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for"}, 
{"Row" : 58, "Column" : 1, "Text" : "patients wt <80kg ($$$) [DI]"}, 
{"Row" : 56, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 60, "Column" : 1, "Text" : "Alternative for patients unable to tolerate or absorb oral oseltamvir: ", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "Peramivir 600 mg IV once ($$$$$) [R]"}, 
{"Row" : 61, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Extending the duration of treatment for oseltamivir or peramivir may be"}, 
{"Row" : 47, "Column" : 1, "Text" : "needed for those patients with prolonged illness or who are immunosuppressed."}, 
{"Row" : 24, "Column" : 1, "Text" : "*Pregnant women and women up to 2 weeks after the end of pregnancy"}, 
{"Row" : 29, "Column" : 1, "Text" : "*Non-Hispanic Black persons, Hispanic or Latino persons, and American Indian"}, 
{"Row" : 30, "Column" : 1, "Text" : "or Alaska Native persons"}, 
{"Row" : 65, "Column" : 1, "Text" : "Centers for Disease Control (CDC) (Accessed 9/20/22)"}, 
{"Row" : 66, "Column" : 1, "Text" : "https://www.cdc.gov/flu/professionals/antivirals/summary-clinician"}, 
{"Row" : 67, "Column" : 1, "Text" : "UpToDate Seasonal influenza in adults: Treatment"}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL TYPE OF MALIGNANCY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :2, "Column" : 1, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Solid Tumors", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Solid tumors do not significantly compromise the cellular immune system."}, 
{"Row" :7, "Column" : 1, "Text" : "Therefore, patients are at low risk for opportunistic viral infections."}, 
{"Row" :8, "Column" : 1, "Text" : "Documented invasive viral infections are very rare. Coincidental"}, 
{"Row" :9, "Column" : 1, "Text" : "mucocutaneous infections by herpes simplex are easily treated and do not"}, 
{"Row" : 10, "Column" : 1, "Text" : "result in life-threatening invasive infections. Reactivation of"}, 
{"Row" : 11, "Column" : 1, "Text" : "Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed."}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute Leukemia", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "In patients with acute leukemia, treatment is highly aggressive and consists"}, 
{"Row" : 16, "Column" : 1, "Text" : "of a combination of various cytotoxic agents administered in sequential"}, 
{"Row" : 17, "Column" : 1, "Text" : "cycles as induction, consolidation and maintenance therapy. Persistent, i.e."}, 
{"Row" : 18, "Column" : 1, "Text" : ">10 days and profound neutropenia (<500 neutrophils) regularly occurs and"}, 
{"Row" : 19, "Column" : 1, "Text" : "correlates with the risk of developing fever and infections. Almost all viral"}, 
{"Row" : 20, "Column" : 1, "Text" : "infections during neutropenia constitute reactivations of herpes viruses."}, 
{"Row" : 21, "Column" : 1, "Text" : "None of the available studies demonstrated an effect of antiviral prophylaxis"}, 
{"Row" : 22, "Column" : 1, "Text" : "on the initiation of antibiotic treatment, number of febrile days, duration"}, 
{"Row" : 23, "Column" : 1, "Text" : "of antibiotic treatment, and onset of opportunistic infections. Therefore,"}, 
{"Row" : 24, "Column" : 1, "Text" : "recommendation for antiviral prophylaxis in patients with acute leukemia can"}, 
{"Row" : 25, "Column" : 1, "Text" : "be given."}, 
{"Row" : 27, "Column" : 1, "Text" : "Lymphoma", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "No Antiviral Prophylaxis Recommended", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Rituximab is a monoclonal anti-CD-20 antibody used for treatment of"}, 
{"Row" : 30, "Column" : 1, "Text" : "lymphomas. It leads to a profound depletion of circulating B-cells. B-cell"}, 
{"Row" : 31, "Column" : 1, "Text" : "recover usually within 3-6 months after treatment. Prolonged administration"}, 
{"Row" : 32, "Column" : 1, "Text" : "of rituximab (e.g., maintenance treatment >12 months) may result in a"}, 
{"Row" : 33, "Column" : 1, "Text" : "significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-"}, 
{"Row" : 34, "Column" : 1, "Text" : "papovavirus infections have been reported with maintenance rituximab therapy"}, 
{"Row" : 35, "Column" : 1, "Text" : "but drugs that would prevent these infections are not available. There is"}, 
{"Row" : 36, "Column" : 1, "Text" : "substantial increase in risk of reactivation of herpes viruses (including"}, 
{"Row" : 37, "Column" : 1, "Text" : "HSV, VZV, and CMV)."}, 
{"Row" : 38, "Column" : 1, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab"}, 
{"Row" : 39, "Column" : 1, "Text" : "therapy in patients."}, 
{"Row" : 41, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in"}, 
{"Row" : 43, "Column" : 1, "Text" : "Cancer Patients"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date (accessed 6-10-11)"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006"}
]},
{"Name" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "DisplayText" : "Appendicitis with perforation (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITH PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "APPENDICITIS WITHOUT PERFORATION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "DisplayText" : "Acute Respiratory Infection (ARI) Symptomatic Therapy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Per CDC: Antibiotics Aren't Always the Answer. Be Antibiotics Aware.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antibiotics do not work on viruses, such as colds and flu, or runny noses,"}, 
{"Row" :6, "Column" : 1, "Text" : "even if the mucus is thick, yellow or green. Antibiotics also won't help"}, 
{"Row" :7, "Column" : 1, "Text" : "some common bacterial infections including most cases of bronchitis, many"}, 
{"Row" :8, "Column" : 1, "Text" : "sinus infections, and some ear infections. When antibiotics aren't needed,"}, 
{"Row" : 19, "Column" : 1, "Text" : "Antitussive Therapy: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID GUAIFENESIN DM 10ML Q4H PRN COUGH", "DisplayText" : "Guaifenesin Dextromethorphan 10 ML PO q4h prn", "Text" : "", "Mnemonic" : "14a"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID GUAIFENESIN W/CODEINE 10ML Q4HPRN COUGH", "DisplayText" : "Guaifenesin with Codeine 10 ML PO q4h prn", "Text" : "", "Mnemonic" : "16a"},
{"Row" : 29, "Column" : 1, "Text" : "Wheezing: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID ALBUTEROL ORAL INHL I2P Q6H PRN", "DisplayText" : "Albuterol Oral Inhaler 2 PUFFS q6h PRN 25DS", "Text" : "", "Mnemonic" : "24a"},
{"Row" : 33, "Column" : 1, "Text" : "Pain and/or Fever: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID ACETAMINOPHEN 650MG PO Q6H PRN", "DisplayText" : "Acetaminophen 650 MG PO q6h prn", "Text" : "", "Mnemonic" : "26a"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID IBUPROFEN 400 MG PO Q6H PRN", "DisplayText" : "Ibuprofen 400 MG PO q6h prn", "Text" : "", "Mnemonic" : "28a"},
{"Row" : 40, "Column" : 1, "Text" : "Throat Pain: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Nasal Congestion: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZID PSEUDOEPHEDRINE 60MG PO Q6H PRN NASAL CONG", "DisplayText" : "Pseudoephedrine 60 MG PO q6h prn", "Text" : "", "Mnemonic" : "48a"},
{"Row" : 54, "Column" : 1, "Text" : "Rhinorrhea and Sneezing: ", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID IPRATROPIUM BR 0.06% NASAL 2 SPRAYS EN QID", "DisplayText" : "Ipratropium nasal spray (0.06%) 2 sprays each nostril", "Text" : "", "Mnemonic" : "50a"},
{"Row" : 58, "Column" : 1, "Text" : "Rhinorrhea: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID OXYMETAZOLINE 0.5% NASAL 2 SPRAYS EN BID FOR 3DAYS", "DisplayText" : "Oxymetazoline 0.5% Nasal Spray 2 sprays each nostril twice daily prn up to 3days", "Text" : "", "Mnemonic" : "46a"},
{"Row" : 45, "Column" : 1, "Item" : "PSOZID SALINE NASAL SPRAY 2 SPRAYS EN Q1H PRN", "DisplayText" : "Saline nasal spray 2 sprays each nostril q1h prn", "Text" : "", "Mnemonic" : "44a"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID THROAT LOZENGE Q1H PRN", "DisplayText" : "Throat lozenge q1h PRN", "Text" : "", "Mnemonic" : "32a"},
{"Row" :9, "Column" : 1, "Text" : "they won't help you, and the side effects could still hurt you. Reactions"}, 
{"Row" : 16, "Column" : 1, "Text" : "ARI: Symptom-based therapy represents the mainstay of treatment.", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID CETIRIZINE 10MG PO QDAY POSTNASAL DRIP", "DisplayText" : "Cetirizine 10 MG PO qday prn", "Text" : "", "Mnemonic" : "52a"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID BENZONATATE 100MG PO TID PRN 10DS", "DisplayText" : "Benzonatate 100 MG PO tid prn", "Text" : "", "Mnemonic" : "18a"},
{"Row" : 10, "Column" : 1, "Text" : "from antibiotics cause 1 out of 5 medication-related visits to ED."}, 
{"Row" : 17, "Column" : 1, "Text" : "Please select only one item from each symptom category patient experencing."}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL CDC ANTIBIOTICS AREN'T THE ANSWER", "DisplayText" : "CDC website Antibiotics aren't always the Answer", "Text" : "<Link> CDC Print Pamphlet-Antibiotics aren't always the answer"},
{"Row" : 11, "Column" : 1, "Text" : "Select links below to print educational material for patient: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX URL RX PRESCRIPTION FOR VIRUSES", "DisplayText" : "Relief RX for viral infections", "Text" : "<Link> CDC Print Pamphlet-Symptomatic RX for Acute Respiratory Infections"},
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Contact the CDSS Team", "Mnemonic" : "02"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID GUAIFENESIN DM 10ML Q4H PRN COUGH", "DisplayText" : "Guaifenesin Dextromethorphan 10 ML PO q4h prn", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID GUAIFENESIN W/CODEINE 10ML Q4HPRN COUGH", "DisplayText" : "Guaifenesin with Codeine 10 ML PO q4h prn", "Text" : "Non-VA for above (*Controlled Substance: Requires written prescription*)", "Mnemonic" : "16b"},
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID BENZONATATE 100MG PO TID PRN 10DS", "DisplayText" : "Benzonatate 100 MG PO tid prn", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID ALBUTEROL ORAL INHL I2P Q6H PRN", "DisplayText" : "Albuterol Oral Inhaler 2 PUFFS q6h PRN 25DS", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID ACETAMINOPHEN 650MG PO Q6H PRN", "DisplayText" : "Acetaminophen 650 MG PO q6h prn", "Text" : "Non-VA order for above", "Mnemonic" : "26b"},
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID IBUPROFEN 400 MG PO Q6H PRN", "DisplayText" : "Ibuprofen 400 MG PO q6h prn", "Text" : "Non-VA order for above", "Mnemonic" : "28b"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID THROAT LOZENGE Q1H PRN", "DisplayText" : "Throat lozenge q1h PRN", "Text" : "Non-VA order for above", "Mnemonic" : "32b"},
{"Row" : 46, "Column" : 1, "Item" : "PSHZID SALINE NASAL SPRAY 2 SPRAYS EN Q1H PRN", "DisplayText" : "Saline nasal spray 2 sprays each nostril q1h prn", "Text" : "Non-VA order for above", "Mnemonic" : "44b"},
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID CETIRIZINE 10MG PO QDAY POSTNASAL DRIP", "DisplayText" : "Cetirizine 10 MG PO qday prn", "Text" : "Non-VA order for above", "Mnemonic" : "52b"},
{"Row" : 52, "Column" : 1, "Item" : "PSHZID PSEUDOEPHEDRINE 60MG PO Q6H PRN NASAL CONGESTION", "DisplayText" : "Pseudoephedrine 60 MG PO q6h prn", "Text" : "Non-VA order for above", "Mnemonic" : "48b"},
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID IPRATROPIUM BR 0.06% NASAL 2 SPRAYS EN QID", "DisplayText" : "Ipratropium nasal spray (0.06%) 2 sprays each nostril", "Text" : "Non-VA order for above", "Mnemonic" : "50b"},
{"Row" : 49, "Column" : 1, "Item" : "PSHZID OXYMETAZOLINE 0.5% NASAL 2 SPRAYS EN BID FOR 3DAYS", "DisplayText" : "Oxymetazoline 0.5% Nasal Spray 2 sprays each nostril twice daily p", "Text" : "Non-VA order for above", "Mnemonic" : "46b"},
{"Row" : 14, "Column" : 1, "Text" : "___________________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient)", "Text" : "Community acquired pneumonia (CAP)< OR >", "Mnemonic" : "4"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "DisplayText" : "Lung abscess (Outpatient)", "Text" : "Lung abscess", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "ASPIRATION PNEUMONIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is"}, 
{"Row" :6, "Column" : 1, "Text" : "often accompanied by fever and/or an infiltrate.Bacterial pneumonia occurs in"}, 
{"Row" :7, "Column" : 1, "Text" : "a minority of patients who aspirate, typically about 3 days later.The patient"}, 
{"Row" :8, "Column" : 1, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia"}, 
{"Row" :9, "Column" : 1, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and"}, 
{"Row" : 10, "Column" : 1, "Text" : "newly purulent sputum."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails"}, 
{"Row" : 13, "Column" : 1, "Text" : "risk of side effects and selection of resistant organisms."}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases"}, 
{"Row" : 16, "Column" : 1, "Text" : "that develop after an episode of aspiration.For more information, consult"}, 
{"Row" : 17, "Column" : 1, "Text" : "Pulmonary or Infectious Diseases."}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for patients with pneumonitis but WITHOUT LUNG ABSCESS or putrid", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "sputum", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary.If"}, 
{"Row" : 22, "Column" : 1, "Text" : "pneumonia is confirmed, treat as"}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to Nosocomial Pneumonia in the Inpatient Antimicrobial CDSS."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treament for patients WITH LUNG ABSCESS", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Chastre J JAMA 2003, 290:2588"}, 
{"Row" : 34, "Column" : 1, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371"}, 
{"Row" : 35, "Column" : 1, "Text" : "Kalil AC et al Clin Infect Dis 2016, 63:1"}, 
{"Row" : 36, "Column" : 1, "Text" : "Luna CMCrit Care Med 2003, 31: 676"}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Infectious Diseases"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405"}, 
{"Row" : 39, "Column" : 1, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119"}
]},
{"Name" : "ORZID3 GMENU ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic bacteriuria (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 100MG BID 5DS", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl >30 mL/min, for 5 days", "Mnemonic" : "4a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 100MG BID 5DS", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "6"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg PO bid ($) [R]", "Text" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days", "Mnemonic" : "10a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "DisplayText" : "Urological procedures", "Text" : "Antimicrobial prophylaxis for urological procedures", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "ASYMPTOMATIC BACTERIURIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Asymptomatic bacteriuria is common in women and elderly people, especially in"}, 
{"Row" :6, "Column" : 1, "Text" : "those with chronic medical problems (e.g., diabetes, spinal cord injury,"}, 
{"Row" :7, "Column" : 1, "Text" : "institutionalized patients, catheterized patients). Most patients have no"}, 
{"Row" :8, "Column" : 1, "Text" : "adverse outcomes and receive no benefit from treatment of asymptomatic"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteriuria."}, 
{"Row" : 11, "Column" : 1, "Text" : "Patients who have no symptoms of cystitis (i.e., no dysuria, pain, urgency)"}, 
{"Row" : 12, "Column" : 1, "Text" : "should not be treated. The presence of pyuria (>7 wbc/hpf) or positive leukocyte"}, 
{"Row" : 13, "Column" : 1, "Text" : "esterase, urine nitrate, or urine bacteria is not a sufficient indication for"}, 
{"Row" : 14, "Column" : 1, "Text" : "antibiotic treatment. Screening and treatment of asymptomatic bacteriuria is"}, 
{"Row" : 15, "Column" : 1, "Text" : "indicated for pregnant women and patients who will have urological procedures"}, 
{"Row" : 16, "Column" : 1, "Text" : "and may be indicated in patients < 1-month post-renal transplant. If an"}, 
{"Row" : 17, "Column" : 1, "Text" : "indwelling catheter is in place and can be removed safely, it should be done as"}, 
{"Row" : 18, "Column" : 1, "Text" : "the bacteriuria may clear."}, 
{"Row" : 20, "Column" : 1, "Text" : "Bacteriuria in pregnant women is associated with pyelonephritis, premature"}, 
{"Row" : 21, "Column" : 1, "Text" : "delivery, and lower birth weight. Screening for bacteriuria is recommended at"}, 
{"Row" : 22, "Column" : 1, "Text" : "least once early in pregnancy. If bacteriuria is not found upon initial testing,"}, 
{"Row" : 23, "Column" : 1, "Text" : "further screening cultures are not needed. If bacteriuria (>10,000 CFU/mL) is"}, 
{"Row" : 24, "Column" : 1, "Text" : "present, the patient should be treated. Testing should be repeated throughout"}, 
{"Row" : 25, "Column" : 1, "Text" : "the pregnancy to detect recurrences."}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Pregnant women, empirical treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 32, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Patients having urological procedures", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Renal transplant recipients < 1 month after transplant", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Screening and treatment of asymptomatic bacteriuria may be indicated. Consult"}, 
{"Row" : 48, "Column" : 1, "Text" : "nephrology for recommendations."}, 
{"Row" : 49, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Mandell chapter: Urinary Tract Infections"}, 
{"Row" : 54, "Column" : 1, "Text" : "Nicolle et al., Clinical Infectious Diseases, 2019, 2.68(10)e83-e110"}, 
{"Row" : 55, "Column" : 1, "Text" : "Sanford keyword: Bacteriuria, Asymptomatic"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in"}, 
{"Row" : 57, "Column" : 1, "Text" : "pregnancy"}, 
{"Row" : 58, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with asymptomatic bacteriuria"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-To-Date article: Kidney transplantation in adults: Urinary tract infection in"}, 
{"Row" : 60, "Column" : 1, "Text" : "kidney transplant recipients"}, 
{"Row" : 61, "Column" : 1, "Text" : "US Preventive Services Task Force, JAMA, 2019, 322(12)1188-1194"}
]},
{"Name" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "DisplayText" : "RESOURCE QTC PROLONGATION FOR DRUGS", "Text" : "Please Click Here for Resource for Drugs that Cause QTc Prolongation", "Mnemonic" : "4"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ GMENU COPD OUTPATIENT ORDERS", "DisplayText" : "COPD Orders...", "Text" : "COPD OUTPATIENT GUIDELINES", "Mnemonic" : "6"},
{"Row" : 52, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN LONGTERM COPD PULM", "DisplayText" : "Azithromycin 250 mg po daily COPD prophylaxis ($1/day) [M]", "Text" : "Azithromycin 250 mg po daily for COPD prophylaxis ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 53, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN LONGTERM COPD PULM", "DisplayText" : "Azithromycin 250 mg po daily COPD prophylaxis ($1/day) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "Azithromycin for Prevention of Exacerbations in Advanced COPD", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)"}, 
{"Row" :5, "Column" : 1, "Text" : "exacerbations in people with advanced COPD (Albert et al, see below)."}, 
{"Row" :6, "Column" : 1, "Text" : "Of note, in the study there was no benefit in the most severely ill"}, 
{"Row" :7, "Column" : 1, "Text" : "subgroup that was on the most pulmonary medications.People"}, 
{"Row" :8, "Column" : 1, "Text" : "with frequent exacerbations have more doctor visits and hospitalizations then"}, 
{"Row" :9, "Column" : 1, "Text" : "people with fewer or no exacerbations.Frequent exacerbations are associated"}, 
{"Row" : 10, "Column" : 1, "Text" : "with rapid decline in lung function and quality of life and increased risk"}, 
{"Row" : 11, "Column" : 1, "Text" : "death."}, 
{"Row" : 13, "Column" : 1, "Text" : "To receive daily azithromycin, patients must meet the following criteria and"}, 
{"Row" : 14, "Column" : 1, "Text" : "receive approval from pulmonary service.The evidence that benefits of daily"}, 
{"Row" : 15, "Column" : 1, "Text" : "azithromycin outweigh risks is limited to people who meet the following"}, 
{"Row" : 16, "Column" : 1, "Text" : "criteria."}, 
{"Row" : 18, "Column" : 1, "Text" : "Eligibility Criteria: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "*Age >40 years"}, 
{"Row" : 20, "Column" : 1, "Text" : "*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of"}, 
{"Row" : 21, "Column" : 1, "Text" : "postbronchodilator forced expiratory volume in 1 second [FEV1] to forced"}, 
{"Row" : 22, "Column" : 1, "Text" : "vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the"}, 
{"Row" : 23, "Column" : 1, "Text" : "predicted value), *AND*"}, 
{"Row" : 24, "Column" : 1, "Text" : "*Were either using continuous supplemental oxygen or had received systemic"}, 
{"Row" : 25, "Column" : 1, "Text" : "glucocorticoids within the previous year, *OR*"}, 
{"Row" : 26, "Column" : 1, "Text" : "*Had gone to an emergency room or had been hospitalized for an acute"}, 
{"Row" : 27, "Column" : 1, "Text" : "exacerbation of COPD."}, 
{"Row" : 28, "Column" : 1, "Text" : "Exclusion criteria: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "*Asthma"}, 
{"Row" : 30, "Column" : 1, "Text" : "*People with hearing impairments"}, 
{"Row" : 31, "Column" : 1, "Text" : "*Congestive Heart Failure"}, 
{"Row" : 32, "Column" : 1, "Text" : "*Resting heart rate > 100 beats per minute"}, 
{"Row" : 33, "Column" : 1, "Text" : "*Use of medications that are associated with torsades de pointes (with the"}, 
{"Row" : 34, "Column" : 1, "Text" : "exception of amiodarone)"}, 
{"Row" : 35, "Column" : 1, "Text" : "*Prolonged QTc interval (>450 msec)"}, 
{"Row" : 36, "Column" : 1, "Text" : "*Use of medications that prolong the QTc interval"}, 
{"Row" : 39, "Column" : 1, "Text" : "If, after trying all of the standard treatments, patients are still having"}, 
{"Row" : 40, "Column" : 1, "Text" : "acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin"}, 
{"Row" : 41, "Column" : 1, "Text" : "may be considered."}, 
{"Row" : 42, "Column" : 1, "Text" : "Note: Guidelines for COPD can be found on the CPRS Tools Menu."}, 
{"Row" : 43, "Column" : 1, "Text" : "Select below for Outpatient COPD order sets for comprehensive management: ", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "If the patient meets the criteria and is willing to have audiometric testing"}, 
{"Row" : 47, "Column" : 1, "Text" : "and an electrocardiogram, please place a Pulmonary Consult for long-term"}, 
{"Row" : 48, "Column" : 1, "Text" : "Azithromycin therapy for the prevention of exacerbations of COPD."}, 
{"Row" : 50, "Column" : 1, "Text" : "Pulmonary is the only approved provider for ordering long-term", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Azithromycin therapy for COPD.", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD."}, 
{"Row" : 57, "Column" : 1, "Text" : "England Journal of Medicine 2011, 365:689-698"}, 
{"Row" : 58, "Column" : 1, "Text" : "Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.New"}, 
{"Row" : 59, "Column" : 1, "Text" : "England Journal of Medicine 2012: 366:1881-1890"}
]},
{"Name" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "BACTEREMIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "DisplayText" : "Bacterial vaginosis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Sexually Transmitted Infections and HIV Exposure", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days", "Text" : "Metronidazole 500 mg PO q12h ($) [DI] for 7 days", "Mnemonic" : "6a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 0.75% VAG GEL 1 APPL INTRAVAG QHS 5DS", "Text" : "Metronidazole vaginal gel 0.75%, contents of 1 applicator intravaginally qhs ($)", "Mnemonic" : "8a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 0.75% VAG GEL 1 APPL INTRAVAG QHS 5DS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 7DS 300MG PO BID", "DisplayText" : "Clindamycin 300mg po bid for 7 days", "Text" : "Clindamycin 300 mg PO q12h ($) [H,O] for 7 days", "Mnemonic" : "10a"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 7DS 300MG PO BID", "DisplayText" : "Clindamycin 300mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN PHOSPHATE VAG 2% CRM 5GM QHS 7DS", "DisplayText" : "Clindamycin phosphate vaginal cream 5 gram (contents of 1 applicator)", "Text" : "Clindamycin phosphate vaginal cream 2%, contents of 1 applicator", "Mnemonic" : "12a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN PHOSPHATE VAG 2% CRM 5GM QHS 7DS", "DisplayText" : "Clindamycin phosphate vaginal cream 5 gram (contents of 1 applic Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "BACTERIAL VAGINOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Vaginitis usually presents with discharge, itching, irritation, odor, or pain."}, 
{"Row" :6, "Column" : 1, "Text" : "Bacterial vaginosis is the most common form of vaginitis. Normal hydrogen"}, 
{"Row" :7, "Column" : 1, "Text" : "peroxide and lactic acid producing vaginal flora, including Lactobacillus"}, 
{"Row" :8, "Column" : 1, "Text" : "species, is reduced and high concentrations of anaerobic bacterial pathogens are"}, 
{"Row" :9, "Column" : 1, "Text" : "present. Pathogenic bacteria commonly include Gardnerella vaginalis, Mycoplasma"}, 
{"Row" : 10, "Column" : 1, "Text" : "hominis, Nobiluncus, Prevotella and other Gram-negative anaerobes."}, 
{"Row" : 12, "Column" : 1, "Text" : "Vaginal pH should be measured, and the specimen should be examined under the"}, 
{"Row" : 13, "Column" : 1, "Text" : "microscope for identification of clue cells (epithelial cell coated with"}, 
{"Row" : 14, "Column" : 1, "Text" : "bacteria). In bacterial vaginosis the vaginal pH is high (> 4.5), the discharge"}, 
{"Row" : 15, "Column" : 1, "Text" : "is homogenous and gray-white, and the specimen has a positive amine or whiff"}, 
{"Row" : 16, "Column" : 1, "Text" : "test characterized by a fishy odor before or after addition of 10% KOH."}, 
{"Row" : 17, "Column" : 1, "Text" : "Bacterial vaginosis nucleic acid amplification tests are available for common"}, 
{"Row" : 18, "Column" : 1, "Text" : "pathogens to aide in identification of pathogen(s)."}, 
{"Row" : 20, "Column" : 1, "Text" : "Bacterial vaginosis may be transmitted sexually. Patients at risk of sexually"}, 
{"Row" : 21, "Column" : 1, "Text" : "transmitted infections should be assessed for treatment."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "[DI] for 5 days"}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" : 36, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "intravaginally qhs ($) [H,O] for 7 days"}, 
{"Row" : 40, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 45, "Column" : 1, "Text" : "Sanford keyword: Bacterial Vaginosis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-to-Date article: Bacterial vaginosis: Clinical manifestations and diagnosis"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date article: Bacterial Vaginosis: Treatment"}, 
{"Row" : 48, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSOZID2 TRIAMCINOLONE 0.1% CRM TOP BID PRN 10DAYS", "DisplayText" : "Triamcinolone 0.1% cream topical bid prn for 10 days", "Text" : "Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]", "Mnemonic" : "4a"},
{"Row" :8, "Column" : 1, "Item" : "PSHZID2 TRIAMCINOLONE 0.1% CRM TOP BID PRN 10DAYS", "DisplayText" : "Triamcinolone 0.1% cream topical bid prn for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 HYDROXYZINE PAMOATE 25MG PO TID THEN 25 TID PRN", "DisplayText" : "Hydroxyzine pamoate 25mg po tid then 25mg po tid prn", "Text" : "Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO", "Mnemonic" : "6a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 HYDROXYZINE PAMOATE 25MG PO TID THEN 25 TID PRN", "DisplayText" : "Hydroxyzine pamoate 25mg po tid then 25mg po tid prn Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "BED BUGS (HEMIPTERA)"}, 
{"Row" :4, "Column" : 1, "Text" : "Antimicrobial treatment is not indicated.Treat itching with topical"}, 
{"Row" :5, "Column" : 1, "Text" : "corticosteroids or systemic antihistamines."}, 
{"Row" : 11, "Column" : 1, "Text" : "TID PRN for itching ($) [H]"}, 
{"Row" : 17, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme Disease", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D", "DisplayText" : "PRED 60MG QID PO 7D VALACYCLOVIR 1000MG PO Q8H 7D", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D", "DisplayText" : "PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D NON-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D", "DisplayText" : "PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO 5X/day ($) [R]", "Mnemonic" : "8a"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D", "DisplayText" : "PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D NON-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "BELL'S PALSY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others"}, 
{"Row" :6, "Column" : 1, "Text" : "include Borrelia burgdorferi trauma. Some cases are idiopathic. Risk factors for"}, 
{"Row" :7, "Column" : 1, "Text" : "Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper"}, 
{"Row" :8, "Column" : 1, "Text" : "respiratory infections. Neurology consult is encouraged."}, 
{"Row" : 10, "Column" : 1, "Text" : "If Lyme disease is suspected, refer to the Lyme disease treatment page: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment with prednisone and an antiviral within 72 hours of symptoms onset"}, 
{"Row" : 14, "Column" : 1, "Text" : "improves the chances of a complete recovery."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 19, "Column" : 1, "Text" : "for 7 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 24, "Column" : 1, "Text" : "for 10 days"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27"}, 
{"Row" : 31, "Column" : 1, "Text" : "Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361"}, 
{"Row" : 32, "Column" : 1, "Text" : "Jalali et al., Laryngoscope, 2021, 131.1615-1625"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Antivirals against Herpes Viruses"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Herpes Simplex, Bell's Palsy"}, 
{"Row" : 35, "Column" : 1, "Text" : "Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Bell's palsy: Treatment and prognosis in adults"}
]},
{"Name" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite wounds with Eikenella corrodens (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "8a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :2, "Column" : 1, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS"}, 
{"Row" :4, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}
]},
{"Name" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-resistant S. aureus (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 10DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 10 days", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 10DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Mnemonic" : "8a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 14DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 14 days", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 14DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :2, "Column" : 1, "Text" : "BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS"}, 
{"Row" :4, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 14, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}
]},
{"Name" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Mnemonic" : "10a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS"}, 
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 14, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treat for 14-21 days."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "", "Mnemonic" : "12a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "12b"}
]},
{"Name" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite wounds with Pasteurella multocida (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "8a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA"}, 
{"Row" :5, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 13, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 34, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}
]},
{"Name" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite wounds with Streptococci (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS WITH STREPTOCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Infection but no arthritis - 10 days joint involved - 14-21 days"}, 
{"Row" :6, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment for infection without joint involvement", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for infection with joint involvement", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "__________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "12"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Text" : "", "Mnemonic" : "14a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 10DAYS", "DisplayText" : "Linezolid 600 mg PO BID for 10 days ($) [DI,O]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600MG PO BID 10DAYS", "DisplayText" : "Linezolid 600 mg po q12h for 10 days ($) [DI,O]", "Text" : "Non-VA order for above", "Mnemonic" : "8b"}
]},
{"Name" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Mnemonic" : "4"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 62, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Text" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 63, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "DisplayText" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "DisplayText" : "Bite wounds with Pasteurella multocida (Outpatient)", "Text" : "Pasteurella multocida", "Mnemonic" : "14"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "DisplayText" : "Bite wounds with Eikenella corrodens (Outpatient)", "Text" : "Eikenella corrodens", "Mnemonic" : "16"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient)", "Text" : "Methicillin-susceptible Staphylococcus aureus", "Mnemonic" : "18"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "DisplayText" : "Bite wounds with Methicillin-resistant S. aureus (Outpatient)", "Text" : "Methicillin-resistant Staphylococcus aureus", "Mnemonic" : "20"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "DisplayText" : "Bite wounds with Streptococci (Outpatient)", "Text" : "Streptococci", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "BITE WOUNDS"}, 
{"Row" :5, "Column" : 1, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried"}, 
{"Row" :6, "Column" : 1, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually"}, 
{"Row" :7, "Column" : 1, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites"}, 
{"Row" :8, "Column" : 1, "Text" : "streptococci and staphylococci."}, 
{"Row" :9, "Column" : 1, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic"}, 
{"Row" : 10, "Column" : 1, "Text" : "and debride non-viable tissue."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consult Orthopedic surgery for all bite wounds involving the hand."}, 
{"Row" : 13, "Column" : 1, "Text" : "Antibiotic Prophylaxis Indications: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,"}, 
{"Row" : 15, "Column" : 1, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,"}, 
{"Row" : 16, "Column" : 1, "Text" : "Advanced liver disease"}, 
{"Row" : 18, "Column" : 1, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients"}, 
{"Row" : 19, "Column" : 1, "Text" : "with superficial wounds with no puncture that do not involve the face/"}, 
{"Row" : 20, "Column" : 1, "Text" : "genitals/hands is not recommended."}, 
{"Row" : 22, "Column" : 1, "Text" : "Antimicrobial Treatment: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Empiric treatment for suspected or established infection following bite wound"}, 
{"Row" : 24, "Column" : 1, "Text" : "In these cases, therapy should be directed against pathogen indentified"}, 
{"Row" : 25, "Column" : 1, "Text" : "by Gram stain and culture whenever possible."}, 
{"Row" : 27, "Column" : 1, "Text" : "Rabies Prophylaxis: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases."}, 
{"Row" : 29, "Column" : 1, "Text" : "Contact Infectious diseases for assistance."}, 
{"Row" : 32, "Column" : 1, "Text" : "Consider tetanus immunization status: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus."}, 
{"Row" : 34, "Column" : 1, "Text" : "If immunization is lacking, and: "}, 
{"Row" : 35, "Column" : 1, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td"}, 
{"Row" : 36, "Column" : 1, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)"}, 
{"Row" : 38, "Column" : 1, "Text" : "Select below for Tetanus vaccination information page: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection."}, 
{"Row" : 43, "Column" : 1, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat"}, 
{"Row" : 44, "Column" : 1, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,"}, 
{"Row" : 45, "Column" : 1, "Text" : "treat 14 to 21 days."}, 
{"Row" : 47, "Column" : 1, "Text" : "Prophylaxis: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Duration 3 to 5 days: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Alternative for patients with penicillin allergy: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Empiric treatment for suspected or estabished infection: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Duration 7 to 14 days: "}, 
{"Row" : 61, "Column" : 1, "Text" : "Alternative for patients with penicllin allergy: "}, 
{"Row" : 65, "Column" : 1, "Text" : "Pathogen-directed bite wound therapy", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "References: "}, 
{"Row" : 75, "Column" : 1, "Text" : "Sanford keyword:Bites"}, 
{"Row" : 76, "Column" : 1, "Text" : "Mandell Chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 77, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 78, "Column" : 1, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85"}
]},
{"Name" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "BODY LICE (PEDICULOSIS CORPORIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "Body lice proliferate in places where crowding of persons with poor hygiene"}, 
{"Row" :6, "Column" : 1, "Text" : "common, especially homeless persons."}, 
{"Row" :7, "Column" : 1, "Text" : "Infested clothing and bed linen should be heat washed or discarded."}, 
{"Row" :9, "Column" : 1, "Text" : "Itching is the most common symptom, but some patients present only with"}, 
{"Row" : 10, "Column" : 1, "Text" : "excoriations and inflammation on the neck and trunk."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "A repeat application may be used if live lice are seen 7-10 days after"}, 
{"Row" : 14, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 17, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE", "DisplayText" : "24 Month Order Set" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Seronegative ONLY and 2-1-5 Rule", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Not until 2 years post HCT and"}, 
{"Row" :4, "Column" : 1, "Text" : ">1 year off all immunosuppressive therapy (IST) and"}, 
{"Row" :5, "Column" : 1, "Text" : "at leat 5 months since last dose of IVIG/VZIG or"}, 
{"Row" :6, "Column" : 1, "Text" : "or most recent plasma transfusion."}, 
{"Row" :8, "Column" : 1, "Item" : "PSCZ MEASLES/MUMPS/RUBELLA VACCINE 0.5ML ONCE", "DisplayText" : "Measles, Mumps, Rubella Vaccine 0.5ml ONCE", "Text" : "", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "PSOZ VARICELLA VACCINE ONCE", "DisplayText" : "Varicella Vaccine ONCE", "Text" : "", "Mnemonic" : "20"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE 2020", "Term" : "CREATED 08/21/2020 BY SR", "DisplayText" : "24 Month Order Set" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Seronegative ONLY and 2-1-5 Rule", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Not until 2 years post HCT and"}, 
{"Row" :4, "Column" : 1, "Text" : ">1 year off all immunosuppressive therapy (IST) and"}, 
{"Row" :5, "Column" : 1, "Text" : "at leat 5 months since last dose of IVIG/VZIG or"}, 
{"Row" :6, "Column" : 1, "Text" : "or most recent plasma transfusion."}, 
{"Row" :9, "Column" : 1, "Item" : "PSCZ MEASLES/MUMPS/RUBELLA VACCINE 0.5ML ONCE 2020", "DisplayText" : "Measles, Mumps, Rubella Vaccine 0.5ml ONCE", "Text" : "", "Mnemonic" : "10"},
{"Row" :7, "Column" : 1, "Text" : "and not on active treatment"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE SEATTLE ALLO 2020", "Term" : "CREATED 08/21/2020 BY SR", "DisplayText" : "24 Month Order Set" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Seronegative ONLY and 2-1-5 Rule", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Not until 2 years post HCT and"}, 
{"Row" :4, "Column" : 1, "Text" : ">1 year off all immunosuppressive therapy (IST) and"}, 
{"Row" :5, "Column" : 1, "Text" : "at leat 5 months since last dose of IVIG/VZIG or"}, 
{"Row" :6, "Column" : 1, "Text" : "or most recent plasma transfusion."}, 
{"Row" :8, "Column" : 1, "Item" : "PSCZ MEASLES/MUMPS/RUBELLA VACCINE 0.5ML ONCE", "DisplayText" : "Measles, Mumps, Rubella Vaccine 0.5ml ONCE", "Text" : "", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Text" : "If chronic GVHD only", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZ PNEUMOCOCCAL 23 VACCINE 0.5ML VIAL BMT ALLO", "DisplayText" : "Pneumococcal 23 Vaccine (PPSV23) ONCE", "Text" : "", "Mnemonic" : "20"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW 5-1-5 RULE", "DisplayText" : "60 Month Order Set" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : ">50yo ONLY and Seropositive ONLY and 5-1-5 Rule", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Not until 5 years post HCT and"}, 
{"Row" :4, "Column" : 1, "Text" : ">1 year off all immunosuppressive therapy (IST) and"}, 
{"Row" :5, "Column" : 1, "Text" : "at leat 5 months since last dose of IVIG/VZIG or"}, 
{"Row" :6, "Column" : 1, "Text" : "or most recent plasma transfusion."}, 
{"Row" :8, "Column" : 1, "Item" : "PSOZ ZOSTER VACCINE ONCE", "DisplayText" : "Zoster Vaccine ONCE", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW INFLUENZA", "DisplayText" : "Influenza " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Place order to be given ONLY ONCE per flu season", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "PSCZ INFLUENZA ONCE", "DisplayText" : "Influenza ONCE", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW LABS", "Term" : "created for heme/onc 8/24/18 JB", "DisplayText" : "Bone Marrow Labs" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "LRTZ CBC & DIFF HEMONC", "DisplayText" : "CBC & Diff", "Text" : ""},
{"Row" :4, "Column" : 1, "Text" : "Order PT/INR if on Warfarin (Coumadin)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "LRTZ PT/INR HEMONC", "DisplayText" : "PT/INR", "Text" : ""}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MAIN", "DisplayText" : "Bone Marrow Transplant Immunization " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Post Bone Marrow Transplant Immunizations", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS", "DisplayText" : "Seattle Autologous", "Text" : "", "Mnemonic" : "40"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC", "DisplayText" : "Seattle Allogeneic", "Text" : "", "Mnemonic" : "30"},
{"Row" :4, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW NASHVILLE", "DisplayText" : "Nashville", "Text" : "", "Mnemonic" : "10"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SAN ANTONIO", "DisplayText" : "San Antonio", "Text" : "", "Mnemonic" : "20"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW U OF M", "DisplayText" : "U of M", "Text" : "", "Mnemonic" : "50"},
{"Row" : 20, "Column" : 1, "Text" : "***TESTING ONLY**", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW MAIN 2020", "DisplayText" : "Bone Marrow Transplant Immunization", "Text" : "Bone Marrow Immunizations", "Mnemonic" : "99"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MAIN 2020", "DisplayText" : "Bone Marrow Transplant Immunization " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Post Bone Marrow Transplant Immunizations", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS 2020", "DisplayText" : "Seattle Autologous", "Text" : "", "Mnemonic" : "40"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC 2020", "DisplayText" : "Seattle Allogeneic", "Text" : "", "Mnemonic" : "30"},
{"Row" :4, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW NASHVILLE 2020", "DisplayText" : "Nashville", "Text" : "", "Mnemonic" : "10"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW SAN ANTONIO", "DisplayText" : "San Antonio", "Text" : "", "Mnemonic" : "20"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW U OF M 2020", "DisplayText" : "U of M", "Text" : "", "Mnemonic" : "50"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW MAYO 2020", "DisplayText" : "Mayo Bone Marrow Transplant Immunizations", "Text" : "", "Mnemonic" : "60"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MAYO 2020", "Term" : "CREATED 08/2020 BY SR FOR CONNIE JAENICKE", "DisplayText" : "Mayo Bone Marrow Transplant Immunizations " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Annual influenza shot (high-dose if >65yo)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "6 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW INFLUENZA", "DisplayText" : "Influenza", "Text" : "", "Mnemonic" : "10"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 6MO 2020", "DisplayText" : "6 Months Immunizations", "Text" : "", "Mnemonic" : "20"},
{"Row" :7, "Column" : 1, "Text" : "8 months (or at least 2m after 6 month)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 8MO 2020", "DisplayText" : "8 Month Immunization", "Text" : "", "Mnemonic" : "30"},
{"Row" : 10, "Column" : 1, "Text" : "10 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 10MO 2020", "DisplayText" : "10 Month Immunizations", "Text" : "", "Mnemonic" : "40"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 12MO 2020", "DisplayText" : "12 Month Immunizations", "Text" : "", "Mnemonic" : "50"},
{"Row" : 13, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 24MO 2020", "DisplayText" : "24 Month Immunizations", "Text" : "", "Mnemonic" : "60"},
{"Row" : 19, "Column" : 1, "Text" : "26 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET BONE MARROW MAYO 26MO 2020", "DisplayText" : "26 Month Immunizations", "Text" : "", "Mnemonic" : "70"},
{"Row" : 22, "Column" : 1, "Text" : "27 months >/= Post Transplant", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZ MENINGOCOCCAL CONJUGATE VACCINE BONE MARROW", "DisplayText" : "Meningococcal Conjugate Vaccine", "Text" : "27 Month Immunization", "Mnemonic" : "80"},
{"Row" : 25, "Column" : 1, "Text" : "29 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZ MENINGOCOCCAL CONJUGATE VACCINE BONE MARROW", "DisplayText" : "Meningococcal Conjugate Vaccine", "Text" : "29 Month Immunizations", "Mnemonic" : "90"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MENINGOCOCCAL", "DisplayText" : "Meningococcal " , "Version" : "Minneapolis", "Contents" : [
{"Row" :7, "Column" : 1, "Item" : "PSOZ MENINGOCOCCAL CONJUGATE VACCINE AGE 19-55", "DisplayText" : "Meningococcal Conjugate Inj ...", "Text" : "", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "PSOZ MENINGOCOCCAL POLYSACCHARIDE VACCINE >AGE 55", "DisplayText" : "Meningococcal Polysaccharide Inj (Age > 55)", "Text" : "", "Mnemonic" : "20"},
{"Row" :2, "Column" : 1, "Text" : "For splenectomized patients or per direction of transplant center"}, 
{"Row" :3, "Column" : 1, "Text" : "Only for those 11-21 yo, those with >21 yo with functional asplenia, have been"}, 
{"Row" :4, "Column" : 1, "Text" : "splenectomized, living in a dorm setting, or military recruits"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MENINGOCOCCAL 2020", "Term" : "CREATED 08/20/2020 BY SR", "DisplayText" : "Meningococcal " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "For splenectomized patients or per direction of transplant center"}, 
{"Row" :3, "Column" : 1, "Text" : "Only for those 11-21 yo, those with >21 yo with functional asplenia, have been"}, 
{"Row" :4, "Column" : 1, "Text" : "splenectomized, living in a dorm setting, or military recruits"}, 
{"Row" :6, "Column" : 1, "Item" : "PSOZ MENINGOCOCCAL CONJUGATE VACCINE BONE MARROW", "DisplayText" : "Meningococcal Conjugate Vaccine", "Text" : "Meningococcal Conjugate Vaccine", "Mnemonic" : "10"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW MMR", "DisplayText" : "Measles/Mumps/Rubella " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "Do NOT give if still on Immunisuppression Treatment or if active GVHD", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "PSCZ MEASLES/MUMPS/RUBELLA VACCINE 0.5ML ONCE", "DisplayText" : "Measles, Mumps, Rubella Vaccine 0.5ml ONCE", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW NASHVILLE", "DisplayText" : "Nashville " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "6 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 6/8/10M", "DisplayText" : "6 Month Order Set", "Text" : "6 Month Order Set", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 12M", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "30"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 24M", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 27, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 28, "Column" : 1, "Text" : "vaccination series is completed."}, 
{"Row" :7, "Column" : 1, "Text" : "8 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 6/8/10M", "DisplayText" : "6 Month Order Set", "Text" : "8 Month Order Set", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Text" : "10 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 6/8/10M", "DisplayText" : "6 Month Order Set", "Text" : "10 Month Order Set", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 16M", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "35"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Influenza: once annually"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW NASHVILLE 2020", "DisplayText" : "Nashville " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "6 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 6/8/10M", "DisplayText" : "6 Month Order Set", "Text" : "6 Month Order Set", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 12M 2020", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "30"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 24M 2020", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 27, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 28, "Column" : 1, "Text" : "vaccination series is completed."}, 
{"Row" :7, "Column" : 1, "Text" : "8 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 8M 2020", "DisplayText" : "8 Month Order Set", "Text" : "8 Month Order Set", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Text" : "10 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 10M 2020", "DisplayText" : "10 Month Order Set", "Text" : "10 Month Order Set", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET BONE MARROW NASHVILLE 16M", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "35"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Influenza: once annually"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW PAPILLOMAVIRUS", "DisplayText" : "Papillomavirus" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Text" : "For Ages 9-26 years old", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "PSOZ PAPILLOMAVIROUS VACCINE ONCE", "DisplayText" : "Papillomavirous Human(Gardisil) Vaccine ONCE", "Text" : "", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Text" : "do not give with GVHD/on IST"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW PNEUMOCOCCAL", "DisplayText" : "Pneumococcal" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "PSOZ PNEUMOCOCCAL 23 VACCINE 0.5ML VIAL", "DisplayText" : "Pneumococcal 23 Vaccine (PPSV23) ONCE", "Text" : "", "Mnemonic" : "10"},
{"Row" :4, "Column" : 1, "Text" : "In patients with chronic GVHD who are unlikely to respond to", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pnemovax, it is preferable to administer a four", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Pneumococcal-conjugate Vaccine (Prevnar 13)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Item" : "PSOZ PNEUMOCOCCAL 13 VALENT VACCINE 0.5ML", "DisplayText" : "Pneumococcal 13 Valent Vaccine (PCV13) ONCE", "Text" : "", "Mnemonic" : "20"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW PNEUMOCOCCAL 2020", "Term" : "CREATED 08/21/2020 BY SR", "DisplayText" : "Pneumococcal" , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "PSOZ PNEUMOCOCCAL 23 VACCINE 0.5ML VIAL", "DisplayText" : "Pneumococcal 23 Vaccine (PPSV23) ONCE", "Text" : "", "Mnemonic" : "10"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW SAN ANTONIO", "DisplayText" : "San Antonio " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZ SET BONE MARROW SAN ANTONIO 12M", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW SAN ANTONIO 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "15"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW SAN ANTONIO 24M", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 10, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 12, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 13, "Column" : 1, "Text" : "vaccination series is completed."}
]},
{"Name" : "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC", "DisplayText" : "Seattle Allogeneic" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "18 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "22 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "60 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 12M", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "15"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 16M", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 18M", "DisplayText" : "18 Month Order Set", "Text" : "", "Mnemonic" : "25"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW PAPILLOMAVIRUS", "DisplayText" : "Papillomavirus", "Text" : "22 Month Order Set", "Mnemonic" : "30"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 5-1-5 RULE", "DisplayText" : "60 Month Order Set", "Text" : "60 Month Order Set", "Mnemonic" : "50"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Haemophilus influenza type B conjugated vaccine: 1 month"}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months"}, 
{"Row" :4, "Column" : 1, "Text" : "Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar"}, 
{"Row" :5, "Column" : 1, "Text" : "Hepatitis A vaccine: 6 months"}, 
{"Row" :6, "Column" : 1, "Text" : "Hepatitis B vaccine: 2 months"}, 
{"Row" :7, "Column" : 1, "Text" : "Papillomavirus human vaccine (Gardasil): "}, 
{"Row" :8, "Column" : 1, "Text" : "2 months after 1st dose, 4 months after 2nd dose"}, 
{"Row" :9, "Column" : 1, "Text" : "TDAP: 1-2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "TD: 1-2 months"}, 
{"Row" : 33, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 35, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 36, "Column" : 1, "Text" : "vaccination series is completed."}
]},
{"Name" : "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC 2020", "Term" : "CREATED 08/21/2020 BY SR", "DisplayText" : "Seattle Allogeneic" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 12, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "18 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "22 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 12M 2020", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 14M 2020", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "15"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 16M 2020", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE DONOR 18M 2020", "DisplayText" : "18 Month Order Set", "Text" : "", "Mnemonic" : "25"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW PAPILLOMAVIRUS", "DisplayText" : "Papillomavirus", "Text" : "22 Month Order Set", "Mnemonic" : "30"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE SEATTLE ALLO 2020", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Haemophilus influenza type B conjugated vaccine: 1 month"}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months"}, 
{"Row" :4, "Column" : 1, "Text" : "Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar"}, 
{"Row" :5, "Column" : 1, "Text" : "Hepatitis A vaccine: 6 months"}, 
{"Row" :6, "Column" : 1, "Text" : "Hepatitis B vaccine: 2 months"}, 
{"Row" :7, "Column" : 1, "Text" : "Papillomavirus human vaccine (Gardasil): "}, 
{"Row" :8, "Column" : 1, "Text" : "2 months after 1st dose, 4 months after 2nd dose"}, 
{"Row" :9, "Column" : 1, "Text" : "TDAP: 1-2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "TD: 1-2 months"}, 
{"Row" : 31, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 33, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 34, "Column" : 1, "Text" : "vaccination series is completed."}
]},
{"Name" : "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS", "DisplayText" : "Seattle Autologous" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 21, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "18 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "60 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 12M", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "50"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 16M", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "60"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 18M", "DisplayText" : "18 Month Order Set", "Text" : "", "Mnemonic" : "70"},
{"Row" : 12, "Column" : 1, "Text" : "6 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "8 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "10 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 6M", "DisplayText" : "6 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 8M/10M", "DisplayText" : "8 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 8M/10M", "DisplayText" : "8 Month Order Set", "Text" : "10 Month Order Set", "Mnemonic" : "30"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "80"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 5-1-5 RULE", "DisplayText" : "60 Month Order Set", "Text" : "60 Month Order Set", "Mnemonic" : "90"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Haemophilus influenza type B conjugated vaccine: 1 month"}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months"}, 
{"Row" :4, "Column" : 1, "Text" : "Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar"}, 
{"Row" :5, "Column" : 1, "Text" : "Hepatitis A vaccine: 6 months"}, 
{"Row" :6, "Column" : 1, "Text" : "Hepatitis B vaccine: 2 months"}, 
{"Row" :7, "Column" : 1, "Text" : "Papillomavirus human vaccine (Gardasil): "}, 
{"Row" :8, "Column" : 1, "Text" : "2 months after 1st dose, 4 months after 2nd dose"}, 
{"Row" :9, "Column" : 1, "Text" : "TDAP: 1-2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "TD: 1-2 months"}, 
{"Row" : 39, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 41, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 42, "Column" : 1, "Text" : "vaccination series is completed."}
]},
{"Name" : "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS 2020", "Term" : "CREATED 08/20/2020 BY SR", "DisplayText" : "Seattle Autologous" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 21, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "16 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "18 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "60 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 12M 2020", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 14M 2020", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "50"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 16M 2020", "DisplayText" : "16 Month Order Set", "Text" : "", "Mnemonic" : "60"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 18M 2020", "DisplayText" : "18 Month Order Set", "Text" : "", "Mnemonic" : "70"},
{"Row" : 12, "Column" : 1, "Text" : "6 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "8 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "10 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 6M 2020", "DisplayText" : "6 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 8M/10M 2020", "DisplayText" : "8 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET BONE MARROW SEATTLE 8M/10M 2020", "DisplayText" : "8 Month Order Set", "Text" : "10 Month Order Set", "Mnemonic" : "30"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 2-1-5 RULE 2020", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "80"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU BONE MARROW 5-1-5 RULE", "DisplayText" : "60 Month Order Set", "Text" : "60 Month Order Set", "Mnemonic" : "90"},
{"Row" :1, "Column" : 1, "Text" : "Minimal Time Interval Between Vaccinations: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Text" : "Haemophilus influenza type B conjugated vaccine: 1 month"}, 
{"Row" :3, "Column" : 1, "Text" : "Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months"}, 
{"Row" :4, "Column" : 1, "Text" : "Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar"}, 
{"Row" :5, "Column" : 1, "Text" : "Hepatitis A vaccine: 6 months"}, 
{"Row" :6, "Column" : 1, "Text" : "Hepatitis B vaccine: 2 months"}, 
{"Row" :7, "Column" : 1, "Text" : "Papillomavirus human vaccine (Gardasil): "}, 
{"Row" :8, "Column" : 1, "Text" : "2 months after 1st dose, 4 months after 2nd dose"}, 
{"Row" :9, "Column" : 1, "Text" : "TDAP: 1-2 months"}, 
{"Row" : 10, "Column" : 1, "Text" : "TD: 1-2 months"}, 
{"Row" : 39, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 41, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 42, "Column" : 1, "Text" : "vaccination series is completed."}
]},
{"Name" : "ORZID3 GMENU BONE MARROW U OF M", "DisplayText" : "U of M" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 12M", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 14M", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 24M", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "30"},
{"Row" : 19, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 21, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 22, "Column" : 1, "Text" : "vaccination series is completed."}, 
{"Row" : 10, "Column" : 1, "Text" : "26 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "27 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "29 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 26M", "DisplayText" : "26 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 27M", "DisplayText" : "27 Month Order Set", "Text" : "", "Mnemonic" : "50"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 29M", "DisplayText" : "29 Month Order Set", "Text" : "", "Mnemonic" : "60"}
]},
{"Name" : "ORZID3 GMENU BONE MARROW U OF M 2020", "Term" : "CREATED 08/25/2020 BY SR", "DisplayText" : "U of M" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "12 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "14 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "24 Months >/= Post Transplant", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 12M 2020", "DisplayText" : "12 Month Order Set", "Text" : "", "Mnemonic" : "10"},
{"Row" :5, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 14M 2020", "DisplayText" : "14 Month Order Set", "Text" : "", "Mnemonic" : "20"},
{"Row" :8, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 24M", "DisplayText" : "24 Month Order Set", "Text" : "", "Mnemonic" : "30"},
{"Row" : 19, "Column" : 1, "Text" : "Postvaccination antibody titers", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "are useful to monitor response and may be needed for additional"}, 
{"Row" : 21, "Column" : 1, "Text" : "doses.Titers should be drawn 1-3 months after the specific"}, 
{"Row" : 22, "Column" : 1, "Text" : "vaccination series is completed."}, 
{"Row" : 10, "Column" : 1, "Text" : "26 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "27 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "29 Months >/= Post Transplant", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 26M", "DisplayText" : "26 Month Order Set", "Text" : "", "Mnemonic" : "40"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 27M", "DisplayText" : "27 Month Order Set", "Text" : "", "Mnemonic" : "50"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET BONE MARROW UOFM 29M", "DisplayText" : "29 Month Order Set", "Text" : "", "Mnemonic" : "60"}
]},
{"Name" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU PERTUSSIS", "DisplayText" : "Pertussis (Outpatient)", "Text" : "Pertussis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "DisplayText" : "Bronchitis not benefited", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Mnemonic" : "6"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Doxcycline 100 mg PO BID for 5 days ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "DisplayText" : "Doxycycline 100 mg BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 45, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]", "Mnemonic" : "12a"},
{"Row" : 46, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]", "Mnemonic" : "14a"},
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "16"},
{"Row" :2, "Column" : 1, "Text" : "BRONCHITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific"}, 
{"Row" :5, "Column" : 1, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray.If an"}, 
{"Row" :6, "Column" : 1, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and"}, 
{"Row" :7, "Column" : 1, "Text" : "need not be treated for it."}, 
{"Row" :9, "Column" : 1, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimicrobials provide no benefit.If bronchitis persists beyond 2 weeks,"}, 
{"Row" : 11, "Column" : 1, "Text" : "additional diagnostic workup is needed to find a cause.If a patient has"}, 
{"Row" : 12, "Column" : 1, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis."}, 
{"Row" : 14, "Column" : 1, "Text" : "For symptomatic treatment dextromethorphan and benzonatate combined with"}, 
{"Row" : 15, "Column" : 1, "Text" : "guaifenesin has shown some benefit. Benzonatate and guaifenesin"}, 
{"Row" : 16, "Column" : 1, "Text" : "alone did not show benefit. Also, allergy medicines and codeine"}, 
{"Row" : 17, "Column" : 1, "Text" : "do not appear to help the symptoms."}, 
{"Row" : 22, "Column" : 1, "Text" : "Acute bronchitis in patients with COPD", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence"}, 
{"Row" : 24, "Column" : 1, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are"}, 
{"Row" : 25, "Column" : 1, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically"}, 
{"Row" : 26, "Column" : 1, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,"}, 
{"Row" : 27, "Column" : 1, "Text" : "pulmonary embolism and pneumonia."}, 
{"Row" : 29, "Column" : 1, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases"}, 
{"Row" : 30, "Column" : 1, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patients"}, 
{"Row" : 31, "Column" : 1, "Text" : "with COPD exacerbation who have increased sputum purulence and volume."}, 
{"Row" : 33, "Column" : 1, "Text" : "Treatment for MILD DISEASE: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "No antibiotics recommended"}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment for MODERATE DISEASE", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Treat for 5 to 7 days."}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "Treatment for SEVERE DISEASE", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "side effects outweigh the benefits.", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017."}, 
{"Row" : 57, "Column" : 1, "Text" : "Access: http://www.goldcopd.org"}, 
{"Row" : 58, "Column" : 1, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125"}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Bronchitis"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Bronchitis"}, 
{"Row" : 61, "Column" : 1, "Text" : "Murphy TF Chest 2000, 118: 204"}, 
{"Row" : 62, "Column" : 1, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503"}
]},
{"Name" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida vulvo-vaginitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150mg po once", "Text" : "Fluconazole 150 mg PO once ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150MG PO ONCE", "DisplayText" : "Fluconazole 150mg po once Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 7DS", "DisplayText" : "Clotrimazole vaginal 1% cream 1 applicatorful qhs 7 days", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 7 days", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 7DS", "DisplayText" : "Clotrimazole vaginal 1% cream 1 applicatorful qhs 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 TERCONAZOLE 0.4% VAG CRM QHS 7DS", "DisplayText" : "Terconazole 0.4% vaginal cream 1 applicatorful qhs 7days", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 7 days", "Mnemonic" : "8a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 TERCONAZOLE 0.4% VAG CRM QHS 7DS", "DisplayText" : "Terconazole 0.4% vaginal cream 1 applicatorful qhs 7days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150 MG PO Q72H 7DS", "DisplayText" : "Fluconazole 150 mg PO every 3 days for 7 days (3 doses) ($) [R,DI]", "Text" : "Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150 MG PO Q72H 7DS", "DisplayText" : "Fluconazole 150 mg PO every 3 days for 7 days (3 doses) ($) [R,D Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 10DS", "DisplayText" : "Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 10-14 days", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 10 days", "Mnemonic" : "12a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 10DS", "DisplayText" : "Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 1 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 TERCONAZOLE 0.4% VAG CRM QHS 10DS", "DisplayText" : "Terconazole 0.4% vaginal cream 1 applicator full at bedtime for 10-14 days", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 10 days", "Mnemonic" : "14a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 TERCONAZOLE 0.4% VAG CRM QHS 10DS", "DisplayText" : "Terconazole 0.4% vaginal cream 1 applicator full at bedtime for Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150MG PO QWEEK 6MO", "DisplayText" : "Fluconazole 150 mg PO QWEEK for 6 months ($) [R,DI]", "Text" : "Fluconazole 150 mg PO every 7 days ($) [R,DI] for 6 months", "Mnemonic" : "16a"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150MG PO QWEEK 6MO", "DisplayText" : "Fluconazole 150 mg PO QWEEK for 6 months ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA VULVOVAGINITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Candida vulvovaginitis typically presents with valvular irritation, burning or"}, 
{"Row" :6, "Column" : 1, "Text" : "pruritus. Vaginal pH should be measured, and the specimen should be examined"}, 
{"Row" :7, "Column" : 1, "Text" : "under the microscope for clue cells (epithelial cell coated with bacteria) to"}, 
{"Row" :8, "Column" : 1, "Text" : "exclude bacterial vaginosis. In candida vulvovaginitis, the vaginal pH is"}, 
{"Row" :9, "Column" : 1, "Text" : "typically normal (4-4.5) and vaginal discharge is typically thick and curdy with"}, 
{"Row" : 10, "Column" : 1, "Text" : "white plaques on vaginal mucosa. Diagnosis is confirmed by identifying fungus or"}, 
{"Row" : 11, "Column" : 1, "Text" : "yeast with KOH prep."}, 
{"Row" : 13, "Column" : 1, "Text" : "Most non-C. albicans species respond to fluconazole treatment except C. krusei"}, 
{"Row" : 14, "Column" : 1, "Text" : "and C. glabrata. C. krusei can be treated with topical agents as for complicated"}, 
{"Row" : 15, "Column" : 1, "Text" : "candida vulvovaginitis below. C. glabrata treatment is complicated and azole"}, 
{"Row" : 16, "Column" : 1, "Text" : "therapy is frequently unsuccessful. Consult Infectious Diseases in patients with"}, 
{"Row" : 17, "Column" : 1, "Text" : "C. glabrata vulvovaginitis."}, 
{"Row" : 19, "Column" : 1, "Text" : "Recurrent candida vulvovaginitis is treated as complicated candida"}, 
{"Row" : 20, "Column" : 1, "Text" : "vulvovaginitis for induction treatment, followed by maintenance regimen for 6"}, 
{"Row" : 21, "Column" : 1, "Text" : "months."}, 
{"Row" : 23, "Column" : 1, "Text" : "Treatment of uncomplicated candida vulvovaginitis", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 29, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "Treatment of complicated candida vulvovaginitis (e.g. immunocompromised, severe", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "disease, pregnancy) or recurrent infection induction treatment", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "Recurrent candida vulvovaginitis maintenance regimen following induction", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "treatment above", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Treatment of C. glabrate vulvovaginitis", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Failure of azole therapy is common, alternative topical treatments below require"}, 
{"Row" : 51, "Column" : 1, "Text" : "compounding by a pharmacist. Please call pharmacy to order."}, 
{"Row" : 52, "Column" : 1, "Text" : "Topical flucytosine cream (17%) qhs for 14 days"}, 
{"Row" : 53, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 54, "Column" : 1, "Text" : "Topical boric acid capsule 600 mg intravaginal qhs for 14 days"}, 
{"Row" : 55, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "References: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 60, "Column" : 1, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409"}, 
{"Row" : 61, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Vulvovaginitis"}, 
{"Row" : 62, "Column" : 1, "Text" : "Up-to-Date article: Candida vulvovaginitis: Treatment"}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-to-Date article: Candida vulvovaginitis: Clinical manifestations and"}, 
{"Row" : 64, "Column" : 1, "Text" : "diagnosis"}, 
{"Row" : 65, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID3 GMENU CAP TREATED IN OUTPT SETTING", "DisplayText" : "CAP treated in an outpatient setting (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "DisplayText" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "DisplayText" : "Amox-clav 875/125mg po bid x5days <AND> Azithromycin 500 then 250", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Mnemonic" : "8a"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "DisplayText" : "Non-VA for above order", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "DisplayText" : "Cefdinir 300mg PO BID for 5 to 7 days ($) [R] <AND> Azithromycin", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin", "Mnemonic" : "10a"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "DisplayText" : "NON-VA order for above", "Text" : "NON-VA order for above", "Mnemonic" : "10b"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "DisplayText" : "Amox-clav 875/125 mg po bid <AND> Doxycycline 100mg po bid x5days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Mnemonic" : "12a"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG BID DOXY 100MG BID", "DisplayText" : "Cefdinir 300mg po bid <AND> Doxycycline 100mg po bid x5 days", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline", "Mnemonic" : "14a"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG BID DOXY 100MG BID", "DisplayText" : "Non-VA for above", "Text" : "Non-VA for above", "Mnemonic" : "14b"},
{"Row" : 40, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "DisplayText" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Mnemonic" : "16"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Text" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Mnemonic" : "18a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :2, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING"}, 
{"Row" :4, "Column" : 1, "Text" : "Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,"}, 
{"Row" :6, "Column" : 1, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing"}, 
{"Row" :7, "Column" : 1, "Text" : "conditions, or use of immunosuppressing drugs)"}, 
{"Row" :9, "Column" : 1, "Text" : "Outpatient and UNcomplicated: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure,"}, 
{"Row" : 18, "Column" : 1, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing"}, 
{"Row" : 19, "Column" : 1, "Text" : "conditions, or use of immunosuppressing drugs)"}, 
{"Row" : 21, "Column" : 1, "Text" : "Outpatient and comorbidity: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]"}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "100 mg PO BID for 5 days ($) [DI]"}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45"}, 
{"Row" : 46, "Column" : 1, "Text" : "Sanford: Community Acquired Pneumonia"}, 
{"Row" : 47, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CARDIOVASCULAR", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" :7, "Column" : 1, "Text" : "Section last reviewed9/2020", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "DisplayText" : "Cat-Scratch Disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "CAT-SCRATCH DISEASE"}, 
{"Row" :4, "Column" : 1, "Text" : "Cat-scratch disease occurs when a cat infected with Bartonella henselae"}, 
{"Row" :5, "Column" : 1, "Text" : "scratches or bites a person or licks a person's open wound.A local pustule"}, 
{"Row" :6, "Column" : 1, "Text" : "develops followed by lymphadenopathy, typically on the same side of the body as"}, 
{"Row" :7, "Column" : 1, "Text" : "the scratch or bite."}, 
{"Row" :9, "Column" : 1, "Text" : "Infections associated with other pathogens such as Francisella tularemia,"}, 
{"Row" : 10, "Column" : 1, "Text" : "Coxiella burnetiid and other slow-growing bacteria may present with similar"}, 
{"Row" : 11, "Column" : 1, "Text" : "symptoms.Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "About 10% of cases of cat-scratch disease present atypically with symptoms"}, 
{"Row" : 14, "Column" : 1, "Text" : "involving the eye, nervous system, or lungs.Consult Infectious Diseases in"}, 
{"Row" : 15, "Column" : 1, "Text" : "these cases."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter: Bartonella, including cat-scratch disease"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: cat-scratch disease"}, 
{"Row" : 29, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 22, "Column" : 1, "Text" : "Consult Infectious Diseases"}
]},
{"Name" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU INI EPISODE ABX ASSOC COLITIS", "DisplayText" : "Initial Episode of Antibiotic Associated Colitis...", "Text" : "Initial Episode", "Mnemonic" : "4"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU FIRST RECURRENCE ABX ASSOCIATED COLITIS", "Text" : "First Recurrence", "Mnemonic" : "6"},
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU SECOND RECURRENCE CDIFF COLITIS", "DisplayText" : "ORZID3 GMENU SECOND RECURRENCE ABX ASSOC COLITIS", "Text" : "Second Recurrence", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic"}, 
{"Row" : 18, "Column" : 1, "Text" : "therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C."}, 
{"Row" : 19, "Column" : 1, "Text" : "difficile PCR testing should be completed to confirm diagnosis of C. difficile"}, 
{"Row" : 20, "Column" : 1, "Text" : "infection."}, 
{"Row" : 22, "Column" : 1, "Text" : "Antibiotic risk (rank order): ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,"}, 
{"Row" : 24, "Column" : 1, "Text" : "Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,"}, 
{"Row" : 25, "Column" : 1, "Text" : "vancomycin, metronidazole"}, 
{"Row" : 26, "Column" : 1, "Text" : "Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampi"}, 
{"Row" : 27, "Column" : 1, "Text" : "Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine"}, 
{"Row" : 29, "Column" : 1, "Text" : "Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence"}, 
{"Row" : 30, "Column" : 1, "Text" : "suggests that antacid therapy, especially with PPIs and H2 blockers, increases"}, 
{"Row" : 31, "Column" : 1, "Text" : "the risk for C. difficile disease and recurrences. Avoid antacid therapy"}, 
{"Row" : 32, "Column" : 1, "Text" : "without clear indication, especially in patients at risk for primary recurrent C"}, 
{"Row" : 33, "Column" : 1, "Text" : "difficile disease."}, 
{"Row" : 35, "Column" : 1, "Text" : "The preferred route of antimicrobial therapy for C. difficile infection is by"}, 
{"Row" : 36, "Column" : 1, "Text" : "mouth. Intravenous metronidazole should be used only when oral therapy cannot"}, 
{"Row" : 37, "Column" : 1, "Text" : "be used to deliver drug to the colon. Intravenous vancomycin does not get into"}, 
{"Row" : 38, "Column" : 1, "Text" : "colonic contents and is not effective."}, 
{"Row" : 40, "Column" : 1, "Text" : "C. difficile infection usually responds to antimicrobial therapy, especially if"}, 
{"Row" : 41, "Column" : 1, "Text" : "other antimicrobial therapy has been stopped. Relapse is usually due to failure"}, 
{"Row" : 42, "Column" : 1, "Text" : "of normal colonic flora to re-establish itself, rather than antimicrobial"}, 
{"Row" : 43, "Column" : 1, "Text" : "treatment failure. If symptoms do not respond to appropriate antimicrobial"}, 
{"Row" : 44, "Column" : 1, "Text" : "therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after"}, 
{"Row" : 45, "Column" : 1, "Text" : "their first episode of C. difficile infection."}, 
{"Row" : 50, "Column" : 1, "Text" : "Third Recurrence: Consult Gastroenterology and/or Infectious Disease", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "References: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 61, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 62, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical"}, 
{"Row" : 63, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 58, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 59, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" :7, "Column" : 1, "Text" : "CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in"}, 
{"Row" :8, "Column" : 1, "Text" : "24 hours after discontinuation of laxatives) and laboratory confirmation of CDI."}, 
{"Row" : 14, "Column" : 1, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory"}, 
{"Row" : 15, "Column" : 1, "Text" : "case of CDI within 12 weeks after a prior episode."}, 
{"Row" : 53, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 54, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 52, "Column" : 1, "Text" : "Fulminant CDI: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Clostridioides difficile Infection (CDI)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "If diarrhea has improved or resolved prior to starting C. difficile"}, 
{"Row" : 10, "Column" : 1, "Text" : "treatment, consider re-assessing the diagnosis before initiating therapy."}, 
{"Row" : 11, "Column" : 1, "Text" : "The Infectious Disease service is always available to discuss CDI testing"}, 
{"Row" : 12, "Column" : 1, "Text" : "and results."}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "<Click here> Information on C. difficile lab testing", "Mnemonic" : "3"}
]},
{"Name" : "ORZID3 GMENU CELLULITIS", "DisplayText" : "Cellulitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT CELLULITIS", "DisplayText" : "The approach to cellulitis", "Text" : "More about cellulitis...", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :2, "Column" : 1, "Text" : "BACTERIAL CELLULITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and is"}, 
{"Row" :5, "Column" : 1, "Text" : "often associated with bacterial pathogens.The most common pathogens are group"}, 
{"Row" :6, "Column" : 1, "Text" : "A streptococci and Staphylococcus aureus.Group B streptococci are associated"}, 
{"Row" :7, "Column" : 1, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on feet"}, 
{"Row" :8, "Column" : 1, "Text" : "and legs of patients with athlete's foot (tinea pedis)."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild cases can be treated with oral antimicrobials.Moderate to severe cases"}, 
{"Row" : 11, "Column" : 1, "Text" : "should be treated initially with intravenous antimicrobials.Switch to oral"}, 
{"Row" : 12, "Column" : 1, "Text" : "drugs after clinical improvement."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma,"}, 
{"Row" : 15, "Column" : 1, "Text" : "history of MRSA infection, injection drug use, or infections not responding"}, 
{"Row" : 16, "Column" : 1, "Text" : "to first line beta-lactams."}, 
{"Row" : 20, "Column" : 1, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "if not improved in this time.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Mild: Cellulitis without systemic signs of infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical treatment for MILD cellulitis", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for Penicillin Allergy or MRSA suspected", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "MRSA Suspected Mild Cellulitis", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Empirical treatment for MODERATE to SEVERE cellulitis", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 40, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 41, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg PO bid ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 39, "Column" : 1, "Text" : "References"}
]},
{"Name" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "Chlamydia & GC PCR/LCR test", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient)", "Text" : "Treatment of recurrent or persistent cervicitis", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "The main diagnostic signs that characterize cervicitis are 1)women who present"}, 
{"Row" :8, "Column" : 1, "Text" : "with purulent or mucopurulent exudate in the endocervical canal or on an"}, 
{"Row" :9, "Column" : 1, "Text" : "endocervical swab specimen and 2)sustained endocervical bleeding induced by"}, 
{"Row" : 10, "Column" : 1, "Text" : "gentle passage of cotton swab through the cervical os. One or both signs may be"}, 
{"Row" : 11, "Column" : 1, "Text" : "present."}, 
{"Row" : 13, "Column" : 1, "Text" : "Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually"}, 
{"Row" : 14, "Column" : 1, "Text" : "transmitted cervicitis pathogens. Nucleic acid amplification tests for these"}, 
{"Row" : 15, "Column" : 1, "Text" : "pathogens are more sensitive than culture and should be used for patients at"}, 
{"Row" : 16, "Column" : 1, "Text" : "risk for sexually transmitted cervicitis."}, 
{"Row" : 19, "Column" : 1, "Text" : "For patients who have recently been treated for cervicitis", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "When diagnosed with sexually transmitted cervicitis, the patient's sexual"}, 
{"Row" : 23, "Column" : 1, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually"}, 
{"Row" : 24, "Column" : 1, "Text" : "transmitted infection. If diagnostic tests for the cause of cervicitis are not"}, 
{"Row" : 25, "Column" : 1, "Text" : "feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to"}, 
{"Row" : 26, "Column" : 1, "Text" : "partners."}, 
{"Row" : 28, "Column" : 1, "Text" : "Initial treatment of patients and sex partners", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C."}, 
{"Row" : 30, "Column" : 1, "Text" : "trachomatis."}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment for Gonococcal and Chlamydial trachomatis co-infections", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916"}
]},
{"Name" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia urethritis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" :7, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1 gm PO x 1 dose ($) [M]", "Mnemonic" : "6a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment for chlamydial or non-gonococcal urethritis or cervicitis", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford keyword: Urethritis, cervicitis: chlamydial"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}, 
{"Row" : 15, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU CHOLANGITIS", "DisplayText" : "Cholangitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days", "Text" : "Moxifloxacin 400 mg PO qday ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP LEVOFLOXACIN 500MG QDAY METRONID 1GM BID 7DAYS", "DisplayText" : "Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg PO bid ($) [DI]", "Text" : "Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg PO bid ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX NV LEVOFLOXACIN 500MG QDAY METRONID 1GM BID 7DAYS", "DisplayText" : "Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :2, "Column" : 1, "Text" : "CHOLANGITIS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for initial IV treatment"}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)"}, 
{"Row" :6, "Column" : 1, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure."}, 
{"Row" :8, "Column" : 1, "Text" : "Step down treatment for completion of antimicrobial course after initial"}, 
{"Row" :9, "Column" : 1, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection"}, 
{"Row" : 10, "Column" : 1, "Text" : "on culture results."}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of treatment for total of 7 to 10 days.", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess"}, 
{"Row" : 24, "Column" : 1, "Text" : "Cholangitis, Cholecystitis)"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Gallbladder Infections"}, 
{"Row" : 26, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Acute cholangitis"}
]},
{"Name" : "ORZID3 GMENU CHOLECYSTITIS", "DisplayText" : "Cholecystitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CHOLECYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "DisplayText" : "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 IBUPROFEN 14DS 400MG PO TID", "DisplayText" : "Ibuprofen 400mg PO TID 14 days", "Text" : "Ibuprofen 400 mg PO q8h for 2 to 3 weeks", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 IBUPROFEN 14DS 400MG PO TID", "DisplayText" : "Ibuprofen 400mg PO TID 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "This syndrome presents with intermittent perineal and/or low back pain,"}, 
{"Row" :6, "Column" : 1, "Text" : "obstructive voiding symptoms, relatively normal examination, and negative urine"}, 
{"Row" :7, "Column" : 1, "Text" : "cultures. Antimicrobial therapy is not indicated."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult urology for non-antimicrobial therapy recommendations (e.g."}, 
{"Row" :9, "Column" : 1, "Text" : "alpha-adrenergic antagonists, anti-inflammatory medications) to reduce symptoms."}, 
{"Row" : 11, "Column" : 1, "Text" : "Anti-inflammatory treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome"}
]},
{"Name" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "DisplayText" : "Chronic bacterial prostatitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture", "Text" : "Urine culture", "Mnemonic" : "4"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "DisplayText" : "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)", "Text" : "Chronic prostate pain syndrome", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 750MG PO QDAY 28D", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks", "Mnemonic" : "8a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 750MG PO QDAY 28D", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 4 weeks", "Mnemonic" : "10a"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC BACTERIAL PROSTATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Chronic bacterial prostatitis usually presents as recurrent urinary tract"}, 
{"Row" :6, "Column" : 1, "Text" : "infections with the same bacterial etiology. Pain, tenderness, and fever may"}, 
{"Row" :7, "Column" : 1, "Text" : "accompany intermittent episodes of cystitis, but men are usually asymptomatic"}, 
{"Row" :8, "Column" : 1, "Text" : "between episodes and the prostate examination may be normal. Non-steroidal anti-"}, 
{"Row" :9, "Column" : 1, "Text" : "inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain or"}, 
{"Row" : 10, "Column" : 1, "Text" : "if the patient's symptoms do not respond to therapy, consult urology. The"}, 
{"Row" : 11, "Column" : 1, "Text" : "presence of hematuria may be a sign of carcinoma, especially in older men, and a"}, 
{"Row" : 12, "Column" : 1, "Text" : "urology consult should be requested."}, 
{"Row" : 14, "Column" : 1, "Text" : "A urine culture should be performed in all patients to guide antimicrobial"}, 
{"Row" : 15, "Column" : 1, "Text" : "therapy: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Chronic prostate pain syndrome should be considered in patients who have"}, 
{"Row" : 19, "Column" : 1, "Text" : "symptoms of prostatitis but have negative urine cultures. Chronic prostate pain"}, 
{"Row" : 20, "Column" : 1, "Text" : "syndrome is discussed elsewhere: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "4 weeks minimum and up to 6 weeks of treatment is required. Durations longer"}, 
{"Row" : 25, "Column" : 1, "Text" : "than 6 weeks may be needed in treatment of resistant organisms. Treatment with"}, 
{"Row" : 26, "Column" : 1, "Text" : "trimethoprim/sulfamethoxazole requires a treatment duration of 1 to 3 months."}, 
{"Row" : 28, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Rees et al., BJU Int, 2015,116.509-525"}, 
{"Row" : 41, "Column" : 1, "Text" : "Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Prostatitis"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-To-Date article: Chronic bacterial prostatitis"}
]},
{"Name" : "ORZID3 GMENU CHRONIC SINUSITIS", "DisplayText" : "Chronic sinusitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "DisplayText" : "Acute sinusitis--Severe disease (Outpatient)", "Text" : "Severe Sinusitis", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "CHRONIC SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4"}, 
{"Row" :6, "Column" : 1, "Text" : "cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires"}, 
{"Row" :7, "Column" : 1, "Text" : "objective evidence of mucosal inflammation using nasal endoscopy and/or CT"}, 
{"Row" :8, "Column" : 1, "Text" : "imaging. The initial therapy for chronic sinusitis is treatment with intranasal"}, 
{"Row" :9, "Column" : 1, "Text" : "corticosteroids and saline. For patients with severe nasal blockage by polyps,"}, 
{"Row" : 10, "Column" : 1, "Text" : "treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3"}, 
{"Row" : 11, "Column" : 1, "Text" : "months of intranasal therapy or after completion of glucocorticoid therapy. If"}, 
{"Row" : 12, "Column" : 1, "Text" : "signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases"}, 
{"Row" : 13, "Column" : 1, "Text" : "as treatment is complex."}, 
{"Row" : 14, "Column" : 1, "Text" : "Acute exacerbations of chronic sinusitis can be caused by discontinuing medical"}, 
{"Row" : 15, "Column" : 1, "Text" : "therapy, viral infections, allergens, noxious inhalants and bacterial or fungal"}, 
{"Row" : 16, "Column" : 1, "Text" : "infections. Bacterial infections should be suspected when the patient has"}, 
{"Row" : 17, "Column" : 1, "Text" : "increased signs/symptoms persisting for more than 10 days. Refer to Severe"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sinusitis recommendations for choice of antimicrobial therapy in these patients."}, 
{"Row" : 19, "Column" : 1, "Text" : "Repeated use of the same agent should be avoided to prevent promotion of drug"}, 
{"Row" : 20, "Column" : 1, "Text" : "resistant bacteria or increased fungal colonization."}, 
{"Row" : 23, "Column" : 1, "Text" : "Cardinal Signs/Symptoms of Chronic Sinusitis", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "1. Anterior and/or posterior nasal mucopurulent drainage"}, 
{"Row" : 25, "Column" : 1, "Text" : "2. Nasal obstruction/nasal blockage/congestion"}, 
{"Row" : 26, "Column" : 1, "Text" : "3. Facial pain, pressure, and/or fullness"}, 
{"Row" : 27, "Column" : 1, "Text" : "4. Reduction or loss of sense of smell"}, 
{"Row" : 29, "Column" : 1, "Text" : "Objective Evidence mucosal inflammation", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions"}, 
{"Row" : 31, "Column" : 1, "Text" : "2. Polyps in the nasal cavity or the middle meatus"}, 
{"Row" : 32, "Column" : 1, "Text" : "3. Radiographic imaging demonstrating mucosal thickening or partial or complete"}, 
{"Row" : 33, "Column" : 1, "Text" : "opacification of the paranasal sinuses"}, 
{"Row" : 35, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 41, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 42, "Column" : 1, "Text" : "Rudmik et al., JAMA. 2015, 314(9) 926-939"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Chronic"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,"}, 
{"Row" : 45, "Column" : 1, "Text" : "pathophysiology, and diagnosis"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic"}, 
{"Row" : 47, "Column" : 1, "Text" : "rhinosinusitis"}
]},
{"Name" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "DisplayText" : "CMV colitis or esophagitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 VALGANCICLOVIR 21DS 900MG PO BID", "DisplayText" : "Valganciclovir 900mg po bid for 21 days", "Text" : "Valganciclovir 900 mg PO BID ($$$) [R,O]", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 VALGANCICLOVIR 21DS 900MG PO BID", "DisplayText" : "Valganciclovir 900mg po bid for 21 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CMV COLITIS OR ESOPHAGITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for 3-6 weeks. Patients may be converted to oral therapy after initial"}, 
{"Row" : 14, "Column" : 1, "Text" : "intravenous therapy and after clinical improvement of severe disease."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of mild to moderate disease or following clinical improvement of", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "severe disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 28, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 32, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID3 GMENU CMV ENCEPHALITIS", "DisplayText" : "CMV encephalitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CMV ENCEPHALITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU CMV PNEUMONIA", "DisplayText" : "CMV pneumonia (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CMV PNEUMONIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "DisplayText" : "CMV polyradiculopathy (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VALGANCICLOVIR 900MG PO BID", "DisplayText" : "Valganciclovir 900 mg PO BID ($$$) [R,O]", "Text" : "Valganciclovir 900 mg PO BID ($$$) [R,O]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VALGANCICLOVIR 900MG PO BID", "DisplayText" : "Valganciclovir 900 mg PO BID ($$$) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CMV POLYRADICULOPATHY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration is likely to be prolonged and is individualized based on response."}, 
{"Row" : 14, "Column" : 1, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and"}, 
{"Row" : 15, "Column" : 1, "Text" : "after clinical improvement of severe disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of mild to moderate disease or following clinical improvement of", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "severe disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 29, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 33, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID3 GMENU CMV RETINITIS", "DisplayText" : "CMV retinitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 VALGANCICLOVIR 14DS 900MG PO BID", "DisplayText" : "Valganciclovir 900mg po bid for 14 days", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Mnemonic" : "4a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 VALGANCICLOVIR 14DS 900MG PO BID", "DisplayText" : "Valganciclovir 900mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID VALGANCICLOVIR 900MG PO QDAY MAINTENANCE", "DisplayText" : "Valganciclovir 900 mg PO QDay ($$$) [R,O]", "Text" : "Valganciclovir 900 mg PO q24h ($$$) [R,O]", "Mnemonic" : "6a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID VALGANCICLOVIR 900MG PO QDAY MAINTENANCE", "DisplayText" : "Valganciclovir 900 mg PO QDay ($$$) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CMV RETINITIS AND ACUTE RETINAL NECROSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infection in immunocompetent patients is rare and usually associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased"}, 
{"Row" :7, "Column" : 1, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving"}, 
{"Row" :8, "Column" : 1, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease"}, 
{"Row" :9, "Column" : 1, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex"}, 
{"Row" : 10, "Column" : 1, "Text" : "and requires Infectious Diseases consultation."}, 
{"Row" : 12, "Column" : 1, "Text" : "For sight threatening lesions (lesions within 1500 microns of the fovea)"}, 
{"Row" : 13, "Column" : 1, "Text" : "intravitreal infections of ganciclovir or foscarnet are recommended in addition"}, 
{"Row" : 14, "Column" : 1, "Text" : "to systemic treatment. Contact Infectious Diseases for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy"}, 
{"Row" : 18, "Column" : 1, "Text" : "after initial intravenous therapy and after clinical improvement of severe"}, 
{"Row" : 19, "Column" : 1, "Text" : "disease. Treat acute retinal necrosis with IV therapy for at least 7 days and"}, 
{"Row" : 20, "Column" : 1, "Text" : "until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance"}, 
{"Row" : 21, "Column" : 1, "Text" : "therapy after completion of treatment is indicated when CD4 count <100."}, 
{"Row" : 22, "Column" : 1, "Text" : "Discontinue maintenance therapy when CD4 count is >100 for 6 months."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment acute retinal necrosis or severe disease", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of mild to moderate retinitis or after clinical improvement of severe", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "retinitis/acute retinal necrosis", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Maintenance therapy", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 41, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Cytomegalovirus"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Cytomegalovirus"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of"}, 
{"Row" : 45, "Column" : 1, "Text" : "cytomegalovirus infection in immunocompetent adults"}
]},
{"Name" : "ORZID3 GMENU CNS OUTPT", "DisplayText" : "Central nervous system (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient)", "Text" : "Bell's Palsy", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme Disease", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "DisplayText" : "Neurosurgery", "Text" : "Neurosurgery prophylaxis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "CENTRAL NERVOUS SYSTEM", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for Other Central Nervous System Infectio", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "(e.g. meningitis, brain abscess, HSV encephalitis,cranial/spinal epidural"}, 
{"Row" : 11, "Column" : 1, "Text" : "abscess, subdural empyema, and suppurative intracranial thrombophilia)."}
]},
{"Name" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "DisplayText" : "Community acquired diarrhea (no recent travel) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile", "Mnemonic" : "4"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Mnemonic" : "8a"},
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Mnemonic" : "10a"},
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Acute diarrhea (< 14 days of symptoms)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Empirical antimicrobials should be given only in cases of severe acute disease"}, 
{"Row" :9, "Column" : 1, "Text" : "or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion"}, 
{"Row" : 10, "Column" : 1, "Text" : "requiring hospitalization, severe abdominal pain, immune compromise, cardiac"}, 
{"Row" : 11, "Column" : 1, "Text" : "disease, >/= 70 years old."}, 
{"Row" : 13, "Column" : 1, "Text" : "If in the preceding two months the patient has taken a PPI or has been"}, 
{"Row" : 14, "Column" : 1, "Text" : "hospitalized for three or more days, consider Clostridium difficile infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 19, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 20, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 21, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 22, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 23, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 24, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 25, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 26, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 28, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 31, "Column" : 1, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 38, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Subacute or chronic (>/= 14 days of symptoms)", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Primary treatment is hydration and electrolyte replacement. Empiric"}, 
{"Row" : 45, "Column" : 1, "Text" : "antimicrobial therapy is not indicated. Investigate for the cause of diarrhea."}, 
{"Row" : 46, "Column" : 1, "Text" : "Gastroenterology and/or Infectious Diseases involvement is encouraged."}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 53, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich"}, 
{"Row" : 55, "Column" : 1, "Text" : "settings"}
]},
{"Name" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "DisplayText" : "CAP Pneumonia Severity Index (PSI) Calculator", "Text" : "CAP Pneumonia Severity Index (PSI) Calculator", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CAP TREATED IN OUTPT SETTING", "DisplayText" : "CAP treated in an outpatient setting (Outpatient)", "Text" : "CAP treated in an outpatient setting", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)"}, 
{"Row" :5, "Column" : 1, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,"}, 
{"Row" :6, "Column" : 1, "Text" : "including atypical pathogens.Specific therapy should be guided by culture"}, 
{"Row" :7, "Column" : 1, "Text" : "results."}, 
{"Row" :8, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk for"}, 
{"Row" : 13, "Column" : 1, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how"}, 
{"Row" : 14, "Column" : 1, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be"}, 
{"Row" : 15, "Column" : 1, "Text" : "treated safely outside of the hospital."}, 
{"Row" : 16, "Column" : 1, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and"}, 
{"Row" : 17, "Column" : 1, "Text" : "should be used to augment clinical judgment. If social circumstances"}, 
{"Row" : 18, "Column" : 1, "Text" : "or cognitive dysfunction would interfere with success of outpatient"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment, the patient should be hospitalized."}, 
{"Row" : 23, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent"}, 
{"Row" : 28, "Column" : 1, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia."}, 
{"Row" : 31, "Column" : 1, "Text" : "(SEE INPATIENT CDSS for CAP treated in an Inpatient Setting)"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Fine MJ, et al. N Engl J Med. (1997) 336: 243-250"}
]},
{"Name" : "ORZID3 GMENU COMM INFECT PNEUMO", "DisplayText" : "Pneumonia (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient)", "Text" : "Aspiration pneumonia", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Nosocomial pneumonia (including HAP or VAP) SEE INPATIENT CDSS", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "++PNEUMONIA - OUTPATIENT++", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019"}, 
{"Row" :8, "Column" : 1, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA"}, 
{"Row" :9, "Column" : 1, "Text" : "and/or P. aeruginosa are use to guide whether to start"}, 
{"Row" : 10, "Column" : 1, "Text" : "appropriate coverage empirically. (See CAP above)"}
]},
{"Name" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "VIRAL GASTROENTERITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,"}, 
{"Row" :6, "Column" : 1, "Text" : "Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes"}, 
{"Row" :7, "Column" : 1, "Text" : "supportive measures such as oral rehydration and unrestricted nutrition."}, 
{"Row" :8, "Column" : 1, "Text" : "Antiviral therapy is not recommended and for most viruses is unavailable."}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimotility agents may be used for one or two days in patients with mild to"}, 
{"Row" : 11, "Column" : 1, "Text" : "moderate volume depletion. Antiemetic agents may be used for one or two days in"}, 
{"Row" : 12, "Column" : 1, "Text" : "patients with vomiting."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 19, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-To-Date article: Acute viral gastroenteritis in adults"}
]},
{"Name" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Pyelonephritis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINE CULTURE MENU", "DisplayText" : "Urine Culture", "Text" : "Urine culture", "Mnemonic" : "6"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "DisplayText" : "Acute bacterial prostatitis (Outpatient)", "Text" : "Acute prostatitis", "Mnemonic" : "8"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "10a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 52, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days", "Mnemonic" : "12a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 57, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "14a"},
{"Row" : 58, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "16a"},
{"Row" : 61, "Column" : 1, "Item" : "PSHZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 63, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 7DAYS", "DisplayText" : "Cefdinir 300mg PO BID ($) [R] for 7 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "18a"},
{"Row" : 64, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 7DAYS", "DisplayText" : "Cefdinir 300 mg PO BID ($) [R] for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "20"},
{"Row" : 68, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "22a"},
{"Row" : 69, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "DisplayText" : "Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" : 79, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "24a"},
{"Row" : 80, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" : 83, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "26"},
{"Row" : 84, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "28a"},
{"Row" : 86, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "28b"},
{"Row" : 95, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "30a"},
{"Row" : 96, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "30b"},
{"Row" :100, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG TID 7DAYS", "DisplayText" : "Amoxicillin 500 mg PO TID for 7 days ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h ($) [R] for 7 days", "Mnemonic" : "32a"},
{"Row" :101, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 500MG TID 7DAYS", "DisplayText" : "Amoxicillin 500 mg PO TID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "32b"},
{"Row" :104, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "34"},
{"Row" :105, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Mnemonic" : "36a"},
{"Row" :106, "Column" : 1, "Item" : "PSHZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "36b"},
{"Row" :108, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days", "Mnemonic" : "38a"},
{"Row" :110, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "38b"},
{"Row" :3, "Column" : 1, "Text" : "COMPLICATED CYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Complicated cystitis is defined as symptomatic bladder inflammation and symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "due to a bacterial infection in people with certain conditions (see below)."}, 
{"Row" :7, "Column" : 1, "Text" : "Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated"}, 
{"Row" :8, "Column" : 1, "Text" : "cystitis is commonly associated with Enterobacteriaceae, but more resistant"}, 
{"Row" :9, "Column" : 1, "Text" : "pathogens occur, including the Gram-positive pathogens staphylococci and"}, 
{"Row" : 10, "Column" : 1, "Text" : "enterococci."}, 
{"Row" : 12, "Column" : 1, "Text" : "Signs and symptoms that may indicate infection has extended beyond the bladder"}, 
{"Row" : 13, "Column" : 1, "Text" : "include fever/other signs of systemic infection, flank pain, costovertebral"}, 
{"Row" : 14, "Column" : 1, "Text" : "tenderness, and pelvic or perianal pain in men. Pyelonephritis should be"}, 
{"Row" : 15, "Column" : 1, "Text" : "considered in these patients: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Urine culture should be obtained before antimicrobials are given to guide"}, 
{"Row" : 19, "Column" : 1, "Text" : "treatment of complicated cystitis: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Prostatitis should be considered in men with recurrence of urinary tract"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection: "}, 
{"Row" : 26, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 27, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 28, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 30, "Column" : 1, "Text" : "Complicating conditions", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Cystitis is considered complicated when one or more of the following is present: "}, 
{"Row" : 32, "Column" : 1, "Text" : "o Pregnant women"}, 
{"Row" : 33, "Column" : 1, "Text" : "o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter"}, 
{"Row" : 34, "Column" : 1, "Text" : "or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)"}, 
{"Row" : 35, "Column" : 1, "Text" : "o Immunocompromise"}, 
{"Row" : 36, "Column" : 1, "Text" : "o Persistent infection, relapse, recurrence, or treatment failure"}, 
{"Row" : 37, "Column" : 1, "Text" : "o In some cases, men and patients admitted to health care settings may be"}, 
{"Row" : 38, "Column" : 1, "Text" : "considered complicated"}, 
{"Row" : 40, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Treat for 7 days. If patient is febrile, may extend duration up to 14 days total"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Mild to moderate disease", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 49, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 51, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 53, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 56, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 59, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 66, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 71, "Column" : 1, "Text" : "Severe disease or if patient cannot take oral therapy", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 73, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 82, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 85, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 88, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" : 89, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" : 90, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" : 91, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" : 92, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 94, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" : 98, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" : 99, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" :103, "Column" : 1, "Text" : "Alternatives: "}, 
{"Row" :107, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :109, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" :111, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :114, "Column" : 1, "Text" : "References: "}, 
{"Row" :115, "Column" : 1, "Text" : "Drekonja et al., JAMA, 2021, 326(4)324-331"}, 
{"Row" :116, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :117, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :118, "Column" : 1, "Text" : "Sanford keyword: Cystitis"}, 
{"Row" :119, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" :120, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" :121, "Column" : 1, "Text" : "Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16"}, 
{"Row" :122, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated urinary tract infection (including"}, 
{"Row" :123, "Column" : 1, "Text" : "pyelonephritis) in adults"}, 
{"Row" :124, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :125, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :126, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}, 
{"Row" :127, "Column" : 1, "Text" : "Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5"}
]},
{"Name" : "ORZID3 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H 7D", "DisplayText" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)", "Text" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)", "Mnemonic" : "4a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H 7D", "DisplayText" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID 5D", "DisplayText" : "Ofloxacin 2 drops in affected eye every 2 hours while awake for 2 days then 2", "Text" : "Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2", "Mnemonic" : "6a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID 5D", "DisplayText" : "Ofloxacin 2 drops in affected eye every 2 hours while awake for Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CONJUNCTIVITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Conjunctivitis is associated with viral or bacterial pathogens. Viral"}, 
{"Row" :6, "Column" : 1, "Text" : "conjunctivitis presents with watery discharge. Bacterial infections are more"}, 
{"Row" :7, "Column" : 1, "Text" : "likely to present with thick exudate and conjunctival injection. Allergic"}, 
{"Row" :8, "Column" : 1, "Text" : "conjunctivitis typically presents with stringy mucus. If there is pus"}, 
{"Row" :9, "Column" : 1, "Text" : "(hypopion), corneal involvement, possible bacterial conjunctivitis, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "keratitis, consult ophthalmology."}, 
{"Row" : 12, "Column" : 1, "Text" : "Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited"}, 
{"Row" : 13, "Column" : 1, "Text" : "and antivirals provide no benefit. Symptomatic treatment with ophthalmic"}, 
{"Row" : 14, "Column" : 1, "Text" : "antihistamine/decongestants and warm or cool compresses may relieve symptoms."}, 
{"Row" : 16, "Column" : 1, "Text" : "Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,"}, 
{"Row" : 17, "Column" : 1, "Text" : "Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,"}, 
{"Row" : 18, "Column" : 1, "Text" : "Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is"}, 
{"Row" : 19, "Column" : 1, "Text" : "generally self-limited, but topical antimicrobials reduce duration of symptoms"}, 
{"Row" : 20, "Column" : 1, "Text" : "and limit person-to-person spread of infection. If symptoms do not improve after"}, 
{"Row" : 21, "Column" : 1, "Text" : "2 days of antimicrobial therapy, the patient should be seen by an"}, 
{"Row" : 22, "Column" : 1, "Text" : "ophthalmologist."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment for acute bacterial conjunctivitis", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "q3h for 7 days ($) [M]"}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment for severe cases of bacterial conjunctivitis involving suppuration or", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "contact lens wearers", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Consult ophthalmology and begin topical antimicrobials."}, 
{"Row" : 33, "Column" : 1, "Text" : "days then 2 drops QID for 5 days ($) [M]"}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Azari eta al, JAMA (2013) 1721-1730"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Microbial conjunctivitis"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date Article: Conjunctivitis"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Conjunctivitis, Bacterial"}
]},
{"Name" : "ORZID3 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "DisplayText" : "[CLICK HERE] for list of MRSA risk factors", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO bid for 7 days ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Perianal/Anorectal Abscess", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "CUTANEOUS ABSCESS"}, 
{"Row" :5, "Column" : 1, "Text" : "Incise and drain and cover the site with a dry dressing.For small abscesses,"}, 
{"Row" :6, "Column" : 1, "Text" : "systemic antimicrobial therapy is rarely necessary."}, 
{"Row" :8, "Column" : 1, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or"}, 
{"Row" :9, "Column" : 1, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases for assistance."}, 
{"Row" : 12, "Column" : 1, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration: Treat for 5 to 7 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mild to Moderate Cases: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Moderate or high suspicion of MRSA", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Low suspicion of MRSA", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "For SEVERE cases empiric coverage with MRSA agent", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "See Inpatient CDSS for intravenous therapy"}, 
{"Row" : 31, "Column" : 1, "Text" : "For Perirectal/Anorectal Abscess Select Below", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword:Skin infections"}, 
{"Row" : 37, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CEFADROXIL 500MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 500 mg PO BID for 7 days($) [R]", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"}
]},
{"Name" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "DisplayText" : "Cutaneous Candidiasis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "DisplayText" : "Clotrimazole 1% cream topical bid for 28 days", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "DisplayText" : "Clotrimazole 1% cream topical bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID NYSTATIN CREAM APPLY BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M]", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Mnemonic" : "6a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID NYSTATIN CREAM APPLY BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "CUTANEOUS CANDIDIASIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Cutaneous candidiasis is a superficial fungal infection of the epidermis."}, 
{"Row" :5, "Column" : 1, "Text" : "Presents with red, erythematous patches, often in areas where skin contact"}, 
{"Row" :6, "Column" : 1, "Text" : "skin, including axillae, groin, and abdominal folds."}, 
{"Row" :8, "Column" : 1, "Text" : "Keep affected areas dry and clean."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 4 weeks."}, 
{"Row" : 15, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-to-date"}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford: Cutaneous Candidiasis"}
]},
{"Name" : "ORZID3 GMENU DECUBITIS ULCERS", "DisplayText" : "Decubitis ulcers (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Perianal/Anorectal Abscess", "Mnemonic" : "10"},
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "DisplayText" : "Cellulitis (Outpatient)", "Text" : "Cellulitis", "Mnemonic" : "12"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis (Outpatient)", "Text" : "Osteomyelitis", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "DECUBITUS ULCERS"}, 
{"Row" :5, "Column" : 1, "Text" : "Relieve pressure and friction, provide good nutrition, and debride the ulcer."}, 
{"Row" :7, "Column" : 1, "Text" : "Decubitus ulcers are colonized with bacteria.Antimicrobial therapy is"}, 
{"Row" :8, "Column" : 1, "Text" : "unnecessary unless the patient has infection of surrounding tissues signified by"}, 
{"Row" :9, "Column" : 1, "Text" : "erythema, warmth, local tenderness, or purulent discharge.Rectal or groin"}, 
{"Row" : 10, "Column" : 1, "Text" : "decubitus ulcers with surrounding infection need broad spectrum antimicrobials."}, 
{"Row" : 11, "Column" : 1, "Text" : "Ulcers located in other sites are usually treated with antimicrobials for"}, 
{"Row" : 12, "Column" : 1, "Text" : "staphylococci and streptococci."}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of therapy usually 7-14 days, but adjust to clinical response", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For deep abscesses away from the rectal area, obtain material for Gram stain and"}, 
{"Row" : 17, "Column" : 1, "Text" : "culture and treat with: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Treatment for Mild to Moderate Infections: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment for severe infection: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Refer to Inpatient CDSS"}, 
{"Row" : 32, "Column" : 1, "Text" : "For PERIRECTAL ABSCESSES that need a systemic antimicrobial: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the"}, 
{"Row" : 37, "Column" : 1, "Text" : "advice page for the appropriate syndrome.Contact the ET nurse, Infectious"}, 
{"Row" : 38, "Column" : 1, "Text" : "Diseases, Dietician, or Vascular surgery for more information."}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 47, "Column" : 1, "Text" : "Parish LC Dermatol Clin 2004, 22: 87"}, 
{"Row" : 48, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Text" : "Alternative for beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID X7DAYS", "DisplayText" : "Linezolid 600 mg PO BID for 7 days ($) [DI,O]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600MG PO BID 7DAYS", "DisplayText" : "Linezolid 600mg po bid for 7days ($) [DI,O]", "Text" : "Non-VA order for above", "Mnemonic" : "8b"}
]},
{"Name" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "DisplayText" : "Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "DEEP OROPHARYNGEAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Deep oropharyngeal infections may threaten life and must be treated immediately."}, 
{"Row" :6, "Column" : 1, "Text" : "Assess the risk of airway compromise and monitor the airway if it is threatened."}, 
{"Row" :7, "Column" : 1, "Text" : "These infections are more common in people with diabetes mellitus and are caused"}, 
{"Row" :8, "Column" : 1, "Text" : "by mixed organisms including streptococcus sp., Staphylococcus aureus and"}, 
{"Row" :9, "Column" : 1, "Text" : "anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases"}, 
{"Row" : 10, "Column" : 1, "Text" : "consults are essential."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "If the patient's condition worsens or does not improve during the first 48 hours"}, 
{"Row" : 14, "Column" : 1, "Text" : "of antimicrobial therapy, surgical drainage is indicated. If surgical drainage"}, 
{"Row" : 15, "Column" : 1, "Text" : "is done, antimicrobials are usually continued for 48 hours after the procedure."}, 
{"Row" : 16, "Column" : 1, "Text" : "If surgical drainage is not done, 2 weeks of antimicrobial therapy until"}, 
{"Row" : 17, "Column" : 1, "Text" : "clinical improvement is observed (e.g. resolution of fever and leukocytosis) is"}, 
{"Row" : 18, "Column" : 1, "Text" : "appropriate."}, 
{"Row" : 20, "Column" : 1, "Text" : "Empiric Treatment", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 23, "Column" : 1, "Text" : "Step-down treatment after initial intravenous therapy. Adjust duration based on", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "criteria above.", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head"}, 
{"Row" : 33, "Column" : 1, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252"}, 
{"Row" : 34, "Column" : 1, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-Date article: Submandibular space infections (Ludwig's angina)"}
]},
{"Name" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "DisplayText" : "Dermatology Infections (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU IMPETIGO", "DisplayText" : "Impetigo (Outpatient)", "Text" : "Impetigo", "Mnemonic" : "5"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU FOLLICULITIS", "DisplayText" : "Folliculitis (Outpatient)", "Text" : "Folliculitis", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas (Outpatient)", "Text" : "Erysipelas", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient)", "Text" : "Furuncles and carbuncles", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "DisplayText" : "Cellulitis (Outpatient)", "Text" : "Cellulitis", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections (Outpatient)", "Text" : "Necrotizing infections", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "DisplayText" : "Ecthyma Gangrenosum (Outpatient)", "Text" : "Ecthyma gangrenosum", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "DisplayText" : "Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient", "Text" : "Scalded Skin Syndrome", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "DisplayText" : "Hidradenitis Suppurativa (Outpatient)", "Text" : "Hidradenitis Suppurativa", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome (Outpatient)", "Text" : "Toxic Shock Syndrome", "Mnemonic" : "22"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ERYTHRASMA", "DisplayText" : "Erythrasma (Outpatient)", "Text" : "Erythrasma", "Mnemonic" : "24"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELOID", "DisplayText" : "Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient", "Text" : "Erysipeloid", "Mnemonic" : "26"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "DisplayText" : "Cat-Scratch Disease (Outpatient)", "Text" : "Cat-scratch disease", "Mnemonic" : "28"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU LEISHMANIASIS", "DisplayText" : "Leishmaniasis", "Text" : "Leishmaniasis", "Mnemonic" : "30"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "DisplayText" : "Rocky Mountain Spotted Fever (Outpatient)", "Text" : "Rocky Mountain Spotted Fever", "Mnemonic" : "32"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "DisplayText" : "Dermatology Recommendations", "Text" : "Dermatology Post-Op Infection", "Mnemonic" : "34"},
{"Row" :3, "Column" : 1, "Text" : "++DERMATOLOGICAL INFECTIONS - OUTPATIENT++", "Header" : 1}, 
{"Row" :5, "Column" : 2, "Item" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "DisplayText" : "Cutaneous Candidiasis (Outpatient)", "Text" : "Candidiasis", "Mnemonic" : "40"},
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU PARONYCHIA", "DisplayText" : "Paronychia (Outpatient)", "Text" : "Paronychia", "Mnemonic" : "42"},
{"Row" :7, "Column" : 2, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "DisplayText" : "Bed Bugs (Hemiptera) - Outpatient", "Text" : "Bed bugs (hemiptera)", "Mnemonic" : "44"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis) - Outpatient", "Text" : "Head lice (pediculosis capitis)", "Mnemonic" : "46"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "DisplayText" : "Body Lice (Pediculosis Corporis) - Outpatient", "Text" : "Body lice (pediculosis corporis)", "Mnemonic" : "48"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient", "Text" : "Pubic lice (pediculosis pubis)", "Mnemonic" : "50"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID3 GMENU SCABIES", "DisplayText" : "Scabies (Outpatient)", "Text" : "Scabies", "Mnemonic" : "52"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme disease", "Mnemonic" : "54"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "DisplayText" : "Blastomyces dermatitidis (Outpatient)", "Text" : "Blastomycosis", "Mnemonic" : "56"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU SPOROTRICHOSIS", "DisplayText" : "Sporotrichosis (Outpatient)", "Text" : "Sporotrichosis", "Mnemonic" : "58"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient)", "Text" : "Genital herpes (Outpatient)", "Mnemonic" : "60"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Text" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Mnemonic" : "62"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "DisplayText" : "Orolabial herpes (Outpatient)", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Mnemonic" : "64"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm) - Outpatient", "Text" : "Tinea capitis (ringworm)", "Mnemonic" : "66"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis)", "Text" : "Tinea unguium (onychomycosis)", "Mnemonic" : "68"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot) - Outpatient", "Text" : "Tinea pedis, Tinea corporis, Tinea cruris", "Mnemonic" : "70"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU TINEA VERSICOLOR", "DisplayText" : "Tinea Versicolor (Outpatient)", "Text" : "Tinea versicolor", "Mnemonic" : "72"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox) - Outpatient", "Text" : "Varicella/Chickenpox (primary infection)", "Mnemonic" : "74"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient", "Text" : "Zoster/Shingles (reactivation)", "Mnemonic" : "76"},
{"Row" : 17, "Column" : 2, "Text" : "Herpes simplex virus infections", "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Text" : "Tinea fungal infections", "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Text" : "Varicella-Zoster virus infections", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ABX ACNE", "DisplayText" : "Acne", "Text" : "Acne", "Mnemonic" : "3"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ABX ROSACEA", "DisplayText" : "Rosacea", "Text" : "Rosacea", "Mnemonic" : "4"}
]},
{"Name" : "ORZID3 GMENU DEVICE-RELATED INFECT", "DisplayText" : "Device-related infections (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Intravascular catheter-related infection", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Prosthetic-valve endocarditis - Empirical Therapy", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Prosthetic valve endocarditis - Selected pathogens", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "DisplayText" : "Cardiovascular Outpatient Main Page", "Text" : "Infections involving cardiovascular devices (except valves)", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "++ DEVICE-RELATED INFECTIONS ++", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "If the desired syndrome is not listed below, return to the main menu and refer"}, 
{"Row" :5, "Column" : 1, "Text" : "to the pertinent organ-system."}, 
{"Row" : 15, "Column" : 1, "Text" : "Last reviewed 11/17", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU DIARRHEA AEROMONAS", "DisplayText" : "Diarrhea with Aeromonas (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH AEROMONAS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8(94)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Aeromonas sp."}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-Date article: Aeromonas infections"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "DisplayText" : "Diarrhea with Cyclospora cayetanensis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID for 7 to 10 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CYCLOSPORA CAYETANENSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with allergy to sulfonamides."}, 
{"Row" :7, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 10, "Column" : 1, "Text" : "Antimicrobial treatment for patients without HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobial treatment for patients with HIV/AIDS", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS."}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Cyclosporiasis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-to-Date article: Cyclospora infection"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA C. PARVUM", "DisplayText" : "Diarrhea with Crytosporidium parvum (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 NITAZOXANIDE 3DS 500MG PO BID", "DisplayText" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Text" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CRYPTOSPORIDIUM PARVUM", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antibiotic therapy is usually used only for persons with severe disease or"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompromised persons."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial treatment for patients without HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobial treatment for patients with HIV/AIDS", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS."}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 21, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Cryptosporidiosis"}, 
{"Row" : 23, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of cryptosporidiosis"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "DisplayText" : "Diarrhea with Campylobacter (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CAMPYLOBACTER", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is"}, 
{"Row" :6, "Column" : 1, "Text" : "rare."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Campylobacter"}, 
{"Row" : 26, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 28, "Column" : 1, "Text" : "Campylobacter infection"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "DisplayText" : "Diarrhea with Entamoeba histolytica (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 750MG TID PAROMOMYCIN 25-35MG/KG/DAY TID", "DisplayText" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Text" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ENTAMOEBA HISTOLYTICA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary treatment for gastroenteritis", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment for gastroenteritis or extraintestinal disease", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must"}, 
{"Row" : 10, "Column" : 1, "Text" : "be order by Infectious Diseases."}, 
{"Row" : 12, "Column" : 1, "Text" : "25-35 mg/kg/day PO TID for 7 days ($) [M]"}, 
{"Row" : 14, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica"}, 
{"Row" : 17, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "DisplayText" : "Diarrhea with enterohemorrhagic E. Coli (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP RIFAXAMIN 3DS 200MG TID", "DisplayText" : "RIFAXAMIN 3DS 200MG TID", "Text" : "Rifaximin 200 mg TID for 3 days ($$) [M]", "Mnemonic" : "8a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID RIFAXAMIN 3DS 200MG TID", "DisplayText" : "Rifaximin 200 mg TID for 3 days ($$) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient)", "Text" : "Link to Shigella/Enteroinvasive E. coli menu", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH ESCHERICHIA COLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Enterotoxigenic E. coli (ETEC)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "EAEC infection can cause watery diarrhea with mucus that is occasionally bloody."}, 
{"Row" :8, "Column" : 1, "Text" : "It is more common in patients with HIV and those who have traveled to developing"}, 
{"Row" :9, "Column" : 1, "Text" : "regions. EPEC infection is associated with severe acute watery diarrhea that is"}, 
{"Row" : 10, "Column" : 1, "Text" : "occasionally bloody. ETEC infection causes acute watery diarrhea that is"}, 
{"Row" : 11, "Column" : 1, "Text" : "occasionally severe. It is most common in travelers to tropical regions who are"}, 
{"Row" : 12, "Column" : 1, "Text" : "exposed to contaminated food and water."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antibiotic therapy is not required for mild to moderate disease caused by these"}, 
{"Row" : 15, "Column" : 1, "Text" : "organisms because diarrhea often resolves on its own. Do not use antimotility"}, 
{"Row" : 16, "Column" : 1, "Text" : "agents in patients with bloody stool."}, 
{"Row" : 18, "Column" : 1, "Text" : "Primary treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial treatment of severe diarrhea"}, 
{"Row" : 25, "Column" : 1, "Text" : "Antimicrobial treatment in patients with AIDS"}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 32, "Column" : 1, "Text" : "Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "EHEC and STEC disease often presents as bloody diarrhea. It is more common in"}, 
{"Row" : 34, "Column" : 1, "Text" : "people who have consumed undercooked meats or poultry, fruits or unpasteurized"}, 
{"Row" : 35, "Column" : 1, "Text" : "fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include"}, 
{"Row" : 36, "Column" : 1, "Text" : "swimming in or drinking untreated fresh water and visiting a farm, petting zoo,"}, 
{"Row" : 37, "Column" : 1, "Text" : "healthcare facility, prison or childcare facility."}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment includes supportive measures such as volume repletion and"}, 
{"Row" : 40, "Column" : 1, "Text" : "administering appropriate nutrition. Do not use antimotility or antimicrobial"}, 
{"Row" : 41, "Column" : 1, "Text" : "agents as they can increase shiga-toxin release and increase the risk of"}, 
{"Row" : 42, "Column" : 1, "Text" : "hemolytic uremia syndrome (HUS)."}, 
{"Row" : 44, "Column" : 1, "Text" : "Enteroinvasive E. coli (EIEC)", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "EIEC disease typically presents as watery diarrhea, sometimes progressing to"}, 
{"Row" : 46, "Column" : 1, "Text" : "bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for"}, 
{"Row" : 47, "Column" : 1, "Text" : "recommendations."}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli"}, 
{"Row" : 55, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date article: Pathogenic Escherichia coli"}, 
{"Row" : 26, "Column" : 1, "Text" : "Treatment is complex, consult Infectious Diseases"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "DisplayText" : "Diarrhea with Giardia lamblia (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 NITAZOXANIDE 3DS 500MG PO BID", "DisplayText" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Text" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Mnemonic" : "4"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 5DS 250MG PO TID", "DisplayText" : "Metronidazole 250 mg PO TID for 5 ($) [DI]", "Text" : "Metronidazole 250 mg PO TID for 5 to 7 days ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 5DS 250MG PO TID", "DisplayText" : "Metronidazole 250 mg PO TID for 5 ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Illness with Giardia is typically subacute but varies widely in its time course."}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment is necessary when the patient has symptomatic disease. Diarrhea,"}, 
{"Row" :7, "Column" : 1, "Text" : "abdominal pain, bloating, belching, flatus, nausea, and vomiting are present"}, 
{"Row" :8, "Column" : 1, "Text" : "acutely and after several days give way to flatus, loose stools, belching, and"}, 
{"Row" :9, "Column" : 1, "Text" : "weight loss."}, 
{"Row" : 11, "Column" : 1, "Text" : "Asymptomatic carriage of Giardia is common in household contacts of people who"}, 
{"Row" : 12, "Column" : 1, "Text" : "are infected with Giardia. Treatment of asymptomatic patients can be considered"}, 
{"Row" : 13, "Column" : 1, "Text" : "if they have contact with immunocompromised or pregnant people or live or work"}, 
{"Row" : 14, "Column" : 1, "Text" : "in settings where there is risk of spreading infection to others (e.g., food"}, 
{"Row" : 15, "Column" : 1, "Text" : "handlers, daycare, nursing home)."}, 
{"Row" : 17, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 20, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Minetti et al, BMJ, 2016, 355.i5369"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Giardiasis: Treatment and prevention"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "DisplayText" : "Diarrhea with Isospora belli (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO BID for 7 to 10 days ($)", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "DisplayText" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Text" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "DisplayText" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg P Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO QID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO QID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "DisplayText" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Text" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Mnemonic" : "10a"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "DisplayText" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg P Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID TMP/SMX 1DS TAB PO 3X/WEEK", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 38, "Column" : 1, "Item" : "PSHZID TMP/SMX 1DS TAB PO 3X/WEEK", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 25MG PO QDAY LEUCOV PO 10MG QDAY PPX", "DisplayText" : "Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg PO QDAY ($)", "Text" : "Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg PO QDAY ($)", "Mnemonic" : "14a"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 25MG PO QDAY LEUCOV PO 10MG QDAY PPX", "DisplayText" : "Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg P Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in"}, 
{"Row" :6, "Column" : 1, "Text" : "immunocompetent persons."}, 
{"Row" :8, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial treatment of persons without HIV/AIDS", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[R,DI]"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 19, "Column" : 1, "Text" : "for 21-28 days"}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Antimicrobial treatment of persons with HIV/AIDS", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Infectious Diseases involvement is essential. Initial treatment of acute"}, 
{"Row" : 25, "Column" : 1, "Text" : "infection is followed by secondary prophylaxis until CD4 count is >200 for >6"}, 
{"Row" : 26, "Column" : 1, "Text" : "months in response to ART without evidence of active C. belli."}, 
{"Row" : 27, "Column" : 1, "Text" : "Initial treatment", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 33, "Column" : 1, "Text" : "for 21 to 28 days"}, 
{"Row" : 36, "Column" : 1, "Text" : "Secondary prophylaxis", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy"}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 48, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Cystoisospora belli"}, 
{"Row" : 50, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-to-Date article: Management of Cystoisospora (Isospora) infections"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "DisplayText" : "Diarrhea with Microsporidia (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 ALBENDAZOLE 7DS 400MG PO BID", "DisplayText" : "Albendazole 400 mg PO BID ($$) [O]", "Text" : "Albendazole 400 mg PO BID for 7 to 14 days ($$) [O]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 ALBENDAZOLE 7DS 400MG PO BID", "DisplayText" : "Albendazole 400 mg PO BID ($$) [O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID ALBENDAZOLE 400MG PO BID", "DisplayText" : "Albendazole 400 mg PO BID ($$) [O]", "Text" : "Albendazole 400 mg PO BID ($$) [O]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID ALBENDAZOLE 400MG PO BID", "DisplayText" : "Albendazole 400 mg PO BID ($$) [O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH MICROSPORIDIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "In patients without HIV/AIDs, symptoms may resolve without antimicrobial"}, 
{"Row" :6, "Column" : 1, "Text" : "therapy. In persons with AIDS, highly active anti-retroviral therapy (HAART) is"}, 
{"Row" :7, "Column" : 1, "Text" : "beneficial because recovery of host defenses helps to control microsporidial"}, 
{"Row" :8, "Column" : 1, "Text" : "disease. Infectious Diseases involvement is essential in patients with HIV/AIDS."}, 
{"Row" : 10, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 13, "Column" : 1, "Text" : "Antimicrobial treatment of persons without HIV/AIDS", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Antimicrobial treatment of persons with HIV/AIDS", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Continue treatment until CD4 count is >200 for >6 months after"}, 
{"Row" : 19, "Column" : 1, "Text" : "initiation of ART."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 27, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Microsporidiosis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date article: Microsporidiosis"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA SALMONELLA", "DisplayText" : "Diarrhea with Salmonella (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "Link to Enteric Fever Menu", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 7DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 7 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 7 days ($) [M]", "Mnemonic" : "8a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 7DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 7 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 14DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 14DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 14DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 14 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 14 days ($) [M]", "Mnemonic" : "12a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 14DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 14 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH SALMONELLA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever"}, 
{"Row" :6, "Column" : 1, "Text" : "Menu: "}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment is not recommended for mild or moderately severe disease in otherwise"}, 
{"Row" : 10, "Column" : 1, "Text" : "healthy individuals <50 years old, because the disease is self-limiting and"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials can prolong the carrier state and increase the risk of relapse."}, 
{"Row" : 12, "Column" : 1, "Text" : "By contrast, treatment should be considered for severe disease, and if the"}, 
{"Row" : 13, "Column" : 1, "Text" : "patient is > 50 years old, is immunocompromised, or has another debilitating"}, 
{"Row" : 14, "Column" : 1, "Text" : "underlying disease."}, 
{"Row" : 16, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 19, "Column" : 1, "Text" : "Antimicrobial treatment of immunocompetent patients", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones"}, 
{"Row" : 27, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 28, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 30, "Column" : 1, "Text" : "Antimicrobial treatment of immunocompromised patients", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones"}, 
{"Row" : 38, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 39, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 42, "Column" : 1, "Text" : "References: "}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Salmonella: Non-typhi"}, 
{"Row" : 45, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 46, "Column" : 1, "Text" : "Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and"}, 
{"Row" : 47, "Column" : 1, "Text" : "carriage"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "DisplayText" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Shigellosis is generally a self-limited infection lasting 5-7 days."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobial resistance is common and continues to rise for all recommended"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobials. Treatment should be reserved for patients who are"}, 
{"Row" :8, "Column" : 1, "Text" : "immunocompromised, or who develop severe illness (e.g., requiring"}, 
{"Row" :9, "Column" : 1, "Text" : "hospitalization, invasive, or with complications) or live or work in settings"}, 
{"Row" : 10, "Column" : 1, "Text" : "where there is risk of spreading infection to others (e.g., food handlers,"}, 
{"Row" : 11, "Column" : 1, "Text" : "daycare, nursing home)."}, 
{"Row" : 13, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 16, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 24, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "CDC advisory: https://emergency.cdc.gov/han/han00401.asp"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Shigella"}, 
{"Row" : 32, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Shigella infection: Treatment and prevention in adults"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "DisplayText" : "Diarrhea with Vibrio cholera (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 300MG PO ONCE", "DisplayText" : "Doxycycline 300 mg PO once ($) [DI]", "Text" : "Doxycycline 300 mg PO once ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 300MG PO ONCE", "DisplayText" : "Doxycycline 300 mg PO once ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 1000MG PO ONCE", "DisplayText" : "Ciprofloxacin 1000 mg PO once ($) [R,DI]", "Text" : "Ciprofloxacin 1000 mg PO once ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 1000MG PO ONCE", "DisplayText" : "Ciprofloxacin 1000 mg PO once ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Mnemonic" : "8a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Primary Treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Aggressive hydration and electrolyte replacement are essential"}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Tetracycline intolerant patient"}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 20, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Vibrio cholerae"}, 
{"Row" : 26, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and"}, 
{"Row" : 28, "Column" : 1, "Text" : "prevention"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "DisplayText" : "Diarrhea with non-cholera vibrio (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 3DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg BID for 3 days ($) [DI]", "Text" : "Doxycycline 100 mg BID for 3-5 days ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 3DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg BID for 3 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "NON-CHOLERA VIBRIO", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound"}, 
{"Row" :6, "Column" : 1, "Text" : "infections. Vibrio vulnificans infections are acquired from contact with"}, 
{"Row" :7, "Column" : 1, "Text" : "seawater or seafood, especially raw oysters. V. vulnificans cases are more"}, 
{"Row" :8, "Column" : 1, "Text" : "severe than cases with other species. V. parahaemolyticus causes"}, 
{"Row" :9, "Column" : 1, "Text" : "gastroenteritis and milder wound infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "Antimicrobials do not shorten the course of disease in immunocompetent patients"}, 
{"Row" : 12, "Column" : 1, "Text" : "with mild gastroenteritis."}, 
{"Row" : 14, "Column" : 1, "Text" : "Primary treatment for gastroenteritis", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 17, "Column" : 1, "Text" : "Antimicrobial treatment of minor wound infection, severe gastroenteritis or", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "immunocompromised patient with gastroenteritis", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for patient intolerant of fluoroquinolones"}, 
{"Row" : 26, "Column" : 1, "Text" : "For intravenous treatment"}, 
{"Row" : 27, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 29, "Column" : 1, "Text" : "Antimicrobial treatment of severe wound infection or septicemia", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Vibrio parahaemolyticus"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date article: Vibrio parahaemolyticus infections"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date article: Vibrio vulnificus infections"}
]},
{"Name" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "DisplayText" : "Diarrhea with Yersinia enterocolitica (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "YERSINIA ENTEROCOLITICA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobials are indicated only for patients with severe disease or immune"}, 
{"Row" :6, "Column" : 1, "Text" : "compromise. For patients with extra-intestinal disease, consult Infectious"}, 
{"Row" :7, "Column" : 1, "Text" : "Diseases or Gastroenterology for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Primary treatment of gastroenteritis", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobial treatment of severe gastroenteritis or immunocompromised patient", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for fluoroquinolone intolerant patients"}, 
{"Row" : 20, "Column" : 1, "Text" : "Antimicrobial treatment of extra-intestinal infection", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Gastroenteritis, Yersinia enterocolitica"}, 
{"Row" : 27, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and"}, 
{"Row" : 29, "Column" : 1, "Text" : "Yersinia pseudotuberculosis infection"}
]},
{"Name" : "ORZID3 GMENU DISKITIS", "DisplayText" : "Diskitis and vertebral osteomyelitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "DISKITIS AND VERTEBRAL OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU DIVERTICULITIS", "DisplayText" : "Diverticulitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7 DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]<AND>", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX NV TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AN Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days", "Text" : "Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "DisplayText" : "Moxifloxacin 400mg po qday for 7days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 7DS 500 BID METRO 7DS 1G BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Mnemonic" : "12a"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 7DS 500 BID METRO 7DS 1G BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "DIVERTICULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in"}, 
{"Row" :6, "Column" : 1, "Text" : "the colon, causing pain and disturbed bowel function."}, 
{"Row" :8, "Column" : 1, "Text" : "Mild disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative for beta-lactam allergy"}, 
{"Row" : 14, "Column" : 1, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Text" : "BID ($) [DI] for 7 to 10 days"}, 
{"Row" : 24, "Column" : 1, "Text" : "Moderate to severe disease", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Diverticulitis and Typhlitis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Diverticulitis"}, 
{"Row" : 32, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management"}
]},
{"Name" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "DisplayText" : "Ecthyma Gangrenosum (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ECTHYMA GANGRENOSUM"}, 
{"Row" :4, "Column" : 1, "Text" : "Ecthyma gangrenosum lesions commonly begin as painless red macules which"}, 
{"Row" :5, "Column" : 1, "Text" : "rapidly evolve into areas of induration that develop into pustules and-or"}, 
{"Row" :6, "Column" : 1, "Text" : "bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions"}, 
{"Row" :7, "Column" : 1, "Text" : "typically progress rapidly within 12 to 18 hours. They are often associate"}, 
{"Row" :8, "Column" : 1, "Text" : "with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients."}, 
{"Row" :9, "Column" : 1, "Text" : "Recommend blood cultures and culture of skin exudates."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Pseudomonas aeruginosa"}, 
{"Row" : 18, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 19, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID3 GMENU EMPYEMA", "DisplayText" : "Empyema (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "EMPYEMA"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU ENDOPHTHALMITIS", "DisplayText" : "Endophthalmitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "ENDOPHTHALMITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Endophthalmitis is a medical emergency and presents with eye pain and visual"}, 
{"Row" :6, "Column" : 1, "Text" : "loss. It may be associated with gram positive or gram-negative bacteria,"}, 
{"Row" :7, "Column" : 1, "Text" : "including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi."}, 
{"Row" :8, "Column" : 1, "Text" : "Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or"}, 
{"Row" :9, "Column" : 1, "Text" : "vitreous fluid sample for gram stain and culture and begin intravitreal"}, 
{"Row" : 10, "Column" : 1, "Text" : "antimicrobials."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment with intravitreal antimicrobials", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 15, "Column" : 1, "Text" : "Fungal endophthalmitis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment"}, 
{"Row" : 17, "Column" : 1, "Text" : "is complicated. Ophthalmology and Infectious Diseases involvement is essential."}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Endophthalmitis"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Endophthalmitis, Hematogenous or Endogenous"}, 
{"Row" : 25, "Column" : 1, "Text" : "Tranos et al., Advances in therapy. 2016, 33(5)727-746"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date article: Bacterial endophthalmitis"}
]},
{"Name" : "ORZID3 GMENU EPIDIDYMITIS", "DisplayText" : "Epididymitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY 10DAYS", "DisplayText" : "CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h", "Mnemonic" : "6a"},
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY 10DAYS", "DisplayText" : "CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Text" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "10a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 750MG PO QDAY", "DisplayText" : "Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 54, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days", "Mnemonic" : "12a"},
{"Row" : 55, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 DOXYC 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "14a"},
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 DOXYC 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRI 1GM IM X1 + DOXY 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]", "Text" : "Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for", "Mnemonic" : "18a"},
{"Row" : 67, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTRI 1GM IM X1 + DOXY 100MG PO BID 10D", "DisplayText" : "Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "22"},
{"Row" : 71, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($)[R,DI]", "Text" : "Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days", "Mnemonic" : "24a"},
{"Row" : 72, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" :3, "Column" : 1, "Text" : "EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Epididymitis is inflammation of the epididymis and when testicles are involved"}, 
{"Row" :6, "Column" : 1, "Text" : "is referred to as epididymo-orchitis. Acute epididymitis is the most common"}, 
{"Row" :7, "Column" : 1, "Text" : "cause of scrotal pain in adults. Other features include scrotal erythema and"}, 
{"Row" :8, "Column" : 1, "Text" : "edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually"}, 
{"Row" :9, "Column" : 1, "Text" : "unilateral. It is primarily caused by infection but can also result from trauma"}, 
{"Row" : 10, "Column" : 1, "Text" : "and autoimmune diseases. Testicular torsion should be ruled out before"}, 
{"Row" : 11, "Column" : 1, "Text" : "treatment. Most cases in men aged 35 and older, those with recent urinary tract"}, 
{"Row" : 12, "Column" : 1, "Text" : "instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated"}, 
{"Row" : 13, "Column" : 1, "Text" : "with enteric Gram-negative rods. Most cases in men under age 35 are associated"}, 
{"Row" : 14, "Column" : 1, "Text" : "with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if"}, 
{"Row" : 15, "Column" : 1, "Text" : "the patient has been in the hospital for more than 48 hours or received a course"}, 
{"Row" : 16, "Column" : 1, "Text" : "of antibiotics. There is increasing resistance in urinary pathogens to"}, 
{"Row" : 17, "Column" : 1, "Text" : "ciprofloxacin."}, 
{"Row" : 19, "Column" : 1, "Text" : "A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)"}, 
{"Row" : 20, "Column" : 1, "Text" : "should be performed in all cases of suspected epididymitis before starting"}, 
{"Row" : 21, "Column" : 1, "Text" : "treatment to guide therapy: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients at risk of sexually transmitted infections should be assessed for"}, 
{"Row" : 25, "Column" : 1, "Text" : "treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve"}, 
{"Row" : 29, "Column" : 1, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal"}, 
{"Row" : 30, "Column" : 1, "Text" : "pain and referral to a urologist should be considered."}, 
{"Row" : 32, "Column" : 1, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older men"}, 
{"Row" : 33, "Column" : 1, "Text" : "should have their residual urinary volume checked. If the residual volume is"}, 
{"Row" : 34, "Column" : 1, "Text" : "elevated, the patient should be seen by a urologist as epididymitis is unlikely"}, 
{"Row" : 35, "Column" : 1, "Text" : "to respond if the prostate is blocking the vas deferens."}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Empirical treatment in men who practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "for 10 days ($) [R, DI]"}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Empirical treatment in men who do not practice insertive anal intercourse", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Age >/= 35 years or", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "biopsy, vasectomy): ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 57, "Column" : 1, "Text" : "Age < 35 years", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Patient weighing less than 300 lbs"}, 
{"Row" : 61, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 64, "Column" : 1, "Text" : "Patients weighing 300 lbs or greater"}, 
{"Row" : 66, "Column" : 1, "Text" : "10 days"}, 
{"Row" : 69, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 73, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis"}, 
{"Row" : 78, "Column" : 1, "Text" : "Sanford keyword: Epididymo-orchitis"}, 
{"Row" : 79, "Column" : 1, "Text" : "Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3"}, 
{"Row" : 80, "Column" : 1, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults"}, 
{"Row" : 81, "Column" : 1, "Text" : "Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187"}
]},
{"Name" : "ORZID3 GMENU EPIGLOTTITIS", "DisplayText" : "Epiglottitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "EPIGLOTTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Maintaining the airway is the key to management. Call ENT service and ask them"}, 
{"Row" :6, "Column" : 1, "Text" : "to see the patient immediately. Blood cultures and epiglottal cultures (in"}, 
{"Row" :7, "Column" : 1, "Text" : "intubated patients) should be used to direct antimicrobial therapy. Empirical"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy should be initiated prior to results of cultures as infection is life"}, 
{"Row" :9, "Column" : 1, "Text" : "threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin"}, 
{"Row" : 10, "Column" : 1, "Text" : "resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)"}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 15, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Epiglottitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "Rafei et al., Pediatric Clinics 2006, 53.2, 215-242"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Epiglottitis, Supraglottis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-date article: Epiglottis (supraglottis): Management"}
]},
{"Name" : "ORZID3 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 PENICILLIN VK 10DS 250MG PO QID", "DisplayText" : "Penicillin VK 250mg po qid for 10 days", "Text" : "Penicillin VK 250 - 500 mg PO QID for 10 days($) [R]", "Mnemonic" : "4a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 PENICILLIN VK 10DS 250MG PO QID", "DisplayText" : "Penicillin VK 250mg po qid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 ERYTHROMYCIN 10DS 250MG PO QID", "DisplayText" : "Erythromycin 250mg po qid for 10 days", "Text" : "Erythromycin 250-500 mg PO QID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 ERYTHROMYCIN 10DS 250MG PO QID", "DisplayText" : "Erythromycin 250mg po qid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "ERYSIPELAS"}, 
{"Row" :4, "Column" : 1, "Text" : "In contrast to cellulitis, erysipelas has sharply demarcated borders and a"}, 
{"Row" :5, "Column" : 1, "Text" : "characteristic raised, orange-peel appearance.Most cases are associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "streptococcus.In a minority of cases, especially those involving the face,"}, 
{"Row" :7, "Column" : 1, "Text" : "Staphylococcus aureus is also a potential pathogen.In severe cases,"}, 
{"Row" :8, "Column" : 1, "Text" : "methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided"}, 
{"Row" :9, "Column" : 1, "Text" : "until microbiology results are available."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 5 to 10days, longer if patient is bacteremic."}, 
{"Row" : 12, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Facial", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Sudden onset of rapidly spreading red edematous tender plaque-like skin on"}, 
{"Row" : 16, "Column" : 1, "Text" : "face in an otherwise healthy host."}, 
{"Row" : 17, "Column" : 1, "Text" : "If erysipelas-like on the face treat as if MRSA is present: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 20, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Non-facial", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "_________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "MILD TO MODERATE disease", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "SEVERE disease", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 38, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Erysipelas"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID3 GMENU ERYSIPELOID", "DisplayText" : "Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 7DS 500MG PO QID", "DisplayText" : "Penicillin V 500mg po qid for 7 days", "Text" : "Penicillin V 500 mg PO QID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 7DS 500MG PO QID", "DisplayText" : "Penicillin V 500mg po qid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 ERYTHROMYCIN 7DS 500MG PO QID", "DisplayText" : "Erythromycin 500mg po qid for 7 days", "Text" : "Erythromycin 500 mg PO QID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 ERYTHROMYCIN 7DS 500MG PO QID", "DisplayText" : "Erythromycin 500mg po qid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)"}, 
{"Row" :4, "Column" : 1, "Text" : "Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae"}, 
{"Row" :5, "Column" : 1, "Text" : "It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by"}, 
{"Row" :6, "Column" : 1, "Text" : "direct animal contact, most commonly with fish, but also with other animals"}, 
{"Row" :7, "Column" : 1, "Text" : "(e.g., swine). It usually affects the hand or fingers and is characterized"}, 
{"Row" :8, "Column" : 1, "Text" : "throbbing pain and a red rash with a purple center and an elevated border."}, 
{"Row" :9, "Column" : 1, "Text" : "Localized infections can be treated with oral antimicrobials."}, 
{"Row" : 11, "Column" : 1, "Text" : "Severe, diffuse cutaneous infections or systemic infections with E."}, 
{"Row" : 12, "Column" : 1, "Text" : "rhusopathiae occur rarely after ingestion of undercooked pork or contaminated"}, 
{"Row" : 13, "Column" : 1, "Text" : "seafood in immunosuppressed individuals.These infections are treated"}, 
{"Row" : 14, "Column" : 1, "Text" : "initially with intravenous antimicrobials."}, 
{"Row" : 16, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of localized infection (erysipeloid)", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "_____________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "___________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of systemic or severe diffuse cutaneous infection with E.", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "rhusopathiae", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "___________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Erysipelothrix"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 38, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 39, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}
]},
{"Name" : "ORZID3 GMENU ERYTHRASMA", "DisplayText" : "Erythrasma (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CLINDAM 1% TOP SOLN BID 14DAYS", "DisplayText" : "Clindamycin 1% topical solution bid for 14 days", "Text" : "Clindamycin 1% topical solution apply twice daily ($) [M]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CLINDAM 1% TOP SOLN BID 14DAYS", "DisplayText" : "Clindamycin 1% topical solution bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CLARITHROMYCIN 500 MG PO BID 14DAYS", "DisplayText" : "Clarithromycin 500 mg po bid ($) [DI]", "Text" : "Clarithromycin 500 mg PO bid ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CLARITHROMYCIN 500 MG PO BID 14DAYS", "DisplayText" : "Clarithromycin 500 mg po bid ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "ERYTHRASMA"}, 
{"Row" :4, "Column" : 1, "Text" : "Erythrasma presents as brownish-red, well circumscribed, irregularly shaped"}, 
{"Row" :5, "Column" : 1, "Text" : "patches in or near skin folds.Patches in the groin often itch."}, 
{"Row" :7, "Column" : 1, "Text" : "Most cases respond to topical therapy.Systemic antibiotics are used for more"}, 
{"Row" :8, "Column" : 1, "Text" : "severe cases or those that do not respond to topical therapy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: erythrasma"}, 
{"Row" : 24, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 25, "Column" : 1, "Text" : "Holdiness MR Drugs 2002, 62:1131"}
]},
{"Name" : "ORZID3 GMENU FEVER OF UNKNOWN ORIGIN", "DisplayText" : "Fever of Unknown Origin (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)", "Text" : "NEUTROPENIC FEVER", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "FEVER OF UNKNOWN ORIGIN", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fever of unknown origin (FUO) is the occurrence of several episodes of fever"}, 
{"Row" :6, "Column" : 1, "Text" : "greater than 101 degrees Fahrenheit over a time period of at least 3 weeks"}, 
{"Row" :7, "Column" : 1, "Text" : "despite 1 week of hospital evaluation. Cases with FUO are often classified in"}, 
{"Row" :8, "Column" : 1, "Text" : "four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever"}, 
{"Row" :9, "Column" : 1, "Text" : "in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated"}, 
{"Row" : 10, "Column" : 1, "Text" : "in patients with FUO."}, 
{"Row" : 12, "Column" : 1, "Text" : "Note that FUO in neutropenic patients refers to persistent fever that has"}, 
{"Row" : 13, "Column" : 1, "Text" : "remained undiagnosed after extensive diagnostic work and empirical antimicrobial"}, 
{"Row" : 14, "Column" : 1, "Text" : "therapy. New fever in patients with profound neutropenia is a different"}, 
{"Row" : 15, "Column" : 1, "Text" : "syndrome and does require empirical antimicrobial therapy. Infectious Diseases"}, 
{"Row" : 16, "Column" : 1, "Text" : "should be involved in any case where empirical treatment for fever of unknown"}, 
{"Row" : 17, "Column" : 1, "Text" : "origin is being considered."}, 
{"Row" : 22, "Column" : 1, "Text" : "References"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell Chapter: Fever of Unknown Origin"}
]},
{"Name" : "ORZID3 GMENU FIRST RECURRENCE ABX ASSOCIATED COLITIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin capsule taper and pulse", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Mnemonic" : "10a"},
{"Row" :8, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if"}, 
{"Row" :9, "Column" : 1, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 11, "Column" : 1, "Text" : "First Recurrence CDI: *The REGIMEN should be different from initial treatment*", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and"}, 
{"Row" : 40, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 35, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 36, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" :5, "Column" : 1, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory"}, 
{"Row" :6, "Column" : 1, "Text" : "confirmed case of CDI within 12 weeks after a prior episode."}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200 MG EXTENDED-PULSE REGIMEN", "DisplayText" : "Fidaxomicin 200mg Extended-pulse regimen ($$$$) [M]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 17, "Column" : 1, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)"}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG EXTENDED PULSE REGIMEN", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "6b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "DisplayText" : "Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "DisplayText" : "Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID VANCOMYCIN 125MG CAP QID 10DS", "DisplayText" : "Vancomycin 125 mg PO QID for 10 days ($) [M]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID VANCOMYCIN 125MG CAP QID 10DS", "DisplayText" : "Vancomycin 125 mg PO QID for 10 days ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin capsule taper and pulse Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with"}, 
{"Row" : 25, "Column" : 1, "Text" : "125 mg po bid for 7 days, then 125mg po qday for 7 days, then"}, 
{"Row" : 26, "Column" : 1, "Text" : "125mg every other day for 6 weeks)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Fulminant CDI: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FIRST RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU FOLLICULITIS", "DisplayText" : "Folliculitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MUPIROCIN 2% OINT TOP TO AFFECT AREA TID 7DS", "DisplayText" : "Mupirocin 2% ointment topical to affected area TID for 7 days ($) [M]", "Text" : "Mupirocin 2% ointment topical to affected area TID for 7 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MUPIROCIN 2% OINT TOP TO AFFECT AREA TID 7DS", "DisplayText" : "Mupirocin 2% ointment topical to affected area TID for 7 days ($ Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "Text" : "Clotrimazole cream to affected area TID for 7 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "FOLLICULITIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Folliculitis is an infection of the hair follicle with purulent exudate in the"}, 
{"Row" :5, "Column" : 1, "Text" : "epidermis. It is usually associated with Staphylococcus aureus.In patients"}, 
{"Row" :6, "Column" : 1, "Text" : "exposed to swimming pools or hot tubs, folliculitis may be associated with"}, 
{"Row" :7, "Column" : 1, "Text" : "Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients"}, 
{"Row" :8, "Column" : 1, "Text" : "receiving antimicrobials and/or corticosteroids. For folliculitis in patients"}, 
{"Row" :9, "Column" : 1, "Text" : "with severe acne, consult Dermatology.For extensive folliculitis or in"}, 
{"Row" : 10, "Column" : 1, "Text" : "patients with HIV, consult Infectious Diseases."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Usually self-limiting. For most cases, treat with daily saline compresses until"}, 
{"Row" : 14, "Column" : 1, "Text" : "symptoms resolve."}, 
{"Row" : 16, "Column" : 1, "Text" : "For moderate to severe cases associated with Staphylococcus aureus: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "For cases associated with Candida albicans", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Folliculitis"}
]},
{"Name" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCERS W/O INFECT SURR TISS", "DisplayText" : "Foot ulcers WITHOUT infection of surrounding tissues (Outpatient)", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCERS W/ INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITH infection of surrounding tissues (Outpatient)", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS"}, 
{"Row" :5, "Column" : 1, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria."}, 
{"Row" :6, "Column" : 1, "Text" : "Antimicrobials should not be used to treat colonization."}, 
{"Row" :8, "Column" : 1, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local"}, 
{"Row" :9, "Column" : 1, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain"}, 
{"Row" : 10, "Column" : 1, "Text" : "may not be present in patients with neuropathy.In patients with substantial"}, 
{"Row" : 11, "Column" : 1, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues"}, 
{"Row" : 12, "Column" : 1, "Text" : "will be dusky, mottled, or cool.Capillary refill may be impaired.Patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "with diabetes and ulcers are at risk for gangrenous infections.If there is any"}, 
{"Row" : 14, "Column" : 1, "Text" : "suggestion of gangrene, consult surgery immediately."}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 23, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}
]},
{"Name" : "ORZID3 GMENU FOOT ULCERS W/ INFECT SURR TISSUES", "DisplayText" : "Foot ulcers WITH infection of surrounding tissues (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Mnemonic" : "14a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES"}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of therapy: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation."}, 
{"Row" :9, "Column" : 1, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved."}, 
{"Row" : 10, "Column" : 1, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe."}, 
{"Row" : 11, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "___________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Mild: ulcer with superficial inflammation", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks"}, 
{"Row" : 18, "Column" : 1, "Text" : "Oral therapy, no MRSA coverage: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Oral therapy, MRSA coverage: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Moderate: Ulcer with inflammation, extension into fascia", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks"}, 
{"Row" : 38, "Column" : 1, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen"}, 
{"Row" : 39, "Column" : 1, "Text" : "is reasonable following clinical improvement."}, 
{"Row" : 41, "Column" : 1, "Text" : "Oral therapy with MRSA coverage: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Regimens for MODERATE intravenous therapy or SEVERE infections: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 54, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 14DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>", "Mnemonic" : "18a"},
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX CLAV 875 + DOXY 14DAYS", "DisplayText" : "Amoxicillin-clavulanate 875 mg po BID ($) [R] <AND> Doxycycline", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline", "Mnemonic" : "20a"},
{"Row" : 47, "Column" : 1, "Text" : "100 mg PO BID for 14 days ($) [DI]"}, 
{"Row" : 43, "Column" : 1, "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]"}, 
{"Row" : 36, "Column" : 1, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial"}, 
{"Row" : 37, "Column" : 1, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data."}, 
{"Row" : 55, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID 14D+DOXY 100MG BID 14D", "DisplayText" : "Amoxicillin-clavulanate 875/125mg bid x14days + Doxycycline 100mg bid x14days", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID + TRIMETH SULF BID 14DAYS", "DisplayText" : "Amoxicillin-clav 875/125 bid x14days +Trimeth-sulfa bid 14days", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "DisplayText" : "Approach to foot ulcers with infection", "Text" : "", "Mnemonic" : "4"}
]},
{"Name" : "ORZID3 GMENU FOOT ULCERS W/O INFECT SURR TISS", "DisplayText" : "Foot ulcers WITHOUT infection of surrounding tissues (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES"}, 
{"Row" :5, "Column" : 1, "Text" : "Clinically uninfected wounds do not need antibiotic treatment."}, 
{"Row" :6, "Column" : 1, "Text" : "Topical antimicrobials are not helpful, are associated with allergic reactions,"}, 
{"Row" :7, "Column" : 1, "Text" : "and select for resistant organisms.In general, local treatment should consist"}, 
{"Row" :8, "Column" : 1, "Text" : "of dressings with frequent changes, soaks, and debridement. Patients with"}, 
{"Row" :9, "Column" : 1, "Text" : "edema or impaired venous return should keep the limb elevated.Wound care and"}, 
{"Row" : 10, "Column" : 1, "Text" : "improved control of diabetes can improve outcomes of infection and prevent"}, 
{"Row" : 11, "Column" : 1, "Text" : "future complications."}, 
{"Row" : 14, "Column" : 1, "Text" : "References: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147"}, 
{"Row" : 16, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132"}
]},
{"Name" : "ORZID3 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "FUNGAL SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Fungal sinusitis mainly affects immunocompromised patients, but occasionally it"}, 
{"Row" :6, "Column" : 1, "Text" : "occurs in immunocompetent hosts. Drainage is essential. Consult ENT and"}, 
{"Row" :7, "Column" : 1, "Text" : "Infectious Disease."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "References: "}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Up-to-Date article: Fungal rhinosinusitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}
]},
{"Name" : "ORZID3 GMENU FUNGI", "DisplayText" : "Fungi (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "DisplayText" : "Aspergillus spp. (Outpatient)", "Text" : "Aspergillus and other moulds", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "DisplayText" : "Blastomyces dermatitidis (Outpatient)", "Text" : "Blastomyces dermatitidis", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Candida albicans", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. GLABRATA", "DisplayText" : "Candida glabrata (Outpatient)", "Text" : "Candida glabrata", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. KRUSEI", "DisplayText" : "Candida krusei (Outpatient)", "Text" : "Candida krusei", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "DisplayText" : "Coccidioidomyces (Outpatient)", "Text" : "Coccidioidomyces", "Mnemonic" : "14"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "DisplayText" : "Cyptococcus Neoformans (outpatient)", "Text" : "Cryptococcus neoformans", "Mnemonic" : "16"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "DisplayText" : "Histoplasma capsulatum (Outpatient)", "Text" : "Histoplasma capsulatum", "Mnemonic" : "18"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient)", "Text" : "Pneumocystis (considered a fungus)", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "++ FUNGI ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome section for more information."}, 
{"Row" : 22, "Column" : 1, "Text" : "Last reviewed 8/18", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "DisplayText" : "Aspergillus spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "ASPERGILLUS SPECIES", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Mild/moderate disease: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative treatment: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 26, "Column" : 1, "Text" : "Consult Infectious Disease for alternative."}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Patterson TF, et al. Clin Infect Dis. (2016) 63(4):433-442"}, 
{"Row" :4, "Column" : 1, "Text" : "-Aspergillus species are ubiquitous, but invasive aspergillosis occurs primarily"}, 
{"Row" :5, "Column" : 1, "Text" : "in immunocompromised hosts. Neutropenia and glucocorticoid use are the most"}, 
{"Row" :6, "Column" : 1, "Text" : "common predisposing factors. Optimal management involves early diagnosis and"}, 
{"Row" :7, "Column" : 1, "Text" : "early initiation of antifungal treatment."}, 
{"Row" : 30, "Column" : 1, "Text" : "UpToDate: Treatment and prevention of invasive aspergillosis"}, 
{"Row" :8, "Column" : 1, "Text" : "-The most common clinical manifestation of invasive aspergillosis is pulmonary"}, 
{"Row" :9, "Column" : 1, "Text" : "disease, but other manifestations include central nervous system infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : "rhinosinusitis, endocarditis, gastrointestinal disease, annd others."}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of therapy should be a minimum of 6 to 12 weeks, although duration"}, 
{"Row" : 14, "Column" : 1, "Text" : "is highly dependent on degree/duration of immunosuppression, disease site, and"}, 
{"Row" : 15, "Column" : 1, "Text" : "and evidence of disease improvement. Consult Infectious Disease."}, 
{"Row" : 17, "Column" : 1, "Text" : "Severe disease: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to Inpatient CDSS for treatment."}
]},
{"Name" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "DisplayText" : "Blastomyces dermatitidis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200BID", "DisplayText" : "Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6-12 months", "Text" : "Itraconazole 200 mg PO TID for 3 days then BID ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200BID", "DisplayText" : "Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6- Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "BLASTOMYCES DERMATITIDIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be"}, 
{"Row" :6, "Column" : 1, "Text" : "required in immunosuppressed patients if immunosuppression cannot be reversed."}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Disease outside of the central nervous system", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for 6-12 months. It is recommended that immunocompromised patients be"}, 
{"Row" : 15, "Column" : 1, "Text" : "treated with at least 1-2 weeks of intravenous treatment and a total treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "duration of 12 months."}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 25, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Central nervous system infection", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 35, "Column" : 1, "Text" : "Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Blastomycosis"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-Date article: Treatment of blastomycosis"}
]},
{"Name" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "DisplayText" : "Clotrimazole troche 10 mg PO 5X/day ($) [M] for 7 days", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "DisplayText" : "Clotrimazole troche 10 mg PO 5X/day ($) [M] for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 200MG PO QDAY 7DS", "DisplayText" : "Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI]", "Text" : "Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 200MG PO QDAY 7DS", "DisplayText" : "Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "DisplayText" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]", "Text" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "DisplayText" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 47, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 800MG PO ONCE THEN 400MG PO QDAY", "DisplayText" : "Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI]", "Text" : "Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 48, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 800MG PO ONCE THEN 400MG PO QDAY", "DisplayText" : "Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA ALBICANS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Avoid using fluconazole empirically to treat candidal infections in patients who"}, 
{"Row" :6, "Column" : 1, "Text" : "have received an imidazole in the previous year."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of thrush or oropharyngeal candidiasis", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white"}, 
{"Row" : 10, "Column" : 1, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with"}, 
{"Row" : 11, "Column" : 1, "Text" : "dentures), or as pseudomembranes."}, 
{"Row" : 12, "Column" : 1, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult MRTC"}, 
{"Row" : 13, "Column" : 1, "Text" : "clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for"}, 
{"Row" : 14, "Column" : 1, "Text" : "more information on treatment of recurrent infection."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild disease"}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "Moderate to severe disease"}, 
{"Row" : 27, "Column" : 1, "Text" : "Esophageal candidiasis", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Esophageal infection requires systemic therapy."}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative for patient who cannot swallow tablets"}, 
{"Row" : 35, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 37, "Column" : 1, "Text" : "Systemic candidal infection", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Fluconazole is preferred empirical therapy in most cases. Amphotericin B should"}, 
{"Row" : 39, "Column" : 1, "Text" : "be used empirically in patients who have received an azole antifungal drug"}, 
{"Row" : 40, "Column" : 1, "Text" : "recently, or in patients who are critically ill."}, 
{"Row" : 42, "Column" : 1, "Text" : "Duration of antimicrobial therapy"}, 
{"Row" : 43, "Column" : 1, "Text" : "Duration of therapy is dependent upon location, severity of infection,"}, 
{"Row" : 44, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 46, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 49, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 52, "Column" : 1, "Text" : "Recent azole antifungal treatment"}, 
{"Row" : 53, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 56, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 59, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "DisplayText" : "Nystatin swish and swallow QID ($) [M] for 7 days", "Text" : "Nystatin swish and swallow QID for 7-14 days ($) [M]", "Mnemonic" : "3a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "3b"}
]},
{"Name" : "ORZID3 GMENU FUNGI C. GLABRATA", "DisplayText" : "Candida glabrata (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA GLABRATA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. glabrata is often resistant to fluconazole and occasionally has some degree"}, 
{"Row" :6, "Column" : 1, "Text" : "of resistance to amphotericin. Higher doses of amphotericin are recommended due"}, 
{"Row" :7, "Column" : 1, "Text" : "to delayed killing effects against Candida glabrata."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 11, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for susceptible isolates", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 26, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}
]},
{"Name" : "ORZID3 GMENU FUNGI C. KRUSEI", "DisplayText" : "Candida krusei (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "DisplayText" : "Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CANDIDA KRUSEI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "C. krusei is resistant to fluconazole, and often has some degree of resistance"}, 
{"Row" :6, "Column" : 1, "Text" : "to amphotericin. Higher doses of amphotericin are recommended for treatment of"}, 
{"Row" :7, "Column" : 1, "Text" : "C. krusei due to decreased susceptibility."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 11, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options."}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Candida Species"}, 
{"Row" : 26, "Column" : 1, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults"}
]},
{"Name" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "DisplayText" : "Coccidioidomyces (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200MG PO BID", "DisplayText" : "Itraconazole 200mg po bid", "Text" : "Itraconazole 200 mg PO BID ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200MG PO BID", "DisplayText" : "Itraconazole 200mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday ($) [R,DI]", "Text" : "Fluconazole 400 mg PO QDay ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "COCCIDIOIDOMYCES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pulmonary and Infectious Diseases consultations are essential for diagnosis and"}, 
{"Row" :6, "Column" : 1, "Text" : "treatment."}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate disease", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Observation alone is indicated for some cases. Consult Infectious Diseases for"}, 
{"Row" : 14, "Column" : 1, "Text" : "more information. If antifungal treatment is indicated: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 24, "Column" : 1, "Text" : "Severe disease (diffuse pneumonia, rapid progression or central nervous system", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "infection)", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell Chapter: Coccidioidomycosis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford guide keyword: Coccidioidomycosis"}
]},
{"Name" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "DisplayText" : "Cyptococcus Neoformans (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday ($) [R,DI]", "Text" : "Fluconazole 400 mg PO QDay ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200MG PO BID", "DisplayText" : "Itraconazole 200mg po bid", "Text" : "Itraconazole 200 mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200MG PO BID", "DisplayText" : "Itraconazole 200mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CRYPTOCOCCUS NEOFORMANS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases."}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of therapy is dependent upon location and severity of infection,"}, 
{"Row" :9, "Column" : 1, "Text" : "and response to therapy. Consult Infectious Diseases for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate infection outside of the central nervous system", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "or step-down treatment once disease has stabilized", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 19, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of central nervous system infection or severe infection outside", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "central nervous system", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus"}, 
{"Row" : 29, "Column" : 1, "Text" : "gattii)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Cryptococcus"}
]},
{"Name" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "DisplayText" : "Histoplasma capsulatum (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "HISTOPLASMA CAPSULATUM", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Mnemonic" : "4"},
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Mnemonic" : "16a"},
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "DisplayText" : "Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 44, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "18a"},
{"Row" : 45, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :3, "Column" : 1, "Text" : "FURUNCLES AND CARBUNCLES"}, 
{"Row" :5, "Column" : 1, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous"}, 
{"Row" :6, "Column" : 1, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a"}, 
{"Row" :7, "Column" : 1, "Text" : "inflamed nodule that usually develops as a complication of folliculitis. A"}, 
{"Row" :8, "Column" : 1, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous"}, 
{"Row" :9, "Column" : 1, "Text" : "tissue.Contact a wound care nurse for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous"}, 
{"Row" : 12, "Column" : 1, "Text" : "abscesses, and large furuncles."}, 
{"Row" : 14, "Column" : 1, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct"}, 
{"Row" : 15, "Column" : 1, "Text" : "to incision and drainage should be made based on the presence of systemic"}, 
{"Row" : 16, "Column" : 1, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired"}, 
{"Row" : 17, "Column" : 1, "Text" : "host defenses."}, 
{"Row" : 19, "Column" : 1, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "recommended consider a decolonization regimen.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Mild infection: Purulent infection without systemic signs of infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Recommend incision and drainage. No antibiotic indicated."}, 
{"Row" : 26, "Column" : 1, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Recommend incision and drainage. Culture material and use results to guide"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy."}, 
{"Row" : 29, "Column" : 1, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time."}, 
{"Row" : 31, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Alternatives", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Severe Infections: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Patients who have failed incision and drainage along with oral antibiotics"}, 
{"Row" : 51, "Column" : 1, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished"}, 
{"Row" : 52, "Column" : 1, "Text" : "neutrophil function."}, 
{"Row" : 53, "Column" : 1, "Text" : "See Inpatient Antimicrobial CDSS"}, 
{"Row" : 55, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 57, "Column" : 1, "Text" : "Sanford keyword: Furuncle, carbuncle"}, 
{"Row" : 58, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 59, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "DisplayText" : "Cefadroxil 1000 mg PO bid ($) [R]", "Text" : "", "Mnemonic" : "8A"},
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 5DAYS", "DisplayText" : "Linezolid 600 mg PO BID for 5 days ($) [DI,O]", "Text" : "", "Mnemonic" : "20a"},
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600 MG PO BID 5DAYS", "DisplayText" : "Linezolid 600 mg PO bid for 5 days ($) [DI,O]", "Text" : "Non-VA order for above", "Mnemonic" : "20b"}
]},
{"Name" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "DisplayText" : "Gastrointestinal (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Hepatic abscess", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)", "Text" : "Intraabdominal abscess", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)", "Text" : "Intraperitoneal abscess", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "DisplayText" : "Perianal/Anorectal Abscess", "Text" : "Perirectal/Anorectal abscess", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "DisplayText" : "Appendicitis without perforation (Outpatient)", "Text" : "Appendicitis without perforation", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "DisplayText" : "Appendicitis with perforation (Outpatient)", "Text" : "Appendicitis with perforation", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU CHOLECYSTITIS", "DisplayText" : "Cholecystitis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "16"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU CHOLANGITIS", "DisplayText" : "Cholangitis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Mild to moderate disease", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "DisplayText" : "Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)", "Text" : "Severe/life-threatening disease", "Mnemonic" : "22"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "24"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU DIVERTICULITIS", "DisplayText" : "Diverticulitis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "26"},
{"Row" :3, "Column" : 1, "Text" : "++ GASTROINTESTINAL ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Abscess", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Appendicitis", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Cholecystitis", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Cholangitis", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Clostridium difficile disease", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "(shock, ileus and megacolon)"}, 
{"Row" : 29, "Column" : 1, "Text" : "Diarrhea, infectious", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Diverticulitis", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "DisplayText" : "Enteric Fever", "Text" : "[click here]", "Mnemonic" : "28"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection (Outpatient)", "Text" : "[click here]", "Mnemonic" : "32"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A", "Text" : "Hepatitis A", "Mnemonic" : "34"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B", "Text" : "Hepatitis B", "Mnemonic" : "36"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C", "Text" : "Hepatitis C", "Mnemonic" : "38"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU TYPHLITIS", "DisplayText" : "Neutropenic enterocolitis (Typhlitis) - Outpatient", "Text" : "[click here]", "Mnemonic" : "40"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU PANCREATITIS", "DisplayText" : "Pancreatitis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "42"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Acute Spontaneous Bacterial Peritonitis (SBP)", "Mnemonic" : "44"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "DisplayText" : "Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...", "Text" : "Peritonitis associated with", "Mnemonic" : "46"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)", "Text" : "Secondary peritonitis", "Mnemonic" : "48"},
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "[click here]", "Mnemonic" : "50"},
{"Row" : 12, "Column" : 2, "Text" : "Helicobacter pylori infection", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : "Hepatitis", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Neutropenic enterocolitis", "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Text" : "(Typhlitis)", "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Text" : "Pancreatitis", "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Text" : "Peritonitis", "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Text" : "peritoneal dialysis"}, 
{"Row" : 33, "Column" : 2, "Text" : "Thrush", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "[click here]", "Mnemonic" : "15"},
{"Row" : 15, "Column" : 1, "Text" : "Asplenia (Vaccines/Abx Prophylaxsis)", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Esophagitis", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "DisplayText" : "Esophagitis (outpatient)", "Text" : "Other", "Mnemonic" : "30"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Candidal", "Mnemonic" : "29"},
{"Row" :5, "Column" : 2, "Text" : "Enteric fever", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R]", "Text" : "Acyclovir 400 mg PO TID for 7-10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Text" : "Valacyclovir 1 gm PO BID for 7-10 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 5 days", "Text" : "Acyclovir 400 mg PO TID for 5 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 2DS 800MG PO TID", "DisplayText" : "Acyclovir 800mg po tid for 2 days", "Text" : "Acyclovir 800 mg PO TID for 2 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 2DS 800MG PO TID", "DisplayText" : "Acyclovir 800mg po tid for 2 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID VALACYCLOVIR 3DS 500MG PO BID", "DisplayText" : "Valacyclovir 500mg po bid for 3 days", "Text" : "Valacyclovir 500 mg PO BID for 3 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID VALACYCLOVIR 3DS 500MG PO BID", "DisplayText" : "Valacyclovir 500mg po bid for 3 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 10DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 10 days", "Text" : "Acyclovir 400 mg PO TID ($) [R]", "Mnemonic" : "14a"},
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 10DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 62, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 10DS 1GM PO BID", "DisplayText" : "Valacyclovir 1gm po bid for 10 days", "Text" : "Valacyclovir 1 gm PO BID ($) [R]", "Mnemonic" : "16a"},
{"Row" : 63, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 10DS 1GM PO BID", "DisplayText" : "Valacyclovir 1gm po bid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 79, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 1YR 400MG PO BID", "DisplayText" : "Acyclovir 400mg po bid for 1 year", "Text" : "Acyclovir 400 mg PO BID ($) [R]", "Mnemonic" : "18a"},
{"Row" : 80, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 1YR 400MG PO BID", "DisplayText" : "Acyclovir 400mg po bid for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 83, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year", "Text" : "Valacyclovir 500 mg PO QDay ($) [R]", "Mnemonic" : "20a"},
{"Row" : 84, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 87, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 1000MG PO QDAY", "DisplayText" : "Valacyclovir 1000mg po qday for 1 year", "Text" : "Valacyclovir 1000 mg PO QDay ($) [R]", "Mnemonic" : "22a"},
{"Row" : 88, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 1000MG PO QDAY", "DisplayText" : "Valacyclovir 1000mg po qday for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" :3, "Column" : 1, "Text" : "GENITAL HERPES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment of the initial episode decreases the duration of pain, lesions, and"}, 
{"Row" : 13, "Column" : 1, "Text" : "viral shedding by 1 to 2 days. Treatment of the initial episode does not"}, 
{"Row" : 14, "Column" : 1, "Text" : "decrease likelihood of recurrent episodes."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 23, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Episodic therapy for relapses", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment of recurrent episodes must be started within 24 hours of symptom"}, 
{"Row" : 29, "Column" : 1, "Text" : "onset. Treatment decreases the duration of pain and lesions, and viral shedding"}, 
{"Row" : 30, "Column" : 1, "Text" : "by 1 to 2 days. Consider suppressive treatment for patients with more than 6"}, 
{"Row" : 31, "Column" : 1, "Text" : "episodes per year."}, 
{"Row" : 34, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 41, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Immunocompromised patients in whom genital herpes simplex disease is often"}, 
{"Row" : 47, "Column" : 1, "Text" : "severe include: patients with HIV infection, organ transplants, malnourishment,"}, 
{"Row" : 48, "Column" : 1, "Text" : "eczema or severe burns, and in patients receiving immunosuppressive"}, 
{"Row" : 49, "Column" : 1, "Text" : "chemotherapy."}, 
{"Row" : 51, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Treat mild to moderate disease for 10 days. In severe disease, treat with"}, 
{"Row" : 53, "Column" : 1, "Text" : "intravenous acyclovir for 2 to 7 days based on clinical response, then treat"}, 
{"Row" : 54, "Column" : 1, "Text" : "with an oral antiviral for a total duration of 10 days."}, 
{"Row" : 56, "Column" : 1, "Text" : "Treatment for mild to moderate disease or after clinical improvement of severe", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "disease", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 65, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "Infectious Diseases consult encouraged."}, 
{"Row" : 67, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 69, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Text" : "Chronic suppressive therapy", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "Suppressive therapy is indicated in patients with more than 6 episodes per year."}, 
{"Row" : 75, "Column" : 1, "Text" : "Suppressive therapy is optional, and some patients may find episodic treatment"}, 
{"Row" : 76, "Column" : 1, "Text" : "more convenient. The frequency of recurrences usually decreases after 1 to 5"}, 
{"Row" : 77, "Column" : 1, "Text" : "years, and suppressive therapy should be stopped every few years to see if it is"}, 
{"Row" : 78, "Column" : 1, "Text" : "still needed."}, 
{"Row" : 82, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 86, "Column" : 1, "Text" : "For a patient with more than 9 episodes per year", "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Text" : "References: "}, 
{"Row" : 93, "Column" : 1, "Text" : "Center for Disease Control. MMWR 55(RR 11) 1-94"}, 
{"Row" : 94, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 95, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"}
]},
{"Name" : "ORZID3 GMENU GENITOURINARY", "DisplayText" : "Genitourinary (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ABX APPROACH TO UTI", "DisplayText" : "APPROACH TO URINARY TRACT INFECTION (UTI)", "Text" : "Approach to Urinary Tract Infection (UTI)", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic bacteriuria (Outpatient)", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "DisplayText" : "Candida Urinary Tract Infections", "Text" : "Candida Urinary Tract Infection", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient)", "Text" : "Complicated cystitis", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient)", "Text" : "Pyelonephritis", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient)", "Text" : "Uncomplicated cystitis", "Mnemonic" : "14"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "DisplayText" : "Acute bacterial prostatitis (Outpatient)", "Text" : "Acute bacterial prostatitis", "Mnemonic" : "16"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ABX BALANITIS", "DisplayText" : "Balanitis and Balanoposthitis", "Text" : "Balanitis and Balanoposthitis", "Mnemonic" : "18"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "DisplayText" : "Chronic bacterial prostatitis (Outpatient)", "Text" : "Chronic bacterial prostatitis", "Mnemonic" : "20"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "DisplayText" : "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)", "Text" : "Chronic prostatitis/Chronic pelvic pain syndrome", "Mnemonic" : "22"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "DisplayText" : "Epididymitis (Outpatient)", "Text" : "Epididymitis and Epididymo-Orchitis", "Mnemonic" : "24"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Urethritis", "Mnemonic" : "26"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "DisplayText" : "Bacterial vaginosis (Outpatient)", "Text" : "Bacterial vaginosis", "Mnemonic" : "28"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "DisplayText" : "Candida vulvo-vaginitis (Outpatient)", "Text" : "Candida vulvovaginitis", "Mnemonic" : "30"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Cervicitis", "Mnemonic" : "32"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "34"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Trichomonas vaginitis", "Mnemonic" : "36"},
{"Row" :3, "Column" : 1, "Text" : "++ GENITOURINARY ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Urinary tract infections", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Bacteremia/sepsis urinary tract source - refer to Inpt CDSS"}, 
{"Row" : 14, "Column" : 1, "Text" : "Male specific infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Female specific Infections", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Last updated July 2022", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Cervicitis", "Mnemonic" : "2"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Epididymitis", "Mnemonic" : "4"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Genital Herpes", "Mnemonic" : "6"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Gonorrhea infection with/without Chlamydia", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Syphilis", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Trichomonas Vaginitis", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Urethritis", "Mnemonic" : "18"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections (Outpatient)", "Text" : "Necrotizing infection", "Mnemonic" : "20"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "Surgical site infection", "Mnemonic" : "22"},
{"Row" :5, "Column" : 2, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" :7, "Column" : 2, "Text" : "Chlamydia (See Cervicitis or Urethritis)"}, 
{"Row" : 17, "Column" : 2, "Text" : "Necrotizing Infection (including Fournier gangrene)", "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Text" : "Surgical Site Infection", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU GI LIVER ABSCESS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "DisplayText" : "Amebic Liver Abscess", "Text" : "Link to Amebic Liver Abscess menu", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "LIVER ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Liver abscess should be suspected in all patients with fever, leukocytosis, and"}, 
{"Row" :6, "Column" : 1, "Text" : "a space-occupying liver lesion. Liver abscesses fall broadly into two"}, 
{"Row" :7, "Column" : 1, "Text" : "categories: pyogenic and amebic. In the United States, pyogenic liver abscess is"}, 
{"Row" :8, "Column" : 1, "Text" : "much more common. Amebic liver abscess occurs almost exclusively in travelers"}, 
{"Row" :9, "Column" : 1, "Text" : "and immigrants. If amebic liver abscess is suspected, select the link below."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment of pyogenic liver abscess", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Infections of the Liver and Biliary System"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Hepatic Abscess"}, 
{"Row" : 20, "Column" : 1, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-Date article: Pyogenic liver abscess"}
]},
{"Name" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 52, "Column" : 1, "Text" : "References: "}, 
{"Row" :8, "Column" : 1, "Text" : "Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "chlamydia."}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients weighing less than 300lbs: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Patients weighing 300lbs or greater: ", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "No reliable alternative treatments are available for pharyngeal gonorrhea."}, 
{"Row" : 46, "Column" : 1, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment"}, 
{"Row" : 47, "Column" : 1, "Text" : "of the reaction is recommended. For persons with an anaphylactic or other"}, 
{"Row" : 48, "Column" : 1, "Text" : "severe reaction to ceftriaxone, consult Infectious Disease for alternative"}, 
{"Row" : 49, "Column" : 1, "Text" : "treatment recommendation."}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRI 1GM IM X1 + DOXY 100MG PO BID 7D GONOCOCC", "DisplayText" : "Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid x7days ($)[DI]", "Text" : "Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]", "Mnemonic" : "14a"},
{"Row" :9, "Column" : 1, "Text" : "-If chlamydial infection has not been excluded, recommend to treat for"}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRI 500MG IM X1 + DOXY 100MG BID 7D GONOCOCC", "DisplayText" : "Ceftriaxone 500MG IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]", "Text" : "", "Mnemonic" : "12a"},
{"Row" : 11, "Column" : 1, "Text" : "-A test-of-cure is unnecessary for uncomplicated urogenital or rectal"}, 
{"Row" : 12, "Column" : 1, "Text" : "gonorrhea for patients treated with the recommended or alternative regimen."}, 
{"Row" : 40, "Column" : 1, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment"}, 
{"Row" : 41, "Column" : 1, "Text" : "of the reaction is recommended."}, 
{"Row" : 53, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP GENTAMICIN 240MG IMX1 +AZITH 2000MG X1 GONOC", "DisplayText" : "Gentamicin 240 MG IM Once ($) [R] <AND> Azithromycin 2000 mg PO Once ($) [DI]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 44, "Column" : 1, "Text" : "Alternative treatment for beta-lactam allergy for pharynx: ", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "-A test-of-cure is recommended for patients with pharyngeal gonorrhea."}, 
{"Row" : 14, "Column" : 1, "Text" : "Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial"}, 
{"Row" : 15, "Column" : 1, "Text" : "treatment, regardless of regimen used for pharyngeal gonorrhea."}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred treatment for patients and no chlamydial co-infection: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred treatment with chlamydial co-infection or chlamydial infection has", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "not been excluded: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Patients weighing less than 300lbs: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Patients weighing 300lbs or greater: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 500MG IM X1 GONOCOCCAL", "DisplayText" : "Ceftriaxone 500 MG IM x1 dose ($) [M]", "Text" : "", "Mnemonic" : "08"},
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IM X1 GONOCOCCAL", "DisplayText" : "Ceftriaxone 1 GM IM x1 dose ($) [M]", "Text" : "", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia urethritis (Outpatient)", "Text" : "[Click here] Chlamydial infection and no co-infection", "Mnemonic" : "06"},
{"Row" : 20, "Column" : 1, "Text" : "Chlamydial infection and no co-infection: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "______________________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "[Click here] Place order for gonorrhea/chlamydia lab NAAT test", "Mnemonic" : "04"},
{"Row" : 17, "Column" : 1, "Text" : "Lab test: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "-When diagnosed with sexually transmitted disease, the patient's sexual"}, 
{"Row" :5, "Column" : 1, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually"}, 
{"Row" :6, "Column" : 1, "Text" : "transmitted infection."}, 
{"Row" :3, "Column" : 1, "Text" : "Gonococcal Infections: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for Doxycycline above", "Mnemonic" : "12b"},
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for Doxycycline above", "Mnemonic" : "14b"}
]},
{"Name" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "DisplayText" : "Gram negative bacteria (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "DisplayText" : "Interim results:Gram-negative bacilli (Outpatient)", "Text" : "Gram-negative bacilli", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "DisplayText" : "Iterim report of Gram-negative cocci (Outpatient)", "Text" : "Gram-negative cocci", "Mnemonic" : "6"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "++ GRAM-NEGATIVE BACTERIA ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome,"}, 
{"Row" :6, "Column" : 1, "Text" : "site of infection, penetration of"}, 
{"Row" :7, "Column" : 1, "Text" : "drug(s)into site, and whether"}, 
{"Row" :8, "Column" : 1, "Text" : "organism is pathogen, colonizer, or"}, 
{"Row" :9, "Column" : 1, "Text" : "contaminant. See disease/syndrome"}, 
{"Row" : 10, "Column" : 1, "Text" : "section for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Interim culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "++ MULTIDRUG RESTANT ORGANISMS ++", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "ESBLS, Amp-C beta-lactamases, and", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Carbapenemases", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Consider whether patient is at risk"}, 
{"Row" : 22, "Column" : 1, "Text" : "for or has evidence of infection with"}, 
{"Row" : 23, "Column" : 1, "Text" : "Gram-negative bacilli carrying"}, 
{"Row" : 24, "Column" : 1, "Text" : "extended-spectrum beta-lactamases"}, 
{"Row" : 25, "Column" : 1, "Text" : "(ESBLs), AmpC beta-lactamases, or"}, 
{"Row" : 26, "Column" : 1, "Text" : "carbapenemases."}, 
{"Row" : 29, "Column" : 1, "Text" : "lactamases, and carbapenemases."}, 
{"Row" : 32, "Column" : 1, "Text" : "Last Reviewed December 2017", "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "DisplayText" : "Acinetobacter baumanni (Outpatient)", "Text" : "Acinetobacter baumanni", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "DisplayText" : "Citrobacter spp. (Outpatient)", "Text" : "Citrobacter spp.", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "DisplayText" : "Enterobacter spp. (Outpatient)", "Text" : "Enterobacter spp.", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG E. COLI", "DisplayText" : "Escherichia coli (Outpatient)", "Text" : "Escherichia coli", "Mnemonic" : "22"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "DisplayText" : "Klebsiella spp. (Outpatient)", "Text" : "Klebsiella spp.", "Mnemonic" : "28"},
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "DisplayText" : "Proteus spp. (Outpatient)", "Text" : "Proteus spp.", "Mnemonic" : "34"},
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "DisplayText" : "Serratia spp. (Outpatient)", "Text" : "Serratia spp.", "Mnemonic" : "40"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "DisplayText" : "Bordetella spp. (Outpatient)", "Text" : "Bordetella spp.", "Mnemonic" : "12"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "DisplayText" : "Brucella spp.", "Text" : "Brucella spp.", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "DisplayText" : "Campylobacter spp. (Outpatient)", "Text" : "Campylobacter spp.", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "DisplayText" : "Haemophilus spp. (Outpatient)", "Text" : "Haemophilus spp.", "Mnemonic" : "24"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection (Outpatient)", "Text" : "Helicobacter pylori", "Mnemonic" : "26"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "DisplayText" : "Legionella spp. (Outpatient)", "Text" : "Legionella spp.", "Mnemonic" : "30"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "DisplayText" : "Pasteurella multocida (Outpatient)", "Text" : "Pasteurella multocida", "Mnemonic" : "32"},
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "DisplayText" : "Pseudomonas spp. (Outpatient)", "Text" : "Pseudomonas spp.", "Mnemonic" : "36"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "DisplayText" : "Salmonella spp. (Outpatient)", "Text" : "Salmonella spp.", "Mnemonic" : "38"},
{"Row" : 32, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient)", "Text" : "Shigella spp (bacillary dysentery)", "Mnemonic" : "42"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis (Outpatient)", "Text" : "Neisseria meningitidis", "Mnemonic" : "50"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae (Outpatient)", "Text" : "Neisseria gonorrhoeae", "Mnemonic" : "48"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis (Outpatient)", "Text" : "Moraxella catarrhalis", "Mnemonic" : "46"},
{"Row" : 35, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (Outpatient)", "Text" : "Bacteroides, Porphyromonas,", "Mnemonic" : "44"},
{"Row" : 11, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Final culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : ">> Gram-negative bacilli <<", "Header" : 1}, 
{"Row" : 34, "Column" : 2, "Text" : ">> Gram-negative cocci <<", "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Text" : "Prevotella"}
]},
{"Name" : "ORZID3 GMENU GRAM POSITIVE BACTERIA" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs (Outpatient)", "Text" : "Gram-positive cocci", "Mnemonic" : "4"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "DisplayText" : "Interim report of Gram-positive Bacilli (Outpatient)", "Text" : "Gram-positive bacilli", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "++ GRAM-POSTITIVE BACTERIA ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome,"}, 
{"Row" :6, "Column" : 1, "Text" : "site of infection, penetration of"}, 
{"Row" :7, "Column" : 1, "Text" : "drug(s) into site, and whether"}, 
{"Row" :8, "Column" : 1, "Text" : "organism is pathogen, colonizer, or"}, 
{"Row" :9, "Column" : 1, "Text" : "contaminant. See disease/syndrome"}, 
{"Row" : 10, "Column" : 1, "Text" : "section for more information."}, 
{"Row" : 11, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Interim culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Last Reviewed December 2017", "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "DisplayText" : "Staphylococci (Outpatient)", "Text" : "Staphylococci", "Mnemonic" : "10"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "DisplayText" : "Group A (S. pyogenes) - Outpatient", "Text" : "Group A (S. pyogenes)", "Mnemonic" : "12"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "DisplayText" : "Group B (S. agalactiae) - Outpatient", "Text" : "Group B (S. agalactiae)", "Mnemonic" : "14"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "DisplayText" : "Streptococci Groups C, F, G (Outpatient)", "Text" : "Groups C, F, G", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "DisplayText" : "Group D Streptococci (S. bovis) - Outpatient", "Text" : "Group D (S. bovis)", "Mnemonic" : "18"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient", "Text" : "Viridans streptococci (including", "Mnemonic" : "20"},
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "DisplayText" : "Streptococcus pneumoniae (Outpatient)", "Text" : "Streptococcus pneumoniae", "Mnemonic" : "22"},
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "DisplayText" : "Streptococcus anginosus (formerly S. milleri) - Outpatient", "Text" : "Streptococcus anginosus (formerly", "Mnemonic" : "24"},
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "DisplayText" : "Anaerobic Gram-positive cocci (Outpatient)", "Text" : "Anaerobic Gram-positive cocci", "Mnemonic" : "26"},
{"Row" : 33, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "DisplayText" : "Enterococci (Outpatient)", "Text" : "Enterococci", "Mnemonic" : "28"},
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "DisplayText" : "Bacilli species (Outpatient)", "Text" : "Bacillus spp.", "Mnemonic" : "30"},
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "DisplayText" : "Clostridium spp. (Outpatient)", "Text" : "Clostridium spp.", "Mnemonic" : "32"},
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "DisplayText" : "Corynebacterium spp. (Outpatient)", "Text" : "Corynebacteriium spp.", "Mnemonic" : "34"},
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "DisplayText" : "Propionibacterium species (Outpatient)", "Text" : "Cutibacterium (formerly", "Mnemonic" : "36"},
{"Row" : 41, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "DisplayText" : "Actinomyces spp. (Outpatient)", "Text" : "Actinomyces spp.", "Mnemonic" : "38"},
{"Row" : 42, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "DisplayText" : "Listeria spp. (Outpatient)", "Text" : "Listeria spp.", "Mnemonic" : "40"},
{"Row" : 11, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Final culture results", "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Text" : "____________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Text" : ">> Gram-positive cocci <<", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "Streptococci", "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Text" : "S. mutans, S. mitis, S. sanguis)"}, 
{"Row" : 28, "Column" : 2, "Text" : "S. milleri)"}, 
{"Row" : 31, "Column" : 2, "Text" : "(including Peptostreptococcus)"}, 
{"Row" : 35, "Column" : 2, "Text" : ">> Gram-positive bacilli <<", "Header" : 1}, 
{"Row" : 40, "Column" : 2, "Text" : "Propionibacterium) spp."}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "DisplayText" : "Acinetobacter baumanni (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases.", "Mnemonic" : "4"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ACINETOBACTER BAUMANNII", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Isolation of Acinetobacter baumannii from a culture often represents"}, 
{"Row" :6, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" :7, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Many isolates are resistant to multiple antimicrobials. If susceptibilities are"}, 
{"Row" : 13, "Column" : 1, "Text" : "not known, start therapy with imipenem or amikacin."}, 
{"Row" : 14, "Column" : 1, "Text" : "If susceptibities are known, use appropriate antimicrobial."}, 
{"Row" : 15, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 17, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 18, "Column" : 1, "Text" : "Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 19, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 23, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Acinetobacter baumannii"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-To-Date article: Acinetobacter infection: Treatment and prevention"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "DisplayText" : "Bacteroides spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID METRONIDAZOLE 1 GM PO BID", "DisplayText" : "Metronidazole 1000 mg PO BID ($) [DI]", "Text" : "Metronidazole 1000 mg PO BID ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID METRONIDAZOLE 1 GM PO BID", "DisplayText" : "Metronidazole 1000 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "These bacteria are strict anaerobes and will only grow in anaerobic media."}, 
{"Row" :7, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :8, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Bacteriodes sp., Overview"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-To-Date article: Anaerobic bacterial infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "DisplayText" : "Bordetella spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "BORDETELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Bordetella pertussis"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "DisplayText" : "Brucella spp. " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP DOXY 100MG PO BID RIFAMP 600MG PO QD", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QDAY ($)", "Text" : "Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QDAY ($)", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX NV DOXY 100MG PO BID RIFAMP 600MG PO QD", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QD Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "BRUCELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment for non-localizing disease only. Consult Infectious Diseases for"}, 
{"Row" :7, "Column" : 1, "Text" : "specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,"}, 
{"Row" :8, "Column" : 1, "Text" : "endocarditis, etc.)"}, 
{"Row" : 10, "Column" : 1, "Text" : "Treat with both drugs for 45 days."}, 
{"Row" : 12, "Column" : 1, "Text" : "[DI,O]"}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Brucellosis"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 21, "Column" : 1, "Text" : "brucellosis"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "DisplayText" : "Campylobacter spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O]", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CAMPYLOBACTER SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal Optimal therapy depends on both the disease or syndrome and the"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogen. See diagnosis/syndrome section for more information. Drugs"}, 
{"Row" :7, "Column" : 1, "Text" : "recommended below are best for most cases. If susceptibility results or other"}, 
{"Row" :8, "Column" : 1, "Text" : "factors make these inappropriate for this case, click need an alternative"}, 
{"Row" : 11, "Column" : 1, "Text" : "For information on gastroenteritis (usually involving C. jejuni), refer to the"}, 
{"Row" : 12, "Column" : 1, "Text" : "Gastrointestinal and Intraabdominal infection section."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment of extraintestinal infectious not involving the central nervous", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "system infections", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment of central nervous system infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Campylobacter jejuni, Campylobacter coli"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 30, "Column" : 1, "Text" : "Campylobacter infection"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "DisplayText" : "Citrobacter spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "CITROBACTER SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 15, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford keyword: Citrobacter sp."}, 
{"Row" : 22, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG E. COLI", "DisplayText" : "Escherichia coli (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "8a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "DisplayText" : "FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose", "Mnemonic" : "10"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "12a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses", "Mnemonic" : "14"},
{"Row" : 40, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "16a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "DisplayText" : "FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses", "Mnemonic" : "18"},
{"Row" :3, "Column" : 1, "Text" : "ESCHERICHIA COLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal"}, 
{"Row" : 11, "Column" : 1, "Text" : "infections section."}, 
{"Row" : 13, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 14, "Column" : 1, "Text" : "E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 15, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 19, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "E. coli carrying ESBL: ", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "E. coli carrying carbapenemase: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "References: "}, 
{"Row" : 48, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 49, "Column" : 1, "Text" : "Sanford keyword: Escherichia coli"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "DisplayText" : "Enterobacter spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROBACTER SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Enterobacter sp."}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "DisplayText" : "Haemophilus spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Mnemonic" : "6a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "HAEMOPHILUS SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 18, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Haemophilus influenzae"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-To-Date article: "}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "DisplayText" : "Klebsiella spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID", "DisplayText" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Text" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID", "DisplayText" : "Cefpodoxime 100 mg PO BID ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "10a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "DisplayText" : "FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "KLEBSIELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 11, "Column" : 1, "Text" : "klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 12, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Klebsiella sp."}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "DisplayText" : "Legionella spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O]", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Mnemonic" : "4a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($)[R,DI]", "Text" : "Levofloxacin 500 mg PO QDAY ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "LEGIONELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Consider treating for up to 21 days in immunosuppressed patients who are"}, 
{"Row" :9, "Column" : 1, "Text" : "severely ill upon presentation."}, 
{"Row" : 11, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for 10 days"}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative for patients intolerant to macrolides"}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 10 days"}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Legionella sp."}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-To-Date article: Treatment and prevention of Legionella infection"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "DisplayText" : "Moraxella catarrhalis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Mnemonic" : "8a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "MORAXELLA CATARRHALIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 19, "Column" : 1, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Moraxella catarrhalis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-To-Date article: Moracella catarrhalis infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "DisplayText" : "Neisseria gonorrhoeae (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NEISSERIA GONORRHOEAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "See diagnosis/syndrome section for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Up-To-Date article: Disseminated gonococcal infection"}, 
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "", "Mnemonic" : "04"},
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 10, "Column" : 1, "Text" : "See Inpatient CDSS for disseminated gonococcal infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916."}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "DisplayText" : "Neisseria meningitidis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NEISSERIA MENINGITIDIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Central nervous system infections require higher doses of antimicrobials."}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Neisseria meningitidis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-To-Date article: Treatment and prevention of meningococcal infection"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "DisplayText" : "Pasteurella multocida (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "PASTEURELLA MULTOCIDA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanford keyword: Pasteurella multocida"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date article: Pasteurella infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "DisplayText" : "Proteus spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "PROTEUS SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 11, "Column" : 1, "Text" : "proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 12, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 16, "Column" : 1, "Text" : "Mild to moderate infections including cystitis", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for allergy to beta-lactam"}, 
{"Row" : 26, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Proteus sp."}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases"}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "6b"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "DisplayText" : "Pseudomonas spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "PSEUDOMONAS SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "In severe cases, addition of an aminoglycoside to a beta"}, 
{"Row" : 11, "Column" : 1, "Text" : "lactam may be beneficial. Aminoglycoside monotherapy is effective only in"}, 
{"Row" : 12, "Column" : 1, "Text" : "treatment of UTI. Refer to genitourinary section for treatment of UTI due to"}, 
{"Row" : 13, "Column" : 1, "Text" : "pseudomonas. Consult Infectious Diseases for more information."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 18, "Column" : 1, "Text" : "Oral treatment for mild infections"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative for severe infections", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Pseudomonas aeruginosa"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas"}, 
{"Row" : 30, "Column" : 1, "Text" : "aeruginosa infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "DisplayText" : "Salmonella spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "8a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "SALMONELLA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis antimicrobials are not usually indicated. Please refer to"}, 
{"Row" : 11, "Column" : 1, "Text" : "the Gastrointestinal and Intra-abdominal infections section for more"}, 
{"Row" : 12, "Column" : 1, "Text" : "information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consider whether patient is at risk for or has evidence of infection with"}, 
{"Row" : 15, "Column" : 1, "Text" : "salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-"}, 
{"Row" : 16, "Column" : 1, "Text" : "lactamase, or carbapenemase."}, 
{"Row" : 20, "Column" : 1, "Text" : "For localized or systemic extraintestinal infections", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 30, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Salmonella sp."}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "DisplayText" : "Serratia spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID", "DisplayText" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Text" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID", "DisplayText" : "Cefpodoxime 100 mg PO BID ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "SERRATIA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 17, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Sanford keyword: Serratia marcescens"}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-To-Date article: Infections due to Serratia species"}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SHIGELLA SPP.", "DisplayText" : "Shigella spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O]", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY ($) [O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "SHIGELLA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are"}, 
{"Row" :7, "Column" : 1, "Text" : "best for most cases. If susceptibility results or other factors make these"}, 
{"Row" :8, "Column" : 1, "Text" : "inappropriate for this case, click need an alternative antimicrobial."}, 
{"Row" : 10, "Column" : 1, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal"}, 
{"Row" : 11, "Column" : 1, "Text" : "infections section for more information. antibiotic resistance is increasing,"}, 
{"Row" : 12, "Column" : 1, "Text" : "especially among men who have sex with men. Drug selection should be based on"}, 
{"Row" : 13, "Column" : 1, "Text" : "antimicrobial susceptibility tests."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment for systemic infections", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 22, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "MMWR (2015) 64.318"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Shigella Sp."}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-To-Date article: Shigella infection: Treatment and prevention in adults"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "DisplayText" : "Actinomyces spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "ACTINOMYCES SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternative for patients with beta-lactam allergy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Actinomycosis"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "DisplayText" : "Anaerobic Gram-positive cocci (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O]", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ANAEROBIC GRAM-POSITIVE COCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Anaerobic Gram-positive cocci, including peptostreptococci, are often involved"}, 
{"Row" :6, "Column" : 1, "Text" : "in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and"}, 
{"Row" :7, "Column" : 1, "Text" : "penicillin) and clindamycin are the drugs of choice against anaerobic gram-"}, 
{"Row" :8, "Column" : 1, "Text" : "positive cocci. Beta-lactam/beta-lactamase inhibitors are active against"}, 
{"Row" :9, "Column" : 1, "Text" : "peptostreptococci, so no additional anaerobic antimicrobials are needed"}, 
{"Row" : 10, "Column" : 1, "Text" : "specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam"}, 
{"Row" : 11, "Column" : 1, "Text" : "or piperacillin-tazobactam are used."}, 
{"Row" : 13, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 14, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 18, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating"}, 
{"Row" : 30, "Column" : 1, "Text" : "Bacilli"}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Peptostreptococcus sp."}
]},
{"Name" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "DisplayText" : "Bacilli species (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O]", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "BACILLUS SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "B. cereus", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 11, "Column" : 1, "Text" : "If isolate is clindamycin-susceptable"}, 
{"Row" : 14, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "B. anthracis", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Start combination therapy and contact Infectious Diseases immediately."}, 
{"Row" : 19, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2"}, 
{"Row" : 25, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "DisplayText" : "Clostridium spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "Clostridium difficile disease", "Mnemonic" : "4"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "CLOSTRIDIUM SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For Clostridium difficile disease refer to"}, 
{"Row" :8, "Column" : 1, "Text" : "Mild to moderate infections may be treated with oral antimicrobials. For"}, 
{"Row" :9, "Column" : 1, "Text" : "neutropenic enterocolitis, gas gangrene, or other necrotizing infection,"}, 
{"Row" : 10, "Column" : 1, "Text" : "intravenous therapy is indicated. Combination therapy may be preferred. Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to the appropriate section of the CDSS or contact Infectious Diseases for more"}, 
{"Row" : 12, "Column" : 1, "Text" : "information."}, 
{"Row" : 14, "Column" : 1, "Text" : "C. perfringens food poisoning is treated with supportive care. Diarrhea resolves"}, 
{"Row" : 15, "Column" : 1, "Text" : "within 24 hours."}, 
{"Row" : 17, "Column" : 1, "Text" : "For severe infection with Clostridium spp. other than perfringens, septicum or"}, 
{"Row" : 18, "Column" : 1, "Text" : "sordellii, call Infectious Diseases."}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred empirical treatment for mild to moderate infections", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "Alternative for beta-lactam allergic patients"}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred empirical therapy for severe infections", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford Table 2: Recommended antimicrobial agents"}, 
{"Row" : 37, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "DisplayText" : "Treatment for Coagulase Negative Staphylococci (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "DisplayText" : "Treatment for Staphylococcus lugdunensis", "Text" : "Treatment for Staphylococcus lugdunensis", "Mnemonic" : "4"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "10a"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI]", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "14a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Mnemonic" : "18a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S."}, 
{"Row" :6, "Column" : 1, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S."}, 
{"Row" :7, "Column" : 1, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S."}, 
{"Row" :8, "Column" : 1, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S."}, 
{"Row" :9, "Column" : 1, "Text" : "warneri and S. xylosus"}, 
{"Row" : 10, "Column" : 1, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to S. lugdunensis page for treatment."}, 
{"Row" : 14, "Column" : 1, "Text" : "Isolation of coagulase-negative staphylococci from a culture often represents"}, 
{"Row" : 15, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" : 16, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" : 18, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" : 19, "Column" : 1, "Text" : "drugs."}, 
{"Row" : 21, "Column" : 1, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are"}, 
{"Row" : 22, "Column" : 1, "Text" : "available."}, 
{"Row" : 24, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred treatment for urinary tract infection associated with S. saprophyticu", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative"}, 
{"Row" : 48, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 49, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 50, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus sp., Coagulase-negative"}, 
{"Row" : 51, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus epidermidis"}, 
{"Row" : 52, "Column" : 1, "Text" : "Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment"}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 37, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "DisplayText" : "Corynebacterium spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID ERYTHROMYCIN 500MG PO TID", "DisplayText" : "Erythromycin 500 mg PO TID ($$) [DI]", "Text" : "Erythromycin 500 mg PO TID ($$) [DI]", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID ERYTHROMYCIN 500MG PO TID", "DisplayText" : "Erythromycin 500 mg PO TID ($$) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID PENICILLIN VK 250MG PO QID", "DisplayText" : "Penicillin VK 250 mg PO QID ($) [R]", "Text" : "Penicillin VK 250 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID PENICILLIN VK 250MG PO QID", "DisplayText" : "Penicillin VK 250 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CORYNEBACTERIUM SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Corynebacterium jeikeium", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 11, "Column" : 1, "Text" : "Corynebacterium diphtheriae", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Diphtheria is usually severe and often fatal. Antitoxin is the most important"}, 
{"Row" : 13, "Column" : 1, "Text" : "treatment. Contact Infectious Diseases immediately."}, 
{"Row" : 15, "Column" : 1, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative for patients intolerant of erythromycin"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium diptheriae"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium jeikeium"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 32, "Column" : 1, "Text" : "diptheria"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "DisplayText" : "Enterococci (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS TREAT ENTEROCOCCI", "DisplayText" : "Treatment for Enterococcal infections (Outpatient)", "Text" : "Treatment for enterococcal infections", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The important human pathogens are Enterococcus faecium and Enterococcus"}, 
{"Row" :6, "Column" : 1, "Text" : "faecalis. The antimicrobial susceptibilities that are reported for enterococci"}, 
{"Row" :7, "Column" : 1, "Text" : "depend on the site of the sample. For all enterococci the microbiology"}, 
{"Row" :8, "Column" : 1, "Text" : "laboratory reports susceptibility for ampicillin and vancomycin. Additionally"}, 
{"Row" :9, "Column" : 1, "Text" : "the lab reports fluoroquinolone susceptibility for urinary isolates and"}, 
{"Row" : 10, "Column" : 1, "Text" : "susceptibility to gentamicin synergy for bloodstream isolates. For more"}, 
{"Row" : 11, "Column" : 1, "Text" : "information on culture and susceptibilities, contact the microbiology laboratory"}, 
{"Row" : 13, "Column" : 1, "Text" : "Ampicillin is the drug of choice for enterococcal infections. Piperacillin is"}, 
{"Row" : 14, "Column" : 1, "Text" : "also active against enterococcus. Cephalosporins are ineffective as single"}, 
{"Row" : 15, "Column" : 1, "Text" : "agents for enterococcal infections. For patients who are allergic to penicillin"}, 
{"Row" : 16, "Column" : 1, "Text" : "or infected with penicillin-resistant enterococcus, vancomycin is the preferred"}, 
{"Row" : 17, "Column" : 1, "Text" : "drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid"}, 
{"Row" : 18, "Column" : 1, "Text" : "must be reserved for cases where no other drug can be used as it has many side"}, 
{"Row" : 19, "Column" : 1, "Text" : "effects and drug interactions, is expensive, is bacteriostatic rather than"}, 
{"Row" : 20, "Column" : 1, "Text" : "bactericidal, and its use promotes resistance."}, 
{"Row" : 22, "Column" : 1, "Text" : "Combination regimens include a primary anti-enterococcal agent (ampicillin or"}, 
{"Row" : 23, "Column" : 1, "Text" : "vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are"}, 
{"Row" : 24, "Column" : 1, "Text" : "needed for severe infections like endocarditis or prosthetic joint infections."}, 
{"Row" : 25, "Column" : 1, "Text" : "See relevant disease/syndrome sections for more information. Milder diseases"}, 
{"Row" : 26, "Column" : 1, "Text" : "like cystitis or wound infection can usually be treated with a single drug. For"}, 
{"Row" : 27, "Column" : 1, "Text" : "more information on treatment of enterococcal infections, contact Infectious"}, 
{"Row" : 28, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and"}, 
{"Row" : 37, "Column" : 1, "Text" : "Leuconostoc Species"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecalis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infection"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infection"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "DisplayText" : "Streptococci Groups C, F, G (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Mnemonic" : "10a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCI GROUPS C, F, G", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 18, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 20, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 24, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,"}, 
{"Row" : 31, "Column" : 1, "Text" : "Groups C and G Streptococci, and Other Related Organisms"}, 
{"Row" : 32, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G"}, 
{"Row" : 34, "Column" : 1, "Text" : "Strep"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-To-Date article: Group C and group G streptococcal infection"}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "12a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "12b"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "DisplayText" : "Listeria spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LISTERIA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :7, "Column" : 1, "Text" : "For meningitis, please refer to the meningitis section for treatment advice."}, 
{"Row" :9, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Listeria monocytogenes"}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-To-Date article: Treatment, prognosis, and prevention of Listeria"}, 
{"Row" : 17, "Column" : 1, "Text" : "monocytogenes infection"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "DisplayText" : "Propionibacterium species (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Isolation of Propionibacterium species from a culture often represents"}, 
{"Row" :6, "Column" : 1, "Text" : "contamination or colonization and not disease. For questions about whether a"}, 
{"Row" :7, "Column" : 1, "Text" : "patient should be treated, contact Infectious Diseases."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "disease/syndrome sections for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)"}, 
{"Row" : 19, "Column" : 1, "Text" : "infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "DisplayText" : "Group B (S. agalactiae) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "GROUP B STREPTOCOCCI (S. AGALACTIAE)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Group B streptococci (Streptococcus agalactiae) are associated most commonly"}, 
{"Row" :6, "Column" : 1, "Text" : "with bacteremia and meningitis in infants and bacteremia and urinary tract"}, 
{"Row" :7, "Column" : 1, "Text" : "infections in elderly people and people with diabetes mellitus."}, 
{"Row" :9, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 10, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 27, "Column" : 1, "Text" : "Severe infections", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)"}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Streptococcus agalactiae, Group B Strep"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Group B streptococcal infections in nonpregnant adults"}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "DisplayText" : "Streptococcus anginosus (formerly S. milleri) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Ceftriaxone or penicillin are preferred for central nervous system infection."}, 
{"Row" :9, "Column" : 1, "Text" : "Cefazolin or penicillin are preferred for infection outside of the central"}, 
{"Row" : 10, "Column" : 1, "Text" : "nervous system."}, 
{"Row" : 12, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Streptococcus anginosus group"}, 
{"Row" : 18, "Column" : 1, "Text" : "Sanford keyword: Streptococcus anginosus group"}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus"}, 
{"Row" : 20, "Column" : 1, "Text" : "milleri) group"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. BOVIS", "DisplayText" : "Group D Streptococci (S. bovis) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "GROUP D STREPTOCOCCI (S. BOVIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Bacteremia with Streptococcus bovis is associated with malignancy of the colon."}, 
{"Row" : 10, "Column" : 1, "Text" : "Resistance to penicillin is uncommon. Vancomycin should only be used in a"}, 
{"Row" : 11, "Column" : 1, "Text" : "patient with beta-lactam allergy, or if beta-lactam resistance is strongly"}, 
{"Row" : 12, "Column" : 1, "Text" : "suspected."}, 
{"Row" : 14, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 17, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of"}, 
{"Row" : 20, "Column" : 1, "Text" : "infections due to group D streptococci (Streptococcus bovis/Streptococcus"}, 
{"Row" : 21, "Column" : 1, "Text" : "equinus complex)"}, 
{"Row" : 22, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "DisplayText" : "Streptococcus pneumoniae (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 1000MG PO TID", "DisplayText" : "Amoxicillin 1000 mg PO TID ($) [R]", "Text" : "Amoxicillin 1000 mg PO TID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 1000MG PO TID", "DisplayText" : "Amoxicillin 1000 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO QDAY ($) [R,DI]", "Text" : "Levofloxacin 750 mg PO QDAY ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID LEVOFLOXACIN 750MG PO Q24H", "DisplayText" : "Levofloxacin 750 mg PO QDAY ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCUS PNEUMONIAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Refer to Central Nervous System section of the Inpatient Antimicrobial CDSS for"}, 
{"Row" :9, "Column" : 1, "Text" : "treatment of meningitis."}, 
{"Row" : 11, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment for infections outside of the central nervous system", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative for patient with beta-lactam allergy, or when beta-lactam resistance"}, 
{"Row" : 21, "Column" : 1, "Text" : "is suspected or proved"}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Streptococcus pneumoniae"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pneumoniae"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections"}, 
{"Row" : 32, "Column" : 1, "Text" : "and bacteremia"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "DisplayText" : "Group A (S. pyogenes) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Mnemonic" : "10a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "GROUP A STREPTOCOCCI (S. PYOGENES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Group A streptococcus (Streptococcus pyogenes) is the most virulent"}, 
{"Row" :6, "Column" : 1, "Text" : "streptococcal species. Important syndromes include pharyngitis, cellulitis,"}, 
{"Row" :7, "Column" : 1, "Text" : "streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic"}, 
{"Row" :8, "Column" : 1, "Text" : "fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on"}, 
{"Row" :9, "Column" : 1, "Text" : "both the disease or syndrome and the pathogen. See diagnosis/syndrome section"}, 
{"Row" : 10, "Column" : 1, "Text" : "for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Mild to moderate infections (non-necrotizing)", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 21, "Column" : 1, "Text" : "for 4 days"}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Bacteremia, toxic shock syndrome and necrotizing infections", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 31, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Streptococcus pyogenes"}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G"}, 
{"Row" : 36, "Column" : 1, "Text" : "Strep"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in"}, 
{"Row" : 38, "Column" : 1, "Text" : "adults"}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "12A"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "12b"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "DisplayText" : "Treatment for Staphylococcus lugdunensis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI]", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Severity of S. lugdenensis infections vary from moderate to severe."}, 
{"Row" :6, "Column" : 1, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin"}, 
{"Row" :7, "Column" : 1, "Text" : "resistance is uncommon, less than 5% of isolates."}, 
{"Row" :9, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" : 10, "Column" : 1, "Text" : "drugs. If not, use vancomycin empirically until final culture and"}, 
{"Row" : 11, "Column" : 1, "Text" : "susceptibilities are available."}, 
{"Row" : 13, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 15, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative"}, 
{"Row" : 33, "Column" : 1, "Text" : "Staphylococci"}, 
{"Row" : 34, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus lugdunensis"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-To-Date article: Staphylococcus lugdunensis"}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "DisplayText" : "Staphylococci (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "DisplayText" : "Treatment for Staphylococcus aureus (Outpatient)", "Text" : "for Staphylococcus aureus", "Mnemonic" : "4"},
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "DisplayText" : "Treatment for Coagulase Negative Staphylococci (Outpatient)", "Text" : "for coagulase-negative staphylococci", "Mnemonic" : "6"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Click Here", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends"}, 
{"Row" :6, "Column" : 1, "Text" : "to relapse. Optimal therapy often involves intravenous therapy for defined"}, 
{"Row" :7, "Column" : 1, "Text" : "durations. See sections on specific syndromes (e.g., bacteremia or"}, 
{"Row" :8, "Column" : 1, "Text" : "endocarditis) for more information."}, 
{"Row" : 10, "Column" : 1, "Text" : "Coagulase-negative staphylococci, including Staphylococcus epidermidis and"}, 
{"Row" : 11, "Column" : 1, "Text" : "several less common species, are less virulent than S. aureus and are most"}, 
{"Row" : 12, "Column" : 1, "Text" : "commonly pathogenic when they colonize plastic or metal devices in a patient"}, 
{"Row" : 13, "Column" : 1, "Text" : "(e.g., intravenous catheters, prosthetic joints or heart valves). S."}, 
{"Row" : 14, "Column" : 1, "Text" : "lugdunensis is an uncommon but virulent coagulase-negative staphylococcus"}, 
{"Row" : 15, "Column" : 1, "Text" : "species. S. saprophyticus is associated with urinary tract infections in women."}, 
{"Row" : 17, "Column" : 1, "Text" : "Beta-lactam antimicrobials are the most active drugs against beta-lactam"}, 
{"Row" : 18, "Column" : 1, "Text" : "susceptible staphylococci. Penicillin is superior for penicillin-susceptible"}, 
{"Row" : 19, "Column" : 1, "Text" : "staphylococci, but most strains are resistant. Nafcillin and oxacillin are"}, 
{"Row" : 20, "Column" : 1, "Text" : "nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are"}, 
{"Row" : 21, "Column" : 1, "Text" : "next best. Vancomycin, a glycopeptide, is less active than the beta-lactams."}, 
{"Row" : 23, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective"}, 
{"Row" : 24, "Column" : 1, "Text" : "than beta-lactams for treatment of methicillin-susceptible staphylococcal"}, 
{"Row" : 25, "Column" : 1, "Text" : "infections, but may be useful in patients with severe penicillin allergy. For"}, 
{"Row" : 26, "Column" : 1, "Text" : "methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,"}, 
{"Row" : 27, "Column" : 1, "Text" : "minocycline, and clindamycin are useful alternatives to to vancomycin, as they"}, 
{"Row" : 28, "Column" : 1, "Text" : "are inexpensive and available in both intravenous and oral formulations. They"}, 
{"Row" : 29, "Column" : 1, "Text" : "are preferred over linezolid in most circumstances because linezolid is"}, 
{"Row" : 30, "Column" : 1, "Text" : "expensive, toxic with long-term use, and needed for treatment of highly"}, 
{"Row" : 31, "Column" : 1, "Text" : "resistant bacteria like vancomycin-resistant enterococci."}, 
{"Row" : 33, "Column" : 1, "Text" : "Combination regimens include a primary anti-staphylococcal agent (beta-lactam or"}, 
{"Row" : 34, "Column" : 1, "Text" : "vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or"}, 
{"Row" : 35, "Column" : 1, "Text" : "rifampin) often synergistic against staphylococci in vitro, but there is no"}, 
{"Row" : 36, "Column" : 1, "Text" : "evidence that combination therapy improves outcomes in staphylococcal infections"}, 
{"Row" : 37, "Column" : 1, "Text" : "in humans. Combination therapy has become the community standard for treatment"}, 
{"Row" : 38, "Column" : 1, "Text" : "of prosthetic-valve staphylococcal endocarditis based on experimental models and"}, 
{"Row" : 39, "Column" : 1, "Text" : "limited clinical data that combination therapy is superior (see endocarditis"}, 
{"Row" : 40, "Column" : 1, "Text" : "section for details)."}, 
{"Row" : 42, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Decolonization", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "References: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Baddour, et al. Circulation 2015, 132.15"}, 
{"Row" : 53, "Column" : 1, "Text" : "Mandell chapter: Endocarditis and Intravascular Infections"}, 
{"Row" : 54, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus aureus"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS TREAT ENTEROCOCCI", "DisplayText" : "Treatment for Enterococcal infections (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Mnemonic" : "8a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR ENTEROCOCCAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Isolation of enterococci in wounds often represents colonization rather than"}, 
{"Row" :9, "Column" : 1, "Text" : "infection. When colonization is suspected, enterococci need not be treated."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment for urinary tract infections", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment for systemic infections", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 23, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 25, "Column" : 1, "Text" : "Alternative for patients unable to take vancomycin or vancomycin resistant"}, 
{"Row" : 26, "Column" : 1, "Text" : "enterococci"}, 
{"Row" : 27, "Column" : 1, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and"}, 
{"Row" : 28, "Column" : 1, "Text" : "promotes bacterial resistance. It should only be used in cases where other"}, 
{"Row" : 29, "Column" : 1, "Text" : "options are not feasible. Contact Infectious Diseases for assistance."}, 
{"Row" : 34, "Column" : 1, "Text" : "References: "}, 
{"Row" : 36, "Column" : 1, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and"}, 
{"Row" : 37, "Column" : 1, "Text" : "Leuconostoc Species"}, 
{"Row" : 38, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 39, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecalis"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Enterococcus faecium"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "DisplayText" : "Treatment for Staphylococcus aureus (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI]", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Mnemonic" : "12a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "TREATMENT FOR STAPHYLOCOCCUS AUREUS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If susceptibility results are known, use them to select one of the following"}, 
{"Row" :6, "Column" : 1, "Text" : "drugs."}, 
{"Row" :7, "Column" : 1, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are"}, 
{"Row" :8, "Column" : 1, "Text" : "available."}, 
{"Row" : 10, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative for resistant organisms", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Staphylococcus aureus"}, 
{"Row" : 30, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Staphylococcus aureus"}, 
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"}
]},
{"Name" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "DisplayText" : "Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "VIRIDANS STREPTOCOCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Viridans streptococci are a heterogeneous group defined by their production of"}, 
{"Row" :6, "Column" : 1, "Text" : "green pigment on blood agar. Clinically important members of this group include"}, 
{"Row" :7, "Column" : 1, "Text" : "S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and"}, 
{"Row" :8, "Column" : 1, "Text" : "Streptococcus bovis are described separately. Viridans streptococci are"}, 
{"Row" :9, "Column" : 1, "Text" : "important, common pathogens in endocarditis and can also be contaminants in"}, 
{"Row" : 10, "Column" : 1, "Text" : "cultures of blood and other specimens. Consult Infectious Diseases for more"}, 
{"Row" : 11, "Column" : 1, "Text" : "information."}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to the Cardiovascular Section of the Inpatient Antimicrobialc CDSS for"}, 
{"Row" : 14, "Column" : 1, "Text" : "diagnosis and treatment of endocarditis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" : 17, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment is penicillin or cefazolin. Vancomycin should be used only"}, 
{"Row" : 20, "Column" : 1, "Text" : "in patients with beta-lactam allergy, or if beta-lactam resistance is strongly"}, 
{"Row" : 21, "Column" : 1, "Text" : "suspected. For serious disease, consider addition of gentamicin for synergy."}, 
{"Row" : 22, "Column" : 1, "Text" : "Contact Infectious Diseases for more information."}, 
{"Row" : 24, "Column" : 1, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS."}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,"}, 
{"Row" : 30, "Column" : 1, "Text" : "Groups C and G Streptococci, and Other Related Organisms"}, 
{"Row" : 31, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Streptococci, viridans group"}
]},
{"Name" : "ORZID3 GMENU H. PYLORI INFECT", "DisplayText" : "Helicobacter pylori infection (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP BIS524MGQID TCN500MGQID METRO250MGQID OMEP20MG", "DisplayText" : "BIS524MGQID TETRACY500MGQID METRO250MGQID OMEP20MG", "Text" : "Bismuth subsalicylate 524 mg PO QID <AND> Tetracycline 500mg QID ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX NV BIS524MGQID TCN500MGQID METRO250MGBID OMEP20MG", "DisplayText" : "BIS524MGQID TCN500MGQID METRO250MGBID OMEP20MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "HELICOBACTER PYLORI INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "H. pylori infection is associated with peptic ulcers, gastritis, gastric"}, 
{"Row" :6, "Column" : 1, "Text" : "adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to"}, 
{"Row" :7, "Column" : 1, "Text" : "patients with confirmed H. pylori infection. Antisecretory therapy should be"}, 
{"Row" :8, "Column" : 1, "Text" : "given concurrently. Contact Gastroenterology for more information or"}, 
{"Row" : 11, "Column" : 1, "Text" : "First line treatment: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "<AND> metronidazole 250 mg PO QID ($) [H,DI] <AND> omeprazole 20 mg PO BID"}, 
{"Row" : 14, "Column" : 1, "Text" : "Take all for 14 days."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-Date article: Treatment regimens for Helicobacter pylori"}, 
{"Row" : 26, "Column" : 1, "Text" : "Chey et al, Am J Gastroenterol, 2017,112:212-239"}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG", "DisplayText" : "CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG", "Text" : "Clarithromycin 500 mg PO BID ($)[R,DI] <AND> Amoxicillin 1000 mg PO BID", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Text" : "($)[R] <AND> metronidazole 500 mg PO BID ($) [H,DI] <AND> omeprazole 20 mg"}, 
{"Row" : 21, "Column" : 1, "Text" : "PO BID. Take all for 14 days."}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG", "DisplayText" : "CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 17, "Column" : 1, "Text" : "Resistance to clarithromycin is increasing, do not use for patients with"}, 
{"Row" : 18, "Column" : 1, "Text" : "prior exposure to macrolides: "}, 
{"Row" :9, "Column" : 1, "Text" : "treatment failures to first line."}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "DisplayText" : "Head and Neck / ENT (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "DisplayText" : "Malignant otitis externa (Outpatient)", "Text" : "Malignant Otitis Externa", "Mnemonic" : "4"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU MASTOIDITIS", "DisplayText" : "Mastoiditis (Outpatient)", "Text" : "Mastoiditis", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU OTITIS EXTERNA", "DisplayText" : "Otitis externa (Outpatient)", "Text" : "Otitis Externa", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU OTITIS MEDIA", "DisplayText" : "Otitis media (Outpatient)", "Text" : "Otitis Media", "Mnemonic" : "10"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "DisplayText" : "Conjunctivitis (Outpatient)", "Text" : "Conjunctivitis", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ENDOPHTHALMITIS", "DisplayText" : "Endophthalmitis (Outpatient)", "Text" : "Endophthalmitis", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU KERATITIS", "DisplayText" : "Keratitis (Outpatient)", "Text" : "Keratitis", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PERIOCULAR INFECTIONS", "DisplayText" : "Periocular Infections", "Text" : "Periocular Infections", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PROPHYLAXIS OPTH SURG", "DisplayText" : "Prophylaxis for Ophthalmic Surgery", "Text" : "Prophylaxis for Ophthalmic Surgery", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "Retinitis", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU UVEITIS", "DisplayText" : "Uveitis", "Text" : "Uveitis", "Mnemonic" : "24"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient)", "Text" : "Bell's Palsy", "Mnemonic" : "26"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal cellulitis (Outpatient)", "Text" : "Pre-septal Cellulitis", "Mnemonic" : "28"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal cellulitis (Orbital cellulitis) - Outpatient", "Text" : "Post-septal Cellulitis (Orbital Cellulitis)", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "++HEAD AND NECK++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Ear/Otologic", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Eye/Ophthalmologic", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Facial", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Section last reviewed June 2021", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "DisplayText" : "ACUTE SINUSITIS", "Text" : "Acute Sinusitis", "Mnemonic" : "38"},
{"Row" :7, "Column" : 2, "Item" : "ORZID3 GMENU CHRONIC SINUSITIS", "DisplayText" : "Chronic sinusitis (Outpatient)", "Text" : "Chronic Sinusitis", "Mnemonic" : "40"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU FUNGAL SINUSITIS", "DisplayText" : "Fungal Sinusitis", "Text" : "Fungal Sinusitis", "Mnemonic" : "42"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU NASAL PACKING", "DisplayText" : "Prevention of infection in patients with nasal packing (Outpatient)", "Text" : "Nasal Packing (to prevent infection)", "Mnemonic" : "44"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "DisplayText" : "Nosocomial sinusitis (Outpatient)", "Text" : "Nosocomial Sinusitis", "Mnemonic" : "46"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "DisplayText" : "Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient", "Text" : "Deep Oropharyngeal Infections", "Mnemonic" : "48"},
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient)", "Text" : "Dental Infections", "Mnemonic" : "50"},
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU EPIGLOTTITIS", "DisplayText" : "Epiglottitis (Outpatient)", "Text" : "Epiglottitis", "Mnemonic" : "52"},
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "DisplayText" : "Esophagitis (outpatient)", "Text" : "Esophagitis", "Mnemonic" : "54"},
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "DisplayText" : "Laryngitis and Croup", "Text" : "Laryngitis", "Mnemonic" : "56"},
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU ABX PAROTITIS", "DisplayText" : "Parotitis (outpatient)", "Text" : "Parotitis", "Mnemonic" : "58"},
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease (Outpatient)", "Text" : "Periodontal Disease", "Mnemonic" : "60"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU PERTUSSIS", "DisplayText" : "Pertussis (Outpatient)", "Text" : "Pertussis", "Mnemonic" : "62"},
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Pharyngitis", "Mnemonic" : "64"},
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "DisplayText" : "Candida albicans (Outpatient)", "Text" : "Thrush", "Mnemonic" : "66"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)", "Text" : "Tonsillitis", "Mnemonic" : "68"},
{"Row" :5, "Column" : 2, "Text" : "Nasal/Sinus", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Throat/Oropharyngeal", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "DisplayText" : "Head Lice (Pediculosis Capitis) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX TREAT HEAD LICE URL", "DisplayText" : "Treating Head Lice URL", "Text" : "http://www.cdc.gov/ncidod/dpd/parasites/lice/2004_PDF_Treating_head_lice.pdf", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "HEAD LICE (PEDICULOSIS CAPITIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse"}, 
{"Row" :6, "Column" : 1, "Text" : "living on the scalp.Dead nits may remain for months after successful"}, 
{"Row" :7, "Column" : 1, "Text" : "treatment.Dead nits are usually located more than 6 mm from the scalp."}, 
{"Row" :9, "Column" : 1, "Text" : "Lice are often transmitted by infected clothing and bedclothes but not by"}, 
{"Row" : 10, "Column" : 1, "Text" : "ordinary furniture that is not typically in contact with hair or scalp.Refer"}, 
{"Row" : 11, "Column" : 1, "Text" : "to the following for advice on household cleaning for lice infestations: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Repeat if live lice are seen 7-10 days after treatment."}, 
{"Row" : 19, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "DisplayText" : "Hepatitis B Evaluation Anti-CD20 Antibody " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX HEPATITIS B ONCOLOGY SHAREPOINT", "DisplayText" : "Hepatitis B Oncology SharePoint", "Text" : "Hepatitis B Oncology SharePoint", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "LRTZ HEPATITIS B SEROLOGY PANEL", "DisplayText" : "Hepatitis B Serology Panel (Hep B)", "Text" : "HEPATITIS B SEROLOGY PANEL", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "DisplayText" : "GI Liver", "Text" : "GASTROENTEROLOGY LIVER OUTPATIENT CONSULT", "Mnemonic" : "8"},
{"Row" : 26, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "DisplayText" : "HIV, Rapid", "Text" : "HIV RAPID TEST (results in 1-2 hours)", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "CONSULT ID FOR HIV POSITIVE PATIENTS", "Mnemonic" : "12"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX LRTZ COMPREHENSIVE METABOLIC + MG + PHOSPHORUS", "Text" : "ORDER LABS: COMPREHENSIVE METABOLIC + PHOSPHORUS", "Mnemonic" : "14"},
{"Row" : 33, "Column" : 1, "Item" : "LRTZ Hepatitis B DNA level (viral load)", "DisplayText" : "Hepatitis B DNA level (viral load)", "Text" : "HEPATITIS B DNA LEVEL (VIRAL LOAD)", "Mnemonic" : "16"},
{"Row" : 37, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "DisplayText" : "GI Liver", "Text" : "GASTROENTEROLOGY LIVER OUTPATIENT CONSULT", "Mnemonic" : "18"},
{"Row" : 46, "Column" : 1, "Item" : "LRTZ Hepatitis B DNA level (viral load)", "DisplayText" : "Hepatitis B DNA level (viral load)", "Text" : "Hepatitis B DNA level (viral load)", "Mnemonic" : "20"},
{"Row" : 55, "Column" : 1, "Item" : "PSOZID ENTECAVIR 0.5MG PO QDAY HEPATITIS B (ANTI-CD20 AB)", "DisplayText" : "Entecavir 0.5 mg po daily (throughout anti-CD20 antibody therapy", "Text" : "Entecavir 0.5 mg po daily (throughout anti-CD20 antibody therapy", "Mnemonic" : "22"},
{"Row" : 60, "Column" : 1, "Item" : "PSOZID ENTECAVIR 1MG PO QDAY HEPATITIS B (ANTI-CD20 AB)", "DisplayText" : "Entecavir 1 mg po daily (througout anti-CD20 antibody therapy", "Text" : "Entecavir 1 mg po daily (througout anti-CD20 antibody therapy", "Mnemonic" : "24"},
{"Row" : 65, "Column" : 1, "Item" : "PSOZID TENOFOVIR 300MG PO QDAY ANTI-CD20 THERAPY", "DisplayText" : "Tenofovir 300 mg PO daily (throughout anti-CD20 antibody therapy", "Text" : "Tenofovir 300 mg PO daily (throughout anti-CD20 antibody therapy", "Mnemonic" : "26"},
{"Row" :2, "Column" : 1, "Text" : "Hepatitis B evaluation for patients receiving Anti-CD20 Antibody Treatment", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "NOTE: OUTPATIENT ORDERS", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Before initiating anti-CD20 antibody treatment (rituximab, obinutuzumab,"}, 
{"Row" :5, "Column" : 1, "Text" : "ofatumumab) test all patients for Hepatitis B. Testing should be completed"}, 
{"Row" :6, "Column" : 1, "Text" : "within the last 6 months prior to the start of the initial infusion (same day"}, 
{"Row" :7, "Column" : 1, "Text" : "is acceptable, but not preferred). Annual Hepatitis B screening is not"}, 
{"Row" :8, "Column" : 1, "Text" : "necessary unless there are risk factors."}, 
{"Row" : 10, "Column" : 1, "Text" : "More information at VHA Oncology SharePoint site for hepatitis B reactivation: ", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Order Hepatitis B Serology Panel for all patients: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Includes hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody"}, 
{"Row" : 16, "Column" : 1, "Text" : "(total anti-HBcAb),and anti-hepatitis B surface antibody (anti-HBsAb)."}, 
{"Row" : 18, "Column" : 1, "Text" : "IF HBsAg or anti-HBcAb is positive, Consult GI for all services except", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Oncology: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "(Includes Rheumatology, Renal, Neurology, and Dermatology)"}, 
{"Row" : 23, "Column" : 1, "Text" : "IF HBsAg or anti-HBcAB is positive for an ONCOLOGY patient initial orders: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "a) Assess HIV status. To avoid potential HIV resistance-"}, 
{"Row" : 25, "Column" : 1, "Text" : "refer HIV positive patients to ID for management."}, 
{"Row" : 29, "Column" : 1, "Text" : "b) Obtain Labs: Comprehensive Metabolic AND Phosphorus"}, 
{"Row" : 32, "Column" : 1, "Text" : "c) Obtain HBV DNA level (viral load) initially"}, 
{"Row" : 35, "Column" : 1, "Text" : "d) Schedule GI Clinic Consult for co-management to order"}, 
{"Row" : 36, "Column" : 1, "Text" : "liver imaging and follow-up as indicated."}, 
{"Row" : 39, "Column" : 1, "Text" : "e) Start hepatitis B antiviral treatment (see below)"}, 
{"Row" : 40, "Column" : 1, "Text" : "Recommended Antiviral Treatment: ", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Continue antivirals throughout anti-CD20 Ab therapy and for an additional"}, 
{"Row" : 42, "Column" : 1, "Text" : "12 months to prevent hepatitis B reactivation, hepatitis, liver failure,"}, 
{"Row" : 43, "Column" : 1, "Text" : "and death."}, 
{"Row" : 45, "Column" : 1, "Text" : "Obtain HBV DNA level (viral load) every 3 months", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "IF PATIENT IS CURRENTLY ON HEPATITIS B ANTIVIRAL THERAPY: ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "(lamivudine, adefovir, or telbivudine)"}, 
{"Row" : 50, "Column" : 1, "Text" : "Consult the provider who ordered the antiviral and inform the"}, 
{"Row" : 51, "Column" : 1, "Text" : "provider the patient is being initiated on Anti-CD20 antibody therapy."}, 
{"Row" : 53, "Column" : 1, "Text" : "IF PATIENT IS NOT ON HEPATITIS B ANTIVIRAL THERAPY: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "Lamivudine-naive patients: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]"}, 
{"Row" : 58, "Column" : 1, "Text" : "Lamivudine-experienced patients: ", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Preferred Treatment: ", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]"}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 63, "Column" : 1, "Text" : "Alternative Treatment: ", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "IF creatinine clearance equal to or greater than 50 ml per minute"}, 
{"Row" : 66, "Column" : 1, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]"}, 
{"Row" : 69, "Column" : 1, "Text" : "References: "}, 
{"Row" : 71, "Column" : 1, "Text" : "Terrault NA, Hepatology 2016, 63:261"}, 
{"Row" : 72, "Column" : 1, "Text" : "Perrillo RP, Gastroenterology 2015, 148:221"}, 
{"Row" : 73, "Column" : 1, "Text" : "Hwang JP, Journal of Clinical Oncology 2015, 33:2212"}, 
{"Row" : 74, "Column" : 1, "Text" : "Up-to-Date"}
]},
{"Name" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 10DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 10 days", "Text" : "Acyclovir 400 mg PO TID for 10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" :7, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 10DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 10DS 1GM PO BID", "DisplayText" : "Valacyclovir 1gm po bid for 10 days", "Text" : "Valacyclovir 1 gm PO BID for 10 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 10DS 1GM PO BID", "DisplayText" : "Valacyclovir 1gm po bid for 10 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "HERPES WHITLOW (DIGIT OR HAND CELLULITIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Alternative for easier compliance schedule", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Whitlow, herpetic"}
]},
{"Name" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "DisplayText" : "Hidradenitis Suppurativa (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID CHLORHEXIDINE GLUCONATE WASH Q24H", "DisplayText" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h", "Text" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]", "Mnemonic" : "4a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID CHLORHEXIDINE GLUCONATE WASH Q24H", "DisplayText" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "DisplayText" : "Benzoyl peroxide 10% wash topically daily q24h ($)[M]", "Text" : "Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]", "Mnemonic" : "6a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "DisplayText" : "Benzoyl peroxide 10% wash topically daily q24h ($)[M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 44, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 1% CRM TOP BID PRN", "DisplayText" : "Clindamycin 1% cream topical bid prn", "Text" : "Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]", "Mnemonic" : "8a"},
{"Row" : 45, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 1% CRM TOP BID PRN", "DisplayText" : "Clindamycin 1% cream topical bid prn Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO Q12H 12WEEKS", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "10a"},
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO Q12H 12WEEKS", "DisplayText" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 51, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 100MG PO Q12H 12WEEKS", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks", "Mnemonic" : "12a"},
{"Row" : 52, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 100MG PO Q12H 12WEEKS", "DisplayText" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 300MG PO Q12H 12WEEKS", "DisplayText" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]", "Text" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]", "Mnemonic" : "14a"},
{"Row" : 56, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 300MG PO Q12H 12WEEKS", "DisplayText" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX OP MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "DisplayText" : "MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "Text" : "Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500", "Mnemonic" : "16a"},
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX NV MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "DisplayText" : "MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" :3, "Column" : 1, "Text" : "HIDRADENITIS SUPPURATIVA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A chronic inflammatory condition that typically involves occlusion, rupture,"}, 
{"Row" :6, "Column" : 1, "Text" : "abscess formation and infection of hair follicles as well as secondary infection"}, 
{"Row" :7, "Column" : 1, "Text" : "of apocrine glands/surrounding tissues. Lesions most often occur in the"}, 
{"Row" :8, "Column" : 1, "Text" : "intertriginous areas (axillae, inguinal and anogenital) in is associated with"}, 
{"Row" :9, "Column" : 1, "Text" : "smoking and obesity. There is a 40% genetic predisposition for hidradenitis"}, 
{"Row" : 10, "Column" : 1, "Text" : "suppurativa (HS) and is often accompanied by pain, malodor, and drainage."}, 
{"Row" : 11, "Column" : 1, "Text" : "Cultures are negative 50% of the time and often are polymicrobial with S."}, 
{"Row" : 12, "Column" : 1, "Text" : "epidermidis and S. aureus most isolated. The Hurley Staging System is often used"}, 
{"Row" : 13, "Column" : 1, "Text" : "to determine severity of HS."}, 
{"Row" : 15, "Column" : 1, "Text" : "Therapy generally consists of treatment of comorbidities that can exacerbate HS,"}, 
{"Row" : 16, "Column" : 1, "Text" : "avoidance of triggers, pain management, wound care, and topical/oral"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be"}, 
{"Row" : 18, "Column" : 1, "Text" : "used to treat certain patients. Biologics may be considered in Stage II-III HS."}, 
{"Row" : 20, "Column" : 1, "Text" : "Consult Dermatology in all cases", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Hurley Staging System: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Stage I: recurrent nodules and abscesses with minimal scarring"}, 
{"Row" : 24, "Column" : 1, "Text" : "Stage II: limited number of sinuses and/or scarring within a body region"}, 
{"Row" : 25, "Column" : 1, "Text" : "Stage III: multiple or extensive sinuses and/or scarring"}, 
{"Row" : 27, "Column" : 1, "Text" : "Duration of Therapy: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Treatment is typically for 12 weeks but may require longer durations in certain"}, 
{"Row" : 29, "Column" : 1, "Text" : "cases. Metronidazole should only be used for a maximum of 6 weeks to avoid"}, 
{"Row" : 30, "Column" : 1, "Text" : "neurologic toxicity."}, 
{"Row" : 32, "Column" : 1, "Text" : "Interventions for All Patients: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Smoking cessation, weight loss, avoidance of triggers, and pain management"}, 
{"Row" : 34, "Column" : 1, "Text" : "should be part of all treatment plans. Consult Dermatology for use of hormonal"}, 
{"Row" : 35, "Column" : 1, "Text" : "agents, steroids, retinoids, and surgery."}, 
{"Row" : 37, "Column" : 1, "Text" : "Optional Topical Treatment, May be Used in Addition to Oral Therapies Below: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 43, "Column" : 1, "Text" : "< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>"}, 
{"Row" : 47, "Column" : 1, "Text" : "Stage I-II Initial Treatment: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 54, "Column" : 1, "Text" : "Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline: ", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Stage II-III Failure of Oral Clindamycin: ", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12"}, 
{"Row" : 61, "Column" : 1, "Text" : "weeks"}, 
{"Row" : 64, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "References: "}, 
{"Row" : 67, "Column" : 1, "Text" : "Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019): "}, 
{"Row" : 68, "Column" : 1, "Text" : "76-90"}, 
{"Row" : 69, "Column" : 1, "Text" : "John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa"}, 
{"Row" : 70, "Column" : 1, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Management"}, 
{"Row" : 71, "Column" : 1, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,"}, 
{"Row" : 72, "Column" : 1, "Text" : "and diagnosis"}
]},
{"Name" : "ORZID3 GMENU HSV ENCEPHALITIS", "DisplayText" : "HSV encephalitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "HERPES SIMPLEX VIRUS ENCEPHALITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU IG DEFICIENCY HIS", "DisplayText" : "Immunoglobulin deficiency (Humoral immune system) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)"}, 
{"Row" :5, "Column" : 1, "Text" : "Antibody deficiency typically leads to recurrent, severe respiratory tract"}, 
{"Row" :6, "Column" : 1, "Text" : "infections associated with encapsulated bacteria, especially Streptococcus"}, 
{"Row" :7, "Column" : 1, "Text" : "pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes."}, 
{"Row" :9, "Column" : 1, "Text" : "Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "rotavirus is also common in some patients."}, 
{"Row" : 12, "Column" : 1, "Text" : "Preferred empirical treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 18, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 19, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "DisplayText" : "Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SEVERE/LIFE-THREATENING CLOSTRIDIUM DIFFICILE INFECTION", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "DisplayText" : "Complement Deficiency (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "COMPLEMENT DEFICIENCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Complement deficiency can be inherited or acquired complement deficiency."}, 
{"Row" :6, "Column" : 1, "Text" : "Acquired defects are usually a consequence of other diseases like systemic lupus"}, 
{"Row" :7, "Column" : 1, "Text" : "erythematosus.Complement deficiency leads to increased rates of infections,"}, 
{"Row" :8, "Column" : 1, "Text" : "usually of the upper respiratory tract, but also occasionally with bacteremia or"}, 
{"Row" :9, "Column" : 1, "Text" : "meningitis.Pathogens are usually Streptococcus pneumoniae, Neisseria"}, 
{"Row" : 10, "Column" : 1, "Text" : "meningitidis, and Neisseria gonorrhea."}, 
{"Row" : 12, "Column" : 1, "Text" : "Patients presenting with fever or other symptoms suggesting systemic bacterial"}, 
{"Row" : 13, "Column" : 1, "Text" : "infection should be treated immediately with antimicrobials active against these"}, 
{"Row" : 14, "Column" : 1, "Text" : "pathogens."}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred empirical treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 22, "Column" : 1, "Text" : "Rich RR et al, eds.Clinical Immunology"}, 
{"Row" : 23, "Column" : 1, "Text" : "Roitt I et al, eds.Immunology"}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)", "Text" : "Neutropenic fever", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "DisplayText" : "Prevention of infection in a patient with malignancy (Outpatient)", "Text" : "Prevention of bacterial infections in a patient with malignancy", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infection in a patient with malignancy", "Text" : "Prevention of fungal infections in a patient with malignancy", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prevention of antiviral infections in a patient with malignancy", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Malignancies affect host defenses in many ways.Hematogenous malignancies can"}, 
{"Row" :6, "Column" : 1, "Text" : "diminish the effectiveness of neutrophils and other cells involved in host"}, 
{"Row" :7, "Column" : 1, "Text" : "defense.Tumors often disrupt mucous membranes or blood vessels and allow"}, 
{"Row" :8, "Column" : 1, "Text" : "contaminating organisms into hollow cavities or the bloodstream.Chemotherapy"}, 
{"Row" :9, "Column" : 1, "Text" : "used to treat these malignancies often impairs mucus membranes and suppresses"}, 
{"Row" : 10, "Column" : 1, "Text" : "neutrophil production and function."}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical antimicrobials are not indicated for patients with malignancy and"}, 
{"Row" : 13, "Column" : 1, "Text" : "fever unless they have neutropenia or a specific infectious disease, except in"}, 
{"Row" : 14, "Column" : 1, "Text" : "specific circumstances."}, 
{"Row" : 23, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 24, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "DisplayText" : "Neurologial Dysfunction (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient)", "Text" : "Aspiration pneumonia", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "NEUROLOGICAL DYSFUNCTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Several types of neurological dysfunction predispose patients to infectious"}, 
{"Row" :6, "Column" : 1, "Text" : "diseases.Comatose patients are unable to keep weight off dependent tissues,"}, 
{"Row" :7, "Column" : 1, "Text" : "predisposing them to decubitus ulcers and pressure necrosis.Atelectasis is"}, 
{"Row" :8, "Column" : 1, "Text" : "common in obtunded patients who cannot cough or breathe deeply.When patients"}, 
{"Row" :9, "Column" : 1, "Text" : "require artificial ventilation, intubation compounds the risk of respiratory"}, 
{"Row" : 10, "Column" : 1, "Text" : "infection."}, 
{"Row" : 12, "Column" : 1, "Text" : "Neurological dysfunction of the bladder can interfere with normal bladder"}, 
{"Row" : 13, "Column" : 1, "Text" : "emptying and predisposes patients to bacteriuria.The risk of bacteruria"}, 
{"Row" : 14, "Column" : 1, "Text" : "increases if patients are catheterized.Antimicrobial treatment is not"}, 
{"Row" : 15, "Column" : 1, "Text" : "indicated for asymptomatic bacteriuria.It provides no benefit and increases"}, 
{"Row" : 16, "Column" : 1, "Text" : "risk of colonization with resistant organisms."}, 
{"Row" : 18, "Column" : 1, "Text" : "Neurological dysfunction of the gastrointestinal or pulmonary systems"}, 
{"Row" : 19, "Column" : 1, "Text" : "predisposes patients to aspiration of oropharyngeal or gastric contents."}, 
{"Row" : 20, "Column" : 1, "Text" : "Aspiration causes fever, inflammation, and/or pulmonary infiltrate, but does not"}, 
{"Row" : 21, "Column" : 1, "Text" : "require antimicrobial treatment. Bacterial pneumonia occurs in a minority of"}, 
{"Row" : 22, "Column" : 1, "Text" : "patients who experience significant aspiration, typically about 3 days later."}, 
{"Row" : 23, "Column" : 1, "Text" : "The patient usually improves for the first 2 days and then worsens as bacterial"}, 
{"Row" : 24, "Column" : 1, "Text" : "pneumonia develops with increased fever, new or progressive infiltrates,"}, 
{"Row" : 25, "Column" : 1, "Text" : "leukocytosis, and newly purulent sputum."}, 
{"Row" : 32, "Column" : 1, "Text" : "Rich RR, et al, eds.Clinical Immunology"}, 
{"Row" : 33, "Column" : 1, "Text" : "Roitt I, et al, eds.Immunology"}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "DisplayText" : "Infections in Immunocompromised patients (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "DisplayText" : "Basic concepts", "Text" : "Basic concepts", "Mnemonic" : "4"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "DisplayText" : "Altered microbial flora", "Text" : "Altered microbial flora", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "DisplayText" : "Complement Deficiency (Outpatient)", "Text" : "Complement deficiency", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "DisplayText" : "Diabetes Mellitus", "Text" : "Diabetes Mellitus", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "DisplayText" : "Hypochlorhydria", "Text" : "Hypochlorhydria", "Mnemonic" : "12"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "DisplayText" : "Malignancy (Outpatient)", "Text" : "Malignancy", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "DisplayText" : "Malnutrition", "Text" : "Malnutrition", "Mnemonic" : "16"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "DisplayText" : "Neurologial Dysfunction (Outpatient)", "Text" : "Neurological dysfunction", "Mnemonic" : "18"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "DisplayText" : "Neutropenia", "Text" : "Neutropenia", "Mnemonic" : "20"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)", "Text" : "Neutropenic fever", "Mnemonic" : "22"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx", "Text" : "Spleen absent or dysfunctional", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "DisplayText" : "Stress", "Text" : "Stress", "Mnemonic" : "26"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "DisplayText" : "Tobacco smoke", "Text" : "Tobacco smoke", "Mnemonic" : "28"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient)", "Text" : "Pneumocystis", "Mnemonic" : "30"},
{"Row" :3, "Column" : 1, "Text" : "++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS - OUTPATIENT ++", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Innate defects", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Last reviewed February 2012", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS", "Text" : "HIV", "Mnemonic" : "34"},
{"Row" :9, "Column" : 2, "Item" : "ORZID2 GMENU CMI DEFECTS", "DisplayText" : "Cell-mediated immunity (CMI) defects", "Text" : "Cell-mediated immunity (CMI) defects", "Mnemonic" : "36"},
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU IG DEFICIENCY HIS", "DisplayText" : "Immunoglobulin deficiency (Humoral immune system) - Outpatient", "Text" : "Immunoglobulin deficiency (humoral immune system)", "Mnemonic" : "38"},
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU TRANSPLANTATION", "DisplayText" : "Transplantation", "Text" : "Transplantation", "Mnemonic" : "40"},
{"Row" :7, "Column" : 2, "Text" : "Immune defects", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU IMPETIGO", "DisplayText" : "Impetigo (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID MUPIROCIN 2% OINT TID FOR 5 DAYS", "DisplayText" : "Mupirocin 2% Oint tid for 5 days ($$) [M]", "Text" : "Mupirocin ointment to affected area TID for 5 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID MUPIROCIN 2% OINT TID FOR 5 DAYS", "DisplayText" : "Mupirocin 2% Oint tid for 5 days ($$) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100MG PO bid ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 38, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "DisplayText" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100MG PO bid ($) [DI]", "Mnemonic" : "14a"},
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "16"},
{"Row" :2, "Column" : 1, "Text" : "Impetigo and Ecthyma"}, 
{"Row" :4, "Column" : 1, "Text" : "Impetigo is a superficial skin infection that rarely causes systemic"}, 
{"Row" :5, "Column" : 1, "Text" : "symptoms. Ecthyma is a skin infection characterized by crusted sores"}, 
{"Row" :6, "Column" : 1, "Text" : "beneath which ulcers form. It is a deep form of impetigo, as the same"}, 
{"Row" :7, "Column" : 1, "Text" : "bacteria causing the infection are involved. Ecthyma causes deeper"}, 
{"Row" :8, "Column" : 1, "Text" : "erosions of the skin into the dermis."}, 
{"Row" : 10, "Column" : 1, "Text" : "Gram stain and culture of the pus or exudates from skin lesions of"}, 
{"Row" : 11, "Column" : 1, "Text" : "impetigo and ecthyma are recommended to help identify whether"}, 
{"Row" : 12, "Column" : 1, "Text" : "Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause."}, 
{"Row" : 14, "Column" : 1, "Text" : "Bullous and non-bullous impetigo can be treated with oral or topical"}, 
{"Row" : 15, "Column" : 1, "Text" : "antimicrobials, but oral therapy is recommended for patients with"}, 
{"Row" : 16, "Column" : 1, "Text" : "numerous lesions or in outbreaks affecting several people to help"}, 
{"Row" : 17, "Column" : 1, "Text" : "decrease transmission of infection. Treatment for ecthyma should be an"}, 
{"Row" : 18, "Column" : 1, "Text" : "oral antimicrobial."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment for impetigo with few lesions", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment for ecthyma and for impetigo with numerous lesions or", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "whose symptoms have not responded to topical treatment", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Treat orally for 7 days"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative for penicillin allergy", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "IF MRSA confirmed or suspected: ", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 45, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014 59: 147"}, 
{"Row" : 46, "Column" : 1, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131"}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 7DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "8"}
]},
{"Name" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "DisplayText" : "Community acquired diarrhea (no recent travel) - Outpatient", "Text" : "Community acquired diarrhea (no recent travel)", "Mnemonic" : "4"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU TRAVELER DIARRHEA", "DisplayText" : "Traveler's diarrhea", "Text" : "Traveler's diarrhea", "Mnemonic" : "6"},
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA AEROMONAS", "DisplayText" : "Diarrhea with Aeromonas (Outpatient)", "Text" : "Aeromonas", "Mnemonic" : "8"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Adenovirus", "Mnemonic" : "10"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Astrovirus", "Mnemonic" : "12"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "DisplayText" : "Diarrhea with Campylobacter (Outpatient)", "Text" : "Campylobacter", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "DisplayText" : "Antibiotic Associated Colitis (C. Difficile Colitis)", "Text" : "[CLICK HERE] for mild to moderate disease", "Mnemonic" : "16"},
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "DisplayText" : "Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)", "Text" : "[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)", "Mnemonic" : "18"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "DisplayText" : "Diarrhea with Isospora belli (Outpatient)", "Text" : "Cystoisospora belli", "Mnemonic" : "20"},
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. PARVUM", "DisplayText" : "Diarrhea with Crytosporidium parvum (Outpatient)", "Text" : "Cryptosporidium parvum", "Mnemonic" : "22"},
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "DisplayText" : "Diarrhea with Cyclospora cayetanensis (Outpatient)", "Text" : "Cyclospora cayetanensis", "Mnemonic" : "24"},
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "DisplayText" : "Diarrhea with Entamoeba histolytica (Outpatient)", "Text" : "Entamoeba histolytica", "Mnemonic" : "26"},
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "DisplayText" : "Diarrhea with enterohemorrhagic E. Coli (Outpatient)", "Text" : "Escherichia coli [CLICK HERE], including varieties listed below: ", "Mnemonic" : "28"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "DisplayText" : "Diarrhea with Giardia lamblia (Outpatient)", "Text" : "Giardia duodenalis", "Mnemonic" : "30"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "DisplayText" : "Diarrhea with Microsporidia (Outpatient)", "Text" : "Microsporidia", "Mnemonic" : "32"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Norovirus", "Mnemonic" : "34"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Rotavirus", "Mnemonic" : "36"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "DisplayText" : "Viral Diarrhea", "Text" : "Sapovirus", "Mnemonic" : "38"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SALMONELLA", "DisplayText" : "Diarrhea with Salmonella (Outpatient)", "Text" : "Salmonella", "Mnemonic" : "40"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "DisplayText" : "Diarrhea with Shigella (Outpatient)", "Text" : "Shigella", "Mnemonic" : "42"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "DisplayText" : "Diarrhea with Vibrio cholera (Outpatient)", "Text" : "Vibrio cholerae", "Mnemonic" : "44"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "DisplayText" : "Diarrhea with non-cholera vibrio (Outpatient)", "Text" : "Vibrio non-cholerae", "Mnemonic" : "46"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "DisplayText" : "Diarrhea with Yersinia enterocolitica (Outpatient)", "Text" : "Yersinia enterocolitica", "Mnemonic" : "48"},
{"Row" :3, "Column" : 1, "Text" : "INFECTIOUS DIARRHEA / GASTROENTERITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most episodes of acute diarrhea are self limited and do not need to be evaluated"}, 
{"Row" :6, "Column" : 1, "Text" : "or treated. In most mild to moderate cases, antimicrobial therapy does not"}, 
{"Row" :7, "Column" : 1, "Text" : "provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is"}, 
{"Row" :8, "Column" : 1, "Text" : "detrimental in cases involving enterohemorrhagic Escherichia coli."}, 
{"Row" : 10, "Column" : 1, "Text" : "The decision for whether to test stool depends on illness severity and duration,"}, 
{"Row" : 11, "Column" : 1, "Text" : "the likelihood of specific infectious agents and the severity of any underlying"}, 
{"Row" : 12, "Column" : 1, "Text" : "diseases. Send stool sample for enteric pathogen PCR testing if the patient has"}, 
{"Row" : 13, "Column" : 1, "Text" : "volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24"}, 
{"Row" : 14, "Column" : 1, "Text" : "hours, temperature >38.4?C, or severe abdominal pain or signs of sepsis, or is"}, 
{"Row" : 15, "Column" : 1, "Text" : ">/= 70 years old or substantially immunocompromised. Replace fluid losses and"}, 
{"Row" : 16, "Column" : 1, "Text" : "correct electrolyte imbalances. Patients with diarrhea who were potentially"}, 
{"Row" : 17, "Column" : 1, "Text" : "exposed during a community outbreak of infectious diarrhea should be tested for"}, 
{"Row" : 18, "Column" : 1, "Text" : "the suspected bacterial, viral, and parasitic agents regardless of symptom"}, 
{"Row" : 19, "Column" : 1, "Text" : "severity."}, 
{"Row" : 21, "Column" : 1, "Text" : "Obtain blood cultures if patients have signs of septicemia, suspected enteric"}, 
{"Row" : 22, "Column" : 1, "Text" : "fever (e.g., fever plus recent travel to an endemic area or contact with someone"}, 
{"Row" : 23, "Column" : 1, "Text" : "who has enteric fever), other systemic symptoms, immune compromise, or other"}, 
{"Row" : 24, "Column" : 1, "Text" : "high-risk conditions."}, 
{"Row" : 26, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 28, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 29, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 30, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 32, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 33, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 34, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 35, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 37, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 40, "Column" : 1, "Text" : "Empirical antimicrobial treatment of diarrhea", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Treatment of diarrhea caused by specific bacteria, parasites, and viruses", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Clostridium difficile: "}, 
{"Row" : 60, "Column" : 1, "Text" : "Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),"}, 
{"Row" : 61, "Column" : 1, "Text" : "Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),"}, 
{"Row" : 62, "Column" : 1, "Text" : "Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)"}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 78, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 79, "Column" : 1, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview"}, 
{"Row" : 80, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 81, "Column" : 1, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich"}, 
{"Row" : 82, "Column" : 1, "Text" : "settings"}
]},
{"Name" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza Vaccination Recommendations", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "DisplayText" : "ANTIVIRAL TREATMENT OUTPATIENT", "Text" : "Antiviral Treatment Recommendations", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA CHEMOPROPHYLAXIS", "DisplayText" : "Early treatment as alternative to chemoprophylaxis: ", "Text" : "Chemoprophylaxis Recommendations", "Mnemonic" : "8"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ GMENU LAB NASOPHARYNGEAL TESTING MAIN", "DisplayText" : "Nasopharyngeal Testing Menu", "Text" : "Lab Influenza Testing Menu", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "Seasonal Influenza", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Last reviewed September 2022", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU INFLUENZA CHEMOPROPHYLAXIS", "DisplayText" : "Early treatment as alternative to chemoprophylaxis: ", "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "Early treatment as alternative to chemoprophylaxis: ", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "In most cases, if a person is suspected of having been exposed to influenza,"}, 
{"Row" :5, "Column" : 1, "Text" : "early treatment should signs or symptoms develop is preferred rather than"}, 
{"Row" :6, "Column" : 1, "Text" : "chemoprophylaxis."}, 
{"Row" :8, "Column" : 1, "Text" : "The provider should explain the early signs and symptoms of influenza to the"}, 
{"Row" :9, "Column" : 1, "Text" : "patient and advise the patient to immediately contact a health care provider"}, 
{"Row" : 10, "Column" : 1, "Text" : "for evaluation and possible early treatment if these symptoms or signs"}, 
{"Row" : 11, "Column" : 1, "Text" : "develop. Influenza-like symptoms or signs include fever, cough, sore throat,"}, 
{"Row" : 12, "Column" : 1, "Text" : "runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and"}, 
{"Row" : 13, "Column" : 1, "Text" : "diarrhea. Influenza can present without fever."}, 
{"Row" : 15, "Column" : 1, "Text" : "Health care providers should use clinical judgment regarding situations where"}, 
{"Row" : 16, "Column" : 1, "Text" : "early recognition of illness and treatment might be an appropriate"}, 
{"Row" : 17, "Column" : 1, "Text" : "alternative to chemoprophylaxis."}, 
{"Row" : 19, "Column" : 1, "Text" : "Early treatment alternative or chemoprophylaxis may be considered: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "*Persons who are part of a high-risk group and are household or close"}, 
{"Row" : 21, "Column" : 1, "Text" : "contacts of someone with influenza-like illness"}, 
{"Row" : 24, "Column" : 1, "Text" : "Chemoprophylaxis recommended: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Chemoprophylaxis considered: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "*Atypical situations (such as case clusters). Contact state health department"}, 
{"Row" : 34, "Column" : 1, "Text" : "for consultation."}, 
{"Row" : 36, "Column" : 1, "Text" : "Antiviral Prophylaxis Recommendations: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such"}, 
{"Row" : 43, "Column" : 1, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have"}, 
{"Row" : 44, "Column" : 1, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using"}, 
{"Row" : 45, "Column" : 1, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the"}, 
{"Row" : 46, "Column" : 1, "Text" : "bronchodilator."}, 
{"Row" : 48, "Column" : 1, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) daily for 14 days ($) [O] Duration based on"}, 
{"Row" : 54, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Chemoprophylaxis duration: 7 days after last known exposure"}, 
{"Row" : 25, "Column" : 1, "Text" : "*For control of outbreaks in institutional settings (long-term care"}, 
{"Row" : 26, "Column" : 1, "Text" : "facilities and hospitals)"}, 
{"Row" : 27, "Column" : 1, "Text" : "Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week"}, 
{"Row" : 28, "Column" : 1, "Text" : "after the last known case identified"}, 
{"Row" : 29, "Column" : 1, "Text" : "Note: Antiviral chemoprophylaxis is recommended for all residents, including"}, 
{"Row" : 30, "Column" : 1, "Text" : "those who have received influenza vaccination."}, 
{"Row" : 37, "Column" : 1, "Text" : "Preferred treatment: ", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 OSELTAMIVIR 75 MG PO QDAY PROPHY 14 DAYS", "DisplayText" : "Oseltamivir 75 mg po daily for 14 days ($) [R] Duration based on last exposure", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID3 OSELTAMIVIR 75 MG PO QDAY 14D PROPHY", "DisplayText" : "Oseltamivir 75 mg po daily for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 41, "Column" : 1, "Text" : "Alternative treatment: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Requires Infectious Disease Approval", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "last exposure"}, 
{"Row" : 50, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 51, "Column" : 1, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for"}, 
{"Row" : 52, "Column" : 1, "Text" : "patients wt <80kg ($$$) [O]"}, 
{"Row" : 55, "Column" : 1, "Text" : "UpToDate Seasonal influenza in adults: Role of antiviral prophylaxis for"}, 
{"Row" : 56, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 57, "Column" : 1, "Text" : "Centers for Disease Control (Accessd 9/20/22)"}, 
{"Row" : 58, "Column" : 1, "Text" : "https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm"}
]},
{"Name" : "ORZID3 GMENU INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MVAHCS Vaccination Recommendations for Outpatients: ", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Annual influenza vaccination is recommended for all persons aged 6"}, 
{"Row" :8, "Column" : 1, "Text" : "months and older without a specific contraindication."}, 
{"Row" : 13, "Column" : 1, "Text" : "B viruses."}, 
{"Row" : 28, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Minneapolis VAHCS Influenza Commitee 2022-2023"}, 
{"Row" : 29, "Column" : 1, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2022, 71(1):1-28"}, 
{"Row" : 22, "Column" : 1, "Text" : "Recommendation for adults aged >/= 65 years: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Recommendation for adults aged <65 years: ", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Per available stock and ACIP 2022-2023 recommendations, the MVAHCS will provide: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Adjuvanted influenza vaccines - an ingredient is added to help create a"}, 
{"Row" : 10, "Column" : 1, "Text" : "stronger immune response."}, 
{"Row" : 11, "Column" : 1, "Text" : "Quadrivalent influenza vaccine - made up of the four flu strains most likely"}, 
{"Row" : 12, "Column" : 1, "Text" : "to cause the flu during the upcoming season (H1N1, H3N2, and two group"}, 
{"Row" : 26, "Column" : 1, "Text" : "*Standard quadrivalent influenza vaccine"}, 
{"Row" : 20, "Column" : 1, "Text" : "*Standing orders - no patient specific order needed"}, 
{"Row" : 15, "Column" : 1, "Text" : "Eggs and latex allergies are NOT considered contraindications to receiving"}, 
{"Row" : 16, "Column" : 1, "Text" : "the vaccine, the only contraindication to the flu vaccination is severe"}, 
{"Row" : 17, "Column" : 1, "Text" : "allergic reaction (i.e. Anaphylactic reactions)."}, 
{"Row" : 23, "Column" : 1, "Text" : "*Adjuvanted influenza vaccine (Flu-Ad)"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZ GTX ABX URL INFLUENZA OUTPATIENT", "DisplayText" : "Influenza vaccine", "Text" : "[Click here] Outpatient Influenza Vaccine Guidelines", "Mnemonic" : "4"}
]},
{"Name" : "ORZID3 GMENU INI EPISODE ABX ASSOC COLITIS", "DisplayText" : "Initial Episode of Antibiotic Associated Colitis... " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID VANCOMYCIN 125MG CAP QID 10DS", "DisplayText" : "Vancomycin 125 mg PO QID for 10 days ($) [M]", "Text" : "Vancomycin 125 mg PO QID for 10 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID VANCOMYCIN 125MG CAP QID 10DS", "DisplayText" : "Vancomycin 125 mg PO QID for 10 days ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :9, "Column" : 1, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic"}, 
{"Row" : 10, "Column" : 1, "Text" : "therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 12, "Column" : 1, "Text" : "Initial Episode Preferred Treatment: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 32, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 33, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 34, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical"}, 
{"Row" : 35, "Column" : 1, "Text" : "manifestations and diagnosis"}, 
{"Row" : 15, "Column" : 1, "Text" : "(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,"}, 
{"Row" : 16, "Column" : 1, "Text" : "and/or immunosuppression)"}, 
{"Row" : 14, "Column" : 1, "Text" : "Patient at increased risk of CDI recurrence: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "DisplayText" : "Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Text" : "Patient not meeting criteria above for increased risk of CDI recurrence: ", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patient with clinical symptom onset (e.g., 3 or more unformed stools in 24 hours"}, 
{"Row" :7, "Column" : 1, "Text" : "after discontinuation of laxatives) and laboratory confirmation of CDI."}, 
{"Row" : 31, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "DisplayText" : "Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Text" : "Fulminant CDI (hypotension or shock, ileus, megacolon)", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "INITIAL EPISODE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Item" : "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING", "DisplayText" : "Clostridioides difficile Infection (CDI) 2-step testing", "Text" : "Information on C difficile lab testing", "Mnemonic" : "3"}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "DisplayText" : "Interim results:Gram-negative bacilli (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE BACILLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can"}, 
{"Row" :6, "Column" : 1, "Text" : "show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and"}, 
{"Row" :7, "Column" : 1, "Text" : "Prevotella spp. usually grow anaerobically (but can show up in an aerobic"}, 
{"Row" :8, "Column" : 1, "Text" : "bottle). Most other gram-negative bacilli are facultative, i.e. they can grow"}, 
{"Row" :9, "Column" : 1, "Text" : "in aerobic or anaerobic culture conditions."}, 
{"Row" : 11, "Column" : 1, "Text" : "Some antimicrobial combinations are synergistic in vitro against some Gram-"}, 
{"Row" : 12, "Column" : 1, "Text" : "negative bacilli. Combination therapy has not been shown to improve outcomes"}, 
{"Row" : 13, "Column" : 1, "Text" : "in most circumstances. Single drug therapy is used in most cases. Contact"}, 
{"Row" : 14, "Column" : 1, "Text" : "Infectious Diseases for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Use susceptibility information to select an antimicrobial when a pathogen is"}, 
{"Row" : 17, "Column" : 1, "Text" : "identified."}, 
{"Row" : 19, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford Keyword: Antibacterial Activity Spectra"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford Keyword: Pseudomonas aeruginosa"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas"}, 
{"Row" : 28, "Column" : 1, "Text" : "aeruginosa infections"}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "DisplayText" : "Iterim report of Gram-negative cocci (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE COCCI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or Moraxella."}, 
{"Row" :7, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 10, "Column" : 1, "Text" : "References: "}, 
{"Row" : 12, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 13, "Column" : 1, "Text" : "Sanford keyword: Neisseria meningitidis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Sanford keyword: Neisseia gonorrhoeae"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Moraxella catarrhalis"}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "DisplayText" : "Interim report of Gram-positive Bacilli (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "DisplayText" : "Large uniform bacilli in an aerobic bottle (Outpatient)", "Text" : "LARGE UNIFORM BACILLI in an AEROBIC bottle", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "DisplayText" : "Large uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "LARGE UNIFORM BACILLI in an ANAEROBIC bottle", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "DisplayText" : "Small uniform bacilli in an anaerobic bottle (Outpatient)", "Text" : "SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "DisplayText" : "Small uniform bacillin in an aerobic bottle (Outpatient)", "Text" : "SMALL PLEOMORPHIC BACILLI in AEROBIC bottle", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE BACILLI", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "There are three typical morphologies (1)large and regular, (2)medium sized and"}, 
{"Row" :6, "Column" : 1, "Text" : "variable, and (3)small and pleomorphic. The large, uniformly rod-shaped Gram-"}, 
{"Row" :7, "Column" : 1, "Text" : "positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species"}, 
{"Row" :8, "Column" : 1, "Text" : "(anaerobic). Bacillus spp. include Bacillus subtilis (usually a contaminant),"}, 
{"Row" :9, "Column" : 1, "Text" : "Bacillus cereus, and Bacillus anthracis. Medium-sized Gram-positive bacilli are"}, 
{"Row" : 10, "Column" : 1, "Text" : "usually Lactobacilli (anaerobic). Small and pleomorphic bacilli are usually"}, 
{"Row" : 11, "Column" : 1, "Text" : "Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and"}, 
{"Row" : 12, "Column" : 1, "Text" : "Corynebacteria (aerobic)"}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "DisplayText" : "Interim report of Gram-positive cocci in pairs (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "Help, additional information: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page (instructions, restrictions, microbiology, etc.)", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "Consult Infectious Diseases", "Mnemonic" : "04"},
{"Row" :6, "Column" : 1, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS"}, 
{"Row" :8, "Column" : 1, "Text" : "A preliminary report of gram-positive cocci in pairs suggests staphylococci,"}, 
{"Row" :9, "Column" : 1, "Text" : "streptococci, or enterococci.If the patient is severely ill, is likely"}, 
{"Row" : 10, "Column" : 1, "Text" : "colonized with resistant organisms, or if staphylococci or enterococci are"}, 
{"Row" : 11, "Column" : 1, "Text" : "likely, treat with vancomycin until susceptibility results are known."}, 
{"Row" : 12, "Column" : 1, "Text" : "Cephalosporins are not active against enterococci or methicillin-resistant"}, 
{"Row" : 13, "Column" : 1, "Text" : "staphylococcus aureus.If encapsulated streptococci are likely, treat with"}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "06"},
{"Row" : 20, "Column" : 1, "Text" : "Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA.The Sanford Guide to"}, 
{"Row" : 21, "Column" : 1, "Text" : "Antimicrobial Therapy.35th ed.Hyde Park, VT: Antimicrobial Therapy Inc,"}, 
{"Row" : 22, "Column" : 1, "Text" : "2005."}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell GL, Bennett JE, Dolin R, eds.Principles and Practice of Infectious"}, 
{"Row" : 25, "Column" : 1, "Text" : "Diseases.6th ed.Philadelphia, PA: Churchill-Livingston, 2005."}, 
{"Row" : 27, "Column" : 1, "Text" : "Medical Letter Treatment Guidelines 2007, 5:57"}, 
{"Row" : 14, "Column" : 1, "Text" : "penicillin or cefazolin.If pneumococci are likely, treat with"}, 
{"Row" : 15, "Column" : 1, "Text" : "penicillin or ceftriaxone."}, 
{"Row" : 17, "Column" : 1, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobiala"}
]},
{"Name" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED INFECTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU KERATITIS", "DisplayText" : "Keratitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Herpes keratitis", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 0.5% OPH 1 DROP Q1H 14DAYS", "DisplayText" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) every 1 hour", "Text" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]", "Mnemonic" : "6a"},
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 0.5% OPH 1 DROP Q1H 14DAYS", "DisplayText" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP CEFAZ 5% OPH GENT 15MG/ML OPH Q1H 14DAYS", "DisplayText" : "Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops <AND> gentamicin 15 mg/ml", "Text" : "Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml", "Mnemonic" : "8a"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX NV CEFAZ 5% OPH GENT 15MG/ML OPH Q1H 14DAYS", "DisplayText" : "Cefazolin 50 Non-VA ophthalmic drops: 1-2 drops <AND> gentamicin 15 mg/ml", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "KERATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Keratitis is an emergency requiring prompt treatment to prevent vision loss."}, 
{"Row" :6, "Column" : 1, "Text" : "Contact Ophthalmology immediately."}, 
{"Row" :8, "Column" : 1, "Text" : "Keratitis is associated with viral or bacterial infection, trauma, foreign"}, 
{"Row" :9, "Column" : 1, "Text" : "bodies, or allergies. About half of cases of infectious keratitis are caused by"}, 
{"Row" : 10, "Column" : 1, "Text" : "bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and"}, 
{"Row" : 11, "Column" : 1, "Text" : "gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites"}, 
{"Row" : 12, "Column" : 1, "Text" : "have also been associated with corneal infection. Obtain corneal scrapings for"}, 
{"Row" : 13, "Column" : 1, "Text" : "gram stain and bacterial and viral cultures and start empirical therapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "immediately."}, 
{"Row" : 16, "Column" : 1, "Text" : "Link to herpes keratitis page"}, 
{"Row" : 19, "Column" : 1, "Text" : "If bacterial keratitis is likely, contact ophthalmology to obtain a corneal"}, 
{"Row" : 20, "Column" : 1, "Text" : "scraping and give empirical antibacterial drops immediately. Modify therapy"}, 
{"Row" : 21, "Column" : 1, "Text" : "based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic"}, 
{"Row" : 22, "Column" : 1, "Text" : "corticosteroids are contraindicated in patients with keratitis."}, 
{"Row" : 24, "Column" : 1, "Text" : "Duration of therapy", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment should be continued until ulcer and other signs of infectious"}, 
{"Row" : 26, "Column" : 1, "Text" : "keratitis have resolved. A minimum of two weeks and in rare cases, up to a month"}, 
{"Row" : 27, "Column" : 1, "Text" : "of therapy may be required."}, 
{"Row" : 29, "Column" : 1, "Text" : "Mild to moderate bacterial keratitis empirical treatment", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Severe (vision-threatening) bacterial keratitis empirical treatment", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)"}, 
{"Row" : 38, "Column" : 1, "Text" : "Suspected MRSA", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin"}, 
{"Row" : 40, "Column" : 1, "Text" : "eye drops. Vancomycin eye drops must be specially compounded and managed by"}, 
{"Row" : 41, "Column" : 1, "Text" : "Ophthalmology."}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Lin et al., Ophthalmology. 2019,126(1):1-55"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Microbial keratitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Keratitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-to-Date article:Complications of contact lenses"}
]},
{"Name" : "ORZID3 GMENU LEISHMANIASIS", "DisplayText" : "Leishmaniasis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LEISHMANIASIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and treatment are complex.Consult Infectious Diseases and/or"}, 
{"Row" :6, "Column" : 1, "Text" : "Dermatology in all cases."}
]},
{"Name" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "DisplayText" : "Large uniform bacilli in an aerobic bottle (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Large uniform bacilli in an aerobic bottle usually suggest Bacillus species."}, 
{"Row" :6, "Column" : 1, "Text" : "Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but"}, 
{"Row" :7, "Column" : 1, "Text" : "usually pathogenic. If Bacillus anthracis is suspected or isolated contact"}, 
{"Row" :8, "Column" : 1, "Text" : "Infectious Diseases immediately."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical treatment of suspected non-anthracis Bacillus spp. associated with", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 13, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Empirical treatment of suspected Bacillus anthracis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 19, "Column" : 1, "Text" : "References"}, 
{"Row" : 21, "Column" : 1, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2"}, 
{"Row" : 22, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species"}
]},
{"Name" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "DisplayText" : "Large uniform bacilli in an anaerobic bottle (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a"}, 
{"Row" :6, "Column" : 1, "Text" : "potentially severe pathogen. Combination therapy is recommended for necrotizing"}, 
{"Row" :7, "Column" : 1, "Text" : "infections as clindamycin has the theoretical benefit of inhibiting toxin"}, 
{"Row" :8, "Column" : 1, "Text" : "production."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical treatment of mild to moderate infection", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 13, "Column" : 1, "Text" : "Empirical treatment of severe or necrotizing infection", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 17, "Column" : 1, "Text" : "References"}, 
{"Row" : 19, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Clostridium perfingens"}, 
{"Row" : 21, "Column" : 1, "Text" : "Stevens et al., Clinical Infectious Diseases 2014 59.2"}
]},
{"Name" : "ORZID3 GMENU LUNG ABSCESS", "DisplayText" : "Lung abscess (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 6WKS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125 mg po bid for 6 weeks", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 6WKS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125 mg po bid for 6 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 6WKS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 6 weeks", "Text" : "Clindamycin 300 mg po q6h ($) [H,O]", "Mnemonic" : "6a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 6WKS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 6 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "LUNG ABSCESS"}, 
{"Row" :5, "Column" : 1, "Text" : "Pulmonary and/or Infectious Diseases consultations are strongly encouraged for"}, 
{"Row" :6, "Column" : 1, "Text" : "all cases.Obtain samples for gram stain and culture from fine needle"}, 
{"Row" :7, "Column" : 1, "Text" : "aspiration whenever possible.Sputum culture is less helpful because it will be"}, 
{"Row" :8, "Column" : 1, "Text" : "contaminated with upper respiratory flora.Classically, lung abscess is a"}, 
{"Row" :9, "Column" : 1, "Text" : "complication of mixed anaerobic and aerobic pulmonary infection. The initial"}, 
{"Row" : 10, "Column" : 1, "Text" : "infection may or may not be clinically apparent.Malaise, weight loss, fever,"}, 
{"Row" : 11, "Column" : 1, "Text" : "chills, and malodorous sputum typically develop over a period of weeks."}, 
{"Row" : 13, "Column" : 1, "Text" : "Cavitation and/or abscess can occur in cases of pneumonia from a single"}, 
{"Row" : 14, "Column" : 1, "Text" : "pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa."}, 
{"Row" : 15, "Column" : 1, "Text" : "Antimicrobial treatment should be directed against the specific pathogen."}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat for 6 to 8 weeks and adjust treatment based on clinical response.Oral"}, 
{"Row" : 18, "Column" : 1, "Text" : "medications should be used in patients who can take them."}, 
{"Row" : 20, "Column" : 1, "Text" : "Preferred oral treatment: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative for patient with severe penicillin allergy: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Bartlett JG Anaerobe 2012, 18:234"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases"}, 
{"Row" : 31, "Column" : 1, "Text" : "Harrison's chapter: Infections due to mixed organisms"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword lung abscess"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "DisplayText" : "Lungs and Mediastinum (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "DisplayText" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "Bronchitis", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU EMPYEMA", "DisplayText" : "Empyema (Outpatient)", "Text" : "Empyema", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "DisplayText" : "Bronchitis/COPD Exacerbation", "Text" : "Exacerbation of chronic obstructive pulmonary disease (COPD)", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "Influenza Seasonal", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "DisplayText" : "Lung abscess (Outpatient)", "Text" : "Lung abscess", "Mnemonic" : "14"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU MEDIASTINITIS", "DisplayText" : "Mediastinitis (Outpatient)", "Text" : "Mediastinitis", "Mnemonic" : "16"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PERTUSSIS", "DisplayText" : "Pertussis (Outpatient)", "Text" : "Pertussis", "Mnemonic" : "18"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU TUBERCULOSIS", "DisplayText" : "Tuberculosis (Outpatient)", "Text" : "Tuberculosis", "Mnemonic" : "20"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Azithromycin for prevention of COPD exacerbations", "Mnemonic" : "22"},
{"Row" :3, "Column" : 1, "Text" : "++LUNGS AND MEDIASTINUM - OUTPATIENT++", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "DisplayText" : "Aspiration pneumonia (Outpatient)", "Text" : "Aspiration pneumonia", "Mnemonic" : "26"},
{"Row" :7, "Column" : 2, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "DisplayText" : "Community acquired pneumonia (Outpatient)", "Text" : "Community-acquired pneumonia (CAP)", "Mnemonic" : "28"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient)", "Text" : "Nosocomial pneumonia (including HAP and VAP)", "Mnemonic" : "30"},
{"Row" :5, "Column" : 2, "Text" : "Pneumonia", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "DisplayText" : "Acute neurological disease associated with Lyme disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more"}, 
{"Row" :6, "Column" : 1, "Text" : "extensive neurological disease with intravenous antimicrobials."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Treat for 14 to 21 days."}, 
{"Row" : 13, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for 14 to 21 days"}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment of neurological disease other than Bell palsy", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 22, "Column" : 1, "Text" : "References"}, 
{"Row" : 24, "Column" : 1, "Text" : "Halperin et. al., Neurology (2007) 69.91-102"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 27, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "DisplayText" : "Arthritis associated with Lyme disease (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 28DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 28 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 28 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 28DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 28 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 28DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 28 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 28 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 28DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 28 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ARTHRITIS ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases respond to a 28 day course of oral antimicrobials. If symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "persist or recur, Consult Infectious Diseases or Rheumatology."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 17, "Column" : 1, "Text" : "References"}, 
{"Row" : 19, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 21, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID3 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" :9, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment of first degree or second degree heart block", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment of third degree heart block or other manifestation", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Refer to inpatient Antimicrobial CDSS"}, 
{"Row" : 19, "Column" : 1, "Text" : "References"}, 
{"Row" : 21, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 22, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 23, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis", "Text" : "Lyme Disease Prophylaxis", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease (Outpatient)", "Text" : "Erythema migrans associated with Lyme disease (outpatient)", "Mnemonic" : "6"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "DisplayText" : "Acute neurological disease associated with Lyme disease (Outpatient)", "Text" : "Acute neurological disease associated with Lyme disease (outpatient)", "Mnemonic" : "8"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "DisplayText" : "Arthritis associated with Lyme disease (Outpatient)", "Text" : "Arthritis associated with Lyme disease (outpatient)", "Mnemonic" : "10"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU LYME CARDIAC DISEASE", "DisplayText" : "Cardiac disease associated with Lyme disease (Outpatient)", "Text" : "Cardiac disease associated with Lyme disease (outpatient)", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an"}, 
{"Row" :6, "Column" : 1, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30"}, 
{"Row" :7, "Column" : 1, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness."}, 
{"Row" :8, "Column" : 1, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and"}, 
{"Row" :9, "Column" : 1, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick"}, 
{"Row" : 10, "Column" : 1, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not"}, 
{"Row" : 11, "Column" : 1, "Text" : "be treated with antimicrobials."}, 
{"Row" : 13, "Column" : 1, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who"}, 
{"Row" : 14, "Column" : 1, "Text" : "have been bitten while in endemic areas."}, 
{"Row" : 17, "Column" : 1, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to"}, 
{"Row" : 18, "Column" : 1, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged."}, 
{"Row" : 26, "Column" : 1, "Text" : "References"}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 29, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 30, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}
]},
{"Name" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "DisplayText" : "Lyme Disease Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "DisplayText" : "IXODES IDENTIFACTION LINK", "Text" : "Ixodes scapularis identification", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX TICKBORNE RISK MAP", "DisplayText" : "TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Mnemonic" : "6"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 200MG PO ONCE", "DisplayText" : "Doxyclycline PO 200mg once ($) [DI]", "Text" : "Doxyclycline PO 200mg once ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 200MG PO ONCE", "DisplayText" : "Doxyclycline PO 200mg once ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "LYME DISEASE PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-"}, 
{"Row" :6, "Column" : 1, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis"}, 
{"Row" :7, "Column" : 1, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%"}, 
{"Row" :8, "Column" : 1, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease."}, 
{"Row" :9, "Column" : 1, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease"}, 
{"Row" : 10, "Column" : 1, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes"}, 
{"Row" : 11, "Column" : 1, "Text" : "scapularis tick."}, 
{"Row" : 13, "Column" : 1, "Text" : "All following criteria must be met to be considered for prophylactic treatment: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)"}, 
{"Row" : 15, "Column" : 1, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes"}, 
{"Row" : 16, "Column" : 1, "Text" : "scalpularis. Follow link below for identification guide: "}, 
{"Row" : 18, "Column" : 1, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of"}, 
{"Row" : 19, "Column" : 1, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area."}, 
{"Row" : 20, "Column" : 1, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed."}, 
{"Row" : 21, "Column" : 1, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes"}, 
{"Row" : 22, "Column" : 1, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota"}, 
{"Row" : 23, "Column" : 1, "Text" : "counties where there is high risk of tickborne disease are shown in the"}, 
{"Row" : 24, "Column" : 1, "Text" : "following link: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the"}, 
{"Row" : 27, "Column" : 1, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B."}, 
{"Row" : 28, "Column" : 1, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed."}, 
{"Row" : 29, "Column" : 1, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick"}, 
{"Row" : 30, "Column" : 1, "Text" : "bite in New England or Mid-Atlantic States."}, 
{"Row" : 32, "Column" : 1, "Text" : "Prophylactic treatment if all above criteria are met", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089"}, 
{"Row" : 40, "Column" : 1, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24"}, 
{"Row" : 41, "Column" : 1, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)"}, 
{"Row" : 42, "Column" : 1, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html"}, 
{"Row" : 43, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)"}, 
{"Row" : 44, "Column" : 1, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf"}, 
{"Row" : 45, "Column" : 1, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)"}, 
{"Row" : 46, "Column" : 1, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf"}
]},
{"Name" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "DisplayText" : "Erythema migrans associated with Lyme disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases."}, 
{"Row" :6, "Column" : 1, "Text" : "It is typically an erythematous circular rash, 5cm or larger in diameter, with"}, 
{"Row" :7, "Column" : 1, "Text" : "induration and central clearing (although other patterns occur). It usually"}, 
{"Row" :8, "Column" : 1, "Text" : "develops at the site of the bite and/or in one or more distant locations. The"}, 
{"Row" :9, "Column" : 1, "Text" : "rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days"}, 
{"Row" : 10, "Column" : 1, "Text" : "after a tick bite are not from Lyme disease."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For pregnant patients or patients with doxycycline allergy"}, 
{"Row" : 21, "Column" : 1, "Text" : "References"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanchez et al., JAMA (2016) 315.16"}, 
{"Row" : 25, "Column" : 1, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134"}
]},
{"Name" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "DisplayText" : "Malignant otitis externa (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 28DS", "DisplayText" : "Ciprofloxacin 750mg po bid for 28 days", "Text" : "Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 28DS", "DisplayText" : "Ciprofloxacin 750mg po bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "MALIGNANT OTITIS EXTERNA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Those who are elderly, diabetic, immunocompromised and debilitated are at"}, 
{"Row" :6, "Column" : 1, "Text" : "highest risk. Most cases are associated with Pseudomonas aeruginosa, but other"}, 
{"Row" :7, "Column" : 1, "Text" : "pathogens can be involved. Obtain culture to identify etiologic agent and"}, 
{"Row" :8, "Column" : 1, "Text" : "susceptibilities. Obtain a CT scan to determine whether osteomyelitis is"}, 
{"Row" :9, "Column" : 1, "Text" : "present. ENT and Infectious Disease consultations are recommended."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of uncomplicated disease", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment of advanced disease, immunocompromised patients, or for coverage of", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "fluoroquinolone resistant Pseudomonas aeruginosa, in addition to above therapy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 18, "Column" : 1, "Text" : "Treatment of early infection or step-down treatment after initial intravenous", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "therapy.", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "References: "}, 
{"Row" : 27, "Column" : 1, "Text" : "Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell"}, 
{"Row" : 28, "Column" : 1, "Text" : "chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Otitis Externa"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date article: Malignant (necrotizing) external otitis"}
]},
{"Name" : "ORZID3 GMENU MASTOIDITIS", "DisplayText" : "Mastoiditis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 CEFUROXIME 500MG PO BID 7DS", "DisplayText" : "Cefuroxime 500 mg PO q12h for 7 days ($) [R]", "Text" : "Cefuroxime 500 mg PO q12h for 7 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 CEFUROXIME 500MG PO BID 7DS", "DisplayText" : "Cefuroxime 500 mg PO q12h for 7 days ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 28 DAYS", "DisplayText" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)", "Mnemonic" : "10a"},
{"Row" : 52, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 28 DAYS", "DisplayText" : "Cipro-Dex otic 4 drops in affected ear(s) BID for 4 weeks ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 28 DAYS", "DisplayText" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Mnemonic" : "12a"},
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 28 DAYS", "DisplayText" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "MASTOIDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Mastoiditis", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Acute mastoiditis most commonly occurs as a suppurative complication of acute"}, 
{"Row" :7, "Column" : 1, "Text" : "otitis media. Diagnosis is supported by CT or MRI imaging and culture of"}, 
{"Row" :8, "Column" : 1, "Text" : "drainage. Antibiotics and drainage of middle ear are sufficient treatment in"}, 
{"Row" :9, "Column" : 1, "Text" : "most cases. Mastoidectomy is necessary if abscess has formed in the mastoid"}, 
{"Row" : 10, "Column" : 1, "Text" : "bone. If complication of first episode of acute otitis media, etiologies"}, 
{"Row" : 11, "Column" : 1, "Text" : "typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,"}, 
{"Row" : 12, "Column" : 1, "Text" : "or Staphylococcus aureus. If secondary to chronic otitis media, etiologies"}, 
{"Row" : 13, "Column" : 1, "Text" : "typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually too ill for outpatient therapy. ENT consultation recommended. Obtain"}, 
{"Row" : 15, "Column" : 1, "Text" : "cultures of auditory canal or middle ear fluid (preferred)."}, 
{"Row" : 17, "Column" : 1, "Text" : "Empirical treatment of uncomplicated disease", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 20, "Column" : 1, "Text" : "Empirical Treatment of complicated disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 23, "Column" : 1, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "who can tolerate oral therapy. Base selection on culture results. Adjust for a", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "total duration of 3 weeks of antimicrobial therapy.", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 34, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Chronic Mastoiditis", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Chronic mastoiditis is usually the result of chronic otitis media with"}, 
{"Row" : 38, "Column" : 1, "Text" : "perforation of the tympanic membrane. There is often associated formation of a"}, 
{"Row" : 39, "Column" : 1, "Text" : "cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and"}, 
{"Row" : 40, "Column" : 1, "Text" : "culture of drainage. Long term treatment with topical antimicrobials is first"}, 
{"Row" : 41, "Column" : 1, "Text" : "line therapy. Infection is often polymicrobial, including Staphylococcus aureus,"}, 
{"Row" : 42, "Column" : 1, "Text" : "Pseudomonas aeruginosa and anaerobes. Treatment should be managed in"}, 
{"Row" : 43, "Column" : 1, "Text" : "collaboration with otolaryngology and includes topical antimicrobials, care of"}, 
{"Row" : 44, "Column" : 1, "Text" : "external auditory canal, and is some cases mastoidectomy. If possible, withhold"}, 
{"Row" : 45, "Column" : 1, "Text" : "therapy until a pathogen is identified by culture of drainage to direct therapy."}, 
{"Row" : 46, "Column" : 1, "Text" : "Specific drug choice dictated by culture results."}, 
{"Row" : 48, "Column" : 1, "Text" : "Empirical Treatment"}, 
{"Row" : 49, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 51, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 54, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 56, "Column" : 1, "Text" : "weeks ($) [M]"}, 
{"Row" : 59, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "References: "}, 
{"Row" : 62, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 63, "Column" : 1, "Text" : "Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104."}, 
{"Row" : 64, "Column" : 1, "Text" : "Sanford keyword: Mastoiditis"}, 
{"Row" : 65, "Column" : 1, "Text" : "Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in"}, 
{"Row" : 66, "Column" : 1, "Text" : "adults"}
]},
{"Name" : "ORZID3 GMENU MEDIASTINITIS", "DisplayText" : "Mediastinitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MEDIASTINITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU MORE ABOUT CELLULITIS", "DisplayText" : "The approach to cellulitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "DisplayText" : "Erysipelas (Outpatient)", "Text" : "Erysipelas", "Mnemonic" : "4"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Foot ulcer in patient with diabetes mellitus", "Mnemonic" : "6"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "THE APPROACH TO CELLULITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments"}, 
{"Row" :6, "Column" : 1, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the"}, 
{"Row" :7, "Column" : 1, "Text" : "affected limb reduces swelling.Heat reduces discomfort."}, 
{"Row" :9, "Column" : 1, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry.In patients with"}, 
{"Row" : 10, "Column" : 1, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence"}, 
{"Row" : 11, "Column" : 1, "Text" : "of recurrent infection."}, 
{"Row" : 13, "Column" : 1, "Text" : "In many cases of cellulitis, the affected area is usually not well-"}, 
{"Row" : 14, "Column" : 1, "Text" : "differentiated from unaffected areas of the skin. Erysipelas is a special case"}, 
{"Row" : 15, "Column" : 1, "Text" : "with typically a well-defined border and raised, orange-peel appearance."}, 
{"Row" : 19, "Column" : 1, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with"}, 
{"Row" : 20, "Column" : 1, "Text" : "advanced diabetes."}, 
{"Row" : 27, "Column" : 1, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904"}, 
{"Row" : 28, "Column" : 1, "Text" : "Sanford keyword: Cellulitis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-to-Date website"}
]},
{"Name" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "DisplayText" : "More About Pharyngitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "As most cases are of viral origin, antimicrobials are not indicated in these"}, 
{"Row" :6, "Column" : 1, "Text" : "cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief"}, 
{"Row" :7, "Column" : 1, "Text" : "of throat pain. Five to 10% of cases are caused by group A Streptococcus."}, 
{"Row" :8, "Column" : 1, "Text" : "Antimicrobial treatment reduces symptoms by one day, prevents suppurative"}, 
{"Row" :9, "Column" : 1, "Text" : "complications and prevents acute rheumatic fever, an uncommon disease in US"}, 
{"Row" : 10, "Column" : 1, "Text" : "adults."}, 
{"Row" : 12, "Column" : 1, "Text" : "Streptococcal pharyngitis or tonsillitis should be suspected when patients have"}, 
{"Row" : 13, "Column" : 1, "Text" : "fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,"}, 
{"Row" : 14, "Column" : 1, "Text" : "nasal congestion, or runny nose that suggest viral infection or common cold. If"}, 
{"Row" : 15, "Column" : 1, "Text" : "streptococcal pharyngitis is suspected in adults, perform PCR testing for group"}, 
{"Row" : 16, "Column" : 1, "Text" : "A streptococci and treat only if positive."}, 
{"Row" : 18, "Column" : 1, "Text" : "Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be"}, 
{"Row" : 19, "Column" : 1, "Text" : "considered for patients with risk factors for sexually transmitted diseases. N."}, 
{"Row" : 20, "Column" : 1, "Text" : "gonorrhoeae infections must be reported to the state health department and this"}, 
{"Row" : 21, "Column" : 1, "Text" : "will be done by Infection Control if the culture is positive."}, 
{"Row" : 23, "Column" : 1, "Text" : "The Modified Centor score", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Used to estimate the likelihood that a patient with sore throat has"}, 
{"Row" : 25, "Column" : 1, "Text" : "streptococcal pharyngitis and whether rapid PCR testing should be performed."}, 
{"Row" : 27, "Column" : 1, "Text" : "1) Absence of cough = 1 point"}, 
{"Row" : 28, "Column" : 1, "Text" : "2) Swollen and tender anterior cervical nodes = 1 point"}, 
{"Row" : 29, "Column" : 1, "Text" : "3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1"}, 
{"Row" : 30, "Column" : 1, "Text" : "point"}, 
{"Row" : 31, "Column" : 1, "Text" : "4) Tonsillar exudates or swelling = 1 point"}, 
{"Row" : 32, "Column" : 1, "Text" : "5) Age: 3-14 years = 1 point"}, 
{"Row" : 33, "Column" : 1, "Text" : "15-44 years = 0 points"}, 
{"Row" : 34, "Column" : 1, "Text" : "45 years and older = -1 point"}, 
{"Row" : 36, "Column" : 1, "Text" : "Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic"}, 
{"Row" : 37, "Column" : 1, "Text" : "treatment are not indicated. Patients with a score of 2 to 4 are at moderate to"}, 
{"Row" : 38, "Column" : 1, "Text" : "high risk. PCR testing should be obtained in these patients to determine if GAS"}, 
{"Row" : 39, "Column" : 1, "Text" : "is present. In patients with a score of 4 or greater, consider empiric"}, 
{"Row" : 40, "Column" : 1, "Text" : "antibiotic treatment."}, 
{"Row" : 42, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 45, "Column" : 1, "Text" : "CDC STD 2015 Guidelines MMWR. 2015, 64(3)1-7"}, 
{"Row" : 46, "Column" : 1, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Streptococcal Pharyngitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis"}
]},
{"Name" : "ORZID3 GMENU NASAL PACKING", "DisplayText" : "Prevention of infection in patients with nasal packing (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in"}, 
{"Row" :6, "Column" : 1, "Text" : "patients with nasal packing is not recommended. Antibiotics increase the risk of"}, 
{"Row" :7, "Column" : 1, "Text" : "adverse events in patients with nasal packing with no proven effectiveness in"}, 
{"Row" :8, "Column" : 1, "Text" : "preventing infection."}, 
{"Row" : 10, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 13, "Column" : 1, "Text" : "Cohn, Annals of emergency medicine 2015, 1.65, 109-111"}, 
{"Row" : 14, "Column" : 1, "Text" : "Kucik et al, Am Fam Physician 2005, 71.2, 305-311"}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-to-Date article: Approach to the adult with epistaxis"}
]},
{"Name" : "ORZID3 GMENU NECROTIZING INFECTIONS", "DisplayText" : "Necrotizing infections (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NECROTIZING INFECTIONS"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "DisplayText" : "Need an alternative antimicrobial? (outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX OP PT ALLERGIC TO RECOM DRUGS", "Text" : "Allergic to recommended drug(s)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP DECREASED RENAL CLR", "Text" : "Decreased renal clearance", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP LIVER SEC METAB IMPAIR", "Text" : "Liver secretory or metabolic impairment", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP DRUG INTERACTION", "Text" : "Drug interaction", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP PT HAS MULT INFECT REQ ABX", "Text" : "Patient has multiple infections requiring antimicrobials", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX OP ADJ THERA BASED ON ABX SUSP", "Text" : "Adjust therapy based on antimicrobial susceptibility", "Mnemonic" : "12"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP OTHER ADVERSE DRUG AFFECT", "Text" : "Other adverse drug effect", "Mnemonic" : "14"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX OP ALTERNATIVE OTHER REASON", "Text" : "Other reason", "Mnemonic" : "16"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "DisplayText" : "Additional assistance...", "Text" : "Please Click Here to contact the CDSS team", "Mnemonic" : "18"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "DisplayText" : "Drug allergies", "Text" : "Information about drug allergies", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "NEED AN ALERNATIVE ANTIMICROBIAL?", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If you cannot use the recommended antimicrobials or you believe another one"}, 
{"Row" :6, "Column" : 1, "Text" : "would be better for your patient, you can order another drug. Please indicate"}, 
{"Row" :7, "Column" : 1, "Text" : "the reason you need an alternative drug below."}, 
{"Row" : 18, "Column" : 1, "Text" : "Note: Alternative antimicrobial selections will be reviewed and we may contact"}, 
{"Row" : 19, "Column" : 1, "Text" : "prescribers to learn more about situations that need alternatives, improve the"}, 
{"Row" : 20, "Column" : 1, "Text" : "CDSS, and in some cases offer suggestions."}, 
{"Row" : 22, "Column" : 1, "Text" : "Clarification/Comments: ", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "DisplayText" : "Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500 BID AMOX-CLAV 875/125 BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> amoxicillin-clavulanate", "Mnemonic" : "6a"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500 BID AMOX-CLAV 875/125 BID", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500 BID CLINDAMYCIN 300 QID X7DAYS", "DisplayText" : "Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po qid ($) [H,O", "Text" : "Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po qid ($) [H,O]", "Mnemonic" : "8a"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500 BID CLINDAMYCIN 300 QID X7DAYS", "DisplayText" : "Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "Can the patient be treated with oral therapy?", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 11, "Column" : 1, "Text" : "875/125 mg PO BID ($) [R]"}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 18, "Column" : 1, "Text" : "References: "}, 
{"Row" : 19, "Column" : 1, "Text" : "Freifeld AG Clinical Infectious Disease 2011, 52: 427-431"}, 
{"Row" : 20, "Column" : 1, "Text" : "Taplitz RA, J Clin Oncol 2018, 36: 1443-1453"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sanford: Neutropenia, Febrile, Low-Risk"}, 
{"Row" : 22, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 23, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}
]},
{"Name" : "ORZID3 GMENU NEUT NOT CAND ORAL THERAPY", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "DisplayText" : "Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient)", "Text" : "If patient IS a candidate for oral therapy", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU NEUT NOT CAND ORAL THERAPY", "DisplayText" : "Neutropenic fever--Patient is NOT a candidate for oral therapy (Outpatient)", "Text" : "If patient is NOT a candidate for oral therapy", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "DisplayText" : "Scoring tool to identify low risk febrile neutropenic patients", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Mnemonic" : "8"},
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC FEVER"}, 
{"Row" :5, "Column" : 1, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute"}, 
{"Row" :6, "Column" : 1, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500"}, 
{"Row" :7, "Column" : 1, "Text" : "cells/microliter.The risk increases dramatically when the ANC is <100"}, 
{"Row" :8, "Column" : 1, "Text" : "cells/microliter.Because of these risks, patients with fever and neutropenia"}, 
{"Row" :9, "Column" : 1, "Text" : "to this degree should receive empirical antimicrobial therapy immediately."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000"}, 
{"Row" : 11, "Column" : 1, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter"}, 
{"Row" : 12, "Column" : 1, "Text" : "within the next 48 hours.For this purpose, fever is defined as a single"}, 
{"Row" : 13, "Column" : 1, "Text" : "temperature greater than 38.3 degrees Celsius."}, 
{"Row" : 15, "Column" : 1, "Text" : "Initial therapy", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum"}, 
{"Row" : 17, "Column" : 1, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined"}, 
{"Row" : 18, "Column" : 1, "Text" : "above.Vancomycin should only be given when there are clear indications for its"}, 
{"Row" : 19, "Column" : 1, "Text" : "use."}, 
{"Row" : 21, "Column" : 1, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who"}, 
{"Row" : 22, "Column" : 1, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of"}, 
{"Row" : 23, "Column" : 1, "Text" : "severe disease, like hypotension.Outpatient antimicrobials for neutropenic"}, 
{"Row" : 24, "Column" : 1, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or"}, 
{"Row" : 25, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Modifcation to therapy", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 38, "Column" : 1, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730"}, 
{"Row" : 39, "Column" : 1, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sipsas NV Cancer 2005, 103: 1103"}
]},
{"Name" : "ORZID3 GMENU NOSO SINUSITIS", "DisplayText" : "Nosocomial sinusitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL SINUSITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Nasogastric tubes increase the risk of bacterial sinus infection associated with"}, 
{"Row" :6, "Column" : 1, "Text" : "Staphylococcus aureus, streptococcus, and gram-negative bacilli, including"}, 
{"Row" :7, "Column" : 1, "Text" : "Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct"}, 
{"Row" :8, "Column" : 1, "Text" : "antimicrobial therapy. Adequate sinus drainage is vital to treatment."}, 
{"Row" : 10, "Column" : 1, "Text" : "Empirical antimicrobial treatment", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 13, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mandell chapter: Sinusitis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212."}, 
{"Row" : 19, "Column" : 1, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Sinusitis, Intubation Associated"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-To-Date article: Complications of the endotracheal tube following initial"}, 
{"Row" : 22, "Column" : 1, "Text" : "placement: Prevention and management in adult intensive care unit patients"}
]},
{"Name" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "DisplayText" : "Nosocomial pneumonia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NOSOCOMIAL PNEUMONIA"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU OROLABIAL HERPES", "DisplayText" : "Orolabial herpes (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG PO TID", "DisplayText" : "Acyclovir 400mg po tid for 5 days", "Text" : "Acyclovir 400 mg PO TID for 5 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG PO 5X/D 5DS", "DisplayText" : "Acyclovir 400mg po 5x/d for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1DAY 2GM PO BID", "DisplayText" : "Valacyclovir 2gm po bid for 1 day", "Text" : "Valacyclovir 2 gm BID for 1 day ($) [R]", "Mnemonic" : "8a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1DAY 2GM PO BID", "DisplayText" : "Valacyclovir 2gm po bid for 1 day Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R]", "Text" : "Acyclovir 400 mg PO TID for 7-14 days($) [R]", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG PO 5X/DAY 7DS", "DisplayText" : "Acyclovir 400 mg PO 5x/day for 7-14 days($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12"},
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Text" : "Valacyclovir 1 gm BID for 7-14 days ($) [R]", "Mnemonic" : "14a"},
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 1YR 400MG PO BID", "DisplayText" : "Acyclovir 400mg po bid for 1 year", "Text" : "Acyclovir 400 mg PO BID ($) [R]", "Mnemonic" : "16a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 1YR 400MG PO BID", "DisplayText" : "Acyclovir 400mg po bid for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year", "Text" : "Valacyclovir 500 mg PO QDay ($) [R]", "Mnemonic" : "18a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "DisplayText" : "Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :3, "Column" : 1, "Text" : "OROLABIAL HERPES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Antiviral therapy is not beneficial after formation of vesicles. However, when"}, 
{"Row" : 11, "Column" : 1, "Text" : "started as soon as prodromal symptoms of burning or tingling occur, antivirals"}, 
{"Row" : 12, "Column" : 1, "Text" : "reduce duration of pain and lesions."}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Immunocompromised patients in whom herpes simplex infections can be more severe"}, 
{"Row" : 26, "Column" : 1, "Text" : "include: patients with HIV infection, organ transplant recipients, patients"}, 
{"Row" : 27, "Column" : 1, "Text" : "undergoing chemotherapy, malnourished patients, and those with compromised skin"}, 
{"Row" : 28, "Column" : 1, "Text" : "integrity."}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 40, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Chronic suppressive therapy", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Indicated for patients with greater than 6 recurrences or severe recurrences,"}, 
{"Row" : 46, "Column" : 1, "Text" : "immunocompromised patients or as adjunct to prevent transmission. Suppressive"}, 
{"Row" : 47, "Column" : 1, "Text" : "therapy is optional, and some patients may find episodic treatment more"}, 
{"Row" : 48, "Column" : 1, "Text" : "convenient. Patients should be reassessed every few years to evaluate if chronic"}, 
{"Row" : 49, "Column" : 1, "Text" : "suppressive therapy is still necessary."}, 
{"Row" : 52, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 59, "Column" : 1, "Text" : "Mandell chapter: Herpes simplex virus"}, 
{"Row" : 60, "Column" : 1, "Text" : "Sanford keyword: Herpes simplex"}, 
{"Row" : 61, "Column" : 1, "Text" : "Up-To-Date article: Treatment of herpes simplex virus type 1 infection in"}, 
{"Row" : 62, "Column" : 1, "Text" : "immunocompetent patients"}
]},
{"Name" : "ORZID3 GMENU OSTEOM EMP THERAPY", "DisplayText" : "Empirical therapy for Osteomyelitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R (Var)", "Text" : "Levofloxacin 500 mg PO qday ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "EMPIRICAL THERAPY FOR OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Therapy should be modified when culture results and patient response to therapy"}, 
{"Row" :6, "Column" : 1, "Text" : "are known.If cultures cannot be obtained, the oral regimens listed below can"}, 
{"Row" :7, "Column" : 1, "Text" : "be used for empirical therapy or to complete a treatment course after the"}, 
{"Row" :8, "Column" : 1, "Text" : "patient's disease has improved. Consult Infectious Diseases for more"}, 
{"Row" :9, "Column" : 1, "Text" : "information."}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of treatment 4 to 6 weeks."}, 
{"Row" : 13, "Column" : 1, "Text" : "ORAL treatment for MILD disease or for completion of treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "course", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "INTRAVENOUS treatment for MODERATE to SEVERE disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 25, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 26, "Column" : 1, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26"}, 
{"Row" : 27, "Column" : 1, "Text" : "Calhoun JH Infect Dis Clin North AM 2005, 19:765"}, 
{"Row" : 28, "Column" : 1, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:393"}
]},
{"Name" : "ORZID3 GMENU OSTEOM GNB", "DisplayText" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 28DS 875/125 MG PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125 mg po bid for 28 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < OR >", "Mnemonic" : "4a"},
{"Row" :7, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 28DS 875/125 MG PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125 mg po bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R (Var)", "Text" : "Levofloxacin 500 mg PO qday ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" :9, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 15, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 17, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}
]},
{"Name" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 28DS", "DisplayText" : "Ciprofloxacin 750mg po bid for 28 days", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" :7, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 28DS", "DisplayText" : "Ciprofloxacin 750mg po bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA"}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 14, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 15, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}
]},
{"Name" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "DisplayText" : "Osteomyelitis with Staphylococcus aureus (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Mnemonic" : "10a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 28DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 28 days", "Text" : "Minocycline 100 mg PO BID ($) [DI] < OR >", "Mnemonic" : "12a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 28DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS"}, 
{"Row" :6, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Methicillin-SUSCEPTIBLE S. aureus", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Methicillin-RESISTANT S. aureus", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "________________________________________________", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Spellberg B Clin Infect Dis 2012, 54:393"}, 
{"Row" : 32, "Column" : 1, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26"}, 
{"Row" : 33, "Column" : 1, "Text" : "Calhoun JH Infect Dis Clin North Am 2005, 19:765"}, 
{"Row" : 16, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 4 weeks"}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 28DS", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 28DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID [R] ($)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"}
]},
{"Name" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "DisplayText" : "Osteomyelitis with Streptococci (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Mnemonic" : "4a"},
{"Row" :8, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS WITH STREPTOCOCCI"}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Osteomyelitis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 17, "Column" : 1, "Text" : "Lew DP Lancet 2004, 364: 369"}, 
{"Row" : 18, "Column" : 1, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287"}, 
{"Row" :5, "Column" : 1, "Text" : "Treat for 4 weeks."}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 28DS", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 28DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID [R] ($)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :9, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM EMP THERAPY", "DisplayText" : "Empirical therapy for Osteomyelitis (Outpatient)", "Text" : "Empirical therapy for osteomyelitis", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "DisplayText" : "Osteomyelitis with Staphylococcus aureus (Outpatient)", "Text" : "Osteomyelitis with Staphylococcus aureus", "Mnemonic" : "6"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "DisplayText" : "Osteomyelitis with Streptococci (Outpatient)", "Text" : "Osteomyelitis with Streptococci", "Mnemonic" : "8"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM GNB", "DisplayText" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient", "Text" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas)", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "DisplayText" : "Osteomyelitis with Pseudomonas aeruginosa (Outpatient)", "Text" : "Osteomyelitis with Pseudomonas aeruginosa", "Mnemonic" : "12"},
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "OSTEOMYELITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "In acute osteomyelitis, symptoms have been present for several days to weeks."}, 
{"Row" :6, "Column" : 1, "Text" : "Chronic osteomyelitis is characterized by a longer duration of symptoms,"}, 
{"Row" :7, "Column" : 1, "Text" : "sometimes months or years, and often dead, necrotic bone is present.There is"}, 
{"Row" :8, "Column" : 1, "Text" : "considerable overlap between the syndromes of acute and chronic osteomyelitis."}, 
{"Row" :9, "Column" : 1, "Text" : "Symptom duration may be unreliable in a patient with neuropathy."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtain material for gram stain and culture before initiating antimicrobials."}, 
{"Row" : 12, "Column" : 1, "Text" : "Blood and bone cultures are ideal.Sinus tracts are often colonized with"}, 
{"Row" : 13, "Column" : 1, "Text" : "multiple species and usually only one or two are pathogens in bone.If"}, 
{"Row" : 14, "Column" : 1, "Text" : "Staphylococcus aureus is present, it is likely to be a pathogen in bone."}, 
{"Row" : 16, "Column" : 1, "Text" : "Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,"}, 
{"Row" : 17, "Column" : 1, "Text" : "but necrotic bone must often be removed for cure of chronic osteomyelitis.If"}, 
{"Row" : 18, "Column" : 1, "Text" : "complete debridement is not possible, long-term suppressive antimicrobials may"}, 
{"Row" : 19, "Column" : 1, "Text" : "be needed.Consult Infectious Diseases for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "The most important pathogens are S. aureus and streptococci.Gram negative"}, 
{"Row" : 22, "Column" : 1, "Text" : "bacilli are common pathogens in osteomyelitis associated with diabetic foot"}, 
{"Row" : 23, "Column" : 1, "Text" : "infection."}, 
{"Row" : 25, "Column" : 1, "Text" : "Empirical treatment regimens", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Pathogen-directed treatment regimens", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry"}, 
{"Row" : 35, "Column" : 1, "Text" : "(for foot infections), and Infectious Diseases consults."}, 
{"Row" : 37, "Column" : 1, "Text" : "Treat for 4 to 6 weeks.Do not place a long-term intravascular access device"}, 
{"Row" : 38, "Column" : 1, "Text" : "(e.g. a PICC line) until it is clear the patient will need long-term intravenous"}, 
{"Row" : 39, "Column" : 1, "Text" : "therapy.Consult Infectious Diseases or Orthopedic Surgery for more"}, 
{"Row" : 40, "Column" : 1, "Text" : "information."}, 
{"Row" : 42, "Column" : 1, "Text" : ">>For patients with infections associated with prosthetic materials see"}, 
{"Row" : 45, "Column" : 1, "Text" : ">>For patients with sternal infection associated with chest surgery, refer to"}, 
{"Row" : 46, "Column" : 1, "Text" : "mediastinitis, under Lungs and Mediastinum, in the Inpatient Antimicrobial"}, 
{"Row" : 47, "Column" : 1, "Text" : "CDSS."}, 
{"Row" : 50, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Osteomyelitis"}, 
{"Row" : 52, "Column" : 1, "Text" : "Lipsky BA Clin Infect Disease 2012, 54:393"}
]},
{"Name" : "ORZID3 GMENU OTHER PATHOGENS", "DisplayText" : "Other Pathogens (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Mnemonic" : "4"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient", "Text" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme disease", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "DisplayText" : "Mycobacterium tuberculosis (Outpatient)", "Text" : "Mycobacterium tuberculosis", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient", "Text" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)", "Mnemonic" : "12"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "DisplayText" : "Mycoplasma pneumonia (Outpatient)", "Text" : "Mycoplasma pneumonia", "Mnemonic" : "14"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient)", "Text" : "Pneumocystis", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "++ OTHER PATHOGENS ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or"}, 
{"Row" :7, "Column" : 1, "Text" : "contaminant. See disease/syndrome section for more information."}, 
{"Row" :9, "Column" : 1, "Text" : "Coxiella and Ehrlichia", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Lyme Disease", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Mycobacteria", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Mycoplasma", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Pneumocystis infection", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU OTITIS EXTERNA", "DisplayText" : "Otitis externa (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "DisplayText" : "Furuncles and Carbuncles (Outpatient)", "Text" : "Furuncles and Carbuncles", "Mnemonic" : "4"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "DisplayText" : "Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s) QID ($)", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "DisplayText" : "Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "DisplayText" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)", "Mnemonic" : "8a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "DisplayText" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "OTITIS EXTERNA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Acute Localized Disease", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus."}, 
{"Row" :7, "Column" : 1, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep"}, 
{"Row" :8, "Column" : 1, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed."}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to the Furuncles and Carbuncles page for antibiotic recommendations."}, 
{"Row" : 11, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Acute diffuse and chronic otitis externa", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and"}, 
{"Row" : 15, "Column" : 1, "Text" : "Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and"}, 
{"Row" : 16, "Column" : 1, "Text" : "purulent material which can improve effectiveness of topical antibiotics. Avoid"}, 
{"Row" : 17, "Column" : 1, "Text" : "products that contain neomycin if the tympanic membrane is perforated."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment if tympanic membrane is intact", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "for 7 days ($) [M]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Complicated Cases", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "For cases resistant to topical therapy alone, patients with poorly controlled"}, 
{"Row" : 32, "Column" : 1, "Text" : "diabetes mellitus, immunocompromised patients, cases where infection has spread"}, 
{"Row" : 33, "Column" : 1, "Text" : "beyond ear canal and in those where topical therapy cannot be delivered"}, 
{"Row" : 34, "Column" : 1, "Text" : "effectively. Culture secretions to guide therapy."}, 
{"Row" : 35, "Column" : 1, "Text" : "In addition to topical therapy above"}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 43, "Column" : 1, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: Otitis Externa"}, 
{"Row" : 45, "Column" : 1, "Text" : "Up-To-Date article: External otitis: Treatment"}
]},
{"Name" : "ORZID3 GMENU OTITIS MEDIA", "DisplayText" : "Otitis media (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 10DS PO TID", "DisplayText" : "Amoxicillin 1000 mg PO TID for 10 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h for 10 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 10DS PO TID", "DisplayText" : "Amoxicillin 1000 mg PO TID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 10DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 10 days ($) [R]", "Text" : "Cefdinir 300 mg PO q12h for 10 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 10DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 10 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFPODOXIME 200MG PO BID 10DS", "DisplayText" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R]", "Text" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R]", "Mnemonic" : "12a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFPODOXIME 200MG PO BID 10DS", "DisplayText" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "OTITIS MEDIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are"}, 
{"Row" :6, "Column" : 1, "Text" : "the most common bacteria to cause otitis media."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Patient has NOT received antibiotics in the prior month"}, 
{"Row" : 13, "Column" : 1, "Text" : "Patient has received antibiotics in the prior month"}, 
{"Row" : 17, "Column" : 1, "Text" : "Alternatives", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Harmes et al, American Family Physician. 2013, 88(7)435-440"}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Otitis media"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-Date Online: Acute otitis media in adults"}
]},
{"Name" : "ORZID3 GMENU OUTPATIENT GENRL ALT LIST", "DisplayText" : "List of antimicrobials - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :2, "Column" : 1, "Item" : "PSJIZID ALT ACYCLOVIR 500MG IV BID", "DisplayText" : "Acyclovir 500mg iv bid", "Text" : "Acyclovir IV", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "PSOZID ALT ACYCLOVIR 800MG PO TID", "DisplayText" : "Acyclovir 800mg po tid", "Text" : "Acyclovir PO", "Mnemonic" : "4a"},
{"Row" :5, "Column" : 1, "Item" : "PSHZID ALT ACYCLOVIR 800MG PO TID", "DisplayText" : "Acyclovir 800mg po tid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :7, "Column" : 1, "Item" : "PSJIZID ALT AMIKACIN 250MG IV QDAY", "DisplayText" : "Amikacin 250mg iv qday", "Text" : "Amikacin IV", "Mnemonic" : "6"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID ALT AMOXICILLIN 500MG PO TID", "DisplayText" : "Amoxicillin 500mg po tid", "Text" : "Amoxicillin PO", "Mnemonic" : "8a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID ALT AMOXICILLIN 500MG PO TID", "DisplayText" : "Amoxicillin 500mg po tid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid", "Text" : "Amoxicillin-clavulanate PO", "Mnemonic" : "10a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID ALT AMPHO B LIPOSOMAL 5MG/KG IV Q24H", "DisplayText" : "Amphotericin B Liposomal (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O]", "Text" : "Amphotericin B IV", "Mnemonic" : "14"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN 2GM IV Q6H", "DisplayText" : "Ampicillin 2gm iv q6h (alt 2)", "Text" : "Ampicillin IV", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN-SULBACTAM 3GM IV Q6H", "DisplayText" : "Ampicillin-sulbactam 3gm iv q6h", "Text" : "Ampicillin-sulbactam IV", "Mnemonic" : "18"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID ALT ATOVAQUONE SUSP 750MG PO BID", "DisplayText" : "Atovaquone susp 750mg po bid (Var)", "Text" : "Atovaquone PO", "Mnemonic" : "20a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID ALT ATOVAQUONE SUSP 750MG PO BID", "DisplayText" : "Atovaquone susp 750mg po bid (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID ALT AZITHROMYCIN 500MG ONCE THEN 250MG QD 4DS", "DisplayText" : "Azithromycin 500mg once then 250mg q24h for 4 days", "Text" : "Azithromycin IV", "Mnemonic" : "22"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 ALT AZITHROMYCIN 500MG ONCE THEN 250 QDAY 4DS", "DisplayText" : "Azithromycin 500mg once then 250mg qday for 4 days", "Text" : "Azithromycin PO", "Mnemonic" : "24a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 ALT AZITHROMYCIN 500MG ONCE THEN 250 QDAY 4DS", "DisplayText" : "Azithromycin 500mg once then 250mg qday for 4 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID ALT AZTREONAM 2GM IV Q8H", "DisplayText" : "Aztreonam 2gm iv q8h", "Text" : "Aztreonam IV", "Mnemonic" : "26"},
{"Row" : 31, "Column" : 1, "Item" : "PSCZID ALT BENZATHINE PENICLLIN 1.2", "Text" : "Benzathine penicillin IM", "Mnemonic" : "28"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID ALT CEFADROXIL 500MG PO BID", "DisplayText" : "Cefadroxil 500 mg PO BID ($) [R]", "Text" : "Cefadroxil PO", "Mnemonic" : "30a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID ALT CEFADROXIL 500MG PO BID", "DisplayText" : "Cefadroxil 500 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "30b"},
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID ALT CEFAZOLIN 2GM IVPB Q8H", "DisplayText" : "Cefazolin IV", "Text" : "", "Mnemonic" : "32"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID ALT CEFDINIR 300MG PO BID", "DisplayText" : "Cefdinir 300 mg PO BID Alt", "Text" : "Cefdinir PO", "Mnemonic" : "34a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID ALT CEFDINIR 300MG PO BID", "DisplayText" : "Cefdinir 300 mg PO BID Alt Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "34b"},
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID ALT CEFEPIME 2GM IV Q8H", "DisplayText" : "Cefepime 2gm iv q8h", "Text" : "Cefepime IV", "Mnemonic" : "36"},
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID ALT CEFOTETAN IV 2GM Q12H", "Text" : "Cefotetan IV", "Mnemonic" : "40"},
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID ALT CEFOXITIN 2GM IV Q6H", "Text" : "Cefoxitin IV", "Mnemonic" : "42"},
{"Row" : 47, "Column" : 1, "Item" : "PSOZID ALT CEFPODOXIME 200 MG PO BID", "DisplayText" : "Cefpodoxime 200 mg po BID", "Text" : "Cefpodoxime PO", "Mnemonic" : "44a"},
{"Row" : 48, "Column" : 1, "Item" : "PSHZID ALT CEFPODOXIME 200 MG PO BID", "DisplayText" : "Cefpodoxime 200 mg po BID Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "44b"},
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID ALT CEFTAZIDIME 2GM IV Q8H", "DisplayText" : "Ceftazidime 2gm iv q8h", "Text" : "Ceftazidime IV", "Mnemonic" : "46"},
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 500MG IM ONCE", "DisplayText" : "Ceftriaxone 500mg im once (ALT)", "Text" : "Ceftriaxone IM", "Mnemonic" : "48"},
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 2GM IV QDAY", "DisplayText" : "Ceftriaxone 2gm iv qday", "Text" : "Ceftriaxone IV", "Mnemonic" : "50"},
{"Row" : 56, "Column" : 1, "Item" : "PSOZID ALT CEFUROXIME 500MG PO BID", "DisplayText" : "Cefuroxime 500mg po bid", "Text" : "Cefuroxime PO", "Mnemonic" : "52a"},
{"Row" : 57, "Column" : 1, "Item" : "PSHZID ALT CEFUROXIME 500MG PO BID", "DisplayText" : "Cefuroxime 500mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "52b"},
{"Row" : 59, "Column" : 1, "Item" : "PSOZID ALT CEPHALEXIN 500MG PO Q6H", "DisplayText" : "Cephalexin 500mg po q6h", "Text" : "Cephalexin PO", "Mnemonic" : "54a"},
{"Row" : 60, "Column" : 1, "Item" : "PSHZID ALT CEPHALEXIN 500MG PO Q6H", "DisplayText" : "Cephalexin 500mg po q6h Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "54b"},
{"Row" : 62, "Column" : 1, "Item" : "PSJIZID ALT CIPROFLOXACIN 400MG IV Q12H", "DisplayText" : "Ciprofloxacin 400mg iv q12h (ALT)", "Text" : "Ciprofloxacin IV", "Mnemonic" : "56"},
{"Row" : 64, "Column" : 1, "Item" : "PSOZID ALT CIPROFLOXACIN 500MG PO BID", "DisplayText" : "Ciprofloxacin 500mg po bid (Var)", "Text" : "Ciprofloxacin PO", "Mnemonic" : "58a"},
{"Row" : 65, "Column" : 1, "Item" : "PSHZID ALT CIPROFLOXACIN 500MG PO BID", "DisplayText" : "Ciprofloxacin 500mg po bid (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "58b"},
{"Row" : 67, "Column" : 1, "Item" : "PSOZID ALT CLARITHROMYCIN 500MG PO BID", "DisplayText" : "Clarithromycin 500mg po bid (Var)", "Text" : "Clarithromycin PO", "Mnemonic" : "60a"},
{"Row" : 68, "Column" : 1, "Item" : "PSHZID ALT CLARITHROMYCIN 500MG PO BID", "DisplayText" : "Clarithromycin 500mg po bid (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "60b"},
{"Row" : 70, "Column" : 1, "Item" : "PSJIZID ALT CLINDAMYCIN 600MG IV Q8H", "DisplayText" : "Clindamycin 600mg iv q8h (ALT)", "Text" : "Clindamycin IV", "Mnemonic" : "62"},
{"Row" : 72, "Column" : 1, "Item" : "PSOZID ALT CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid", "Text" : "Clindamycin PO", "Mnemonic" : "64a"},
{"Row" : 73, "Column" : 1, "Item" : "PSHZID ALT CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "64b"},
{"Row" : 75, "Column" : 1, "Item" : "PSOZID2 ALT CLINDAMYCIN 2% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Clindamycin vaginal 1 applicatorful qhs for 30 days", "Text" : "Clindamycin Vaginal", "Mnemonic" : "66a"},
{"Row" : 76, "Column" : 1, "Item" : "PSHZID2 ALT CLINDAMYCIN 2% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Clindamycin vaginal 1 applicatorful qhs for 30 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "66b"},
{"Row" : 78, "Column" : 1, "Item" : "PSOZID2 ALT CLOTRIMAZOLE 1% CRM TOP AFFECT AREA QID", "DisplayText" : "Clotrimazole 1% cream topical to affected area qid", "Text" : "Clotrimazole Topical", "Mnemonic" : "68a"},
{"Row" : 79, "Column" : 1, "Item" : "PSHZID2 ALT CLOTRIMAZOLE 1% CRM TOP AFFECT AREA QID", "DisplayText" : "Clotrimazole 1% cream topical to affected area qid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "68b"},
{"Row" : 81, "Column" : 1, "Item" : "PSOZID2 ALT CLOTRIM 1% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Clotrimazole 1% cream vaginal 1 applicatorful qhs for 30 days", "Text" : "Clotrimazole Vaginal", "Mnemonic" : "70a"},
{"Row" : 82, "Column" : 1, "Item" : "PSHZID2 ALT CLOTRIM 1% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Clotrimazole 1% cream vaginal 1 applicatorful qhs for 30 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "70b"},
{"Row" : 85, "Column" : 1, "Item" : "PSJIZID ALT DOXYCYCLINE 100MG IV Q12H", "DisplayText" : "Doxycycline 100mg iv q12h (ALT)", "Text" : "Doxycycline IV", "Mnemonic" : "74"},
{"Row" : 87, "Column" : 1, "Item" : "PSOZID ALT DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100mg po bid", "Text" : "Doxycycline PO", "Mnemonic" : "76a"},
{"Row" : 88, "Column" : 1, "Item" : "PSHZID ALT DOXYCYCLINE 100MG PO BID", "DisplayText" : "Doxycycline 100mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "76b"},
{"Row" : 90, "Column" : 1, "Item" : "PSJIZID ALT ERTAPENEM 1GM IV Q24H", "DisplayText" : "Ertapenem 1gm iv q24h (ALT)", "Text" : "Ertapenem IV", "Mnemonic" : "78"},
{"Row" : 92, "Column" : 1, "Item" : "PSJIZID ALT ERYTHROMYCIN 500MG IV Q6H", "DisplayText" : "Erythromycin 500mg iv q6h (ALT)", "Text" : "Erythromycin IV", "Mnemonic" : "80"},
{"Row" : 94, "Column" : 1, "Item" : "PSOZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "DisplayText" : "Erythromycin 0.5% oint oph to affected eye qid", "Text" : "Erythromycin OPTH", "Mnemonic" : "82a"},
{"Row" : 95, "Column" : 1, "Item" : "PSHZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "DisplayText" : "Erythromycin 0.5% oint oph to affected eye qid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "82b"},
{"Row" : 97, "Column" : 1, "Item" : "PSOZID ALT ERYTHROMYCIN 500MG PO FQID", "DisplayText" : "Erythromycin 500mg po fqid", "Text" : "Erythromycin PO", "Mnemonic" : "84a"},
{"Row" : 98, "Column" : 1, "Item" : "PSHZID ALT ERYTHROMYCIN 500MG PO FQID", "DisplayText" : "Erythromycin 500mg po fqid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "84b"},
{"Row" :1, "Column" : 1, "Text" : "ALTERNATIVE ANTIMICROBIALS", "Header" : 1}, 
{"Row" :4, "Column" : 2, "Item" : "PSJIZID ALT FLUCONAZOLE 400MG IV Q24H", "DisplayText" : "Fluconazole 400mg iv q24h (ALT)", "Text" : "Fluconazole IV", "Mnemonic" : "130"},
{"Row" :6, "Column" : 2, "Item" : "PSOZID ALT FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday (Var)", "Text" : "Fluconazole PO", "Mnemonic" : "132a"},
{"Row" :7, "Column" : 2, "Item" : "PSHZID ALT FLUCONAZOLE 400MG PO QDAY", "DisplayText" : "Fluconazole 400mg po qday (Var) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "132b"},
{"Row" :9, "Column" : 2, "Item" : "PSJIZID ALT GANCICLOVIR 500MG IV Q12H", "DisplayText" : "Ganciclovir 500mg iv q12h", "Text" : "Gancicilovir IV", "Mnemonic" : "134"},
{"Row" : 11, "Column" : 2, "Item" : "PSJIZID ALT GENTAMICIN 5MG/KG IV Q24H", "DisplayText" : "Gentamicin 5 mg/kg iv q24h", "Text" : "Gentamicin IV", "Mnemonic" : "136"},
{"Row" : 13, "Column" : 2, "Item" : "PSOZID ALT ITRACONAZOLE 200MG PO QDAY", "DisplayText" : "Itraconazole 200mg po qday", "Text" : "Itraconazole PO", "Mnemonic" : "138a"},
{"Row" : 14, "Column" : 2, "Item" : "PSHZID ALT ITRACONAZOLE 200MG PO QDAY", "DisplayText" : "Itraconazole 200mg po qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "138b"},
{"Row" : 16, "Column" : 2, "Item" : "PSJIZID ALT LEVOFLOXACIN 500MG IV Q24H", "DisplayText" : "Levofloxacin IV", "Text" : "Levofloxacin IV", "Mnemonic" : "140"},
{"Row" : 18, "Column" : 2, "Item" : "PSOZID ALT LEVOFLOXACIN 500MG PO Q24H", "DisplayText" : "Levofloxacin PO", "Text" : "Levofloxacin PO", "Mnemonic" : "142a"},
{"Row" : 19, "Column" : 2, "Item" : "PSHZID ALT LEVOFLOXACIN 500MG PO Q24H", "DisplayText" : "Levofloxacin PO Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "142b"},
{"Row" : 24, "Column" : 2, "Item" : "PSJIZID ALT MEROPENEM 1GM IV Q8H", "DisplayText" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Text" : "Meropenem IV", "Mnemonic" : "144"},
{"Row" : 26, "Column" : 2, "Item" : "PSJIZID ALT METRONIDAZOLE 500MG IV Q6H", "DisplayText" : "Metronidazole 500mg iv q6h (ALT)", "Text" : "Metronidazole IV", "Mnemonic" : "146"},
{"Row" : 28, "Column" : 2, "Item" : "PSOZID ALT METRONIDAZOLE 500MG PO TID", "DisplayText" : "Metronidazole 500mg po tid (alt 2)", "Text" : "Metronidazole PO", "Mnemonic" : "148a"},
{"Row" : 29, "Column" : 2, "Item" : "PSHZID ALT METRONIDAZOLE 500MG PO TID", "DisplayText" : "Metronidazole 500mg po tid (alt 2) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "148b"},
{"Row" : 31, "Column" : 2, "Item" : "PSOZID2 ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "DisplayText" : "Metronidazole 0.75% gel vaginal 1 applicatorful qhs", "Text" : "Metronidazole Vaginal", "Mnemonic" : "150a"},
{"Row" : 32, "Column" : 2, "Item" : "PSHZID2 ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "DisplayText" : "Metronidazole 0.75% gel vaginal 1 applicatorful qhs Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "150b"},
{"Row" : 34, "Column" : 2, "Item" : "PSOZID ALT MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid", "Text" : "Minocycline PO", "Mnemonic" : "152a"},
{"Row" : 35, "Column" : 2, "Item" : "PSHZID ALT MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "152b"},
{"Row" : 37, "Column" : 2, "Item" : "PSOZID2 ALT MOXIFLOXACIN SOLN OPH 1DRP TID 7DAYS", "DisplayText" : "Moxifloxacin soln oph 1 drop tid for 7 days", "Text" : "Moxifloxacin OPTH", "Mnemonic" : "154a"},
{"Row" : 38, "Column" : 2, "Item" : "PSHZID2 ALT MOXIFLOXACIN SOLN OPH 1DRP TID 7DAYS", "DisplayText" : "Moxifloxacin soln oph 1 drop tid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "154b"},
{"Row" : 40, "Column" : 2, "Item" : "PSJIZID ALT NAFCILLIN 2GM IV Q4H", "DisplayText" : "Nafcillin 2gm iv q4h", "Text" : "Nafcillin IV", "Mnemonic" : "156"},
{"Row" : 42, "Column" : 2, "Item" : "PSOZID ALT NEOMYCIN 1000MG PO TID", "DisplayText" : "Neomycin 1000mg po tid", "Text" : "Neomycin PO", "Mnemonic" : "158a"},
{"Row" : 43, "Column" : 2, "Item" : "PSHZID ALT NEOMYCIN 1000MG PO TID", "DisplayText" : "Neomycin 1000mg po tid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "158b"},
{"Row" : 45, "Column" : 2, "Item" : "PSOZID ALT NITROFURANTOIN 100MG PO BID", "DisplayText" : "Nitrofurantoin 100mg po bid", "Text" : "Nitrofurantoin PO", "Mnemonic" : "160a"},
{"Row" : 46, "Column" : 2, "Item" : "PSHZID ALT NITROFURANTOIN 100MG PO BID", "DisplayText" : "Nitrofurantoin 100mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "160b"},
{"Row" : 50, "Column" : 2, "Item" : "PSOZID ALT PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin 500mg po qid (Alt 2)", "Text" : "Penicillin PO", "Mnemonic" : "162a"},
{"Row" : 51, "Column" : 2, "Item" : "PSHZID ALT PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin 500mg po qid (Alt 2) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "162b"},
{"Row" : 53, "Column" : 2, "Item" : "PSJIZID ALT PENICILLIN 4MU IV Q4H", "DisplayText" : "Penicillin 4MU iv q4h", "Text" : "Penicillin IV", "Mnemonic" : "164"},
{"Row" : 55, "Column" : 2, "Item" : "PSJIZID ALT PIP/TAZO 3.375 GM IV Q6H", "DisplayText" : "Piperacillin/tazobactam 3.375 GM IV Q6H (ALT)", "Text" : "Piperacillin/tazobactam IV", "Mnemonic" : "166"},
{"Row" : 57, "Column" : 2, "Item" : "PSOZID ALT PYRIMETHAMINE 75MG PO QDAY", "DisplayText" : "Pyrimethamine 75mg po qday", "Text" : "Pyrimethamine PO", "Mnemonic" : "168a"},
{"Row" : 58, "Column" : 2, "Item" : "PSHZID ALT PYRIMETHAMINE 75MG PO QDAY", "DisplayText" : "Pyrimethamine 75mg po qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "168b"},
{"Row" : 60, "Column" : 2, "Item" : "PSJIZID ALT RIFAMPIN 300MG IV Q12H", "DisplayText" : "Rifampin 300mg iv q12h (ALT)", "Text" : "Rifampin IV", "Mnemonic" : "170"},
{"Row" : 62, "Column" : 2, "Item" : "PSOZID ALT RIFAMPIN 300MG PO BID", "DisplayText" : "Rifampin 300mg po bid (Alt 2)", "Text" : "Rifampin PO", "Mnemonic" : "172a"},
{"Row" : 63, "Column" : 2, "Item" : "PSHZID ALT RIFAMPIN 300MG PO BID", "DisplayText" : "Rifampin 300mg po bid (Alt 2) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "172b"},
{"Row" : 65, "Column" : 2, "Item" : "PSOZID2 ALT SULFACETAMIDE 10% SOLN OPH 1DRP QID 7DAYS", "DisplayText" : "Sulfacetamide 10% soln oph 1 drop qid for 7 days", "Text" : "Sulfacetamide OPTH", "Mnemonic" : "174a"},
{"Row" : 66, "Column" : 2, "Item" : "PSHZID2 ALT SULFACETAMIDE 10% SOLN OPH 1DRP QID 7DAYS", "DisplayText" : "Sulfacetamide 10% soln oph 1 drop qid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "174b"},
{"Row" : 68, "Column" : 2, "Item" : "PSOZID ALT SULFADIAZINE 1000MG PO QID", "DisplayText" : "Sulfadiazine 1000mg po qid", "Text" : "Sulfadiazine PO", "Mnemonic" : "176a"},
{"Row" : 69, "Column" : 2, "Item" : "PSHZID ALT SULFADIAZINE 1000MG PO QID", "DisplayText" : "Sulfadiazine 1000mg po qid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "176b"},
{"Row" : 71, "Column" : 2, "Item" : "PSOZID ALT TERBINAFINE 250 MG PO QDAY", "Text" : "Terbinabine PO", "Mnemonic" : "178a"},
{"Row" : 72, "Column" : 2, "Item" : "PSHZID ALT TERBINAFINE 250 MG PO QDAY", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "178b"},
{"Row" : 74, "Column" : 2, "Item" : "PSOZID2 ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Terconazole 0.4% cream vaginal 1 applicatorful qhs for 30 days", "Text" : "Terconazole 0.4% Vaginal", "Mnemonic" : "180a"},
{"Row" : 75, "Column" : 2, "Item" : "PSHZID2 ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS 30DS", "DisplayText" : "Terconazole 0.4% cream vaginal 1 applicatorful qhs for 30 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "180b"},
{"Row" : 77, "Column" : 2, "Item" : "PSJIZID ALT TOBRAMYCIN 5 MG/KG IV Q24H", "DisplayText" : "Tobramycin 5 mg/kg iv q24h (ALT)", "Text" : "Tobramycin IV", "Mnemonic" : "184"},
{"Row" : 79, "Column" : 2, "Item" : "PSOZID ALT TRIMETHOPRIM PO QD", "Text" : "Trimethoprim PO", "Mnemonic" : "186a"},
{"Row" : 80, "Column" : 2, "Item" : "PSHZID ALT TRIMETHOPRIM PO QD", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "186b"},
{"Row" : 82, "Column" : 2, "Item" : "PSJIZID ALT TRIMETH/SULFA 5MG/KG IV Q12H", "DisplayText" : "Trimethoprim/sulfamethoxazole 5 mg/kg iv q12h", "Text" : "Trimethoprim-sulfamethoxazole IV", "Mnemonic" : "188"},
{"Row" : 84, "Column" : 2, "Item" : "PSOZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1ds tablet po bid", "Text" : "Trimethoprim-sulfamethoxazole PO", "Mnemonic" : "190a"},
{"Row" : 85, "Column" : 2, "Item" : "PSHZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1ds tablet po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "190b"},
{"Row" : 87, "Column" : 2, "Item" : "PSOZID ALT VALACYCLOVIR 1000MG PO BID", "DisplayText" : "Valacyclovir 1000mg po bid", "Text" : "Valacyclovir PO", "Mnemonic" : "192a"},
{"Row" : 88, "Column" : 2, "Item" : "PSHZID ALT VALACYCLOVIR 1000MG PO BID", "DisplayText" : "Valacyclovir 1000mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "192b"},
{"Row" : 90, "Column" : 2, "Item" : "PSJIZID ALT VANCOMYCIN 1000MG IV Q12H", "DisplayText" : "Vancomycin 1000mg iv q12h", "Text" : "Vancomycin IV", "Mnemonic" : "194"},
{"Row" : 48, "Column" : 2, "Text" : "Oseltamivir PO (see Influenza Menu)"}, 
{"Row" : 21, "Column" : 2, "Item" : "PSOZID2 ALT LINEZOLID 600MG PO BID 5DAYS", "DisplayText" : "Linezolid 600 mg PO bid for 5 days ($) [DI,O]", "Text" : "", "Mnemonic" : "143a"},
{"Row" : 22, "Column" : 2, "Item" : "PSHZID2 ALT LINEZOLID 600 MG PO BID 5DAYS", "DisplayText" : "Linezolid 600 mg PO bid for 5 days ($) [DI,O]", "Text" : "Non-VA order for above", "Mnemonic" : "143b"},
{"Row" : 92, "Column" : 2, "Text" : "Vancomycin PO (see C diff menu)"}, 
{"Row" :2, "Column" : 2, "Text" : "Fidaxomicin PO (see C diff menu)"}
]},
{"Name" : "ORZID3 GMENU PANCREATITIS", "DisplayText" : "Pancreatitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PANCREATITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU PARASITE BABESIA SPP.", "DisplayText" : "Babesia spp. (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 500 THEN 250 X6DS ATOVA 750MG Q12H 7DS", "Text" : "Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO QDay ($) [M] for 6", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 500 THEN 250 X6DS ATOVA 750MG Q12H 7DS", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "BABESIA SPECIES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6"}, 
{"Row" :9, "Column" : 1, "Text" : "weeks including 2 weeks after babesia are no longer detected in blood smear."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "days <AND> atovaquone 750 mg PO BID ($) [M] for 7 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 17, "Column" : 1, "Text" : "*Consult Infectious Diseases, requires NF consult for quinine."}, 
{"Row" : 18, "Column" : 1, "Text" : "Clindamycin 600 mg PO TID <AND> quinine 650mg PO TID"}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 24, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Mandell chapter: Babesia Species"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Babesiosis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-Date article: Babesiosis: Treatment and prevention"}, 
{"Row" : 29, "Column" : 1, "Text" : "Vannier et al. N Engl J Med. 2012 (366)2397-407"}
]},
{"Name" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "DisplayText" : "Toxoplasma spp. (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG", "DisplayText" : "PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>", "Mnemonic" : "4a"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG", "DisplayText" : "PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG", "DisplayText" : "PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG", "DisplayText" : "PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 200 THEN 50 CLINDA 600 LEUCOV 10MG", "DisplayText" : "PYRIMETH 200 THEN 50 CLINDA 300 LEUCOV 10MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 200 THEN 50 CLINDA 600 LEUCOV 10MG", "DisplayText" : "PYRIMETH 200 THEN 50 CLINDA 300 LEUCOV 10MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG", "DisplayText" : "PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>", "Mnemonic" : "10a"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG", "DisplayText" : "PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 44, "Column" : 1, "Item" : "PSOZID TRIMETH 5MG/KG-SULFA 25MG/KG PO BID", "DisplayText" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO bid", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO BID ($) [R,DI]", "Mnemonic" : "12a"},
{"Row" : 45, "Column" : 1, "Item" : "PSHZID TRIMETH 5MG/KG-SULFA 25MG/KG PO BID", "DisplayText" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 56, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG", "DisplayText" : "PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG", "Text" : "Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO QID", "Mnemonic" : "14a"},
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG", "DisplayText" : "PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 50MG CLINDA 600MG LEUCO 10MG", "DisplayText" : "PYRIM 50MG CLINDA 600MG LEUCO 10MG", "Text" : "Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> clindamycin 600 mg PO TID ($)", "Mnemonic" : "16a"},
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 50MG CLINDA 600MG LEUCO 10MG", "DisplayText" : "PYRIM 50MG CLINDA 600MG LEUCO 10MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 25MG ATOVA 750MG LEUCO 10MG", "DisplayText" : "PYRIM 25MG ATOVA 750MG LEUCO 10MG", "Text" : "Pyrimethamine 25 mg PO QDay ($$) [DI,O] <AND> atovaquone 750-1500 mg PO", "Mnemonic" : "18a"},
{"Row" : 68, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 25MG ATOVA 750MG LEUCO 10MG", "DisplayText" : "PYRIM 25MG ATOVA 750MG LEUCO 10MG Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 70, "Column" : 1, "Item" : "PSOZID TRIEMTH/SULFA 1 DS TABLET PO QDAY", "DisplayText" : "Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI]", "Text" : "Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI]", "Mnemonic" : "20a"},
{"Row" : 71, "Column" : 1, "Item" : "PSHZID TRIEMTH/SULFA 1 DS TABLET PO QDAY", "DisplayText" : "Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 73, "Column" : 1, "Item" : "PSOZID ATOVAQUONE SUSP 750MG PO BID", "DisplayText" : "Atovaquone susp 750mg po bid", "Text" : "Atovaquone 750-1500 mg PO BID ($) [M]", "Mnemonic" : "22a"},
{"Row" : 74, "Column" : 1, "Item" : "PSHZID ATOVAQUONE SUSP 750MG PO BID", "DisplayText" : "Atovaquone susp 750mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" : 85, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "DisplayText" : "PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "Text" : "Pyrimethamine 50 mg BID for 2 days, then 50 mg PO QDay ($$) [DI,O] <AND>", "Mnemonic" : "24a"},
{"Row" : 89, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "DisplayText" : "PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" :3, "Column" : 1, "Text" : "TOXOPLASMA SPP.", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "If patient is immunocompetent and not pregnant, treatment is usually not needed"}, 
{"Row" :6, "Column" : 1, "Text" : "as disease is usually self-limited. Patients who are immunocompromised, pregnant"}, 
{"Row" :7, "Column" : 1, "Text" : "or have severe disease should be treated. Consult Infectious Diseases in all"}, 
{"Row" :8, "Column" : 1, "Text" : "cases."}, 
{"Row" :9, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Non-pregnant patients", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients"}, 
{"Row" : 16, "Column" : 1, "Text" : "for 6 weeks or longer if radiologic disease is extensive or response is"}, 
{"Row" : 17, "Column" : 1, "Text" : "incomplete at 6 weeks."}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Patients weighing <60 kg"}, 
{"Row" : 22, "Column" : 1, "Text" : "sulfadiazine 1 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]"}, 
{"Row" : 25, "Column" : 1, "Text" : "Patients weighing >60kg"}, 
{"Row" : 27, "Column" : 1, "Text" : "sulfadiazine 1.5 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]"}, 
{"Row" : 30, "Column" : 1, "Text" : "Preferred alternative for sulfa allergy", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Patients weighing <60 kg"}, 
{"Row" : 33, "Column" : 1, "Text" : "clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]"}, 
{"Row" : 36, "Column" : 1, "Text" : "Patients weighing >60 kg"}, 
{"Row" : 38, "Column" : 1, "Text" : "clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]"}, 
{"Row" : 41, "Column" : 1, "Text" : "Secondary alternatives", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 43, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 47, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "Chronic Maintenance therapy for immunocompromised patients", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >"}, 
{"Row" : 53, "Column" : 1, "Text" : "200 cells per microliter."}, 
{"Row" : 55, "Column" : 1, "Text" : "Maintenance therapy", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "($$) <AND> leucovorin 10-25 mg PO QDay ($) [M]"}, 
{"Row" : 60, "Column" : 1, "Text" : "Preferred alternative for sulfa allergy", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "[H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]"}, 
{"Row" : 65, "Column" : 1, "Text" : "Secondary alternatives", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "BID ($) [M] <AND> leucovorin 10-25 mg PO QDay ($) [M]"}, 
{"Row" : 69, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 72, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 75, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Text" : "Pregnant patients", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "Patient diagnosed <16-18 weeks of gestation", "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Text" : "*Contact Infectious Diseases, non-formulary consult is required for spiramycin"}, 
{"Row" : 82, "Column" : 1, "Text" : "Spiramycin 1 gm po TID until week 18 of gestation"}, 
{"Row" : 84, "Column" : 1, "Text" : "Patient diagnosed >16-18 weeks of gestation", "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Text" : "sulfadiazine 75mg/kg once, then 50mg/kg BID ($$) [DI,O] <AND> leucovorin 10-25"}, 
{"Row" : 87, "Column" : 1, "Text" : "mg PO QDay ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence"}, 
{"Row" : 88, "Column" : 1, "Text" : "of fetal distress"}, 
{"Row" : 91, "Column" : 1, "Text" : "References: "}, 
{"Row" : 93, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 94, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 95, "Column" : 1, "Text" : "Mandell chapter: Toxoplasma gondii"}, 
{"Row" : 96, "Column" : 1, "Text" : "Sanford keyword: Toxoplasmosis"}, 
{"Row" : 97, "Column" : 1, "Text" : "Up-to-Date article: Toxoplasmosis in immunocompetent hosts"}
]},
{"Name" : "ORZID3 GMENU PARASITES MAIN", "DisplayText" : "Parasites (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE BABESIA SPP.", "DisplayText" : "Babesia spp. (Outpatient)", "Text" : "Babesia spp.", "Mnemonic" : "4"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "Diarrhea, parasitic", "Mnemonic" : "6"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient)", "Text" : "Pneumocystis", "Mnemonic" : "8"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "DisplayText" : "Toxoplasma spp. (Outpatient)", "Text" : "Toxoplasma", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "++ PARASITES ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)"}, 
{"Row" :6, "Column" : 1, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See"}, 
{"Row" :7, "Column" : 1, "Text" : "disease/syndrome section for more information."}, 
{"Row" : 16, "Column" : 1, "Text" : "Last reviewed 2/2018", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PARONYCHIA", "DisplayText" : "Paronychia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP QDAY 14DAYS", "DisplayText" : "Clotrimazole 1% cream topical qday for 14 days", "Text" : "Clotrimazole 1% apply to affected area once daily ($) [M]", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP QDAY 14DAYS", "DisplayText" : "Clotrimazole 1% cream topical qday for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID NYSTATIN CREAM APPLY BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M]", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID NYSTATIN CREAM APPLY BID", "DisplayText" : "Nystatin Cream to affected area BID ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Text" : "Link to Herpes whitlow", "Mnemonic" : "12"},
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "14"},
{"Row" :2, "Column" : 1, "Text" : "PARONYCHIA"}, 
{"Row" :4, "Column" : 1, "Text" : "Cutaneous infection of the hand, cuticle or fingers usually occurring near"}, 
{"Row" :5, "Column" : 1, "Text" : "around the nail."}, 
{"Row" :6, "Column" : 1, "Text" : "Treatment depends on etiology.Candida spp. are commonly involved when the"}, 
{"Row" :7, "Column" : 1, "Text" : "patient has extensive exposure to water (e.g. dishwashers).Staphylococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "aureus is more commonly after manicures or nail biting.Herpes simplex"}, 
{"Row" :9, "Column" : 1, "Text" : "(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or"}, 
{"Row" : 10, "Column" : 1, "Text" : "anesthetists)."}, 
{"Row" : 11, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment for paronychia associated with Candida", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Treat for 14 days"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment for paronychia associated with Staphylococcus", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Treat for 10 days."}, 
{"Row" : 31, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Treatment for paronychia associated with Herpes whitlow", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 44, "Column" : 1, "Text" : "Sanford keyword: paronychia"}
]},
{"Name" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "DisplayText" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" :7, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 12, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis"}, 
{"Row" : 15, "Column" : 1, "Text" : "MMWR RR. 2016, 65 (2) 1-44"}, 
{"Row" : 16, "Column" : 1, "Text" : "Sanford keyword: Ehrlichia sp., Anaplasma sp."}, 
{"Row" : 17, "Column" : 1, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis"}
]},
{"Name" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "DisplayText" : "Disseminated Mycobacterium avium disease (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITHRO 500MG ETHAMBU 15 MG/KG", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITHRO 500MG ETHAMBU 15 MG/KG", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP AZITHRO 250 MG ETHAMBUTOL 15 MG/KG", "Text" : "Azithromycin 250 mg PO QDay ($) [M] <AND> ethambutol 15 mg/kg PO QDay [R]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX NV AZITHRO 250 MG ETHAMBUTOL 15 MG/KG", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Clarithromycin 500 mg PO BID($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Mnemonic" : "8a"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITH 500 ETHAMB 15 RIFABUTIN 300", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]", "Mnemonic" : "10a"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 250 ETHAMB 15 RIFABUTIN 300", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Many of these patients have HIV/AIDS. Management is complex. Consult"}, 
{"Row" :6, "Column" : 1, "Text" : "Infectious Diseases."}, 
{"Row" :8, "Column" : 1, "Text" : "Rifabutin is optional for disseminated disease. Rifabutin can improve cure"}, 
{"Row" :9, "Column" : 1, "Text" : "rates, but may decrease blood concentrations of many drugs. Consult Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases or Pharmacy for more information."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment is continued for 12 months and until CD4 count is >100 cells per"}, 
{"Row" : 14, "Column" : 1, "Text" : "microliter for at least 6 months."}, 
{"Row" : 16, "Column" : 1, "Text" : "Two-drug treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 19, "Column" : 1, "Text" : "($$) [R]"}, 
{"Row" : 22, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 26, "Column" : 1, "Text" : "Three-drug treatment", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 29, "Column" : 1, "Text" : "($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]"}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 34, "Column" : 1, "Text" : "<AND> rifabutin 300 mg QDay ($$) [R,DI]"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 40, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 41, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium complex"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected"}, 
{"Row" : 45, "Column" : 1, "Text" : "patients"}
]},
{"Name" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "DisplayText" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5DS", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] 5DS", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5DS", "DisplayText" : "Doxycycline 100 mg PO BID ($) [DI] 5DS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Treat for at least 5 to 7 days, up to 10 days may be required for more severe or"}, 
{"Row" :7, "Column" : 1, "Text" : "complicated cases"}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options"}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis"}, 
{"Row" : 19, "Column" : 1, "Text" : "MMWR RR. 2016, 65 (2) 1-44"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)"}, 
{"Row" : 21, "Column" : 1, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis"}
]},
{"Name" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "DisplayText" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia (Outpatient)", "Text" : "Treatment for pneumonia", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "DisplayText" : "Disseminated Mycobacterium avium disease (Outpatient)", "Text" : "Treatment for disseminated disease", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "DisplayText" : "Prophylaxis against Mycobacterium avium disease... (Outpatient)", "Text" : "Prophylaxis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "MAI colonization in patients with chronic lung disease is common. These"}, 
{"Row" :6, "Column" : 1, "Text" : "patients should not be treated with antimicrobials."}, 
{"Row" :8, "Column" : 1, "Text" : "Occasionally, MAI causes pulmonary disease in patients who are not"}, 
{"Row" :9, "Column" : 1, "Text" : "immunosuppressed. Diagnosis and management are complex. Consult Infectious"}, 
{"Row" : 10, "Column" : 1, "Text" : "Diseases and/or Pulmonary."}, 
{"Row" : 12, "Column" : 1, "Text" : "MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these"}, 
{"Row" : 13, "Column" : 1, "Text" : "cases do not involve the lungs. After treatment, long-term prophylaxis is"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually given. Consult Infectious Diseases in all cases."}
]},
{"Name" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "DisplayText" : "Mycobacterium avium pneumonia (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITH 500 ETHAMB 15 RIFABUTIN 300", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]", "Mnemonic" : "6a"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 250 ETHAMB 15 RIFABUTIN 300", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM AVIUM PNEUMONIA", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are"}, 
{"Row" :6, "Column" : 1, "Text" : "usually recommended, but two drug regimens may be sufficient in some cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Consult Infectious Diseases and/or Pulmonary in all cases."}, 
{"Row" :9, "Column" : 1, "Text" : "Duration of antimicrobial therapy", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment is continued until sputum cultures are consecutively negative for 12"}, 
{"Row" : 11, "Column" : 1, "Text" : "months."}, 
{"Row" : 13, "Column" : 1, "Text" : "Three-drug regimens", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Preferred treatment"}, 
{"Row" : 16, "Column" : 1, "Text" : "($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 21, "Column" : 1, "Text" : "<AND> rifabutin 300 mg QDay ($$) [R,DI]"}, 
{"Row" : 24, "Column" : 1, "Text" : "Four-drug regimens may be recommended for advanced (severe) or previously", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "treated disease-Consult Infectious Diseases", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium Complex"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in"}, 
{"Row" : 33, "Column" : 1, "Text" : "adults"}
]},
{"Name" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "DisplayText" : "Mycoplasma pneumonia (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 5DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QD for 5 days ($) [R,DI]", "Text" : "Levofloxacin 500 mg PO QDay for 5 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 5DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QD for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "MYCOPLASMA PNEUMONIAE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See"}, 
{"Row" :6, "Column" : 1, "Text" : "diagnosis/syndrome section for more information."}, 
{"Row" :8, "Column" : 1, "Text" : "Preferred treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 16, "Column" : 1, "Text" : "Intolerance to doxycycline and azithromycin"}, 
{"Row" : 21, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Mycoplasma pneumoniae"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-to-Date article: Mycoplasma pneumoniae infection in adults"}
]},
{"Name" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "DisplayText" : "Prophylaxis against Mycobacterium avium disease... (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 1200MG PO Q WEEK", "DisplayText" : "Azithromycin 1200mg po q week", "Text" : "Azithromycin 1200 mg PO q week ($) [M]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 1200MG PO Q WEEK", "DisplayText" : "Azithromycin 1200mg po q week Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID CLARITHROMYCIN 500MG PO BID", "DisplayText" : "Clarithromycin 500mg po bid", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID CLARITHROMYCIN 500MG PO BID", "DisplayText" : "Clarithromycin 500mg po bid Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Infectious Diseases should be involved in all cases. Patients with CD4 count <"}, 
{"Row" :6, "Column" : 1, "Text" : "50 cells per microliter, after ruling out disseminated MC disease, should"}, 
{"Row" :7, "Column" : 1, "Text" : "receive prophylaxis until CD4 count is >100 for at least 3 months in response to"}, 
{"Row" :8, "Column" : 1, "Text" : "antiretroviral therapy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Preferred prophylaxis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 21, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 22, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Mycobacterium avium complex"}, 
{"Row" : 24, "Column" : 1, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare"}, 
{"Row" : 25, "Column" : 1, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected"}, 
{"Row" : 26, "Column" : 1, "Text" : "patients"}
]},
{"Name" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "DisplayText" : "Mycobacterium tuberculosis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "MYCOBACTERIUM TUBERCULOSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Management of tuberculosis is complex. Contact Infectious Diseases and/or"}, 
{"Row" :6, "Column" : 1, "Text" : "Pulmonary service for more information."}
]},
{"Name" : "ORZID3 GMENU PBE DENTAL ORAL RESP PROC", "DisplayText" : "Drugs for pt undergoing dental, oral, resp... (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :7, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 2GM PO ONCE 'C'", "DisplayText" : "Amoxicillin 2gm po once", "Text" : "Amoxicillin 2 gm PO 1 hour before procedure ($) [R]", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of beta-lactam reaction", "Mnemonic" : "6"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 500MG PO ONCE 'C'", "DisplayText" : "Azithromycin 500mg po once", "Text" : "Azithromycin 500mg PO 1 hour before procedure ($) [M]", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "BACTERIAL ENDOCARDITIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Preferred", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "< OR >"}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis"}, 
{"Row" : 11, "Column" : 1, "Text" : "Primary Alternative", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis"}, 
{"Row" : 17, "Column" : 1, "Text" : "Secondary Alternative, after assessment of beta-lactam reaction above", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "References: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 24, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 25, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}, 
{"Row" : 14, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 2000MG PO ONCE", "DisplayText" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Text" : "", "Mnemonic" : "8"}
]},
{"Name" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "DisplayText" : "Cefazolin PD 15 mg/kg once daily with supplies" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZOLIN 1GM QDAY", "DisplayText" : "PD CEFAZOLIN 1GM QDAY", "Text" : "Cefazolin 1 gm PD once daily", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZOLIN 2GM QDAY", "DisplayText" : "OP PD CEFAZOLIN 2GM QDAY", "Text" : "Cefazolin 2 gm PD once daily", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFAZOLIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose dose based on patient's actual body weight (ABW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "ABW < 100 kg: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "ABW >/= 100kg", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG Q24H GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Cefazolin and gentamicin for PD associated peritonitis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZ 1GM QDAY GENT QDAY", "DisplayText" : "PD CEFAZ 1GM QDAY GENT QDAY", "Text" : "Cefazolin 1 gm PD once daily", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZ 2GM QDAY GENT QDAY", "DisplayText" : "PD CEFAZ 2GM QDAY GENT QDAY", "Text" : "Cefazolin 2 gm PD once daily", "Mnemonic" : "4"},
{"Row" :2, "Column" : 1, "Text" : "CEFAZOLIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose dose based on patient's actual body weight (ABW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "ABW < 100 kg: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "ABW >/= 100kg", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY", "DisplayText" : "Gentamicin 0.6 mg/kg once daily for outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 40MG QDAY", "DisplayText" : "Gentamicin 40mg daily", "Text" : "Gentamicin 40 mg PD once daily", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 60MG QDAY", "DisplayText" : "Gentamicin 60mg PD daily", "Text" : "Gentamicin 60 mg PD once daily", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 80MG QDAY", "DisplayText" : "Gentamicin 80 mg PD daily", "Text" : "Gentamicin 80 mg PD once daily", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "GENTAMICIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(see below for AJBW calculation)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "AJBW < 80 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "AJBW >/= 80kg and <120 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "AJBW >/= 120 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Calculations: "}, 
{"Row" : 20, "Column" : 1, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)"}, 
{"Row" : 22, "Column" : 1, "Text" : "IBW: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" : 24, "Column" : 1, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet"}
]},
{"Name" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "DisplayText" : "Gentamicin 0.6 mg/kg once daily with supplies " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 40MG QDAY", "DisplayText" : "PD GENTAMICIN 40MG QDAY WITH SUPPLIES", "Text" : "Gentamicin 40 mg PD once daily", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 60MG QDAY", "DisplayText" : "PD GENTAMICIN 60MG QDAY WITH SUPPLIES", "Text" : "Gentamicin 60 mg PD once daily", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 80MG QDAY", "DisplayText" : "PD GENTAMICIN 80MG QDAY WITH SUPPLIES", "Text" : "Gentamicin 80 mg PD once daily", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "GENTAMICIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(see below for AJBW calculation)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "AJBW < 80 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "AJBW >/= 80kg and <120 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "AJBW >/= 120 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Calculations: "}, 
{"Row" : 20, "Column" : 1, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)"}, 
{"Row" : 22, "Column" : 1, "Text" : "IBW: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" : 24, "Column" : 1, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet"}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LD CEFEPIME 1GM Q24H", "DisplayText" : "Vancomycin 30 mg/kg loading dose and cefepime 1 gm once daily " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 1000MG LD REDOSE Q3-7D CEFEPIME QD", "DisplayText" : "VANCO 1000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 2000MG LD REDOSE Q3-7D CEFEPIME QD", "DisplayText" : "PD VANCO 2000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 3000MG LD REDOSE Q3-7D CEFEPIME QD", "DisplayText" : "PD VANCO 3000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "VANCOMYCIN", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(see below for AJBW calculation)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "AJBW < 50 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "AJBW >/= 50kg and <85 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "AJBW >/= 85 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Calculations: "}, 
{"Row" : 20, "Column" : 1, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)"}, 
{"Row" : 22, "Column" : 1, "Text" : "IBW: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" : 24, "Column" : 1, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LD GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Vancomycin and gentamicin for PD associated peritonitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 1000MG LD REDOSE Q3-7D GENT QD", "DisplayText" : "PD VANCO 1000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 2000MG LD REDOSE Q3-7D GENT QD", "DisplayText" : "PD VANCO 2000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 3000MG LD REDOSE Q3-7D GENT QD", "DisplayText" : "PD VANCO 3000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "VANCOMYCIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(see below for AJBW calculation)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "AJBW < 50 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "AJBW >/= 50kg and <85 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "AJBW >/= 85 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Calculations: "}, 
{"Row" : 20, "Column" : 1, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)"}, 
{"Row" : 22, "Column" : 1, "Text" : "IBW: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" : 24, "Column" : 1, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet"}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "DisplayText" : "Vancomycin 30 mg/kg loading dose with supplies" , "Version" : "Minneapolis", "Contents" : [
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 1000MG LOADING DOSE REDOSE Q3-7D", "DisplayText" : "PD VANCOMYCIN 1000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 2000MG LOADING DOSE REDOSE Q3-7D", "DisplayText" : "PD VANCOMYCIN 2000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 3000MG LOADING DOSE REDOSE Q3-7D", "DisplayText" : "PD VANCOMYCIN 3000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "VANCOMYCIN", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "(see below for AJBW calculation)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "AJBW < 50 kg: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "AJBW >/= 50kg and <85 kg: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "AJBW >/= 85 kg: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Calculations: "}, 
{"Row" : 20, "Column" : 1, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)"}, 
{"Row" : 22, "Column" : 1, "Text" : "IBW: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet"}, 
{"Row" : 24, "Column" : 1, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet"}
]},
{"Name" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "DisplayText" : "Pelvic inflammatory disorder (PID) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP CEFT IM DOXY 14DS 100MG METRO 14DS 500MG", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg BID for 14", "Mnemonic" : "4a"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX NV CEFT IM DOXY 14DS 100MG METRO 14DS 500MG", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 DOXYC 7DS 100 PO BID", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg PO BID for", "Mnemonic" : "6a"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 500MG IM X1 DOXYC 7DS 100 PO BID", "DisplayText" : "Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CEFT 500MG IM ONCE AZITH 1GM PO ONCE", "DisplayText" : "Ceftriaxone 500 mg IM x 1 dose ($) <AND> azithromycin 1 gm PO x 1 dose ($)", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > azithromycin 1 gm PO x 1 dose", "Mnemonic" : "8a"},
{"Row" :3, "Column" : 1, "Text" : "PELVIC INFLAMMATORY DISEASE (PID)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Pelvic inflammatory disease (PID) refers to bacterial infection of the upper"}, 
{"Row" :8, "Column" : 1, "Text" : "female reproductive tract. Likely bacterial pathogens include Neisseria"}, 
{"Row" :9, "Column" : 1, "Text" : "gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and"}, 
{"Row" : 10, "Column" : 1, "Text" : "Streptococcus agalactiae. PID should be considered in sexually active women"}, 
{"Row" : 11, "Column" : 1, "Text" : "with pelvic tenderness and signs of lower genital tract inflammation. Signs and"}, 
{"Row" : 12, "Column" : 1, "Text" : "symptoms may be mild or non-specific, and providers should have a low threshold"}, 
{"Row" : 13, "Column" : 1, "Text" : "to initiate treatment. All women who are diagnosed with acute PID should be"}, 
{"Row" : 14, "Column" : 1, "Text" : "tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of"}, 
{"Row" : 15, "Column" : 1, "Text" : "patients with PID should be examined and treated (see below) if they had sexual"}, 
{"Row" : 16, "Column" : 1, "Text" : "contact within the 60 days before onset of the patient's symptoms."}, 
{"Row" : 18, "Column" : 1, "Text" : "Judge severity of infection based on clinical signs and symptoms, including"}, 
{"Row" : 19, "Column" : 1, "Text" : "blood pressure, pulse, mental status, and degree of fever."}, 
{"Row" : 20, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 25, "Column" : 1, "Text" : "days ($) [DI] < OPTIONAL > metronidazole 500 mg PO BID ($) [DI]"}, 
{"Row" : 28, "Column" : 1, "Text" : "For patients who cannot take ceftriaxone and doxycycline, call ID", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Treatment of sex partner who is a veteran", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Treat for both Chlamydia and Gonorrhea"}, 
{"Row" : 33, "Column" : 1, "Text" : "7 days ($) [DI]"}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 37, "Column" : 1, "Text" : "($) [M]"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Treatment for severe disease", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS"}, 
{"Row" : 44, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Pelvic inflammatory disease"}, 
{"Row" : 49, "Column" : 1, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"}
]},
{"Name" : "ORZID3 GMENU PENTAMADINE MENU" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE HOME PROSTHETIC AND CLINIC", "DisplayText" : "Prosthetic request for home nebulizer and clinic education visit", "Text" : ">>Click here to order this set", "Mnemonic" : "4"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB HOME", "DisplayText" : "Pentamidine inhalation home orders (call 612-467-5193 for 3V LPN appt)", "Text" : ">>Click here to order this set", "Mnemonic" : "6"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "Pentamidine Home Administration"}, 
{"Row" :5, "Column" : 1, "Text" : "Pentamidine may be administered at home for patients who find it difficult"}, 
{"Row" :6, "Column" : 1, "Text" : "going to monthly clinic visits and are capable of performing home"}, 
{"Row" :7, "Column" : 1, "Text" : "administration. Patients who decide to take pentamidine at home require"}, 
{"Row" :8, "Column" : 1, "Text" : "a LPN clinic visit for education and a nebulizer with their first"}, 
{"Row" :9, "Column" : 1, "Text" : "prescription."}, 
{"Row" : 11, "Column" : 1, "Text" : "Initial Pentamidine Prescription orders (90 day supply)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "3V LPN clinic visit"}, 
{"Row" : 13, "Column" : 1, "Text" : "Pentamidine Neb Air Compressor prosthetic consult"}, 
{"Row" : 14, "Column" : 1, "Text" : ">>Equipment Requested: Pentamidine Neb Air Compressor"}, 
{"Row" : 15, "Column" : 1, "Text" : "Medical Condition: Pneumocystosis prevention"}, 
{"Row" : 16, "Column" : 1, "Text" : "Choose provisional diagnosis (e.g. lymphocytopenia)"}, 
{"Row" : 17, "Column" : 1, "Text" : "Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]"}, 
{"Row" : 18, "Column" : 1, "Text" : "Albuterol inhaler"}, 
{"Row" : 19, "Column" : 1, "Text" : "Syringes (10mL)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Needles (22 gauge, 1.5 inch)"}, 
{"Row" : 21, "Column" : 1, "Text" : "Sterile Water vials (10mL)"}, 
{"Row" : 22, "Column" : 1, "Text" : "Iso-Neb Filtered Nebulizer System"}, 
{"Row" : 26, "Column" : 1, "Text" : "Subsequent Pentamidine Prescription orders (90 day supply)", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]"}, 
{"Row" : 28, "Column" : 1, "Text" : "Albuterol inhaler"}, 
{"Row" : 29, "Column" : 1, "Text" : "Syringes (10mL)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Needles (22 gauge, 1.5 inch)"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sterile Water vials (10mL)"}, 
{"Row" : 32, "Column" : 1, "Text" : "Iso-Neb Filtered Nebulizer System"}
]},
{"Name" : "ORZID3 GMENU PERI ASSOC CAPD", "DisplayText" : "Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis..." , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 88, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 200MG PO QOD", "DisplayText" : "Fluconazole 200 mg PO every other day ($) [R,DI]", "Text" : "Fluconazole 200 mg PO every other day ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 89, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 200MG PO QOD", "DisplayText" : "Fluconazole 200 mg PO every other day ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 91, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 100MG PO QDAY", "DisplayText" : "Fluconazole 100 mg PO QDay ($) [R,DI]", "Text" : "Fluconazole 100 mg PO QDay ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 92, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 100MG PO QDAY", "DisplayText" : "Fluconazole 100 mg PO QDay ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP PD HEPARIN SYRINGE/NEEDLE", "DisplayText" : "Heparin 1000 units PD qday", "Text" : "Heparin 1000 units PD q24h", "Mnemonic" : "8"},
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFEP 1GM Q24H SNPW", "DisplayText" : "Cefepime 1 gm PD Qday SNPW", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Mnemonic" : "10"},
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG Q24H GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Cefazolin and gentamicin for PD associated peritonitis", "Text" : "Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h", "Mnemonic" : "12"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 30MG/KG LD CEFEP 0.6MG/KG SNPW", "DisplayText" : "Vancomycin 15-30 mg/kg and cefepime 1 gm PD Qday SNPW", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Mnemonic" : "14"},
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LD GENTAMICIN 0.6MG/KG Q24H", "DisplayText" : "Vancomycin and gentamicin for PD associated peritonitis", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Mnemonic" : "16"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "DisplayText" : "Cefazolin PD 15 mg/kg once daily with supplies", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Mnemonic" : "18"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "DisplayText" : "Vancomycin 30 mg/kg loading dose with supplies", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Mnemonic" : "20"},
{"Row" : 67, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFEP 1GM Q24H SNPW", "DisplayText" : "Cefepime 1 gm PD Qday SNPW", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Mnemonic" : "22"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "DisplayText" : "Gentamicin 0.6 mg/kg once daily with supplies", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Mnemonic" : "24"},
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "DisplayText" : "Cefazolin PD 15 mg/kg once daily with supplies", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Mnemonic" : "26"},
{"Row" : 75, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFTAZ 1GM Q24H SNPW", "DisplayText" : "Ceftazidime 1 gm PD Qday SNPW", "Text" : "Ceftazidime 1 gm PD q24h ($) [R]", "Mnemonic" : "28"},
{"Row" : 77, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFTRI 1GM Q24H SNPW", "DisplayText" : "Ceftriaxone 1 gm PD Qday SNPW", "Text" : "Ceftriaxone 1 gm PD q24h ($) [M]", "Mnemonic" : "30"},
{"Row" : 79, "Column" : 1, "Item" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "DisplayText" : "Gentamicin 0.6 mg/kg once daily with supplies", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Mnemonic" : "32"},
{"Row" : 81, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "DisplayText" : "Vancomycin 30 mg/kg loading dose with supplies", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Mnemonic" : "34"},
{"Row" :3, "Column" : 1, "Text" : "PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Peritonitis associated with peritoneal dialysis usually presents with abdominal"}, 
{"Row" :6, "Column" : 1, "Text" : "pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte"}, 
{"Row" :7, "Column" : 1, "Text" : "concentration is greater than 100 cells/microliter of dialysate, with more than"}, 
{"Row" :8, "Column" : 1, "Text" : "50% neutrophils."}, 
{"Row" : 10, "Column" : 1, "Text" : "Obtain Gram stain, culture, and cell count with differential of dialysate before"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials are given. Nephrology consultation is essential. If cultures"}, 
{"Row" : 12, "Column" : 1, "Text" : "show Gram-negative or mixed bacterial infection, a gastrointestinal tract"}, 
{"Row" : 13, "Column" : 1, "Text" : "infectious source is more likely. Gram-positive organisms like staphylococci"}, 
{"Row" : 14, "Column" : 1, "Text" : "usually result from external contamination. Fungal peritonitis is rare and"}, 
{"Row" : 15, "Column" : 1, "Text" : "requires immediate catheter removal."}, 
{"Row" : 17, "Column" : 1, "Text" : "**Antimicrobial recommendations are for empirical therapy only. Regimens should"}, 
{"Row" : 18, "Column" : 1, "Text" : "be tailored according to patient response and microbiology results in"}, 
{"Row" : 19, "Column" : 1, "Text" : "consultation with Nephrology and/or Infectious Diseases for more information."}, 
{"Row" : 21, "Column" : 1, "Text" : "To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin"}, 
{"Row" : 22, "Column" : 1, "Text" : "per dialysis bag each day until one day after the dialysate is clear."}, 
{"Row" : 24, "Column" : 1, "Text" : "If vancomycin is used, trough serum concentrations should be kept above 15"}, 
{"Row" : 25, "Column" : 1, "Text" : "mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be"}, 
{"Row" : 26, "Column" : 1, "Text" : "given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more"}, 
{"Row" : 27, "Column" : 1, "Text" : "information."}, 
{"Row" : 83, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Text" : "Antifungal prophylaxis may be used for the duration of antimicrobial therapy to"}, 
{"Row" : 86, "Column" : 1, "Text" : "possibly reduce the risk of fungal peritonitis."}, 
{"Row" : 90, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "**Heparin add on therapy", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "If heparin PD therapy is needed in addition to antimicrobial therapy, click on"}, 
{"Row" : 33, "Column" : 1, "Text" : "the heparin order below."}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "Antimicrobial therapy", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Duration of therapy depends on the pathogen identified. Treat staphylococcal and"}, 
{"Row" : 41, "Column" : 1, "Text" : "streptococcal infections for 2 weeks and all other gram-positive infections for"}, 
{"Row" : 42, "Column" : 1, "Text" : "3 weeks. In patients who have Staphylococcus isolated and had a previous"}, 
{"Row" : 43, "Column" : 1, "Text" : "staphylococcal infection, treat for 3 weeks."}, 
{"Row" : 45, "Column" : 1, "Text" : "All antimicrobials below are administered via peritoneal dialysate bag over 6", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "hours", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Empirical treatment while waiting for results of gram stain", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 53, "Column" : 1, "Text" : "MRSA risk factors"}, 
{"Row" : 55, "Column" : 1, "Text" : "cefepime 1 gm PD q24h ($) [R]"}, 
{"Row" : 57, "Column" : 1, "Text" : "Alternative for severe penicillin or cephalosporin allergy"}, 
{"Row" : 59, "Column" : 1, "Text" : "gentamicin 0.6 mg/kg PD q24h ($) [R,O]"}, 
{"Row" : 61, "Column" : 1, "Text" : "Gram positive organism", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 66, "Column" : 1, "Text" : "Gram negative organism", "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Text" : "Alternative for severe penicillin allergy"}, 
{"Row" : 72, "Column" : 1, "Text" : "Alternative treatments for narrowing coverage based on isolate susceptibilities", "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 76, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 78, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 80, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 95, "Column" : 1, "Text" : "References: "}, 
{"Row" : 97, "Column" : 1, "Text" : "De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15"}, 
{"Row" : 98, "Column" : 1, "Text" : "Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508"}, 
{"Row" : 99, "Column" : 1, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses"}, 
{"Row" :100, "Column" : 1, "Text" : "Sanford keyword: Peritonitis, Dialysis (CAPD) Associated"}, 
{"Row" :101, "Column" : 1, "Text" : "Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal"}, 
{"Row" :102, "Column" : 1, "Text" : "dialysis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Consult Nephrology in a all cases.", "Header" : 1}, 
{"Row" : 84, "Column" : 1, "Text" : "Fungal prophylaxis: ", "Header" : 1}, 
{"Row" : 93, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PERIOCULAR INFECTIONS", "DisplayText" : "Periocular Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PERIOCULAR INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Eyelid infections", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Patients with moderate or severe eyelid infections should be referred to"}, 
{"Row" :7, "Column" : 1, "Text" : "ophthalmology."}, 
{"Row" :8, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Blepharitis", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Wash margins with baby shampoo daily and use warm compresses daily."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antimicrobials have no benefit."}, 
{"Row" : 13, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Hordeolum (stye)", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "For external disease (involving the gland of Zeis), daily hot pack massage"}, 
{"Row" : 17, "Column" : 1, "Text" : "encourages drainage and relieves symptoms. For internal disease (involving"}, 
{"Row" : 18, "Column" : 1, "Text" : "Meibomian glands) ophthalmology consult is encouraged, as the infection seldom"}, 
{"Row" : 19, "Column" : 1, "Text" : "drains without intervention."}, 
{"Row" : 20, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Lacrimal infections", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Refer cases of lacrimal infection to ophthalmology, including infections of the"}, 
{"Row" : 24, "Column" : 1, "Text" : "lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts"}, 
{"Row" : 25, "Column" : 1, "Text" : "(canaliculitis)."}, 
{"Row" : 27, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "References: "}, 
{"Row" : 30, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 31, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-To-Date article: Blepharitis"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-To-Date article: Eyelid lesions"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Blepharitis"}, 
{"Row" : 35, "Column" : 1, "Text" : "Sanford keyword: Hordeolum, Stye"}
]},
{"Name" : "ORZID3 GMENU PERIODENTAL DISEASE", "DisplayText" : "Periodental disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CHLORHEXIDINE 0.12% ORAL SWISH BID 7DAYS", "DisplayText" : "Chlorhexidine 0.12% PO rinse, swish for 30 seconds then spit, 15 ml BID for 7", "Text" : "Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 CHLORHEXIDINE 0.12% ORAL SWISH BID 7DAYS", "DisplayText" : "Chlorhexidine 0.12% PO rinse, swish for 30 seconds then spit, 15 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "PERIODONTAL DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Periodontal disease, including gingivitis and periodontitis, may progress into"}, 
{"Row" :6, "Column" : 1, "Text" : "more severe disease or cause hematogenous spreading of bacteria if left"}, 
{"Row" :7, "Column" : 1, "Text" : "untreated. All patients with periodontal disease should be referred to the"}, 
{"Row" :8, "Column" : 1, "Text" : "dental service for assessment and direction of treatment. In the presence of"}, 
{"Row" :9, "Column" : 1, "Text" : "gingivitis, the most commonly isolated subgingival flora includes Prevotella"}, 
{"Row" : 10, "Column" : 1, "Text" : "intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the"}, 
{"Row" : 11, "Column" : 1, "Text" : "presence of periodontitis, flora increases in complexity to most commonly"}, 
{"Row" : 12, "Column" : 1, "Text" : "include Porphyromonas gingivalis, P. intermedia, Aggregatibacter"}, 
{"Row" : 13, "Column" : 1, "Text" : "actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola."}, 
{"Row" : 14, "Column" : 1, "Text" : "Consult Dental Service", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Non-severe periodontitis or acute simple gingivitis treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "daily for 7 days ($) [M]"}, 
{"Row" : 21, "Column" : 1, "Text" : "Severe periodontitis or acute complicated gingivitis (ulceration, rapidly", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "advancing disease, severe pain, patients with immunocompromising conditions)", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "treatment", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Consult Dental Service"}, 
{"Row" : 26, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 30, "Column" : 1, "Text" : "Mandel Chapter: Infections of the Oral Cavity, Neck and Head"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-To-Date article: Complications, diagnosis, and treatment of odontogenic"}, 
{"Row" : 32, "Column" : 1, "Text" : "infections"}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-To-Date article: Overview of gingivitis and periodontitis in adults"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Vincent's Angina"}, 
{"Row" : 35, "Column" : 1, "Text" : "Slots et al., Periodontology. 2002, 28(1)106-176"}, 
{"Row" : 36, "Column" : 1, "Text" : "Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172."}
]},
{"Name" : "ORZID3 GMENU PERTUSSIS", "DisplayText" : "Pertussis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "DisplayText" : "Diagnosis of Pertussis", "Text" : "Diagnosis of pertussis", "Mnemonic" : "4"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "DisplayText" : "Prevention of pertussis (Outpatient)", "Text" : "Prevention of pertussis", "Mnemonic" : "6"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]", "Mnemonic" : "8a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "PERTUSSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Pertussis is associated with persistent cough in adolescents and adults."}, 
{"Row" :6, "Column" : 1, "Text" : "Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1"}, 
{"Row" :7, "Column" : 1, "Text" : "to 2 weeks of disease resembles viral upper respiratory infection. After this,"}, 
{"Row" :8, "Column" : 1, "Text" : "the characteristic cough with whoop is present for 1 to 6 weeks, followed by a"}, 
{"Row" :9, "Column" : 1, "Text" : "2 to 3 week period of gradual resolution."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative for macrolide intolerant or allergic patients", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References"}, 
{"Row" : 25, "Column" : 1, "Text" : "Kline et al, Am Fam Physician (2013) 88.8, 507-514"}, 
{"Row" : 26, "Column" : 1, "Text" : "Langley et al, Pediatrics (2004), e96-e101"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Pertussis"}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Bordetella pertussis"}
]},
{"Name" : "ORZID3 GMENU PHARYNGITIS", "DisplayText" : "Pharyngitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment of Gonorrheal Infections", "Mnemonic" : "4"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "DisplayText" : "More About Pharyngitis", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "DisplayText" : "Strep A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 500MG PO BID 10DS", "DisplayText" : "Penicillin V 500 mg PO BID ($) for 10 days [R]", "Text" : "Penicillin V 500 mg PO BID for 10 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 500MG PO BID 10DS", "DisplayText" : "Penicillin V 500 mg PO BID ($) for 10 days [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 29, "Column" : 1, "Item" : "PSCZID2 BENZATHINE PENICILLIN 1.2MU IM ONCE", "DisplayText" : "Benzathine penicillin 1.2 million units IM once ($$$) [M]", "Text" : "Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]", "Mnemonic" : "14a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 BENZATHINE PENICILLIN 1.2MU IM ONCE", "DisplayText" : "Benzathine penicillin 1.2 million units IM once ($$$) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "[Click here] Assess Beta-lactam allergy prior to ordering alternative", "Mnemonic" : "16"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)", "Mnemonic" : "20a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" :3, "Column" : 1, "Text" : "PHARYNGITIS AND TONSILLITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and"}, 
{"Row" :6, "Column" : 1, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal"}, 
{"Row" :7, "Column" : 1, "Text" : "pharyngitis, use link below for recommendations."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consider HIV screening for patients with pharyngitis"}, 
{"Row" : 13, "Column" : 1, "Text" : "Streptococcal Pharyngitis and Tonsillitis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by"}, 
{"Row" : 15, "Column" : 1, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk"}, 
{"Row" : 16, "Column" : 1, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for"}, 
{"Row" : 17, "Column" : 1, "Text" : "Modified Centor score criteria and for more details."}, 
{"Row" : 21, "Column" : 1, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Antimicrobials are not indicated"}, 
{"Row" : 24, "Column" : 1, "Text" : "GAS Pharyngitis and Tonsillitis Treatment", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Preferred"}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: "}, 
{"Row" : 40, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 43, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "References: "}, 
{"Row" : 46, "Column" : 1, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390"}, 
{"Row" : 47, "Column" : 1, "Text" : "Mandell chapter: Pharyngitis"}, 
{"Row" : 48, "Column" : 1, "Text" : "Sanford keyword: Streptococcal Pharyngitis"}, 
{"Row" : 49, "Column" : 1, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629"}, 
{"Row" : 50, "Column" : 1, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults"}, 
{"Row" : 51, "Column" : 1, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis"}, 
{"Row" : 11, "Column" : 1, "Item" : "LRTZ HIV AG/AB", "DisplayText" : "HIV AG/AB", "Text" : "HIV AG/AB Lab", "Mnemonic" : "6"},
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID x10days ($) [R]", "Text" : "", "Mnemonic" : "18a"},
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID X10DAYS", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "18b"}
]},
{"Name" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "DisplayText" : "Pneumocyctis Jirovecii Disease (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocystis Jirovecii Prophylaxis", "Text" : "[CLICK HERE]", "Mnemonic" : "4"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 2DS TABLETS PO Q8H 21DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 2 ds tablets po q8h for 21 days", "Text" : "Trimethoprim-sulfamethoxazole 2 DS tablets PO TID for 21 days ($)[R,DI]", "Mnemonic" : "6a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 2DS TABLETS PO Q8H 21DAYS", "DisplayText" : "Trimethoprim-sulfamethoxazole 2 ds tablets po q8h for 21 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP TMP 5MG/KG QD DAPSONE 100MG PO QD", "Text" : "Trimethoprim-sulfamethoxazole 5mg/kg PO TID ($)[R,DI] <AND> dapsone 100mg", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV TMP 5MG/KG QD DAPSONE 100MG PO QD", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP CLINDAM 450MG Q6H PRIMAQUINE 26.3MG QD", "Text" : "Clindamycin 450mg PO QID ($)[H,O] <AND> Primaquine 26.3 mg PO QDay ($)[DI]", "Mnemonic" : "10a"},
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX NV CLINDAM 450MG Q6H PRIMAQUINE 26.3MG QD", "DisplayText" : "Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 ATOVAQUONE 750MG PO BID 21DAYS", "DisplayText" : "Atovaquone 750mg po bid for 21 days", "Text" : "Atovaquone 750mg PO BID for 21 days ($)[M]", "Mnemonic" : "12a"},
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 ATOVAQUONE 750MG PO BID 21DAYS", "DisplayText" : "Atovaquone 750mg po bid for 21 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 PREDNISONE 40MG BID 5DS THEN 40 QD 6DS THEN 20 QD", "DisplayText" : "Prednisone 40mg bid 5days then 40mg qday 6days then 20mg qday 10days", "Text" : "Prednisone 40mg PO twice daily for 5 days, then 40mg PO daily for 6 days,", "Mnemonic" : "14a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 PREDNISONE 40MG BID 5DS THEN 40 QD 6DS THEN 20 QD", "DisplayText" : "Prednisone 40mg bid 5days then 40mg qday 6days then 20mg qday 10 Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "PNEUMOCYSTIS JIROVECII DISEASE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Diagnosis and treatment are complex, consult Infectious Diseases in all cases."}, 
{"Row" :7, "Column" : 1, "Text" : "Pneumocystis jirovecii (formerly termed Pneumocystis carinii) in an ubiquitious"}, 
{"Row" :8, "Column" : 1, "Text" : "organism that causes disease in people with compromised cell-mediated immunity."}, 
{"Row" :9, "Column" : 1, "Text" : "Disease is exceedingly rare in people with intact host defenses. Pneumonia is"}, 
{"Row" : 10, "Column" : 1, "Text" : "the usual manifestation but P. jirovecii can infect extrapulmonary sites,"}, 
{"Row" : 11, "Column" : 1, "Text" : "especially in patients who have been receiving prophylaxis with aerosolized"}, 
{"Row" : 12, "Column" : 1, "Text" : "pentanmidine. P. jirovecii disease occurs most commonly in people with AIDS and"}, 
{"Row" : 13, "Column" : 1, "Text" : "fewer than 200 CD4 T lymphocytes/microliter."}, 
{"Row" : 15, "Column" : 1, "Text" : "The abbreviation PCP is often used for Pneumocystis pneumonia. It was derived"}, 
{"Row" : 16, "Column" : 1, "Text" : "from the old species name, Pneumocystis carinii."}, 
{"Row" : 18, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole (TMP-SMZ) is the treatment of choice for P."}, 
{"Row" : 19, "Column" : 1, "Text" : "jirovecii disease, including disease that occurs despite TMP-SMZ prophylaxis."}, 
{"Row" : 20, "Column" : 1, "Text" : "Corticosteriods should be prescribed for patients with AIDS and P. jirovecii"}, 
{"Row" : 21, "Column" : 1, "Text" : "pneumonia and an arterial oxygen tension <70 torr or an alveolar-arterial oxygen"}, 
{"Row" : 22, "Column" : 1, "Text" : "gradient of >35 torr."}, 
{"Row" : 27, "Column" : 1, "Text" : "Preferred treatment for mild to moderate disease or step-down treatment once", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "disease has stabilized", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 33, "Column" : 1, "Text" : "PO QDay ($)[DI] for 21 days"}, 
{"Row" : 36, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 38, "Column" : 1, "Text" : "for 21 days"}, 
{"Row" : 40, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 44, "Column" : 1, "Text" : "Preferred treatment for severe disease", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 47, "Column" : 1, "Text" : "Prednisone for patient WITH AIDS", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "then 20 mg daily for 10 days."}, 
{"Row" : 53, "Column" : 1, "Text" : "References: "}, 
{"Row" : 55, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 56, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282"}, 
{"Row" : 57, "Column" : 1, "Text" : "Mandell chapter: Mandell Chapter Management of Opportunistic Infections"}, 
{"Row" : 58, "Column" : 1, "Text" : "Associated with Human Immunodeficiency Virus Infection"}, 
{"Row" : 59, "Column" : 1, "Text" : "Sanford keyword: pneumocystis pneumonia, Adult"}, 
{"Row" : 60, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis infection in HIV-"}, 
{"Row" : 61, "Column" : 1, "Text" : "infected patients"}, 
{"Row" : 24, "Column" : 1, "Text" : "Prophylaxis for Pneumocystis jirovecii", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocystis Jirovecii Prophylaxis" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID TMP/SMX 1 DS TABLET QDAY", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 ds tablet qday", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q day ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID TMP/SMX 1 DS TABLET QDAY", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 ds tablet qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID TMP/SMX 1 SS TABLET QDAY", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 ss tablet qday", "Text" : "Trimethoprim-sulfamethoxazole 1 SS tablet q day ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID TMP/SMX 1 SS TABLET QDAY", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 ss tablet qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 38, "Column" : 1, "Item" : "PSOZID DAPSONE 100MG PO QDAY", "DisplayText" : "Dapsone 100mg po qday", "Text" : "Dapsone 100mg PO q day ($) [O]", "Mnemonic" : "8a"},
{"Row" : 39, "Column" : 1, "Item" : "PSHZID DAPSONE 100MG PO QDAY", "DisplayText" : "Dapsone 100mg po qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB RTC LPN", "DisplayText" : "ALBUTEROL AND PENTAMIDINE ORDERS", "Text" : "Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%", "Mnemonic" : "12"},
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU PENTAMADINE MENU", "Text" : "Pentamidine for home administration", "Mnemonic" : "14"},
{"Row" :3, "Column" : 1, "Text" : "PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Indications for primary prophylaxis of P. jirovecii include: "}, 
{"Row" :6, "Column" : 1, "Text" : "1) HIV/AIDS patients with CD4 count <200 cells/microliter"}, 
{"Row" :7, "Column" : 1, "Text" : "2) Hematopoietic or organ transplantation patients during immunosuppression"}, 
{"Row" :8, "Column" : 1, "Text" : "3) Patients receiving Alemtuzumab, temozolomide or fludarabine"}, 
{"Row" :9, "Column" : 1, "Text" : "4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month"}, 
{"Row" : 10, "Column" : 1, "Text" : "5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving"}, 
{"Row" : 11, "Column" : 1, "Text" : "immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe"}, 
{"Row" : 12, "Column" : 1, "Text" : "combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM syndrome)"}, 
{"Row" : 14, "Column" : 1, "Text" : "Dose and duration of prophylaxis varies with the indication. Please contact"}, 
{"Row" : 15, "Column" : 1, "Text" : "Infectious Diseases or Hematology/Oncology for more information."}, 
{"Row" : 17, "Column" : 1, "Text" : "Prophylaxis should be discontinued when host defenses are restored. In persons"}, 
{"Row" : 18, "Column" : 1, "Text" : "with AIDS on highly active antiretroviral therapy, Prophylaxis should be"}, 
{"Row" : 19, "Column" : 1, "Text" : "discontinued when the CD4 cell concentrations remain over 200 cells/microliter"}, 
{"Row" : 20, "Column" : 1, "Text" : "for 3-6 months in patients, except that prophylaxis should be continued for"}, 
{"Row" : 21, "Column" : 1, "Text" : "life in those who have had P. jirovecii disease."}, 
{"Row" : 26, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated: ", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN"}, 
{"Row" : 52, "Column" : 1, "Text" : "appointment)"}, 
{"Row" : 53, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 56, "Column" : 1, "Text" : "References"}, 
{"Row" : 62, "Column" : 1, "Text" : "Sanford keyword: Pneumocystis pneumonia, Adult"}, 
{"Row" : 63, "Column" : 1, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-"}, 
{"Row" : 64, "Column" : 1, "Text" : "Uninfected patients"}, 
{"Row" : 23, "Column" : 1, "Text" : "Recommended FIRST-LINE prophylaxis: ", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)"}, 
{"Row" : 32, "Column" : 1, "Text" : "deficiency before starting dapsone. Individuals deficient in G6-PD"}, 
{"Row" : 33, "Column" : 1, "Text" : "show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic"}, 
{"Row" : 34, "Column" : 1, "Text" : "anemia."}, 
{"Row" : 35, "Column" : 1, "Text" : "G6-PD lab test are resulted the same day or next day. May be add on lab."}, 
{"Row" : 36, "Column" : 1, "Text" : "G6-PD lab result should be \"normal\" to start dapsone therapy."}, 
{"Row" : 47, "Column" : 1, "Text" : "Alternative to the above regimens: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Due to efficacy and complicated logistics for administration, alternative"}, 
{"Row" : 49, "Column" : 1, "Text" : "when above recommendations not appropriate for patient."}, 
{"Row" : 41, "Column" : 1, "Text" : "Alternative to the above preferred regimens: ", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Atovaquone is alternative for patient for clinical reason: ", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "(e.g. patients with SLE, hematologic concerns, G6PD deficiency)"}, 
{"Row" : 58, "Column" : 1, "Text" : "Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404"}, 
{"Row" : 59, "Column" : 1, "Text" : "Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9"}, 
{"Row" : 60, "Column" : 1, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV"}, 
{"Row" : 61, "Column" : 1, "Text" : "Infected Adults and Adolescents. AIDSinfo (2018)"}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZIDATOVAQUONE 1500MG QDAY PCP PROPHYLAXIS", "DisplayText" : "Atovaquone 1500mg qday for PCP prophylaxis ($$) [DI]", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 45, "Column" : 1, "Item" : "PSHZID ATOVAQUONE 1500MG SUSP QDAY PCP PROPHYLAXIS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "10b"},
{"Row" : 37, "Column" : 1, "Item" : "LRTZ G6-PD SCREEN", "DisplayText" : "G6-PD Screen", "Text" : "[Click here] G6-PD Screen Lab Order", "Mnemonic" : "7"}
]},
{"Name" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "DisplayText" : "Postseptal cellulitis (Orbital cellulitis) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 2DS 7DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >", "Mnemonic" : "4a"},
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875 BID + TMP/SULFA 2DS 7DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2ds non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS", "DisplayText" : "CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS", "DisplayText" : "CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS NON-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and"}, 
{"Row" :6, "Column" : 1, "Text" : "requires immediate consultation with otolaryngology and ophthalmology. Urgent"}, 
{"Row" :7, "Column" : 1, "Text" : "surgical drainage may be necessary. The most common pathogenic organisms in"}, 
{"Row" :8, "Column" : 1, "Text" : "adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus"}, 
{"Row" :9, "Column" : 1, "Text" : "aureus."}, 
{"Row" : 11, "Column" : 1, "Text" : "Contact otolaryngology or ophthalmology immediately for urgent surgical"}, 
{"Row" : 12, "Column" : 1, "Text" : "drainage. Broad-spectrum empirical antimicrobials should be used until a"}, 
{"Row" : 13, "Column" : 1, "Text" : "pathogen can be identified from the drainage fluid."}, 
{"Row" : 15, "Column" : 1, "Text" : "Duration of treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Orbital cellulitis should be treated until all signs of infection have resolved."}, 
{"Row" : 17, "Column" : 1, "Text" : "Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and"}, 
{"Row" : 18, "Column" : 1, "Text" : "complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of"}, 
{"Row" : 19, "Column" : 1, "Text" : "sinus) should be treated for at least 4 weeks."}, 
{"Row" : 21, "Column" : 1, "Text" : "Empiric treatment", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 24, "Column" : 1, "Text" : "Step-down treatment after initial intravenous therapy. Base selection on cultur", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "results.Adjust duration based on criteria above.", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days"}, 
{"Row" : 30, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 33, "Column" : 1, "Text" : "q12h ($) [R,DI] for 7 days"}, 
{"Row" : 36, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-to-Date article: Orbital Cellulitis"}, 
{"Row" : 42, "Column" : 1, "Text" : "Sanford keyword: Orbital cellulitis"}
]},
{"Name" : "ORZID3 GMENU PREGNANCY RISK INFO" , "Term1" : "Pregnancy risk factors for antimicrobials", "DisplayText" : "List of Antimicrobials with Pregnancy Risk Category " , "Version" : "Minneapolis", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD PREGNANCY", "DisplayText" : "Sanford Guide Pregnancy and Lactation Info Page", "Text" : "Sanford Guide Pregnancy Risk & Lactation Safety Table", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "RISK FACTORS FOR ANTIMICROBIALS DURING PREGNANCY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "The FDA amended its rules in 2015 concerning the Pregnancy, Labor and delivery,", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "and Nursing mothers subsections of the Use in Specific Populations section of", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "product labeling. Pregnancy categories A, B, C, D, and X have been removed.", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Drugs approved after June 30 will use the new format immediately, while drugs", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "approved after June 30, 2001 will be phased in gradually.", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "See Sanford Guide for comprehensive antimicrobial pregnancy risk and lactation"}, 
{"Row" : 12, "Column" : 1, "Text" : "safety information"}, 
{"Row" : 15, "Column" : 1, "Text" : "Risk Factors (A,B,C,D,X) were assigned to all drugs, based on the"}, 
{"Row" : 16, "Column" : 1, "Text" : "level of risk the drug poses to the fetus. Risk Factors were designed to"}, 
{"Row" : 17, "Column" : 1, "Text" : "help the clinician quickly classify a drug for use during pregnancy. They"}, 
{"Row" : 18, "Column" : 1, "Text" : "do not refer to breastfeeding risk. The definitions of the Risk Factors"}, 
{"Row" : 19, "Column" : 1, "Text" : "are those used by the FDA."}, 
{"Row" : 21, "Column" : 1, "Text" : "Category Description", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "A Controlled studies show no risk", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Adequate, well-controlled studies in pregnant women"}, 
{"Row" : 25, "Column" : 1, "Text" : "have failed to demonstrate risk to the fetus."}, 
{"Row" : 27, "Column" : 1, "Text" : "B No evidence of risk in humans", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Either animal findings show risk (but human"}, 
{"Row" : 29, "Column" : 1, "Text" : "findings do not) or, if no adequate human studies"}, 
{"Row" : 30, "Column" : 1, "Text" : "have been done, animal findings are negative."}, 
{"Row" : 32, "Column" : 1, "Text" : "C Risk cannot be ruled out", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Human studies are lacking and animal studies"}, 
{"Row" : 34, "Column" : 1, "Text" : "are either positive for fetal risk or lacking"}, 
{"Row" : 35, "Column" : 1, "Text" : "as well. However, potential benefits may"}, 
{"Row" : 36, "Column" : 1, "Text" : "justify the potential risk."}, 
{"Row" : 38, "Column" : 1, "Text" : "D Positive evidence of risk", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Investigational or postmarketing data show risk"}, 
{"Row" : 40, "Column" : 1, "Text" : "to fetus. Nevertheless, potential benefits may"}, 
{"Row" : 41, "Column" : 1, "Text" : "outweigh the risk."}, 
{"Row" : 43, "Column" : 1, "Text" : "X Contraindicated in pregnancy", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Studies in animals or humans, or investigational"}, 
{"Row" : 45, "Column" : 1, "Text" : "or postmarketing reports have shown fetal risk"}, 
{"Row" : 46, "Column" : 1, "Text" : "which clearly outweighs any possible benefit to"}, 
{"Row" : 47, "Column" : 1, "Text" : "the patient."}, 
{"Row" : 50, "Column" : 1, "Text" : "References"}, 
{"Row" : 52, "Column" : 1, "Text" : "Up-to-Date website"}, 
{"Row" : 53, "Column" : 1, "Text" : "Sanford website"}
]},
{"Name" : "ORZID3 GMENU PREGNANCY VACCINE" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "DisplayText" : "Patient Specific Vaccine History and JLV Link", "Text" : "Patient vaccine history", "Mnemonic" : "4"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "DisplayText" : "CDC Recommended Adult Immunization Schedule", "Text" : "CDC Recommended Adult Immunization Schedule", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Mnemonic" : "8"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: if at risk for infection or severe outcome from infection during", "Mnemonic" : "10"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: if at risk for infection or severe outcome from infection during", "Mnemonic" : "12"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Mnemonic" : "14"},
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Mnemonic" : "16"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Zoster (shingles) Information Page", "Mnemonic" : "18"},
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza: one dose annually.", "Mnemonic" : "20"},
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Mnemonic" : "22"},
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal B: Delay until after pregnancy unless at increased risk and", "Mnemonic" : "24"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Mnemonic" : "26"},
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX OP TD/TDAP VACCINE 3 DOSE SERIES", "DisplayText" : "TD/Tdap vaccine 3 dose series", "Text" : "Tetanus, diphtheria and pertussis: Tdap booster dose during each pregnancy.", "Mnemonic" : "28"},
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "DisplayText" : "Haemophilus Influenza Type B Information Page", "Text" : "Haemophilus influenzae type b (Hib)", "Mnemonic" : "30"},
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A Vaccine Information Page", "Text" : "Hepatitis A (HepA)", "Mnemonic" : "32"},
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis B Vaccine Information Page", "Text" : "Hepatitis B (HepB)", "Mnemonic" : "34"},
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "DisplayText" : "Hepatitis A and Hepatitis B Vaccine Information Page", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Mnemonic" : "36"},
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "DisplayText" : "Zoster (shingles) Information Page", "Text" : "Herpes zoster (RZV)", "Mnemonic" : "38"},
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "DisplayText" : "Human Papillomavirus Vaccine Information Page", "Text" : "Human papillomavirus (HPV)", "Mnemonic" : "40"},
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION", "DisplayText" : "INFLUENZA VACCINATION RECOMMENDATIONS", "Text" : "Influenza", "Mnemonic" : "42"},
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "DisplayText" : "Measles, Mumps, Rubella Vaccine Information Page", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Mnemonic" : "44"},
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Conjugate Vaccine Information Page", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Mnemonic" : "46"},
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "DisplayText" : "Meningococcal Serogroup B Vaccine Information Page", "Text" : "Meningococcal serogroup B (MenB)", "Mnemonic" : "48"},
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "DisplayText" : "Pneumococcal Vaccine Information Page", "Text" : "Pneumococcal 20-valent (PCV20)", "Mnemonic" : "50"},
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "DisplayText" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Mnemonic" : "52"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "DisplayText" : "Varicella Vaccine Information Page", "Text" : "Varicella (VAR)", "Mnemonic" : "54"},
{"Row" :4, "Column" : 1, "Text" : "IMMUNIZATION OF PREGNANT PATIENTS", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Pregnant women should receive the tetanus, diphtheria, and acellular pertussis"}, 
{"Row" :7, "Column" : 1, "Text" : "vaccine (Tdap) during pregnancy and the influenza vaccine during or before"}, 
{"Row" :8, "Column" : 1, "Text" : "pregnancy. Live vaccines are contraindicated (e.g. MMR and Varicella). See"}, 
{"Row" :9, "Column" : 1, "Text" : "immunization information pages located at the bottom of this page for other"}, 
{"Row" : 10, "Column" : 1, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines."}, 
{"Row" : 15, "Column" : 1, "Text" : "Specific vaccine orders for pregnant patients: ", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations"}, 
{"Row" : 18, "Column" : 1, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b"}, 
{"Row" : 19, "Column" : 1, "Text" : "vaccine information menu below."}, 
{"Row" : 22, "Column" : 1, "Text" : "pregnancy."}, 
{"Row" : 25, "Column" : 1, "Text" : "pregnancy."}, 
{"Row" : 32, "Column" : 1, "Text" : "Herpes zoster: delay until after pregnancy unless at increased risk and"}, 
{"Row" : 33, "Column" : 1, "Text" : "information menu below."}, 
{"Row" : 35, "Column" : 1, "Text" : "Human papillomavirus: *CONTRAINDICATED*."}, 
{"Row" : 39, "Column" : 1, "Text" : "Measles, mumps, and rubella *CONTRAINDICATED*."}, 
{"Row" : 42, "Column" : 1, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college"}, 
{"Row" : 43, "Column" : 1, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or"}, 
{"Row" : 44, "Column" : 1, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below."}, 
{"Row" : 47, "Column" : 1, "Text" : "vaccination benefits outweigh potential risks. Refer to Meningococcal B vaccine"}, 
{"Row" : 48, "Column" : 1, "Text" : "information menu below."}, 
{"Row" : 51, "Column" : 1, "Text" : "specific immunization recommendations for patients with these indications or"}, 
{"Row" : 52, "Column" : 1, "Text" : "refer to the Pneumococcal vaccine information menus below."}, 
{"Row" : 56, "Column" : 1, "Text" : "Varicella: *CONTRAINDICATED*."}, 
{"Row" : 57, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Text" : "Specific vaccine information pages: ", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Text" : "References: "}, 
{"Row" : 77, "Column" : 1, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443"}
]},
{"Name" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "DisplayText" : "Preseptal cellulitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 2DS 5DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2DS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875 BID + TMP/SULFA 2DS 5DAYS", "DisplayText" : "Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2 DS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "6"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS", "DisplayText" : "CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 1 DS PO", "Mnemonic" : "8a"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS", "DisplayText" : "CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS NON-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "PRESEPTAL CELLULITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Preseptal cellulitis involves soft tissues in front of the orbital septum and"}, 
{"Row" :6, "Column" : 1, "Text" : "the eyelids and is often preceded by sinusitis. Infection does not involve the"}, 
{"Row" :7, "Column" : 1, "Text" : "orbital contents. The most common pathogenic organisms in adults are"}, 
{"Row" :8, "Column" : 1, "Text" : "streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatunder the guidance of ophthalmology and/or otolaryngology. Intravenous"}, 
{"Row" : 11, "Column" : 1, "Text" : "antimicrobials are indicated initially for treatment of moderate to severe"}, 
{"Row" : 12, "Column" : 1, "Text" : "disease. Switch to oral antimicrobials when the patient's symptoms improve and"}, 
{"Row" : 13, "Column" : 1, "Text" : "the patient can tolerate oral medications."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment of mild to moderate disease", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($) [R,DI] for 5 days"}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative: "}, 
{"Row" : 24, "Column" : 1, "Text" : "BID ($) [R,DI] for 5 days"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment of severe disease", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 30, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "References: "}, 
{"Row" : 33, "Column" : 1, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112"}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Periocular infections"}, 
{"Row" : 35, "Column" : 1, "Text" : "Johns Hopkins website"}, 
{"Row" : 36, "Column" : 1, "Text" : "Up-to-date article: Preseptal cellulitis"}
]},
{"Name" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "DisplayText" : "Prevention of infection in a patient with malignancy (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]", "Text" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID X7DAYS", "DisplayText" : "Cefpodofor ime 100 mg PO BID x7days ($$) [R]", "Text" : "Cefpodofor ime 100 mg PO BID x7days ($$) [R]", "Mnemonic" : "10a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID X7DAYS", "DisplayText" : "Cefpodofor ime 100 mg PO BID x7days ($$) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antimicrobial prophylaxis is often given to patients likely to have profound,"}, 
{"Row" :6, "Column" : 1, "Text" : "prolonged neutropenia.Profound neutropenia is less than 100 neutrophils and"}, 
{"Row" :7, "Column" : 1, "Text" : "bands per microliter, and such neutropenia is considered prolonged when it is"}, 
{"Row" :8, "Column" : 1, "Text" : "expected to last more than 7 days.Most patients who should receive prophylaxis"}, 
{"Row" :9, "Column" : 1, "Text" : "have received stem cell transplants or are undergoing induction chemotherapy for"}, 
{"Row" : 10, "Column" : 1, "Text" : "acute leukemia."}, 
{"Row" : 12, "Column" : 1, "Text" : "If antibacterial prophylaxis is indicated", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of therapy: During period of expected neutropenia"}, 
{"Row" : 18, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 26, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043"}, 
{"Row" : 27, "Column" : 1, "Text" : "Mandell chapter:Prophylaxis and Empirical Therapy for Infection in Cancer-"}, 
{"Row" : 28, "Column" : 1, "Text" : "Patients"}, 
{"Row" : 29, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 30, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}
]},
{"Name" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infection in a patient with malignancy " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY X10DAYS", "DisplayText" : "Fluconazole 400 mg po qday for 10 days ($) [R,DI]", "Text" : "Fluconazole 400 mg po qday for 10 days ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY X10DAYS", "DisplayText" : "Fluconazole 400 mg po qday for 10 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY"}, 
{"Row" :5, "Column" : 1, "Text" : "Antifungal chemoprophylaxis is often given to patients undergoing induction"}, 
{"Row" :6, "Column" : 1, "Text" : "chemotherapy for acute leukemia expected to have profound neutropenia (less than"}, 
{"Row" :7, "Column" : 1, "Text" : "100 neutrophils and bands per milliliter) for more than 10 days and for patients"}, 
{"Row" :8, "Column" : 1, "Text" : "receiving allogeneic stem cell transplantation.For most other patients the"}, 
{"Row" :9, "Column" : 1, "Text" : "expected benefits do not outweigh the risks of adverse effects and selection of"}, 
{"Row" : 10, "Column" : 1, "Text" : "resistant fungi."}, 
{"Row" : 12, "Column" : 1, "Text" : "Antifungal is usually given until the absolute neutrophil concentration"}, 
{"Row" : 13, "Column" : 1, "Text" : "increases to more than 500 cells/microliter in patients undergoing induction"}, 
{"Row" : 14, "Column" : 1, "Text" : "chemotherapy for leukemia.Duration is 100 days for patients undergoing stem"}, 
{"Row" : 15, "Column" : 1, "Text" : "cell transplantation.Some physicians continue prevention after 100 days if"}, 
{"Row" : 16, "Column" : 1, "Text" : "corticosteroids are part of the immunosuppressive regimen."}, 
{"Row" : 17, "Column" : 1, "Text" : "Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia."}, 
{"Row" : 18, "Column" : 1, "Text" : "Contact Hematology Oncology or Infectious Disease for more information."}, 
{"Row" : 20, "Column" : 1, "Text" : "Patients who have had invasive fungal infection in the recent past and who are"}, 
{"Row" : 21, "Column" : 1, "Text" : "about to become neutropenic may require chemoprophylaxis.Contact Hematology-"}, 
{"Row" : 22, "Column" : 1, "Text" : "Oncology or Infectious Diseases for more information."}, 
{"Row" : 24, "Column" : 1, "Text" : "If antifungal prophylaxis is indicated", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Duration of therapy: during period of expected neutropenia"}, 
{"Row" : 29, "Column" : 1, "Text" : "For patients being treated for AML: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Requires Infectious Disease approval: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on"}, 
{"Row" : 32, "Column" : 1, "Text" : "day 2 and thereafter. Continue for 7 days after the neutrophil count"}, 
{"Row" : 33, "Column" : 1, "Text" : "rises above 500/mm3. ($$$$) [DI]"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043"}, 
{"Row" : 38, "Column" : 1, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-"}, 
{"Row" : 39, "Column" : 1, "Text" : "Related Infections. Version 1.2019. nccn.org"}, 
{"Row" : 40, "Column" : 1, "Text" : "Mandell chapter: Prophylaxis and empirical therapy for infection in cancer"}, 
{"Row" : 41, "Column" : 1, "Text" : "patients"}
]},
{"Name" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "DisplayText" : "Prevention of bacterial endocarditis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX DENTAL ABX PPX SOP", "DisplayText" : "DENTAL ABX PPX SOP", "Text" : "SOP for dental surgery antimicrobial prophylaxis", "Mnemonic" : "4"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU PBE DENTAL ORAL RESP PROC", "DisplayText" : "Drugs for pt undergoing dental, oral, resp... (Outpatient)", "Text" : "Patients undergoing dental or oral mucosa procedures", "Mnemonic" : "6"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "DisplayText" : "Head and neck surgery", "Text" : "Patients undergoing procedures on the respiratory tract that involve incision or", "Mnemonic" : "8"},
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT", "Text" : "Patients undergoing procedures for infected skin, skin structures, or infected", "Mnemonic" : "10"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF BACTERIAL ENDOCARDITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Bacteremia occurs several times a day during daily activities like eating and"}, 
{"Row" :6, "Column" : 1, "Text" : "brushing teeth and rarely results in endocarditis, even in people with abnormal"}, 
{"Row" :7, "Column" : 1, "Text" : "valves.While bacteremia might occur following dental or other procedures, most"}, 
{"Row" :8, "Column" : 1, "Text" : "cases of endocarditis are from the millions more episodes of transient"}, 
{"Row" :9, "Column" : 1, "Text" : "bacteremia a person experiences per year from ordinary daily activities.There"}, 
{"Row" : 10, "Column" : 1, "Text" : "is no evidence that antimicrobial prophylaxis prevents endocarditis after"}, 
{"Row" : 11, "Column" : 1, "Text" : "procedures.The best available evidence suggests that prophylactic"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobials confer more risks than benefits in most situations.A decision"}, 
{"Row" : 13, "Column" : 1, "Text" : "about whether to administer antimicrobial prophylaxis should be based on both"}, 
{"Row" : 14, "Column" : 1, "Text" : "the risk of endocarditis conferred by the patient's cardiac defect and the risk"}, 
{"Row" : 15, "Column" : 1, "Text" : "of bacteremia from a planned dental or surgical procedure."}, 
{"Row" : 17, "Column" : 1, "Text" : "Minneapolis VAHCS SOP antimicrobial prophylaxis for dental surgery: ", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Determine the need for prophylaxis through the 2-step process outlined", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "below.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Step 1.Assess the risk of endocarditis for your patient", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Prophylaxis is recommended if a patient has any of the following conditions: "}, 
{"Row" : 25, "Column" : 1, "Text" : "oProsthetic cardiac valve or material including: Presence of cardiac"}, 
{"Row" : 26, "Column" : 1, "Text" : "prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR"}, 
{"Row" : 27, "Column" : 1, "Text" : "cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left"}, 
{"Row" : 28, "Column" : 1, "Text" : "ventricular assist devices or implantable heart"}, 
{"Row" : 29, "Column" : 1, "Text" : "oA history of infective endocarditis"}, 
{"Row" : 30, "Column" : 1, "Text" : "oCertain specific congenital heart conditions - refer to the full SOP"}, 
{"Row" : 31, "Column" : 1, "Text" : "(link above) or consult Cardiology for more detailed recommendations"}, 
{"Row" : 32, "Column" : 1, "Text" : "oCardiac transplant that develops a problem in the heart valve"}, 
{"Row" : 34, "Column" : 1, "Text" : "Step 2.Assess the risk of bacteremia from the planned procedure", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Prophylaxis is indicated for these procedures: "}, 
{"Row" : 36, "Column" : 1, "Text" : "oAll dental procedures that involve manipulation of gingival tissue or the"}, 
{"Row" : 37, "Column" : 1, "Text" : "periapical region of teeth or perforation of the oral mucosa."}, 
{"Row" : 38, "Column" : 1, "Text" : "oProcedures on the respiratory tract that involve incision or biopsy of the"}, 
{"Row" : 39, "Column" : 1, "Text" : "respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is"}, 
{"Row" : 40, "Column" : 1, "Text" : "recommended for bronchoscopy when it involves incision of the respiratory"}, 
{"Row" : 41, "Column" : 1, "Text" : "tract mucosa."}, 
{"Row" : 42, "Column" : 1, "Text" : "oProcedures that involve incision through infected skin, skin structures, or"}, 
{"Row" : 43, "Column" : 1, "Text" : "musculoskeletal tissue."}, 
{"Row" : 44, "Column" : 1, "Text" : "oDermatologic procedures that breach the oral mucosa."}, 
{"Row" : 46, "Column" : 1, "Text" : "Prophylactic Antimicrobials select below: ", "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Text" : "biopsy of the respiratory mucosa"}, 
{"Row" : 51, "Column" : 1, "Text" : "musculoskeletal tissues"}, 
{"Row" : 52, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "References: "}, 
{"Row" : 56, "Column" : 1, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial"}, 
{"Row" : 57, "Column" : 1, "Text" : "endocarditis"}, 
{"Row" : 58, "Column" : 1, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978"}
]},
{"Name" : "ORZID3 GMENU PREVENTION OF INFECT", "DisplayText" : "Prevention of Infection - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "DisplayText" : "Prevention of bacterial endocarditis (Outpatient)", "Text" : "Prevention of bacterial endocarditis", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "DisplayText" : "Prevention of prosthetic joint infection before dental procedures", "Text" : "Before dental procedures", "Mnemonic" : "6"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "DisplayText" : "Prevention of infection in a patient with malignancy (Outpatient)", "Text" : "Antibacterial prophylaxis", "Mnemonic" : "10"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "DisplayText" : "Prevention of fungal infection in a patient with malignancy", "Text" : "Antifungal prophylaxis", "Mnemonic" : "12"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis", "Mnemonic" : "14"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "DisplayText" : "Spontaneous Bacterial Peritonitis (Outpatient)", "Text" : "Spontaneous bacterial peritonitis", "Mnemonic" : "16"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "DisplayText" : "Pneumocystis Jirovecii Prophylaxis", "Text" : "Pneumocystis jirovecii prophylaxis", "Mnemonic" : "18"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Click Here", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "++PREVENTION OF INFECTION - OUTPATIENT++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Prevention of bacterial endocarditis", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Prevention of prosthetic joint infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Prevention of infection in patient with malignancy", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Prevention of infection in patients with liver disease", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Prevention of Pneumocystis infection", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Prevention of recurrent Staphylococcus aureus skin infection", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "DisplayText" : "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS", "Text" : "Before procedures that involve infected skin, skin structures or musculoskeletal", "Mnemonic" : "8"},
{"Row" : 11, "Column" : 1, "Text" : "tissue"}
]},
{"Name" : "ORZID3 GMENU PREVENTION PERTUSSIS", "DisplayText" : "Prevention of pertussis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "PREVENTION OF PERTUSSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Immunization", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in"}, 
{"Row" :7, "Column" : 1, "Text" : "adults regardless of interval between most recent Td vaccine. One dose of Tdap"}, 
{"Row" :8, "Column" : 1, "Text" : "vaccine is given to pregnant women during each pregnancy."}, 
{"Row" : 10, "Column" : 1, "Text" : "Postexposure prophylaxis in adults", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Household contacts with symptomatic coughing should be treated as if they have"}, 
{"Row" : 12, "Column" : 1, "Text" : "pertussis. Consult Infectious Diseases (outpatient) for all suspected cases of"}, 
{"Row" : 13, "Column" : 1, "Text" : "pertussis and exposure to pertussis."}, 
{"Row" : 15, "Column" : 1, "Text" : "CDC recommends postexposure prophylaxis in household contacts within 21 days"}, 
{"Row" : 16, "Column" : 1, "Text" : "after exposure to pertussis regardless of immunization history. Non-household"}, 
{"Row" : 17, "Column" : 1, "Text" : "contacts who are at high risk of severe illness or who have close contact with"}, 
{"Row" : 18, "Column" : 1, "Text" : "high risk individuals should receive post exposure prophylaxis within 21 days of"}, 
{"Row" : 19, "Column" : 1, "Text" : "exposure. Those at high risk of severe illness are infants less than one year of"}, 
{"Row" : 20, "Column" : 1, "Text" : "age, women in third trimester of pregnancy and those with preexisting health"}, 
{"Row" : 21, "Column" : 1, "Text" : "conditions that may be exacerbated by pertussis (e.g. immunosuppressed and"}, 
{"Row" : 22, "Column" : 1, "Text" : "asthmatic individuals). A single dose of Tdap should be administered in those"}, 
{"Row" : 23, "Column" : 1, "Text" : "who are not up to date."}, 
{"Row" : 24, "Column" : 1, "Text" : "Prophylaxis: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Alternative for macrolide intolerant or allergic patients"}, 
{"Row" : 33, "Column" : 1, "Text" : "References"}, 
{"Row" : 35, "Column" : 1, "Text" : "CDC:https://www.cdc.gov/pertussis/outbreaks/pep.html (Accessed 3-17-17)"}, 
{"Row" : 36, "Column" : 1, "Text" : "Kim et al, Annals of internal medicine (2016) 184-194"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Pertussis"}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Bordetella species"}
]},
{"Name" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "DisplayText" : "Acyclovir 800mg po 5x/d for 5 days", "Text" : "Acyclovir 800 mg PO 5x/day for 5-7 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "DisplayText" : "Acyclovir 800mg po 5x/d for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 5DS 1GM PO TID", "DisplayText" : "Valacyclovir 1gm po tid for 5 days", "Text" : "Valacyclovir 1 gm PO TID for 5 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 5DS 1GM PO TID", "DisplayText" : "Valacyclovir 1gm po tid for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 800MG PO 5X/DAY 7DS", "DisplayText" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R]", "Text" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 800MG PO 5X/DAY 7DS", "DisplayText" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "PRIMARY INFECTION (CHICKENPOX)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Vaccinate all adults without evidence of immunity except for pregnant women."}, 
{"Row" : 12, "Column" : 1, "Text" : "Test antibody first in adults who have uncertain history of chickenpox or"}, 
{"Row" : 13, "Column" : 1, "Text" : "vaccination."}, 
{"Row" : 14, "Column" : 1, "Text" : "Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose"}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Therapy must be started within 24 hrs onset of rash."}, 
{"Row" : 21, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Therapy must be started within 24 hrs onset of rash."}, 
{"Row" : 26, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Immunocompromised patients without prior immunity to varicella who are at risk"}, 
{"Row" : 33, "Column" : 1, "Text" : "for disease include: patients with malignancy, current immunosuppressive"}, 
{"Row" : 34, "Column" : 1, "Text" : "therapy, or HIV infection. Vaccination is not recommended while patients are"}, 
{"Row" : 35, "Column" : 1, "Text" : "immunocompromised."}, 
{"Row" : 37, "Column" : 1, "Text" : "Contact Infectious Diseases for more information."}, 
{"Row" : 39, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "Treatment for severe disease, or if mild to moderate disease doesn't improve on", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "above therapy", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 51, "Column" : 1, "Text" : "References: "}, 
{"Row" : 53, "Column" : 1, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220"}, 
{"Row" : 54, "Column" : 1, "Text" : "Sanford keyword: Varicella-Zoster Virus"}, 
{"Row" : 55, "Column" : 1, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)"}
]},
{"Name" : "ORZID3 GMENU PROPHYLAXIS OPTH SURG", "DisplayText" : "Prophylaxis for Ophthalmic Surgery" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PROPHYLAXIS FOR OPHTHALMIC SURGERY", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before"}, 
{"Row" :6, "Column" : 1, "Text" : "procedures."}
]},
{"Name" : "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "ORZ SET ABX CIPRO CEFUROXIME MAIL PO", "DisplayText" : "Ciprofloxacin Cefuroxime po MAIL", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND >", "Mnemonic" : "4"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX CIPRO CEFUROXIME PO WINDOW", "DisplayText" : "Ciprofloxacin Cefuroxime po WINDOW", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND >", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "Antibiotic Prophylaxis Transrectal Ultrasound Prostate Biopsy Procedures (TRUSP)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "The recommendations for prophylaxis for TRUSP procedures have been updated based"}, 
{"Row" :7, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Outpatient Prescriptions for Mailing: ", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before"}, 
{"Row" : 11, "Column" : 1, "Text" : "scheduled prostate biopsy."}, 
{"Row" : 13, "Column" : 1, "Text" : "Outpatient Prescriptions for Window Pick-up: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before"}, 
{"Row" : 16, "Column" : 1, "Text" : "scheduled prostate biopsy."}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative for patients with anaphylactic or other serious beta-lactam allergy", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "Administer in clinic on the day of procedure.", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "Becopoulos T et alJ Chemother 1990 2:244-246"}, 
{"Row" : 37, "Column" : 1, "Text" : "Charalabopoolos et al Chemotherapy 2003 49:269-279"}, 
{"Row" : 38, "Column" : 1, "Text" : "Nam R et al J Urol 2010 183:963-969"}, 
{"Row" :5, "Column" : 1, "Text" : "based on emergence of resistant E-coli bacteria strains."}, 
{"Row" :6, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Alternative for patients who have not taken the oral medications: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRIAXONE 500 IM AND CIPRO 500 PO X1", "DisplayText" : "Ceftriaxone 500 mg IM and Ciprofloxacin 500 mg po x1", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Ceftriaxone 500 mg", "Mnemonic" : "8"},
{"Row" : 19, "Column" : 1, "Text" : "Administer in clinic on the day of procedure.", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Intramuscularly once ($) [M] BOTH given 1 hour before the procedure."}, 
{"Row" : 28, "Column" : 1, "Text" : "_________________________________________________________________", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP AZTREONAM 1GM + CIPRO 500 ONCE PROPHYLAXIS TRUSP", "DisplayText" : "Aztreonam 1 gm mg IM and Ciprofloxacin 500 mg po once", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Aztreonam 1 gm intramuscularly", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Text" : "once ($$$$) [R] BOTH given 1 hour before the procedure."}, 
{"Row" : 21, "Column" : 1, "Text" : "Patients weighing less than 300lbs: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "Patients weighing 300lbs or greater: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRIAXONE 1GM IM AND CIPRO 500PO TRUSP", "DisplayText" : "Ceftriaxone 1 gram IM and Ciprofloxacin 500 mg po x1", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Ceftriaxone 1 gram", "Mnemonic" : "10"},
{"Row" : 26, "Column" : 1, "Text" : "Intramuscularly once ($) [M] BOTH given 1 hour before the procedure."}
]},
{"Name" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI]", "Text" : "Minocycline 100mg PO BID ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 32, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O]", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Mnemonic" : "10a"},
{"Row" : 33, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "DisplayText" : "Linezolid 600 mg PO BID ($) [DI,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. For severe infections, add an aminoglycoside for"}, 
{"Row" :7, "Column" : 1, "Text" : "synergy during the first weeks of therapy. Mild infections can be treated with"}, 
{"Row" :8, "Column" : 1, "Text" : "oral antibiotics only."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Treatement", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 14, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 16, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 19, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Allergy to penicillin"}, 
{"Row" : 31, "Column" : 1, "Text" : "For resistant isolates only"}, 
{"Row" : 36, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 39, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID3 GMENU PROS B/J GNB", "DisplayText" : "Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "PROSTHESES", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :7, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :8, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" : 10, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 12, "Column" : 1, "Text" : "Duration of Treatment", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 14, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 16, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 19, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 27, "Column" : 1, "Text" : "Alternative Oral Treatment for Intolerance to Above Oral Antibiotics", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "For treatment of mild infections and continuation of therapy"}, 
{"Row" : 32, "Column" : 1, "Text" : "For Chronic Suppression"}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 40, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "DisplayText" : "Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "DisplayText" : "Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :7, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 11, "Column" : 1, "Text" : "Duration of Treatment", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression"}, 
{"Row" : 13, "Column" : 1, "Text" : "may follow treatment based on individual patient circumstances."}, 
{"Row" : 15, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 18, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, For Continuation of Therapy", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Oral Treatment for Chronic Suppression", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 29, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 30, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 31, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID3 GMENU PROS B/J S. AUREUS", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 44, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 45, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 47, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI]", "Text" : "Minocycline 100mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 48, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "DisplayText" : "Minocycline 100 mg PO BID ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX OP RIFAMPIN 600MG PO QDAY", "DisplayText" : "RIFAMPIN 600MG PO QDAY", "Text" : "Rifampin 600 mg PO QDay ($) [DI,O]", "Mnemonic" : "14a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID RIFAMPIN 600MG PO QDAY", "DisplayText" : "Rifampin 600mg po qday Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment Following Debridement and Retention of Prosthesis", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of"}, 
{"Row" :9, "Column" : 1, "Text" : "an oral antibiotic combined with rifampin (3 months in total hip, elbow,"}, 
{"Row" : 10, "Column" : 1, "Text" : "shoulder and ankle arthroplasty and 6 months in total knee arthroplasty)."}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Staged Reimplantation of Prosthesis", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 6 weeks for all joint types."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment Following 1-Stage Exchange of Prosthesis", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an"}, 
{"Row" : 18, "Column" : 1, "Text" : "oral antibiotic combined with rifampin for all joint types."}, 
{"Row" : 20, "Column" : 1, "Text" : "Rifampin Synergy", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Rifampin is recommended for treatment with debridement and retention or one"}, 
{"Row" : 22, "Column" : 1, "Text" : "stage exchange. When rifampin is combined with a beta-lactam or vancomycin in"}, 
{"Row" : 23, "Column" : 1, "Text" : "vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial"}, 
{"Row" : 24, "Column" : 1, "Text" : "resistance develops rapidly. If patient does not tolerate rifampin it may be"}, 
{"Row" : 25, "Column" : 1, "Text" : "omitted from treatment regimen. Contact Infectious Diseases for more"}, 
{"Row" : 26, "Column" : 1, "Text" : "information."}, 
{"Row" : 28, "Column" : 1, "Text" : "Chronic Suppression", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Chronic suppression with oral antimicrobials may follow treatment based on"}, 
{"Row" : 30, "Column" : 1, "Text" : "individual patient circumstances."}, 
{"Row" : 32, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 37, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Text" : "Oral Treatment for Continuation of Therapy or Chronic Suppression", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Text" : "MRSA or allergy to penicillin or cephalosporin"}, 
{"Row" : 46, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 50, "Column" : 1, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Chronic Suppression)", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "In addition to PO treatment above < ADD >"}, 
{"Row" : 57, "Column" : 1, "Text" : "References: "}, 
{"Row" : 58, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 59, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 60, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 61, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 41, "Column" : 1, "Item" : "PSHZID CEFADROXIL 1000MG PO BID", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"}
]},
{"Name" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "DisplayText" : "Streptococci infections in bone or joint prostheses (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R]", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Mnemonic" : "6a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "DisplayText" : "Penicillin VK 500 mg PO QID ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O]", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Mnemonic" : "8a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "DisplayText" : "Clindamycin 300 mg PO QID ($) [H,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics"}, 
{"Row" :6, "Column" : 1, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral"}, 
{"Row" :7, "Column" : 1, "Text" : "antibiotics only."}, 
{"Row" :9, "Column" : 1, "Text" : "Consult Infectious Diseases for specific management advice."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consult Infectious Diseases in all cases for specific management advice.", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Duration of Treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat for a total duration of 4-6 weeks. Chronic suppression with oral"}, 
{"Row" : 15, "Column" : 1, "Text" : "antimicrobials may follow treatment based on individual patient circumstances."}, 
{"Row" : 17, "Column" : 1, "Text" : "Intravenous Treatment", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS."}, 
{"Row" : 20, "Column" : 1, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy or Chronic", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Suppression", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 28, "Column" : 1, "Text" : "Allergy to penicillin or cephalosporin"}, 
{"Row" : 33, "Column" : 1, "Text" : "References: "}, 
{"Row" : 34, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 35, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 36, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 37, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J S. AUREUS", "DisplayText" : "Staphylococcus aureus infections in bone or joint prostheses (Outpatient)", "Text" : "Staphylococcus aureus infections", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "DisplayText" : "Streptococci infections in bone or joint prostheses (Outpatient)", "Text" : "Streptococci infections", "Mnemonic" : "6"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "DisplayText" : "Enterococci infections in bone or joint prostheses (Outpatient)", "Text" : "Enterococci infections", "Mnemonic" : "8"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J GNB", "DisplayText" : "Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses", "Text" : "Gram negative bacilli (other than Pseudomonas) infections", "Mnemonic" : "10"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "DisplayText" : "Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient)", "Text" : "Pseudomonas aeruginosa infections", "Mnemonic" : "12"},
{"Row" :3, "Column" : 1, "Text" : "INFECTIONS IN BONE OR JOINT PROSTHESES", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Common important pathogens include coagulase-negative staphylococci,"}, 
{"Row" :6, "Column" : 1, "Text" : "Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli."}, 
{"Row" :7, "Column" : 1, "Text" : "Obtain material for gram stain and culture and base antimicrobial therapy on"}, 
{"Row" :8, "Column" : 1, "Text" : "results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are"}, 
{"Row" :9, "Column" : 1, "Text" : "ideal specimens to culture. Sinus tracts are often colonized and isolates from"}, 
{"Row" : 10, "Column" : 1, "Text" : "drainage may not be pathogens. If Staphylococcus aureus is present,it is likely"}, 
{"Row" : 11, "Column" : 1, "Text" : "to be a pathogen in the bone."}, 
{"Row" : 13, "Column" : 1, "Text" : "Pathogen-directed Treatment Regimens", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Acute infections can often be cured with debridement with joint retention"}, 
{"Row" : 21, "Column" : 1, "Text" : "followed by antimicrobials. Infections with duration of symptoms greater then 3"}, 
{"Row" : 22, "Column" : 1, "Text" : "weeks or infection within 4 weeks of implantation require one or two stage"}, 
{"Row" : 23, "Column" : 1, "Text" : "remimplantation. Cases that are inoperable can be managed with long-term"}, 
{"Row" : 24, "Column" : 1, "Text" : "suppressive antimicrobial therapy or joint removal without replacement depending"}, 
{"Row" : 25, "Column" : 1, "Text" : "on patient's condition. Consult Infectious Diseases for more information."}, 
{"Row" : 27, "Column" : 1, "Text" : "Infectious Disease and Orthopedics consultations are essential."}, 
{"Row" : 29, "Column" : 1, "Text" : "Empirical Therapy Before a Pathogen is Identified is Not Recommended.", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Text" : "If patient has sepsis or is otherwise unstable, empiric treatment before culture"}, 
{"Row" : 31, "Column" : 1, "Text" : "results are obtained may be justified."}, 
{"Row" : 32, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for IV treatment options."}, 
{"Row" : 35, "Column" : 1, "Text" : "References: "}, 
{"Row" : 37, "Column" : 1, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections"}, 
{"Row" : 38, "Column" : 1, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment"}, 
{"Row" : 39, "Column" : 1, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Prosthetic Joint Infection"}
]},
{"Name" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "DisplayText" : "Pubic Lice (Pediculosis Pubis) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min", "Text" : "Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "DisplayText" : "Permethrin 1% lotion for 10 min Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "PUBIC LICE (PEDICULOSIS PUBIS)"}, 
{"Row" :4, "Column" : 1, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood."}, 
{"Row" :5, "Column" : 1, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse"}, 
{"Row" :6, "Column" : 1, "Text" : "living in pubic hair."}, 
{"Row" :8, "Column" : 1, "Text" : "The presence of nits on a hair shaft, especially when they are located more"}, 
{"Row" :9, "Column" : 1, "Text" : "than 6 mm from the skin, does NOT indicate active infestation.Nits may remain"}, 
{"Row" : 10, "Column" : 1, "Text" : "present for months after successful treatment."}, 
{"Row" : 12, "Column" : 1, "Text" : "Household contacts and persons who may have come into contact with personal"}, 
{"Row" : 13, "Column" : 1, "Text" : "belongings of an infested individual should be examined for evidence of lice"}, 
{"Row" : 14, "Column" : 1, "Text" : "and discarded or cleaned if contaminated."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "A repeat application may be used if live lice are seen 7-10 days after"}, 
{"Row" : 18, "Column" : 1, "Text" : "treatment."}, 
{"Row" : 21, "Column" : 1, "Text" : "nits ($) [M]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: lice"}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU PYELONEPHRITIS", "DisplayText" : "Pyelonephritis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX LAB MENU", "DisplayText" : "Antimicrobial CDSS Lab Menu", "Text" : "Lab menu", "Mnemonic" : "4"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "6a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM ONCE IV", "DisplayText" : "Ceftriaxone 2 gm IV once ($) [M]", "Text" : "Ceftriaxone 2 gm IV once ($) [M] < THEN > one of the oral regimens below", "Mnemonic" : "8"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "10a"},
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12"},
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] for 14 days", "Mnemonic" : "14a"},
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "14b"},
{"Row" : 56, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 14DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 14 days ($) [R]", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 14 days", "Mnemonic" : "16a"},
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 14DAYS", "DisplayText" : "Cefdinir 300 mg PO BID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 60, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "18a"},
{"Row" : 61, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 7DAYS", "DisplayText" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 68, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Mnemonic" : "20a"},
{"Row" : 69, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "22"},
{"Row" : 73, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days", "Mnemonic" : "24a"},
{"Row" : 75, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "26"},
{"Row" : 85, "Column" : 1, "Item" : "PSOZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days", "Mnemonic" : "28a"},
{"Row" : 86, "Column" : 1, "Item" : "PSHZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "28b"},
{"Row" : 90, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R] for 14 days", "Mnemonic" : "30a"},
{"Row" : 91, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "30b"},
{"Row" : 94, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "32"},
{"Row" : 95, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days", "Mnemonic" : "34a"},
{"Row" : 96, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600MG PO BID 14DAYS", "DisplayText" : "Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_", "Text" : "Non-VA order for above", "Mnemonic" : "34b"},
{"Row" :3, "Column" : 1, "Text" : "PYELONEPHRITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Features of pyelonephritis include fever/other signs of systemic infection,"}, 
{"Row" :6, "Column" : 1, "Text" : "flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most"}, 
{"Row" :7, "Column" : 1, "Text" : "cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus"}, 
{"Row" :8, "Column" : 1, "Text" : "and Pseudomonas, are more likely if the patient is elderly, has been in the"}, 
{"Row" :9, "Column" : 1, "Text" : "hospital for more than 48 hours, or received a course of antibiotics."}, 
{"Row" : 11, "Column" : 1, "Text" : "Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide"}, 
{"Row" : 12, "Column" : 1, "Text" : "antimicrobial therapy: "}, 
{"Row" : 15, "Column" : 1, "Text" : "Drugs active against enterococci (ampicillin, piperacillin) or staphylococci"}, 
{"Row" : 16, "Column" : 1, "Text" : "needn't be used if Gram-negative bacilli predominate on the smear. Broad"}, 
{"Row" : 17, "Column" : 1, "Text" : "spectrum antimicrobials are needed if patient is at risk of having a multi-drug"}, 
{"Row" : 18, "Column" : 1, "Text" : "resistant (MDR) organism."}, 
{"Row" : 20, "Column" : 1, "Text" : "Judge severity of infection based on clinical signs and symptoms, including"}, 
{"Row" : 21, "Column" : 1, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever."}, 
{"Row" : 22, "Column" : 1, "Text" : "Oral regimens are preferred over IV if severity is mild or moderate and patient"}, 
{"Row" : 23, "Column" : 1, "Text" : "can tolerate oral antibiotics. In patients with severe or persistent disease,"}, 
{"Row" : 24, "Column" : 1, "Text" : "new renal failure, or suspected urinary obstruction, obtain a renal ultrasound"}, 
{"Row" : 25, "Column" : 1, "Text" : "to rule out obstruction or other complicating condition. Consult urology if"}, 
{"Row" : 26, "Column" : 1, "Text" : "abnormalities are found."}, 
{"Row" : 28, "Column" : 1, "Text" : "When patients who require paraenteral therapy are afebrile, clinically stable,"}, 
{"Row" : 29, "Column" : 1, "Text" : "and can take oral medication, convert to oral therapy based on the"}, 
{"Row" : 30, "Column" : 1, "Text" : "identification and susceptibility of the isolate."}, 
{"Row" : 32, "Column" : 1, "Text" : "Duration", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical"}, 
{"Row" : 34, "Column" : 1, "Text" : "response, 7 days of treatment may be adequate. A longer duration may be required"}, 
{"Row" : 35, "Column" : 1, "Text" : "in severe infection, resistant organisms, presence of obstruction, underlying"}, 
{"Row" : 36, "Column" : 1, "Text" : "renal disease, immunosuppression, neurologic or structural abnormality, and men"}, 
{"Row" : 37, "Column" : 1, "Text" : "in some cases. A 7-day course of ciprofloxacin has been shown to be as effective"}, 
{"Row" : 38, "Column" : 1, "Text" : "as a 14-day course."}, 
{"Row" : 39, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Empirical treatment", "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 48, "Column" : 1, "Text" : "Oral treatment after single dose of ceftriaxone IV above: "}, 
{"Row" : 50, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 52, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 55, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 59, "Column" : 1, "Text" : "History of Gram-negative MDR bacteria: "}, 
{"Row" : 62, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Text" : "Treatment for specific pathogens", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "Enterobacteria including E. coli, klebsiella, and proteus", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 71, "Column" : 1, "Text" : "Alternative or isolate resistant to preferred antimicrobials: "}, 
{"Row" : 74, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 77, "Column" : 1, "Text" : "Staphylococcus aureus", "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Text" : "S. aureus is an uncommon urinary tract pathogen and presence in the urine may be"}, 
{"Row" : 79, "Column" : 1, "Text" : "due to hematogenous seeding from another site. Blood cultures are indicated to"}, 
{"Row" : 80, "Column" : 1, "Text" : "rule out bacteremia in patients who have S. aureus isolated from the urine."}, 
{"Row" : 81, "Column" : 1, "Text" : "Consult Infectious Diseases for more information."}, 
{"Row" : 83, "Column" : 1, "Text" : "Pseudomonas", "Header" : 1}, 
{"Row" : 84, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 88, "Column" : 1, "Text" : "Enterococcus", "Header" : 1}, 
{"Row" : 89, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 93, "Column" : 1, "Text" : "Resistant isolate or alternative to preferred antimicrobials: "}, 
{"Row" : 97, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :100, "Column" : 1, "Text" : "References: "}, 
{"Row" :101, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" :102, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :103, "Column" : 1, "Text" : "Sanford keyword: Pyelonephritis, Acute"}, 
{"Row" :104, "Column" : 1, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis"}, 
{"Row" :105, "Column" : 1, "Text" : "Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary"}, 
{"Row" :106, "Column" : 1, "Text" : "tract, gastrointestinal tract, and central nervous system"}, 
{"Row" :107, "Column" : 1, "Text" : "Up-To-Date article: Treatment of enterococcal infections"}
]},
{"Name" : "ORZID3 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "PYOMYOSITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID PREDNISONE TAPER FOR HERPES ZOSTER", "DisplayText" : "PREDNISONE TAPER FOR HERPES ZOSTER", "Text" : "Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg", "Mnemonic" : "6a"},
{"Row" : 43, "Column" : 1, "Item" : "PSHZID PREDNISONE TAPER FOR HERPES ZOSTER", "DisplayText" : "PREDNISONE TAPER FOR HERPES ZOSTER Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "DisplayText" : "Valacyclovir 1000mg po tid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Zoster represents reactivation of varicella-zoster virus. After primary"}, 
{"Row" :6, "Column" : 1, "Text" : "infection, virus remains latent in the sensory dorsal root ganglia."}, 
{"Row" :7, "Column" : 1, "Text" : "Reactivation syndrome is characterized by painful, unilateral, vesicular,"}, 
{"Row" :8, "Column" : 1, "Text" : "dermatomal rash."}, 
{"Row" : 10, "Column" : 1, "Text" : "Prevention", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Vaccinate all adults greater than or equal to 50 years of age with the"}, 
{"Row" : 12, "Column" : 1, "Text" : "recombinant zoster vaccine regardless of past episode or receipt of the live"}, 
{"Row" : 13, "Column" : 1, "Text" : "zoster vaccine."}, 
{"Row" : 14, "Column" : 1, "Text" : "Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first"}, 
{"Row" : 15, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Immunocompetent patients", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment in persons <50 years", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment is not beneficial, none is recommended."}, 
{"Row" : 24, "Column" : 1, "Text" : "Treatment in persons >=50 years", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment with antivirals can shorten duration of pain and rash in patients over"}, 
{"Row" : 26, "Column" : 1, "Text" : "50 years old. Treatment must be started within 72 hours of onset."}, 
{"Row" : 31, "Column" : 1, "Text" : "There is evidence that addition of corticosteroids to antiviral"}, 
{"Row" : 32, "Column" : 1, "Text" : "therapy decreases pain and duration of rash and improves quality of life"}, 
{"Row" : 33, "Column" : 1, "Text" : "modestly during the acute shingles episode. Corticosteroids do not decrease the"}, 
{"Row" : 34, "Column" : 1, "Text" : "incidence of post-herpetic neuralgia. Some authorities recommend addition of"}, 
{"Row" : 35, "Column" : 1, "Text" : "corticosteroid therapy to antiviral therapy for patients over age 50 years."}, 
{"Row" : 36, "Column" : 1, "Text" : "Corticosteroids are not recommended for patients at greater risk for steroid"}, 
{"Row" : 37, "Column" : 1, "Text" : "toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic"}, 
{"Row" : 38, "Column" : 1, "Text" : "ulcer disease) or for immunocompromised patients."}, 
{"Row" : 40, "Column" : 1, "Text" : "Optional Recommendation: "}, 
{"Row" : 42, "Column" : 1, "Text" : "daily for 7 days. ($)"}, 
{"Row" : 45, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Immunocompromised patients", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "________________________________", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Text" : "Immunocompromised patients at increased risk for complications of VZV disease"}, 
{"Row" : 52, "Column" : 1, "Text" : "include: patients with malignancy, current immunosuppressive therapy, or HIV"}, 
{"Row" : 53, "Column" : 1, "Text" : "infection. Treatment with antivirals shortens duration of symptoms and reduces"}, 
{"Row" : 54, "Column" : 1, "Text" : "incidence of complications. In immunocompromised patients, treatment is"}, 
{"Row" : 55, "Column" : 1, "Text" : "recommended to be started at any point during an active infection."}, 
{"Row" : 57, "Column" : 1, "Text" : "Treatment for mild to moderate disease", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "Treatment for severe disease or progression from mild to moderate disease in", "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Text" : "patients <=65 years", "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 65, "Column" : 1, "Text" : "Treatment for severe disease or progression from mild to moderate disease in", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "patients >65 years", "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 70, "Column" : 1, "Text" : "References: "}, 
{"Row" : 72, "Column" : 1, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220"}, 
{"Row" : 73, "Column" : 1, "Text" : "Sanford keyword: Varicella-Zoster Virus"}, 
{"Row" : 74, "Column" : 1, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)"}
]},
{"Name" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 2GM PO X1 AZITHRO 1GM PO X1", "DisplayText" : "Metronidazole 2 gm PO x 1 dose ($) [DI] Azithromycin 1 gm PO x 1 dose ($)", "Text" : "Metronidazole 2 gm PO x 1 dose ($) [DI] Azithromycin 1 gm PO x 1 dose ($)", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Retreat with initial treatment regimen if patient was non-compliant with initial"}, 
{"Row" :6, "Column" : 1, "Text" : "treatment regimen or re-exposed to an untreated sex partner. If infection is not"}, 
{"Row" :7, "Column" : 1, "Text" : "due to non-compliance with treatment regimen or re-exposure to an untreated sex"}, 
{"Row" :8, "Column" : 1, "Text" : "partner, infection is most commonly caused by M. genitalium and less commonly T."}, 
{"Row" :9, "Column" : 1, "Text" : "vaginalis."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treatment for persistent or recurrent urethritis and failure of initial", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "doxycycline treatment", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "[M]"}, 
{"Row" : 16, "Column" : 1, "Text" : "Failure of above treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Consult Infectious Diseases (outpatient)"}, 
{"Row" : 20, "Column" : 1, "Text" : "References: "}, 
{"Row" : 22, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Urethritis, Recurrent/Persistent"}, 
{"Row" : 26, "Column" : 1, "Text" : "Up-To-Date article: Acute cervicitis"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}
]},
{"Name" : "ORZID3 GMENU RELIEF RX INFORMATION", "DisplayText" : "RELIEF RX Information -Antimicrobial Stewardship Team " , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Text" : "Acute Respiratory Tract Infections typically do not require an antimicrobial"}, 
{"Row" :4, "Column" : 1, "Text" : "prescription, however, patient's may be left unsatisfied. Relief Rx,"}, 
{"Row" :5, "Column" : 1, "Text" : "a symptom care pack including educational material, to ease veterans' symptoms"}, 
{"Row" :6, "Column" : 1, "Text" : "and help limit inappropriate antimicrobial prescriptions for viral infections."}, 
{"Row" : 11, "Column" : 1, "Text" : "Select clinics are participating in the Relief RX program with the Antimicrobial"}, 
{"Row" : 12, "Column" : 1, "Text" : "Stewardship Team. Please use link below to contact the team with questions"}, 
{"Row" : 13, "Column" : 1, "Text" : "or to obtain more Relief RX packages for your site."}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "DisplayText" : "E-mail Antimicrobial CDSS Staff", "Text" : "<Select Here> Contact ASP/CDSS Team", "Mnemonic" : "10"},
{"Row" :8, "Column" : 1, "Text" : "Note: The Relief RX package does not contain medications (other than throat"}, 
{"Row" :9, "Column" : 1, "Text" : "lozenges). Provider may order additional symptomatic medications."}, 
{"Row" :1, "Column" : 1, "Text" : "RELIEF RX =SYMPTOMATIC CARE PACK FOR VIRAL RESPIRATORY INFECTION", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "DisplayText" : "CMV retinitis (Outpatient)", "Text" : "Link to Treatment of CMV Retinitis and ARN", "Mnemonic" : "4"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "DisplayText" : "Acyclovir 800mg po 5x/d for 5 days", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Mnemonic" : "6a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "DisplayText" : "Acyclovir 800mg po 5x/d for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 5DS 1GM PO TID", "DisplayText" : "Valacyclovir 1gm po tid for 5 days", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Mnemonic" : "8a"},
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 5DS 1GM PO TID", "DisplayText" : "Valacyclovir 1gm po tid for 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R]", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Mnemonic" : "10a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "DisplayText" : "Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Mnemonic" : "12a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "DisplayText" : "Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "RETINITIS AND ACUTE RETINAL NECROSIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Retinitis is a subset of uveitis, is rare in immunocompetent people: in these"}, 
{"Row" :6, "Column" : 1, "Text" : "individuals it is usually caused by varicella-zoster virus (VZV) or herpes"}, 
{"Row" :7, "Column" : 1, "Text" : "simplex virus (HSV). Retinitis is more common in immunocompromised patients and"}, 
{"Row" :8, "Column" : 1, "Text" : "cytomegalovirus being the most common pathogen in these patients. Other"}, 
{"Row" :9, "Column" : 1, "Text" : "retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma"}, 
{"Row" : 10, "Column" : 1, "Text" : "capsulatum, and Treponema pallidum. In most cases, patients have other"}, 
{"Row" : 11, "Column" : 1, "Text" : "neurological symptoms or signs.Patients with candidemia may present with 1-3"}, 
{"Row" : 12, "Column" : 1, "Text" : "mm white punctate retinal lesions called cotton-wool spots. These may only be"}, 
{"Row" : 13, "Column" : 1, "Text" : "visible on fundus examination. Treatment of candidal retinitisis systemic"}, 
{"Row" : 14, "Column" : 1, "Text" : "antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for"}, 
{"Row" : 15, "Column" : 1, "Text" : "help."}, 
{"Row" : 17, "Column" : 1, "Text" : "VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small"}, 
{"Row" : 18, "Column" : 1, "Text" : "number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis"}, 
{"Row" : 19, "Column" : 1, "Text" : "that occurs primarily in immunocompetent people and can cause vision loss."}, 
{"Row" : 20, "Column" : 1, "Text" : "Treatment with intravenous acyclovir or valacyclovir is essential to halt"}, 
{"Row" : 21, "Column" : 1, "Text" : "progression of ARN."}, 
{"Row" : 23, "Column" : 1, "Text" : "Ophthalmology and Infectious Diseases consultation is essential"}, 
{"Row" : 25, "Column" : 1, "Text" : "Treatment of Non-viral Retinitis or ARN", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Refer to specific pathogen treatment recommendations of the CDSS to treat"}, 
{"Row" : 27, "Column" : 1, "Text" : "underlying infection"}, 
{"Row" : 29, "Column" : 1, "Text" : "Treatment of Retinitis or ARN due to CMV: ", "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Text" : "Treatment of VZV Retinitis", "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 36, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 38, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 42, "Column" : 1, "Text" : "Treatment of HSV Retinitis", "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 46, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 48, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 52, "Column" : 1, "Text" : "Treatment of VZV and HSV Acute Retinal Necrosis", "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Text" : "Ophthalmologist involvement is essential for treatment including"}, 
{"Row" : 54, "Column" : 1, "Text" : "corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in"}, 
{"Row" : 55, "Column" : 1, "Text" : "addition to a systemic antiviral may provide added therapeutic efficacy."}, 
{"Row" : 57, "Column" : 1, "Text" : "Duration"}, 
{"Row" : 58, "Column" : 1, "Text" : "Treat with intravenous therapy for a minimum of 7 days until disease has"}, 
{"Row" : 59, "Column" : 1, "Text" : "stabilized then treat with or therapy for a minimum of 6 weeks"}, 
{"Row" : 61, "Column" : 1, "Text" : "Treatment"}, 
{"Row" : 62, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy"}, 
{"Row" : 64, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Text" : "References: "}, 
{"Row" : 67, "Column" : 1, "Text" : "Lau et al, Ophthalmology. 2007, 114(4)756-762"}, 
{"Row" : 68, "Column" : 1, "Text" : "Mandell chapter: Infectious causes of uveitis"}, 
{"Row" : 69, "Column" : 1, "Text" : "Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392"}, 
{"Row" : 70, "Column" : 1, "Text" : "Sanford keyword: Acute Retinal Necrosis"}, 
{"Row" : 71, "Column" : 1, "Text" : "Sanford keyword: Herpes Simplex"}, 
{"Row" : 72, "Column" : 1, "Text" : "Sanford keyword: Retinitis"}, 
{"Row" : 73, "Column" : 1, "Text" : "Sanford keyword: Varicella-zoster Virus (Chickenpox)"}
]},
{"Name" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "DisplayText" : "Rocky Mountain Spotted Fever (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "ROCKY MOUNTAIN SPOTTED FEVER"}, 
{"Row" :4, "Column" : 1, "Text" : "Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening"}, 
{"Row" :5, "Column" : 1, "Text" : "rickettsial disease. The highest incidence in the United States is in the"}, 
{"Row" :6, "Column" : 1, "Text" : "Southeastern and South-central states. Clinical diagnosis include fever in"}, 
{"Row" :7, "Column" : 1, "Text" : "endemic area, known or possible tick bite, with or without rash. Rash typically"}, 
{"Row" :8, "Column" : 1, "Text" : "spreads from the extremities to the trunk."}, 
{"Row" : 10, "Column" : 1, "Text" : "Diagnosis is difficult, consult Infectious Diseases for assistance."}, 
{"Row" : 12, "Column" : 1, "Text" : "Consider empirical therapy with doxycycline for a patient with an undiagnosed"}, 
{"Row" : 13, "Column" : 1, "Text" : "febrile illness and relevant tick exposure."}, 
{"Row" : 15, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Treat for 7 days."}, 
{"Row" : 20, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Rocky mountain spotted fever"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 28, "Column" : 1, "Text" : "Masters EJ Arch Intern Med 2003, 163: 769"}
]},
{"Name" : "ORZID3 GMENU SCABIES", "DisplayText" : "Scabies (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 5% CRM TOP APPL FROM HEAD TO FEET", "DisplayText" : "Permethrin 5% cream topical apply from head to feet", "Text" : "Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then", "Mnemonic" : "4a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 5% CRM TOP APPL FROM HEAD TO FEET", "DisplayText" : "Permethrin 5% cream topical apply from head to feet Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "SCABIES"}, 
{"Row" :4, "Column" : 1, "Text" : "Scabies is an infestation of the skin by the mite Sarcoptes scabiei."}, 
{"Row" :5, "Column" : 1, "Text" : "It is transmitted by skin to skin contact. Outbreaks occur in nursing"}, 
{"Row" :6, "Column" : 1, "Text" : "homes, day care centers, and residential institutions.Scabies is highly"}, 
{"Row" :7, "Column" : 1, "Text" : "contagious and meticulous infection control is needed."}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment is a single application of permethrin cream.Some experts recommend"}, 
{"Row" : 10, "Column" : 1, "Text" : "a second application 7-10 days after the first application if the patient is"}, 
{"Row" : 11, "Column" : 1, "Text" : "still symptomatic or if live mites are found at that time.Contact Dermatology"}, 
{"Row" : 12, "Column" : 1, "Text" : "or Infectious Diseases for more information."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treat family members and other close contacts to prevent spread and recurrence."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Repeat application 7-10 days after the first application if patient is still"}, 
{"Row" : 18, "Column" : 1, "Text" : "experiencing symptoms, or if lives mites are found."}, 
{"Row" : 21, "Column" : 1, "Text" : "wash cream off with soap and water ($) [M]"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Scabies"}, 
{"Row" : 27, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU SECOND RECURRENCE CDIFF COLITIS", "DisplayText" : "ORZID3 GMENU SECOND RECURRENCE ABX ASSOC COLITIS" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin capsule taper and pulse", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Mnemonic" : "8a"},
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 VANCOMYCIN TAPER AND PULSE DOSING", "DisplayText" : "Vancomycin capsule taper and pulse Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :8, "Column" : 1, "Text" : "Patients with more than one recurrence of C. difficile infection are complex and"}, 
{"Row" :9, "Column" : 1, "Text" : "difficult."}, 
{"Row" : 12, "Column" : 1, "Text" : "Discontinue any antibiotics if possible and avoid high-risk antibiotic if"}, 
{"Row" : 13, "Column" : 1, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible."}, 
{"Row" : 15, "Column" : 1, "Text" : "Second Recurrence: ", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)"}, 
{"Row" : 35, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 42, "Column" : 1, "Text" : "Mandell chapter: Clostridium difficile infection"}, 
{"Row" : 43, "Column" : 1, "Text" : "Sanford keyword: Clostridium difficile"}, 
{"Row" : 44, "Column" : 1, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and"}, 
{"Row" : 45, "Column" : 1, "Text" : "prevention"}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200 MG EXTENDED-PULSE REGIMEN", "DisplayText" : "Fidaxomicin 200mg Extended-pulse regimen ($$$$) [M]", "Text" : "Fidaxomicin Extended-Pulse Regimen ($$) [M]", "Mnemonic" : "6a"},
{"Row" : 23, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG EXTENDED PULSE REGIMEN", "DisplayText" : "Non-VA order for above", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 41, "Column" : 1, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)"}, 
{"Row" : 40, "Column" : 1, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044"}, 
{"Row" : 20, "Column" : 1, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)"}, 
{"Row" : 10, "Column" : 1, "Text" : "*Infectious Disease or Gastroenterology consultation is recommended*"}, 
{"Row" : 31, "Column" : 1, "Text" : "Third or more recurrence: Consult Gastroenterology or Infectious Disease", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "DisplayText" : "Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "DisplayText" : "Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 18, "Column" : 1, "Text" : "< OR>"}, 
{"Row" : 25, "Column" : 1, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with"}, 
{"Row" : 26, "Column" : 1, "Text" : "125 mg po BID for 7 days, then 125mg po qday for 7 days, then"}, 
{"Row" : 27, "Column" : 1, "Text" : "125mg every other day for 6 weeks)"}, 
{"Row" : 33, "Column" : 1, "Text" : "Fulminant CDI: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory"}, 
{"Row" :6, "Column" : 1, "Text" : "confirmed case of CDI within 12 weeks after a prior episode."}, 
{"Row" :3, "Column" : 1, "Text" : "SECOND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU SECONDARY PERITONITIS", "DisplayText" : "Secondary peritonitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SEPSIS, SEVERE SEPSIS, AND SEPTIC SHOCK"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Enterococci - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Administer parenteral therapy initially then can be converted to appropriate"}, 
{"Row" :6, "Column" : 1, "Text" : "oral therapy."}, 
{"Row" :7, "Column" : 1, "Text" : "Duration of treatment for 2-4 weeks, depending on response"}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment, MILD-MODERATE infections", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Treatment, SEVERE infections", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 19, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 21, "Column" : 1, "Text" : "Stevens DL Clin Inf Dis 2014, 59:e10-52"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH GNB", "DisplayText" : "Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Mnemonic" : "4a"},
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "DisplayText" : "Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 14DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R", "Text" : "Levofloxacin 500mg PO qday ($) [R,DI]", "Mnemonic" : "6a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 14DS 500MG PO QDAY", "DisplayText" : "Levofloxacin 500mg po qday ($0.19/day)[R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN"}, 
{"Row" :4, "Column" : 1, "Text" : "PSEUDOMONAS)"}, 
{"Row" :6, "Column" : 1, "Text" : "Administer parenteral therapy initially for approximately 1-2 weeks"}, 
{"Row" :7, "Column" : 1, "Text" : "then can be converted to appropriate oral therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of treatment for 4 weeks depending on response"}, 
{"Row" : 10, "Column" : 1, "Text" : "Oral therapy to complete the course after intravenous therapy initially: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "References: "}, 
{"Row" : 18, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 20, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 21, "Column" : 1, "Text" : "Mathews CJ Lancet 2010 375:846"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "DisplayText" : "Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Mnemonic" : "16a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Mnemonic" : "18a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "DisplayText" : "Doxycycline 100mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE"}, 
{"Row" :5, "Column" : 1, "Text" : "Treat presumptively also for Chlamydia trachomatis infection"}, 
{"Row" :6, "Column" : 1, "Text" : "(asymptomatic urethritis) and test for HIV.Infection control will"}, 
{"Row" :7, "Column" : 1, "Text" : "report cases with N. gonorrhea isolated to the state department of health."}, 
{"Row" :8, "Column" : 1, "Text" : "Sexual partners within 60 days should be referred for evaluation and treatment."}, 
{"Row" : 10, "Column" : 1, "Text" : "Parenteral therapy recommended until clinical improvement, then switch to oral"}, 
{"Row" : 11, "Column" : 1, "Text" : "therapy to complete 1-2 weeks of therapy."}, 
{"Row" : 12, "Column" : 1, "Text" : "Susceptibility results are required to guide potential switch to an oral medicat"}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment for N. gonorrheae (Plus see below for Chlamydia treatment)", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for initial parenteral treatment"}, 
{"Row" : 17, "Column" : 1, "Text" : "______________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Concomitant treatment for C. trachomatis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Preferred treatment: "}, 
{"Row" : 23, "Column" : 1, "Text" : "Alternative treatment: "}, 
{"Row" : 27, "Column" : 1, "Text" : "References"}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Coakley G Lancet 2010, 375:846"}, 
{"Row" : 31, "Column" : 1, "Text" : "MMWR Recommendations and Reports CDC 2015, 64:1-137"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "DisplayText" : "Septic arthritis (Native Joint) with P. aeruginosa - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 CIPROFLOX 14DS 750MG PO BID", "DisplayText" : "Ciprofloxacin 750mg po bid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA"}, 
{"Row" :5, "Column" : 1, "Text" : "Administer parenteral therapy initially then can be converted to appropriate"}, 
{"Row" :6, "Column" : 1, "Text" : "oral therapy."}, 
{"Row" :7, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Treat for 4 weeks"}, 
{"Row" : 13, "Column" : 1, "Text" : "References: "}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 15, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 16, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 17, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "DisplayText" : "Septic arthristis (Native Joint) with S. aureus - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "10a"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 28DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 28 days", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Mnemonic" : "12a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 28DS 100MG PO BID", "DisplayText" : "Minocycline 100mg po bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS"}, 
{"Row" :5, "Column" : 1, "Text" : "Administer parenteral therapy initially for approximately two weeks"}, 
{"Row" :6, "Column" : 1, "Text" : "then can be converted to appropriate oral therapy."}, 
{"Row" :7, "Column" : 1, "Text" : "Total duration of treatment 4-6 weeks depending on clinical response"}, 
{"Row" :8, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Methicillin-SUSCEPTIBLE Staphylococcus aureus", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Methicillin-RESISTANT Staphylococcus aureus", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "________________________________________________________", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "References: "}, 
{"Row" : 29, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 30, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 32, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}, 
{"Row" : 33, "Column" : 1, "Text" : "Coakley G Rheumatology (Oxford) 2006, 45:1039"}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 28DS", "DisplayText" : "Cefadroxil 1000 mg PO BID ($) [R]", "Text" : "", "Mnemonic" : "6a"},
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 28DAYS", "DisplayText" : "Cefadroxil 1000 mg PO BID [R] ($)", "Text" : "Non-VA order for above", "Mnemonic" : "6b"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Streptococci - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R]", "Text" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R]", "Mnemonic" : "4a"},
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "DisplayText" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 14DS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 14 days", "Text" : "Clindamycin 300mg PO qid for 14 days ($) [H]", "Mnemonic" : "6a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 14DS 300MG PO QID", "DisplayText" : "Clindamycin 300mg po qid for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI"}, 
{"Row" :5, "Column" : 1, "Text" : "Administer parenteral therapy initially and then can be converted to"}, 
{"Row" :6, "Column" : 1, "Text" : "appropriate oral therapy."}, 
{"Row" :8, "Column" : 1, "Text" : "Duration of therapy 2-4 weeks total"}, 
{"Row" :9, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References: "}, 
{"Row" : 16, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-to-date online"}, 
{"Row" : 19, "Column" : 1, "Text" : "Mathews CJ Lancet 2010, 375:846"}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native Joint) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)", "Text" : "Bite wounds", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme disease", "Mnemonic" : "8"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "DisplayText" : "Septic arthristis (Native Joint) with S. aureus - Outpatient", "Text" : "Staphylococcus aureus", "Mnemonic" : "10"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Streptococci - Outpatient", "Text" : "Streptococci", "Mnemonic" : "12"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "DisplayText" : "Septic arthritis (Native Joint) with Enterococci - Outpatient", "Text" : "Enterococci", "Mnemonic" : "14"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH GNB", "DisplayText" : "Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient", "Text" : "Gram negative bacilli (other than Pseudomonas)", "Mnemonic" : "16"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "DisplayText" : "Septic arthritis (Native Joint) with P. aeruginosa - Outpatient", "Text" : "Pseudomonas aeruginosa", "Mnemonic" : "18"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "DisplayText" : "Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient", "Text" : "Neisseria gonorrhoeae", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT)"}, 
{"Row" :5, "Column" : 1, "Text" : ">>For arthritis associated with a PROSTHETIC JOINT see"}, 
{"Row" :8, "Column" : 1, "Text" : ">>For arthritis associated with a BITE WOUND see"}, 
{"Row" : 11, "Column" : 1, "Text" : ">>For arthritis associated with TICK EXPOSURE in an endemic area, consider"}, 
{"Row" : 14, "Column" : 1, "Text" : "Septic arthritis native joint: ", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Aspirate the joint for gram stain and culture."}, 
{"Row" : 16, "Column" : 1, "Text" : "Use the gram stain of aspirated fluid to select initial therapy."}, 
{"Row" : 17, "Column" : 1, "Text" : "Use culture results to guide definitive therapy."}, 
{"Row" : 18, "Column" : 1, "Text" : "In addition to antimicrobial treatment, successful managemet of acute"}, 
{"Row" : 19, "Column" : 1, "Text" : "septic arthritis requires removal of intra-articular pus."}, 
{"Row" : 21, "Column" : 1, "Text" : "See Inpatient CDSS for initial parenteral treatment"}, 
{"Row" : 23, "Column" : 1, "Text" : "Pathogen-specific septic arthritis treatment regimens", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Duration of therapy based on pathogen and clinical response. (See pathogen)"}, 
{"Row" : 26, "Column" : 1, "Text" : "If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of"}, 
{"Row" : 27, "Column" : 1, "Text" : "antimicrobials may be needed, depending on clinical response."}, 
{"Row" : 28, "Column" : 1, "Text" : "Consult Rheumatology for more information."}, 
{"Row" : 38, "Column" : 1, "Text" : "References: "}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 40, "Column" : 1, "Text" : "Sanford keyword: Septic arthritis"}, 
{"Row" : 41, "Column" : 1, "Text" : "Sharff KA Curr Rheumatol Rep 2013, 15:332"}, 
{"Row" : 42, "Column" : 1, "Text" : "Coakley G Lancet 2010, 375:846"}
]},
{"Name" : "ORZID3 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Text" : "Doxycycline 100 mg PO BID($) [DI]", "Mnemonic" : "6a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "DisplayText" : "Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET 14DS PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($0.18/day) [R", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET 14DS PO BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($0.18/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" :3, "Column" : 1, "Text" : "SEPTIC BURSITIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Aspiration for treatment and diagnostic confirmation should be performed"}, 
{"Row" :6, "Column" : 1, "Text" : "in all cases. Obtain synovial fluid for gram stain and culture to guide"}, 
{"Row" :7, "Column" : 1, "Text" : "therapy. Most cases are associated with Staphylococcus aureus."}, 
{"Row" :9, "Column" : 1, "Text" : "Intravenous therapy is recommended. Some clinicians treat mild cases in"}, 
{"Row" : 10, "Column" : 1, "Text" : "otherwise healthy individuals with intravenous therapy for part of the"}, 
{"Row" : 11, "Column" : 1, "Text" : "course and then switch to oral therapy. Other clinicians treat mild cases"}, 
{"Row" : 12, "Column" : 1, "Text" : "with oral therapy for the entire course. Drug selection should be based on"}, 
{"Row" : 13, "Column" : 1, "Text" : "microbiological results. Close clinical follow-up is needed for all cases."}, 
{"Row" : 15, "Column" : 1, "Text" : "Moderate to severe cases", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Refer to Inpatient CDSS"}, 
{"Row" : 18, "Column" : 1, "Text" : "Mild cases", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Treat for 14 days."}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 32, "Column" : 1, "Text" : "Sanford keyword: Bursitis, Septic"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Infectious arthritis of native joints"}, 
{"Row" : 34, "Column" : 1, "Text" : "Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359"}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days", "Text" : "", "Mnemonic" : "4a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CEFADROXIL 1000MG PO BID 14DAYS", "DisplayText" : "Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 22, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 25, "Column" : 1, "Text" : "< OR >"}
]},
{"Name" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "14"},
{"Row" :5, "Column" : 1, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity"}, 
{"Row" :3, "Column" : 1, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "DisplayText" : "Epididymitis (Outpatient)", "Text" : "Epididymitis", "Mnemonic" : "28"},
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "DisplayText" : "Pelvic inflammatory disorder (PID) - Outpatient", "Text" : "Pelvic Inflammatory Disease (PID)", "Mnemonic" : "32"},
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "DisplayText" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Text" : "Cervicitis", "Mnemonic" : "26"},
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU GENITAL HERPES", "DisplayText" : "Genital herpes (Outpatient)", "Text" : "Genital herpes", "Mnemonic" : "30"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)", "Text" : "Urethritis", "Mnemonic" : "34"},
{"Row" : 25, "Column" : 1, "Text" : "Sexually Transmitted Infections (STIs)", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS (outpatient)", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "38"},
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "42"},
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "40"},
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "DisplayText" : "Trichomonas vaginitis (Outpatient)", "Text" : "Trichomonas Vaginitis, Urethritis and Male Sex Partners", "Mnemonic" : "36"},
{"Row" :6, "Column" : 1, "Text" : "that could result in HIV exposure. Recommendation is for the provider to"}, 
{"Row" :7, "Column" : 1, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "HIV acquisition.If the patient is interested, the provider should place a"}, 
{"Row" :9, "Column" : 1, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP."}, 
{"Row" : 12, "Column" : 1, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have"}, 
{"Row" : 13, "Column" : 1, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by"}, 
{"Row" : 14, "Column" : 1, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or"}, 
{"Row" : 15, "Column" : 1, "Text" : "injection drug use, these medicines can work to keep the virus from"}, 
{"Row" : 16, "Column" : 1, "Text" : "establishing a permanent infection."}, 
{"Row" : 18, "Column" : 1, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies"}, 
{"Row" : 19, "Column" : 1, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about"}, 
{"Row" : 20, "Column" : 1, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently."}, 
{"Row" : 21, "Column" : 1, "Text" : "As PrEP only protects against HIV, condoms are important for the protection"}, 
{"Row" : 22, "Column" : 1, "Text" : "against other STIs. Condoms are also an important prevention strategy"}, 
{"Row" : 23, "Column" : 1, "Text" : "if PrEP is not taken consistently."}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia urethritis (Outpatient)", "Text" : "Chlamydia", "Mnemonic" : "20"},
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Gonorrhea", "Mnemonic" : "22"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX SYPHILIS", "DisplayText" : "Syphilis", "Text" : "Syphilis", "Mnemonic" : "24"}
]},
{"Name" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS (outpatient)", "Text" : "Human Immunodeficiency Virus (HIV)", "Mnemonic" : "4"},
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "6"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "DisplayText" : "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "Sexually Transmitted Infections (STI)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity"}, 
{"Row" :6, "Column" : 1, "Text" : "that could result in HIV exposure. Recommendation is for the provider to"}, 
{"Row" :7, "Column" : 1, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of"}, 
{"Row" :8, "Column" : 1, "Text" : "HIV acquisition.If the patient is interested, the provider should place a"}, 
{"Row" :9, "Column" : 1, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP."}, 
{"Row" : 11, "Column" : 1, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have"}, 
{"Row" : 12, "Column" : 1, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by"}, 
{"Row" : 13, "Column" : 1, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or"}, 
{"Row" : 14, "Column" : 1, "Text" : "injection drug use, these medicines can work to keep the virus from"}, 
{"Row" : 15, "Column" : 1, "Text" : "establishing a permanent infection."}, 
{"Row" : 17, "Column" : 1, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies"}, 
{"Row" : 18, "Column" : 1, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about"}, 
{"Row" : 19, "Column" : 1, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently."}, 
{"Row" : 20, "Column" : 1, "Text" : "As PrEP only protects against HIV, condoms are important for the protection"}, 
{"Row" : 21, "Column" : 1, "Text" : "against other STIs. Condoms are also an important prevention strategy"}, 
{"Row" : 22, "Column" : 1, "Text" : "if PrEP is not taken consistently."}
]},
{"Name" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "DisplayText" : "Small uniform bacillin in an aerobic bottle (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are"}, 
{"Row" :6, "Column" : 1, "Text" : "usually contaminants. Uncommonly such organisms prove to be Listeria"}, 
{"Row" :7, "Column" : 1, "Text" : "monocytogenes, which when present in a blood culture is likely a pathogen."}, 
{"Row" :8, "Column" : 1, "Text" : "Listeria is more likely in patients with impaired cell-mediated immunity,"}, 
{"Row" :9, "Column" : 1, "Text" : "pregnant women, elderly and patients on immunosuppressive therapy for"}, 
{"Row" : 10, "Column" : 1, "Text" : "transplantation."}, 
{"Row" : 12, "Column" : 1, "Text" : "Empirical treatment if there is a strong suspicion of listeria", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 14, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Empirical treatment if therapy is indicated and listeria is not suspected", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 20, "Column" : 1, "Text" : "References"}, 
{"Row" : 22, "Column" : 1, "Text" : "Mandell chapter: Listeria Monocytogenes"}, 
{"Row" : 23, "Column" : 1, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci"}, 
{"Row" : 24, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 25, "Column" : 1, "Text" : "Sanford keyword: Listeria monocytogenes"}, 
{"Row" : 26, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 27, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium"}
]},
{"Name" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "DisplayText" : "Small uniform bacilli in an anaerobic bottle (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria."}, 
{"Row" :6, "Column" : 1, "Text" : "These are often contaminants."}, 
{"Row" :8, "Column" : 1, "Text" : "Treatment if therapy is indicated", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options"}, 
{"Row" : 12, "Column" : 1, "Text" : "References"}, 
{"Row" : 14, "Column" : 1, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci"}, 
{"Row" : 15, "Column" : 1, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94"}, 
{"Row" : 16, "Column" : 1, "Text" : "Sanford keyword: Propionibacterium acnes"}, 
{"Row" : 17, "Column" : 1, "Text" : "Sanford keyword: Corynebacterium"}
]},
{"Name" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "DisplayText" : "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "DisplayText" : "Bite wounds (Outpatient)", "Text" : "Bite wounds", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "DisplayText" : "Septic bursitis (Outpatient)", "Text" : "Septic bursitis", "Mnemonic" : "6"},
{"Row" :8, "Column" : 1, "Item" : "ORZID3 GMENU ABSCESSES", "DisplayText" : "Abscesses (Outpatient)", "Text" : "Abscesses", "Mnemonic" : "8"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "DisplayText" : "Cutaneous abscess (Outpatient)", "Text" : "Cutaneous abscess", "Mnemonic" : "10"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU PYOMYOSITIS", "DisplayText" : "Pyomyositis", "Text" : "Pyomyositis (Refer to Inpt)", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "DisplayText" : "Decubitis ulcers (Outpatient)", "Text" : "Decubitis ulcers", "Mnemonic" : "14"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection", "Text" : "Surgical wound infections", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "++ SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS - OUTPATIENT++", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Update/review in process Jan2019"}, 
{"Row" :5, "Column" : 2, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "DisplayText" : "Foot ulcer in patient with diabetes mellitus (Outpatient)", "Text" : "Foot ulcer in patient with diabetes mellitus", "Mnemonic" : "20"},
{"Row" :7, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "DisplayText" : "Osteomyelitis (Outpatient)", "Text" : "Osteomyelitis", "Mnemonic" : "22"},
{"Row" :8, "Column" : 2, "Item" : "ORZID3 GMENU DISKITIS", "DisplayText" : "Diskitis and vertebral osteomyelitis (Outpatient)", "Text" : "Diskitis and vertebral osteomyelitis", "Mnemonic" : "24"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Infections in bone or joint prostheses", "Mnemonic" : "26"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "DisplayText" : "Septic arthritis (Native Joint) - Outpatient", "Text" : "Native joint", "Mnemonic" : "28"},
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "DisplayText" : "Infections in bone or joint prostheses (Outpatient)", "Text" : "Prosthetic joint", "Mnemonic" : "30"},
{"Row" : 11, "Column" : 2, "Text" : "Septic arthritis", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY DAILY ANTIBIOTIC", "DisplayText" : "Asplenic Empiric Antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Text" : "HELP, additional information: ", "Header" : 1}, 
{"Row" :2, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "DisplayText" : "Help page (instructions, microbiology, drug properties, etc.)", "Text" : "Help page (instructions, microbiology, etc.)", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "DisplayText" : "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,", "Text" : "", "Mnemonic" : "04"},
{"Row" :4, "Column" : 1, "Text" : "[DI]=important drug interactions, [O]=other, [M]= minimal risk)"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "DisplayText" : "Need an alternative antimicrobial? (outpatient)", "Text" : "", "Mnemonic" : "06"},
{"Row" :6, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "DisplayText" : "Consult Infectious Diseases (outpatient)", "Text" : "Consult Infectious Diseases (outpatient)", "Mnemonic" : "08"},
{"Row" :7, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "DisplayText" : "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)", "Text" : "", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-Date online"}, 
{"Row" : 10, "Column" : 1, "Text" : "Daily Antibiotic Prophylaxis for Asplenia", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "The need for daily antibiotic prophylaxis and its duration is typically"}, 
{"Row" : 12, "Column" : 1, "Text" : "determined individually based on patient age, immune status, history of"}, 
{"Row" : 13, "Column" : 1, "Text" : "infection, potential for adverse drug reactions and other factors."}, 
{"Row" : 24, "Column" : 1, "Text" : "Daily antibiotic prophylaxis is in addition to the emergency supply.", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500MG PO BID FOR ASPLENIA DAILY PROPHYLAXIS", "DisplayText" : "Amoxicillin 500MG PO bid for daily prophylaxis for asplenic patient ($) [R]", "Text" : "", "Mnemonic" : "14"},
{"Row" : 27, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 250MG PO BID DAILY PROPHYLAXIS ASPLENIA", "DisplayText" : "Cephalexin 250MG PO bid for daily propylaxis for asplenic patient ($) [R]", "Text" : "", "Mnemonic" : "16"},
{"Row" : 25, "Column" : 1, "Text" : "Recommended: ", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Alternative for penicillin and beta lactam allergy: ", "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 250 MG QDAY DAILY PROPYLAXIS ASPLENIA", "DisplayText" : "Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($)[DI]", "Text" : "", "Mnemonic" : "18"},
{"Row" : 15, "Column" : 1, "Text" : "Consider Prophylaxis: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "1) Approximately 1 year prophylaxis for all patients following splenectomy."}, 
{"Row" : 17, "Column" : 1, "Text" : "2) Lifelong prophylaxis for patients with history of sepsis or other severe"}, 
{"Row" : 18, "Column" : 1, "Text" : "infections caused by encapsulated organisms."}, 
{"Row" : 19, "Column" : 1, "Text" : "3) Prophylaxis for as long as the patient is immunocompromised or for life"}, 
{"Row" : 20, "Column" : 1, "Text" : "for patients with concurrent immunocompromising conditions (e.g. hematologic"}, 
{"Row" : 21, "Column" : 1, "Text" : "malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver"}, 
{"Row" : 22, "Column" : 1, "Text" : "disease, or HIV infection)."}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "DisplayText" : "Asplenic Empiric Antibiotics" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID AMOXICILLIN-CLAVULANATE 875/125MG PO BID ASPLENIA", "DisplayText" : "Amoxicillin-clavulanate 875MG PO BID for asplenia empiric antibiotic ($) [R]", "Text" : "Amoxicillin-clavulanate 875MG PO BID for asplenia empiric antibiotic ($) [R]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "PSOZID CEFUROXIME 500MG PO BID ASPLENIA", "DisplayText" : "Cefuroxime 500MG PO BID for asplenia empiric antibiotic ($) [R]", "Text" : "Cefuroxime 500MG PO BID for asplenia empiric antibiotic ($) [R]", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 750MG PO QDAILY ASPLENIA", "DisplayText" : "Levofloxacin 750MG PO QDAY for asplenia empiric antibiotic ($) [R,DI]", "Text" : "Levofloxacin 750MG PO QDAY for asplenia empiric antibiotic ($) [R,DI]", "Mnemonic" : "8"},
{"Row" :2, "Column" : 1, "Text" : "Self-medicate Empiric Antibiotics for Fever or Other Signs of Systemic Infectio", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Patients should keep an emergency supply of antibiotics on hand to be used"}, 
{"Row" :4, "Column" : 1, "Text" : "for the development of fever or other signs of systemic infection, and"}, 
{"Row" :5, "Column" : 1, "Text" : "seek medical care immediately if these symptoms develop."}, 
{"Row" :7, "Column" : 1, "Text" : "Recommendations to self- medicate: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Alternative recommendation for penicillin/beta-lactam allergy: ", "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Up-to-Date online"}, 
{"Row" : 16, "Column" : 1, "Text" : "Keenan RD, Br J Haematol 1999. 105:509"}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY OPT CHART", "DisplayText" : "Splenectomy Vaccines" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "02"},
{"Row" :3, "Column" : 1, "Text" : "Functional or Anatomical Asplenia", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "", "Mnemonic" : "08"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC 2 DOSE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "", "Mnemonic" : "10"},
{"Row" :6, "Column" : 1, "Item" : "ORZ SET ABX OP HAEMOPHILUS B VACCINE ONE DOSE", "DisplayText" : "HAEMOPHILUS B VACCINE ONE DOSE", "Text" : "", "Mnemonic" : "04"},
{"Row" : 22, "Column" : 1, "Text" : "Repeat every 5 years: ", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC ONCE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) ONE DOSE", "Mnemonic" : "12"},
{"Row" :4, "Column" : 1, "Text" : "Note: Please select EACH recommended vaccine to place orders"}, 
{"Row" : 16, "Column" : 1, "Text" : "Revaccination (booster)required: ", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "Repeat 1 year after completing the primary series and every 2 to 3 years", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "thereafter: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 20-VALENT VACCINE ONCE", "DisplayText" : "PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE", "Text" : "", "Mnemonic" : "06"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE ONE DOSE", "DisplayText" : "MENINGOCOCCAL B VACCINE ONE DOSE", "Text" : "", "Mnemonic" : "12"}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "DisplayText" : "Asplenia Recommendations Vaccines Empiric Abx " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY OPT CHART", "DisplayText" : "Splenectomy Vaccines", "Text" : "[click here] Place order for specific vaccines for asplenia", "Mnemonic" : "6"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY DAILY ANTIBIOTIC", "DisplayText" : "Asplenic Empiric Antibiotics", "Text" : "Daily Antibiotic Prophylaxis", "Mnemonic" : "8"},
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "DisplayText" : "Asplenic Empiric Antibiotics", "Text" : "Self-medicate Empiric Antibiotics", "Mnemonic" : "10"},
{"Row" :2, "Column" : 1, "Text" : "Functional or Anatomical Asplenia Vaccine & Antibiotic Prophylaxis Guideline", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Following a splenectomy there is considerably increased risk of developing"}, 
{"Row" :4, "Column" : 1, "Text" : "septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,"}, 
{"Row" :5, "Column" : 1, "Text" : "Haemophilus inluenza type b and meningococcus. Key measures to prevent"}, 
{"Row" :6, "Column" : 1, "Text" : "such infections include education, vaccination, prophylactic antimicrobial"}, 
{"Row" :7, "Column" : 1, "Text" : "therapy in selected patients, and early empirical therapy for febrile"}, 
{"Row" :8, "Column" : 1, "Text" : "epsisodes. It is critically important to educate patients regarding the"}, 
{"Row" :9, "Column" : 1, "Text" : "lifelong risk of postsplenectomy sepsis, the importance of vaccinations,"}, 
{"Row" : 10, "Column" : 1, "Text" : "and the need for urgent action in response to a febrile episode."}, 
{"Row" : 12, "Column" : 1, "Text" : "Management of an Episode of Fever in an Asplenic Patient", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "*See Inpatient CDSS*"}, 
{"Row" : 15, "Column" : 1, "Text" : "Initiation of vaccine regimen: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Routine vaccines should be up to date."}, 
{"Row" : 17, "Column" : 1, "Text" : "See CDSS Immunization section to order, if needed."}, 
{"Row" : 20, "Column" : 1, "Text" : "Ideally splenectomy vaccinations should be given 10 to 12 weeks before"}, 
{"Row" : 21, "Column" : 1, "Text" : "elective splenectomy.Where this is not possible they can be given up to"}, 
{"Row" : 22, "Column" : 1, "Text" : "two weeks before or at least two weeks post-splenectomy."}, 
{"Row" : 26, "Column" : 1, "Text" : "Use of Antibiotic Prophylaxis for Asplenia: ", "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Text" : "Use of antibiotic prophylaxis, in addition to vaccination, further reduces"}, 
{"Row" : 28, "Column" : 1, "Text" : "the risk of infection and poor outcomes."}, 
{"Row" : 30, "Column" : 1, "Text" : "Daily Antibiotic Prophylaxis: (in addition to emergency supply)", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection: ", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Text" : "References"}, 
{"Row" : 38, "Column" : 1, "Text" : "Clin Infect Dis 2014, 58:e44-100"}, 
{"Row" : 39, "Column" : 1, "Text" : "Up-to-Date: Prevention of infection in patients with impaired splenic function"}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX URL ASPLENIA VACCINATION RECOMMENDATIONS", "DisplayText" : "Vaccinations for Adults without a Spleen", "Text" : "[click here] Vaccinations for Adults without a Spleen", "Mnemonic" : "4"},
{"Row" : 37, "Column" : 1, "Text" : "MMWR Morb Mortal Wkly Rep 2022, 71(7):229"}
]},
{"Name" : "ORZID3 GMENU SPOROTRICHOSIS", "DisplayText" : "Sporotrichosis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 ITRACONAZOLE 200MG PO QDAY 90DAYS", "DisplayText" : "Itraconazole 200mg po qday for 90 days", "Text" : "Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions", "Mnemonic" : "4a"},
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 ITRACONAZOLE 200MG PO QDAY 90DAYS", "DisplayText" : "Itraconazole 200mg po qday for 90 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :2, "Column" : 1, "Text" : "SPOROTRICHOSIS"}, 
{"Row" :4, "Column" : 1, "Text" : "Sporotrichosis occurs most often in people who have had significant outdoor"}, 
{"Row" :5, "Column" : 1, "Text" : "exposure to soil.In immunocompetent people, disease is usually limited to the"}, 
{"Row" :6, "Column" : 1, "Text" : "skin.In people with decreased host defenses (eg, HIV/AIDS, alcoholism,"}, 
{"Row" :7, "Column" : 1, "Text" : "diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis"}, 
{"Row" :8, "Column" : 1, "Text" : "often disseminates to bones, joints, or lungs.Consult Infectious Diseases or"}, 
{"Row" :9, "Column" : 1, "Text" : "Dermatology"}, 
{"Row" : 11, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Cutaneous infection in a patient without HIV infection", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "resolved, usually for a total of 3-6 months ($) [DI]"}, 
{"Row" : 19, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Consult Dermatology or Infectious Diseases."}, 
{"Row" : 22, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Extracutaneous infection or any infection in a patient with HIV/AIDS", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "____________________________________________________________________________", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Text" : "Consult Dermatology or Infectious Diseases."}, 
{"Row" : 31, "Column" : 1, "Text" : "Kaufman CA Clin Infect Dis 2000, 30: 684"}, 
{"Row" : 32, "Column" : 1, "Text" : "Up-to-date website"}
]},
{"Name" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "DisplayText" : "Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)"}, 
{"Row" :5, "Column" : 1, "Text" : "Staphylococcal scalded skin syndrome (SSSS) presents with severe skin"}, 
{"Row" :6, "Column" : 1, "Text" : "blistering and exfoliation resulting from toxins produced by Staphylococcus"}, 
{"Row" :7, "Column" : 1, "Text" : "aureus.SSSS is usually found in children and rarely in older adults.Obtain"}, 
{"Row" :8, "Column" : 1, "Text" : "a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis."}, 
{"Row" : 10, "Column" : 1, "Text" : "Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities."}, 
{"Row" : 11, "Column" : 1, "Text" : "If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change"}, 
{"Row" : 12, "Column" : 1, "Text" : "to nafcillin or cefazolin for better antimicrobial activity."}, 
{"Row" : 14, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}, 
{"Row" : 19, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 20, "Column" : 1, "Text" : "Sanford keyword: Staph. Scalded skin syndrome"}, 
{"Row" : 21, "Column" : 1, "Text" : "Mandell chapter: The acutely ill patient with fever and rash"}, 
{"Row" : 22, "Column" : 1, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147"}, 
{"Row" : 23, "Column" : 1, "Text" : "Patel GK Am J Clin Dermatol 2003, 4:165"}
]},
{"Name" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "DisplayText" : "Suppurative odontogenic infections (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 5DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 5 days ($) [R]", "Text" : "Amoxicillin 500 mg PO q8h for 5 days ($) [R]", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 5DS 500MG PO TID", "DisplayText" : "Amoxicillin 500 mg PO TID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 5 days ($) [R]", "Mnemonic" : "8"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10"},
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "12"},
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "14"},
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "DisplayText" : "Cefdinir 300 mg PO BID 5 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Mnemonic" : "18"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "DisplayText" : "Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20"},
{"Row" :3, "Column" : 1, "Text" : "DENTAL INFECTIONS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential. All"}, 
{"Row" :6, "Column" : 1, "Text" : "patients should be referred to the dental service for assessment and direction"}, 
{"Row" :7, "Column" : 1, "Text" : "of treatment. Empirical coverage for likely pathogens (streptococci,"}, 
{"Row" :8, "Column" : 1, "Text" : "Peptostreptococcus, Finegoldia, Bacteriodes and other oral anaerobes) is"}, 
{"Row" :9, "Column" : 1, "Text" : "required."}, 
{"Row" : 11, "Column" : 1, "Text" : "Consult Dental Service", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Preferred: ", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 20, "Column" : 1, "Text" : "Primary alternative: ", "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above: ", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "_______________________________________________________________________________"}, 
{"Row" : 30, "Column" : 1, "Text" : "References: "}, 
{"Row" : 31, "Column" : 1, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27"}, 
{"Row" : 32, "Column" : 1, "Text" : "Lockhart et al. JADA. 2019, 150(11)906-921"}, 
{"Row" : 33, "Column" : 1, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head"}, 
{"Row" : 34, "Column" : 1, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252"}, 
{"Row" : 35, "Column" : 1, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279"}, 
{"Row" : 36, "Column" : 1, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina"}, 
{"Row" : 37, "Column" : 1, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic"}, 
{"Row" : 38, "Column" : 1, "Text" : "Infections"}
]},
{"Name" : "ORZID3 GMENU SURG SITE INFECT", "DisplayText" : "Surgical site infection " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "SURGICAL SITE INFECTION"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "DisplayText" : "Systemic Infectious Diseases (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "DisplayText" : "Bacteremia (Outpatient)", "Text" : "Bacteremia", "Mnemonic" : "4"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "DisplayText" : "Intravascular catheter-associated infection (Outpatient)", "Text" : "Intravascular catheter-associated infection", "Mnemonic" : "6"},
{"Row" :7, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "DisplayText" : "Sepsis, severe sepsis, and septic shock (Outpatient)", "Text" : "Sepsis and septic shock", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "DisplayText" : "Leukocytosis", "Text" : "Leukocytosis", "Mnemonic" : "10"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU FEVER OF UNKNOWN ORIGIN", "DisplayText" : "Fever of Unknown Origin (Outpatient)", "Text" : "Fever of unknown origin", "Mnemonic" : "12"},
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "DisplayText" : "Neutropenic fever (Outpatient)", "Text" : "Neutropenic fever", "Mnemonic" : "14"},
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "DisplayText" : "Lyme Disease (Outpatient)", "Text" : "Lyme disease", "Mnemonic" : "16"},
{"Row" :3, "Column" : 1, "Text" : "++SYSTEMIC INFECTIOUS DISEASES - OUTPATIENT++", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Last reviewed July 2017", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU TACE IR CHEMOEMBOLIZATION", "DisplayText" : "Antibiotic Prophylaxis for IR Chemoembolization " , "Version" : "Minneapolis", "Contents" : [
{"Row" :4, "Column" : 1, "Text" : "-Antibiotic prophylaxis in patients undergoing transarterial therapy for"}, 
{"Row" :5, "Column" : 1, "Text" : "hepatocellular carcinoma may not be routinely necessary."}, 
{"Row" :6, "Column" : 1, "Text" : "-However, patients with an incompetent sphincter of Oddi from previous"}, 
{"Row" :7, "Column" : 1, "Text" : "surgery, sphincterotomy, biliary drainage, or prior biliary instrumentation"}, 
{"Row" :8, "Column" : 1, "Text" : "are at increased risk of infection following embolization."}, 
{"Row" : 10, "Column" : 1, "Text" : "If no antimicrobial prophylaxis recommended, select below: ", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "Antimicrobial Pre-Procedure Prophylaxis Transarterial Chemoembolization (TACE)", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "References: "}, 
{"Row" : 20, "Column" : 1, "Text" : "Gaba RC, et al. J Vasc Interv Radiol 2017, 28:1210-1223"}, 
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "02"},
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV IR TACE PRE-PROCEDURE", "DisplayText" : "Levofloxacin 500mg IVPB once 60 minutes prior to TACE procedure", "Text" : "Levofloxacin 500 mg IVPB once 60 minutes prior to TACE procedure", "Mnemonic" : "12"},
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN-TAZO 3.375GM IV IR TACE PRE-PROCEDURE", "DisplayText" : "Piperacillin-tazobactam 3.375 gm IVPB once 60 minutes prior to TACE procedure", "Text" : "", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Text" : "Alternative for penicillin allergy: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Minneapolis VAHCS Interventional Radiology"}, 
{"Row" : 13, "Column" : 1, "Text" : "Recommended prophylaxis: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP TACE URL NURSE GENERIC ORDER", "DisplayText" : "*No antimicrobial prophylaxis recommended for TACE procedure", "Text" : "*No antimicrobial prophylaxis recommended for TACE procedure", "Mnemonic" : "08"}
]},
{"Name" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "DisplayText" : "Tinea Capitis (Ringworm) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY 28DAYS", "DisplayText" : "Terbinafine 250mg po qday for 28 days", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Mnemonic" : "4a"},
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 250MG PO QDAY 28DAYS", "DisplayText" : "Terbinafine 250mg po qday for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "TINEA CAPITIS (RINGWORM)"}, 
{"Row" :5, "Column" : 1, "Text" : "Tinea capitis is a common fungal infection of the scalp and hair. It is"}, 
{"Row" :6, "Column" : 1, "Text" : "characterized by itchy, red, raised, scaly patches often sharply defined."}, 
{"Row" :7, "Column" : 1, "Text" : "redder margins than centers create impression of ring. Tinea capitis primarily"}, 
{"Row" :8, "Column" : 1, "Text" : "affects prepubescent children, but can affect people of any age."}, 
{"Row" : 10, "Column" : 1, "Text" : "Treatment: ", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 4 weeks."}, 
{"Row" : 18, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 19, "Column" : 1, "Text" : "Sanford keyword: Tinea"}
]},
{"Name" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "DisplayText" : "Tinea Pedis (Athlete's Foot) - Outpatient " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "DisplayText" : "Clotrimazole 1% cream topical bid for 28 days", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "4a"},
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "DisplayText" : "Clotrimazole 1% cream topical bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 1% CRM TOP BID 28DAYS", "DisplayText" : "Terbinafine 1% cream topical bid for 28 days", "Text" : "Terbinafine 1% cream apply to affected area BID ($) [M]", "Mnemonic" : "6a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 1% CRM TOP BID 28DAYS", "DisplayText" : "Terbinafine 1% cream topical bid for 28 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 21, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 150MG QWEEK X2-4 WEEKS", "DisplayText" : "Fluconazole 150mg q week x 2-4 weeks", "Text" : "Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 22, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 150MG QWEEK X2-4 WEEKS", "DisplayText" : "Fluconazole 150mg q week x 2-4 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY 14DAYS", "DisplayText" : "Terbinafine 250 mg PO QDAY x 2 weeks", "Text" : "Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]", "Mnemonic" : "10a"},
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 250MG PO QDAY 14DAYS", "DisplayText" : "Terbinafine 250 mg PO QDAY x 2 weeks Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "Dermatophyte (tinea) Infections", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Dermatophyte fungal infections are common worldwide. Dermatophytes"}, 
{"Row" :6, "Column" : 1, "Text" : "metabolize and subsist upon keratin in the skin, hair, and nails."}, 
{"Row" :7, "Column" : 1, "Text" : "Most tinea infections can often be cured with topical therapy alone.Systemic"}, 
{"Row" :8, "Column" : 1, "Text" : "therapy is reserved for severe or refractory infection, recurrent infection, or"}, 
{"Row" :9, "Column" : 1, "Text" : "in immunocompromised patients."}, 
{"Row" : 11, "Column" : 1, "Text" : "Treat for 4 weeks"}, 
{"Row" : 12, "Column" : 1, "Text" : "Treatment", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Alternative", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Systemic treatment", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "Up-to-date website"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Tinea"}
]},
{"Name" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "DisplayText" : "Tinea Unguium (Onychomycosis) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 42DAYS 250MG PO QDAY", "DisplayText" : "Terbinafine 250mg po qday for 42 days", "Text" : "Terbinafine 250 mg PO qday for 6 weeks ($) [R,H,DI,O]", "Mnemonic" : "6a"},
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 42DAYS 250MG PO QDAY", "DisplayText" : "Terbinafine 250mg po qday for 42 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" :3, "Column" : 1, "Text" : "TINEA UNGUIUM (ONYCHOMYCOSIS)"}, 
{"Row" : 67, "Column" : 1, "Text" : "References"}, 
{"Row" : 71, "Column" : 1, "Text" : "Sanford keyword: Tinea"}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 300MG QWEEK FOR 6 MONS TOENAIL", "DisplayText" : "Fluconazole 300 mg PO q week for total of 6 months ($) [R,DI]", "Text" : "", "Mnemonic" : "8a"},
{"Row" : 46, "Column" : 1, "Text" : "Alternative oral therapy: ", "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Text" : "Toenail infections treat for at least 6 months"}, 
{"Row" : 51, "Column" : 1, "Text" : "Fingernail infections treat for 3 months"}, 
{"Row" : 52, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 300MG PO QWEEK FOR 3MONS FINGERNAIL", "DisplayText" : "Fluconazole 300 mg PO q week for 3 months ($) [R,DI]", "Text" : "", "Mnemonic" : "10a"},
{"Row" : 55, "Column" : 1, "Text" : "Topical Treatment: ", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : "PSOZID CICLOPIROX TOPICAL QDAY AFFECTED NAILS", "DisplayText" : "Ciclopirox 8% nail lacquer: Apply once daily to affected nail(s)", "Text" : "", "Mnemonic" : "12a"},
{"Row" : 62, "Column" : 1, "Text" : "Remove with rubbing alcohol every 7 days. ($) [M]"}, 
{"Row" : 63, "Column" : 1, "Text" : "See accompanying medication pamphlet for specific instructions."}, 
{"Row" : 64, "Column" : 1, "Text" : "Treatment is continued until nail clearance or up to 48 weeks."}, 
{"Row" : 69, "Column" : 1, "Text" : "Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299"}, 
{"Row" : 70, "Column" : 1, "Text" : "Up-to-date website: Onychomycosis Management"}, 
{"Row" : 35, "Column" : 1, "Text" : "Preferred Terbinafine first-line oral: ", "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Text" : "Ciclopirox is a topical first-line treatment for both fingernails and toenails."}, 
{"Row" : 57, "Column" : 1, "Text" : "Complete resolution occurs in approximately 7 percent of patients treated"}, 
{"Row" : 58, "Column" : 1, "Text" : "daily for 48 weeks.Ciclopirox is a well-tolerated treatment. Potential side"}, 
{"Row" : 59, "Column" : 1, "Text" : "effects include temporary nail changes and local skin irritation."}, 
{"Row" : 41, "Column" : 1, "Text" : "Fingernail infections treat for 6 weeks"}, 
{"Row" : 37, "Column" : 1, "Text" : "Toenail infections treat for 12 weeks"}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY X12 WEEKS TOENAIL", "DisplayText" : "Terbinafine 250 mg PO qday for 12 weeks (R,H,DI,O]", "Text" : "", "Mnemonic" : "4a"},
{"Row" :5, "Column" : 1, "Text" : "Onychomycosis is a fungal infection of the nail that presents with yellow,"}, 
{"Row" :6, "Column" : 1, "Text" : "thick, or crumbling nails. Obtain a fungal stain of nail sample prior to"}, 
{"Row" :7, "Column" : 1, "Text" : "initiating treatment. Using large nail clippers, remove as much of the"}, 
{"Row" :8, "Column" : 1, "Text" : "unattached dystrophic nail as possible. Place the piece of clipped nail plate"}, 
{"Row" :9, "Column" : 1, "Text" : "in formalin jar and send to pathology for fungal stain (PAS). Treatment should"}, 
{"Row" : 10, "Column" : 1, "Text" : "only be initiated if stain is positive for fungal elements. Fungal culture is"}, 
{"Row" : 11, "Column" : 1, "Text" : "NOT recommended."}, 
{"Row" : 13, "Column" : 1, "Text" : "Cure is unlikely if the entire nail is involved, or if a portion of the lunula"}, 
{"Row" : 14, "Column" : 1, "Text" : "is involved. Sometimes after treatment the fungus is cured, but the nail"}, 
{"Row" : 15, "Column" : 1, "Text" : "still does not appear normal because once nail dystrophy occurs, that"}, 
{"Row" : 16, "Column" : 1, "Text" : "is not reversible."}, 
{"Row" : 18, "Column" : 1, "Text" : "Systemic therapy is most likely to achieve a cure, especially with more nail"}, 
{"Row" : 19, "Column" : 1, "Text" : "involvement. If <25% involvement topical therapy may be considered. If"}, 
{"Row" : 20, "Column" : 1, "Text" : ">50-75% involvement systemic therapy should be considered."}, 
{"Row" : 27, "Column" : 1, "Text" : "Terbinafine works about 70% of the time to cure the fungus, and reinfection"}, 
{"Row" : 28, "Column" : 1, "Text" : "is common, so many patients will need to do more than one course"}, 
{"Row" : 29, "Column" : 1, "Text" : "of treatment.Fluconazole pulse dosing response rate is approximately 50%."}, 
{"Row" : 30, "Column" : 1, "Text" : "May consider retreatment with oral therapy after one year."}, 
{"Row" : 32, "Column" : 1, "Text" : "Recommend Dermatology Consult for retreatment after failure of 2 courses of"}, 
{"Row" : 33, "Column" : 1, "Text" : "terbinafine or fluconazole."}, 
{"Row" : 38, "Column" : 1, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine"}, 
{"Row" : 42, "Column" : 1, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine"}, 
{"Row" : 26, "Column" : 1, "Text" : "Oral Treatment: ", "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Text" : "Toenails take 12-18 months to grow out completely, so improvement should not"}, 
{"Row" : 23, "Column" : 1, "Text" : "be expected to be observed for at least 6-9 months.Continued improvement can"}, 
{"Row" : 24, "Column" : 1, "Text" : "be experienced following treatment completion."}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG QWEEK FOR 3-6 MONTHS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "8b"},
{"Row" : 53, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG QWEEK FOR 3-6 MONTHS", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "10b"},
{"Row" : 65, "Column" : 1, "Item" : "PSHZID CICLOPIROX 8% NAIL LACQUER FUNGAL NAIL INFECTION", "DisplayText" : "Non-VA order for above", "Text" : "", "Mnemonic" : "12b"}
]},
{"Name" : "ORZID3 GMENU TINEA VERSICOLOR", "DisplayText" : "Tinea Versicolor (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 KETOCONAZOLE 2% CREAM TOP QDAY 14DAYS", "DisplayText" : "Ketoconazole 2% cream top qday for 14 days", "Text" : "Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]", "Mnemonic" : "4a"},
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 KETOCONAZOLE 2% CREAM TOP QDAY 14DAYS", "DisplayText" : "Ketoconazole 2% cream top qday for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 1% CREAM TOP QDAY 14DAYS", "DisplayText" : "Terbinafine 1% cream topical qday for 14 days", "Text" : "Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 1% CREAM TOP QDAY 14DAYS", "DisplayText" : "Terbinafine 1% cream topical qday for 14 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 SELENIUM LOT 2.5% 10MIN 7DAYS", "DisplayText" : "Selenium lotion 2.5% leave on for 10min then rinse qday for 7 days", "Text" : "Selenium sulfide lotion 2.5% apply to affected area, leave on for 10", "Mnemonic" : "8a"},
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 SELENIUM LOT 2.5% 10MIN 7DAYS", "DisplayText" : "Selenium lotion 2.5% leave on for 10min then rinse qday for 7 da Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 28, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "DisplayText" : "Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R", "Text" : "Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R", "Mnemonic" : "10a"},
{"Row" : 29, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "DisplayText" : "Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "DisplayText" : "References", "Text" : "References", "Mnemonic" : "12"},
{"Row" :2, "Column" : 1, "Text" : "TINEA VERSICOLOR"}, 
{"Row" :4, "Column" : 1, "Text" : "Pityriasis or tinea versicolor is a common superficial fungal infection."}, 
{"Row" :5, "Column" : 1, "Text" : "Patients often present with erythematous, hypo- or hyperpigmented patches,"}, 
{"Row" :6, "Column" : 1, "Text" : "usually on the trunk or extremities."}, 
{"Row" :8, "Column" : 1, "Text" : "Topical antifungals can be used for limited disease.For disease that involves"}, 
{"Row" :9, "Column" : 1, "Text" : "nails or does not respond to topical therapy, use oral antifungals."}, 
{"Row" : 11, "Column" : 1, "Text" : "Oily skin products or exposure to hot environments often lead to recurrences."}, 
{"Row" : 13, "Column" : 1, "Text" : "Return of normal skin color often takes several weeks after the treatment"}, 
{"Row" : 14, "Column" : 1, "Text" : "course is finished."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment limited disease: ", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]"}, 
{"Row" : 27, "Column" : 1, "Text" : "Treatment extensive disease: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Up-to-date"}, 
{"Row" : 34, "Column" : 1, "Text" : "Sanford keyword: Tinea"}, 
{"Row" : 35, "Column" : 1, "Text" : "AK Gupta AK, J Cutan Med Surg. 2014, 18:79"}
]},
{"Name" : "ORZID3 GMENU TIX-CIL EUA", "DisplayText" : "Tix-cil " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 15, "Column" : 1, "Text" : "Tix-Cil (Tixagevimab plus cilgavimab)", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "On December 8, 2021 the FDA issued an EUA for AstraZeneca's Evusheld"}, 
{"Row" : 17, "Column" : 1, "Text" : "(tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis"}, 
{"Row" : 18, "Column" : 1, "Text" : "(prevention) of COVID-19 in certain adult and pediatric patients."}, 
{"Row" : 30, "Column" : 1, "Text" : "The product is only authorized for those individuals who are not currently"}, 
{"Row" : 31, "Column" : 1, "Text" : "infected with SARS-CoV-2 virus and who have not recently been exposed to an"}, 
{"Row" : 32, "Column" : 1, "Text" : "individual infected with SARS-CoV-2. The authorization also requires that"}, 
{"Row" : 33, "Column" : 1, "Text" : "individuals either have: "}, 
{"Row" : 34, "Column" : 1, "Text" : "-moderate to severely compromised immune systems due to a medical condition or"}, 
{"Row" : 35, "Column" : 1, "Text" : "or due to taking immunosuppressive medications or treatments and may not"}, 
{"Row" : 36, "Column" : 1, "Text" : "mount an adequate immune response to COVID-19 vaccination (examples of such"}, 
{"Row" : 37, "Column" : 1, "Text" : "medical conditions or treatments can be found in the fact sheet for health"}, 
{"Row" : 38, "Column" : 1, "Text" : "care providers) [see link top of page]"}, 
{"Row" : 39, "Column" : 1, "Text" : "[ OR ]"}, 
{"Row" : 40, "Column" : 1, "Text" : "-a history of severe adverse reactions to a COVID-19 vaccine and/or component(s)"}, 
{"Row" : 41, "Column" : 1, "Text" : "of those vaccines, therefore vaccination with an available COVID-19 vaccine,"}, 
{"Row" : 42, "Column" : 1, "Text" : "according to the approved or authorized schedule, is not recommended."}, 
{"Row" : 45, "Column" : 1, "Text" : "-One dose of Evusheld, administered as two separate consecutive intramuscular"}, 
{"Row" : 46, "Column" : 1, "Text" : "injections (one injection per monoclonal antibody, given in immediate"}, 
{"Row" : 47, "Column" : 1, "Text" : "succession), reduces the risk of developing COVID-19 for six months."}, 
{"Row" : 49, "Column" : 1, "Text" : "-Evusheld is NOT authorized for the treatment of COVID-19 or for post-exposure"}, 
{"Row" : 50, "Column" : 1, "Text" : "prevention of COVID-19."}, 
{"Row" : 51, "Column" : 1, "Text" : "-Pre-exposure prevention with Evusheld is not a substitute for vaccination in"}, 
{"Row" : 52, "Column" : 1, "Text" : "in individuals for whom COVID-19 vaccination is recommended."}, 
{"Row" : 22, "Column" : 1, "Text" : "Monoclonal antibodies are laboratory-made proteins that mimic the immune"}, 
{"Row" : 23, "Column" : 1, "Text" : "system's ability to fight off harmful pathogens such as viruses. Tixagevimab and"}, 
{"Row" : 24, "Column" : 1, "Text" : "cilgavimab are long-acting monoclonal antibodies that are specifically directed"}, 
{"Row" : 25, "Column" : 1, "Text" : "against the spike protein of SARS-CoV-2, designed to block the virus' attachment"}, 
{"Row" : 26, "Column" : 1, "Text" : "and entry into human cells. Tigagevimab and cilgavimab bind to different,"}, 
{"Row" : 27, "Column" : 1, "Text" : "non-overlapping sites on the spike protein of the virus."}, 
{"Row" :3, "Column" : 1, "Text" : "Emergency Use Authorization (EUA): Tixagevimab plus Cilgavimab (EVUSHELD)", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "Tixagevimab plus Cilgavimab combination is available via FDA Emergency Use"}, 
{"Row" :5, "Column" : 1, "Text" : "Authorization (EUA) for pre-exposure prophylaxis for COVID-19 for patients"}, 
{"Row" :6, "Column" : 1, "Text" : "that meet specific criteria. They are not FDA approved drugs."}, 
{"Row" : 19, "Column" : 1, "Text" : "There are no adequate, approved and available alternatives to Evusheld"}, 
{"Row" : 20, "Column" : 1, "Text" : "for the pre-exposure prevention of COVID-19 in the authorized population."}, 
{"Row" : 53, "Column" : 1, "Text" : "-In patients with prior COVID-19 vaccination, at least 2 weeks are required"}, 
{"Row" : 54, "Column" : 1, "Text" : "between the vaccination and the administration of Evusheld."}, 
{"Row" : 56, "Column" : 1, "Text" : "**PBM EUA Criteria to be completed on web link: ", "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Text" : "Answer to ALL of the following statements should be YES for administration: ", "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Text" : "2)Patient has no known recent exposure to an individual infected with SARS-CoV-2"}, 
{"Row" : 58, "Column" : 1, "Text" : "1)Patient has no symptoms consistent with COVID-19, or if any symptoms, has a"}, 
{"Row" : 59, "Column" : 1, "Text" : "a documented negative SARS-CoV-2 test within 72 hours prior to administration"}, 
{"Row" : 61, "Column" : 1, "Text" : "3)Patient has moderate to severe immunocompromise per the EUA definition or"}, 
{"Row" : 62, "Column" : 1, "Text" : "a documented medical contraindication to vaccination. (Note: refusal to"}, 
{"Row" : 63, "Column" : 1, "Text" : "be vaccinated does not constitute a contraindication for the purpose of"}, 
{"Row" : 64, "Column" : 1, "Text" : "eligibility for this drug.)"}, 
{"Row" : 65, "Column" : 1, "Text" : "4)In patients with prior COVID-19 vaccination (e.g. immunosuppressed) at least,"}, 
{"Row" : 66, "Column" : 1, "Text" : "2 weeks have passed since the last dose was given (if no prior vaccination"}, 
{"Row" : 67, "Column" : 1, "Text" : "answer YES)"}, 
{"Row" : 68, "Column" : 1, "Text" : "5)The Fact Sheet for patients/caregivers has been made available to the patient/"}, 
{"Row" : 69, "Column" : 1, "Text" : "caregiver prior to administration of this drug"}, 
{"Row" : 71, "Column" : 1, "Text" : "Note: Our staff is identifying the highest risk patients from our database", "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Text" : "for this medication. We will contact patients who are currently eligible", "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Text" : "for the limited doses currently allocated.", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Text" : "Patient Criteria for Use: ", "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Text" : "Important information: ", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "1)Providers approved to order: Dr. Klein (oncology) and ID Staff only"}, 
{"Row" : 81, "Column" : 1, "Text" : "2)Second dose is not being scheduled/addressed at this time. We will pull"}, 
{"Row" : 82, "Column" : 1, "Text" : "list of patients and assess the overall situation close to 6 month timeframe."}, 
{"Row" : 79, "Column" : 1, "Text" : "NOTES: ", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Link to complete EUA documentation: ", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] Pharmacist to complete EUA prior to dispensing medication", "Mnemonic" : "04"},
{"Row" : 11, "Column" : 1, "Text" : "Printable Fact Sheets for EUA: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Evusheld"}, 
{"Row" : 13, "Column" : 1, "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Tix-Cil"}, 
{"Row" : 74, "Column" : 1, "Text" : "Minneapolis VAHCS is using the Minnesota Health Department's framework"}, 
{"Row" : 75, "Column" : 1, "Text" : "for allocation of the medication. Our ID physicians shared in the development"}, 
{"Row" : 76, "Column" : 1, "Text" : "of the plan and provides for consistency in the community."}, 
{"Row" : 83, "Column" : 1, "Text" : "3)Administration in separate area from where COVID positive patients being seen"}, 
{"Row" : 84, "Column" : 1, "Text" : "4)Pharmacy dispense in original kit to clinic (decrease waste/short expiration)"}, 
{"Row" : 85, "Column" : 1, "Text" : "5)Separate clinic created for patient appointments (23537 MSP 3V INJECTION)"}, 
{"Row" : 77, "Column" : 1, "Text" : "[Click here] Minnesota Dept of Health-Prioritization of patients"}
]},
{"Name" : "ORZID3 GMENU TIX-CIL Provider Andrea S. Clinics", "DisplayText" : "Tix-Cil Provider Orders " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :8, "Column" : 1, "Text" : "Emergency Use Authorization (EUA): Tixagevimab plus Cilgavimab (EVUSHELD)", "Header" : 1}, 
{"Row" :9, "Column" : 1, "Text" : "Tixagevimab plus Cilgavimab combination is available via FDA Emergency Use"}, 
{"Row" : 10, "Column" : 1, "Text" : "Authorization (EUA) for pre-exposure prophylaxis for COVID-19 for patients"}, 
{"Row" : 11, "Column" : 1, "Text" : "that meet specific criteria. They are not FDA approved drugs."}, 
{"Row" : 28, "Column" : 1, "Text" : "Printable Fact Sheets for Evusheld EUA: ", "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Text" : "Minneapolis VAHCS is following the Minnesota Health Department's framework"}, 
{"Row" : 34, "Column" : 1, "Text" : "for allocation of Evusheld. Our ID physicians shared in the development"}, 
{"Row" : 38, "Column" : 1, "Text" : "Nursing pre-screening questions prior to Evusheld administration: ", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "(Note: COVID-19 vaccination is not required to receive Evusheld)"}, 
{"Row" : 41, "Column" : 1, "Text" : "-No current symptoms consistent with COVID-19 or recent exposure (last 10 days)"}, 
{"Row" : 42, "Column" : 1, "Text" : "-No hypersensitivity to any COVID-19 vaccines, polysorbate 80, or polyethylene"}, 
{"Row" : 43, "Column" : 1, "Text" : "glycol (PEG)"}, 
{"Row" : 39, "Column" : 1, "Text" : "-At least 2 weeks have passed since last dose of COVID-19 vaccine"}, 
{"Row" : 45, "Column" : 1, "Text" : "to patient/caregiver prior to administration"}, 
{"Row" : 44, "Column" : 1, "Text" : "-Nursing will provide hardcopy of Evusheld Patient/Caregiver Fact Sheet"}, 
{"Row" : 57, "Column" : 1, "Text" : "ii) If provider would like to provide patient with Evusheld fact sheet: ", "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Text" : "iii) Place medication order, nurse text order and RTC order: ", "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Text" : "*** IF patient meets criteria for Evusheld: ", "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Text" : "i) Provider to document discussed Evusheld with patient in CPRS", "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Text" : "(e.g. progress note, patient contact note, addendum)"}, 
{"Row" : 35, "Column" : 1, "Text" : "of the document and allows for consistency with our local healthcare community."}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX EVUSHELD MED+NURSE TEXT+APPT", "DisplayText" : "Evusheld medication orders + RTC Appt", "Text" : "[Click here] Evusheld medication order + Nurse Text Order + RTC Appointment", "Mnemonic" : "12"},
{"Row" : 59, "Column" : 1, "Text" : "-or- patient may access information on the internet at Evusheld.com"}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX EVUSHELD_PATIENT", "DisplayText" : "Evusheld_Allocation", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Evusheld", "Mnemonic" : "4"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX EVUSHELD_PROVIDER", "DisplayText" : "Evusheld_Provider", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Evusheld *NEW 10/22", "Mnemonic" : "6"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX EVUSHELD_ALLOCATION", "DisplayText" : "Evusheld_Allocation", "Text" : "[Click here] Prioritization of patients (See pages 7-8)", "Mnemonic" : "8"},
{"Row" : 58, "Column" : 1, "Item" : "ORZ GTX ABX EVUSHELD_PATIENT", "DisplayText" : "Evusheld_Allocation", "Text" : "[Click here to print] Fact Sheet for Patients/Caregivers EUA Evusheld", "Mnemonic" : "10"},
{"Row" : 32, "Column" : 1, "Text" : "Prioritization/eligibility of patients: ", "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Text" : "__________________________________________________________________", "Header" : 1}, 
{"Row" :3, "Column" : 1, "Text" : "This menu for ordering Evusheld may be used by providers in these clinics: ", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cardiology, Endocrine, GI, Hem/Onc, Infectious Disease, MRTC, Pulmonary,"}, 
{"Row" :6, "Column" : 1, "Text" : "Renal, Rheumatology and Neurology."}, 
{"Row" :4, "Column" : 1, "Text" : "(...because of Evusheld administration clinic assignment.)"}, 
{"Row" : 13, "Column" : 1, "Text" : "Evusheld is NOT authorized for the treatment of COVID-19 or for post-exposure"}, 
{"Row" : 14, "Column" : 1, "Text" : "prevention of COVID-19."}, 
{"Row" : 25, "Column" : 1, "Text" : "Link to complete EUA documentation: ", "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "DisplayText" : "LINK EUA PROVIDER TO FILL OUT", "Text" : "[Click here] Pharmacist to complete EUA prior to dispensing medication", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Text" : "Patients who have received a COVID-19 vaccine, Evusheld should be administered"}, 
{"Row" : 18, "Column" : 1, "Text" : "at least two weeks after vaccination, per Evusheld EUA."}, 
{"Row" : 19, "Column" : 1, "Text" : "Note: COVID-19 vaccine not required to receive Evusheld."}, 
{"Row" : 16, "Column" : 1, "Text" : "Evusheld and COVID-19 vaccine: ", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "Per CDC: Patients who previously received antibody products as part of COVID-19"}, 
{"Row" : 22, "Column" : 1, "Text" : "treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be"}, 
{"Row" : 23, "Column" : 1, "Text" : "vaccinated at any time."}, 
{"Row" : 47, "Column" : 1, "Text" : "Evusheld administration notes: ", "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Text" : "Evusheld administered as 2 IM injections at one clinic visit, patient to"}, 
{"Row" : 49, "Column" : 1, "Text" : "remain in clinic for 1 hour after administration, current redosing q6months"}, 
{"Row" : 64, "Column" : 1, "Text" : "Evusheld REPEAT dose q6 months orders", "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX TIX-CIL REPEAT DOSE + NURSING INSTRUCT + RTC", "DisplayText" : "Tix-Cil med + nursing instructions + RTC order", "Text" : "[Click here] Orders for Evusheld REPEAT dose q6months", "Mnemonic" : "14"},
{"Row" : 51, "Column" : 1, "Text" : "New Patients (See below for REPEAT q6month dose orders)", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "DisplayText" : "Toxic Shock Syndrome (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "TOXIC SHOCK SYNDROME"}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to Inpatient Antimicrobial CDSS."}
]},
{"Name" : "ORZID3 GMENU TRAVEL MEDICINE", "DisplayText" : "Travel Medications" , "Version" : "Minneapolis", "Contents" : [
{"Row" :3, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO BID PRN 3DS TRAVEL MED", "DisplayText" : "Ciprofloxacin PO 500mg BID PRN 3ds", "Text" : "Ciprofloxacin PO 500mg BID PRN", "Mnemonic" : "2"},
{"Row" :4, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY PRN 3DS TRAVEL CLINIC", "DisplayText" : "Azithromycin PO 500mg QDAY PRN 3DS", "Text" : "Azithromycin PO 500mg QDAY PRN", "Mnemonic" : "4"},
{"Row" :5, "Column" : 1, "Item" : "PSOZID2 LOPERAMIDE 2-4MG QID PRN TRAVEL MED", "DisplayText" : "Loperamide 2-4mg QID PRN", "Text" : "Loperamide 2-4mg QID PRN", "Mnemonic" : "6"},
{"Row" :6, "Column" : 1, "Item" : "PSOZID2 BISMUTH SUBSALICYLATE 524MG QID PRN TRAVEL MED", "DisplayText" : "Bismuth Subsalicylate 524mg QID PRN", "Text" : "Bismuth Subsalicylate 524mg QID PRN", "Mnemonic" : "8"},
{"Row" :8, "Column" : 1, "Item" : "PSOZID2 BISMUTH SUBSALICYLATE 524MG QID 15 DAYS TRAVEL MED", "DisplayText" : "Bismuth Subsalicylate 524mg QID", "Text" : "Bismuth Subsalicylate 524mg QID", "Mnemonic" : "10"},
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP CHOLERA VACCINE PO 100ML ONE DOSE", "DisplayText" : "Cholera vaccine po 100ML one dose", "Text" : "Cholera Vaccine ONCE", "Mnemonic" : "12"},
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A VACCINE 2 DOSE SERIES", "DisplayText" : "HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A 2 Dose Series", "Mnemonic" : "14"},
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B 3 Dose Series", "Mnemonic" : "16"},
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS B VACCINE 4 DOSE SERIES", "DisplayText" : "HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)", "Mnemonic" : "18"},
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE 3 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) 3 Dose Series", "Mnemonic" : "20"},
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX OP HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "DisplayText" : "HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) Accelerated 4 Dose Series", "Mnemonic" : "22"},
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX OP ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "DisplayText" : "ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster (Shingrix) 2 dose series", "Mnemonic" : "24"},
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX OP JAPANESE ENCEPHALITIS VIRUS VACC 2 DOSE SERIES", "DisplayText" : "JAPANESE ENCEPHALITIS VIRUS VACC 2 DOSE SERIES", "Text" : "Japanese Encephalitis Virus Vaccine 2 Dose Series", "Mnemonic" : "28"},
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, Mumps, Rubella Vaccine ONCE", "Mnemonic" : "30"},
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "DisplayText" : "MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, Mumps, Rubella Vaccine 2 Dose Series", "Mnemonic" : "32"},
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "DisplayText" : "MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B Vaccine 2 Dose Series", "Mnemonic" : "34"},
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACC ONCE", "DisplayText" : "MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES", "Text" : "Meningococcal Conjugate (MenACWY) Vaccine Booster", "Mnemonic" : "36"},
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "DisplayText" : "PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 23-valent vaccine ONCE", "Mnemonic" : "40"},
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP POLIOVIRUS VACCINE ONCE", "DisplayText" : "POLIOVIRUS VACCINE ONCE", "Text" : "Poliovirus Vaccine ONCE", "Mnemonic" : "42"},
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP POLIOVIRUS VACCINE 3 DOSE SERIES", "DisplayText" : "POLIOVIRUS VACCINE 3 DOSE SERIES", "Text" : "Poliovirus Vaccine 3 Dose Series", "Mnemonic" : "44"},
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES VACCINE 2 DOSE SERIES", "DisplayText" : "RABIES VACCINE 2 DOSE SERIES", "Text" : "Rabies Pre-exposure Vaccine 2 Dose Series", "Mnemonic" : "47"},
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES BOOSTER VACCINE ONE DOSE", "DisplayText" : "RABIES BOOSTER VACCINE ONE DOSE", "Text" : "Rabies Pre-exposure Vaccine Booster dose", "Mnemonic" : "48"},
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Tetanus Diphtheria Vaccine booster dose", "Mnemonic" : "50"},
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "DisplayText" : "TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tetanus/Diphtheria/Pertussis (TDAP) Vaccine booster dose", "Mnemonic" : "51"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP TYPHOID VACCINE INJ ONCE", "DisplayText" : "TYPHOID VACCINE INJ ONCE", "Text" : "Typhoid Vaccine Inj ONCE", "Mnemonic" : "54"},
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX OP YELLOW FEVER VACCINE ONE DOSE", "DisplayText" : "YELLOW FEVER VACCINE ONE DOSE", "Text" : "Yellow Fever Vaccine ONCE", "Mnemonic" : "58"},
{"Row" : 41, "Column" : 1, "Item" : "PSOZID ATOVAQUONE/PROGUANIL 1TAB PO QDAY 24DS", "DisplayText" : "Atovaquone/Proguanil 1Tab PO QDAY 24DS", "Text" : "Atovaquone/Proguanil 1Tab PO QDAY 24DS", "Mnemonic" : "60"},
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX CHLOROQUINE 500MG PO QWEEK", "DisplayText" : "Chloroquine 500mg QWEEK", "Text" : "Chloroquine 500mg PO QWEEK 56DS", "Mnemonic" : "62"},
{"Row" : 43, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO QDAY TRAVEL MED", "DisplayText" : "Doxycycline 100mg QDAY 30DS", "Text" : "Doxycycline 100mg PO QDAY 30DS", "Mnemonic" : "64"},
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX MEFLOQUINE 250MG PO QWEEK TRAVEL MED", "DisplayText" : "Mefloquine 250mg QWEEK 56DS", "Text" : "Mefloquine 250mg PO QWEEK 56DS", "Mnemonic" : "66"},
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Pre-exposure prophylaxis recommendations", "Mnemonic" : "70"},
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Post-exposure Prophylaxis", "Text" : "Post-exposure prophylaxis recommendations", "Mnemonic" : "68"},
{"Row" :1, "Column" : 1, "Text" : "Travelers Diarrhea", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Prevention: "}, 
{"Row" : 10, "Column" : 1, "Text" : "Vaccines - Administered in Clinic", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Malaria Prevention", "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Text" : "Rabies", "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Rabies Pre-exposure Prophylaxis Recommendations", "Mnemonic" : "46"},
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Post-exposure Prophylaxis", "Text" : "Rabies Post-exposure Prophylaxis Recommendations", "Mnemonic" : "45"},
{"Row" :2, "Column" : 1, "Text" : "Treatment: "}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP TICK-BORNE ENCEPHALITIS VACCINE ONCE", "DisplayText" : "Tick-Borne Encephalitis Vaccine Once", "Text" : "Tick-Borne Encephalitis Vaccine ONCE", "Mnemonic" : "52"},
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP TICK-BORNE ENCEPHALITIS VACCINE 3 DOSE SERIES", "DisplayText" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Text" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Mnemonic" : "53"},
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP JAPANESE ENCEPHALITIS VIRUS VACCINE ONCE", "DisplayText" : "Japanese Encephalitis Virus Vaccine 0.5ml ONCE", "Text" : "Japanese Encephalitis Virus Vaccine Booster", "Mnemonic" : "27"},
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP PNEUMOCOCCAL 20-VALENT VACCINE ONCE", "DisplayText" : "PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 20-valent (PCV20) vaccine ONCE", "Mnemonic" : "38"},
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 TYPHOID VACCINE 1 CAP PO EVERY OTHER DAY 4 DOSES", "DisplayText" : "Typhoid Vaccine 1 CAP PO Every Other Day for 4 doses", "Text" : "Typhoid Vaccine PO every other day for 4 doses (Opt Med)", "Mnemonic" : "56"}
]},
{"Name" : "ORZID3 GMENU TRAVELER DIARRHEA", "DisplayText" : "Traveler's diarrhea " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M]", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Mnemonic" : "4a"},
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "DisplayText" : "Azithromycin 1000 mg PO once ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "4b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Mnemonic" : "6a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "DisplayText" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Mnemonic" : "8a"},
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP RIFAXAMIN 3DS 200MG TID", "DisplayText" : "RIFAXAMIN 3DS 200MG TID", "Text" : "Rifaximin 200 mg TID for 3 days ($$) [M]", "Mnemonic" : "10a"},
{"Row" : 37, "Column" : 1, "Item" : "PSHZID RIFAXAMIN 3DS 200MG TID", "DisplayText" : "Rifaximin 200 mg TID for 3 days ($$) [M] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "TRAVELER'S DIARRHEA", "Header" : 1}, 
{"Row" :4, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" :6, "Column" : 1, "Text" : "Acute non-bloody diarrhea (< 14 days of symptoms)", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Most cases are mild and self-limited. Reserve antimicrobial therapy for"}, 
{"Row" :8, "Column" : 1, "Text" : "patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or"}, 
{"Row" :9, "Column" : 1, "Text" : "diarrhea that is incapacitating."}, 
{"Row" : 11, "Column" : 1, "Text" : "Bloody diarrhea", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial"}, 
{"Row" : 13, "Column" : 1, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody"}, 
{"Row" : 14, "Column" : 1, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these"}, 
{"Row" : 15, "Column" : 1, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve"}, 
{"Row" : 16, "Column" : 1, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric"}, 
{"Row" : 17, "Column" : 1, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm."}, 
{"Row" : 18, "Column" : 1, "Text" : "For more information on when an antimicrobial is indicated or if the patient has"}, 
{"Row" : 19, "Column" : 1, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious"}, 
{"Row" : 20, "Column" : 1, "Text" : "Diseases."}, 
{"Row" : 22, "Column" : 1, "Text" : "Primary treatment", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Hydration and electrolyte replacement"}, 
{"Row" : 25, "Column" : 1, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea", "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 32, "Column" : 1, "Text" : "Alternative"}, 
{"Row" : 35, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 38, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Text" : "Subacute diarrhea (>/= 14 days of symptoms)", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Primary treatment is hydration and electrolyte replacement. Empirical"}, 
{"Row" : 42, "Column" : 1, "Text" : "antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for"}, 
{"Row" : 43, "Column" : 1, "Text" : "example, enteric pathogen PCR testing, Clostridium difficile testing in those"}, 
{"Row" : 44, "Column" : 1, "Text" : "who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and"}, 
{"Row" : 45, "Column" : 1, "Text" : "endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present"}, 
{"Row" : 46, "Column" : 1, "Text" : "the case should be evaluated by Gastroenterology and/or Infectious Diseases."}, 
{"Row" : 49, "Column" : 1, "Text" : "References: "}, 
{"Row" : 51, "Column" : 1, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea"}, 
{"Row" : 52, "Column" : 1, "Text" : "Sanford keyword: Travelers Diarrhea"}, 
{"Row" : 53, "Column" : 1, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80"}, 
{"Row" : 54, "Column" : 1, "Text" : "Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and"}, 
{"Row" : 55, "Column" : 1, "Text" : "treatment"}
]},
{"Name" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "DisplayText" : "Trichomonas vaginitis (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "4"},
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "6a"},
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "6b"},
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Mnemonic" : "8a"},
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "DisplayText" : "Metronidazole 500mg po bid for 7 days Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 7DS 2GM PO QDAY", "DisplayText" : "Metronidazole 2 gm PO qday for 7 days ($) [DI]", "Text" : "Metronidazole 2 gm PO q24h for 7 days ($) [DI]", "Mnemonic" : "10a"},
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 7DS 2GM PO QDAY", "DisplayText" : "Metronidazole 2 gm PO qday for 7 days ($) [DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" :3, "Column" : 1, "Text" : "TRICHOMONAS VAGINITIS AND URETHRITIS", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "Male sexual partners of women with trichomonas vaginitis will not have symptoms"}, 
{"Row" :8, "Column" : 1, "Text" : "but should be treated to prevent recurrent vaginitis in the female sexual"}, 
{"Row" :9, "Column" : 1, "Text" : "partner."}, 
{"Row" : 11, "Column" : 1, "Text" : "Diagnosis", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "The discharge is purulent, malodorous, and thin. The vaginal pH is greater"}, 
{"Row" : 13, "Column" : 1, "Text" : "than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved"}, 
{"Row" : 14, "Column" : 1, "Text" : "sensitivities and specifities compared to wet mount."}, 
{"Row" : 16, "Column" : 1, "Text" : "Treatment of Initial Episode in Men and Woman", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Pregnant women with trichomonas infection may be treated with metronidazole"}, 
{"Row" : 18, "Column" : 1, "Text" : "during any trimester."}, 
{"Row" : 22, "Column" : 1, "Text" : "Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "Referred to Non-VA Care)", "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Text" : "1st failure"}, 
{"Row" : 28, "Column" : 1, "Text" : "2nd failure"}, 
{"Row" : 32, "Column" : 1, "Text" : "3rd failure"}, 
{"Row" : 33, "Column" : 1, "Text" : "Consult Infectious Disease"}, 
{"Row" : 34, "Column" : 1, "Text" : "________________________________________________________________________", "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Text" : "References: "}, 
{"Row" : 38, "Column" : 1, "Text" : "Sanford keyword: Trichomoniasis"}, 
{"Row" : 39, "Column" : 1, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis"}, 
{"Row" : 40, "Column" : 1, "Text" : "CDC STD Treatment Guidelines: MMWR (2021) 70.4"}, 
{"Row" : 41, "Column" : 1, "Text" : "Up-To-Date article: Trichomoniasis"}
]},
{"Name" : "ORZID3 GMENU TUBERCULOSIS", "DisplayText" : "Tuberculosis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "TUBERCULOSIS"}, 
{"Row" :5, "Column" : 1, "Text" : "Evaluation and management are complex.Consult Pulmonary and/or Infectious"}, 
{"Row" :6, "Column" : 1, "Text" : "Diseases."}, 
{"Row" :8, "Column" : 1, "Text" : "Patients with suspected or proven pulmonary tuberculosis must be in respiratory"}, 
{"Row" :9, "Column" : 1, "Text" : "isolation."}, 
{"Row" : 11, "Column" : 1, "Text" : "References: ", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "Centers for Disease Control (CDC). Tuberculosis"}
]},
{"Name" : "ORZID3 GMENU TYPHLITIS", "DisplayText" : "Neutropenic enterocolitis (Typhlitis) - Outpatient" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :3, "Column" : 1, "Text" : "NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Refer to the Inpatient Antimicrobial CDSS"}
]},
{"Name" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "DisplayText" : "Uncomplicated Cystitis (Outpatient) " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "DisplayText" : "Complicated Cystitis (Outpatient)", "Text" : "Complicated cystitis", "Mnemonic" : "4"},
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "DisplayText" : "Asymptomatic bacteriuria (Outpatient)", "Text" : "Asymptomatic bacteriuria", "Mnemonic" : "6"},
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days", "Mnemonic" : "8a"},
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "DisplayText" : "Nitrofurantoin SA 7DS 100 MG PO BID Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "8b"},
{"Row" : 45, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Mnemonic" : "10a"},
{"Row" : 46, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "10b"},
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Mnemonic" : "12a"},
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "12b"},
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "14"},
{"Row" : 54, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 5 days", "Mnemonic" : "16a"},
{"Row" : 55, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "16b"},
{"Row" : 59, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 100MG BID 5DS", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O]", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 5 days", "Mnemonic" : "18a"},
{"Row" : 61, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 100MG BID 5DS", "DisplayText" : "Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "18b"},
{"Row" : 63, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 3 days", "Mnemonic" : "20a"},
{"Row" : 65, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "DisplayText" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R, Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "20b"},
{"Row" : 68, "Column" : 1, "Item" : "ORZ SET ABX OP FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "DisplayText" : "FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3GM sachet PO ($$)[M] once", "Mnemonic" : "22a"},
{"Row" : 69, "Column" : 1, "Item" : "PSHZID FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "DisplayText" : "Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "22b"},
{"Row" : 71, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days", "Mnemonic" : "24a"},
{"Row" : 72, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "DisplayText" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "24b"},
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "DisplayText" : "Beta-lactam Allergy Assessment", "Text" : "Assessment of Beta-lactam Reaction", "Mnemonic" : "26"},
{"Row" : 76, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 3 days", "Mnemonic" : "28a"},
{"Row" : 77, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "DisplayText" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA", "Text" : "Non-VA order for above", "Mnemonic" : "28b"},
{"Row" : 82, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1/2 SS PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]", "Mnemonic" : "30a"},
{"Row" : 83, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1/2 SS PO QDAY", "DisplayText" : "Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]", "Text" : "Non-VA order for above", "Mnemonic" : "30b"},
{"Row" : 85, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 SS PO POSTCOITUS", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]", "Text" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]", "Mnemonic" : "32a"},
{"Row" : 86, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 SS PO POSTCOITUS", "DisplayText" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "32b"},
{"Row" : 88, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO QHS", "DisplayText" : "Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min", "Text" : "Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min", "Mnemonic" : "34a"},
{"Row" : 89, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO QHS", "DisplayText" : "Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min (NOon-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "34b"},
{"Row" : 91, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO POSTCOITUS", "DisplayText" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min", "Text" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min", "Mnemonic" : "36a"},
{"Row" : 92, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO POSTCOITUS", "DisplayText" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O] (Non-VA)", "Text" : "Non-VA order for above", "Mnemonic" : "36b"},
{"Row" :3, "Column" : 1, "Text" : "UNCOMPLICATED CYSTITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Uncomplicated cystitis is defined as symptomatic bladder inflammation caused by"}, 
{"Row" :6, "Column" : 1, "Text" : "bacterial infections in people with structurally and neurogenically normal"}, 
{"Row" :7, "Column" : 1, "Text" : "urinary tract. Symptoms usually include dysuria, lower abdominal pain, and"}, 
{"Row" :8, "Column" : 1, "Text" : "urgency. Most cases of uncomplicated cystitis occur in pre-menopausal,"}, 
{"Row" :9, "Column" : 1, "Text" : "non-pregnant, sexually active young women and is commonly associated with"}, 
{"Row" : 10, "Column" : 1, "Text" : "Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S."}, 
{"Row" : 11, "Column" : 1, "Text" : "saprophyticus."}, 
{"Row" : 13, "Column" : 1, "Text" : "Cystitis is considered complicated when it occurs in pregnant women, people"}, 
{"Row" : 14, "Column" : 1, "Text" : "with abnormalities of the urinary tract, immunocompromised individuals and those"}, 
{"Row" : 15, "Column" : 1, "Text" : "who have persistent, recurrent, or relapsed infections, or treatment failure are"}, 
{"Row" : 16, "Column" : 1, "Text" : "considered complicated. Diagnosis and treatment of complicated cystitis is"}, 
{"Row" : 17, "Column" : 1, "Text" : "discussed elsewhere."}, 
{"Row" : 20, "Column" : 1, "Text" : "The presence of pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine"}, 
{"Row" : 21, "Column" : 1, "Text" : "nitrate, or urine bacteria is not a sufficient indication for antibiotic"}, 
{"Row" : 22, "Column" : 1, "Text" : "treatment. Asymptomatic bacteriuria occurs in patients who have bacteria in the"}, 
{"Row" : 23, "Column" : 1, "Text" : "urine with no symptoms of cystitis, and with few exceptions, should not be"}, 
{"Row" : 24, "Column" : 1, "Text" : "treated. Diagnosis and treatment of asymptomatic bacteriuria is further"}, 
{"Row" : 25, "Column" : 1, "Text" : "discussed elsewhere: "}, 
{"Row" : 28, "Column" : 1, "Text" : "The prevalence of antimicrobial resistance among bacteria associated with"}, 
{"Row" : 29, "Column" : 1, "Text" : "uncomplicated cystitis has increased. A urine culture should be considered in a"}, 
{"Row" : 30, "Column" : 1, "Text" : "patient who has had substantial involvement with healthcare or exposure to"}, 
{"Row" : 31, "Column" : 1, "Text" : "antimicrobials. If a patient fails to respond to therapy, a urine culture should"}, 
{"Row" : 32, "Column" : 1, "Text" : "be done."}, 
{"Row" : 34, "Column" : 1, "Text" : "For women with recurrent uncomplicated cystitis (2 episodes in 6 months or 3 or"}, 
{"Row" : 35, "Column" : 1, "Text" : "more episodes in 12 months), suppressive therapy is indicated after infection is"}, 
{"Row" : 36, "Column" : 1, "Text" : "eradicated and non-antimicrobial prevention methods, such as increased fluid"}, 
{"Row" : 37, "Column" : 1, "Text" : "intake and avoiding spermicide, are considered. Consider consulting Women's"}, 
{"Row" : 38, "Column" : 1, "Text" : "Clinic for treatment recommendations."}, 
{"Row" : 40, "Column" : 1, "Text" : "Men, empirical treatment", "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 44, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 48, "Column" : 1, "Text" : "Primary alternative: "}, 
{"Row" : 52, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 57, "Column" : 1, "Text" : "Women, empirical treatment", "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Text" : "Preferred: "}, 
{"Row" : 60, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 62, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 64, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 67, "Column" : 1, "Text" : "Primary alternatives: "}, 
{"Row" : 70, "Column" : 1, "Text" : "<OR>"}, 
{"Row" : 74, "Column" : 1, "Text" : "Secondary alternative: "}, 
{"Row" : 79, "Column" : 1, "Text" : "Women, suppression", "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Text" : "*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters"}, 
{"Row" : 81, "Column" : 1, "Text" : "*Avoid nitrofurantoin in the third trimester"}, 
{"Row" : 84, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 87, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 90, "Column" : 1, "Text" : "< OR >"}, 
{"Row" : 93, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 96, "Column" : 1, "Text" : "References: "}, 
{"Row" : 97, "Column" : 1, "Text" : "Drekonja et al., JAMA, 2021, 326(4)324-331"}, 
{"Row" : 98, "Column" : 1, "Text" : "Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20"}, 
{"Row" : 99, "Column" : 1, "Text" : "Mandell chapter: Urinary tract infections"}, 
{"Row" :100, "Column" : 1, "Text" : "Sanford keyword: UTI, Acute, Uncomplicated, Adult, Female"}, 
{"Row" :101, "Column" : 1, "Text" : "Sanford keyword: UTI, Adult, Male"}, 
{"Row" :102, "Column" : 1, "Text" : "Sanford keyword: Prevention of Recurrent UTI, Female"}, 
{"Row" :103, "Column" : 1, "Text" : "Up-To-Date article: Acute simple cystitis in men"}, 
{"Row" :104, "Column" : 1, "Text" : "Up-To-Date article: Acute simple cystitis in women"}, 
{"Row" :105, "Column" : 1, "Text" : "Up-To-Date article: Recurrent simple cystitis in women"}
]},
{"Name" : "ORZID3 GMENU URETHRITIS ASSOC STD", "DisplayText" : "Urethritis associated with sexually transmitted disease (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC URINE NAAT", "DisplayText" : "Chlamydia/GC Urine NAAT", "Text" : "Chlamydia & GC PCR/LCR test", "Mnemonic" : "4"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "DisplayText" : "Recurrent or persistent urethritis (Outpatient)", "Text" : "Treatment of recurrent or persistent urethritis", "Mnemonic" : "6"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "DisplayText" : "Chlamydia urethritis (Outpatient)", "Text" : "Treatment for chlamydial or non-gonococcal urethritis", "Mnemonic" : "8"},
{"Row" :3, "Column" : 1, "Text" : "URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES", "Header" : 1}, 
{"Row" :7, "Column" : 1, "Text" : "The main differential in a person who presents with dysuria is between cystitis"}, 
{"Row" :8, "Column" : 1, "Text" : "and urethritis. Bacterial urethritis is more likely in people with mild"}, 
{"Row" :9, "Column" : 1, "Text" : "dysuria, onset over a few days, or recent sexual contact."}, 
{"Row" : 10, "Column" : 1, "Text" : "The two most common sexually transmitted urethritis pathogens are Neisseria"}, 
{"Row" : 11, "Column" : 1, "Text" : "gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for"}, 
{"Row" : 12, "Column" : 1, "Text" : "these pathogens are more sensitive than culture and should be used for patients"}, 
{"Row" : 13, "Column" : 1, "Text" : "at risk for sexually transmitted urethritis."}, 
{"Row" : 16, "Column" : 1, "Text" : "For patients who have recently been treated for urethritis", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "Initial treatment of patients and sex partners", "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C."}, 
{"Row" : 21, "Column" : 1, "Text" : "trachomatis."}, 
{"Row" : 25, "Column" : 1, "Text" : "References: "}, 
{"Row" : 28, "Column" : 1, "Text" : "Mandell chapter: Urethritis"}, 
{"Row" : 29, "Column" : 1, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis"}, 
{"Row" : 30, "Column" : 1, "Text" : "Up-To-Date article: Urethritis in men"}, 
{"Row" :5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "DisplayText" : "Sexually Transmitted Infections (STI) HIV Exposure", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Mnemonic" : "3"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "DisplayText" : "Neisseria gonorrhoeae STI", "Text" : "Treatment for gonococcal infections", "Mnemonic" : "10"},
{"Row" : 27, "Column" : 1, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916"}
]},
{"Name" : "ORZID3 GMENU UROLOGY CIPRO IN CLINIC" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX UROLOGY CIPRO PO ORDER AND NURSE TEXT ORDER", "DisplayText" : "Urology Order: ciprofloxacin 500mg give in clinic and nurse text order", "Text" : "Ciprofloxacin 500 mg x1 orally ($0.10/day) [R,DI] give in clinic and nurse text", "Mnemonic" : "10"},
{"Row" :4, "Column" : 1, "Text" : "In cases where prolonged catheterization follows a procedure, antimicrobial"}, 
{"Row" :5, "Column" : 1, "Text" : "therapy at the time of catheter removal may be considered, since"}, 
{"Row" :6, "Column" : 1, "Text" : "colonization has likely occurred. The recommendation to treat empirically"}, 
{"Row" :7, "Column" : 1, "Text" : "depends on host factors, the duration of catheterization, and the"}, 
{"Row" :8, "Column" : 1, "Text" : "potential of morbidity or mortality."}, 
{"Row" : 10, "Column" : 1, "Text" : "Single dose of fluoroquinolone may significantly lower incidence"}, 
{"Row" : 11, "Column" : 1, "Text" : "of bacteriuria for patients undergoing ureteroscopy for stone removal."}, 
{"Row" :2, "Column" : 1, "Text" : "Urologic Clinic Procedures", "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Text" : "References", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis"}, 
{"Row" : 17, "Column" : 1, "Text" : "(2008) (Reviewed and validity confirmed 2011, updated February 2012)"}, 
{"Row" : 18, "Column" : 1, "Text" : "www.aua.org"}
]},
{"Name" : "ORZID3 GMENU UVEITIS", "DisplayText" : "Uveitis " , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Mnemonic" : "2"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "DisplayText" : "Retinitis (Outpatient)", "Text" : "VZV or HSV retinitis and ARN", "Mnemonic" : "4"},
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "DisplayText" : "CMV retinitis (Outpatient)", "Text" : "CMV retinitis and ARN", "Mnemonic" : "6"},
{"Row" :3, "Column" : 1, "Text" : "UVEITIS", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Most cases are non-infectious. Most infectious cases are associated with a"}, 
{"Row" :6, "Column" : 1, "Text" : "pathogen causing systemic or central nervous system infection. Diagnosis of"}, 
{"Row" :7, "Column" : 1, "Text" : "uveitis usually must be made presumptively due to the technical difficulty of"}, 
{"Row" :8, "Column" : 1, "Text" : "sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and"}, 
{"Row" :9, "Column" : 1, "Text" : "protozoa like Toxoplasma gondii."}, 
{"Row" : 11, "Column" : 1, "Text" : "For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)", "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Text" : "due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Text" : "Treatment of uveitis involves treating the underlying infection and is usually", "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Text" : "systemic. Refer to specific pathogen recommendations for treatment of underlyin", "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Text" : "infection. Contact Ophthalmology and/or Infectious Diseases for assistance.", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "_______________________________________________________________________________", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "References: "}, 
{"Row" : 24, "Column" : 1, "Text" : "Mandell chapter: Infectious causes of uveitis"}
]},
{"Name" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "DisplayText" : "Viruses (Outpatient)" , "Version" : "Minneapolis", "Contents" : [
{"Row" :1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "DisplayText" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Text" : "", "Mnemonic" : "2"},
{"Row" :6, "Column" : 1, "Item" : "ORZID3 GMENU ABX CMV MAIN PAGE", "DisplayText" : "Cytomegalovirus (CMV) Main Page (outpatient)", "Text" : "[click here]", "Mnemonic" : "4"},
{"Row" :9, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "DisplayText" : "Infectious diarrhea/Gastroenteritis (Outpatient)", "Text" : "[click here]", "Mnemonic" : "6"},
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS A", "DisplayText" : "Hepatitis A (outpatient)", "Text" : "Hepatitis A", "Mnemonic" : "8"},
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS B", "DisplayText" : "Hepatitis B (outpatient)", "Text" : "Hepatitis B", "Mnemonic" : "10"},
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS C", "DisplayText" : "Hepatitis C (outpatient)", "Text" : "Hepatitis C", "Mnemonic" : "12"},
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient)", "Text" : "Bell's palsy", "Mnemonic" : "14"},
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU HSV ENCEPHALITIS", "DisplayText" : "HSV encephalitis (Outpatient)", "Text" : "Encephalitis", "Mnemonic" : "16"},
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "DisplayText" : "Sexually Transmitted Infections", "Text" : "Genital herpes", "Mnemonic" : "18"},
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "DisplayText" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Text" : "Herpes Whitlow (digit or hand", "Mnemonic" : "20"},
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "DisplayText" : "HERPES KERATITIS", "Text" : "Keratitis", "Mnemonic" : "22"},
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "DisplayText" : "Orolabial herpes (Outpatient)", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Mnemonic" : "24"},
{"Row" :3, "Column" : 1, "Text" : "++ VIRUSES ++", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Cytomegalovirus (CMV)", "Header" : 1}, 
{"Row" :8, "Column" : 1, "Text" : "Diarrhea, viral", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Hepatitis", "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Text" : "Herpes Simplex", "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Text" : "cellulitis)"}, 
{"Row" : 27, "Column" : 1, "Text" : "Last reviewed 8/2018", "Header" : 1}, 
{"Row" :6, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "DisplayText" : "HIV-AIDS (outpatient)", "Text" : "[click here]", "Mnemonic" : "28"},
{"Row" :9, "Column" : 2, "Item" : "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT", "DisplayText" : "Influenza Seasonal 2021-2022", "Text" : "[click here]", "Mnemonic" : "30"},
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU ABX PARAINFLUENZA", "DisplayText" : "Parainfluenza (outpatient)", "Text" : "[click here]", "Mnemonic" : "32"},
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU ABX RSV", "DisplayText" : "Respiratory Syncytial Virus (RSV) (outpatient)", "Text" : "[click here]", "Mnemonic" : "34"},
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU BELL PALSY", "DisplayText" : "Bell's palsy (Outpatient)", "Text" : "Bell's palsy", "Mnemonic" : "36"},
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "DisplayText" : "Primary infection (Chickenpox) - Outpatient", "Text" : "Varicella/Chickenpox (primary infection)", "Mnemonic" : "38"},
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "DisplayText" : "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient", "Text" : "Zoster/Shingles (reactivation)", "Mnemonic" : "40"},
{"Row" :5, "Column" : 2, "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 1}, 
{"Row" :8, "Column" : 2, "Text" : "Influenza, Seasonal", "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Text" : "Parainfluenza", "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Text" : "Respiratory Syncytial Virus (RSV)", "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Text" : "Varicella-zoster", "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Text" : "Rabies", "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Text" : "Post-Exposure Prophylaxis"}, 
{"Row" : 17, "Column" : 2, "Text" : "is available in ED CDSS only"}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "DisplayText" : "Rabies Pre-exposure Prophylaxis", "Text" : "Pre-Exposure Prophylaxis", "Mnemonic" : "33"}
]},
{"Name" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS" , "Term1" : "Antimicrobial interactions with warfarin " , "Term2" : "Warfarin interactions with antimicrobials" , "Version" : "Minneapolis", "Contents" : [
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX LEXICOMP INTERACTIONS", "DisplayText" : "Lexicomp Drug interactions", "Text" : "Lexicomp Drug Interactions", "Mnemonic" : "4"},
{"Row" :3, "Column" : 1, "Text" : "DRUG-DRUG INTERACTIONS BETWEEN ANTIMICROBIALS AND WARFARIN", "Header" : 1}, 
{"Row" :5, "Column" : 1, "Text" : "Several antimicrobials will affect metabolism or the effect of"}, 
{"Row" :6, "Column" : 1, "Text" : "warfarin on a patient's clotting function. If possible, avoid using an"}, 
{"Row" :7, "Column" : 1, "Text" : "antimicrobial with a significant interaction with warfarin. If you"}, 
{"Row" :8, "Column" : 1, "Text" : "decide that an antimicrobial that interacts with warfarin is needed or"}, 
{"Row" :9, "Column" : 1, "Text" : "you stop an antimicrobial that could interact with warfarin, you"}, 
{"Row" : 10, "Column" : 1, "Text" : "should determine the INR more frequently than usual and adjust dosage"}, 
{"Row" : 11, "Column" : 1, "Text" : "accordingly. Instruct patients to inform their primary warfarin"}, 
{"Row" : 12, "Column" : 1, "Text" : "provider whenever an antimicrobial is prescribed for them."}, 
{"Row" : 14, "Column" : 1, "Text" : "Antimicrobials can alter warfarin's anticoagulant effect by decreasing"}, 
{"Row" : 15, "Column" : 1, "Text" : "intestinal synthesis or absorption of vitamin K or by affecting"}, 
{"Row" : 16, "Column" : 1, "Text" : "distribution or metabolism of the vitamin. Some antimicrobials increase"}, 
{"Row" : 17, "Column" : 1, "Text" : "synthesis of coagulation factors."}, 
{"Row" : 19, "Column" : 1, "Text" : "Antimicrobials can decrease the rate of warfarin absorption, compete"}, 
{"Row" : 20, "Column" : 1, "Text" : "with warfarin at sites of warfarin metabolism, induce warfarin"}, 
{"Row" : 21, "Column" : 1, "Text" : "metabolic enzymes, or inhibit the function or synthesis warfarin"}, 
{"Row" : 22, "Column" : 1, "Text" : "metabolic enzymes. Some antimicrobials displace warfarin from protein"}, 
{"Row" : 23, "Column" : 1, "Text" : "binding sites."}, 
{"Row" : 25, "Column" : 1, "Text" : "Check for warfarin-antimicrobial interactions on Lexicomp: "}, 
{"Row" : 29, "Column" : 1, "Text" : "References"}, 
{"Row" : 31, "Column" : 1, "Text" : "Holbrook, Anne M., et al. Archives of internal medicine 165.10 (2005): 1095-"}, 
{"Row" : 32, "Column" : 1, "Text" : "1106"}, 
{"Row" : 33, "Column" : 1, "Text" : "Lexicomp website"}
]}
]